<SEC-DOCUMENT>0001070081-20-000128.txt : 20200805
<SEC-HEADER>0001070081-20-000128.hdr.sgml : 20200805
<ACCEPTANCE-DATETIME>20200805164632
ACCESSION NUMBER:		0001070081-20-000128
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		93
CONFORMED PERIOD OF REPORT:	20200630
FILED AS OF DATE:		20200805
DATE AS OF CHANGE:		20200805

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PTC THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001070081
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043416587
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35969
		FILM NUMBER:		201078268

	BUSINESS ADDRESS:	
		STREET 1:		100 CORPORATE COURT
		CITY:			SOUTH PLAINFIELD
		STATE:			NJ
		ZIP:			07080-2449
		BUSINESS PHONE:		9082227000

	MAIL ADDRESS:	
		STREET 1:		100 CORPORATE COURT
		CITY:			SOUTH PLAINFIELD
		STATE:			NJ
		ZIP:			07080-2449

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PTC THERAPEUTICS INC
		DATE OF NAME CHANGE:	19980909
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ptct-20200630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:a91ddaa9-e688-473f-b70e-08f6db5630cb,g:e05438c1-8a2e-4af1-b39d-a16533f5ad44,d:95cf61a5c7074910ae3cf29c5ee08838--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ptct="http://www.ptcbio.com/20200630" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:utr="http://www.xbrl.org/2009/utr" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ptct-20200630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80L2ZyYWc6M2Y3ZGZhMTcwODVjNGQwYWFjMjdlNDhmZTMxMmNmYzkvdGFibGU6MjczOWU3ZjU2MjFiNDQ3MWJkMWUxYjExNDYxNTUyY2QvdGFibGVyYW5nZToyNzM5ZTdmNTYyMWI0NDcxYmQxZTFiMTE0NjE1NTJjZF8yLTEtMS0xLTA_40e3acfb-1f94-4ced-a6bb-3af78fbed39d">0001070081</ix:nonNumeric><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80L2ZyYWc6M2Y3ZGZhMTcwODVjNGQwYWFjMjdlNDhmZTMxMmNmYzkvdGFibGU6MjczOWU3ZjU2MjFiNDQ3MWJkMWUxYjExNDYxNTUyY2QvdGFibGVyYW5nZToyNzM5ZTdmNTYyMWI0NDcxYmQxZTFiMTE0NjE1NTJjZF8zLTEtMS0xLTA_ca467985-b091-4a1b-b4ec-845562049d21">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80L2ZyYWc6M2Y3ZGZhMTcwODVjNGQwYWFjMjdlNDhmZTMxMmNmYzkvdGFibGU6MjczOWU3ZjU2MjFiNDQ3MWJkMWUxYjExNDYxNTUyY2QvdGFibGVyYW5nZToyNzM5ZTdmNTYyMWI0NDcxYmQxZTFiMTE0NjE1NTJjZF80LTEtMS0xLTA_8323eb79-531a-4924-a3cc-693d79b8232f">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80L2ZyYWc6M2Y3ZGZhMTcwODVjNGQwYWFjMjdlNDhmZTMxMmNmYzkvdGFibGU6MjczOWU3ZjU2MjFiNDQ3MWJkMWUxYjExNDYxNTUyY2QvdGFibGVyYW5nZToyNzM5ZTdmNTYyMWI0NDcxYmQxZTFiMTE0NjE1NTJjZF81LTEtMS0xLTA_65cce506-fb84-4920-93c9-1a2df67a59aa">2020</ix:nonNumeric><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80L2ZyYWc6M2Y3ZGZhMTcwODVjNGQwYWFjMjdlNDhmZTMxMmNmYzkvdGFibGU6MjczOWU3ZjU2MjFiNDQ3MWJkMWUxYjExNDYxNTUyY2QvdGFibGVyYW5nZToyNzM5ZTdmNTYyMWI0NDcxYmQxZTFiMTE0NjE1NTJjZF82LTEtMS0xLTA_a8b1263e-11b9-4768-b54c-1ffb3f4ce29d">Q2</ix:nonNumeric><ix:nonNumeric contextRef="i7a54a031534840f0b962ea11b19c1d3c_D20170501-20170531" name="ptct:DebtInstrumentInterestPaymentPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTM2Mg_e91d3869-d03c-4b8b-84d9-15ddf6e4e1da">P24M</ix:nonNumeric><ix:nonNumeric contextRef="i7a54a031534840f0b962ea11b19c1d3c_D20170501-20170531" name="ptct:DebtInstrumentInterestPaymentPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMjc0ODc3OTA4OTc4OA_adc62e20-6b69-4ee6-aa71-28d59137d971">P24M</ix:nonNumeric><ix:nonNumeric contextRef="i8dc375e5e9f24bf9b690d042d600041f_D20190901-20190930" name="ptct:DebtInstrumentConvertibleThresholdBusinessDays" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMzQwMg_7f893db8-e0cf-4d5a-83ac-33f975ce7592">P5D</ix:nonNumeric><ix:nonNumeric contextRef="i8dc375e5e9f24bf9b690d042d600041f_D20190901-20190930" name="ptct:DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMzQzNQ_36968acf-1345-44be-9245-319a6078d531">P5D</ix:nonNumeric><ix:nonNumeric contextRef="idab0eeb8f1e24e3389eda446498f9b4c_D20150801-20150831" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfODk3MQ_ee20cb45-d925-46df-bb1a-8dfa5015d89d">P7Y</ix:nonNumeric><ix:nonNumeric contextRef="i8dc375e5e9f24bf9b690d042d600041f_D20190901-20190930" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfOTYwOA_9ed8f64e-ddb8-4035-b1f3-c92bbadb8041">P7Y</ix:nonNumeric><ix:nonNumeric contextRef="i8dc375e5e9f24bf9b690d042d600041f_D20190901-20190930" name="ptct:DebtInstrumentConvertibleThresholdBusinessDays" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTE4NTA_7f893db8-e0cf-4d5a-83ac-33f975ce7592">P5D</ix:nonNumeric><ix:nonNumeric contextRef="i8dc375e5e9f24bf9b690d042d600041f_D20190901-20190930" name="ptct:DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTE4ODM_36968acf-1345-44be-9245-319a6078d531">P5D</ix:nonNumeric><ix:nonNumeric contextRef="idab0eeb8f1e24e3389eda446498f9b4c_D20150801-20150831" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTc2MzM_ee20cb45-d925-46df-bb1a-8dfa5015d89d">P7Y</ix:nonNumeric><ix:nonNumeric contextRef="i8dc375e5e9f24bf9b690d042d600041f_D20190901-20190930" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTgyNzA_9ed8f64e-ddb8-4035-b1f3-c92bbadb8041">P7Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ptct-20200630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i169de841172649f2b7a67e115481f695_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i53a9a4e5a7004ee289a81b8ed4b249e4_I20200803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i45814e0e64094044a82fcf8bbad4c123_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80823282f4634ae8844d0174883b097c_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c2dcea8d5894a6aaba983f5a911388c_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd94b62990744751ae48321dad1d6eab_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1856787732484c15a0bc9dd59846d7df_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:GrantAndCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31e4fee5acef46b09a3f7ab4d447b758_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:GrantAndCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia37e22b92f244d44941f5498dd31a614_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:GrantAndCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i846b2660ee9a46aa8e191f0a79737479_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:GrantAndCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieec6c9a44e1a4fa0b02c65d76e099de2_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2217d6be0da04b3c9aa7801351f5b23f_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic903ce63d61344bb93ea8a3c7cd2e5fd_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f5abb3d22174bc5baaf5959060f4f75_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb8114d4f418487782c0740ca1ed1bfc_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2522e73523e4feda4f9fd68c9be8c32_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3ffc2fc75914fddbf65e6f5960bc8d5_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85184b2a023d436aae89f6d066cfbfec_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i533ee7ba976f46e396724aba128c444e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie459585656ec4c888bad0072cb787216_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if99a5f5b88c44e239963a271d78fd4d0_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib08418efd9054e53865f0aad58f50b9d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94b08961287e4bd28403b18fb27d1ef3_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e93050dc1a94baf9a24faf44c845fc2_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ff2de3d9580494aa4f84424a72b83aa_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i930a0deb5fe14f56b2dfe784709c3a46_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id107e0ac152043d8b3217fec423c7ff5_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa534d8c4a3b44998ead7885db0ad530_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42fbe8f0476c44e48fe505660057da1a_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ae47019f2ba40a8aefbc1d239cdc94b_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfcb85f561bb41318c256dcacaf6a1a2_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i289d8cdd90cd4be0a90a0932fe6572f6_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id81dc5f706a14ac69c50d7c1adccc558_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5628af8116db4f9a9c32020225574c39_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifeea6088e2ed4f849936ae7bdd7cbcfd_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28563c013fff4be6aba8b90a75baf135_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6416f0fda976465288b8a99fee841a11_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c24f8e9d344416dbdacd07f1624ad0c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebab310c097741efb22ea6ccc61c24b1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if79b05d131bf402dac7e50420745aeff_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e33cecb164a48a0aa1eba2f1728140b_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b35f4ed68ad4e4d905a31fd652afbca_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31d6e1bdb5ca471392964fa03ef36c08_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bff894d600845e29a8c4faf34680df2_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5972ed6730144a8ae9bdb30fcd5fffd_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib056d8d4512a4814801eaea43e457f5f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d8fb8ff546849248d177b17b67ea09b_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6eadb591f1b34ddaa289055d8b4379c3_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i785bae8d0f37453b828968b15c63b74f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4042444983714690acf2456c51c245ff_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice0e67612cf54d9c91dea97e80e5cbec_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27feb6dc967a41579d7c19c8a1cb7e84_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24ef21dbfe234c0591a9b24a236878c6_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9eece550dff4e4780cef9d288202a33_D20180823-20180823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-23</xbrli:startDate><xbrli:endDate>2018-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e759cb2d2394853b69b11290ac5d21a_I20180823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-08-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if89af7698cdf43d1915f30dc403dc6af_I20200429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:RightsExchangeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i921570c76d4f4e23870b19798c531218_D20200429-20200429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:RightsExchangeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-29</xbrli:startDate><xbrli:endDate>2020-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44fac1cb95fa4331b63d8afeb4d83f20_D20200429-20200429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:RightsExchangeAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-29</xbrli:startDate><xbrli:endDate>2020-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id61e01344c6b402983658d905475cc0f_I20200429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i56959b5fb9c34914b2d086de6704c201_I20200429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56a3188c726c4476a6115fcc0dc1091f_I20200429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2869c1675c5a404e9bb85cad2eb71998_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes1.5DueSeptember152026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28655a9b21d647eb9144da8fa8cdd911_I20150831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic07a476967de416b843f81c02e185244_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:FifthAnniversaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5e09658503d4a019b7c66616efd1b4d_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70f85cc7508547529a1ddd69bf58968d_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fcd6ae0b0b244eb992a22b9f010a8a9_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cac55e0c942455e8be47df4a5540bf5_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b2299918005400d83e8169cdceaa098_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if04847b5828f40ffb96ff09abbfbe7f0_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i245f190c344b472682efecbcf65a617f_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i084808ce47024c3e9355cdfb5214b4ee_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8742fae222d34cac83b189f51096e426_D20200529-20200529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:CensaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-29</xbrli:startDate><xbrli:endDate>2020-05-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28fa54ad024443b18973875cc89f36e3_I20200529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:CensaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="operating_lease"><xbrli:measure>ptct:operating_lease</xbrli:measure></xbrli:unit><xbrli:context id="i534a161919c644babf7b581f8815a9ae_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee26b7ab0eb3427894a7e80a6ab4b557_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b91bdabba504b27a63eb72dd4e14072_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">ptct:FinanceLeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:MassBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad9435fcf1974f729382cb45345d15cf_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">ptct:FinanceLeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:MassBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2eddd9a393564222bc0988444831fd19_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">ptct:FinanceLeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:MassBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i70c896353309469f838542acfc22aa9e_I20200501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ptct:BridgewaterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffc234810342492fa6bacab33891f92b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ptct:MountainviewMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8062aff1c79b49feb68143984343e9ea_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ptct:HopewellCampusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad498f0eada24a34916bb8f896e4c6a1_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ptct:HopewellCampusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="term"><xbrli:measure>ptct:Term</xbrli:measure></xbrli:unit><xbrli:context id="i70364109a58442d999d1529aa97f2b6b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ptct:HopewellNewBuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6a7756ab1084e378dab79f603770a11_I20190531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba78e43751ff4a8f8903200b06897a60_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b06422408ed4884889f98fec6b585e7_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab70e96c6dcd4cf38e8acc5f76da5a1c_D20200101-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e35023e351f4322a3c1e517dc55d17f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40c26ba683a24d9e98f2ec75db288d77_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99c95301a4884daa9e367f37995284bd_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e7e649fe3864de3976f553389445c8b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9d447580c3b40f3beffae2bafa97465_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44f6355301964dabbb766e645f3cf148_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15f90f09637a4cb1bb715dfe4f05297a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b16af03a6464f1daa8673b162ab2586_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i761da636d68a44a59452ea0f2aa77729_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ca9ba441e8d4540804f886f1cc9c954_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3c1cca7bff548549723c72b62c5cabd_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc5b2ebfb0104a74a263ad842ff6c5b7_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if300ba06104942c0b9bc9c2620d5efae_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i846b553e2ead487080c5135cbfabf245_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93db7a3e36c54bccb14ea9da633b0ca2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice1694004db8457f8428afa653a62360_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i093049f7698c438ea17d8d78b2999a3b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i460293d39eb74292bfa8379e3e079d05_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15b6700152f74cd99d7930f13a61958e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6422d57bbb764a51b28c5b9584e9df0b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f81bf0a978b4c9f9854bd8827a16c63_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia246a01c67a4480ebec435e73307c0dc_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i876ed796b3d14bf1be51f08fb4114515_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90486133108543398e32deae8f47a34d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ab2c343b8eb419cbede80402b0f7f2a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8d66a66f5c44284a1bfe69359df8592_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3c822dd8f524ec2a293c01f04eecc3b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2693d4b1ad594235b8ea223db85dc081_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18f98e56934a450c999dc68774136109_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05c1fab5886147afbd189c9f7d96801e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i808602a5926949c8ac25d08dcc142c0a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26723ef219cf40f79fc4b63185834f6a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43e763aab42b473cb26af800270f6b3e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes1.5DueSeptember152026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08c7971cf8d6469fbda565dec2419938_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fc57b5184a54d248eb826766cbbb088_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia20c4a3be1bf491aaf06ea4818f97179_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e34d9d90204473c8ea049d991956012_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife1e487e2c3c44508eb4f48b2ea5cd9e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:NoncollaborativeArrangementTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa7979ad51144297ab5f7100771cad69_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i163271c9c18a44a7acbdd4d53ae6113f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15a832ee781448adb2f8888811fbc346_I20200629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8aa17e0adf804ca986cfd400e121c2ea_I20200629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6094c414acd64e8eb18a8f8306f9c263_I20200629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if54601c17d0343ec8d9cd0af73df9a5b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ca2052e537349099f8500140b79c830_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82a7d5029292453a9d8665965b2a0597_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f89da40eb9542899d61cec5f576ce4d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe63e39ea26a457a88e2e66409ca6e52_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:ProbabilityofSuccessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46d96bc3957b4332a199fc5c2ba22aa2_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06c3f1148d284ba19fd288779c3f2c67_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:ProbabilityofSuccessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5a07c3011f2483691088bb12f4ed468_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i307a45a921aa4ac98cbf6914b2e129b6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i442f4b08d467498fa51f7601498e0665_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief55fa56f05642ae9c7051bbcc123a7e_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c7c09a50e6e4ba8839d07d7a35718fb_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf63c553ba564cb8bd94fab03c3290ab_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d5a9b90a7664e9ca2c85d0f043d14b8_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d889af7642941098bf2c2aadc6af779_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab08ed7f127f42a4870b894f05e31311_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34ddd62e28264378a9b8a8810c84e304_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43a9f70ea53c4278ac5294a289217733_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6901fa0b994f45b1b11bb7852f30e63e_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9b011ab666643deb05f06b8b1928ac7_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69fef5796fd9485e91f00768f2ee4f15_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i492676ae9f954509b5671e6270ebd50f_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6abf1ab717cb4553b5a379a89528951c_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bb52be78ac04fb99f1f51bf469e5f11_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia63a5a2116d74541955a8c47217140bb_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d5cbe2fe3d241869ba45bf5f3259eaf_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:DevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e3ab83b0ac24b1f8726a085e96bde2b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:DevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97b5568d815c48fcaeba6264529028d7_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:ProbabilityofSuccessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f2ea92199454f8fbd535326a97a91d7_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:ProbabilityofSuccessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i142a5ba947234d00bdda31557ab02053_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic24cf29b77fa4211a03dfd961242ace4_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if778d097ba124606b84b432e35ce14f2_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icde04c74d7d14859bd0c3c1fec8bf23b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:PotentialNetSalesMilestonesDomain</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i841cadf7f1ab42329b55f05f8b682241_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:PotentialNetSalesMilestonesDomain</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id290d0f494dc48b394820ca85e03d713_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:ProbabilityofSuccessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b1d4bc93668470fb8dc3d2484cd7377_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:ProbabilityofSuccessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i032e49103b7940008966b0abb2c816bf_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:PercentageofSalesforRoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7aeb677d725d4e7587c00dcd29b216d8_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:PercentageofSalesforRoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia922f94529a94215b26acb871b50ccef_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a37cc547e3f49848c674109573d923a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95e964e1da464dd788d6a99f05370274_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c93370f63d94e1aac4ee54439ff6b56_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffe61d144e3f45a68d1cf62be52068fc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6c94b6543dd43d288ab57eb081f624f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee49fff9a55c42e7a46ef038efca561d_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37afd9374ab2456f9adc2e123d047a8d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41984dd1229341a3adf191f855e3437a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:DevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9f423a27b8747658dbca67347391ba2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:DevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9cb29f6a24b456e9193911f1294da2e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:ProbabilityofSuccessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i896363143c604488b15264f3f0863d75_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:ProbabilityofSuccessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e93577925ee429e9cfb5138f9eb301c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia90fac7174b946d2a3f4eb2d0130831f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9de748e71a0a41f892580d81dc59723c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia365849e92bd4987b8c1a8f48af0e949_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:SalesMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8a23607d13242b087cdf7ef0d75fbf0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:SalesMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e30234883ae400a8e1754f0ba49366e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:ProbabilityofSuccessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7418d3bad6a54d2d94c44b530ec3c8ef_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:ProbabilityofSuccessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6558018b150492b8245e18dd9d4171c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:PercentageofSalesforRoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92a0fdc9f2104055b10e7852fda23d64_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:PercentageofSalesforRoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01dac52020be426eb733231d3b86e6ac_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i928aeea3fbed4653a9c7504d776b8545_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic451340f512342608177bf840c932205_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2f410476d4d4014828565f0ff529e4b_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a5bfe4b544f4ab3b6857b0ebb80918e_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73427926a3e341daaacaf169fb831162_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ea979e0426d48798c5a50c5f7a7aa15_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ab1ac66d020429d96c29af31d72ab26_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdcaac852b5047fa90c10c82a5c82f80_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddbe94caf0424d3fa43a0628a5730a6f_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfb151bb79164c7a924ed3a43feda689_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31727b5e545f4438bb09f0aee02b36cf_D20190801-20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22a6b3907e334ad095459c22452a31a8_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20afcd7c10c14ac495fc02e16fe69b2d_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if241e524337e420a90c40125ab0af552_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:RightsExchangeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i732b4791ae044c3982d3fc5b40507c4a_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4340507e56e749d38aa6d877e17f6f11_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4dfd70561f44b3389920eecf82405aa_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ptct:RestrictedStockAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6512ed24942b4cf78a18c42c69f878df_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ptct:RestrictedStockAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25d7f62000cb47619cacff7feea40ec4_I20130305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:StockIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-03-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae41b38768a04ebfa621ede89b1e1eba_D20130305-20130305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:StockIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-03-05</xbrli:startDate><xbrli:endDate>2013-03-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4acdb340b0784c54b281fc72cd460037_D20130305-20130305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:StockIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-03-05</xbrli:startDate><xbrli:endDate>2013-03-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf26f417473642be92ba8eea00337e07_I20130305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:StockIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-03-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62a5ccc71de84104a8745951ca1a9aa7_D20130501-20130531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:EquityAndLongTermIncentivePlan2009Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-05-01</xbrli:startDate><xbrli:endDate>2013-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65727f1a834a481f8553fbb4bb642903_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:EquityAndLongTermIncentivePlan2009Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1efd0cb53b6044d78f74b229bd2b52aa_I20130531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7090aa93ba846e4b5c5820dcecfd98a_I20130531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ptct:EmployeeDirectorAndConsultantStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf07b2dff77d4ca1a51f7b625a38192b_D20130501-20130531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:LongTermIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-05-01</xbrli:startDate><xbrli:endDate>2013-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93ba015b7d0a44aaaf029eb718c780c2_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd063a6e802542888865b12d471371c5_D20200101-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:A2020inducementstockincentiveplanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12f2cd9f617e471d9081d454d8ab7810_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:A2020inducementstockincentiveplanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7af21e8197c4484c8a8abf452ef76b07_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf32b31395a2491ebc2ee0715f74c386_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a7e99b59db24353a85559f303336e06_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if901bdf36a4e4a1a81a16393f47a9fb6_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62acf5ed7adb4666851a78792c6fd991_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d4c0457ced344f0b16ef87b8b77d3ae_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b0a569c469e4b6596d336467dd05160_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40fe1e237dd2460982e61df9b93e25de_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e1f2793036044c09455f3aed8a471a5_D20160501-20160531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-05-01</xbrli:startDate><xbrli:endDate>2016-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8edf5809ef1e4a8c9d7d12ead5870765_I20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia49191cff53044aeb0f18b552f15edb0_D20160601-20160630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-06-01</xbrli:startDate><xbrli:endDate>2016-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia00d8392741940a5a0455a9ec5a070dc_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c05af13913c4e2d87e2cca2be0ef9a6_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23b23527dd664848b751f1f40cd0477f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacdbc7fbbfab4c83935a46b395d3c1c4_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1bd8bc0a2d94ff7b16f1f994b27455f_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14204fc508b343cb8ca99de636b507e4_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i895a331c1a6f453c87f851e30384f906_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14ebe4de831348188d0069a40d328e56_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5f804d6c3184fdea8f69c3a97350d43_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide6d6c0db1274c47ab5146ea275d8c88_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia31f7d7b519f40d5a5aa9977431540c2_I20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ptct:MidCapFinancialTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0047c24fb89c4b3aa1349dbfc482fe10_D20170505-20170505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ptct:MidCapFinancialTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-05</xbrli:startDate><xbrli:endDate>2017-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i624b7b9db16e4728a041aaf0fe8e3bbc_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ptct:MidCapFinancialTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i396045a4f2b246abb303f6334b534fc5_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ptct:MidCapFinancialTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a54a031534840f0b962ea11b19c1d3c_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ptct:MidCapFinancialTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99e6e03adee54a9ca0a6a21ec4cddd55_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes1.5DueSeptember152026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="day"><xbrli:measure>ptct:day</xbrli:measure></xbrli:unit><xbrli:context id="i8dc375e5e9f24bf9b690d042d600041f_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbd02289ccd34e7a886bf4e86089dadc_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">ptct:DebtInstrumentConversionPeriodOnOrAfterAugust202018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9710b6f008d64a8e9b038ddfbc4f20cb_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes1.5DueSeptember152026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8781119cc5804767a8721ec1e62367b7_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">ptct:DebtInstrumentConversionPeriodOnOrAfterAugust202018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idab0eeb8f1e24e3389eda446498f9b4c_D20150801-20150831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-08-01</xbrli:startDate><xbrli:endDate>2015-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74ae1a7412804eb39f158945860fdc92_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes1.5DueSeptember152026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73b5dc373fe54df282ef490ee32d7654_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes1.5DueSeptember152026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0563616514554f76bb3cb942f7310b61_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9c66ca599c4439faa67414af9011439_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e58b009dcb346afa5fe00025d1c8d43_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a6dca67e5ed44bcae174fc956c744bb_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb3d2f86e29542fd99ac08fe93500645_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1f05bd3af07411fbeaa9695faa9b8f5_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f68521ddf23433db2233ba19286dfae_I20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:WellcomeTrustLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdf769cde4f8456998cb633ecc67a74a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:WellcomeTrustLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id48de54c835343b9b2c5c1d3ce609ab1_I20170420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:NoncollaborativeArrangementTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:MarathonPharmaceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-04-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a92bf7bb7524f61a93f2c8959d0be71_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b11444730184724a2297b26b10e055d_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:RightsExchangeAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38631b4cb53445c299e2d62fbae00216_D20200629-20200629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:RightsExchangeAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-06-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04fa4a18d65a48a9a4f7a021a18243d8_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:RightsExchangeAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fd11bc6a99940fd88c85b0f84932bf6_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:BioElectronMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1c12a4aacaf45c6b83d421f91bcc1a3_I20200529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:CensaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i652c4548495c438db5c41a0492a229a2_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:AkceaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0753aa5ed002421a95716b8d6332e418_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:NoncollaborativeArrangementTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:AkceaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia033e797f8104feca5e0e2c9aef70ffb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:AkceaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>ptct:segment</xbrli:measure></xbrli:unit><xbrli:unit id="number_distributor"><xbrli:measure>ptct:Number_Distributor</xbrli:measure></xbrli:unit><xbrli:context id="ifed0db43ebe049f185e04d30bd4e1b71_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2020-07-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia96d9cae808a4c3784211e0141d85ae1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2020-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id60b94195bb147c181fa7ec372ed8691_D20111101-20111130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:LicensingAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ptct:MilestoneAxis">ptct:ResearchAndDevelopmentEventMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2011-11-01</xbrli:startDate><xbrli:endDate>2011-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b34ee3e697448668a9c788ce80598fb_D20111101-20111130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:LicensingAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ptct:MilestoneAxis">ptct:SalesMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2011-11-01</xbrli:startDate><xbrli:endDate>2011-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib692f789ea234d29951422720218faa2_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:LicensingAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ptct:MilestoneAxis">ptct:ResearchAndDevelopmentEventMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2835b8eed94641e2ab9c3c4491078285_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:LicensingAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ptct:MilestoneAxis">ptct:SalesMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5b76a0a42be443893da3eb686237ab7_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:LicensingAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i298b567a840a479b841a1c7cae6b2b42_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:LicensingAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21cc52aa842546b39066bbc6d2f4ec24_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:LicensingAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id33464a3934340609397e4ae7f1b281c_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:LicensingAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib46a34ef31754b4badaaae6fccf85a47_I20170420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:EmflazaassetacquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-04-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i667dbebd49c148f3993ce8cc26b0f8f3_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d48ddbb90814f6daa9feea1cb72ad27_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:EmflazaassetacquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07ceae4bafba47cea561662c5f6b04a2_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:EmflazaassetacquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ef2c3542e8941dea35d5efd0bdc7a5c_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:NoncollaborativeArrangementTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:AkceaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61a6fc1556ef4b3fa72296db809eb593_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:NoncollaborativeArrangementTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:AkceaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b0512f2780f4b8eb0826df908c1fcb3_D20200701-20200701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia95450bc6d4d4073acbfc602735fef93_I20200717"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i574baa6db99049d2ba9e1203ea243658_D20200717-20200717"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-17</xbrli:startDate><xbrli:endDate>2020-07-17</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i95cf61a5c7074910ae3cf29c5ee08838_1"></div><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i95cf61a5c7074910ae3cf29c5ee08838_7">Table of Contents</a></span></div></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;">UNITED STATES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Washington, D.C. 20549</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:24.415%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;">FORM&#160;<ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGV4dHJlZ2lvbjpjZWMwYWU2YmIxY2I0ZDJiODYwZjg4MDJhY2JkNDEwYl8yMTg5_7376180a-3994-4715-b277-ffd917f5173c">10-Q</ix:nonNumeric> </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Mark One)</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGV4dHJlZ2lvbjpjZWMwYWU2YmIxY2I0ZDJiODYwZjg4MDJhY2JkNDEwYl8yMTky_f4b2a679-8e60-492b-97a6-3b4e43afe71b">&#9745;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">For the quarterly period ended <ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGV4dHJlZ2lvbjpjZWMwYWU2YmIxY2I0ZDJiODYwZjg4MDJhY2JkNDEwYl8yMzk_093519b2-02b1-4646-adc7-4702117b29fc">June&#160;30, 2020</ix:nonNumeric> </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">or</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGV4dHJlZ2lvbjpjZWMwYWU2YmIxY2I0ZDJiODYwZjg4MDJhY2JkNDEwYl8yMTkw_f23d3eec-c99d-4a42-9f02-7ce97cea79a2">&#9744;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Commission file number: <ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGV4dHJlZ2lvbjpjZWMwYWU2YmIxY2I0ZDJiODYwZjg4MDJhY2JkNDEwYl8yMTkx_90d0cacb-7894-459a-ab83-702926844c52">001-35969</ix:nonNumeric> </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGV4dHJlZ2lvbjpjZWMwYWU2YmIxY2I0ZDJiODYwZjg4MDJhY2JkNDEwYl8yMTkz_5ada9cc5-0938-418c-b7d9-edfdc199d47a">PTC Therapeutics,&#160;Inc.</ix:nonNumeric> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(Exact name of registrant as specified in its charter)</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:46.093%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.665%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:46.242%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGFibGU6NTgwYTRkOGM5NzNkNDMzMzlmNmFiMmZjZDA2MmU2MDAvdGFibGVyYW5nZTo1ODBhNGQ4Yzk3M2Q0MzMzOWY2YWIyZmNkMDYyZTYwMF8wLTAtMS0xLTA_7769ce35-8b50-4d74-b6dc-768805f141a0">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGFibGU6NTgwYTRkOGM5NzNkNDMzMzlmNmFiMmZjZDA2MmU2MDAvdGFibGVyYW5nZTo1ODBhNGQ4Yzk3M2Q0MzMzOWY2YWIyZmNkMDYyZTYwMF8wLTItMS0xLTA_7866f25a-85ed-40a0-b6fc-bd795777815f">04-3416587</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:22.158%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.469%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.666%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:44.707%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGFibGU6NWNmNGFjZGZlZDc2NDQ2MmE1ZWRjYjM3YmY4YjcwMzMvdGFibGVyYW5nZTo1Y2Y0YWNkZmVkNzY0NDYyYTVlZGNiMzdiZjhiNzAzM18wLTAtMS0xLTA_366a70f5-9bd7-473a-aa3b-e32bf69272a3">100 Corporate Court</ix:nonNumeric></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGFibGU6NWNmNGFjZGZlZDc2NDQ2MmE1ZWRjYjM3YmY4YjcwMzMvdGFibGVyYW5nZTo1Y2Y0YWNkZmVkNzY0NDYyYTVlZGNiMzdiZjhiNzAzM18xLTAtMS0xLTA_421d4f96-75d1-48c5-b4fc-c9ef0eb67c36">South Plainfield,</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGFibGU6NWNmNGFjZGZlZDc2NDQ2MmE1ZWRjYjM3YmY4YjcwMzMvdGFibGVyYW5nZTo1Y2Y0YWNkZmVkNzY0NDYyYTVlZGNiMzdiZjhiNzAzM18xLTEtMS0xLTA_44ebea8d-2c67-43f7-bf4d-abe7c4b7bb74">NJ</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGFibGU6NWNmNGFjZGZlZDc2NDQ2MmE1ZWRjYjM3YmY4YjcwMzMvdGFibGVyYW5nZTo1Y2Y0YWNkZmVkNzY0NDYyYTVlZGNiMzdiZjhiNzAzM18xLTMtMS0xLTA_1934fed1-0dbd-49b9-8c61-786c472b8c01">07080</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Address of principal executive offices)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Zip Code)</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(<ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGV4dHJlZ2lvbjpjZWMwYWU2YmIxY2I0ZDJiODYwZjg4MDJhY2JkNDEwYl8yMTg1_11d026d8-b6a2-4f48-901c-7f27cc940728">908</ix:nonNumeric>) <ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGV4dHJlZ2lvbjpjZWMwYWU2YmIxY2I0ZDJiODYwZjg4MDJhY2JkNDEwYl8yMTg2_e97b9727-f834-4b87-85dd-e4a237ce36ec">222-7000</ix:nonNumeric> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center;"><span><br/></span></div><div style="margin-bottom:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:38.735%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:16.235%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:39.030%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Title of each class</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Trading Symbol(s)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGFibGU6OTUzMmYxNmIwN2U4NDRlZDgxMGJlMTEwMGYzYmMzNTIvdGFibGVyYW5nZTo5NTMyZjE2YjA3ZTg0NGVkODEwYmUxMTAwZjNiYzM1Ml8xLTAtMS0xLTA_ecaed0bf-61c5-43cb-921f-fb3491fd6247">Common Stock, $0.001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGFibGU6OTUzMmYxNmIwN2U4NDRlZDgxMGJlMTEwMGYzYmMzNTIvdGFibGVyYW5nZTo5NTMyZjE2YjA3ZTg0NGVkODEwYmUxMTAwZjNiYzM1Ml8xLTEtMS0xLTA_4d506fb5-02f4-46d6-b80d-c52f92575252">PTCT</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGFibGU6OTUzMmYxNmIwN2U4NDRlZDgxMGJlMTEwMGYzYmMzNTIvdGFibGVyYW5nZTo5NTMyZjE2YjA3ZTg0NGVkODEwYmUxMTAwZjNiYzM1Ml8xLTItMS0xLTA_69c01256-f7e3-4f6e-b1d2-28fe1c67cd2f">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160; <ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGV4dHJlZ2lvbjpjZWMwYWU2YmIxY2I0ZDJiODYwZjg4MDJhY2JkNDEwYl8yMTg3_9f7204b9-b823-485c-b692-07d0e353723c">Yes</ix:nonNumeric>&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#254;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160; No&#160;&#9744;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160; <ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGV4dHJlZ2lvbjpjZWMwYWU2YmIxY2I0ZDJiODYwZjg4MDJhY2JkNDEwYl8yMTg4_af9f9ad5-d550-48c8-b1ef-c7353a0e2099">Yes</ix:nonNumeric>&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#254;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160; No&#160;&#9744;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:70.029%;"><tr><td style="width:1.0%;"></td><td style="width:43.929%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.966%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:44.137%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.968%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGFibGU6NjZhMjUwNjY2ZjMyNDE4ZmIzMDlhMTIxMWI1MWE5NmIvdGFibGVyYW5nZTo2NmEyNTA2NjZmMzI0MThmYjMwOWExMjExYjUxYTk2Yl8wLTAtMS0xLTA_8c154f07-81fc-48a7-a4cd-efcebc9c9642">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Wingdings',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#254;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accelerated filer</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-accelerated filer<br/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#160;&#9744;</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Smaller reporting company</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGFibGU6NjZhMjUwNjY2ZjMyNDE4ZmIzMDlhMTIxMWI1MWE5NmIvdGFibGVyYW5nZTo2NmEyNTA2NjZmMzI0MThmYjMwOWExMjExYjUxYTk2Yl8yLTMtMS0xLTA_040afd5a-4b2f-4d8d-aa90-01da2ca1f5a0">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Emerging growth company</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGFibGU6NjZhMjUwNjY2ZjMyNDE4ZmIzMDlhMTIxMWI1MWE5NmIvdGFibGVyYW5nZTo2NmEyNTA2NjZmMzI0MThmYjMwOWExMjExYjUxYTk2Yl8zLTMtMS0xLTA_bfa6e3f3-a853-4afa-ba34-910b60d0256e">&#9744;</ix:nonNumeric></span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;   </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160; Yes&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGV4dHJlZ2lvbjpjZWMwYWU2YmIxY2I0ZDJiODYwZjg4MDJhY2JkNDEwYl8yMTk0_49c8cebb-ec88-4112-9c7c-33be76cfd5a9">&#9744;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160; No&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#254;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of August&#160;3, 2020, there were <ix:nonFraction unitRef="shares" contextRef="i53a9a4e5a7004ee289a81b8ed4b249e4_I20200803" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGV4dHJlZ2lvbjpjZWMwYWU2YmIxY2I0ZDJiODYwZjg4MDJhY2JkNDEwYl8yMTE2_448e30f3-fa47-429d-b8f3-21774d8518cc">67,703,214</ix:nonFraction> shares of Common Stock, $0.001 par value per share, outstanding.</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:2pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><div id="i95cf61a5c7074910ae3cf29c5ee08838_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:88.043%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.957%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TABLE OF CONTENTS</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">PTC Therapeutics, Inc.</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Page No.</span></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;" href="#i95cf61a5c7074910ae3cf29c5ee08838_13">PART&#160;I&#8212;FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i95cf61a5c7074910ae3cf29c5ee08838_16">Item 1. Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i95cf61a5c7074910ae3cf29c5ee08838_16">4</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i95cf61a5c7074910ae3cf29c5ee08838_103">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i95cf61a5c7074910ae3cf29c5ee08838_103">39</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i95cf61a5c7074910ae3cf29c5ee08838_115">Item 3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i95cf61a5c7074910ae3cf29c5ee08838_115">56</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i95cf61a5c7074910ae3cf29c5ee08838_118">Item 4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i95cf61a5c7074910ae3cf29c5ee08838_118">56</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;" href="#i95cf61a5c7074910ae3cf29c5ee08838_121">PART&#160;II&#8212;OTHER INFORMATION</a></span></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i95cf61a5c7074910ae3cf29c5ee08838_124">Item 1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i95cf61a5c7074910ae3cf29c5ee08838_124">57</a></span></div></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i95cf61a5c7074910ae3cf29c5ee08838_127">Item 1A. Risk Factors</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i95cf61a5c7074910ae3cf29c5ee08838_127">58</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i95cf61a5c7074910ae3cf29c5ee08838_154">Item 6. Exhibits</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i95cf61a5c7074910ae3cf29c5ee08838_154">60</a></span></div></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">i</span></div></div></div><div id="i95cf61a5c7074910ae3cf29c5ee08838_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">FORWARD-LOOKING STATEMENTS </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;continue,&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The forward-looking statements in this Quarterly Report on Form&#160;10-Q include, among other things, statements about:</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">expectations with respect to our gene therapy platform, including any potential regulatory submissions and potential approvals, including those related to our gene therapy for the treatment of Aromatic L-Amino Acid Decarboxylase, or AADC deficiency, or PTC-AADC, our manufacturing capabilities and the potential financial impact and benefits of our leased biologics manufacturing facility and the potential achievement of development, regulatory and sales milestones and contingent payments that we may be obligated to make;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to negotiate, secure and maintain adequate pricing, coverage and reimbursement terms and processes on a timely basis, or at all, with third-party payors for our products or product candidates that we commercialize or may commercialize in the future;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to maintain our marketing authorization of Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy, or nmDMD, in the European Economic Area, or EEA, which is subject to the specific obligation to conduct and submit the results of Study 041 to the European Medicines Agency, or EMA, and annual review and renewal by the European Commission following reassessment of the benefit-risk balance of the authorization by the EMA;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to enroll, fund, and complete Study 041, a multicenter, randomized, double-blind, 18-month, placebo-controlled clinical trial of Translarna for the treatment of nmDMD followed by an 18-month open label extension, according to the protocol agreed with the EMA, and by the EMA&#8217;s deadline;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the anticipated period of market exclusivity for Emflaza for the treatment of DMD in the United States under the Orphan Drug Act&#160;of 1983, or Orphan Drug Act, the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to complete any dystrophin study necessary in order to resolve the matters set forth in the United States Food and Drug Administration's, or the FDA, denial of our appeal to the Complete Response Letter we received from the FDA in connection with our New Drug Application, or NDA, for Translarna for the treatment of nmDMD, and our ability to perform additional clinical trials, non-clinical studies or CMC assessments or analyses at significant cost;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the timing and scope of our commercialization of our products and product candidates;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our expectations with respect to the COVID-19 pandemic and related response measures and their effects on our business, operations, clinical trials, potential regulatory submissions and approvals, our collaborators, contract research organizations, suppliers and manufacturers;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to obtain additional and maintain existing reimbursed named patient and cohort early access programs, or EAP programs, for our products on adequate terms, or at all;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our expectations with respect to the development, regulatory and commercial status of our product candidates and program directed against spinal muscular atrophy in collaboration with F. Hoffmann La Roche Ltd and Hoffmann La Roche Inc., which we refer to collectively as Roche, and the Spinal Muscular Atrophy Foundation, or the SMA Foundation, and our estimates regarding future revenues from sales-based royalty payments or the achievement of milestones in that program;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our expectations and the potential financial impact and benefits related to our Collaboration and Licensing Agreement with Akcea Therapeutics,&#160;Inc., or Akcea, including with respect to the timing of regulatory approval of Tegsedi</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">TM</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;(inotersen) and Waylivra</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">TM</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;(volanesorsen) in countries in which we are licensed to commercialize them, the commercialization of Tegsedi and Waylivra, and our expectations with respect to contingent payments to Akcea </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">based on the potential achievement of certain regulatory milestones and royalty payments by us to Akcea based on our potential achievement of certain net sales thresholds;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our estimates regarding the potential market opportunity for our products or product candidates, including the size of eligible patient populations and our ability to identify such patients;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our estimates regarding expenses, future revenues, third-party discounts and rebates, capital requirements and needs for additional financing, including our ability to maintain the level of our expenses consistent with our internal budgets and forecasts and to secure additional funds on favorable terms or at all;</span></div><div style="text-indent:-18pt;padding-left:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">the timing and conduct of our ongoing, planned and potential future clinical trials and studies in our gene therapy, splicing, Bio-e and oncology programs, studies of PTC923 for phenylketonuria, or PKU, and studies of PTC299 for COVID-19 as well as studies in our products for maintaining authorizations, label extensions and additional indications, including the timing of initiation, enrollment and completion of the trials and the period during which the results of the trials will become available;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to realize the anticipated benefits of our acquisitions or other strategic transactions, including the possibility that the expected impact of benefits from the acquisitions or strategic transactions will not be realized or will not be realized within the expected time period, significant transaction costs, the integration of operations and employees into our business, our ability to obtain marketing approval of our product candidates we acquired from the acquisitions or other strategic transactions and unknown liabilities;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the rate and degree of market acceptance and clinical utility of any of our products or product candidates;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the ability and willingness of patients and healthcare professionals to access our product and product candidates through alternative means if pricing and reimbursement negotiations in the applicable territory do not have a positive outcome;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to complete the FDA post-marketing requirements to the marketing authorization of Emflaza and any other post-marketing requirements for our products;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the timing of, and our ability to obtain additional marketing authorizations for our products and product candidates;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the ability of our products and our product candidates to meet existing or future regulatory standards;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to maintain the current labeling under the marketing authorization in the EEA or expand the approved product label of Translarna for the treatment of nmDMD;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the potential receipt of revenues from future sales of our products or product candidates;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the potential impact that enrollment, funding and completion of Study 041 may have on our revenue growth;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our sales, marketing and distribution capabilities and strategy, including the ability of our third-party manufacturers to manufacture and deliver our products and product candidates in clinically and commercially sufficient quantities and the ability of distributors to process orders in a timely manner and satisfy their other obligations to us;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to establish and maintain arrangements for the manufacture of our products and product candidates that are sufficient to meet clinical trial and commercial launch requirements;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to establish and grow our manufacturing capabilities for our gene therapy platform;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our expectations with respect to the potential financial impact and benefits of our leased biologics manufacturing facility and our ability to satisfy our obligations under the terms of the lease agreement for such facility;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to satisfy our obligations under the indenture governing our 3.00% convertible senior notes due August&#160;15, 2022 and under the indenture governing our 1.50% convertible senior notes due September 15, 2026;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our regulatory submissions, including with respect to timing and outcome of regulatory review;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our plans to advance our earlier stage programs and pursue research and development of other product candidates, including our splicing, gene therapy, Bio-e and oncology programs;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">whether we may pursue business development opportunities, including potential collaborations, alliances, and acquisition or licensing of assets and our ability to successfully develop or commercialize any assets to which we may gain rights pursuant to such business development opportunities;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the potential advantages of our products and any product candidate;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our intellectual property position;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the impact of government laws and regulations;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the impact of litigation that has been or may be brought against us or of litigation that we are pursuing against others; and</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our competitive position.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Quarterly Report on Form&#160;10-Q, particularly in Part&#160;II,&#160;Item 1A. Risk Factors as well as in Part&#160;I,&#160;Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2019, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">You should read this Quarterly Report on Form&#160;10-Q and the documents that we have filed as exhibits to this Quarterly Report on Form&#160;10-Q and our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2019 completely and with the understanding that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In this Quarterly Report on Form&#160;10-Q, unless otherwise stated or the context otherwise requires, references to &#8220;PTC,&#8221; &#8220;PTC Therapeutics,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and similar references refer to PTC Therapeutics,&#160;Inc. and, where appropriate, its subsidiaries. The trademarks, trade names and service marks appearing in this Quarterly Report on Form&#160;10-Q are the property of their respective owners.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">All website addresses given in this Quarterly Report on Form&#160;10-Q are for information only and are not intended to be an active link or to incorporate any website information into this document.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3</span></div></div></div><div id="i95cf61a5c7074910ae3cf29c5ee08838_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART&#160;I&#8212;FINANCIAL INFORMATION</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i95cf61a5c7074910ae3cf29c5ee08838_16"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 1. Financial Statements.</span></div><div><span><br/></span></div><div id="i95cf61a5c7074910ae3cf29c5ee08838_19"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PTC Therapeutics,&#160;Inc.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Consolidated Balance Sheets (unaudited)</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">In thousands (except shares)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:68.234%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.076%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.224%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMy0yLTEtMS0w_1d1f2d08-5c8d-44b0-8ef7-c8722c7e02db">158,461</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMy00LTEtMS0w_7d3e0215-e687-4311-be7e-3a79f26da6e8">288,028</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:6.75pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfNC0yLTEtMS0w_945419a4-10b1-4db8-9905-d71e4bfae415">340,430</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfNC00LTEtMS0w_cea49b77-2fbf-498f-b629-08f15905ff30">398,535</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:6.75pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Trade receivables, net</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfNS0yLTEtMS0w_cff4c314-28b7-473e-b3f1-ad92508c8745">53,644</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfNS00LTEtMS0w_85b8d15a-18bc-4c10-9f04-bb0cb6b3cf38">55,538</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:6.75pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inventory, net</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfNi0yLTEtMS0w_1489cc26-158d-44b6-bcfc-0b263565465a">18,373</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfNi00LTEtMS0w_1b4415e0-265f-45f6-9dc7-139d1a594c61">19,285</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:6.75pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfNy0yLTEtMS0w_7fda0302-0f7e-4a83-bd9a-10b3ae89ebfc">34,116</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfNy00LTEtMS0w_fa319f27-8a27-4c64-a984-e425c1f1167f">17,898</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:6.75pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfOC0yLTEtMS0w_335dadaa-1015-47f7-81a7-35b4a0d5cc74">605,024</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfOC00LTEtMS0w_5688a734-346c-46a9-aa5b-681a309eca01">779,284</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fixed assets, net</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfOS0yLTEtMS0w_b7b246a8-9b8f-4c04-9271-10f192aa63ff">26,806</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfOS00LTEtMS0w_4bbb2d87-d742-4ee4-9df7-7036ce94b7e6">21,549</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangible assets, net</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMTAtMi0xLTEtMA_8dfa9ac0-6522-4f10-b8f7-06509b08cf36">708,814</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMTAtNC0xLTEtMA_97467c54-d1ef-432e-8aa6-b083024b07cb">710,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMTEtMi0xLTEtMA_277ee1f9-3921-4621-86e5-5e5add369609">82,341</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMTEtNC0xLTEtMA_0b40967b-361e-4e8e-a63c-940703209a09">82,341</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deposits and other assets</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="ptct:DepositsAndOtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMTItMi0xLTEtMA_72a9500e-81d2-492b-8cb2-5509621974ad">53,652</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="ptct:DepositsAndOtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMTItNC0xLTEtMA_3ef726bc-151a-4af8-b629-94fd6e6c738b">30,108</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMTMtMi0xLTEtMA_8febb20e-902e-4d31-995f-1e7b96d8aee8">1,476,637</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMTMtNC0xLTEtMA_51041121-b1a2-4077-b2c1-5cfae83e0343">1,623,782</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable and accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMTYtMi0xLTEtMA_2491c4d0-bb6c-4272-90c0-2401ad527dc4">164,376</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMTYtNC0xLTEtMA_503d834c-d745-4312-bb9d-4c9225daf06c">159,276</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:6.75pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current portion of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMTctMi0xLTEtMA_c3905214-3d0a-4d12-8acc-95d59b7bf5f0">18,333</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMTctNC0xLTEtMA_e9160177-b046-4986-9ba6-dc143e29ee8f">20,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMTgtMi0xLTEtMA_aa348a93-a565-41a7-89e6-22266283d984">7,702</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMTgtNC0xLTEtMA_b179cdc4-c110-4ba7-aad9-fff2b5938ab2">8,242</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance lease liabilities- current</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMTktMi0xLTEtODYxMw_29485bcf-c18c-4ac1-827e-cae2cd73d767">4,180</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMTktNC0xLTEtODYyMg_bbcddd90-4edd-445b-8dbc-6c2d64da6112">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMTktMi0xLTEtMA_1d35d7be-c4c2-4d48-a799-0e279879137c">4,868</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMTktNC0xLTEtMA_b38ccdf9-cc53-43bd-b185-490c07ed2919">8,339</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;Deferred consideration payable</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMjAtMi0xLTEtMA_1bce71c1-051c-41ec-8176-19fe0e49c81a">2,384</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMjAtNC0xLTEtMA_65590239-e455-419c-8a8c-291b3ee2ec8a">40,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMjEtMi0xLTEtMA_265d19d9-1743-4a23-9fdb-c988550b98c1">201,843</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMjEtNC0xLTEtMA_b84ff17b-1278-4bab-84cc-51824e9f79ed">235,857</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue- long term</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMjItMi0xLTEtMA_d05d5225-523b-458a-a34b-8c78453469f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMjItNC0xLTEtMA_467ff02d-76f7-4d77-892f-60f646dd27e4">3,415</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMjMtMi0xLTEtMA_3e09e136-8054-42b9-8410-bdade0af5a23">297,029</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMjMtNC0xLTEtMA_50941f33-bd4d-466f-a8d6-edbd58504fe4">293,859</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration payable</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMjQtMi0xLTEtMA_5b8cc4d9-f2fe-4baa-bb33-4b3f1411b381">225,700</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMjQtNC0xLTEtMA_3057585e-cba1-49f2-896c-84e9077ff287">356,300</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax liability</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMjYtMi0xLTEtMA_8a58563d-9c62-4877-be43-adeeed28eeff">130,862</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMjYtNC0xLTEtMA_2b6fc2eb-7105-4508-88c2-e30229b62581">130,862</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance lease liabilities- noncurrent</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMjgtMi0xLTEtODYxNw_0b3f5a21-63a2-4883-a74e-fdc452a32488">22,031</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMjgtNC0xLTEtODYyOA_89eb8c33-20ac-44bf-ae37-2c9f4e428fcc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMjctMi0xLTEtMA_9687328b-3eb2-453a-a046-45daf54d00e2">26,678</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMjctNC0xLTEtMA_0eb62673-180c-4d86-ae3e-13562b650c15">9,159</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMjgtMi0xLTEtMA_464ac03d-384e-4583-97fe-552dafd42b9c">904,143</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMjgtNC0xLTEtMA_1818ad59-4132-4e7a-80c8-66ac2ccfc1a2">1,029,452</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjE1M2IzZmQzY2Y1ZDRkMzI4ZmE0ZWU1ZmZhNjBhOWFkXzkzNDU4NDg4MzYzMzM_e4a7a2fe-76ea-4378-a856-7ed013388280">0.001</ix:nonFraction> par value. Authorized <ix:nonFraction unitRef="shares" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjE1M2IzZmQzY2Y1ZDRkMzI4ZmE0ZWU1ZmZhNjBhOWFkXzkzNDU4NDg4MzYzMjY_f33fdf9d-d8f5-4b47-baa9-46cba750ccd5">125,000,000</ix:nonFraction> shares; issued and outstanding&#160;<ix:nonFraction unitRef="shares" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjE1M2IzZmQzY2Y1ZDRkMzI4ZmE0ZWU1ZmZhNjBhOWFkXzkzNDU4NDg4MzYzNzE_ea607410-5204-43ce-a40c-474b2dcf2009">67,240,679</ix:nonFraction> shares at June 30, 2020. Authorized <ix:nonFraction unitRef="shares" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjE1M2IzZmQzY2Y1ZDRkMzI4ZmE0ZWU1ZmZhNjBhOWFkXzkzNDU4NDg4MzYzNDc_61df78d7-c36e-4b60-9cc0-7199ae8782a4">125,000,000</ix:nonFraction> shares; issued and&#160;outstanding <ix:nonFraction unitRef="shares" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjE1M2IzZmQzY2Y1ZDRkMzI4ZmE0ZWU1ZmZhNjBhOWFkXzkzNDU4NDg4MzYzNTk_bfde2791-a766-47da-b161-d11a486fbc76">61,935,870</ix:nonFraction> shares at December&#160;31, 2019.</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMzAtMi0xLTEtMA_eb1a72e4-92a0-4556-984c-740f4cb83ca5">67</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMzAtNC0xLTEtMA_eed0fe19-b40b-4461-91f0-cea5cc03a2ee">62</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:6.75pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional paid-in capital</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMzEtMi0xLTEtMA_d3a17ddf-b9fe-412a-a491-257e9b42186f">2,067,274</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMzEtNC0xLTEtMA_bd57c09f-1e50-42dc-a9ff-50a1c2aac696">1,795,351</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:6.75pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMzItMi0xLTEtMA_90dc67ab-23d4-454d-86ba-099c9094b060">10,016</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMzItNC0xLTEtMA_782281dd-5606-4980-94f6-60ae41698111">10,584</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:6.75pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMzMtMi0xLTEtMA_7a77db56-f8f2-4ac6-94df-c8d53327cdba">1,484,831</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMzMtNC0xLTEtMA_0c85572c-0d15-47ca-8aad-097b2861824e">1,190,499</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:6.75pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMzQtMi0xLTEtMA_8e8e4ce4-cdae-4ea5-8810-6e99f28a774c">572,494</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMzQtNC0xLTEtMA_40f82721-417d-4682-ba4c-24dd6dd8f4fd">594,330</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMzUtMi0xLTEtMA_7b03c47a-fa2b-40af-a6fa-8e3ea58bae91">1,476,637</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMzUtNC0xLTEtMA_51086afe-a306-4b75-bf0d-161d65cfe2ab">1,623,782</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See accompanying unaudited notes.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4</span></div></div></div><div id="i95cf61a5c7074910ae3cf29c5ee08838_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PTC Therapeutics,&#160;Inc.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Consolidated Statements of Operations (unaudited)</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">In thousands (except shares and per share data)</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:45.953%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.035%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.035%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.526%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.531%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net product revenue</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i45814e0e64094044a82fcf8bbad4c123_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMy0yLTEtMS0w_77950a34-3447-4315-9fce-761994118b2f">75,239</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i80823282f4634ae8844d0174883b097c_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMy00LTEtMS0w_e20aa6bf-3ba8-4240-a250-99fef9f159ad">85,476</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3c2dcea8d5894a6aaba983f5a911388c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMy02LTEtMS0w_71d487ce-8914-4ec1-abb5-ac26755f8daf">143,435</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd94b62990744751ae48321dad1d6eab_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMy04LTEtMS0w_eedbac3e-319a-4fce-ae79-51a5e11cafab">138,530</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Collaboration and grant revenue</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1856787732484c15a0bc9dd59846d7df_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfNC0yLTEtMS0w_4b6163cf-d261-4be8-bec1-c24bcec47d4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i31e4fee5acef46b09a3f7ab4d447b758_D20190401-20190630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfNC00LTEtMS0w_86c5aa9c-be64-4bf0-aaad-9beb4e062e8f">46</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia37e22b92f244d44941f5498dd31a614_D20200101-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfNC02LTEtMS0w_ba719783-8a40-4290-a9da-693e1df3cd5a">63</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i846b2660ee9a46aa8e191f0a79737479_D20190101-20190630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfNC04LTEtMS0w_42e2a0ce-f744-496d-aca2-3590d2f09712">575</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfNS0yLTEtMS0w_59a0a5f4-a4e0-4694-9349-2934746ffcde">75,239</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfNS00LTEtMS0w_9f72e5f7-9809-4e3b-9a82-80261c128dcb">85,522</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfNS02LTEtMS0w_8867d62e-ea5b-4c67-979a-661c7526d7de">143,498</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfNS04LTEtMS0w_97325daf-43f8-43a5-91a5-3f702ef8d436">139,105</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of product sales, excluding amortization of acquired intangible assets</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="ptct:CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfNy0yLTEtMS0w_416bde12-a1e4-49e9-a2b6-738e9042d2e6">5,304</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="ptct:CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfNy00LTEtMS0w_7fcb60e5-53f5-4fea-abb2-97c468a43c09">3,211</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="ptct:CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfNy02LTEtMS0w_145b6507-f29f-4ba1-833a-682f3585b4a1">9,389</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="ptct:CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfNy04LTEtMS0w_3e75a9b2-bd9b-41b3-a616-7320497e6840">5,587</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of acquired intangible assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfOC0yLTEtMS0w_0e20d2ef-d2a6-45e1-aa2b-31bfe79810ae">8,731</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfOC00LTEtMS0w_57ceb3df-b42e-4b63-8bc8-3bd61d22af79">6,575</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfOC02LTEtMS0w_50cc4106-32c4-4945-937d-cd80718ed4ab">16,679</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfOC04LTEtMS0w_19b6dd5a-df96-403b-9b61-2e11f4b47e2e">12,652</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfOS0yLTEtMS0w_d4449995-7252-4ecf-a3c0-f65cbff9d40e">176,525</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfOS00LTEtMS0w_f14155cb-bb7b-48c1-8dd1-defae8eff7a9">59,979</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfOS02LTEtMS0w_a8b118f0-f3d8-4b62-9c28-602a1c074de4">266,632</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfOS04LTEtMS0w_e1caafc7-fa7a-4a5b-b496-95808d714a34">112,544</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTAtMi0xLTEtMA_8d554cd0-677e-48a3-b640-3e93631a2dfb">53,659</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTAtNC0xLTEtMA_bd260256-2fa1-4a72-9598-2e50b99dbb02">49,215</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTAtNi0xLTEtMA_6e8463bb-e2a0-424d-84f7-4b6c517b04a5">111,869</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTAtOC0xLTEtMA_16422856-0b64-4e5e-b9c4-3a77546db3a1">89,760</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:4.5pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in the fair value of deferred and contingent consideration  </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTEtMi0xLTEtMA_b73fa5a5-0b9c-42b1-8e19-6b8f1651e993">7,680</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTEtNC0xLTEtMA_8d9d2488-cc54-47e1-a626-d23ffd866c20">5,300</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTEtNi0xLTEtMA_81231436-a7c8-4767-b79c-18857a355c1e">8,580</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTEtOC0xLTEtMA_1465da65-ff67-4564-b59e-5b636d1a1180">26,460</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;Settlement of deferred and contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="ptct:SettlementOfDeferredAndContingentConsideration" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTItMi0xLTEtMzMwNA_8d043207-259d-4f53-ad14-92a3732af50b">10,613</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="ptct:SettlementOfDeferredAndContingentConsideration" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTItNC0xLTEtMzMwNA_2bf2cbf9-a229-4cb0-aaf2-fd6f5a0276b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="ptct:SettlementOfDeferredAndContingentConsideration" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTItNi0xLTEtMzMwNA_324b3904-d1fc-467b-875e-34423df0e152">10,613</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="ptct:SettlementOfDeferredAndContingentConsideration" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTItOC0xLTEtMzMwNA_c62f6317-c122-4533-b04c-4cbf2d079719">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTItMi0xLTEtMA_94c7f0dc-f848-49cb-9ab4-cedc6151951f">262,512</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTItNC0xLTEtMA_59b8b125-4064-4269-8831-cd30aca7df7b">124,280</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTItNi0xLTEtMA_00952990-e32c-4543-a869-dc7d857505e1">423,762</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTItOC0xLTEtMA_11782fda-1390-4c2d-bd1f-877e3d4da481">247,003</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTMtMi0xLTEtMA_49d3f104-f446-44b0-8e8c-07dea3e6e8c5">187,273</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTMtNC0xLTEtMA_6663a041-b9c8-4e69-bfa8-644cc9c6319f">38,758</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTMtNi0xLTEtMA_22ef4b0d-1852-4390-a5c5-a793a72df5d8">280,264</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTMtOC0xLTEtMA_b24ddabb-d8b3-4340-82ba-662fa33203c7">107,898</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTQtMi0xLTEtMA_1879a58b-e8b8-484a-8206-ba524c0c68b6">5,379</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTQtNC0xLTEtMA_b6376e85-eb80-4da0-82bd-9db56edb920a">2,074</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTQtNi0xLTEtMA_69ecc715-1dc4-48ea-9e51-a36a1b96a41c">11,021</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTQtOC0xLTEtMA_ba3e37b5-4229-4ab0-97da-853f547e2135">4,362</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense), net</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTUtMi0xLTEtMA_d71f264b-b566-4bab-874d-d47e52f6074f">11,309</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTUtNC0xLTEtMA_47cc953d-aef4-4fd8-8ae5-16d675ce3670">183</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTUtNi0xLTEtMA_ec4d00dc-eae9-463f-b7e8-172919f9b43b">2,523</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTUtOC0xLTEtMA_30f19847-1e20-4feb-95ce-c5dd24aef75f">292</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss before income tax expense</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTYtMi0xLTEtMA_4068b490-f917-495d-a98a-78add44babc4">181,343</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTYtNC0xLTEtMA_aa25eefb-58a3-4c82-b06f-b4e6fb9c5577">41,015</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTYtNi0xLTEtMA_c24f2f3b-9fc8-48a3-866d-62aa2cb3ef22">293,808</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTYtOC0xLTEtMA_f938a986-007e-49fb-a8d0-42608d65e3cc">112,552</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTctMi0xLTEtMA_9e6843fd-488a-4f1a-8aea-16a3ac7f6e8d">84</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTctNC0xLTEtMA_273e9a6f-b19b-4d0a-b367-8aa74eb25286">774</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTctNi0xLTEtMA_461d866d-6744-4bd7-beb1-254c37f7994f">306</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTctOC0xLTEtMA_91aefe07-2b2b-4706-828d-82f4ca60d5eb">1,350</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTgtMi0xLTEtMA_582392a0-bef3-4f16-8c26-361e301e72c6">181,427</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTgtNC0xLTEtMA_8505bb56-ba78-4133-bcea-bfc9c9f1057b">41,789</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTgtNi0xLTEtMA_faefabd0-25d5-4812-a85c-f40f81016d08">294,114</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTgtOC0xLTEtMA_4e639c0d-513d-47ea-b492-04474a9c0333">113,902</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted (in shares)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMjEtMi0xLTEtMA_a8fad56e-88be-429e-bdab-82546ff35a18">65,150,780</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMjEtNC0xLTEtMA_8ed598a8-17ac-4a1a-abff-995bf73e9924">55,912,748</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMjEtNi0xLTEtMA_4bc33011-aea5-4ea0-94e1-b2dfa8ca5731">63,769,958</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMjEtOC0xLTEtMA_eb1fef99-dd70-4ff2-baf0-1dd868bd0ad1">57,113,141</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss per share&#8212;basic and diluted (in dollars per share)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMjItMi0xLTEtMA_903677c7-9807-4c5b-8d8d-7bf814a20c5c">2.78</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMjItNC0xLTEtMA_40f89379-1c18-4824-8f31-e6f3173dd47d">0.75</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMjItNi0xLTEtMA_a0ce7fa1-ad23-477d-9c0c-6fc2957dca24">4.61</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMjItOC0xLTEtMA_623c9d87-d5e6-431d-a880-7dc38c30ea84">1.99</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See accompanying unaudited notes.</span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5</span></div></div></div><div id="i95cf61a5c7074910ae3cf29c5ee08838_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PTC Therapeutics,&#160;Inc.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Consolidated Statements of Comprehensive Loss (unaudited)</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">In thousands</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.152%;"><tr><td style="width:1.0%;"></td><td style="width:50.018%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.576%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.180%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.576%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.335%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.576%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.180%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.576%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.183%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yOC9mcmFnOmM2NGVlMTEyOGExMDRjZTJiNTI4YjBiODk2OWI1MDE1L3RhYmxlOjJmNzA4ODA0N2ZhNTQxMjJhNjhjODc2ZjY0MTVkMGUxL3RhYmxlcmFuZ2U6MmY3MDg4MDQ3ZmE1NDEyMmE2OGM4NzZmNjQxNWQwZTFfMi0yLTEtMS0w_4cc60fe9-2fbb-4ce4-b80b-db3beb2130d2">181,427</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yOC9mcmFnOmM2NGVlMTEyOGExMDRjZTJiNTI4YjBiODk2OWI1MDE1L3RhYmxlOjJmNzA4ODA0N2ZhNTQxMjJhNjhjODc2ZjY0MTVkMGUxL3RhYmxlcmFuZ2U6MmY3MDg4MDQ3ZmE1NDEyMmE2OGM4NzZmNjQxNWQwZTFfMi00LTEtMS0w_4e2d42b9-3b10-4edc-bfc5-877d6074a79e">41,789</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yOC9mcmFnOmM2NGVlMTEyOGExMDRjZTJiNTI4YjBiODk2OWI1MDE1L3RhYmxlOjJmNzA4ODA0N2ZhNTQxMjJhNjhjODc2ZjY0MTVkMGUxL3RhYmxlcmFuZ2U6MmY3MDg4MDQ3ZmE1NDEyMmE2OGM4NzZmNjQxNWQwZTFfMi02LTEtMS0w_2cd7001d-d5a9-454d-b826-160b1eb0cda6">294,114</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yOC9mcmFnOmM2NGVlMTEyOGExMDRjZTJiNTI4YjBiODk2OWI1MDE1L3RhYmxlOjJmNzA4ODA0N2ZhNTQxMjJhNjhjODc2ZjY0MTVkMGUxL3RhYmxlcmFuZ2U6MmY3MDg4MDQ3ZmE1NDEyMmE2OGM4NzZmNjQxNWQwZTFfMi04LTEtMS0w_221da6e6-97b7-4586-88d7-5aee7edd2a99">113,902</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive (loss) income:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized gain on marketable securities, net of tax</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yOC9mcmFnOmM2NGVlMTEyOGExMDRjZTJiNTI4YjBiODk2OWI1MDE1L3RhYmxlOjJmNzA4ODA0N2ZhNTQxMjJhNjhjODc2ZjY0MTVkMGUxL3RhYmxlcmFuZ2U6MmY3MDg4MDQ3ZmE1NDEyMmE2OGM4NzZmNjQxNWQwZTFfNC0yLTEtMS0w_2cbabe54-0905-4d41-abab-91bb17e3f3b8">2,718</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yOC9mcmFnOmM2NGVlMTEyOGExMDRjZTJiNTI4YjBiODk2OWI1MDE1L3RhYmxlOjJmNzA4ODA0N2ZhNTQxMjJhNjhjODc2ZjY0MTVkMGUxL3RhYmxlcmFuZ2U6MmY3MDg4MDQ3ZmE1NDEyMmE2OGM4NzZmNjQxNWQwZTFfNC00LTEtMS0w_39d52d9e-3efd-4921-9d60-d0adeb800dae">839</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yOC9mcmFnOmM2NGVlMTEyOGExMDRjZTJiNTI4YjBiODk2OWI1MDE1L3RhYmxlOjJmNzA4ODA0N2ZhNTQxMjJhNjhjODc2ZjY0MTVkMGUxL3RhYmxlcmFuZ2U6MmY3MDg4MDQ3ZmE1NDEyMmE2OGM4NzZmNjQxNWQwZTFfNC02LTEtMS0w_010ecdb7-c45d-4f44-87d8-5c5b9531c3d7">2,655</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yOC9mcmFnOmM2NGVlMTEyOGExMDRjZTJiNTI4YjBiODk2OWI1MDE1L3RhYmxlOjJmNzA4ODA0N2ZhNTQxMjJhNjhjODc2ZjY0MTVkMGUxL3RhYmxlcmFuZ2U6MmY3MDg4MDQ3ZmE1NDEyMmE2OGM4NzZmNjQxNWQwZTFfNC04LTEtMS0w_cd0c15a8-44e6-4174-808c-229b68ed9a75">898</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency translation (loss) gain, net of tax</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yOC9mcmFnOmM2NGVlMTEyOGExMDRjZTJiNTI4YjBiODk2OWI1MDE1L3RhYmxlOjJmNzA4ODA0N2ZhNTQxMjJhNjhjODc2ZjY0MTVkMGUxL3RhYmxlcmFuZ2U6MmY3MDg4MDQ3ZmE1NDEyMmE2OGM4NzZmNjQxNWQwZTFfNS0yLTEtMS0w_90eb952a-8ffd-4cbb-8c33-534ced4ce459">10,749</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yOC9mcmFnOmM2NGVlMTEyOGExMDRjZTJiNTI4YjBiODk2OWI1MDE1L3RhYmxlOjJmNzA4ODA0N2ZhNTQxMjJhNjhjODc2ZjY0MTVkMGUxL3RhYmxlcmFuZ2U6MmY3MDg4MDQ3ZmE1NDEyMmE2OGM4NzZmNjQxNWQwZTFfNS00LTEtMS0w_440ca2ee-1109-4ee2-b719-ef748fd795f7">278</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yOC9mcmFnOmM2NGVlMTEyOGExMDRjZTJiNTI4YjBiODk2OWI1MDE1L3RhYmxlOjJmNzA4ODA0N2ZhNTQxMjJhNjhjODc2ZjY0MTVkMGUxL3RhYmxlcmFuZ2U6MmY3MDg4MDQ3ZmE1NDEyMmE2OGM4NzZmNjQxNWQwZTFfNS02LTEtMS0w_173c9639-76d1-4726-a45e-f99b8e73ea97">2,087</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yOC9mcmFnOmM2NGVlMTEyOGExMDRjZTJiNTI4YjBiODk2OWI1MDE1L3RhYmxlOjJmNzA4ODA0N2ZhNTQxMjJhNjhjODc2ZjY0MTVkMGUxL3RhYmxlcmFuZ2U6MmY3MDg4MDQ3ZmE1NDEyMmE2OGM4NzZmNjQxNWQwZTFfNS04LTEtMS0w_74d1edea-0dd1-41e0-95ad-7d639c25372b">438</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yOC9mcmFnOmM2NGVlMTEyOGExMDRjZTJiNTI4YjBiODk2OWI1MDE1L3RhYmxlOjJmNzA4ODA0N2ZhNTQxMjJhNjhjODc2ZjY0MTVkMGUxL3RhYmxlcmFuZ2U6MmY3MDg4MDQ3ZmE1NDEyMmE2OGM4NzZmNjQxNWQwZTFfNi0yLTEtMS0w_2068ff36-45cd-4f6f-b04c-7a4ea8587991">189,458</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yOC9mcmFnOmM2NGVlMTEyOGExMDRjZTJiNTI4YjBiODk2OWI1MDE1L3RhYmxlOjJmNzA4ODA0N2ZhNTQxMjJhNjhjODc2ZjY0MTVkMGUxL3RhYmxlcmFuZ2U6MmY3MDg4MDQ3ZmE1NDEyMmE2OGM4NzZmNjQxNWQwZTFfNi00LTEtMS0w_f371208a-df8d-41fd-92ce-80a0ae5bfab0">40,672</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yOC9mcmFnOmM2NGVlMTEyOGExMDRjZTJiNTI4YjBiODk2OWI1MDE1L3RhYmxlOjJmNzA4ODA0N2ZhNTQxMjJhNjhjODc2ZjY0MTVkMGUxL3RhYmxlcmFuZ2U6MmY3MDg4MDQ3ZmE1NDEyMmE2OGM4NzZmNjQxNWQwZTFfNi02LTEtMS0w_1a585871-6556-4d4b-a942-1a43db3110ac">293,546</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yOC9mcmFnOmM2NGVlMTEyOGExMDRjZTJiNTI4YjBiODk2OWI1MDE1L3RhYmxlOjJmNzA4ODA0N2ZhNTQxMjJhNjhjODc2ZjY0MTVkMGUxL3RhYmxlcmFuZ2U6MmY3MDg4MDQ3ZmE1NDEyMmE2OGM4NzZmNjQxNWQwZTFfNi04LTEtMS0w_6869036c-5c59-4fb5-8051-bba9f6083fa5">113,442</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See accompanying unaudited notes.</span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">6</span></div></div></div><div id="i95cf61a5c7074910ae3cf29c5ee08838_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PTC Therapeutics,&#160;Inc.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Consolidated Statements of Stockholders' Equity (unaudited)</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">In thousands (except shares)</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> </span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:35.134%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.210%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.771%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.502%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.111%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.087%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.535%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Three months ended June 30, 2020</span></div></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>other<br/>comprehensive (loss) income</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>deficit</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total<br/>stockholders&#8217;<br/>equity</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ieec6c9a44e1a4fa0b02c65d76e099de2_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfMi0xLTEtMS0w_f2e9ebfd-1ea6-4489-9116-6ff945098026">62,758,520</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieec6c9a44e1a4fa0b02c65d76e099de2_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfMi0zLTEtMS0w_dcb0b5b5-350c-4653-b9b7-fa3e1eef30d6">62</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2217d6be0da04b3c9aa7801351f5b23f_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfMi01LTEtMS0w_811fe209-6782-4612-94b6-199acb3203f3">1,834,061</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic903ce63d61344bb93ea8a3c7cd2e5fd_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfMi03LTEtMS0w_f2901897-2be8-41c4-a072-5fd725eaa42a">1,985</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5f5abb3d22174bc5baaf5959060f4f75_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfMi05LTEtMS0w_ccf2e1ad-bcb6-4dfb-afa6-32dd5939b15a">1,303,404</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb8114d4f418487782c0740ca1ed1bfc_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfMi0xMS0xLTEtMA_07adaf8d-c8d8-468a-93da-fa75d3a8238d">528,734</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock related to equity offering</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib2522e73523e4feda4f9fd68c9be8c32_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfNC0xLTEtMS0w_7fb2a93b-6232-42a7-8696-422163fcaad2">106,309</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib2522e73523e4feda4f9fd68c9be8c32_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfNC0zLTEtMS0w_1515fb60-bcfb-42db-90ad-af98fb25b5a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic3ffc2fc75914fddbf65e6f5960bc8d5_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfNC01LTEtMS0w_38b9b958-8a4b-47a6-81f8-b13937b706c1">5,447</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfNC0xMS0xLTEtMA_c018318d-3873-41fd-b833-f07c88d97c37">5,447</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock related to acquisition</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib2522e73523e4feda4f9fd68c9be8c32_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfNi0xLTEtMS0yMDYw_55e45da4-c73f-40e9-a117-eb699e289ec5">845,364</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib2522e73523e4feda4f9fd68c9be8c32_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfNi0zLTEtMS0yMDYw_977eb3ff-e8a2-47ef-90f5-ebad31eb9a48">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic3ffc2fc75914fddbf65e6f5960bc8d5_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfNi01LTEtMS0yMDYw_77ce7770-a311-4c80-957f-082d0313a8dd">42,868</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfNi0xMS0xLTEtMjA2MA_4dac51fc-3b2b-45dd-8cc9-7de12ff5d0d0">42,869</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock related to rights exchange</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib2522e73523e4feda4f9fd68c9be8c32_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="ptct:StockIssuedDuringPeriodSharesExchangeRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfNy0xLTEtMS02ODgz_344f5e7f-1710-445e-a886-f0e1d1914054">2,821,176</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib2522e73523e4feda4f9fd68c9be8c32_D20200401-20200630" decimals="-3" name="ptct:StockIssuedDuringPeriodValueExchangeRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfNy0zLTEtMS0yNTI0_8085dca6-95ef-4302-a143-51f504caae58">3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic3ffc2fc75914fddbf65e6f5960bc8d5_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="ptct:StockIssuedDuringPeriodValueExchangeRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfNy01LTEtMS0yNTI0_03495ac0-113f-481d-8c08-001495ae06d8">150,525</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="ptct:StockIssuedDuringPeriodValueExchangeRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfNy0xMS0xLTEtMjUyNA_5f68144d-255b-4772-a021-0b738f24f7f3">150,528</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise of options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib2522e73523e4feda4f9fd68c9be8c32_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfNy0xLTEtMS0w_cac02e9a-1e67-48e5-9bac-f77b4193e115">654,604</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib2522e73523e4feda4f9fd68c9be8c32_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfNy0zLTEtMS0w_cbd0c577-9134-4568-9762-0256bc611256">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic3ffc2fc75914fddbf65e6f5960bc8d5_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfNy01LTEtMS0w_16fa1798-4eac-42fb-83ae-830084d87b0f">15,057</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfNy0xMS0xLTEtMA_7f921303-193b-4d87-b272-4a2e65e45337">15,058</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock vesting and issuance, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="ib2522e73523e4feda4f9fd68c9be8c32_D20200401-20200630" decimals="INF" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfOC0xLTEtMS0w_87a14ad2-a1ed-4026-85e9-1f2b05c72bd3">3,985</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfOC0xMS0xLTEtMA_c0c93f51-5575-4938-b4d5-bdbbfd297a83">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock in connection with an employee stock purchase plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib2522e73523e4feda4f9fd68c9be8c32_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfMTAtMS0xLTEtMjA2MA_135c5d00-f91a-4b44-a629-f23042de973f">58,691</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib2522e73523e4feda4f9fd68c9be8c32_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfMTAtMy0xLTEtMjA2MA_8fd5b248-654c-42ef-afda-047273c2e065">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic3ffc2fc75914fddbf65e6f5960bc8d5_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfMTAtNS0xLTEtMjA2MA_8019bfa7-e252-45aa-98cf-e5a29e1a1b7c">2,406</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfMTAtMTEtMS0xLTIwNjA_9ada32c6-2ed7-408a-9417-f6f13e19e7fc">2,406</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic3ffc2fc75914fddbf65e6f5960bc8d5_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfMTEtNS0xLTEtMjA2MA_50b5db7b-4780-4e95-b9db-da41fb1c9888">16,910</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfMTEtMTEtMS0xLTIwNjA_4bad3cb6-c5cc-4308-8890-92666ab7b409">16,910</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfMTMtOS0xLTEtMA_8842f6d1-aae2-4793-8989-829682caf12f">181,427</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfMTMtMTEtMS0xLTA_fb6dfde5-208e-4718-b255-00b02233922f">181,427</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Comprehensive loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i85184b2a023d436aae89f6d066cfbfec_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfMTQtNy0xLTEtMA_0d0e7504-17da-40f3-bfae-64120b59149a">8,031</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfMTQtMTEtMS0xLTA_886c7099-1b5c-4645-882e-437e2a376268">8,031</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, June 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i533ee7ba976f46e396724aba128c444e_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfMTUtMS0xLTEtMA_14f4b538-4a82-460d-909a-b3cb84f1b15a">67,240,679</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i533ee7ba976f46e396724aba128c444e_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfMTUtMy0xLTEtMA_9ecdda58-76e5-4293-b300-e8f4498103ad">67</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie459585656ec4c888bad0072cb787216_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfMTUtNS0xLTEtMA_f0fe2ee2-b693-4a54-ad91-fcfeb066e991">2,067,274</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if99a5f5b88c44e239963a271d78fd4d0_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfMTUtNy0xLTEtMA_51ef3599-85ef-4f33-a1af-be07b469f24d">10,016</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib08418efd9054e53865f0aad58f50b9d_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfMTUtOS0xLTEtMA_15d63434-2e5c-4d95-86d4-07d3cde56a00">1,484,831</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfMTUtMTEtMS0xLTA_d0bca0ba-83da-4d4b-a935-a9c73291a37d">572,494</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:34.857%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.251%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.810%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.544%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.160%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.132%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.576%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Three months ended June 30, 2019</span></div></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>other<br/>comprehensive<br/>income (loss)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>deficit</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total<br/>stockholders&#8217;<br/>equity</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, March 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i94b08961287e4bd28403b18fb27d1ef3_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfMi0xLTEtMS0w_36035ac6-be8c-445f-b674-9b3ef74add7c">58,418,790</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i94b08961287e4bd28403b18fb27d1ef3_I20190331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfMi0zLTEtMS0w_5cb3760d-21ca-4edb-bb5d-8e6fe1144663">58</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2e93050dc1a94baf9a24faf44c845fc2_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfMi01LTEtMS0w_d984ca3f-d6db-4edd-8cd7-a6d4e4d94be0">1,523,115</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9ff2de3d9580494aa4f84424a72b83aa_I20190331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfMi03LTEtMS0w_8172c6b3-b339-42f3-8e64-e019c24bc8af">805</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i930a0deb5fe14f56b2dfe784709c3a46_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfMi05LTEtMS0w_740b9f05-73c9-44aa-9b01-a7bb6c70f86b">1,011,036</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id107e0ac152043d8b3217fec423c7ff5_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfMi0xMS0xLTEtMA_5abf8771-8f65-49ce-a5fa-1e8b88ef778f">512,942</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock related to equity offering</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iaa534d8c4a3b44998ead7885db0ad530_D20190401-20190630" decimals="INF" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfMy0xLTEtMS0xOTY4_e4aa45cd-8936-4f84-96d7-131d655831a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaa534d8c4a3b44998ead7885db0ad530_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfMy0zLTEtMS0xOTc0_df446879-0659-476f-9cf4-9ea96f7bd698">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42fbe8f0476c44e48fe505660057da1a_D20190401-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfMy01LTEtMS0xOTk0_d8c646c8-26e7-4bfe-8e68-042e7e98312c">106</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfMy0xMS0xLTEtMjAxMw_b0fe8603-7097-4f4b-a695-11d37671a2e7">106</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise of options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iaa534d8c4a3b44998ead7885db0ad530_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfNC0xLTEtMS0w_19b6b8a4-29ec-485d-b072-ca5a472bab25">230,176</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42fbe8f0476c44e48fe505660057da1a_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfNC01LTEtMS0w_10013fee-0f5c-4d7c-8d82-faa0efe11bf1">2,847</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfNC0xMS0xLTEtMA_d190f108-ba60-4f1b-b99a-bbeadcac900f">2,847</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock vesting and issuance, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iaa534d8c4a3b44998ead7885db0ad530_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfNy0xLTEtMS0w_8e892401-3d0c-4f35-9c46-d19e40baa043">3,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfNy0xMS0xLTEtMA_7677c1e2-a5b5-47dd-a59f-755371c665f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock in connection with an employee stock purchase plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iaa534d8c4a3b44998ead7885db0ad530_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfOC0xLTEtMS0w_d258d153-7dee-496a-951b-f861dfc2c470">54,719</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaa534d8c4a3b44998ead7885db0ad530_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfOC0zLTEtMS0w_b6868a36-e9f8-4865-a7eb-4a1af0fd8837">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42fbe8f0476c44e48fe505660057da1a_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfOC01LTEtMS0w_e93e485b-8603-4cb0-b5f9-70f30bce421b">1,564</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfOC0xMS0xLTEtMA_ef8cad18-b2de-499c-ba15-2ec1ef0632bb">1,564</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42fbe8f0476c44e48fe505660057da1a_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfOS01LTEtMS0w_28fea305-4ed1-44ba-8af7-7df380ea1829">10,920</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfOS0xMS0xLTEtMA_fc4a4dd1-2016-4541-ad21-6e499f6c049c">10,920</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Receivable from investor</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42fbe8f0476c44e48fe505660057da1a_D20190401-20190630" decimals="-3" name="ptct:AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfOC01LTEtMS0xOTk0_34eb79fe-152f-40f1-ac36-5d1822758e27">978</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630" decimals="-3" name="ptct:AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfMTAtMTEtMS0xLTA_e2d6c9ed-bba7-4d80-ab99-3b75fa0f1821">978</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6ae47019f2ba40a8aefbc1d239cdc94b_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfMTEtOS0xLTEtMA_2cad0b29-b5e9-48ed-9c64-9e0ae30c2cfa">41,789</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfMTEtMTEtMS0xLTA_24aacd74-ddb2-4f26-bf7a-438efad93b8c">41,789</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Comprehensive income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icfcb85f561bb41318c256dcacaf6a1a2_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfMTItNy0xLTEtMA_cf71f8ac-330f-42d4-a4fc-a9cdc550a4ea">1,117</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfMTItMTEtMS0xLTA_65ac12d5-8f28-4cf1-a52b-f23a7d5e99e9">1,117</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, June 30, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i289d8cdd90cd4be0a90a0932fe6572f6_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfMTMtMS0xLTEtMA_c82bf398-1146-4663-b2c2-02c511e67a27">58,707,185</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i289d8cdd90cd4be0a90a0932fe6572f6_I20190630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfMTMtMy0xLTEtMA_cc61b53c-8607-47c6-8497-9c3b6bda0eb6">58</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id81dc5f706a14ac69c50d7c1adccc558_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfMTMtNS0xLTEtMA_2349c0b1-d349-40b4-9b00-d98cd35d0d7e">1,539,530</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5628af8116db4f9a9c32020225574c39_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfMTMtNy0xLTEtMA_5b35455e-13d0-489d-9864-bfc905da5958">1,922</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifeea6088e2ed4f849936ae7bdd7cbcfd_I20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfMTMtOS0xLTEtMA_17806d18-8b7e-47d4-b241-d035d10e5438">1,052,825</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i28563c013fff4be6aba8b90a75baf135_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfMTMtMTEtMS0xLTA_397ca147-fd0f-48db-829c-dc2e22b17b4b">488,685</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:34.857%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.251%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.810%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.544%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.160%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.132%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.576%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:34.988%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.233%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.795%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.333%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.111%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.941%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.095%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30, 2020</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional paid-in capital</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated other comprehensive (loss) income</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stockholders&#8217; equity</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i6416f0fda976465288b8a99fee841a11_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfMi0xLTEtMS0yMDgw_0a80e41a-0ffe-4f28-a914-731c9ec1528d">61,935,870</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6416f0fda976465288b8a99fee841a11_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfMi0zLTEtMS0yMDgw_3cda82f2-68de-426b-babb-03005003bbf3">62</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0c24f8e9d344416dbdacd07f1624ad0c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfMi01LTEtMS0yMDgw_cb9a88f7-260d-41e2-9aae-83f58e0468e3">1,795,351</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iebab310c097741efb22ea6ccc61c24b1_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfMi03LTEtMS0yMDgw_c606efa2-b7b7-440d-978c-7ffda2ccfe8f">10,584</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if79b05d131bf402dac7e50420745aeff_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfMi05LTEtMS0yMDgw_82c37f3e-c36e-4307-b5be-f793b68df169">1,190,499</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfMi0xMS0xLTEtMjA4MA_6c571f13-fb85-4e5d-93c2-ab9e82fa90be">594,330</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock related to equity offering</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i9e33cecb164a48a0aa1eba2f1728140b_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfNC0xLTEtMS0yMDgw_929f147b-7ed8-4a91-9bf4-90bf802995ce">368,514</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e33cecb164a48a0aa1eba2f1728140b_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfNC0zLTEtMS0yMDgw_97bc3fe1-ef09-4766-a502-5b64e25275b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3b35f4ed68ad4e4d905a31fd652afbca_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfNC01LTEtMS0yMDgw_f385c5eb-9023-48ca-8501-a403a1ecfee6">18,950</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfNC0xMS0xLTEtMjA4MA_a82ca02f-8a61-403c-936b-da4277522367">18,950</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock related to acquisition</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i9e33cecb164a48a0aa1eba2f1728140b_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfNi0xLTEtMS0yMDgw_a4b34432-a48b-45bd-bb4f-73454421d049">845,364</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e33cecb164a48a0aa1eba2f1728140b_D20200101-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfNi0zLTEtMS0yMDgw_e315c953-f79b-4e24-9f34-5af1e7c4a0bb">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3b35f4ed68ad4e4d905a31fd652afbca_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfNi01LTEtMS0yMDgw_bd3ed5e2-0d24-4295-b9dc-2cbd4364a425">42,868</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfNi0xMS0xLTEtMjA4MA_0dba8b05-6b8e-4167-b4c2-5558635f1037">42,869</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock related to rights exchange</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i9e33cecb164a48a0aa1eba2f1728140b_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="ptct:StockIssuedDuringPeriodSharesExchangeRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfNy0xLTEtMS0yNTQz_fe43a1f4-28c7-416e-a7c6-928eb19a390c">2,821,176</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e33cecb164a48a0aa1eba2f1728140b_D20200101-20200630" decimals="-3" name="ptct:StockIssuedDuringPeriodValueExchangeRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfNy0zLTEtMS0yNTQz_82790385-2a3e-4f5c-b135-6e0cefcff4d8">3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3b35f4ed68ad4e4d905a31fd652afbca_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="ptct:StockIssuedDuringPeriodValueExchangeRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfNy01LTEtMS0yNTQz_4b213611-12db-4352-b19f-aff321f47c9a">150,525</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="ptct:StockIssuedDuringPeriodValueExchangeRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfNy0xMS0xLTEtMjU0Mw_c8d3a3d9-f7be-48a9-8135-be0d2ae86686">150,528</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise of options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i9e33cecb164a48a0aa1eba2f1728140b_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfNy0xLTEtMS0yMDgw_2bc7ec48-6b2e-4a17-b481-ce2fe4c623e4">1,034,288</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e33cecb164a48a0aa1eba2f1728140b_D20200101-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfNy0zLTEtMS0yMDgw_38b7ed6c-3dd1-4ee4-bec3-fba1901aae4b">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3b35f4ed68ad4e4d905a31fd652afbca_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfNy01LTEtMS0yMDgw_e07720c3-f04d-41cb-9851-82f34d605444">25,044</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfNy0xMS0xLTEtMjA4MA_34bedc9d-c9fb-4d9e-ac52-ce23339ad75f">25,045</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock vesting and issuance, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i9e33cecb164a48a0aa1eba2f1728140b_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfOC0xLTEtMS0yMDgw_3e5f5560-1a10-4c36-8655-87ae1ffdeca8">176,776</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfOC0xMS0xLTEtMjA4MA_0cdd1a98-ac91-4682-9515-47f56b2bb702">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock in connection with an employee stock purchase plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i9e33cecb164a48a0aa1eba2f1728140b_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfOS0xLTEtMS0yMDgw_3de6ec30-3752-4bbe-a80f-d15b78339cb5">58,691</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e33cecb164a48a0aa1eba2f1728140b_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfOS0zLTEtMS0yMDgw_3f6a6fd5-ef3b-4f5d-88be-2484c28b80c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3b35f4ed68ad4e4d905a31fd652afbca_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfOS01LTEtMS0yMDgw_e17d5dc6-c3f0-4dc6-9193-4cb203234a69">2,406</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfOS0xMS0xLTEtMjA4MA_fd01d958-e11c-42a3-b45f-46db039f3e27">2,406</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3b35f4ed68ad4e4d905a31fd652afbca_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfMTAtNS0xLTEtMjA4MA_7fc0d6e6-baa3-4860-9c9d-2d139cffc613">32,130</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfMTAtMTEtMS0xLTIwODA_89203406-4ae6-418a-b97e-9f6e2c958c2e">32,130</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfMTItOS0xLTEtMjU0OQ_f28ab753-fe4e-4a4a-988f-767a9d7acabf">218</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfMTItMTEtMS0xLTI1NDk_4d46cab0-d0d0-4267-9f2e-4c3e2c7fe6dd">218</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i31d6e1bdb5ca471392964fa03ef36c08_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfMTMtOS0xLTEtMjA4MA_44fb51ff-d7e6-409f-a1fc-eeda8559df03">294,114</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfMTMtMTEtMS0xLTIwODA_9fe22c5c-7a4f-4152-8795-3a2a74c43129">294,114</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Comprehensive income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9bff894d600845e29a8c4faf34680df2_D20200101-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfMTQtNy0xLTEtMjA4MA_6e0384da-91b8-427d-a1ca-7144fe019ace">568</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfMTQtMTEtMS0xLTIwODA_ed7f933e-dbdb-4c29-9e8f-7a831ebab126">568</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, June 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i533ee7ba976f46e396724aba128c444e_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfMTUtMS0xLTEtMjA4MA_84f9f4fa-6b51-44f8-b84d-7b6dd46dfb49">67,240,679</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i533ee7ba976f46e396724aba128c444e_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfMTUtMy0xLTEtMjA4MA_94294d91-52b0-4f88-b64b-9e765462530b">67</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie459585656ec4c888bad0072cb787216_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfMTUtNS0xLTEtMjA4MA_2fa51d5f-94b5-4f26-a129-8d18affcf942">2,067,274</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if99a5f5b88c44e239963a271d78fd4d0_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfMTUtNy0xLTEtMjA4MA_b9d6e181-1fab-4fc2-ace9-023043200962">10,016</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib08418efd9054e53865f0aad58f50b9d_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfMTUtOS0xLTEtMjA4MA_8e9bd49d-d28a-408a-8176-aaf44d0c2ced">1,484,831</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfMTUtMTEtMS0xLTIwODA_9b7dbc17-cd4a-4c59-8e3d-4df9ba66b0bf">572,494</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:34.456%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.370%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.638%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.516%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.127%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.102%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.131%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30, 2019</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional paid-in capital</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated other comprehensive income (loss)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stockholders&#8217; equity</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib5972ed6730144a8ae9bdb30fcd5fffd_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfMi0xLTEtMS05NDI_e18ad369-36e0-4e56-b953-e8812bbdecca">50,606,147</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib5972ed6730144a8ae9bdb30fcd5fffd_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfMi0zLTEtMS05ODU_8c82d317-77c4-4eef-b792-8c0582c2a877">51</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib056d8d4512a4814801eaea43e457f5f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfMi01LTEtMS05ODk_7e68bcaf-5573-4e6d-b475-3fbbc241b634">1,288,137</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9d8fb8ff546849248d177b17b67ea09b_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfMi03LTEtMS05OTM_ac75e8bc-1d5a-47a4-90fb-dfb09ff0a392">1,462</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6eadb591f1b34ddaa289055d8b4379c3_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfMi05LTEtMS05OTc_3c1c7425-1e77-4ad5-bef0-45f469f1574c">938,923</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i785bae8d0f37453b828968b15c63b74f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfMi0xMS0xLTEtMTAwMQ_8f7453dd-e480-49fd-af7a-ef7724956c3e">350,727</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock related to equity offering</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4042444983714690acf2456c51c245ff_D20190101-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfNC0xLTEtMS05NTg_8728f80d-c240-4ffc-853d-1de72e39f6a3">7,563,725</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4042444983714690acf2456c51c245ff_D20190101-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfNC0zLTEtMS05ODU_4e4b947a-85a6-441c-aceb-1c86d6bf7e4c">7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ice0e67612cf54d9c91dea97e80e5cbec_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfNC01LTEtMS05ODk_2a8b4d60-7c0d-43f7-877b-597f1cf2dfad">224,538</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfNC0xMS0xLTEtMTAwMQ_1ade9f0c-1504-4d6d-88c5-9f1df5c643f9">224,545</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise of options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4042444983714690acf2456c51c245ff_D20190101-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfNi0xLTEtMS05NTg_075af42e-adc7-410b-b6ea-1f6919c88adc">311,002</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4042444983714690acf2456c51c245ff_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfNi0zLTEtMS05ODU_ac5b07fc-ea14-439c-aea3-c2217fc67f8b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ice0e67612cf54d9c91dea97e80e5cbec_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfNi01LTEtMS05ODk_a52e79c0-a660-4f03-8176-2d94d6ecd1b9">4,129</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfNi0xMS0xLTEtMTAwMQ_22da63d3-dc86-4c84-ab5d-89238f350859">4,129</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock vesting and issuance, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4042444983714690acf2456c51c245ff_D20190101-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfNy0xLTEtMS05NTg_6b302447-42e3-4227-926b-7b2e9935be40">171,592</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfNy0xMS0xLTEtMTAwMQ_97355262-6c92-4aaa-aa6b-32d77869c543">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock in connection with an employee stock purchase plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4042444983714690acf2456c51c245ff_D20190101-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfOC0xLTEtMS05NTg_93c51a2f-0dc5-41f0-9907-adbd89054640">54,719</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4042444983714690acf2456c51c245ff_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfOS0zLTEtMS05ODU_b638f1a0-5a29-4f46-8fad-66059e678007">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ice0e67612cf54d9c91dea97e80e5cbec_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfOS01LTEtMS05ODk_e4bb8063-2c0b-4f0f-86d9-42b33df2d137">1,564</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfOS0xMS0xLTEtMTAwMQ_11c7c0a2-ba1d-4e75-a126-32272f72ea9d">1,564</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ice0e67612cf54d9c91dea97e80e5cbec_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfMTAtNS0xLTEtOTg5_d2c717a4-3f12-4be3-a187-a0c21aca6e4c">20,184</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfMTAtMTEtMS0xLTEwMDE_3b0b40ba-dcf4-4d93-8c1e-d64ebbc64669">20,184</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Receivable from investor</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ice0e67612cf54d9c91dea97e80e5cbec_D20190101-20190630" decimals="-3" name="ptct:AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfMTEtNS0xLTEtOTg5_bc6f2410-af57-4f6e-9f25-f6db755e7997">978</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" name="ptct:AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfMTEtMTEtMS0xLTEwMDE_dd2200c8-6dcd-4d70-bfd1-4f3d3529029a">978</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i27feb6dc967a41579d7c19c8a1cb7e84_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfMTItOS0xLTEtOTk3_9fbe362b-5d4c-4cf5-a4f6-9c17479cd22d">113,902</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfMTItMTEtMS0xLTEwMDE_68ee5d52-c2f9-4f8d-898b-f6a2606da1d8">113,902</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Comprehensive income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i24ef21dbfe234c0591a9b24a236878c6_D20190101-20190630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfMTMtNy0xLTEtOTkz_4dea2be4-1ee7-4895-9ffc-47629e6ee558">460</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfMTMtMTEtMS0xLTEwMDE_43dcb310-3979-4152-821f-9e672bbe43d3">460</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, June 30, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i289d8cdd90cd4be0a90a0932fe6572f6_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfMTMtMS0xLTEtOTU4_f34608bf-1f8b-40a2-8d68-f0e19da14ac7">58,707,185</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i289d8cdd90cd4be0a90a0932fe6572f6_I20190630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfMTQtMy0xLTEtOTg1_6bc38f10-596a-435d-93a2-6e666c97f5ea">58</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id81dc5f706a14ac69c50d7c1adccc558_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfMTQtNS0xLTEtOTg5_4d76cda1-254d-4127-9bc8-29314c6eb8ce">1,539,530</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5628af8116db4f9a9c32020225574c39_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfMTQtNy0xLTEtOTkz_09888f02-dd69-4304-9c70-051de38523c7">1,922</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifeea6088e2ed4f849936ae7bdd7cbcfd_I20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfMTQtOS0xLTEtOTk3_6c79ea74-f073-44a7-b4fe-72ee45e99c22">1,052,825</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i28563c013fff4be6aba8b90a75baf135_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfMTQtMTEtMS0xLTEwMDE_2f415b7e-36c6-4dc7-9247-553cd8beb7dc">488,685</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="36" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">See accompanying unaudited notes.</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">8</span></div></div></div><div id="i95cf61a5c7074910ae3cf29c5ee08838_34"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:68.234%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.076%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.224%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">PTC Therapeutics,&#160;Inc.<br/>Consolidated Statements of Cash Flows (unaudited)                                                   In thousands<br/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNC0yLTEtMS0w_0ab8ea0d-1694-41be-9aac-69f602251509">294,114</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNC00LTEtMS0w_3d77311b-dda9-4cab-82d0-0309deb2c3b2">113,902</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNi0yLTEtMS0w_20acda61-a07d-44c0-a203-a67484818e5f">19,445</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNi00LTEtMS0w_763d730f-1fee-4c00-a6e9-62c0ef240378">14,760</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-cash operating lease expense</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="ptct:OperatingLeaseCostNonCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNy0yLTEtMS0w_2e52a163-ab5a-4634-b8cc-33fda44e3ac9">2,401</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="ptct:OperatingLeaseCostNonCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNy00LTEtMS0w_df0385c6-ae66-4575-aed5-5ba0414bba31">1,256</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-cash finance lease amortization expense</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="ptct:FinanceLeaseCostNonCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfOC0yLTEtMS03Njkx_86db4d12-4e11-4541-a9db-e6030b3ce9c3">41,212</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="ptct:FinanceLeaseCostNonCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfOC00LTEtMS03Njk1_b6f9f719-3b3a-4d94-b6c3-fcb9b15c3074">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in valuation of deferred and contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfOS0yLTEtMS0w_fd3373de-344f-4357-a5f1-32f2d4a3bd60">8,580</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfOS00LTEtMS0w_6be58a22-28ae-4e84-a915-738e2307b23f">26,460</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Settlement of deferred and contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="ptct:SettlementOfDeferredAndContingentConsideration" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMTAtMi0xLTEtMA_d6385f7c-4a92-4fcb-a2ec-b94223b66968">10,613</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="ptct:SettlementOfDeferredAndContingentConsideration" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMTAtNC0xLTEtMA_a3888fc9-0624-4d1e-989a-7d8583571977">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-cash stock consideration, acquisition</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="ptct:SharesIssuedAssetAcquisition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMTEtMi0xLTEtMA_c536bd91-53a2-4669-8a82-7ebfe997c0cb">42,869</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="ptct:SharesIssuedAssetAcquisition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMTEtNC0xLTEtMA_f9953227-34b6-4bd6-b95f-ba7f341d99ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized loss on equity investment</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMTItMi0xLTEtMA_17da5669-e642-4ff9-aae3-609e99aff8c7">1,600</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMTItNC0xLTEtMA_4cb264ac-bdd8-4dcc-b749-6040fd2aba70">129</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized loss on ClearPoint convertible debt security</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" name="ptct:UnrealizedGainLossonConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMTMtMi0xLTEtMA_c72c09b0-875a-450d-bd28-8fe2ac5f88cc">749</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="ptct:UnrealizedGainLossonConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMTMtNC0xLTEtMA_382954fa-6737-4531-b4c2-4063a7bca463">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-cash interest expense</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaidInKindInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMTQtMi0xLTEtMA_ffa6463e-b783-4ee7-bf36-f902763b78c7">10,993</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaidInKindInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMTQtNC0xLTEtMA_0db7809c-589a-4019-87a7-9bf359fed7a3">4,055</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss on disposal of asset</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMTUtMi0xLTEtMA_8f637b57-7c3d-4602-af34-ea411dd806ff">26</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMTUtNC0xLTEtMA_5141bde2-f15e-4c0f-a489-c634ba9002fb">50</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of discounts on investments, net</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMTYtMi0xLTEtMA_0d7b7853-ae4d-4511-998b-71edf9122b29">635</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMTYtNC0xLTEtMA_561f0280-c5df-497c-a05c-462984dce154">907</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMTctMi0xLTEtMA_7403c8d3-4b7d-4943-9b7e-eee412fbd80a">510</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMTctNC0xLTEtMA_224d64eb-1adc-413b-a670-3a3c9b280e03">280</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMTgtMi0xLTEtMA_a4be30bb-709a-47e0-8b96-798e48b79faf">32,130</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMTgtNC0xLTEtMA_5d426425-40b3-4bdc-a9b5-a43e1d6076a9">20,184</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized foreign currency transaction (gains) losses, net</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMjAtMi0xLTEtMA_71a4fb80-f23f-463d-8e99-ce4815ad97e8">3,248</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMjAtNC0xLTEtMA_051c3df4-f827-4af7-836d-d1f8ee1046b4">62</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inventory, net</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMjItMi0xLTEtMA_604bd09c-3f26-4e11-85ec-869cad94f5b8">943</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMjItNC0xLTEtMA_a1d578c4-9da6-4e71-b8fa-e6e07d87e642">852</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMjMtMi0xLTEtMA_f892c2f3-8f5f-4fd4-8c59-00011e814a81">16,569</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMjMtNC0xLTEtMA_fa80ba61-43bc-41e1-afa4-c9950d9f2f99">7,250</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Trade receivables, net</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMjQtMi0xLTEtMA_64345d57-ceca-4bb1-8aed-bff172910241">1,860</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMjQtNC0xLTEtMA_183617b9-499e-42d8-8684-3c1504e270c5">9,702</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deposits and other assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" name="us-gaap:IncreaseDecreaseInDepositOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMjUtMi0xLTEtMzM2Mw_78b76fd8-c177-42af-9d44-0e56d4bf6707">175</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDepositOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMjUtNC0xLTEtMzM2Mw_c12c9f17-0c94-4663-a1d2-fca8184eb507">9,656</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable and accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMjYtMi0xLTEtMzM2Mw_bd8b0c68-9c9c-449c-b4a5-66b9e576c9d5">7,497</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMjYtNC0xLTEtMzM2Mw_e4455306-ce27-45e9-bdd9-76780c45d782">7,546</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMjUtMi0xLTEtMA_b581eb94-fa1c-4f5b-91a2-ea94ff5628ac">4,132</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMjUtNC0xLTEtMA_48a7d2b5-d904-428d-bfd4-8b72dc6f5815">7,395</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMjYtMi0xLTEtMA_9a254b93-4215-4131-a8f2-e3bff3cb8a41">3,925</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMjYtNC0xLTEtMA_a6800787-c243-4eec-b4d1-a50ffe899295">2,511</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMjctMi0xLTEtMA_68009595-50d8-49b3-84cd-b5ed43651259">156,364</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMjctNC0xLTEtMA_ef731f5c-1b6c-4e2c-8b8a-b3e475b13d9e">72,931</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of fixed assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMjktMi0xLTEtMA_b8a449f0-45e8-4211-bd7a-798b156f33e1">8,183</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMjktNC0xLTEtMA_1c978741-b154-4f0c-81ad-e67c33235c7c">4,851</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchase of convertible debt security</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="ptct:PaymentsToAcquireConvertibleDebtInvestment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMzAtMi0xLTEtMA_53439327-ffd5-4522-931e-61c3345be39a">10,000</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="ptct:PaymentsToAcquireConvertibleDebtInvestment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMzAtNC0xLTEtMA_dbb7b049-e64c-4452-b0c3-445654ca8b1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of marketable securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMzEtMi0xLTEtMA_a2c60f64-b4ff-48db-980a-99d6e13d02bb">367,102</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMzEtNC0xLTEtMA_b041975e-81dd-4c27-9c24-e74e811f83c9">226,261</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sale and redemption of marketable securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMzItMi0xLTEtMA_ebaf5ec4-9f79-42a7-a397-41b03e21d0b6">428,490</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMzItNC0xLTEtMA_77fbcaf6-3c52-4520-9628-d49ef6b8ea70">58,424</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquisition of product rights and licenses<br/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMzMtMi0xLTEtMA_23784620-8dc1-4e07-946b-b12cec2e36df">2,422</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMzMtNC0xLTEtMA_0c4ddafd-7899-417a-959e-d81a647e3b08">11,981</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchase of equity investment</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMzQtMi0xLTEtMA_3e45552b-0aae-4250-902f-77b198623285">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMzQtNC0xLTEtMA_c278d908-6a11-4fb1-83f9-550a50f765e6">4,000</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by (used in) investing activities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMzUtMi0xLTEtMA_2442be8a-3f3b-402c-b28d-347d91e0ea1f">40,783</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMzUtNC0xLTEtMA_eb845a89-3073-428f-aa5f-b3ef12c20efd">188,669</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from exercise of options</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMzctMi0xLTEtMA_42e9d20a-81c7-4999-b4be-baa370b5efee">25,045</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMzctNC0xLTEtMA_ba966865-857b-4470-95d8-623fb385fb05">4,129</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net proceeds from public offerings</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMzgtMi0xLTEtMA_f958ff5e-51f3-435e-b244-216d12bbd36c">18,950</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMzgtNC0xLTEtMA_afce5998-2690-4e6a-8d37-eeeb15fff12f">224,545</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Repayment of senior secured term loan</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfSecuredDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMzktMi0xLTEtMA_141c0564-483f-4f32-a82c-98994dc46234">10,000</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfSecuredDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMzktNC0xLTEtMA_57a260ea-738c-4c58-82e5-43529845fdee">1,667</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments on deferred consideration obligation</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="ptct:PaymentsOnDeferredConsiderationObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNDItMi0xLTEtMzM5NQ_c2b3c133-f56d-48ec-b2c8-43805a87e319">35,829</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="ptct:PaymentsOnDeferredConsiderationObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNDItNC0xLTEtMzM5NQ_3fdaeb8a-cae7-40c2-829b-f8cb27b75588">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from employee stock purchase plan</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNDAtMi0xLTEtMA_9d429e55-0aad-4ac8-8e4a-e5f07d9c41c1">2,406</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNDAtNC0xLTEtMA_7c44a80a-c500-4c2c-91bf-ebfc682114ac">1,564</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payment of finance lease principal</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="ptct:PaymentOfFinanceLeasePrincipal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNDEtMi0xLTEtMA_7ba14371-1db9-431f-9d2a-62a4fb9b82e7">15,000</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="ptct:PaymentOfFinanceLeasePrincipal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNDEtNC0xLTEtMA_be0c6dc4-9229-4e63-83d4-d60997428276">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by financing activities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNDMtMi0xLTEtMA_0d09220b-f6be-4723-ac22-a27323d7c6eb">14,428</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNDMtNC0xLTEtMA_d088dd0a-0c72-4424-bc54-886b5a54a4a0">228,571</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effect of exchange rate changes on cash</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNDQtMi0xLTEtMA_c16bd481-22d2-4dea-8add-f629e73a5b0c">442</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNDQtNC0xLTEtMA_e6252d63-c8c0-4e23-ba55-a732f2866903">375</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net decrease in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNDUtMi0xLTEtMA_76997401-50f4-436f-b733-d714d66f7646">129,567</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNDUtNC0xLTEtMA_4198a07f-efff-4e12-9b0e-03a1ceadf6ec">33,404</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents, and restricted cash beginning of period</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNDYtMi0xLTEtMA_81171aa6-3c8b-437f-912a-dc726ecbc380">295,528</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i785bae8d0f37453b828968b15c63b74f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNDYtNC0xLTEtMA_76c27e72-946e-4271-b601-4e95021ce65c">169,498</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents, and restricted cash end of period</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNDctMi0xLTEtMA_51cce6dd-6e3a-4027-b4c2-fd292b0d66bd">165,961</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i28563c013fff4be6aba8b90a75baf135_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNDctNC0xLTEtMA_86512b4d-639f-4a8e-b7ef-9ac82df4097f">136,094</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:68.234%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.076%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.224%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Supplemental disclosure of cash information</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid for interest</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNDktMi0xLTEtMA_31dd0c64-0241-4fd1-9257-36a4ed2a51f7">5,286</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNDktNC0xLTEtMA_660bf907-694a-4ab0-ab98-e1a2808cc5ff">3,111</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid for income taxes</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNTAtMi0xLTEtMA_2768a8a2-a888-425c-b850-42d7fdf048a8">1,140</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNTAtNC0xLTEtMA_a517a566-2b98-4bd0-b29b-16cb19edd4ee">1,013</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Supplemental disclosure of non-cash investing and financing activity</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized gain on marketable securities, net of tax</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNTItMi0xLTEtMA_808e8333-3c76-43e3-a358-7b13d8c47702">2,655</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNTItNC0xLTEtMA_cd346860-d6b2-49ab-9a93-8777760b1b9a">898</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-use assets obtained in exchange for operating lease obligations</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNTMtMi0xLTEtMA_a3af0de8-2d2c-489a-8711-ae29089981f4">18,117</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNTMtNC0xLTEtMA_b3b0516a-4c96-4b31-9dc5-39af42296005">11,643</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-use assets obtained in exchange for finance lease obligations</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNTYtMi0xLTEtNTE5OQ_c14d9087-e89c-4acf-9afe-751a51cf04a7">41,212</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNTYtNC0xLTEtNTIwMw_8add1f2f-0c65-4eef-b8c6-affd0a5b64bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquisition of product rights and licenses</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNTQtMi0xLTEtMA_ecc4d105-def9-4364-97a0-9de8f78faa64">12,186</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNTQtNC0xLTEtMA_1a74b60c-13b2-4041-ae94-c27ec0767f1b">8,269</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock related to rights exchange</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="ptct:StockIssuedDuringPeriodValueExchangeRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNTktMi0xLTEtNzgzMA_e247d44c-fe47-4006-9e6b-44c72e23f7f1">150,528</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="ptct:StockIssuedDuringPeriodValueExchangeRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNTktNC0xLTEtODEyMw_cfdda05e-a91d-4200-8afc-b5715731f1ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See accompanying unaudited notes.</span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10</span></div></div></div><div id="i95cf61a5c7074910ae3cf29c5ee08838_37"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PTC Therapeutics,&#160;Inc.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Notes to Consolidated Financial Statements (unaudited)</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">June&#160;30, 2020 </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">In thousands (except per share data unless otherwise noted)</span></div><div><span><br/></span></div><div id="i95cf61a5c7074910ae3cf29c5ee08838_40"></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">1.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:700;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80MC9mcmFnOmM3MjE3M2MxMmMzZTQwMDdiN2ZhM2JhN2I5MjdiMmMwL3RleHRyZWdpb246YzcyMTczYzEyYzNlNDAwN2I3ZmEzYmE3YjkyN2IyYzBfMTMyNzk_db49635a-ac14-41ff-a96e-bbc353c99e39" continuedAt="i8bbbb9b820534c349c51a9fcd965d523" escape="true">The Company</ix:nonNumeric></span></div><ix:continuation id="i8bbbb9b820534c349c51a9fcd965d523" continuedAt="ia1e7938cad894c9cab78b9602388ed8a"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">PTC Therapeutics,&#160;Inc. (the &#8220;Company&#8221; or &#8220;PTC&#8221;) is a science-driven global biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. The Company&#8217;s ability to globally commercialize products is the foundation that drives its continued investment in a robust diversified pipeline of transformative medicines and its mission to provide access to best-in-class treatments for patients who have an unmet medical need. The Company&#8217;s strategy is to bring best-in-class therapies with differentiated clinical benefit to patients affected by rare disorders and to leverage its global commercial infrastructure to maximize value for its patients and other stakeholders.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company has two products, Translarna</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;">&#8482; </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(ataluren) and Emflaza&#8482; (deflazacort), for the treatment of Duchenne muscular dystrophy, or DMD, a rare, life threatening disorder. Translarna has marketing authorization in the European Economic Area (the &#8220;EEA&#8221;) for the treatment of nonsense mutation Duchenne muscular dystrophy, or nmDMD, in ambulatory patients aged 2&#160;years and older and in Brazil for the treatment of nmDMD in ambulatory patients aged 5&#160;years and older, subject to annual renewal and other conditions. In June 2020, the Committee for Medicinal Products for Human Use (the "CHMP") of the European Medicines Agency ("EMA") recommended to remove the statement &#8220;efficacy has not been demonstrated in non-ambulatory patients&#8221; from the product label for Translarna. The CHMP's opinion is subject to final approval by the European Commission, which is typically provided within two months of the CHMP's recommendation. Emflaza is approved in the United States for the treatment of DMD in patients two years and older.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has a pipeline of gene therapy product candidates for rare monogenic diseases that affect the central nervous system (&#8220;CNS&#8221;) including PTC-AADC for the treatment of Aromatic L-Amino Acid Decarboxylase, or AADC deficiency, a rare CNS disorder arising from reductions in the enzyme AADC that results from mutations in the dopa decarboxylase gene. The Company is preparing a biologics license application ("BLA") for PTC-AADC for the treatment of AADC deficiency in the United States and it anticipates initiating the BLA submission to the United States Food and Drug Administration ("FDA") in the second half of 2020. In January 2020, the Company submitted a marketing authorization application ("MAA") to the EMA for PTC-AADC for the treatment of AADC deficiency in the EEA, and the Company expects an opinion from the CHMP in the first quarter of 2021.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company holds the rights for the commercialization of Tegsedi&#8482; (inotersen) and Waylivra&#8482; (volanesorsen) for the treatment of rare diseases in countries in Latin America and the Caribbean pursuant to the Company&#8217;s Collaboration and License Agreement with Akcea Therapeutics, Inc. (&#8220;Akcea&#8221;). Tegsedi has received marketing authorization in the United States, the European Union (the &#8220;EU&#8221;) and Brazil for the treatment of stage&#160;1 or stage&#160;2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis, or hATTR amyloidosis. Waylivra has received marketing authorization in the EU for the treatment of familial chylomicronemia syndrome, or FCS. The Company filed for marketing authorization for Waylivra for the treatment of FCS with ANVISA, the Brazilian health regulatory authority, in June 2020 and, subject to potential delays in the review process related to the COVID-19 pandemic, expects a regulatory decision on approval from ANVISA in 2021.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company also has a spinal muscular atrophy ("SMA") collaboration with F. Hoffman-La Roche&#160;Ltd and Hoffman-La Roche&#160;Inc., referred to collectively as Roche, and the Spinal Muscular Atrophy Foundation ("SMA Foundation"). The lead compound in the SMA program is risdiplam (RG7916, RO7034067). Roche submitted an NDA for risdiplam to the FDA in the fourth quarter of 2019. In April 2020, the FDA extended the Prescription Drug User Fee Act ("PDUFA") date for a decision from May 24, 2020&#160;to August 24, 2020 as a result of additional data that Roche submitted, including comprehensive data from the Sunfish part 2 study. Risdiplam is expected to be indicated in the United States for SMA type 1, 2 and 3 patients, if approved. Roche anticipates submitting an MAA for risdiplam in the EEA imminently.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">On October 25, 2019, the Company completed the acquisition of substantially all of the assets of BioElectron Technology Corporation (&#8220;BioElectron&#8221;), a Delaware corporation, including certain compounds that the Company has begun to develop as part of its Bio-e platform, (the &#8220;Asset Acquisition&#8221;) pursuant to an asset purchase agreement by and between the Company and BioElectron, dated October 1, 2019 (the &#8220;Asset Acquisition Agreement&#8221;). The transaction was accounted for as an asset acquisition. The two most advanced molecules in the Company's Bio-e platform are vatiquinone, formerly known as PTC743, and PTC857. The Company expects to initiate a potential registrational Phase 2 placebo-controlled trial of vatiquinone in approximately 60 children with mitochondrial disease and associated refractory epilepsy in the third quarter of 2020. The Company also expects to initiate a potential registrational Phase 3 trial of vatiquinone in approximately 100 patients with </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="ia1e7938cad894c9cab78b9602388ed8a" continuedAt="i15adbcd1e28e4edaaf5272041663b5b8"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Friedrich ataxia in the fourth quarter of 2020. In the second quarter of 2020, the Company initiated a Phase 1 trial in healthy volunteers to evaluate the safety and pharmacology of PTC857. The Company expects data from the single ascending dose and multiple ascending dose studies from the Phase 1 trial to be available by the end of 2020.</span></div><div style="text-align:justify;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In addition, the Company has a pipeline of product candidates and discovery programs that are in early clinical, pre-clinical and research and development stages focused on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s marketing authorization for Translarna in the EEA is subject to annual review and renewal by the European Commission following reassessment by the EMA of the benefit-risk balance of the authorization, which the Company refers to as the annual EMA reassessment. This marketing authorization is further subject to the specific obligation to conduct and submit the results of a multi-center, randomized, double-blind, 18-month, placebo-controlled trial, followed by an 18-month open-label extension, according to an agreed protocol, in order to confirm the efficacy and safety of Translarna. The final report on the trial and open-label extension is to be submitted by the Company to the EMA by the end of the third quarter of 2022. The Company refers to the trial and open-label extension together as Study 041.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The marketing authorization in the EEA was last renewed in June 2020 and is effective, unless extended, through August 5, 2021. The renewal was based on the Company&#8217;s commitment to conduct Study 041 and the totality of the clinical data available from its trials and studies of Translarna for the treatment of nmDMD, including the safety and efficacy results of the Phase 2b and Phase 3 clinical trials. The primary efficacy endpoint was not achieved in either trial within the pre-specified level of statistical significance.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Translarna is an investigational new drug in the United States. During the first quarter of 2017, the Company filed a New Drug Application, or NDA, over protest with the FDA, for which the FDA granted a standard review. In October 2017, the Office of Drug Evaluation I of the FDA issued a complete response letter for the NDA, stating that it was unable to approve the application in its current form. In response, the Company filed a formal dispute resolution request with the Office of New Drugs of the FDA. In February 2018, the Office of New Drugs of the FDA denied the Company's appeal of the Complete Response Letter. In its response, the Office of New Drugs recommended a possible path forward for the ataluren NDA submission based on the accelerated approval pathway. This would involve a re-submission of an NDA containing the current data on effectiveness of ataluren with new data to be generated on dystrophin production in nmDMD patients&#8217; muscles. The Company intends to follow the FDA&#8217;s recommendation and will collect, using newer technologies via procedures and methods that the Company designed, such dystrophin data in a new study, Study 045, which the Company initiated in the fourth quarter of 2018. As a result of intermittent discontinuations of certain elective procedures at the Company's clinical trial site in response to the COVID-19 pandemic, the Company's expected completion of Study 45 has been delayed as certain patients still require final study muscle biopsies. Once the clinical trial site is open for the necessary procedures and patients are able to safely travel to the site, the Company expects to be able to complete the final biopsies and the data from Study 045 would be available thereafter, followed by a potential re-submission of an NDA. Additionally, should a re-submission of an NDA receive accelerated approval, the Office of New Drugs stated that Study 041, which is currently enrolling, could serve as the confirmatory post-approval trial required in connection with the accelerated approval framework.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On August 23, 2018, the Company completed its acquisition of Agilis Biotherapeutics, Inc., or Agilis, pursuant to an Agreement and Plan of Merger, dated as of July 19, 2018 (the &#8220;Merger Agreement&#8221;), by and among the Company, Agility Merger Sub, Inc., a Delaware corporation and the Company's wholly owned, indirect subsidiary, Agilis and, solely in its capacity as the representative, agent and attorney-in-fact of the equityholders of Agilis, Shareholder Representative Services LLC, (the "Merger").</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Upon the closing of the Merger, the Company paid to Agilis equityholders total upfront consideration comprised of $<ix:nonFraction unitRef="usd" contextRef="ib9eece550dff4e4780cef9d288202a33_D20180823-20180823" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80MC9mcmFnOmM3MjE3M2MxMmMzZTQwMDdiN2ZhM2JhN2I5MjdiMmMwL3RleHRyZWdpb246YzcyMTczYzEyYzNlNDAwN2I3ZmEzYmE3YjkyN2IyYzBfMTAxNTA_f346ff9d-4282-4a66-8d3d-03f7a6f42656">49.2</ix:nonFraction> million in cash and <ix:nonFraction unitRef="shares" contextRef="ib9eece550dff4e4780cef9d288202a33_D20180823-20180823" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80MC9mcmFnOmM3MjE3M2MxMmMzZTQwMDdiN2ZhM2JhN2I5MjdiMmMwL3RleHRyZWdpb246YzcyMTczYzEyYzNlNDAwN2I3ZmEzYmE3YjkyN2IyYzBfMTAxNjU_026d96cf-c21f-412a-9034-74e93df86fe8">3,500,907</ix:nonFraction> shares of the Company&#8217;s common stock (the &#8220;Closing Stock Consideration&#8221;). The Closing Stock Consideration was determined by dividing $<ix:nonFraction unitRef="usd" contextRef="i0e759cb2d2394853b69b11290ac5d21a_I20180823" decimals="-5" format="ixt:numdotdecimal" name="ptct:BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80MC9mcmFnOmM3MjE3M2MxMmMzZTQwMDdiN2ZhM2JhN2I5MjdiMmMwL3RleHRyZWdpb246YzcyMTczYzEyYzNlNDAwN2I3ZmEzYmE3YjkyN2IyYzBfMTAzMDE_475430ee-2065-4b43-9c13-4a6e51d1872b">150.0</ix:nonFraction> million by the volume-weighted average price per share of the Company&#8217;s common stock on the Nasdaq Global Select Market for the <ix:nonNumeric contextRef="ib9eece550dff4e4780cef9d288202a33_D20180823-20180823" format="ixt-sec:durday" name="ptct:BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80MC9mcmFnOmM3MjE3M2MxMmMzZTQwMDdiN2ZhM2JhN2I5MjdiMmMwL3RleHRyZWdpb246YzcyMTczYzEyYzNlNDAwN2I3ZmEzYmE3YjkyN2IyYzBfMTA0MjQ_6c2423a3-519d-41de-b5e5-0e9dde77c0f4">10</ix:nonNumeric> consecutive trading-day period ending on the second trading-day immediately preceding the closing of the Merger. Agilis equityholders are entitled to receive contingent payments from the Company based on the achievement of certain development, regulatory and net sales milestones as well as based upon a percentage of net sales of certain products.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">On April 29, 2020, the Company, certain of the former equity holders of Agilis, and, for the limited purposes set forth in the agreement, Shareholder Representative Services LLC, entered into a Rights Exchange Agreement (the &#8220;Rights Exchange Agreement&#8221;). Pursuant to the Rights Exchange Agreement, the Company issued <ix:nonFraction unitRef="shares" contextRef="if89af7698cdf43d1915f30dc403dc6af_I20200429" decimals="INF" format="ixt:numdotdecimal" name="ptct:SharestoissueunderRightsExchangeAgreement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80MC9mcmFnOmM3MjE3M2MxMmMzZTQwMDdiN2ZhM2JhN2I5MjdiMmMwL3RleHRyZWdpb246YzcyMTczYzEyYzNlNDAwN2I3ZmEzYmE3YjkyN2IyYzBfNDM5ODA0NjU1OTAwNw_fb75e6f5-7b3f-432c-a757-e7dea335d4c4">2,821,176</ix:nonFraction> shares of its common stock (the &#8220;Common Stock Consideration&#8221;) and paid $<ix:nonFraction unitRef="usd" contextRef="i921570c76d4f4e23870b19798c531218_D20200429-20200429" decimals="-5" format="ixt:numdotdecimal" name="ptct:CashconsiderationpaymentunderRightsExchangeAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80MC9mcmFnOmM3MjE3M2MxMmMzZTQwMDdiN2ZhM2JhN2I5MjdiMmMwL3RleHRyZWdpb246YzcyMTczYzEyYzNlNDAwN2I3ZmEzYmE3YjkyN2IyYzBfNDM5ODA0NjU1OTAxOA_463d6e4b-2074-4a36-be10-25019471ee77">36.9</ix:nonFraction>&#160;million (the &#8220;Cash Consideration&#8221;), in the aggregate, to such former equity holders of Agilis (the &#8220;Participating Rightholders&#8221;) in exchange for the cancellation and forfeiture by the Participating Rightholders of their rights to receive certain milestone-based contingent payments under the Merger Agreement, pursuant to which the Company completed the Merger. </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i15adbcd1e28e4edaaf5272041663b5b8"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Pursuant to the terms of the Rights Exchange Agreement, the Participating Rightholders have canceled and forfeited their rights under the Merger Agreement to receive (i) $<ix:nonFraction unitRef="usd" contextRef="i44fac1cb95fa4331b63d8afeb4d83f20_D20200429-20200429" decimals="-5" format="ixt:numdotdecimal" name="ptct:ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80MC9mcmFnOmM3MjE3M2MxMmMzZTQwMDdiN2ZhM2JhN2I5MjdiMmMwL3RleHRyZWdpb246YzcyMTczYzEyYzNlNDAwN2I3ZmEzYmE3YjkyN2IyYzBfNDM5ODA0NjU1OTA2Nw_e6b01f53-07b8-4beb-b2b7-e47f7dc175c9">174.0</ix:nonFraction>&#160;million, in the aggregate, of potential milestone payments based on the achievement of certain regulatory milestones and (ii) $<ix:nonFraction unitRef="usd" contextRef="i44fac1cb95fa4331b63d8afeb4d83f20_D20200429-20200429" decimals="-5" format="ixt:numdotdecimal" name="ptct:DevelopmentMilestonePaymentObligationsCancellationAndForfeiture" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80MC9mcmFnOmM3MjE3M2MxMmMzZTQwMDdiN2ZhM2JhN2I5MjdiMmMwL3RleHRyZWdpb246YzcyMTczYzEyYzNlNDAwN2I3ZmEzYmE3YjkyN2IyYzBfNDM5ODA0NjU1OTA1Mg_0333cead-06f4-4459-8ed5-840497178955">37.6</ix:nonFraction>&#160;million, in the aggregate, of $<ix:nonFraction unitRef="usd" contextRef="id61e01344c6b402983658d905475cc0f_I20200429" decimals="-5" format="ixt:numdotdecimal" name="ptct:DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80MC9mcmFnOmM3MjE3M2MxMmMzZTQwMDdiN2ZhM2JhN2I5MjdiMmMwL3RleHRyZWdpb246YzcyMTczYzEyYzNlNDAwN2I3ZmEzYmE3YjkyN2IyYzBfNDM5ODA0NjU1OTA4Mw_f91f9e6e-f36f-48da-9db5-afa2253a0aa0">40.0</ix:nonFraction>&#160;million in development milestone payments that would have been due upon the passing of the second anniversary of the closing of the Merger, regardless of whether the milestones are achieved.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Rights Exchange Agreement has no effect on the Merger Agreement other than to provide for the cancellation and forfeiture of the Participating Rightholders&#8217; rights to receive $<ix:nonFraction unitRef="usd" contextRef="i44fac1cb95fa4331b63d8afeb4d83f20_D20200429-20200429" decimals="-5" format="ixt:numdotdecimal" name="ptct:ContingentLiabilityCancellationAndForfeiture" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80MC9mcmFnOmM3MjE3M2MxMmMzZTQwMDdiN2ZhM2JhN2I5MjdiMmMwL3RleHRyZWdpb246YzcyMTczYzEyYzNlNDAwN2I3ZmEzYmE3YjkyN2IyYzBfNDM5ODA0NjU1OTA5OA_2dfc6811-289b-4b49-9b8f-d199790e6814">211.6</ix:nonFraction>&#160;million, in the aggregate, of the milestone payments described above. As a result, all other rights and obligations under the Merger Agreement remain in effect pursuant to their terms, including the Company&#8217;s obligation to pay up to an aggregate maximum amount of $<ix:nonFraction unitRef="usd" contextRef="i44fac1cb95fa4331b63d8afeb4d83f20_D20200429-20200429" decimals="-5" format="ixt:numdotdecimal" name="ptct:DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80MC9mcmFnOmM3MjE3M2MxMmMzZTQwMDdiN2ZhM2JhN2I5MjdiMmMwL3RleHRyZWdpb246YzcyMTczYzEyYzNlNDAwN2I3ZmEzYmE3YjkyN2IyYzBfNDM5ODA0NjU1OTE0NA_da5cdf9c-64d8-4490-8d11-05980a4c425a">22.4</ix:nonFraction>&#160;million upon the achievement of certain development milestones (representing the remaining portion of potential development milestone payments for which rights were not canceled and forfeited pursuant to the Rights Exchange Agreement after deducting the $<ix:nonFraction unitRef="usd" contextRef="i44fac1cb95fa4331b63d8afeb4d83f20_D20200429-20200429" decimals="-5" format="ixt:numdotdecimal" name="ptct:DevelopmentMilestonePaymentObligationsCancellationAndForfeiture" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80MC9mcmFnOmM3MjE3M2MxMmMzZTQwMDdiN2ZhM2JhN2I5MjdiMmMwL3RleHRyZWdpb246YzcyMTczYzEyYzNlNDAwN2I3ZmEzYmE3YjkyN2IyYzBfNDM5ODA0NjU1OTExNA_166662bc-6888-42ca-98ba-3c2592a782e4">37.6</ix:nonFraction>&#160;million for which rights were canceled and forfeited pursuant to the Rights Exchange Agreement from the $<ix:nonFraction unitRef="usd" contextRef="id61e01344c6b402983658d905475cc0f_I20200429" decimals="-5" format="ixt:numdotdecimal" name="ptct:DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80MC9mcmFnOmM3MjE3M2MxMmMzZTQwMDdiN2ZhM2JhN2I5MjdiMmMwL3RleHRyZWdpb246YzcyMTczYzEyYzNlNDAwN2I3ZmEzYmE3YjkyN2IyYzBfNDM5ODA0NjU1OTEyOQ_32930531-5578-47c4-bd3a-0fe2e030d816">40.0</ix:nonFraction>&#160;million in development milestone payments that are due upon the passing of the second anniversary of the closing of the Merger), up to an aggregate maximum amount of $<ix:nonFraction unitRef="usd" contextRef="i44fac1cb95fa4331b63d8afeb4d83f20_D20200429-20200429" decimals="-5" format="ixt:numdotdecimal" name="ptct:ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80MC9mcmFnOmM3MjE3M2MxMmMzZTQwMDdiN2ZhM2JhN2I5MjdiMmMwL3RleHRyZWdpb246YzcyMTczYzEyYzNlNDAwN2I3ZmEzYmE3YjkyN2IyYzBfNDM5ODA0NjU1OTE1OQ_29ea3b68-75d4-4d51-a833-832eb376355d">361.0</ix:nonFraction>&#160;million upon the achievement of certain regulatory milestones (representing the remaining portion of potential regulatory milestone payments for which rights were not canceled and forfeited pursuant to the Rights Exchange Agreement), up to a maximum aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="id61e01344c6b402983658d905475cc0f_I20200429" decimals="-5" format="ixt:numdotdecimal" name="ptct:ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80MC9mcmFnOmM3MjE3M2MxMmMzZTQwMDdiN2ZhM2JhN2I5MjdiMmMwL3RleHRyZWdpb246YzcyMTczYzEyYzNlNDAwN2I3ZmEzYmE3YjkyN2IyYzBfNDM5ODA0NjU1OTE3NQ_88d1af95-b6b3-46ac-b510-277abe6c74bb">150.0</ix:nonFraction>&#160;million upon the achievement of certain net sales milestones and a percentage of annual net sales for Friedreich ataxia and Angelman syndrome during specified terms, ranging from <ix:nonFraction unitRef="number" contextRef="i56959b5fb9c34914b2d086de6704c201_I20200429" decimals="2" name="ptct:ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80MC9mcmFnOmM3MjE3M2MxMmMzZTQwMDdiN2ZhM2JhN2I5MjdiMmMwL3RleHRyZWdpb246YzcyMTczYzEyYzNlNDAwN2I3ZmEzYmE3YjkyN2IyYzBfNDM5ODA0NjU1OTE5MQ_d6dedafa-cc67-4747-9dc5-dd3e3b2d7fe4">2</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i56a3188c726c4476a6115fcc0dc1091f_I20200429" decimals="2" name="ptct:ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80MC9mcmFnOmM3MjE3M2MxMmMzZTQwMDdiN2ZhM2JhN2I5MjdiMmMwL3RleHRyZWdpb246YzcyMTczYzEyYzNlNDAwN2I3ZmEzYmE3YjkyN2IyYzBfNDM5ODA0NjU1OTE5NQ_1434504f-58b8-498b-bb9b-009c8fe6fae9">6</ix:nonFraction>%, pursuant to the terms of the Merger Agreement. Refer to Note 5 for further details regarding the Rights Exchange Agreement.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">On May 29, 2020, the Company completed its acquisition of Censa Pharmaceuticals, Inc., (&#8220;Censa&#8221;) pursuant to an Agreement and Plan of Merger, dated as of May 5, 2020, (the "Censa Merger Agreement"), by and among the Company, Hydro Merger Sub, Inc., the Company's wholly owned, indirect subsidiary, and, solely in its capacity as the representative, agent and attorney-in-fact of the securityholders of Censa, Shareholder Representative Services LLC (the "Censa Merger"). The transaction was accounted for as an asset acquisition.  In connection with the Censa Merger, the Company acquired PTC923 (formerly known as CNSA-001), which is being pursued as a possible treatment for orphan metabolic diseases associated with defects in the tetrahydrobiopterin biochemical pathways, including phenylketonuria ("PKU").  Refer to Note 3 for further details.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, the Company had an accumulated deficit of approximately $<ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80MC9mcmFnOmM3MjE3M2MxMmMzZTQwMDdiN2ZhM2JhN2I5MjdiMmMwL3RleHRyZWdpb246YzcyMTczYzEyYzNlNDAwN2I3ZmEzYmE3YjkyN2IyYzBfMTIwNTk_b1bc5f25-dd18-423f-9652-3bb3a1ce453f">1,484.8</ix:nonFraction> million. The Company has financed its operations to date primarily through the private offerings in September 2019 of <ix:nonFraction unitRef="number" contextRef="i2869c1675c5a404e9bb85cad2eb71998_I20191231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80MC9mcmFnOmM3MjE3M2MxMmMzZTQwMDdiN2ZhM2JhN2I5MjdiMmMwL3RleHRyZWdpb246YzcyMTczYzEyYzNlNDAwN2I3ZmEzYmE3YjkyN2IyYzBfMTIxNzI_1067a0d9-d5bd-44bf-8e46-16bffcec3a39">1.50</ix:nonFraction>% convertible senior notes due 2026 and in August&#160;2015 of <ix:nonFraction unitRef="number" contextRef="i28655a9b21d647eb9144da8fa8cdd911_I20150831" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80MC9mcmFnOmM3MjE3M2MxMmMzZTQwMDdiN2ZhM2JhN2I5MjdiMmMwL3RleHRyZWdpb246YzcyMTczYzEyYzNlNDAwN2I3ZmEzYmE3YjkyN2IyYzBfMTIyMzE_7c96ac7c-d3ea-44ca-9cb6-11f395c7529f">3.00</ix:nonFraction>% convertible senior notes due 2022 (see Note 11), public offerings of common stock in February 2014, October 2014, April 2018, January 2019, and September 2019, "at the market offerings" of its common stock, its initial public offering of common stock in June 2013, private placements of its convertible preferred stock, collaborations, bank debt, the Company's credit and security agreement (the "Credit Agreement"), with MidCap Financial Trust, or MidCap Financial, as administrative agent and MidCap Financial and other certain institutions as lenders thereto (see Note 11), grant funding and clinical trial support from governmental and philanthropic organizations and patient advocacy groups in the disease area addressed by the Company&#8217;s product candidates. Since 2014, the Company has also relied on revenue generated from net sales of Translarna for the treatment of nmDMD in territories outside of the United States, and since May 2017, the Company has generated revenue from net sales of Emflaza for the treatment of DMD in the United States. The Company expects&#160;that cash flows from the sales of its products, together with the Company's cash, cash equivalents and marketable securities, will be sufficient to fund its operations for at least the next twelve months.</span></div></ix:continuation><div style="text-align:justify;"><span><br/></span></div><div id="i95cf61a5c7074910ae3cf29c5ee08838_43"></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">2.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:700;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMjkwNDE_9a1d0591-e5e1-400a-aba1-5adbb597f499" continuedAt="i357af2a576f04cbc920fc46533ce22f1" escape="true">Summary of significant accounting policies</ix:nonNumeric></span></div><ix:continuation id="i357af2a576f04cbc920fc46533ce22f1" continuedAt="i7446b94b0c4a48488acb09c6e8db0904"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s complete listing of significant accounting policies is set forth in Note 2 of the notes to the Company&#8217;s audited financial statements as of December&#160;31, 2019 included in the Company&#8217;s Annual Report on Form&#160;10-K filed with the Securities and Exchange Commission (the "SEC") on March 2, 2020 (the "2019 Form&#160;10-K"). Additional significant accounting policies adopted during the six month period ended June&#160;30, 2020 are discussed in further detail below.</span></div><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMjkwODE_896826cc-6742-410f-834c-142ff750c711" continuedAt="i46987ee5ea454fd5820cdca05516bebe" escape="true"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Basis of presentation</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying financial information as of June&#160;30, 2020 and for the three and six months ended June&#160;30, 2020 and 2019 has been prepared by the Company, without audit, pursuant to the rules&#160;and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States ("GAAP") have been condensed or omitted pursuant to such rules&#160;and regulations. These interim financial statements should be read in conjunction with the Company&#8217;s audited financial statements as of December&#160;31, 2019 and notes thereto included in the 2019 Form&#160;10-K.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the opinion of management, the unaudited financial information as of June&#160;30, 2020 and for the three and six months ended June&#160;30, 2020 and 2019 reflects all adjustments, which are normal recurring adjustments, necessary to present a fair statement </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i7446b94b0c4a48488acb09c6e8db0904" continuedAt="i1716f7681f6f4f9680ae1020ec71018c"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i46987ee5ea454fd5820cdca05516bebe">of financial position, results of operations, stockholders' equity, and cash flows. The results of operations for the three and six month period ended June&#160;30, 2020 are not necessarily indicative of the results to be expected for the year ended December&#160;31, 2020 or for any other interim period or for any other future year.</ix:continuation></span></div><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMjkwNTY_4c5121e6-0534-402f-b079-6a82935d6e7a" escape="true"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Use of estimates</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates in these consolidated financial statements have been made in connection with the calculation of net product sales, certain accruals related to the Company&#8217;s research and development expenses, valuation procedures for convertible notes, fair value of the contingent consideration, and the provision for or benefit from income taxes. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</span></div></ix:nonNumeric><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Restricted cash</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Restricted cash included in deposits and other assets on the consolidated balance sheet relates to an unconditional, irrevocable and transferable letter of credit that was entered into during the twelve-month period ended December 31, 2019 in connection with obligations under a facility lease for our leased biologics manufacturing facility in Hopewell Township, New Jersey. The amount of the letter of credit is $<ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LettersOfCreditOutstandingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMjc3Ng_658f14b3-b544-45f9-a5b6-b9c1280a88d9">7.5</ix:nonFraction> million, is to be maintained for a term of not less than <ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" format="ixt-sec:durwordsen" name="ptct:Termforletterofcredit" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMjgyOA_b8d84fb8-6d6d-4142-95da-086659bf18a9">five years</ix:nonNumeric> and has the potential to be reduced to $<ix:nonFraction unitRef="usd" contextRef="ic07a476967de416b843f81c02e185244_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LettersOfCreditOutstandingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMjg3MA_41a70b82-c812-4cb4-aec6-a51520771c3f">3.8</ix:nonFraction> million if after <ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" format="ixt-sec:durwordsen" name="ptct:Termforletterofcredit" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMjg4Mg_b8d84fb8-6d6d-4142-95da-086659bf18a9">five years</ix:nonNumeric> the Company is not in default of its lease. The amount is classified within deposits and other assets on the consolidated balance sheet due to the long-term nature of the letter of credit.</span></div><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMjkwMzc_0a314bab-c71c-46b3-bab7-248a4a1b3fc6" escape="true"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheet that sum to the total of the same amounts shown in the statement of cash flows:</span></div><div style="text-align:center;margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.421%;"><tr><td style="width:1.0%;"></td><td style="width:71.395%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.582%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.519%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.582%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.522%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Beginning of period- December 31, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">End of period- June 30, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RhYmxlOjE2MTA0YTc4MzBhNDQyODA5YmY5NTU5NmM5NzAyNGNiL3RhYmxlcmFuZ2U6MTYxMDRhNzgzMGE0NDI4MDliZjk1NTk2Yzk3MDI0Y2JfMS0yLTEtMS0w_7d3e0215-e687-4311-be7e-3a79f26da6e8">288,028</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RhYmxlOjE2MTA0YTc4MzBhNDQyODA5YmY5NTU5NmM5NzAyNGNiL3RhYmxlcmFuZ2U6MTYxMDRhNzgzMGE0NDI4MDliZjk1NTk2Yzk3MDI0Y2JfMS00LTEtMS0w_1d1f2d08-5c8d-44b0-8ef7-c8722c7e02db">158,461</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash included in deposits and other assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RhYmxlOjE2MTA0YTc4MzBhNDQyODA5YmY5NTU5NmM5NzAyNGNiL3RhYmxlcmFuZ2U6MTYxMDRhNzgzMGE0NDI4MDliZjk1NTk2Yzk3MDI0Y2JfMi0yLTEtMS0w_6dfa1943-2adf-43f3-aaf4-437ec54a27d0">7,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RhYmxlOjE2MTA0YTc4MzBhNDQyODA5YmY5NTU5NmM5NzAyNGNiL3RhYmxlcmFuZ2U6MTYxMDRhNzgzMGE0NDI4MDliZjk1NTk2Yzk3MDI0Y2JfMi00LTEtMS0w_540215d7-ace4-4817-94ce-88377d21340d">7,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Cash, cash equivalents and restricted cash per statement of cash flows</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RhYmxlOjE2MTA0YTc4MzBhNDQyODA5YmY5NTU5NmM5NzAyNGNiL3RhYmxlcmFuZ2U6MTYxMDRhNzgzMGE0NDI4MDliZjk1NTk2Yzk3MDI0Y2JfMy0yLTEtMS0w_1521378e-b2a8-477c-8c9b-bc0c633c3f25">295,528</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RhYmxlOjE2MTA0YTc4MzBhNDQyODA5YmY5NTU5NmM5NzAyNGNiL3RhYmxlcmFuZ2U6MTYxMDRhNzgzMGE0NDI4MDliZjk1NTk2Yzk3MDI0Y2JfMy00LTEtMS0w_1c353283-8f05-41d9-a696-26488fe0d388">165,961</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMjkwNzU_b3e169ed-607b-45dd-aeeb-a4df57dbd117" continuedAt="icb2f3e85aaa9465995a24dd2425d2b52" escape="true">Marketable securities</ix:nonNumeric></span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="icb2f3e85aaa9465995a24dd2425d2b52">The Company considers securities with original maturities of greater than 90&#160;days to be available for sale securities. Securities under this classification are recorded at fair value and unrealized gains and losses within accumulated other comprehensive income. The estimated fair value of the available for sale securities is determined based on quoted market prices or rates for similar instruments. In addition, the cost of debt securities in this category is adjusted for amortization of premium and accretion of discount to maturity. For available for sale debt securities in an unrealized loss position, the Company assesses whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security's amortized cost basis is written down to fair value. If the criteria are not met, the Company evaluates whether the decline in fair value has resulted from a credit loss or other factors. In making this assessment, management considers, among other factors, the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security are compared to the amortized cost basis of the security. If the present value of the cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss, limited by the amount that the fair value is less than the amortized costs basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income.</ix:continuation> For the three month and six month periods ended June&#160;30, 2020, <ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfNTI2NA_4adeeeed-643b-4e36-82ca-ba7aa0ec431c">no</ix:nonFraction> allowance was recorded for credit losses.</span></div><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="ptct:InventoriesAndCostOfProductSalesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMjkwODY_033867fd-d15e-490a-8a56-ef31a91cdcc3" continuedAt="i4e4a9b07be7c47af9bf5f34b0c13b9d0" escape="true"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Inventory and cost of product sales</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Inventory</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Inventories are stated at the lower of cost and net realizable value with cost determined on a first-in, first-out basis by product. The Company capitalizes inventory costs associated with products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. Products which may be used in clinical development programs are included in inventory and charged to research and development expense when the product enters the research and development process and no longer can be used for commercial purposes. Inventory used for </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i1716f7681f6f4f9680ae1020ec71018c" continuedAt="i0396c824498d4b3b8fa8dbfd308d8f8e"><ix:continuation id="i4e4a9b07be7c47af9bf5f34b0c13b9d0"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">marketing efforts are charged to selling, general and administrative expense. Amounts related to clinical development programs and marketing efforts are immaterial.</span></div><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMjkwNzY_9742177a-7fd7-40bf-9301-2fbb248316ad" escape="true"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the components of the Company&#8217;s inventory for the periods indicated:</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:71.099%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.672%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.769%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" name="us-gaap:InventoryRawMaterials" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RhYmxlOjMwMjY3N2M4NGE1MzRjYTRhNTY2OWEzMmRhODA1ZTM5L3RhYmxlcmFuZ2U6MzAyNjc3Yzg0YTUzNGNhNGE1NjY5YTMyZGE4MDVlMzlfMS0yLTEtMS0w_2484ae53-8d6b-462c-b34c-8956b17cadb7">877</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" name="us-gaap:InventoryRawMaterials" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RhYmxlOjMwMjY3N2M4NGE1MzRjYTRhNTY2OWEzMmRhODA1ZTM5L3RhYmxlcmFuZ2U6MzAyNjc3Yzg0YTUzNGNhNGE1NjY5YTMyZGE4MDVlMzlfMS00LTEtMS0w_8bd07d88-23f3-44b6-9448-39e0a19fe085">874</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Work in progress</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RhYmxlOjMwMjY3N2M4NGE1MzRjYTRhNTY2OWEzMmRhODA1ZTM5L3RhYmxlcmFuZ2U6MzAyNjc3Yzg0YTUzNGNhNGE1NjY5YTMyZGE4MDVlMzlfMi0yLTEtMS0w_be0ad90d-1d51-4534-a3dc-7240bec9c7f4">8,666</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RhYmxlOjMwMjY3N2M4NGE1MzRjYTRhNTY2OWEzMmRhODA1ZTM5L3RhYmxlcmFuZ2U6MzAyNjc3Yzg0YTUzNGNhNGE1NjY5YTMyZGE4MDVlMzlfMi00LTEtMS0w_dc5256d0-7fa7-4928-a79a-bf29346920b5">9,652</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RhYmxlOjMwMjY3N2M4NGE1MzRjYTRhNTY2OWEzMmRhODA1ZTM5L3RhYmxlcmFuZ2U6MzAyNjc3Yzg0YTUzNGNhNGE1NjY5YTMyZGE4MDVlMzlfMy0yLTEtMS0w_871896be-49f7-4fb5-a6b0-69d16eb0565c">8,830</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RhYmxlOjMwMjY3N2M4NGE1MzRjYTRhNTY2OWEzMmRhODA1ZTM5L3RhYmxlcmFuZ2U6MzAyNjc3Yzg0YTUzNGNhNGE1NjY5YTMyZGE4MDVlMzlfMy00LTEtMS0w_c9303268-0848-4f63-8c4b-bbd22eca7977">8,759</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventory</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RhYmxlOjMwMjY3N2M4NGE1MzRjYTRhNTY2OWEzMmRhODA1ZTM5L3RhYmxlcmFuZ2U6MzAyNjc3Yzg0YTUzNGNhNGE1NjY5YTMyZGE4MDVlMzlfNC0yLTEtMS0w_ad52c739-d9f9-4a11-992f-e21a4b4eadc6">18,373</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RhYmxlOjMwMjY3N2M4NGE1MzRjYTRhNTY2OWEzMmRhODA1ZTM5L3RhYmxlcmFuZ2U6MzAyNjc3Yzg0YTUzNGNhNGE1NjY5YTMyZGE4MDVlMzlfNC00LTEtMS0w_fc177104-3f16-438e-9f35-2b1c60786019">19,285</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company periodically reviews its inventories for excess amounts or obsolescence and writes down obsolete or otherwise unmarketable inventory to its estimated net realizable value. For the three months ended June 30, 2020, inventory write downs were immaterial. For the six months ended June 30, 2020, the Company recorded a $<ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfNjQ2OQ_58ccd245-2187-41f7-8a5e-ce65228b21c5">0.2</ix:nonFraction> million inventory write-down, primarily related to product approaching expiration.  <ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:InventoryWriteDown" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfNjU0OA_7c577c8c-3e29-430e-be41-48343c79c82b"><ix:nonFraction unitRef="usd" contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:InventoryWriteDown" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfNjU0OA_80fc5353-e921-4440-9f1b-3fd216280237">No</ix:nonFraction></ix:nonFraction> write downs were recorded for the three and six month periods ended June&#160;30, 2019. Additionally, though the Company&#8217;s product is subject to strict quality control and monitoring which it performs throughout the manufacturing processes, certain batches or units of product may not meet quality specifications resulting in a charge to cost of product sales. For the three and six month periods ended June&#160;30, 2020 and 2019, these amounts were immaterial.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cost of product sales</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cost of product sales consists of the cost of inventory sold, manufacturing and supply chain costs, storage costs, amortization of the acquired intangible asset and royalty payments associated with net product sales.  Production costs are expensed as cost of product sales when the related products are sold.</span></div></ix:continuation><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Revenue recognition</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Net product revenue</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company's net product revenue primarily consists of sales of Translarna in territories outside of the U.S. for the treatment of nmDMD and sales of Emflaza in the U.S. for the treatment of DMD.  The Company recognizes revenue when its performance obligations with its customers have been satisfied.  The Company&#8217;s performance obligations are to provide products based on customer orders from distributors, hospitals, specialty pharmacies or retail pharmacies.  The performance obligations are satisfied at a point in time when the Company&#8217;s customer obtains control of the product, which is typically upon delivery. The Company invoices its customers after the products have been delivered and invoice payments are generally due within 30 to 90 days of the invoice date.  The Company determines the transaction price based on fixed consideration in its contractual agreements. Contract liabilities arise in certain circumstances when consideration is due for goods the Company has yet to provide. As the Company has identified only one distinct performance obligation, the transaction price is allocated entirely to product sales. In determining the transaction price, a significant financing component does not exist since the timing from when the Company delivers product to when the customers pay for the product is typically less than one year. Customers in certain countries pay in advance of product delivery. In those instances, payment and delivery typically occur in the same month. </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company records product sales net of any variable consideration, which includes discounts, allowances, rebates related to Medicaid and other government pricing programs, and distribution fees. The Company uses the expected value or most likely amount method when estimating its variable consideration, unless discount or rebate terms are specified within contracts. The identified variable consideration is recorded as a reduction of revenue at the time revenues from product sales are recognized. These estimates for variable consideration are adjusted to reflect known changes in factors and may impact such estimates in the quarter those changes are known. Revenue recognized does not include amounts of variable consideration that are constrained.  For the three months ended June 30, 2020 and 2019, net product sales outside of the United States were $<ix:nonFraction unitRef="usd" contextRef="ib5e09658503d4a019b7c66616efd1b4d_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="ptct:NetProductSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfOTY1Mg_472e88fb-4d6e-4d7b-b5bf-d1b32d6d0959">39.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i70f85cc7508547529a1ddd69bf58968d_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="ptct:NetProductSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfOTY2MA_866acd3e-e209-4752-b956-71dcafbaf816">57.8</ix:nonFraction> million, respectively, and net product sales in the United States were $<ix:nonFraction unitRef="usd" contextRef="i9fcd6ae0b0b244eb992a22b9f010a8a9_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="ptct:NetProductSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfOTcyNQ_af08c740-5c75-4849-b710-027bbf9ae6aa">36.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0cac55e0c942455e8be47df4a5540bf5_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="ptct:NetProductSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfOTczMg_95510f06-07a4-4c13-a7c2-0f567fc3ba17">27.6</ix:nonFraction> million, respectively. For the six months ended June 30, 2020 and 2019, net product sales outside of the United States were $<ix:nonFraction unitRef="usd" contextRef="i8b2299918005400d83e8169cdceaa098_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="ptct:NetProductSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMTA0NDUzNjA0OTMyNjE_bbf8eb57-17c9-4b0a-b53e-0d65aa69baa0">79.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if04847b5828f40ffb96ff09abbfbe7f0_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="ptct:NetProductSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMTA0NDUzNjA0OTMyODk_1dd9044a-026b-4879-b477-be23aa250530">93.0</ix:nonFraction> million, respectively, and net product sales in the United States were $<ix:nonFraction unitRef="usd" contextRef="i245f190c344b472682efecbcf65a617f_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="ptct:NetProductSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMTA0NDUzNjA0OTMzODA_9effde0e-f268-4720-8a85-eb6c2c0b3be9">63.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i084808ce47024c3e9355cdfb5214b4ee_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="ptct:NetProductSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMTA0NDUzNjA0OTM0MDg_dfd4e89f-6713-4367-8eb4-9874f72feeb5">45.4</ix:nonFraction> million, respectively.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In relation to customer contracts, the Company incurs costs to fulfill a contract but does not incur costs to obtain a contract.  These costs to fulfill a contract do not meet the criteria for capitalization and are expensed as incurred. The Company considers any shipping and handling costs that are incurred after the customer has obtained control of the product as a cost to fulfill a promise. Shipping and handling costs associated with finished goods delivered to customers are recorded as a selling expense.  </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i0396c824498d4b3b8fa8dbfd308d8f8e" continuedAt="icc4cac88129d4362a88de2592447944d"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaboration revenue</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The terms of these agreements typically include payments to the Company of one or more of the following: nonrefundable, upfront license fees; milestone payments; research funding and royalties on future product sales. In addition, the Company generates service revenue through agreements that generally provide for fees for research and development services and may include additional payments upon achievement of specified events.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At the inception of a collaboration arrangement, the Company needs to first evaluate if the arrangement meets the criteria in ASC Topic 808 &#8220;Collaborative Arrangements&#8221; to then determine if ASC Topic 606 is applicable by considering whether the collaborator meets the definition of a customer.  If the criteria are met, the Company assesses the promises in the arrangement to identify distinct performance obligations.  </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For licenses of intellectual property, the Company assesses, at contract inception, whether the intellectual property is distinct from other performance obligations identified in the arrangement.  If the licensing of intellectual property is determined to be distinct, revenue is recognized for nonrefundable, upfront license fees when the license is transferred to the customer and the customer can use and benefit from the license.  If the licensing of intellectual property is determined not to be distinct, then the license will be bundled with other promises in the arrangement into one distinct performance obligation.  The Company needs to determine if the bundled performance obligation is satisfied over time or at a point in time.  If the Company concludes that the nonrefundable, upfront license fees will be recognized over time, the Company will need to assess the appropriate method of measuring proportional performance.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For milestone payments, the Company assesses, at contract inception, whether the development or sales-based milestones are considered probable of being achieved.  If it is probable that a significant revenue reversal will occur, the Company will not record revenue until the uncertainty has been resolved.  Milestone payments that are contingent upon regulatory approval are not considered probable of being achieved until the applicable regulatory approvals or other external conditions are obtained as such conditions are not within the Company's control.  If it is probable that a significant revenue reversal will not occur, the Company will estimate the milestone payments using the most likely amount method.  The Company will re-assess the development and sales-based milestones each reporting period to determine the probability of achievement.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company recognizes revenue for reimbursements of research and development costs under collaboration agreements as the services are performed. The Company records these reimbursements as revenue and not as a reduction of research and development expenses as the Company has the risks and rewards as the principal in the research and development activities.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMjkwNTU_1f5d4488-0d59-44b5-876e-bda73fe80b84" continuedAt="i5a8ba91963ac46c8ae5fcbee0f88c154" escape="true">Allowance for doubtful accounts</ix:nonNumeric></span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i5a8ba91963ac46c8ae5fcbee0f88c154">The Company maintains an allowance for estimated losses resulting from the inability of its customers to make required payments. The Company estimates uncollectible amounts based upon current customer receivable balances, the age of customer receivable balances, the customer&#8217;s financial condition and current economic trends.</ix:continuation> The allowance for doubtful accounts was $<ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMTM2ODg_658bd215-0df9-4581-b56b-5ce4af704251">0.2</ix:nonFraction> million as of June&#160;30, 2020 and $<ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMTM3MDQ_4a50c10d-9203-4a86-b9af-de4ccd60cece">0.3</ix:nonFraction> million as of December&#160;31, 2019. Bad debt expense was immaterial for the three and six month periods ended June&#160;30, 2020 and 2019. For the three and six month periods ended June&#160;30, 2020, <ix:nonFraction unitRef="usd" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMTM4Mjg_8d4daedc-1e2c-4208-a81a-24349c35c271"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMTM4Mjg_d9b8c139-e6bc-4734-8fa3-77c65c03de01">no</ix:nonFraction></ix:nonFraction> allowances were recorded for credit losses.</span></div><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMjkwNjk_f6d92ecd-c7c0-4953-80af-0bb7aaf19941" continuedAt="i058ed42dec0147e483014ac878324c38" escape="true"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Indefinite-lived intangible assets</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indefinite-lived intangible assets consist of in process research and development ("IPR&amp;D").  IPR&amp;D acquired directly in a transaction other than a business combination is capitalized if the projects will be further developed or have an alternative future use; otherwise they are expensed. The fair values of IPR&amp;D projects and license agreement assets acquired in business combinations are capitalized. Several methods may be used to determine the estimated fair value of the IPR&amp;D and license agreement asset acquired in a business combination. The Company utilizes the "income method&#8221; and uses estimated future net cash flows that are derived from projected sales revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, and expected pricing and industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. Intangible assets with indefinite lives, including IPR&amp;D, are tested for impairment if impairment indicators arise and, at a minimum, annually. However, an entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that an indefinite-lived intangible asset&#8217;s fair value is less than its carrying amount. Otherwise, no further impairment testing is required. The indefinite-lived intangible asset impairment test consists of a one-step analysis that compares the fair value of the intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company considers many factors in evaluating whether the value of its intangible assets with indefinite lives may not be recoverable, including, but not </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="icc4cac88129d4362a88de2592447944d" continuedAt="iecf82ae55dca4f41a4b975e6061ae637"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i058ed42dec0147e483014ac878324c38">limited to, expected growth rates, the cost of equity and debt capital, general economic conditions, the Company's outlook and market performance of the Company's industry and recent and forecasted financial performance.</ix:continuation></span></div><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMjkwNDM_500ba435-314d-4208-b28f-eaf233951559" escape="true"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Goodwill</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Goodwill represents the amount of consideration paid in excess of the fair value of net assets acquired as a result of the Company&#8217;s business acquisitions accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing at a reporting unit level on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. The Company reassess its reporting units as part of its annual segment review. An entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMjkwODQ_f3186c19-13b2-4ded-946c-7dbd3e7e938a" escape="true"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Income Taxes</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">O</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">n March 27, 2020, the United States enacted the Coronavirus Aid, Relief, and Economic Security Act, referred to herein as the CARES Act, as a response to the economic uncertainty resulting from a strain of novel coronavirus, COVID-19. The CARES Act includes modifications for net operating loss carryovers and carrybacks, limitations of business interest expense for tax, immediate refund of alternative minimum tax (AMT) credit carryovers as well as a technical correction to the 2017 Tax Cuts and Jobs Act ("the 2017 Tax Act"), referred to herein as the U.S. Tax Act, for qualified improvement property. As of June 30, 2020, the Company expects that these provisions will not have a material impact. Tax provisions of the Act also include the deferral of certain payroll taxes, relief for retaining employees, and other provisions. The Company is evaluating the impact of the Act and currently expects to benefit from the deferral of certain payroll taxes and retention credit through the end of calendar year 2020. The ultimate impact of the CARES Act may differ from this estimate due to changes in interpretations and guidance that may be issued and actions the Company may take in response to the CARES Act. The Company will continue to assess the impact that various provisions will have on its business.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On December 22, 2017, the U.S. government enacted the 2017 Tax Act, which significantly revises U.S. tax law by, among other provisions, lowering the U.S. federal statutory income tax rate to 21%, imposing a mandatory one-time transition tax on previously deferred foreign earnings, and eliminating or reducing certain income tax deductions. The Global Intangible Low-tax Income ("GILTI") provisions of the 2017 Tax Act require the Company to include in its U.S. income tax return foreign subsidiary earnings in excess of an allowable return on the foreign subsidiary&#8217;s tangible assets. The Company has elected to account for GILTI tax in the period in which it is incurred, and therefore has not provided any deferred tax impacts of GILTI in its consolidated financial statements for the period ended&#160;June&#160;30, 2020. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss and credit carryforwards. Deferred tax assets and liabilities are measured at rates expected to apply to taxable income in the years in which those temporary differences and carryforwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the statement of operations in the period that includes the enactment date. A valuation allowance is recorded when it is not more likely than not that all or a portion of the net deferred tax assets will be realized.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company recorded a deferred tax liability in conjunction with the Merger of $<ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMjAxMjc_6b562acd-cf2f-483a-9ac7-0fb0cc01183e">122.0</ix:nonFraction> million related to the tax basis difference in the IPR&amp;D indefinite-lived intangibles acquired. The Company's policy is to record a deferred tax liability related to acquired IPR&amp;D which may eventually be realized either upon amortization of the asset when the research is completed and a product is successfully launched or the write-off of the asset if it is abandoned or unsuccessful.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMjkwNDU_3b51ffb8-0517-4160-8c6f-66916517b678" continuedAt="if7ed5a4753e1472ea512fdcba6d10799" escape="true"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Leases</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. The Company has lease agreements which include lease and non-lease components, which the Company accounts for as a single lease component for all leases. Operating and finance leases are classified as right of use ("ROU") assets, short term lease liabilities, and long term lease liabilities. Operating and finance lease ROU assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. ROU assets are amortized and lease liabilities accrete to yield straight-line expense over the term of the lease. Lease payments included in the measurement of the lease liability are comprised of fixed payments. </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="iecf82ae55dca4f41a4b975e6061ae637" continuedAt="iea1daa343dbf49fb89e3a6c48ebcdbe3"><ix:continuation id="if7ed5a4753e1472ea512fdcba6d10799" continuedAt="i317f968336a0441783bb78064d5de75a"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Variable lease payments associated with the Company&#8217;s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented in the Company&#8217;s consolidated statements of operations in the same line item as expense arising from fixed lease payments for operating leases.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet and the Company recognizes lease expense for these leases on a straight-line basis over the lease term.  The Company applies this policy to all underlying asset categories.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A lessee is required to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As most of the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The Company gives consideration to its recent debt issuances as well as publicly available data for instruments with similar characteristics when calculating its incremental borrowing rates.</span></div></ix:continuation><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i317f968336a0441783bb78064d5de75a">The lease term for all of the Company&#8217;s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. Leasehold improvements are capitalized and depreciated over the lesser of useful life or lease term. See Note 4 Leases for additional information.</ix:continuation> </span></div><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMjkwODg_dcf57bc9-1ef9-46fa-9fcf-cfbd1089fee0" continuedAt="ibc91ae3e93994f62a6f9ed384a512209" escape="true"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Impact of recently adopted accounting pronouncements</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the FASB issued ASU 2019-12,"Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&#8221;.  ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principals in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending the existing guidance. For public business entities, the guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. For all other entities, it is effective for annual periods beginning after December 15, 2021 and interim periods in annual periods beginning after December 15, 2022. Early adoption is permitted, including adoption in any interim period. The Company early adopted this guidance January 1, 2020. The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June&#160;2016, the FASB issued ASU No.&#160;2016-13, &#8220;Financial Instruments &#8212; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#8221;. This standard requires financial assets measured at amortized cost basis to be presented at the net amount expected to be collected. This standard is effective for public companies who are SEC filers for fiscal years beginning after December&#160;15, 2019, including interim periods within those years. In November 2019, the FASB issued ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments - Credit Losses, which expands the scope of the practical expedient that allows entities to exclude the accrued interest component of amortized cost from various disclosures required by ASC 326 to also include certain disclosures required by ASC 320. Entities that elect to apply the practical expedient must disclose the total amount of accrued interest that they exclude from their disclosures of amortized cost. The amendments have the same effective dates as ASU 2016-13 (Topic 326) for entities that have not yet adopted that standard. The Company adopted ASU 2016-13 and ASU 2019-11 effective January 1, 2020. The adoption of the guidance did not have a material impact on the consolidated financial statements. The Company has updated its accounting policy for marketable securities within this footnote as well as its fair value footnote (Note 5) with additional disclosures as required by the standard upon adoption. </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued ASU 2018-13, "Fair Value Measurement (Topic 820), Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement". This standard eliminates certain disclosure requirements for fair value measurements for all entities, requires public entities to disclose certain new information and modifies some disclosure requirements. The new guidance is effective for all entities for fiscal years beginning after December 15, 2019 and for interim periods within those fiscal years. An entity is permitted to early adopt either the entire standard or only the provisions that eliminate or modify requirements. Entities can elect to early adopt in interim periods, including periods for which they have not yet issued financial statements or made their financial statements available for issuance. The Company adopted this guidance January 1, 2020.  The adoption of the guidance did not have a material impact on the consolidated financial statements. The Company has updated its fair value footnote (Note 5) with additional and modified disclosures as required by the standard upon adoption. </span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued ASU 2018-15,"Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract". ASU 2018-15 requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in Accounting Standards Codification 350-40 to determine which implementation costs to defer and recognize as an asset. For public business entities, the guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2019. For all other entities, it is effective for annual periods beginning after </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="iea1daa343dbf49fb89e3a6c48ebcdbe3"><ix:continuation id="ibc91ae3e93994f62a6f9ed384a512209"><div style="text-align:justify;margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">December 15, 2020 and interim periods in annual periods beginning after December 15, 2021. Early adoption is permitted, including adoption in any interim period for all entities. The Company adopted this guidance January 1, 2020.  The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2018, the FASB issued ASU 2018-18,"Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&#8221;.  ASU 2018-18 provides guidance on whether certain transactions between collaborative arrangement participants should be accounted for with revenue under Topic 606. For public business entities, the guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2019. For all other entities, it is effective for annual periods beginning after December 15, 2020 and interim periods in annual periods beginning after December 15, 2021. Early adoption is permitted, including adoption in any interim period for all entities.  The Company adopted this guidance January 1, 2020.  The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.</span></div></ix:continuation></ix:continuation><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8232;</span></div><div id="i95cf61a5c7074910ae3cf29c5ee08838_1426"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">3.&#160;<ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xNDI2L2ZyYWc6MGRiNWQ1MGE5ZWFmNDQ1ODliNjRiODdiYTE3MzNmMGUvdGV4dHJlZ2lvbjowZGI1ZDUwYTllYWY0NDU4OWI2NGI4N2JhMTczM2YwZV80Mzk4MDQ2NTUwMjQ0_92f6f939-4207-42b1-9c95-69f641f1a1aa" continuedAt="ibb8d97127cb6419bbb3285936181ca3a" escape="true">Acquisition&#8232;&#8232;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"><ix:continuation id="ibb8d97127cb6419bbb3285936181ca3a" continuedAt="iaa8b863f60eb46d8b13c066d328d808a">Censa Acquisition&#8232;</ix:continuation></span></div><ix:continuation id="iaa8b863f60eb46d8b13c066d328d808a"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">On May 29, 2020, the Company acquired Censa, pursuant to the Censa Merger Agreement. Upon the closing of the Censa Merger, the Company paid to the Censa securityholders (i) cash consideration of $<ix:nonFraction unitRef="usd" contextRef="i8742fae222d34cac83b189f51096e426_D20200529-20200529" decimals="-5" format="ixt:numdotdecimal" name="ptct:PaymentsforAssetAcquisitions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xNDI2L2ZyYWc6MGRiNWQ1MGE5ZWFmNDQ1ODliNjRiODdiYTE3MzNmMGUvdGV4dHJlZ2lvbjowZGI1ZDUwYTllYWY0NDU4OWI2NGI4N2JhMTczM2YwZV80Mzk4MDQ2NTQ5OTcw_ec2eb31e-438d-48f3-a281-25cdc495bf31">15.0</ix:nonFraction>&#160;million, which consisted of an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i8742fae222d34cac83b189f51096e426_D20200529-20200529" decimals="-5" format="ixt:numdotdecimal" name="ptct:PaymentsForAssetAcquisitionsUpfrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xNDI2L2ZyYWc6MGRiNWQ1MGE5ZWFmNDQ1ODliNjRiODdiYTE3MzNmMGUvdGV4dHJlZ2lvbjowZGI1ZDUwYTllYWY0NDU4OWI2NGI4N2JhMTczM2YwZV80Mzk4MDQ2NTUwMjMw_7c806709-bfa8-43ff-a3a5-a5a801ee982b">10.4</ix:nonFraction>&#160;million and an additional $<ix:nonFraction unitRef="usd" contextRef="i8742fae222d34cac83b189f51096e426_D20200529-20200529" decimals="-5" format="ixt:numdotdecimal" name="ptct:PaymentsForAssetAcquisitionsNetAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xNDI2L2ZyYWc6MGRiNWQ1MGE5ZWFmNDQ1ODliNjRiODdiYTE3MzNmMGUvdGV4dHJlZ2lvbjowZGI1ZDUwYTllYWY0NDU4OWI2NGI4N2JhMTczM2YwZV80Mzk4MDQ2NTQ5OTg1_74731d89-eb8a-46ba-aef1-6282a52ce137">4.6</ix:nonFraction>&#160;million for the net assets on Censa's opening balance sheet as of the date of the acquisition, and (ii) <ix:nonFraction unitRef="shares" contextRef="i8742fae222d34cac83b189f51096e426_D20200529-20200529" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xNDI2L2ZyYWc6MGRiNWQ1MGE5ZWFmNDQ1ODliNjRiODdiYTE3MzNmMGUvdGV4dHJlZ2lvbjowZGI1ZDUwYTllYWY0NDU4OWI2NGI4N2JhMTczM2YwZV80Mzk4MDQ2NTQ5OTk5_9507216f-a1ca-4b1f-a4d3-483377609a35">845,364</ix:nonFraction> shares of the Company's common stock, which were valued at $<ix:nonFraction unitRef="usd" contextRef="i8742fae222d34cac83b189f51096e426_D20200529-20200529" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xNDI2L2ZyYWc6MGRiNWQ1MGE5ZWFmNDQ1ODliNjRiODdiYTE3MzNmMGUvdGV4dHJlZ2lvbjowZGI1ZDUwYTllYWY0NDU4OWI2NGI4N2JhMTczM2YwZV80Mzk4MDQ2NTUwMDA4_4e4fb3ea-e784-4396-98bd-189c553c9552">42.9</ix:nonFraction>&#160;million based on the closing stock price on the acquisition date. The number of shares issued was determined using a 30-day VWAP pursuant to the Censa Merger Agreement.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company determined that substantially all of the fair value is concentrated in PTC923 and accounted for the transaction as an asset acquisition under ASC 805-50.  The purchase price consisted of the cash consideration of $<ix:nonFraction unitRef="usd" contextRef="i8742fae222d34cac83b189f51096e426_D20200529-20200529" decimals="-5" format="ixt:numdotdecimal" name="ptct:ConsiderationForAssetAcquisitions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xNDI2L2ZyYWc6MGRiNWQ1MGE5ZWFmNDQ1ODliNjRiODdiYTE3MzNmMGUvdGV4dHJlZ2lvbjowZGI1ZDUwYTllYWY0NDU4OWI2NGI4N2JhMTczM2YwZV80Mzk4MDQ2NTUwMDY2_ccc6eeab-0f0a-49aa-b1c8-8d1580a6b202">15.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="shares" contextRef="i8742fae222d34cac83b189f51096e426_D20200529-20200529" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xNDI2L2ZyYWc6MGRiNWQ1MGE5ZWFmNDQ1ODliNjRiODdiYTE3MzNmMGUvdGV4dHJlZ2lvbjowZGI1ZDUwYTllYWY0NDU4OWI2NGI4N2JhMTczM2YwZV80Mzk4MDQ2NTUwMDgx_1f188276-5a63-451b-92e6-13614821c0ca">42.9</ix:nonFraction>&#160;million in the Company's common stock, in addition to $<ix:nonFraction unitRef="usd" contextRef="i8742fae222d34cac83b189f51096e426_D20200529-20200529" decimals="-5" sign="-" format="ixt:numdotdecimal" name="ptct:AssetAcquisitionTransactionCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xNDI2L2ZyYWc6MGRiNWQ1MGE5ZWFmNDQ1ODliNjRiODdiYTE3MzNmMGUvdGV4dHJlZ2lvbjowZGI1ZDUwYTllYWY0NDU4OWI2NGI4N2JhMTczM2YwZV80Mzk4MDQ2NTUwMDIz_794c2b66-b343-45b3-a833-d98f71813f15">0.7</ix:nonFraction>&#160;million of acquisition costs. As such, the total consideration transferred was determined to be $<ix:nonFraction unitRef="usd" contextRef="i8742fae222d34cac83b189f51096e426_D20200529-20200529" decimals="-5" format="ixt:numdotdecimal" name="ptct:AssetAcquisitionConsiderationTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xNDI2L2ZyYWc6MGRiNWQ1MGE5ZWFmNDQ1ODliNjRiODdiYTE3MzNmMGUvdGV4dHJlZ2lvbjowZGI1ZDUwYTllYWY0NDU4OWI2NGI4N2JhMTczM2YwZV80Mzk4MDQ2NTUwMDM3_ac41794a-bf13-4d49-b56c-261e8ced5b54">58.6</ix:nonFraction>&#160;million. The opening balance sheet net assets of $<ix:nonFraction unitRef="usd" contextRef="i8742fae222d34cac83b189f51096e426_D20200529-20200529" decimals="-5" format="ixt:numdotdecimal" name="ptct:PaymentsForAssetAcquisitionsNetAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xNDI2L2ZyYWc6MGRiNWQ1MGE5ZWFmNDQ1ODliNjRiODdiYTE3MzNmMGUvdGV4dHJlZ2lvbjowZGI1ZDUwYTllYWY0NDU4OWI2NGI4N2JhMTczM2YwZV8xOTI0MTQ1MzUyNTI1Mg_fda350ce-3859-4e99-b9b2-23fe1e698597">4.6</ix:nonFraction>&#160;million, which consisted of cash of $<ix:nonFraction unitRef="usd" contextRef="i28fa54ad024443b18973875cc89f36e3_I20200529" decimals="-5" format="ixt:numdotdecimal" name="ptct:AssetAcquisitionCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xNDI2L2ZyYWc6MGRiNWQ1MGE5ZWFmNDQ1ODliNjRiODdiYTE3MzNmMGUvdGV4dHJlZ2lvbjowZGI1ZDUwYTllYWY0NDU4OWI2NGI4N2JhMTczM2YwZV80Mzk4MDQ2NTUwMTEx_dc6d342b-f058-4ae7-9ed0-898fe67e061d">3.8</ix:nonFraction>&#160;million and other current assets of $<ix:nonFraction unitRef="usd" contextRef="i28fa54ad024443b18973875cc89f36e3_I20200529" decimals="-5" format="ixt:numdotdecimal" name="ptct:AssetAcquisitionOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xNDI2L2ZyYWc6MGRiNWQ1MGE5ZWFmNDQ1ODliNjRiODdiYTE3MzNmMGUvdGV4dHJlZ2lvbjowZGI1ZDUwYTllYWY0NDU4OWI2NGI4N2JhMTczM2YwZV80Mzk4MDQ2NTUwMDUy_955b9deb-f490-416d-86d2-009c7e6c6383">0.8</ix:nonFraction>&#160;million, were determined to be non-qualifying assets and recorded at their fair values, respectively. The remaining consideration of $<ix:nonFraction unitRef="usd" contextRef="i28fa54ad024443b18973875cc89f36e3_I20200529" decimals="-5" format="ixt:numdotdecimal" name="ptct:AssetAcquisitionInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xNDI2L2ZyYWc6MGRiNWQ1MGE5ZWFmNDQ1ODliNjRiODdiYTE3MzNmMGUvdGV4dHJlZ2lvbjowZGI1ZDUwYTllYWY0NDU4OWI2NGI4N2JhMTczM2YwZV80Mzk4MDQ2NTUwMDk2_c83e0bc5-6e71-4e46-a203-7896afd9a333">54.0</ix:nonFraction>&#160;million was allocated to PTC923. As PTC923 is an IPR&amp;D asset, the Company concluded that it did not have any alternative future use, and accordingly, the fair value amount allocated to the IPR&amp;D was expensed. Of the $<ix:nonFraction unitRef="usd" contextRef="i28fa54ad024443b18973875cc89f36e3_I20200529" decimals="-5" format="ixt:numdotdecimal" name="ptct:AssetAcquisitionInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xNDI2L2ZyYWc6MGRiNWQ1MGE5ZWFmNDQ1ODliNjRiODdiYTE3MzNmMGUvdGV4dHJlZ2lvbjowZGI1ZDUwYTllYWY0NDU4OWI2NGI4N2JhMTczM2YwZV80Mzk4MDQ2NTUwMTQw_5dae782e-d98a-4a5c-87f2-c58c2b9bc43d">54.0</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i8742fae222d34cac83b189f51096e426_D20200529-20200529" decimals="-5" format="ixt:numdotdecimal" name="ptct:AssetAcquisitionResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xNDI2L2ZyYWc6MGRiNWQ1MGE5ZWFmNDQ1ODliNjRiODdiYTE3MzNmMGUvdGV4dHJlZ2lvbjowZGI1ZDUwYTllYWY0NDU4OWI2NGI4N2JhMTczM2YwZV80Mzk4MDQ2NTUwMTI1_bd6670bf-1cc6-49e4-b292-e595532fa5e5">53.3</ix:nonFraction>&#160;million is included in research and development expense and $<ix:nonFraction unitRef="usd" contextRef="i8742fae222d34cac83b189f51096e426_D20200529-20200529" decimals="-5" format="ixt:numdotdecimal" name="ptct:AssetAcquisitionSellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xNDI2L2ZyYWc6MGRiNWQ1MGE5ZWFmNDQ1ODliNjRiODdiYTE3MzNmMGUvdGV4dHJlZ2lvbjowZGI1ZDUwYTllYWY0NDU4OWI2NGI4N2JhMTczM2YwZV80Mzk4MDQ2NTUwMTU1_35143be8-ca37-421d-9ea4-caf5ac7e4e2e">0.7</ix:nonFraction>&#160;million is included in selling, general, and administrative expense within the Company's statement of operations for the three and six month periods ended June 30, 2020. In addition, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="i8742fae222d34cac83b189f51096e426_D20200529-20200529" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xNDI2L2ZyYWc6MGRiNWQ1MGE5ZWFmNDQ1ODliNjRiODdiYTE3MzNmMGUvdGV4dHJlZ2lvbjowZGI1ZDUwYTllYWY0NDU4OWI2NGI4N2JhMTczM2YwZV8zMjk4NTM0OTIyODc0_e5842f55-35b9-4532-8345-4da17f832dc5">0.3</ix:nonFraction>&#160;million of other expenses related to Censa, which was included in research and development expense for the three and six month periods ended June 30, 2020. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Subject to the terms and conditions of the Censa Merger Agreement, Censa securityholders may become entitled to receive contingent payments from the Company based on (i) the achievement of certain development and regulatory milestones up to an aggregate maximum amount of $<ix:nonFraction unitRef="usd" contextRef="i28fa54ad024443b18973875cc89f36e3_I20200529" decimals="-5" format="ixt:numdotdecimal" name="ptct:AssetAcquisitionMilestoneAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xNDI2L2ZyYWc6MGRiNWQ1MGE5ZWFmNDQ1ODliNjRiODdiYTE3MzNmMGUvdGV4dHJlZ2lvbjowZGI1ZDUwYTllYWY0NDU4OWI2NGI4N2JhMTczM2YwZV80Mzk4MDQ2NTUwMTY5_27e3a955-d59c-438f-a958-68fe34703c32">217.5</ix:nonFraction>&#160;million for PTC923's two most advanced programs and receipt of a priority review voucher from the FDA as set forth in the Censa Merger Agreement, (ii) $<ix:nonFraction unitRef="usd" contextRef="i28fa54ad024443b18973875cc89f36e3_I20200529" decimals="-5" format="ixt:numdotdecimal" name="ptct:AssetAcquisitionDevelopmentAndRegulatoryMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xNDI2L2ZyYWc6MGRiNWQ1MGE5ZWFmNDQ1ODliNjRiODdiYTE3MzNmMGUvdGV4dHJlZ2lvbjowZGI1ZDUwYTllYWY0NDU4OWI2NGI4N2JhMTczM2YwZV80Mzk4MDQ2NTUwMTg1_0424ba6a-2fc6-41a0-8d9b-2e1429151054">109</ix:nonFraction>&#160;million in development and regulatory milestones for each additional indication of PTC923, (iii) the achievement of certain net sales milestones up to an aggregate maximum amount of $<ix:nonFraction unitRef="usd" contextRef="i28fa54ad024443b18973875cc89f36e3_I20200529" decimals="-5" format="ixt:numdotdecimal" name="ptct:AssetAcquisitionNetSalesMilestone" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xNDI2L2ZyYWc6MGRiNWQ1MGE5ZWFmNDQ1ODliNjRiODdiYTE3MzNmMGUvdGV4dHJlZ2lvbjowZGI1ZDUwYTllYWY0NDU4OWI2NGI4N2JhMTczM2YwZV80Mzk4MDQ2NTUwMTk5_0a1a804b-e104-4ea9-a820-fe45026cb622">160.0</ix:nonFraction>&#160;million, (iv) a percentage of annual net sales during specified terms, ranging from single to low double digits of the applicable net sales threshold amount, and (v) any sublicense fees paid to the Company in consideration of any sublicense of Censa&#8217;s intellectual property to commercialize PTC923, on a country-by-country basis, which contingent payment shall equal to a mid-double digit percentage of any such sublicense fees. Pursuant to the Censa Merger Agreement, the Company has the option to pay the initial $<ix:nonFraction unitRef="usd" contextRef="i28fa54ad024443b18973875cc89f36e3_I20200529" decimals="-5" format="ixt:numdotdecimal" name="ptct:AssetAcquisitionInitialMilestone" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xNDI2L2ZyYWc6MGRiNWQ1MGE5ZWFmNDQ1ODliNjRiODdiYTE3MzNmMGUvdGV4dHJlZ2lvbjowZGI1ZDUwYTllYWY0NDU4OWI2NGI4N2JhMTczM2YwZV80Mzk4MDQ2NTUwMjE1_62022df5-55f6-4bd1-84c0-1d278cff5a19">30.0</ix:nonFraction>&#160;million development milestone, for the completion of enrollment of a Phase 3 clinical trial for PTC923 for PKU, if achieved, in cash or shares of the Company&#8217;s common stock (the &#8220;Initial Milestone&#8221;). The Company will record the milestone and royalty payments when they become payable. Milestone payments prior to FDA approval of PTC923 for PKU (or other indications) will be expensed accordingly and milestone payments that will only occur after PTC923 for PKU (or other indications) is FDA approved, will be capitalized and amortized over their expected useful lives.</span></div></ix:continuation><div style="text-align:justify;"><span><br/></span></div><div id="i95cf61a5c7074910ae3cf29c5ee08838_46"></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">4.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:700;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfNDM5ODA0NjUyOTA2OQ_0caea49c-a7ec-4cf9-97bd-4dd7b80d44b7" continuedAt="icdcb6bfe5a9444e981de3bfc78d4090b" escape="true">Leases</ix:nonNumeric></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;"><ix:continuation id="icdcb6bfe5a9444e981de3bfc78d4090b" continuedAt="i192f32391b294a2dbdd0d42b63754fb5">The Company leases office space in South Plainfield, New Jersey for its principal office under <ix:nonFraction unitRef="operating_lease" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="ptct:NumberOfOperatingLeases" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfMTEw_390357e0-3ab1-4fb4-93c0-bdc65f0a28e1">three</ix:nonFraction> noncancelable operating leases through May 2022 and August 2024, in addition to office space in various countries for international employees primarily through workspace providers. The Company also leases certain vehicles, lab equipment, and office equipment under operating leases. The Company&#8217;s leases have remaining operating lease terms ranging from <ix:nonNumeric contextRef="i534a161919c644babf7b581f8815a9ae_I20200630" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfNDY3_49dae317-cdae-492a-8eaf-07a5f4382d3a">0.3</ix:nonNumeric> years to <ix:nonNumeric contextRef="iee26b7ab0eb3427894a7e80a6ab4b557_I20200630" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfNDc5_535e75ed-7f0d-4d8d-9e2c-9c201903b78b">6.9</ix:nonNumeric> years and certain of the leases include renewal options to extend the lease for up to <ix:nonNumeric contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfNTY4_d1c62799-21b7-43a1-b21a-108c2c1222e7">10</ix:nonNumeric> years. Rent expense was approximately $<ix:nonFraction unitRef="usd" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfNjAz_e966b4d3-2fba-4bdd-ba10-72991796b543">2.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfNjEw_8ce0fdf9-255d-4a45-9bf5-4de50af94db4">5.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfMzI5ODUzNDg4ODkxNw_7d58506e-f83a-44b8-9f99-9747e31f8d7f">1.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfMzI5ODUzNDg4ODkzMg_83ef49ac-45e4-433d-bce4-eaefd4f779cd">2.1</ix:nonFraction> million for the three and six month periods ended June 30, 2020 and 2019, respectively. </ix:continuation></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i192f32391b294a2dbdd0d42b63754fb5" continuedAt="id78f488c8bc647cd83aaa82cbb3c5886"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">&#8232;&#8232;On June 19, 2020, the Company entered into a commercial manufacturing service agreement for a term of <ix:nonNumeric contextRef="i9b91bdabba504b27a63eb72dd4e14072_I20200630" format="ixt-sec:duryear" name="us-gaap:LesseeFinanceLeaseTermOfContract1" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfMjc0ODc3OTA4MDM1Nw_3e9edc82-814e-4732-b0dc-35005855d277">12.5</ix:nonNumeric> years with MassBiologics of the University of Massachusetts Medical School ("MassBio"). The agreement will expire on December 31, 2032 unless the Company terminates it on 24 months prior written notice to MassBio. Pursuant to the terms of the agreement, MassBio agreed to provide the Company with four dedicated rooms for its gene therapy AADC program. The Company concluded that the agreement contains an embedded lease as the Company controls the use of the four dedicated rooms and the equipment therein. As the present value of the facilities exceeds the assessed fair value, the Company determined that it is a finance lease. Given that the embedded finance lease is designed for the production of PTC&#8217;s AADC program and would not have an alternate use outside the PTC gene therapy platform without incurring significant costs, the Company determined that the lease should be treated as research and development expense under ASC 730 and accordingly, expensed the present value of all g</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">uaranteed future cash payments of $<ix:nonFraction unitRef="usd" contextRef="iad9435fcf1974f729382cb45345d15cf_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfMzI5ODUzNDg5ODI3Nw_368d8cea-d495-4cbd-a64a-a61a7b9b59f5"><ix:nonFraction unitRef="usd" contextRef="i2eddd9a393564222bc0988444831fd19_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfMzI5ODUzNDg5ODI3Nw_5e4ce2f2-8cfc-43f1-a210-adfcf0e41fc9">41.2</ix:nonFraction></ix:nonFraction> million during the three and six month periods ending June 30, 2020. Additionally, during the three and six month periods ending June 30, 2020, the Company did not record finance lease costs as these amounts were not material due to timing of entering into the lease. The Company will record finance lease costs in the third quarter of 2020. </span></div><div style="text-align:justify;"><span><br/></span></div><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfNDgwMg_c794adb8-26e4-40ca-b690-867bf928a030" continuedAt="ic4e511387c9d4370b80eabbf1d240848" escape="true"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The components of operating lease expense were as follows:</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:33.672%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.643%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.643%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.643%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.501%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30, 2019</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating Lease Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fixed lease cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjhlNGM5NzRhNWY4ODQyZDg4OGYyMDZlYzkzYmUyZGY0L3RhYmxlcmFuZ2U6OGU0Yzk3NGE1Zjg4NDJkODg4ZjIwNmVjOTNiZTJkZjRfMi0xLTEtMS0w_d5e570b8-7427-4dbd-be79-b07ef76848d5">1,970</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjhlNGM5NzRhNWY4ODQyZDg4OGYyMDZlYzkzYmUyZGY0L3RhYmxlcmFuZ2U6OGU0Yzk3NGE1Zjg4NDJkODg4ZjIwNmVjOTNiZTJkZjRfMi0yLTEtMS0w_3ac1f93f-04e9-410b-81f9-3c24b2c6c77d">835</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjhlNGM5NzRhNWY4ODQyZDg4OGYyMDZlYzkzYmUyZGY0L3RhYmxlcmFuZ2U6OGU0Yzk3NGE1Zjg4NDJkODg4ZjIwNmVjOTNiZTJkZjRfMi00LTEtMS0w_da5455ed-e67f-4dc1-924a-2f9afc5f249c">4,089</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjhlNGM5NzRhNWY4ODQyZDg4OGYyMDZlYzkzYmUyZGY0L3RhYmxlcmFuZ2U6OGU0Yzk3NGE1Zjg4NDJkODg4ZjIwNmVjOTNiZTJkZjRfMy03LTEtMS0xMzA3_3221c32b-7881-4e84-bb77-42d3fb9f2903">1,647</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Variable lease cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjhlNGM5NzRhNWY4ODQyZDg4OGYyMDZlYzkzYmUyZGY0L3RhYmxlcmFuZ2U6OGU0Yzk3NGE1Zjg4NDJkODg4ZjIwNmVjOTNiZTJkZjRfMy0xLTEtMS0w_709cd8e3-c117-4e02-80bc-123b9a0fc56f">507</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjhlNGM5NzRhNWY4ODQyZDg4OGYyMDZlYzkzYmUyZGY0L3RhYmxlcmFuZ2U6OGU0Yzk3NGE1Zjg4NDJkODg4ZjIwNmVjOTNiZTJkZjRfMy0yLTEtMS0w_40bd3450-4dec-48d2-a5b4-325b984fc522">161</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjhlNGM5NzRhNWY4ODQyZDg4OGYyMDZlYzkzYmUyZGY0L3RhYmxlcmFuZ2U6OGU0Yzk3NGE1Zjg4NDJkODg4ZjIwNmVjOTNiZTJkZjRfMy00LTEtMS0w_f6f9340e-7e74-4342-a344-9199857a1263">734</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjhlNGM5NzRhNWY4ODQyZDg4OGYyMDZlYzkzYmUyZGY0L3RhYmxlcmFuZ2U6OGU0Yzk3NGE1Zjg4NDJkODg4ZjIwNmVjOTNiZTJkZjRfNC03LTEtMS0xMzA3_eede8cd4-3fa7-4c8b-9925-4fed2550f376">304</ix:nonFraction></span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term lease cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjhlNGM5NzRhNWY4ODQyZDg4OGYyMDZlYzkzYmUyZGY0L3RhYmxlcmFuZ2U6OGU0Yzk3NGE1Zjg4NDJkODg4ZjIwNmVjOTNiZTJkZjRfNC0xLTEtMS0w_7d13a9f8-85c1-46da-98c9-830ed6078e04">88</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjhlNGM5NzRhNWY4ODQyZDg4OGYyMDZlYzkzYmUyZGY0L3RhYmxlcmFuZ2U6OGU0Yzk3NGE1Zjg4NDJkODg4ZjIwNmVjOTNiZTJkZjRfNC0yLTEtMS0w_b611711c-b584-4201-aa06-57dc485b57b6">88</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjhlNGM5NzRhNWY4ODQyZDg4OGYyMDZlYzkzYmUyZGY0L3RhYmxlcmFuZ2U6OGU0Yzk3NGE1Zjg4NDJkODg4ZjIwNmVjOTNiZTJkZjRfNC00LTEtMS0w_4bab1c9a-2867-47fc-b6dd-790d9ca08fd6">165</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjhlNGM5NzRhNWY4ODQyZDg4OGYyMDZlYzkzYmUyZGY0L3RhYmxlcmFuZ2U6OGU0Yzk3NGE1Zjg4NDJkODg4ZjIwNmVjOTNiZTJkZjRfNS03LTEtMS0xMzA3_f5bbea37-ad80-4674-9dc3-712046494a41">141</ix:nonFraction></span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating lease cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjhlNGM5NzRhNWY4ODQyZDg4OGYyMDZlYzkzYmUyZGY0L3RhYmxlcmFuZ2U6OGU0Yzk3NGE1Zjg4NDJkODg4ZjIwNmVjOTNiZTJkZjRfNS0xLTEtMS0w_c9532530-d9bf-4cfb-95d7-aa83faac406d">2,565</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjhlNGM5NzRhNWY4ODQyZDg4OGYyMDZlYzkzYmUyZGY0L3RhYmxlcmFuZ2U6OGU0Yzk3NGE1Zjg4NDJkODg4ZjIwNmVjOTNiZTJkZjRfNS0yLTEtMS0w_24fa97f6-e63c-4496-914c-0ff61f0c6a49">1,084</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjhlNGM5NzRhNWY4ODQyZDg4OGYyMDZlYzkzYmUyZGY0L3RhYmxlcmFuZ2U6OGU0Yzk3NGE1Zjg4NDJkODg4ZjIwNmVjOTNiZTJkZjRfNS00LTEtMS0w_e51508b1-cebd-4613-aa19-b395d0502c2a">4,988</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjhlNGM5NzRhNWY4ODQyZDg4OGYyMDZlYzkzYmUyZGY0L3RhYmxlcmFuZ2U6OGU0Yzk3NGE1Zjg4NDJkODg4ZjIwNmVjOTNiZTJkZjRfNi03LTEtMS0xMzA3_ab6bb1a1-fdc0-45a1-a4df-3e44d3f367f6">2,092</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total operating lease cost is a component of operating expenses on the consolidated statements of operations. </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Supplemental balance sheet information related to leases was as follows:</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:56.187%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:18.614%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:18.615%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease ROU asset</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjA1ZjAyOTM5YmVhNzRlY2ZhNzI3MmQ5MDJkNDMzYTcxL3RhYmxlcmFuZ2U6MDVmMDI5MzliZWE3NGVjZmE3MjcyZDkwMmQ0MzNhNzFfMi0xLTEtMS0w_b09120d3-2858-4c8b-998b-548d7621083d">29,475</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjA1ZjAyOTM5YmVhNzRlY2ZhNzI3MmQ5MDJkNDMzYTcxL3RhYmxlcmFuZ2U6MDVmMDI5MzliZWE3NGVjZmE3MjcyZDkwMmQ0MzNhNzFfMi0yLTEtMS0w_8d85015b-72d6-4518-8631-fe249d36c0cc">13,693</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities- current</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjA1ZjAyOTM5YmVhNzRlY2ZhNzI3MmQ5MDJkNDMzYTcxL3RhYmxlcmFuZ2U6MDVmMDI5MzliZWE3NGVjZmE3MjcyZDkwMmQ0MzNhNzFfNC0xLTEtMS0w_db819f10-15c4-43a1-9524-f66881c26b77">4,868</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjA1ZjAyOTM5YmVhNzRlY2ZhNzI3MmQ5MDJkNDMzYTcxL3RhYmxlcmFuZ2U6MDVmMDI5MzliZWE3NGVjZmE3MjcyZDkwMmQ0MzNhNzFfNC0yLTEtMS0w_003876c3-9642-4a28-ae51-32ac2b7c5460">5,153</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities- noncurrent</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjA1ZjAyOTM5YmVhNzRlY2ZhNzI3MmQ5MDJkNDMzYTcxL3RhYmxlcmFuZ2U6MDVmMDI5MzliZWE3NGVjZmE3MjcyZDkwMmQ0MzNhNzFfNS0xLTEtMS0w_2068e039-355b-4e39-b4ab-761935b813c7">25,510</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjA1ZjAyOTM5YmVhNzRlY2ZhNzI3MmQ5MDJkNDMzYTcxL3RhYmxlcmFuZ2U6MDVmMDI5MzliZWE3NGVjZmE3MjcyZDkwMmQ0MzNhNzFfNS0yLTEtMS0w_3eb63484-fb09-4e93-aaae-463a7695ac37">9,018</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating lease liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjA1ZjAyOTM5YmVhNzRlY2ZhNzI3MmQ5MDJkNDMzYTcxL3RhYmxlcmFuZ2U6MDVmMDI5MzliZWE3NGVjZmE3MjcyZDkwMmQ0MzNhNzFfNi0xLTEtMS0w_e7e7ce70-8253-453a-af47-d6c2655b68fe">30,378</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjA1ZjAyOTM5YmVhNzRlY2ZhNzI3MmQ5MDJkNDMzYTcxL3RhYmxlcmFuZ2U6MDVmMDI5MzliZWE3NGVjZmE3MjcyZDkwMmQ0MzNhNzFfNi0yLTEtMS0w_05304848-83d1-4862-9773-ab61a44ba8f1">14,171</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8232;&#8232;</span></div><div><ix:continuation id="ic4e511387c9d4370b80eabbf1d240848" continuedAt="i5b0928ccfad948e895338887fde4cc1f"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:56.064%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:18.674%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.386%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:18.676%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance lease liabilities- current</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjliZjAxZDFmZDc5NTQ3NjhiMGQzNjY1NGU0NmE0MDdhL3RhYmxlcmFuZ2U6OWJmMDFkMWZkNzk1NDc2OGIwZDM2NjU0ZTQ2YTQwN2FfNC0xLTEtMS00NDA3_92f8cbd7-90bb-45e0-b215-eb585d292ee2">4,180</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjliZjAxZDFmZDc5NTQ3NjhiMGQzNjY1NGU0NmE0MDdhL3RhYmxlcmFuZ2U6OWJmMDFkMWZkNzk1NDc2OGIwZDM2NjU0ZTQ2YTQwN2FfNC0yLTEtMS00NDEy_c8349600-1eed-4c2f-87fe-2b5cd6c1169a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance lease liabilities- noncurrent</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjliZjAxZDFmZDc5NTQ3NjhiMGQzNjY1NGU0NmE0MDdhL3RhYmxlcmFuZ2U6OWJmMDFkMWZkNzk1NDc2OGIwZDM2NjU0ZTQ2YTQwN2FfNS0xLTEtMS00NDA3_09aaa71f-399c-41c9-8bae-98fd51dbf7fa">22,031</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjliZjAxZDFmZDc5NTQ3NjhiMGQzNjY1NGU0NmE0MDdhL3RhYmxlcmFuZ2U6OWJmMDFkMWZkNzk1NDc2OGIwZDM2NjU0ZTQ2YTQwN2FfNS0yLTEtMS00NDEy_b916372e-1032-4be5-980e-13e1f95834c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total finance lease liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjliZjAxZDFmZDc5NTQ3NjhiMGQzNjY1NGU0NmE0MDdhL3RhYmxlcmFuZ2U6OWJmMDFkMWZkNzk1NDc2OGIwZDM2NjU0ZTQ2YTQwN2FfNi0xLTEtMS02NDA1_1f96dec5-254c-4914-8706-c980a5e4cf08">26,211</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:FinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjliZjAxZDFmZDc5NTQ3NjhiMGQzNjY1NGU0NmE0MDdhL3RhYmxlcmFuZ2U6OWJmMDFkMWZkNzk1NDc2OGIwZDM2NjU0ZTQ2YTQwN2FfNi0zLTEtMS02NDA3_29687407-4d6c-4a90-9cb8-38e0cf9f1401">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8232;Operating lease ROU asset is a component of deposits and other assets on the consolidated balance sheets. The current portion of operating lease liabilities is a component of other current liabilities on the consolidated balance sheets. The long term portion of operating lease liabilities is a component of other long term liabilities on the consolidated balance sheets.  The Company entered into a lease agreement with COE Bridgewater LLC on March 20, 2020 relating to the lease of office and laboratory space located in Bridgewater, New Jersey. This lease replaced the Company's existing lease on the property beginning on May 1, 2020 and includes additional rental property of approximately <ix:nonFraction unitRef="sqft" contextRef="i70c896353309469f838542acfc22aa9e_I20200501" decimals="0" format="ixt:numdotdecimal" name="ptct:LeaseArea" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfNDM5ODA0NjUyOTA1MA_c410803f-2450-4cab-82e1-ae45600bca99">59,000</ix:nonFraction> square feet and is the primary driver of the increase in total operating lease ROU asset and total operating lease liability from December 31, 2029 to June 30, 2020.  </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i5b0928ccfad948e895338887fde4cc1f" continuedAt="i227741b3d80d4ab2a271bcad605b66d1">Supplemental lease term and discount rate information related to leases was as follows as of June 30, 2020 and 2019:</ix:continuation></span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="id78f488c8bc647cd83aaa82cbb3c5886" continuedAt="i4e7cadbe3dbd40b9887af8ae2fdfb07d"><ix:continuation id="i227741b3d80d4ab2a271bcad605b66d1"><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:56.125%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:18.644%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.385%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:18.646%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average remaining lease terms - operating leases (years)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjU4MDJmNmJjYTE2ZjQ4ZWQ5OGIzODZhZWRjNjUzYzgyL3RhYmxlcmFuZ2U6NTgwMmY2YmNhMTZmNDhlZDk4YjM4NmFlZGM2NTNjODJfMi0xLTEtMS0w_af614e2b-5e9b-4051-bfca-05fd104c8784">5.87</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjU4MDJmNmJjYTE2ZjQ4ZWQ5OGIzODZhZWRjNjUzYzgyL3RhYmxlcmFuZ2U6NTgwMmY2YmNhMTZmNDhlZDk4YjM4NmFlZGM2NTNjODJfMi0yLTEtMS0w_04b3ffb3-2927-49fc-8f78-4da2dcacc333">3.38</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average discount rate - operating leases</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjU4MDJmNmJjYTE2ZjQ4ZWQ5OGIzODZhZWRjNjUzYzgyL3RhYmxlcmFuZ2U6NTgwMmY2YmNhMTZmNDhlZDk4YjM4NmFlZGM2NTNjODJfMy0xLTEtMS0w_6350988c-3b57-4aba-a989-9b2ddca3f2b3">6.77</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjU4MDJmNmJjYTE2ZjQ4ZWQ5OGIzODZhZWRjNjUzYzgyL3RhYmxlcmFuZ2U6NTgwMmY2YmNhMTZmNDhlZDk4YjM4NmFlZGM2NTNjODJfMy0yLTEtMS0w_713e75bb-c8dc-49c4-a2ae-ecb27ee93b03">7.33</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average remaining lease terms - finance lease (years)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjU4MDJmNmJjYTE2ZjQ4ZWQ5OGIzODZhZWRjNjUzYzgyL3RhYmxlcmFuZ2U6NTgwMmY2YmNhMTZmNDhlZDk4YjM4NmFlZGM2NTNjODJfNC0xLTEtMS00NTAw_cb373db2-61c2-4493-942b-690039602ffb">12.50</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average discount rate - finance lease</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="4" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjU4MDJmNmJjYTE2ZjQ4ZWQ5OGIzODZhZWRjNjUzYzgyL3RhYmxlcmFuZ2U6NTgwMmY2YmNhMTZmNDhlZDk4YjM4NmFlZGM2NTNjODJfNS0xLTEtMS00NTA2_05c8efa5-bb24-4fa8-aaa1-4d7860fd3e67">7.80</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8232;</span></div><div style="margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Supplemental cash flow information related to leases was as follows as of June 30, 2020 and 2019:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:56.125%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:18.644%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.385%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:18.646%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Month Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating cash flows from operating leases</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjc5MGI1MWIzMzg5ZTRkMjg5MTRkNmY0Zjk1ZDcwNDdlL3RhYmxlcmFuZ2U6NzkwYjUxYjMzODllNGQyODkxNGQ2ZjRmOTVkNzA0N2VfMy0xLTEtMS0zNDc5_8a9afd81-4b36-474c-a65b-5e476337cf03">3,414</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjc5MGI1MWIzMzg5ZTRkMjg5MTRkNmY0Zjk1ZDcwNDdlL3RhYmxlcmFuZ2U6NzkwYjUxYjMzODllNGQyODkxNGQ2ZjRmOTVkNzA0N2VfMy0zLTEtMS02ODI0_8cb36620-fabd-47bf-8af2-58cd738140fa">1,508</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financing cash flows from finance lease</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjc5MGI1MWIzMzg5ZTRkMjg5MTRkNmY0Zjk1ZDcwNDdlL3RhYmxlcmFuZ2U6NzkwYjUxYjMzODllNGQyODkxNGQ2ZjRmOTVkNzA0N2VfNC0xLTEtMS00NTQ0_99e74311-6d3f-4325-be4e-9cc1e8c8f579">15,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjc5MGI1MWIzMzg5ZTRkMjg5MTRkNmY0Zjk1ZDcwNDdlL3RhYmxlcmFuZ2U6NzkwYjUxYjMzODllNGQyODkxNGQ2ZjRmOTVkNzA0N2VfNC0zLTEtMS00NTQ4_baa7a191-ada0-48e7-b94d-c3bb495c6a13">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating leases</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjc5MGI1MWIzMzg5ZTRkMjg5MTRkNmY0Zjk1ZDcwNDdlL3RhYmxlcmFuZ2U6NzkwYjUxYjMzODllNGQyODkxNGQ2ZjRmOTVkNzA0N2VfNS0xLTEtMS0zNTE1_0224a9f6-33fb-4aba-b803-633bcfa13eb5">18,117</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjc5MGI1MWIzMzg5ZTRkMjg5MTRkNmY0Zjk1ZDcwNDdlL3RhYmxlcmFuZ2U6NzkwYjUxYjMzODllNGQyODkxNGQ2ZjRmOTVkNzA0N2VfNS0zLTEtMS0zNTE5_65a44c65-ca93-4109-b2a2-15c82800a193">11,643</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance lease</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjc5MGI1MWIzMzg5ZTRkMjg5MTRkNmY0Zjk1ZDcwNDdlL3RhYmxlcmFuZ2U6NzkwYjUxYjMzODllNGQyODkxNGQ2ZjRmOTVkNzA0N2VfOC0xLTEtMS00NTU0_c3753d39-11fe-459b-9f23-0fa3dd97c60d">41,212</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjc5MGI1MWIzMzg5ZTRkMjg5MTRkNmY0Zjk1ZDcwNDdlL3RhYmxlcmFuZ2U6NzkwYjUxYjMzODllNGQyODkxNGQ2ZjRmOTVkNzA0N2VfOC0zLTEtMS00NTU4_67607836-0beb-44a6-becd-5c4e5fb30ab8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:continuation><div style="margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8232;&#8232;<ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfNDc5NQ_d0967cb8-db4e-438a-936a-cacf57f8829d" continuedAt="i21680aa985714deab374631cf62e478b" escape="true">Future minimum lease payments under non-cancelable leases as of June&#160;30, 2020 were as follows:</ix:nonNumeric></span></div><div style="margin-bottom:6pt;"><ix:continuation id="i21680aa985714deab374631cf62e478b"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:35.134%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:29.140%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:29.142%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating Leases</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance Lease</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020 (excludes the six months ended June 30, 2020)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjQwNmJmMmQ1OTNlYzRkMjVhMWU5YzAwNTBmMzVjMTBlL3RhYmxlcmFuZ2U6NDA2YmYyZDU5M2VjNGQyNWExZTljMDA1MGYzNWMxMGVfMS0xLTEtMS0w_a3e7fe89-7bb7-4950-a770-af9391af75d0">3,719</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjQwNmJmMmQ1OTNlYzRkMjVhMWU5YzAwNTBmMzVjMTBlL3RhYmxlcmFuZ2U6NDA2YmYyZDU5M2VjNGQyNWExZTljMDA1MGYzNWMxMGVfMS0yLTEtMS00NTcw_d0e8bb9f-6e03-4c0c-ba6b-4a0e4a8a7852">3,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjQwNmJmMmQ1OTNlYzRkMjVhMWU5YzAwNTBmMzVjMTBlL3RhYmxlcmFuZ2U6NDA2YmYyZDU5M2VjNGQyNWExZTljMDA1MGYzNWMxMGVfMi0xLTEtMS0w_6438a5ef-90c5-489f-aebd-1a6461f37bc0">6,667</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjQwNmJmMmQ1OTNlYzRkMjVhMWU5YzAwNTBmMzVjMTBlL3RhYmxlcmFuZ2U6NDA2YmYyZDU5M2VjNGQyNWExZTljMDA1MGYzNWMxMGVfMi0yLTEtMS00NTcw_6c5e8cb0-21e8-4e44-864f-a4226abda94c">3,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjQwNmJmMmQ1OTNlYzRkMjVhMWU5YzAwNTBmMzVjMTBlL3RhYmxlcmFuZ2U6NDA2YmYyZDU5M2VjNGQyNWExZTljMDA1MGYzNWMxMGVfMy0xLTEtMS0w_826dcba9-5d89-4aad-aac8-52de8262f534">6,314</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjQwNmJmMmQ1OTNlYzRkMjVhMWU5YzAwNTBmMzVjMTBlL3RhYmxlcmFuZ2U6NDA2YmYyZDU5M2VjNGQyNWExZTljMDA1MGYzNWMxMGVfMy0yLTEtMS00NTcw_277978d0-8c2b-4e5e-bc03-f6dcfcf344e9">3,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjQwNmJmMmQ1OTNlYzRkMjVhMWU5YzAwNTBmMzVjMTBlL3RhYmxlcmFuZ2U6NDA2YmYyZDU5M2VjNGQyNWExZTljMDA1MGYzNWMxMGVfNC0xLTEtMS0w_29922930-dde2-4de3-b929-e246c93e65cd">5,960</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjQwNmJmMmQ1OTNlYzRkMjVhMWU5YzAwNTBmMzVjMTBlL3RhYmxlcmFuZ2U6NDA2YmYyZDU5M2VjNGQyNWExZTljMDA1MGYzNWMxMGVfNC0yLTEtMS00NTcw_f5d78054-9e6e-493f-9dd1-b4d8294f03d0">3,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024 and thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="ptct:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjQwNmJmMmQ1OTNlYzRkMjVhMWU5YzAwNTBmMzVjMTBlL3RhYmxlcmFuZ2U6NDA2YmYyZDU5M2VjNGQyNWExZTljMDA1MGYzNWMxMGVfNS0xLTEtMS0w_0f017bae-dcf3-4c28-b76c-a53fbf710c40">14,844</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjQwNmJmMmQ1OTNlYzRkMjVhMWU5YzAwNTBmMzVjMTBlL3RhYmxlcmFuZ2U6NDA2YmYyZDU5M2VjNGQyNWExZTljMDA1MGYzNWMxMGVfNS0yLTEtMS00NTcw_f1027256-9a22-404b-947b-3cf39970ee03">27,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjQwNmJmMmQ1OTNlYzRkMjVhMWU5YzAwNTBmMzVjMTBlL3RhYmxlcmFuZ2U6NDA2YmYyZDU5M2VjNGQyNWExZTljMDA1MGYzNWMxMGVfNi0xLTEtMS0w_fc5d6b65-2515-49fd-a149-9d3bc2fbaa43">37,504</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjQwNmJmMmQ1OTNlYzRkMjVhMWU5YzAwNTBmMzVjMTBlL3RhYmxlcmFuZ2U6NDA2YmYyZDU5M2VjNGQyNWExZTljMDA1MGYzNWMxMGVfNi0yLTEtMS00NTcw_17b388d8-c686-451c-9704-a786783dd609">39,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Imputed Interest expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjQwNmJmMmQ1OTNlYzRkMjVhMWU5YzAwNTBmMzVjMTBlL3RhYmxlcmFuZ2U6NDA2YmYyZDU5M2VjNGQyNWExZTljMDA1MGYzNWMxMGVfNy0xLTEtMS0w_747b7fc8-0014-41f7-9d64-6e59966d5bfa">7,126</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjQwNmJmMmQ1OTNlYzRkMjVhMWU5YzAwNTBmMzVjMTBlL3RhYmxlcmFuZ2U6NDA2YmYyZDU5M2VjNGQyNWExZTljMDA1MGYzNWMxMGVfNy0yLTEtMS00NTcw_d4985458-c39c-4b59-ada8-39dfda07cff9">12,789</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjQwNmJmMmQ1OTNlYzRkMjVhMWU5YzAwNTBmMzVjMTBlL3RhYmxlcmFuZ2U6NDA2YmYyZDU5M2VjNGQyNWExZTljMDA1MGYzNWMxMGVfOC0xLTEtMS0w_57061215-8ab3-4973-9d74-8584a316f3d9">30,378</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjQwNmJmMmQ1OTNlYzRkMjVhMWU5YzAwNTBmMzVjMTBlL3RhYmxlcmFuZ2U6NDA2YmYyZDU5M2VjNGQyNWExZTljMDA1MGYzNWMxMGVfOC0yLTEtMS00NTcw_c9646ab6-5656-4e9a-901a-642013df7ced">26,211</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;"><span><br/></span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In conjunction with the Asset Acquisition, the Company acquired BioElectron&#8217;s lease in Mountainview, California. As substantially all of the fair value of the gross assets acquired was related to vatiquinone, the relative fair value allocated to the right of use asset and corresponding lease liability for the Mountainview lease was determined to be immaterial, and accordingly is not included in the tables above. The future minimum lease payments for the Mountainview lease as of June&#160;30, 2020 are $<ix:nonFraction unitRef="usd" contextRef="iffc234810342492fa6bacab33891f92b_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfMjA3Ng_9dec34ce-6517-4630-be2e-ec8055226881">0.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="iffc234810342492fa6bacab33891f92b_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfMjA4MA_9bf16824-6dae-43e7-9941-17662efadbc6">1.8</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="iffc234810342492fa6bacab33891f92b_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfMjA4OA_75eda567-c8d9-48b3-a75c-4815d03d6c84">1.4</ix:nonFraction> million for 2020, 2021 and 2022, respectively.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On August 4, 2019, the Company and Bristol-Myers Squibb Company, (the &#8220;Landlord&#8221;), entered into a Lease Agreement&#160;(the &#8220;Lease&#8221;), relating to the lease&#160;of approximately <ix:nonFraction unitRef="sqft" contextRef="i8062aff1c79b49feb68143984343e9ea_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfMjg5Nw_6a9de44d-0f52-40f7-8ab5-dc182f787ed6">185,000</ix:nonFraction> square feet of office, manufacturing and laboratory space at a facility located in Hopewell Township, New Jersey (the &#8220;Campus&#8221;). On March 25, 2020, the Company entered into an amendment increasing the rented space to approximately <ix:nonFraction unitRef="sqft" contextRef="iad498f0eada24a34916bb8f896e4c6a1_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfMzEzMQ_5bc28d5b-c747-4ec8-ae81-e7023556065d">220,500</ix:nonFraction> square feet.  As of June 30, 2020, the Lease had not yet commenced, and accordingly, is not reflected in the table above. The rental term of the Lease commenced on July 1, 2020 and has an initial term of <ix:nonNumeric contextRef="iad498f0eada24a34916bb8f896e4c6a1_I20200630" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfMzM3Mg_14394d76-6575-4c31-8773-8cf701e9c13e">fifteen years</ix:nonNumeric> (the &#8220;Initial Term&#8221;), with <ix:nonFraction unitRef="term" contextRef="iad498f0eada24a34916bb8f896e4c6a1_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="ptct:Numberofterms" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfMzQwMg_fbd5496b-5315-4f49-88a5-409a5b226e45">two</ix:nonFraction> consecutive <ix:nonNumeric contextRef="i70364109a58442d999d1529aa97f2b6b_I20200630" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfNDM5ODA0NjUyOTA1Nw_5a47f7f3-6a0f-4530-9520-7739af64af28">five year</ix:nonNumeric> renewal periods, each at the Company&#8217;s option.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The aggregate rent for the Initial Term will be approximately $<ix:nonFraction unitRef="usd" contextRef="iad498f0eada24a34916bb8f896e4c6a1_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfMzUzNA_76491cb5-4b4b-42d8-927f-543c43ae017e">111.5</ix:nonFraction> million. The rental rate for the renewal periods will be <ix:nonFraction unitRef="number" contextRef="iad498f0eada24a34916bb8f896e4c6a1_I20200630" decimals="INF" name="ptct:PercentOfMarketRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfMzU4Ng_c0476244-28df-42f9-b790-2d44872b940f">95</ix:nonFraction>% of the Prevailing Market Rate (as defined in the Lease) and determined at the time of the exercise of the renewal. The Company is also responsible for maintaining certain insurance and the payment of proportional taxes, utilities and common area operating expenses. The Lease contains customary events of default, representations, warranties and covenants.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Subject to the terms of the Lease, the Company has a right of first refusal to rent certain other space of the Campus, which would be triggered upon the Landlord&#8217;s issuance of a second round proposal or letter of intent to another tenant for such space. </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i4e7cadbe3dbd40b9887af8ae2fdfb07d">The Company also may seek to build a new separate building on the Campus, which may not contain less than <ix:nonFraction unitRef="sqft" contextRef="i70364109a58442d999d1529aa97f2b6b_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfNDMwNg_03abb701-0dea-4946-9cd5-2399e9701b95">75,000</ix:nonFraction> square feet (the &#8220;New Building&#8221;). Upon receipt of notice of the Company&#8217;s intention to build the New Building, the Landlord may, in its sole discretion, construct and lease the New Building to the Company or enter into a ground lease with the Company permitting the Company to construct the New Building. Rent terms for the New Building would be determined based on the land value, construction and project costs subject to whether the Landlord or Company constructs the New Building.</ix:continuation></span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span><br/></span></div><div id="i95cf61a5c7074910ae3cf29c5ee08838_52"></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> 5.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:700;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfMTIyMzM_28965538-da05-4de1-a565-a95282828f13" continuedAt="i621164c2cf144b2f9e1501487a0380aa" escape="true"><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfMTIyMzM_b9efc197-7805-45ca-836d-8fae3d3d1ac5" continuedAt="if170b415d4004cb2acb424c9d5c8d785" escape="true">Fair value of financial instruments and marketable securities</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="i621164c2cf144b2f9e1501487a0380aa" continuedAt="i8db19cdc4ff94e81bd5978e3215f5065"><ix:continuation id="if170b415d4004cb2acb424c9d5c8d785" continuedAt="i6fb726a81e3e4d5082ce5e781d5ad08d"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company follows the fair value measurement rules, which provide&#160;guidance on the use of fair value in accounting and disclosure for assets and liabilities when such accounting and disclosure is called for by other accounting literature. These rules&#160;establish a fair value hierarchy for inputs to be used to measure fair value of financial assets and liabilities. This hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels: Level 1 (highest priority), Level 2, and Level 3 (lowest priority).</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;&#160;Level 1&#8212;Unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the balance sheet date.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 2&#8212;Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves,&#160;etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 3&#8212;Inputs are unobservable and reflect the Company&#8217;s assumptions as to what market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash equivalents and marketable securities are reflected in the accompanying financial statements at fair value. The carrying amount of receivables and accounts payable and accrued expenses approximates fair value due to the short-term nature of those instruments. The carrying amounts for borrowings under the credit and security agreement with MidCap Financial approximate fair value based on market activity for other debt instruments with similar characteristics and comparable risk.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2019, the Company purchased $<ix:nonFraction unitRef="usd" contextRef="ie6a7756ab1084e378dab79f603770a11_I20190531" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentOwnedBalancePrincipalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfMjExNw_b20aa176-3db2-47db-9197-a7cb4fe999c8">4.0</ix:nonFraction> million of shares of ClearPoint Neuro, Inc.'s ("ClearPoint"), formerly known as MRI Interventions, Inc., common stock, at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ie6a7756ab1084e378dab79f603770a11_I20190531" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfMjI1NA_aee42b2f-20a7-4be3-a467-c5f505520137">3.10</ix:nonFraction> per share, in connection with a securities purchase agreement that the Company entered into with ClearPoint, a publicly traded medical device company. The Company determined that the equity investment represents a financial instrument and therefore, recorded it at fair value, which is readily determinable. The equity investment is a component of deposits and other assets on the consolidated balance sheet. During the three and six month periods ended June&#160;30, 2020, the Company recorded unrealized losses of $<ix:nonFraction unitRef="usd" contextRef="iba78e43751ff4a8f8903200b06897a60_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfMjc0Ng_3208edd2-b545-40a9-916a-0ad3b9be3338">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4b06422408ed4884889f98fec6b585e7_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfNDk0NzgwMjMzNzI3OA_12ed13b2-6e08-4f40-bc06-2c2aa5f9c9ac">1.6</ix:nonFraction> million, respectively, which are components of other expense, net within the consolidated statement of operations. The fair value of the equity investment was $<ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-5" format="ixt:numdotdecimal" name="ptct:InvestmentInMRI" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfMjg4Ng_c78e6408-0b61-40b6-b91c-96ac6d2d6070">4.6</ix:nonFraction> million as of June&#160;30, 2020. The Company classifies its equity investment in ClearPoint as a Level 1 asset within the fair value hierarchy, as the value is based on a quoted market price in an active market, which is not adjusted.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2020, the Company purchased a $<ix:nonFraction unitRef="usd" contextRef="iab70e96c6dcd4cf38e8acc5f76da5a1c_D20200101-20200131" decimals="-5" format="ixt:numdotdecimal" name="ptct:PaymentsToAcquireConvertibleDebtInvestment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfMzE0Mg_1c7b5500-7ec0-494e-ab7d-72aff0a503d0">10.0</ix:nonFraction> million convertible note from ClearPoint that the Company can convert into ClearPoint shares at a conversion rate of $<ix:nonFraction unitRef="usdPerShare" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfMzI1NA_b9cecef0-c7ba-491e-914a-3b8ff941a7bf">6.00</ix:nonFraction> per share at any point throughout the term of the loan, which matures <ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" format="ixt-sec:durwordsen" name="ptct:DebtInstrumentConvertiblePeriod" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfMzMyNw_d2a78efa-5746-497a-916f-4a1ce4f85683">five years</ix:nonNumeric> from the purchase date.  The Company determined that the convertible note represents an available for sale debt security and the Company has elected to record it at fair value under ASC 825.  The Company classifies its ClearPoint convertible debt security as a Level 2 asset within the fair value hierarchy, as the value is based on inputs other than quoted prices that are observable. The fair value of the ClearPoint convertible debt security is determined at each reporting period by utilizing a Black-Scholes option pricing model, as well as a present value of expected cash flows from the debt security utilizing the risk free rate and the estimated credit spread as of the valuation date as the discount rate. During the three and six month periods ended June&#160;30, 2020, the Company recorded an unrealized gain of $<ix:nonFraction unitRef="usd" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfNDEyOQ_13ab549e-fd34-4090-b219-99016518c13e">2.1</ix:nonFraction> million and an unrealized loss of $<ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfNDk0NzgwMjMzNzMzNQ_bcdd07c9-fa5f-4cc7-80c0-d97ba00bfba9">0.7</ix:nonFraction> million, respectively, which are components of other expense and other income, net within the consolidated statement of operations. The fair value of the convertible debt security was $<ix:nonFraction unitRef="usd" contextRef="i3e35023e351f4322a3c1e517dc55d17f_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfNDI3Nw_f9087dfe-43c8-475a-889e-080b1a0d3892">9.3</ix:nonFraction> million as of June&#160;30, 2020. The convertible debt security is considered to be long term and is included as a component of deposits and other assets on the consolidated balance sheet. Other than the equity investment and the convertible debt security, no other items included in deposits and other assets on the consolidated balance sheets are fair valued.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Fair value of certain marketable securities is based upon market prices using quoted prices in active markets for identical assets quoted on the last day of the period. In establishing the estimated fair value of the remaining investments, the Company used the fair value as determined by its investment advisors using observable inputs other than quoted prices.</span></div></ix:continuation></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i8db19cdc4ff94e81bd5978e3215f5065" continuedAt="if3db5c6711aa4fad87dec9ea5d8557d0"><ix:continuation id="i6fb726a81e3e4d5082ce5e781d5ad08d" continuedAt="i004c5331559c42d2977cd11be55788b6"><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfMTIyMzg_548bd6df-7824-4c0b-8f9d-42f5a072036a" escape="true"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following represents the fair value using the hierarchy described above for the Company&#8217;s financial assets and liabilities that are required to be measured at fair value on a recurring basis as of June&#160;30, 2020 and December&#160;31, 2019:</span></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%;"><tr><td style="width:1.0%;"></td><td style="width:51.323%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.538%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.078%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.538%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.373%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.538%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.487%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.538%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.787%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted&#160;prices<br/>in&#160;active<br/>markets&#160;for<br/>identical&#160;assets<br/>(level&#160;1)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>other<br/>observable<br/>inputs<br/>(level&#160;2)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>unobservable<br/>inputs<br/>(level&#160;3)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i40c26ba683a24d9e98f2ec75db288d77_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfMi0yLTEtMS0w_cc84f992-a6c5-48be-b333-71cf5691d7ee">340,430</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i99c95301a4884daa9e367f37995284bd_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfMi00LTEtMS0w_9912525c-86b1-4b2e-a327-b182e735bd78">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e7e649fe3864de3976f553389445c8b_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfMi02LTEtMS0w_aa6fa7d7-5ea3-44fa-a198-9d3487069c8f">340,430</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie9d447580c3b40f3beffae2bafa97465_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfMi04LTEtMS0w_894c8be9-2d70-487b-bb7b-37445381d20b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity investment in ClearPoint</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44f6355301964dabbb766e645f3cf148_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfMy0yLTEtMS0w_91d2cb34-e2ca-4551-813f-bf882af57f3b">4,594</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i15f90f09637a4cb1bb715dfe4f05297a_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfMy00LTEtMS0w_c8e3fd71-4b16-445f-9c58-dfd843f1a683">4,594</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b16af03a6464f1daa8673b162ab2586_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfMy02LTEtMS0w_594f03e1-7474-4865-8d70-812092047c91">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i761da636d68a44a59452ea0f2aa77729_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfMy04LTEtMS0w_279131df-5ec2-4d18-a1a1-4c7895c7bf66">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ClearPoint convertible debt security</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3e35023e351f4322a3c1e517dc55d17f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfNC0yLTEtMS0w_ce388884-297d-4b67-ba93-aab2762cb9f4">9,251</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6ca9ba441e8d4540804f886f1cc9c954_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfNC00LTEtMS0w_ae0ab5b8-f283-4f81-a52d-f53fb2a58e94">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if3c1cca7bff548549723c72b62c5cabd_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfNC02LTEtMS0w_d4d9e136-7b1e-4c00-ba0b-a9817c033ba6">9,251</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifc5b2ebfb0104a74a263ad842ff6c5b7_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfNC04LTEtMS0w_85a32e7a-9995-4721-b3bd-d3361aac2ce6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred consideration payable</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44f6355301964dabbb766e645f3cf148_I20200630" decimals="-3" format="ixt:numdotdecimal" name="ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfNS0yLTEtMS0w_0113eee4-8550-48f1-9ad4-c9332c756085">2,384</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i15f90f09637a4cb1bb715dfe4f05297a_I20200630" decimals="-3" format="ixt:zerodash" name="ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfNS00LTEtMS0w_8e26b56a-582f-4553-b68d-4af09d2dbf89">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b16af03a6464f1daa8673b162ab2586_I20200630" decimals="-3" format="ixt:numdotdecimal" name="ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfNS02LTEtMS0w_548486ba-c330-4315-8985-a2ef3edfc836">2,384</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i761da636d68a44a59452ea0f2aa77729_I20200630" decimals="-3" format="ixt:zerodash" name="ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfNS04LTEtMS0w_44b0349f-6903-49b3-801f-c3e302a2c283">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration payable- development and regulatory milestones</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44f6355301964dabbb766e645f3cf148_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfNi0yLTEtMS0w_98e9569d-4c3e-47bd-9676-d932f08b8537">136,100</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i15f90f09637a4cb1bb715dfe4f05297a_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfNi00LTEtMS0w_163bc132-cadc-4812-9ec2-8a683ed9e000">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b16af03a6464f1daa8673b162ab2586_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfNi02LTEtMS0w_c5ed9d7c-2bb4-4ac5-8a89-b4a904dbea89">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i761da636d68a44a59452ea0f2aa77729_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfNi04LTEtMS0w_1eab5a50-af1c-4254-90a4-f13992ef49d8">136,100</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration payable- net sales milestones and royalties </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44f6355301964dabbb766e645f3cf148_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfNy0yLTEtMS0w_a26ca153-72f4-4bd9-bb61-fd2e7a57d230">89,600</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i15f90f09637a4cb1bb715dfe4f05297a_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfNy00LTEtMS0w_5090d8cb-70fe-4e3c-8b88-9926ae5b00c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b16af03a6464f1daa8673b162ab2586_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfNy02LTEtMS0w_d0ccef17-7f7e-4f40-a059-59f776a4935a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if300ba06104942c0b9bc9c2620d5efae_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfNy04LTEtMS0w_a6bef3b6-9558-44b1-836a-be00ec7b600c">89,600</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%;"><tr><td style="width:1.0%;"></td><td style="width:51.244%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.209%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.799%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.181%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted&#160;prices<br/>in&#160;active<br/>markets&#160;for<br/>identical&#160;assets<br/>(level&#160;1)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>other<br/>observable<br/>inputs<br/>(level&#160;2)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>unobservable<br/>inputs<br/>(level&#160;3)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i846b553e2ead487080c5135cbfabf245_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfMi0yLTEtMS0w_ff8a82ca-9079-4784-9181-8a833c196be3">398,535</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i93db7a3e36c54bccb14ea9da633b0ca2_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfMi00LTEtMS0w_0194d6dd-64b2-4d49-bd58-0ed00d9bec4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ice1694004db8457f8428afa653a62360_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfMi02LTEtMS0w_9adf4bed-c13c-4211-8fc9-ea6725aec5f5">398,535</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i093049f7698c438ea17d8d78b2999a3b_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfMi04LTEtMS0w_9d625c0f-8141-444c-b88b-a4b67d67f51e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity investment in ClearPoint</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i846b553e2ead487080c5135cbfabf245_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfMy0yLTEtMS0w_af9c523a-f0b8-42c6-a452-6ebe95233a26">6,194</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i93db7a3e36c54bccb14ea9da633b0ca2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfMy00LTEtMS0w_023f6f4c-3ef4-4323-b720-98902a721be9">6,194</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ice1694004db8457f8428afa653a62360_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfMy02LTEtMS0w_559ea80b-1845-438d-b580-fc81f369cb0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i093049f7698c438ea17d8d78b2999a3b_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfMy04LTEtMS0w_5851bded-49bd-4a42-995b-c656defce29d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock appreciation rights liability</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i846b553e2ead487080c5135cbfabf245_I20191231" decimals="-3" format="ixt:numdotdecimal" name="ptct:StockAppreciationRightsLiabilityOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfNC0yLTEtMS0w_394b8273-2c84-48c1-ab18-1d727e6213ea">3,186</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i93db7a3e36c54bccb14ea9da633b0ca2_I20191231" decimals="-3" format="ixt:zerodash" name="ptct:StockAppreciationRightsLiabilityOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfNC00LTEtMS0w_0c5793bc-6d2c-4b91-a6f7-0ce6c11b343c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ice1694004db8457f8428afa653a62360_I20191231" decimals="-3" format="ixt:zerodash" name="ptct:StockAppreciationRightsLiabilityOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfNC02LTEtMS0w_a4ebcd62-b631-4b48-b1cc-65d9ead45700">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i093049f7698c438ea17d8d78b2999a3b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="ptct:StockAppreciationRightsLiabilityOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfNC04LTEtMS0w_5042d08d-3e96-44e6-9d52-0d515750fc11">3,186</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred consideration payable</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i846b553e2ead487080c5135cbfabf245_I20191231" decimals="-3" format="ixt:numdotdecimal" name="ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfNS0yLTEtMS0w_93f64b0a-a57d-4199-991d-99ca73bc9763">40,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i93db7a3e36c54bccb14ea9da633b0ca2_I20191231" decimals="-3" format="ixt:zerodash" name="ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfNS00LTEtMS0w_708d3790-e782-4b17-ac99-779169e6e39a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ice1694004db8457f8428afa653a62360_I20191231" decimals="-3" format="ixt:numdotdecimal" name="ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfNS02LTEtMS0w_b0bf3bb4-f53e-45c1-9c84-9c80bb6495e9">40,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i093049f7698c438ea17d8d78b2999a3b_I20191231" decimals="-3" format="ixt:zerodash" name="ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfNS04LTEtMS0w_32920139-386c-4a4a-ae92-8529fd04560f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration payable- development and regulatory milestones</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i846b553e2ead487080c5135cbfabf245_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfNi0yLTEtMS0w_dfe67169-5cf5-4e91-87c3-7e1fb63f1e8a">290,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i93db7a3e36c54bccb14ea9da633b0ca2_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfNi00LTEtMS0w_f4a139bd-54be-4238-b058-c109a13f4646">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ice1694004db8457f8428afa653a62360_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfNi02LTEtMS0w_a74e54b2-c501-46c1-b2ba-fcee1ff4acfb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i093049f7698c438ea17d8d78b2999a3b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfNi04LTEtMS0w_36222f6f-3a1a-47be-8258-7310795a6f97">290,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration payable- net sales milestones and royalties </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i846b553e2ead487080c5135cbfabf245_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfNy0yLTEtMS0w_9b3c4b08-566a-40cc-9dd2-608e0302fab4">65,800</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i93db7a3e36c54bccb14ea9da633b0ca2_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfNy00LTEtMS0w_8d679a05-ba01-4978-ba1c-0c044169352e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ice1694004db8457f8428afa653a62360_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfNy02LTEtMS0w_af157320-5c9f-46ba-83d3-acbf5f211a6b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i460293d39eb74292bfa8379e3e079d05_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfNy04LTEtMS0w_ad89c3f7-c18b-4678-bd46-db856b578853">65,800</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">No transfers of assets between Level 1, Level 2, or Level 3 of the fair value measurement hierarchy occurred during the periods ended June&#160;30, 2020 and December&#160;31, 2019.</span></div><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfMTIyNTc_9094496a-0ba1-4841-a02f-d6f89d9ac956" escape="true"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following is a summary of marketable securities accounted for as available-for-sale securities at June&#160;30, 2020 and December&#160;31, 2019:</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:44.120%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.741%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross&#160;Unrealized</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i15b6700152f74cd99d7930f13a61958e_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjViZWM2OGIyMzBjZDQ4NjhiNzQzYjliMGYzMTIwMDNkL3RhYmxlcmFuZ2U6NWJlYzY4YjIzMGNkNDg2OGI3NDNiOWIwZjMxMjAwM2RfMy0yLTEtMS0w_b84d683b-1a48-45fe-b50d-64edd8aedb81">53,638</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i15b6700152f74cd99d7930f13a61958e_I20200630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjViZWM2OGIyMzBjZDQ4NjhiNzQzYjliMGYzMTIwMDNkL3RhYmxlcmFuZ2U6NWJlYzY4YjIzMGNkNDg2OGI3NDNiOWIwZjMxMjAwM2RfMy00LTEtMS0w_c8bd3206-3445-4723-be66-7017ad494b6e">178</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i15b6700152f74cd99d7930f13a61958e_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjViZWM2OGIyMzBjZDQ4NjhiNzQzYjliMGYzMTIwMDNkL3RhYmxlcmFuZ2U6NWJlYzY4YjIzMGNkNDg2OGI3NDNiOWIwZjMxMjAwM2RfMy02LTEtMS0w_8cd8c072-f0bd-45f5-a9eb-f7f7a82e18d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i15b6700152f74cd99d7930f13a61958e_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjViZWM2OGIyMzBjZDQ4NjhiNzQzYjliMGYzMTIwMDNkL3RhYmxlcmFuZ2U6NWJlYzY4YjIzMGNkNDg2OGI3NDNiOWIwZjMxMjAwM2RfMy04LTEtMS0w_1c874ff1-c655-4c4b-9449-a624e3f42633">53,816</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6422d57bbb764a51b28c5b9584e9df0b_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjViZWM2OGIyMzBjZDQ4NjhiNzQzYjliMGYzMTIwMDNkL3RhYmxlcmFuZ2U6NWJlYzY4YjIzMGNkNDg2OGI3NDNiOWIwZjMxMjAwM2RfNC0yLTEtMS0w_be81a7ae-8d42-41e8-a4f4-e248f64b43c0">221,068</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6422d57bbb764a51b28c5b9584e9df0b_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjViZWM2OGIyMzBjZDQ4NjhiNzQzYjliMGYzMTIwMDNkL3RhYmxlcmFuZ2U6NWJlYzY4YjIzMGNkNDg2OGI3NDNiOWIwZjMxMjAwM2RfNC00LTEtMS0w_9a17a556-18ad-467a-9ffd-efb36003e0c2">2,882</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6422d57bbb764a51b28c5b9584e9df0b_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjViZWM2OGIyMzBjZDQ4NjhiNzQzYjliMGYzMTIwMDNkL3RhYmxlcmFuZ2U6NWJlYzY4YjIzMGNkNDg2OGI3NDNiOWIwZjMxMjAwM2RfNC02LTEtMS0w_622fdfc1-51e1-48d5-9e30-6f84d78ee213">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6422d57bbb764a51b28c5b9584e9df0b_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjViZWM2OGIyMzBjZDQ4NjhiNzQzYjliMGYzMTIwMDNkL3RhYmxlcmFuZ2U6NWJlYzY4YjIzMGNkNDg2OGI3NDNiOWIwZjMxMjAwM2RfNC04LTEtMS0w_bea15efa-c0f8-4b5f-b01b-22e9f2131b24">223,950</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5f81bf0a978b4c9f9854bd8827a16c63_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjViZWM2OGIyMzBjZDQ4NjhiNzQzYjliMGYzMTIwMDNkL3RhYmxlcmFuZ2U6NWJlYzY4YjIzMGNkNDg2OGI3NDNiOWIwZjMxMjAwM2RfNS0yLTEtMS0w_b07df317-34ff-4017-b601-ae6b814453f2">44,492</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5f81bf0a978b4c9f9854bd8827a16c63_I20200630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjViZWM2OGIyMzBjZDQ4NjhiNzQzYjliMGYzMTIwMDNkL3RhYmxlcmFuZ2U6NWJlYzY4YjIzMGNkNDg2OGI3NDNiOWIwZjMxMjAwM2RfNS00LTEtMS0w_ee02368e-7cfd-4765-a830-c20e07995d07">332</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5f81bf0a978b4c9f9854bd8827a16c63_I20200630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjViZWM2OGIyMzBjZDQ4NjhiNzQzYjliMGYzMTIwMDNkL3RhYmxlcmFuZ2U6NWJlYzY4YjIzMGNkNDg2OGI3NDNiOWIwZjMxMjAwM2RfNS02LTEtMS0w_6a994bb7-be22-4ae3-9119-769769566b8f">1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5f81bf0a978b4c9f9854bd8827a16c63_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjViZWM2OGIyMzBjZDQ4NjhiNzQzYjliMGYzMTIwMDNkL3RhYmxlcmFuZ2U6NWJlYzY4YjIzMGNkNDg2OGI3NDNiOWIwZjMxMjAwM2RfNS04LTEtMS0w_d36fe903-4e11-49b1-a9cd-f0b0cee46701">44,823</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government obligations</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia246a01c67a4480ebec435e73307c0dc_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjViZWM2OGIyMzBjZDQ4NjhiNzQzYjliMGYzMTIwMDNkL3RhYmxlcmFuZ2U6NWJlYzY4YjIzMGNkNDg2OGI3NDNiOWIwZjMxMjAwM2RfNi0yLTEtMS0w_7af971ea-bb46-4fc7-aeae-a606be1823d8">17,823</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia246a01c67a4480ebec435e73307c0dc_I20200630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjViZWM2OGIyMzBjZDQ4NjhiNzQzYjliMGYzMTIwMDNkL3RhYmxlcmFuZ2U6NWJlYzY4YjIzMGNkNDg2OGI3NDNiOWIwZjMxMjAwM2RfNi00LTEtMS0w_0a8a5560-6399-49ff-9827-d5611836e0b4">19</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia246a01c67a4480ebec435e73307c0dc_I20200630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjViZWM2OGIyMzBjZDQ4NjhiNzQzYjliMGYzMTIwMDNkL3RhYmxlcmFuZ2U6NWJlYzY4YjIzMGNkNDg2OGI3NDNiOWIwZjMxMjAwM2RfNi02LTEtMS0w_da5d15a1-4d99-4c88-94ab-dcc9be83edfe">1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia246a01c67a4480ebec435e73307c0dc_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjViZWM2OGIyMzBjZDQ4NjhiNzQzYjliMGYzMTIwMDNkL3RhYmxlcmFuZ2U6NWJlYzY4YjIzMGNkNDg2OGI3NDNiOWIwZjMxMjAwM2RfNi04LTEtMS0w_29ced024-78f1-4a78-b2a2-034cf3e56376">17,841</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjViZWM2OGIyMzBjZDQ4NjhiNzQzYjliMGYzMTIwMDNkL3RhYmxlcmFuZ2U6NWJlYzY4YjIzMGNkNDg2OGI3NDNiOWIwZjMxMjAwM2RfNy0yLTEtMS0w_32c16888-882f-4fe4-9c09-2435133d57a7">337,021</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjViZWM2OGIyMzBjZDQ4NjhiNzQzYjliMGYzMTIwMDNkL3RhYmxlcmFuZ2U6NWJlYzY4YjIzMGNkNDg2OGI3NDNiOWIwZjMxMjAwM2RfNy00LTEtMS0w_295501be-2653-4756-b30c-2e388cf7b025">3,411</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjViZWM2OGIyMzBjZDQ4NjhiNzQzYjliMGYzMTIwMDNkL3RhYmxlcmFuZ2U6NWJlYzY4YjIzMGNkNDg2OGI3NDNiOWIwZjMxMjAwM2RfNy02LTEtMS0w_124eaa31-99fe-46a5-803f-16fba27cf383">2</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjViZWM2OGIyMzBjZDQ4NjhiNzQzYjliMGYzMTIwMDNkL3RhYmxlcmFuZ2U6NWJlYzY4YjIzMGNkNDg2OGI3NDNiOWIwZjMxMjAwM2RfNy04LTEtMS0w_130d328e-adcc-45da-bc25-e879b5f89115">340,430</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:44.120%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.741%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross&#160;Unrealized</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i876ed796b3d14bf1be51f08fb4114515_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ2MDczNjNmNTU0OTQzNGFiMzZmOTQ1Mjk1ODU2Y2Q5L3RhYmxlcmFuZ2U6NDYwNzM2M2Y1NTQ5NDM0YWIzNmY5NDUyOTU4NTZjZDlfMy0yLTEtMS0w_06b09fa2-89b6-48c4-a326-dc5f433dcfa2">157,936</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i876ed796b3d14bf1be51f08fb4114515_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ2MDczNjNmNTU0OTQzNGFiMzZmOTQ1Mjk1ODU2Y2Q5L3RhYmxlcmFuZ2U6NDYwNzM2M2Y1NTQ5NDM0YWIzNmY5NDUyOTU4NTZjZDlfMy00LTEtMS0w_b90cbc05-fdfd-4874-96e7-28d600691f57">162</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i876ed796b3d14bf1be51f08fb4114515_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ2MDczNjNmNTU0OTQzNGFiMzZmOTQ1Mjk1ODU2Y2Q5L3RhYmxlcmFuZ2U6NDYwNzM2M2Y1NTQ5NDM0YWIzNmY5NDUyOTU4NTZjZDlfMy02LTEtMS0w_14feb88f-0ebb-49d3-b1be-4c8a3f89451e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i876ed796b3d14bf1be51f08fb4114515_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ2MDczNjNmNTU0OTQzNGFiMzZmOTQ1Mjk1ODU2Y2Q5L3RhYmxlcmFuZ2U6NDYwNzM2M2Y1NTQ5NDM0YWIzNmY5NDUyOTU4NTZjZDlfMy04LTEtMS0w_e14e967d-fca5-4896-8ed3-eb1a2aac3649">158,098</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i90486133108543398e32deae8f47a34d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ2MDczNjNmNTU0OTQzNGFiMzZmOTQ1Mjk1ODU2Y2Q5L3RhYmxlcmFuZ2U6NDYwNzM2M2Y1NTQ5NDM0YWIzNmY5NDUyOTU4NTZjZDlfNC0yLTEtMS0w_6ebad033-1dbb-4fd2-b4dd-6d69cb339aa8">188,778</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i90486133108543398e32deae8f47a34d_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ2MDczNjNmNTU0OTQzNGFiMzZmOTQ1Mjk1ODU2Y2Q5L3RhYmxlcmFuZ2U6NDYwNzM2M2Y1NTQ5NDM0YWIzNmY5NDUyOTU4NTZjZDlfNC00LTEtMS0w_a7f1b11f-39ee-444c-8f13-5a2e1911f42d">576</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i90486133108543398e32deae8f47a34d_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ2MDczNjNmNTU0OTQzNGFiMzZmOTQ1Mjk1ODU2Y2Q5L3RhYmxlcmFuZ2U6NDYwNzM2M2Y1NTQ5NDM0YWIzNmY5NDUyOTU4NTZjZDlfNC02LTEtMS0w_0beed1e1-87eb-4eb7-a87d-8a20c7c7be4a">20</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i90486133108543398e32deae8f47a34d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ2MDczNjNmNTU0OTQzNGFiMzZmOTQ1Mjk1ODU2Y2Q5L3RhYmxlcmFuZ2U6NDYwNzM2M2Y1NTQ5NDM0YWIzNmY5NDUyOTU4NTZjZDlfNC04LTEtMS0w_b7e9765f-3ef1-4ad0-be65-b485eed1444c">189,334</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2ab2c343b8eb419cbede80402b0f7f2a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ2MDczNjNmNTU0OTQzNGFiMzZmOTQ1Mjk1ODU2Y2Q5L3RhYmxlcmFuZ2U6NDYwNzM2M2Y1NTQ5NDM0YWIzNmY5NDUyOTU4NTZjZDlfNS0yLTEtMS0w_8f554fac-8649-4fd4-aefc-d4e40f437a11">51,062</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2ab2c343b8eb419cbede80402b0f7f2a_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ2MDczNjNmNTU0OTQzNGFiMzZmOTQ1Mjk1ODU2Y2Q5L3RhYmxlcmFuZ2U6NDYwNzM2M2Y1NTQ5NDM0YWIzNmY5NDUyOTU4NTZjZDlfNS00LTEtMS0w_d01dedba-2dc2-45be-988d-f8a37ca871e1">49</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2ab2c343b8eb419cbede80402b0f7f2a_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ2MDczNjNmNTU0OTQzNGFiMzZmOTQ1Mjk1ODU2Y2Q5L3RhYmxlcmFuZ2U6NDYwNzM2M2Y1NTQ5NDM0YWIzNmY5NDUyOTU4NTZjZDlfNS02LTEtMS0w_114954ef-785c-4694-ab85-9b7a8625690c">8</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2ab2c343b8eb419cbede80402b0f7f2a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ2MDczNjNmNTU0OTQzNGFiMzZmOTQ1Mjk1ODU2Y2Q5L3RhYmxlcmFuZ2U6NDYwNzM2M2Y1NTQ5NDM0YWIzNmY5NDUyOTU4NTZjZDlfNS04LTEtMS0w_ea16ca18-f8f5-4f83-919e-1d558e7416af">51,103</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ2MDczNjNmNTU0OTQzNGFiMzZmOTQ1Mjk1ODU2Y2Q5L3RhYmxlcmFuZ2U6NDYwNzM2M2Y1NTQ5NDM0YWIzNmY5NDUyOTU4NTZjZDlfNi0yLTEtMS0w_d9a0b920-bc90-4508-90eb-9b89c5a1dde9">397,776</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ2MDczNjNmNTU0OTQzNGFiMzZmOTQ1Mjk1ODU2Y2Q5L3RhYmxlcmFuZ2U6NDYwNzM2M2Y1NTQ5NDM0YWIzNmY5NDUyOTU4NTZjZDlfNi00LTEtMS0w_9fb94df3-f20c-4b1d-af94-841301385369">787</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ2MDczNjNmNTU0OTQzNGFiMzZmOTQ1Mjk1ODU2Y2Q5L3RhYmxlcmFuZ2U6NDYwNzM2M2Y1NTQ5NDM0YWIzNmY5NDUyOTU4NTZjZDlfNi02LTEtMS0w_b21b1ccd-190c-485c-b00e-ea3f722b7af5">28</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ2MDczNjNmNTU0OTQzNGFiMzZmOTQ1Mjk1ODU2Y2Q5L3RhYmxlcmFuZ2U6NDYwNzM2M2Y1NTQ5NDM0YWIzNmY5NDUyOTU4NTZjZDlfNi04LTEtMS0w_41d9b3e7-c948-478b-b8c3-e5ba6f974aec">398,535</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For available for sale debt securities in an unrealized loss position, the Company assesses whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security's amortized cost basis is written down to fair value. For </span></div></ix:continuation></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="if3db5c6711aa4fad87dec9ea5d8557d0" continuedAt="i13339d506d6841ffafb06d615580780b"><ix:continuation id="i004c5331559c42d2977cd11be55788b6" continuedAt="i21cbc7488a20469a9bf6e0be44f99f4f"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">the three month and six month periods ended June&#160;30, 2020, no write downs occurred. &#160;The Company does not intend to sell the investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be maturity. The Company also reviews its available for sale debt securities in an unrealized loss position and evaluates whether the decline in fair value has resulted from credit losses or other factors. This review is subjective, as it requires management to evaluate whether an event or change in circumstances has occurred in that period that may be related to credit issues. For the three month and six month periods ended June&#160;30, 2020, no allowance was recorded for credit losses. Unrealized gains and losses are reported as a component of accumulated other comprehensive (loss) income in stockholders&#8217; equity. </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three month and six month periods ended June&#160;30, 2020, the Company had $<ix:nonFraction unitRef="usd" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfODI0NjMzNzIyNTIwOQ_272f9083-0d5d-4101-87b6-e7b31ebf4493"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfODI0NjMzNzIyNTIwOQ_e30bfe3b-0846-422d-be17-911abc611604">0.2</ix:nonFraction></ix:nonFraction>&#160;million realized gains from the sale of marketable securities. Realized gains are reported as a component of interest expense, net in the consolidated statement of operations.</span></div><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfMTIyNjg_8ddb3720-85e6-4603-b782-312f3737f776" escape="true"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of&#160;June&#160;30, 2020 are as follows:</span></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:19.585%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.334%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.334%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.334%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.334%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.334%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.341%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="33" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Securities in an unrealized loss position less than 12 months</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Securities in an unrealized loss position greater than 12 months</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5f81bf0a978b4c9f9854bd8827a16c63_I20200630" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjM1MWRlY2RlYWI1NzQ1MmY5ZDNjMDE3MDRjODA3M2ZhL3RhYmxlcmFuZ2U6MzUxZGVjZGVhYjU3NDUyZjlkM2MwMTcwNGM4MDczZmFfNS0yLTEtMS0w_487e7e9d-1377-4575-8883-dc9de0075307">1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5f81bf0a978b4c9f9854bd8827a16c63_I20200630" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjM1MWRlY2RlYWI1NzQ1MmY5ZDNjMDE3MDRjODA3M2ZhL3RhYmxlcmFuZ2U6MzUxZGVjZGVhYjU3NDUyZjlkM2MwMTcwNGM4MDczZmFfNS00LTEtMS0w_538f7937-6bae-443a-8df1-39d80d00b0ee">594</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5f81bf0a978b4c9f9854bd8827a16c63_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjM1MWRlY2RlYWI1NzQ1MmY5ZDNjMDE3MDRjODA3M2ZhL3RhYmxlcmFuZ2U6MzUxZGVjZGVhYjU3NDUyZjlkM2MwMTcwNGM4MDczZmFfNS02LTEtMS0w_c5406fd5-7743-472d-9e38-6439e0e6cbe1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5f81bf0a978b4c9f9854bd8827a16c63_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjM1MWRlY2RlYWI1NzQ1MmY5ZDNjMDE3MDRjODA3M2ZhL3RhYmxlcmFuZ2U6MzUxZGVjZGVhYjU3NDUyZjlkM2MwMTcwNGM4MDczZmFfNS04LTEtMS0w_84052e7c-9f01-4ce7-8437-152ce01d66ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5f81bf0a978b4c9f9854bd8827a16c63_I20200630" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjM1MWRlY2RlYWI1NzQ1MmY5ZDNjMDE3MDRjODA3M2ZhL3RhYmxlcmFuZ2U6MzUxZGVjZGVhYjU3NDUyZjlkM2MwMTcwNGM4MDczZmFfNS0xMC0xLTEtMA_20105428-950e-4991-b0f1-39da54dd4481">1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5f81bf0a978b4c9f9854bd8827a16c63_I20200630" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjM1MWRlY2RlYWI1NzQ1MmY5ZDNjMDE3MDRjODA3M2ZhL3RhYmxlcmFuZ2U6MzUxZGVjZGVhYjU3NDUyZjlkM2MwMTcwNGM4MDczZmFfNS0xMi0xLTEtMA_e3592941-597e-4ad8-95b1-4dd21743e58a">594</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government obligations</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia246a01c67a4480ebec435e73307c0dc_I20200630" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjM1MWRlY2RlYWI1NzQ1MmY5ZDNjMDE3MDRjODA3M2ZhL3RhYmxlcmFuZ2U6MzUxZGVjZGVhYjU3NDUyZjlkM2MwMTcwNGM4MDczZmFfNi0yLTEtMS0w_13c4a842-9787-4136-b52d-5b7d628e5be1">1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia246a01c67a4480ebec435e73307c0dc_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjM1MWRlY2RlYWI1NzQ1MmY5ZDNjMDE3MDRjODA3M2ZhL3RhYmxlcmFuZ2U6MzUxZGVjZGVhYjU3NDUyZjlkM2MwMTcwNGM4MDczZmFfNi00LTEtMS0w_467ee3d9-8bdf-481e-8ae6-47166c3ee83b">8,602</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia246a01c67a4480ebec435e73307c0dc_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjM1MWRlY2RlYWI1NzQ1MmY5ZDNjMDE3MDRjODA3M2ZhL3RhYmxlcmFuZ2U6MzUxZGVjZGVhYjU3NDUyZjlkM2MwMTcwNGM4MDczZmFfNi02LTEtMS0w_a3b2bac6-8a69-44b8-b968-5aa67f1f8a76">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia246a01c67a4480ebec435e73307c0dc_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjM1MWRlY2RlYWI1NzQ1MmY5ZDNjMDE3MDRjODA3M2ZhL3RhYmxlcmFuZ2U6MzUxZGVjZGVhYjU3NDUyZjlkM2MwMTcwNGM4MDczZmFfNi04LTEtMS0w_df6c9cbb-fe9c-402f-b46f-b09e6a9c37f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia246a01c67a4480ebec435e73307c0dc_I20200630" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjM1MWRlY2RlYWI1NzQ1MmY5ZDNjMDE3MDRjODA3M2ZhL3RhYmxlcmFuZ2U6MzUxZGVjZGVhYjU3NDUyZjlkM2MwMTcwNGM4MDczZmFfNi0xMC0xLTEtMA_ff05f2ea-45da-4d4d-97ab-26ac2cef9911">1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia246a01c67a4480ebec435e73307c0dc_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjM1MWRlY2RlYWI1NzQ1MmY5ZDNjMDE3MDRjODA3M2ZhL3RhYmxlcmFuZ2U6MzUxZGVjZGVhYjU3NDUyZjlkM2MwMTcwNGM4MDczZmFfNi0xMi0xLTEtMA_651a23ac-3d47-481a-bc17-d41df0461430">8,602</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjM1MWRlY2RlYWI1NzQ1MmY5ZDNjMDE3MDRjODA3M2ZhL3RhYmxlcmFuZ2U6MzUxZGVjZGVhYjU3NDUyZjlkM2MwMTcwNGM4MDczZmFfNy0yLTEtMS0w_2fbb1bf1-d6d4-44f7-97ac-f87592cc37c4">2</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjM1MWRlY2RlYWI1NzQ1MmY5ZDNjMDE3MDRjODA3M2ZhL3RhYmxlcmFuZ2U6MzUxZGVjZGVhYjU3NDUyZjlkM2MwMTcwNGM4MDczZmFfNy00LTEtMS0w_f4ddc2af-2fac-4e0e-80cd-28e94bf54fe9">9,196</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjM1MWRlY2RlYWI1NzQ1MmY5ZDNjMDE3MDRjODA3M2ZhL3RhYmxlcmFuZ2U6MzUxZGVjZGVhYjU3NDUyZjlkM2MwMTcwNGM4MDczZmFfNy02LTEtMS0w_61454cfd-8915-4c3d-9f76-7b83ba9eaed3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjM1MWRlY2RlYWI1NzQ1MmY5ZDNjMDE3MDRjODA3M2ZhL3RhYmxlcmFuZ2U6MzUxZGVjZGVhYjU3NDUyZjlkM2MwMTcwNGM4MDczZmFfNy04LTEtMS0w_7c874e22-4526-4c50-bf66-b239a4b101a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjM1MWRlY2RlYWI1NzQ1MmY5ZDNjMDE3MDRjODA3M2ZhL3RhYmxlcmFuZ2U6MzUxZGVjZGVhYjU3NDUyZjlkM2MwMTcwNGM4MDczZmFfNy0xMC0xLTEtMA_e9f1fa90-5f48-495e-a8a2-43109b8d4155">2</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjM1MWRlY2RlYWI1NzQ1MmY5ZDNjMDE3MDRjODA3M2ZhL3RhYmxlcmFuZ2U6MzUxZGVjZGVhYjU3NDUyZjlkM2MwMTcwNGM4MDczZmFfNy0xMi0xLTEtMA_f63bd4f5-4d63-4f64-9b75-32eec3517ecb">9,196</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of&#160;December&#160;31, 2019 are as follows:</span></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:19.585%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.334%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.334%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.334%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.334%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.334%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.341%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="33" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Securities in an unrealized loss position less than 12 months</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Securities in an unrealized loss position greater than 12 months</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i90486133108543398e32deae8f47a34d_I20191231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA1Y2MwMzljMjNlODRhOTg5YjA5YzUwYmY4OTcwYTk3L3RhYmxlcmFuZ2U6MDVjYzAzOWMyM2U4NGE5ODliMDljNTBiZjg5NzBhOTdfNS0yLTEtMS0w_d8c4dfb5-05bf-4457-8929-1d597776d15d">20</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i90486133108543398e32deae8f47a34d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA1Y2MwMzljMjNlODRhOTg5YjA5YzUwYmY4OTcwYTk3L3RhYmxlcmFuZ2U6MDVjYzAzOWMyM2U4NGE5ODliMDljNTBiZjg5NzBhOTdfNS00LTEtMS0w_fe21f427-0b19-47ba-a08b-ab0f25e614c9">71,779</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i90486133108543398e32deae8f47a34d_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA1Y2MwMzljMjNlODRhOTg5YjA5YzUwYmY4OTcwYTk3L3RhYmxlcmFuZ2U6MDVjYzAzOWMyM2U4NGE5ODliMDljNTBiZjg5NzBhOTdfNS02LTEtMS0w_becfb471-88d4-4f21-a672-29aee3f576b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i90486133108543398e32deae8f47a34d_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA1Y2MwMzljMjNlODRhOTg5YjA5YzUwYmY4OTcwYTk3L3RhYmxlcmFuZ2U6MDVjYzAzOWMyM2U4NGE5ODliMDljNTBiZjg5NzBhOTdfNS04LTEtMS0w_baa60f21-7d05-41df-b929-b087bd88fc0c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i90486133108543398e32deae8f47a34d_I20191231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA1Y2MwMzljMjNlODRhOTg5YjA5YzUwYmY4OTcwYTk3L3RhYmxlcmFuZ2U6MDVjYzAzOWMyM2U4NGE5ODliMDljNTBiZjg5NzBhOTdfNS0xMC0xLTEtMA_6cf890e2-1c17-440f-8855-c5a63bf84756">20</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i90486133108543398e32deae8f47a34d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA1Y2MwMzljMjNlODRhOTg5YjA5YzUwYmY4OTcwYTk3L3RhYmxlcmFuZ2U6MDVjYzAzOWMyM2U4NGE5ODliMDljNTBiZjg5NzBhOTdfNS0xMi0xLTEtMA_b0dbbfea-2fe1-486e-b38a-500f86102222">71,779</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2ab2c343b8eb419cbede80402b0f7f2a_I20191231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA1Y2MwMzljMjNlODRhOTg5YjA5YzUwYmY4OTcwYTk3L3RhYmxlcmFuZ2U6MDVjYzAzOWMyM2U4NGE5ODliMDljNTBiZjg5NzBhOTdfNi0yLTEtMS0w_ad13f4c8-b3d9-4e59-9253-d205a3148b3e">8</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2ab2c343b8eb419cbede80402b0f7f2a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA1Y2MwMzljMjNlODRhOTg5YjA5YzUwYmY4OTcwYTk3L3RhYmxlcmFuZ2U6MDVjYzAzOWMyM2U4NGE5ODliMDljNTBiZjg5NzBhOTdfNi00LTEtMS0w_925853b8-8b93-4c70-b073-2009a6c62e89">24,211</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2ab2c343b8eb419cbede80402b0f7f2a_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA1Y2MwMzljMjNlODRhOTg5YjA5YzUwYmY4OTcwYTk3L3RhYmxlcmFuZ2U6MDVjYzAzOWMyM2U4NGE5ODliMDljNTBiZjg5NzBhOTdfNi02LTEtMS0w_8a45f884-a098-4be3-9877-0c202ed07d8b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2ab2c343b8eb419cbede80402b0f7f2a_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA1Y2MwMzljMjNlODRhOTg5YjA5YzUwYmY4OTcwYTk3L3RhYmxlcmFuZ2U6MDVjYzAzOWMyM2U4NGE5ODliMDljNTBiZjg5NzBhOTdfNi04LTEtMS0w_1c40938c-3586-4253-a991-c18b0343a3bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2ab2c343b8eb419cbede80402b0f7f2a_I20191231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA1Y2MwMzljMjNlODRhOTg5YjA5YzUwYmY4OTcwYTk3L3RhYmxlcmFuZ2U6MDVjYzAzOWMyM2U4NGE5ODliMDljNTBiZjg5NzBhOTdfNi0xMC0xLTEtMA_d356f263-a13f-4c87-84d8-d482ab066331">8</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2ab2c343b8eb419cbede80402b0f7f2a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA1Y2MwMzljMjNlODRhOTg5YjA5YzUwYmY4OTcwYTk3L3RhYmxlcmFuZ2U6MDVjYzAzOWMyM2U4NGE5ODliMDljNTBiZjg5NzBhOTdfNi0xMi0xLTEtMA_141e26f9-0700-4245-9af2-f48855b238af">24,211</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA1Y2MwMzljMjNlODRhOTg5YjA5YzUwYmY4OTcwYTk3L3RhYmxlcmFuZ2U6MDVjYzAzOWMyM2U4NGE5ODliMDljNTBiZjg5NzBhOTdfNy0yLTEtMS0w_7f7a6d6b-f6ae-42ff-8404-e19e0a450276">28</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA1Y2MwMzljMjNlODRhOTg5YjA5YzUwYmY4OTcwYTk3L3RhYmxlcmFuZ2U6MDVjYzAzOWMyM2U4NGE5ODliMDljNTBiZjg5NzBhOTdfNy00LTEtMS0w_730b04a4-bde8-40f5-a81a-b3459200c56a">95,990</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA1Y2MwMzljMjNlODRhOTg5YjA5YzUwYmY4OTcwYTk3L3RhYmxlcmFuZ2U6MDVjYzAzOWMyM2U4NGE5ODliMDljNTBiZjg5NzBhOTdfNy02LTEtMS0w_e01d4ed0-2ced-4789-b2b8-db8ea375e51d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA1Y2MwMzljMjNlODRhOTg5YjA5YzUwYmY4OTcwYTk3L3RhYmxlcmFuZ2U6MDVjYzAzOWMyM2U4NGE5ODliMDljNTBiZjg5NzBhOTdfNy04LTEtMS0w_b153aea4-b74f-4781-9958-c2d97f574716">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA1Y2MwMzljMjNlODRhOTg5YjA5YzUwYmY4OTcwYTk3L3RhYmxlcmFuZ2U6MDVjYzAzOWMyM2U4NGE5ODliMDljNTBiZjg5NzBhOTdfNy0xMC0xLTEtMA_0ea1a940-e939-4c01-9a69-b61408ff3476">28</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA1Y2MwMzljMjNlODRhOTg5YjA5YzUwYmY4OTcwYTk3L3RhYmxlcmFuZ2U6MDVjYzAzOWMyM2U4NGE5ODliMDljNTBiZjg5NzBhOTdfNy0xMi0xLTEtMA_b4b21150-6385-4234-b9a7-e6e0ed9ce5c0">95,990</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="us-gaap:MarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfMTIyMzU_a4d31bde-152f-481b-9957-77d9bdb02ae9" escape="true"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Marketable securities on the balance sheet at June&#160;30, 2020 and December&#160;31, 2019 mature as follows:</span></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:71.060%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.739%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less&#160;Than<br/>12&#160;Months</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">More&#160;Than<br/>12&#160;Months</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8d66a66f5c44284a1bfe69359df8592_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjIxZTQ0OGEyZTE3NDQ5OTViMDc5ODUzYjExYzBmYmU3L3RhYmxlcmFuZ2U6MjFlNDQ4YTJlMTc0NDk5NWIwNzk4NTNiMTFjMGZiZTdfMi0yLTEtMS0w_1f0683c3-7a98-424b-ab7a-5b0ed324dccb">53,816</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8d66a66f5c44284a1bfe69359df8592_I20200630" decimals="-3" format="ixt:zerodash" name="ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjIxZTQ0OGEyZTE3NDQ5OTViMDc5ODUzYjExYzBmYmU3L3RhYmxlcmFuZ2U6MjFlNDQ4YTJlMTc0NDk5NWIwNzk4NTNiMTFjMGZiZTdfMi00LTEtMS0w_eb0a1202-a2ce-4728-af27-97251175995d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib3c822dd8f524ec2a293c01f04eecc3b_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjIxZTQ0OGEyZTE3NDQ5OTViMDc5ODUzYjExYzBmYmU3L3RhYmxlcmFuZ2U6MjFlNDQ4YTJlMTc0NDk5NWIwNzk4NTNiMTFjMGZiZTdfMy0yLTEtMS0w_8f1d1a03-e00b-4d5a-b76a-b4626f524595">168,250</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib3c822dd8f524ec2a293c01f04eecc3b_I20200630" decimals="-3" format="ixt:numdotdecimal" name="ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjIxZTQ0OGEyZTE3NDQ5OTViMDc5ODUzYjExYzBmYmU3L3RhYmxlcmFuZ2U6MjFlNDQ4YTJlMTc0NDk5NWIwNzk4NTNiMTFjMGZiZTdfMy00LTEtMS0w_5e783b25-664d-4983-a61b-c96a346df008">55,700</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2693d4b1ad594235b8ea223db85dc081_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjIxZTQ0OGEyZTE3NDQ5OTViMDc5ODUzYjExYzBmYmU3L3RhYmxlcmFuZ2U6MjFlNDQ4YTJlMTc0NDk5NWIwNzk4NTNiMTFjMGZiZTdfNC0yLTEtMS0w_17838488-132d-4aa9-afae-75d618a1d6fc">26,320</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2693d4b1ad594235b8ea223db85dc081_I20200630" decimals="-3" format="ixt:numdotdecimal" name="ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjIxZTQ0OGEyZTE3NDQ5OTViMDc5ODUzYjExYzBmYmU3L3RhYmxlcmFuZ2U6MjFlNDQ4YTJlMTc0NDk5NWIwNzk4NTNiMTFjMGZiZTdfNC00LTEtMS0w_4b3a0781-7664-4070-b593-44be4e380309">18,503</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government obligations</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i18f98e56934a450c999dc68774136109_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjIxZTQ0OGEyZTE3NDQ5OTViMDc5ODUzYjExYzBmYmU3L3RhYmxlcmFuZ2U6MjFlNDQ4YTJlMTc0NDk5NWIwNzk4NTNiMTFjMGZiZTdfNS0yLTEtMS0w_7ff0de10-9450-408d-9cc5-905d5047b6b2">7,201</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i18f98e56934a450c999dc68774136109_I20200630" decimals="-3" format="ixt:numdotdecimal" name="ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjIxZTQ0OGEyZTE3NDQ5OTViMDc5ODUzYjExYzBmYmU3L3RhYmxlcmFuZ2U6MjFlNDQ4YTJlMTc0NDk5NWIwNzk4NTNiMTFjMGZiZTdfNS00LTEtMS0w_f6ef5793-44dc-44c3-8127-6766b3e7c5fe">10,640</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjIxZTQ0OGEyZTE3NDQ5OTViMDc5ODUzYjExYzBmYmU3L3RhYmxlcmFuZ2U6MjFlNDQ4YTJlMTc0NDk5NWIwNzk4NTNiMTFjMGZiZTdfNi0yLTEtMS0w_2131f913-57c4-4112-805a-4a3d250f8780">255,587</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjIxZTQ0OGEyZTE3NDQ5OTViMDc5ODUzYjExYzBmYmU3L3RhYmxlcmFuZ2U6MjFlNDQ4YTJlMTc0NDk5NWIwNzk4NTNiMTFjMGZiZTdfNi00LTEtMS0w_c260f1b8-ca1b-4579-a751-0d3baaceab14">84,843</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:71.060%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.739%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less&#160;Than<br/>12&#160;Months</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">More&#160;Than<br/>12&#160;Months</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i05c1fab5886147afbd189c9f7d96801e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA2YjdkMTFlOGZjZjRmNTY5M2YwNTk3NmQyYmI0MzgyL3RhYmxlcmFuZ2U6MDZiN2QxMWU4ZmNmNGY1NjkzZjA1OTc2ZDJiYjQzODJfMi0yLTEtMS0w_22d64952-bcde-4e36-a425-d46216100c4d">158,098</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i05c1fab5886147afbd189c9f7d96801e_I20191231" decimals="-3" format="ixt:zerodash" name="ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA2YjdkMTFlOGZjZjRmNTY5M2YwNTk3NmQyYmI0MzgyL3RhYmxlcmFuZ2U6MDZiN2QxMWU4ZmNmNGY1NjkzZjA1OTc2ZDJiYjQzODJfMi00LTEtMS0w_d42bc939-674e-43c3-9437-51510267913e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i808602a5926949c8ac25d08dcc142c0a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA2YjdkMTFlOGZjZjRmNTY5M2YwNTk3NmQyYmI0MzgyL3RhYmxlcmFuZ2U6MDZiN2QxMWU4ZmNmNGY1NjkzZjA1OTc2ZDJiYjQzODJfMy0yLTEtMS0w_3a1949e7-d776-4a51-b312-30cc53f1ca79">139,596</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i808602a5926949c8ac25d08dcc142c0a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA2YjdkMTFlOGZjZjRmNTY5M2YwNTk3NmQyYmI0MzgyL3RhYmxlcmFuZ2U6MDZiN2QxMWU4ZmNmNGY1NjkzZjA1OTc2ZDJiYjQzODJfMy00LTEtMS0w_d139178b-a151-4c4f-9220-517613304d94">49,738</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i26723ef219cf40f79fc4b63185834f6a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA2YjdkMTFlOGZjZjRmNTY5M2YwNTk3NmQyYmI0MzgyL3RhYmxlcmFuZ2U6MDZiN2QxMWU4ZmNmNGY1NjkzZjA1OTc2ZDJiYjQzODJfNC0yLTEtMS0w_d88ec30c-4c98-4e07-93df-841120ed8a51">44,724</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i26723ef219cf40f79fc4b63185834f6a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA2YjdkMTFlOGZjZjRmNTY5M2YwNTk3NmQyYmI0MzgyL3RhYmxlcmFuZ2U6MDZiN2QxMWU4ZmNmNGY1NjkzZjA1OTc2ZDJiYjQzODJfNC00LTEtMS0w_dffe2be8-0725-4f56-9188-85e270d76ab1">6,379</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA2YjdkMTFlOGZjZjRmNTY5M2YwNTk3NmQyYmI0MzgyL3RhYmxlcmFuZ2U6MDZiN2QxMWU4ZmNmNGY1NjkzZjA1OTc2ZDJiYjQzODJfNS0yLTEtMS0w_60c23d5f-2fea-472e-9b45-079e922a721b">342,418</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA2YjdkMTFlOGZjZjRmNTY5M2YwNTk3NmQyYmI0MzgyL3RhYmxlcmFuZ2U6MDZiN2QxMWU4ZmNmNGY1NjkzZjA1OTc2ZDJiYjQzODJfNS00LTEtMS0w_45c6dd45-7d2d-4578-805e-e4e8d987b54e">56,117</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company classifies all of its marketable securities as current as they are all available for sale and are available for current operations.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Convertible senior notes</span></div></ix:continuation></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i13339d506d6841ffafb06d615580780b" continuedAt="iff354c456a24417fabbba33fa5426457"><ix:continuation id="i21cbc7488a20469a9bf6e0be44f99f4f" continuedAt="i44741c94afce4210bbdae17a6c775666"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2015, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i28655a9b21d647eb9144da8fa8cdd911_I20150831" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfNzQ5MQ_20770c23-44d4-4f2c-9144-d6bb43ebd220">150.0</ix:nonFraction> million of <ix:nonFraction unitRef="number" contextRef="i28655a9b21d647eb9144da8fa8cdd911_I20150831" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfNzQ5Nw_b4a1f215-f6d8-463e-9bee-f597b3ec7626">3.00</ix:nonFraction>% convertible senior notes due August&#160;15, 2022 (the &#8220;2022 Convertible Notes&#8221;). In September 2019, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i43e763aab42b473cb26af800270f6b3e_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfNzYxNQ_2f1ab4b2-a38a-4157-bde1-c2ac7e7c80e7">287.5</ix:nonFraction> million of <ix:nonFraction unitRef="number" contextRef="i2869c1675c5a404e9bb85cad2eb71998_I20191231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfNzYyMQ_1067a0d9-d5bd-44bf-8e46-16bffcec3a39">1.50</ix:nonFraction>% convertible senior notes due September&#160;15, 2026 (the &#8220;2026 Convertible Notes,&#8221; together with the &#8220;2022 Convertible Notes,&#8221; the &#8220;Convertible Notes&#8221;). The Company separately accounted for the liability and equity components of the Convertible Notes by allocating the proceeds between the liability component and equity component, as further discussed in Note&#160;11. The fair value of the Convertible Notes, which differs from their carrying values, is influenced by interest rates, the Company&#8217;s stock price and stock price volatility and is determined by prices for the Convertible Notes observed in market trading which are Level&#160;2 inputs. The estimated fair value of the 2022 Convertible Notes at June&#160;30, 2020 and December&#160;31, 2019 was $<ix:nonFraction unitRef="usd" contextRef="i08c7971cf8d6469fbda565dec2419938_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfODMzMw_c5611df4-58f3-4167-b1db-32081a51ab12">175.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5fc57b5184a54d248eb826766cbbb088_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfODM0MA_3f10d794-eecf-4900-86b6-df873346cc27">171.2</ix:nonFraction> million, respectively. The estimated fair value of the 2026 Convertible Notes at June&#160;30, 2020 and December&#160;31, 2019 was $<ix:nonFraction unitRef="usd" contextRef="i43e763aab42b473cb26af800270f6b3e_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfODQzMA_bf13061a-39da-428e-88f1-e74ef88fadfc">343.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2869c1675c5a404e9bb85cad2eb71998_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfODQzNw_117b0bcb-a879-4244-ab6c-e75f20b39fa6">335.0</ix:nonFraction> million, respectively.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Deferred and contingent consideration payable</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the Merger Agreement, Agilis equityholders were previously entitled to receive contingent consideration payments from the Company based on&#160;the achievement of certain development milestones up to an aggregate maximum amount of $<ix:nonFraction unitRef="usd" contextRef="ia20c4a3be1bf491aaf06ea4818f97179_I20200630" decimals="-5" format="ixt:numdotdecimal" name="ptct:DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfODcxOQ_04fbdc85-2973-4d67-8476-dbd21b5876c8">60.0</ix:nonFraction> million and&#160;the achievement of certain regulatory approval milestones together with a milestone payment following the receipt of a priority review voucher up to an aggregate maximum amount of $<ix:nonFraction unitRef="usd" contextRef="i7e34d9d90204473c8ea049d991956012_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="ptct:ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfODkwNg_40139581-ffee-427d-bc62-6feb409db928">535.0</ix:nonFraction> million. The Company was required to pay $<ix:nonFraction unitRef="usd" contextRef="ife1e487e2c3c44508eb4f48b2ea5cd9e_I20200630" decimals="-5" format="ixt:numdotdecimal" name="ptct:DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfODk0MQ_6db045fa-0d24-4fca-97da-13db372bd275">40.0</ix:nonFraction> million of development milestone payments upon the passing of the second anniversary of the closing of the Merger, regardless of whether the applicable milestones have been achieved. The $<ix:nonFraction unitRef="usd" contextRef="ife1e487e2c3c44508eb4f48b2ea5cd9e_I20200630" decimals="-5" format="ixt:numdotdecimal" name="ptct:DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfNTQ5NzU1ODE1Mzk0Mg_6db045fa-0d24-4fca-97da-13db372bd275">40.0</ix:nonFraction> million of development milestones were classified as deferred consideration on the Company's consolidated balance sheets. </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the terms of the Rights Exchange Agreement, in the three month period ended June 30, 2020, the Company issued <ix:nonFraction unitRef="shares" contextRef="ifa7979ad51144297ab5f7100771cad69_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="ptct:StockIssuedDuringPeriodSharesExchangeRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfNDM5ODA0NjUyODAwNw_d6668d97-0d38-4796-a180-f836ec03dcc8">2,821,176</ix:nonFraction> shares of its common stock and paid $<ix:nonFraction unitRef="usd" contextRef="i163271c9c18a44a7acbdd4d53ae6113f_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="ptct:SharesIssuedAssetAcquisition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfNDM5ODA0NjUyODEzNg_8c1e305a-243d-4465-80ed-6979b817982d">36.9</ix:nonFraction>&#160;million in the aggregate, to Participating Rightholders, who in exchange have canceled and forfeited their rights under the Merger Agreement to receive (i) $<ix:nonFraction unitRef="usd" contextRef="i15a832ee781448adb2f8888811fbc346_I20200629" decimals="-5" format="ixt:numdotdecimal" name="ptct:MilestonePaymentObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfNDM5ODA0NjUyODAxOA_5cc8416c-c8dd-447e-9fca-58fd3838670e">174.0</ix:nonFraction>&#160;million, in the aggregate, of potential milestone payments based on the achievement of certain regulatory milestones and (ii) $<ix:nonFraction unitRef="usd" contextRef="i8aa17e0adf804ca986cfd400e121c2ea_I20200629" decimals="-5" format="ixt:numdotdecimal" name="ptct:DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfNDM5ODA0NjUyODAzNA_3def36b2-f6b0-4d7f-886c-e3f1857bcbc0">37.6</ix:nonFraction>&#160;million, in the aggregate, of $<ix:nonFraction unitRef="usd" contextRef="i6094c414acd64e8eb18a8f8306f9c263_I20200629" decimals="-5" format="ixt:numdotdecimal" name="ptct:DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfNDM5ODA0NjUyODA0OQ_e436384f-598c-479c-a079-fbf2b63df4e0">40.0</ix:nonFraction>&#160;million in development milestone payments, or the deferred consideration, that would have been due upon the passing of the second anniversary of the closing of the Merger. As a result of the Rights Exchange Agreement, the remaining deferred consideration payable at June&#160;30, 2020 was $<ix:nonFraction unitRef="usd" contextRef="i44f6355301964dabbb766e645f3cf148_I20200630" decimals="-5" format="ixt:numdotdecimal" name="ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfOTE5OQ_c7c8f0b5-48ca-429a-b0a3-1efa5eccc449">2.4</ix:nonFraction> million, which was also determined to be the fair value. The Company did not apply a discount, as the milestones will be paid within one calendar year.  Accordingly, as of June&#160;30, 2020, the $<ix:nonFraction unitRef="usd" contextRef="if54601c17d0343ec8d9cd0af73df9a5b_I20200630" decimals="-5" format="ixt:numdotdecimal" name="ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfOTMyNg_9efe63af-dfd1-4ba8-9815-7af6205763f5">2.4</ix:nonFraction> million of the deferred consideration payable was classified as current on the balance sheet.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As of result of the Rights Exchange Agreement, the Company recognized a gain of $<ix:nonFraction unitRef="usd" contextRef="i163271c9c18a44a7acbdd4d53ae6113f_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="ptct:GainOfSettlementDevelopmentMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfNDM5ODA0NjUyODA3OQ_c07471a4-010d-4b2e-8392-cc8e8b009757">0.7</ix:nonFraction>&#160;million on the settlement of the development milestones and a loss of $<ix:nonFraction unitRef="usd" contextRef="i163271c9c18a44a7acbdd4d53ae6113f_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="ptct:LossOfSettlementRegulatoryMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfNDM5ODA0NjUyODA2NA_eb20c3af-69f5-4b7d-a9d8-a6cdf239524d">11.3</ix:nonFraction>&#160;million on the settlement of the regulatory milestones. The $<ix:nonFraction unitRef="usd" contextRef="i163271c9c18a44a7acbdd4d53ae6113f_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="ptct:GainOfSettlementDevelopmentMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfNDM5ODA0NjUyODEyMg_b7baa6f2-02fa-4c70-b0ab-8bfee9e9a7fa">0.7</ix:nonFraction>&#160;million gain and $<ix:nonFraction unitRef="usd" contextRef="i163271c9c18a44a7acbdd4d53ae6113f_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="ptct:LossOfSettlementRegulatoryMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfNDM5ODA0NjUyODA5Mw_91750322-72c8-4017-b303-299ab8f30835">11.3</ix:nonFraction>&#160;million loss are included in the settlement of deferred and contingent consideration in the Company&#8217;s statement of operations for the three and six month periods ended June 30, 2020. Additionally, as of the date of the Rights Exchange Agreement, the Company recognized a gain on the fair value of the contingent consideration of $<ix:nonFraction unitRef="usd" contextRef="i163271c9c18a44a7acbdd4d53ae6113f_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfNDM5ODA0NjUyODEwOA_d0c83173-b263-4ec0-9b59-16f5375365f0">1.0</ix:nonFraction>&#160;million related to the portion of regulatory milestones that were forfeited, which is included in the change in fair value of the deferred and contingent liability within the Company&#8217;s statement of operations for the three and six month periods ended June 30, 2020. This non-recurring Level 3 fair value measurement was estimated using the same valuation methoolody and unobservable inputs for development and regulatory milestones in the Level 3 valuation section below. In conjunction with the Rights Exchange Agreement, the Company also incurred $<ix:nonFraction unitRef="usd" contextRef="i163271c9c18a44a7acbdd4d53ae6113f_D20200401-20200630" decimals="-5" name="ptct:ContingentConsiderationTransactionFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfNjA0NzMxMzk2OTM4Ng_33136fef-c4a0-472a-8092-a455e6f08d94"><ix:nonFraction unitRef="usd" contextRef="i5ca2052e537349099f8500140b79c830_D20200101-20200630" decimals="-5" name="ptct:ContingentConsiderationTransactionFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfNjA0NzMxMzk2OTM4Ng_9ba1f5e6-cc92-4e82-bc33-a57430890f94">2.0</ix:nonFraction></ix:nonFraction> million of transaction fees, which were included in other expense in the Company&#8217;s statement of operations for the three and six month periods ended June 30, 2020.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Level 3 valuation</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The stock appreciation rights ("SARs") liability is classified in other liabilities on the Company&#8217;s consolidated balance sheets. The SARs liability is marked-to-market each reporting period with the change in fair value recorded as compensation expense on the Company&#8217;s consolidated statements of operations until the SARs vest. The fair value of the SARs liability is determined at each reporting period by utilizing the Black-Scholes option pricing model. The last payment of the SARs liability was made in the three month period ended March 31, 2020, and accordingly, the balance of the SARS liability as of June 30, 2020 was $<ix:nonFraction unitRef="usd" contextRef="i82a7d5029292453a9d8665965b2a0597_I20200630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfMTAwNjQ_03354036-172f-43bc-bcb8-87061bcbeb9b">0</ix:nonFraction>. </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The contingent consideration payable is fair valued each reporting period with the change in fair value recorded as a gain or loss within the change in the fair value of deferred and contingent consideration on the consolidated statements of operations.  The fair value of the development and regulatory milestones is estimated utilizing a probability adjusted, discounted cash flow approach. The discount rates are estimated utilizing Corporate B rated bonds maturing in the years of expected payments based on the Company&#8217;s estimated development timelines for the acquired product candidate. At June&#160;30, 2020, the weighted average discount rate for the development and regulatory milestones was <ix:nonFraction unitRef="number" contextRef="i6f89da40eb9542899d61cec5f576ce4d_I20200630" decimals="3" name="us-gaap:AlternativeInvestmentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfMTA3NTU_7e6dde8d-b5dd-4860-9d54-04f2af72a909">5.4</ix:nonFraction>% and the weighted average probability of success was <ix:nonFraction unitRef="number" contextRef="ibe63e39ea26a457a88e2e66409ca6e52_I20200630" decimals="2" name="us-gaap:AlternativeInvestmentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfMTA4MTA_8be8c9e5-513b-4f40-b596-f00ab85306ac">43</ix:nonFraction>%.  The fair value of the net sales milestones and royalties is determined utilizing an option pricing model with Monte Carlo simulation to simulate a range of possible payment scenarios, and the average of the payments in these scenarios is then discounted to calculate present fair value. At June&#160;30, 2020, the weighted average discount rate for the net sales milestones and royalties was <ix:nonFraction unitRef="number" contextRef="i46d96bc3957b4332a199fc5c2ba22aa2_I20200630" decimals="3" name="us-gaap:AlternativeInvestmentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfMTExOTE_9286b873-a68c-42f6-8d2c-18160b23a9e3">12.0</ix:nonFraction>% and the weighted average probability of success for the net sales milestones was <ix:nonFraction unitRef="number" contextRef="i06c3f1148d284ba19fd288779c3f2c67_I20200630" decimals="2" name="us-gaap:AlternativeInvestmentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfMTEyNzU_ba55a679-7e39-48d5-ac5d-fabd2e0ff04a">50</ix:nonFraction>%.</span></div></ix:continuation></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="iff354c456a24417fabbba33fa5426457" continuedAt="id0a437b7856443a98b945193f0ac76ce"><ix:continuation id="i44741c94afce4210bbdae17a6c775666" continuedAt="i13ed41bf30fb49aeb5a4adbd936ebc99"><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfMTIyNDA_4b60bfb0-cace-4dd3-a4f1-cf736f3025c7" escape="true"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The table presented below is a summary of changes in the fair value of the Company&#8217;s Level 3 valuations for the SARs liability, and the contingent consideration payable for the periods ended June&#160;30, 2020 and June&#160;30, 2019. </span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.549%;"><tr><td style="width:1.0%;"></td><td style="width:50.533%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.644%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.033%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.644%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.033%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.475%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.038%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3 liabilities</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SARs</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration payable- development and regulatory milestones</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration payable- net sales milestones and royalties</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Beginning balance as of December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5a07c3011f2483691088bb12f4ed468_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjY3ZTQ4ZjA4YmQ3MTRhNTNhNGIyMzM5ZTllZTZlMjg0L3RhYmxlcmFuZ2U6NjdlNDhmMDhiZDcxNGE1M2E0YjIzMzllOWVlNmUyODRfMi0yLTEtMS0w_2b2e043d-6d53-4ef0-99c4-c883097d99a3">3,186</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i307a45a921aa4ac98cbf6914b2e129b6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjY3ZTQ4ZjA4YmQ3MTRhNTNhNGIyMzM5ZTllZTZlMjg0L3RhYmxlcmFuZ2U6NjdlNDhmMDhiZDcxNGE1M2E0YjIzMzllOWVlNmUyODRfMi00LTEtMS0w_5d21e950-d1b7-44bc-89be-dc505e09ab75">290,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i442f4b08d467498fa51f7601498e0665_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjY3ZTQ4ZjA4YmQ3MTRhNTNhNGIyMzM5ZTllZTZlMjg0L3RhYmxlcmFuZ2U6NjdlNDhmMDhiZDcxNGE1M2E0YjIzMzllOWVlNmUyODRfMi01LTEtMS0w_4b233b70-29bd-4a14-b044-e226eeed9d10">65,800</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjY3ZTQ4ZjA4YmQ3MTRhNTNhNGIyMzM5ZTllZTZlMjg0L3RhYmxlcmFuZ2U6NjdlNDhmMDhiZDcxNGE1M2E0YjIzMzllOWVlNmUyODRfMy0yLTEtMS0w_858ca554-ae81-4eb2-989b-47ca2dba80fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ief55fa56f05642ae9c7051bbcc123a7e_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjY3ZTQ4ZjA4YmQ3MTRhNTNhNGIyMzM5ZTllZTZlMjg0L3RhYmxlcmFuZ2U6NjdlNDhmMDhiZDcxNGE1M2E0YjIzMzllOWVlNmUyODRfMy00LTEtMS0w_81afff1e-6b4b-4e12-bff0-f3bcb235b1a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1c7c09a50e6e4ba8839d07d7a35718fb_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjY3ZTQ4ZjA4YmQ3MTRhNTNhNGIyMzM5ZTllZTZlMjg0L3RhYmxlcmFuZ2U6NjdlNDhmMDhiZDcxNGE1M2E0YjIzMzllOWVlNmUyODRfMy01LTEtMS0w_bd763250-3308-4906-8e01-6eac1ce5033d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf63c553ba564cb8bd94fab03c3290ab_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjY3ZTQ4ZjA4YmQ3MTRhNTNhNGIyMzM5ZTllZTZlMjg0L3RhYmxlcmFuZ2U6NjdlNDhmMDhiZDcxNGE1M2E0YjIzMzllOWVlNmUyODRfNC0yLTEtMS0w_480a9ae6-9ba9-494c-a742-bbfd8b83472a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ief55fa56f05642ae9c7051bbcc123a7e_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjY3ZTQ4ZjA4YmQ3MTRhNTNhNGIyMzM5ZTllZTZlMjg0L3RhYmxlcmFuZ2U6NjdlNDhmMDhiZDcxNGE1M2E0YjIzMzllOWVlNmUyODRfNC00LTEtMS0w_13766409-3d0d-4ace-9688-252c39cfc343">15,220</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1c7c09a50e6e4ba8839d07d7a35718fb_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjY3ZTQ4ZjA4YmQ3MTRhNTNhNGIyMzM5ZTllZTZlMjg0L3RhYmxlcmFuZ2U6NjdlNDhmMDhiZDcxNGE1M2E0YjIzMzllOWVlNmUyODRfNC01LTEtMS0w_1f71f2e3-bcbf-4744-9c2c-d3af9e6d6766">23,800</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaf63c553ba564cb8bd94fab03c3290ab_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjY3ZTQ4ZjA4YmQ3MTRhNTNhNGIyMzM5ZTllZTZlMjg0L3RhYmxlcmFuZ2U6NjdlNDhmMDhiZDcxNGE1M2E0YjIzMzllOWVlNmUyODRfNS0yLTEtMS0w_398cae56-079e-4264-9e5a-408be923673e">3,186</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ief55fa56f05642ae9c7051bbcc123a7e_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjY3ZTQ4ZjA4YmQ3MTRhNTNhNGIyMzM5ZTllZTZlMjg0L3RhYmxlcmFuZ2U6NjdlNDhmMDhiZDcxNGE1M2E0YjIzMzllOWVlNmUyODRfNS00LTEtMS0w_a1a903c5-b6a7-48bc-b708-cdb6c06ad372">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1c7c09a50e6e4ba8839d07d7a35718fb_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjY3ZTQ4ZjA4YmQ3MTRhNTNhNGIyMzM5ZTllZTZlMjg0L3RhYmxlcmFuZ2U6NjdlNDhmMDhiZDcxNGE1M2E0YjIzMzllOWVlNmUyODRfNS01LTEtMS0w_9d5e35ca-9a38-4984-babf-d2a4574cb3b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Rights Exchange settlement</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf63c553ba564cb8bd94fab03c3290ab_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="ptct:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsRightsExchangeSettlement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjY3ZTQ4ZjA4YmQ3MTRhNTNhNGIyMzM5ZTllZTZlMjg0L3RhYmxlcmFuZ2U6NjdlNDhmMDhiZDcxNGE1M2E0YjIzMzllOWVlNmUyODRfNi0yLTEtMS03MTIw_9856f745-fb08-4c6f-b3c9-d316faa7d4ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ief55fa56f05642ae9c7051bbcc123a7e_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="ptct:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsRightsExchangeSettlement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjY3ZTQ4ZjA4YmQ3MTRhNTNhNGIyMzM5ZTllZTZlMjg0L3RhYmxlcmFuZ2U6NjdlNDhmMDhiZDcxNGE1M2E0YjIzMzllOWVlNmUyODRfNi00LTEtMS03MTIw_0488b33e-506e-45b9-a6e1-fc30a287f71a">139,180</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1c7c09a50e6e4ba8839d07d7a35718fb_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="ptct:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsRightsExchangeSettlement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjY3ZTQ4ZjA4YmQ3MTRhNTNhNGIyMzM5ZTllZTZlMjg0L3RhYmxlcmFuZ2U6NjdlNDhmMDhiZDcxNGE1M2E0YjIzMzllOWVlNmUyODRfNi02LTEtMS03MTIw_6a43f3dd-141d-435e-a051-8983951f08c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ending balance as of June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i82a7d5029292453a9d8665965b2a0597_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjY3ZTQ4ZjA4YmQ3MTRhNTNhNGIyMzM5ZTllZTZlMjg0L3RhYmxlcmFuZ2U6NjdlNDhmMDhiZDcxNGE1M2E0YjIzMzllOWVlNmUyODRfNi0yLTEtMS0w_4deafb1f-e9e3-41c9-a885-9849ac20c220">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4d5a9b90a7664e9ca2c85d0f043d14b8_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjY3ZTQ4ZjA4YmQ3MTRhNTNhNGIyMzM5ZTllZTZlMjg0L3RhYmxlcmFuZ2U6NjdlNDhmMDhiZDcxNGE1M2E0YjIzMzllOWVlNmUyODRfNi00LTEtMS0w_d4a99368-54ec-4508-a69a-c051f782a13f">136,100</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6d889af7642941098bf2c2aadc6af779_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjY3ZTQ4ZjA4YmQ3MTRhNTNhNGIyMzM5ZTllZTZlMjg0L3RhYmxlcmFuZ2U6NjdlNDhmMDhiZDcxNGE1M2E0YjIzMzllOWVlNmUyODRfNi01LTEtMS0w_e7bf967e-6979-436b-85b6-243a908bf51f">89,600</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.573%;"><tr><td style="width:1.0%;"></td><td style="width:49.919%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.634%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.858%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.634%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.858%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.467%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.030%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3 liabilities</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SARs</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration payable- development and regulatory milestones</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration payable- net sales milestones and royalties</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Beginning balance as of December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iab08ed7f127f42a4870b894f05e31311_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjAxMWU0YmUyZjdmMTRhZGY4NzY3YjM3MDdkMzE1OGFhL3RhYmxlcmFuZ2U6MDExZTRiZTJmN2YxNGFkZjg3NjdiMzcwN2QzMTU4YWFfMi0yLTEtMS0w_552a870b-8523-4793-9d98-6578867ab9ce">3,814</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i34ddd62e28264378a9b8a8810c84e304_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjAxMWU0YmUyZjdmMTRhZGY4NzY3YjM3MDdkMzE1OGFhL3RhYmxlcmFuZ2U6MDExZTRiZTJmN2YxNGFkZjg3NjdiMzcwN2QzMTU4YWFfMi00LTEtMS0w_f48ee237-ae59-4dd1-89d2-404cffce951f">257,040</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i43a9f70ea53c4278ac5294a289217733_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjAxMWU0YmUyZjdmMTRhZGY4NzY3YjM3MDdkMzE1OGFhL3RhYmxlcmFuZ2U6MDExZTRiZTJmN2YxNGFkZjg3NjdiMzcwN2QzMTU4YWFfMi01LTEtMS0w_c8f39e57-5f15-40cd-9fe3-6562103502d5">53,200</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjAxMWU0YmUyZjdmMTRhZGY4NzY3YjM3MDdkMzE1OGFhL3RhYmxlcmFuZ2U6MDExZTRiZTJmN2YxNGFkZjg3NjdiMzcwN2QzMTU4YWFfMy0yLTEtMS0w_89ca4392-01ed-4e51-a6a7-bfb24f79d77c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6901fa0b994f45b1b11bb7852f30e63e_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjAxMWU0YmUyZjdmMTRhZGY4NzY3YjM3MDdkMzE1OGFhL3RhYmxlcmFuZ2U6MDExZTRiZTJmN2YxNGFkZjg3NjdiMzcwN2QzMTU4YWFfMy00LTEtMS0w_f41cffba-b729-446d-b755-3e00e7d71566">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9b011ab666643deb05f06b8b1928ac7_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjAxMWU0YmUyZjdmMTRhZGY4NzY3YjM3MDdkMzE1OGFhL3RhYmxlcmFuZ2U6MDExZTRiZTJmN2YxNGFkZjg3NjdiMzcwN2QzMTU4YWFfMy01LTEtMS0w_9ac768de-18bf-4c9e-8ef7-27796463055e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i69fef5796fd9485e91f00768f2ee4f15_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjAxMWU0YmUyZjdmMTRhZGY4NzY3YjM3MDdkMzE1OGFhL3RhYmxlcmFuZ2U6MDExZTRiZTJmN2YxNGFkZjg3NjdiMzcwN2QzMTU4YWFfNC0yLTEtMS0w_e446012a-125d-4460-a526-ec0384f3a43a">1,961</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6901fa0b994f45b1b11bb7852f30e63e_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjAxMWU0YmUyZjdmMTRhZGY4NzY3YjM3MDdkMzE1OGFhL3RhYmxlcmFuZ2U6MDExZTRiZTJmN2YxNGFkZjg3NjdiMzcwN2QzMTU4YWFfNC00LTEtMS0w_5d2d0526-136f-41b6-8da6-ce732c055d5c">20,360</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9b011ab666643deb05f06b8b1928ac7_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjAxMWU0YmUyZjdmMTRhZGY4NzY3YjM3MDdkMzE1OGFhL3RhYmxlcmFuZ2U6MDExZTRiZTJmN2YxNGFkZjg3NjdiMzcwN2QzMTU4YWFfNC01LTEtMS0w_86b3e04f-825c-4810-9089-f084d60ae9ce">5,600</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i69fef5796fd9485e91f00768f2ee4f15_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjAxMWU0YmUyZjdmMTRhZGY4NzY3YjM3MDdkMzE1OGFhL3RhYmxlcmFuZ2U6MDExZTRiZTJmN2YxNGFkZjg3NjdiMzcwN2QzMTU4YWFfNS0yLTEtMS0w_9fa8d9ca-eda8-4d04-918c-d0053f098572">3,815</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6901fa0b994f45b1b11bb7852f30e63e_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjAxMWU0YmUyZjdmMTRhZGY4NzY3YjM3MDdkMzE1OGFhL3RhYmxlcmFuZ2U6MDExZTRiZTJmN2YxNGFkZjg3NjdiMzcwN2QzMTU4YWFfNS00LTEtMS0w_de9c8531-9d46-4a24-af4f-ef31b8fdd85d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9b011ab666643deb05f06b8b1928ac7_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjAxMWU0YmUyZjdmMTRhZGY4NzY3YjM3MDdkMzE1OGFhL3RhYmxlcmFuZ2U6MDExZTRiZTJmN2YxNGFkZjg3NjdiMzcwN2QzMTU4YWFfNS01LTEtMS0w_47e82508-e7c8-4dc3-833e-6a7c3ce3f2a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ending balance as of June 30, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i492676ae9f954509b5671e6270ebd50f_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjAxMWU0YmUyZjdmMTRhZGY4NzY3YjM3MDdkMzE1OGFhL3RhYmxlcmFuZ2U6MDExZTRiZTJmN2YxNGFkZjg3NjdiMzcwN2QzMTU4YWFfNi0yLTEtMS0w_4ce0d802-2f10-42ad-9613-0c74b0967cd9">1,960</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6abf1ab717cb4553b5a379a89528951c_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjAxMWU0YmUyZjdmMTRhZGY4NzY3YjM3MDdkMzE1OGFhL3RhYmxlcmFuZ2U6MDExZTRiZTJmN2YxNGFkZjg3NjdiMzcwN2QzMTU4YWFfNi00LTEtMS0w_7306247f-f103-474f-a48b-5a2cf035e309">277,400</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0bb52be78ac04fb99f1f51bf469e5f11_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjAxMWU0YmUyZjdmMTRhZGY4NzY3YjM3MDdkMzE1OGFhL3RhYmxlcmFuZ2U6MDExZTRiZTJmN2YxNGFkZjg3NjdiMzcwN2QzMTU4YWFfNi01LTEtMS0w_8ec9235f-a02d-4c4c-bd85-92c1c5be8189">58,800</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfMTIyNjk_96ee7967-2a84-4ec2-96cf-9917983feadf" continuedAt="i0a61368a8ea143c8805d39a63aba92d6" escape="true"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following significant unobservable inputs were used in the valuation of the contingent consideration payable for the periods ended June&#160;30, 2020 and December&#160;31, 2019 and of the SARs liability for the period ended December 31, 2019:</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:18.998%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.415%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.481%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.415%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.823%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.121%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:21.494%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.415%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.038%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value </span></td><td colspan="3" rowspan="10" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Valuation Technique</span></td><td colspan="3" rowspan="10" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unobservable Input</span></td><td colspan="3" rowspan="10" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Range</span></td></tr><tr><td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration payable- development and regulatory milestones<br/></span></td><td colspan="3" rowspan="9" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usd" contextRef="ia63a5a2116d74541955a8c47217140bb_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmM1YmE0NjQ0ZmNiMjQyZjdiMzdlMGEyODM5NmU2YTMwL3RhYmxlcmFuZ2U6YzViYTQ2NDRmY2IyNDJmN2IzN2UwYTI4Mzk2ZTZhMzBfMi0yLTEtMS0w_5cc89422-c3b1-48a2-bd8c-674992b90751">136,100</ix:nonFraction></span></td><td colspan="3" style="display:none;"></td><td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Probability-adjusted discounted cash flow</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Potential development and regulatory milestones</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">$<ix:nonFraction unitRef="usd" contextRef="i7d5cbe2fe3d241869ba45bf5f3259eaf_I20200630" decimals="-6" name="ptct:AlternativeInvestmentMilestone" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmM1YmE0NjQ0ZmNiMjQyZjdiMzdlMGEyODM5NmU2YTMwL3RhYmxlcmFuZ2U6YzViYTQ2NDRmY2IyNDJmN2IzN2UwYTI4Mzk2ZTZhMzBfMi04LTEtMS0wL3RleHRyZWdpb246ZGIxYjhlMTllZGFiNGM3NTllN2NmMmEyNDA5OGU4OTNfNjA0NzMxMzk1Mjc5MQ_642f3173-8d72-4a63-8bb7-edcdd02da812">0</ix:nonFraction> - $<ix:nonFraction unitRef="usd" contextRef="i8e3ab83b0ac24b1f8726a085e96bde2b_I20200630" decimals="-6" name="ptct:AlternativeInvestmentMilestone" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmM1YmE0NjQ0ZmNiMjQyZjdiMzdlMGEyODM5NmU2YTMwL3RhYmxlcmFuZ2U6YzViYTQ2NDRmY2IyNDJmN2IzN2UwYTI4Mzk2ZTZhMzBfMi04LTEtMS0wL3RleHRyZWdpb246ZGIxYjhlMTllZGFiNGM3NTllN2NmMmEyNDA5OGU4OTNfNjA0NzMxMzk1Mjc5Nw_c5875052-561c-4375-b546-c47afd8b27d4">381</ix:nonFraction> million</span></div></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Probabilities of success</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="i97b5568d815c48fcaeba6264529028d7_I20200630" decimals="2" name="us-gaap:AlternativeInvestmentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmM1YmE0NjQ0ZmNiMjQyZjdiMzdlMGEyODM5NmU2YTMwL3RhYmxlcmFuZ2U6YzViYTQ2NDRmY2IyNDJmN2IzN2UwYTI4Mzk2ZTZhMzBfMy04LTEtMS0wL3RleHRyZWdpb246NmMyNjc0Y2NjZTgwNDU0N2JkZWY5MmNkNjZmNjkxYzVfNjA0NzMxMzk1Mjc4NA_9608cc67-54c3-4449-a88d-3a010cbb050d">25</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i7f2ea92199454f8fbd535326a97a91d7_I20200630" decimals="2" name="us-gaap:AlternativeInvestmentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmM1YmE0NjQ0ZmNiMjQyZjdiMzdlMGEyODM5NmU2YTMwL3RhYmxlcmFuZ2U6YzViYTQ2NDRmY2IyNDJmN2IzN2UwYTI4Mzk2ZTZhMzBfMy04LTEtMS0wL3RleHRyZWdpb246NmMyNjc0Y2NjZTgwNDU0N2JkZWY5MmNkNjZmNjkxYzVfNjA0NzMxMzk1Mjc4OQ_581e6355-0c09-44de-b2a0-6fa895976e97">94</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discount rates</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="i142a5ba947234d00bdda31557ab02053_I20200630" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmM1YmE0NjQ0ZmNiMjQyZjdiMzdlMGEyODM5NmU2YTMwL3RhYmxlcmFuZ2U6YzViYTQ2NDRmY2IyNDJmN2IzN2UwYTI4Mzk2ZTZhMzBfNC04LTEtMS0wL3RleHRyZWdpb246N2MyNDljMzk2MDA2NGU1ZDkyMGIwNzVhMjY5ZjI0NTdfNjA0NzMxMzk1Mjc4Nw_6cb37775-3fb2-4213-b4a3-1d1f7bf52e3c">4.6</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ic24cf29b77fa4211a03dfd961242ace4_I20200630" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmM1YmE0NjQ0ZmNiMjQyZjdiMzdlMGEyODM5NmU2YTMwL3RhYmxlcmFuZ2U6YzViYTQ2NDRmY2IyNDJmN2IzN2UwYTI4Mzk2ZTZhMzBfNC04LTEtMS0wL3RleHRyZWdpb246N2MyNDljMzk2MDA2NGU1ZDkyMGIwNzVhMjY5ZjI0NTdfNjA0NzMxMzk1Mjc5Mw_5befb9ef-474f-4b6f-8cfc-bdd3af6a51ea">6.1</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Projected years of payments</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021 - 2027</span></td></tr><tr><td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent considerable payable- net sales milestones and royalties</span></td><td colspan="3" style="display:none;"></td><td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usd" contextRef="if778d097ba124606b84b432e35ce14f2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmM1YmE0NjQ0ZmNiMjQyZjdiMzdlMGEyODM5NmU2YTMwL3RhYmxlcmFuZ2U6YzViYTQ2NDRmY2IyNDJmN2IzN2UwYTI4Mzk2ZTZhMzBfNi0yLTEtMS0w_bd21f0c8-b110-44db-84d9-fa10fcd72491">89,600</ix:nonFraction></span></td><td colspan="3" style="display:none;"></td><td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Option-pricing model with Monte Carlo simulation<br/></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Potential net sales milestones</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">$<ix:nonFraction unitRef="usd" contextRef="icde04c74d7d14859bd0c3c1fec8bf23b_I20200630" decimals="-6" name="ptct:AlternativeInvestmentMilestone" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmM1YmE0NjQ0ZmNiMjQyZjdiMzdlMGEyODM5NmU2YTMwL3RhYmxlcmFuZ2U6YzViYTQ2NDRmY2IyNDJmN2IzN2UwYTI4Mzk2ZTZhMzBfNi04LTEtMS0wL3RleHRyZWdpb246YzUyNTc5NTExMWM5NDA2Yzg5ZTNmZDRhN2Y3MWNiOWJfNjA0NzMxMzk1Mjc5MQ_c005888c-bab5-4086-a75e-cc224c1d0743">0</ix:nonFraction> - $<ix:nonFraction unitRef="usd" contextRef="i841cadf7f1ab42329b55f05f8b682241_I20200630" decimals="-6" name="ptct:AlternativeInvestmentMilestone" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmM1YmE0NjQ0ZmNiMjQyZjdiMzdlMGEyODM5NmU2YTMwL3RhYmxlcmFuZ2U6YzViYTQ2NDRmY2IyNDJmN2IzN2UwYTI4Mzk2ZTZhMzBfNi04LTEtMS0wL3RleHRyZWdpb246YzUyNTc5NTExMWM5NDA2Yzg5ZTNmZDRhN2Y3MWNiOWJfNjA0NzMxMzk1Mjc5OQ_253e8caf-dbe4-4a93-9ec0-16196d336155">150</ix:nonFraction> million</span></div></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Probabilities of success</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="id290d0f494dc48b394820ca85e03d713_I20200630" decimals="2" name="us-gaap:AlternativeInvestmentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmM1YmE0NjQ0ZmNiMjQyZjdiMzdlMGEyODM5NmU2YTMwL3RhYmxlcmFuZ2U6YzViYTQ2NDRmY2IyNDJmN2IzN2UwYTI4Mzk2ZTZhMzBfNy04LTEtMS0wL3RleHRyZWdpb246NGM1Y2MwMTM5NDc1NDBjNDhmYmQwYTkxNjA3YTczZDVfMjc0ODc3OTA2OTQ1Ng_318ca686-1000-4c30-a6ef-5b236c858964">25</ix:nonFraction>% -<ix:nonFraction unitRef="number" contextRef="i7b1d4bc93668470fb8dc3d2484cd7377_I20200630" decimals="2" name="us-gaap:AlternativeInvestmentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmM1YmE0NjQ0ZmNiMjQyZjdiMzdlMGEyODM5NmU2YTMwL3RhYmxlcmFuZ2U6YzViYTQ2NDRmY2IyNDJmN2IzN2UwYTI4Mzk2ZTZhMzBfNy04LTEtMS0wL3RleHRyZWdpb246NGM1Y2MwMTM5NDc1NDBjNDhmYmQwYTkxNjA3YTczZDVfMjc0ODc3OTA2OTQ2Mg_b72d868a-bcd9-4633-9c01-77d72754f423">94</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Potential percentage of net sales for royalties </span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="i032e49103b7940008966b0abb2c816bf_I20200630" decimals="2" name="us-gaap:AlternativeInvestmentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmM1YmE0NjQ0ZmNiMjQyZjdiMzdlMGEyODM5NmU2YTMwL3RhYmxlcmFuZ2U6YzViYTQ2NDRmY2IyNDJmN2IzN2UwYTI4Mzk2ZTZhMzBfOC04LTEtMS0wL3RleHRyZWdpb246MWIyYTQxOTU1MzE3NDY4MThlYWQ3ZWNlMzk1YzlmMTNfMjc0ODc3OTA2OTQ1Mw_df828af1-925d-4978-bb71-8076718fca22">2</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i7aeb677d725d4e7587c00dcd29b216d8_I20200630" decimals="2" name="us-gaap:AlternativeInvestmentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmM1YmE0NjQ0ZmNiMjQyZjdiMzdlMGEyODM5NmU2YTMwL3RhYmxlcmFuZ2U6YzViYTQ2NDRmY2IyNDJmN2IzN2UwYTI4Mzk2ZTZhMzBfOC04LTEtMS0wL3RleHRyZWdpb246MWIyYTQxOTU1MzE3NDY4MThlYWQ3ZWNlMzk1YzlmMTNfMjc0ODc3OTA2OTQ1Nw_2b8c4db2-45c2-4bdd-9a4d-44340fa107bf">6</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discount rate</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i46d96bc3957b4332a199fc5c2ba22aa2_I20200630" decimals="3" name="us-gaap:AlternativeInvestmentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmM1YmE0NjQ0ZmNiMjQyZjdiMzdlMGEyODM5NmU2YTMwL3RhYmxlcmFuZ2U6YzViYTQ2NDRmY2IyNDJmN2IzN2UwYTI4Mzk2ZTZhMzBfOS04LTEtMS0w_f16af69f-a6d2-4732-aec8-dd1ec8af39ce">12.0</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Projected years of payments</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022 - 2039</span></td></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="id0a437b7856443a98b945193f0ac76ce"><ix:continuation id="i13ed41bf30fb49aeb5a4adbd936ebc99"><div style="text-align:center;margin-top:8pt;margin-bottom:6pt;"><ix:continuation id="i0a61368a8ea143c8805d39a63aba92d6"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:18.998%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.415%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.481%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.415%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.823%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.121%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:21.494%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.415%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.038%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value </span></td><td colspan="3" rowspan="15" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Valuation Technique</span></td><td colspan="3" rowspan="15" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unobservable Input</span></td><td colspan="3" rowspan="15" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Range</span></td></tr><tr><td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SARs</span></td><td colspan="3" rowspan="14" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usd" contextRef="ia922f94529a94215b26acb871b50ccef_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE0ZGFhMTA0MWExNTRiMzc5NjE3OWM4OWRkZWZmOTJkL3RhYmxlcmFuZ2U6YTRkYWExMDQxYTE1NGIzNzk2MTc5Yzg5ZGRlZmY5MmRfMi0yLTEtMS0w_9c748396-1948-4713-9c16-0698047cac46">3,186</ix:nonFraction></span></td><td colspan="3" style="display:none;"></td><td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Option-pricing model</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Volatility</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i8a37cc547e3f49848c674109573d923a_I20191231" decimals="4" format="ixt:numdotdecimal" name="us-gaap:AlternativeInvestmentMeasurementInput" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE0ZGFhMTA0MWExNTRiMzc5NjE3OWM4OWRkZWZmOTJkL3RhYmxlcmFuZ2U6YTRkYWExMDQxYTE1NGIzNzk2MTc5Yzg5ZGRlZmY5MmRfMi04LTEtMS0w_84825556-e8a5-4b12-be69-f42b7702148e">28.93</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk free interest rate</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i95e964e1da464dd788d6a99f05370274_I20191231" decimals="4" format="ixt:numdotdecimal" name="us-gaap:AlternativeInvestmentMeasurementInput" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE0ZGFhMTA0MWExNTRiMzc5NjE3OWM4OWRkZWZmOTJkL3RhYmxlcmFuZ2U6YTRkYWExMDQxYTE1NGIzNzk2MTc5Yzg5ZGRlZmY5MmRfMy04LTEtMS0w_4ec041bf-7865-4ba4-b8fa-d7c963a837a2">0.19</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Strike price</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">$<ix:nonFraction unitRef="usdPerShare" contextRef="i0c93370f63d94e1aac4ee54439ff6b56_I20191231" decimals="2" name="us-gaap:AlternativeInvestmentMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE0ZGFhMTA0MWExNTRiMzc5NjE3OWM4OWRkZWZmOTJkL3RhYmxlcmFuZ2U6YTRkYWExMDQxYTE1NGIzNzk2MTc5Yzg5ZGRlZmY5MmRfNC04LTEtMS0wL3RleHRyZWdpb246NDdkNDk3NTQwODhjNGVjY2EzOWQwYzNkOTlmMzY1OTlfODI0NjMzNzIwODM0Mw_20894b66-dd38-4b82-964d-cf7fb09c293c">6.76</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="iffe61d144e3f45a68d1cf62be52068fc_I20191231" decimals="2" name="us-gaap:AlternativeInvestmentMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE0ZGFhMTA0MWExNTRiMzc5NjE3OWM4OWRkZWZmOTJkL3RhYmxlcmFuZ2U6YTRkYWExMDQxYTE1NGIzNzk2MTc5Yzg5ZGRlZmY5MmRfNC04LTEtMS0wL3RleHRyZWdpb246NDdkNDk3NTQwODhjNGVjY2EzOWQwYzNkOTlmMzY1OTlfODI0NjMzNzIwODM1MQ_222dfdcd-eb29-4b05-9ac6-88885832e529">30.86</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of common stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usdPerShare" contextRef="ic6c94b6543dd43d288ab57eb081f624f_I20191231" decimals="2" name="us-gaap:AlternativeInvestmentMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE0ZGFhMTA0MWExNTRiMzc5NjE3OWM4OWRkZWZmOTJkL3RhYmxlcmFuZ2U6YTRkYWExMDQxYTE1NGIzNzk2MTc5Yzg5ZGRlZmY5MmRfNS04LTEtMS0w_d7b99cb5-9f7a-44e7-82a0-38e13028a6bc">48.03</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected life</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="iee49fff9a55c42e7a46ef038efca561d_D20190101-20190331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE0ZGFhMTA0MWExNTRiMzc5NjE3OWM4OWRkZWZmOTJkL3RhYmxlcmFuZ2U6YTRkYWExMDQxYTE1NGIzNzk2MTc5Yzg5ZGRlZmY5MmRfNi04LTEtMS0w_7e49bbb2-214f-4919-b2da-88043e192e7a">0.01</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Contingent consideration payable- development and regulatory milestones</span></div><div style="text-align:center;"><span><br/></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usd" contextRef="i37afd9374ab2456f9adc2e123d047a8d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE0ZGFhMTA0MWExNTRiMzc5NjE3OWM4OWRkZWZmOTJkL3RhYmxlcmFuZ2U6YTRkYWExMDQxYTE1NGIzNzk2MTc5Yzg5ZGRlZmY5MmRfNy0yLTEtMS0w_5222ca44-157d-45e8-ae93-6fc3880afb10">290,500</ix:nonFraction></span></td><td colspan="3" style="display:none;"></td><td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Probability-adjusted discounted cash flow</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Potential development and regulatory milestones</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">$<ix:nonFraction unitRef="usd" contextRef="i41984dd1229341a3adf191f855e3437a_I20191231" decimals="-6" name="ptct:AlternativeInvestmentMilestone" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE0ZGFhMTA0MWExNTRiMzc5NjE3OWM4OWRkZWZmOTJkL3RhYmxlcmFuZ2U6YTRkYWExMDQxYTE1NGIzNzk2MTc5Yzg5ZGRlZmY5MmRfNy04LTEtMS0wL3RleHRyZWdpb246MWE0YzFmMjliZGJiNDY2MWIxMWI4YzA4MWI2NTUwMjNfODI0NjMzNzIwODM0NA_2704c2e1-a789-4f84-a319-00f700828811">0</ix:nonFraction>- $<ix:nonFraction unitRef="usd" contextRef="id9f423a27b8747658dbca67347391ba2_I20191231" decimals="-6" name="ptct:AlternativeInvestmentMilestone" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE0ZGFhMTA0MWExNTRiMzc5NjE3OWM4OWRkZWZmOTJkL3RhYmxlcmFuZ2U6YTRkYWExMDQxYTE1NGIzNzk2MTc5Yzg5ZGRlZmY5MmRfNy04LTEtMS0wL3RleHRyZWdpb246MWE0YzFmMjliZGJiNDY2MWIxMWI4YzA4MWI2NTUwMjNfODI0NjMzNzIwODM1Mw_02fda7f6-119f-4e13-8d45-08109729aaa0">555</ix:nonFraction> million</span></div></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Probabilities of success</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="id9cb29f6a24b456e9193911f1294da2e_I20191231" decimals="2" name="us-gaap:AlternativeInvestmentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE0ZGFhMTA0MWExNTRiMzc5NjE3OWM4OWRkZWZmOTJkL3RhYmxlcmFuZ2U6YTRkYWExMDQxYTE1NGIzNzk2MTc5Yzg5ZGRlZmY5MmRfOC04LTEtMS0wL3RleHRyZWdpb246NzNlOTc5Yjk3ZTQ1NDJmY2EyY2U4Nzg0NmEwY2RhYzZfODI0NjMzNzIwODMzNg_28c4a25f-6c7f-4cdb-8c2e-f858ea9e5fde">25</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i896363143c604488b15264f3f0863d75_I20191231" decimals="2" name="us-gaap:AlternativeInvestmentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE0ZGFhMTA0MWExNTRiMzc5NjE3OWM4OWRkZWZmOTJkL3RhYmxlcmFuZ2U6YTRkYWExMDQxYTE1NGIzNzk2MTc5Yzg5ZGRlZmY5MmRfOC04LTEtMS0wL3RleHRyZWdpb246NzNlOTc5Yjk3ZTQ1NDJmY2EyY2U4Nzg0NmEwY2RhYzZfODI0NjMzNzIwODM0MQ_61dbaa03-706b-400d-94c0-1e5e616aadac">94</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discount rates</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="i4e93577925ee429e9cfb5138f9eb301c_I20191231" decimals="3" name="us-gaap:AlternativeInvestmentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE0ZGFhMTA0MWExNTRiMzc5NjE3OWM4OWRkZWZmOTJkL3RhYmxlcmFuZ2U6YTRkYWExMDQxYTE1NGIzNzk2MTc5Yzg5ZGRlZmY5MmRfOS04LTEtMS0wL3RleHRyZWdpb246ZDU0MmQxNWJmYWExNDUyNGJmZmFhOTgwMTc0NTdkNTdfODI0NjMzNzIwODMzOQ_2cfead7a-093d-41da-92d6-8fc18fadd7a3">2.2</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ia90fac7174b946d2a3f4eb2d0130831f_I20191231" decimals="3" name="us-gaap:AlternativeInvestmentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE0ZGFhMTA0MWExNTRiMzc5NjE3OWM4OWRkZWZmOTJkL3RhYmxlcmFuZ2U6YTRkYWExMDQxYTE1NGIzNzk2MTc5Yzg5ZGRlZmY5MmRfOS04LTEtMS0wL3RleHRyZWdpb246ZDU0MmQxNWJmYWExNDUyNGJmZmFhOTgwMTc0NTdkNTdfODI0NjMzNzIwODM0NQ_e2805679-2110-478d-bda3-4e3c3438d4da">4.7</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Projected years of payments</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020 - 2026</span></td></tr><tr><td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent considerable payable- net sales milestones and royalties</span></td><td colspan="3" style="display:none;"></td><td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usd" contextRef="i9de748e71a0a41f892580d81dc59723c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE0ZGFhMTA0MWExNTRiMzc5NjE3OWM4OWRkZWZmOTJkL3RhYmxlcmFuZ2U6YTRkYWExMDQxYTE1NGIzNzk2MTc5Yzg5ZGRlZmY5MmRfMTEtMi0xLTEtMA_395ad3b5-e5b2-4129-8323-c4e828bfb966">65,800</ix:nonFraction></span></td><td colspan="3" style="display:none;"></td><td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Option-pricing model with Monte Carlo simulation<br/></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Potential net sales milestones</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">$<ix:nonFraction unitRef="usd" contextRef="ia365849e92bd4987b8c1a8f48af0e949_I20191231" decimals="-5" name="ptct:AlternativeInvestmentMilestone" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE0ZGFhMTA0MWExNTRiMzc5NjE3OWM4OWRkZWZmOTJkL3RhYmxlcmFuZ2U6YTRkYWExMDQxYTE1NGIzNzk2MTc5Yzg5ZGRlZmY5MmRfMTEtOC0xLTEtMC90ZXh0cmVnaW9uOjZjZTJlYWIzZWVkZjRhNjVhMzcxMDVjZWQ5MDRkMmQyXzgyNDYzMzcyMDgzNDM_97987f82-a4b6-48b2-9703-4bdadea5b0d2">0</ix:nonFraction> - $<ix:nonFraction unitRef="usd" contextRef="ie8a23607d13242b087cdf7ef0d75fbf0_I20191231" decimals="-6" name="ptct:AlternativeInvestmentMilestone" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE0ZGFhMTA0MWExNTRiMzc5NjE3OWM4OWRkZWZmOTJkL3RhYmxlcmFuZ2U6YTRkYWExMDQxYTE1NGIzNzk2MTc5Yzg5ZGRlZmY5MmRfMTEtOC0xLTEtMC90ZXh0cmVnaW9uOjZjZTJlYWIzZWVkZjRhNjVhMzcxMDVjZWQ5MDRkMmQyXzgyNDYzMzcyMDgzNTI_2aeef922-a5b9-4bad-bf5a-2d16ff943839">150</ix:nonFraction> million</span></div></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Probabilities of success</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="i2e30234883ae400a8e1754f0ba49366e_I20191231" decimals="2" name="us-gaap:AlternativeInvestmentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE0ZGFhMTA0MWExNTRiMzc5NjE3OWM4OWRkZWZmOTJkL3RhYmxlcmFuZ2U6YTRkYWExMDQxYTE1NGIzNzk2MTc5Yzg5ZGRlZmY5MmRfMTItOC0xLTEtMC90ZXh0cmVnaW9uOmJjMDVlZWZmNDhhODQ1NWQ5OGIyNTU2ZGNiMWUzY2IyXzgyNDYzMzcyMDgzMzY_37323882-0da4-4c1f-a817-a1fe87e9dbae">25</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i7418d3bad6a54d2d94c44b530ec3c8ef_I20191231" decimals="2" name="us-gaap:AlternativeInvestmentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE0ZGFhMTA0MWExNTRiMzc5NjE3OWM4OWRkZWZmOTJkL3RhYmxlcmFuZ2U6YTRkYWExMDQxYTE1NGIzNzk2MTc5Yzg5ZGRlZmY5MmRfMTItOC0xLTEtMC90ZXh0cmVnaW9uOmJjMDVlZWZmNDhhODQ1NWQ5OGIyNTU2ZGNiMWUzY2IyXzgyNDYzMzcyMDgzNDE_873ebec7-ac45-4431-a267-d369d47a2cf9">89</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Potential percentage of net sales for royalties </span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="id6558018b150492b8245e18dd9d4171c_I20191231" decimals="2" name="us-gaap:AlternativeInvestmentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE0ZGFhMTA0MWExNTRiMzc5NjE3OWM4OWRkZWZmOTJkL3RhYmxlcmFuZ2U6YTRkYWExMDQxYTE1NGIzNzk2MTc5Yzg5ZGRlZmY5MmRfMTMtOC0xLTEtMC90ZXh0cmVnaW9uOjQ3OWNjNDJlMDNjZDQyMjBhMGRlZDE3ZGQ1YWFlZDc5XzgyNDYzMzcyMDgzMzM_b33002cd-8445-4302-b19d-c01ac856597c">2</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i92a0fdc9f2104055b10e7852fda23d64_I20191231" decimals="2" name="us-gaap:AlternativeInvestmentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE0ZGFhMTA0MWExNTRiMzc5NjE3OWM4OWRkZWZmOTJkL3RhYmxlcmFuZ2U6YTRkYWExMDQxYTE1NGIzNzk2MTc5Yzg5ZGRlZmY5MmRfMTMtOC0xLTEtMC90ZXh0cmVnaW9uOjQ3OWNjNDJlMDNjZDQyMjBhMGRlZDE3ZGQ1YWFlZDc5XzgyNDYzMzcyMDgzMzc_e69b304e-546a-49ec-9e6e-e2f013959b26">6</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discount rate</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i01dac52020be426eb733231d3b86e6ac_I20191231" decimals="3" name="us-gaap:AlternativeInvestmentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE0ZGFhMTA0MWExNTRiMzc5NjE3OWM4OWRkZWZmOTJkL3RhYmxlcmFuZ2U6YTRkYWExMDQxYTE1NGIzNzk2MTc5Yzg5ZGRlZmY5MmRfMTQtOC0xLTEtMA_9e8cc096-875d-48ee-bd5b-5fcf6acd1c7b">14.5</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Projected years of payments</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021 - 2038</span></td></tr></table></ix:continuation></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The contingent consideration payables are classified Level 3 liabilities as their valuation requires substantial judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for the various inputs to the valuation approaches, including but not limited to, assumptions involving probability adjusted sales estimates for the gene therapy platform and estimated discount rates, the estimated fair value could be significantly higher or lower than the fair value determined.</span></div></ix:continuation></ix:continuation><div style="text-align:justify;margin-top:6pt;"><span><br/></span></div><div id="i95cf61a5c7074910ae3cf29c5ee08838_58"></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">6.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:700;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RleHRyZWdpb246MWUxN2ExZWMyNDhkNGNiYmIwYTM4ZjM1NmNhMTliMDVfNDAy_6712ad11-73ce-44a7-91d3-8e4aa5bbf6a9" continuedAt="i1998170cb5164c9998cd430f92721519" escape="true">Other comprehensive income (loss) and accumulated other comprehensive items</ix:nonNumeric></span></div><ix:continuation id="i1998170cb5164c9998cd430f92721519" continuedAt="i93fb3466e85c424fbd18266ba767b0d4"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other comprehensive income (loss) includes changes in equity that are excluded from net income (loss), such as unrealized gains and losses on marketable securities.</span></div><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RleHRyZWdpb246MWUxN2ExZWMyNDhkNGNiYmIwYTM4ZjM1NmNhMTliMDVfNDA2_5df39ff8-00fb-465d-b97a-658dbc21e20c" continuedAt="ia2e21a1051c0454b87b502848317a7bc" escape="true"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following tables summarize other comprehensive income (loss) and the changes in accumulated other comprehensive items for the three and six months periods ended June&#160;30, 2020:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:57.590%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.740%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Gains/(Losses) On Marketable Securities, net of tax</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign Currency Translation</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Accumulated Other Comprehensive Items</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at March 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i928aeea3fbed4653a9c7504d776b8545_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjRkYzAwNGUyOTYzYTQ1Yjg4MDEyODMxZmUzMmY3MWFjL3RhYmxlcmFuZ2U6NGRjMDA0ZTI5NjNhNDViODgwMTI4MzFmZTMyZjcxYWNfMS0yLTEtMS0yOTc3_0a4b6bb4-d946-4f19-b173-7ee62278bffd">692</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic451340f512342608177bf840c932205_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjRkYzAwNGUyOTYzYTQ1Yjg4MDEyODMxZmUzMmY3MWFjL3RhYmxlcmFuZ2U6NGRjMDA0ZTI5NjNhNDViODgwMTI4MzFmZTMyZjcxYWNfMS00LTEtMS0yOTgx_1736707e-68e7-441f-b50a-40faa01d5035">2,677</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic903ce63d61344bb93ea8a3c7cd2e5fd_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjRkYzAwNGUyOTYzYTQ1Yjg4MDEyODMxZmUzMmY3MWFjL3RhYmxlcmFuZ2U6NGRjMDA0ZTI5NjNhNDViODgwMTI4MzFmZTMyZjcxYWNfMS02LTEtMS0yOTg1_25ac70db-d399-4133-88cb-ae37619067bf">1,985</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id2f410476d4d4014828565f0ff529e4b_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjRkYzAwNGUyOTYzYTQ1Yjg4MDEyODMxZmUzMmY3MWFjL3RhYmxlcmFuZ2U6NGRjMDA0ZTI5NjNhNDViODgwMTI4MzFmZTMyZjcxYWNfMi0yLTEtMS0yOTc3_a7339f89-c684-4be9-9e73-adf2f251b5ab">2,718</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2a5bfe4b544f4ab3b6857b0ebb80918e_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjRkYzAwNGUyOTYzYTQ1Yjg4MDEyODMxZmUzMmY3MWFjL3RhYmxlcmFuZ2U6NGRjMDA0ZTI5NjNhNDViODgwMTI4MzFmZTMyZjcxYWNfMi00LTEtMS0yOTgx_c35e17e2-3db0-4726-a9b4-508a36c4e98f">10,749</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjRkYzAwNGUyOTYzYTQ1Yjg4MDEyODMxZmUzMmY3MWFjL3RhYmxlcmFuZ2U6NGRjMDA0ZTI5NjNhNDViODgwMTI4MzFmZTMyZjcxYWNfMi02LTEtMS0yOTg1_4272d426-a8b5-4e6b-91f8-f064197cceee">8,031</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amounts reclassified from other comprehensive items</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id2f410476d4d4014828565f0ff529e4b_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjRkYzAwNGUyOTYzYTQ1Yjg4MDEyODMxZmUzMmY3MWFjL3RhYmxlcmFuZ2U6NGRjMDA0ZTI5NjNhNDViODgwMTI4MzFmZTMyZjcxYWNfMy0yLTEtMS0yOTc3_e52e71f4-0ca7-4155-8fa0-e395f3c40ca2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2a5bfe4b544f4ab3b6857b0ebb80918e_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjRkYzAwNGUyOTYzYTQ1Yjg4MDEyODMxZmUzMmY3MWFjL3RhYmxlcmFuZ2U6NGRjMDA0ZTI5NjNhNDViODgwMTI4MzFmZTMyZjcxYWNfMy00LTEtMS0yOTgx_778e3199-0f2f-4d0d-985c-13615833cfc9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjRkYzAwNGUyOTYzYTQ1Yjg4MDEyODMxZmUzMmY3MWFjL3RhYmxlcmFuZ2U6NGRjMDA0ZTI5NjNhNDViODgwMTI4MzFmZTMyZjcxYWNfMy02LTEtMS0yOTg1_3ce054f7-8022-4cd4-a54d-f1365a284e7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id2f410476d4d4014828565f0ff529e4b_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjRkYzAwNGUyOTYzYTQ1Yjg4MDEyODMxZmUzMmY3MWFjL3RhYmxlcmFuZ2U6NGRjMDA0ZTI5NjNhNDViODgwMTI4MzFmZTMyZjcxYWNfNC0yLTEtMS0yOTc3_31017551-1f57-4c8d-95e6-4de51cdd82ce">2,718</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2a5bfe4b544f4ab3b6857b0ebb80918e_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjRkYzAwNGUyOTYzYTQ1Yjg4MDEyODMxZmUzMmY3MWFjL3RhYmxlcmFuZ2U6NGRjMDA0ZTI5NjNhNDViODgwMTI4MzFmZTMyZjcxYWNfNC00LTEtMS0yOTgx_500896e5-1372-4334-aeb0-5372b204a8d1">10,749</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjRkYzAwNGUyOTYzYTQ1Yjg4MDEyODMxZmUzMmY3MWFjL3RhYmxlcmFuZ2U6NGRjMDA0ZTI5NjNhNDViODgwMTI4MzFmZTMyZjcxYWNfNC02LTEtMS0yOTg1_7e79794d-92f5-4b74-b77b-7de20af0e594">8,031</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i73427926a3e341daaacaf169fb831162_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjRkYzAwNGUyOTYzYTQ1Yjg4MDEyODMxZmUzMmY3MWFjL3RhYmxlcmFuZ2U6NGRjMDA0ZTI5NjNhNDViODgwMTI4MzFmZTMyZjcxYWNfNS0yLTEtMS0yOTc3_cd5682c7-60e4-4c61-bf3b-9e1539ec2c9d">3,410</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8ea979e0426d48798c5a50c5f7a7aa15_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjRkYzAwNGUyOTYzYTQ1Yjg4MDEyODMxZmUzMmY3MWFjL3RhYmxlcmFuZ2U6NGRjMDA0ZTI5NjNhNDViODgwMTI4MzFmZTMyZjcxYWNfNS00LTEtMS0yOTgx_5785b8fa-c6d4-4e1e-80c3-fb4c1fbf0163">13,426</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if99a5f5b88c44e239963a271d78fd4d0_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjRkYzAwNGUyOTYzYTQ1Yjg4MDEyODMxZmUzMmY3MWFjL3RhYmxlcmFuZ2U6NGRjMDA0ZTI5NjNhNDViODgwMTI4MzFmZTMyZjcxYWNfNS02LTEtMS0yOTg1_e438f041-33e9-49fc-8ca3-dbb2eecfe0df">10,016</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:8pt;margin-bottom:6pt;"><ix:continuation id="i93fb3466e85c424fbd18266ba767b0d4"><ix:continuation id="ia2e21a1051c0454b87b502848317a7bc"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:57.590%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.740%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized<br/>Gains/(Losses)<br/>On<br/>Marketable<br/>Securities,&#160;net<br/>of&#160;tax</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign<br/>Currency<br/>Translation</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total<br/>Accumulated<br/>Other<br/>Comprehensive<br/>Items</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8ab1ac66d020429d96c29af31d72ab26_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjlhYjY4ODI3NDUxODQ1ZDliZGZjM2M3NWEzZWMyMTYyL3RhYmxlcmFuZ2U6OWFiNjg4Mjc0NTE4NDVkOWJkZmMzYzc1YTNlYzIxNjJfMS0yLTEtMS0w_231b37b3-5aee-4ee6-9dea-74832ff619aa">755</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icdcaac852b5047fa90c10c82a5c82f80_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjlhYjY4ODI3NDUxODQ1ZDliZGZjM2M3NWEzZWMyMTYyL3RhYmxlcmFuZ2U6OWFiNjg4Mjc0NTE4NDVkOWJkZmMzYzc1YTNlYzIxNjJfMS00LTEtMS0w_93a980be-83e8-4ffa-ac43-2ba8b61b4dcf">11,339</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iebab310c097741efb22ea6ccc61c24b1_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjlhYjY4ODI3NDUxODQ1ZDliZGZjM2M3NWEzZWMyMTYyL3RhYmxlcmFuZ2U6OWFiNjg4Mjc0NTE4NDVkOWJkZmMzYzc1YTNlYzIxNjJfMS02LTEtMS0w_ac69a212-bac3-40c4-9f82-28aae3bbcab7">10,584</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iddbe94caf0424d3fa43a0628a5730a6f_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjlhYjY4ODI3NDUxODQ1ZDliZGZjM2M3NWEzZWMyMTYyL3RhYmxlcmFuZ2U6OWFiNjg4Mjc0NTE4NDVkOWJkZmMzYzc1YTNlYzIxNjJfMi0yLTEtMS0w_69b897c9-85b3-4135-8603-9009a8113a16">2,655</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idfb151bb79164c7a924ed3a43feda689_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjlhYjY4ODI3NDUxODQ1ZDliZGZjM2M3NWEzZWMyMTYyL3RhYmxlcmFuZ2U6OWFiNjg4Mjc0NTE4NDVkOWJkZmMzYzc1YTNlYzIxNjJfMi00LTEtMS0w_ab8a9ea6-bf80-4717-b457-06fed989c5e8">2,087</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjlhYjY4ODI3NDUxODQ1ZDliZGZjM2M3NWEzZWMyMTYyL3RhYmxlcmFuZ2U6OWFiNjg4Mjc0NTE4NDVkOWJkZmMzYzc1YTNlYzIxNjJfMi02LTEtMS0w_8200be1c-cd6b-4bb1-b663-a799f6cf41a7">568</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amounts reclassified from other comprehensive items</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iddbe94caf0424d3fa43a0628a5730a6f_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjlhYjY4ODI3NDUxODQ1ZDliZGZjM2M3NWEzZWMyMTYyL3RhYmxlcmFuZ2U6OWFiNjg4Mjc0NTE4NDVkOWJkZmMzYzc1YTNlYzIxNjJfMy0yLTEtMS0w_f689f47e-b397-4725-8a94-b3aa19ce52f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idfb151bb79164c7a924ed3a43feda689_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjlhYjY4ODI3NDUxODQ1ZDliZGZjM2M3NWEzZWMyMTYyL3RhYmxlcmFuZ2U6OWFiNjg4Mjc0NTE4NDVkOWJkZmMzYzc1YTNlYzIxNjJfMy00LTEtMS0w_07648297-b904-4361-9d19-eeef1425c0cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjlhYjY4ODI3NDUxODQ1ZDliZGZjM2M3NWEzZWMyMTYyL3RhYmxlcmFuZ2U6OWFiNjg4Mjc0NTE4NDVkOWJkZmMzYzc1YTNlYzIxNjJfMy02LTEtMS0w_8323dc1a-77db-4ea9-8753-3694ed3a4ad8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income (loss)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iddbe94caf0424d3fa43a0628a5730a6f_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjlhYjY4ODI3NDUxODQ1ZDliZGZjM2M3NWEzZWMyMTYyL3RhYmxlcmFuZ2U6OWFiNjg4Mjc0NTE4NDVkOWJkZmMzYzc1YTNlYzIxNjJfNC0yLTEtMS0w_d11299b4-44de-4f4c-9683-519c46f268ab">2,655</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idfb151bb79164c7a924ed3a43feda689_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjlhYjY4ODI3NDUxODQ1ZDliZGZjM2M3NWEzZWMyMTYyL3RhYmxlcmFuZ2U6OWFiNjg4Mjc0NTE4NDVkOWJkZmMzYzc1YTNlYzIxNjJfNC00LTEtMS0w_df2e72e9-ccc3-4dac-b077-4436f8f4f864">2,087</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjlhYjY4ODI3NDUxODQ1ZDliZGZjM2M3NWEzZWMyMTYyL3RhYmxlcmFuZ2U6OWFiNjg4Mjc0NTE4NDVkOWJkZmMzYzc1YTNlYzIxNjJfNC02LTEtMS0w_4de6fe85-4668-498e-a38c-a27bd8678d33">568</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i73427926a3e341daaacaf169fb831162_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjlhYjY4ODI3NDUxODQ1ZDliZGZjM2M3NWEzZWMyMTYyL3RhYmxlcmFuZ2U6OWFiNjg4Mjc0NTE4NDVkOWJkZmMzYzc1YTNlYzIxNjJfNS0yLTEtMS0w_143d919f-778e-46e5-98c7-01fbf92139e3">3,410</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8ea979e0426d48798c5a50c5f7a7aa15_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjlhYjY4ODI3NDUxODQ1ZDliZGZjM2M3NWEzZWMyMTYyL3RhYmxlcmFuZ2U6OWFiNjg4Mjc0NTE4NDVkOWJkZmMzYzc1YTNlYzIxNjJfNS00LTEtMS0w_f8547c50-bc0e-419b-9288-77b61d146db7">13,426</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if99a5f5b88c44e239963a271d78fd4d0_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjlhYjY4ODI3NDUxODQ1ZDliZGZjM2M3NWEzZWMyMTYyL3RhYmxlcmFuZ2U6OWFiNjg4Mjc0NTE4NDVkOWJkZmMzYzc1YTNlYzIxNjJfNS02LTEtMS0w_227a46e9-9b4b-438f-92d8-3f20f9711f70">10,016</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></ix:continuation></div><div id="i95cf61a5c7074910ae3cf29c5ee08838_61"></div><div style="margin-top:8pt;margin-bottom:8pt;"><span><br/></span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">7.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:700;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82MS9mcmFnOjMxMDI3ZjA1NzM4NTRkYjg4YTZhOTJlN2EzZDA0YmVlL3RleHRyZWdpb246MzEwMjdmMDU3Mzg1NGRiODhhNmE5MmU3YTNkMDRiZWVfMTM0_e044be2a-5b86-4ad4-ac14-ee35025c5196" continuedAt="i13385be2cdfb4dc093608d5782e3099c" escape="true">Accounts payable and accrued expenses</ix:nonNumeric></span></div><ix:continuation id="i13385be2cdfb4dc093608d5782e3099c"><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82MS9mcmFnOjMxMDI3ZjA1NzM4NTRkYjg4YTZhOTJlN2EzZDA0YmVlL3RleHRyZWdpb246MzEwMjdmMDU3Mzg1NGRiODhhNmE5MmU3YTNkMDRiZWVfMTQx_ec7c91b8-93ec-4bd6-b518-755f88935713" escape="true"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accounts payable and accrued expenses at June&#160;30, 2020 and December&#160;31, 2019 consist of the following:</span></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:71.060%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.739%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employee compensation, benefits, and related accruals</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82MS9mcmFnOjMxMDI3ZjA1NzM4NTRkYjg4YTZhOTJlN2EzZDA0YmVlL3RhYmxlOjdmYmQ0ZmJlY2UzYzQwNzBhN2U4MjI5MTFjNDQxNjZmL3RhYmxlcmFuZ2U6N2ZiZDRmYmVjZTNjNDA3MGE3ZTgyMjkxMWM0NDE2NmZfMS0yLTEtMS0w_b18b90f8-849b-4522-9ee0-415ee06caa07">24,861</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82MS9mcmFnOjMxMDI3ZjA1NzM4NTRkYjg4YTZhOTJlN2EzZDA0YmVlL3RhYmxlOjdmYmQ0ZmJlY2UzYzQwNzBhN2U4MjI5MTFjNDQxNjZmL3RhYmxlcmFuZ2U6N2ZiZDRmYmVjZTNjNDA3MGE3ZTgyMjkxMWM0NDE2NmZfMS00LTEtMS0w_1287a6bf-694f-467a-9d90-125cc08516f6">38,889</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Consulting and contracted research</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="ptct:AccruedConsultingAndContractedResearchCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82MS9mcmFnOjMxMDI3ZjA1NzM4NTRkYjg4YTZhOTJlN2EzZDA0YmVlL3RhYmxlOjdmYmQ0ZmJlY2UzYzQwNzBhN2U4MjI5MTFjNDQxNjZmL3RhYmxlcmFuZ2U6N2ZiZDRmYmVjZTNjNDA3MGE3ZTgyMjkxMWM0NDE2NmZfMi0yLTEtMS0w_e2a044b2-c2ac-4432-b684-b1c8ca2511d0">13,452</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="ptct:AccruedConsultingAndContractedResearchCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82MS9mcmFnOjMxMDI3ZjA1NzM4NTRkYjg4YTZhOTJlN2EzZDA0YmVlL3RhYmxlOjdmYmQ0ZmJlY2UzYzQwNzBhN2U4MjI5MTFjNDQxNjZmL3RhYmxlcmFuZ2U6N2ZiZDRmYmVjZTNjNDA3MGE3ZTgyMjkxMWM0NDE2NmZfMi00LTEtMS0w_5057f156-f2cc-49be-860b-06192133b2dd">12,969</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Professional fees</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82MS9mcmFnOjMxMDI3ZjA1NzM4NTRkYjg4YTZhOTJlN2EzZDA0YmVlL3RhYmxlOjdmYmQ0ZmJlY2UzYzQwNzBhN2U4MjI5MTFjNDQxNjZmL3RhYmxlcmFuZ2U6N2ZiZDRmYmVjZTNjNDA3MGE3ZTgyMjkxMWM0NDE2NmZfMy0yLTEtMS0w_eb07f316-e03d-416e-8e35-62858037150c">3,295</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82MS9mcmFnOjMxMDI3ZjA1NzM4NTRkYjg4YTZhOTJlN2EzZDA0YmVlL3RhYmxlOjdmYmQ0ZmJlY2UzYzQwNzBhN2U4MjI5MTFjNDQxNjZmL3RhYmxlcmFuZ2U6N2ZiZDRmYmVjZTNjNDA3MGE3ZTgyMjkxMWM0NDE2NmZfMy00LTEtMS0w_2788dd0a-e4d4-439a-b632-1a716919216c">3,562</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sales allowance and other costs</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="ptct:SalesAllowanceAndOtherRelatedCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82MS9mcmFnOjMxMDI3ZjA1NzM4NTRkYjg4YTZhOTJlN2EzZDA0YmVlL3RhYmxlOjdmYmQ0ZmJlY2UzYzQwNzBhN2U4MjI5MTFjNDQxNjZmL3RhYmxlcmFuZ2U6N2ZiZDRmYmVjZTNjNDA3MGE3ZTgyMjkxMWM0NDE2NmZfNC0yLTEtMS0w_2ede34f6-3b92-4d0c-a4e0-f377f1f0a1f6">45,848</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="ptct:SalesAllowanceAndOtherRelatedCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82MS9mcmFnOjMxMDI3ZjA1NzM4NTRkYjg4YTZhOTJlN2EzZDA0YmVlL3RhYmxlOjdmYmQ0ZmJlY2UzYzQwNzBhN2U4MjI5MTFjNDQxNjZmL3RhYmxlcmFuZ2U6N2ZiZDRmYmVjZTNjNDA3MGE3ZTgyMjkxMWM0NDE2NmZfNC00LTEtMS0w_c5f026ea-4085-4b00-857c-db259fa80afd">41,155</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sales rebates and royalties</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="ptct:SalesRebatesAndRoyaltiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82MS9mcmFnOjMxMDI3ZjA1NzM4NTRkYjg4YTZhOTJlN2EzZDA0YmVlL3RhYmxlOjdmYmQ0ZmJlY2UzYzQwNzBhN2U4MjI5MTFjNDQxNjZmL3RhYmxlcmFuZ2U6N2ZiZDRmYmVjZTNjNDA3MGE3ZTgyMjkxMWM0NDE2NmZfNS0yLTEtMS0w_807e072b-91ab-49aa-a744-c6849904971f">56,870</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="ptct:SalesRebatesAndRoyaltiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82MS9mcmFnOjMxMDI3ZjA1NzM4NTRkYjg4YTZhOTJlN2EzZDA0YmVlL3RhYmxlOjdmYmQ0ZmJlY2UzYzQwNzBhN2U4MjI5MTFjNDQxNjZmL3RhYmxlcmFuZ2U6N2ZiZDRmYmVjZTNjNDA3MGE3ZTgyMjkxMWM0NDE2NmZfNS00LTEtMS0w_bff4afa1-d7d8-40d6-a53c-30cd612b34e6">42,997</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82MS9mcmFnOjMxMDI3ZjA1NzM4NTRkYjg4YTZhOTJlN2EzZDA0YmVlL3RhYmxlOjdmYmQ0ZmJlY2UzYzQwNzBhN2U4MjI5MTFjNDQxNjZmL3RhYmxlcmFuZ2U6N2ZiZDRmYmVjZTNjNDA3MGE3ZTgyMjkxMWM0NDE2NmZfNi0yLTEtMS0w_16014a96-71b5-43c9-a400-154696c42926">15,465</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82MS9mcmFnOjMxMDI3ZjA1NzM4NTRkYjg4YTZhOTJlN2EzZDA0YmVlL3RhYmxlOjdmYmQ0ZmJlY2UzYzQwNzBhN2U4MjI5MTFjNDQxNjZmL3RhYmxlcmFuZ2U6N2ZiZDRmYmVjZTNjNDA3MGE3ZTgyMjkxMWM0NDE2NmZfNi00LTEtMS0w_44406350-2a30-4ae6-8155-a361fcd43224">10,324</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82MS9mcmFnOjMxMDI3ZjA1NzM4NTRkYjg4YTZhOTJlN2EzZDA0YmVlL3RhYmxlOjdmYmQ0ZmJlY2UzYzQwNzBhN2U4MjI5MTFjNDQxNjZmL3RhYmxlcmFuZ2U6N2ZiZDRmYmVjZTNjNDA3MGE3ZTgyMjkxMWM0NDE2NmZfNy0yLTEtMS0w_310579ca-375c-4914-a17b-48675ce65c8e">4,585</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82MS9mcmFnOjMxMDI3ZjA1NzM4NTRkYjg4YTZhOTJlN2EzZDA0YmVlL3RhYmxlOjdmYmQ0ZmJlY2UzYzQwNzBhN2U4MjI5MTFjNDQxNjZmL3RhYmxlcmFuZ2U6N2ZiZDRmYmVjZTNjNDA3MGE3ZTgyMjkxMWM0NDE2NmZfNy00LTEtMS0w_547d9003-782f-4879-aa4b-ca3578e23c42">9,380</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82MS9mcmFnOjMxMDI3ZjA1NzM4NTRkYjg4YTZhOTJlN2EzZDA0YmVlL3RhYmxlOjdmYmQ0ZmJlY2UzYzQwNzBhN2U4MjI5MTFjNDQxNjZmL3RhYmxlcmFuZ2U6N2ZiZDRmYmVjZTNjNDA3MGE3ZTgyMjkxMWM0NDE2NmZfOC0yLTEtMS0w_ac235f03-1497-4912-b745-243739c7f56b">164,376</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82MS9mcmFnOjMxMDI3ZjA1NzM4NTRkYjg4YTZhOTJlN2EzZDA0YmVlL3RhYmxlOjdmYmQ0ZmJlY2UzYzQwNzBhN2U4MjI5MTFjNDQxNjZmL3RhYmxlcmFuZ2U6N2ZiZDRmYmVjZTNjNDA3MGE3ZTgyMjkxMWM0NDE2NmZfOC00LTEtMS0w_8b3d7399-ae36-405b-9a89-94a2ccd32983">159,276</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i95cf61a5c7074910ae3cf29c5ee08838_64"></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">8.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:700;line-height:120%;">&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82NC9mcmFnOmM5YTA4NjRiYzE0NTRkZmJiNmU2OWQxZjAzMzdhODRlL3RleHRyZWdpb246YzlhMDg2NGJjMTQ1NGRmYmI2ZTY5ZDFmMDMzN2E4NGVfNDM5ODA0NjUxNjE4MA_4a72dbb0-badd-4225-9c72-d8754c957b30" continuedAt="i8021fe37072f440ca014b141de9e88f0" escape="true">Capitalization</ix:nonNumeric></span></div><ix:continuation id="i8021fe37072f440ca014b141de9e88f0"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2019, the Company entered into an At the Market Offering Sales Agreement (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald and RBC Capital Markets, LLC (together, the &#8220;Sales Agents&#8221;), pursuant to which, the Company may offer and sell shares of its common stock, having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="i31727b5e545f4438bb09f0aee02b36cf_D20190801-20190831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82NC9mcmFnOmM5YTA4NjRiYzE0NTRkZmJiNmU2OWQxZjAzMzdhODRlL3RleHRyZWdpb246YzlhMDg2NGJjMTQ1NGRmYmI2ZTY5ZDFmMDMzN2E4NGVfMzM2_b52c0d2c-2e35-4ccc-a036-7f4039194712">125.0</ix:nonFraction> million from time to time through the Sales Agents by any method that is deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended. During the three and six month periods ending June 30, 2020, the Company issued and sold an aggregate of <ix:nonFraction unitRef="shares" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82NC9mcmFnOmM5YTA4NjRiYzE0NTRkZmJiNmU2OWQxZjAzMzdhODRlL3RleHRyZWdpb246YzlhMDg2NGJjMTQ1NGRmYmI2ZTY5ZDFmMDMzN2E4NGVfNDk0NzgwMjMyNzc1OQ_d8db293a-2be8-4b08-8c33-9ce64469c5e3">106,309</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82NC9mcmFnOmM5YTA4NjRiYzE0NTRkZmJiNmU2OWQxZjAzMzdhODRlL3RleHRyZWdpb246YzlhMDg2NGJjMTQ1NGRmYmI2ZTY5ZDFmMDMzN2E4NGVfNjI5_f757dd07-ce6c-479c-b4e9-1b840cfd7dd7">368,514</ix:nonFraction> shares of common stock pursuant to the Sales Agreement at a weighted average public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i22a6b3907e334ad095459c22452a31a8_D20200401-20200630" decimals="2" name="ptct:SaleOfStockWeightedAveragePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82NC9mcmFnOmM5YTA4NjRiYzE0NTRkZmJiNmU2OWQxZjAzMzdhODRlL3RleHRyZWdpb246YzlhMDg2NGJjMTQ1NGRmYmI2ZTY5ZDFmMDMzN2E4NGVfNDk0NzgwMjMyNzc2Nw_e781cca7-4886-4c6d-a929-b7c38b81d011">53.08</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i20afcd7c10c14ac495fc02e16fe69b2d_D20200101-20200630" decimals="2" name="ptct:SaleOfStockWeightedAveragePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82NC9mcmFnOmM5YTA4NjRiYzE0NTRkZmJiNmU2OWQxZjAzMzdhODRlL3RleHRyZWdpb246YzlhMDg2NGJjMTQ1NGRmYmI2ZTY5ZDFmMDMzN2E4NGVfNzM0_87f756b3-f01f-404a-9d22-095134a167de">52.89</ix:nonFraction> per share, respectively. During the three and six month periods ending June 30, 2020, the Company received net proceeds of $<ix:nonFraction unitRef="usd" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82NC9mcmFnOmM5YTA4NjRiYzE0NTRkZmJiNmU2OWQxZjAzMzdhODRlL3RleHRyZWdpb246YzlhMDg2NGJjMTQ1NGRmYmI2ZTY5ZDFmMDMzN2E4NGVfNDk0NzgwMjMyNzg2Mg_4308e0df-225f-449f-93dd-e1eb2e88e53c">5.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82NC9mcmFnOmM5YTA4NjRiYzE0NTRkZmJiNmU2OWQxZjAzMzdhODRlL3RleHRyZWdpb246YzlhMDg2NGJjMTQ1NGRmYmI2ZTY5ZDFmMDMzN2E4NGVfNzg1_8f949ced-0834-4182-8675-ce1abdedc007">19.0</ix:nonFraction> million, respectively, after deducting underwriting discounts and commissions and other offering expenses payable by the Company.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As a result of the Rights Exchange Agreement, during the three and six month periods ended June 30, 2020, the Company issued <ix:nonFraction unitRef="shares" contextRef="if89af7698cdf43d1915f30dc403dc6af_I20200429" decimals="INF" format="ixt:numdotdecimal" name="ptct:SharestoissueunderRightsExchangeAgreement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82NC9mcmFnOmM5YTA4NjRiYzE0NTRkZmJiNmU2OWQxZjAzMzdhODRlL3RleHRyZWdpb246YzlhMDg2NGJjMTQ1NGRmYmI2ZTY5ZDFmMDMzN2E4NGVfMTM3NDM4OTUzNDgyNjc_fb75e6f5-7b3f-432c-a757-e7dea335d4c4">2,821,176</ix:nonFraction> shares of its common stock to Participating Rightholders. The shares had a fair value of $<ix:nonFraction unitRef="usd" contextRef="if241e524337e420a90c40125ab0af552_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82NC9mcmFnOmM5YTA4NjRiYzE0NTRkZmJiNmU2OWQxZjAzMzdhODRlL3RleHRyZWdpb246YzlhMDg2NGJjMTQ1NGRmYmI2ZTY5ZDFmMDMzN2E4NGVfNDM5ODA0NjUxNjE2NA_3b9d13e3-0186-4edf-bdd5-84abfc1b927a">150.5</ix:nonFraction>&#160;million upon issuance.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As a result of the Censa Merger, during the three and six month periods ended June 30, 2020, the Company issued <ix:nonFraction unitRef="shares" contextRef="i8742fae222d34cac83b189f51096e426_D20200529-20200529" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82NC9mcmFnOmM5YTA4NjRiYzE0NTRkZmJiNmU2OWQxZjAzMzdhODRlL3RleHRyZWdpb246YzlhMDg2NGJjMTQ1NGRmYmI2ZTY5ZDFmMDMzN2E4NGVfMTM3NDM4OTUzNDkzNDg_9507216f-a1ca-4b1f-a4d3-483377609a35">845,364</ix:nonFraction> shares of the Company's common stock to Censa security holders, which were valued at $<ix:nonFraction unitRef="usd" contextRef="i8742fae222d34cac83b189f51096e426_D20200529-20200529" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82NC9mcmFnOmM5YTA4NjRiYzE0NTRkZmJiNmU2OWQxZjAzMzdhODRlL3RleHRyZWdpb246YzlhMDg2NGJjMTQ1NGRmYmI2ZTY5ZDFmMDMzN2E4NGVfMTM3NDM4OTUzNDk0MTA_4e4fb3ea-e784-4396-98bd-189c553c9552">42.9</ix:nonFraction>&#160;million based on the closing stock price on the acquisition date. The number of shares issued was determined using a 30-day VWAP pursuant to the Censa Merger Agreement.</span></div></ix:continuation><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span><br/></span></div><div id="i95cf61a5c7074910ae3cf29c5ee08838_67"></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">9.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:700;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82Ny9mcmFnOjgxNDdkOWMwNWNmZTRjNGJiYTc2OTVmZTM5MmM1OTA4L3RleHRyZWdpb246ODE0N2Q5YzA1Y2ZlNGM0YmJhNzY5NWZlMzkyYzU5MDhfNzc2_77cd41c2-d350-4e8a-8edb-7d9d6d9e4ea3" continuedAt="i5f026cacbc8a491893eff10acfe4f79b" escape="true">Net loss per share</ix:nonNumeric></span></div><ix:continuation id="i5f026cacbc8a491893eff10acfe4f79b" continuedAt="ibd78b11fdb3d46e3b289cca349278401"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Basic earnings per share is computed by dividing net loss by the weighted-average number of common shares outstanding. Diluted earnings per share is computed by dividing net loss by the weighted-average number of common shares plus the effect of any dilutive potential common shares outstanding during the period.</span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82Ny9mcmFnOjgxNDdkOWMwNWNmZTRjNGJiYTc2OTVmZTM5MmM1OTA4L3RleHRyZWdpb246ODE0N2Q5YzA1Y2ZlNGM0YmJhNzY5NWZlMzkyYzU5MDhfNzgx_b0cb4bdf-2a35-4dc5-93cc-0a111c22a1ca" continuedAt="i3524e0fdf74948db819f103fb29a319b" escape="true">The following tables set forth the computation of basic and diluted net loss per share:</ix:nonNumeric></span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="ibd78b11fdb3d46e3b289cca349278401"><ix:continuation id="i3524e0fdf74948db819f103fb29a319b"><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:34.173%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.407%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.475%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.407%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.615%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.474%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.615%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.614%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.620%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82Ny9mcmFnOjgxNDdkOWMwNWNmZTRjNGJiYTc2OTVmZTM5MmM1OTA4L3RhYmxlOmZmNmNmMGFjMzcxZTQxYzJhNDI0YTdhN2ExZjc5OTk3L3RhYmxlcmFuZ2U6ZmY2Y2YwYWMzNzFlNDFjMmE0MjRhN2E3YTFmNzk5OTdfMy0xLTEtMS0w_01288f27-71f1-4587-89b9-e14072c9431e">181,427</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82Ny9mcmFnOjgxNDdkOWMwNWNmZTRjNGJiYTc2OTVmZTM5MmM1OTA4L3RhYmxlOmZmNmNmMGFjMzcxZTQxYzJhNDI0YTdhN2ExZjc5OTk3L3RhYmxlcmFuZ2U6ZmY2Y2YwYWMzNzFlNDFjMmE0MjRhN2E3YTFmNzk5OTdfMy0zLTEtMS0w_739a5176-9c76-43bb-91c5-a401242b102a">41,789</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82Ny9mcmFnOjgxNDdkOWMwNWNmZTRjNGJiYTc2OTVmZTM5MmM1OTA4L3RhYmxlOmZmNmNmMGFjMzcxZTQxYzJhNDI0YTdhN2ExZjc5OTk3L3RhYmxlcmFuZ2U6ZmY2Y2YwYWMzNzFlNDFjMmE0MjRhN2E3YTFmNzk5OTdfMy01LTEtMS0w_25460ff2-2cbd-43f5-962f-068e37bfe91e">294,114</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82Ny9mcmFnOjgxNDdkOWMwNWNmZTRjNGJiYTc2OTVmZTM5MmM1OTA4L3RhYmxlOmZmNmNmMGFjMzcxZTQxYzJhNDI0YTdhN2ExZjc5OTk3L3RhYmxlcmFuZ2U6ZmY2Y2YwYWMzNzFlNDFjMmE0MjRhN2E3YTFmNzk5OTdfMy03LTEtMS0w_f9220f16-4b67-48a9-b34f-28823c25a665">113,902</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator for basic and diluted net loss per share</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82Ny9mcmFnOjgxNDdkOWMwNWNmZTRjNGJiYTc2OTVmZTM5MmM1OTA4L3RhYmxlOmZmNmNmMGFjMzcxZTQxYzJhNDI0YTdhN2ExZjc5OTk3L3RhYmxlcmFuZ2U6ZmY2Y2YwYWMzNzFlNDFjMmE0MjRhN2E3YTFmNzk5OTdfNS0xLTEtMS0w_0bb14804-66d0-498c-9ccb-3f4b8df26d92">65,150,780</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82Ny9mcmFnOjgxNDdkOWMwNWNmZTRjNGJiYTc2OTVmZTM5MmM1OTA4L3RhYmxlOmZmNmNmMGFjMzcxZTQxYzJhNDI0YTdhN2ExZjc5OTk3L3RhYmxlcmFuZ2U6ZmY2Y2YwYWMzNzFlNDFjMmE0MjRhN2E3YTFmNzk5OTdfNS0zLTEtMS0w_1ccda0e1-608c-43d1-b8ca-d4608e946af3">55,912,748</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82Ny9mcmFnOjgxNDdkOWMwNWNmZTRjNGJiYTc2OTVmZTM5MmM1OTA4L3RhYmxlOmZmNmNmMGFjMzcxZTQxYzJhNDI0YTdhN2ExZjc5OTk3L3RhYmxlcmFuZ2U6ZmY2Y2YwYWMzNzFlNDFjMmE0MjRhN2E3YTFmNzk5OTdfNS01LTEtMS0w_86073b43-f3d7-4f59-855d-6c55f3658241">63,769,958</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82Ny9mcmFnOjgxNDdkOWMwNWNmZTRjNGJiYTc2OTVmZTM5MmM1OTA4L3RhYmxlOmZmNmNmMGFjMzcxZTQxYzJhNDI0YTdhN2ExZjc5OTk3L3RhYmxlcmFuZ2U6ZmY2Y2YwYWMzNzFlNDFjMmE0MjRhN2E3YTFmNzk5OTdfNS03LTEtMS0w_0f5e51c2-de60-4a0d-a240-e134e93dea9b">57,113,141</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss per share:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82Ny9mcmFnOjgxNDdkOWMwNWNmZTRjNGJiYTc2OTVmZTM5MmM1OTA4L3RhYmxlOmZmNmNmMGFjMzcxZTQxYzJhNDI0YTdhN2ExZjc5OTk3L3RhYmxlcmFuZ2U6ZmY2Y2YwYWMzNzFlNDFjMmE0MjRhN2E3YTFmNzk5OTdfNy0xLTEtMS0w_302d7bf4-8bb9-41e1-a216-b52e1c21d490">2.78</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82Ny9mcmFnOjgxNDdkOWMwNWNmZTRjNGJiYTc2OTVmZTM5MmM1OTA4L3RhYmxlOmZmNmNmMGFjMzcxZTQxYzJhNDI0YTdhN2ExZjc5OTk3L3RhYmxlcmFuZ2U6ZmY2Y2YwYWMzNzFlNDFjMmE0MjRhN2E3YTFmNzk5OTdfNy0zLTEtMS0w_90e195a6-b644-4d03-a189-265f99b353ec">0.75</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82Ny9mcmFnOjgxNDdkOWMwNWNmZTRjNGJiYTc2OTVmZTM5MmM1OTA4L3RhYmxlOmZmNmNmMGFjMzcxZTQxYzJhNDI0YTdhN2ExZjc5OTk3L3RhYmxlcmFuZ2U6ZmY2Y2YwYWMzNzFlNDFjMmE0MjRhN2E3YTFmNzk5OTdfNy01LTEtMS0w_59d72ae2-64cd-4006-8033-9e8700ec83cd">4.61</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82Ny9mcmFnOjgxNDdkOWMwNWNmZTRjNGJiYTc2OTVmZTM5MmM1OTA4L3RhYmxlOmZmNmNmMGFjMzcxZTQxYzJhNDI0YTdhN2ExZjc5OTk3L3RhYmxlcmFuZ2U6ZmY2Y2YwYWMzNzFlNDFjMmE0MjRhN2E3YTFmNzk5OTdfNy03LTEtMS0w_14d5d1ea-9a29-4e64-96ef-970b809a52cd">1.99</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:40.935%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">*In the three and six months ended June&#160;30, 2020 and 2019, the Company experienced a net loss and therefore did not report any dilutive share impact.</span></div></ix:continuation><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82Ny9mcmFnOjgxNDdkOWMwNWNmZTRjNGJiYTc2OTVmZTM5MmM1OTA4L3RleHRyZWdpb246ODE0N2Q5YzA1Y2ZlNGM0YmJhNzY5NWZlMzkyYzU5MDhfNzkx_53fdebf5-0a9d-4927-84fb-2ad87ee05e20" escape="true"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table shows historical dilutive common share equivalents outstanding, which are not included in the above historical calculation, as the effect of their inclusion is anti-dilutive during each period.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:69.700%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.636%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.931%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock Options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i732b4791ae044c3982d3fc5b40507c4a_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82Ny9mcmFnOjgxNDdkOWMwNWNmZTRjNGJiYTc2OTVmZTM5MmM1OTA4L3RhYmxlOjI4YTkzYWZjYTliMzRjZDZiZGJhOWNkMmNiZGZmNjM4L3RhYmxlcmFuZ2U6MjhhOTNhZmNhOWIzNGNkNmJkYmE5Y2QyY2JkZmY2MzhfMi0xLTEtMS0w_c76b26af-21e2-49b2-8e7d-c96a7ad3b804">11,954,684</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4340507e56e749d38aa6d877e17f6f11_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82Ny9mcmFnOjgxNDdkOWMwNWNmZTRjNGJiYTc2OTVmZTM5MmM1OTA4L3RhYmxlOjI4YTkzYWZjYTliMzRjZDZiZGJhOWNkMmNiZGZmNjM4L3RhYmxlcmFuZ2U6MjhhOTNhZmNhOWIzNGNkNmJkYmE5Y2QyY2JkZmY2MzhfMi0zLTEtMS0w_c827a24d-e847-4feb-9f64-951868e7ea52">10,853,301</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested restricted stock awards and units</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie4dfd70561f44b3389920eecf82405aa_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82Ny9mcmFnOjgxNDdkOWMwNWNmZTRjNGJiYTc2OTVmZTM5MmM1OTA4L3RhYmxlOjI4YTkzYWZjYTliMzRjZDZiZGJhOWNkMmNiZGZmNjM4L3RhYmxlcmFuZ2U6MjhhOTNhZmNhOWIzNGNkNmJkYmE5Y2QyY2JkZmY2MzhfMy0xLTEtMS0w_3644920d-bd1c-46e3-9438-e8c5d9a49124">936,922</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i6512ed24942b4cf78a18c42c69f878df_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82Ny9mcmFnOjgxNDdkOWMwNWNmZTRjNGJiYTc2OTVmZTM5MmM1OTA4L3RhYmxlOjI4YTkzYWZjYTliMzRjZDZiZGJhOWNkMmNiZGZmNjM4L3RhYmxlcmFuZ2U6MjhhOTNhZmNhOWIzNGNkNmJkYmE5Y2QyY2JkZmY2MzhfMy0zLTEtMS0w_64d23f13-d9b0-47ec-9338-abee7dbb5ca5">665,002</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82Ny9mcmFnOjgxNDdkOWMwNWNmZTRjNGJiYTc2OTVmZTM5MmM1OTA4L3RhYmxlOjI4YTkzYWZjYTliMzRjZDZiZGJhOWNkMmNiZGZmNjM4L3RhYmxlcmFuZ2U6MjhhOTNhZmNhOWIzNGNkNmJkYmE5Y2QyY2JkZmY2MzhfNC0xLTEtMS0w_2506441d-5856-497e-8e4c-79fb7d24cc09">12,891,606</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82Ny9mcmFnOjgxNDdkOWMwNWNmZTRjNGJiYTc2OTVmZTM5MmM1OTA4L3RhYmxlOjI4YTkzYWZjYTliMzRjZDZiZGJhOWNkMmNiZGZmNjM4L3RhYmxlcmFuZ2U6MjhhOTNhZmNhOWIzNGNkNmJkYmE5Y2QyY2JkZmY2MzhfNC0zLTEtMS0w_fc9f85d3-01f8-4e54-87af-cdd4e0a07036">11,518,303</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i95cf61a5c7074910ae3cf29c5ee08838_70"></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">10.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:700;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfNzY2Mw_a0a8cbe9-9f71-4a66-adb6-ffa848c2e0a6" continuedAt="ib8eca1c0c9584c7085cf36f3674c2b17" escape="true">Stock award plan</ix:nonNumeric></span></div><ix:continuation id="ib8eca1c0c9584c7085cf36f3674c2b17" continuedAt="i3e05d354a8594db89bd2a042e5e6a6c8"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On March&#160;5, 2013, the Company&#8217;s Board of Directors approved the 2013 Stock Incentive Plan, which provides for the granting of stock option awards, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards in the aggregate of <ix:nonFraction unitRef="shares" contextRef="i25d7f62000cb47619cacff7feea40ec4_I20130305" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfMjg5_7af3a7ca-7083-4e20-beac-4219f8965865">739,937</ix:nonFraction> shares of common stock. On March&#160;5, 2013, the Company's Board of Directors approved a grant of <ix:nonFraction unitRef="shares" contextRef="iae41b38768a04ebfa621ede89b1e1eba_D20130305-20130305" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfMzg3_e1083001-9351-4482-a22e-9972777b063c">735,324</ix:nonFraction> shares of restricted stock and <ix:nonFraction unitRef="shares" contextRef="i4acdb340b0784c54b281fc72cd460037_D20130305-20130305" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfNDIx_25e1bf7e-4c9a-4e07-a0eb-0875c550a56a">4,613</ix:nonFraction> stock options. There are <ix:nonFraction unitRef="shares" contextRef="idf26f417473642be92ba8eea00337e07_I20130305" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfNDQ5_ee63eb44-f30f-48de-afab-df6305dab68a">no</ix:nonFraction> additional shares available for issuance under this plan.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In 2009, the Company&#8217;s shareholders approved the 2009 Equity and Long-Term Incentive Plan, which provides for the granting of stock option awards, restricted stock awards, and other stock-based and cash-based awards, subject to certain adjustments and annual increases. In May&#160;2013, the Company&#8217;s Board of Directors and stockholders increased by <ix:nonFraction unitRef="shares" contextRef="i62a5ccc71de84104a8745951ca1a9aa7_D20130501-20130531" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfODU2_2b8c52ee-4b62-4331-8bb5-e440e071a6ed">2,500,000</ix:nonFraction> the number of shares authorized under the 2009 Equity and Long Term Incentive Plan, which provides for the granting of stock option awards, restricted stock awards, and other stock-based and cash-based awards. There are <ix:nonFraction unitRef="shares" contextRef="i65727f1a834a481f8553fbb4bb642903_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfMTA3OQ_12066613-70c6-45cd-b77f-363106a8d4ff">no</ix:nonFraction> additional shares available for issuance under this plan.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May&#160;2013, the Company&#8217;s Board of Directors and stockholders approved the 2013 Long Term Incentive Plan, which became effective upon the closing of the Company&#8217;s initial public offering.&#160; The 2013 Long Term Incentive Plan provides for the grant of incentive stock options, nonstatutory stock options, restricted stock awards and other stock-based awards. The number of shares of common stock reserved for issuance under the 2013 Long Term Incentive Plan is the sum of (1)&#160;<ix:nonFraction unitRef="shares" contextRef="i1efd0cb53b6044d78f74b229bd2b52aa_I20130531" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfMTYxNA_edfdea0a-1f4b-4064-b1e4-184f16bbb587">122,296</ix:nonFraction> shares of common stock available for issuance under the Company&#8217;s 2009 Equity and Long Term Incentive Plan and 2013 Stock Incentive Plan, (2) the number of shares (up to <ix:nonFraction unitRef="shares" contextRef="ie7090aa93ba846e4b5c5820dcecfd98a_I20130531" decimals="INF" format="ixt:numdotdecimal" name="ptct:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfMTc4Nw_008e7ce6-8326-46eb-b8e2-ca949765a19e">3,040,444</ix:nonFraction> shares) equal to the sum of the number of shares of common stock subject to outstanding awards under the Company&#8217;s 1998 Employee, Director and Consultant Stock Option Plan, 2009 Equity and Long Term Incentive Plan and 2013 Stock Incentive Plan that expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right plus (3)&#160;an annual increase, to be added on the first day of each fiscal year until the expiration of the 2013 Long Term Incentive Plan, equal to the lowest of <ix:nonFraction unitRef="shares" contextRef="ibf07b2dff77d4ca1a51f7b625a38192b_D20130501-20130531" decimals="INF" format="ixt:numdotdecimal" name="ptct:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfMjM3Mw_a26ea8c7-1067-4668-ba2c-01b062e23bf9">2,500,000</ix:nonFraction> shares of common stock, <ix:nonFraction unitRef="number" contextRef="ibf07b2dff77d4ca1a51f7b625a38192b_D20130501-20130531" decimals="INF" name="ptct:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfMjQwMA_2b2e4295-c03c-4bd2-9162-9554a96f0d70">4</ix:nonFraction>% of the number of shares of common stock outstanding on the first day of the fiscal year and an amount determined by the Company&#8217;s Board of Directors. As of June&#160;30, 2020, awards for <ix:nonFraction unitRef="shares" contextRef="i93ba015b7d0a44aaaf029eb718c780c2_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfMjU3NA_1098af7d-66a1-471d-b736-bd5309d47f3a">914,406</ix:nonFraction> shares of common stock are available for issuance under the 2013 Long Term Incentive Plan.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2020, the Company's Board of Directors approved the 2020 Inducement Stock Incentive Plan. The 2020 Inducement Stock Incentive Plan provides for the grant of incentive stock options, nonstatutory stock options, restricted stock awards and other stock-based awards for up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="ifd063a6e802542888865b12d471371c5_D20200101-20200131" decimals="INF" format="ixt:numdotdecimal" name="ptct:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfMjk2OA_d9a862fd-2e4b-496b-b2d1-25bf7ea84a17">1,000,000</ix:nonFraction> shares of common stock. Any grants made under the 2020 Inducement Stock Incentive Plan must be made pursuant to the Nasdaq Listing Rule 5635(c)(4) inducement grant exception as a material component of the Company's new hires&#8217; employment compensation. As of June 30, 2020, awards for <ix:nonFraction unitRef="shares" contextRef="i12f2cd9f617e471d9081d454d8ab7810_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfMzI1NQ_f41151a6-4ca6-4657-b93a-a6a8b9aa1712">442,880</ix:nonFraction> shares of common stock are available for issuance under the 2020 Inducement Stock Incentive Plan.</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i3e05d354a8594db89bd2a042e5e6a6c8" continuedAt="i9351475995aa46a192667365dab7989b"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From January&#160;1, 2020 through June&#160;30, 2020, the Company issued a total of <ix:nonFraction unitRef="shares" contextRef="i7af21e8197c4484c8a8abf452ef76b07_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfMzQxNw_13628c51-abcf-4f4f-92ef-23c75f26e497">2,515,200</ix:nonFraction> stock options to various employees.&#160; Of those, <ix:nonFraction unitRef="shares" contextRef="i7af21e8197c4484c8a8abf452ef76b07_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="ptct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfMzQ2Nw_1a4d5f09-6d03-4e9a-af4f-ee64fa43c0df">542,450</ix:nonFraction> were inducement grants for non-statutory stock options, all of which were made pursuant to the 2020 Inducement Stock Incentive Plan.</span></div><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfNzY1Nw_299f641e-4c08-439e-b50e-6c04536f4d76" escape="true"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A summary of stock option activity is as follows:</span></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:41.777%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.909%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.909%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.740%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number&#160;of<br/>options</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-<br/>average<br/>exercise<br/>price</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-<br/>average<br/>remaining<br/>contractual<br/>term</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate<br/>intrinsic<br/>value (in<br/>thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ibf32b31395a2491ebc2ee0715f74c386_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmNkNTNkMzQ0OTdiNjQxMzJiNzE2ZjNhMzM5MTQ5MTIzL3RhYmxlcmFuZ2U6Y2Q1M2QzNDQ5N2I2NDEzMmI3MTZmM2EzMzkxNDkxMjNfMi0yLTEtMS0w_76f45562-a8f9-4eaa-9166-d86f919456c6">11,043,939</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ibf32b31395a2491ebc2ee0715f74c386_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmNkNTNkMzQ0OTdiNjQxMzJiNzE2ZjNhMzM5MTQ5MTIzL3RhYmxlcmFuZ2U6Y2Q1M2QzNDQ5N2I2NDEzMmI3MTZmM2EzMzkxNDkxMjNfMi00LTEtMS0w_5255a44e-3ad2-4d0a-b952-2f00ee43fbc5">31.67</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i7af21e8197c4484c8a8abf452ef76b07_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmNkNTNkMzQ0OTdiNjQxMzJiNzE2ZjNhMzM5MTQ5MTIzL3RhYmxlcmFuZ2U6Y2Q1M2QzNDQ5N2I2NDEzMmI3MTZmM2EzMzkxNDkxMjNfMy0yLTEtMS0w_0b5ffdf5-b03b-40fa-8942-a867a6e702f4">2,515,200</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i7af21e8197c4484c8a8abf452ef76b07_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmNkNTNkMzQ0OTdiNjQxMzJiNzE2ZjNhMzM5MTQ5MTIzL3RhYmxlcmFuZ2U6Y2Q1M2QzNDQ5N2I2NDEzMmI3MTZmM2EzMzkxNDkxMjNfMy00LTEtMS0w_f820c8f7-1dd3-4d25-813a-1b83f50049c4">50.98</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i7af21e8197c4484c8a8abf452ef76b07_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmNkNTNkMzQ0OTdiNjQxMzJiNzE2ZjNhMzM5MTQ5MTIzL3RhYmxlcmFuZ2U6Y2Q1M2QzNDQ5N2I2NDEzMmI3MTZmM2EzMzkxNDkxMjNfNC0yLTEtMS0w_839fdff3-1ef6-4787-b346-7b7b8b94c96a">1,034,288</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i7af21e8197c4484c8a8abf452ef76b07_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmNkNTNkMzQ0OTdiNjQxMzJiNzE2ZjNhMzM5MTQ5MTIzL3RhYmxlcmFuZ2U6Y2Q1M2QzNDQ5N2I2NDEzMmI3MTZmM2EzMzkxNDkxMjNfNC00LTEtMS0w_df60cd0d-b69e-4a05-9cbd-876c770473d1">24.21</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited/Cancelled</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i7af21e8197c4484c8a8abf452ef76b07_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmNkNTNkMzQ0OTdiNjQxMzJiNzE2ZjNhMzM5MTQ5MTIzL3RhYmxlcmFuZ2U6Y2Q1M2QzNDQ5N2I2NDEzMmI3MTZmM2EzMzkxNDkxMjNfNS0yLTEtMS0w_a3061f85-9bf8-4bd8-aca5-c0c629f401bf">570,167</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i7af21e8197c4484c8a8abf452ef76b07_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmNkNTNkMzQ0OTdiNjQxMzJiNzE2ZjNhMzM5MTQ5MTIzL3RhYmxlcmFuZ2U6Y2Q1M2QzNDQ5N2I2NDEzMmI3MTZmM2EzMzkxNDkxMjNfNS00LTEtMS0w_b5855fd4-9a40-4b8e-a05c-97575d67de24">42.27</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at June 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i7a7e99b59db24353a85559f303336e06_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmNkNTNkMzQ0OTdiNjQxMzJiNzE2ZjNhMzM5MTQ5MTIzL3RhYmxlcmFuZ2U6Y2Q1M2QzNDQ5N2I2NDEzMmI3MTZmM2EzMzkxNDkxMjNfNi0yLTEtMS0w_a5351ed6-1a6a-4a14-9901-aa502e5a934b">11,954,684</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i7a7e99b59db24353a85559f303336e06_I20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmNkNTNkMzQ0OTdiNjQxMzJiNzE2ZjNhMzM5MTQ5MTIzL3RhYmxlcmFuZ2U6Y2Q1M2QzNDQ5N2I2NDEzMmI3MTZmM2EzMzkxNDkxMjNfNi00LTEtMS0w_6ea2c514-68e0-4d5c-ad26-61bfcd6d8f0e">35.84</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i7af21e8197c4484c8a8abf452ef76b07_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmNkNTNkMzQ0OTdiNjQxMzJiNzE2ZjNhMzM5MTQ5MTIzL3RhYmxlcmFuZ2U6Y2Q1M2QzNDQ5N2I2NDEzMmI3MTZmM2EzMzkxNDkxMjNfNi02LTEtMS0w_653f2e06-d8cc-43ce-92c7-0ebfcc6a9052">7.48</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7a7e99b59db24353a85559f303336e06_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmNkNTNkMzQ0OTdiNjQxMzJiNzE2ZjNhMzM5MTQ5MTIzL3RhYmxlcmFuZ2U6Y2Q1M2QzNDQ5N2I2NDEzMmI3MTZmM2EzMzkxNDkxMjNfNi04LTEtMS0w_946d0597-9706-4820-a186-ed490a46678e">183,488</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested or Expected to vest at June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i7a7e99b59db24353a85559f303336e06_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmNkNTNkMzQ0OTdiNjQxMzJiNzE2ZjNhMzM5MTQ5MTIzL3RhYmxlcmFuZ2U6Y2Q1M2QzNDQ5N2I2NDEzMmI3MTZmM2EzMzkxNDkxMjNfNy0yLTEtMS0w_d23da98d-be3b-43b8-ba72-5f8d15ae418c">5,690,848</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i7a7e99b59db24353a85559f303336e06_I20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmNkNTNkMzQ0OTdiNjQxMzJiNzE2ZjNhMzM5MTQ5MTIzL3RhYmxlcmFuZ2U6Y2Q1M2QzNDQ5N2I2NDEzMmI3MTZmM2EzMzkxNDkxMjNfNy00LTEtMS0w_e535dbfe-a86b-4767-80b2-8d916dcf52bc">39.16</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i7af21e8197c4484c8a8abf452ef76b07_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmNkNTNkMzQ0OTdiNjQxMzJiNzE2ZjNhMzM5MTQ5MTIzL3RhYmxlcmFuZ2U6Y2Q1M2QzNDQ5N2I2NDEzMmI3MTZmM2EzMzkxNDkxMjNfNy02LTEtMS0w_64ef2a5f-a057-4710-b918-5bebed1d4050">8.86</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7a7e99b59db24353a85559f303336e06_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmNkNTNkMzQ0OTdiNjQxMzJiNzE2ZjNhMzM5MTQ5MTIzL3RhYmxlcmFuZ2U6Y2Q1M2QzNDQ5N2I2NDEzMmI3MTZmM2EzMzkxNDkxMjNfNy04LTEtMS0w_963f890f-89d3-467d-8229-e57371b4bb7d">66,986</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable at June 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i7a7e99b59db24353a85559f303336e06_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmNkNTNkMzQ0OTdiNjQxMzJiNzE2ZjNhMzM5MTQ5MTIzL3RhYmxlcmFuZ2U6Y2Q1M2QzNDQ5N2I2NDEzMmI3MTZmM2EzMzkxNDkxMjNfOC0yLTEtMS0w_2f8bade9-5527-4807-9f40-1213ec8b5da4">5,512,252</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i7a7e99b59db24353a85559f303336e06_I20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmNkNTNkMzQ0OTdiNjQxMzJiNzE2ZjNhMzM5MTQ5MTIzL3RhYmxlcmFuZ2U6Y2Q1M2QzNDQ5N2I2NDEzMmI3MTZmM2EzMzkxNDkxMjNfOC00LTEtMS0w_479aea93-4508-4c13-89dc-9b43bc80e16a">31.61</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i7af21e8197c4484c8a8abf452ef76b07_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmNkNTNkMzQ0OTdiNjQxMzJiNzE2ZjNhMzM5MTQ5MTIzL3RhYmxlcmFuZ2U6Y2Q1M2QzNDQ5N2I2NDEzMmI3MTZmM2EzMzkxNDkxMjNfOC02LTEtMS0w_7386053f-ab32-48ac-9d2e-4139a9afebf6">5.85</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7a7e99b59db24353a85559f303336e06_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmNkNTNkMzQ0OTdiNjQxMzJiNzE2ZjNhMzM5MTQ5MTIzL3RhYmxlcmFuZ2U6Y2Q1M2QzNDQ5N2I2NDEzMmI3MTZmM2EzMzkxNDkxMjNfOC04LTEtMS0w_b1c9dca9-2448-42d2-8125-e858cef1a772">110,222</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfNzY2OA_30fd4560-6e94-4db5-a113-00313fc5b14c" escape="true"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of grants made in the six months ended June&#160;30, 2020 was contemporaneously estimated on the date of grant using the following assumptions:</span></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:63.592%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.410%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:30.798%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended<br/>June 30, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="if901bdf36a4e4a1a81a16393f47a9fb6_D20200101-20200630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOjI0YzVhOWMyNDA1MTQwYWY5MzQ1ZjBmMTY4NzAyODlkL3RhYmxlcmFuZ2U6MjRjNWE5YzI0MDUxNDBhZjkzNDVmMGYxNjg3MDI4OWRfMS0yLTEtMS0wL3RleHRyZWdpb246NWUxYjA5ZTJmZTI5NDIxMGE2OGM3ZDZiZDllZjJmOGRfMjc0ODc3OTA2OTQ2MA_cdbbefaf-8304-4714-96e2-27d6d27db04a">0.40</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i62acf5ed7adb4666851a78792c6fd991_D20200101-20200630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOjI0YzVhOWMyNDA1MTQwYWY5MzQ1ZjBmMTY4NzAyODlkL3RhYmxlcmFuZ2U6MjRjNWE5YzI0MDUxNDBhZjkzNDVmMGYxNjg3MDI4OWRfMS0yLTEtMS0wL3RleHRyZWdpb246NWUxYjA5ZTJmZTI5NDIxMGE2OGM3ZDZiZDllZjJmOGRfMjc0ODc3OTA2OTQ2Nw_d2a5d902-164e-4a64-878f-619497400f37">1.45</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="if901bdf36a4e4a1a81a16393f47a9fb6_D20200101-20200630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOjI0YzVhOWMyNDA1MTQwYWY5MzQ1ZjBmMTY4NzAyODlkL3RhYmxlcmFuZ2U6MjRjNWE5YzI0MDUxNDBhZjkzNDVmMGYxNjg3MDI4OWRfMi0yLTEtMS0wL3RleHRyZWdpb246Mzc5YzNiZGVhZTJjNDU1OTgyNGFmN2VhZTM0YWFjODNfMjc0ODc3OTA2OTQ2Mw_09a38c2a-6c00-4e81-ac4f-0d632aa488b2">87.50</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i62acf5ed7adb4666851a78792c6fd991_D20200101-20200630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOjI0YzVhOWMyNDA1MTQwYWY5MzQ1ZjBmMTY4NzAyODlkL3RhYmxlcmFuZ2U6MjRjNWE5YzI0MDUxNDBhZjkzNDVmMGYxNjg3MDI4OWRfMi0yLTEtMS0wL3RleHRyZWdpb246Mzc5YzNiZGVhZTJjNDU1OTgyNGFmN2VhZTM0YWFjODNfMjc0ODc3OTA2OTQ3MQ_f2a4e874-06c4-4c46-870c-1caf49ab30ee">89.31</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="i7af21e8197c4484c8a8abf452ef76b07_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOjI0YzVhOWMyNDA1MTQwYWY5MzQ1ZjBmMTY4NzAyODlkL3RhYmxlcmFuZ2U6MjRjNWE5YzI0MDUxNDBhZjkzNDVmMGYxNjg3MDI4OWRfMy0yLTEtMS0wL3RleHRyZWdpb246NjlkY2JkNDA0ZDJlNGY1NThhYmJlOTI2MTJlNzAwYWZfMjc0ODc3OTA2OTQ2NA_db39985b-8389-4b2a-a1a2-8502d266179a">5.75</ix:nonNumeric> years</span></div></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company assumed <ix:nonFraction unitRef="number" contextRef="i7af21e8197c4484c8a8abf452ef76b07_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfMzgxOQ_f81a439b-0013-400f-904d-4a42bad69991">no</ix:nonFraction> expected dividends for all grants. The weighted average grant date fair value of options granted during the six month period ended June&#160;30, 2020 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i7af21e8197c4484c8a8abf452ef76b07_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfMzk1OQ_e6e3a19d-02aa-4454-8ee6-1dd6f06fba49">36.95</ix:nonFraction> per share.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The expected term of options was estimated based on the Company's historical exercise data and the expected volatility of options was estimated based on the Company's historical stock volatility.  The risk-free rate of the options was based on U.S. Government Securities Treasury Constant Maturities yields at the date of grant for a term similar to the expected term of the option. </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Restricted Stock Awards and Restricted Stock Units</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8212;Restricted stock awards and restricted stock units are granted subject to certain restrictions, including in some cases service or time conditions (restricted stock). The grant-date fair value of restricted stock awards and restricted stock units, which have been determined based upon the market value of the Company&#8217;s shares on the grant date, are expensed over the vesting period.</span></div><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfNzY3Mw_9fb18155-5dbc-4af2-83bc-edf2668c1184" escape="true"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes information on the Company&#8217;s restricted stock awards and units:</span></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:69.888%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.909%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.739%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted&#160;Stock&#160;Awards&#160;and&#160;Units</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number&#160;of<br/>Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted<br/>Average<br/>Grant<br/>Date&#160;Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1d4c0457ced344f0b16ef87b8b77d3ae_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmMzM2I1YjU3NjhiMDQ5YjE5YzU0N2UyNjRjNWY1MzE2L3RhYmxlcmFuZ2U6YzMzYjViNTc2OGIwNDliMTljNTQ3ZTI2NGM1ZjUzMTZfMi0yLTEtMS0w_61220bd0-a80a-4833-9041-e7bc1dece498">642,419</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i1d4c0457ced344f0b16ef87b8b77d3ae_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmMzM2I1YjU3NjhiMDQ5YjE5YzU0N2UyNjRjNWY1MzE2L3RhYmxlcmFuZ2U6YzMzYjViNTc2OGIwNDliMTljNTQ3ZTI2NGM1ZjUzMTZfMi00LTEtMS0w_471f27d7-70bd-4615-b7b7-dacdb7de5752">24.50</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1b0a569c469e4b6596d336467dd05160_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmMzM2I1YjU3NjhiMDQ5YjE5YzU0N2UyNjRjNWY1MzE2L3RhYmxlcmFuZ2U6YzMzYjViNTc2OGIwNDliMTljNTQ3ZTI2NGM1ZjUzMTZfMy0yLTEtMS0w_06ffa462-23f9-4103-9da9-7e2acb977a25">589,070</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i1b0a569c469e4b6596d336467dd05160_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmMzM2I1YjU3NjhiMDQ5YjE5YzU0N2UyNjRjNWY1MzE2L3RhYmxlcmFuZ2U6YzMzYjViNTc2OGIwNDliMTljNTQ3ZTI2NGM1ZjUzMTZfMy00LTEtMS0w_ffdbcc4e-6090-4775-9468-7de999e69d29">49.67</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i1b0a569c469e4b6596d336467dd05160_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmMzM2I1YjU3NjhiMDQ5YjE5YzU0N2UyNjRjNWY1MzE2L3RhYmxlcmFuZ2U6YzMzYjViNTc2OGIwNDliMTljNTQ3ZTI2NGM1ZjUzMTZfNC0yLTEtMS0w_71202c27-1a73-4aa6-862b-edc3a780d6e6">229,076</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i1b0a569c469e4b6596d336467dd05160_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmMzM2I1YjU3NjhiMDQ5YjE5YzU0N2UyNjRjNWY1MzE2L3RhYmxlcmFuZ2U6YzMzYjViNTc2OGIwNDliMTljNTQ3ZTI2NGM1ZjUzMTZfNC00LTEtMS0w_bda296fa-a088-43c4-acde-14195516f813">23.53</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i1b0a569c469e4b6596d336467dd05160_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmMzM2I1YjU3NjhiMDQ5YjE5YzU0N2UyNjRjNWY1MzE2L3RhYmxlcmFuZ2U6YzMzYjViNTc2OGIwNDliMTljNTQ3ZTI2NGM1ZjUzMTZfNS0yLTEtMS0w_fdedc584-f8cc-44cd-93f2-4806512d3726">65,491</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i1b0a569c469e4b6596d336467dd05160_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmMzM2I1YjU3NjhiMDQ5YjE5YzU0N2UyNjRjNWY1MzE2L3RhYmxlcmFuZ2U6YzMzYjViNTc2OGIwNDliMTljNTQ3ZTI2NGM1ZjUzMTZfNS00LTEtMS0w_2e476590-6b73-4a46-9d88-4164030b8afd">36.11</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested at June 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i40fe1e237dd2460982e61df9b93e25de_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmMzM2I1YjU3NjhiMDQ5YjE5YzU0N2UyNjRjNWY1MzE2L3RhYmxlcmFuZ2U6YzMzYjViNTc2OGIwNDliMTljNTQ3ZTI2NGM1ZjUzMTZfNi0yLTEtMS0w_f09a2962-8d1f-4495-9743-d6d4386cbbeb">936,922</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i40fe1e237dd2460982e61df9b93e25de_I20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmMzM2I1YjU3NjhiMDQ5YjE5YzU0N2UyNjRjNWY1MzE2L3RhYmxlcmFuZ2U6YzMzYjViNTc2OGIwNDliMTljNTQ3ZTI2NGM1ZjUzMTZfNi00LTEtMS0w_46140e20-2d68-4d17-95a6-72b7cf22d236">39.97</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Stock Appreciation Rights</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8212;SARs entitle the holder to receive, upon exercise, an amount of the Company's common stock or cash (or a combination thereof) determined by reference to appreciation, from and after the date of grant, in the fair market value of a share of the Company's common stock over the measurement price based on the exercise date.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May&#160;2016, a total of <ix:nonFraction unitRef="shares" contextRef="i9e1f2793036044c09455f3aed8a471a5_D20160501-20160531" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfNTI2MQ_df063fba-fb33-415a-9bcc-70814adbb7f3">897,290</ix:nonFraction> SARs were granted to non-executive employees (the "2016 SARs"). The 2016 SARs vested annually in equal installments over four years and were settled in cash on each vest date, which required the Company to </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i9351475995aa46a192667365dab7989b"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">remeasure the SARs at each reporting period until vesting occurs. For the six month period ended June&#160;30, 2020, a total of <ix:nonFraction unitRef="shares" contextRef="iaf63c553ba564cb8bd94fab03c3290ab_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfNTU3OQ_bf7bc58f-c4aa-4dd4-a44c-e235f6e7085c">132,136</ix:nonFraction> SARs vested. The last payment of the SARs liability was made in the three month period ended March 31, 2020, and accordingly, the balance of the SARS liability as of June 30, 2020 was $<ix:nonFraction unitRef="usd" contextRef="i82a7d5029292453a9d8665965b2a0597_I20200630" decimals="0" name="ptct:StockAppreciationRightsLiabilityOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfNTc2Nw_fbfa588a-dbd1-41af-9b25-469cf3db6a86">0</ix:nonFraction>. </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Employee Stock Purchase Plan</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8212;In June 2016, the Company established an Employee Stock Purchase Plan (&#8220;ESPP&#8221; or the "Plan&#8221;) for certain eligible employees. The Plan is administered by the Company&#8217;s Board of Directors or a committee appointed by the Company's Board of Directors. The total number of shares available for purchase under the Plan is <ix:nonFraction unitRef="shares" contextRef="i8edf5809ef1e4a8c9d7d12ead5870765_I20160930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfNjExNw_3e6980ae-8741-4cbc-a030-cf87cf9d91cf">one</ix:nonFraction> million shares of the Company&#8217;s common stock. Employees may participate over a <ix:nonNumeric contextRef="ia49191cff53044aeb0f18b552f15edb0_D20160601-20160630" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfNDM5ODA0NjUxOTIwMw_9a670cf4-360c-4039-a1f0-7b84b798788a">six month</ix:nonNumeric> period through payroll withholdings and may purchase, at the end of the <ix:nonNumeric contextRef="ia49191cff53044aeb0f18b552f15edb0_D20160601-20160630" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfNDM5ODA0NjUxOTIwNA_c351d053-f185-4ac7-a2b0-6b6c6d351642">six month</ix:nonNumeric> period, the Company&#8217;s common stock at a purchase price of at least <ix:nonFraction unitRef="number" contextRef="ia49191cff53044aeb0f18b552f15edb0_D20160601-20160630" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfNjM0OA_a0dcb216-bf2e-4c7c-b5a6-d721a159ea79">85</ix:nonFraction>% of the closing price of a share of the Company&#8217;s common stock on the first business day of the offering period or the closing price of a share of the Company&#8217;s common stock on the last business day of the offering period, whichever is lower. No participant will be granted a right to purchase the Company&#8217;s common stock under the Plan if such participant would own more than <ix:nonFraction unitRef="number" contextRef="ia49191cff53044aeb0f18b552f15edb0_D20160601-20160630" decimals="INF" name="ptct:EmployeeStockPurchasePlanVotingPercentageLimitPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfNjcyNg_b8fdcd20-1e17-49d9-9af2-15aea59734ec">5</ix:nonFraction>% of the total combined voting power of the Company or any subsidiary of the Company after such purchase. For the three and six month periods ended June&#160;30, 2020, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="ia00d8392741940a5a0455a9ec5a070dc_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfNjg4OA_84c92ccd-d9b1-4953-b0d4-4831eb726d37">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4c05af13913c4e2d87e2cca2be0ef9a6_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfNDk0NzgwMjMzMjk0NA_194f3128-d712-42cd-ac5a-ee87ee94a486">0.7</ix:nonFraction> million in compensation expense related to the ESPP.</span></div><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfNzY4MQ_1bb736e8-d6d7-4d5e-b040-8504d2d184b4" escape="true"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company recorded share-based compensation expense in the statement of operations related to incentive stock options, nonstatutory stock options, restricted stock awards, restricted stock units and the ESPP as follows:</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:40.020%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.909%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.909%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.289%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.740%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i23b23527dd664848b751f1f40cd0477f_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOjcyOTkyMDAxNzRmZDRiNGFhMWJmYjY4YWEyMzEwMzI1L3RhYmxlcmFuZ2U6NzI5OTIwMDE3NGZkNGI0YWExYmZiNjhhYTIzMTAzMjVfMi0yLTEtMS0w_0bacdd0c-f26b-4951-adc3-d711a25df287">8,562</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iacdbc7fbbfab4c83935a46b395d3c1c4_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOjcyOTkyMDAxNzRmZDRiNGFhMWJmYjY4YWEyMzEwMzI1L3RhYmxlcmFuZ2U6NzI5OTIwMDE3NGZkNGI0YWExYmZiNjhhYTIzMTAzMjVfMi00LTEtMS0w_c8a13172-383e-460d-9857-e9ff75b02b50">5,516</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1bd8bc0a2d94ff7b16f1f994b27455f_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOjcyOTkyMDAxNzRmZDRiNGFhMWJmYjY4YWEyMzEwMzI1L3RhYmxlcmFuZ2U6NzI5OTIwMDE3NGZkNGI0YWExYmZiNjhhYTIzMTAzMjVfMi02LTEtMS0w_096f5453-2c5a-410e-adfc-1f3d1caa7c37">16,741</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i14204fc508b343cb8ca99de636b507e4_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOjcyOTkyMDAxNzRmZDRiNGFhMWJmYjY4YWEyMzEwMzI1L3RhYmxlcmFuZ2U6NzI5OTIwMDE3NGZkNGI0YWExYmZiNjhhYTIzMTAzMjVfMi04LTEtMS0w_d7cfd5ca-ed10-4183-8b0a-64a04f1e77e6">10,203</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i895a331c1a6f453c87f851e30384f906_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOjcyOTkyMDAxNzRmZDRiNGFhMWJmYjY4YWEyMzEwMzI1L3RhYmxlcmFuZ2U6NzI5OTIwMDE3NGZkNGI0YWExYmZiNjhhYTIzMTAzMjVfMy0yLTEtMS0w_45c86b3c-aa3c-4944-81d0-1d735a64f6f2">8,348</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i14ebe4de831348188d0069a40d328e56_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOjcyOTkyMDAxNzRmZDRiNGFhMWJmYjY4YWEyMzEwMzI1L3RhYmxlcmFuZ2U6NzI5OTIwMDE3NGZkNGI0YWExYmZiNjhhYTIzMTAzMjVfMy00LTEtMS0w_30b62cca-703f-4d03-be32-0c4087a44035">5,404</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if5f804d6c3184fdea8f69c3a97350d43_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOjcyOTkyMDAxNzRmZDRiNGFhMWJmYjY4YWEyMzEwMzI1L3RhYmxlcmFuZ2U6NzI5OTIwMDE3NGZkNGI0YWExYmZiNjhhYTIzMTAzMjVfMy02LTEtMS0w_be25b7cf-e56e-45c4-9849-732050f1700e">15,389</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ide6d6c0db1274c47ab5146ea275d8c88_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOjcyOTkyMDAxNzRmZDRiNGFhMWJmYjY4YWEyMzEwMzI1L3RhYmxlcmFuZ2U6NzI5OTIwMDE3NGZkNGI0YWExYmZiNjhhYTIzMTAzMjVfMy04LTEtMS0w_dfd7d826-577a-46f6-8fe7-4dcd0e9ccc68">9,981</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOjcyOTkyMDAxNzRmZDRiNGFhMWJmYjY4YWEyMzEwMzI1L3RhYmxlcmFuZ2U6NzI5OTIwMDE3NGZkNGI0YWExYmZiNjhhYTIzMTAzMjVfNC0yLTEtMS0w_15bda321-798b-43da-976a-6561a1dc6f37">16,910</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOjcyOTkyMDAxNzRmZDRiNGFhMWJmYjY4YWEyMzEwMzI1L3RhYmxlcmFuZ2U6NzI5OTIwMDE3NGZkNGI0YWExYmZiNjhhYTIzMTAzMjVfNC00LTEtMS0w_832045ec-8037-4cdc-ab53-590768bb235c">10,920</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOjcyOTkyMDAxNzRmZDRiNGFhMWJmYjY4YWEyMzEwMzI1L3RhYmxlcmFuZ2U6NzI5OTIwMDE3NGZkNGI0YWExYmZiNjhhYTIzMTAzMjVfNC02LTEtMS0w_3af365f3-68a9-4606-b20d-b91cd6797ad4">32,130</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOjcyOTkyMDAxNzRmZDRiNGFhMWJmYjY4YWEyMzEwMzI1L3RhYmxlcmFuZ2U6NzI5OTIwMDE3NGZkNGI0YWExYmZiNjhhYTIzMTAzMjVfNC04LTEtMS0w_754685f9-5c9b-497d-aa9e-ec86c09f7ef9">20,184</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, there was approximately $<ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfNzE5NA_aba44c8a-7747-451c-bfdc-45b2d64ce59c">187.2</ix:nonFraction> million of total unrecognized compensation cost related to unvested share-based compensation arrangements granted under the 2009 Equity and Long Term Incentive Plan, the 2013 Long Term Incentive Plan and equity awards made pursuant to the Nasdaq Listing Rule 5635(c)(4) inducement grant exception for new hires. This cost is expected to be recognized as share-based compensation expense over the weighted average remaining service period of approximately <ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfNzY0NA_354f888e-7ef8-4e1f-a10b-5d8568df277e">3.08</ix:nonNumeric> years.</span></div></ix:continuation><div id="i95cf61a5c7074910ae3cf29c5ee08838_76"></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">11.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:700;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="us-gaap:LongTermDebtTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfNDM5ODA0NjUzMTUyMw_66a42d1f-0153-4b2e-9b21-e296489dbb10" continuedAt="i2b9df8e6b5d249e49bccf2c110d5803d" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="i2b9df8e6b5d249e49bccf2c110d5803d" continuedAt="id10d456c962c468296923621080485f4"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">2017 Credit Facility</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2017, the Company entered into the Credit Agreement, which provided for a senior secured term loan facility of $<ix:nonFraction unitRef="usd" contextRef="ia31f7d7b519f40d5a5aa9977431540c2_I20170531" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMzcw_f3cf5cff-c1bf-4e00-86c3-79a3f9624a89">60.0</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="i0047c24fb89c4b3aa1349dbfc482fe10_D20170505-20170505" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMzgz_3d2cbc42-4308-41ee-b7e5-d55e1cd66c12">40.0</ix:nonFraction> million was drawn by the Company on May 5, 2017 (the "Credit Facility"). The Company's ability to draw on the remaining $<ix:nonFraction unitRef="usd" contextRef="ia31f7d7b519f40d5a5aa9977431540c2_I20170531" decimals="-5" format="ixt:numdotdecimal" name="ptct:LineOfCreditFacilityAdditionalCapacityAvailable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfNDc0_aa67c96f-e63c-4c07-95eb-e281d0ba179a">20.0</ix:nonFraction> million under the senior secured term loan facility expired on December 31, 2018. The Company capitalized approximately $<ix:nonFraction unitRef="usd" contextRef="ia31f7d7b519f40d5a5aa9977431540c2_I20170531" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtIssuanceCostsLineOfCreditArrangementsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfNTg5_f0113eef-c4bf-455e-a456-f2169cf96a01">0.4</ix:nonFraction> million of debt issuance costs, which were netted against the carrying value of the Credit Facility and were amortized over the term of the Credit Facility.  As of June&#160;30, 2020, the Company had made loan repayments of $<ix:nonFraction unitRef="usd" contextRef="i624b7b9db16e4728a041aaf0fe8e3bbc_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfNzk2_f6d599ee-e91a-4a2c-89e4-39a871295462">21.7</ix:nonFraction> million on the Credit Facility. The remaining balance of the Credit Facility as of&#160;June&#160;30, 2020&#160;was $<ix:nonFraction unitRef="usd" contextRef="i396045a4f2b246abb303f6334b534fc5_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfODgx_b42ca84d-5c49-44c3-811f-677bdfa914d1">18.3</ix:nonFraction> million,&#160;which was classified as current portion of long term debt on the consolidated balance sheet.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Borrowings under the Credit Agreement bore interest at a rate per annum equal to the London Interbank Offered Rate, or LIBOR, (with a LIBOR floor rate of <ix:nonFraction unitRef="number" contextRef="ia31f7d7b519f40d5a5aa9977431540c2_I20170531" decimals="INF" name="ptct:DebtInstrumentFloorInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTE4MA_8c0afb6d-2a27-4a0c-aa7f-5cc7cc721889">1.00</ix:nonFraction>%) plus <ix:nonFraction unitRef="number" contextRef="i7a54a031534840f0b962ea11b19c1d3c_D20170501-20170531" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTE4OQ_4208e19c-d5b6-4890-8d52-5e052f33c155">6.15</ix:nonFraction>%. The Company was obligated to make interest only payments (payable monthly in arrears) through April 30, 2019. Commencing on May 1, 2019 and continuing for the remaining <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTM2Mg_e91d3869-d03c-4b8b-84d9-15ddf6e4e1da">twenty-four</span> months of the facility, the Company was required to make monthly interest payments and monthly principal payments. The principal payments were made based on straight-line amortization of the principal over the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMjc0ODc3OTA4OTc4OA_adc62e20-6b69-4ee6-aa71-28d59137d971">twenty-four</span> month period. The maturity date of the Credit Agreement was May 1, 2021, unless terminated earlier.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Credit Facility is subject to certain financial covenants. As of&#160;June&#160;30, 2020, the Company was in compliance with all required covenants. On July 1, 2020, the Company terminated the Credit Facility. Refer to Note 15 for further details.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">2026 Convertible Notes</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In&#160;September 2019, the Company issued, at par value,&#160;$<ix:nonFraction unitRef="usd" contextRef="i43e763aab42b473cb26af800270f6b3e_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTg4OQ_2f1ab4b2-a38a-4157-bde1-c2ac7e7c80e7">287.5</ix:nonFraction> million&#160;aggregate principal amount of&#160;<ix:nonFraction unitRef="number" contextRef="i43e763aab42b473cb26af800270f6b3e_I20200630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTkyMg_f1d8b5c5-1047-42f4-97af-04d527b0cc7f">1.50</ix:nonFraction>%&#160;convertible senior notes due 2026, which included an option to purchase up to an additional $<ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="ptct:DebtInstrumentAdditionalAmountAvailableForRepurchase" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMjAxNw_751eacf4-01ee-4229-90f7-5de891812580">37.5</ix:nonFraction> million in aggregate principal amount of the 2026 Convertible Notes. The 2026 Convertible Notes bear cash interest at a rate of&#160;<ix:nonFraction unitRef="number" contextRef="i43e763aab42b473cb26af800270f6b3e_I20200630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMjE0MA_fc32f055-e4d7-4c53-8ba1-19eb5b5643cc">1.50</ix:nonFraction>%&#160;per year, payable semi-annually on&#160;March&#160;15&#160;and&#160;September&#160;15&#160;of each year, beginning on&#160;March 15, 2020. The 2026 Convertible Notes will mature on&#160;September 15, 2026, unless earlier repurchased or converted. The net proceeds to the Company from the offering were&#160;$<ix:nonFraction unitRef="usd" contextRef="i99e6e03adee54a9ca0a6a21ec4cddd55_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMjQwNQ_8dde4c46-e3fd-425f-afe2-fe40132e68dc">279.3</ix:nonFraction> million after deducting the initial purchasers&#8217; discounts and commissions and the offering expenses payable by the Company.</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="id10d456c962c468296923621080485f4" continuedAt="i7e711565a7fe47dd9b291ebd4bf87e97"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The 2026 Convertible Notes are governed by an indenture (the "2026 Convertible Notes Indenture") with U.S Bank National Association as trustee (the "2026 Convertible Notes Trustee").</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Holders may convert their 2026 Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding&#160;March 15, 2026&#160;only under the following circumstances:</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> during any calendar quarter commencing on or after&#160;December 31, 2019&#160;(and only during such calendar quarter), if the last reported sale price of the Company&#8217;s common stock for at least&#160;<ix:nonFraction unitRef="day" contextRef="i8dc375e5e9f24bf9b690d042d600041f_D20190901-20190930" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMzExNg_986f3df1-03cf-4c5a-86fa-8339f77059c7">20</ix:nonFraction>&#160;trading days (whether or not consecutive) during a period of&#160;<ix:nonFraction unitRef="day" contextRef="ifbd02289ccd34e7a886bf4e86089dadc_D20190901-20190930" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMzE4MA_5c4afc5a-83d6-4077-bd12-9bd505ef9e07">30</ix:nonFraction>&#160;consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to&#160;<ix:nonFraction unitRef="number" contextRef="i8dc375e5e9f24bf9b690d042d600041f_D20190901-20190930" decimals="2" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMzMxMw_1aa6b209-310e-4a06-82e4-85f2a91ad5fe">130</ix:nonFraction>%&#160;of the conversion price on each applicable trading day;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> during the&#160;<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMzQwMg_7f893db8-e0cf-4d5a-83ac-33f975ce7592">five</span>&#160;business day period after any&#160;<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMzQzNQ_36968acf-1345-44be-9245-319a6078d531">five</span>&#160;consecutive trading day period (the &#8220;measurement period&#8221;) in which the trading price (as defined in the 2026 Convertible Notes Indenture) per $1,000 principal amount of 2026 Convertible Notes for each trading day of the measurement period was less than&#160;<ix:nonFraction unitRef="number" contextRef="i08c7971cf8d6469fbda565dec2419938_I20200630" decimals="2" name="ptct:DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMzY4Nw_cce6c2b1-5ca7-491d-8240-0d5478d791d2">98</ix:nonFraction>%&#160;of the product of the last reported sale price of the Company&#8217;s common stock and the conversion rate on each such trading day;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> during any period after the Company has issued notice of redemption until the close of business on the scheduled trading day immediately preceding the relevant redemption date; or</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> upon the occurrence of specified corporate events.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On or after March 15, 2026, until the close of business on the business day immediately preceding the maturity date, holders may convert their 2026 Convertible Notes at any time, regardless of the foregoing circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of the Company's common stock or any combination thereof at the Company's election.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The conversion rate for the 2026 Convertible Notes was initially, and remains, <ix:nonFraction unitRef="number" contextRef="i9710b6f008d64a8e9b038ddfbc4f20cb_D20190901-20190930" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfNDU1NA_8ae608a5-02eb-463f-9680-52b62c162127">19.0404</ix:nonFraction> shares of the Company&#8217;s common stock per $1,000 principal amount of the 2026 Convertible Notes, which is equivalent to an initial conversion price of approximately&#160;$<ix:nonFraction unitRef="usdPerShare" contextRef="i43e763aab42b473cb26af800270f6b3e_I20200630" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfNDcxNw_5bba4383-e0b8-46da-98d3-a76a354c390e">52.52</ix:nonFraction> per share of the Company&#8217;s common stock. The conversion rate may be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is not permitted to redeem the 2026 Convertible Notes prior to September 20, 2023. The Company may redeem for cash all or any portion of the 2026 Convertible Notes, at its option, if the last reported sale price of its common stock has been at least <ix:nonFraction unitRef="number" contextRef="ifbd02289ccd34e7a886bf4e86089dadc_D20190901-20190930" decimals="2" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfNTE0OQ_6438c313-5547-4569-a720-dca4bdf52934">130</ix:nonFraction>% of the conversion price then in effect on the last trading day of, and for at least <ix:nonFraction unitRef="day" contextRef="ifbd02289ccd34e7a886bf4e86089dadc_D20190901-20190930" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfNTIzNg_996c8182-c5b0-47b3-891b-18497efc57a8">19</ix:nonFraction> other trading days (whether or not consecutive) during, any <ix:nonFraction unitRef="day" contextRef="ifbd02289ccd34e7a886bf4e86089dadc_D20190901-20190930" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfNTI5OQ_c107688e-f828-4dbb-a06c-8b806ca79700">30</ix:nonFraction> consecutive trading day period ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to <ix:nonFraction unitRef="number" contextRef="ifbd02289ccd34e7a886bf4e86089dadc_D20190901-20190930" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfNTQ4OQ_abd63032-d306-4818-9497-91d77f0cb6a5">100</ix:nonFraction>% of the principal amount of the 2026 Convertible Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. <ix:nonFraction unitRef="usd" contextRef="i8781119cc5804767a8721ec1e62367b7_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtInstrumentCumulativeSinkingFundPayments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfNTYzNQ_4f7e1aac-36df-4322-8734-3a7611a09641">No</ix:nonFraction> sinking fund is provided for the 2026 Convertible Notes, which means that the Company is not required to redeem or retire the 2026 Convertible Notes periodically. </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If the Company undergoes a &#8220;fundamental change&#8221; (as defined in the 2026 Convertible Notes Indenture), subject to certain conditions, holders of the 2026 Convertible Notes may require the Company to repurchase for cash all or part of their 2026 Convertible Notes at a repurchase price equal to <ix:nonFraction unitRef="number" contextRef="i8dc375e5e9f24bf9b690d042d600041f_D20190901-20190930" decimals="2" name="ptct:ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfNjA5NQ_8eddb489-3342-4d90-8188-e2400bc59520">100</ix:nonFraction>% of the principal amount of the 2026 Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The 2026 Convertible Notes represent senior unsecured obligations and will rank senior in right of payment to the Company&#8217;s future indebtedness that is expressly subordinated in right of payment to the notes, equal in right of payment to the Company&#8217;s existing and future unsecured indebtedness that is not so subordinated, effectively junior in right of payment to any of the Company&#8217;s secured indebtedness to the extent of the value of the assets securing such indebtedness, and structurally subordinated to all existing and future indebtedness and other liabilities (including trade payables) incurred by the Company&#8217;s subsidiaries. The 2026 Convertible Notes Indenture contains customary events of default with respect to the 2026 Convertible Notes, including that upon certain events of default (including the Company&#8217;s failure to make any payment of principal or interest on the 2026 Convertible Notes when due and payable) occurring and continuing, the 2026 Convertible Notes Trustee by notice to the Company, or the holders of at least <ix:nonFraction unitRef="number" contextRef="i8dc375e5e9f24bf9b690d042d600041f_D20190901-20190930" decimals="2" name="ptct:MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfNzMwNw_be5058a0-37e3-4983-aa97-80492518de93">25</ix:nonFraction>% in principal amount of the outstanding 2026 Convertible Notes by notice to the Company and the Convertible Notes Trustee, may, and the 2026 Convertible Notes Trustee at the request of such holders (subject to the provisions of the 2026 Convertible Notes Indenture) shall, declare <ix:nonFraction unitRef="number" contextRef="ifbd02289ccd34e7a886bf4e86089dadc_D20190901-20190930" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfNzU5MA_894ee09c-d008-4717-9766-ce06ab3f5e11">100</ix:nonFraction>% of the principal of and accrued and unpaid interest, if any, on all the 2026 Convertible Notes to be due and payable. In case of certain events of bankruptcy, insolvency or reorganization, involving the Company or a significant subsidiary, <ix:nonFraction unitRef="number" contextRef="ifbd02289ccd34e7a886bf4e86089dadc_D20190901-20190930" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfNzgzMw_f24020d2-49ef-4f72-aeb6-f7f1e6701fc0">100</ix:nonFraction>% of the principal of and accrued and unpaid interest on the 2026 Convertible Notes will automatically become due and payable. Upon such a declaration of acceleration, such principal and accrued and unpaid interest, if any, will be due and payable immediately.</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i7e711565a7fe47dd9b291ebd4bf87e97" continuedAt="i426e41361a894c0fa862f2328a37f650"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for the 2026 Convertible Notes as a liability and equity component where the carrying value of the liability component will be valued based on a similar instrument. In accounting for the issuance of the 2026 Convertible Notes, the Company separated the 2026 Convertible Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of a similar liability that does not have an associated convertible feature. The carrying amount of the equity component representing the conversion option was determined by deducting the fair value of the liability component from the par value of the 2026 Convertible Notes as a whole. The excess of the principal amount of the liability component over its carrying amount, referred to as the debt discount, is amortized to interest expense over the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfODk3MQ_ee20cb45-d925-46df-bb1a-8dfa5015d89d">seven</span>-year term of the 2026 Convertible Notes. The equity component is not re-measured as long as it continues to meet the conditions for equity classification. The equity component recorded at issuance related to the 2026 Convertible Notes was $<ix:nonFraction unitRef="usd" contextRef="i9710b6f008d64a8e9b038ddfbc4f20cb_D20190901-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfOTIxMw_38daba00-bc2e-4b77-bbcc-a3098676b290">123.0</ix:nonFraction> million&#160;and was recorded in additional paid-in capital.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In accounting for the transaction costs related to the issuance of the 2026 Convertible Notes, the Company allocated the total costs incurred to the liability and equity components of the 2026 Convertible Notes based on their relative values. Transaction costs attributable to the liability component are amortized to interest expense over the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfOTYwOA_9ed8f64e-ddb8-4035-b1f3-c92bbadb8041">seven</span>-year term of the 2026 Convertible Notes, and transaction costs attributable to the equity component are netted with the equity components in stockholders&#8217; equity. Additionally, the Company initially recorded a net deferred tax liability of $<ix:nonFraction unitRef="usd" contextRef="i43e763aab42b473cb26af800270f6b3e_I20200630" decimals="-5" format="ixt:numdotdecimal" name="ptct:NetDeferredTaxLiabilitiesConvertibleDebtInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfOTg1MQ_a6fa56e1-62a3-4730-9bbf-ba0397fc61f1">25.3</ix:nonFraction> million in connection with the 2026 Convertible Notes.</span></div><ix:nonNumeric contextRef="i74ae1a7412804eb39f158945860fdc92_D20200101-20200630" name="us-gaap:ConvertibleDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTkwNDM_0d4e002d-152b-419a-bdcc-a2940b71258d" escape="true"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The 2026 Convertible Notes consist of the following:</span></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:61.436%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.621%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.387%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.622%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liability&#160;component</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Principal</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i43e763aab42b473cb26af800270f6b3e_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmNjYTJiOTI2MTAyYjQ2ZDg5ZDliZjhkYmFmN2M1OTFhL3RhYmxlcmFuZ2U6Y2NhMmI5MjYxMDJiNDZkODlkOWJmOGRiYWY3YzU5MWFfMS0yLTEtMS0w_a20cfadd-6bb0-4b8f-965d-67ae81aba07b">287,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2869c1675c5a404e9bb85cad2eb71998_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmNjYTJiOTI2MTAyYjQ2ZDg5ZDliZjhkYmFmN2M1OTFhL3RhYmxlcmFuZ2U6Y2NhMmI5MjYxMDJiNDZkODlkOWJmOGRiYWY3YzU5MWFfMS0zLTEtMS0w_5a42722b-de69-43fb-9ee5-36cc2b8342ec">287,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Debt issuance costs</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i43e763aab42b473cb26af800270f6b3e_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnamortizedDebtIssuanceExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmNjYTJiOTI2MTAyYjQ2ZDg5ZDliZjhkYmFmN2M1OTFhL3RhYmxlcmFuZ2U6Y2NhMmI5MjYxMDJiNDZkODlkOWJmOGRiYWY3YzU5MWFfMi0yLTEtMS0w_9d35f64a-54fa-4d61-94f5-eaa6595d4e1a">4,319</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2869c1675c5a404e9bb85cad2eb71998_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnamortizedDebtIssuanceExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmNjYTJiOTI2MTAyYjQ2ZDg5ZDliZjhkYmFmN2M1OTFhL3RhYmxlcmFuZ2U6Y2NhMmI5MjYxMDJiNDZkODlkOWJmOGRiYWY3YzU5MWFfMi0zLTEtMS0w_45c8abc0-ef4b-4acc-9c14-d6ca66d84209">4,567</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Debt discount, net(1)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i43e763aab42b473cb26af800270f6b3e_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmNjYTJiOTI2MTAyYjQ2ZDg5ZDliZjhkYmFmN2M1OTFhL3RhYmxlcmFuZ2U6Y2NhMmI5MjYxMDJiNDZkODlkOWJmOGRiYWY3YzU5MWFfMy0yLTEtMS0w_f28cab4f-831e-40f1-9ef5-7bac65022efb">112,877</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2869c1675c5a404e9bb85cad2eb71998_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmNjYTJiOTI2MTAyYjQ2ZDg5ZDliZjhkYmFmN2M1OTFhL3RhYmxlcmFuZ2U6Y2NhMmI5MjYxMDJiNDZkODlkOWJmOGRiYWY3YzU5MWFfMy0zLTEtMS0w_2aeb8697-5884-4b14-b30d-2c3cbe7790be">119,350</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net carrying amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i43e763aab42b473cb26af800270f6b3e_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmNjYTJiOTI2MTAyYjQ2ZDg5ZDliZjhkYmFmN2M1OTFhL3RhYmxlcmFuZ2U6Y2NhMmI5MjYxMDJiNDZkODlkOWJmOGRiYWY3YzU5MWFfNC0yLTEtMS0w_0f6730da-e4a1-4dba-9e01-a6bce2d2be02">170,304</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2869c1675c5a404e9bb85cad2eb71998_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmNjYTJiOTI2MTAyYjQ2ZDg5ZDliZjhkYmFmN2M1OTFhL3RhYmxlcmFuZ2U6Y2NhMmI5MjYxMDJiNDZkODlkOWJmOGRiYWY3YzU5MWFfNC0zLTEtMS0w_3975cb58-01db-4ab9-bd22-fc55f3310f02">163,583</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1)&#160;Included in the consolidated balance sheets within convertible senior notes (due 2026) and amortized to interest expense over the remaining life of the 2026 Convertible Notes using the effective interest rate method.</span></div></ix:nonNumeric><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, the remaining contractual life of the 2026 Convertible Notes is approximately <ix:nonNumeric contextRef="i73b5dc373fe54df282ef490ee32d7654_D20200401-20200630" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTAyNjU_1fac162c-712b-4e22-ad8a-a9815f8d7b5d">6.2</ix:nonNumeric> years.</span></div><ix:nonNumeric contextRef="i74ae1a7412804eb39f158945860fdc92_D20200101-20200630" name="ptct:ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTkwNTg_1afd1a8b-da6e-4a2e-bed5-4ca166e7f268" escape="true"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth total interest expense recognized related to the 2026 Convertible Notes:</span></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:77.631%;"><tr><td style="width:1.0%;"></td><td style="width:48.282%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.306%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:21.163%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.553%;"></td><td style="width:0.1%;"></td><td colspan="3" style="display:none;"></td><td style="width:0.1%;"></td><td style="width:0.741%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:20.598%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.557%;"></td><td style="width:0.1%;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contractual interest expense</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i73b5dc373fe54df282ef490ee32d7654_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmJhNzc0M2VmNzkwNTQxYjA5MjZlNmU2OGY3NjhkYzQzL3RhYmxlcmFuZ2U6YmE3NzQzZWY3OTA1NDFiMDkyNmU2ZTY4Zjc2OGRjNDNfMi0yLTEtMS0w_84de16b1-aa8c-464c-bf37-3a3ad1fe8993">1,066</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i99e6e03adee54a9ca0a6a21ec4cddd55_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmJhNzc0M2VmNzkwNTQxYjA5MjZlNmU2OGY3NjhkYzQzL3RhYmxlcmFuZ2U6YmE3NzQzZWY3OTA1NDFiMDkyNmU2ZTY4Zjc2OGRjNDNfMi02LTEtMS0zMTI5_e06433c8-d825-4452-b60e-9def0792840e">2,142</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i73b5dc373fe54df282ef490ee32d7654_D20200401-20200630" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmJhNzc0M2VmNzkwNTQxYjA5MjZlNmU2OGY3NjhkYzQzL3RhYmxlcmFuZ2U6YmE3NzQzZWY3OTA1NDFiMDkyNmU2ZTY4Zjc2OGRjNDNfMy0yLTEtMS0w_38a21e61-942c-4260-9d9c-c9a1efcca228">124</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i99e6e03adee54a9ca0a6a21ec4cddd55_D20200101-20200630" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmJhNzc0M2VmNzkwNTQxYjA5MjZlNmU2OGY3NjhkYzQzL3RhYmxlcmFuZ2U6YmE3NzQzZWY3OTA1NDFiMDkyNmU2ZTY4Zjc2OGRjNDNfMy02LTEtMS0zMTI5_5c99c80a-209f-4ecc-8662-8f502a206492">248</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of debt discount</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i73b5dc373fe54df282ef490ee32d7654_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmJhNzc0M2VmNzkwNTQxYjA5MjZlNmU2OGY3NjhkYzQzL3RhYmxlcmFuZ2U6YmE3NzQzZWY3OTA1NDFiMDkyNmU2ZTY4Zjc2OGRjNDNfNC0yLTEtMS0w_209cc0d9-5539-4e6d-b01f-e455c74d66db">3,239</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i99e6e03adee54a9ca0a6a21ec4cddd55_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmJhNzc0M2VmNzkwNTQxYjA5MjZlNmU2OGY3NjhkYzQzL3RhYmxlcmFuZ2U6YmE3NzQzZWY3OTA1NDFiMDkyNmU2ZTY4Zjc2OGRjNDNfNC02LTEtMS0zMTI5_d40a0241-09f5-4706-a9f2-845485eee4de">6,473</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i73b5dc373fe54df282ef490ee32d7654_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmJhNzc0M2VmNzkwNTQxYjA5MjZlNmU2OGY3NjhkYzQzL3RhYmxlcmFuZ2U6YmE3NzQzZWY3OTA1NDFiMDkyNmU2ZTY4Zjc2OGRjNDNfNS0yLTEtMS0w_5c68956f-c403-467c-963a-20c6a1bc193e">4,429</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i99e6e03adee54a9ca0a6a21ec4cddd55_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmJhNzc0M2VmNzkwNTQxYjA5MjZlNmU2OGY3NjhkYzQzL3RhYmxlcmFuZ2U6YmE3NzQzZWY3OTA1NDFiMDkyNmU2ZTY4Zjc2OGRjNDNfNS02LTEtMS02OTQ4_d3c65829-2fdd-4661-8258-c62b029d7ba0">8,863</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effective interest rate of the liability component</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i43e763aab42b473cb26af800270f6b3e_I20200630" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmJhNzc0M2VmNzkwNTQxYjA5MjZlNmU2OGY3NjhkYzQzL3RhYmxlcmFuZ2U6YmE3NzQzZWY3OTA1NDFiMDkyNmU2ZTY4Zjc2OGRjNDNfNi0yLTEtMS0w_89d80422-85c5-4242-96fd-dc2a8b181739">10.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i43e763aab42b473cb26af800270f6b3e_I20200630" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmJhNzc0M2VmNzkwNTQxYjA5MjZlNmU2OGY3NjhkYzQzL3RhYmxlcmFuZ2U6YmE3NzQzZWY3OTA1NDFiMDkyNmU2ZTY4Zjc2OGRjNDNfNi02LTEtMS0w_5d06bd98-1a13-4243-83a6-a1d420e81f7f">10.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">2022 Convertible Notes</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In&#160;August&#160;2015, the Company issued, at par value,&#160;$<ix:nonFraction unitRef="usd" contextRef="i28655a9b21d647eb9144da8fa8cdd911_I20150831" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTA0NTQ_e9cd6dba-7609-4a66-bf24-a4caa7f5da03">150.0</ix:nonFraction> million&#160;aggregate principal amount of&#160;<ix:nonFraction unitRef="number" contextRef="i28655a9b21d647eb9144da8fa8cdd911_I20150831" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTA0ODc_8cdca5b8-140f-410e-a410-a0116e1dce35">3.00</ix:nonFraction>%&#160;convertible senior notes due 2022. The 2022 Convertible Notes bear cash interest at a rate of&#160;<ix:nonFraction unitRef="number" contextRef="i28655a9b21d647eb9144da8fa8cdd911_I20150831" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTA1ODQ_3d0f5b56-e449-4de2-843a-6aa4975617af">3.00</ix:nonFraction>%&#160;per year, payable semi-annually on&#160;February&#160;15&#160;and&#160;August&#160;15&#160;of each year, beginning on&#160;February&#160;15, 2016. The 2022 Convertible Notes will mature on&#160;August&#160;15, 2022, unless earlier repurchased or converted. The net proceeds to the Company from the offering were&#160;$<ix:nonFraction unitRef="usd" contextRef="idab0eeb8f1e24e3389eda446498f9b4c_D20150801-20150831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTA4NDk_64bfe4e2-a229-4f40-82a3-5fea56070963">145.4</ix:nonFraction> million&#160;after deducting the initial purchasers&#8217; discounts and commissions and the offering expenses payable by the Company.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The 2022 Convertible Notes are governed by an indenture (the "2022 Convertible Notes Indenture") with U.S Bank National Association as trustee (the "2022 Convertible Notes Trustee").</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Holders may convert their 2022 Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding&#160;February&#160;15, 2022&#160;only under the following circumstances:</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> during any calendar quarter commencing on or after&#160;September&#160;30, 2015&#160;(and only during such calendar quarter), if the last reported sale price of the Company&#8217;s common stock for at least&#160;<ix:nonFraction unitRef="day" contextRef="i8dc375e5e9f24bf9b690d042d600041f_D20190901-20190930" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTE1NjQ_986f3df1-03cf-4c5a-86fa-8339f77059c7">20</ix:nonFraction>&#160;trading days (whether or not consecutive) during a period of&#160;<ix:nonFraction unitRef="day" contextRef="ifbd02289ccd34e7a886bf4e86089dadc_D20190901-20190930" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTE2Mjg_5c4afc5a-83d6-4077-bd12-9bd505ef9e07">30</ix:nonFraction>&#160;consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to&#160;<ix:nonFraction unitRef="number" contextRef="i8dc375e5e9f24bf9b690d042d600041f_D20190901-20190930" decimals="2" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTE3NjE_1aa6b209-310e-4a06-82e4-85f2a91ad5fe">130</ix:nonFraction>%&#160;of the conversion price on each applicable trading day;</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i426e41361a894c0fa862f2328a37f650" continuedAt="i6cc27d0f6e6b4710af30f4a49d3129bb"><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> during the&#160;<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTE4NTA_7f893db8-e0cf-4d5a-83ac-33f975ce7592">five</span>&#160;business day period after any&#160;<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTE4ODM_36968acf-1345-44be-9245-319a6078d531">five</span>&#160;consecutive trading day period (the &#8220;measurement period&#8221;) in which the trading price (as defined in the 2022 Convertible Notes Indenture) per $1,000 principal amount of 2022 Convertible Notes for each trading day of the measurement period was less than&#160;<ix:nonFraction unitRef="number" contextRef="i08c7971cf8d6469fbda565dec2419938_I20200630" decimals="2" name="ptct:DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTIxMzU_cce6c2b1-5ca7-491d-8240-0d5478d791d2">98</ix:nonFraction>%&#160;of the product of the last reported sale price of the Company&#8217;s common stock and the conversion rate on each such trading day;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> during any period after the Company has issued notice of redemption until the close of business on the scheduled trading day immediately preceding the relevant redemption date; or</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> upon the occurrence of specified corporate events.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On or after February&#160;15, 2022, until the close of business on the business day immediately preceding the maturity date, holders may convert their 2022 Convertible Notes at any time, regardless of the foregoing circumstances. Upon conversion, the Company will pay cash up to the aggregate principal amount of the 2022 Convertible Notes to be converted and deliver shares of its common stock in respect of the remainder, if any, of its conversion obligation in excess of the aggregate principal amount of 2022 Convertible Notes being converted.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The conversion rate for the 2022 Convertible Notes was initially, and remains, <ix:nonFraction unitRef="number" contextRef="idab0eeb8f1e24e3389eda446498f9b4c_D20150801-20150831" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTMxNTY_ef22898c-afce-44fb-be8c-fe34ed7dee3c">17.7487</ix:nonFraction> shares of the Company&#8217;s common stock per $1,000 principal amount of the 2022 Convertible Notes, which is equivalent to an initial conversion price of approximately&#160;$<ix:nonFraction unitRef="usdPerShare" contextRef="i28655a9b21d647eb9144da8fa8cdd911_I20150831" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTMzMTk_355db875-251a-48dd-8df4-a7037306a82d">56.34</ix:nonFraction>&#160;per share of the Company&#8217;s common stock. The conversion rate may be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company was not permitted to redeem the 2022 Convertible Notes prior to August&#160;20, 2018. As of August 20, 2018, the Company may redeem for cash all or any portion of the 2022 Convertible Notes, at its option, if the last reported sale price of its common stock has been at least <ix:nonFraction unitRef="number" contextRef="ifbd02289ccd34e7a886bf4e86089dadc_D20190901-20190930" decimals="2" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTM3NzI_6438c313-5547-4569-a720-dca4bdf52934">130</ix:nonFraction>% of the conversion price then in effect on the last trading day of, and for at least <ix:nonFraction unitRef="day" contextRef="ifbd02289ccd34e7a886bf4e86089dadc_D20190901-20190930" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTM4NTk_996c8182-c5b0-47b3-891b-18497efc57a8">19</ix:nonFraction> other trading days (whether or not consecutive) during, any <ix:nonFraction unitRef="day" contextRef="ifbd02289ccd34e7a886bf4e86089dadc_D20190901-20190930" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTM5MjI_c107688e-f828-4dbb-a06c-8b806ca79700">30</ix:nonFraction> consecutive trading day period ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to <ix:nonFraction unitRef="number" contextRef="ifbd02289ccd34e7a886bf4e86089dadc_D20190901-20190930" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTQxMTI_abd63032-d306-4818-9497-91d77f0cb6a5">100</ix:nonFraction>% of the principal amount of the 2022 Convertible Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. <ix:nonFraction unitRef="usd" contextRef="i8781119cc5804767a8721ec1e62367b7_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtInstrumentCumulativeSinkingFundPayments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTQyNTg_4f7e1aac-36df-4322-8734-3a7611a09641">No</ix:nonFraction> sinking fund is provided for the 2022 Convertible Notes, which means that the Company is not required to redeem or retire the 2022 Convertible Notes periodically. There have been no redemptions to date.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If the Company undergoes a &#8220;fundamental change&#8221; (as defined in the 2022 Convertible Notes Indenture), subject to certain conditions, holders of the 2022 Convertible Notes may require the Company to repurchase for cash all or part of their 2022 Convertible Notes at a repurchase price equal to <ix:nonFraction unitRef="number" contextRef="i8dc375e5e9f24bf9b690d042d600041f_D20190901-20190930" decimals="2" name="ptct:ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTQ3NTc_8eddb489-3342-4d90-8188-e2400bc59520">100</ix:nonFraction>% of the principal amount of the 2022 Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The 2022 Convertible Notes represent senior unsecured obligations and will rank senior in right of payment to the Company&#8217;s future indebtedness that is expressly subordinated in right of payment to the notes, equal in right of payment to the Company&#8217;s existing and future unsecured indebtedness that is not so subordinated, effectively junior in right of payment to any of the Company&#8217;s secured indebtedness to the extent of the value of the assets securing such indebtedness, and structurally subordinated to all existing and future indebtedness and other liabilities (including trade payables) incurred by the Company&#8217;s subsidiaries. The 2022 Convertible Notes Indenture contains customary events of default with respect to the 2022 Convertible Notes, including that upon certain events of default (including the Company&#8217;s failure to make any payment of principal or interest on the 2022 Convertible Notes when due and payable) occurring and continuing, the 2022 Convertible Notes Trustee by notice to the Company, or the holders of at least <ix:nonFraction unitRef="number" contextRef="i8dc375e5e9f24bf9b690d042d600041f_D20190901-20190930" decimals="2" name="ptct:MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTU5Njk_be5058a0-37e3-4983-aa97-80492518de93">25</ix:nonFraction>% in principal amount of the outstanding 2022 Convertible Notes by notice to the Company and the Convertible Notes Trustee, may, and the 2022 Convertible Notes Trustee at the request of such holders (subject to the provisions of the 2022 Convertible Notes Indenture) shall, declare <ix:nonFraction unitRef="number" contextRef="ifbd02289ccd34e7a886bf4e86089dadc_D20190901-20190930" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTYyNTI_894ee09c-d008-4717-9766-ce06ab3f5e11">100</ix:nonFraction>% of the principal of and accrued and unpaid interest, if any, on all the 2022 Convertible Notes to be due and payable. In case of certain events of bankruptcy, insolvency or reorganization, involving the Company or a significant subsidiary, <ix:nonFraction unitRef="number" contextRef="ifbd02289ccd34e7a886bf4e86089dadc_D20190901-20190930" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTY0OTU_f24020d2-49ef-4f72-aeb6-f7f1e6701fc0">100</ix:nonFraction>% of the principal of and accrued and unpaid interest on the 2022 Convertible Notes will automatically become due and payable. Upon such a declaration of acceleration, such principal and accrued and unpaid interest, if any, will be due and payable immediately.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for the 2022 Convertible Notes as a liability and equity component where the carrying value of the liability component will be valued based on a similar instrument. In accounting for the issuance of the 2022 Convertible Notes, the Company separated the 2022 Convertible Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of a similar liability that does not have an associated convertible feature. The carrying amount of the equity component representing the conversion option was determined by deducting the fair value of the liability component from the par value of the 2022 Convertible Notes as a whole. The excess of the principal amount of the liability component over its carrying amount, referred to as the debt discount, is amortized to interest expense over the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTc2MzM_ee20cb45-d925-46df-bb1a-8dfa5015d89d">seven</span>-year term of the 2022 Convertible Notes. The equity component is not re-measured as long as it continues to meet the conditions for equity classification. The equity component recorded at issuance related to the 2022 Convertible Notes was&#160;$<ix:nonFraction unitRef="usd" contextRef="idab0eeb8f1e24e3389eda446498f9b4c_D20150801-20150831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTc4NzU_70f42955-f583-44af-bba5-4ed44a60d2e2">57.5</ix:nonFraction> million&#160;and was recorded in additional paid-in capital.</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i6cc27d0f6e6b4710af30f4a49d3129bb"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In accounting for the transaction costs related to the issuance of the 2022 Convertible Notes, the Company allocated the total costs incurred to the liability and equity components of the 2022 Convertible Notes based on their relative values. Transaction costs attributable to the liability component are amortized to interest expense over the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTgyNzA_9ed8f64e-ddb8-4035-b1f3-c92bbadb8041">seven</span>-year term of the 2022 Convertible Notes, and transaction costs attributable to the equity component are netted with the equity components in stockholders&#8217; equity. Additionally, the Company initially recorded a net deferred tax liability of $<ix:nonFraction unitRef="usd" contextRef="i28655a9b21d647eb9144da8fa8cdd911_I20150831" decimals="-5" format="ixt:numdotdecimal" name="ptct:NetDeferredTaxLiabilitiesConvertibleDebtInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTg1MTM_15466ea5-cd48-4f84-b1b3-ed2a3f4b99af">22.3</ix:nonFraction> million in connection with the 2022 Convertible Notes.</span></div><ix:nonNumeric contextRef="i0563616514554f76bb3cb942f7310b61_D20200101-20200630" name="us-gaap:ConvertibleDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTkwNDQ_67190607-a9d8-4a7f-a4fe-de386c00b262" escape="true"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The 2022 Convertible Notes consist of the following:</span></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:61.343%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.595%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.596%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liability&#160;component</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Principal</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i08c7971cf8d6469fbda565dec2419938_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOjg4ZDk3MDhjM2QyMTQ2YzE4ZWVmYzc0MTBiYjQ1MzdiL3RhYmxlcmFuZ2U6ODhkOTcwOGMzZDIxNDZjMThlZWZjNzQxMGJiNDUzN2JfMS0yLTEtMS0w_19ade0d5-d9aa-4555-ae4c-bd5163fb15a3">150,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5fc57b5184a54d248eb826766cbbb088_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOjg4ZDk3MDhjM2QyMTQ2YzE4ZWVmYzc0MTBiYjQ1MzdiL3RhYmxlcmFuZ2U6ODhkOTcwOGMzZDIxNDZjMThlZWZjNzQxMGJiNDUzN2JfMS00LTEtMS0w_3304b0f6-81aa-4bad-b216-27450464d76a">150,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Debt issuance costs</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i08c7971cf8d6469fbda565dec2419938_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnamortizedDebtIssuanceExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOjg4ZDk3MDhjM2QyMTQ2YzE4ZWVmYzc0MTBiYjQ1MzdiL3RhYmxlcmFuZ2U6ODhkOTcwOGMzZDIxNDZjMThlZWZjNzQxMGJiNDUzN2JfMi0yLTEtMS0w_0be855cf-6ac3-46f2-8c33-b18ac5101558">1,104</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5fc57b5184a54d248eb826766cbbb088_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnamortizedDebtIssuanceExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOjg4ZDk3MDhjM2QyMTQ2YzE4ZWVmYzc0MTBiYjQ1MzdiL3RhYmxlcmFuZ2U6ODhkOTcwOGMzZDIxNDZjMThlZWZjNzQxMGJiNDUzN2JfMi00LTEtMS0w_cd434f41-7b3c-4aa1-b10b-7c7179e99945">1,329</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Debt discount, net(1)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i08c7971cf8d6469fbda565dec2419938_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOjg4ZDk3MDhjM2QyMTQ2YzE4ZWVmYzc0MTBiYjQ1MzdiL3RhYmxlcmFuZ2U6ODhkOTcwOGMzZDIxNDZjMThlZWZjNzQxMGJiNDUzN2JfMy0yLTEtMS0w_556c5f69-3984-4fb9-a94d-db3fc19128bc">22,166</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5fc57b5184a54d248eb826766cbbb088_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOjg4ZDk3MDhjM2QyMTQ2YzE4ZWVmYzc0MTBiYjQ1MzdiL3RhYmxlcmFuZ2U6ODhkOTcwOGMzZDIxNDZjMThlZWZjNzQxMGJiNDUzN2JfMy00LTEtMS0w_972c2ffc-05a4-4947-8613-d254c65ddda7">26,686</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net carrying amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i08c7971cf8d6469fbda565dec2419938_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOjg4ZDk3MDhjM2QyMTQ2YzE4ZWVmYzc0MTBiYjQ1MzdiL3RhYmxlcmFuZ2U6ODhkOTcwOGMzZDIxNDZjMThlZWZjNzQxMGJiNDUzN2JfNC0yLTEtMS0w_4fddbb1a-9519-4729-8ae1-044ba05e34dd">126,730</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5fc57b5184a54d248eb826766cbbb088_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOjg4ZDk3MDhjM2QyMTQ2YzE4ZWVmYzc0MTBiYjQ1MzdiL3RhYmxlcmFuZ2U6ODhkOTcwOGMzZDIxNDZjMThlZWZjNzQxMGJiNDUzN2JfNC00LTEtMS0w_22e83d7d-4769-44b9-aec4-100de1683423">121,985</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1)&#160;Included in the consolidated balance sheets within convertible senior notes (due 2022) and amortized to interest expense over the remaining life of the 2022 Convertible Notes using the effective interest rate method.</span></div></ix:nonNumeric><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, the remaining contractual life of the 2022 Convertible Notes is approximately <ix:nonNumeric contextRef="ic9c66ca599c4439faa67414af9011439_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTg5Mjc_39ca2c1a-97d2-434e-b6ce-708900ae94c5">2.1</ix:nonNumeric> years.</span></div><ix:nonNumeric contextRef="i0563616514554f76bb3cb942f7310b61_D20200101-20200630" name="ptct:ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTkwNTk_f2d59c63-1b01-43ad-8a60-0dc8d49d28ba" escape="true"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth total interest expense recognized related to the 2022 Convertible Notes:</span></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.222%;"><tr><td style="width:1.0%;"></td><td style="width:37.548%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.551%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.285%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.551%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.285%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.551%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.285%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.551%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.593%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contractual interest expense</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4e58b009dcb346afa5fe00025d1c8d43_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmE5ZTRjYzI0Yzk2YzRiY2NhYzM3N2I1MmUyNDQ1MjMxL3RhYmxlcmFuZ2U6YTllNGNjMjRjOTZjNGJjY2FjMzc3YjUyZTI0NDUyMzFfMi0yLTEtMS0w_6b25d2f2-f66b-44c1-aa5e-fcb10155f37a">1,125</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2a6dca67e5ed44bcae174fc956c744bb_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmE5ZTRjYzI0Yzk2YzRiY2NhYzM3N2I1MmUyNDQ1MjMxL3RhYmxlcmFuZ2U6YTllNGNjMjRjOTZjNGJjY2FjMzc3YjUyZTI0NDUyMzFfMi00LTEtMS0w_ec919709-42d1-4e13-bb9e-58346da4e86b">1,131</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9c66ca599c4439faa67414af9011439_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmE5ZTRjYzI0Yzk2YzRiY2NhYzM3N2I1MmUyNDQ1MjMxL3RhYmxlcmFuZ2U6YTllNGNjMjRjOTZjNGJjY2FjMzc3YjUyZTI0NDUyMzFfMi02LTEtMS0xMjE5_153934c6-c5d8-45d4-8f56-8585b69d2548">2,244</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb3d2f86e29542fd99ac08fe93500645_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmE5ZTRjYzI0Yzk2YzRiY2NhYzM3N2I1MmUyNDQ1MjMxL3RhYmxlcmFuZ2U6YTllNGNjMjRjOTZjNGJjY2FjMzc3YjUyZTI0NDUyMzFfMi04LTEtMS0xMjIz_708614db-6c01-4558-98f4-bbb7747ac709">2,241</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4e58b009dcb346afa5fe00025d1c8d43_D20200401-20200630" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmE5ZTRjYzI0Yzk2YzRiY2NhYzM3N2I1MmUyNDQ1MjMxL3RhYmxlcmFuZ2U6YTllNGNjMjRjOTZjNGJjY2FjMzc3YjUyZTI0NDUyMzFfMy0yLTEtMS0w_05487c82-36ab-4910-a6bc-d20f4e741cad">114</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2a6dca67e5ed44bcae174fc956c744bb_D20190401-20190630" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmE5ZTRjYzI0Yzk2YzRiY2NhYzM3N2I1MmUyNDQ1MjMxL3RhYmxlcmFuZ2U6YTllNGNjMjRjOTZjNGJjY2FjMzc3YjUyZTI0NDUyMzFfMy00LTEtMS0w_c9925e63-4b5d-4259-9801-81cf965ee0b2">103</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9c66ca599c4439faa67414af9011439_D20200101-20200630" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmE5ZTRjYzI0Yzk2YzRiY2NhYzM3N2I1MmUyNDQ1MjMxL3RhYmxlcmFuZ2U6YTllNGNjMjRjOTZjNGJjY2FjMzc3YjUyZTI0NDUyMzFfMy02LTEtMS0xMjE5_76e884e6-587c-4c45-a476-43bcf9fa0808">225</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb3d2f86e29542fd99ac08fe93500645_D20190101-20190630" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmE5ZTRjYzI0Yzk2YzRiY2NhYzM3N2I1MmUyNDQ1MjMxL3RhYmxlcmFuZ2U6YTllNGNjMjRjOTZjNGJjY2FjMzc3YjUyZTI0NDUyMzFfMy04LTEtMS0xMjIz_49c4af5f-3d0b-45dd-bced-65748569c5a5">202</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of debt discount</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4e58b009dcb346afa5fe00025d1c8d43_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmE5ZTRjYzI0Yzk2YzRiY2NhYzM3N2I1MmUyNDQ1MjMxL3RhYmxlcmFuZ2U6YTllNGNjMjRjOTZjNGJjY2FjMzc3YjUyZTI0NDUyMzFfNC0yLTEtMS0w_30f9778b-a9f3-4c34-a6ad-92afb3256bf5">2,295</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2a6dca67e5ed44bcae174fc956c744bb_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmE5ZTRjYzI0Yzk2YzRiY2NhYzM3N2I1MmUyNDQ1MjMxL3RhYmxlcmFuZ2U6YTllNGNjMjRjOTZjNGJjY2FjMzc3YjUyZTI0NDUyMzFfNC00LTEtMS0w_79db3967-8d31-4ad2-b5ce-fe9d54990d1a">2,074</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9c66ca599c4439faa67414af9011439_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmE5ZTRjYzI0Yzk2YzRiY2NhYzM3N2I1MmUyNDQ1MjMxL3RhYmxlcmFuZ2U6YTllNGNjMjRjOTZjNGJjY2FjMzc3YjUyZTI0NDUyMzFfNC02LTEtMS0xMjE5_df9cef6c-0775-42fa-84e3-0e45c8ce4f18">4,520</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb3d2f86e29542fd99ac08fe93500645_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmE5ZTRjYzI0Yzk2YzRiY2NhYzM3N2I1MmUyNDQ1MjMxL3RhYmxlcmFuZ2U6YTllNGNjMjRjOTZjNGJjY2FjMzc3YjUyZTI0NDUyMzFfNC04LTEtMS0xMjIz_b02ff162-24ab-43e9-86a5-f8f5d8ceb1d2">4,055</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4e58b009dcb346afa5fe00025d1c8d43_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmE5ZTRjYzI0Yzk2YzRiY2NhYzM3N2I1MmUyNDQ1MjMxL3RhYmxlcmFuZ2U6YTllNGNjMjRjOTZjNGJjY2FjMzc3YjUyZTI0NDUyMzFfNS0yLTEtMS0w_4872a75e-b770-4897-a438-b23693463175">3,534</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2a6dca67e5ed44bcae174fc956c744bb_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmE5ZTRjYzI0Yzk2YzRiY2NhYzM3N2I1MmUyNDQ1MjMxL3RhYmxlcmFuZ2U6YTllNGNjMjRjOTZjNGJjY2FjMzc3YjUyZTI0NDUyMzFfNS00LTEtMS0w_84be7bd1-f8a6-47dd-9356-3e14f2b39b87">3,308</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9c66ca599c4439faa67414af9011439_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmE5ZTRjYzI0Yzk2YzRiY2NhYzM3N2I1MmUyNDQ1MjMxL3RhYmxlcmFuZ2U6YTllNGNjMjRjOTZjNGJjY2FjMzc3YjUyZTI0NDUyMzFfNS02LTEtMS0xMjE5_eaa870a2-257d-44b9-b9d5-de8eb375a543">6,989</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb3d2f86e29542fd99ac08fe93500645_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmE5ZTRjYzI0Yzk2YzRiY2NhYzM3N2I1MmUyNDQ1MjMxL3RhYmxlcmFuZ2U6YTllNGNjMjRjOTZjNGJjY2FjMzc3YjUyZTI0NDUyMzFfNS04LTEtMS0xMjIz_be668c14-b4e1-488e-bf46-b3912ed75f58">6,498</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effective interest rate of the liability component</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i08c7971cf8d6469fbda565dec2419938_I20200630" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmE5ZTRjYzI0Yzk2YzRiY2NhYzM3N2I1MmUyNDQ1MjMxL3RhYmxlcmFuZ2U6YTllNGNjMjRjOTZjNGJjY2FjMzc3YjUyZTI0NDUyMzFfNi0yLTEtMS0w_3d8814c8-a2cf-4265-a794-96ed1043b1bc">11.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ic1f05bd3af07411fbeaa9695faa9b8f5_I20190630" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmE5ZTRjYzI0Yzk2YzRiY2NhYzM3N2I1MmUyNDQ1MjMxL3RhYmxlcmFuZ2U6YTllNGNjMjRjOTZjNGJjY2FjMzc3YjUyZTI0NDUyMzFfNi00LTEtMS0w_6eea50b3-5772-4dcc-9500-e86d8b509830">11.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i08c7971cf8d6469fbda565dec2419938_I20200630" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmE5ZTRjYzI0Yzk2YzRiY2NhYzM3N2I1MmUyNDQ1MjMxL3RhYmxlcmFuZ2U6YTllNGNjMjRjOTZjNGJjY2FjMzc3YjUyZTI0NDUyMzFfNi02LTEtMS0xMjE5_712ab88a-51cc-480e-936e-592e6de42d16">11.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ic1f05bd3af07411fbeaa9695faa9b8f5_I20190630" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmE5ZTRjYzI0Yzk2YzRiY2NhYzM3N2I1MmUyNDQ1MjMxL3RhYmxlcmFuZ2U6YTllNGNjMjRjOTZjNGJjY2FjMzc3YjUyZTI0NDUyMzFfNi04LTEtMS0xMjIz_572682ad-d4d0-475b-9b25-624c1a18ad83">11.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i95cf61a5c7074910ae3cf29c5ee08838_82"></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:8pt;margin-bottom:8pt;"><span><br/></span></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">12.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:700;line-height:120%;">&#160;</span><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfNTk1NQ_f310a8f8-4132-454d-8590-847b8e94fb44" continuedAt="i7ac535389a0f4e218e3dfe1b92a2e8be" escape="true"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Commitments</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">and contingencies</span></ix:nonNumeric></div><ix:continuation id="i7ac535389a0f4e218e3dfe1b92a2e8be" continuedAt="i87e75b8de20846c2b0af3c48c8ad78c4"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under various agreements, the Company will be required to pay royalties and milestone payments upon the successful development and commercialization of products. The Company has entered into funding agreements with The Wellcome Trust Limited ("Wellcome Trust") for the research and development of small molecule compounds in connection with the Company's oncology and antibacterial programs. As the Company has discontinued development under its antibacterial program, it no longer expects that milestone and royalty payments from the Company to Wellcome Trust will apply under that agreement, resulting in a change to the total amount of development and regulatory milestone payments the Company may become obligated to pay for this program.  Under the oncology program funding agreement, to the extent that the Company develops and commercializes program intellectual property on a for-profit basis itself or in collaboration with a partner (provided the Company retains overall control of worldwide commercialization), the Company may become obligated to pay to Wellcome Trust development and regulatory milestone payments and single-digit royalties on sales of any research program product. The Company&#8217;s obligation to pay such royalties would continue on a country-by-country basis until the longer of the expiration of the last patent in the program intellectual property in such country covering the research program product and the expiration of market exclusivity of such product in such country. The Company&#8217;s first such milestone payment of $<ix:nonFraction unitRef="usd" contextRef="i1f68521ddf23433db2233ba19286dfae_I20160930" decimals="-5" format="ixt:numdotdecimal" name="ptct:DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMTU5MQ_a863862d-565d-4a1d-8774-0c8ad362f5e1">0.8</ix:nonFraction> million payable to Wellcome Trust occurred in the second quarter of 2016.  Additional milestone payments of up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="ifdf769cde4f8456998cb633ecc67a74a_I20200630" decimals="-5" format="ixt:numdotdecimal" name="ptct:DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMTcxNg_388ec3df-e882-4b26-8906-a4803b9feb4c">22.4</ix:nonFraction> million may become payable by the Company to Wellcome Trust under this agreement.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has also entered into a collaboration agreement with the SMA Foundation. The Company may become obligated to pay the SMA Foundation single-digit royalties on worldwide net product sales of any collaboration product that is successfully developed and subsequently commercialized or, if the Company outlicenses rights to a collaboration product, a specified percentage of certain payments the Company receives from its licensee. The Company is not obligated to make such payments unless and until annual sales of a collaboration product exceed a designated threshold. The Company&#8217;s obligation to make such payments would end upon the Company's payment to the SMA Foundation of a specified amount.&#160;</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the asset purchase agreement ("Asset Purchase Agreement") between the Company and Marathon Pharmaceuticals, LLC (now known as Complete Pharma Holdings, LLC), or Marathon, Marathon is entitled to receive contingent payments from the Company based on annual net sales of Emflaza up to a specified aggregate maximum amount over the expected commercial life of the asset. In addition, Marathon has the opportunity to receive a single $<ix:nonFraction unitRef="usd" contextRef="id48de54c835343b9b2c5c1d3ce609ab1_I20170420" decimals="-5" format="ixt:numdotdecimal" name="ptct:DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMjgxNg_575e8867-09d4-4abb-9e97-0296338f9a0e">50.0</ix:nonFraction> million sales-based milestone.</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i87e75b8de20846c2b0af3c48c8ad78c4" continuedAt="i2117cbea77494a7ca90143041fdeb534"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the Merger Agreement with Agilis, Agilis equityholders were previously entitled to receive contingent consideration payments from the Company based on (i)&#160;the achievement of certain development milestones up to an aggregate maximum amount of $<ix:nonFraction unitRef="usd" contextRef="ia20c4a3be1bf491aaf06ea4818f97179_I20200630" decimals="-5" format="ixt:numdotdecimal" name="ptct:DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMTA5OTUxMTYzMzc1Ng_e7f14cc3-516b-47aa-9b44-9d6caeb3d35e">60.0</ix:nonFraction>&#160;million, (ii)&#160;the achievement of certain regulatory approval milestones together with a milestone payment following the receipt of a priority review voucher up to an aggregate maximum amount of $<ix:nonFraction unitRef="usd" contextRef="i7e34d9d90204473c8ea049d991956012_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="ptct:ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMTA5OTUxMTYzMzc5Mg_7aeac0a3-97ef-4bbd-9ef6-ebd0e4098592">535.0</ix:nonFraction>&#160;million, (iii)&#160;the achievement of certain net sales milestones up to an aggregate maximum amount of $<ix:nonFraction unitRef="usd" contextRef="ia20c4a3be1bf491aaf06ea4818f97179_I20200630" decimals="-5" format="ixt:numdotdecimal" name="ptct:ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMTA5OTUxMTYzMzgyOQ_f74f3069-65fb-4661-b2c8-6e84d15d0ad4">150.0</ix:nonFraction>&#160;million, and (iv)&#160;a percentage of annual net sales for&#160;Friedreich ataxia and Angelman syndrome during specified terms, ranging from <ix:nonFraction unitRef="number" contextRef="i2a92bf7bb7524f61a93f2c8959d0be71_I20200630" decimals="2" name="ptct:ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMTA5OTUxMTYzMzg2Mw_5ee326d4-7640-4abb-986a-1fffe9071dfa">2</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="ia20c4a3be1bf491aaf06ea4818f97179_I20200630" decimals="2" name="ptct:ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMTA5OTUxMTYzMzg2Nw_afda207b-be2b-4d46-9bf1-48088da03c35">6</ix:nonFraction>%. The Company was required to pay $<ix:nonFraction unitRef="usd" contextRef="if54601c17d0343ec8d9cd0af73df9a5b_I20200630" decimals="-5" format="ixt:numdotdecimal" name="ptct:DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMzU0MQ_3010c54d-b2f6-4970-b21e-8092660f1957">40.0</ix:nonFraction> million of the development milestone payments upon the passing of the second anniversary of the closing of the Merger, regardless of whether the applicable milestones have been achieved. </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Pursuant to the terms of the Rights Exchange Agreement, the Participating Rightholders have canceled and forfeited their rights under the Merger Agreement to receive (i) $<ix:nonFraction unitRef="usd" contextRef="i1b11444730184724a2297b26b10e055d_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="ptct:ContingentLiabilityCancellationAndForfeitureMilestonePotentialAchievementsPriorityReviewVoucherAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMTkyNDE0NTM1MTIxNjg_f64a271d-4118-430f-ae2f-d894d2aec365">174.0</ix:nonFraction>&#160;million, in the aggregate, of potential milestone payments based on the achievement of certain regulatory milestones and (ii) $<ix:nonFraction unitRef="usd" contextRef="i1b11444730184724a2297b26b10e055d_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="ptct:DevelopmentMilestonePaymentObligationsCancellationAndForfeiture" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMTkyNDE0NTM1MTIxODQ_4b942f20-6fd3-483c-820e-3f720fd06761">37.6</ix:nonFraction>&#160;million, in the aggregate, of $<ix:nonFraction unitRef="usd" contextRef="if54601c17d0343ec8d9cd0af73df9a5b_I20200630" decimals="-5" format="ixt:numdotdecimal" name="ptct:DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMTkyNDE0NTM1MTIxOTk_d4ed802c-383b-4815-8add-a6ee614a3afd">40.0</ix:nonFraction>&#160;million in development milestone payments that would have been due upon the passing of the second anniversary of the closing of the Merger, regardless of whether the milestones are achieved.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Rights Exchange Agreement has no effect on the Merger Agreement other than to provide for the cancellation and forfeiture of the Participating Rightholders&#8217; rights to receive $<ix:nonFraction unitRef="usd" contextRef="i38631b4cb53445c299e2d62fbae00216_D20200629-20200629" decimals="-5" format="ixt:numdotdecimal" name="ptct:ContingentLiabilityCancellationAndForfeiture" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMTkyNDE0NTM1MTIwODI_298e3f4f-5ad7-47e2-b854-d5eddd9c4bc2">211.6</ix:nonFraction>&#160;million, in the aggregate, of the milestone payments described above. As a result, all other rights and obligations under the Merger Agreement remain in effect pursuant to their terms, including the Company&#8217;s obligation to pay up to an aggregate maximum amount of $<ix:nonFraction unitRef="usd" contextRef="i5ca2052e537349099f8500140b79c830_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="ptct:DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMTkyNDE0NTM1MTIwOTg_1a3414bb-6313-477a-a005-5ea6b38ad88a">22.4</ix:nonFraction>&#160;million upon the achievement of certain development milestones (representing the remaining portion of potential development milestone payments for which rights were not canceled and forfeited pursuant to the Rights Exchange Agreement after deducting the $<ix:nonFraction unitRef="usd" contextRef="i1b11444730184724a2297b26b10e055d_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="ptct:DevelopmentMilestonePaymentObligationsCancellationAndForfeiture" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMTkyNDE0NTM1MTIxMTM_53364a5a-5a58-4580-940f-ffb2f8e2ad44">37.6</ix:nonFraction>&#160;million for which rights were canceled and forfeited pursuant to the Rights Exchange Agreement from the $<ix:nonFraction unitRef="usd" contextRef="if54601c17d0343ec8d9cd0af73df9a5b_I20200630" decimals="-5" format="ixt:numdotdecimal" name="ptct:DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMTkyNDE0NTM1MTIyNTk_852c6770-a374-4fd0-94b4-ca54d3833eec">40.0</ix:nonFraction>&#160;million in development milestone payments that are due upon the passing of the second anniversary of the closing of the Acquisition), up to an aggregate maximum amount of $<ix:nonFraction unitRef="usd" contextRef="i04fa4a18d65a48a9a4f7a021a18243d8_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="ptct:ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMTkyNDE0NTM1MTIxMjg_0b27f2ec-ed1d-4818-ae7d-97714523d115">361.0</ix:nonFraction>&#160;million upon the achievement of certain regulatory milestones (representing the remaining portion of potential regulatory milestone payments for which rights were not canceled and forfeited pursuant to the Rights Exchange Agreement), up to a maximum aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="ia20c4a3be1bf491aaf06ea4818f97179_I20200630" decimals="-5" format="ixt:numdotdecimal" name="ptct:ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMTkyNDE0NTM1MTIxNDQ_d3e62c6b-e856-49f1-b852-41c573b3a10a">150.0</ix:nonFraction>&#160;million upon the achievement of certain net sales milestones and a percentage of annual net sales for Friedreich ataxia and Angelman syndrome during specified terms, ranging from <ix:nonFraction unitRef="number" contextRef="i2a92bf7bb7524f61a93f2c8959d0be71_I20200630" decimals="2" name="ptct:ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMTkyNDE0NTM1MTIxNjA_e588ed32-38e1-4c55-8325-39a2f4c88882">2</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ia20c4a3be1bf491aaf06ea4818f97179_I20200630" decimals="2" name="ptct:ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMTkyNDE0NTM1MTIxNjQ_f0c081c1-2f64-4bf8-b7cd-5d42aa9cff2e">6</ix:nonFraction>%, pursuant to the terms of the Merger Agreement.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Subject to the terms and conditions of the Asset Acquisition Agreement, BioElectron may become entitled to receive contingent milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="i4fd11bc6a99940fd88c85b0f84932bf6_I20200630" decimals="-5" format="ixt:numdotdecimal" name="ptct:DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMzg3OA_5945d385-2473-4573-abff-42b427415039">200.0</ix:nonFraction> million (in cash or in shares of the Company&#8217;s common stock, as determined by the Company) from the Company based on the achievement of certain regulatory and net sales milestones.  Subject to the terms and conditions of the Asset Acquisition Agreement, BioElectron may also become entitled to receive contingent payments based on a percentage of net sales of certain products.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">Subject to the terms and conditions of the Censa Merger Agreement, Censa securityholders may become entitled to receive contingent payments from the Company based on (i) the achievement of certain development and regulatory milestones up to an aggregate maximum amount of $<ix:nonFraction unitRef="usd" contextRef="id1c12a4aacaf45c6b83d421f91bcc1a3_I20200529" decimals="-5" format="ixt:numdotdecimal" name="ptct:AssetAcquisitionMilestoneAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMTkyNDE0NTM1MTIyMTQ_ab622ee7-bd46-43f9-8be2-e11cee3e2a1d">217.5</ix:nonFraction>&#160;million for PTC923's two most advanced programs and receipt of a priority review voucher from the FDA as set forth in the Censa Merger Agreement, (ii) $<ix:nonFraction unitRef="usd" contextRef="i28fa54ad024443b18973875cc89f36e3_I20200529" decimals="-5" format="ixt:numdotdecimal" name="ptct:AssetAcquisitionDevelopmentAndRegulatoryMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMTkyNDE0NTM1MTIyMzA_69e3f7b1-7bbc-4742-97eb-0007ec334c2c">109</ix:nonFraction>&#160;million in development and regulatory milestones for each additional indication of PTC923, (iii) the achievement of certain net sales milestones up to an aggregate maximum amount of $<ix:nonFraction unitRef="usd" contextRef="i28fa54ad024443b18973875cc89f36e3_I20200529" decimals="-5" format="ixt:numdotdecimal" name="ptct:AssetAcquisitionNetSalesMilestone" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMTkyNDE0NTM1MTIyNzQ_a83b54e5-b58a-498f-895e-b59882b26564">160.0</ix:nonFraction>&#160;million, (iv) a percentage of annual net sales during specified terms, ranging from single to low double digits of the applicable net sales threshold amount, and (v) any sublicense fees paid to the Company in consideration of any sublicense of Censa&#8217;s intellectual property to commercialize PTC923, on a country-by-country basis, which contingent payment shall equal to a mid-double digit percentage of any such sublicense fees. Pursuant to the Censa Merger Agreement, the Company has the option to pay the initial $<ix:nonFraction unitRef="usd" contextRef="i28fa54ad024443b18973875cc89f36e3_I20200529" decimals="-5" format="ixt:numdotdecimal" name="ptct:AssetAcquisitionInitialMilestone" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMTkyNDE0NTM1MTIyNDQ_f2570a01-f7e1-47ba-83a0-4fb5d46b593b">30.0</ix:nonFraction>&#160;million development milestone, for the completion of enrollment of a Phase 3 clinical trial for PTC923 for PKU, if achieved, in cash or shares of the Company&#8217;s common stock.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company also has a Collaboration and License Agreement with Akcea for the commercialization of Tegsedi and Waylivra, and products containing those compounds in countries in Latin America and the Caribbean (the "Akcea Collaboration and License Agreement").  Pursuant to the agreement, the Company paid Akcea an upfront licensing fee, which included an initial payment of $<ix:nonFraction unitRef="usd" contextRef="i652c4548495c438db5c41a0492a229a2_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="ptct:UpfrontLicensingFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfNDY1NA_03805483-76b4-4e04-8fef-043d79606ca7">12.0</ix:nonFraction> million. In 2019, a $<ix:nonFraction unitRef="usd" contextRef="i0753aa5ed002421a95716b8d6332e418_I20190930" decimals="-5" format="ixt:numdotdecimal" name="ptct:MilestonePotentialAchievementsRegulatoryApproval" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfNDY2OQ_c64a1f1e-40b9-4b89-9483-9e8fb4677bf9">6.0</ix:nonFraction> million milestone was paid upon receipt of regulatory approval of Waylivra from the EMA and a $<ix:nonFraction unitRef="usd" contextRef="ia033e797f8104feca5e0e2c9aef70ffb_I20191231" decimals="-5" format="ixt:numdotdecimal" name="ptct:MilestonePotentialAchievementsRegulatoryApproval" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfNDc1OA_d97e10b4-f4de-4598-acbc-6b53ce5adbbf">4.0</ix:nonFraction> million milestone was paid upon regulatory approval of Tegsedi from ANVISA, the Brazilian health regulatory authority, upon receipt of regulatory approval for Waylivra from ANVISA. In addition, Akcea is eligible to receive an additional milestone payment of $<ix:nonFraction unitRef="usd" contextRef="ia033e797f8104feca5e0e2c9aef70ffb_I20191231" decimals="-5" format="ixt:numdotdecimal" name="ptct:MilestonePotentialAchievementsRegulatoryApproval" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfNTAxMQ_d97e10b4-f4de-4598-acbc-6b53ce5adbbf">4.0</ix:nonFraction> million upon receipt of regulatory approval for Waylivra from ANVISA. Akcea is also entitled to receive royalty payments subject to certain terms set forth in the Akcea Collaboration and License Agreement.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has employment agreements with certain employees which require the funding of a specific level of payments, if certain events, such as a change in control or termination without cause, occur. Additionally, the Company has royalty payments associated with Translarna and Emflaza product net sales, payable quarterly or annually in accordance with the terms of the related agreements. </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i2117cbea77494a7ca90143041fdeb534">From time to time in the ordinary course of its business, the Company is subject to claims, legal proceedings and disputes, including as a result of patients seeking to participate in the Company's clinical trials or otherwise gain access to its product candidates. The Company is not currently aware of any material legal proceedings against it.</ix:continuation></span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span><br/></span></div><div id="i95cf61a5c7074910ae3cf29c5ee08838_85"></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">13.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:700;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMTkyNDE0NTM0OTQ5NTk_bfd48147-495f-43f7-bada-efcbbf0acf46" continuedAt="i595e79fa0451428db31dab583a46617b" escape="true">Revenue recognition</ix:nonNumeric></span></div><ix:continuation id="i595e79fa0451428db31dab583a46617b" continuedAt="idb89a8134c7d479bac696d06242ebea4"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Net product sales</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company views its operations and manages its business in <ix:nonFraction unitRef="segment" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMTA4_a1a81c25-11f1-4449-a978-c7cde9ca9f0d">one</ix:nonFraction> operating segment.  </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended June 30, 2020 and 2019, net product sales in the United States were $<ix:nonFraction unitRef="usd" contextRef="i9fcd6ae0b0b244eb992a22b9f010a8a9_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="ptct:NetProductSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMTk2_af08c740-5c75-4849-b710-027bbf9ae6aa">36.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0cac55e0c942455e8be47df4a5540bf5_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="ptct:NetProductSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMjAz_95510f06-07a4-4c13-a7c2-0f567fc3ba17">27.6</ix:nonFraction> million, respectively, consisting solely of Emflaza, and net product sales not in the United States were $<ix:nonFraction unitRef="usd" contextRef="ib5e09658503d4a019b7c66616efd1b4d_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="ptct:NetProductSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMzAz_472e88fb-4d6e-4d7b-b5bf-d1b32d6d0959">39.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i70f85cc7508547529a1ddd69bf58968d_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="ptct:NetProductSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMzEx_866acd3e-e209-4752-b956-71dcafbaf816">57.8</ix:nonFraction> million, respectively, consisting of Translarna and Tegsedi. For the three months ended June 30, 2020 and 2019, the Company had a total of <ix:nonFraction unitRef="number_distributor" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="INF" format="ixt-sec:numwordsen" name="ptct:Numberofdistributors" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfNDM5ODA0NjUyMDE3Ng_81741bec-2a94-49ac-b009-d9f778295217">two</ix:nonFraction> and <ix:nonFraction unitRef="number_distributor" contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630" decimals="INF" format="ixt-sec:numwordsen" name="ptct:Numberofdistributors" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfNDM5ODA0NjUyMDE4NA_32f9c631-bd5c-41b1-b19a-ed9ee7450b52">two</ix:nonFraction> distributors, respectively, that each accounted for over <ix:nonFraction unitRef="number" contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630" decimals="2" name="ptct:Percentageofnetproductsales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMTA0NDUzNjA0NzA4MDA_2f16e88c-9b37-4e24-ac7b-bc76068b8c31"><ix:nonFraction unitRef="number" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="2" name="ptct:Percentageofnetproductsales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMTA0NDUzNjA0NzA4MDA_7f9bd06d-85a9-45e3-a653-5cb9aa4fe20d">10</ix:nonFraction></ix:nonFraction>% of the Company's net product sales.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the six months ended June 30, 2020 and 2019, net product sales in the United States were $<ix:nonFraction unitRef="usd" contextRef="i245f190c344b472682efecbcf65a617f_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="ptct:NetProductSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMTA0NDUzNjA0Njc3MDk_9effde0e-f268-4720-8a85-eb6c2c0b3be9">63.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i084808ce47024c3e9355cdfb5214b4ee_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="ptct:NetProductSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMTA0NDUzNjA0Njc3MTY_dfd4e89f-6713-4367-8eb4-9874f72feeb5">45.4</ix:nonFraction> million, respectively, consisting solely of Emflaza, and net product sales not in the United States were $<ix:nonFraction unitRef="usd" contextRef="i8b2299918005400d83e8169cdceaa098_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="ptct:NetProductSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMTA0NDUzNjA0Njc4MjA_bbf8eb57-17c9-4b0a-b53e-0d65aa69baa0">79.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if04847b5828f40ffb96ff09abbfbe7f0_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="ptct:NetProductSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMTA0NDUzNjA0Njc4Mjc_1dd9044a-026b-4879-b477-be23aa250530">93.0</ix:nonFraction> million, respectively, consisting of Translarna and Tegsedi. For the six months ended June 30, 2020 and 2019, the Company had a total of <ix:nonFraction unitRef="number_distributor" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="ptct:Numberofdistributors" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfNDM5ODA0NjUyMDIwMw_d0cf6d5f-ba6b-4707-8bfc-199ce8aacbfd">two</ix:nonFraction> and <ix:nonFraction unitRef="number_distributor" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="INF" format="ixt-sec:numwordsen" name="ptct:Numberofdistributors" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfNDM5ODA0NjUyMDIwNg_733256ba-bf74-4ab0-bae6-9bdbccd18d7e">two</ix:nonFraction> distributors, respectively, that each accounted for over <ix:nonFraction unitRef="number" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="2" name="ptct:Percentageofnetproductsales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMTA0NDUzNjA0NzI5ODk_143253c6-ab44-4668-ba5a-92d86fec6291"><ix:nonFraction unitRef="number" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="2" name="ptct:Percentageofnetproductsales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMTA0NDUzNjA0NzI5ODk_ced704e5-f65d-49f5-9072-abbdd9957254">10</ix:nonFraction></ix:nonFraction>% of the Company's net product sales.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s contract liabilities balances as of June&#160;30, 2020 and as of December 31, 2019 were $<ix:nonFraction unitRef="usd" contextRef="ifed0db43ebe049f185e04d30bd4e1b71_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfNjcw_d5c384a8-ed79-4ca1-b856-241d60fa7eb4">7.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia96d9cae808a4c3784211e0141d85ae1_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfNjc3_4963a7af-0a1e-471c-a0c6-d8043680b0d5">11.7</ix:nonFraction> million, respectively. The Company did not have any contract assets as of June&#160;30, 2020 and as of December 31, 2019. During the three and six month periods ended June&#160;30, 2020, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfODE3_01890b70-7daf-4e8c-b9b7-0f719b26ecec">2.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMTA0NDUzNjA0Njg2NzY_457c7eaf-7707-42d8-b1f1-293277425d4c">4.0</ix:nonFraction> million of revenue, respectively, related to the amounts included in the contract liability balance at the beginning of the period. For the three and six month periods ended June&#160;30, 2019, the Company did not recognize any revenues relating to the contract liability balance at the beginning of the period. The Company has not made significant changes to the judgments made in applying ASC Topic 606 for the three and six month periods ending June&#160;30, 2020 and 2019.  </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Remaining performance obligations</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Remaining performance obligations&#160;represent the transaction price for goods the Company has yet to provide. As of June&#160;30, 2020 and December 31, 2019, the aggregate amount of the transaction price allocated to&#160;the remaining performance obligations&#160;relating to Translarna net product revenue was $<ix:nonFraction unitRef="usd" contextRef="ifed0db43ebe049f185e04d30bd4e1b71_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMTA0NDUzNjA0Njg5MTM_afc4a521-b74c-4b56-9fc1-d5348fb119c3">7.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia96d9cae808a4c3784211e0141d85ae1_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMTA0NDUzNjA0Njg5MTY_45fa3fa1-2f77-4bad-817c-b74afbd85710">11.7</ix:nonFraction> million, respectively.  The Company expects to recognize revenue within the next <ix:nonNumeric contextRef="ifed0db43ebe049f185e04d30bd4e1b71_I20200630" format="ixt-sec:durwordsen" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfNDM5ODA0NjUyMDE2MA_0e5cee40-52fa-43b1-a5a9-6fd3c79a27b8"><ix:nonNumeric contextRef="ia96d9cae808a4c3784211e0141d85ae1_I20191231" format="ixt-sec:durwordsen" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfNDM5ODA0NjUyMDE2MA_e232d02b-ec5f-4e73-a628-fc77b9155464">one year</ix:nonNumeric></ix:nonNumeric>, as the specific timing for satisfying the performance obligations is contingent upon a number of factors, including customers&#8217; needs and schedules.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Collaboration revenue</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2011, the Company and the Spinal Muscular Atrophy Foundation (SMA Foundation) entered into a licensing and collaboration agreement with F. Hoffman-La Roche&#160;Ltd and Hoffman- La Roche&#160;Inc. (collectively, Roche) for a spinal muscular atrophy program. Under the terms of the agreement, Roche acquired an exclusive worldwide license to the Company&#8217;s spinal muscular atrophy program.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is eligible to receive additional payments from Roche if specified events are achieved with respect to each licensed product, including up to $<ix:nonFraction unitRef="usd" contextRef="id60b94195bb147c181fa7ec372ed8691_D20111101-20111130" decimals="-5" format="ixt:numdotdecimal" name="ptct:RevenueRecognitionMilestonePotentialAchievements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMjI5OQ_b5d2797c-22d9-49a6-be97-f5c192d9a979">135.0</ix:nonFraction> million in research and development event milestones, up to $<ix:nonFraction unitRef="usd" contextRef="i8b34ee3e697448668a9c788ce80598fb_D20111101-20111130" decimals="-5" format="ixt:numdotdecimal" name="ptct:RevenueRecognitionMilestonePotentialAchievements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMjM1NA_b3e7211b-966e-4134-8c0f-1646572d0124">325.0</ix:nonFraction> million in sales milestones upon achievement of specified sales events, and up to double digit royalties on worldwide annual net sales of a commercial product.  As of June&#160;30, 2020, the remaining potential research and development event milestones that can be received is $<ix:nonFraction unitRef="usd" contextRef="ib692f789ea234d29951422720218faa2_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="ptct:RevenueRecognitionMilestonePotentialAchievements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMjYxMA_74f531b0-c3c7-4cc9-8af0-f22f6b4aaf6a">72.5</ix:nonFraction> million. The remaining potential sales milestones as of June&#160;30, 2020 is $<ix:nonFraction unitRef="usd" contextRef="i2835b8eed94641e2ab9c3c4491078285_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="ptct:RevenueRecognitionMilestonePotentialAchievements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMjY2Nw_bef54e58-5f7c-4dbd-b5a3-bd559ec7b459">325.0</ix:nonFraction> million upon achievement of certain sales events. In addition, the Company is eligible to receive up to double digit royalties on worldwide annual net sales of a commercial product.</span></div></ix:continuation><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="idb89a8134c7d479bac696d06242ebea4">For the three months ended June&#160;30, 2020, the Company did <ix:nonFraction unitRef="usd" contextRef="ic5b76a0a42be443893da3eb686237ab7_D20200401-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMTkyNDE0NTM0OTQ5NjQ_48a7f7dc-c9b4-4680-930c-fb68f00acb91"><ix:nonFraction unitRef="usd" contextRef="ic5b76a0a42be443893da3eb686237ab7_D20200401-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMTkyNDE0NTM0OTQ5NjQ_5d452f7d-0a1f-4378-8821-620e061d0fe1">no</ix:nonFraction></ix:nonFraction>t recognize revenue related to the licensing and collaboration agreement with Roche. For the three months ended June 30, 2019, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i298b567a840a479b841a1c7cae6b2b42_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMTA0NDUzNjA0NzIwNzc_f2be9aac-0492-41f7-a68f-cf99926df88d">0.1</ix:nonFraction> million of revenue related to the licensing and collaboration agreement with Roche. For the six months ended June&#160;30, 2020 and 2019, the Company recognized revenue related to the licensing and collaboration agreement with Roche of $<ix:nonFraction unitRef="usd" contextRef="i21cc52aa842546b39066bbc6d2f4ec24_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMTA0NDUzNjA0NzIzMDU_3867a72e-65c6-43fc-9f29-7e865a50a95f">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id33464a3934340609397e4ae7f1b281c_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMTA0NDUzNjA0NzIzMTI_21bef64b-11a6-444a-88d7-a2845398d043">0.1</ix:nonFraction> million, respectively.</ix:continuation>  </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span><br/></span></div><div id="i95cf61a5c7074910ae3cf29c5ee08838_91"></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">14.&#160;<ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85MS9mcmFnOjI4ODkzNzRmNzNiNTQ5OTc5MGI2YWVlNmI5MDc3YTJjL3RleHRyZWdpb246Mjg4OTM3NGY3M2I1NDk5NzkwYjZhZWU2YjkwNzdhMmNfNDY3MA_ace62aa6-9a74-4438-85da-3e02c8da27cc" continuedAt="i4cddbea746ca4f9a84d7d4afe927d510" escape="true">Intangible assets and goodwill</ix:nonNumeric></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i4cddbea746ca4f9a84d7d4afe927d510" continuedAt="ie9116ec8cc2c4ceeafacb4d2de00663b"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Definite-lived intangibles</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 20, 2017, the Company completed its previously announced acquisition of all rights to Emflaza pursuant to the Asset Purchase Agreement, dated March 15, 2017, and amended on April 20, 2017, by and between the Company and Marathon. The assets acquired by the Company in the transaction include intellectual property rights related to Emflaza, inventories of Emflaza, and certain contractual rights related to Emflaza. In accordance with ASU 2017-01, the Company determined that substantially all of the fair value is concentrated in the Emflaza rights intangible asset and as such accounted for the transaction as an asset acquisition under ASC 805-50 and recorded an intangible asset of $<ix:nonFraction unitRef="usd" contextRef="ib46a34ef31754b4badaaae6fccf85a47_I20170420" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85MS9mcmFnOjI4ODkzNzRmNzNiNTQ5OTc5MGI2YWVlNmI5MDc3YTJjL3RleHRyZWdpb246Mjg4OTM3NGY3M2I1NDk5NzkwYjZhZWU2YjkwNzdhMmNfNzYy_0614d237-7cfc-4969-9fc3-48a789a7fbad">148.4</ix:nonFraction> million, which is being amortized to cost of product sales over its expected useful life of approximately <ix:nonNumeric contextRef="i667dbebd49c148f3993ce8cc26b0f8f3_D20200101-20200331" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85MS9mcmFnOjI4ODkzNzRmNzNiNTQ5OTc5MGI2YWVlNmI5MDc3YTJjL3RleHRyZWdpb246Mjg4OTM3NGY3M2I1NDk5NzkwYjZhZWU2YjkwNzdhMmNfODYz_cfeef9fd-460b-4bea-82a3-e7161685298e">seven years</ix:nonNumeric> on a straight line basis.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Marathon is entitled to receive contingent payments from the Company based on annual net sales of Emflaza beginning in 2018, up to a specified aggregate maximum amount over the expected commercial life of the asset. In accordance with the guidance for an asset acquisition, the Company records the milestone payment when it becomes payable to Marathon and increases the cost basis for the Emflaza rights intangible asset. As of June&#160;30, 2020 and 2019, milestone payments of $<ix:nonFraction unitRef="usd" contextRef="i6d48ddbb90814f6daa9feea1cb72ad27_I20200630" decimals="-5" format="ixt:numdotdecimal" name="ptct:MilestonePotentialAchievementsRegulatoryApproval" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85MS9mcmFnOjI4ODkzNzRmNzNiNTQ5OTc5MGI2YWVlNmI5MDc3YTJjL3RleHRyZWdpb246Mjg4OTM3NGY3M2I1NDk5NzkwYjZhZWU2YjkwNzdhMmNfMTM3Nw_d3cb415a-85c7-42ee-a540-2922cba8792a">12.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i07ceae4bafba47cea561662c5f6b04a2_I20190630" decimals="-5" format="ixt:numdotdecimal" name="ptct:MilestonePotentialAchievementsRegulatoryApproval" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85MS9mcmFnOjI4ODkzNzRmNzNiNTQ5OTc5MGI2YWVlNmI5MDc3YTJjL3RleHRyZWdpb246Mjg4OTM3NGY3M2I1NDk5NzkwYjZhZWU2YjkwNzdhMmNfMTA0NDUzNjA0Njg4MTU_e9e8abbf-7abb-45a6-a5fd-39a14539f2be">8.3</ix:nonFraction> million, respectively, were recorded and are included on the balance sheet within accounts payable and accrued expenses. These payments are being amortized over the remaining useful life of the Emflaza rights asset on a straight line basis.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the Akcea Collaboration and License Agreement, in May 2019 the Company made a $<ix:nonFraction unitRef="usd" contextRef="i0753aa5ed002421a95716b8d6332e418_I20190930" decimals="-5" format="ixt:numdotdecimal" name="ptct:MilestonePotentialAchievementsRegulatoryApproval" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85MS9mcmFnOjI4ODkzNzRmNzNiNTQ5OTc5MGI2YWVlNmI5MDc3YTJjL3RleHRyZWdpb246Mjg4OTM3NGY3M2I1NDk5NzkwYjZhZWU2YjkwNzdhMmNfMTczMw_c64a1f1e-40b9-4b89-9483-9e8fb4677bf9">6.0</ix:nonFraction> million milestone payment to Akcea upon regulatory approval of Waylivra from the EMA. The payment was recorded as an intangible asset and is being amortized to cost of product sales over its expected useful life of approximately <ix:nonNumeric contextRef="i4ef2c3542e8941dea35d5efd0bdc7a5c_D20200101-20200630" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85MS9mcmFnOjI4ODkzNzRmNzNiNTQ5OTc5MGI2YWVlNmI5MDc3YTJjL3RleHRyZWdpb246Mjg4OTM3NGY3M2I1NDk5NzkwYjZhZWU2YjkwNzdhMmNfMTk1Nw_6f66a841-b072-4fa5-83c3-a4cee59f5aad">ten years</ix:nonNumeric> on a straight line basis. Additionally, in December 2019, the Company made a $<ix:nonFraction unitRef="usd" contextRef="i61a6fc1556ef4b3fa72296db809eb593_I20200630" decimals="-5" format="ixt:numdotdecimal" name="ptct:MilestonePotentialAchievementsRegulatoryApproval" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85MS9mcmFnOjI4ODkzNzRmNzNiNTQ5OTc5MGI2YWVlNmI5MDc3YTJjL3RleHRyZWdpb246Mjg4OTM3NGY3M2I1NDk5NzkwYjZhZWU2YjkwNzdhMmNfMjAzNw_a07a1dea-23dd-4261-b327-c843d6fe30de">4.0</ix:nonFraction> million milestone payment to Akcea upon regulatory approval of Tegsedi from ANVISA. The payment was recorded as an intangible asset and is being amortized to cost of product sales over its expected useful life of approximately <ix:nonNumeric contextRef="i4ef2c3542e8941dea35d5efd0bdc7a5c_D20200101-20200630" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85MS9mcmFnOjI4ODkzNzRmNzNiNTQ5OTc5MGI2YWVlNmI5MDc3YTJjL3RleHRyZWdpb246Mjg4OTM3NGY3M2I1NDk5NzkwYjZhZWU2YjkwNzdhMmNfMjI1OQ_854b5d69-a5f7-4361-9fa9-328355965214">ten years</ix:nonNumeric> on a straight line basis.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Akcea is also entitled to receive royalty payments subject to certain terms set forth in the Akcea Collaboration and License Agreement related to sales of Waylivra. In accordance with the guidance for an asset acquisition, the Company will record royalty payments when they become payable to Akcea and increase the cost basis for the Waylivra intangible asset. </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three months ended June 30, 2020 and 2019, the Company recognized amortization expense of $<ix:nonFraction unitRef="usd" contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85MS9mcmFnOjI4ODkzNzRmNzNiNTQ5OTc5MGI2YWVlNmI5MDc3YTJjL3RleHRyZWdpb246Mjg4OTM3NGY3M2I1NDk5NzkwYjZhZWU2YjkwNzdhMmNfMjc0Mg_f5e994ad-b9ca-4e29-bf74-c5f9a2ab57da">8.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85MS9mcmFnOjI4ODkzNzRmNzNiNTQ5OTc5MGI2YWVlNmI5MDc3YTJjL3RleHRyZWdpb246Mjg4OTM3NGY3M2I1NDk5NzkwYjZhZWU2YjkwNzdhMmNfMjc1MA_5865cf7a-7a38-44cc-8ac1-0b6585ab3034">6.6</ix:nonFraction> million, respectively, related to the Emflaza rights, Waylivra, and Tegsedi intangible assets. For the six months ended June 30, 2020 and 2019, the Company recognized amortization expense of $<ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85MS9mcmFnOjI4ODkzNzRmNzNiNTQ5OTc5MGI2YWVlNmI5MDc3YTJjL3RleHRyZWdpb246Mjg4OTM3NGY3M2I1NDk5NzkwYjZhZWU2YjkwNzdhMmNfMTA0NDUzNjA0NjkxMzI_b916467c-84d9-4e2b-90d6-76f90212a436">16.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85MS9mcmFnOjI4ODkzNzRmNzNiNTQ5OTc5MGI2YWVlNmI5MDc3YTJjL3RleHRyZWdpb246Mjg4OTM3NGY3M2I1NDk5NzkwYjZhZWU2YjkwNzdhMmNfMTA0NDUzNjA0NjkxMzk_ab104a4c-b6f5-4e37-9dea-0d6b60c1f921">12.7</ix:nonFraction> million, respectively. The estimated future amortization of the Emflaza rights, Waylivra, and Tegsedi intangible assets is expected to be as follows:</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:6pt;"><ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85MS9mcmFnOjI4ODkzNzRmNzNiNTQ5OTc5MGI2YWVlNmI5MDc3YTJjL3RleHRyZWdpb246Mjg4OTM3NGY3M2I1NDk5NzkwYjZhZWU2YjkwNzdhMmNfNDY2Ng_8db7dd6a-4d41-416e-9ab6-08c438000614" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%;"><tr><td style="width:1.0%;"></td><td style="width:77.675%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.589%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of June 30, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85MS9mcmFnOjI4ODkzNzRmNzNiNTQ5OTc5MGI2YWVlNmI5MDc3YTJjL3RhYmxlOjkwZTVmNDg4OTJiZjRjNGE4ZjVkYTM5OTJiYjIyMWNiL3RhYmxlcmFuZ2U6OTBlNWY0ODg5MmJmNGM0YThmNWRhMzk5MmJiMjIxY2JfMS0yLTEtMS0w_3cb3b30f-824a-4ee4-8363-f8c2efd1fbe1">17,460</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85MS9mcmFnOjI4ODkzNzRmNzNiNTQ5OTc5MGI2YWVlNmI5MDc3YTJjL3RhYmxlOjkwZTVmNDg4OTJiZjRjNGE4ZjVkYTM5OTJiYjIyMWNiL3RhYmxlcmFuZ2U6OTBlNWY0ODg5MmJmNGM0YThmNWRhMzk5MmJiMjIxY2JfMi0yLTEtMS0w_73ac0c62-86fe-4298-bd0e-cf26c9cf14d5">34,920</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85MS9mcmFnOjI4ODkzNzRmNzNiNTQ5OTc5MGI2YWVlNmI5MDc3YTJjL3RhYmxlOjkwZTVmNDg4OTJiZjRjNGE4ZjVkYTM5OTJiYjIyMWNiL3RhYmxlcmFuZ2U6OTBlNWY0ODg5MmJmNGM0YThmNWRhMzk5MmJiMjIxY2JfMy0yLTEtMS0w_db91b32c-20b7-46ec-bef9-a452f641811c">34,920</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85MS9mcmFnOjI4ODkzNzRmNzNiNTQ5OTc5MGI2YWVlNmI5MDc3YTJjL3RhYmxlOjkwZTVmNDg4OTJiZjRjNGE4ZjVkYTM5OTJiYjIyMWNiL3RhYmxlcmFuZ2U6OTBlNWY0ODg5MmJmNGM0YThmNWRhMzk5MmJiMjIxY2JfNC0yLTEtMS0w_37fcbd76-9a76-4cad-998f-f6801c24633d">34,920</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="ptct:FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85MS9mcmFnOjI4ODkzNzRmNzNiNTQ5OTc5MGI2YWVlNmI5MDc3YTJjL3RhYmxlOjkwZTVmNDg4OTJiZjRjNGE4ZjVkYTM5OTJiYjIyMWNiL3RhYmxlcmFuZ2U6OTBlNWY0ODg5MmJmNGM0YThmNWRhMzk5MmJiMjIxY2JfNS0yLTEtMS0w_7059a9ec-4d74-4254-ba14-cc6211699623">10,094</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85MS9mcmFnOjI4ODkzNzRmNzNiNTQ5OTc5MGI2YWVlNmI5MDc3YTJjL3RhYmxlOjkwZTVmNDg4OTJiZjRjNGE4ZjVkYTM5OTJiYjIyMWNiL3RhYmxlcmFuZ2U6OTBlNWY0ODg5MmJmNGM0YThmNWRhMzk5MmJiMjIxY2JfNi0yLTEtMS0w_4ad3e4c4-fe90-4714-aa4d-29d8a1d44c9b">132,314</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:nonNumeric></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The weighted average remaining amortization period of the definite-lived intangibles as of June&#160;30, 2020 is <ix:nonNumeric contextRef="i20afcd7c10c14ac495fc02e16fe69b2d_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85MS9mcmFnOjI4ODkzNzRmNzNiNTQ5OTc5MGI2YWVlNmI5MDc3YTJjL3RleHRyZWdpb246Mjg4OTM3NGY3M2I1NDk5NzkwYjZhZWU2YjkwNzdhMmNfMzA2Ng_b35c81ac-5e25-47eb-9852-6e1134b4d78c">4.0</ix:nonNumeric> years.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Indefinite-lived intangibles</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the acquisition of the Company&#8217;s gene therapy platform from Agilis, the Company acquired rights to PTC-AADC, for the treatment of AADC deficiency. AADC deficiency is a rare CNS disorder arising from reductions in the enzyme AADC that result from mutations in the dopa decarboxylase gene. The gene therapy platform also includes an asset targeting Friedreich ataxia, a rare and life-shortening neurodegenerative disease caused by a single defect in the FXN gene which causes reduced production of the frataxin protein. Additionally, the gene therapy platform includes two other programs targeting CNS disorders, including Angelman syndrome, a rare, genetic, neurological disorder characterized by severe developmental delays.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In accordance with the acquisition method of accounting, the Company allocated the acquisition cost for the Merger to the underlying assets acquired and liabilities assumed, based upon the estimated fair values of those assets and liabilities at the date of acquisition.  The Company classified the fair value of the acquired IPR&amp;D as indefinite lived intangible assets until the successful completion or abandonment of the associated research and development efforts.&#160;The value allocated to the indefinite lived intangible assets was $<ix:nonFraction unitRef="usd" contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IndefinitelivedIntangibleAssetsAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85MS9mcmFnOjI4ODkzNzRmNzNiNTQ5OTc5MGI2YWVlNmI5MDc3YTJjL3RleHRyZWdpb246Mjg4OTM3NGY3M2I1NDk5NzkwYjZhZWU2YjkwNzdhMmNfNDM4NQ_b0e6936e-1c61-4f89-b281-40ce3f4a6627">576.5</ix:nonFraction> million. There have been no changes to the balance of the indefinite-lived intangibles since the Merger.</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="ie9116ec8cc2c4ceeafacb4d2de00663b"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Goodwill</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a result of the Merger on August 23, 2018, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85MS9mcmFnOjI4ODkzNzRmNzNiNTQ5OTc5MGI2YWVlNmI5MDc3YTJjL3RleHRyZWdpb246Mjg4OTM3NGY3M2I1NDk5NzkwYjZhZWU2YjkwNzdhMmNfNDU2MQ_22d9704f-76b8-4d10-8928-add32fcdc85e">82.3</ix:nonFraction> million of goodwill. There were no changes to the recorded value of goodwill for the three and six month periods ended June&#160;30, 2020.</span></div></ix:continuation><div id="i95cf61a5c7074910ae3cf29c5ee08838_97"></div><div style="margin-top:8pt;margin-bottom:8pt;"><span><br/></span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">15.&#160;<ix:nonNumeric contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85Ny9mcmFnOjI5YTI2MzdjOWZmMjQ1MDE5ZjZjZDMzZjkwNDQ3ZTgyL3RleHRyZWdpb246MjlhMjYzN2M5ZmYyNDUwMTlmNmNkMzNmOTA0NDdlODJfMzI0OA_bf0928cd-9d62-4075-8374-baee4ee0fb98" continuedAt="i317f9cd9db964c7d883da5ca4a9f3a79" escape="true">Subsequent events</ix:nonNumeric></span></div><ix:continuation id="i317f9cd9db964c7d883da5ca4a9f3a79"><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">MidCap Credit Facility Termination</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On July 1, 2020, the Company terminated the Credit Facility. In connection with the termination of the Credit Facility, the Company repaid outstanding principal and accrued interest thereunder totaling $<ix:nonFraction unitRef="usd" contextRef="i0b0512f2780f4b8eb0826df908c1fcb3_D20200701-20200701" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85Ny9mcmFnOjI5YTI2MzdjOWZmMjQ1MDE5ZjZjZDMzZjkwNDQ3ZTgyL3RleHRyZWdpb246MjlhMjYzN2M5ZmYyNDUwMTlmNmNkMzNmOTA0NDdlODJfMTkyNDE0NTM1MTQ0MzE_0ec35555-1ee0-49c7-b8d0-7bfa555f95dd">18.4</ix:nonFraction>&#160;million and paid an additional $<ix:nonFraction unitRef="usd" contextRef="i0b0512f2780f4b8eb0826df908c1fcb3_D20200701-20200701" decimals="-5" format="ixt:numdotdecimal" name="ptct:LineOfCreditFacilityTerminationAndExitFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85Ny9mcmFnOjI5YTI2MzdjOWZmMjQ1MDE5ZjZjZDMzZjkwNDQ3ZTgyL3RleHRyZWdpb246MjlhMjYzN2M5ZmYyNDUwMTlmNmNkMzNmOTA0NDdlODJfMTkyNDE0NTM1MTQ0NDY_697edba4-4939-4a3d-8559-cfa35b82f927">0.6</ix:nonFraction>&#160;million in termination and exit fees. All liens and security interests securing the term loan made pursuant to the Credit Facility were released upon termination.</span></div></ix:continuation><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Monetization of a Portion of Risdiplam Royalty Stream</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On July 17, 2020, the Company, RPI 2019 Intermediate Finance Trust (&#8220;RPI&#8221;), and, for the limited purposes set forth in the agreement, Royalty Pharma PLC, entered into a Royalty Purchase Agreement (the &#8220;Royalty Purchase Agreement&#8221;).</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the Royalty Purchase Agreement, the Company sold to RPI <ix:nonFraction unitRef="number" contextRef="ia95450bc6d4d4073acbfc602735fef93_I20200717" decimals="5" name="ptct:AssignedRoyaltyPaymentPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85Ny9mcmFnOjI5YTI2MzdjOWZmMjQ1MDE5ZjZjZDMzZjkwNDQ3ZTgyL3RleHRyZWdpb246MjlhMjYzN2M5ZmYyNDUwMTlmNmNkMzNmOTA0NDdlODJfMTkyNDE0NTM1MTQ0NjA_92fd1ca6-c46a-43f7-ad07-bdee7d44205f">42.933</ix:nonFraction>% (the &#8220;Assigned Royalty Payment&#8221;) of the Company&#8217;s right to receive sales-based royalty payments (the &#8220;Royalty&#8221;) on worldwide net sales of Roche&#8217;s risdiplam product and any other product (the &#8220;Products&#8221;) developed pursuant to the License and Collaboration Agreement (the &#8220;License Agreement&#8221;), dated as of November 23, 2011, by and among the Company, F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc. (together with F. Hoffman-La Roche Ltd, &#8220;Roche&#8221;), and, for the limited purposes set forth therein, the SMA Foundation under the SMA program. In consideration for the sale of the Assigned Royalty Payments, RPI paid the Company $<ix:nonFraction unitRef="usd" contextRef="i574baa6db99049d2ba9e1203ea243658_D20200717-20200717" decimals="-5" format="ixt:numdotdecimal" name="ptct:ProceedsAssignedRoyaltyPaymentAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85Ny9mcmFnOjI5YTI2MzdjOWZmMjQ1MDE5ZjZjZDMzZjkwNDQ3ZTgyL3RleHRyZWdpb246MjlhMjYzN2M5ZmYyNDUwMTlmNmNkMzNmOTA0NDdlODJfMTkyNDE0NTM1MTQ1MDg_1d0a8f74-6082-4aa8-b1c9-afac32a89926">650.0</ix:nonFraction>&#160;million in cash consideration. The Company has retained a <ix:nonFraction unitRef="number" contextRef="ia95450bc6d4d4073acbfc602735fef93_I20200717" decimals="5" name="ptct:AssignedRoyaltyPaymentRetainedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85Ny9mcmFnOjI5YTI2MzdjOWZmMjQ1MDE5ZjZjZDMzZjkwNDQ3ZTgyL3RleHRyZWdpb246MjlhMjYzN2M5ZmYyNDUwMTlmNmNkMzNmOTA0NDdlODJfMTkyNDE0NTM1MTQ0Njk_d9dc15ac-b3cd-4cc9-a1d4-1b4ef25be964">57.067</ix:nonFraction>% interest in the Royalty and all economic rights to receive the remaining potential regulatory and sales milestone payments under the License Agreement, which milestone payments equal $<ix:nonFraction unitRef="usd" contextRef="i574baa6db99049d2ba9e1203ea243658_D20200717-20200717" decimals="-5" format="ixt:numdotdecimal" name="ptct:RevenueRecognitionMilestonePotentialAchievements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85Ny9mcmFnOjI5YTI2MzdjOWZmMjQ1MDE5ZjZjZDMzZjkwNDQ3ZTgyL3RleHRyZWdpb246MjlhMjYzN2M5ZmYyNDUwMTlmNmNkMzNmOTA0NDdlODJfMTkyNDE0NTM1MTQ0Nzg_bb1a42e5-a002-4498-b3af-5e923906e57d">397.5</ix:nonFraction>&#160;million in the aggregate. The Royalty Purchase Agreement will terminate <ix:nonNumeric contextRef="i574baa6db99049d2ba9e1203ea243658_D20200717-20200717" format="ixt-sec:durday" name="ptct:RoyaltyPurchaseAgreementTerminationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85Ny9mcmFnOjI5YTI2MzdjOWZmMjQ1MDE5ZjZjZDMzZjkwNDQ3ZTgyL3RleHRyZWdpb246MjlhMjYzN2M5ZmYyNDUwMTlmNmNkMzNmOTA0NDdlODJfMTkyNDE0NTM1MTQ1MzA_ba6a6d23-bfe0-4bd0-ade5-e51ce396f788">60</ix:nonNumeric> days following the earlier of the date on which Roche is no longer obligated to make any payments of the Royalty pursuant to the License Agreement and the date on which RPI has received $<ix:nonFraction unitRef="usd" contextRef="ia95450bc6d4d4073acbfc602735fef93_I20200717" decimals="-8" format="ixt:numdotdecimal" name="ptct:RoyaltyPurchaseAgreementPaymentMaximum" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85Ny9mcmFnOjI5YTI2MzdjOWZmMjQ1MDE5ZjZjZDMzZjkwNDQ3ZTgyL3RleHRyZWdpb246MjlhMjYzN2M5ZmYyNDUwMTlmNmNkMzNmOTA0NDdlODJfMTkyNDE0NTM1MTQ0OTQ_2342d7f8-0a62-4fca-aa90-7d5a5bbc1751">1.3</ix:nonFraction>&#160;billion in respect of the Assigned Royalty Payments.</span></div><div style="text-align:justify;margin-top:8pt;"><span><br/></span></div><div id="i95cf61a5c7074910ae3cf29c5ee08838_103"></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The following discussion of our financial condition and results of operations should be read in conjunction with our financial statements and the notes to those financial statements appearing elsewhere in this Quarterly Report on Form&#160;10-Q and the audited consolidated financial statements and notes thereto and management&#8217;s discussion and analysis of financial condition and results of operations for the year ended&#160;December&#160;31, 2019 included in our Annual Report on Form&#160;10-K filed with the Securities and Exchange Commission on March 2, 2020, or our 2019 Annual Report. This discussion contains forward-looking statements that involve significant risks and uncertainties. As a result of many factors, such as those set forth in Part&#160;II,&#160;Item 1A. (Risk Factors) of this Quarterly Report on Form&#160;10-Q, Part&#160;I,&#160;Item 1A. (Risk Factors) of our 2019 Annual Report and Part&#160;II,&#160;Item 1A. (Risk Factors) of our Quarterly Report on Form&#160;10-Q for the period ended March 31, 2020,  our actual results may differ materially from those anticipated in these forward-looking statements.</span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Our Company</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a science-driven global biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. Our ability to commercialize products is the foundation that drives our continued investment in a robust diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. Our strategy is to bring best-in-class therapies with differentiated clinical benefit to patients affected by rare disorders and to leverage our global commercial infrastructure to maximize value for our patients and other stakeholders. We have a portfolio pipeline that includes commercial products as well as product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology.</span></div><div style="text-align:justify;"><span><br/></span></div><div id="i95cf61a5c7074910ae3cf29c5ee08838_106"></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Corporate Updates</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">COVID-19 Impact</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The global pandemic caused by a strain of novel coronavirus, COVID-19, has impacted and is continuing to impact the timing of certain of our clinical trials and regulatory submissions as well as other aspects of our business operations.  In addition to our previous disclosures regarding the impact of the COVID-19 pandemic, such as those set forth in our Quarterly Report on Form 10-Q for the period ended March 31, 2020, the following expectations have been revised as a result of the impact or expected impact of the COVID-19 pandemic:</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">As a result of the COVID-19 pandemic, our expected completion of Study 045 has been delayed as certain patients still require final study muscle biopsies. Due to the pandemic, we cannot ensure that our patients are able to safely travel to our clinical trial site at the University of California, Los Angeles, which has also experienced intermittent discontinuations of certain elective procedures, further complicating our patients' ability to have the biopsies performed. During the delay, patients are remaining on drug until the biopsies can be performed. Once the clinical trial site is open for the necessary procedures and patients are able to safely travel to the site, we expect to be able to complete the final biopsies and the data from Study 045 would be available thereafter, followed by a potential resubmission of the New Drug Application, or NDA, for Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy, or nmDMD. We are continuously monitoring the situation to determine when it will be possible to safely obtain the final biopsies and we are exploring all potential options in order to have the data from Study045 be available by the end of 2020.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt;">Certain of the third-party development and manufacturing organizations that we contract with for analytical testing have prioritized materials and testing kits to support SARS-CoV-2 testing, diverted employees to support COVID-19 related programs and reduced their workforce to comply with social distancing requirements imposed in connection with the COVID-19 pandemic.  As a result of this shift in resources, we experienced a delay in generating analytical data needed to respond to questions sent by the European Medicines Agency, or EMA, regarding our marketing authorization application, or MAA, for PTC-AADC for the treatment of Aromatic L-Amino Acid Decarboxylase, or AADC, deficiency in the EEA and we have been granted a clock stop extension to respond to the EMA&#8217;s questions. We now expect an opinion from the Committee for Medicinal Products for Human Use, or CHMP, in the first quarter of 2021.</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt;">The COVID-19 pandemic has impacted the activities enabling the first-in-human studies for our gene therapy programs targeting Friedrich ataxia and Angelman syndrome. We continue</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;">to anticipate the filings in support of the first-in-human study</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;">for each of these programs to be delayed by at least one quarter.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">As a result of the COVID-19 pandemic, the Brazilian Ministry of Health is experiencing significant delays processing centralized group purchase orders.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Almost all of our Brazilian product revenue for Translarna is attributable to such purchase orders. These centralized group purchase order delays have caused, and may continue to cause, fluctuations in our ability to generate revenue in Brazil.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">To date, except as otherwise disclosed with respect to Brazil, our ability to generate revenue has not been significantly affected by the COVID-19 pandemic.  However, due to travel restrictions, social distancing and the continued global uncertainty resulting from the COVID-19 pandemic, we may have difficulty identifying and accessing new patients, supporting existing patients and meeting with regulatory authorities or other governmental entities, which may negatively affect our future revenue. We continue to remotely connect with our existing patient base and have not encountered any material issues in supplying those patients.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">As previously disclosed, in response to the global uncertainty caused by the COVID-19 pandemic, we are continuing to prioritize our expenses where we deem appropriate and strategically positioning our capital allocation. </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The COVID-19 pandemic and responsive measures thereto may result in further negative impacts, including additional delays in our clinical and regulatory activities and further fluctuations in our revenue. We cannot be certain what the overall impact of the COVID-19 pandemic will be on our business and it has the potential to materially adversely affect our business, financial condition, results of operations, and prospects. For additional information, see &#8220;Item 1A. Risk Factors - We face risks related to health epidemics and other widespread outbreaks of contagious disease, which are, and may continue to, delay our ability to complete our ongoing clinical trials and initiate future clinical trials, disrupt regulatory activities and have other adverse effects on our business and operations, including the novel coronavirus (COVID-19) pandemic, which has disrupted, and may continue to disrupt, our operations and may significantly impact our operating results. In addition, this pandemic has caused substantial disruption in the financial markets and economies, which could result in adverse effects on our business and operations.&#8221;</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">PTC299 for COVID-19</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2020, the FDA authorized the initiation of a Phase 2/3 clinical trial evaluating PTC299, a dihydroorotate dehydrogenase inhibitor that we have also been developing in oncological indications, as a potential treatment for COVID-19. PTC299 is an </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">oral investigational drug with a novel dual-mechanism of action that we believe has the potential to address the two critical elements of COVID-19: (i) the high viral replication and (ii) the uncontrolled inflammatory response that ensues after infection. The integrated Phase 2/3 study, which is being completed in two stages, will evaluate the efficacy and safety of PTC299 in patients hospitalized with SARS-CoV-2 infection. The primary objective of the study is to evaluate the clinical efficacy of PTC299 compared with placebo assessed by time to respiratory improvement in adult individuals hospitalized with COVID-19. We expect Stage 1 of the clinical trial to be completed in the second half of 2020 and we anticipate reporting top-line results from both stages in the first half of 2021.</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Agilis Rights Exchange Agreement</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">On April 29, 2020, we, certain of the former equityholders of Agilis Biotherapeutics, Inc., or Agilis, and, for the limited purposes set forth in the agreement, Shareholder Representative Services LLC, entered into a Rights Exchange Agreement, or the Rights Exchange Agreement. Pursuant to the Rights Exchange Agreement, we issued 2,821,176 shares of our common stock, or the Common Stock Consideration, and paid $36.9 million, or the Cash Consideration, in the aggregate, to such former equityholders of Agilis, or the Participating Rightholders, in exchange for the cancellation and forfeiture by the Participating Rightholders of their rights to receive certain milestone-based contingent payments under the Agreement and Plan of Merger, or the Merger Agreement, by and among us, Agility Merger Sub, Inc., Agilis, and, solely in its capacity as the representative, agent and attorney-in-fact of the equityholders of Agilis, Shareholder Representative Services LLC, dated as of July 19, 2018, pursuant to which we acquired Agilis in 2018, or the Merger. </span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Pursuant to the terms of the Rights Exchange Agreement, the Participating Rightholders have canceled and forfeited their rights under the Merger Agreement to receive (i) $174.0 million, in the aggregate, of potential milestone payments based on the achievement of certain regulatory milestones and (ii) $37.6 million, in the aggregate, of $40.0 million in development milestone payments that would have been due upon the passing of the second anniversary of the closing of the Merger, regardless of whether the milestones are achieved.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Rights Exchange Agreement has no effect on the Merger Agreement other than to provide for the cancellation and forfeiture of the Participating Rightholders&#8217; rights to receive $211.6 million, in the aggregate, of the milestone payments described above. As a result, all other rights and obligations under the Merger Agreement remain in effect pursuant to their terms, including our obligation to pay up to an aggregate maximum amount of $22.4 million upon the achievement of certain development milestones (representing the remaining portion of potential development milestone payments for which rights were not canceled and forfeited pursuant to the Rights Exchange Agreement after deducting the $37.6 million for which rights were canceled and forfeited pursuant to the Rights Exchange Agreement from the $40.0 million in development milestone payments that would have been due upon the passing of the second anniversary of the closing of the Merger), up to an aggregate maximum amount of $361.0 million upon the achievement of certain regulatory milestones (representing the remaining portion of potential regulatory milestone payments for which rights were not canceled and forfeited pursuant to the Rights Exchange Agreement), up to a maximum aggregate amount of $150.0 million upon the achievement of certain net sales milestones and a percentage of annual net sales for Friedreich ataxia and Angelman syndrome during specified terms, ranging from 2% to 6%, pursuant to the terms of the Merger Agreement.</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Acquisition of Censa Pharmaceuticals, Inc.</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On May 29, 2020, we acquired Censa Pharmaceuticals, Inc., or Censa, pursuant to an Agreement and Plan of Merger, dated as of May 5, 2020, or the Censa Merger Agreement, by and among us, Hydro Merger Sub, Inc., our wholly owned, indirect subsidiary, and, solely in its capacity as the representative, agent and attorney-in-fact of the securityholders of Censa, Shareholder Representative Services LLC, or the Censa Merger.</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Upon the closing of the Censa Merger, we paid to the Censa securityholders (i) cash consideration of $15.0 million, which consisted of an upfront payment of $10.4 million and an additional $4.6 million for the net assets on Censa's opening balance sheet as of the date of the acquisition, and (ii) 845,364 shares of our common stock. Subject to the terms and conditions of the Censa Merger Agreement, Censa securityholders may become entitled to receive contingent payments from us based on the achievement of certain development, regulatory and net sales milestones as well as based upon a percentage of net sales of PTC923 and sublicense fees paid to us in consideration of any sublicense of Censa&#8217;s intellectual property to commercialize PTC923. Pursuant to the Censa Merger Agreement, we have the option to pay the initial $30.0 million development milestone, if achieved, in cash or shares of our common stock.</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the Censa Merger, we acquired PTC923, an oral formulation of synthetic sepiapterin, a precursor to intracellular tetrahydrobiopterin, which is a critical enzymatic cofactor involved in metabolism and synthesis of numerous metabolic products.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">PTC923 has been pursued as a possible treatment for orphan metabolic diseases associated with defects in the tetrahydrobiopterin biochemical pathways, including phenylketonuria, or PKU. PKU is an inborn error of metabolism caused predominantly by mutations in the phenylalanine hydroxylase gene resulting in toxic buildup of the amino acid </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">phenylalanine, or Phe, in the brain, and, if left untreated, severe and irreversible disabilities such as permanent intellectual disability, seizures, delayed development, behavioral problems and possibly psychiatric disorders can occur. In December 2019, Censa announced that the Phase 2 trial for PTC923 as a potential treatment for PKU met is primary and secondary endpoints, achieving statistically-significant and clinically-meaningful reduction in blood Phe levels compared to both baseline and an active control group. We expect to initiate a Phase 3 trial for PTC923 for PKU in 2021.</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Monetization of a Portion of Risdiplam Royalty Stream</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On July 17, 2020, we, RPI 2019 Intermediate Finance Trust, or RPI, and, for the limited purposes set forth in the agreement, Royalty Pharma PLC, entered into a Royalty Purchase Agreement, or the Royalty Purchase Agreement.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the Royalty Purchase Agreement, we sold to RPI 42.933%, or the Assigned Royalty Payment, of our right to receive sales-based royalty payments, or Royalty, on worldwide net sales of Roche&#8217;s risdiplam product and any other product developed pursuant to the License and Collaboration Agreement, or the License Agreement, dated as of November 23, 2011, by and among us, F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., or, together with F. Hoffman-La Roche Ltd, Roche, and, for the limited purposes set forth therein, the SMA Foundation under our SMA program. In consideration for the sale of the Assigned Royalty Payments, RPI paid us $650.0 million in cash consideration. We have retained a 57.067% interest in the Royalty and all economic rights to receive the remaining potential regulatory and sales milestone payments under the License Agreement, which milestone payments equal to $397.5 million in the aggregate. The Royalty Purchase Agreement will terminate 60 days following the earlier of the date on which Roche is no longer obligated to make any payments of the Royalty pursuant to the License Agreement and the date on which RPI has received one billion three hundred million U.S. dollars in respect of the Assigned Royalty Payments.</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Global Commercial Footprint</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Global DMD Franchise</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We have two products, Translarna&#8482;&#160;(ataluren) and Emflaza&#8482; (deflazacort), for the treatment of Duchenne muscular dystrophy, or DMD, a rare, life threatening disorder. Translarna has marketing authorization in the EEA for the treatment of  nmDMD in ambulatory patients aged&#160;two&#160;years and older and in Brazil for the treatment of nmDMD in ambulatory patients aged&#160;five&#160;years and older.&#160;In June 2020, the CHMP recommended to remove the statement &#8220;efficacy has not been demonstrated in non-ambulatory patients&#8221; from the product label for Translarna. The CHMP's opinion is subject to final approval by the European Commission, which is typically provided within two months of the CHMP's recommendation. During the quarter ended June&#160;30, 2020, we recognized $38.6 million in net sales from Translarna. </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;"> </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We hold worldwide commercialization rights to Translarna for all indications in all territories. Emflaza is approved in the United States for the treatment of DMD in patients two years and older. During the quarter ended&#160;June&#160;30, 2020, we recognized $36.2 million in net sales from Emflaza. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our marketing authorization for Translarna in the EEA is subject to annual review and renewal by the European Commission following reassessment by the EMA of the benefit-risk balance of the authorization, which we refer to as the annual EMA reassessment.  In June 2020, the European Commission renewed our marketing authorization, making it effective, unless extended, through August 5, 2021.&#160;This marketing authorization is further subject to a specific obligation to conduct and submit the results of an 18-month, placebo-controlled trial, followed by an 18-month open-label extension, which we refer to together as Study 041. The final report on the trial and open-label extension is to be submitted by us to the EMA by the end of the third quarter of 2022.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Each country, including each member state of the EEA, has its own pricing and reimbursement regulations. In order to commence commercial sale of product pursuant to our Translarna marketing authorization in any particular country in the EEA, we must finalize pricing and reimbursement negotiations with the applicable government body in such country.  As a result, our commercial launch will continue to be on a country-by-country basis.&#160;We also have made, and expect to continue to make, product available under early access programs, or EAP programs, both in countries in the EEA and other territories. Our ability to negotiate, secure and maintain reimbursement for product under commercial and EAP programs can be subject to challenges in any particular country and can also be affected by political, economic and regulatory developments in such country.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There is substantial risk that if we are unable to renew our EEA marketing authorization during any annual renewal cycle, or if our product label is materially restricted, or if Study 041 does not provide the data necessary to maintain our marketing authorization, we would lose all, or a significant portion of, our ability to generate revenue from sales of Translarna in the EEA and other territories.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Translarna is an investigational new drug in the United States. During the first quarter of 2017, we filed an NDA for Translarna for the treatment of nmDMD over protest with the FDA. In October 2017, the Office of Drug Evaluation I of the FDA issued a Complete Response Letter for the NDA, stating that it was unable to approve the application in its current form. In response, we </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">filed a formal dispute resolution request with the Office of New Drugs of the FDA. In February 2018, the Office of New Drugs of the FDA denied our appeal of the Complete Response Letter. In its response, the Office of New Drugs recommended a possible path forward for the ataluren NDA submission based on the accelerated approval pathway. This would involve a re-submission of an NDA containing the current data on effectiveness of ataluren with new data to be generated on dystrophin production in nmDMD patients&#8217; muscles. We intend to follow the FDA&#8217;s recommendation and will collect, using newer technologies via procedures and methods that we designed, such dystrophin data in a new study, Study 045, which we initiated in the fourth quarter of 2018. As a result of the COVID-19 pandemic, our expected completion of Study 45 has been delayed as certain patients still require final study muscle biopsies. Once the clinical trial site is open for the necessary procedures and patients are able to safely travel to the site, we expect to be able to complete the final biopsies and the data from Study 045 would be available thereafter, followed by a potential re-submission of an NDA. Additionally, should a re-submission of an NDA receive accelerated approval, the Office of New Drugs stated that Study 041, which is currently enrolling, could serve as the confirmatory post-approval trial required in connection with the accelerated approval framework.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There is substantial risk that Study 045, or any other studies we may use to collect the dystrophin data, will not provide the necessary data to support a marketing approval for Translarna for the treatment of nmDMD in the U.S.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">LATAM Commercialization</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We hold the rights for the commercialization of Tegsedi&#8482; (inotersen) and Waylivra&#8482; (volanesorsen) for the treatment of rare diseases in countries in Latin America and the Caribbean pursuant to our Collaboration and License Agreement with Akcea Therapeutics, Inc., or Akcea. Tegsedi has received marketing authorization in the United States, EU and Brazil for the treatment of stage&#160;1 or stage&#160;2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis, or hATTR amyloidosis. Waylivra has received marketing authorization in the European Union, or EU, for the treatment of familial chylomicronemia syndrome, or FCS. We filed for marketing authorization for Waylivra for the treatment of FCS with ANVISA, the Brazilian health regulatory authority, in June 2020 and, subject to potential delays in the review process related to the COVID-19 pandemic, expect a regulatory decision on approval from ANVISA in 2021.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Diversified Development Pipeline</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Gene Therapy Platform</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have a pipeline of gene therapy product candidates for rare monogenic diseases that affect the central nervous system, or CNS, including PTC-AADC for the treatment of AADC deficiency, a rare CNS disorder arising from reductions in the enzyme AADC that result from mutations in the dopa decarboxylase gene. We are preparing a biologics license application, or BLA, for PTC-AADC for the treatment of AADC deficiency in the United States and we anticipate initiating the BLA submission to the FDA in the second half of 2020. In January 2020, we submitted an MAA for PTC-AADC for the treatment of AADC deficiency in the EEA to the EMA and we expect an opinion from the CHMP in the first quarter of 2021.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Splicing Platform</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We also have a spinal muscular atrophy, or SMA, collaboration with F. Hoffman-La Roche&#160;Ltd. and Hoffman-La Roche&#160;Inc., which we refer to collectively as Roche, and the Spinal Muscular Atrophy Foundation, or SMA Foundation. The lead compound in the SMA program is risdiplam (RG7916, RO7034067). Roche submitted an NDA for risdiplam to the FDA in the fourth quarter of 2019. In April 2020, we announced that the FDA extended the Prescription Drug User Fee Act, or PDUFA, date for a decision from May 24, 2020&#160;to August 24, 2020. Roche submitted additional data to the FDA including comprehensive data from the SUNFISH part 2 study to help provide access to risdiplam for a broad range of people living with SMA, triggering this extension. Risdiplam is expected to be indicated in the United States for SMA type 1, 2 and 3 patients, if approved. Roche anticipates submitting an MAA for risdiplam for the treatment of SMA in the EEA imminently.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Bio-e Platform</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In 2019, we acquired substantially all of the assets of BioElectron Technology Corporation, or BioElectron, including certain compounds that we have begun to develop as part of our Bio-e platform, pursuant to an asset purchase agreement by and between us and BioElectron, dated October 1, 2019. The two most advanced molecules in our Bio-e platform are vatiquinone, formerly known as PTC743, and PTC857. We expect to initiate a potential registrational Phase 2 placebo-controlled trial of vatiquinone in approximately 60 children with mitochondrial disease and associated refractory epilepsy in the third quarter of 2020. We also expect to initiate a potential registrational Phase 3 trial of vatiquinone in approximately 100 patients with Friedrich ataxia in the fourth quarter of 2020. In the second quarter of 2020, we initiated a Phase 1 trial in healthy volunteers to evaluate the safety and pharmacology of PTC857. We expect data from the single ascending dose and multiple ascending dose studies from the Phase 1 trial to be available by the end of 2020.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Multi-Platform Discovery</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, we have a pipeline of product candidates and discovery programs that are in early clinical, pre-clinical and research and development stages focused on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology.</span></div><div style="text-align:justify;"><span><br/></span></div><div id="i95cf61a5c7074910ae3cf29c5ee08838_109"></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Funding</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The success of our products and any other product candidates we may develop, depends largely on obtaining and maintaining reimbursement from governments and third-party insurers. Our revenues are primarily generated from sales of Translarna for the treatment of nmDMD in countries where we were able to obtain acceptable commercial pricing and reimbursement terms and in select countries where we are permitted to distribute Translarna under our EAP programs and from sales of Emflaza for the treatment of DMD in the United States.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To date, we have financed our operations primarily through our offering of 3.00% convertible senior notes due August&#160;15, 2022, or the 2022 Convertible Notes, our offering of 1.50% convertible senior notes due September 15, 2026, or the 2026 Convertible Notes, and, together with the 2022 Convertible Notes, the Convertible Notes, our public offerings of common stock in February 2014, in October 2014, in April 2018, in January 2019, and in September 2019, the common stock issued in our &#8220;at the marketing offering&#8221;, our initial public offering of common stock in June 2013, proceeds from the Royalty Purchase Agreement, private placements of our preferred stock, collaborations, bank debt and convertible debt financings, our credit and security agreement, or the Credit Agreement, with MidCap Financial Trust, or MidCap Financial, as administrative agent and MidCap Financial and other certain institutions as lenders thereto, and grants and clinical trial support from governmental and philanthropic organizations and patient advocacy groups in the disease areas addressed by our product candidates. Since 2014, we have also relied on revenue generated from net sales of Translarna for the treatment of nmDMD in territories outside of the United States, and since May 2017, we have generated revenue from net sales of Emflaza for the treatment of DMD in the United States.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The 2022 Convertible Notes consist of $150.0 million in aggregate principal amount of 3.00% convertible senior notes due 2022. The 2022 Convertible Notes bear cash interest payable on February&#160;15 and August&#160;15 of each year, beginning on February&#160;15, 2016. The 2022 Convertible Notes are senior unsecured obligations of ours and will mature on August&#160;15, 2022, unless earlier converted, redeemed or repurchased in accordance with their terms prior to such date. We received net proceeds from the offering of approximately $145.4 million, after deducting the initial purchasers&#8217; discounts and commissions and the estimated offering expenses payable by us.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Credit Agreement provided for a senior secured term loan facility of $60.0 million, of which $40.0 million was drawn by us on May 5, 2017. Our ability to draw on the remaining $20.0 million under the senior secured term loan facility expired on December 31, 2018.  As of June&#160;30, 2020, we made loan repayments of $21.7 million on the Credit Agreement. On July 1, 2020, we terminated the Credit Agreement and repaid outstanding principal and accrued interest thereunder totaling $18.4 million and paid an additional $0.6 million in termination and exit fees.  All liens and security interests securing the term loan made pursuant to the Credit Agreement were released upon termination.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2019, we entered into an At the Market Offering Sales Agreement, or the Sales Agreement, with Cantor Fitzgerald and RBC Capital Markets, LLC, or together, the Sales Agents, pursuant to which, we may offer and sell shares of our common stock, having an aggregate offering price of up to $125.0 million from time to time through the Sales Agents by any method that is deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, or the Securities Act. During the twelve month period ending December 31, 2019, we issued and sold an aggregate of 63,926 shares of common stock pursuant to the Sales Agreement at a weighted average public offering price of $46.60 per share. We received net proceeds of $2.6 million after deducting agent discounts and commissions and other offering expenses payable by us. During the six month period ending June 30, 2020, we issued and sold an aggregate of 368,514 shares of common stock pursuant to the Sales Agreement at a weighted average public offering price of $52.89 per share. We received net proceeds of $19.0 million after deducting underwriting discounts and commissions and other offering expenses payable by us.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The 2026 Convertible Notes consist of $287.5 million&#160;aggregate principal amount of&#160;1.50%&#160;convertible senior notes due 2026. The 2026 Convertible Notes bear cash interest at a rate of&#160;1.50%&#160;per year, payable semi-annually on March 15 and September 15 of each year, beginning on March 15, 2020. The 2026 Convertible Notes will mature on&#160;September 15, 2026, unless earlier repurchased or converted. We received net proceeds of&#160;$279.3 million after deducting the initial purchasers&#8217; discounts and commissions and the offering expenses payable by us.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, we had an accumulated deficit of $1,484.8 million. We had a net loss of $294.1 million and $113.9 million for the six month periods ended June 30, 2020 and 2019, respectively.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We anticipate that our expenses will continue to increase&#160;in connection with our commercialization efforts in the United States, the EEA, Latin America and other territories, including the expansion of our infrastructure and corresponding sales and marketing, legal and regulatory, distribution and manufacturing, including expanding our direct manufacturing capabilities at our leased biologics manufacturing facility and administrative and employee-based expenses. In addition to the foregoing, we expect to continue to incur ongoing research and development expenses for our products and product candidates, including our gene therapy, splicing, Bio-e and oncology programs, our studies of PTC923 for PKU and our studies of PTC299 for COVID-19 as well as studies in our products for maintaining authorizations, including Study 041, label extensions and additional indications. In addition, we may incur substantial costs in connection with our efforts to advance our regulatory submissions. We continue to seek marketing authorization for Translarna for the treatment of nmDMD in territories that we do not currently have marketing authorization in and we may also seek marketing authorization for Translarna for other indications. We submitted an MAA to the EMA for the treatment of AADC deficiency with PTC-AADC in the EEA.  We are also preparing a BLA for PTC-AADC for the treatment of AADC deficiency in the United States and we anticipate initiating the BLA submission to the FDA in the second half of 2020. We filed for marketing authorization for Waylivra with ANVISA in  June 2020 and, subject to potential delays in the review process related to the COVID-19 pandemic, expect a regulatory decision on approval from ANVISA in 2021. These efforts may significantly impact the timing and extent of our commercialization expenses.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may seek to expand and diversify our product pipeline through opportunistically in-licensing or acquiring the rights to products, product candidates or technologies and we may incur expenses, including with respect to transaction costs, subsequent development costs or any upfront, milestone or other payments or other financial obligations associated with any such transaction, which would increase our future capital requirements.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">With respect to our outstanding 2022 Convertible Notes, cash interest payments are payable on a semi-annual basis in arrears, which require total funding of $4.5 million annually. With respect to our outstanding 2026 Convertible Notes, cash interest payments are payable on a semi-annual basis in arrears, which will require total funding of $4.3 million annually. Prior to termination, we made cash payments on a monthly basis in arrears under our Credit Agreement. On April 29, 2020, pursuant to the Rights Exchange Agreement, we paid $36.9 million as partial consideration to the Participating Rightholders in exchange for the cancellation and forfeiture by the Participating Rightholders of their rights to receive certain milestone-based contingent payments under the Merger Agreement. We are still required to pay an additional $2.4 million&#160;in development milestone payments upon the passing of the second anniversary of the closing of the Agilis acquisition, August 23, 2020, regardless of whether the applicable milestones have been achieved. In addition, Akcea is eligible to receive from us an additional milestone payment of $4.0 million upon receipt of regulatory approval for Waylivra from ANVISA, the determination for which we expect to potentially occur, subject to potential delays in the review process related to the COVID-19 pandemic, in 2021. Furthermore, since we are a public company, we have incurred and expect to continue to incur additional costs associated with operating as such including significant legal, accounting, investor relations and other expenses.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have never been profitable and we will need to generate significant revenues to achieve and sustain profitability, and we may never do so. Accordingly, we may need to obtain substantial additional funding in connection with our continuing operations. Adequate additional financing may not be available to us on acceptable terms, or at all. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or our commercialization efforts.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Financial operations overview</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenues</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Net product revenues. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To date, our net product revenues have consisted primarily of sales of Translarna for the treatment of nmDMD in territories outside of the United States and sales of Emflaza for the treatment of DMD in the United States. We recognize revenue when performance obligations with customers have been satisfied.  Our performance obligations are to provide products based on customer orders from distributors, hospitals, specialty pharmacies or retail pharmacies.  The performance obligations are satisfied at a point in time when our customer obtains control of the product, which is typically upon delivery. We invoice customers after the products have been delivered and invoice payments are generally due within 30 to 90 days of invoice date.  We determine the transaction price based on fixed consideration in its contractual agreements. Contract liabilities arise in certain circumstances when consideration is due for goods not yet provided. As we have identified only one distinct performance obligation, the transaction price is allocated entirely to the product sale.  In determining the transaction price, a significant financing component does not exist since the timing from when we deliver product to when the customers pay for the product is typically less than one year. Customers in certain countries pay in advance of product delivery. In those instances, payment and delivery typically occur in the same month. </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We record product sales net of any variable consideration, which includes discounts, allowances, rebates related to Medicaid and other government pricing programs, and distribution fees. We use the expected value or most likely amount method when estimating variable consideration, unless discount or rebate terms are specified within contracts. The identified variable consideration is recorded as a reduction of revenue at the time revenues from product sales are recognized. These estimates for variable consideration are adjusted to reflect known changes in factors and may impact such estimates in the quarter those changes are known. Revenue recognized does not include amounts of variable consideration that are constrained. For the three months ended June 30, 2020 and 2019, net product sales outside of the United States were $39.0 million and $57.8 million respectively, and net product sales in the United States were $36.2 million and $27.6 million respectively.  For the six months ended June 30, 2020 and 2019, net product sales outside of the United States were $79.8 million and $93.0 million, respectively, and net product sales in the United States were $63.6 million and $45.4 million, respectively.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In relation to customer contracts, we incur costs to fulfill a contract but do not incur costs to obtain a contract.  These costs to fulfill a contract do not meet the criteria for capitalization and are expensed as incurred. We consider any shipping and handling costs that are incurred after the customer has obtained control of the product as a cost to fulfill a promise. Shipping and handling costs associated with finished goods delivered to customers are recorded as a selling expense. </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Roche and the SMA Foundation Collaboration.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160; In November&#160;2011, we entered into the License Agreement pursuant to which we are collaborating with Roche and the SMA Foundation to further develop and commercialize compounds identified under our SMA program with the SMA Foundation. The research component of this agreement terminated effective December&#160;31, 2014. We are eligible to receive additional payments from Roche if specified events are achieved with respect to each licensed product, including up to $135.0 million in research and development event milestones, up to $325.0 million in sales milestones upon achievement of specified sales events, and up to double digit royalties on worldwide annual net sales of a commercial product.   As of June 30, 2020, we had received a total of $62.5 million in milestone payments and no royalties on net sales pursuant to the License Agreement. As of June&#160;30, 2020, the remaining potential research and development event milestones that can be received is $72.5 million. The remaining potential sales milestones as of June&#160;30, 2020 is $325.0 million upon achievement of certain sales events.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the Royalty Purchase Agreement, we sold to RPI the Assigned Royalty Payment in consideration for $650.0 million. We have retained a 57.067% interest in the Royalty and all economic rights to receive the remaining potential regulatory and sales milestone payments under the License Agreement, which milestone payments equal $397.5 million in the aggregate. The Royalty Purchase Agreement will terminate 60 days following the earlier of the date on which Roche is no longer obligated to make any payments of the Royalty pursuant to the License Agreement and the date on which RPI has received one billion three hundred million U.S. dollars in respect of the Assigned Royalty Payments.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and development expense</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development expenses consist of the costs associated with our research activities, as well as the costs associated with our drug discovery efforts, conducting preclinical studies and clinical trials, manufacturing development efforts and activities related to regulatory filings. Our research and development expenses consist of:</span></div><div style="text-indent:18pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;&#160;external research and development expenses incurred under agreements with third-party contract research organizations and investigative sites, third-party manufacturing organizations and consultants;</span></div><div style="text-indent:18pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;&#160;employee-related expenses, which include salaries and benefits, including share-based compensation, for the personnel involved in our drug discovery and development activities; and</span></div><div style="text-indent:18pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;&#160;facilities, depreciation and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities,&#160;IT, human resources and other support functions, depreciation of leasehold improvements and equipment, and laboratory and other supplies.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We use our employee and infrastructure resources across multiple research projects, including our drug development programs. We track expenses related to our clinical programs and certain preclinical programs on a per project basis.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We expect our research and development expenses to fluctuate in connection with our ongoing activities, particularly in connection with Study 041 and other studies for Translarna for the treatment of nmDMD, our activities under our gene therapy, splicing, Bio-e and oncology programs, our studies of PTC923 for PKU, our studies of PTC299 for COVID-19, our studies of Translarna for additional indications, and performance of our FDA post-marketing requirements with respect to Emflaza in the United States. The timing and amount of these expenses will depend upon the outcome of our ongoing clinical trials and the costs associated with our planned clinical trials. The timing and amount of these expenses will also depend on the costs associated with potential future clinical trials of our products or product candidates and the related expansion of our research and development organization, regulatory requirements, advancement of our preclinical programs, and product and product candidate manufacturing costs.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following tables provide research and development expense for our most advanced principal product development programs, for the three and six months ended June 30, 2020 and 2019.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:63.065%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.527%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.739%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.527%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.742%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in&#160;thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Translarna (nmDMD, aniridia and Dravet)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,427&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,021&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">PTC923</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,587&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gene Therapy</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">68,567&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,305&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Bio-e</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,800&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Oncology</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,030&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,833&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Emflaza</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,717&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,381&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other research and preclinical</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,397&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,439&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total research and development</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">176,525&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59,979&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:63.350%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.374%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.816%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Translarna (nmDMD, aniridia and Dravet)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">52,735&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,778&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">PTC923</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,587&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gene Therapy</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105,349&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,740&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Bio-e</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,356&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Oncology</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,844&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,204&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Emflaza</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,918&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,382&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other research and preclinical</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,843&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,440&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total research and development</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">266,632&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">112,544&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The successful development of our products and product candidates is highly uncertain. This is due to the numerous risks and uncertainties associated with developing drugs, including the uncertainty of:</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">the scope, rate of progress and expense of our clinical trials and other research and development activities;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">the potential benefits of our products and product candidates over other therapies;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;&#160;our ability to market, commercialize and achieve market acceptance for any of our products or product candidates that we are developing or may develop in the future, including our ability to negotiate pricing and reimbursement terms acceptable to us and to obtain and maintain marketing authorizations we currently have or may receive in the future for our products and product candidates;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">clinical trial results;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">the terms and timing of regulatory approvals; and</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">the expense of filing, prosecuting, defending and enforcing patent claims and other intellectual property rights.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A change in the outcome of any of these variables with respect to the development of our products or product candidates could mean a significant change in the costs and timing associated with the development of that product or product candidate. For example, if the EMA or FDA or other regulatory authority were to require us to conduct clinical trials beyond those which we currently anticipate will be required for the completion of clinical development of any of our products or product candidates or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development. In addition, the uncertainty with respect to the duration, nature and extent of negative impacts of the COVID-19 pandemic and responsive measures relating thereto on our ability to successfully enroll our current and future clinical trials, is causing us to experience delays, and may cause us to experience further delays, in our clinical trials and regulatory submissions.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Selling, general and administrative expense</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Selling, general and administrative expenses consist primarily of salaries and other related costs for personnel, including share-based compensation expenses, in our executive, legal, business development, commercial, finance, accounting, information technology and human resource functions. Other selling, general and administrative expenses include facility-related costs not otherwise included in research and development expense; advertising and promotional expenses; costs associated with industry and trade shows; and professional fees for legal services, including patent-related expenses, accounting services and miscellaneous selling costs.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect that selling, general and administrative expenses will increase in future periods in connection with our continued efforts to commercialize our products, including increased payroll, expanded infrastructure, commercial operations, increased consulting, legal, accounting and investor relations expenses.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Interest expense, net</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest expense, net consists of interest income earned on investments and interest expense from the Convertible Notes outstanding and interest expense from the Credit Agreement.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Critical accounting policies and significant judgments and estimates</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which we have prepared in accordance with generally accepted accounting principles in the United States. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. Actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three and six months ended June&#160;30, 2020, there were no material changes to our critical accounting policies as reported in our 2019 Annual Report on Form&#160;10-K.</span></div><div style="text-align:justify;"><span><br/></span></div><div id="i95cf61a5c7074910ae3cf29c5ee08838_112"></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> Results of operations</span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Three months ended June&#160;30, 2020 compared to three months ended June&#160;30, 2019 </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes revenues and selected expense and other income data for the three months ended June 30, 2020 and 2019.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:57.590%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.740%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change<br/>2020 vs. <br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in&#160;thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net product revenue</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75,239&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">85,476&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,237)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Collaboration and grant revenue</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(46)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of product sales, excluding amortization of acquired intangible asset</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,304&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,211&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,093&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of acquired intangible asset</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,731&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,575&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,156&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development expense</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">176,525&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59,979&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">116,546&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative expense</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,659&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49,215&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,444&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in the fair value of deferred and contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,680&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,300&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,380&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Settlement of deferred and contingent consideration</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,613&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,613&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5,379)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,074)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,305)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense), net</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,309&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(183)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,492&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(84)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(774)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">690&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Net product revenues.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Net product revenues were $75.2 million for the three months ended June 30, 2020, a decrease of $10.2 million, or 12%, from $85.5 million for the three months ended June 30, 2019. The decrease in net product revenue was due to the decrease in net product sales of Translarna primarily related to a delay in the anticipated timing of a group purchase order from Brazil. Due to the impact of the COVID-19 pandemic, there was an administrative delay by the Brazilian Ministry of Health in receiving the centralized Translarna group purchase order. The second quarter of 2019 included a material group purchase order from Brazil. This decrease was partially offset by an increase in net product sales of Emflaza. The increase in net product sales of Emflaza was due to new patient prescriptions and continued operational improvements and efficiencies in our commercial business. </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaboration and grant revenues.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Collaboration and grant revenues remained relatively flat at $0.0 million for the three months ended June 30, 2020 and the three months ended June 30, 2019. Collaboration and grant revenues is related to our ongoing collaboration arrangements.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cost of product sales, excluding amortization of acquired intangible asset</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Cost of product sales, excluding amortization of acquired intangible asset, were $5.3 million for the three months ended June 30, 2020, an increase of $2.1 million, or 65%, from $3.2 million for the three months ended June 30, 2019. Cost of product sales consist primarily of royalty payments associated with Emflaza and Translarna net product sales, excluding contingent payments to Marathon Pharmaceuticals, LLC (now known as Complete Pharma Holdings, LLC), or Marathon, and costs associated with Emflaza and Translarna product sold during the period.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Amortization of acquired intangible asset</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Amortization of our intangible assets was $8.7 million for the three months ended June 30, 2020, an increase of $2.2 million, or 33%, from $6.6 million for the three months ended June 30, 2019. These amounts are related to the acquisition of all rights to Emflaza acquired in May 2017, Marathon contingent payments, and our Waylivra and Tegsedi intangible assets. The increase is primarily related to additional Marathon contingent payments. The amount allocated to the Emflaza intangible asset is amortized on a straight-line basis over its estimated useful life of approximately seven years from the date of the completion of the acquisition of all rights to Emflaza, the period of estimated future cash flows. The Marathon contingent payments are amortized prospectively as incurred, straight-line, over the remaining useful life of the Emflaza intangible asset. The Waylivra and Tegsedi assets are amortized on a straight-line basis over their estimated useful life of approximately ten years, respectively.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Research and development expense.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> Research and development expense was $176.5 million for the three months ended June 30, 2020, an increase of $116.5 million, or 194%, from $60.0 million for the three months ended June 30, 2019. The increase in research and development expenses includes $53.6 million in acquisition related and other expenses from the Censa Merger, $41.2 million related to our commercial manufacturing service agreement with MassBiologics of the University of Massachusetts Medical School, or MassBio, related to dedicated manufacturing space for our lead gene therapy program, AADC deficiency. The increase also reflects additional costs associated with advancing the gene therapy and Bio-e platforms and increased investment in research programs as well as advancement of the clinical pipeline.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Selling, general and administrative expense.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Selling, general and administrative expense was $53.7 million for the three months ended June 30, 2020, an increase of $4.4 million, or 9%, from $49.2 million for the three months ended June 30, 2019. The increase was primarily due to continued investment to support our commercial activities including our expanding commercial portfolio.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Change in the fair value of deferred and contingent consideration.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The change in the fair value of deferred and contingent consideration was $7.7 million for the three months ended June 30, 2020, an increase of $2.4 million, or 45%, from $5.3 million for the three months ended June 30, 2019.  The change is related to the fair valuation of the potential future consideration to be paid to former equityholders of Agilis as a result of our merger with Agilis which closed in August 2018. Changes in the fair value were due to the re-calculation of discounted cash flows for the passage of time and changes to certain other estimated assumptions.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Settlement of deferred and contingent consideration</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Settlement of deferred and contingent consideration was $10.6 million for  three months ended June 30, 2020. The settlement of deferred and contingent consideration is related to a loss upon the settlement of the deferred and contingent consideration liabilities as a result of the Rights Exchange Agreement with certain former equityholders of Agilis, whereby we exchanged their pro rata share of specific future cash milestone payments in the aggregate amount of $225.0 million for a mixture of cash and equity. We paid $36.9 million in cash and&#160;issued&#160;2,821,176 shares of common stock in exchange for the cancellation and forfeiture of the participating shareholders' rights to receive (i) $174.0&#160;million, in the aggregate, of potential milestone payments based on the achievement of certain regulatory milestones and (ii) $37.6&#160;million, in the aggregate, of $40.0&#160;million in development milestone payments that would have been due upon the passing of the second anniversary of the closing of the Merger, regardless of whether the milestones are achieved. </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Interest expense, net.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#160;Interest expense, net was $5.4 million for the three months ended June 30, 2020, an increase of $3.3 million, or 159%, from $2.1 million for the three months ended June 30, 2019.&#160; The increase in interest expense, net was primarily due to interest expense recorded from the 2022 and 2026 Convertible Notes and the Credit Agreement, partially offset by interest income from our investments.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Other income (expense), net</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Other income was $11.3 million for the three months ended June 30, 2020, an increase of $11.5 million, or over 100%, from other expense of $0.2 million for the three months ended June 30, 2019. The increase in other income (expense), net resulted primarily from a foreign exchange gain from the remeasurement of our intercompany loan, and an unrealized gain on our convertible debt security in ClearPoint Neuro, Inc. of $2.1 million.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income tax expense.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Income tax expense was $0.1 million for the three months ended June 30, 2020 compared to income tax expense of $0.8 million for the three months ended June 30, 2019. We incurred income tax expense in various foreign jurisdictions, and our foreign tax liabilities are largely dependent upon the distribution of pre-tax earnings among these different jurisdictions. We are paying minimum income taxes in the United States because of incurred losses in the various state jurisdictions. </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Six months ended June&#160;30, 2020 compared to six months ended June&#160;30, 2019 </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes revenues and selected expense and other income data for the six months ended June 30, 2020 and 2019.</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:57.677%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.756%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.386%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.756%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.759%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change 2020 vs. 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net product revenue</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">143,435&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">138,530&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,905&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Collaboration and grant revenue</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">575&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(512)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of product sales, excluding amortization of acquired intangible asset</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,389&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,587&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,802&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of acquired intangible asset</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,679&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,652&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,027&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development expense</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">266,632&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">112,544&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">154,088&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative expense</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">111,869&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">89,760&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,109&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in the fair value of deferred and contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,580&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,460&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(17,880)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Settlement of deferred and contingent consideration</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,613&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,613&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11,021)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,362)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,659)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other expense, net</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,523)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(292)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,231)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(306)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,350)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,044&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Net product revenues.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Net product revenues were $143.4 million for the six months ended June 30, 2020, an increase of $4.9 million, or 4%, from $138.5 million for the six months ended June 30, 2019. The increase in net product revenue was primarily due to the increase in net product sales of Emflaza. The increase in net product sales of Emflaza was due to new patient prescriptions and continued operational improvements and efficiencies in our commercial business. This increase was partially offset by a decrease in net product sales of Translarna, primarily related to a delay in the anticipated timing of a group purchase order from Brazil. Due to the impact of the COVID-19 pandemic, there was an administrative delay by the Brazilian Ministry of Health in receiving the centralized Translarna group purchase order. The second quarter of 2019 included a material group purchase order from Brazil.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaboration and grant revenues.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Collaboration and grant revenues were $0.1 million for the six months ended June 30, 2020 , a decrease of 0.5 million, or 89%, from $0.6 million for the six months ended June 30, 2019. The decrease in collaboration and grant revenues is related to our ongoing collaboration arrangements.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cost of product sales, excluding amortization of acquired intangible asset</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Cost of product sales, excluding amortization of acquired intangible asset, were $9.4 million for the six months ended June 30, 2020, an increase of $3.8 million, or 68%, from $5.6 million for the six months ended June 30, 2019. Cost of product sales consist primarily of royalty payments associated with Emflaza and Translarna net product sales, excluding contingent payments to Marathon and costs associated with Emflaza and Translarna product sold during the period.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Amortization of acquired intangible asset</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Amortization of our intangible assets was $16.7 million for the six months ended June 30, 2020, an increase of $4.0 million, or 32%, from $12.7 million six months ended June 30, 2019. These amounts are related to the acquisition of all rights to Emflaza acquired in May 2017, Marathon contingent payments, and our Waylivra and Tegsedi intangible assets. The increase is primarily related to additional Marathon contingent payments. The amount allocated to the Emflaza intangible asset is amortized on a straight-line basis over its estimated useful life of approximately seven years from the date of the completion of the acquisition of all rights to Emflaza, the period of estimated future cash flows. The Marathon contingent payments are amortized prospectively as incurred, straight-line, over the remaining useful life of the Emflaza intangible asset. The Waylivra and Tegsedi assets are amortized on a straight-line basis over their estimated useful life of approximately ten years, respectively.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Research and development expense.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Research and development expense was $266.6 million for the six months ended June 30, 2020, an increase of $154.1 million, or 137%, from $112.5 million for the six months ended June 30, 2019. The increase in research and development expenses includes $53.6 million in acquisition related and other expenses from the Censa Merger and $41.2 million related to our commercial manufacturing service agreement with MassBio related to dedicated manufacturing space for our lead gene therapy program, AADC deficiency. The increase also reflects additional costs associated with </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">advancing the gene therapy and Bio-e platforms and increased investment in research programs as well as advancement of the clinical pipeline.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Selling, general and administrative expense.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Selling, general and administrative expense was $111.9 million for the six months ended June 30, 2020, an increase of $22.1 million, or 25%, from $89.8 million for the six months ended June 30, 2019. The increase was primarily due to continued investment to support our commercial activities including our expanding commercial portfolio.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Change in the fair value of deferred and contingent consideration.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The change in the fair value of deferred and contingent consideration was $8.6 million for the six months ended June 30, 2020, a decrease of $17.9 million, or 68%, from $26.5 million for the six months ended June 30, 2019.  The change is related to the fair valuation of the potential future consideration to be paid to former equityholders of  Agilis as a result of our merger with Agilis which closed in August 2018. Changes in the fair value were due to the re-calculation of discounted cash flows for the passage of time and changes to certain other estimated assumptions.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Settlement of deferred and contingent consideration</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Settlement of deferred and contingent consideration was $10.6 million for  six months ended June 30, 2020. The settlement of deferred and contingent consideration is related to a loss upon the settlement of the deferred and contingent consideration liabilities as a result of the Rights Exchange Agreement with certain former equityholders of Agilis, whereby we exchanged their pro rata share of specific future cash milestone payments in the aggregate amount of $225.0 million for a combination of cash and equity. We paid $36.9 million in cash and&#160;issued&#160;2,821,176 shares of common stock in exchange for the cancellation and forfeiture of the participating shareholders' rights to receive (i) $174.0&#160;million, in the aggregate, of potential milestone payments based on the achievement of certain regulatory milestones and (ii) $37.6&#160;million, in the aggregate, of $40.0&#160;million in development milestone payments that would have been due upon the passing of the second anniversary of the closing of the Merger, regardless of whether the milestones are achieved.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Interest expense, net.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#160;Interest expense, net was $11.0 million for the six months ended June 30, 2020 , an increase of $6.7  million, or 153%, from $4.4 million for the six months ended June 30, 2019.&#160; The increase in interest expense, net was primarily due to interest expense recorded from the 2022 and 2026 Convertible Notes and the Credit Agreement, partially offset by interest income from our investments.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Other expense net</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Other expense, net was $2.5 million for the six months ended June 30, 2020, an increase of $2.2 million, or over 100%, from other expense, net of $0.3 million for the six months ended June 30, 2019. The increase in other expense, net resulted primarily from unrealized losses on our equity investment and convertible debt security in ClearPoint Neuro, Inc. of $1.6 million and $0.7 million,  respectively, Agilis Rights Exchange transaction fees of $2.0 million, and a foreign exchange loss from the remeasurement of our intercompany loan. </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income tax expense.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Income tax expense was $0.3 million for the six months ended June 30, 2020  compared to income tax expense of $1.4 million for the six months ended June 30, 2019. We incurred income tax expense in various foreign jurisdictions, and our foreign tax liabilities are largely dependent upon the distribution of pre-tax earnings among these different jurisdictions. We are paying minimum income taxes in the United States because of incurred losses in the various state jurisdictions. </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Liquidity and capital resources</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Sources of liquidity</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since inception, we have incurred significant operating losses.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a growing commercial-stage biopharmaceutical company, we are engaging in significant commercialization efforts for our products while also devoting a substantial portion of our efforts on research and development related to our products, product candidates and other programs. To date, almost all of our product revenue has been attributable to sales of Translarna for the treatment of nmDMD in territories outside of the United States and from Emflaza for the treatment of DMD in the United States.  Our ongoing ability to generate revenue from sales of Translarna for the treatment of nmDMD is dependent upon our ability to maintain our marketing authorization in Brazil and in the EEA and secure market access through commercial programs following the conclusion of pricing and reimbursement terms at sustainable levels in the member states of the EEA or through EAP programs in the EEA and other territories. The marketing authorization requires annual review and renewal by the European Commission following reassessment by the EMA of the benefit-risk balance of the authorization and is subject to the specific obligation to conduct Study 041. Our ability to generate product revenue from Emflaza will largely depend on the coverage and reimbursement levels set by governmental authorities, private health insurers and other third-party payors.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have historically financed our operations primarily through the issuance and sale of our common stock in public offerings, our &#8220;at the market offering&#8221; of our common stock, proceeds from the Royalty Purchase Agreement, the private placements of </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">our preferred stock, collaborations, bank debt, convertible debt financings, the Credit Agreement and grants and clinical trial support from governmental and philanthropic organizations and patient advocacy groups in the disease areas addressed by our product candidates. We expect to continue to incur significant expenses and operating losses for at least the next several years. The net losses we incur may fluctuate significantly from quarter to quarter.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August&#160;2015, we closed a private offering of $150.0 million in aggregate principal amount of 3.00% convertible senior notes due 2022 including the exercise by the initial purchasers of an option to purchase an additional $25.0 million in aggregate principal amount of the 2022 Convertible Notes. The 2022 Convertible Notes bear cash interest payable on February&#160;15 and August&#160;15 of each year, beginning on February&#160;15, 2016. The 2022 Convertible Notes are senior unsecured obligations of ours and will mature on August&#160;15, 2022, unless earlier converted, redeemed or repurchased in accordance with their terms prior to such date. We received net proceeds from the offering of approximately $145.4 million, after deducting the initial purchasers&#8217; discounts and commissions and the estimated offering expenses payable by us.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On May 5, 2017, we entered into the Credit Agreement with MidCap Financial, which provides for a senior secured term loan facility of $60.0 million, of which $40.0 million was drawn by us on May 5, 2017. Our ability to draw on the remaining $20.0 million under the senior secured term loan facility expired on December 31, 2018.  The facility was structured to require only monthly interest payments for the initial two years with principal amortization beginning in years three and four.  The facility bore interest at a rate per annum equal to the London Interbank Offered Rate, or LIBOR (with a LIBOR floor rate of 1.00%) plus 6.15%, as well as additional upfront and administrative fees and expenses. On July 1, 2020, we terminated the Credit Agreement with MidCap Financial.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2019, we entered into the Sales Agreement, pursuant to which, we may offer and sell shares of our common stock, having an aggregate offering price of up to $125.0 million from time to time through the Sales Agents by any method that is deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) promulgated under the Securities Act. During the twelve month period ending December 31, 2019, we issued and sold an aggregate of 63,926 shares of common stock pursuant to the Sales Agreement at a weighted average public offering price of $46.60 per share. We received net proceeds of $2.6 million after deducting agent discounts and commissions and other offering expenses payable by us. During the six month period ending June 30, 2020, we issued and sold an aggregate of 368,514 shares of common stock pursuant to the Sales Agreement at a weighted average public offering price of $52.89 per share. We received net proceeds of $19.0 million after deducting underwriting discounts and commissions and other offering expenses payable by us.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In&#160;September 2019, we closed a private offering of&#160;$287.5 million&#160;aggregate principal amount of&#160;1.50%&#160;convertible senior notes due 2026 including the exercise by the initial purchasers of an option to purchase an additional $37.5 million in aggregate principal amount of the 2026 Convertible Notes. The 2026 Convertible Notes bear cash interest at a rate of&#160;1.50%&#160;per year, payable semi-annually on&#160;March&#160;15&#160;and&#160;September&#160;15&#160;of each year, beginning on&#160;March 15, 2020. The 2026 Convertible Notes will mature on&#160;September 15, 2026, unless earlier repurchased or converted. We received net proceeds of&#160;$279.3 million after deducting the initial purchasers&#8217; discounts and commissions and the offering expenses payable by us.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In July 2020, we entered into the Royalty Purchase Agreement.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the Royalty Purchase Agreement, we sold to RPI the Assigned Royalty Payment in consideration for $650.0 million.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash flows</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, we had cash, cash equivalents and marketable securities of $498.9 million.</span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides information regarding our cash flows and our capital expenditures for the periods indicated.</span></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:67.546%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.494%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.496%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in&#160;thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating activities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(156,364)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(72,931)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investing activities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40,783&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(188,669)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financing activities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(14,428)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">228,571&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net cash used in operating activities was $156.4 million for the six months ended June 30, 2020 and $72.9 million for the six months ended June 30, 2019. The net cash used in operating activities primarily relates to supporting clinical development and commercial activities. </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net cash provided by investing activities was $40.8 million for the six months ended June 30, 2020. Cash provided by investing activities for the six months ended June 30, 2020 was primarily related to net sales and redemptions of marketable securities. </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net cash used in investing activities was $188.7 million for the six months ended June 30, 2019 and was primarily related to net purchases of marketable securities. </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net cash used in financing activities was $14.4 million for the six months ended June 30, 2020. Cash used in financing activities for the six months ended June 30, 2020 was primarily attributable to payments on our deferred consideration obligation, our finance lease principal, and our senior secured term loan, partially offset by proceeds from our at the market equity offering and the exercise of options. Cash provided by financing activities was $228.6 million for the six months ended June 30, 2019. Cash provided by financing activities for the six months ended June 30, 2019 was primarily attributable to our equity offering in January 2019 and the exercise of options.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Funding requirements</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We anticipate that our expenses will continue to increase&#160;in connection with our commercialization efforts in the United States, the EEA, Latin America and other territories, including the expansion of our infrastructure and corresponding sales and marketing, legal and regulatory, distribution and manufacturing and administrative and employee-based expenses. In addition to the foregoing, we expect to continue to incur significant costs&#160;in connection with the research and development of our gene therapy, splicing, Bio-e and oncology programs, our studies of PTC923 for PKU and our studies of PTC299 for COVID-19 as well as studies in our products for maintaining authorizations, including Study 041, label extensions and additional indications. In addition, we may incur substantial costs in connection with our efforts to advance our regulatory submissions. We continue to seek marketing authorization for Translarna for the treatment of nmDMD in territories that we do not currently have marketing authorization in and we may also seek marketing authorization for Translarna for other indications. We submitted an MAA to the EMA for the treatment of AADC deficiency with PTC-AADC in the EEA. We are preparing a BLA for PTC-AADC for the treatment of AADC deficiency in the United States and we anticipate initiating the BLA submission to the FDA in the second half of 2020. We filed for marketing authorization for Waylivra with ANVISA in June 2020 and, subject to potential delays in the review process related to the COVID-19 pandemic, expect a regulatory decision on approval from ANVISA in 2021. These efforts may significantly impact the timing and extent of our commercialization expenses.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, our expenses will increase if and as we:</span></div><div style="text-indent:-13.5pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">seek to satisfy contractual and regulatory obligations we assumed in connection with the Agilis acquisition;</span></div><div style="text-indent:-13.5pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">seek to satisfy contractual and regulatory obligations in conjunction with the Akcea Agreement;</span></div><div style="text-indent:-13.5pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">satisfy contractual and regulatory obligations that we assumed through our other acquisitions and collaborations;&#160;</span></div><div style="text-indent:-13.5pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">execute our commercialization strategy for our products and product candidates that may receive marketing authorization;</span></div><div style="text-indent:-13.5pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">are required to complete any additional clinical trials, non-clinical studies or Chemistry, Manufacturing and Controls, or CMC, assessments or analyses in order to advance Translarna for the treatment of nmDMD in the United States or elsewhere;</span></div><div style="text-indent:-13.5pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">utilize the Hopewell Facility to begin manufacturing program materials for certain of our gene therapy product candidates;</span></div><div style="text-indent:-13.5pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">initiate or continue the research and development of our gene therapy, splicing, Bio-e and oncology programs, our studies of PTC923 for PKU, our studies of PTC299 for COVID-19 as well as studies in our products for maintaining authorizations, including Study 041, label extensions and additional indications;</span></div><div style="text-indent:-13.5pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">seek to discover and develop additional product candidates;</span></div><div style="text-indent:-13.5pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">seek to expand and diversify our product pipeline through strategic transactions;</span></div><div style="text-indent:-13.5pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">maintain, expand and protect our intellectual property portfolio; and</span></div><div style="text-indent:-13.5pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">add operational, financial and management information systems and personnel, including personnel to support our product development and commercialization efforts.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We believe that our cash flows from product sales, together with existing cash and cash equivalents, our offerings of the Convertible Notes, public offerings of common stock, our &#8220;at the market offering&#8221; of our common stock, and marketable securities, will be sufficient to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our future capital requirements will depend on many factors, including:</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to commercialize and market our products and product candidates that may receive marketing authorization;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to negotiate, secure and maintain adequate pricing, coverage and reimbursement terms, on a timely basis, with third-party payors for our products and products candidates;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to maintain the marketing authorization for our products, including in the EEA for Translarna for the treatment of nmDMD and whether the EMA determines on an annual basis that the benefit-risk balance of Translarna supports renewal of our marketing authorization in the EEA, on the current approved label;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the costs, timing and outcome of Study 041;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the costs, timing and outcome of our efforts to advance Translarna for the treatment of nmDMD in the United States, including, whether we will be required to perform additional clinical trials, non-clinical studies or CMC assessments or analyses at significant cost which, if successful, may enable FDA review of an NDA submission by us and, ultimately, may support approval of Translarna for nmDMD in the United States;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to maintain orphan exclusivity in the United States for Emflaza and successfully completing all post-marketing requirements with respect to Emflaza and any other products;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the progress and results of activities under our gene therapy, splicing, Bio-e and oncology programs, our studies of PTC923 for PKU and our studies of PTC299 for COVID-19 as well as studies in our products for maintaining authorizations, label extensions and additional indications;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the scope, costs and timing of our commercialization activities, including product sales, marketing, legal, regulatory, distribution and manufacturing, for any of our products and for any of our other product candidates that may receive marketing authorization or any additional indications or territories in which we receive authorization to market Translarna;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the costs, timing and outcome of regulatory review of our gene therapy, splicing, Bio-e and oncology programs, PTC923 for PKU, PTC299 for COVID-19 and Translarna for additional indications and in other territories;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">unexpected decreases in revenue or increase in expenses resulting from the COVID-19 pandemic;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to utilize the Hopewell Facility to begin manufacturing program materials for certain of our gene therapy product candidates;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to satisfy our obligations under the indentures governing the Convertible Notes;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the timing and scope of growth in our employee base;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the scope, progress, results and costs of preclinical development, laboratory testing and clinical trials for our other product candidates, including those in our gene therapy, splicing, Bio-e and oncology programs, PTC923 for PKU, PTC299 for COVID-19 and Translarna for additional indications;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">revenue received from commercial sales of our products or any of our product candidates;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to obtain additional and maintain existing reimbursed named patient and cohort EAP programs for Translarna for the treatment of nmDMD on adequate terms, or at all;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the ability and willingness of patients and healthcare professionals to access Translarna through alternative means if pricing and reimbursement negotiations in the applicable territory do not have a positive outcome;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the costs of preparing, filing and prosecuting patent applications, maintaining, and protecting our intellectual property rights and defending against intellectual property-related claims;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the extent to which we acquire or invest in other businesses, products, product candidates, and technologies, including the success of any acquisition, in-licensing or other strategic transaction we may pursue, and the costs of subsequent development requirements and commercialization efforts, including with respect to our acquisition of Emflaza, our acquisition of Agilis, our licensing of Tegsedi and Waylivra, our acquisition of our Bio-e platform and our acquisition of Censa; and</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to establish and maintain collaborations, including our collaborations with Roche and the SMA Foundation, and our ability to obtain research funding and achieve milestones under these agreements.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">With respect to our outstanding 2022 Convertible Notes, cash interest payments are payable on a semi-annual basis in arrears, which require total funding of $4.5 million annually. With respect to our outstanding 2026 Convertible Notes, cash interest payments are payable on a semi-annual basis in arrears, which will require total funding of $4.3 million annually. Furthermore, since we are a public company, we have incurred and expect to continue to incur additional costs associated with operating as such, including significant legal, accounting, investor relations and other expenses.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We will need to generate significant revenues to achieve and sustain profitability, and we may never do so. We may need to obtain substantial additional funding in connection with our continuing operations. Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs primarily through a combination of equity offerings, debt financings, collaborations, strategic alliances, grants and clinical trial support from governmental and philanthropic organizations and patient advocacy groups in the disease areas addressed by our product and product candidates and marketing, distribution or licensing arrangements. Adequate additional financing may not be available to us on acceptable terms, or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, our shareholders ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we are unable to raise additional funds through equity or debt financings when needed or on attractive terms, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Off-Balance Sheet Arrangements</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under Securities and Exchange Commission rules.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Contractual obligations</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the period ended June&#160;30, 2020, there were no material changes to our contractual obligations and commitments outside the ordinary course of business from those disclosed under the heading &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations-Contractual Obligations&#8221; in our 2019 Annual Report on Form 10-K, other than as disclosed below.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:45.794%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.852%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.852%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.852%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.852%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.858%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less than<br/>1&#160;year</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;-&#160;3&#160;years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3&#160;-&#160;5&#160;years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">More than<br/>5&#160;years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease obligations, not yet commenced (1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">111,527&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,387&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,419&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,961&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">78,760&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease obligations&#160;(2)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,034&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,361&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,976&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,329&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,368&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance lease obligations&#160;(3)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total contractual obligations</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">175,561&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,748&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,395&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,290&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">107,128&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1) Obligations stem from our lease agreement entered into with Bristol-Myers Squibb Company in August 2019 relating to the lease&#160;of approximately 185,000 square feet of office, manufacturing and laboratory space at a facility located in Hopewell Township, New Jersey. On March 25, 2020, we entered into an amendment increasing the rented space to approximately 220,500 square feet.  The rental term of the lease commenced on July 1, 2020 and is accordingly reflected as not yet commenced as of June 30, 2020.&#8232;&#8232;(2) Obligations stem from our lease agreement entered into with COE Bridgewater LLC on March 20, 2020 relating to the lease of office and laboratory space located in Bridgewater, New Jersey. This lease replaced our existing lease on the property beginning on May 1, 2020 and includes additional rental property of approximately 59,000 square feet. </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(3) Obligations stem from a commercial manufacturing service agreement entered into with MassBio on June 19, 2020, for a term of 12.5 years. Pursuant to the terms of the agreement, MassBio agreed to provide us with four dedicated rooms for our AADC program. We concluded that the agreement contains an embedded lease as we control the use of the four dedicated rooms and the equipment therein. As the present value of the facilities exceed the fair value, we determined that it is a finance lease. </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">55</span></div></div></div><div id="i95cf61a5c7074910ae3cf29c5ee08838_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 3. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the period ended June&#160;30, 2020, there were no material changes in our market risk or how our market risk is managed, compared to those disclosed under the heading &#8220;Quantitative and Qualitative Disclosures about Market Risk&#8221; in our 2019 Annual Report on Form 10-K.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span><br/></span></div><div id="i95cf61a5c7074910ae3cf29c5ee08838_118"></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 4. Controls and Procedures.</span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Evaluation of Disclosure Controls and Procedures</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of June&#160;30, 2020. The term &#8220;disclosure controls and procedures&#8221;, as defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission&#8217;s rules&#160;and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of June&#160;30, 2020, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Changes in Internal Control over Financial Reporting</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">No change in our internal control over financial reporting occurred during the quarter ended June&#160;30, 2020 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="i95cf61a5c7074910ae3cf29c5ee08838_121"></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART&#160;II&#8212;OTHER INFORMATION</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i95cf61a5c7074910ae3cf29c5ee08838_124"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 1. Legal Proceedings. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From time to time in the ordinary course of our business, we are subject to claims, legal proceedings and disputes, including as a result of patients seeking to participate in our clinical trials or otherwise gain access to our product candidates. We are not currently aware of any material legal proceedings to which we are a party or of which any of our property is subject.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">57</span></div></div></div><div id="i95cf61a5c7074910ae3cf29c5ee08838_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 1A.&#160; Risk Factors</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have set forth in Item 1A to our Annual Report on Form 10-K for the year ended December&#160;31, 2019, risk factors relating to our business, our industry, our structure and our common stock. Readers of this Quarterly Report on Form 10-Q are referred to such Item 1A for a more complete understanding of risks concerning us. The COVID-19 pandemic has heightened, and in some cases manifested, certain of the risks we normally face in operating our business, including those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2019, and the risk factor disclosure in our Annual Report on Form 10-K for the year ended December 31, 2019 is qualified by the information related to COVID-19 that is described in this Quarterly Report on Form 10-Q, including the new risk factor set forth below.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other than as set forth below there have been no material changes in our risk factors since those published in such Form 10-K for the year ended December&#160;31, 2019.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We face risks related to health epidemics and other widespread outbreaks of contagious disease, which are, and may continue to, delay our ability to complete our ongoing clinical trials and initiate future clinical trials, disrupt regulatory activities and have other adverse effects on our business and operations, including the novel coronavirus (COVID-19) pandemic, which has disrupted, and may continue to disrupt, our operations and may significantly impact our operating results. In addition, the COVID-19 pandemic has caused substantial disruption in the financial markets and economies, which could result in adverse effects on our business and operations.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"> </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Significant outbreaks of contagious diseases, and other adverse public health developments, could have a material impact on our business operations and operating results. In December 2019, a strain of novel&#160;coronavirus, COVID-19,&#160;causing respiratory illness emerged in the city of Wuhan in the Hubei province of China. Since that time, multiple other countries throughout the world, including the United States, have been affected by the spread of the virus. To date, responsive measures such as social distancing, travel bans and quarantines have been put into place in many countries throughout the world, including the United States. These responsive measures have had a significant impact, both direct and indirect, on business and commerce worldwide, as worker shortages have occurred, supply chains have been disrupted and facilities and production have been suspended or curtailed.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The spread of COVID-19 and the responsive measures taken to date have limited our access to our facilities and caused the majority of our employees to work from home. We continue to monitor the global spread and response of international, national and local authorities of COVID-19 and have put in place and will continue to put in place measures as appropriate and necessary for our business and the safety of our employees and our business. While we expect the pandemic to continue to have an adverse effect on our business and operations, and the pandemic may have an adverse effect on our financial conditions and results of operations, we are unable to predict the extent or nature of the future progression of the outbreak or its effects on our business, operations, financial condition and results of operations at this time.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Furthermore, we have clinical trial sites located in countries that have been affected by COVID-19 that have been and may continue to be disrupted, including the United States. The disruption of our clinical trial sites is having an adverse impact on our clinical trial plans and timelines. For example, we initiated Study 045 in the fourth quarter of 2018 to evaluate the ability of ataluren to increase dystrophin protein levels in boys with nmDMD. We intend to use the data from Study 045 in support of our potential NDA resubmission for Translarna for the treatment of nmDMD. As a result of the COVID-19 pandemic, we cannot ensure that our patients are able to safely travel to our clinical trial site at the University of California, Los Angeles, which has also experienced intermittent discontinuations of certain elective procedures, further complicating our patients' ability to have final study muscle biopsies performed. During the delay, patients are remaining on drug until the biopsies can be performed.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Once the clinical trial site is open for the necessary procedures and patients are able to safely travel to the site, we expect to complete the final biopsies and the data from Study 045 would be available thereafter, followed by a potential re-submission of an NDA, however, the current pandemic may cause additional unforeseen delays. Other clinical trial sites as well as significant suppliers and manufacturing located in countries that have been affected by COVID-19 may also be disrupted, which may affect our ability to procure items that are essential for our research and development activities and may cause disruptions. The response to the COVID-19 pandemic may redirect resources with respect to regulatory matters in a way that would adversely impact our ability to progress regulatory approval. We may also choose to redirect our own resources in a way that may adversely impact or delay certain of our programs. In addition, we may face impediments to regulatory meetings and approvals due to measures intended to limit in-person interactions.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We cannot foresee if and when the outbreak of COVID-19 will be effectively contained, nor can we predict the severity and duration of its impact. If the COVID-19 pandemic is not effectively and timely controlled, we may experience prolonged disruption of our clinical trials, suppliers or contract manufacturers, extended closures of facilities, such as clinical trial sites, suppliers, manufacturers and distributors, including single source suppliers, and further delays with </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">respect to regulatory approvals or the commercialization of any current or future products.  Such events may materially and adversely affect our business operations and financial condition. Additionally, the pandemic has caused significant disruptions in the financial markets, and may continue to cause such disruptions, which could impact our ability to raise additional funds and has also impacted, and may continue to impact, the volatility of our stock price and trading in our stock. Moreover, it is possible the pandemic will significantly impact economies worldwide, which could result in adverse effects on our business and operations. We cannot be certain what the overall impact of the COVID-19 pandemic will be on our business and it has the potential to materially adversely affect our business, financial condition, results of operations, and prospects.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We face risks related to the development of PTC299 as a potential treatment for COVID-19 and we may ultimately be unsuccessful in developing a treatment for the virus in a timely manner or at all.  Even if we are able to produce a drug that successfully treats the virus, there is significant competition in the search for a treatment for COVID-19 and our product may not be the only effective treatment.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In June 2020, the FDA authorized the initiation of a Phase2/3 clinical trial evaluating PTC299 as a potential treatment for COVID-19. Our clinical trial for PTC299 may reveal unfavorable characteristics, including safety concerns, and may not demonstrate efficacy. We cannot be certain that the planned Phase 2/3 clinical trial will be sufficient to enable us to obtain marketing approval of PTC299 for the treatment of COVID-19, and we may need to conduct additional clinical trials before we are able to apply for marketing approval.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Additionally, the FDA and other regulators may not agree with our interpretation of the results of the clinical data from our trial. If we are unable to successfully complete our clinical trial, if the results of this clinical trial are not positive or are only modestly positive, or if there are safety concerns, we may be unable to produce a drug that successfully treats COVID-19 and receives regulatory approval in a timely manner, if at all.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The timing and success of our clinical trial of PTC299 for the treatment of patients with COVID-19 will depend on our ability to enroll patients in the trial. Our inability to enroll a sufficient number of patients could result in significant delays or could require us to abandon the trial and development of PTC299 for the treatment of COVID-19 altogether.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Patient enrollment may be affected by the availability of commercially available treatments and other ongoing clinical trials. There is significant competition, including from other companies and governmental organizations, to find a treatment for COVID-19. Many of these entities have substantially greater resources, including capital and personnel, than we do, and these entities may be further ahead in pursuit of a treatment than we are. As a result, even if we are able to sufficiently enroll our clinical trial and produce an effective treatment for COVID-19, there is no guarantee that we will have the only effective treatment for COVID-19 or that we will be able to commercialize our product prior to our competitors.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">59</span></div></div></div><div id="i95cf61a5c7074910ae3cf29c5ee08838_154"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 6. Exhibits. </span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.807%;"><tr><td style="width:1.0%;"></td><td style="width:10.406%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.736%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:81.858%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exhibit&#160;Number</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Description&#160;of&#160;Exhibit</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.1&#8224;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1070081/000110465920057485/tm2018807d1_ex2-1.htm">Agreement and Plan of Merger, dated May 5, 2020, by and among PTC Therapeutics, Inc., Hydro Merger Sub, Inc., Censa Pharmaceuticals Inc. and, solely in its capacity as securityholder representative, Shareholder Representative Services LLC  (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by the Registrant on May 6, 2020)</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1&#8224;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="ex101shiratorilicensea.htm">License Agreement dated as of February 8, 2016, as amended, by and between Shiratori Pharmaceutical Co. Ltd. and Censa Pharmaceuticals Inc.</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.2&#8224;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="ex102rpiroyaltypurchas.htm">Royalty Purchase Agreement, dated as of July 17, 2020, by and among PTC Therapeutics, Inc., RPI 2019 Intermediate Finance Trust, and, solely for the limited purposes set forth therein, Royalty Pharma PLC</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3+</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="ex103kleinemploymentag.htm">Employment Agreement, as amended, between the Registrant and Matthew Klein</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.4+</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="ex104pauwelsemployment.htm">Employment Agreement, as amended, between the Registrant and Eric Pauwels</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.5&#8224;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1070081/000107008120000095/rightsexchangeagreement.htm">Rights Exchange Agreement, by and among PTC Therapeutics, Inc., the Rightholders set forth therein, and, for the limited purposes set forth therein, Shareholder Representatives Services LLC, dated as of April 29, 2020 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by the Registrant on April 30, 2020)</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.1</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="ptct06302020ex-311.htm">Certification of Principal Executive Officer pursuant to Rule&#160;13a-14(a)&#160;or Rule&#160;15d-14(a)&#160;of the Securities Exchange Act of 1934, as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.2</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="ptct06302020ex-312.htm">Certification of Principal Financial Officer pursuant to Rule&#160;13a-14(a)&#160;or Rule&#160;15d-14(a)&#160;of the Securities Exchange Act of 1934, as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32.1</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="ptct06302020ex-321.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32.2</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="ptct06302020ex-322.htm">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.INS</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Instance Document*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.SCH</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Schema Document*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.CAL</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Calculation Linkbase Document*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.LAB</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Label Linkbase Database*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.PRE</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Presentation Linkbase Document*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.DEF</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Definition Linkbase Document*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">104</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">The cover page from this Quarterly Report on Form 10-Q, formatted in Inline XBRL</span></td></tr></table></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:19.444%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">* Submitted electronically herewith.</span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8224; Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.</span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">+ Management contract, compensatory plan or arrangement.</span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In accordance with SEC Release 33-8238, Exhibits 32.1 and 32.2 are being furnished and not filed. </span></div><div id="i95cf61a5c7074910ae3cf29c5ee08838_157"></div><div style="text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SIGNATURES</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:47.048%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:4.881%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:42.071%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">PTC THERAPEUTICS,&#160;INC.</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date: August 5, 2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Emily Hill</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Emily Hill</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Financial Officer and Duly Authorized Signatory)</span></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">61</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex101shiratorilicensea.htm
<DESCRIPTION>EX-10.1 SHIRATORI LICENSE AGREEMENT
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i69ffa761f2d04a238bf9fcc813d3316c_1"></div><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">EXHIBIT 10.1</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed.  Double asterisks denote omissions.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:6pt;margin-bottom:18pt;"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> LICENSE AGREEMENT</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">DATED AS OF FEBRUARY 8</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;vertical-align:top;">TH</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">, 2015</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">BETWEEN</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">SHIRATORI PHARMACEUTICAL CO., LTD.</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">AND</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">CENSA PHARMACEUTICALS INC.</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="margin-top:6pt;margin-bottom:6pt;"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:67.5pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">ARTICLE 1  &#160;DEFINITIONS</font></div><div style="margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">ARTICLE 2  &#160;LICENSES</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">2.1&#160;License Grant to Censa</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">2.2&#160;Sublicense Rights</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">2.3&#160;Disclosure Of Licensed Know-How</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">2.4&#160;Additional Rights</font></div><div style="margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">ARTICLE 3  &#160;DEVELOPMENT AND COMMERCIALIZATION</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">3.1&#160;Development</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">3.2&#160;Regulatory Matters</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">3.3&#160;Commercialization of Product</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">3.4&#160;Censa Access to Development Information and Shiratori Personnel and Consultants</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">3.5&#160;Joint Manufacturing Committee and Joint Concerns</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">3.6&#160;Development Phase Drug Substance Supply</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">3.7&#160;Development Assistance Services</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">3.8&#160;Commercial Phase Drug Substance Supply</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">3.9&#160;Failure to Supply and Second Source of Supply</font></div><div style="margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">ARTICLE 4&#160;INITIAL PAYMENT AND MILESTONE PAYMENTS</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">4.1&#160;Milestone Payments</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">4.2&#160;Backup or Alternative Revenue</font></div><div style="margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">ARTICLE 5&#160;ROYALTIES</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">5.1&#160;Royalty Rates</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">5.2&#160;Term of Royalties</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">5.3&#160;No Obligation</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">5.4&#160;Offset</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">5.5&#160;Reports and Payments</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">5.6&#160;Taxes and Withholding</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">5.7&#160;Currency Exchange</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">5.8&#160;Maintenance of Records&#59; Audits</font></div><div style="margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">ARTICLE 6&#160;REPRESENTATIONS, WARRANTIES, AND COVENANTS</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">6.1&#160;Mutual Representation and Warranties</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">6.2&#160;Additional Shiratori Respresentations, Warranties, and Covenants</font></div><div style="margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">ARTICLE 7&#160;CONFIDENTIALITY&#59; PUBLIC ANNOUNCEMENTS</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">7.1&#160;Confidentiality</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">7.2&#160;Authorized Disclosure</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">7.3&#160;SEC Filings</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">7.4&#160;Public Announcements</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">7.5&#160;Survival</font></div><div style="margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">ARTICLE 8&#160;INDEMNIFICATION</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">8.1&#160;Indemnification by Censa</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">8.2&#160;Indemnification by Shiratori</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">8.3&#160;Insurance Proceeds</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">8.4&#160;Survival</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">8.5&#160;Insurance</font></div><div style="position:relative;width:100%;height:67.5pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div><div style="padding-right:18pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">ARTICLE 9&#160;TERM AND TERMINATION</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">9.1&#160;Term</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">9.2&#160;Voluntary Termination by Censa</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">9.3&#160;Termination for Material Breach</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">9.4&#160;Consequences of Termination or Material Breach</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">9.5&#160;Bankruptcy</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">9.6&#160;Liabilities</font></div><div style="margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">ARTICLE 10&#160;INTELLECTUAL PROPERTY</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">10.1&#160;Ownership of Intellectual Property</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">10.2&#160;Patent Prosecution</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">10.3&#160;Infringement Actions Against Thrid Parties</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">10.4&#160;Infringement of Third Party Intellectual Property Rights</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">10.5&#160;Offset</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">10.6&#160;Compulsory Licenses</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">10.7&#160;Marks for the Product</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">10.8&#160;No Trademark Rights</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">10.9&#160;Invention Dates</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">10.10&#160;No Other Rights to Censa Intellectual Property</font></div><div style="margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">ARTICLE 11&#160;DISPUTES, GOVERNING LAW</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">11.1&#160;Disputes</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">11.2&#160;Governing Law</font></div><div style="margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">ARTICLE 12&#160;MISCELLANEOUS</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">12.1&#160;Assignment</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">12.2&#160;Further Actions</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">12.3&#160;Force Majeure</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">12.4&#160;Notices</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">12.5&#160;Amendment</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">12.6&#160;Waiver</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">12.7&#160;Counterparts</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">12.8&#160;Descriptive Headings</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">12.9&#160;Severability</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">12.10&#160;Entire Agreement of the Parties</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">12.11&#160;Independent Contractors</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">12.12&#160;Accrued Rights&#59; Surviving Obligations</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">12.13&#160;Compliance With Export Regulations</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">12.14&#160;No Third Party Beneficiaries</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">12.15&#160;No Strict Construction</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">12.16&#160;Language</font></div><div style="margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Schedules &#47; APPENDICES</font></div><div style="padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Schedule 6.2(b) &#8211; Licensed Patents &#47; Appendix A &#8211; Development Plan</font></div><div><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="position:relative;width:100%;height:67.5pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div><div style="padding-right:18pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">LICENSE AGREEMENT</font></div><div style="text-align:center;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">THIS LICENSE AGREEMENT (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), dated as of February 8th, 2016 (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Effective Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), is made by and between Shiratori Pharmaceutical Co., Ltd., a Kabushiki Kaisha (KK) corporation organized and existing under the laws of Japan and having its principal office at 2-3-7 Akanehama, Narashino-shi, Chiba-ken, 275-0024 JAPAN (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Shiratori</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) and Censa Pharmaceuticals Inc., a corporation organized and existing under the laws of the State of Delaware and having its principal office at 222 Third Street, Suite 2240, Cambridge, Massachusetts 02142 USA (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Censa</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  Capitalized terms not otherwise defined in this Agreement shall have the meanings set forth in Article 1.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">WITNESSETH&#58;</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">WHEREAS, Shiratori has developed the Product and is the owner of, or has the right to license to Censa, certain Licensed Technology relating thereto&#59;</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">WHEREAS, manufacture of the Product involves the practice of patented inventions and relies on know-how developed at the expense of Shiratori&#59;</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">WHEREAS, Censa is a specialty pharmaceutical company focusing on development and commercialization of innovative pharmaceutical drug products for the treatment of Central Nervous System (CNS) diseases&#59;</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">WHEREAS, Shiratori wishes to serve as supplier of the Product for clinical and commercial purposes&#59;</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">WHEREAS, Censa wishes to gain access to the Product for use in connection with and furtherance of its development and commercialization&#59;</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">WHEREAS, Shiratori </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">qua</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> licensor wishes to grant a license to Censa under the Licensed Technology to research, have researched, develop, have developed, make, have made, use, import, market, have marketed, offer for sale, sell and have sold the Product in the Territory&#59; and </font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">WHEREAS, Censa </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">qua</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> licensee wishes to obtain such a license from Shiratori, subject to the terms and conditions set forth in this Agreement&#59;</font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth in this Agreement, and for other good and valuable consideration the receipt and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows&#58;</font></div><div style="text-align:justify;"><font><br></font></div><div style="padding-left:193.5pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE 1.</font></div><div style="text-align:center;margin-top:0.06pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">DEFINITIONS</font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">When used in this Agreement, each of the following capitalized terms shall have the meanings set forth in this Article 1.</font></div><div style="position:relative;width:100%;height:67.5pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div><div style="padding-right:18pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">4</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:54pt;margin-top:0.06pt;margin-bottom:0.06pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.1 &#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Affiliate</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any corporation, company, partnership or other entity which controls, is controlled by, or is under common control with a specified entity. For purposes of this definition, &#8220;control&#8221; shall be presumed to exist where one entity owns directly or indirectly more than fifty percent (50%) (or such lesser percentage as may be the maximum percentage allowed to be owned by a foreign corporation under the applicable laws or regulations of a particular jurisdiction outside of the United States) of the equity having the power to vote in the election of directors or to direct the management and policies of another entity.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.2&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Business Day</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any day except a Saturday, Sunday, or any other day on which a commercial bank in Tokyo, Japan or Boston, Massachusetts is authorized to close.  Any reference in this Agreement to &#8220;day&#8221; whether or not capitalized shall refer to a calendar day, not a Business Day.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.3 &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Commercially Reasonable Efforts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means efforts and resources commonly used by a Party for a product owned by it or to which it has rights at a similar stage in its development or product life and of similar market potential taking into account efficacy, safety, the anticipated Regulatory Authority approved labeling, the competitiveness of alternative products in the marketplace or under development, the patent and other proprietary position of the product, the likelihood of Regulatory Approval, the profitability of the product and other relevant factors.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.4&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Confidential Information</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means all proprietary materials, know-how or other information (whether or not patentable) regarding a Party&#8217;s technology, products, business information or objectives, which is designated as confidential in writing by the Disclosing Party, whether by letter or by the use of an appropriate stamp or legend, prior to or at the time any such material, know-how or other information is disclosed by the Disclosing Party to the other Party.  Notwithstanding anything contained in the foregoing to the contrary, materials, know-how or other information which is orally, electronically or visually disclosed by a Party, or is disclosed in writing without an appropriate letter, stamp or legend, shall constitute Confidential Information of a Party (i) if the Disclosing Party, within &#91;**&#93; days after such disclosure, delivers to the other Party a written document or documents describing the materials, know-how or other information and referencing the place and date of such oral, visual, electronic or written disclosure and the names of the persons to whom such disclosure was made, or (ii) such information is of the type that is customarily considered to be confidential information by persons engaged in activities that are substantially similar to the activities being engaged in by the Parties.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.5&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Controls</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; or &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Controlled</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means with respect to the Licensed Technology, ownership or the possession of a respective license prior to or during the term of this Agreement and the ability to grant licenses or sublicenses without violating applicable laws or the terms of any agreement or other arrangement with, or the rights of, any Third Party.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.6&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Effective Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the date set forth in the preamble to this Agreement.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.7&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">European Union</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means, from time to time, those countries that are members of the European Union.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.8&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Evaluation Period</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the period of &#91;**&#93; months commencing with the Effective Date.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.9&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">FDA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the United States Food and Drug Administration, or any successor agency thereof.</font></div><div style="position:relative;width:100%;height:67.5pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div><div style="padding-right:18pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">5</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.10&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">First Commercial Sale</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means, with respect to any Product approved for commercial sale, the first arm's length sale by Censa or its Affiliates or sublicensees of such Product to a Third Party.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.11&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Force Majeure</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any occurrence beyond the reasonable control of a Party that prevents or substantially interferes with the performance by the Party of any of its obligations hereunder, if such occurs by reason of any act of God, flood, fire, explosion, earthquake, strike, lockout, labor dispute, casualty or accident&#59; or war, revolution, civil commotion, acts of public enemies, blockage or embargo&#59; or any injunction, law, order, proclamation, regulation, ordinance, demand or requirement of any government or of any subdivision, authority or representative of any such government&#59; or breakdown of plant, inability to procure or use materials, labor, equipment, transportation, or energy sufficient to meet manufacturing needs without the necessity of allocation&#59; or any other cause whatsoever, whether similar or dissimilar to those above enumerated, beyond the reasonable control of such Party, if and only if the Party affected shall have used reasonable efforts to avoid such occurrence and to remedy it promptly if it shall have occurred.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.12&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">IND</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means an Investigational New Drug Application, as defined in the U.S. Federal Food, Drug, and Cosmetic Act, as amended, and the regulations promulgated thereunder, and its foreign equivalent for initiating clinical trials in the United States or any corresponding foreign country.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.13&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Licensed Know-How</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the following to the extent owned or Controlled by Shiratori and&#47;or its Affiliates (a) as of the Effective Date or (b) arising at any time during the term of this Agreement solely by Shiratori or jointly by Shiratori and Censa&#58; technical, scientific and other know-how, data, materials, information, trade secrets, ideas, formulae, inventions, discoveries, processes, protocols, techniques, manufacturing processes, equipment for use in manufacturing and testing, sources of supply of components and raw materials and results of experimentation and testing as are reasonably necessary or useful for the research, development, registration, packaging, manufacture, use, distribution, or sale of the Product in the Territory, and shall include, without limitation, all data related to pre-clinical data, chemistry manufacturing control (CMC) data, regulatory information, reports, studies, clinical studies, processes and pre-clinical, chemistry manufacturing control (CMC), and other data.  Licensed Know-How excludes Licensed Patents.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.14&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Licensed Patents</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the following patent applications and patents owned or Controlled by Shiratori (a) as of the Effective Date or (b) arising at any time during the term of this Agreement solely by Shiratori or jointly by Shiratori and Censa, and all patents issuing from such patent applications and patents and otherwise arising from any improvement or enhancement of the manufacturing processes for or methods related to Sepiapterin, during the term of this Agreement&#58; (i) &#91;**&#93; (ii)  &#91;**&#93; entitled &#91;**&#93;&#59; and (iii) certain other patents owned by Shiratori, as are reasonably necessary or useful for the manufacture, use, and sale of the Product in the Territory, including the patent applications and&#47;or patents listed on Schedule 6.2 (b) attached hereto, and all foreign counterparts of any or to any of the aforesaid patents and&#47;or patent applications, and including, without limitation, as it may relate to any such patent applications and patents all provisional applications, substitutions, continuations, continuations-in-part, divisions, and renewals, all letters patent granted thereon, and </font></div><div style="position:relative;width:100%;height:67.5pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div><div style="padding-right:18pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">6</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">all patents-of-addition, reissues, reexaminations and extensions or restorations by existing or future extension or restoration mechanisms, certificates of invention or applications for certificates of invention, all supplementary protection certificates, substitutions, confirmations, registrations, revalidations, additions, continuations, continuations in-part, and divisions of any or to any of the aforesaid patent applications and patents.  Licensed Patents excludes Licensed Know-How.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.15&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Licensed Technology</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the Licensed Know-How and the Licensed Patents.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.16&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">NDA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means a New Drug Application pursuant to 21 U.S.C. Section 355(b)(1), as amended, and the regulations promulgated thereunder, submitted to the FDA or any successor application or procedure and any foreign counterpart of a U.S. New Drug Application for approval to market, including, where applicable, applications for pricing and reimbursement approval.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.17&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Net Sales</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the gross amount invoiced by Censa and&#47;or its Affiliates and&#47;or sublicensees on account of sales of the Product to Third Parties (including without limitation Third Party distributors and wholesalers), less the total of&#58;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;Trade, cash, quantity or other discounts not already reflected in the invoice price&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;Excise, sales and other consumption taxes (including VAT on the sale of the Product) and custom duties to the extent included in the invoice price&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;Freight, insurance and other transportation charges to the extent included in the invoice price&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;Amounts repaid or credited by reason of rejections, defects, recalls or returns or because of chargebacks, retroactive price reductions, refunds or billing errors&#59; and</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)&#160;Compulsory payments and rebates directly related to sales of the Product, accrued, paid or deducted pursuant to agreements (including, but not limited to, managed care agreements) or governmental regulations. </font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Use of the Product for promotional or sampling purposes and for use in clinical trials contemplated under this Agreement shall not be considered in determining Net Sales.  In the case of any sale of the Product between or among Censa and its Affiliates or sublicensees for resale, Net Sales shall be calculated as above only on the value charged or invoiced on the first arm&#8217;s length sale thereafter to a Third Party.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.18&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means Censa or Shiratori each individually as the case may be, and &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Parties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means Censa and Shiratori together collectively.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.19&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Person</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any individual, firm, corporation, partnership, limited liability company, trust, unincorporated organization or other entity or a government agency or political thereto, and shall include any successor (by merger or otherwise) of such Person.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.20&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Product</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any final pharmaceutical product in finished form containing Sepiapterin as active pharmaceutical ingredient (API) covered by Licensed Patents or using Licensed Know-How. </font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.21&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Drug Substance</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means Sepiapterin for use in the Product.</font></div><div style="position:relative;width:100%;height:67.5pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div><div style="padding-right:18pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">7</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.22&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Regulatory Approval</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the technical, medical and scientific licenses, registrations, authorizations and approvals (including, without limitation, IND's, approvals of NDAs, supplements and amendments, pre- and post- approvals, pricing and Third Party reimbursement approvals, and labeling approvals, together with all supplements thereto) of any national, supra-national, regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity, necessary for the development, manufacture, distribution, marketing, promotion, offer for sale, use, import, export or sale of Product(s) in a regulatory jurisdiction.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.23&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Regulatory Authority</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any national (</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">e.g</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">., the FDA), supra-national (</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">e.g</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">., the European Commission, the Council of the European Union, or the European Agency for the Evaluation of Medicinal Products), regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity in each country of the Territory involved in the granting of Regulatory Approval.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.24&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Regulatory Filings</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means, collectively, INDs, Biologics License Applications, Drug Master Files, NDAs and any other comparable filings as may be required by Regulatory Authorities to obtain Regulatory Approvals.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.25&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Territory&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> means all the countries and territories of the world outside of Japan.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.26&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Third Party(ies)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any Person other than Shiratori, Censa, and their respective Affiliates.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.27&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Valid Claim</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means a claim of an issued and unexpired patent or supplementary protection certificate within the Licensed Patents, which claim or supplementary protection certificate has not been held invalid or unenforceable by a court or other government agency of competent jurisdiction from which no appeal can be taken as of right or has been taken and has not been admitted to be invalid, canceled, or unenforceable through re-examination or disclaimer, opposition procedure, nullity suit.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.28&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Additional Definitions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Each of the following terms is defined in the section of this Agreement indicated below&#58;</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Term</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Breach Notice&#160;9.3</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Breaching Party&#160;9.3</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Censa&#160;Introductory Paragraph</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Censa Indemnified Parties&#160;8.2</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Censa Inventions&#160;10.1(a)</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Development Plan&#160;3.1</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Disclosing Party&#160;7.1</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Initial Term&#160;3.8(a)</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Insolvent Party&#160;9.5</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Inventions&#160;10.1</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Joint Inventions&#160;10.1(c)</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Joint Manufacturing Committee or JMC&#160;3.5</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Manufacturing Cost&#160;3.6</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Marks&#160;10.7</font></div><div style="position:relative;width:100%;height:67.5pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div><div style="padding-right:18pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#91;**&#93;&#160;2.4</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Non-Breaching Party&#160;9.3</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Paragraph IV Notice&#160;10.3(e)</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Receiving Party&#160;7.1</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Services Agreement&#160;3.7</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Shiratori&#160;Introductory Paragraph</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Shiratori Indemnified Parties&#160;8.1</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Shiratori Inventions&#160;10.1(b)</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Supply Agreement&#160;3.8</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Withholding Taxes&#160;5.6</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:center;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE 2.</font></div><div style="text-indent:18pt;text-align:center;margin-top:0.06pt;margin-bottom:0.18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">LICENSES</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.1&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">License Grants to Censa</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Shiratori hereby grants to Censa the sole and exclusive, even as to Shiratori, worldwide right and license, with the right to sublicense, under the Licensed Technology to research, have researched, develop, have developed, use, import, export, market, have marketed, offer for sale, sell and have sold, and otherwise commercialize the Product in the Territory.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.2&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Sublicense Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Censa shall have the right in its sole discretion to grant sublicenses and&#47;or to transfer this Agreement without consent by Shiratori.  In the event of sublicense by Censa, Censa promptly shall notify Shiratori in writing of the granting of such sublicense.  Each sublicense granted by Censa shall not conflict with the terms of this Agreement and Censa shall be responsible for the performance of each sublicensee of all obligations incumbent on Censa under this Agreement.  In addition, Censa may, without Shiratori&#8217;s consent, appoint distributors and sub-distributors throughout the Territory to assist in the commercialization of the Product if those distributors and sub-distributors do not require a sublicense under the License to commercialize the Product&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided, however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that no such appointment may adversely impact payments due from Censa to Shiratori.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.3&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Disclosure of Licensed Know-How</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  To the extent Shiratori has not already done so, promptly after the Effective Date, Shiratori shall make available to Censa the Licensed Know-How not previously furnished to Censa.  During the term of this Agreement, Shiratori shall disclose Licensed Know-How promptly to Censa as soon as such Licensed Know-How becomes available to Shiratori.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.4&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Additional Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Upon Censa&#8217;s written request, Shiratori shall make Commercially Reasonable Efforts to assist Censa in obtaining the exclusive license to certain intellectual property owned or Controlled by &#91;**&#93; related to the clinical use of Sepiapterin, including but not limited to &#91;**&#93; (the &#8220;&#91;**&#93;&#8221;).  In the event that Censa obtains the &#91;**&#93;, Censa shall sublicense licensed rights to Shiratori in Japan.  The Parties equitably shall share the cost of obtaining the &#91;**&#93; on a pro-rata basis to be mutually determined.</font></div><div style="text-align:center;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE 3.</font></div><div style="text-align:center;margin-top:0.06pt;margin-bottom:0.18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">DEVELOPMENT AND COMMERCIALIZATION</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3.1&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Development</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  </font></div><div style="position:relative;width:100%;height:67.5pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div><div style="padding-right:18pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;During the Evaluation Period, (i) Censa shall conduct initial pre-clinical studies in order to determine the feasibility of the Product as provided for in the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Development Plan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; set forth as Appendix A to and incorporated by reference in this Agreement and (ii) Shiratori shall supply to Censa the amount of Drug Substance reasonably necessary, and in any event at least &#91;**&#93; grams of Drug Substance, to conduct such studies.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;From and after the Effective Date, Censa shall have full legal and financial responsibility for all costs that are incurred and all activities that are undertaken after the signing of this Agreement, which are related to the development, safety, Regulatory Filings, required periodic reporting to the Regulatory Authorities, Regulatory Approvals, and other activities required by Censa or its sublicensee(s) (or their respective agents or distributors) to obtain appropriate Regulatory Approvals for, and to commercialize, the Product in the Territory.  Other than as expressly provided for in this Agreement, Censa shall not assume, nor shall Censa be liable for, any costs or activities (whether scientific, financial or otherwise) relating to the Product that were incurred or undertaken prior to the signing of this Agreement (including without limitation any costs, expenses, damages, losses, fines, penalties or the like that may be awarded or assessed after the signing of this Agreement, but which arise out of the events and activities that occurred prior to the signing of this Agreement)</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;Provided that the Affiliates, sublicensees and other Third Parties agree to substantially the same terms of confidentiality in Article 7, Censa may appoint such Affiliates, sublicensee(s) and other Third Parties to perform any and all development activities necessary to obtain Regulatory Approvals for the Product in the Territory.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;Censa shall, in a manner consistent with the effort Censa devotes to its own products having the same or similar potential value as the Product, exercise its Commercially Reasonable Efforts and diligence in developing and commercializing the Product, and in undertaking those investigations and actions required to obtain appropriate Regulatory Approvals to market the Product in the Territory.  All such activity shall be undertaken at Censa&#8217;s expense.  Shiratori shall use reasonable efforts to assist or to provide consultation at Censa&#8217;s expense in support of the pre-clinical and clinical development of the Product.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3.2&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Regulatory Matters</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Censa shall have complete control over, and authority and responsibility for, the regulatory strategies relating to the development and commercialization of the Product in the Territory and shall be responsible for all Regulatory Filings and Regulatory Approvals relating to the Product immediately after the Effective Date.  Shiratori shall transfer to Censa or take other action necessary to make available to Censa any Regulatory Filings and Regulatory Approvals (and updates thereof) initially filed by Shiratori.  Censa shall oversee, monitor and coordinate all regulatory actions, communications and filings with and submissions, including filings and submissions of supplements and amendments thereto, to any Regulatory Authority with respect to the Product.  Shiratori shall provide to Censa on a timely basis all necessary information to enable compliance with all regulatory obligations on a global basis, including without limitation filing updates, records related to product manufacturing and processes, pharmacovigilance filings, and investigator notifications.  Censa shall be responsible for interfacing, corresponding and meeting with all Regulatory Authorities with respect to the Product.  Shiratori shall cooperate with Censa to provide </font></div><div style="position:relative;width:100%;height:67.5pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div><div style="padding-right:18pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">10</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">all reasonable assistance and take all actions reasonably requested by Censa that are necessary or desirable (a) to enable Censa to comply with any law applicable to the Product, including, but not limited to, report adverse drug experience reports (and serious adverse drug experience reports) to Regulatory Authorities and (b) to coordinate with Censa regarding regulatory, development, manufacturing, and related status of the Product, Drug Substance, and its precursors in Japan.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3.3&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Commercialization of Product</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Censa shall have the sole discretion and exclusive right to commercialize, sell, market, promote and distribute the Product in the Territory.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3.4&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Censa Access to Development Information and Shiratori Personnel and Consultants</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.    Shiratori shall make available to Censa all relevant and readily available material and information related to Drug Substance, including but not limited to process development and manufacturing quality assurance (QA) &#47; quality control (QC) documentation, GMP and government inspection reports and certifications, preclinical data, clinical data, and regulatory filings and correspondence, within the reasonable control of Shiratori, as soon as reasonably practicable and in any event within &#91;**&#93; days of execution and delivery of a this Agreement.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3.5&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Joint Manufacturing Committee and Joint Concerns</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Parties shall establish a Joint Manufacturing Committee (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">JMC</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) comprised of an equal number of members from each Party.  The JMC shall manage the overall relationship between the Parties, including chemistry manufacturing and control information in support of Regulatory Filings for Regulatory Approval of the Product in the Territory and forecast for supply of Drug Substance.  In furtherance of the overall relationship between the Parties in general and Drug Substance supply in particular, whether for development-phase purposes under Section 3.6 below or commercialization-phase purposes under Section 3.8 below, Shiratori promptly and continuously shall inform the JMC of any and all discoveries, improvements, inventions, intellectual property or other proprietary rights, title, and interest that arise (including without limitation invention or similar disclosures) in Japan relevant to the Product, Licensed Patents, or Licensed Know-How.  Improvements by Censa to the manufacturing method specifically described in the Licensed Patent set forth in Section 1.14(i) above that are dominated by the claims of such Licensed Patent shall be communicated by Censa to Shiratori and may be used solely by Shiratori without compensation to Censa.  Pre-clinical and clinical data developed by either of the Parties in connection with development and use of the Product shall be communicated between the Parties and may be used as the case may be (i) by Censa in the Territory and (ii) by Shiratori in Japan, respectively, without compensation by either Party to the other Party.  The JMC shall establish a process for joint evaluation relative to the relationship between the Parties and performance of this Agreement, including without limitation as it may relate to patent filing, prosecution, maintenance, and enforcement pursuant to this Agreement.</font></div><div style="text-indent:54pt;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3.6&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Development Phase Drug Substance Supply</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;Shiratori shall be solely responsible for supplying Drug Substance for manufacturing pre-clinical and clinical supplies of Product.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;Shiratori shall supply Drug Substance solely to Censa and shall not, either directly or indirectly, market or sell Drug Substance anywhere in the Territory, excluding only the supply of Drug Substance to Censa under this Agreement.  Censa shall procure Drug Substance solely from Shiratori during the development phase.  For clarity and the avoidance of doubt, (i) Shiratori shall not supply Drug Substance to any Third Party </font></div><div style="position:relative;width:100%;height:67.5pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div><div style="padding-right:18pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">11</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">and (ii) Censa shall not procure Drug Substance from any Third Party during the development phase.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;Shiratori may use qualified Third-Party subcontractors to manufacture Drug Substance with the prior written approval of Censa.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;Shiratori shall supply Drug Substance to Censa in sufficient quantities for Censa to conduct its Development Plan (as set forth in Appendix A) at a price determined by the lowest of (i) the Manufacturing Cost plus &#91;**&#93; percent (&#91;**&#93;%) or (ii) the following respective amounts&#58; Shiratori&#8217;s &#8220;Manufacturing Cost&#8221; for this purpose, whether manufactured directly by Shiratori or through approved subcontractors, shall mean the direct materials cost, direct labor cost, and reasonably allocated manufacturing overhead consistent with generally accepted accounting principles (GAAP) in the contract manufacturing of pharmaceutical products.&#12288;</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.274%;"><tr><td style="width:1.0%;"></td><td style="width:30.765%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:31.333%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:31.902%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Product</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Amount of Drug Substance (as denominated in grams or kilograms)</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Price to Censa</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Non-GLP</font></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">GLP </font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#91;**&#93;g</font></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#91;**&#93;g </font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#165;    &#91;**&#93;</font></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#165;  &#91;**&#93;</font></div></td></tr></table></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.052%;"><tr><td style="width:1.0%;"></td><td style="width:30.293%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:31.027%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:32.680%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">cGMP</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;**&#93;g</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#165;  &#91;**&#93;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">cGMP</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;**&#93;Kg</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#165;  &#91;**&#93;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">cGMP</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;**&#93;Kg</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#165; &#91;**&#93;</font></td></tr></table></div><div style="padding-left:72pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">For clarity and the avoidance of doubt, in no event shall the actual price paid by Censa exceed the applicable amount set forth in the &#8220;Price to Censa&#8221; column of the table immediately above.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)&#160;The dates for the actual supply of Drug Substance during the Evaluation Period and the development phase shall be agreed upon between the Parties but in any event Shiratori shall not be obligated to supply Drug Substance earlier than the following dates&#58; (i) For the &#91;**&#93;g of Drug Substance for non-GLP Product, &#91;**&#93; months from the Effective Date, (ii) for the &#91;**&#93;g of Drug Substance for GLP and&#47;or cGMP Product as the case may be, &#91;**&#93; months from the Effective Date, or (iii) For &#91;**&#93;Kg of Drug Substance for cGMP Product, &#91;**&#93; months from the Effective Date.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(f)&#160;From and after the Effective Date, Shiratori shall work with Censa in good faith to improve Drug Substance manufacturing processes, manufacturing efficiencies and yield, and to reduce the overall Manufacturing Cost of Drug Substance.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(g)&#160;As soon as reasonably practicable, and in any event within &#91;**&#93; months from the Effective Date, Shiratori and Censa mutually shall execute and deliver a quality agreement providing for the quality of Drug Substance being supplied by Shiratori to Censa with related provisions customary for an agreement of that nature.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3.7&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Development Assistance Services Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  In the event Censa desires to have Shiratori provide advisory assistance or other services not otherwise expressly provided for in thisAgreement, and Shiratori agrees to do so, then the parties will endeavor to negotiate and enter into a definitive agreement on mutually acceptable terms and conditions, providing for the specified services to be performed by Shiratori (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Services Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) to be more fully described in one or more Scopes of Work, each Scope of Work to provide the basis for the payment by Censa to Shiratori for the services to be rendered by Shiratori and estimating the cost to Censa (provisions for determining </font></div><div style="position:relative;width:100%;height:67.5pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div><div style="padding-right:18pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">the cost shall be negotiated and included in the Services Agreement).  Neither Party will have any legal obligation to enter into any Services Agreement.  If a Services Agreement is entered into, then neither Party will have any legal obligation to enter into any Scope of Work thereunder.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3.9&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Commercialization Phase Drug Substance Supply</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;During the Evaluation Period the Parties shall negotiate in good faith the terms and conditions of a commercial-scale Drug Substance supply agreement (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Supply Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  The conditions to be negotiated shall include customary terms and conditions as may be found in comparable contract manufacturing agreements in the pharmaceutical industry, including customary rights for audit, inspection, quality systems assurance, forecasting and ordering, and governance of the Supply Agreement.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;For clarity and the avoidance of doubt, in no event shall any actual price to be paid by Censa under the Supply Agreement exceed the applicable amount set forth in the &#8220;Price to Censa&#8221; column of the table set forth in Section 3.6(d) above or Manufacturing Cost plus &#91;**&#93; percent (&#91;**&#93;%), whichever amount is less.  Notwithstanding the foregoing sentence, if Shiratori notifies Censa in writing during the Evaluation Period that it is not interested in entering into the Supply Agreement, then Censa shall have all rights provided for in Section 3.9 below including without limitation the right to enter into a commercial supply agreement with a Third Party.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3.9&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Failure to Supply and Second Source of Supply</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Supply Agreement shall contain failure to supply provisions pursuant to which Censa has the right to manufacture Drug Substance itself and&#47;or to engage a Third Party to manufacture Drug Substance on Censa&#8217;s behalf if Shiratori fails to supply Drug Substance pursuant to Censa&#8217;s purchase orders.  In the event such failure to supply continues for the period of time mutually set forth in the Supply Agreement, this Agreement shall be amended to include the license granted from Shiratori to Censa under Section 2.1 above the right to make and have made the Product in the Territory.  The Supply Agreement also shall contain second source provisions pursuant to which Censa in any event has the right to supply Drug Substance for itself or through a qualified Third Party to meet marketing needs in the Territory.</font></div><div style="text-align:center;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE 4.</font></div><div style="text-align:center;margin-top:0.06pt;margin-bottom:0.18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">INITIAL PAYMENT AND MILESTONE PAYMENTS</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">4.1&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Milestone Payments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Each of the following amounts shall be payable by Censa to Shiratori in U.S. Dollars within &#91;**&#93; days following confirmation by Censa that the specified event has occurred&#58;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;US$&#91;**&#93; upon &#91;**&#93;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;US$&#91;**&#93; upon &#91;**&#93;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;US$&#91;**&#93; upon &#91;**&#93;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;US$&#91;**&#93; upon &#91;**&#93;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)&#160;US$&#91;**&#93; upon &#91;**&#93;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(f)&#160;US$&#91;**&#93; upon &#91;**&#93;</font></div><div style="position:relative;width:100%;height:67.5pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div><div style="padding-right:18pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">13</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">For clarity and the avoidance of doubt, the obligation of Censa (or its sublicensee, as the case may be) to pay the foregoing amounts shall apply and shall survive notwithstanding any sublicense by Censa under this Agreement.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">4.2&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Backup or Alternative Product</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  For clarity and the avoidance of doubt, it is understood that if, for any reason whatsoever, the development of the Product is discontinued in any indication prior to such Product achieving Regulatory Approval, the selection of a backup of such Product or a different Product for development in that same or a different indication shall not trigger the reimbursement by Shiratori or further payment by Censa of any milestone already paid with respect to the terminated Product.</font></div><div style="text-align:center;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE 5.</font></div><div style="text-align:center;margin-top:0.06pt;margin-bottom:0.18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ROYALTIES</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">5.1&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Royalty Rates</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  In further consideration of the licenses granted in this Agreement, Censa shall pay to Shiratori royalties on the Product based on aggregate Net Sales of such Product on a country-by-country basis in the Territory in the amount of &#91;**&#93; percent (&#91;**&#93;%).</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">5.2&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Term of Royalties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Royalties shall be payable for each full calendar year during the term of this Agreement and on an aggregate </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">pro rata</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> basis for the first and last year of commercialization during the term of this Agreement if such first and last years are not comprised of a full twelve (12) months, as follows&#58;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;With respect to royalties payable for the countries of the European Union, until expiration of the last-to-expire Licensed Patent Controlled by Shiratori covering the European Union if the making, having made, using, offering to sell, selling or importing of such Product by Censa, its Affiliates or its sublicensees (or the distributors of any of them) in the absence of this Agreement, would infringe one or more Valid Claim of the Licensed Patents in the European Union.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;With respect to royalties payable for the United States, until the expiration of the last-to-expire Licensed Patent Controlled by Shiratori covering the United States if the making, having made, using, offering to sell, selling or importing of such Product by Censa, its Affiliates or its sublicensees (or the distributors of any of them) in the absence of this Agreement, would infringe one or more Valid Claim of the Licensed Patents in the United States.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;With respect to royalties payable for any other country in the Territory, until the expiration of the last-to-expire Licensed Patent Controlled by Shiratori covering the relevant country on a country-by-country basis if the making, having made, using, offering to sell, selling or importing of such Product by Censa, its Affiliates or its sublicensees (or the distributors of any of them) in the absence of this Agreement, would infringe one or more Valid Claim of the Licensed Patents in the relevant country.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">5.3&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">No Obligation.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  Notwithstanding any other provision in this Agreement to the contrary, Censa shall have no obligation to launch any Product in any country.  In addition, Censa may, in its sole discretion, discontinue its commercialization of any Product in any country.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">5.4&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Offset</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  </font></div><div style="position:relative;width:100%;height:67.5pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div><div style="padding-right:18pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">14</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;In the event that Censa is required to pay a non-affiliated Third Party royalty or other amounts with respect to a Product under agreements for patent rights or other technologies that Censa in its reasonable judgment determines are necessary or desirable to license or acquire with respect to the Product or Licensed Technology (including without limitation amounts paid in connection with the &#91;**&#93;), and only if Censa obtains a prior written consent from Shiratori (which consent shall not be unreasonably, conditioned, delayed, or withheld by Shiratori) to pay such royalty or other amounts, then amounts owed by Censa to Shiratori under this Agreement will be reduced by the amounts paid by Censa to non-affiliated Third Parties&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided, however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that the maximum reduction shall be &#91;**&#93; percent (&#91;**&#93;%) of the amounts otherwise owed by Censa to Shiratori.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">5.5&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Reports and Payments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Cumulative Royalties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The obligation to pay royalties under this Article 5 shall be imposed only once (i) with respect to any sale of the same unit of Product and (ii) with respect to a single unit of Product regardless of how many Valid Claims or other Licensed Patents included in the Licensed Technology would, but for this Agreement, be infringed by the making, using or selling of such Product.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Statements and Payments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Censa shall deliver to Shiratori within &#91;**&#93; days after the end of each calendar quarter a report setting forth for such calendar quarter the following information on a Product-by-Product basis and a country-by country basis&#58; (i) Net Sales of such Product and (ii) the royalty due hereunder for the sale of such Product.  The total royalty due for the sale of the Product during such calendar quarter shall be remitted within &#91;**&#93; business days from the time such report is made if and to the extent Censa actually then has received corresponding proceeds from applicable Net Sales, or, if and to extent Censa then has not received such proceeds, as soon as reasonably practicable after receiving such proceeds.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">5.6&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Taxes and Withholding</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Any payments made by Censa to Shiratori under this Agreement shall be reduced by the amount that Censa is required to pay or withhold pursuant to any applicable law, including, but not limited to, foreign and United States federal, state or local tax law (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Withholding Taxes</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  Any such Withholding Taxes required by law to be paid or withheld shall be an expense of, and borne solely by, Shiratori.  Censa shall submit to Shiratori reasonable proof of payment of the Withholding Taxes within a reasonable period of time after such Withholding Taxes are remitted to the proper authority.  The Parties shall reasonably cooperate in completing and filing documents required under the provisions of any applicable tax laws or under any other applicable law in connection with the making of any required tax payment or withholding payment, or in connection with any claim to a refund of or credit for any such payment.  The Parties shall charge each other value-added taxes in accordance with the applicable law in addition to any consideration or payment agreed upon.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">5.7&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Currency Exchange</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  With respect to Net Sales invoiced in U.S. dollars, the Net Sales and the amounts due to Shiratori hereunder shall be expressed in U.S. dollars.  With respect to Net Sales invoiced in a currency other than U.S. dollars, the Net Sales shall be expressed in the domestic currency of the entity making the sale, together with the U.S. dollar equivalent, calculated using the arithmetic average of the spot rates on the last Business Day of each month of the calendar </font></div><div style="position:relative;width:100%;height:67.5pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div><div style="padding-right:18pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">15</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">quarter in which the Net Sales were made.  The &#8220;closing mid-point rates&#8221; found in the &#8220;Dollar spot forward against the Dollar&#8221; table published by </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">The Financial Times</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> or any other publication as agreed to by the Parties shall be used as the source of spot rates to calculate the average as defined in the preceding sentence.  All payments shall be made in United States dollars.  If at any time legal restrictions in any country in the Territory prevent the prompt remittance of any payments with respect to sales in that country, Censa shall have the right and option to make such payments by depositing the amount thereof in local currency to Shiratori&#8217;s account in a bank or depository in such country.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">5.8&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Maintenance of Records&#59; Audit</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  For a period of &#91;**&#93; years, Censa shall maintain and shall cause its Affiliates and sublicensees to maintain complete and accurate books and records in connection with the sale of the Product, as necessary to allow the accurate calculation of royalties due hereunder including any records required to calculate any royalty adjustments hereunder.  &#91;**&#93; per calendar year, Shiratori shall have the right to engage an independent accounting firm acceptable to Censa, at Shiratori&#8217;s expense, which shall have the right to examine in confidence the relevant Censa records as may be reasonably necessary to determine and&#47;or verify the amount of royalty payments due hereunder.  Such examination shall be conducted during Censa&#8217;s normal business hours, after at least &#91;**&#93; days' prior written notice to Censa and shall take place at Censa&#8217;s facility(ies) where such records are maintained.  Each such examination shall be limited to pertinent books and records for any year ending not more than &#91;**&#93; months prior to the date of request.  Before permitting such independent accounting firm to have access to such books and records, Censa may require such independent accounting firm and its personnel involved in such audit, to sign a confidentiality agreement (in form and substance reasonably acceptable to Censa) as to any of the confidential information of Censa, its Affiliates or sublicensees which is to be provided to such accounting firm or to which such accounting firm shall have access, while conducting the audit under this Section.  Shiratori&#8217;s independent accounting firm shall prepare and provide to both Shiratori and Censa a written report disclosing only whether the royalty reports submitted and royalties paid by Censa are correct or incorrect and the specific details concerning any discrepancies.  No other information shall be provided to Shiratori.  In the event there was an underpayment by Censa hereunder, Censa shall promptly (but in no event later than &#91;**&#93; days after Censa&#8217;s receipt of the independent auditor&#8217;s report so correctly concluding) make payment to Shiratori of any shortfall.  In the event that there was an overpayment by Censa hereunder, Shiratori shall promptly (but in no event later than &#91;**&#93; days after Shiratori&#8217;s receipt of the independent auditor&#8217;s report so correctly concluding) refund to Censa the excess amount.  In the event any payment by Censa shall prove to have been incorrect by more than &#91;**&#93; percent (&#91;**&#93;%) to Shiratori&#8217;s detriment, Censa shall pay the reasonable fees and costs of Shiratori&#8217;s independent auditor for conducting such audit.</font></div><div style="text-align:center;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE 6.</font></div><div style="text-align:center;margin-top:0.06pt;margin-bottom:0.18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">REPRESENTATIONS, WARRANTIES, AND COVENANTS</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">6.1&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Mutual Representations and Warranties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Each Party respectively hereby represents and warrants to the other Party that&#58;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;such Party is a corporation duly organized, validly existing and in good standing under the laws of the state or other jurisdiction of incorporation or formation and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof&#59;</font></div><div style="position:relative;width:100%;height:67.5pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div><div style="padding-right:18pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">16</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;such Party is duly authorized, by all requisite corporate action, to execute and deliver this Agreement and the execution, delivery and performance of this Agreement by such Party does not require any shareholder action or approval, and the Person executing this Agreement on behalf of such Party is duly authorized to do so by all requisite corporate action&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;no consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any federal, state or local governmental authority is required on the part of such Party in connection with the valid execution, delivery and performance of this Agreement, except where the failure to obtain any of the foregoing would not have a material adverse impact on the ability of such Party to meet its obligations hereunder&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;this Agreement is a legal and valid obligation binding upon such Party and enforceable in accordance with its terms except as (i) enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the enforcement of creditors&#8217; rights and (ii) equitable principles of general applicability&#59; and</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)&#160;the execution, delivery and performance by it of this Agreement and its compliance with the terms and provisions of this Agreement does not and shall not conflict with or result in a breach of any of the terms or provisions of (i) any other contractual or other obligations of such Party, (ii) the provisions of its charter, operating documents or bylaws, or (iii) any order, writ, injunction or decree of any court or governmental authority entered against it or by which it or any of its property is bound except where such breach or conflict would not materially impact the Party&#8217;s ability to meet its obligations hereunder.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">6.2&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Additional Shiratori Representations, Warranties, and Covenants</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Shiratori represents, warrants, and covenants to Censa that&#58; </font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;it has the full right, power and authority to grant the licenses granted to Censa under Article 2 hereof&#59; </font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;all Licensed Patents included within the Licensed Technology which are existing as of the Effective Date are listed on Schedule 6.2(b) hereto and, as of the Effective Date, such Licensed Patents are existing and, to its knowledge, are not invalid or unenforceable, in whole or in part&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;except as previously disclosed to Censa in writing (i) it is the sole and exclusive owner or the exclusive Censa of the rights, title, and interest in and to the Licensed Technology, free and clear of any liens, charges or encumbrances, including, without limitation, all Licensed Patents included in the Licensed Technology, and (ii) no Third Party has any right, title or interest in or to the Licensed Technology&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;except as disclosed to Censa in writing (i) all inventors (who are known as of the Effective Date) of any inventions included within the Licensed Technology have assigned (or are deemed to have assigned by applicable law) their entire right, title and interest in and to such inventions and the corresponding Licensed Patents to Shiratori and (ii) no Person, other than those Persons named as inventors on any patent or patent </font></div><div style="position:relative;width:100%;height:67.5pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div><div style="padding-right:18pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">17</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">application included within the Licensed Technology, is an inventor of the invention(s) claimed in such patent or patent application&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)&#160;as of the Effective Date, there are no claims, judgments or settlements against, or owed by, Shiratori or, to its knowledge, pending or threatened claims or litigation relating to the Licensed Technology and during the term of this Agreement Shiratori shall promptly notify Censa in writing upon learning of any such actual or threatened claim, judgment or settlement&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(f)&#160;during the term of this Agreement, Shiratori shall use Commercially Reasonable Efforts not to diminish the rights under the Licensed Technology&#59; </font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(g)&#160;except as previously disclosed to Censa in writing, as of the Effective Date it is not aware of any patent, patent application or other intellectual property right of any Third Party which could materially adversely affect the ability of either Party to carry out its respective obligations hereunder or the ability of Censa to exercise or exploit any of the rights or licenses granted to it under this Agreement&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(h)&#160;except as previously disclosed to Censa in writing, it has no knowledge of any material information which would negatively affect the ability of Censa to use the Licensed Technology&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(i)&#160;during the term of this Agreement, Shiratori shall not grant any right to any Third Party relating to any of the Licensed Technology which would conflict with, limit or adversely affect the rights granted to Censa hereunder&#59; </font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(j)&#160;Shiratori shall fulfill its covenants in relation to the JMC as provided for in Section 3.5 above&#59; and</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(k)&#160;Drug Substance sold by Shiratori to Censa for use in preclinical development and clinical trials of the Product shall meet applicable specifications at the time of delivery, and shall have been manufactured in compliance with law applicable in the country of manufacture, the United States, and the European Union.</font></div><div style="text-align:center;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE 7.</font></div><div style="text-align:center;margin-top:0.06pt;margin-bottom:0.18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">CONFIDENTIALITY&#59; PUBLIC ANNOUNCEMENTS</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">7.1&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Confidentiality</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Except to the extent expressly authorized by this Agreement or otherwise agreed in writing, the Parties agree that, until &#91;**&#93; years after the expiration or termination of this Agreement, each Party (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Receiving Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) receiving hereunder any Confidential Information of the other Party (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Disclosing Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) or information of the other Party marked &#8220;Confidential&#8221; shall keep such information confidential and shall not publish or otherwise disclose or use for any purpose other than as provided for in this Agreement, except to the extent that it can be established by the Receiving Party that the Confidential Information&#58;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;was already known to the Receiving Party, or its Affiliates (other than under an obligation of confidentiality) at the time of disclosure by the Disclosing Party, and such Receiving Party can so demonstrate by documentary evidence to that effect&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;was generally available to the public or otherwise part of the public domain at the time of its disclosure to the Receiving Party&#59;</font></div><div style="position:relative;width:100%;height:67.5pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div><div style="padding-right:18pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">18</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission in breach of a confidentiality obligation&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;was disclosed to the Receiving Party or its Affiliates other than under an obligation of confidentiality by a Third Party who had no obligation to the Disclosing Party or its Affiliate not to disclose such information to others&#59; or</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)&#160;was independently discovered or developed by the Receiving Party or its Affiliates without the use of the Confidential Information belonging to the Disclosing Party or its Affiliates and the Receiving Party can so demonstrate by documentary evidence to that effect.</font></div><div style="padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Each Party's Affiliates may receive, use and provide Confidential Information in the performance of the rights and obligations described in this Agreement.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">7.2&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Authorized Disclosure</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Each Party may disclose Confidential Information belonging to the other Party to the extent such disclosure is reasonably necessary to&#58;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;file or prosecute patent applications claiming inventions included within the Licensed Technology&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;prosecute or defend litigation&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;exercise rights hereunder provided such disclosure is covered by terms of confidentiality similar to those set forth in this Agreement&#59; and</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;comply with applicable governmental laws and regulations.</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">In the event a Party shall deem it necessary to disclose, pursuant to this Section 7.2, Confidential Information belonging to the other Party, such Party shall, to the extent possible, give reasonable advance notice of such disclosure to the other Party and take reasonable measures to ensure confidential treatment of such information.  For clarity and the avoidance of doubt, Censa in any event may disclose (i) the existence of its license and related Product rights under this Agreement, (ii) under appropriate confidentiality protection the terms and conditions of this Agreement to current and potential investors, investment bankers and other financial advisors, and strategic partners, and (iii) as required by government and regulatory authorities including without limitation the United States Securities and Exchange Commission.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">7.3&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">SEC Filings</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Parties shall agree in advance with each other on the terms of this Agreement to be redacted in any Securities and Exchange Commission filings.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">7.4&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Public Announcements</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Parties agree on the importance of coordinating their public announcements respecting this Agreement and the subject matter thereof. Neither Party shall make any public release, public statement or other disclosure concerning this Agreement or its terms, without the prior written consent and approval of the other Party, which approval shall not be unreasonably conditioned, delayed, or withheld.  Notwithstanding the preceding sentence, each Party may make any disclosures, statements or releases regarding this Agreement or its terms as are required by applicable law&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided, however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that the Party seeking to make such disclosure gives the other Party at least &#91;**&#93; days prior written notice of such disclosure (unless a shorter time period for such </font></div><div style="position:relative;width:100%;height:67.5pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div><div style="padding-right:18pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">19</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">disclosure is required by applicable law) and provides such Party in good faith the right to review and comment upon such disclosure.  In addition, Censa may disclose the existence and terms of this Agreement to its accountants, attorneys, and other professional advisors under a duty of confidentiality and to a Third Party under a duty of confidentiality in connection with any proposed or consummated financing or a proposed or consummated sale of all or substantially all of Censa&#8217;s business to which this Agreement relates.</font></div><div style="text-indent:54pt;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">7.5&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Survival</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.    The provisions of this Article 7 shall survive termination or expiration of this Agreement.</font></div><div style="text-align:center;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE 8.</font></div><div style="text-align:center;margin-top:0.06pt;margin-bottom:0.18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">INDEMNIFICATION</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8.1&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Indemnification by Censa</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Censa agrees to defend Shiratori and its Affiliates at Censa&#8217;s cost and expense, and shall indemnify and hold Shiratori and its Affiliates and their respective directors, officers, employees and agents (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Shiratori Indemnified Parties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) harmless from and against any losses, costs, damages, fees or expenses arising out of any Third Party claim relating to (i) any material breach by Censa of any of its representations, warranties or obligations pursuant to this Agreement, (ii) the negligence or willful misconduct of Censa in the performance of any of its obligations pursuant to this Agreement, or (iii) Censa&#8217;s use of the Drug Substance or Product if and to the extent Drug Substance or Product meets or exceeds applicable written specifications.  In the event of any such claim against the Shiratori Indemnified Parties by any Third Party, Shiratori shall promptly notify Censa in writing of the claim and Censa shall manage and control, at its sole expense, the defense of the claim and its settlement&#59; provided that Censa shall not agree to any settlement that would admit liability on the part of Shiratori or involve relief other than the payment of money, without the approval of Shiratori, such approval not to be unreasonably conditioned, delayed, or withheld.  The Shiratori Indemnified Parties shall cooperate with Censa and may, at their option and expense, be represented in any such action or proceeding.  Censa shall not be liable for any litigation costs or expenses incurred by the Shiratori Indemnified Parties without Censa&#8217;s prior written authorization.  In addition, Censa shall not be responsible for the indemnification or defense of any Shiratori Indemnified Party arising from any negligent or intentional acts by any Shiratori Indemnified Party or the breach by Shiratori of any representation, warranty or obligation under this Agreement, or any claims compromised or settled without its prior written consent.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8.2&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Indemnification by Shiratori</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Shiratori agrees to defend Censa and its Affiliates at Shiratori&#8217;s cost, and shall indemnify and hold Censa and its Affiliates and their respective directors, officers, employees and agents (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Censa Indemnified Parties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) harmless from and against any losses, costs, damages, fees or expenses arising out of any Third Party claim relating to (i) any material breach by Shiratori of any of its representations, warranties or obligations pursuant to this Agreement or (ii) the negligence or willful misconduct of Shiratori in the performance of any of its obligations pursuant to this Agreement.  In the event of any claim against the Censa Indemnified Parties by any Third Party, Censa shall promptly notify Shiratori in writing of the claim and Shiratori shall manage and control, at its sole expense, the defense of the claim and its settlement&#59; provided that Shiratori shall not agree to any settlement that would admit liability on the part of Censa or involve relief other than the payment of money, without the approval of Censa, not to be unreasonably conditioned, delayed, or withheld.  The Censa Indemnified Parties shall cooperate with Shiratori and may, at their option and expense, be represented in any such action or proceeding.  Shiratori shall not be liable for </font></div><div style="position:relative;width:100%;height:67.5pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div><div style="padding-right:18pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">20</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">any litigation costs or expenses incurred by the Censa Indemnified Parties without Shiratori&#8217;s prior written authorization.  In addition, Shiratori shall not be responsible for the indemnification or defense of any Censa Indemnified Party arising from any negligent or intentional acts by any Censa Indemnified Party, or the breach by Censa of any representation, warranty or obligation under this Agreement, or any claims compromised or settled without its prior written consent.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8.3&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Insurance Proceeds</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Any indemnification hereunder shall be made net of any insurance proceeds recovered by the indemnified Party&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided, however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that if, following the payment to the indemnified Party of any amount under this Article 8, such indemnified Party recovers any insurance proceeds in respect of the claim for which such indemnification payment was made, the indemnified Party shall promptly pay an amount equal to the amount of such proceeds (but not exceeding the amount of such indemnification payment) to the indemnifying Party.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8.4&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Survival</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.    The indemnification obligations set forth in this Article 8 shall survive the termination or expiration of this Agreement.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8.5&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Insurance</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Each Party further agrees to use its Commercially Reasonable Efforts to obtain and maintain commercial general liability insurance, including products liability insurance in timely fashion with respect to clinical-trial commencement, with reputable and financially secure insurance carriers or self-insurance, in such amounts and subject to such deductibles as the Parties may agree based upon standards prevailing in the industry at the time.</font></div><div style="text-align:center;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE 9.</font></div><div style="text-align:center;margin-top:0.06pt;margin-bottom:0.18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">TERM AND TERMINATION</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9.1&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Term</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;Unless earlier terminated by mutual agreement of the Parties or pursuant to the provisions of this Article 9, this Agreement shall continue in full force and effect on a country-by-country and Product-by-Product basis until the obligation to pay royalties with respect to the sale of such Product in such country expires or this Agreement is earlier terminated in accordance with the terms hereof.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;On a country-by-country basis and on a Product-by-Product basis, upon the scheduled expiration (as contemplated in Section 5.2) of the obligation to pay Royalties with respect to the sale of such Product in such country, the licenses granted hereunder shall become non-exclusive, fully paid up, royalty-free, perpetual and irrevocable, notwithstanding subsequent expiration or termination of this Agreement.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9.2&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Voluntary Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  </font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">By Censa</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  At any time during the term of this Agreement, Censa may elect to terminate this Agreement upon sixty (60) days&#8217; prior written notice to Shiratori.  Censa shall, as of the effectiveness of such termination, be relieved of any and all further obligations to make payments to Shiratori under this Agreement to the extent not accrued prior to such termination.  Censa also shall be relieved of any and all further obligations with respect to patents and patent applications in the Territory</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">By Shiratori</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Unless otherwise agreed between the Parties in writing, Shiratori may elect to terminate this Agreement upon sixty (60) days&#8217; prior written notice to Censa in the event that Censa fails (i) to achieve Regulatory Approval in either the United States </font></div><div style="position:relative;width:100%;height:67.5pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div><div style="padding-right:18pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">21</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">or European Union for at least one indication within six (6) years or (ii) to launch the Product in the United States or European Union within seven (7) years from the Effective Date.  Censa shall, as of the effectiveness of such termination, be relieved of any and all further obligations to make payments to Shiratori under this Agreement to the extent not accrued prior to such termination.  Censa also shall be relieved of any and all further obligations with respect to patents and patent applications in the Territory.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9.3&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Termination for Material Breach</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  </font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;Upon a material breach of this Agreement by Censa or Shiratori (in such capacity, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Breaching Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), the other Party (in such capacity, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Non-Breaching Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) may provide written notice (a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Breach Notice</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) to the Breaching Party specifying the material breach.  If the Breaching Party fails to cure such material breach during the &#91;**&#93; day period (or, if applicable, such longer period, but not to exceed &#91;**&#93; days, as would be reasonably necessary for a diligent party to cure such material breach, provided the Breaching Party has commenced and continues its diligent efforts to cure during the initial &#91;**&#93; day period following the date on which the Breach Notice is provided) following the date on which the Breach Notice is provided, then the other Party may terminate this Agreement immediately upon the expiration of the &#91;**&#93; day (or other longer) period upon written notice to the Breaching Party.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;Notwithstanding any other provisions of this Agreement to the contrary, the consequences of termination for material breach set forth above shall not become effective until after final and unappealable adjudication of the occurrence and failure to timely cure any such material breach.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9.4&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Consequences of Termination or Material Breach</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Voluntary Termination by Censa</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  In the event this Agreement is voluntarily terminated by Censa pursuant to Section 9.2(a) above, all licenses granted by Shiratori to Censa pursuant to Section 2.1 above shall terminate</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Voluntary Termination by Shiratori</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  In the event this Agreement is voluntarily terminated by Shiratori pursuant to Section 9.2(b) above, all licenses granted by Shiratori to Censa pursuant to Section 2.1 above shall terminate.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Material Breach by Censa</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  In the event that Censa commits a material breach of this Agreement and such material breach is not cured in accordance with the provisions of Section 9.3 above, then at Shiratori&#8217;s election to terminate this Agreement, all licenses granted by Shiratori to Censa pursuant to Section 2.1 shall terminate.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Material Breach by Shiratori</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  In the event that Shiratori commits a material breach of this Agreement and such material breach is not cured in accordance with the provisions of Section 9.3 above, then Censa may in its discretion, terminate this Agreement, in which event all licenses granted by Shiratori to Censa pursuant to Section 2.1 above shall terminate, but Censa (in addition to its indemnification rights under Section 8.2 above) shall have the right to compensation from Shiratori for any and all losses, costs, damages, fees or expenses Censa and its Affiliates and sublicensees may incur as a result of such material breach.  In the event Censa decides </font></div><div style="position:relative;width:100%;height:67.5pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div><div style="padding-right:18pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">22</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">not to terminate this Agreement for material breach by Shiratori, Censa shall have the right to continue to develop and to commercialize the Product provided that the royalties otherwise payable by Censa to Shiratori pursuant to Article 5 shall be reduced by &#91;**&#93; Percent (&#91;**&#93;%), and Censa shall also have the right to offset any costs it may incur as a result of such material breach against the amounts payable to Shiratori hereunder.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Additional Remedies</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The rights of the Non-Breaching Party set forth in paragraphs (b) or (c) of this Section 9.4 above shall be in addition to any other remedies to which the Non-Breaching Party may otherwise be entitled at law or equity for such breaches.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(f)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Rights and Duties Upon Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Upon early termination of this Agreement, in its entirety or with respect to any country or Product, Censa shall notify Shiratori of the amount of Product that Censa, its Affiliates and sublicensees then have on hand for sale in such country(ies), the sale of which would, but for the termination, be subject to royalty.  Censa, its Affiliates and sublicensees shall thereupon be permitted to sell that amount of Product, provided that Censa shall pay the royalty thereon to Shiratori at the time provided for in this Agreement.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9.5&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Bankruptcy</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Each Party may, in addition to any other remedies available to it by law or in equity, exercise the rights set forth below by written notice to the other Party (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Insolvent Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), in the event the Insolvent Party shall have become insolvent or bankrupt, or shall have made an assignment for the benefit of its creditors, or there shall have been appointed a trustee or receiver of the Insolvent Party or for all or a substantial part of its property, or any case or proceeding shall have been commenced or other action taken by or against the Insolvent Party in bankruptcy or seeking reorganization, liquidation, dissolution, winding-up arrangement, composition or readjustment of its debts or any other relief under any bankruptcy, insolvency, reorganization or other similar act or law of any jurisdiction now or hereafter in effect, or there shall have been issued a warrant of attachment, execution, restraint or similar process against any substantial part of the property of the Insolvent Party, and any such event shall have continued for &#91;**&#93; days undismissed, unbonded, or undischarged.  All rights and licenses granted under or pursuant to this Agreement by Shiratori are, and shall otherwise be deemed to be, for purposes of Section 365 (n) of the U.S.  Bankruptcy Code, licenses of rights to &#8220;intellectual property&#8221; as defined under Section 101 of the U.S.  Bankruptcy Code.  The Parties agree that Censa as licensee of such rights under this Agreement shall retain and may fully exercise all of its rights and elections under the U.S.  Bankruptcy Code.  The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against Shiratori under the U.S.  Bankruptcy Code, Censa shall be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, and same, if not already in the its possession, shall be promptly delivered to it (i) upon any such commencement of a bankruptcy proceeding upon its written request therefor, unless Shiratori elects to continue to perform all of its obligations under this Agreement or (ii) if not delivered under (i) above, upon the rejection of this Agreement by or on behalf of Shiratori upon written request therefor by Censa.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9.6&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Liabilities</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Expiration or termination of this Agreement shall not release either Party from any obligation or liability which shall have accrued at the time of termination, or preclude </font></div><div style="position:relative;width:100%;height:67.5pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div><div style="padding-right:18pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">23</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">either Party from pursuing all rights at law and in equity with respect to any breach under this Agreement.  Notwithstanding the foregoing, except as may be the case under Article 8, neither Party shall be liable for punitive, exemplary or consequential damages incurred by the other Party arising out of any default under this Agreement.</font></div><div style="text-align:center;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE 10.</font></div><div style="text-indent:18pt;text-align:center;margin-top:0.06pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">INTELLECTUAL PROPERTY</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">10.1&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Ownership of Intellectual Property</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  It is anticipated that during the course and as a result of the Parties&#8217; performance under this Agreement discoveries, improvements, inventions, writings, and other technology, whether or not patentable or copyrightable (collectively, &#8220;Inventions&#8221;) may be conceived, made, or reduced to practice by the respective personnel of Censa and&#47;or Shiratori.  Ownership of Inventions shall be determined as follows&#58;  </font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;Any Inventions conceived, made, or reduced to practice solely by employees of or Third Parties acting on behalf of Censa or a Censa Affiliate or sublicensee (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Censa Inventions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) shall be owned by Censa and recorded in a conception register and shall be submitted to Censa patent counsel.  Censa promptly shall disclose to Shiratori the conception, making, or reduction to practice of Censa Inventions.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;Any Inventions conceived, made, or reduced to practice solely by employees of or Third Parties acting on behalf of Shiratori or a Shiratori Affiliate (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Shiratori Inventions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) shall be owned by Shiratori and recorded in a conception register and shall be submitted to Shiratori patent counsel.  Shiratori promptly shall disclose to Censa the conception, making, or reduction to practice of Shiratori Inventions.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;All Inventions that are conceived, made, or reduced to practice jointly by employees of Censa or a Censa Affiliate or sublicensee or Third Parties acting on their behalf, on the one hand, and Shiratori or a Shiratori Affiliate or Third Parties acting on their behalf, on the other hand, and which are not Censa Inventions or Shiratori Inventions, are &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Joint Inventions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; and shall be jointly owned by the Parties (with patent-related responsibilities allocated at a ratio agreed upon by the Parties in good faith as provided for in Section 10.2(b) below) and recorded in a conception register and shall be submitted to both Censa and Shiratori patent counsel. Each Party promptly shall disclose to the other Party the conception, making, or reduction to practice of Joint Inventions.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;Inventorship of Inventions will be determined in accordance with principles of U.S. patent law.  In the case of trade secrets or know-how not intended for patent application, inventorship will be determined under such principles by treating such Inventions as if they were patentable.</font></div><div style="text-indent:54pt;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">10.2&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Patent Prosecution</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Patent Prosecution of Solely Owned Inventions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  As to Censa Inventions or Shiratori Inventions, respectively, the Party owing such Inventions shall be solely responsible for the filing, prosecution (including oppositions), and maintenance of all patent applications of such Inventions, and such Party shall have sole responsibility for all fees with respect to such patent applications and all fees necessary for maintenance and enforcement, both in the Territory and in Japan.</font></div><div style="position:relative;width:100%;height:67.5pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div><div style="padding-right:18pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">24</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Patent Prosecution of Joint Inventions.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  In the Territory, as between the Parties, Censa shall be responsible for the filing, prosecution (including oppositions), and maintenance of all patent applications of Joint Inventions, and in Japan, Shiratori shall be responsible for filing, prosecution (including oppositions), and maintenance of all patent applications of Joint Inventions.  The Parties shall share pro-rata based on each Party&#8217;s respective ownership share in the applicable patent the obligation and responsibility for all fees with respect to such patent applications and all fees necessary for maintenance and enforcement equitably.  In Japan, as between the Parties, Shiratori be responsible for, and shall keep Censa currently apprised of, all steps taken or to be taken in the prosecution of the Licensed Patents and any improvements and shall promptly furnish Censa with copies of all patent applications and material correspondence with all patent offices in Japan.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Patent Applications Issued</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  In the event any patent applications having Valid Claims issue during the term of this Agreement, Shiratori shall notify Censa within &#91;**&#93; Business Days thereof and shall assist Censa in listing the patents with the appropriate Regulatory Authority in the Territory within &#91;**&#93; days of issuance thereof.  If the regulatory law changes in the Territory, Shiratori agrees to assist Censa with any patent listing with a Regulatory Authority within the appropriate period of time.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Patent Extensions and Supplementary Protection Certificates</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Shiratori shall file all applications and take all actions necessary to obtain patent extensions pursuant to 35 USC 156 or like foreign statutes for Licensed Patents licensed to Censa hereunder.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Licensed Patents and Related Technology Generally</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Shiratori and its patent counsel or other legally authorized or agents shall consult with Censa in all aspects of the filing, prosecution (including oppositions), and maintenance of the Licensed Patents and other Licensed Technology and shall provide Censa sufficient opportunity to comment on any related document that Shiratori intends to file or to cause to be filed with the relevant governmental authority in advance of such filing.  Any actions recommended by Censa for such purpose shall not be unreasonably denied or delayed by Shiratori.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">10.3&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Infringement Actions Against Third Parties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;Shiratori and Censa shall promptly notify each other of any infringement or unauthorized use of any Licensed Technology that may come to their attention.  Shiratori shall promptly undertake, at Shiratori&#8217;s expense, reasonable efforts to obtain a discontinuance of the aforesaid infringement or unauthorized use and, if not successful, Shiratori shall bring suit against such infringer or unauthorized user.  Censa, within a reasonable period of time and at its option and expense, shall have the right to participate in any such suit.  Shiratori shall not enter into any settlement agreement with respect to such suit without Censa's consent.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;If Shiratori fails to obtain a discontinuance of said infringement or unauthorized use and&#47;or fails to promptly bring suit against such Third Party, then in any such event Shiratori shall give notice in writing to Censa of the circumstance of such infringement or unauthorized use, including such evidence of infringement as Shiratori may possess and the numbers of the patents and patent applications so infringed.  Censa may, in its </font></div><div style="position:relative;width:100%;height:67.5pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div><div style="padding-right:18pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">25</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">discretion (but is not required to) (i) obtain a discontinuance of the alleged infringing operation or unauthorized use or (ii) bring suit against such Third Party.  Any suit by Censa shall be either in the name of Censa, or in the name of Shiratori, or jointly by Censa and Shiratori, as may be required by the law of the forum.  For this purpose, Shiratori shall execute such legal papers necessary for the prosecution of such suit as may be reasonably requested by Censa.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;It is understood and agreed that the Party to this Agreement that institutes the suit or action shall bear solely all costs and expenses associated therewith (excepted as otherwise provided in this Agreement) and shall be entitled to retain and keep any and all sums received, obtained, collected or recovered whether by judgment, settlement or otherwise, as a result of such suit.  In addition, with respect to any suit for infringement or unauthorized use of the Licensed Know-How and&#47;or Licensed Patents, the Party that did not institute suit, shall render all reasonable assistance to the Party that did institute suit at the assisting Party's cost and expense, including executing all documents as may be reasonably requested by the Party that did institute suit.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;Shiratori and Censa shall keep each other fully informed of all efforts to obtain discontinuation of unauthorized uses and infringements.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)&#160;Infringements also shall include notices received by Shiratori or Censa under 21 USC &#167;355(b)(3) or &#167;355(j)(2)(3) (a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Paragraph IV Notice</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  When a Paragraph IV Notice is received by Shiratori or Censa, each shall notify the other in writing within &#91;**&#93; Business Days after receipt thereof.  If Shiratori has not brought suit within &#91;**&#93; days of the date of the Paragraph IV Notice, Censa, at its sole discretion, may bring suit.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">10.4&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Infringement of Third Party Intellectual Property Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Each Party hereto shall notify the other Party promptly in the event of the receipt of notice of any action, suit or claim alleging infringement by Drug Substance or Product of any Third Party patent, trademark, know-how or intellectual property in the Territory.  Shiratori shall indemnify and hold Censa harmless in the event that the use, promotion, or sale of Drug Substance infringe or violate any Third Party&#8217;s patent or know-how, provided such infringement or unauthorized use does not arise or result from the negligence, misconduct or omission of Censa.  In such event, Shiratori shall immediately and thoroughly inform Censa of such Third Party&#8217;s claim or action, and Shiratori shall take all provisional measures so as to protect and preserve Censa&#8217;s interests hereunder.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">10.5&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Offset</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  In the event that it is necessary, in Censa's reasonable judgment, for Censa to make royalty or other payments to a Third Party in order for Censa to exercise or continue to exercise the rights granted to Censa pursuant to the terms of this Agreement in relation to the Product, or Licensed Technology, and only if Censa obtains a prior written consent from Shiratori (which consent shall not be unreasonably conditioned, delayed, or withheld by Shiratori) to pay such royalty or other payments,  Censa shall be entitled to offset any amounts so paid to any Third Party against amounts due or which may become due to Shiratori under this Agreement&#59; provided, however, that the maximum reduction shall be &#91;**&#93; percent (&#91;**&#93;%) of the amounts otherwise owed by Censa to Shiratori. Shiratori shall exercise its maximum efforts to protect the rights or interests of Censa obtained hereunder. </font></div><div style="text-indent:54pt;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">10.6&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Compulsory Licenses</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="position:relative;width:100%;height:67.5pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div><div style="padding-right:18pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">26</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;In the event that during the term of this Agreement a Regulatory Authority in the Territory grants or compels Shiratori to grant a license to any Third Party(ies) for the Product in any country in the Territory, Censa shall have the benefit of any lower royalty rates granted to such Third Party(ies), but only to the extent that such royalty rates to such Third Party(ies) are more favorable than those granted Censa pursuant to this Agreement, and only during the period such Third Party(ies) sell Product in those countries of the Territory where compulsory license(s) exist and have achieved for a period of at least &#91;**&#93; consecutive months a combined total sales volume of at least &#91;**&#93; percent (&#91;**&#93;%) of Censa's, its Affiliate's and sublicensee&#8217;s sales of Product in such country(ies).</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;If a Regulatory Authority in a country in the Territory imposes a maximum royalty rate, such that lower royalty rates than would otherwise apply under this Agreement are mandated in such country, then the royalty rates provided for in this Agreement shall be reduced to equal such lower rates for sales of the Product in such country for the period such lower royalty rate is required by any Regulatory Authority and shall cease when Censa's royalty payment obligations to Shiratori cease under this Agreement.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">10.7&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Marks for the Product</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Censa shall own all trademarks, service marks, trade names, brand names, slogans, logos, copyrights, trade dress, know-how (except as otherwise provided in this Agreement) and goodwill developed by Censa and associated with commercializing a Product (collectively, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Marks</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  Censa shall also own any domain names including any Marks.  Shiratori shall not have any right, title, interest or other license in or to any of the Marks, and all uses of such Marks shall inure solely to the benefit of Censa.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">10.8&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">No Trademark Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  </font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;Except as otherwise provided in this Agreement, no right, express or implied, is granted by this Agreement to use in any manner the name &#8220;Shiratori Pharmaceutical,&#8221; &#8220;Censa Pharmaceuticals,&#8221; or any other trade name or trademark of the other Party or its Affiliates in connection with the performance of this Agreement.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;Notwithstanding the foregoing, Censa shall be entitled, at its option, to use Shiratori's brand name on its packaging and&#47;or promotional materials&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided, however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that the use by Censa of Shiratori's brand name, Shiratori's corporate name, or any phrase incorporating such name, shall be prohibited unless and until Shiratori has agreed in advance in writing to the use, the language employed and its location on any packaging and&#47;or promotional materials.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">10.9&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Invention Dates</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  In order to protect the Licensed Patents under United States law, Shiratori agrees to maintain a policy which requires its employees to record and maintain all data and information relating to the Licensed Patents is such a manner as to enable the Parties to use such records to establish the earliest date of invention and&#47;or diligence to reduction to practice.  At a minimum, the policy shall require such individuals to record all inventions generated by them in standard laboratory notebooks which are dated and corroborated by non-inventors on a regular, contemporaneous basis.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">10.9&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">No Other Rights to Censa Intellectual Property</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Nothing in this Agreement shall be construed as granting to Shiratori any ownership interest, license, express or implied, or other right or </font></div><div style="position:relative;width:100%;height:67.5pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div><div style="padding-right:18pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">27</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">title, in or to any technology or intellectual property of Censa, including but not limited to, know-how, patents, patent applications, trade secrets, products, formulations, delivery devices and chemical or biological materials.</font></div><div style="text-align:center;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE 11.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:35.36pt;">                                                                </font></div><div style="text-indent:18pt;text-align:center;margin-top:0.06pt;margin-bottom:0.18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">DISPUTES, GOVERNING LAW                                                                                             </font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">11.1&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Disputes</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  If the Parties are unable to resolve a dispute within &#91;**&#93; days after a matter is first considered, Censa or Shiratori, by written notice to the other, may have such dispute referred to its respective executive officer designated by each Party for attempted resolution by good faith negotiations.  Any such dispute shall be submitted to such executive officers no later than &#91;**&#93; days following such request by either Censa or Shiratori.  Such designated executive officers shall attempt in good faith to resolve any such dispute within &#91;**&#93; days after submission of the dispute.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">11.2&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Governing Law</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. This Agreement shall be construed and the respective rights of the Parties determined according to the substantive laws of the State of Delaware in the United States, notwithstanding the provisions governing conflict of laws under Delaware law to the contrary.  Each Party hereby irrevocably submits to the jurisdiction of any federal or state court in the State of Delaware to resolve any disputes arising out of or in any way relating to this Agreement.  The UNCITRAL Convention for the International Sale of Goods, as well as any other unified law relating to the conclusion and implementation of contracts for the international sale of goods, shall not apply.</font></div><div style="text-align:center;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE 12.</font></div><div style="text-indent:18pt;text-align:center;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">MISCELLANEOUS</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12.1&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Assignment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Either Party hereto may assign this Agreement without the other Party&#8217;s consent to an Affiliate or to the successor or assignee of all or substantially all of such Party&#8217;s business or assets related to the subject matter of this Agreement.  Other than by Censa, this Agreement shall not otherwise be assignable by either Party without the prior written consent of the other Party, which consent shall not be unreasonably conditioned, delayed, or withheld.  This Agreement shall be binding upon and inure to the benefit of the Parties&#8217; permitted successors and assigns.  Notwithstanding any of the foregoing provisions of this Agreement, in the event such an assignment would trigger Withholding Taxes on amounts payable by the assigning Party to the other Party, the assigning Party shall be responsible for the payment of all such Withholding Taxes&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided, however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that if such Party uses a foreign tax credit received as a result of this payment of Withholding Taxes by the assigning Party and thereby reduces the amount of income tax that such Party otherwise would have paid, such Party shall refund to the assigning Party the amount of such reduction with respect to such foreign tax credit.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12.2&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Further Actions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12.3&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Force Majeure</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  No Party shall be liable to the other Party for loss or damages or shall have any right to terminate this Agreement for any default or delay attributable to any Force Majeure, if the Party affected shall give prompt notice of any such cause to the other Party.  The Party giving such notice shall thereupon be excused from such of its obligations hereunder as it is thereby disabled from performing for so long as it is so disabled, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided, however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that such affected Party commences and continues to use its Commercially Reasonable Efforts to cure such cause.</font></div><div style="position:relative;width:100%;height:67.5pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div><div style="padding-right:18pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">28</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:54pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12.4&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Notices</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="padding-left:36pt;text-align:justify;"><font><br></font></div><div style="padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notices to Shiratori shall be addressed to&#58;</font></div><div style="padding-left:72pt;"><font><br></font></div><div style="padding-left:108pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Shiratori Pharmaceutical Co., Ltd.</font></div><div style="padding-left:108pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">2-3-7 Akanehama, Narashino-shi, Chiba-ken</font></div><div style="padding-left:108pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">275-0024 JAPAN</font></div><div style="padding-left:108pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Facsimile No.&#58;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">&#91;**&#93;</font></div><div><font><br></font></div><div style="padding-left:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Notices to Censa shall be addressed to&#58;</font></div><div style="padding-left:72pt;text-align:justify;"><font><br></font></div><div style="padding-left:108pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Censa Pharmaceuticals Inc.</font></div><div style="padding-left:108pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">222 Third Street, Suite 2240</font></div><div style="padding-left:108pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Cambridge, Massachusetts 02142&#160;USA</font></div><div style="padding-left:108pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Attention&#58;&#160;Jonathan Reis, M.D., MBA, Director</font></div><div style="padding-left:108pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Facsimile No.&#58;&#160;+1 (617) 225-7780</font></div><div style="padding-left:72pt;text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Either Party may change its address to which notices shall be sent by giving notice to the other Party in the manner provided in this Agreement.  Any notice required or provided for by the terms of this Agreement shall be in writing and shall be sent by (a) registered or certified mail, return receipt requested, postage prepaid, (b) a reputable overnight courier service, (c) first class mail, postage prepaid, (d) personal delivery, or (e) facsimile transmission, in each case properly addressed in accordance with the paragraph above.  The effective date of notice shall be the actual date of receipt by the Party receiving the same.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12.5&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Amendment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  No amendment, modification or supplement of any provision of this Agreement shall be valid or effective unless made in writing and signed by a duly authorized officer of each Party.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12.6&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Waiver</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  No provision of this Agreement shall be waived by any act, omission or knowledge of a Party or its agents or employees except by an instrument in writing expressly waiving such provision and signed by a duly authorized officer of the waiving Party.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12.7&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Counterparts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  This Agreement may be executed in counterparts and such counterparts taken together shall constitute one and the same agreement.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12.8&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Descriptive Headings</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The descriptive headings of this Agreement are for convenience only, and shall be of no force or effect in construing or interpreting any of the provisions of this Agreement.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12.9&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Severability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  If any provision hereof is held invalid, illegal or unenforceable in any respect in any jurisdiction, the Parties hereto shall substitute, by mutual consent, valid provisions for such invalid, illegal or unenforceable provisions which valid provisions in their economic effect are sufficiently similar to the invalid, illegal or unenforceable provisions that it can be reasonably assumed that the Parties would have entered into this Agreement with such valid provisions.  In case such valid provisions cannot be agreed upon, the invalid, illegal or unenforceable of one or several provisions of this Agreement shall not affect the validity of this Agreement as a whole, unless the invalid, illegal or unenforceable provisions are of such essential importance to this Agreement that it is to be reasonably </font></div><div style="position:relative;width:100%;height:67.5pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div><div style="padding-right:18pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">29</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">assumed that the Parties would not have entered into this Agreement without the invalid, illegal or unenforceable provisions.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12.10&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Entire Agreement of the Parties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  This Agreement, together with the CDA, and any schedules or exhibits hereto, constitutes and contains the complete, final and exclusive understanding and agreement of the Parties and cancels and supersedes any and all prior negotiations, correspondence, understandings and agreements whether oral or written, among the Parties respecting the subject matter hereof and thereof.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12.11&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Independent Contractors</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The relationship between Censa and Shiratori created by this Agreement is one of independent contractors and neither Party shall have the power or authority to bind or obligate the other except as may be expressly set forth in this Agreement.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12.12&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Accrued Rights&#59; Surviving Obligations</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Unless explicitly provided otherwise in this Agreement, termination, relinquishment or expiration of the Agreement for any reason shall be without prejudice to any rights which shall have accrued to the benefit to any Party prior to such termination, relinquishment or expiration, including damages arising from any breach hereunder.  Such termination, relinquishment or expiration shall not relieve any Party from obligations which are expressly indicated to survive termination or expiration of the Agreement, including, without limitation, those obligations set forth in Articles 6, 7, 8, and 9, respectively.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12.13&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Compliance with Export Regulations</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Neither Party shall export any technology licensed to it by the other Party under this Agreement except in compliance with U.S. export laws and regulations.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12.14&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">No Third Party Beneficiaries</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  No person or entity other than Censa, Shiratori and their respective Affiliates and permitted assignees hereunder shall be deemed an intended beneficiary hereunder or have any right to enforce any obligation of this Agreement.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12.15&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">No Strict Construction</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  This Agreement has been prepared jointly and shall not be strictly construed against either Party.</font></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12.16&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Language</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  All documents and correspondence relating to this Agreement shall be in the English language.</font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">IN WITNESS WHEREOF, duly authorized representatives of the Parties have duly executed and delivered this Agreement as of the Effective Date.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">&#91;THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK&#59; </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">THE SIGNATURE PAGE IMMEDIATELY FOLLOWS&#93;</font></div><div style="position:relative;width:100%;height:67.5pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div><div style="padding-right:18pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">30</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">SHIRATORI PHARMACEUTICAL CO., LTD.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47; Yutaka Shiratori</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Name&#58;&#160;Yutaka Shiratori</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Title&#58;&#160;President</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">CENSA PHARMACEUTICALS INC.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47; Jonathan Reis</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Name&#58;&#160;Jonathan Reis </font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Title&#58;&#160;Chief Executive Officer  </font></div><div><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="position:relative;width:100%;height:67.5pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div><div style="padding-right:18pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">31</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="i69ffa761f2d04a238bf9fcc813d3316c_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-top:12pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Amendment No. 1 to License Agreement</font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Amendment No. 1 to</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">License</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Agreement</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">This Amendment No. 1 to License</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Agreement (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Amendment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) dated July 31</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">st</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, 2017 (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Effective Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) amends that certain License</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Agreement dated as of February 8, 2015 by and between Shiratori Pharmaceutical Co., Ltd. having a principal place of business at 2-3-7 Akenahma, Narashina-shi, Chiba-ken, 275-0024 JAPAN (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Shiratori</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) and Censa Pharmaceuticals Inc., having a principal place of business at 222 Third Street, Suite 2240, Cambridge, MA 02142 (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Censa</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">WHEREAS, the parties desire to modify the Agreement to reflect the understandings they have reached with respect to their relationship&#59; and</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;WHEREAS, capitalized terms used in this Amendment but not otherwise defined shall have the meaning ascribed to such terms in the Agreement.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, the parties hereto agree as follows&#58;</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Amendments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Agreement is hereby amended as follows&#58;</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:9pt;">Amended to Section 4.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.   The parties hereby acknowledge that the milestone payments set forth in Section 4.1(a) and 4.2(b) have been made in accordance with the Agreement. The remaining milestone payments due under Sections 4.1(c)-(f) (&#8220;Milestones&#8221;) are hereby replaced with the following&#58;</font></div><div style="padding-left:54pt;text-align:justify;"><font><br></font></div><div style="padding-left:54pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)  USD&#91;**&#93;- upon &#91;**&#93;  This milestone shall be subject to the payment terms set forth in Section 2 and 3 below.</font></div><div style="padding-left:54pt;text-align:justify;"><font><br></font></div><div style="padding-left:54pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d) USD&#91;**&#93; upon &#91;**&#93; </font></div><div style="padding-left:54pt;text-align:justify;"><font><br></font></div><div style="padding-left:54pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e) USD&#91;**&#93; upon &#91;**&#93;</font></div><div style="padding-left:54pt;text-align:justify;"><font><br></font></div><div style="padding-left:54pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(f) USD&#91;**&#93; upon &#91;**&#93;</font></div><div style="padding-left:54pt;text-align:justify;"><font><br></font></div><div style="padding-left:54pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(g) USD&#91;**&#93; upon &#91;**&#93;</font></div><div style="padding-left:54pt;text-align:justify;"><font><br></font></div><div style="padding-left:54pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(h)USD&#91;**&#93; upon &#91;**&#93;</font></div><div style="padding-left:54pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(i)  USD&#91;**&#93; upon &#91;**&#93;</font></div><div style="padding-left:54pt;text-align:justify;"><font><br></font></div><div style="padding-left:54pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#91;**&#93; </font></div><div style="padding-left:54pt;text-align:justify;"><font><br></font></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:9pt;">Manufacturing and Supply of &#91;**&#93;kg of Drug Substance</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. By &#91;**&#93;, Shiratori shall manufacture and deliver to Censa &#91;**&#93;kg of Drug Substance manufactured in </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-top:12pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Amendment No. 1 to License Agreement</font></div></div><div style="padding-left:54pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">accordance with cGMP and the terms and conditions of the Agreement (&#8220;&#91;**&#93;kg Batch&#8221;).  </font></div><div style="padding-left:54pt;text-align:justify;"><font><br></font></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:9pt;">Payment for the &#91;**&#93;Kg Batch and Milestone 4.1(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Payment for the &#91;**&#93;kg Batch and Milestone 4.1(c) shall be made by Censa in either cash or equity, at Censa&#8217;s option and in accordance with Section 4 below, within &#91;**&#93; of receipt and acceptance by Censa of the &#91;**&#93;kg Batch.  Censa shall pay interest on the said amounts due at an interest rate of &#91;**&#93; percent (&#91;**&#93;%) per annum.</font></div><div style="padding-left:54pt;text-align:justify;"><font><br></font></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:9pt;">Payment in Equity</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. At any time on or before the due date of the amounts set forth in Section 3 (the &#8220;Conversion Date&#8221;), Censa shall have the option to convert the unpaid amounts due, plus any accrued interest thereon through the Conversion Date, into common shares at a price equal to &#91;**&#93;% less than the purchase price per share of paid by the investors for securities in the Qualified Financing or in absence of a Qualified Financing at a purchase price equal to &#91;**&#93;% less than the price paid by investors in the 2016 Series A financing. For the purposes of this Agreement, &#8220;Qualified Financing&#8221; shall mean an investment in preferred or common stock of Censa in which Censa receives gross proceeds of at least $&#91;**&#93;.  Upon payment in equity, Shiratori shall execute Censa&#8217;s stockholders&#8217; agreement.</font></div><div style="padding-left:54pt;text-align:justify;"><font><br></font></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Inventorship of &#91;**&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.   Shiratori&#8217;s personnel will be named as co-inventors, as identified on Exhibit A, for patent claims directed to the &#91;**&#93; as set forth in the provisional patent application entitled &#91;**&#93;.    </font></div><div><font><br></font></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:9pt;">Assignment to Censa&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> Shiratori shall assign to Censa all of Shiratori&#8217;s right, title, and interest in the &#91;**&#93; as detailed in Exhibit B.  Shiratori shall be solely responsible for any remuneration due to its personnel named as co-inventors in accordance with Section 5, including any remuneration required by the Japanese Patent Act or other applicable law. </font></div><div style="padding-left:36pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">7.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:9pt;">Ownership of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#91;**&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  Upon the filing of non-provisional applications from the &#91;**&#93;, Censa shall assign to Shiratori any Japanese national phase patent application of the Patent Property as detailed in Exhibit C, which  discloses various &#91;**&#93;, as detailed in Exhibit C. Shiratori shall fully own such patent application in Japan and shall be responsible for any prosecution, maintenance and expenses (including the patent application filing expenses) thereof.</font></div><div style="padding-left:36pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:9pt;">License to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#91;**&#93;&#58;  Censa hereby grants to Shiratori a non-exclusive license to make, use, and sell products solely in Japan which would otherwise infringe claims directed to &#91;**&#93;.  In consideration for the license grant by Censa, Shiratori shall reimburse Censa for &#91;**&#93;% of the cost associated with filing, prosecution and maintenance of claims directed to &#91;**&#93;. The non-exclusive license by Censa to Shiratori shall terminate immediately upon any Shiratori breach or termination of the License Agreement and&#47;or this Amendment.  </font></div><div style="padding-left:36pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-top:12pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Amendment No. 1 to License Agreement</font></div></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:9pt;">Technology Transfer to Commercial Manufacturer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Shiratori will transfer all the technology and know-how necessary for Censa to manufacture Drug Substance as defined in the License Agreement.  Upon Censa&#8217;s request, Shiratori shall disclose the Licensed Technology as defined in the License Agreement to Censa&#8217;s designated third party manufacturer. Shiratori shall (a) designate qualified technical liaisons for communications with Censa's and its manufacturer&#8217;s technical staff, and (b) provide Censa&#8217;s and its manufacturer&#8217;s technical staff with technical assistance, including answering questions concerning the manufacture of the Product as Licensee reasonably requests.  Censa agrees to pay for reasonable and actual time spent by Shiratori for such technology transfer and support at a rate of $&#91;**&#93; per hour and in accordance with Section 3.7 of the Agreement and as agreed in advance by the Parties.</font></div><div style="padding-left:36pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">10.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:3pt;">Miscellaneous</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Except as modified and amended by this Amendment, the Agreement shall remain in full force and effect and in all other respects is ratified and confirmed by the parties. </font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">IN WITNESS WHEREOF, the parties have caused this Amendment to be executed by their duly authorized representatives as of the date set forth in the introductory paragraph of this Amendment.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div id="i69ffa761f2d04a238bf9fcc813d3316c_7"></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:48.000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:48.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">CENSA PHARMACEUTICALS INC.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SHIRATORI PHARMACEUTICAL CO., LTD</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58;  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47; Jonathan Reis</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58;  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47; Satoshi Shiratori</font></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:40pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Jonathan Reis, CEO</font></div></td><td colspan="3" style="height:40pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Satoshi Shiratori</font></div></td></tr></table></div><div id="i69ffa761f2d04a238bf9fcc813d3316c_10"></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3</font></div></div></div><div id="i69ffa761f2d04a238bf9fcc813d3316c_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%;">Amendment No. 2 to License Agreement</font></div><div style="text-align:center;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Amendment No. 2 (&#8220;2</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:174%;vertical-align:top;">nd</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;"> Amendment&#8221;) dated May 28</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:174%;vertical-align:top;">th</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">, 2019 (the &#8220;Effective Date&#8221;) amends the License Agreement dated February 8, 2016 and Amendment No. 1 to the License Agreement dated July 31, 2017 (collectively the &#8220;Agreement&#8221;) between Shiratori Pharmaceutical Co., Ltd. having a principal place of business at 28F WBG Marive east 2-6-1 Nakase, Mihama-ku, Chiba-shi, Chiba 261-7090 JAPAN (&#8220;Shiratori&#8221;) and Censa Pharmaceuticals Inc., having a principal place of business at 65 Willian Street, Suite 200, Wellesley, MA 02481 (&#8220;Censa&#8221;).</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;WHEREAS, the parties desire to modify the Agreement to reflect the understandings they have reached with respect to their relationship&#59; and</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;WHEREAS, capitalized terms used in this 2</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:174%;vertical-align:top;">nd</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;"> Amendment but not otherwise defined shall have the meaning ascribed to such terms in the Agreement.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, the parties hereto agree as follows&#58;</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%;text-decoration: underline;">Amendments.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;"> The Agreement is hereby amended as follows&#58;</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">Sepiapterin </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;">&#91;**&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">&#58;  </font></div><div style="text-indent:-36pt;padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">1.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%;text-decoration: underline;">Inventorship of the </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration: underline;">&#91;**&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">  Shiratori&#8217;s personnel, as identified in Exhibit A, will be named as co-inventors for patent claims solely directed to the </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;">&#91;**&#93;.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;"> </font></div><div style="text-indent:-36pt;padding-left:72pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">2.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%;text-decoration: underline;">Assignment to Censa.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;"> Shiratori shall obtain assignments from Shiratori personnel, as identified in Exhibit A, and shall then assign to Censa of all of Shiratori&#8217;s right, title, and interest in the inventions of, or applications claiming priority to, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;">&#91;**&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">.  Shiratori shall be solely responsible for any remuneration due to its personnel named as co-inventors in accordance with Section 1, including any remuneration required by the Japanese Patent Act or other applicable law.</font></div><div style="text-indent:-36pt;padding-left:72pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%;">3. &#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%;text-decoration: underline;">Section 7 of Amendment No. 1 to the License Agreement dated July 31, 2017 is hereby replaced in its entirety with the following&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;"> Censa shall file one or more Japanese national stage applications of, and&#47;or Japanese divisional applications claiming priority to, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;">&#91;**&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">.  Within </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;">&#91;**&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">days after grant of each Japanese each, Censa will assign all right, title, and interest in the Japanese granted patent to Shiratori subject to Shiratori reimbursing Censa for the prosecution expenses (including the Japanese patent application filing expenses) thereof.  </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="margin-top:6pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-top:12pt;margin-bottom:3pt;"><font><br></font></div></div><div style="text-indent:-36pt;padding-left:72pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">4.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%;text-decoration: underline;">Section 8 of Amendment No. 1 to the License Agreement dated July 31, 2017 is replaced in its entirety with the following&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">  Censa hereby grants to Shiratori a non-exclusive license to make, use, and sell products solely in Japan which would otherwise infringe claims directed to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;">&#91;**&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;"> in Japanese national stage applications of, and&#47;or Japanese divisional applications claiming priority to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;">&#91;**&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">.  In consideration for the license grant by Censa, Shiratori shall reimburse Censa for </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;">&#91;**&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">% of the cost associated with filing, prosecution, and maintenance of claims directed to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;">&#91;**&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">.  The non-exclusive license by Censa to Shiratori shall terminate immediately upon any Shiratori breach or termination of the License Agreement as amended.</font></div><div style="text-indent:-36pt;padding-left:72pt;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;">&#91;**&#93;&#58;</font></div><div style="text-indent:-36pt;padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">5.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%;text-decoration: underline;">Section 1.14 of the License Agreement is hereby replaced in its entirety with the following&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;"> &#8220;Licensed Patents&#8221; means the following patent applications and patents owned or Controlled by Shiratori (a) as of the Effective Date or (b) arising at any time during the term of this Agreement solely by Shiratori or jointly by Shiratori and Censa, and all patents issuing from such patent applications and patents and otherwise arising from any improvement or enhancement of the manufacturing processes for or methods related to Sepiapterin, during the term of this Agreement&#58; (i) </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;">&#91;**&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;"> (ii) </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;">&#91;**&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">&#59; (iii) </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;">&#91;**&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">&#59; and (iv) certain other patents owned by Shiratori, as are reasonably necessary or useful for the manufacture, use, and sale of the Product </font></div><div style="padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">in the Territory, including the patent applications and&#47;or patents listed on Schedule 6.2(b) as amended, and all foreign counterparts of any or to any of the aforesaid patents and&#47;or patent applications, and including, without limitation, as it may relate to any such patent applications and patents all provisional applications, substitutions, continuations, continuations-in-part, divisions, and renewals, all letters patent granted thereon, and all patents-of-addition, reissues, reexaminations and extensions or restorations by existing or future extension or restoration mechanisms, certificates, substitutions, confirmations, registrations, revalidations, additions, continuations, continuations-in-part, and divisions of any or to any of the aforesaid patent applications and patents.  Licensed Patents excludes Licensed Know-How.</font></div><div style="text-indent:-36pt;padding-left:72pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">6.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%;text-decoration: underline;">Schedule 6.2(b) of the License Agreement is hereby replaced with the following&#58;</font></div><div style="text-indent:-36pt;padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Licensed Patents</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2 of 4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-top:12pt;margin-bottom:3pt;"><font><br></font></div></div><div style="padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;">&#91;**&#93;</font></div><div style="text-indent:-36pt;padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Granted Patent No. or Application No.</font></div><div style="text-indent:-36pt;padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;">&#91;**&#93;</font></div><div style="text-indent:-36pt;padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;">&#91;**&#93;</font></div><div style="text-indent:-36pt;padding-left:72pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">7.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%;text-decoration: underline;">Assignment of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration: underline;">&#91;**&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%;text-decoration: underline;">% Interest in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration: underline;">&#91;**&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%;text-decoration: underline;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;"> Subject to consent from </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;">&#91;**&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">, Censa shall assign a </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;">&#91;**&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">% interest in the inventions of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;">&#91;**&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;"> (&#8220;the Inventions&#8221;)  to Shiratori such that Censa will own a </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;">&#91;**&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">% interest in the Inventions and Shiratori will own a </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;">&#91;**&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">% interest in the Inventions.  Censa will control prosecution of any applications based on the Inventions and pay all associated costs with such prosecution, and shall by itself register its </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;">&#91;**&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">% interest in the Inventions and Shiratori&#8217;s </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;">&#91;**&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">% interest in the Inventions at the United States Patent and Trademark Office within </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;">&#91;**&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;"> months after the conclusion of this 2</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:174%;vertical-align:top;">nd</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;"> Amendment. Shiratori shall provide any necessary documents and take any necessary actions requested by Censa for such registration.</font></div><div style="padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">In the event that Censa Discontinues (as defined herein), then at the written request of Shiratori, Censa shall terminate the </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;">&#91;**&#93;.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;"> &#8220;Discontinue(s)&#8221; shall mean when Censa or its assignee meets all of the following criteria at the same time&#58; 1) it does not have any active pre-clinical or clinical studies of sepiapterin for a period of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;">&#91;**&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">months after the  last report or presentation on pre-clinical or clinical studies provided to Shiratori, 2) it is not marketing or selling sepiapterin, and 3) it does not have any regulatory submissions (e.g., IND, NDA, IMPD, or sNDA) relating to sepiapterin pending with either FDA,EMA or other regulatory authority.  </font></div><div style="padding-left:72pt;"><font><br></font></div><div style="padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">In the event of the termination of the </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;">&#91;**&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">, Censa shall provide any necessary documents and take any reasonable action requested by Shiratori in order that Shiratori will register its interests in the Inventions. </font></div><div style="padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">In the event that Shiratori discontinues operations or files for bankruptcy, then Shiratori shall assign their </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;">&#91;**&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">% interest in the inventions of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;">&#91;**&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;"> to Censa, its successor, or designated assignee.</font></div><div style="padding-left:72pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">8.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%;text-decoration: underline;">Effect of the termination of the Agreement.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;"> Notwithstanding any articles of the Agreement, the provision of section 1,2,3,4 and 7 of this 2</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:174%;vertical-align:top;">nd</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;"> Amendment shall survive the termination of the Agreement.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3 of 4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-top:12pt;margin-bottom:3pt;"><font><br></font></div></div><div style="padding-left:72pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">9.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%;text-decoration: underline;">Miscellaneous.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;"> Except as modified and amended by this 2</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:174%;vertical-align:top;">nd</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;"> Amendment, the Agreement shall remain in full force and effect and in all other respects is ratified and confirmed by the parties.</font></div><div style="text-indent:36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">IN WITNESS THEREOF, the parties have caused this 2</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:174%;vertical-align:top;">nd</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;"> Amendment to be executed by their duly authorized representatives as of the date set forth in the introductory paragraph of this 2</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:174%;vertical-align:top;">nd</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;"> Amendment.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">CENSA PHARMACEUTICALS INC.&#160;&#160;&#160;       SHIRATORI PHARMACEUTICAL CO., LTD</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47;Jonathan Reis</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;     &#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47; Satoshi Shiratori</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Jonathan Reis&#160;&#160;&#160;&#160;&#160;&#160;       Satoshi Shiratori</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">President &#38; CEO&#160;&#160;&#160;&#160;&#160;       President</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">4 of 4</font></div></div></div><div id="i69ffa761f2d04a238bf9fcc813d3316c_16"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%;">Amendment No. 3 to License Agreement</font></div><div style="text-align:center;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Amendment No. 3 (&#8220;3</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:174%;vertical-align:top;">rd</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">  Amendment&#8221;) dated January 8</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:174%;vertical-align:top;">th</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">, 2020 (the &#8220;Effective Date&#8221;) amends the License Agreement dated February 8, 2016 and Amendment No. 1 to the License Agreement dated July 31, 2017 and  Amendment No. 2 to the License Agreement dated May 28</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:174%;vertical-align:top;">th</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">, 2019 (collectively the &#8220;Agreement&#8221;) between Shiratori Pharmaceutical Co., Ltd. having a principal place of business at 28F WBG Marive east 2-6-1 Nakase, Mihama-ku, Chiba-shi, Chiba 261-7090 JAPAN (&#8220;Shiratori&#8221;) and Censa Pharmaceuticals Inc., having a principal place of business at 65 Willian Street, Suite 200, Wellesley, MA 02481 (&#8220;Censa&#8221;).</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;WHEREAS, the parties desire to modify the Agreement to reflect the understandings they have reached related to target dates for certain regulatory and commercial milestones&#59; and</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;WHEREAS, capitalized terms used in this 3</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:174%;vertical-align:top;">rd</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;"> Amendment but not otherwise defined shall have the meaning ascribed to such terms in the Agreement.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, the parties hereto agree as follows&#58;</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%;text-decoration: underline;">Amendments.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;"> The Agreement is hereby amended as follows&#58;</font></div><div style="text-indent:-36pt;padding-left:72pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%;text-decoration: underline;padding-left:9.67pt;">Section 9.2b of the License Agreement is hereby replaced in its entirety with the following&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;"> </font></div><div style="padding-left:18pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;text-decoration: underline;">By Shiratori</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">.  Unless otherwise agreed between the Parties in writing, Shiratori may elect to terminate this Agreement upon sixty (60) days&#8217; prior written notice to Censa in the event that Censa fails (i) to achieve Regulatory Approval in either the United States or European Union for at least one indication within eight (8) years from the Effective Date or (ii) to launch the Product in the United States or European Union within nine (9) years from the Effective Date.  Censa shall, as of the effectiveness of such termination, be relieved of any and all further obligations to make payments to Shiratori under this Agreement to the extent not accrued prior to such termination.  Censa also shall be relieved of any and all further obligations with respect to patents and patent applications in the Territory.</font></div><div style="padding-left:18pt;margin-bottom:8pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%;text-decoration: underline;padding-left:9.67pt;">Section 5.1 of the License Agreement is hereby replaced in its entirety with the following&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;"> </font></div><div style="padding-left:18pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">Royalty Rates.  In further consideration of the licenses granted in this Agreement, Censa shall pay to Shiratori royalties on the Product based on aggregate Net Sales of such Product on a country-by-country basis in the Territory in the amount of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;">&#91;**&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;"> percent (</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;">&#91;**&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">%) &#8221;Royalty Rate&#8221; or </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;">&#91;**&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">percent (</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;">&#91;**&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">%) &#8220;Reduced Royalty Rate&#8221;.</font></div><div style="padding-left:36pt;text-align:justify;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="margin-top:6pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-top:12pt;margin-bottom:3pt;"><font><br></font></div></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%;text-decoration: underline;padding-left:9.67pt;">Section 5.2 of the License Agreement is hereby replaced in its entirety with the following&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;"> </font></div><div style="padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font><br></font></div><div style="padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;text-decoration: underline;">Term of Royalties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">.  Royalties under 5.1 shall be payable for each full calendar year during the term of this Agreement and on an aggregate </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%;">pro rata</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;"> basis for the first and last year of commercialization during the term of this Agreement if such first and last years are not comprised of a full twelve (12) months, as follows&#58;</font></div><div style="text-indent:-36pt;padding-left:72pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">Royalty Rate shall be payable for the countries of the European Union, until expiration of the last-to-expire Licensed Patent Controlled by Shiratori covering the European Union if the making, having made, using, offering to sell, selling or importing of such Product by Censa, its Affiliates or its sublicensees (or the distributors of any of them) in the absence of this Agreement, would infringe one or more Valid Claim of the Licensed Patents in the European Union.  </font></div><div style="text-indent:-36pt;padding-left:72pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">Royalty Rate shall be payable for the United States, until the expiration of the last-to-expire Licensed Patent Controlled by Shiratori covering the United States if the making, having made, using, offering to sell, selling or importing of such Product by Censa, its Affiliates or its sublicensees (or the distributors of any of them) in the absence of this Agreement, would infringe one or more Valid Claim of the Licensed Patents in the United States.</font></div><div style="text-indent:-36pt;padding-left:72pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">Royalty Rate shall be payable for any other country in the Territory, until the expiration of the last-to-expire Licensed Patent Controlled by Shiratori covering the relevant country on a country-by-country basis if the making, having made, using, offering to sell, selling or importing of such Product by Censa, its Affiliates or its sublicensees (or the distributors of any of them) in the absence of this Agreement, would infringe one or more Valid Claim of the Licensed Patents in the relevant country.</font></div><div style="text-indent:-31.5pt;padding-left:72pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">(d)      Reduced Royalty Rate shall be payable for any country under Section 5.2 (a), 5.2 (b) or 5.2(c) for </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;">&#91;**&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;"> years after the expiration of the last-to-expire Licensed Patent Controlled by Shiratori covering the relevant country on a country-by-country basis. </font></div><div style="padding-left:18pt;margin-bottom:8pt;"><font><br></font></div><div style="padding-left:18pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">2.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%;text-decoration: underline;">Miscellaneous.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;"> Except as modified and amended by this 3</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:174%;vertical-align:top;">rd</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;"> Amendment, the Agreement shall remain in full force and effect and in all other respects is ratified and confirmed by the parties.</font></div><div style="text-indent:36pt;padding-left:36pt;"><font><br></font></div><div><font><br></font></div><div style="text-indent:36pt;padding-left:36pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:36pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2 of 3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-top:12pt;margin-bottom:3pt;"><font><br></font></div></div><div style="text-indent:36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">IN WITNESS THEREOF, the parties have caused this 3</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:174%;vertical-align:top;">rd</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;"> Amendment to be executed by their duly authorized representatives as of the date set forth in the introductory paragraph of this 3</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:174%;vertical-align:top;">rd</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;"> Amendment.</font></div><div style="margin-bottom:8pt;"><font><br></font></div><div style="margin-bottom:8pt;"><font><br></font></div><div style="margin-bottom:8pt;"><font><br></font></div><div style="margin-bottom:8pt;"><font><br></font></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">CENSA PHARMACEUTICALS INC.&#160;&#160;&#160;       SHIRATORI PHARMACEUTICAL CO., LTD</font></div><div style="margin-bottom:8pt;"><font><br></font></div><div style="margin-bottom:8pt;"><font><br></font></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration: underline;">&#47;s&#47; Jonathan Reis</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">&#160;&#160;                    &#160;&#160;      </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration: underline;"> &#47;s&#47; Satoshi Shiratori</font></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">Jonathan Reis&#160;&#160;&#160;&#160;&#160;&#160;       Satoshi Shiratori</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">President &#38; CEO&#160;&#160;&#160;&#160;&#160;       President</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3 of 3</font></div></div></div><div id="i69ffa761f2d04a238bf9fcc813d3316c_19"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;text-decoration: underline;">Amendment No. 4 to License Agreement</font></div><div style="text-align:center;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Amendment No. 4 (the &#8220;4</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:174%;vertical-align:top;">th</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;"> Amendment&#8221;) dated April 9</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:174%;vertical-align:top;">th</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">, 2020 amends the License Agreement dated February 8, 2016 (the &#8220;Original Agreement&#8221;), as amended by Amendment No. 1 to the License Agreement dated July 31, 2017 (the &#8220;1</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:174%;vertical-align:top;">st</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;"> Amendment&#8221;), as further amended by Amendment No. 2 to the License Agreement dated May 28</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:174%;vertical-align:top;">th</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">, 2019 (the 2</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:174%;vertical-align:top;">nd</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;"> Amendment&#8221;) and as further amended by Amendment No. 3 to the License Agreement dated January 8</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:174%;vertical-align:top;">th</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">, 2020 (the &#8220;3</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:174%;vertical-align:top;">rd</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;"> Amendment&#8221;, together with the Original Agreement, 1</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:174%;vertical-align:top;">st</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;"> Amendment, and 2</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:174%;vertical-align:top;">nd</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;"> Amendment, the &#8220;Agreement&#8221;) by and between Shiratori Pharmaceutical Co., Ltd. having a principal place of business at 28F WBG Marive east 2-6-1 Nakase, Mihama-ku, Chiba-shi, Chiba 261-7090 JAPAN (&#8220;Shiratori&#8221;) and Censa Pharmaceuticals Inc., having a principal place of business at 65 Willian Street, Suite 200, Wellesley, MA 02481 (&#8220;Censa&#8221;).</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;WHEREAS, the parties desire to modify the Agreement to reflect the understandings they have reached related to certain termination rights, royalty payments, and milestone payments&#59; and</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;WHEREAS, capitalized terms used in this 4</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:174%;vertical-align:top;">th</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;"> Amendment not otherwise defined shall have the meaning ascribed to such terms in the Agreement </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, the parties hereto agree as follows&#58;</font></div><div style="text-indent:-36pt;padding-left:72pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:9.67pt;">Section 9.2(b) of the Agreement, previously amended by the 3rd Amendment, is hereby deleted in its entirety and replaced with the following&#58; </font></div><div style="padding-left:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">(b)   </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;text-decoration: underline;">By Shiratori</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">.  Unless otherwise agreed between the Parties in writing, Shiratori may elect to terminate this Agreement upon sixty (60) days&#8217; prior written notice to Censa in the event that Censa fails (i) to achieve Regulatory Approval in either the United States or European Union for at least one indication within ten (10) years from the Effective Date or (ii) to launch the Product in the United States or European Union within eleven (11) years from the Effective Date.  Censa shall, as of the effectiveness of such termination, be relieved of any and all further obligations to make payments to Shiratori under this Agreement to the extent not accrued prior to such termination.  Censa also shall be relieved of any and all further obligations with respect to patents and patent applications in the Territory. </font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:9.67pt;">Section 5.2 (d) of the Agreement, previously amended by the 3rd Amendment, is hereby deleted it its entirety and replaced with the following&#58; </font></div><div style="text-indent:-22.5pt;padding-left:58.5pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">(d)  Reduced Royalty Rate shall be payable for any country under Section 5.2 (a), 5.2 (b) or 5.2(c) for </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;">&#91;**&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;"> years after the expiration of the last-to-expire Licensed Patent Controlled by Shiratori covering the relevant country on a country-by-country basis. </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Amendment No. 4 to License Agreement</font></div><div><font><br></font></div></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:9.67pt;">Section 4.1 of the Agreement, previously amended by 1st Amendment, is hereby amended as follows&#58; </font></div><div style="padding-left:18pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">The parties hereby acknowledge that the milestone payments set forth in Section 4.1(a), 4.1(b) and 4.1 (c) have been already made in accordance with the Agreement. The remaining milestone payments set forth in Sections 4.1(d)-(i) (&#8220;Milestones&#8221;) are hereby deleted in their entirety and replaced with the following&#58;</font></div><div style="padding-left:54pt;text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">(d) USD</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;">&#91;**&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">&#8211; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;">&#91;**&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">upon </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;">&#91;**&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">. </font></div><div style="padding-left:54pt;text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">(e) USD</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;">&#91;**&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">&#8211; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;">&#91;**&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;"> upon </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;">&#91;**&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">.</font></div><div style="padding-left:54pt;text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">(f) USD</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;">&#91;**&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">&#8211; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;">&#91;**&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;"> upon </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;">&#91;**&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">.</font></div><div style="padding-left:54pt;text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">(g) USD</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;">&#91;**&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;">&#91;**&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;"> upon </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;">&#91;**&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">. </font></div><div style="padding-left:54pt;text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">(h)  USD</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;">&#91;**&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;">&#91;**&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;"> upon </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;">&#91;**&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">.</font></div><div style="padding-left:54pt;text-align:justify;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">(i)  USD</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;">&#91;**&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">- </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;">&#91;**&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;"> upon </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;">&#91;**&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">.  </font></div><div style="padding-left:18pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">4.&#160;Miscellaneous&#58; Except as modified and amended by this 4th Amendment, the Agreement shall remain in full force and effect and in all other respects is ratified and confirmed by the parties.</font></div><div style="text-indent:36pt;padding-left:36pt;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">IN WITNESS THEREOF, the parties have caused this 4</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:174%;vertical-align:top;">th</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;"> Amendment to be executed by their duly authorized representatives as of the date set forth in the introductory paragraph of this 4</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:174%;vertical-align:top;">th</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;"> Amendment.</font></div><div style="margin-bottom:8pt;"><font><br></font></div><div style="margin-bottom:8pt;"><font><br></font></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">CENSA PHARMACEUTICALS INC.&#160;&#160;&#160;       SHIRATORI PHARMACEUTICAL CO., LTD</font></div><div style="margin-bottom:8pt;"><font><br></font></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration: underline;">&#47;s&#47; Jonathan Reis&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">&#160;&#160;       </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration: underline;">&#47;s&#47; Satoshi Shiratori&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">Jonathan Reis&#160;&#160;&#160;&#160;&#160;&#160;       Satoshi Shiratori</font></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">President &#38; CEO&#160;&#160;&#160;&#160;&#160;       President</font></div><div><img alt="image012.jpg" src="image012.jpg" style="height:30px;width:624px;"></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>ex102rpiroyaltypurchas.htm
<DESCRIPTION>EX-10.2 RPI ROYALTY PURCHASE AGREEMENT
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i03566d449d174758906421cece0f1f1c_1"></div><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">EXHIBIT 10.2</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Execution Version</font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed.  Double asterisks denote omissions.</font></div><div style="text-align:center;margin-bottom:12pt;"><font><br></font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Royalty Purchase Agreement</font></div><div style="text-align:center;margin-bottom:0.12pt;"><font><br></font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">By and Among</font></div><div style="text-align:center;margin-bottom:0.12pt;"><font><br></font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">PTC Therapeutics, Inc.,</font></div><div style="text-align:center;margin-bottom:0.12pt;"><font><br></font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">RPI 2019 Intermediate Finance Trust</font></div><div style="text-align:center;margin-bottom:0.12pt;"><font><br></font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">and</font></div><div style="text-align:center;margin-bottom:0.12pt;"><font><br></font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Solely for the Purposes of Section 5.15 Hereof,</font></div><div style="text-align:center;margin-bottom:0.12pt;"><font><br></font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Royalty Pharma plc</font></div><div style="text-align:center;margin-bottom:0.12pt;"><font><br></font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Dated as of July 17, 2020</font></div><div style="margin-bottom:12pt;"><font><br></font></div><div style="margin-bottom:12pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><div id="i03566d449d174758906421cece0f1f1c_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">TABLE OF CONTENTS</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:92.444%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:3.556%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">ARTICLE 1  DEFINED TERMS AND RULES OF CONSTRUCTION</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">1</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 1.1</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Definitions</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">1</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 1.2</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Certain Interpretations</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">9</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 1.3</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Headings</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">10</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">ARTICLE 2  PURCHASE, SALE AND ASSIGNMENT OF THE ROYALTY</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">10</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2.1</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Purchase and Sale</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">10</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2.2</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Purchase Price</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">10</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2.3</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">No Assumed Obligations, Etc</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">10</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2.4</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">True Sale</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">10</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">ARTICLE 3  CLOSING</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">11</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 3.1</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Closing&#59; Payment of Purchase Price</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">11</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 3.2</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Closing Certificates</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">11</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 3.3</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Bill of Sale</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">12</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 3.4</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Form W-9</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">12</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 3.5</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Form W-8BEN-E</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">12</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 3.6</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Data Room</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">12</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">ARTICLE 4  REPRESENTATIONS AND WARRANTIES</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">12</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4.1</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Seller&#8217;s Representations and Warranties</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">12</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4.2</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">The Buyer&#8217;s Representations and Warranties</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">19</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4.3</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">No Implied Representations and Warranties</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">20</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">ARTICLE 5  COVENANTS</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">20</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5.1</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Disclosures</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">20</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5.2</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Payments</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">21</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5.3</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Royalty Reductions</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">22</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5.4</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Royalty Reports&#59; Other Product Information</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">23</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5.5</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Actions under the License Agreement Prior to a Control Shift</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">24</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5.6</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Actions under the License Agreement Following a Control Shift</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">25</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5.7</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Inspections and Audits of Licensee</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">27</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5.8</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Termination of License Agreement</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">28</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5.9</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">No Liens</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">30</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5.10</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Enforcement&#59; Defense&#59; Prosecution and Maintenance</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">30</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5.11</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Additional Monetizations</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">32</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5.12</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Efforts to Consummate Transactions</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">32</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5.13</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Further Assurances</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">33</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5.14</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Tax Matters</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">33</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5.15</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Standstill</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">33</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">ARTICLE 6  CONFIDENTIALITY</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">33</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6.1</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Confidentiality</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">34</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6.2</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Authorized Disclosure</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">34</a></font></div></td></tr></table></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- i -</font></div><div><img alt="image011.jpg" src="image011.jpg" style="height:28px;width:6px;"></div><div style="margin-bottom:0.12pt;"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:92.444%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:3.556%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">ARTICLE 7  TERMINATION</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">35</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 7.1</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Automatic Termination</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">35</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 7.2</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Survival</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">35</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">ARTICLE 8  MISCELLANEOUS</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">36</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 8.1</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Notices</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">36</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 8.2</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Expenses</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">37</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 8.3</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Assignment</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">37</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 8.4</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Amendment and Waiver</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">37</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 8.5</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Independent Nature of Relationship</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">37</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 8.6</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Entire Agreement</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">38</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 8.7</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">No Third Party Beneficiaries</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">38</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 8.8</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Governing Law</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">38</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 8.9</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">JURISDICTION&#59; VENUE</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">38</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 8.10</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Severability</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">39</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 8.11</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Specific Performance</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">39</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 8.12</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Limitations on Liability&#59; Prevailing Party</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">39</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 8.13</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Trustee Capacity of Wilmington Trust, National Association</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">40</a></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 8.14</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</a><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Counterparts</a></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i03566d449d174758906421cece0f1f1c_7" style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">40</a></font></div></td></tr></table></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Index of Exhibits</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Exhibit A&#58;&#160;Revaluation Procedures</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Exhibit B&#58;&#160;Escrow Agreement</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Exhibit C&#58;&#160;Seller&#8217;s Wire Transfer Instructions</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Exhibit D&#58;&#160;Form of Bill of Sale</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Exhibit E&#58;&#160;License Agreement</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Exhibit F&#58;&#160;Sponsored Research Agreement</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Exhibit G&#58;&#160;Form of Licensee Instruction Letter</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Exhibit H&#58;&#160;Form of Royalty Report Certification</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Exhibit I&#58; &#160;Product Information Plan</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Index of Schedules</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Schedule 1.1&#58;&#160;Risdiplam Structure</font></div><div style="margin-bottom:12pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- ii -</font></div><div><img alt="image011.jpg" src="image011.jpg" style="height:28px;width:6px;"></div><div style="margin-bottom:0.12pt;"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="i03566d449d174758906421cece0f1f1c_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ROYALTY PURCHASE AGREEMENT</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">This ROYALTY PURCHASE AGREEMENT, dated as of July 17, 2020 (this &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), is made and entered into by and among PTC Therapeutics, Inc., a Delaware corporation (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Seller</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), RPI 2019 Intermediate Finance Trust, a Delaware statutory trust (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Buyer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), and, solely for the purposes of Section 5.15 hereof, Royalty Pharma plc, a limited company organized under the laws of England and Wales.</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">W I T N E S S E T H</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#58;</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">WHEREAS, pursuant to the License Agreement, the Seller and Licensee granted to each other certain licenses and other development and collaboration rights, and the Seller granted Licensee the exclusive right to (among other activities) develop and commercialize the Products, and Licensee, in partial consideration thereof, agreed to pay the Royalty to the Seller&#59; </font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">WHEREAS, the Seller and the Spinal Muscular Atrophy Foundation (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Foundation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) are party to that certain Sponsored Research Agreement, dated June 1, 2016, as amended on October 12, 2007, May 1, 2009, January 1, 2011 and November 22, 2011 (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Sponsored Research Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), pursuant to which the Seller is obligated to pay the Foundation single-digit royalties on worldwide net product sales of the Products&#59; and</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">WHEREAS, the Buyer desires to purchase the Assigned Royalty Payments from the Seller, and the Seller desires to sell the Assigned Royalty Payments to the Buyer.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">NOW THEREFORE, in consideration of the representations, warranties, covenants and agreements set forth herein and for good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Seller and the Buyer hereby agree as follows&#58;</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">ARTICLE 1.</font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">DEFINED TERMS AND RULES OF CONSTRUCTION</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 1.1 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Definitions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  As used in this Agreement, the following terms shall have the following meanings&#58;</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Affiliate</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; (a) means, with respect to the Buyer, any individual, corporation, association or other business entity that directly or indirectly controls, is controlled by, or is under common control with the party in question.  As used in this definition of &#8220;Affiliate,&#8221; the term &#8220;control&#8221; shall mean the direct or indirect ownership of more than fifty percent (&#62;50%) of the stock having the right to vote for directors thereof or the ability to otherwise control the management of the corporation or other business entity whether through the ownership of voting securities, by contract, resolution, regulation or otherwise and (b) with respect to the Seller or the Licensee, shall have the meaning ascribed thereto in Section 1.1. of the License Agreement.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; is defined in the preamble.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Alliance Director</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall refer to those Alliance Directors described in Section 7.10 of the License Agreement.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 1 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Applicable Listed Patents</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; is defined in Section 5.10(c).</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Assigned Royalty Cap</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; is defined within the definition of &#8220;Assigned Royalty Payments.&#8221; </font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Assigned Royalty Payments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means 42.933% (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Buyer Royalty Percentage</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) of the amounts due, payable, owed or owing, accrued or otherwise to be paid in respect of the Royalty for all Calendar Year Net Sales arising on or after the Closing Date for any Calendar Year until such Buyer Royalty Percentage of such amounts equals $1.3 billion (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Assigned Royalty Cap</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Bankruptcy Laws</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means, collectively, bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, fraudulent transfer or other similar laws affecting the enforcement of creditors&#8217; rights generally.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Bill of Sale</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; is defined in Section 3.3.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Business Day</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any day other than (i) a Saturday or Sunday or (ii) a day on which banking institutions located in New York are permitted or required by applicable law or regulation to remain closed.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Buyer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; is defined in the preamble.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Buyer Negotiated Arrangement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; is defined in Section 5.8(b)(iii).</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Buyer Royalty Percentage</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; is defined within the definition of &#8220;Assigned Royalty Payments.&#8221;</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Calendar Quarter</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall have the meaning ascribed thereto in Section 1.7 of the License Agreement.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Calendar Year</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall have the meaning ascribed thereto in Section 1.8 of the License Agreement.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Change of Control</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall have the meaning ascribed thereto in Section 1.9 of the License Agreement.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Closing</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; is defined in Section 3.1.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Closing Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the date on which the Closing occurs.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Commercialization Reports</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means those reports deliverable by Licensee pursuant to Section 10 of the License Agreement.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Compound</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall have the meaning ascribed thereto in Section 1.13 of the License Agreement.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 2 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Confidential Information</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; is defined in Section 6.1.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Confidentiality Breach</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; is defined in Section 5.4(d).</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Consensus Value</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the net present value (applying a &#91;**&#93;% discount rate) of the projected Net Sales of the Products using projections of Wall Street sell-side analysts then covering the Licensee and the Seller, as determined in accordance with  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Exhibit A</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Contracts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; is defined in Section 4.1(h)(i).</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Control Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means (a) the Seller, (i) from the Closing until a Control Shift occurs, (ii) after a Control Shift occurs, from the occurrence of a Revaluation Event in favor of the Seller until another Control Shift or a Revaluation Event in favor of the Buyer occurs&#59; and (b) the Buyer (i) after a Control Shift occurs and until a Revaluation Event in favor of the Seller occurs, and (ii) after a Revaluation Event in favor of the Seller occurs, from the occurrence of another Control Shift or a Revaluation Event in favor of the Buyer until another Revaluation Event in favor of the Seller occurs. </font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Control Shift</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any assignment, conveyance, monetization, or imposition of a Lien by the Seller on, following the Closing, any percentage of the Royalty, with the result that the Seller and its Affiliates no longer own, free and clear of all Liens (other than Permitted Liens) the right to receive a majority of the then remaining Royalty based on the Consensus Value.  </font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Credit Event</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any insolvency, bankruptcy, receivership, assignment for the benefit of creditors, or similar proceeding, following or as a result of which the Licensee fails to pay amounts owing under the License Agreement in respect of the Royalty as a result of the Licensee&#8217;s financial distress, creditworthiness, or insolvency.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Data Room</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; is defined in Section 3.6.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Deciding Valuation Firm</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Exhibit A</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Disclosing Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; is defined in Section 6.1.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Disclosure Schedule</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the Disclosure Schedule, dated as of the date hereof, delivered to the Buyer by the Seller concurrently with the execution of this Agreement. </font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Escrow Account</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the account controlled by the Escrow Agent pursuant to which Licensee has been instructed to direct all amounts payable by it under the License Agreement.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Escrow Agent</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means U.S. Bank National Association, or the escrow agent under the Escrow Agreement or any permitted successor thereof under the Escrow Agreement.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Escrow Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the Escrow Agreement that may be entered into among the Seller, the Buyer, and the Escrow Agent in accordance with Section 5.2(a)(i), substantially in the form attached hereto as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Exhibit B</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 3 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#91;**&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the product that is the subject of New Drug Application number 213535 that contains risdiplam as the active ingredient.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Field</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall have the meaning ascribed thereto in Section 1.25 of the License Agreement. </font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Final Counter Proposed Consensus Value</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Exhibit A</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Final Proposed Consensus Value</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Exhibit A</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">First Commercial Sale</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall have the meaning ascribed thereto in Section 1.28 of the License Agreement.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Foundation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; is defined in the recitals.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Governmental Entity</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any&#58;  (i) nation, principality, republic, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature&#59; (ii) federal, state, local, municipal, foreign or other government&#59; (iii) governmental or quasi-governmental authority of any nature (including any governmental division, subdivision, department, agency, bureau, branch, office, commission, council, board, instrumentality, officer, official, representative, organization, unit, body or other entity and any court, arbitrator or other tribunal)&#59; (iv) multi-national organization or body&#59; or (v) individual, body or other entity exercising, or entitled to exercise, any executive, legislative, judicial, administrative, regulatory, police, military or taxing authority or power of any nature.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Handle</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; or &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Handling</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning ascribed thereto in Section 1.35 of the License Agreement.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">JIPT</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall have the meaning ascribed thereto in Section 7.4 of the License Agreement.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Joint Invention</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall have the meaning ascribed thereto in Section 1.42 of the License Agreement.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Joint Patent Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall have the meaning ascribed thereto in Section 1.44 of the License Agreement.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">JOT</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall have the meaning ascribed thereto in Section 7.4 of the License Agreement.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">JSC</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall have the meaning ascribed thereto in Section 7.1 of the License Agreement.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Judgment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any judgment, order, writ, injunction, citation, award or decree of any nature.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Knowledge of the Seller</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the actual knowledge of &#91;**&#93; after due inquiry.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">License Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means that certain License and Collaboration Agreement, dated November 23, 2011, by and among F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 4 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Seller and, solely with respect to the Foundation Provisions (as defined therein), the Foundation, as amended by such parties by means of that First Amendment to License and Collaboration Agreement on April 18, 2013.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Licensed IP</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means, collectively, the Licensed PTC IP and the Licensed Roche IP.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Licensed Patents</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; is defined in Section 4.1(j)(i).</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Licensed PTC IP</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the PTC Patent Rights, PTC Know-How and the Seller&#8217;s interest in the Joint Inventions.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Licensed Roche IP</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the Roche Patent Rights, the Roche Know-How and Licensee&#8217;s interest in the Joint Inventions.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Licensee</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., collectively.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Licensee Instruction Letter</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; is defined in Section 5.2(a)(i).</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Lien</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any mortgage, lien, pledge, charge, adverse claim, security interest, encumbrance or restriction of any kind, including any restriction on use, transfer or exercise of any other attribute of ownership of any kind&#59; provided, that, for the avoidance of doubt, Lien shall not include the license of any rights.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Loss</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any and all Judgments, damages, losses, claims, costs, liabilities and expenses, including reasonable fees and out-of-pocket expenses of counsel. </font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Net Sales</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall have the meaning ascribed thereto in Section 1.50 of the License Agreement.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">New Product</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall have the meaning ascribed thereto in Section 1.53 of the License Agreement.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">New Product Development Plan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall have the meaning ascribed thereto in Section 1.54 of the License Agreement.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Marketed Product</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; is defined in Section 5.8(b)(iii). </font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Ordinary Course Licenses or Sublicenses</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means licenses or sublicenses entered into in the ordinary course of business with respect to the (i) development or manufacture of Products, (ii) distribution, third party logistics, warehousing, packaging, labeling or other commercialization activities that are ancillary to marketing, promotion or selling of Products or (iii) commercial sale of Products outside of &#91;**&#93;.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Original Counter Proposed Consensus Value</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Exhibit A</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Original Proposed Consensus Value</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Exhibit A</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 5 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Patent Office</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the applicable patent office, including the United States Patent and Trademark Office and any comparable foreign patent office, for the registration of any patents and patent applications.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Patent Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall have the meaning ascribed thereto in Section 1.56 of the License Agreement.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Permitted Liens</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any (i) mechanic&#8217;s, materialmen&#8217;s, and similar liens for amounts not yet due and payable, (ii) statutory liens for taxes not yet due and payable or for taxes that the taxpayer is contesting in good faith, (iii)  Liens in favor of the Buyer, and (iv) other liens and encumbrances not incurred in connection with the borrowing of money that do not materially and adversely affect the use or value of the affected assets provided that, in each case, such liens are automatically released upon the sale or other transfer of the affected assets (it being understood that any obligations secured by such &#8220;Permitted Liens&#8221; shall remain the obligations of the Seller).</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Permitted Royalty Reduction</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means a reduction to the Royalty pursuant to Sections 11.5.3, 11.5.4, 11.5.5 or 14.2 of the License Agreement or a Permitted Withholding Tax Royalty Reduction, except, in each case, to the extent that such reduction was the direct result of a material breach or default by the Seller of the License Agreement or this Agreement.  For the avoidance of doubt, no amounts paid or owed to Foundation, including under the Sponsored Research Agreement, shall be considered a Permitted Royalty Reduction.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Permitted Withholding Tax Royalty Reduction</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means a reduction to a Royalty payment pursuant to Section 13 of the License Agreement, provided that reductions to a Royalty payment under Section 13 of the License Agreement shall not constitute Permitted Withholding Tax Royalty Reductions if such reductions result from changes to the Seller (or its Affiliate&#8217;s) jurisdiction or corporate structure, or the taking of any action by the Seller which has the effect of subjecting such Person (or payments made by or on their behalf) to additional Taxes or Tax laws.</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;"> </sup></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Person</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any individual, firm, corporation, company, partnership, limited liability company, trust, joint venture, association, estate, trust, Governmental Entity or other entity, enterprise, association or organization.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Prime Rate</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the prime rate published by the Wall Street Journal, from time to time, as the prime rate.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Pro Rata Portion</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means (a) with respect to the Buyer, 42.933%, and (b) with respect to the Seller, 57.067%.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Proceeds</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any amounts actually recovered by the Seller (or its designee) as a result of any settlement or resolution of any actions, suits, proceedings, claims or disputes related to the License Agreement, the Sponsored Research Agreement or otherwise related to or involving the Royalty or any Product.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 6 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Product</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall have the meaning ascribed thereto in Section 1.61 of the License Agreement.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Product Information</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means (a) all notices between, to or from the Seller and Licensee under the License Agreement and (b) all other information the Seller receives or furnishes under the License Agreement with respect to matters that would reasonably be expected to result in a Product MAE.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Product MAE</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means (i) a material adverse effect on the legality, validity or enforceability of any provision of this Agreement, (ii) a material adverse effect on the ability of the Seller to perform any of its obligations hereunder, (iii) a material adverse effect on the rights or remedies of the Buyer hereunder, (iv) an adverse effect on the rights of the Seller under the License Agreement or the Sponsored Research Agreement, other than as a result of Credit Event, that has a material adverse effect on the Royalty, (v) an adverse effect on the performance of the parties under the License Agreement or the Sponsored Research Agreement, including related to the approval or commercialization of the Products, other than as a result of a Credit Event, that has a material adverse effect on the Royalty, or (vi) any other adverse effect in any material respect on the timing, amount or duration of the payments to be made to the Buyer in respect of any portion of the Royalty or the right of the Buyer to receive such payments, in each case other than as a result of a Credit Event or Permitted Royalty Reduction&#59; provided, however, that a delay in obtaining or failure to obtain regulatory approval for any Product shall not in and of itself constitute a Product MAE, it being understood that the underlying facts and circumstances giving rise to such delay or failure may constitute, and may be taken into account in determining whether there has been, a Product MAE as described in the foregoing clauses (i)-(vi).</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">PTC Know-How</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall have the meaning ascribed thereto in Section 1.64 of the License Agreement.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">PTC Patent Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall have the meaning ascribed thereto in Section 1.65 of the License Agreement, only to the extent that such PTC Patent Rights relate to risdiplam or a Marketed Product.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Purchase Price</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means $650,000,000.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Receiving Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; is defined in Section 6.1.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Representative</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means, with respect to any Person, any manager, director, officer, employee, agent, advisor or other representative (including attorneys, accountants, consultants, bankers, financial advisors and actual and potential lenders and investors) of such Person. </font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Research Plan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall have the meaning ascribed thereto in Section 1.69 of the License Agreement.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Revaluation Event</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Exhibit A</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Revaluation Notice</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Exhibit A</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 7 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Reversionary Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; is defined in Section 5.8(b)(ii).</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Risdiplam</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the compound with the chemical structure set forth in Schedule 1.1 hereto, regardless of whether such term is capitalized herein. </font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Roche Know-How</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall have the meaning set forth in Section 1.74 of the License Agreement.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Roche Patent Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall have the meaning set forth in Section 1.75 of the License Agreement.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Royalty</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means (i) all payments payable to the Seller under Section 11.5 of the License Agreement, (ii) any payments to the Seller under the License Agreement in lieu of such payments of the foregoing clause (i), (iii) amounts payable to the Seller under Section 14.2 of the License Agreement in respect of payments described in the foregoing clauses (i) and (ii) (other than reimbursed audit costs under such section), (iv) subject to Section 5.10(f), amounts payable to the Seller under Section 15.8 of the License Agreement (other than reimbursed expenses as provided in Section 5.10(f)) and (v) any interest payments to the Seller under Section 12.2 of the License Agreement assessed on any payments described in the foregoing clauses (i), (ii), (iii) or (iv).  For the avoidance of doubt, the Royalty shall not include any payments or amounts payable to the Seller under Sections 11.1, 11.2, 11.3, or 11.4 of the License Agreement, including any amounts payable to the Seller under Sections 12.2 or 14.2 of the License Agreement in respect of such payments.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Royalty Reduction</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; is defined in Section 4.1(h)(xii).</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Royalty Report Certification</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; is defined in Section 5.4(b).</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Royalty Reports</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the quarterly reports deliverable by Licensee pursuant to Section 12.5 of the License Agreement.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Royalty Term</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall have the meaning ascribed thereto in Section 1.77 of the License Agreement.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Seller</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; is defined in the preamble.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Seller Business Combination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; is defined in Section 5.15.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Seller Closing Certificate</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; is defined in Section 3.2(a).</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Seller Direct Undertaking</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; is defined in Section 5.8(b)(i).</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Seller New Arrangement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; is defined in Section 5.8(b)(i).</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Seller New Licensee</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; is defined in Section 5.8(b)(i).</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 8 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">SMAF Clinical Trials Advisory Committee</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall have the meaning ascribed thereto in Section 5.1.1 of the License Agreement </font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Sponsored Research Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; is defined in the recitals.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">SRA Compound</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall have the meaning ascribed thereto in Section 1.82 of the License Agreement.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">SRA Development Plan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall have the meaning ascribed thereto in Section 1.81 of the License Agreement.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">SRA Product</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall have the meaning ascribed thereto in Section 1.81 of the License Agreement.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Standstill Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; is defined in Section 5.15.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Tax</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; or &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Taxes</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any federal, state, local or non-U.S. income, gross receipts, license, payroll, employment, excise, severance, occupation, premium, windfall profits, environmental, customs duties, capital stock, franchise, profits, withholding, social security, unemployment, disability, real property, personal property, abandoned property, value added, alternative or add-on minimum, estimated or other tax of any kind whatsoever, including any interest, penalty or addition thereto, whether disputed or not.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Territory</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall have the meaning ascribed thereto in Section 1.85 of the License Agreement. </font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Third Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any Person other than the Buyer, the Seller or any of their respective Affiliates. </font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Transaction Documents</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means this Agreement, the Bill of Sale, the Disclosure Schedule and the Licensee Instruction Letter.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Triggering Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; is defined in Section 5.8(b)(ii).</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">UCC</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means Article 9 of the New York Uniform Commercial Code, as in effect from time to time.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 1.2&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Certain Interpretations</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Except where expressly stated otherwise in this Agreement, the following rules of interpretation apply to this Agreement&#58;</font></div><div style="text-indent:60.69pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(i)&#8220;either&#8221; and &#8220;or&#8221; are not exclusive and &#8220;include,&#8221; &#8220;includes&#8221; and &#8220;including&#8221; are not limiting and shall be deemed to be followed by the words &#8220;without limitation&#59;&#8221;</font></div><div style="text-indent:57.36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(ii)&#8220;extent&#8221; in the phrase &#8220;to the extent&#8221; means the degree to which a subject or other thing extends, and such phrase does not mean simply &#8220;if&#59;&#8221;</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 9 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:54.03pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(iii)&#8220;hereof,&#8221; &#8220;hereto,&#8221; &#8220;herein&#8221; and &#8220;hereunder&#8221; and words of similar import when used in this Agreement refer to this Agreement as a whole and not to any particular provision of this Agreement&#59;</font></div><div style="text-indent:54.69pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(iv)references to a Person are also to its permitted successors and assigns&#59;</font></div><div style="text-indent:58.02pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(v)definitions are applicable to the singular as well as the plural forms of such terms&#59;</font></div><div style="text-indent:54.69pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(vi)unless otherwise indicated, references to an &#8220;Article&#8221;, &#8220;Section&#8221; or &#8220;Exhibit&#8221; refer to an Article or Section of, or an Exhibit to, this Agreement, and references to a &#8220;Schedule&#8221; refer to the corresponding part of the Disclosure Schedule&#59;</font></div><div style="text-indent:51.36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(vii)references to &#8220;$&#8221; or otherwise to dollar amounts refer to the lawful currency of the United States&#59; and </font></div><div style="text-indent:48.03pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(viii)references to a law include any amendment or modification to such law and any rules and regulations issued thereunder, whether such amendment or modification is made, or issuance of such rules and regulations occurs, before or after the date of this Agreement.</font></div><div style="text-indent:45pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 1.3&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Headings</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The table of contents and the descriptive headings of the several Articles and Sections of this Agreement and the Exhibits and Schedules are for convenience only, do not constitute a part of this Agreement and shall not control or affect, in any way, the meaning or interpretation of this Agreement.</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">ARTICLE 2.</font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">PURCHASE, SALE AND ASSIGNMENT OF THE ROYALTY</font></div><div style="margin-bottom:0.12pt;"><font><br></font></div><div style="text-indent:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 2.1&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Purchase and Sale</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Upon the terms and subject to the conditions of this Agreement, at the Closing, the Seller shall sell, transfer, assign and convey to the Buyer, and the Buyer shall purchase, acquire and accept from the Seller, free and clear of all Liens, all of the Seller&#8217;s right, title and interest in and to the Assigned Royalty Payments.  </font></div><div style="text-indent:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 2.2&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Purchase Price</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  In full consideration for the sale, assignment, transfer and conveyance of the Assigned Royalty Payments, and subject to the terms and conditions set forth herein, at the Closing, the Buyer shall pay (or cause to be paid) to the Seller, or the Seller&#8217;s designee, the Purchase Price, to be paid in immediately available funds by wire transfer to one or more accounts specified by the Seller on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Exhibit C</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="text-indent:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 2.3&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">No Assumed Obligations, Etc</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Notwithstanding any provision in this Agreement to the contrary, the Buyer is purchasing, acquiring and accepting only the Assigned Royalty Payments, and is not assuming any liability or obligation of the Seller of whatever nature, whether presently in existence or arising or asserted hereafter, under the License Agreement, the Sponsored Research Agreement or otherwise, including any payments due to the Foundation under the Sponsored Research Agreement.  Except as specifically set forth herein in respect of the Assigned Royalty Payments purchased, acquired and accepted hereunder, the </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 10 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Buyer does not, by such purchase, acquisition and acceptance, acquire any other contract rights of the Seller under the License Agreement, the Sponsored Research Agreement or any other assets of the Seller.</font></div><div style="text-indent:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 2.4&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">True Sale</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  It is the intention of the parties hereto that, as between the parties hereto, the sale, transfer, assignment and conveyance contemplated by this Agreement constitute a sale of the Assigned Royalty Payments from the Seller to the Buyer and not a financing transaction, borrowing or loan.  Following the Closing, the Buyer will be the owner of the Assigned Royalty Payments, the Buyer will have no right to return the Assigned Royalty Payments to the Seller, and the Seller will have no right to repurchase the Assigned Royalty Payments from the Buyer.  The sole recourse of the Buyer against the Seller in respect of the Assigned Royalty Payments will be (a) for Royalty Reductions, only to the extent permitted under Section 5.3 hereof, and (b) claims by the Buyer for breach of the representations, warranties, and covenants of the Seller set forth herein.  Accordingly, the Seller shall treat the sale, transfer, assignment and conveyance of the Assigned Royalty Payments as a sale of an &#8220;account&#8221; or a &#8220;payment intangible&#8221; (as appropriate) in accordance with the UCC for legal purposes, and the Seller hereby authorizes the Buyer to file financing statements (and continuation statements with respect to such financing statements when applicable) naming the Seller as the debtor and the Buyer as the secured party in respect of the Assigned Royalty Payments.  Not in derogation of the foregoing statement of the intent of the parties hereto in this regard, and for the purposes of providing additional assurance to the Buyer in the event that, despite the intent of the parties hereto, the sale, transfer, assignment and conveyance contemplated hereby is hereafter held not to be a sale, the Seller does hereby grant to the Buyer, as security for the obligations of the Seller hereunder, a first priority security interest in and to all right, title and interest of the Seller, in, to and under the Assigned Royalty Payments and any &#8220;proceeds&#8221; (as such term is defined in the UCC) thereof, and the Seller does hereby authorize the Buyer, from and after the Closing, to file such financing statements (and continuation statements with respect to such financing statements when applicable) as are necessary to perfect such security interest.  Nothing herein shall mandate or limit the tax or accounting treatment of the transactions contemplated hereby by either party hereto.</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">ARTICLE 3.</font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">CLOSING</font></div><div style="margin-bottom:0.12pt;"><font><br></font></div><div style="text-indent:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 3.1&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Closing&#59; Payment of Purchase Price</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The purchase and sale of the Assigned Royalty Payments shall take place on the date hereof, or at such other place, time and date as the parties hereto may mutually agree (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Closing</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  </font></div><div style="text-indent:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 3.2&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Closing Certificates</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Seller&#8217;s Closing Certificate</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  At the Closing, the Seller shall deliver to the Buyer a certificate of the Secretary of the Seller, dated as of the Closing Date, certifying (i) as to the incumbency of the officer of the Seller executing this Agreement and (ii) as to the attached copies of Seller&#8217;s certificate of incorporation, bylaws and resolutions adopted by the Seller&#8217;s board of directors authorizing the execution and delivery by the Seller of this Agreement </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 11 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">and the consummation by the Seller of the transactions contemplated hereby (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Seller Closing Certificate</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).</font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Buyer&#8217;s Incumbency Certificate</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  At the Closing, the Buyer shall deliver to the Seller a certificate of an authorized person of the owner trustee of the Buyer certifying as to the incumbency of the officers executing this Agreement on behalf of the Buyer (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Buyer Incumbency Certificate</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).</font></div><div style="text-indent:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 3.3&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Bill of Sale</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  At the Closing, upon confirmation of the receipt of the Purchase Price, the Seller shall deliver to the Buyer a duly executed bill of sale evidencing the sale, transfer, assignment and conveyance of the Assigned Royalty Payments, substantially in the form attached hereto as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Exhibit D</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Bill of Sale</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).</font></div><div style="text-indent:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 3.4&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Form W-9</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  At the Closing, the Seller shall deliver to the Buyer a valid, properly executed IRS Form W-9 certifying that the Seller is exempt from U.S. federal withholding tax and &#8220;backup&#8221; withholding tax.</font></div><div style="text-indent:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 3.5&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Form W-8BEN-E</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  At the Closing, the Buyer shall deliver to the Seller a valid, properly executed IRS Form W-8BEN-E certifying that the Buyer is exempt from U.S. federal withholding tax with respect to any and all payments of in respect of the Assigned Royalty Payments. </font></div><div style="text-indent:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 3.6&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Data Room</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  At the Closing, the Seller shall deliver to the Buyer an electronic copy of all of the information and documents posted as of the date hereof to the virtual data room established by the Seller and made available to the Buyer &#91;**&#93; (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Data Room</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) for archival purposes only.</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">ARTICLE 4.</font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">REPRESENTATIONS AND WARRANTIES</font></div><div style="margin-bottom:0.12pt;"><font><br></font></div><div style="text-indent:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 4.1&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Seller&#8217;s Representations and Warranties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Except as set forth in the Disclosure Schedule, the Seller represents and warrants to the Buyer that as of the date hereof&#58;</font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Existence&#59; Good Standing</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Seller is a corporation duly incorporated, validly existing and in good standing under the laws of Delaware.  The Seller is duly licensed or qualified to do business and is in corporate good standing in each jurisdiction in which the nature of the business conducted by it or the character or location of the properties and assets owned, leased or operated by it makes such licensing or qualification necessary, except where the failure to be so licensed or qualified and in corporate good standing has not and would not reasonably be expected to result in, either individually or in the aggregate, a Product MAE.</font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Authorization</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Seller has all requisite corporate power and authority to execute, deliver and perform its obligations under this Agreement.  The execution, delivery and performance of this Agreement, and the consummation of the transactions </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 12 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">contemplated hereby, have been duly authorized by all necessary corporate action on the part of the Seller.</font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Enforceability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  This Agreement has been duly executed and delivered and constitutes a valid and binding obligation of the Seller enforceable against the Seller in accordance with its terms, except as such enforceability may be limited by applicable Bankruptcy Laws or by other equitable principles of general application.</font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">No Conflicts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The execution, delivery and performance by the Seller of this Agreement and the consummation of the transactions contemplated hereby do not (i) contravene or conflict with the organizational documents of the Seller, (ii) contravene or conflict with or constitute a material default under any law or Judgment binding upon or applicable to the Seller, (iii) contravene or conflict with or constitute a default under the License Agreement or the Sponsored Research Agreement or (iv) except as would not reasonably be expected to result in a Product MAE, contravene or conflict with or constitute a default under any other contract or agreement binding upon or applicable to the Seller.</font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Consents</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Except for filings required by the federal securities laws or stock exchange rules, no consent, approval, license, order, authorization, registration, declaration or filing with or of any Governmental Entity or other Person is required to be done or obtained by the Seller in connection with (i) the execution and delivery by the Seller of this Agreement, (ii) the performance by the Seller of its obligations under this Agreement or (iii) the consummation by the Seller of any of the transactions contemplated by this Agreement.</font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(f)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">No Litigation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  There is no action, suit, investigation or proceeding pending before any Governmental Entity or, to the Knowledge of the Seller, threatened to which the Seller is a party that, individually or in the aggregate would, if determined adversely, reasonably be expected to result in a Product MAE.</font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(g)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Compliance with Laws</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Seller is not in violation of and, to the Knowledge of the Seller, the Seller is not under investigation with respect to, nor has the Seller been threatened to be charged with or given notice of any violation of, any law or Judgment applicable to the Seller, which violation would reasonably be expected to result in a Product MAE.</font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(h)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">License Agreement&#59; Sponsored Research Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Attached hereto as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Exhibits E</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">F</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> are true, correct and complete copies of, respectively, the License Agreement and the Sponsored Research Agreement, including any amendments, modifications, consents, assignments, ancillary agreements, licenses, sublicenses, transfers or waivers thereto or thereof as of the date hereof.  To the Knowledge of the Seller, the Seller has delivered to the Buyer, or has provided the Buyer access to, true, correct and complete copies of &#91;**&#93;. </font></div><div style="text-indent:54pt;padding-left:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(i)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">No Other Agreements</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Exhibits E</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">F</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> include all material agreements, instruments, arrangements, waivers or understandings (collectively, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Contracts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) between, by or among the Seller (or any predecessor or Affiliate thereof), Licensee (or any predecessor or Affiliate </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 13 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">thereof) and&#47;or the Foundation (or any predecessor or Affiliate thereof), relating to the subject matter thereof, and there are no other Contracts between the Seller (or any predecessor or any Affiliate thereof), on the one hand, and Licensee (or any predecessor or Affiliate thereof) and&#47;or the Foundation (or any predecessor or Affiliate thereof), on the other hand, that relate to the Royalty or that are primarily related to any Product (including the development or commercialization thereof), or that (with or without the giving of notice or passage of time, or both) would reasonably be expected to result in a Product MAE.  The Seller has not proposed, or received any proposal, to amend or waive any provision of the License Agreement or the Sponsored Research Agreement in any manner that would reasonably be expected (with or without the giving of notice or the passage of time, or both) to result in a Product MAE.  None of the executed Contracts included in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Exhibits E</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">F</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, contain any provision, term or condition that would reasonably be expected to result in a Product MAE. </font></div><div style="text-indent:54pt;padding-left:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(ii)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Licenses&#47;Sublicenses</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  To the Knowledge of the Seller, other than Ordinary Course Licenses or Sublicenses or licenses or sublicenses among Licensee and its Affiliates (and its and their predecessors), (A) there are no licenses or sublicenses entered into by Licensee or any other Person (or any predecessor or Affiliate thereof) in respect of Licensee&#8217;s rights and obligations under the License Agreement (including any Licensed IP) and (B) there are no licenses or sublicenses entered into by the Foundation or any other Person (or any predecessor or Affiliate thereof) in respect of the Foundation&#8217;s rights and obligations under the Sponsored Research Agreement (including any Licensed IP).  The Seller has not received any notice from Licensee pursuant to Section 3.3 or Section 11.5.4 of the License Agreement, nor has the Seller been requested by or given consent to, nor is the Seller in negotiation with, Licensee, pursuant to such provisions.</font></div><div style="text-indent:54pt;padding-left:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(iii)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Validity and Enforceability of License Agreement and the Sponsored Research Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Each of the License Agreement and the Sponsored Research Agreement is legal, valid, binding, enforceable, and in full force and effect except as may be limited by applicable Bankruptcy Laws or by general principles of equity (whether considered in a proceeding in equity or at law) or by any Credit Event.  Each of the License Agreement and the Sponsored Research Agreement will not cease to be legal, valid, binding, enforceable, and in full force and effect on identical terms, immediately following the consummation of the transactions contemplated by this Agreement, as a result of the consummation of the transactions contemplated by this Agreement.  The Seller is not, and, to the Knowledge of the Seller, neither the Licensee nor the Foundation is, in breach of the License Agreement or the Sponsored Research Agreement, as applicable, or in default thereunder, and no event has occurred that with notice or lapse of time would (i) permit termination of the License Agreement or the Sponsored Research </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 14 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Agreement or (ii) constitute a breach, default, modification or trigger acceleration under or to the License Agreement or the Sponsored Research Agreement that would reasonably be expected (with or without the giving of notice or the passage of time, or both) to result in a Product MAE.  No party to the License Agreement or the Sponsored Research Agreement has repudiated any provision of the License Agreement or the Sponsored Research Agreement, as applicable, and the Seller has not received any notice in connection with the License Agreement or the Sponsored Research Agreement challenging the validity, enforceability or interpretation of any provision of such agreement or any obligation to pay any portion of the Royalty without set-off, rescission, counterclaim, reduction, credit or other deduction of any kind.</font></div><div style="text-indent:54pt;padding-left:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(iv)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">No Event Triggering Reversionary Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Seller has not received any notice of and is not aware of any acts or omissions, including those of Licensee or its Affiliates, that would reasonably be expected to result in a Reversionary Right.  </font></div><div style="text-indent:54pt;padding-left:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(v)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Products</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Risdiplam and any products containing risdiplam as the active pharmaceutical ingredient that are owned or controlled by Seller or Licensee, including &#91;**&#93;, constitute SRA Products under the License Agreement.  As of the date hereof, &#91;**&#93; (risdiplam) is the only Product that is currently being developed or commercialized under the License Agreement.</font></div><div style="text-indent:54pt;padding-left:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(vi)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">No Liens or Assignments by the Seller</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Except for Permitted Liens and as contemplated hereby, the Seller has not conveyed, assigned or in any other way transferred all or any portion of its right, title and interest in and to the Royalty or any Product.  There are no Liens, other than Permitted Liens, on all or any portion of the Seller&#8217;s right, title and interest in and to the Royalty or any Product.</font></div><div style="text-indent:54pt;padding-left:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(vii)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">No Waivers or Releases</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Except as provided in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Exhibits E</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">F</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, the Seller has not granted any waiver under the License Agreement or the Sponsored Research Agreement, nor has the Seller released, in whole or in part, any counterparty from any of such counterparty&#8217;s obligations under the License Agreement or the Sponsored Research Agreement, in each case in any manner that is primarily related to any Product or that (with or without the giving of notice or passage of time, or both) would reasonably be expected to result in a Product MAE.  </font></div><div style="text-indent:54pt;padding-left:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(viii)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">No Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Seller has not (A) given Licensee any notice of termination of the License Agreement (whether in whole or in part) or any notice expressing any intention to terminate the License Agreement or (B) received any notice of termination of the License Agreement (whether in whole or in part) or any notice expressing any intention to terminate either the License Agreement.  To the Knowledge of the </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 15 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Seller, no event has occurred that would give rise to the expiration or termination of the License Agreement.  The Seller has not (A) given the Foundation any notice of termination of the Sponsored Research Agreement (whether in whole or in part) or any notice expressing any intention to terminate the Sponsored Research Agreement or (B) received any notice of termination of the Sponsored Research Agreement (whether in whole or in part) or any notice expressing any intention to terminate either the Sponsored Research Agreement.  To the Knowledge of the Seller, no event has occurred that would give rise to the expiration or termination of the Sponsored Research Agreement.</font></div><div style="text-indent:54pt;padding-left:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(ix)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Payments Made</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Seller has timely received from Licensee the full amount of the payments due and payable under the License Agreement in accordance with the terms thereof.  The Seller has timely paid all amounts due under the Sponsored Research Agreement in accordance with the terms thereof.</font></div><div style="text-indent:54pt;padding-left:85.5pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(x)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">No Assignments by Licensee</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Seller has not consented to any assignment, delegation or other transfer by Licensee or the Foundation or any of their respective predecessors of any of their respective rights or obligations related, directly or indirectly, to the Royalty or that primarily relate to any Product or that (with or without the giving of notice or passage of time, or both) would reasonably be expected to result in a Product MAE, under the License Agreement or the Sponsored Research Agreement, as applicable.  To the Knowledge of the Seller, neither Licensee nor the Foundation has assigned or otherwise transferred or granted any Liens with respect to any of its respective rights or obligations related, directly or indirectly, to the Royalty or that primarily relate to any Product or that (with or without the giving of notice or passage of time, or both) would reasonably be expected to result in a Product MAE.</font></div><div style="text-indent:54pt;padding-left:85.5pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(xi)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">No Indemnification Claims</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Seller has not notified Licensee or the Foundation or any other Person of, or otherwise made, any claims for indemnification under the License Agreement or the Sponsored Research Agreement, nor has the Seller received any claims for indemnification under the License Agreement or the Sponsored Research Agreement, whether pursuant to Section 5.1.4 or Article 17 of the License Agreement or Article 8 of the Sponsored Research Agreement, or otherwise.</font></div><div style="text-indent:54pt;padding-left:85.5pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(xii)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">No Royalty Reductions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The amount of the Royalty due and payable under Section 11.5 of the License Agreement is not, as of the date hereof, subject to any claim against the Seller pursuant to any right of set-off, rescission, counterclaim, reduction, credit, deduction or defense by contract or otherwise (any reduction on account of any such claim, a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Royalty Reduction</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), including under Sections 11.5.3, 11.5.4, 11.5.5, 13 or 14.2 of the </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 16 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:85.5pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">License Agreement.  To the Knowledge of the Seller, other than with respect to any Royalty Reductions under Section 11.5.3 of the License Agreement, no event or condition exists that, upon notice or passage of time or both, would reasonably be expected to permit Licensee to claim, or have the right to claim, a Royalty Reduction.</font></div><div style="text-indent:54pt;padding-left:85.5pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(xiii)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">No Notice of Infringement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Seller has not received any notice from, or given any notice to, Licensee or the Foundation (or any of their respective predecessors or Affiliates) alleging any actual, potential, suspected or threatened infringement, misappropriation or other violation by a Third Party of any intellectual property rights related to any Product.</font></div><div style="text-indent:54pt;padding-left:85.5pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(xiv)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Audits</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  None of the Seller, the Licensee nor the Foundation has initiated, pursuant to Section 14 of the License Agreement or otherwise, any inspection or audit of books of accounts or other records pertaining to any Product, Net Sales, the calculation of royalties or other amounts payable to the Seller under the License Agreement.</font></div><div style="text-indent:54pt;padding-left:85.5pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(xiv)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Adverse Events</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  None of the Seller, Licensee or the Foundation has informed the other about serious adverse events occurring or having occurred in connection with the use of any Product under Section 9.2.1 of the License Agreement that has had, or would reasonably be expected to result in, a Product MAE, and no pharmacovigilance agreement under Section 9.2.3 of the License Agreement is or has been required. </font></div><div style="text-indent:54pt;padding-left:85.5pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(xvi)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Committee Membership</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  As of the date hereof, the parties to the License Agreement have established the JSC, the SMAF Clinical Trials Advisory Committee, the JIPT, and the JOTs identified on Schedule 4.1(i)(xvi) of the Disclosure Schedule.  Schedule 4.1(i)(xvi) includes a list of the Alliance Directors and members of JSC, the SMAF Clinical Trials Advisory Committee, the JIPT, and the JOTs as of the date hereof.  All such committees have the authority under, and have been operating under the objectives, responsibilities and in the manner provided in, the License Agreement, and no material disputes have arisen in connection with any matters subject to the oversight of such committees.  The Seller has not exercised its rights pursuant to Section 7.14 of the License Agreement to determine not to appoint to, or withdraw members of, the JSC and any JOC and not to appoint or remove an Alliance Director, or withdraw from participation in the JSC and any JOT or other committee under the License Agreement.</font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(i)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Title to Royalty</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Seller has good and marketable title to the Royalty free and clear of all Liens (other than Permitted Liens).  Upon payment of the Purchase Price by the Buyer, the Buyer will acquire, subject to the terms and conditions set forth in this Agreement and the License Agreement, good and marketable title to the Assigned Royalty Payments, free and clear of all Liens (other than any Permitted Lien).</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 17 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(j)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Intellectual Property</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="text-indent:36pt;padding-left:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(i)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Schedule 4.1(j)(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> of the Disclosure Schedule lists all Joint Patent Rights, PTC Patent Rights and, to the Knowledge of the Seller, Roche Patent Rights (collectively, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Licensed Patents</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  The Seller is the sole owner of, and has the sole interest in, all of the PTC Patent Rights.  To the Knowledge of the Seller, Licensee is the sole owner of, and has the sole interest in, all of the Roche Patent Rights.  The Seller and Licensee collectively are the sole owners of, and collectively have the sole interest in, the Joint Patent Rights, and the Seller is the sole owner of, and has the sole interest in, its undivided half interest in each of the Joint Patent Rights.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Schedule 4.1(j)(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> of the Disclosure Schedule specifies as to each of the (x) PTC Patent Rights and Joint Patent Rights Handled by the Seller and (y) to the extent the following information has been provided by Licensee to the Seller with respect to the Roche Patent Rights, as applicable, the jurisdictions by or in which each such patent has issued as a patent or such patent application has been filed, including the respective patent numbers and application numbers and issue and filing dates.</font></div><div style="text-indent:54pt;padding-left:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(ii)&#160;There are no pending or, to the Knowledge of the Seller, threatened, litigations, interferences, reexamination, re-issue, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">inter partes</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> reviews, post-grant-reviews, oppositions or like procedures involving any PTC Patent Rights or Joint Patent Rights.  To the Knowledge of the Seller, there are no pending or threatened litigations, interferences, reexamination, re-issue, inter partes reviews, post-grant-reviews, oppositions or the like procedures involving any Roche Patent Right. </font></div><div style="text-indent:54pt;padding-left:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(iii)&#160;All of the issued PTC Patent Rights and the Joint Patent Rights Handled by the Seller are in full force and effect and have not lapsed, expired or otherwise terminated, and, to the Knowledge of the Seller, are valid and enforceable.  The Seller has not received any written notice relating to the lapse, expiration or other termination of any of the PTC Patent Rights or the Joint Patent Rights Handled by the Seller, or any written legal opinion that alleges that any of the issued PTC Patent Rights or the Joint Patent Rights Handled by the Seller is invalid or unenforceable.  To the Knowledge of the Seller, all of the issued Roche Patent Rights are in full force and effect and have not lapsed, expired or otherwise terminated, and are valid and enforceable.</font></div><div style="text-indent:54pt;padding-left:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(iv)&#160;Each individual associated with the prosecution of the PTC Patent Rights, the Joint Patent Rights Handled by the Seller and, to the Knowledge of the Seller, all other Joint Patent Rights, including the named inventors, has complied in all material respects with all applicable duties of candor and good faith in dealing with any Patent Office, including any duty to disclose to any Patent Office all information known by such inventors to be </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 18 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">material to the patentability of each of the PTC Patent Rights and Joint Patent Rights (including any relevant prior art), in each case, in those jurisdictions where such duties exist.  There is no Person who is or claims to be an inventor under any of the PTC Patent Rights or the Joint Patent Rights Handled by the Seller or, to the Knowledge of the Seller, any other Joint Patent Rights, who is not a named inventor thereof.</font></div><div style="text-indent:54pt;padding-left:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(v)&#160;The Seller has not, and, to the Knowledge of the Seller, Licensee has not, received any written notice of any claim by any Person challenging the inventorship or ownership of, the rights of the Seller or Licensee, as applicable, in and to, or the patentability, validity or enforceability of, any Licensed Patent, or asserting that the development, manufacture, importation, sale, offer for sale or use of the Product infringes any Patent Rights or other intellectual property rights of such Person.</font></div><div style="text-indent:54pt;padding-left:85.5pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(vi)&#160;To the Knowledge of the Seller, the development, manufacture, use, marketing, sale, offer for sale, importation or distribution of the Product has not infringed, misappropriated or otherwise violated any Patent Rights or other intellectual property rights owned by any other Person.  Neither the Seller nor, to the Knowledge of the Seller, Licensee, has in-licensed any Patent Rights or other intellectual property rights covering the manufacture, use, marketing, sale, offer for sale, importation or distribution of the Product.</font></div><div style="text-indent:54pt;padding-left:85.5pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(vii)&#160;To the Knowledge of the Seller, no Third Party has infringed, misappropriated or otherwise violated, or is infringing, misappropriating or otherwise violating, any of the Licensed Patents or any other Patent Rights claiming the composition of matter of, or the method of making or using, the Product, except as would not reasonably be expected to result in a Product MAE.</font></div><div style="text-indent:54pt;padding-left:85.5pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(viii)&#160;All required maintenance fees, annuities and like payments with respect to the PTC Patent Rights and Joint Patent Rights Handled by the Seller in accordance with Section 15.3 or 15.5 of the License Agreement, and to the Knowledge of the Seller, with respect to all other Licensed Patents, have been paid timely.</font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(k)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">UCC Representation and Warranties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Seller&#8217;s exact legal name is, and for the immediately preceding ten (10) years has been, &#8220;PTC Therapeutics, Inc.&#8221;.  The Seller is, and for the prior ten (10) years has been, incorporated in Delaware.</font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(l)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Brokers&#8217; Fees</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  There is no investment banker, broker, finder, financial advisor or other intermediary who has been retained by or is authorized to act on behalf of the Seller who might be entitled to any fee or commission in connection with the transactions contemplated by this Agreement.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 19 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 4.2&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">The Buyer&#8217;s Representations and Warranties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Buyer represents and warrants to the Seller that as of the date hereof&#58;</font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Existence&#59; Good Standing</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Buyer is a statutory trust duly organized, validly existing and in good standing under the laws of the State of Delaware.</font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Authorization</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Buyer has the requisite trust right, power and authority to execute, deliver and perform its obligations under this Agreement.  The execution, delivery and performance of this Agreement, and the consummation of the transactions contemplated hereby, have been duly authorized by all necessary action on the part of the Buyer.</font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Enforceability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  This Agreement has been duly executed and delivered by an authorized person of the owner trustee of the Buyer and constitutes the valid and binding obligation of the Buyer, enforceable against the Buyer in accordance with its terms, except as may be limited by applicable Bankruptcy Laws or by general principles of equity (whether considered in a proceeding in equity or at law).</font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">No Conflicts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The execution, delivery and performance by the Buyer of this Agreement do not and shall not (i) contravene or conflict with the organizational documents of the Buyer, (ii) contravene or conflict with or constitute a default under any material provision of any law binding upon or applicable to the Buyer or (iii) contravene or conflict with or constitute a default under any material contract or other material agreement or Judgment binding upon or applicable to the Buyer.</font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Consents</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  No consent, approval, license, order, authorization, registration, declaration or filing with or of any Governmental Entity or other Person is required to be done or obtained by the Buyer in connection with (i) the execution and delivery by the Buyer of this Agreement, (ii) the performance by the Buyer of its obligations under this Agreement, other than the filing of financing statement(s) in accordance with Section 2.4, or (iii) the consummation by the Buyer of any of the transactions contemplated by this Agreement.</font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(f)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">No Litigation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  There is no action, suit, investigation or proceeding pending or, to the knowledge of the Buyer, threatened before any Governmental Entity to which the Buyer is a party that would, if determined adversely, reasonably be expected to prevent or materially and adversely affect the ability of the Buyer to perform its obligations under this Agreement.</font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(g)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Financing</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Buyer has sufficient cash on hand to pay the entire Purchase Price.  The Buyer acknowledges that its obligations under this Agreement are not contingent on obtaining financing.</font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(h)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Brokers&#8217; Fees</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  There is no investment banker, broker, finder, financial advisor or other intermediary who has been retained by or is authorized to act on behalf of the Buyer who might be entitled to any fee or commission in connection with the transactions contemplated by this Agreement.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 20 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 4.3&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">No Implied Representations and Warranties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  EXCEPT AS EXPRESSLY SET FORTH IN SECTION 4.1, THE SELLER MAKES NO REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, AT LAW OR IN EQUITY, INCLUDING WITH RESPECT TO MERCHANTABILITY, FITNESS FOR ANY PARTICULAR PURPOSE OR NONINFRINGEMENT, AND ANY SUCH REPRESENTATIONS OR WARRANTIES ARE HEREBY EXPRESSLY DISCLAIMED.  THE BUYER ACKNOWLEDGES THAT, EXCEPT AS SPECIFICALLY PROVIDED IN THIS ARTICLE 4, THE SELLER HAS ASSUMED NO RESPONSIBILITIES OF ANY KIND WITH RESPECT TO ANY ACT OR OMISSION OF LICENSEE WITH RESPECT TO THE DESIGN, DEVELOPMENT, MANUFACTURE, USE, SALE, DISTRIBUTION, MARKETING OR OTHER ACTIVITIES OF LICENSEE WITH RESPECT TO THE PRODUCT.</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">ARTICLE 5.</font></div><div style="text-indent:18pt;text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">COVENANTS</font></div><div style="text-align:center;margin-bottom:0.12pt;"><font><br></font></div><div style="text-indent:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 5.1&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Disclosures</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Except for a press release previously approved in form and substance by the Seller and the Buyer, or any other public announcement using substantially the same text as such press release, neither the Buyer nor the Seller shall, and each party hereto shall cause its respective Representatives, Affiliates and Affiliates&#8217; Representatives not to, issue a press release or other public announcement or otherwise make any public disclosure with respect to this Agreement or the subject matter hereof without the prior written consent of the other party hereto (which consent shall not be unreasonably withheld, conditioned or delayed), except as may be required by applicable law or stock exchange rule (in which case the party hereto required to make the press release or other public announcement or disclosure shall use commercially reasonably efforts to allow the other party hereto reasonable time to comment on such press release or other public announcement or disclosure in advance of such issuance).</font></div><div style="text-indent:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 5.2&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Payments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Payments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  </font></div><div style="text-indent:54pt;padding-left:85.5pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(i)&#160;Promptly, and in any event, within &#91;**&#93; following the Closing, the Seller shall deliver to the Licensee (x) an instruction letter, in substantially the form attached hereto as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Exhibit G</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Licensee Instruction Letter</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), duly executed by the Buyer and the Seller, requesting that the Licensee pay the Assigned Royalty Payments to an account designated by the Buyer and deliver Royalty Reports directly to the Buyer simultaneously with delivery of Royalty Reports to the Seller, and (y) an IRS Form W-8BEN-E provided by Buyer pursuant to Section 3.5 hereof.  If, prior to the first Commercial Sale of Product, the Licensee does not agree to make payment of the Assigned Royalty Payments to an account designated by the Buyer, then (x) the parties shall execute and deliver to the Escrow Agent within &#91;**&#93; after the First Commercial Sale of a Product the Escrow Agreement and (y) the Seller shall instruct the Licensee to make all payments of the Royalty to the </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 21 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:85.5pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Escrow Account until such time as the Assigned Royalty Cap is met.  In the event that the Seller sells, transfers, assigns or otherwise conveys any portion of its retained rights in the Royalty to an Affiliate or Third Party, the Buyer agrees not to object to amending, and to reasonably cooperate to amend, the Escrow Agreement to add any such Affiliate or Third Party for the purposes of directing to such Third Party any portion of the Royalty to which such Third Party may be entitled as a result of such transaction.  In no event shall the Escrow Agreement permit the Escrow Agent to distribute payments of the Royalty to the parties other than in accordance with each party&#8217;s applicable Pro Rata Portion, or to withhold any distribution to the parties (whether as a result of any claims between the parties or otherwise), in each case without the prior written consent of both parties.</font></div><div style="text-indent:54pt;padding-left:85.5pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(ii)&#160;If, notwithstanding the terms of this Agreement, the Licensee Instruction Letter and the Escrow Agreement, as applicable, the Licensee, or any other Person, makes any payment in respect of the Assigned Royalty Payments to the Seller (or to any of the Seller&#8217;s Affiliates or designees) instead of to the Buyer or the Escrow Account, as applicable, then&#58;  (A) the Seller shall hold (or shall cause such Affiliate or designee to hold) such payment in trust for the sole benefit of the Buyer, (B) the Seller (or such Affiliate or designee) shall have no right, title or interest whatsoever in such payment and shall not create or suffer to exist any Lien thereon, and (C) the Seller (or such Affiliate or designee) promptly, and in any event no later than &#91;**&#93; following the receipt by the Seller (or such Affiliate or designee) of such payment, shall remit, or cause to be remitted, an amount equal to such payment to an account designated in writing by the Buyer or to the Escrow Account to be distributed pursuant to the Escrow Agreement, as applicable.</font></div><div style="text-indent:54pt;padding-left:85.5pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(iii)&#160;If, notwithstanding the terms of this Agreement, the Licensee Instruction Letter and the Escrow Agreement, as applicable, the Licensee, or any other Person, makes any payment due under the License Agreement that does not constitute an Assigned Royalty Payment, to the Buyer (or to any of the Buyer&#8217;s Affiliates or designees) instead of to the Seller or the Escrow Account, as applicable, or as otherwise instructed by the Seller, then&#58;  (A) the Buyer shall hold (or shall cause such Affiliate or designee to hold) such payment in trust for the sole benefit of the Seller, (B) the Buyer (or such Affiliate or designee) shall have no right, title or interest whatsoever in such payment and shall not create or suffer to exist any Lien thereon, and (C) the Buyer (or such Affiliate or designee) promptly, and in any event no later than &#91;**&#93; following the receipt by the Buyer (or such Affiliate or designee) of such payment, shall remit, or cause to be remitted, an amount equal to such payment to an account designated in writing by the Seller or to the Escrow Account to be distributed pursuant to the Escrow Agreement, as applicable.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 22 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;If either the Seller or the Buyer fails to timely comply with their respective obligations under Section 5.2(a), then all amounts not timely paid by the due date provided therein shall accrue interest from and including the date such amount was due through but excluding the date such payment in full (together with all interest thereon) is made to the applicable party, at a rate, calculated on a 365-day or 366-day basis, as applicable, equal to the then-current Prime Rate plus &#91;**&#93; percent (&#91;**&#93;%), compounded annually, not to exceed the maximum interest that may be charged under applicable law.</font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;Except as set forth in Section 5.2(a)(i), the Seller shall not revoke, amend, modify, supplement, restate, waive, cancel or terminate the Licensee Instruction Letter or any instruction to the Licensee to make payments in respect of the Royalty to the Escrow Agent without the prior written consent of Buyer.</font></div><div style="text-indent:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 5.3&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Royalty Reductions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  If Licensee exercises any Royalty Reduction against any payment of the Royalty that is not (a) a Permitted Royalty Reduction, (b) the result of any Credit Event or (c) a breach by Licensee of its payment obligations under the License Agreement, such Royalty Reduction shall not reduce the amount of any Assigned Royalty Payments to which the Buyer is entitled, and if such Royalty Reduction reduces any payment of the Assigned Royalty Payments to less than the full amount of the Assigned Royalty Payments, then the Seller shall promptly (and in any event within &#91;**&#93; following the payment of the Assigned Royalty Payments affected by such Royalty Reduction) make a true-up payment to the Buyer such that the Buyer receives the full amount of such Assigned Royalty Payments that would have been payable to the Buyer had such Royalty Reduction not occurred.  The Seller agrees to notify the Buyer in writing as promptly as possible (and in any event within &#91;**&#93;) of becoming aware of any actual or potential Royalty Reductions, including Permitted Royalty Reductions.  For the avoidance of doubt, any nonpayment by Licensee as a result of a Credit Event or a breach by Licensee of its payment obligations under the License Agreement shall not constitute a Royalty Reduction for purposes of this Section 5.3 and shall not obligate the Seller to make any payment under this Section 5.3 (unless and until such nonpayment is cured).  For all purposes hereunder, any true-up payment made pursuant to this Section 5.3 will be treated as paid with respect to the Royalty for U.S. federal income tax purposes to the fullest extent permitted by applicable law.</font></div><div style="text-indent:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 5.4&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Royalty Reports&#59; Other Product Information</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;Until such time as the Licensee has agreed to provide copies of Royalty Reports directly to the Buyer pursuant to the Instruction Letter, as promptly as possible (and in any event within &#91;**&#93;) following the receipt by the Seller of any Royalty Report, the Seller shall deliver to the Buyer a report in the form attached hereto as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Exhibit H</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> prepared by the Seller and certified by a duly authorized official of the Seller as to the authenticity of such Royalty Report (a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Royalty Report Certification</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  From and after such time as the Licensee has agreed to provide copies of Royalty Reports directly to the Buyer pursuant to the Instruction Letter, the Seller shall as promptly as possible (and in any event within &#91;**&#93;) deliver to the Buyer copies of any Royalty Reports not provided to the Buyer directly, and any supporting </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 23 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">documentation, information, or other reports (if any) received by the Seller from Licensee relating to the Royalty for such Calendar Quarter to the extent not provided to the Buyer directly.  </font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;The Seller agrees to request that Roche deliver Product Information (other than a Royalty Report as provided in Section 5.4(a) above) to the Buyer directly as more fully described in, and in accordance with the terms of, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Exhibit I</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Until such time as the Licensee has agreed to deliver Product Information (other than Royalty Reports) directly to the Buyer, the Seller agrees to deliver to the Buyer, at least on a &#91;**&#93; basis, new or updated Product Information that the Seller receives from the Licensee.  On an at least &#91;**&#93; basis, the Seller shall deliver to the Buyer a reasonably detailed summary of new or updated information of which it has Knowledge about any decision, order, dispute or challenge, of or related to the validity, patentability, scope, priority, construction, non-infringement, inventorship, ownership or enforceability of any of the PTC Patent Rights, the Joint Patent Rights Patent or Roche Patent Rights or any claim thereof, or opposition of the grant of any patent that falls within the PTC Patent Rights, Joint Patent Rights or Roche Patent Rights, in any legal or administrative proceedings, including in a court of law, before the United States Patent and Trademark Office or other agency or tribunal in any jurisdiction, or in arbitration, including by reexamination, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">inter partes</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> review, opposition, interference, post-grant review, nullity proceeding, preissuance submission, third party submission, derivation proceeding or declaratory judgment action.</font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;The Seller agrees to notify the Buyer within &#91;**&#93; after the Seller&#8217;s receipt or Knowledge of a Third Party Paragraph IV certification with respect to the PTC Patent Rights, the Joint Patent Rights or the Roche Patent Rights.  The Seller shall provide the Buyer &#91;**&#93; with a list, substantially in the form of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Schedule 4.1(j)(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> of the Disclosure Schedule, of PTC Patent Rights and Joint Patent Rights Handled by the Seller or of which the Seller then has Knowledge covering the Product. </font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;Notwithstanding the foregoing, until such time as the Licensee has agreed to deliver Product Information directly to the Buyer, if the Seller is advised by its counsel that providing the Buyer with a true, correct and complete copy of Product Information or other documents or information pursuant to this Agreement (whether pursuant to this Section 5.4 or otherwise) would be reasonably expected to constitute a material breach by the Seller of its confidentiality obligations under the License Agreement (a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Confidentiality Breach</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), then the Seller shall, in lieu of delivery of such Product Information, provide a written summary thereof to the Buyer describing in as much detail as would not result in a Confidentiality Breach, the substance of such Product Information or other documents or information.  </font></div><div style="text-indent:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 5.5&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Actions under the License Agreement while the Seller is the Control Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The following provisions shall only apply while the Seller is the Control Party&#58;</font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Compliance&#59; No Modifications to Reduce Assigned Royalty Payments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Seller shall comply in all material respects with its obligations under the License Agreement and the Sponsored Research Agreement.  The Seller shall not, without the prior written consent of the Buyer, make, propose, effect, deliver, execute or grant any amendment, modification, consent, notice or waiver, or take (or fail to take) any other action, under the License Agreement or the Sponsored Research Agreement that (with or without the giving of notice or passage of </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 24 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">time, or both) would reasonably be expected to result in a Product MAE.  Promptly (and in any event within &#91;**&#93;) after the Seller&#8217;s receipt of any written notice from Licensee of an alleged breach or default under the License Agreement or the Sponsored Research Agreement by the Seller, the Seller shall give written notice thereof to the Buyer, including delivering to the Buyer a copy of any such written notice.  The Seller shall use commercially reasonable efforts to cure any material breach or default by the Seller under the License Agreement or the Sponsored Research Agreement, as applicable, and shall give written notice to the Buyer upon curing any such breach or default.  The Seller shall pay all of its costs and expenses (including of counsel) in connection with any such breach or default.  Promptly (and in any event within &#91;**&#93;) after the Seller becomes aware of, or comes to believe in good faith that there has been, a breach of the License Agreement or the Sponsored Research Agreement by Licensee or the Foundation, the Seller shall provide notice of such breach to the Buyer.  If such breach (with or without the giving of notice or passage of time, or both) would reasonably be expected to result in a Product MAE, the Seller shall consult with the Buyer regarding the timing, manner and conduct of any enforcement of Licensee&#8217;s obligations under the License Agreement and shall consider in good faith all of Buyer&#8217;s timely comments and suggestions regarding such enforcement, provided that (i) nothing in this Section 5.5(a) shall obligate the Seller to take or refrain from taking any action in respect of any such enforcement and (ii) the Buyer shall pay its Pro Rata Portion of the reasonable and documented costs and expenses of any such enforcement (excluding any costs and expenses of or reimbursable by Licensee).  </font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Notices, Correspondence and Other Information Delivered by the Seller</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Seller shall send a copy of any Product Information that the Seller delivers to Licensee, the Foundation, any Governmental Entity or other governing authority, as the case may be, concurrently to the Buyer&#59; provided, however, that the Seller shall (a) deliver to the Buyer any notices it intends to provide to Licensee pursuant to Section 7.15 of the License Agreement to the Buyer at least &#91;**&#93; prior to providing such notice to Licensee and shall consult with the Buyer regarding such notice.</font></div><div style="text-indent:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 5.6&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Actions under the License Agreement while the Buyer is the Control Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The following provisions shall only apply while the Buyer is the Control Party&#58;</font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Notices and Other Information to the Licensee</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Seller shall not send, without the prior written consent of the Buyer (or refrain from sending if instructed to do so by the Buyer), any written notice or correspondence to Licensee, the Foundation, any Governmental Entity or any other Person if such notice or correspondence relates solely to the Assigned Royalty Payment or if such notice or correspondence would reasonably be expected (with or without the giving of notice or passage of time, or both) to result in a Product MAE.  Notwithstanding the foregoing, no prior consent of the Buyer shall be required for the Seller to deliver notice pursuant to Sections 7.15 or 20.2 of the License Agreement, provided, that the Seller shall deliver to the Buyer any notices it delivers to Licensee pursuant to Section 7.15 of the License Agreement substantially concurrently with delivery of such notice to Licensee.  The Seller shall deliver to the Buyer true, correct and complete copies of any notices it actually provides pursuant to the License Agreement concurrently with the Seller&#8217;s delivery thereof to the Licensee, Foundation or any other Person, as applicable.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 25 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Amendment of License Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Seller shall not, except with the prior written consent of the Buyer (such consent not to be unreasonably withheld, conditioned or delayed if such amendment would not reasonably be expected, with or without the giving of notice or the passage of time, or both, to result in a Product MAE), amend, modify, waive, consent to or supplement or restate (or consent to any amendment, modification, waiver, consent, supplement or restatement of or to) any provision of the License Agreement or the Sponsored Research Agreement, including any plans or budgets thereunder.  Subject to the foregoing, promptly, and in any event within &#91;**&#93;, following receipt by the Seller of any final amendment, modification, waiver, consent, supplement or restatement of the License Agreement, or the Sponsored Research Agreement, the Seller shall furnish a copy of the same to the Buyer.</font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Maintenance of License Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  </font></div><div style="text-indent:54pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(i)&#160;The Seller shall comply in all material respects with its obligations under the License Agreement and the Sponsored Research Agreement and shall not take any action or forego any action that would reasonably be expected to constitute a material breach or default thereof.  Promptly, and in any event within &#91;**&#93;, after receipt of any (written or oral) notice from Licensee of an alleged breach or default under the License Agreement or the Sponsored Research Agreement by the Seller under the License Agreement or the Sponsored Research Agreement, the Seller shall give written notice thereof to the Buyer, including delivering the Buyer a copy of any such written notice.  The Seller shall use its reasonable efforts to cure any breach or default by the Seller under the License Agreement or the Sponsored Research Agreement, as applicable, as reasonably instructed by the Buyer, and shall give written notice to the Buyer upon curing any such breach or default.  The Seller shall pay all of its costs and expenses (including of counsel) in connection with any such breach or default.</font></div><div style="text-indent:54pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(ii)&#160;In connection with any dispute regarding any such alleged breach or default by Licensee that is related to the Royalty or primarily related to any Product or that would reasonably be expected (with or without the giving of notice or passage of time, or both) to result in a Product MAE, the Seller shall employ such counsel reasonably acceptable to the Seller as the Buyer shall select for such purpose, provided that the Buyer shall pay its Pro Rata Portion of the reasonable and documented costs and expenses incurred by the Seller in connection with any such dispute (net of any amounts recovered by the Seller).</font></div><div style="text-indent:54pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(iii)&#160;The Seller shall consult with the Buyer prior to appointing to or withdrawing members of the JSC and any JOC and prior to appointing or removing an Alliance Director, or withdrawing from participation in the JSC and any JOT or other committee under the License Agreement.</font></div><div style="text-indent:54pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(iv)&#160;The Seller shall not, except as mutually agreed by the parties, (a) forgive, release, settle or compromise any amount owed to or becoming owed to the Seller under the License Agreement in respect of the Royalty or (b) waive any obligation of, or grant any consent to, the Licensee under, in respect of or </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 26 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">related to the Royalty&#59; provided, that neither the occurrence of a Credit Event nor any automatic effect of a Credit Event under the License Agreement without an affirmative action of the Seller shall itself be deemed any forgiving, release, settlement, compromise, waiver or consent by the Seller.</font></div><div style="text-indent:54pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(v)&#160;If the Seller is provided with an opportunity to assist with the establishment of any budgets in connection with New Product development as provided in Section 5.2 of the License Agreement, or to agree to matters related to a diagnostic Product as provided in Section 11.7 of the License Agreement, the Seller shall undertake such activities in consultation with the Buyer.  The Seller further agrees to consult with and give due consideration to the Buyer&#8217;s input in connection with the matters provided in Sections 7.8 and 10 of the License Agreement.</font></div><div style="text-indent:54pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(vi)&#160;The Seller shall not exercise its rights under the License Agreement or the Sponsored Research Agreement in any manner that would result in a breach of this Agreement or would reasonably be expected (with or without the giving of notice or the passage of time, or both) to result in a Product MAE.</font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Enforcement of License Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:54pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(i)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Notice of Breaches by Licensee</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Promptly (and in any event within &#91;**&#93;) after the Seller becomes aware of, or comes to believe in good faith that there has been, a breach of the License Agreement or the Sponsored Research Agreement by Licensee or the Foundation, the Seller shall provide notice of such breach to the Buyer.  In addition, the Seller shall provide to the Buyer a copy of any written notice of such breach or alleged breach of the License Agreement or the Sponsored Research Agreement delivered by the Seller to Licensee as soon as practicable and in any event not less than &#91;**&#93; following such delivery.</font></div><div style="text-indent:54pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(ii)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Enforcement of License Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  In the case of any breach by Licensee or the Foundation referred to in Section 5.6(d)(i), the Seller shall consult with the Buyer regarding the timing, manner and conduct of any enforcement of Licensee&#8217;s obligations under the License Agreement or the Foundation&#8217;s obligations under the Sponsored Research Agreement.  Following such consultation, the Seller shall, (i) as reasonably instructed by the Buyer, exercise such rights and remedies relating to any such breach as shall be available to the Seller, whether under the License Agreement, the Sponsored Research Agreement or by operation of law and, (ii) if such breach is related to the Royalty or would reasonably be expected (with or without the giving of notice or passage of time, or both) to result in a Product MAE, employ such counsel reasonably acceptable to the Seller as the Buyer shall select for such purpose.</font></div><div style="text-indent:54pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(iii)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Allocation of Proceeds and Costs of Enforcement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Each of the Buyer and the Seller shall bear its own fees and expenses incurred in enforcing Licensee&#8217;s obligations under the License Agreement pursuant to this Section </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 27 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">5.6(d), provided that the Buyer shall pay its Pro Rata Portion of the reasonable and documented costs and expenses incurred by the Seller in connection with the Seller&#8217;s enforcement of the License Agreement in accordance with Section 5.6(d)(ii) (net of any amounts reimbursable by Licensee).  The Proceeds resulting from any enforcement of Licensee&#8217;s obligations under the License Agreement shall be applied first to reimburse the Seller and the Buyer for any expenses incurred by them in connection with such enforcement, and the remainder of the Proceeds shall be allocated between the Seller and the Buyer as though such Proceeds constituted Royalty payments.  The Seller hereby assigns and, if not presently assignable, agrees to assign to the Buyer the amount of Proceeds due to the Buyer in accordance with this Section 5.6(d).</font></div><div style="text-indent:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 5.7&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Inspections and Audits of Licensee</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  If either party desires to cause an inspection as provided under Section 14 of the License Agreement, then the Seller and the Buyer agree to consult in good faith with each other in connection therewith.  Following such consultation, the Seller may, or if requested by the Buyer, shall, promptly provide written notice to Licensee to cause such an inspection.  The Seller shall, for purposes of Section 14 of the License Agreement, select such independent certified public accounting firm as is reasonably acceptable to both the Seller and the Buyer (as long as such independent certified public accountant is reasonably acceptable to Licensee as required by Section 14 of the License Agreement).  Each of the Buyer and the Seller shall be responsible for its Pro Rata Portion of the expense of any inspection or audit undertaken by either the Buyer or the Seller (including the fees and expenses of such independent certified public accounting firm designated for such purpose) that would otherwise be borne by the Seller pursuant to the License Agreement (if and as such expenses are actually incurred by the Seller).  The Seller shall deliver to the Buyer a copy of the results of any audit conducted pursuant to Section 14 of the License Agreement within &#91;**&#93; following the Seller&#8217;s receipt thereof (and the results of any such audit shall be considered Product Information).  If an audit reveals an underpayment by the Licensee, then the Royalty shall include the amount paid by the Licensee to the Seller to compensate for such underpayment in accordance with Section 14.2 of the License Agreement, with interest thereon as set forth in Section 12.2 of the License Agreement.  If an audit reveals an overpayment by the Licensee, then the Seller shall comply with its obligations set forth in Section 14.2 of the License Agreement and, in furtherance thereof, may, in its sole discretion, require that the Buyer pay the Seller an amount equal to the Buyer&#8217;s Pro Rata Portion of such overpayment or credit an amount equal to the Buyer&#8217;s Pro Rata Portion of such overpayment against future Assigned Royalty Payments.</font></div><div style="text-indent:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 5.8&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Termination of License Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  </font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;The Seller shall not, without the prior written consent of the Buyer, (i) exercise any right to terminate the License Agreement, in whole or in part, (ii) agree with Licensee to terminate the License Agreement, in whole or in part, or (iii) take, or permit any Affiliate or sublicensee to take, any action that would reasonably be expected to give Licensee the right to terminate the License Agreement, in whole or in part.  The Seller shall not take any action, fail to take an action or permit an action to be taken, that would give Licensee the right to terminate the License Agreement under Section 20.3.1 thereof, provided that in no event shall the </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 28 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Seller be obligated to prevent any termination of the License Agreement as a result of a Credit Event so long as such termination is not also a result of any affirmative action of the Seller.</font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Effect of Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:54pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(i)&#160;In the event that the License Agreement is terminated while the Seller is the Control Party and prior to a Change of Control of the Seller, and the Seller has rights under Section 20.4 of the License Agreement, the Seller shall have the right in its sole discretion to determine whether and how to continue the development and commercialization of Compounds and Products as provided in Section 20.4 of the License Agreement (including via direct sales by the Seller or its Affiliates and licenses to one or more distributors and other Third Parties on a regional basis)&#59; provided, that, the Seller shall consult with the Buyer as to its plans (a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Seller Direct Undertaking</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  If the Seller, in its sole discretion, determines to completely out-license to one or more Third Parties (each, a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Seller New Licensee</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) the global development and commercialization of Compounds and Products (a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Seller New Arrangement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), the Seller shall notify the Buyer in writing and shall promptly provide copies of any license agreement with a Seller New Licensee for the continued commercialization of the Compounds and Products, and commercialization plans therefor.</font></div><div style="text-indent:54pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(ii)&#160;If the License Agreement is terminated in whole or in part by Licensee pursuant to Section 20.3.3 (Termination Without a Cause) or by the Seller pursuant to Section 20.3.1 (Termination for Breach), Section 20.3.4 (Termination for Patent Challenge) or Section 20.3.5 (Termination for Post-Change of Control Material Change) in each case of the License Agreement while the Buyer is the Control Party or following a Change of Control of the Seller (any such termination while the Buyer is the Control Party or following a Change of Control of the Seller, a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Triggering Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), then the Seller shall have the first right to continue development and commercialization of Compounds and Products as provided in Section 20.4.1 of the License Agreement and pursue its rights under Sections 20.4.1.1, 20.4.1.2, 20.4.1.3, 20.4.1.4(i), 20.4.1.4(ii), 20.4.1.4(iii), 20.4.1.4(iv), 20.4.1.4(v), 20.4.1.5, 20.4.1.6, 20.4.1.7, 20.4.1.8 and 20.4.3 of the License Agreement (collectively, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Reversionary Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  The Seller shall inform the Buyer in writing within &#91;**&#93; of a Triggering Termination whether or not it has elected to pursue the Reversionary Rights and shall thereafter keep Buyer reasonably informed as to the status of, and shall use commercially reasonable efforts in connection with, the pursuit of such development and commercialization under the Reversionary Rights, including delivering to the Buyer concurrently with deliver of the same to Licensee, notice pursuant to Section 20.4.1.9 of the License Agreement.  In the event that the Seller does not notify the Buyer in writing that the Seller has elected to pursue the Reversionary Rights within &#91;**&#93; of a Triggering Termination, the Buyer shall have the right to cause the Seller to pursue the Reversionary Rights by delivering written notice to the Seller and the Seller shall act as reasonably instructed by the </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 29 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Buyer to pursue the Reversionary Rights.  The Buyer shall indemnify, defend and hold harmless the Seller and its Affiliates against and in respect of all Losses suffered or incurred by the Seller or its Affiliates to the extent arising out of or resulting from the Seller&#8217;s or its Affiliates&#8217; exercise of the Reversionary Rights solely at the Buyer&#8217;s direction following a Triggering Termination, other than (A) the Seller&#8217;s Pro Rata Portion of any out of pocket fees, including attorneys&#8217;, consultants&#8217; or other professional advisor costs and expenses incurred in connection with exercising its Reversionary Rights pursuant to this Section 5.8(b)(ii) or as contemplated by Section 5.8(b)(iii) and (B) costs, expenses or other amounts attributable to the development, manufacture and commercialization of Compounds and Products under the License Agreement or the Sponsored Research Agreement that would otherwise have been borne by the Seller and its Affiliates.  The Seller shall promptly, and in any event within &#91;**&#93;, provide the Buyer with access to all materials, reports, information and property delivered, provided or otherwise made available to the Seller in connection with such Triggering Termination, the Licensee&#8217;s ongoing obligations and the Reversionary Rights.</font></div><div style="text-indent:54pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(iii)&#160;If there is a Triggering Termination and the Buyer is pursuing the Reversionary Rights pursuant to Section 5.8(b)(ii), the Buyer shall have the exclusive right to negotiate one or more licenses or sublicenses to continue to commercialize any Product that has obtained Regulatory Approval (each, a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Marketed Product</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) with one or more Third Parties under the Reversionary Rights (each such license or sublicense, a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Buyer Negotiated Arrangement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  The Seller shall reasonably cooperate with the Buyer, at the Buyer&#8217;s direction, in connection with the negotiation, execution and delivery of any Buyer Negotiated Arrangement.  Except with respect to the license or sublicense of any intellectual property rights included in the Reversionary Rights (which licenses or sublicenses shall be limited to the commercialization of the Marketed Product and any related development activities specifically with respect to such Marketed Product), no Buyer Negotiated Arrangement shall include terms, conditions and limitations that are, in the aggregate, more burdensome to the Seller than the licensing or sublicensing terms contained in the License Agreement.  The Buyer shall reimburse the Seller for the Buyer&#8217;s Pro Rata Portion of any out of pocket fees, including attorneys&#8217;, consultants&#8217; or other profession advisor costs and expenses incurred in connection with the pursuit, negotiation or execution of any Buyer Negotiated Arrangement. </font></div><div style="text-indent:54pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(iv)&#160;In connection with any Seller Direct Undertaking, Seller New Arrangement or Buyer Negotiated Arrangement, (a) the Buyer shall be provided with economic rights equivalent to those remaining under this Agreement and with substantially the same other rights as provided in this Agreement, and (b) the Seller&#8217;s rights and obligations under this Agreement in respect of the License Agreement shall otherwise apply to any Seller Direct Undertaking, any Seller New Arrangement or any Buyer Negotiated Arrangement, in each case </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">mutatis </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 30 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">mutandis</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  In connection with any Buyer Negotiated Arrangement, the Seller shall be provided with economic rights equivalent to those remaining under this Agreement and with substantially the same other rights as provided in this Agreement.  As soon as practicable following the Seller delivering written notice to the Buyer of any Seller Direct Undertaking or the execution of any Seller New Arrangement or Buyer Negotiated Arrangement by each party thereto, the Buyer and the Seller shall cooperate with one another to enter into new agreements (or to make amendments or modifications to this Agreement, the Bill of Sale and such other documents and the Buyer may reasonably request) to effect this clause (iv). </font></div><div style="text-indent:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 5.9&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">No Liens</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Seller shall not hereafter mortgage, pledge, hypothecate or grant a security interest or other Lien of any kind in (i) the Assigned Royalty Payments (other than a Permitted Lien) or (ii) any of its interest in any portion of the PTC Patent Rights, Joint Patent Rights, any Product or the License Agreement (other than a Permitted Lien).</font></div><div style="text-indent:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 5.10&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Enforcement&#59; Defense&#59; Prosecution and Maintenance</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;The Seller shall promptly inform the Buyer of any suspected infringement by a Third Party of any of the Licensed IP or if any Third Party alleges that manufacture, use, sale, offer for sale or import of a Product infringes the intellectual property rights of a Third Party.  The Seller shall (i) provide to the Buyer a copy of any written notice of any such suspected infringement and all pleadings filed in such action and (ii) notify the Buyer of any material developments in any claim, suit or proceeding resulting from such infringement that are delivered by or to Licensee or the Seller under Sections 15.8 and 15.9 of the License Agreement or otherwise as soon as practicable and in any event not less than &#91;**&#93; following such delivery.  </font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;In the event the Buyer is the Control Party, and if the Seller has the right to join or assume the defense or pursuit of an enforcement action pursuant to Section 15.8 or 15.9 of the License Agreement, the Seller shall, if requested in writing by the Buyer, promptly, and in any event within &#91;**&#93; after receipt of such request, exercise such right as reasonably instructed by the Buyer and, if requested by the Buyer, the Seller shall employ such counsel reasonably acceptable to the Seller as the Buyer shall select for such purpose, provided that the Buyer shall pay its Pro Rata Portion of the costs and expenses of any such counsel.  In the event the Buyer is the Control Party, the Seller shall not, except as reasonably instructed by the Buyer,  exercise any consent or consultation rights under Section 15.8 or 15.9 of the License Agreement.  In the event the Buyer is the Control Party, the Seller shall not, except as reasonably instructed by the Buyer, join any infringement action under Section 15.8 or 15.9 of the License Agreement.  To the extent the Seller exercises its right to join or assume the defense or pursue an action while the Buyer is the Control Party pursuant to this Section 5.10(b), the Seller shall act as reasonably instructed by the Buyer satisfy its obligations under Section 15.8 or 15.9 of the License Agreement, including to (1) diligently defend or enforce any Licensed Patents (including by bringing and defending any counterclaim of invalidity or unenforceability, defending against any action of a Third Party for declaratory judgment of non-infringement or non-interference or bringing any legal action for infringement) and (2) not disclaim or abandon, or fail to take any </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 31 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">action necessary or desirable to prevent the disclaimer, abandonment or dismissal (including through lack of enforcement against Third Party infringers) of any defense of invalidity or unenforceability or any legal action for infringement of any Licensed Patents in the Territory for which it has elected to join or assume the defense or pursue an enforcement action pursuant to this Section 5.10(b).  </font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;Promptly (and in any event within &#91;**&#93;) following the Seller&#8217;s receipt of written notice from the Licensee pursuant to Section 15.4 or 15.5 of the License Agreement of the Licensee&#8217;s intention to allow any of the Roche Patent Rights or the Joint Patent Rights in the Territory to lapse or become abandoned or to not file patent applications for any of the Roche Patent Rights or Joint Patent Rights in the Territory (such Patent Rights, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Applicable Listed Patents</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), the Seller shall inform the Buyer of such notice and, if the Buyer is the Control Party, the Seller shall, as mutually agreed with the Buyer, exercise its rights under Section 15.4 or 15.5 of the License Agreement to assume the prosecution and maintenance of any such Applicable Listed Patents and each of the Buyer and the Seller shall pay its Pro Rata Portion of the expenses in connection therewith.  If the Seller, in its reasonable discretion and after consultation with the Buyer, determines to abandon or not file any patent applications, the Buyer shall have the right, at its sole expense, to direct the Seller to assume the prosecution and maintenance of any such Applicable Listed Patents and the Buyer shall be solely responsible for the expenses in connection therewith.</font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;The Seller shall satisfy, at its own expense, its prosecution obligations under Sections 15.3, 15.4 and 15.5 of the License Agreement, which actions while the Buyer is the Control Party shall be reasonably determined by the Buyer after consultation with the Seller, including to (i) take any and all actions, and prepare, execute, deliver and file any and all agreements, documents and instruments, that are reasonably necessary or desirable to diligently prosecute, preserve and maintain any Licensed Patents in the Territory for which it controls the prosecution and maintenance, including payment of maintenance fees or annuities on any such Licensed Patents, (ii) prosecute any corrections, substitutions, reissues, reviews, interferences and reexaminations of any Licensed Patents in the Territory, for which it controls the prosecution and maintenance, and file any other forms of patent term restoration in any applicable jurisdiction in the Territory, (iii) diligently defend any Licensed Patents for which it controls the prosecution and maintenance against any opposition, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">inter partes</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> review, post-grant review or other proceeding before any Patent Office, and (iv) not disclaim or abandon, or fail to take any action necessary or desirable to prevent the disclaimer or abandonment, of any Licensed Patents in the Territory for which it controls the prosecution and maintenance.  To the extent the Seller does not control the prosecution and maintenance obligations under Sections 15.3, 15.4 and 15.5 of the License Agreement, the Seller shall use commercially reasonable efforts to cause Licensee (or the Foundation, as applicable) to satisfy its prosecution and maintenance obligations thereunder and the Seller shall at its own expense exercise its consulting, request, consent, approval or similar rights, with such exercise to be reasonably determined by the Buyer after consultation with the Seller in the event the Buyer is the Control Party.   </font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)&#160;Nothing in this Section 5.10 shall be construed to limit the Seller&#8217;s obligations pursuant to Section 5.5(a) while the Seller is the Control Party.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 32 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(f)&#160;The Proceeds resulting from any enforcement actions under Section 15.8 of the License Agreement shall be applied first to reimburse for any expenses incurred by the Seller and the Buyer in connection with such enforcement, and the remainder of the Proceeds shall be allocated between the Seller and the Buyer as though such Proceeds constituted Royalty payments&#59; provided, however, that in the event that the Seller initiates an action pursuant to Section 15.8 of the License Agreement, the Seller shall promptly notify the Buyer of such action and the Proceeds of any such action shall be allocated between the Seller and the Buyer as though such Proceeds constituted Royalty payments only if the Buyer funds its Pro Rata Portion of the costs of such action.</font></div><div style="text-indent:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 5.11&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Additional Monetizations</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Seller agrees to notify the Buyer in writing at least &#91;**&#93; prior to entering into a definitive agreement with a Third Party to assign, convey, monetize, impose a Lien upon or otherwise transfer or encumber any or all of its retained interest in the Royalty (a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Definitive Monetization Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  For the avoidance of doubt, nothing herein shall prevent or limit the ability of the Seller to enter into or consummate any such Definitive Monetization Agreement&#59; provided, that, if the Seller is the Control Party, the Seller agrees that if any Definitive Monetization Agreement provides a Third Party with information rights that are more favorable than the information rights provided to the Buyer in this Agreement, the Seller shall provide the Buyer with information rights that are as favorable to the Buyer as those provided to such Third Party, and the Seller shall effect such amendments or modifications to this Agreement or execute such other documents as the Buyer may reasonable request to effect the foregoing and provided further, that, for the avoidance of doubt, nothing in this Section 5.11 shall in any way limit the Buyer&#8217;s rights pursuant to Section 5.5(a).</font></div><div style="text-indent:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 5.12&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Efforts to Consummate Transactions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Subject to the terms and conditions of this Agreement, each of the Seller and the Buyer shall use its commercially reasonable efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things reasonably necessary under applicable law to consummate the transactions contemplated by this Agreement.  Each of the Buyer and the Seller agrees to execute and deliver such other documents, certificates, agreements and other writings and to take such other actions as may be reasonably necessary in order to consummate or implement expeditiously the transactions contemplated by this Agreement.</font></div><div style="text-indent:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 5.13&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Further Assurances</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  After the Closing, the Seller and the Buyer agree to execute and deliver such other documents, certificates, agreements and other writings and to take such other actions as may be reasonably necessary in order to give effect to the transactions contemplated by this Agreement.  </font></div><div style="text-indent:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 5.14&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Tax Matters</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  </font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;The Seller and Buyer shall treat the transactions contemplated by the Transaction Documents as a sale of the Assigned Royalty Payments for all United States federal state, local and non-U.S. Tax purposes.  Accordingly, any and all Assigned Royalty Payments made after the Closing Date shall be treated as made to the Buyer for United States federal, state, local and non-U.S. Tax purposes.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 33 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;If there is a Permitted Withholding Tax Royalty Reduction, the Seller shall reasonably cooperate with, and assist, Buyer in delivering the prescribed forms necessary to reduce the applicable rate of, or to eliminate, withholding to the extent Buyer is entitled under any applicable tax treaty, in accordance with Section 13 of the License Agreement.</font></div><div style="text-indent:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 5.15&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Standstill</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Buyer agrees that during the term of this Agreement, or upon an earlier Standstill Termination, without the consent of the Seller, the Buyer shall not, and shall cause its Affiliates not to, (a) propose any merger, consolidation, business combination, tender or exchange offer or other business combination or change of control transaction involving all or substantially all of the Seller&#8217;s equity, businesses or assets, on a consolidated basis (a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Seller Business Combination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;)&#59; (b) provide financing to any Third Party in connection with a Seller Business Combination&#59; (c) propose or seek, whether alone or in concert with others, any &#8220;solicitation&#8221; (as such term is used in the rules of the Securities and Exchange Commission) of proxies or consents to vote any securities of the Seller&#59; (d) nominate any person as a director of the Seller&#59; (e) propose any matter to be voted upon by the stockholders of the Seller&#59; (f) directly or indirectly, form, join or in any way participate in a Third Party &#8220;group&#8221; (as such term is used in the rules of the Securities and Exchange Commission) (or discuss with any Third Party the potential formation of a group) with respect to any securities of the Seller or a Seller Business Combination&#59; provided that, for the avoidance of doubt, nothing in this Section 5.15 shall prohibit the Buyer from agreeing to purchase any pharmaceutical royalties from the Seller or any Third Party.  The term &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Standstill Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall mean the earliest of (1) the public announcement that the Seller has entered into a definitive agreement with a Third Party for a Change of Control or a transaction involving a Seller Business Combination&#59; (2) if any person(s) or &#8220;group&#8221; publicly announces or commences a tender or exchange offer to acquire voting securities of the Seller, that, if successful, would result in such person or group beneficially owning more than 50% of the then outstanding voting securities of the Seller&#59; (3) if any person(s) or &#8220;group&#8221; commences a proxy contest with respect to the Seller and (4) if any person(s) or &#8220;group&#8221; files a Schedule 13D with respect to the beneficial ownership of at least &#91;**&#93;% of the then outstanding voting securities of the Seller by such person(s) or &#8220;group&#8221;.</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">ARTICLE 6.</font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">CONFIDENTIALITY</font></div><div style="text-indent:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 6.1&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Confidentiality</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Except as provided in this Article 6 or otherwise agreed in writing by the parties, the parties hereto agree that each party (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Receiving Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as provided for in this Agreement (which includes the exercise of any rights or the performance of any obligations hereunder) any information furnished to it by or on behalf of the other party (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Disclosing Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) pursuant to this Agreement (such information, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Confidential Information</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; of the Disclosing Party), except for that portion of such information that&#58;</font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;was already known to the Receiving Party, other than under an obligation of confidentiality, at the time of disclosure by the Disclosing Party&#59;</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 34 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;was generally available to the public or otherwise part of the public domain at the time of its disclosure to the Receiving Party&#59;</font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the Receiving Party in breach of this Agreement&#59; </font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;is independently developed by the Receiving Party or any of its Affiliates, as evidenced by written records, without the use of or reference of the Confidential Information&#59; or</font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)&#160;is subsequently disclosed to the Receiving Party on a non-confidential basis by a Third Party without obligations of confidentiality with respect thereto.</font></div><div style="text-indent:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 6.2&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Authorized Disclosure</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;Either party may disclose Confidential Information with the prior written consent of the Disclosing Party or to the extent such disclosure is reasonably necessary in the following situations&#58;</font></div><div style="text-indent:54pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(i)&#160;prosecuting or defending litigation&#59;</font></div><div style="text-indent:54pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(ii)&#160;complying with applicable laws and regulations, including regulations promulgated by securities exchanges&#59; </font></div><div style="text-indent:54pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(iii)&#160;complying with a valid order of a court of competent jurisdiction or other Governmental Entity&#59; </font></div><div style="text-indent:54pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(iv)&#160;for regulatory, tax or customs purposes&#59;</font></div><div style="text-indent:54pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(v)&#160;for audit purposes, provided that each recipient of Confidential Information must be bound by customary obligations of confidentiality and non-use prior to any such disclosure (which obligations must be consistent with the obligations of confidentiality set forth in the License Agreement and no less protective than those in this Agreement)&#59;</font></div><div style="text-indent:54pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(vi)&#160;disclosure to its Affiliates and Representatives on a need-to-know basis, provided that each recipient of Confidential Information must be bound by customary obligations of confidentiality and non-use prior to any such disclosure (which obligations must be consistent with the obligations of confidentiality set forth in the License Agreement and no less protective than those in this Agreement)&#59; or</font></div><div style="text-indent:54pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(vii)&#160;disclosure to its actual or potential investors and co-investors, and other sources of funding, including debt financing, or potential partners, collaborators or acquirers, and their respective accountants, financial advisors and other professional representatives, provided, that such disclosure shall be made </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 35 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">only to the extent customarily required to consummate such investment, financing transaction partnership, collaboration or acquisition and that each recipient of Confidential Information must be bound by customary obligations of confidentiality and non-use prior to any such disclosure (which obligations must be consistent with the obligations of confidentiality set forth in the License Agreement and no less protective than those in this Agreement).</font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;Notwithstanding the foregoing, in the event the Receiving Party is required to make a disclosure of the Disclosing Party&#8217;s Confidential Information pursuant to Sections 6.2(a)(i), (ii), (iii) or (iv), it will, except where impracticable, give reasonable advance notice to the Disclosing Party of such disclosure and use reasonable efforts to secure confidential treatment of such information.  In any event, the Buyer shall not file any patent application based upon or using the Confidential Information of the Seller provided hereunder.  </font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">ARTICLE 7.</font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">TERMINATION</font></div><div style="margin-bottom:0.12pt;"><font><br></font></div><div style="text-indent:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 7.1&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Automatic Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  This Agreement shall continue in full force and effect until the earlier of sixty (60) days after such time as (A) the Buyer has received payments hereunder in an amount equal to the Assigned Royalty Cap and (B) Licensee (or any other applicable Third Party, including a New Licensee or a Buyer Selected Licensee) is no longer obligated to make any payments of the Royalty, at which point this Agreement, the Escrow Agreement and the Licensee Instruction Letter shall automatically terminate, except with respect to any rights that shall have accrued prior to such termination.</font></div><div style="text-indent:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 7.2&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Survival</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Notwithstanding anything to the contrary in this Article 7, the following provisions shall survive termination of this Agreement&#58;  Section 5.1 (Disclosures), Section 5.2(a) (Payments&#59; Adjustments for Pre-Closing Royalty Reductions), Article 6 (Confidentiality), Section 7.2 (Survival) and Article 8 (Miscellaneous).  Termination of the Agreement shall not relieve any party of liability in respect of breaches under this Agreement by any party on or prior to termination. </font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">ARTICLE 8.</font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">MISCELLANEOUS</font></div><div style="margin-bottom:0.12pt;"><font><br></font></div><div style="text-indent:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 8.1&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Notices</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  All notices and other communications under this Agreement shall be in writing and shall be by email with PDF attachment, courier service or personal delivery to the following addresses, or to such other addresses as shall be designated from time to time by a party hereto in accordance with this Section 8.1&#58;</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">If to the Seller, to it at&#58;</font></div><div style="padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">PTC Therapeutics, Inc.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 36 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:72pt;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">100 Corporate Court</font></div><div style="padding-left:72pt;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">South Plainfield, New Jersey 07080</font></div><div style="padding-left:72pt;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Attention&#58;  Legal Department</font></div><div style="padding-left:72pt;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Email&#58; &#91;**&#93;</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">With a copy to&#58;</font></div><div style="padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Wilmer Cutler Pickering Hale and Dorr LLP</font></div><div style="padding-left:72pt;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">60 State Street</font></div><div style="padding-left:72pt;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Boston, Massachusetts 02109</font></div><div style="padding-left:72pt;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Attention&#58;  Steven D. Barrett and George W. Shuster, Jr.</font></div><div style="padding-left:72pt;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Email&#58;  steven.barrett&#64;wilmerhale.com&#59; george.shuster&#64;wilmerhale.com</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">If to the Buyer, to it at&#58;</font></div><div style="padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">RP Management, LLC</font></div><div style="padding-left:72pt;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">110 E. 59th Street, Suite 3300</font></div><div style="padding-left:72pt;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">New York, New York 0022</font></div><div style="padding-left:72pt;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Attention&#58;  George Lloyd</font></div><div style="padding-left:72pt;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Email&#58;  &#91;**&#93;</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">With a copy to&#58;</font></div><div style="padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Goodwin Procter LLP</font></div><div style="padding-left:72pt;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">100 Northern Avenue</font></div><div style="padding-left:72pt;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Boston, Massachusetts 02210</font></div><div style="padding-left:72pt;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Attention&#58;  Arthur R. McGivern &#38; Robert M. Crawford</font></div><div style="padding-left:72pt;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Email&#58;  amcgivern&#64;goodwinlaw.com&#59; rcrawford&#64;goodwinlaw.com</font></div><div style="margin-bottom:0.12pt;"><font><br></font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">All notices and communications under this Agreement shall be deemed to have been duly given (i) when delivered by hand, if personally delivered, (ii) when received by a recipient, if sent by e mail with delivery confirmation thereof, (iii) when sent, if sent by facsimile, with an acknowledgement of sending being produced by the sending facsimile machine or (iv) one (1) Business Day following sending within the United States by overnight delivery via commercial one- (1-)day overnight courier service.  </font></div><div style="text-indent:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 8.2&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Expenses</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Except as otherwise provided herein, all fees, costs and expenses (including any legal, accounting and banking fees) incurred in connection with the preparation, negotiation, execution and delivery of this Agreement and to consummate the transactions contemplated hereby shall be paid by the party hereto incurring such fees, costs and expenses.</font></div><div style="text-indent:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 8.3&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Assignment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  </font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;The Seller shall not sell, assign or otherwise transfer all or any portion of its interest in the Licensed PTC IP, any Product, the License Agreement, the Sponsored </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 37 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Research Agreement or this Agreement to any Third Party, the Licensee or the Foundation by operation of law, merger, change of control, or otherwise, unless in connection therewith (a) such Person acquires all of the Seller&#8217;s interest in all of the Licensed PTC IP, all Products, the License Agreement, the Sponsored Research Agreement and this Agreement and (b) prior to closing any such transaction, the Seller causes such Person to deliver to the Buyer a writing in which (i) if such Person is not the Licensee, such Person assumes all of the obligations of the Seller to the Buyer under this Agreement, or (ii) if such Person is the Licensee, the Licensee assumes all of the obligations of the Seller to the Buyer hereunder and agrees to pay the Assigned Royalty Payments directly to the Buyer notwithstanding any subsequent termination of the License Agreement by the Licensee.  </font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;The Buyer may assign this Agreement in whole or in part&#59; provided that in connection with any such assignment of this Agreement in whole or substantially in whole to a Third Party, or if a Third Party acquires all of the assets or securities of Royalty Pharma plc, on a consolidated basis, in a merger, tender offer, asset acquisition or similar transaction, the Buyer shall destroy or return to the Seller the Data Room and shall not transfer any rights to the Data Room in connection with such assignment or transaction.  </font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;This Agreement shall be binding upon, inure to the benefit of and be enforceable by, the parties hereto and their respective permitted successors and assigns.  Any purported assignment in violation of this Section 8.3 shall be null and void.</font></div><div style="text-indent:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 8.4&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Amendment and Waiver</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;This Agreement may be amended, modified or supplemented only in a writing signed by each of the parties hereto.  Any provision of this Agreement may be waived only in a writing signed by the parties hereto granting such waiver.</font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;No failure or delay on the part of any party hereto in exercising any right, power or remedy hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such right, power or remedy preclude any other or further exercise thereof or the exercise of any other right, power or remedy.  No course of dealing between the parties hereto shall be effective to amend, modify, supplement or waive any provision of this Agreement.</font></div><div style="text-indent:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 8.5&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Independent Nature of Relationship</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The relationship between the Seller and the Buyer is solely that of seller and buyer, and neither the Seller nor the Buyer has any fiduciary or other special relationship with the other party hereto or any of its Affiliates.  Nothing in this Agreement shall be deemed in any way or for any purpose as constituting or creating any partnership or joint venture between the Seller and the Buyer or any other party for U.S. federal income tax or any other purpose.  Each of the Seller and the Buyer agree that they shall not take any inconsistent position with respect to such treatment in any filing with any Governmental Entity. </font></div><div style="text-indent:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 8.6&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Entire Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  This Agreement, the Exhibits annexed hereto and the Disclosure Schedule constitute the entire understanding between the parties hereto with </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 38 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">respect to the subject matter hereof and supersede all other understandings and negotiations with respect thereto.</font></div><div style="text-indent:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 8.7&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">No Third Party Beneficiaries</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  This Agreement is for the sole benefit of the Seller and the Buyer and their permitted successors and assigns and nothing herein expressed or implied shall give or be construed to give to any Person, other than the parties hereto and such successors and assigns, any legal or equitable rights hereunder.</font></div><div style="text-indent:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 8.8&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Governing Law</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York without giving effect to any choice or conflict of law provision or rule that would cause the application of the laws of any other jurisdiction.</font></div><div style="text-indent:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 8.9&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">JURISDICTION&#59; VENUE</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  </font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY AND UNCONDITIONALLY SUBMITS, FOR ITSELF AND ITS RESPECTIVE PROPERTY AND ASSETS, TO THE EXCLUSIVE JURISDICTION OF ANY NEW YORK STATE COURT OR FEDERAL COURT OF THE UNITED STATES OF AMERICA SITTING IN NEW YORK COUNTY, NEW YORK, AND ANY APPELLATE COURT THEREOF, IN ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT, OR FOR RECOGNITION OR ENFORCEMENT OF ANY JUDGMENT IN RESPECT THEREOF, AND THE BUYER AND THE SELLER HEREBY IRREVOCABLY AND UNCONDITIONALLY AGREE THAT ALL CLAIMS IN RESPECT OF ANY SUCH ACTION OR PROCEEDING MAY BE HEARD AND DETERMINED IN ANY SUCH NEW YORK STATE COURT OR, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, IN SUCH FEDERAL COURT.  THE BUYER AND THE SELLER HEREBY AGREE THAT A FINAL JUDGMENT IN ANY SUCH ACTION OR PROCEEDING SHALL BE CONCLUSIVE AND MAY BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON THE JUDGMENT OR IN ANY OTHER MANNER PROVIDED BY APPLICABLE LAW.  EACH OF THE BUYER AND THE SELLER HEREBY SUBMITS TO THE EXCLUSIVE PERSONAL JURISDICTION AND VENUE OF SUCH NEW YORK STATE AND FEDERAL COURTS.  THE BUYER AND THE SELLER AGREE, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, THAT PROCESS MAY BE SERVED ON THE BUYER OR THE SELLER IN THE SAME MANNER THAT NOTICES MAY BE GIVEN PURSUANT TO SECTION 8.1 HEREOF.</font></div><div style="text-indent:90pt;padding-left:4.5pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE FULLEST EXTENT IT MAY LEGALLY AND EFFECTIVELY DO SO, ANY OBJECTION THAT IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT IN ANY NEW YORK STATE OR FEDERAL COURT.  EACH OF THE BUYER AND THE SELLER HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, THE DEFENSE OF AN INCONVENIENT FORUM TO THE MAINTENANCE OF SUCH ACTION OR PROCEEDING IN ANY SUCH COURT.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 39 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:54pt;padding-left:4.5pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 8.10&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Severability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  If any term or provision of this Agreement shall for any reason be held to be invalid, illegal or unenforceable in any situation in any jurisdiction, then, to the extent that the economic and legal substance of the transactions contemplated hereby is not affected in a manner that is materially adverse to either party hereto, all other terms and provisions of this Agreement shall nevertheless remain in full force and effect and the enforceability and validity of the offending term or provision shall not be affected in any other situation or jurisdiction. </font></div><div style="text-indent:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 8.11&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Specific Performance</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Each of the parties acknowledges and agrees that the other parties would be damaged irreparably in the event any of the provisions of this Agreement are not performed in accordance with their specific terms or otherwise are breached or violated.  Accordingly, each of the parties agrees that, without posting bond or other undertaking, the other parties shall be entitled to an injunction or injunctions to prevent breaches or violations of the provisions of this Agreement and to enforce specifically this Agreement and the terms and provisions hereof in any action, suit or other proceeding instituted in any court of the United States or any state thereof having jurisdiction over the parties and the matter in addition to any other remedy to which it may be entitled, at law or in equity.  </font></div><div style="text-indent:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 8.12&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Limitations on Liability&#59; Prevailing Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  </font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;Each party shall be liable to the other for damages arising out of or relating to such party&#8217;s performance or failure to perform under this Agreement&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that the liability of a party to the other party, whether based on an action or claim in contract, equity, negligence, tort or otherwise, for all events, acts or omissions shall not exceed in the aggregate an amount equal to the Assigned Royalty Cap less the amount of Assigned Royalty Payments received by the Buyer.  No party hereto shall be liable for any consequential, punitive, special, indirect or incidental damages as a result of any breach or violation of any covenant or agreement of such party in or pursuant to this Agreement.  For the avoidance of doubt, and notwithstanding anything to the contrary in this Agreement, the Buyer shall have no recourse against the Company as a result of any Credit Event, any Permitted Royalty Reduction or any breach of the License Agreement by Licensee.  </font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;In connection with the foregoing, the parties hereto acknowledge and agree that (i) the Buyer&#8217;s damages, if any, for any such action or claim will typically include Losses for Assigned Royalty Payments that the Buyer was entitled to receive in respect of its ownership of the Assigned Royalty Payments but did not receive timely or at all due to the Seller&#8217;s breach, default or failure to perform under this Agreement and (ii) the Buyer shall be entitled to make claims for all such missing or delayed Assigned Royalty Payments as damages hereunder, and such missing or delayed Assigned Royalty Payments shall not be deemed consequential, punitive, special, indirect or incidental damages.</font></div><div style="text-indent:90pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;If any dispute, litigation or other court action, arbitration or similar adjudicatory proceeding is commenced by any party to enforce its rights or to seek damages under this Agreement against the other party, all fees, costs and expenses, including, reasonable attorneys&#8217; fees and court and collection costs, incurred by the prevailing party in such dispute, litigation, action, arbitration or proceeding shall be reimbursed by the non-prevailing party&#59; </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 40 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">provided, that if a party to such dispute litigation, action, arbitration or proceeding prevails in part, and loses in part, the court, arbitrator or other adjudicator presiding over such litigation, action, arbitration or proceeding shall award a reimbursement of the fees, costs and expenses incurred by such Party on an equitable basis.</font></div><div style="text-indent:54pt;padding-left:4.5pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 8.13&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Trustee Capacity of Wilmington Trust, National Association</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Notwithstanding anything contained herein to the contrary, it is expressly understood and agreed by the parties hereto that (i) this Agreement is executed and delivered by Wilmington Trust, National Association, not individually or personally but solely in its trustee capacity, in the exercise of the powers and authority conferred and vested in it under the trust deed of the Buyer, (ii) each of the representations, undertakings and agreements herein made on the part of the Buyer is made and intended not as a personal representation, undertaking and agreement by Wilmington Trust, National Association but is made and intended for the purpose of binding only the Buyer and (iii) under no circumstances shall Wilmington Trust, National Association be personally liable for the payment of any indebtedness or expenses of the Buyer or be liable for the breach or failure of any obligation, representation, warranty or covenant made or undertaken by the Buyer under this Agreement or any related documents.</font></div><div style="text-indent:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 8.14&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Counterparts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  This Agreement may be executed in any number of counterparts and by the parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.  Copies of executed counterparts transmitted by telecopy, facsimile or other similar means of electronic transmission, including &#8220;PDF,&#8221; shall be considered original executed counterparts, provided receipt of such counterparts is confirmed.</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#91;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Signature Page Follows</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#93;</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 41 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="i03566d449d174758906421cece0f1f1c_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">IN WITNESS WHEREOF, the parties hereto have caused this Royalty Purchase Agreement to be executed and delivered by their respective representatives thereunto duly authorized as of the date first above written.</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.628%;"><tr><td style="width:1.0%;"></td><td style="width:48.000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:48.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">PTC THERAPEUTICS, INC.</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">&#47;s&#47; Stuart Peltz</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Name&#58; Stuart Peltz</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Title&#58; CEO</font></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">RPI 2019 INTERMEDIATE FINANCE TRUST</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Wilmington Trust, National Association, not in its individual capacity but solely in its capacity as owner trustee</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">&#47;s&#47; Cynthia L. Major</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Name&#58; Cynthia L. Major</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Title&#58; Banking Officer</font></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ROYALTY PHARMA PLC</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(solely for the purposes of Section 5.15 hereof)</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">&#47;s&#47; George W. Lloyd</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Name&#58; George W. Lloyd</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Title&#58; EVP, Investments &#38; General Counsel</font></td></tr></table></div><div style="margin-bottom:12pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#91;SIGNATURE PAGE TO THE ROYALTY PURCHASE AGREEMENT&#93;</font></div><div><font><br></font></div></div></div><div id="i03566d449d174758906421cece0f1f1c_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Exhibit E</font></div><div style="text-align:center;margin-bottom:0.12pt;"><font><br></font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">License Agreement</font></div><div style="margin-bottom:12pt;"><font><br></font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Incorporated by reference to Exhibit 10.14 of the Company&#8217;s Form S-1 Registration Statement filed with the Securities and Exchange Commission on May 16, 2013</font></div><div style="margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div><div style="margin-bottom:0.12pt;"><font><br></font></div><div style="margin-bottom:0.12pt;"><font><br></font></div><div style="margin-bottom:0.12pt;"><font><br></font></div><div style="margin-bottom:0.12pt;"><font><br></font></div><div style="margin-bottom:0.12pt;"><font><br></font></div><div style="margin-bottom:0.12pt;"><font><br></font></div><div style="margin-bottom:0.12pt;"><font><br></font></div><div style="margin-bottom:0.12pt;"><font><br></font></div><div style="margin-bottom:0.12pt;"><font><br></font></div><div style="margin-bottom:0.12pt;"><font><br></font></div><div style="margin-bottom:0.12pt;"><font><br></font></div><div style="margin-bottom:0.12pt;"><font><br></font></div><div style="margin-bottom:0.12pt;"><font><br></font></div><div style="margin-bottom:0.12pt;"><font><br></font></div><div style="margin-bottom:0.12pt;"><font><br></font></div><div style="margin-bottom:0.12pt;"><font><br></font></div><div style="margin-bottom:0.12pt;"><font><br></font></div><div style="margin-bottom:0.12pt;"><font><br></font></div><div style="margin-bottom:0.12pt;"><font><br></font></div><div style="margin-bottom:0.12pt;"><font><br></font></div><div style="margin-bottom:0.12pt;"><font><br></font></div><div style="margin-bottom:0.12pt;"><font><br></font></div><div style="margin-bottom:0.12pt;"><font><br></font></div><div style="margin-bottom:0.12pt;"><font><br></font></div><div style="margin-bottom:0.12pt;"><font><br></font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Exhibit E</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="margin-bottom:0.12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Exhibit F</font></div><div style="text-align:center;margin-bottom:0.12pt;"><font><br></font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Sponsored Research Agreement</font></div><div style="margin-bottom:12pt;"><font><br></font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Incorporated by reference to Exhibit 10.15 of the Company&#8217;s Form S-1 Registration Statement filed with the Securities and Exchange Commission on May 16, 2013</font></div><div style="margin-bottom:12pt;"><font><br></font></div><div style="margin-bottom:12pt;"><font><br></font></div><div style="margin-bottom:12pt;"><font><br></font></div><div style="margin-bottom:12pt;"><font><br></font></div><div style="margin-bottom:12pt;"><font><br></font></div><div style="margin-bottom:12pt;"><font><br></font></div><div style="margin-bottom:12pt;"><font><br></font></div><div style="margin-bottom:12pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Exhibit F</font></div><div><img alt="image111.jpg" src="image111.jpg" style="height:57px;width:6px;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">  </font></div><div style="margin-bottom:0.12pt;"><font><br></font></div><div style="margin-bottom:0.12pt;"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>ex103kleinemploymentag.htm
<DESCRIPTION>EX-10.3 KLEIN EMPLOYMENT AGREEMENT
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="idc29821dde344a069424170847f26ee1_1"></div><div style="min-height:49pt;width:100%;"><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EXHIBIT 10.3</font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:139%;">EMPLOYMENT AGREEMENT</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">This EMPLOYMENT AGREEMENT (the &#8220;Agreement&#8221;) is made as of October 28, 2019 (the &#8220;Effective Date&#8221;), by and between PTC Therapeutics, Inc., a Delaware corporation (the &#8220;Company&#8221;) and Matthew Klein (&#8220;Executive&#8221;).  In consideration of the mutual covenants contained in this Agreement, the Company and Executive agree as follows&#58;</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;padding-left:27pt;">Employment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  The Company agrees to employ Executive and Executive agrees to be employed by the Company on the terms and conditions set forth in this Agreement.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Capacity</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  Executive shall serve the Company as Global Head of Gene and Mitochondrial Therapies, reporting to Marcio Souza, Chief Operating Officer, or such senior executive as the Company shall specify.  Executive shall have the responsibilities, duties and authority commensurate with the position of Global Head of Gene and Mitochondrial Therapies.  In addition to Executive&#8217;s primary duties, Executive shall perform such other services for the Company that are consistent with his&#47;her position as Global Head of Gene and Mitochondrial Therapies as may be reasonably assigned to Executive from time to time by the individual to whom s&#47;he reports or the Board of Directors of the Company (the &#8220;Board&#8221;) or their respective designees.  The principal location at which Executive shall perform such services shall be the Company&#8217;s corporate headquarters currently located at 100 Corporate Court, Middlesex Business Center, South Plainfield, New Jersey , subject to Section 2(c)(i) of this Agreement.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Devotion of Duties&#59; Representations</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  During the Term (as defined below) of Executive&#8217;s employment with the Company, Executive shall devote his&#47;her best efforts and full business time and energies to the business and affairs of the Company, and shall endeavor to perform the duties and services contemplated hereunder to the reasonable satisfaction of the  individual to whom s&#47;he reports and the Board.  During the Term, Executive shall adhere to, and perform all of Executive&#8217;s duties in accordance with, all applicable laws, rules and regulations and all policies and procedures of the Company, as may be in effect from time to time. During the Term of Executive&#8217;s employment with the Company, Executive shall not, without the prior written approval of the Company (by action of the Board), undertake any other employment from any person or entity or serve as a director of any other company&#59; provided, however, that (i) the Company will entertain requests as to such other employment or directorships in good faith and (ii) Executive will be eligible to participate in any policy relating to outside activities that is applicable to the senior executives of the Company and approved by the Board after the date hereof.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Term of Employment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">Executive&#8217;s employment hereunder shall commence on the Effective Date.  Executive&#8217;s employment hereunder shall be terminated upon the first to occur of the following&#58;</font></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;padding-left:27.68pt;">Immediately upon Executive&#8217;s death&#59;</font></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">By the Company</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">&#58;</font></div><div style="position:relative;width:100%;height:14pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:49pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:72pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(A)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">By written notice to Executive effective the date of such notice, following the Disability of Executive.  &#8220;Disability&#8221; means that Executive (i) is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment which can be expected to result in death or can be expected to last for a continuous period of not less than 12 months, or (ii) is, by reason of any medically determinable physical or mental impairment which can be expected to last for a continuous period of not less than 12 months, receiving income replacement benefits for a period of not less than three months under an accident and health plan covering employees of the Company.  Such incapacity shall be determined by a physician chosen by the Company and reasonably satisfactory to Executive (or Executive&#8217;s legal representative) upon examination requested by the Company (to which Executive hereby agrees to submit). Notwithstanding the foregoing, such Disability must result in Executive becoming &#8220;Disabled&#8221; within the meaning of Section 409A(a)(2)(C) of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) and the guidance issued thereunder.  (In this Agreement we refer to Section 409A of the Code and any guidance issued thereunder as &#8220;Section 409A&#8221;).</font></div><div style="text-indent:72pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(B)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">By written notice to Executive, effective the date of such notice, for Cause (as defined below)&#59; or</font></div><div style="text-indent:72pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(C)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">By written notice to Executive, effective ninety (90) days after the date of such notice and subject to Section 4 hereof, without Cause&#59; or</font></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(iii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">By Executive</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">&#58;</font></div><div style="text-indent:72pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(A)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">At any time by written notice to the Company, effective forty-five (45) days after the date of such notice</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;">&#59;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> or</font></div><div style="text-indent:72pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(B)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">By written notice to the Company for Good Reason (as defined below), effective on the date specified in such notice.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">The term of Executive&#8217;s employment by the Company under this Agreement is referred to herein as the &#8220;Term.&#8221;</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Definition of &#8220;Cause&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  For purposes of this Agreement, &#8220;Cause&#8221; shall, pursuant to the reasonable good faith determination by a majority of the Board (excluding Executive) as documented in writing, include&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(i) the willful and continued failure by Executive to substantially perform Executive&#8217;s material duties or responsibilities under this Agreement (other than such a failure as a result of Disability)&#59; (ii) any action or</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">omission by Executive involving willful misconduct or gross negligence with regard to the Company, which has a detrimental effect on the Company&#59; (iii) Executive&#8217;s conviction of a felony, either in connection with the performance of Executive&#8217;s obligations to the Company or which otherwise shall adversely affect Executive&#8217;s ability to perform such obligations or shall materially adversely affect the business activities, reputation, goodwill or image of the Company&#59;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(iv) the material breach of a fiduciary duty to the Company&#59; or (v) the material breach by Executive of any of the provisions of this Agreement, </font></div><div style="position:relative;width:100%;height:14pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:49pt;width:100%;"><div><font><br></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">provided that any breach of Executive&#8217;s obligations with respect to Sections 5 or 6 of this Agreement, subject to the cure provision in the next sentence, shall be deemed &#8220;material.&#8221;  In respect of the events described in clauses (i) and (v) above, the Company shall give Executive notice of the failure of performance or breach, reasonable as to time, place and manner in the circumstances, and a 30-day opportunity to cure, provided that such failure of performance or breach is reasonably amenable to cure as determined by the Board in its sole discretion.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Definition of &#8220;Good Reason&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  For purposes of this Agreement, a &#8220;Good Reason&#8221; shall mean any of the following, unless (i) the basis for such Good Reason is cured within a reasonable period of time (determined in the light of the cure appropriate to the basis of such Good Reason, but in no event less than thirty (30) nor more than ninety (90) days) after the Company receives written notice (which must be received from Executive within ninety (90) days of the initial existence of the condition giving rise to such Good Reason) specifying the basis for such Good Reason or (ii) Executive has consented to the condition that would otherwise be a basis for Good Reason&#58;</font></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">A change in the principal location at which Executive provides services to the Company to a location more than fifty (50) miles from such principal location and&#47;or to a location in New York City (either of which change, the Company has reasonably determined as of the date hereof, would constitute a material change in the geographic location at which Executive provides services to the Company), provided that such a relocation shall not be deemed to occur under circumstances where Executive&#8217;s responsibilities require him&#47;her to work at a location other than the corporate headquarters for a reasonable period of time&#59;</font></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">A material adverse change by the Company in Executive&#8217;s duties, authority or responsibilities as Global Head of Gene and Mitochondrial Therapies which causes Executive&#8217;s position with the Company to become of materially less responsibility or authority than Executive&#8217;s position immediately following the Effective Date.  For purposes of this definition of &#8220;Good Reason,&#8221; a &#8220;material adverse change&#8221; following a Corporate Change shall not include any diminution in authority, duties or responsibilities that is solely attributable to the change in the Company&#8217;s ownership structure but does not otherwise change Executive&#8217;s authority, duties or responsibilities (except in a positive manner) otherwise with respect to the Company&#8217;s business.</font></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(iii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">A material reduction in Executive&#8217;s base compensation (including Base Salary) except if the reduction is in connection with a general reduction of not more than 20% in compensation of senior executives of the Company generally that occurs prior to the effective date of any Corporate Change&#59;</font></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(iv)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">A material breach of this Agreement by the Company which has not been cured within thirty (30) days after written notice thereof by Executive&#59; or</font></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(v)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">Failure to obtain the assumption (assignment) of this Agreement by any successor to the Company.</font></div><div style="position:relative;width:100%;height:14pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:49pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Definition of &#8220;Corporate Change&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  For purposes of this Agreement, &#8220;Corporate Change&#8221; shall mean any circumstance in which (i) the Company is not the surviving entity in any merger, consolidation or other reorganization (or survives only as a subsidiary or affiliate of an entity other than a previously wholly-owned subsidiary of the Company)&#59; (ii) the Company sells, leases or exchanges or agrees to sell, lease or exchange all or substantially all of its assets to any other person or entity (other than a wholly-owned subsidiary of the Company)&#59; (iii) any person or entity, including a &#8220;group&#8221; as contemplated by Section 13(d)(3) of the Securities Exchange Act of 1934 (excluding, for this purpose, the Company or any Subsidiary, or any employee benefit plan of the Company or any Subsidiary, or any &#8220;group&#8221; in which all or substantially all of its members or its members&#8217; affiliates are individuals or entities who are or were beneficial owners of the Company&#8217;s outstanding shares prior to the initial public offering, if any, of the Company&#8217;s stock), acquires or gains ownership or control (including, without limitations, powers to vote) of more than 50% of the outstanding shares of the Company&#8217;s voting stock (based upon voting power)&#59; or (iv) as a result of or in connection with a contested election of directors, the persons who were directors of the Company before such election shall cease to constitute a majority of the Board of Directors of the Company.  Notwithstanding the foregoing, a &#8220;Corporate Change&#8221; shall not occur as a result of an initial public offering of the Company&#8217;s common stock, or as a result of a merger, consolidation, reorganization or restructuring after which either (1) a majority of the Board of Directors of the controlling entity consists of persons who were directors of the Company prior to the merger, consolidation, reorganization or restructuring or (2) Executive forms part of an executive management team that consists of substantially the same group of individuals and Executive is performing in a similar role, with similar authority and responsibility (other than changes solely attributable to the change in ownership structure), to that which existed prior to the reorganization or restructuring.  Notwithstanding the foregoing, for any payments or benefits hereunder that are subject to Section 409A, the Corporate Change must constitute a &#8220;change in control event&#8221; within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(i).</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Compensation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Base Salary</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  Executive&#8217;s minimum base salary during the Term shall be at the rate of $400,000 per year (the &#8220;Base Salary&#8221;).  Base Salary shall be payable in substantially equal installments in accordance with the Company&#8217;s payroll practices as in effect from time to time, less any amounts required to be withheld under applicable law.  The Base Salary will be subject to adjustment from time to time in the sole discretion of the Board&#59; provided that, the Company covenants that it shall not reduce the Base Salary below $400,000 or the Base Salary then in effect immediately prior to the reduction unless (i) Executive consents to such reduction, or (ii) the reduction is in connection with a general reduction of not more than 20% in compensation of senior executives of the Company generally that occurs prior to the effective date of any Corporate Change.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Bonus</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  In addition to the Base Salary, the Company may pay Executive an annual bonus (the &#8220;Bonus&#8221;) as determined by the Board, solely in its discretion (it being understood that Executive&#8217;s target annual bonus shall be at 40% of the Base Salary, but may be higher or lower in any year in the Board&#8217;s discretion).  The Board&#8217;s decision to issue a Bonus to Executive in any </font></div><div style="position:relative;width:100%;height:14pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:49pt;width:100%;"><div><font><br></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">particular year shall have no effect on the absolute discretion of the Board to grant or not to grant a Bonus in subsequent years.  Any Bonus for a particular year shall be paid or provided to Executive in a lump sum no later than March 15</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:139%;vertical-align:top;">th</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> of the calendar year following the calendar year in which the Bonus was earned. Executive will not be eligible for a 2019 Bonus.</font></div><div style="padding-left:8pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Equity Compensation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  Executive will receive an inducement grant of 100,000 options to purchase shares of common stock of PTC, subject to formal approval by the Compensation Committee of the Board (or a majority of the Company&#8217;s independent directors) (the &#8220;Inducement Grant&#8221;). Such award is granted pursuant to the inducement grant exception under NASDAQ rules and is intended to serve as a material inducement to Executive entering into employment with PTC. Executive shall be eligible to participate in PTC&#8217;s annual equity and long term incentive plan(s) and may be eligible to receive discretionary awards under such plan(s), subject to the terms and conditions of such plan(s). Executive shall not be eligible to participate in PTC&#8217;s annual equity program for the current calendar year. For the avoidance of doubt, Executive shall not be eligible to receive a discretionary award in 2020. Except as explicitly set forth below, Executive&#8217;s rights with respect to equity (including stock options) shall be covered in PTC&#8217;s equity and long term incentive plan(s) and separate stock option certificates or agreements for each grant. </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Accelerated Vesting</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.</font></div><div style="text-indent:72pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(A)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">For the avoidance of doubt, in the event that Executive&#8217;s employment hereunder is terminated by the Company without Cause or by Executive for Good Reason, neither the unvested portion of the Inducement Grant nor any unvested equity awards granted under the Company&#8217;s equity and long- term incentive plan(s) shall be subject to any accelerated vesting except as otherwise provided for in the applicable award agreement or in Section 3(c)(i)(B) below.</font></div><div style="text-indent:72pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(B)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">Except as otherwise provided in the applicable award, in the event that Executive&#8217;s employment hereunder is terminated by the Company without Cause or by Executive for Good Reason within the period of three (3) months prior to (but only if negotiations relating to the particular Corporate Change that occurs are ongoing at the date of the notice of termination) or twelve (12) months after a Corporate Change that occurs during the Term (such fifteen-month period, the &#8220;Protected Period&#8221;), one hundred percent (100%) of the unvested portion of the Inducement Grant and all of Executive&#8217;s outstanding unvested equity awards granted under the Company&#8217;s equity and long-term incentive plan(s) shall vest immediately.</font></div><div style="position:relative;width:100%;height:14pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><div id="idc29821dde344a069424170847f26ee1_4"></div><hr style="page-break-after:always"><div style="min-height:65pt;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div style="margin-bottom:12pt;"><font><br></font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Vacation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  Executive is eligible for time off programs outlined in the Company&#8217;s Time Off Policies.  Executive shall accrue over the calendar year 160 hours of paid vacation.   Executive may accrue up to 200 hours of vacation.  Once Executive has reached the maximum accrual, no further vacation time will be accrued unless and until the Executive uses vacation time. Upon termination of employment, the value of Executive&#8217;s current balance of accrued but unused vacation shall be paid out based on his&#47;her Base Salary that was in effect immediately prior to his&#47;her termination of employment.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Fringe Benefits</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  Executive shall be entitled to participate in any employee benefit plans that the Company makes available to its senior executives (including, without limitation, group life, disability, medical, dental and other insurance, retirement, pension, profit-sharing and similar plans) (collectively, the &#8220;Fringe Benefits&#8221;), provided that the Fringe Benefits shall not include any stock option or similar plans relating to the grant of equity securities of the Company.  These benefits may be modified or changed from time to time at the sole discretion of the Company.  Where a particular benefit is subject to a formal plan (for example, medical or life insurance), eligibility to participate in and receive any particular benefit is governed solely by the applicable plan document, and eligibility to participate in such plan(s) may be dependent upon, among other things, a physical examination.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(f)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Reimbursement of Expenses</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  Executive shall be entitled to reimbursement for all ordinary and reasonable out-of-pocket business expenses that are reasonably incurred by him&#47;her in furtherance of the Company&#8217;s business in accordance with reasonable policies adopted from time to time by the Company for senior executives. The Company agrees to reimburse Executive for reasonable out-of-pocket fees related to maintaining Executive&#8217;s medical license.</font></div><div style="text-indent:72pt;padding-right:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">(g)&#160;Relocation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Executive is eligible to be reimbursed for moving-related expenses incurred by Executive in relocating his residence from Menlo Park, California to such domicile that is within a reasonable commuting distance of PTC&#8217;s offices in South Plainfield, New Jersey in an amount not to exceed $250,000, subject to PTC&#8217;s applicable policies and procedures with respect to relocation and reimbursements&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, however, that, Executive will be required to refund 100% such relocation expenses and reimbursements to the Company in the event that, prior to the first anniversary of Effective Date, Executive resigns his employment for any reason or PTC terminates Executive&#8217;s employment for Cause. Executive will be required to refund 50% of such relocation expenses and reimbursements to the Company in the event that, after the first anniversary of the Start Date but prior to the second anniversary of the Start Date Executive resigns his employment for any reason or PTC terminates Executive&#8217;s employment for Cause. Unless otherwise extended in writing by the Company, Executive&#8217;s relocation must be completed by June 30, 2020 and Executive will not be reimbursed for any relocation expenses that are incurred after such date. Relocation-related expenses may be considered taxable income as specified by IRS tax regulations. Executive agrees relocation to New Jersey is a condition of employment and that a failure to complete his relocation to New Jersey by June 30, 2020 (unless otherwise extended by the Company in </font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:65pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 7 -</font></div><div style="text-align:center;"><font><br></font></div></div><div style="padding-right:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">writing) will constitute a breach of this Agreement and could cause the Executive&#8217;s employment to be terminated for Cause as defined in section 2(b).</font></div><div style="margin-top:0.55pt;margin-bottom:12pt;"><font><br></font></div><div style="text-indent:72pt;padding-right:8.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(h) &#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Cost of Living Adjustment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Executive will be eligible to receive a cost of living adjustment of $8,200, per month, commencing on the Effective Date and ending on the earlier of the completion of Executive&#8217;s relocation to New Jersey or March 31, 2020. The cost of living allowance will be paid in accordance with the company&#8217;s regular payroll practices.</font></div><div style="margin-top:0.45pt;margin-bottom:12pt;"><font><br></font></div><div style="text-indent:72pt;padding-right:6.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(i)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Sign</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">-On Bonus. Executive will be eligible to receive a one-time, lump sum bonus of $61,823, payable on March 15, 2020&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, however, that Executive must be employed by PTC and must not be in breach of this Agreement (as determined by the Board, in its discretion) at the time such bonus is to be paid in order to receive such bonus.</font></div><div style="margin-top:0.5pt;margin-bottom:12pt;"><font><br></font></div><div style="text-indent:72pt;padding-right:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(j)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Taxes and Withholdings</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. The Company shall deduct and withhold from all compensation and benefits under this Agreement all social security and other federal, state and local taxes and charges which currently are or which hereafter may be required by law to be so deducted and withheld.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font><br></font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Severance Compensation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">In the event of any termination of Executive&#8217;s employment for any reason the Company shall pay Executive (or Executive&#8217;s estate) such portions of Executive&#8217;s Base Salary as have accrued prior to such termination and have not yet been paid, together with (i) amounts for accrued unused vacation days (as provided above), (ii) any amounts for expense reimbursement which have been properly incurred or the Company has become obligated to pay prior to termination and have not been paid as of the date of such termination and (iii) the amount of any Bonus previously granted to Executive by the Board but not yet paid, which amount shall not include any pro rata portion of any Bonus which would have been earned if such termination had not occurred (the &#8220;Accrued Obligations&#8221;).  </font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">In the event that Executive&#8217;s employment hereunder is terminated (i) by Executive for a Good Reason or (ii) by the Company without Cause, the Company shall pay to Executive the Accrued Obligations. In addition, the Company shall pay to Executive the severance benefits set forth in Section (b)(i) below for twelve (12) months following Executive&#8217;s termination of employment (the &#8220;Severance Period&#8221;), and pay to Executive the severance benefits set forth in Section (b)(ii). The receipt of any severance benefits provided in this Section shall be dependent upon Executive&#8217;s execution (and, as applicable, nonrevocation) of a standard separation agreement and general release of claims, substantially in the form attached hereto as Exhibit A (the &#8220;Release&#8221;). The Company will also consider in good faith (but without any </font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:65pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 8 -</font></div><div style="text-align:center;"><font><br></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">binding commitment) requests from Executive that the Company include in the Release a release of Executive by the Company from matters specifically disclosed to the Company by Executive in writing in advance of execution of the Release and not involving any illegality, fraud, concealment, criminal acts or acts outside the scope of Executive's employment. The distribution of severance benefits in this Section 4 is subject to section (iii) of this Section 4(b).</font></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">If Executive&#8217;s employment is terminated (A) by Executive for a Good Reason or (B) by the Company without Cause, in either case before or after the Protected Period, the Company shall pay Executive his&#47;her Base Salary, less any amounts required to be withheld under applicable law, for the Severance Period in substantially equal installments in accordance with the Company&#8217;s payroll practices as in effect from time to time, commencing no later than sixty (60) days following the effective date of such termination.  If Executive&#8217;s employment is terminated (A) by Executive for a Good Reason or (B) by the Company without Cause, in either case during the Protected Period, the Company shall pay Executive his&#47;her Base Salary for the Severance Period, which total amount shall be payable in a lump sum no later than sixty (60) days following Executive&#8217;s termination of employment.  In each case, payments shall commence or be paid provided that the Release has been executed and any applicable revocation period has expired as of the 60</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:139%;vertical-align:top;">th</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> day following Executive&#8217;s termination.</font></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">The Company shall provide Executive with a lump sum payment representing the net value of the contributions to Executive&#8217;s current group health premiums that PTC would have paid on Executive&#8217;s behalf (had Executive continued to be an employee of PTC) for the Severance Period, less any amounts required to be withheld under applicable law. Such payment shall be made no later than sixty (60) days following the effective date of Executive&#8217;s termination&#59; provided that the Release has been executed and any applicable revocation period has expired as of the 60th day following Executive&#8217;s termination. The foregoing shall not be construed to extend any period of continuation coverage (e.g., COBRA) required by Federal law.</font></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(iii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Compliance with Section 409A</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  Subject to the provisions in this Section 4(b)(iii), any severance payments or benefits under this Agreement shall begin only upon the date of Executive&#8217;s &#8220;separation from service&#8221; (determined as set forth below) which occurs on or after the date of termination of Executive&#8217;s employment.  The following rules shall apply with respect to the distribution of the severance payments and benefits, if any, to be provided to Executive under this Agreement&#58;</font></div><div style="text-indent:72pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(1)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">It is intended that each installment of the severance payments and benefits provided under this Agreement shall be treated as a separate &#8220;payment&#8221; for purposes of Section 409A.  Neither the Company nor Executive </font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:65pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 9 -</font></div><div style="text-align:center;"><font><br></font></div></div><div style="padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">shall have the right to accelerate or defer the delivery of any such payments or benefits except to the extent specifically permitted or required by Section 409A.</font></div><div style="text-indent:72pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(2)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">If, as of the date of Executive&#8217;s &#8220;separation from service&#8221; from the Company, Executive is not a &#8220;specified employee&#8221; (within the meaning of Section 409A), then each installment of the severance payments and benefits shall be made on the dates and terms set forth in this Agreement.</font></div><div style="text-indent:72pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(3)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">If, as of the date of Executive&#8217;s &#8220;separation from service&#8221; from the Company, Executive is a &#8220;specified employee&#8221; (within the meaning of Section 409A), then&#58;</font></div><div style="text-indent:108pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(A)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">Each installment of the severance payments and benefits due under this Agreement that, in accordance with the dates and terms set forth herein, will in all circumstances, regardless of when the separation from service occurs, be paid within the short-term deferral period (as defined under Section 409A) shall be treated as a short-term deferral within the meaning of Treasury Regulation Section 1.409A-1(b)(4) to the maximum extent permissible under Section 409A and such payments and benefits shall be paid or provided on the dates and terms set forth in this Agreement&#59; and</font></div><div style="text-indent:108pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(B)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">Each installment of the severance payments and benefits due this Agreement that is not described in Section 4(b)(iii)(3)(A) above and that would, absent this subsection, be paid within the six-month period following Executive&#8217;s &#8220;separation from service&#8221; from the Company shall not be paid until the date that is six months and one day after such separation from service (or, if earlier, Executive&#8217;s death), with any such installments that are required to be delayed being accumulated during the six-month period and paid in a lump sum on the date that is six months and one day following Executive&#8217;s separation from service and any subsequent installments, if any, being paid in accordance with the dates and terms set forth herein&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">, that the preceding provisions of this sentence shall not apply to any installment of severance payments and benefits if and to the maximum extent that such installment is deemed to be paid under a separation pay plan that does not provide for a deferral of compensation by reason of the application of Treasury Regulation 1.409A-1(b)(9)(iii) (relating to separation pay upon an involuntary separation from service).  Any installments that qualify for the exception under Treasury Regulation Section 1.409A-1(b)(9)(iii) must be paid no later than the last day of Executive&#8217;s second taxable year following the taxable year in which the separation from service occurs.</font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:65pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 10 -</font></div><div style="text-align:center;"><font><br></font></div></div><div style="text-indent:72pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(4)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">The determination of whether and when Executive&#8217;s separation from service from the Company has occurred shall be made in a manner consistent with, and based on the presumptions set forth in, Treasury Regulation Section 1.409A-1(h).  Solely for purposes of this Section 4(b)(iii), &#8220;Company&#8221; shall include all persons with whom the Company would be considered a single employer under Section 414(b) and 414(c) of the Code.</font></div><div style="text-indent:72pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(5)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">All reimbursements and in-kind benefits provided under this Agreement shall be made or provided in accordance with the requirements of Sections 409A to the extent that such reimbursements or in-kind benefits are subject to Section 409A, including, where applicable, the requirements that (i) any reimbursement is for expenses incurred during Executive&#8217;s lifetime (or during a shorter period of time specified in this Agreement), (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year, (iii) the reimbursement of an eligible expense will be made on or before the last day of the calendar year following the year in which the expense is incurred and (iv) the right to reimbursement is not subject to set off or liquidation or exchange for any other benefit.</font></div><div style="text-indent:72pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(6)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">Notwithstanding anything herein to the contrary, the Company shall have no liability to Executive or to any other person if the payments and benefits provided hereunder that are intended to be exempt from or compliant with Section 409A are not so exempt or compliant.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">In the event that Executive&#8217;s employment hereunder is terminated (i) by Executive for other than a Good Reason, or (ii) by the Company for Cause, or (iii) as a result of Executive&#8217;s death or Disability, then the Company will pay to Executive the Accrued Obligations.  The Company shall have no obligation to pay Executive (or Executive&#8217;s estate) any other compensation following such termination except as provided in Section 4(a).</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Modified Section 280G Cutback</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.</font></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(i)&#160;Notwithstanding any other provision of this Agreement, except as set forth in Section 4(d)(ii), in the event that the Company undergoes a &#8220;Change in Ownership or Control&#8221; (as defined below), the Company shall not be obligated to provide to Executive a portion of any &#8220;Contingent Compensation Payments&#8221; (as defined below) that Executive would otherwise be entitled to receive to the extent necessary to eliminate any &#8220;excess parachute payments&#8221; (as defined in Section 280G(b)(1) of the Code) for Executive.  For purposes of this Section&#160;4(d), the Contingent Compensation Payments so eliminated shall be referred to as the &#8220;Eliminated Payments&#8221; and the aggregate amount (determined in accordance with Treasury Regulation Section 1.280G-1, Q&#47;A-30 or any </font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:65pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 11 -</font></div><div style="text-align:center;"><font><br></font></div></div><div style="padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">successor provision) of the Contingent Compensation Payments so eliminated shall be referred to as the &#8220;Eliminated Amount.&#8221;</font></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(ii) &#160;Notwithstanding the provisions of Section 4(d)(i), no such reduction in Contingent Compensation Payments shall be made if (1) the Eliminated Amount (computed without regard to this sentence) exceeds (2) 100% of the aggregate present value (determined in accordance with Treasury Regulation Section&#160;1.280G-1, Q&#47;A-31 and Q&#47;A-32 or any successor provisions) of the amount of any additional taxes that would be incurred by Executive if the Eliminated Payments (determined without regard to this sentence) were paid to him&#47;her (including, state and federal income taxes on the Eliminated Payments, the excise tax imposed by Section 4999 of the Code payable with respect to all of the Contingent Compensation Payments in excess of Executive&#8217;s &#8220;base amount&#8221; (as defined in Section 280G(b)(3) of the Code), and any withholding taxes).  The override of such reduction in Contingent Compensation Payments pursuant to this Section&#160;4(d)(ii) shall be referred to as a &#8220;Section&#160;4(d)(ii) Override.&#8221;  For purpose of this paragraph, if any federal or state income taxes would be attributable to the receipt of any Eliminated Payment, the amount of such taxes shall be computed by multiplying the amount of the Eliminated Payment by the maximum combined federal and state income tax rate provided by law.</font></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(iii)&#160;For purposes of this Section 4(d) the following terms shall have the following respective meanings&#58;</font></div><div style="text-indent:72pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(1)&#160;&#8220;Change in Ownership or Control&#8221; shall mean a change in the ownership or effective control of the Company or in the ownership of a substantial portion of the assets of the Company determined in accordance with Section 280G(b)(2) of the Code.</font></div><div style="text-indent:72pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(2)&#160;&#8220;Contingent Compensation Payment&#8221; shall mean any payment (or benefit) in the nature of compensation that is made or made available (under this Agreement or otherwise) to a &#8220;disqualified individual&#8221; (as defined in Section 280G(c) of the Code) and that is contingent (within the meaning of Section 280G(b)(2)(A)(i) of the Code) on a Change in Ownership or Control of the Company.</font></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(iv)&#160;Any payments or other benefits otherwise due to Executive following a Change in Ownership or Control that could reasonably be characterized (as determined by the Company) as Contingent Compensation Payments (the &#8220;Potential Payments&#8221;) shall not be made until the dates provided for in this Section&#160;4(d)(iv).  Within 30 days after each date on which Executive first becomes entitled to receive (whether or not then due) a Contingent Compensation Payment relating to such Change in Ownership or Control, the Company shall determine and notify Executive (with reasonable detail </font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:65pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 12 -</font></div><div style="text-align:center;"><font><br></font></div></div><div style="padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">regarding the basis for its determinations) (1) which Potential Payments constitute Contingent Compensation Payments, (2) the Eliminated Amount and (3)&#160;whether the Section&#160;4(d)(ii) Override is applicable.  Within 30 days after delivery of such notice to Executive, Executive shall deliver a response to the Company (the &#8220;Executive Response&#8221;) stating either (A) that s&#47;he agrees with the Company&#8217;s determination pursuant to the preceding sentence or (B) that s&#47;he disagrees with such determination, in which case</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">s&#47;he</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">shall set forth (x) which Potential Payments should be characterized as Contingent Compensation Payments, (y) the Eliminated Amount, and (z) whether the Section&#160;4(d)(ii) Override is applicable.  In the event that Executive fails to deliver an Executive Response on or before the required date, the Company&#8217;s initial determination shall be final.  If Executive states in the Executive Response that s&#47;he</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">agrees with the Company&#8217;s determination, the Company shall make the Potential Payments to Executive within three business days following delivery to the Company of the Executive Response (except for any Potential Payments which are not due to be made until after such date, which Potential Payments shall be made on the date on which they are due).  If Executive states in the Executive Response that s&#47;he disagrees with the Company&#8217;s determination, then, for a period of 60 days following delivery of the Executive Response, Executive and the Company shall use good faith efforts to resolve such dispute.  If such dispute is not resolved within such 60-day period, such dispute shall be settled exclusively by arbitration in South Plainfield, New Jersey, in accordance with the rules of the American Arbitration Association then in effect.  Judgment may be entered on the arbitrator&#8217;s award in any court having jurisdiction.  The Company shall, within three business days following delivery to the Company of the Executive Response, make to Executive those Potential Payments as to which there is no dispute between the Company and Executive regarding whether they should be made (except for any such Potential Payments which are not due to be made until after such date, which Potential Payments shall be made on the date on which they are due).  The balance of the Potential Payments shall be made within three business days following the resolution of such dispute.</font></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> (v)&#160;The Contingent Compensation Payments to be treated as Eliminated Payments shall be determined by the Company by determining the &#8220;Contingent Compensation Payment Ratio&#8221; (as defined below) for each Contingent Compensation Payment and then reducing the Contingent Compensation Payments in order beginning with the Contingent Compensation Payment with the highest Contingent Compensation Payment Ratio.  For Contingent Compensation Payments with the same Contingent Compensation Payment Ratio, such Contingent Compensation Payment shall be reduced based on the time of payment of such Contingent Compensation Payments with amounts having later payment dates being reduced first.  For Contingent Compensation Payments with the same Contingent Compensation Payment Ratio and the same time of payment, such Contingent Compensation Payments shall be reduced on a </font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:65pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 13 -</font></div><div style="text-align:center;"><font><br></font></div></div><div style="padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">pro rata basis (but not below zero) prior to reducing Contingent Compensation Payment with a lower Contingent Compensation Payment Ratio.  The term &#8220;Contingent Compensation Payment Ratio&#8221; shall mean a fraction the numerator of which is the value of the applicable Contingent Compensation Payment that must be taken into account by Executive for purposes of Section 4999(a) of the Code, and the denominator of which is the actual amount to be received by Executive in respect of the applicable Contingent Compensation Payment.  For example, in the case of an equity grant that is treated as contingent on the Change in Ownership or Control because the time at which the payment is made or the payment vests is accelerated, the denominator shall be determined by reference to the fair market value of the equity at the acceleration date, and not in accordance with the methodology for determining the value of accelerated payments set forth in Treasury Regulation Section 1.280G-1Q&#47;A-24(b) or (c)).</font></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(vi)&#160;The provisions of this Section 4(d) are intended to apply to any and all payments or benefits available to Executive under this Agreement or any other agreement or plan of the Company under which Executive receives Contingent Compensation Payments.</font></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(vii)&#160;Notwithstanding Sections 4(d)(i)-(vi) hereof, until the closing of the first underwritten public offering of common stock of the Company, in the event that it shall be determined that any payment or benefit (including any accelerated vesting of options or other equity awards) made or provided, or to be made or provided, by the Company (or any successor thereto or affiliate thereof) to or for the benefit of Executive, whether pursuant to the terms of this Agreement, any other agreement, plan, program or arrangement of or with the Company (or any successor thereto or affiliate thereof) or otherwise, may be subject to the excise tax imposed by Section 4999 of the Code or any comparable tax imposed by any replacement or successor provision of United States tax law, then upon the request of Executive, the Company shall use reasonable efforts to procure a shareholder vote in satisfaction of the shareholder approval requirements described in Treas. Reg. Section 1.280G-1, Q&#38;A-7.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Executive Covenants</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Confidential Information</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  Executive recognizes and acknowledges the competitive and proprietary aspects of the business of the Company, and that as a result of Executive&#8217;s employment, Executive recognizes and acknowledges that s&#47;he will have access to, and will be involved in the development of, Confidential Information (as defined below) of the Company.  As used herein, &#8220;Confidential Information&#8221; shall mean and include trade secrets, knowledge and other confidential information of the Company, which Executive has acquired, no matter from whom or on what matter such knowledge or information may have been acquired, heretofore or hereafter, concerning the content and details of the business of the </font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:65pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 14 -</font></div><div style="text-align:center;"><font><br></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">Company, and which is not known to the general public, including but not limited to&#58; (a) new products, product betterments and other inventions, formulas, processes, methods, materials, material combinations, manner of preparations, technical production procedures and information, alarm and security codes and procedures, sources of technology, and sources of supply of raw and finished materials and other products&#59; (b) financial and accounting records&#59; (c) the identity of employees, consultants, independent contractors, customers, business development partners, licensees, suppliers, creditors or other parties with which the Company has business dealings, the nature of the relationship with such persons, or any other information relating to such persons or the Company&#8217;s dealings with such persons&#59; and (d) computer software used by the Company or provided to the customers of the Company unless publicly available.</font></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">For as long as Executive is employed and at all times thereafter, Executive shall not, directly or indirectly, communicate, disclose or divulge to any person or entity, or use for Executive&#8217;s own benefit or the benefit of any person (other than the Company), any Confidential Information, except as permitted in subparagraph (iii) below.  Upon termination of Executive&#8217;s employment, or at any other time at the request of the Company, Executive agrees to deliver promptly to the Company all Confidential Information, including, but not limited to, customer and supplier lists, files and records, in Executive&#8217;s possession or under Executive&#8217;s control.  Executive further agrees that s&#47;he will not make or retain any copies of any of the foregoing and will so represent to the Company upon termination of Executive&#8217;s employment.</font></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">Executive shall disclose immediately to the Company any trade secrets or other Confidential Information conceived or developed by Executive at any time during Executive&#8217;s employment.  Executive hereby assigns and agrees to assign to the Company Executive&#8217;s entire right, title and interest in and to all Confidential Information.  Such assignment shall include, without limitation, the rights to obtain patent or copyright protection, thereon in the United States and foreign countries.  Executive agrees to provide all reasonable assistance to enable the Company to prepare and prosecute any application before any governmental agency for patent or copyright protection or any similar application with respect to any Confidential Information.  Executive further agrees to execute all documents and assignments and to make all oaths necessary to vest ownership of such intellectual property rights in the Company, as the Company may request.  These obligations shall apply whether or not the subject thereof was conceived or developed at the suggestion of the Company, and whether or not developed during regular hours of work or while on the premises of the Company. Executive shall at all times, both during and after termination of this Agreement by either Executive or the Company, maintain in confidence and shall not, without prior written consent of the Company, use, except in the course of performance of Executive&#8217;s duties for the Company or as required by legal process (provided that Executive will promptly notify the Company of such legal process except with respect to any confidential government </font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:65pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 15 -</font></div><div style="text-align:center;"><font><br></font></div></div><div style="padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">investigation), disclose or give to others any Confidential Information.  In the event Executive is questioned by anyone not employed by the Company or by an employee of or a consultant to the Company not authorized to receive such information, in regard to any such information or any other secret or confidential work of the Company, or concerning any fact or circumstance relating thereto, Executive will promptly notify the Company.</font></div><div style="text-indent:72pt;padding-left:36pt;padding-right:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(iii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.03pt;">Nothing in this Agreement, including but not limited to Section 5 (Executive Covenants), including sub-sections 5(a) (Confidential Information) and 5(b) (Non-Competition and Non-Solicitation) and Section 6 (Ownership of Ideas, Copyrights and Patents (Inventions), shall prohibit or restrict Executive, or be construed to prohibit or restrict Executive, from filing a charge or complaint with, reporting possible violations of any law or regulation, making disclosures to (including providing documents or other information), and&#47;or participating in any investigation or proceeding conducted by any self-regulatory organization or governmental agency, authority or legislative body, including, but not limited to, the Securities and Exchange Commission and&#47;or Equal Employment Opportunity Commission or as otherwise required by law.</font></div><div style="padding-left:108pt;padding-right:8pt;"><font><br></font></div><div style="text-indent:72pt;padding-left:36pt;padding-right:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(iv)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt;">Executive is hereby notified that under the Defend Trade Secrets Act&#58; (a) no individual will be held criminally or civilly liable under Federal or State trade secret law for disclosure of a trade secret (as defined in the Economic Espionage Act) that is&#58; (1) made in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney, and made solely for the purpose of reporting or investigating a suspected violation of law&#59; or, (2) made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal so that it is not made public&#59; and (b) an individual who pursues a lawsuit for retaliation by an employer for reporting a suspected violation of the law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the individual files any document containing the trade secret under seal, and does not disclose the trade secret, except as permitted by court order.</font></div><div style="padding-left:36pt;"><font><br></font></div><div style="padding-left:108pt;padding-right:8pt;"><font><br></font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Non-Competition and Non-Solicitation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  Executive recognizes that the Company is engaged in a competitive business and that the Company has a legitimate interest in protecting its trade secrets, confidential business information, and customer, business development partner, licensee, supplier, and credit and&#47;or financial relationships.  Accordingly, in exchange for valuable consideration, including without limitation Executive&#8217;s access to confidential business information and continued at-will employment, Executive agrees that, during the Term hereof and for a period of eighteen (18) months thereafter, Executive shall not&#58;</font></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">directly or indirectly, whether for himself or for any other person or entity, and whether as a proprietor, principal, shareholder, partner, agent, employee, consultant, independent contractor, or in any other capacity whatsoever, undertake or have any interest in (other than the passive ownership of publicly registered securities </font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:65pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 16 -</font></div><div style="text-align:center;"><font><br></font></div></div><div style="padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">representing an ownership interest of less than 1%), engage in or assume any role directly competitive with the Company&#8217;s Field of Interest (or any portion thereof) or any other business in which the Company is engaged and for which the employee has rendered services while employed by the Company, or enter into any agreement to do any of the foregoing&#59; or</font></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">initiate contact with (including without limitation phone calls, press releases and the sending or delivering of announcements), or in any manner solicit, directly or indirectly, any customers, business development partners, licensors, licensees, or creditors (including institutional lenders, bonding companies and trade creditors) of the Company in an attempt to induce or motivate them either to discontinue or modify their then prevailing or future relationship with the Company or to transfer any of their business with the Company to any person or entity other than the Company&#59; or</font></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(iii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">initiate contact with, or in any manner solicit, directly or indirectly, any supplier of goods, services or materials to the Company in an attempt to induce or motivate them either to discontinue or modify their then prevailing or future relationship with the Company or to supply the same or similar inventory, goods, services or materials (except generally available inventory, goods, services or materials) to any person or entity other than the Company&#59; or</font></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(iv)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">directly or indirectly recruit, solicit or otherwise induce or influence any employee or independent contractor of the Company to discontinue or modify his or her employment or engagement with the Company, or employ or contract with any such employee or contractor for the provision of services.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Definition of &#8220;Field of Interest&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  The term Company&#8217;s &#8220;Field of Interest&#8221; shall mean the research, development and commercialization of products and strategies relating to&#58; (i) therapies for genetic disorders or specific diseases within each of AADC deficiency, Friedreich Ataxia, Angelman, Mitochondrial diseases, Duchenne muscular dystrophy, and (ii) any other diseases or products, in each case, that Executive directly managed or supported during his&#47;her employment with the Company.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Definition of &#8220;Customer&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  The term &#8220;customer&#8221; or &#8220;customers&#8221; shall include any person or entity (a) that is a current customer of the Company, (b) that was a customer of the Company at any time during the preceding twenty-four (24) months or (c) to which the Company made a written presentation for the solicitation of business at any time during the preceding twenty-four (24) months.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Reasonableness of Restrictions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  Executive further recognizes and acknowledges that (i) the types of employment which are prohibited by this Section 5 are narrow and reasonable in relation to the skills which represent Executive&#8217;s principal salable asset both to </font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:65pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 17 -</font></div><div style="text-align:center;"><font><br></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">the Company and to Executive&#8217;s other prospective employers, and (ii) the broad geographical scope of the provisions of this Section 5 is reasonable, legitimate and fair to Executive in light of the global nature of the Company&#8217;s business, particularly pharmaceutical research and development, and in light of the limited restrictions on the type of employment prohibited herein compared to the types of employment for which Executive is qualified to earn Executive&#8217;s livelihood.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(f)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Remedies</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  Executive acknowledges that a breach of this Section 5 will cause great and irreparable injury and damage, which cannot be reasonably or adequately compensated by money damages.  Accordingly, Executive acknowledges that the remedies of injunction and specific performance shall be available in the event of such a breach, in addition to money damages, costs and attorneys&#8217; fees, and other legal or equitable remedies, and that the Company shall be entitled as a matter of course to an injunction pending trial, without the posting of bond or other security.  Any period of restriction set forth in this Section 5 shall be extended for a period of time equal to the duration of any breach or violation hereof.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(g)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Notification</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  Any person employing Executive or evidencing any intention to employ Executive may be notified as to the existence and provisions of this Agreement.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(h)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Modification of Covenants&#59; Enforceability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  In the event that any provision of this Section 5 is held to be in any respect an unreasonable restriction, then the court so holding may modify the terms thereof, including the period of time during which it operates or the geographic area to which it applies, or effect any other change to the extent necessary to render this section enforceable, it being acknowledged by the parties that the representations and covenants set forth herein are of the essence of this Agreement.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Subsidiaries</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  For purposes of Sections 5 and 6 of this Agreement, &#8220;Company&#8221; shall include all direct and indirect subsidiaries of the Company.  An entity shall be deemed to be a subsidiary of the Company if the Company directly or indirectly owns or controls 50% or more of the equity interest in such entity.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Ownership of Ideas, Copyrights and Patents</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Property of the Company</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  Executive agrees that all ideas, discoveries, creations, manuscripts and properties, innovations, improvements, know&#30;how, inventions, designs, developments, apparatus, techniques, methods, biological processes, cell lines, laboratory notebooks and formulae, whether patentable, copyrightable or not, which Executive may conceive, reduce to practice or develop, alone or in conjunction with another, or others, whether during or out of regular business hours, and whether at the request or upon the suggestion of the Company, or otherwise, in the course of performing services for the Company in any capacity, whether heretofore or hereafter, (collectively, &#8220;the Inventions&#8221;) are and shall be the sole and exclusive property of the Company, and that Executive shall not publish any of the </font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:65pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 18 -</font></div><div style="text-align:center;"><font><br></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">Inventions without the prior written consent of the Company.  Executive hereby assigns to the Company all of Executive&#8217;s right, title and interest in and to all of the foregoing.  Executive further represents and agrees that to the best of Executive&#8217;s knowledge and belief none of the Inventions will violate or infringe upon any right, patent, copyright, trademark or right of privacy, or constitute libel or slander against or violate any other rights of any person, firm or corporation and that Executive will use his&#47;her best efforts to prevent any such violation.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Cooperation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  At any time during or after the Term, Executive agrees that s&#47;he will fully cooperate with the Company, its attorneys and agents in the preparation and filing of all papers and other documents as may be required to perfect the Company&#8217;s rights in and to any of such Inventions, including, but not limited to, executing any lawful document (including, but not limited to, applications, assignments, oaths, declarations and affidavits) and joining in any proceeding to obtain letters patent, copyrights, trademarks or other legal rights of the United States and of any and all other countries on such Inventions, provided that any patent or other legal right so issued to Executive, personally, shall be assigned by Executive to the Company without charge by Executive.  Executive further designates the Company as his&#47;her agent for, and grants to the Company a power of attorney with full power of substitution, which power of attorney shall be deemed coupled with an interest, for the purpose of effecting the foregoing assignments from Executive to the Company.  Company will bear the reasonable expenses which it causes to be incurred in Executive&#8217;s assisting and cooperating hereunder.  Executive waives all claims to moral rights in any Inventions.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">7.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Disclosure to Future Employers</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  The Company may provide in its discretion, a copy of this Agreement (in whole or in part, including the covenants contained in Sections 5 and 6 of this Agreement) to&#58; (a) any business or enterprise which Executive may directly, or indirectly, own, manage, operate, finance, join, control or in which Executive participates in the ownership, management, operation, financing, or control, or with which Executive may be connected as an officer, director, employee, partner, principal, agent, representative, consultant or otherwise, or (b) any third party who may be affected by the restrictive covenants in this Agreement.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">8.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Records</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  Upon termination of Executive&#8217;s relationship with the Company, and at any time requested by the Company, Executive shall deliver to the Company any property of the Company which may be in Executive&#8217;s possession including products, materials, memoranda, notes, records, reports, or other documents or photocopies of the same.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">9.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Insurance</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  The Company, in its sole discretion, may apply for and procure in its own name (whether or not for its own benefit) policies of insurance insuring Executive&#8217;s life.  Executive agrees to submit to reasonable medical or other examinations and to execute and deliver any applications or other instruments in writing that are reasonably necessary to effectuate such insurance.  No adverse employment actions may be based upon the results of any such exam or the failure by the Company to obtain such insurance.</font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:65pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 19 -</font></div><div style="text-align:center;"><font><br></font></div></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">10.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">No Conflicting Agreements</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  Executive hereby represents and warrants that Executive has no commitments or obligations inconsistent with this Agreement.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">11.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">&#8220;Market Stand-Off&#8221; Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  Executive agrees, if requested by the Company and an underwriter of common stock (or other securities) of the Company, not to sell or otherwise transfer or dispose of any common stock (or other securities) of the Company held by Executive during a period not to exceed one hundred and eighty (180) days following the effective date of the first underwritten public offering of common stock of the Company, offered on a firm commitment basis pursuant to a registration statement filed with the Securities and Exchange Commission (or any successor agency of the Federal government administrating the Securities Act of 1933, as amend, and the Securities Exchange Act of 1934, as amended) under the Securities Act of 1933, as amended, on Form S-1 or its then equivalent, and to enter into an agreement to such effect.  The Company may impose stop-transfer instructions with respect to the shares (or securities) subject to the foregoing restriction until the end of said period.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">12.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">General</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Notices</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  All notices, requests, consents and other communications hereunder shall be in writing, shall be addressed to the receiving party&#8217;s address as follows&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If to the Company&#58;&#160;PTC Therapeutics Inc.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">  </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;100 Corporate Court</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;South Plainfield, NJ 07080</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;USA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Attention&#58; Legal Department</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Telephone&#58; (908) 222-7000</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;With an email copy to&#58; legal&#64;ptcbio.com</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If to Executive&#58; &#160;Matthew Klein</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;184 Sand Hill Circle</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Menlo Park, CA 94025</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">or to such other address as a party may designate by notice hereunder, and shall be either (i)&#160;delivered by hand, (ii)&#160;sent by overnight courier, or (iii)&#160;sent by registered or certified mail, return receipt requested, postage prepaid.  All notices, requests, consents and other communications hereunder shall be deemed to have been given either (i)&#160;if by hand, at the time of the delivery thereof to the receiving party at the address of such party set forth above, (ii)&#160;if sent by overnight courier, on the next business day following the day such notice is delivered to the courier service, or (iii) if sent by registered or certified mail, on the fifth (5th) business day following the day such mailing is made.</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:65pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 20 -</font></div><div style="text-align:center;"><font><br></font></div></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Entire Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  This Agreement embodies the entire agreement and understanding between the parties hereto with respect to the subject matter hereof and supersedes all prior oral or written agreements and understandings relating to the subject matter hereof, except with respect to the equity and fringe benefit arrangements referred to in Subsections 3(c) and (e) above.  No statement, representation, warranty, covenant or agreement of any kind not expressly set forth in this Agreement shall affect, or be used to interpret, change or restrict, the express terms and provisions of this Agreement.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Modifications and Amendments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  The terms and provisions of this Agreement may be modified or amended only by written agreement executed by the parties hereto.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Waivers and Consents</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  The terms and provisions of this Agreement may be waived, or consent for the departure therefrom granted, only by written document executed by the party entitled to the benefits of such terms or provisions.  No such waiver or consent shall be deemed to be or shall constitute a waiver or consent with respect to any other terms or provisions of this Agreement, whether or not similar.  Each such waiver or consent shall be effective only in the specific instance and for the purpose for which it was given, and shall not constitute a continuing waiver or consent.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Assignment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  The Company shall assign its rights and obligations hereunder to any person or entity that succeeds to all or substantially all of the Company&#8217;s business or that aspect of the Company&#8217;s business in which Executive is principally involved.  Executive may not assign Executive&#8217;s rights and obligations under this Agreement without the prior written consent of the Company.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(f)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Benefit</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  All statements, representations, warranties, covenants and agreements in this Agreement shall be binding on the parties hereto and shall inure to the benefit of the respective successors and permitted assigns of each party hereto.  Nothing in this Agreement shall be construed to create any rights or obligations except among the parties hereto, and no person or entity shall be regarded as a third&#30;party beneficiary of this Agreement.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(g)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Governing Law</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  This Agreement and the rights and obligations of the parties hereunder shall be construed in accordance with and governed by the laws of The State of New Jersey, without giving effect to the conflict of law principles thereof.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(h)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Arbitration</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  Executive and the Company hereby agree that the sole remedy for any and all disputes arising out of or based on this Agreement or Executive&#8217;s employment with the Company (&#34;Arbitrable Claims&#34;), shall be binding  arbitration, which shall be conducted in New Jersey, before a single arbitrator, in accordance with the then applicable rules of the Judicial Arbitration and  Mediation  Service (&#34;JAMS&#34;) or by  a non- JAMS process to which the parties may otherwise agree.  By  agreeing to arbitrate, the parties are waiving their respective rights to a jury trial with regard to any of the above referenced claims. Executive understands and agrees </font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:65pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 21 -</font></div><div style="text-align:center;"><font><br></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">that notwithstanding the foregoing, the Company may pursue legal or equitable relief against Executive in the event of a breach of a restrictive covenant as per Section 5(f) above.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Severability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  The parties intend this Agreement to be enforced as written.  However, (i) if any portion or provision of this Agreement shall to any extent be declared illegal or unenforceable by a duly authorized court having jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law&#59; and (ii) if any provision, or part thereof, is held to be unenforceable because of the duration of such provision or the geographic area covered thereby or otherwise, the Company and Executive agrees that the court or arbitrator making such determination shall have the power to reduce the duration and&#47;or geographic area of such provision, and&#47;or to delete specific words and phrases (&#8220;blue-penciling&#8221;), and in its reduced or blue-penciled form such provision shall then be enforceable and shall be enforced.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(j)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Headings and Captions&#59; Interpretation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  The headings and captions of the various subdivisions of this Agreement are for convenience of reference only and shall in no way modify, or affect the meaning or construction of any of the terms or provisions hereof.  The provisions of the following Sections of this Agreement are in addition to, and do not limit, each other&#58; Sections 6 and 5(a)&#59; Sections 7 and 5(g)&#59; Sections 12(k) and 12(f)&#59; and Sections 12(l) and 12(d).</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(k)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Injunctive Relief</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  Executive hereby expressly acknowledges that any breach or threatened breach of any of the terms and&#47;or conditions set forth in Section 5 or 6 of this Agreement will result in substantial, continuing and irreparable injury to the Company.  Therefore, Executive hereby agrees that, in addition to any other remedy that may be available to the Company, the Company shall be entitled to injunctive or other equitable relief by a court of appropriate jurisdiction.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(l)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">No Waiver of Rights, Powers and Remedies</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  No failure or delay by a party hereto in exercising any right, power or remedy under this Agreement, and no course of dealing between the parties hereto, shall operate as a waiver of any such right, power or remedy of the party.  No single or partial exercise of any right, power or remedy under this Agreement by a party hereto, nor any abandonment or discontinuance of steps to enforce any such right, power or remedy, shall preclude such party from any other or further exercise thereof or the exercise of any other right, power or remedy hereunder.  The election of any remedy by a party hereto shall not constitute a waiver of the right of such party to pursue other available remedies.  No notice to or demand on a party not expressly required under this Agreement shall entitle the party receiving such notice or demand to any other or further notice or demand in similar or other </font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:65pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 22 -</font></div><div style="text-align:center;"><font><br></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">circumstances or constitute a waiver of the rights of the party giving such notice or demand to any other or further action in any circumstances without such notice or demand.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(m)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Counterparts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  This Agreement may be executed in one or more counterparts, and by different parties hereto on separate counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(n)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Survival</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  The provisions of Sections 4, 5, 6, 7, 8, 11 and 12 shall survive the termination of this Agreement and Executive&#8217;s employment hereunder in accordance with their terms.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(o)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Knowing and Voluntary Nature of Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  Executive acknowledges and agrees that Executive is executing this Agreement knowingly and voluntarily and without any duress or undue influence by PTC or anyone else.  Executive further acknowledges and agrees that Executive has carefully read this Agreement and fully understands it, including that Executive is waiving the right to a jury trial.  Executive further agrees that Executive has been provided an opportunity to seek the advice of an attorney of Executive&#8217;s choice before signing this Agreement.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">IN WITNESS THEREOF, the parties hereto have executed this Agreement as of the day and year first above written.</font></div><div style="margin-bottom:24pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">PTC Therapeutics, Inc.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">&#47;s&#47; Mark E. Boulding&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">Name&#58;  Mark E. Boulding</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">Title&#58; &#160;EVP, Chief Legal Officer</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">Agreed and Accepted</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">&#47;s&#47; Matthew Klein&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">Name&#58; Matthew Klein</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><div id="idc29821dde344a069424170847f26ee1_7"></div><hr style="page-break-after:always"><div style="min-height:49pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 23 -</font></div><div style="text-align:center;"><font><br></font></div></div><div style="text-align:center;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;">EXHIBIT A</font></div><div style="text-align:center;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;">Sample Separation and Release Agreement</font></div><div style="text-align:center;"><font><br></font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;">&#91;Insert Date&#93;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;">&#91;Insert Employee Name&#93;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;">&#91;Insert Employee Address&#93;</font></div><div><font><br></font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">Dear </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;">&#91;Insert Employee Name&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">&#58;</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">In connection with the termination of your employment with PTC Therapeutics, Inc. (the &#8220;Company&#8221;) on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;">&#91;Termination Date&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">, you are eligible to receive the Severance Compensation as described in Section 4 of the Employment Agreement executed between you and the Company on &#91;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;">Insert Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">&#93; (the &#8220;Employment Agreement&#8221;) if you sign and return this letter agreement to me by </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;">&#91;Return Date &#8211; e.g., 21 days from date of receipt of this letter agreement&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">and it becomes binding between you and the Company.  By signing and returning this letter agreement and not revoking your acceptance, you will be agreeing to the terms and conditions set forth in the numbered paragraphs below, including the release of claims set forth in paragraph 3.  Therefore, you are advised to consult with an attorney before signing this letter agreement and you may take up to twenty-one (21) days to do so.  If you sign this letter agreement, you may change your mind and revoke your agreement during the seven (7) day period after you have signed it by notifying me  in writing.  If you do not so revoke, this letter agreement will become a binding agreement between you and the Company upon the expiration of the seven (7) day period.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">If you choose not to sign and return this letter agreement by </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;">&#91;Return Date-Same as Above&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">, or if you timely revoke your acceptance in writing, you shall not receive any Severance Compensation from the Company.  You will, however, receive payment for your final wages and any unused vacation time accrued through the Termination Date, as defined below.  Also, regardless of signing this letter agreement, you may elect to continue receiving group medical insurance pursuant to the federal &#8220;COBRA&#8221; law, 29 U.S.C. &#167;&#160;1161 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">et</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">seq.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">  If you so elect, you shall pay all premium costs on a monthly basis for as long as, and to the extent that, you remain eligible for COBRA  continuation.  You should consult the COBRA materials to be provided by the Company for details regarding these benefits.  All other benefits will cease upon your Termination Date in accordance with the plan documents.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">The following numbered paragraphs set forth the terms and conditions that will apply if you timely sign and return this letter agreement and do not revoke it in writing within the seven (7) day period.</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration: underline;padding-left:9pt;">Termination Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> &#8211; Your effective date of termination from the Company is&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;">&#91;Insert Date&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> (the &#8220;Termination Date&#8221;).</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration: underline;padding-left:9pt;">Release</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> &#8211; In consideration of the payment of the Severance Compensation, which you acknowledge you would not otherwise be entitled to receive, you hereby fully, forever, irrevocably and unconditionally release, remise and discharge the Company, its affiliates, subsidiaries, parent companies, predecessors, and successors, and all of their respective past </font></div><div style="position:relative;width:100%;height:14pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:49pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 24 -</font></div><div style="text-align:center;"><font><br></font></div></div><div style="padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">and present officers, directors, stockholders, partners, members, employees, agents, representatives, plan administrators, attorneys, insurers and fiduciaries (each in their individual and corporate capacities) (collectively, the &#8220;Released Parties&#8221;) from any and all claims, charges, complaints, demands, actions, causes of action, suits, rights, debts, sums of money, costs, accounts, reckonings, covenants, contracts, agreements, promises, doings, omissions, damages, executions, obligations, liabilities, and expenses (including attorneys&#8217; fees and costs), of every kind and nature that you ever had or now have against any or all of the Released Parties, including, but not limited to, any and all claims arising out of or relating to your employment with and&#47;or separation from the Company, including, but not limited to, all claims under Title VII of the Civil Rights Act of 1964, 42 U.S.C. &#167; 2000e </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">et seq.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">, the Americans With Disabilities Act of 1990, 42 U.S.C. &#167; 12101 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">et</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">seq.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">, the Age Discrimination in Employment Act, 29 U.S.C. &#167; 621 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">et seq.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">, the Genetic Information Nondiscrimination Act of 2008, 42 U.S.C. &#167; 2000ff </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">et</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">seq.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">, the Family and Medical Leave Act, 29 U.S.C. &#167; 2601 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">et</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">seq.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">, the Worker Adjustment and Retraining Notification Act (&#8220;WARN&#8221;), 29 U.S.C. &#167; 2101 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">et seq.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">, the Rehabilitation Act of 1973, 29 U.S.C. &#167; 701 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">et</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">seq.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">, Executive Order 11246, Executive Order 11141, the Fair Credit Reporting Act, 15 U.S.C. &#167; 1681 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">et</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">seq.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">, and the Employee Retirement Income Security Act of 1974 (&#8220;ERISA&#8221;), 29 U.S.C. &#167; 1001 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">et</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">seq.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">, all as amended&#59; all claims arising out of the New Jersey Law Against Discrimination, N.J. Stat. Ann.&#160;&#167;&#160;10&#58;5-1 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">et seq.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">, the New Jersey Family Leave Act, N.J. Stat. Ann. &#167; 34&#58;11B-1 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">et seq.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">, the New Jersey Conscientious Employee Protection Act, N.J. Stat. Ann. &#160;&#167;&#160;34&#58;19-1 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">et seq.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">, and the N.J. Stat. Ann.&#160;&#167;&#160;34&#58;11-56.1 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">et seq.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> (New Jersey equal pay law), all as amended&#59; all common law claims including, but not limited to, actions in defamation, intentional infliction of emotional distress, misrepresentation, fraud, wrongful discharge, and breach of contract, including without limitation, all claims arising from the Employment Agreement&#59; all state and federal whistleblower claims to the maximum extent permitted by law&#59; all claims to any non-vested ownership interest in the Company, contractual or otherwise&#59; and any claim or damage arising out of your employment with and&#47;or separation from the Company (including a claim for retaliation) under any common law theory or any federal, state or local statute or ordinance not expressly referenced above&#59; provided, however, that nothing in this letter agreement shall (i) prevent you from filing a charge with, cooperating with, or participating in any proceeding before the Equal Employment Opportunity Commission or a state fair employment practices agency (except that you acknowledge that you may not recover any monetary benefits in connection with any such claim, charge or proceeding) or (ii) deprive you of any rights you may have to be indemnified by the Company as provided in any agreement between the Company and you or pursuant to the Company&#8217;s Certificate of Incorporation or by-laws.</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration: underline;padding-left:9pt;">Non-Disclosure, Non-Competition, Confidential Information and Non-Solicitation and Inventions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">&#8211; You acknowledge and reaffirm your obligations to keep confidential and not disclose all non-public information concerning the Company with respect to Confidential Information, non-solicitation, and Inventions and its clients that you acquired during the course of your employment with the Company, as stated more fully in Sections 5 and 6 of the Employment Agreement, which remains in full force and effect.</font></div><div style="position:relative;width:100%;height:14pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:49pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 25 -</font></div><div style="text-align:center;"><font><br></font></div></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration: underline;padding-left:9pt;">Return of Company Property</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> &#8211; You acknowledge and reaffirm your obligations to the Company with respect to Company property, as stated more fully in Section 6 and 8 of the Employment Agreement. You confirm that you have returned to the Company all keys, files, records (and copies thereof), equipment (including, but not limited to, computer hardware, software and printers, wireless handheld devices, cellular phones, smartphones, tablets, etc.), Company identification, and any other Company-owned property in your possession or control and have left intact all electronic Company documents, including but not limited to those which you developed or helped to develop during your employment.  You further confirm that you have cancelled all accounts for your benefit, if any, in the Company's name, including but not limited to, credit cards, telephone charge cards, cellular phone and&#47;or wireless data accounts and computer accounts.</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration: underline;padding-left:9pt;">Business Expenses and Final Compensation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> &#8211; You acknowledge that you have been reimbursed by the Company for all business expenses incurred in conjunction with the performance of your employment and that no other reimbursements are owed to you.  You further acknowledge that you have received payment in full for all services rendered in conjunction with your employment by the Company, including payment for all wages, bonuses and accrued, unused vacation time, and that no other compensation is owed to you except as provided herein.</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration: underline;padding-left:9pt;">Non-Disparagement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> &#8211; To the extent permitted by law, you understand and agree that as a condition for payment to you of the Severance Compensation herein described, you shall not make any false, disparaging or derogatory statements to any person or entity, including any media outlet, regarding the Company or any of its directors, officers, employees, agents or representatives or about the Company&#8217;s business affairs and financial condition. </font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">7.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration: underline;padding-left:9pt;">Continued Assistance</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> &#8211; You acknowledge and reaffirm your obligations to the Company with respect to cooperation, as stated more fully in Section 6 of the Employment Agreement. You agree that after the Termination Date you will provide all reasonable cooperation to the Company, including but not limited to, assisting the Company transition your job duties, assisting the Company in defending against and&#47;or prosecuting any litigation or threatened litigation, and performing any other tasks as reasonably requested by the Company.</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;">8.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration: underline;padding-left:9pt;">Cooperation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">&#8211; To the extent permitted by law, you agree to cooperate fully with the Company in the defense or prosecution of any claims or actions which already have been brought, are currently pending, or which may be brought in the future against or on behalf of the Company</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;">,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> whether before a state or federal court, any state or federal government agency, or a mediator or arbitrator.  Your full cooperation in connection with such claims or actions shall include, but not be limited to, being available to meet with counsel to prepare its claims or defenses, to prepare for trial or discovery or an administrative hearing or a mediation or arbitration and to act as a witness when requested by the Company at reasonable times designated by the Company.  You agree that you will notify the Company promptly in the event that you are served with a subpoena or in the event that you are asked to provide a third party with information concerning any actual or potential complaint or claim against the Company.</font></div><div style="position:relative;width:100%;height:14pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:49pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 26 -</font></div><div style="text-align:center;"><font><br></font></div></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;">9.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration: underline;padding-left:9pt;">Amendment and Waiver</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">&#8211; This letter agreement shall be binding upon the parties and may not be modified in any manner, except by an instrument in writing of concurrent or subsequent date signed by duly authorized representatives of the parties hereto.  This letter agreement is binding upon and shall inure to the benefit of the parties and their respective agents, assigns, heirs, executors, successors and administrators.  No delay or omission by the Company in exercising any right under this letter agreement shall operate as a waiver of that or any other right.  A waiver or consent given by the Company on any one occasion shall be effective only in that instance and shall not be construed as a bar to or waiver of any right on any other occasion.</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">10.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration: underline;padding-left:3pt;">Validity</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> &#8211; Should any provision of this letter agreement be declared or be determined by any court of competent jurisdiction to be illegal or invalid, the validity of the remaining parts, terms or provisions shall not be affected thereby and said illegal or invalid part, term or provision shall be deemed not to be a part of this letter agreement.</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">11.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration: underline;padding-left:3pt;">Confidentiality</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> &#8211; To the extent permitted by law, you understand and agree that as a condition for payment to you of the Severance Compensation herein described, the terms and contents of this letter agreement, and the contents of the negotiations and discussions resulting in this letter agreement, shall be maintained as confidential by you and your agents and representatives and shall not be disclosed except to the extent required by federal or state law or as otherwise agreed to in writing by the Company.</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">12.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration: underline;padding-left:3pt;">Nature of Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">&#8211; You understand and agree that this letter agreement is a severance agreement and does not constitute an admission of liability or wrongdoing on the part of the Company.</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">13.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration: underline;padding-left:3pt;">Acknowledgments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;"> &#8211; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">You acknowledge that you have been given at least &#91;twenty-one (21) days&#93; to consider this letter agreement, and that the Company advised you to consult with an attorney of your own choosing prior to signing this letter agreement.  &#91;You understand that you may revoke this letter agreement for a period of seven (7) days after you sign this letter agreement by notifying me in writing, and the letter agreement shall not be effective or enforceable until the expiration of this seven (7) day revocation period.&#93; You understand and agree that by entering into this agreement, you are waiving any and all rights or claims you might have under the Age Discrimination in Employment Act, as amended by the Older Workers Benefits Protection Act, and that you have received consideration beyond that to which you were previously entitled.</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">14.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration: underline;padding-left:3pt;">Voluntary Assent</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> &#8211; You affirm that no other promises or agreements of any kind have been made to or with you by any person or entity whatsoever to cause you to sign this letter agreement, and that you fully understand the meaning and intent of this letter agreement.  You state and represent that you have had an opportunity to fully discuss and review the terms of this letter agreement with an attorney.  You further state and represent that you have carefully read this letter agreement, understand the contents herein, freely and voluntarily assent to all of the terms and conditions hereof and sign your name of your own free act.</font></div><div style="position:relative;width:100%;height:14pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><div id="idc29821dde344a069424170847f26ee1_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">15. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Protected Conduct </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8211; Nothing in this Agreement shall prohibit or restrict you, or be cnstrued to prohibit or restrict you, from filing a charge or complaint with, reporting possible violations of any law or regulation, making disclosures to (including providing documents or other information), and&#47;or participating in any investigation or proceeding conducted by any self-regulatory organization or governmental agency, authority or legislative body, including, but not limited to, the Securities and Exchange Commission and&#47;or Equal Employment Opportunity Commission or as otherwise required by law.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">16. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration: underline;">Applicable Law</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> &#8211; This letter agreement shall be interpreted and construed by the laws of the State of New Jersey, without regard to conflict of laws provisions.  You hereby irrevocably submit to and acknowledge and recognize the jurisdiction of the courts of the State of New Jersey, or if appropriate, a federal court located in the State of New Jersey (which courts, for purposes of this letter agreement, are the only courts of competent jurisdiction), over any suit, action or other proceeding arising out of, under or in connection with this letter agreement or the subject matter hereof.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">17. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration: underline;">Entire Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> &#8211; This letter agreement contains and constitutes the entire understanding and agreement between the parties hereto with respect to your Severance Compensation and the settlement of claims against the Company and cancels all previous oral and written negotiations, agreements and commitments in connection therewith, except as otherwise set forth herein. For example, nothing in this paragraph shall modify, cancel or supersede your obligations set forth in paragraph 3 herein.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">18. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration: underline;">Tax Acknowledgement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> &#8211; In connection with the payments and consideration provided to you pursuant to this letter agreement, the Company shall withhold and remit to the tax authorities the amounts required under applicable law, and you shall be responsible for all applicable taxes with respect to such payments and consideration under applicable law.  You acknowledge that you are not relying upon the advice or representation of the Company with respect to the tax treatment of any of the Severance Compensation set forth in Section 4 of the Employment Agreement.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">If you have any questions about the matters covered in this letter agreement, please call me at </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;">&#91;Insert Phone Number&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.</font></div><div style="padding-left:216pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">Very truly yours,</font></div><div style="padding-left:216pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">By&#58; &#160;__________________________________</font></div><div style="text-indent:-36pt;padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#91;Name&#93;</font></div><div style="text-indent:252pt;margin-bottom:24pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;">&#91;Title&#93;</font></div><div style="margin-bottom:19pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">I hereby agree to the terms and conditions set forth above.  I have been given at least &#91;twenty-one (21) days&#93; to consider this letter agreement and I have chosen to execute this on the date below.  </font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 2 -</font></div><div style="text-align:center;"><font><br></font></div></div><div style="margin-bottom:19pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">I intend that this letter agreement will become a binding agreement between me and the Company &#91;if I do not revoke my acceptance in seven (7) days&#93;.</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:48.163%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:47.837%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">_____________________________</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;Insert Employee Name&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">_________________________</font></div><div style="margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Date</font></div></td></tr></table></div><div style="text-align:center;margin-top:3pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">To be returned to me</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">by </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;">&#91;Return Date &#8211; e.g., 21 days from date of receipt of this letter&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.</font></div><div style="text-align:center;margin-bottom:6pt;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><div id="idc29821dde344a069424170847f26ee1_13"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%;"><div style="text-align:right;"><font><br></font></div><div style="text-align:right;"><font><br></font></div><div style="text-align:right;"><font><br></font></div><div style="text-align:right;"><font><br></font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">April 10, 2020</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Matthew Klein </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">304 Franklin Avenue </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Princeton, NJ 08540</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Dear Matthew,</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Congratulations on your proposed appointment to Chief Development Officer of PTC Therapeutics, Inc. Your success with PTC has been impressive and we look forward to your continued contributions to PTC&#8217;s business and mission.  The effective date of your appointment is the date that your appointment is approved by the Board of Directors of PTC following receipt of a signed copy of this letter from you indicating your acceptance of your appointment.  In this new role you will report to our CEO and Founder, Stu Peltz.  </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Outlined below are details of your appointment&#58;  </font></div><div><font><br></font></div><div style="text-indent:-18pt;padding-left:54pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt;">Your annual base salary will be increased to $450,000 annually, subject to deductions for taxes and other withholdings as required by law. Please allow 1 to 2 pay periods for your new base salary to be reflected in your paycheck. </font></div><div style="padding-left:54pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt;">Your bonus target will increase to 45.00% of your annual salaried earnings paid in accordance with the terms of conditions of PTC&#8217;s annual incentive compensation plan. </font></div><div><font><br></font></div><div style="text-indent:-18pt;padding-left:54pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt;">You will receive a one-time grant of 50,000 stock options to purchase shares of common stock of PTC, and 10,000 restricted stock units</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> subject to formal approval by the Compensation Committee of the Board of Directors (or a majority of the PTC&#8217;s independent directors) and to the terms of the applicable grant agreements. The options will vest over four years, with 25% vesting on the one-year anniversary of your grant date and 6.25% vesting every three-month period thereafter over the following three years. The restricted stock units will vest over four years, with 25% vesting annually on the anniversary of the grant date. </font></div><div style="padding-left:36pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:54pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt;">This letter supersedes any other recent discussions or communications from PTC with respect to changes in your pay, title, role in the organization, or equity grants. All other terms of your employment with PTC will remain consistent with existing signed employment and equity agreements and applicable policies.</font></div><div><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">On behalf of PTC, let me again congratulate you on your proposed appointment.  Please return a signed copy of this letter to me by close of business on Monday, April 13</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">th</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, 2020. Feel free to contact me if you have any questions concerning this letter.</font></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.861%;"><tr><td style="width:1.0%;"></td><td style="width:44.831%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:51.169%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sincerely,</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accepted by&#58;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Martin Rexroad</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Matthew Klein</font></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Martin Rexroad</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Matthew Klein</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SVP, Human Resources </font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">April 11, 2020</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cc&#58; Stuart Peltz</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></font></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>5
<FILENAME>ex104pauwelsemployment.htm
<DESCRIPTION>EX-10.4 PAUWELS EMPLOYMENT AGREEMENT
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i84187e9be43c4fcba8b93646692621d7_1"></div><div style="min-height:65pt;width:100%;"><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;">EXHIBIT 10.4</font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:139%;">EMPLOYMENT AGREEMENT</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">This EMPLOYMENT AGREEMENT (the &#8220;Agreement&#8221;) is made as of March 9, 2015 (the &#8220;Effective Date&#8221;), by and between PTC Therapeutics, Inc., a Delaware corporation (the &#8220;Company&#8221;) and Eric Pauwels (&#8220;Executive&#8221;).  In consideration of the mutual covenants contained in this Agreement, the Company and Executive agree as follows&#58;</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;padding-left:27pt;">Employment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  The Company agrees to continue to employ Executive and Executive agrees to continue to be employed by the Company on the terms and conditions set forth in this Agreement.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Capacity</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  Executive shall serve the Company as Senior Vice President &#38; General Manager - Americas reporting to Mark Rothera, Chief Commercial Officer, or such senior executive as the Company shall specify.  Executive shall have the responsibilities, duties and authority commensurate with the position of Senior Vice President &#38; General Manager - Americas.  In addition to Executive&#8217;s primary duties, Executive shall perform such other services for the Company that are consistent with his&#47;her position as Senior Vice President &#38; General Manager - Americas as may be reasonably assigned to Executive from time to time by the individual to whom s&#47;he reports or the Board of Directors of the Company (the &#8220;Board&#8221;) or their respective designees.  The principal location at which Executive shall perform such services shall be the Company&#8217;s corporate headquarters currently located at 100 Corporate Court, Middlesex Business Center, South Plainfield, NJ  07080, subject to relocation and Section 2(c)(i) of this Agreement.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Devotion of Duties&#59; Representations</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  During the Term (as defined below) of Executive&#8217;s employment with the Company, Executive shall devote his&#47;her best efforts and full business time and energies to the business and affairs of the Company, and shall endeavor to perform the duties and services contemplated hereunder to the reasonable satisfaction of the  individual to whom s&#47;he reports and the Board.  During the Term of Executive&#8217;s employment with the Company, Executive shall not, without the prior written approval of the Company (by action of the Board), undertake any other employment from any person or entity or serve as a director of any other company&#59; provided, however, that (i) the Company will entertain requests as to such other employment or directorships in good faith and (ii) Executive will be eligible to participate in any policy relating to outside activities that is applicable to the senior executives of the Company and approved by the Board after the date hereof.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Term of Employment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">Executive&#8217;s employment hereunder shall continue on the Effective Date.  Executive&#8217;s employment hereunder shall be terminated upon the first to occur of the following&#58;</font></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;padding-left:27.68pt;">Immediately upon Executive&#8217;s death&#59;</font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:65pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 2 -</font></div><div style="text-align:center;"><font><br></font></div></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">By the Company</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">&#58;</font></div><div style="text-indent:72pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(A)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">By written notice to Executive effective the date of such notice, following the Disability of Executive.  &#8220;Disability&#8221; means that Executive (i) is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment which can be expected to result in death or can be expected to last for a continuous period of not less than 12 months, or (ii) is, by reason of any medically determinable physical or mental impairment which can be expected to last for a continuous period of not less than 12 months, receiving income replacement benefits for a period of not less than three months under an accident and health plan covering employees of the Company.  Such incapacity shall be determined by a physician chosen by the Company and reasonably satisfactory to Executive (or Executive&#8217;s legal representative) upon examination requested by the Company (to which Executive hereby agrees to submit). Notwithstanding the foregoing, such Disability must result in Executive becoming &#8220;Disabled&#8221; within the meaning of Section 409A(a)(2)(C) of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) and the guidance issued thereunder.  (In this Agreement we refer to Section 409A of the Code and any guidance issued thereunder as &#8220;Section 409A&#8221;).</font></div><div style="text-indent:72pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(B)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">By written notice to Executive, effective the date of such notice, for Cause (as defined below)&#59; or</font></div><div style="text-indent:72pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(C)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">By written notice to Executive, effective ninety (90) days after the date of such notice and subject to Section 4 hereof, without Cause&#59; or</font></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(iii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">By Executive</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">&#58;</font></div><div style="text-indent:72pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(A)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">At any time by written notice to the Company, effective forty-five (45) days after the date of such notice</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;">&#59;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> or</font></div><div style="text-indent:72pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(B)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">By written notice to the Company for Good Reason (as defined below), effective on the date specified in such notice.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">The term of Executive&#8217;s employment by the Company under this Agreement is referred to herein as the &#8220;Term.&#8221;</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Definition of &#8220;Cause&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  For purposes of this Agreement, &#8220;Cause&#8221; shall, pursuant to the reasonable good faith determination by a majority of the Board (excluding Executive) as documented in writing, include&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(i) the willful and continued failure by Executive to substantially perform Executive&#8217;s material duties or responsibilities under this Agreement (other than such a failure as a result of Disability)&#59; (ii) any action or</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">omission by Executive </font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:65pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 3 -</font></div><div style="text-align:center;"><font><br></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">involving willful misconduct or gross negligence with regard to the Company, which has a detrimental effect on the Company&#59; (iii) Executive&#8217;s conviction of a felony, either in connection with the performance of Executive&#8217;s obligations to the Company or which otherwise shall adversely affect Executive&#8217;s ability to perform such obligations or shall materially adversely affect the business activities, reputation, goodwill or image of the Company&#59;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(iv) the material breach of a fiduciary duty to the Company&#59; or (v) the material breach by Executive of any of the provisions of this Agreement, provided that any breach of Executive&#8217;s obligations with respect to Sections 5 or 6 of this Agreement, subject to the cure provision in the next sentence, shall be deemed &#8220;material.&#8221;  In respect of the events described in clauses (i) and (v) above, the Company shall give Executive notice of the failure of performance or breach, reasonable as to time, place and manner in the circumstances, and a 30-day opportunity to cure, provided that such failure of performance or breach is reasonably amenable to cure as determined by the Board in its sole discretion.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Definition of &#8220;Good Reason&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  For purposes of this Agreement, a &#8220;Good Reason&#8221; shall mean any of the following, unless (i) the basis for such Good Reason is cured within a reasonable period of time (determined in the light of the cure appropriate to the basis of such Good Reason, but in no event less than thirty (30) nor more than ninety (90) days) after the Company receives written notice (which must be received from Executive within ninety (90) days of the initial existence of the condition giving rise to such Good Reason) specifying the basis for such Good Reason or (ii) Executive has consented to the condition that would otherwise be a basis for Good Reason&#58;</font></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">A change in the principal location at which Executive provides services to the Company to a location more than fifty (50) miles from such principal location and&#47;or to a location in New York City (either of which change, the Company has reasonably determined as of the date hereof, would constitute a material change in the geographic location at which Executive provides services to the Company), provided that such a relocation shall not be deemed to occur under circumstances where Executive&#8217;s responsibilities require him&#47;her to work at a location other than the corporate headquarters for a reasonable period of time&#59;</font></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">A material adverse change by the Company in Executive&#8217;s duties, authority or responsibilities as Senior Vice President &#38; General Manager - Americas of the Company which causes Executive&#8217;s position with the Company to become of materially less responsibility or authority than Executive&#8217;s position immediately following the Effective Date.  For purposes of this definition of &#8220;Good Reason,&#8221; a &#8220;material adverse change&#8221; following a Corporate Change shall not include any diminution in authority, duties or responsibilities that is solely attributable to the change in the Company&#8217;s ownership structure but does not otherwise change Executive&#8217;s </font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:65pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 4 -</font></div><div style="text-align:center;"><font><br></font></div></div><div style="padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">authority, duties or responsibilities (except in a positive manner) otherwise with respect to the Company&#8217;s business.</font></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(iii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">A material reduction in Executive&#8217;s base compensation (including Base Salary) except if the reduction is in connection with a general reduction of not more than 20% in compensation of senior executives of the Company generally that occurs prior to the effective date of any Corporate Change&#59;</font></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(iv)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">A material breach of this Agreement by the Company which has not been cured within thirty (30) days after written notice thereof by Executive&#59; or</font></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(v)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">Failure to obtain the assumption (assignment) of this Agreement by any successor to the Company.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Definition of &#8220;Corporate Change&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  For purposes of this Agreement, &#8220;Corporate Change&#8221; shall mean any circumstance in which (i) the Company is not the surviving entity in any merger, consolidation or other reorganization (or survives only as a subsidiary or affiliate of an entity other than a previously wholly-owned subsidiary of the Company)&#59; (ii) the Company sells, leases or exchanges or agrees to sell, lease or exchange all or substantially all of its assets to any other person or entity (other than a wholly-owned subsidiary of the Company)&#59; (iii) any person or entity, including a &#8220;group&#8221; as contemplated by Section 13(d)(3) of the Securities Exchange Act of 1934 (excluding, for this purpose, the Company or any Subsidiary, or any employee benefit plan of the Company or any Subsidiary, or any &#8220;group&#8221; in which all or substantially all of its members or its members&#8217; affiliates are individuals or entities who are or were beneficial owners of the Company&#8217;s outstanding shares prior to the initial public offering, if any, of the Company&#8217;s stock), acquires or gains ownership or control (including, without limitations, powers to vote) of more than 50% of the outstanding shares of the Company&#8217;s voting stock (based upon voting power)&#59; or (iv) as a result of or in connection with a contested election of directors, the persons who were directors of the Company before such election shall cease to constitute a majority of the Board of Directors of the Company.  Notwithstanding the foregoing, a &#8220;Corporate Change&#8221; shall not occur as a result of an initial public offering of the Company&#8217;s common stock, or as a result of a merger, consolidation, reorganization or restructuring after which either (1) a majority of the Board of Directors of the controlling entity consists of persons who were directors of the Company prior to the merger, consolidation, reorganization or restructuring or (2) Executive forms part of an executive management team that consists of substantially the same group of individuals and Executive is performing in a similar role, with similar authority and responsibility (other than changes solely attributable to the change in ownership structure), to that which existed prior to the reorganization or restructuring.  Notwithstanding the foregoing, for any payments or benefits hereunder that are subject to Section 409A, the Corporate Change must constitute a &#8220;change in control event&#8221; within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(i).</font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:65pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 5 -</font></div><div style="text-align:center;"><font><br></font></div></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Compensation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Base Salary</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  Executive&#8217;s minimum base salary during the Term shall be at the rate of $335,000 per year (the &#8220;Base Salary&#8221;).  Base Salary shall be payable in substantially equal installments in accordance with the Company&#8217;s payroll practices as in effect from time to time, less any amounts required to be withheld under applicable law.  The Base Salary will be subject to adjustment from time to time in the sole discretion of the Board&#59; provided that, the Company covenants that it shall not reduce the Base Salary below $335,000 or the Base Salary then in effect immediately prior to the reduction unless (i) Executive consents to such reduction, or (ii) the reduction is in connection with a general reduction of not more than 20% in compensation of senior executives of the Company generally that occurs prior to the effective date of any Corporate Change.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Bonus</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  In addition to the Base Salary, the Company may pay Executive an annual bonus (the &#8220;Bonus&#8221;) as determined by the Board, solely in its discretion (it being understood that Executive&#8217;s target annual bonus shall be at 40% of Base Salary, but may be higher or lower in any year in the Board&#8217;s discretion).  The Board&#8217;s decision to issue a Bonus to Executive in any particular year shall have no effect on the absolute discretion of the Board to grant or not to grant a Bonus in subsequent years.  Any Bonus for a particular year shall be paid or provided to Executive in a lump sum no later than March 15</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:139%;vertical-align:top;">th</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> of the calendar year following the calendar year in which the Bonus was earned.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Equity Compensation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  Executive will receive an inducement grant of 70,000 options to purchase shares of common stock of PTC, subject to formal approval by the Compensation Committee of the Board (or a majority of the Company&#8217;s independent directors) (the &#8220;Inducement Grant&#8221;). Such award is granted pursuant to the inducement grant exception under NASDAQ rules and is intended to serve as a material inducement to Executive entering into employment with PTC. Executive shall be eligible to participate in PTC&#8217;s annual equity and long term incentive plan(s) and may be eligible to receive discretionary awards under such plan(s), subject to the terms and conditions of such plan(s).  Except as explicitly set forth below, Executive&#8217;s rights with respect to equity (including stock options) shall be covered in PTC&#8217;s equity and long term incentive plan(s) and separate stock option certificates or agreements for each grant.</font></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Accelerated Vesting</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.</font></div><div style="text-indent:72pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(A)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">For the avoidance of doubt, in the event that Executive&#8217;s employment hereunder is terminated by the Company without Cause or by Executive for Good Reason, neither the unvested portion of the Inducement Grant nor any unvested equity awards granted under the Company&#8217;s equity and long-term incentive plan(s) following the date hereof shall be subject to any accelerated </font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:65pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 6 -</font></div><div style="text-align:center;"><font><br></font></div></div><div style="padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">vesting except as otherwise provided for in the applicable award agreement or in Section 3(c)(i)(B) below.</font></div><div style="text-indent:72pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(B)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">Except as otherwise provided in the applicable award, in the event that Executive&#8217;s employment hereunder is terminated by the Company without Cause or by Executive for Good Reason within the period of three (3) months prior to (but only if negotiations relating to the particular Corporate Change that occurs are ongoing at the date of the notice of termination) or twelve (12) months after a Corporate Change that occurs during the Term (such fifteen-month period, the &#8220;Protected Period&#8221;), one hundred percent (100%) of all of Executive&#8217;s outstanding unvested equity awards granted under the Company&#8217;s equity and long-term incentive plan(s) following the date hereof shall vest immediately.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Vacation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  Executive is eligible for time off programs outlined in the Company&#8217;s Time Off Policy.  Executive shall accrue over the calendar year 160 hours of paid vacation.   Executive may accrue up to 200 hours of vacation.  Once Executive has reached the maximum accrual, no further vacation time will be accrued unless and until the Executive uses vacation time. Upon termination of employment, the value of Executive&#8217;s current balance of accrued but unused vacation shall be paid out in cash based on his&#47;her Base Salary that was in effect immediately prior to his&#47;her termination of employment.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Fringe Benefits</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  Executive shall be entitled to participate in any employee benefit plans that the Company makes available to its senior executives (including, without limitation, group life, disability, medical, dental and other insurance, retirement, pension, profit-sharing and similar plans) (collectively, the &#8220;Fringe Benefits&#8221;), provided that the Fringe Benefits shall not include any stock option or similar plans relating to the grant of equity securities of the Company.  These benefits may be modified or changed from time to time at the sole discretion of the Company.  Where a particular benefit is subject to a formal plan (for example, medical or life insurance), eligibility to participate in and receive any particular benefit is governed solely by the applicable plan document, and eligibility to participate in such plan(s) may be dependent upon, among other things, a physical examination.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(f)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Reimbursement of Expenses</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  Executive shall be entitled to reimbursement for all ordinary and reasonable out-of-pocket business expenses that are reasonably incurred by him&#47;her in furtherance of the Company&#8217;s business in accordance with reasonable policies adopted from time to time by the Company for senior executives.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(g)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Taxes and Withholdings</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  The Company shall deduct and withhold from all compensation and benefits under this Agreement all social security and other federal, state and local taxes and charges which currently are or which hereafter may be required by law to be so deducted and withheld.</font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:65pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 7 -</font></div><div style="text-align:center;"><font><br></font></div></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Severance Compensation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">In the event of any termination of Executive&#8217;s employment for any reason the Company shall pay Executive (or Executive&#8217;s estate) such portions of Executive&#8217;s Base Salary as have accrued prior to such termination and have not yet been paid, together with (i) amounts for accrued unused vacation days (as provided above), (ii) any amounts for expense reimbursement which have been properly incurred or the Company has become obligated to pay prior to termination and have not been paid as of the date of such termination and (iii) the amount of any Bonus previously granted to Executive by the Board but not yet paid, which amount shall not include any pro rata portion of any Bonus which would have been earned if such termination had not occurred (the &#8220;Accrued Obligations&#8221;).  Such amounts shall be paid as soon as possible after termination.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">In the event that Executive&#8217;s employment hereunder is terminated (i) by Executive for a Good Reason or (ii) by the Company without Cause, the Company shall pay to Executive the Accrued Obligations.  In addition, the Company shall pay to Executive the severance benefits set forth below for twelve (12) months following Executive&#8217;s termination of employment (the &#8220;Severance Period&#8221;).  The receipt of any severance benefits provided in this Section shall be dependent upon Executive&#8217;s execution (and, as applicable, non-revocation) of a standard separation agreement and general release of claims, substantially in the form attached hereto as Exhibit A (the &#8220;Release&#8221;).  The Company will also consider in good faith (but without any binding commitment) requests from Executive that the Company include in the Release a release of Executive by the Company from matters specifically disclosed to the Company by Executive in writing in advance of execution of the Release and not involving any illegality, fraud, concealment, criminal acts or acts outside the scope of Executive's employment.  The distribution of severance benefits in this Section 4 is subject to section (iii) of this Section 4(b).</font></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">If Executive&#8217;s employment is terminated (A) by Executive for a Good Reason or (B) by the Company without Cause, in either case before or after the Protected Period, the Company shall pay Executive his&#47;her Base Salary, less any amounts required to be withheld under applicable law, for the Severance Period in substantially equal installments in accordance with the Company&#8217;s payroll practices as in effect from time to time, commencing no later than sixty (60) days following the effective date of such termination.  If Executive&#8217;s employment is terminated (A) by Executive for a Good Reason or (B) by the Company without Cause, in either case during the Protected Period, the Company shall pay Executive his&#47;her Base Salary for the Severance Period, which total amount shall be payable in a lump sum no later than sixty (60) days following Executive&#8217;s termination of employment.  In each case, payments shall commence or be paid provided that the Release has been executed and any applicable revocation period has expired as of the 60</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:139%;vertical-align:top;">th</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> day following Executive&#8217;s termination.</font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:65pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 8 -</font></div><div style="text-align:center;"><font><br></font></div></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">Only if Executive&#8217;s employment is terminated (A) by Executive for a Good Reason or (B) by the Company without Cause, in either case during the Protected Period, the Company shall pay Executive his target annual bonus, described in section 3(b) hereof, for the year in which the termination of employment occurs, which total amount shall be payable in a lump sum 30 days following Executive&#8217;s termination of employment, provided that the Release has been executed and any applicable revocation period has expired as of such date.</font></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(iii)&#160;The Company shall continue to provide Executive and his&#47;her then-enrolled eligible dependents with group health insurance and shall continue to pay the amount of the premium as in effect on the date of such termination for the Severance Period commencing on the effective date of such termination, subject to applicable law and the terms of the respective policies&#59; provided that the Company&#8217;s obligation to provide the benefits contemplated herein shall terminate upon Executive&#8217;s becoming eligible for coverage under the medical benefits program of a subsequent employer.  The foregoing shall not be construed to extend any period of continuation coverage (e.g., COBRA) required by Federal law.</font></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(iv)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Compliance with Section 409A</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  Subject to the provisions in this Section 4(b)(iii), any severance payments or benefits under this Agreement shall begin only upon the date of Executive&#8217;s &#8220;separation from service&#8221; (determined as set forth below) which occurs on or after the date of termination of Executive&#8217;s employment.  The following rules shall apply with respect to the distribution of the severance payments and benefits, if any, to be provided to Executive under this Agreement&#58;</font></div><div style="text-indent:72pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(1)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">It is intended that each installment of the severance payments and benefits provided under this Agreement shall be treated as a separate &#8220;payment&#8221; for purposes of Section 409A.  Neither the Company nor Executive shall have the right to accelerate or defer the delivery of any such payments or benefits except to the extent specifically permitted or required by Section 409A.</font></div><div style="text-indent:72pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(2)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">If, as of the date of Executive&#8217;s &#8220;separation from service&#8221; from the Company, Executive is not a &#8220;specified employee&#8221; (within the meaning of Section 409A), then each installment of the severance payments and benefits shall be made on the dates and terms set forth in this Agreement.</font></div><div style="text-indent:72pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(3)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">If, as of the date of Executive&#8217;s &#8220;separation from service&#8221; from the Company, Executive is a &#8220;specified employee&#8221; (within the meaning of Section 409A), then&#58;</font></div><div style="text-indent:108pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(A)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">Each installment of the severance payments and benefits due under this Agreement that, in accordance with the dates and terms set </font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:65pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 9 -</font></div><div style="text-align:center;"><font><br></font></div></div><div style="padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">forth herein, will in all circumstances, regardless of when the separation from service occurs, be paid within the short-term deferral period (as defined under Section 409A) shall be treated as a short-term deferral within the meaning of Treasury Regulation Section 1.409A-1(b)(4) to the maximum extent permissible under Section 409A and such payments and benefits shall be paid or provided on the dates and terms set forth in this Agreement&#59; and</font></div><div style="text-indent:108pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(B)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">Each installment of the severance payments and benefits due this Agreement that is not described in Section 4(b)(iii)(3)(A) above and that would, absent this subsection, be paid within the six-month period following Executive&#8217;s &#8220;separation from service&#8221; from the Company shall not be paid until the date that is six months and one day after such separation from service (or, if earlier, Executive&#8217;s death), with any such installments that are required to be delayed being accumulated during the six-month period and paid in a lump sum on the date that is six months and one day following Executive&#8217;s separation from service and any subsequent installments, if any, being paid in accordance with the dates and terms set forth herein&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">, that the preceding provisions of this sentence shall not apply to any installment of severance payments and benefits if and to the maximum extent that such installment is deemed to be paid under a separation pay plan that does not provide for a deferral of compensation by reason of the application of Treasury Regulation 1.409A-1(b)(9)(iii) (relating to separation pay upon an involuntary separation from service).  Any installments that qualify for the exception under Treasury Regulation Section 1.409A-1(b)(9)(iii) must be paid no later than the last day of Executive&#8217;s second taxable year following the taxable year in which the separation from service occurs.</font></div><div style="text-indent:72pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(4)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">The determination of whether and when Executive&#8217;s separation from service from the Company has occurred shall be made in a manner consistent with, and based on the presumptions set forth in, Treasury Regulation Section 1.409A-1(h).  Solely for purposes of this Section 4(b)(iii), &#8220;Company&#8221; shall include all persons with whom the Company would be considered a single employer under Section 414(b) and 414(c) of the Code.</font></div><div style="text-indent:72pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(5)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">All reimbursements and in-kind benefits provided under this Agreement shall be made or provided in accordance with the requirements of Sections 409A to the extent that such reimbursements or in-kind benefits are subject to Section 409A, including, where applicable, the requirements that (i) any reimbursement is for expenses incurred during Executive&#8217;s lifetime (or during a shorter period of time specified in this Agreement), (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses </font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:65pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 10 -</font></div><div style="text-align:center;"><font><br></font></div></div><div style="padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">eligible for reimbursement in any other calendar year, (iii) the reimbursement of an eligible expense will be made on or before the last day of the calendar year following the year in which the expense is incurred and (iv) the right to reimbursement is not subject to set off or liquidation or exchange for any other benefit.</font></div><div style="text-indent:72pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(6)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">Notwithstanding anything herein to the contrary, the Company shall have no liability to Executive or to any other person if the payments and benefits provided hereunder that are intended to be exempt from or compliant with Section 409A are not so exempt or compliant.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">In the event that Executive&#8217;s employment hereunder is terminated (i) by Executive for other than a Good Reason, or (ii) by the Company for Cause, or (iii) as a result of Executive&#8217;s death or Disability, then the Company will pay to Executive the Accrued Obligations.  The Company shall have no obligation to pay Executive (or Executive&#8217;s estate) any other compensation following such termination except as provided in Section 4(a).</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Modified Section 280G Cutback</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.</font></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(i)&#160;Notwithstanding any other provision of this Agreement, except as set forth in Section 4(d)(ii), in the event that the Company undergoes a &#8220;Change in Ownership or Control&#8221; (as defined below), the Company shall not be obligated to provide to Executive a portion of any &#8220;Contingent Compensation Payments&#8221; (as defined below) that Executive would otherwise be entitled to receive to the extent necessary to eliminate any &#8220;excess parachute payments&#8221; (as defined in Section 280G(b)(1) of the Code) for Executive.  For purposes of this Section&#160;4(d), the Contingent Compensation Payments so eliminated shall be referred to as the &#8220;Eliminated Payments&#8221; and the aggregate amount (determined in accordance with Treasury Regulation Section 1.280G-1, Q&#47;A-30 or any successor provision) of the Contingent Compensation Payments so eliminated shall be referred to as the &#8220;Eliminated Amount.&#8221;</font></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(ii) &#160;Notwithstanding the provisions of Section 4(d)(i), no such reduction in Contingent Compensation Payments shall be made if (1) the Eliminated Amount (computed without regard to this sentence) exceeds (2) 100% of the aggregate present value (determined in accordance with Treasury Regulation Section&#160;1.280G-1, Q&#47;A-31 and Q&#47;A-32 or any successor provisions) of the amount of any additional taxes that would be incurred by Executive if the Eliminated Payments (determined without regard to this sentence) were paid to him&#47;her (including, state and federal income taxes on the Eliminated Payments, the excise tax imposed by Section 4999 of the Code payable with respect to all of the Contingent Compensation Payments in excess of Executive&#8217;s &#8220;base amount&#8221; (as defined in Section 280G(b)(3) of the Code), and any withholding taxes).  The override of such reduction in Contingent Compensation Payments pursuant to this </font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:65pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 11 -</font></div><div style="text-align:center;"><font><br></font></div></div><div style="padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">Section&#160;4(d)(ii) shall be referred to as a &#8220;Section&#160;4(d)(ii) Override.&#8221;  For purpose of this paragraph, if any federal or state income taxes would be attributable to the receipt of any Eliminated Payment, the amount of such taxes shall be computed by multiplying the amount of the Eliminated Payment by the maximum combined federal and state income tax rate provided by law.</font></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(iii)&#160;For purposes of this Section 4(d) the following terms shall have the following respective meanings&#58;</font></div><div style="text-indent:72pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(1)&#160;&#8220;Change in Ownership or Control&#8221; shall mean a change in the ownership or effective control of the Company or in the ownership of a substantial portion of the assets of the Company determined in accordance with Section 280G(b)(2) of the Code.</font></div><div style="text-indent:72pt;padding-left:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(2)&#160;&#8220;Contingent Compensation Payment&#8221; shall mean any payment (or benefit) in the nature of compensation that is made or made available (under this Agreement or otherwise) to a &#8220;disqualified individual&#8221; (as defined in Section 280G(c) of the Code) and that is contingent (within the meaning of Section 280G(b)(2)(A)(i) of the Code) on a Change in Ownership or Control of the Company.</font></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(iv)&#160;Any payments or other benefits otherwise due to Executive following a Change in Ownership or Control that could reasonably be characterized (as determined by the Company) as Contingent Compensation Payments (the &#8220;Potential Payments&#8221;) shall not be made until the dates provided for in this Section&#160;4(d)(iv).  Within 30 days after each date on which Executive first becomes entitled to receive (whether or not then due) a Contingent Compensation Payment relating to such Change in Ownership or Control, the Company shall determine and notify Executive (with reasonable detail regarding the basis for its determinations) (1) which Potential Payments constitute Contingent Compensation Payments, (2) the Eliminated Amount and (3)&#160;whether the Section&#160;4(d)(ii) Override is applicable.  Within 30 days after delivery of such notice to Executive, Executive shall deliver a response to the Company (the &#8220;Executive Response&#8221;) stating either (A) that s&#47;he agrees with the Company&#8217;s determination pursuant to the preceding sentence or (B) that s&#47;he disagrees with such determination, in which case</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">s&#47;he</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">shall set forth (x) which Potential Payments should be characterized as Contingent Compensation Payments, (y) the Eliminated Amount, and (z) whether the Section&#160;4(d)(ii) Override is applicable.  In the event that Executive fails to deliver an Executive Response on or before the required date, the Company&#8217;s initial determination shall be final.  If Executive states in the Executive Response that s&#47;he</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">agrees with the Company&#8217;s determination, the Company shall make the Potential Payments to Executive within three business days following delivery to the Company of the Executive Response </font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:65pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 12 -</font></div><div style="text-align:center;"><font><br></font></div></div><div style="padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(except for any Potential Payments which are not due to be made until after such date, which Potential Payments shall be made on the date on which they are due).  If Executive states in the Executive Response that s&#47;he disagrees with the Company&#8217;s determination, then, for a period of 60 days following delivery of the Executive Response, Executive and the Company shall use good faith efforts to resolve such dispute.  If such dispute is not resolved within such 60-day period, such dispute shall be settled exclusively by arbitration in South Plainfield, New Jersey, in accordance with the rules of the American Arbitration Association then in effect.  Judgment may be entered on the arbitrator&#8217;s award in any court having jurisdiction.  The Company shall, within three business days following delivery to the Company of the Executive Response, make to Executive those Potential Payments as to which there is no dispute between the Company and Executive regarding whether they should be made (except for any such Potential Payments which are not due to be made until after such date, which Potential Payments shall be made on the date on which they are due).  The balance of the Potential Payments shall be made within three business days following the resolution of such dispute.</font></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> (v)&#160;The Contingent Compensation Payments to be treated as Eliminated Payments shall be determined by the Company by determining the &#8220;Contingent Compensation Payment Ratio&#8221; (as defined below) for each Contingent Compensation Payment and then reducing the Contingent Compensation Payments in order beginning with the Contingent Compensation Payment with the highest Contingent Compensation Payment Ratio.  For Contingent Compensation Payments with the same Contingent Compensation Payment Ratio, such Contingent Compensation Payment shall be reduced based on the time of payment of such Contingent Compensation Payments with amounts having later payment dates being reduced first.  For Contingent Compensation Payments with the same Contingent Compensation Payment Ratio and the same time of payment, such Contingent Compensation Payments shall be reduced on a pro rata basis (but not below zero) prior to reducing Contingent Compensation Payment with a lower Contingent Compensation Payment Ratio.  The term &#8220;Contingent Compensation Payment Ratio&#8221; shall mean a fraction the numerator of which is the value of the applicable Contingent Compensation Payment that must be taken into account by Executive for purposes of Section 4999(a) of the Code, and the denominator of which is the actual amount to be received by Executive in respect of the applicable Contingent Compensation Payment.  For example, in the case of an equity grant that is treated as contingent on the Change in Ownership or Control because the time at which the payment is made or the payment vests is accelerated, the denominator shall be determined by reference to the fair market value of the equity at the acceleration date, and not in accordance with the methodology for determining the value of accelerated payments set forth in Treasury Regulation Section 1.280G-1Q&#47;A-24(b) or (c)).</font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:65pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 13 -</font></div><div style="text-align:center;"><font><br></font></div></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(vi)&#160;The provisions of this Section 4(d) are intended to apply to any and all payments or benefits available to Executive under this Agreement or any other agreement or plan of the Company under which Executive receives Contingent Compensation Payments.</font></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(vii)&#160;Notwithstanding Sections 4(d)(i)-(vi) hereof, until the closing of the first underwritten public offering of common stock of the Company, in the event that it shall be determined that any payment or benefit (including any accelerated vesting of options or other equity awards) made or provided, or to be made or provided, by the Company (or any successor thereto or affiliate thereof) to or for the benefit of Executive, whether pursuant to the terms of this Agreement, any other agreement, plan, program or arrangement of or with the Company (or any successor thereto or affiliate thereof) or otherwise, may be subject to the excise tax imposed by Section 4999 of the Code or any comparable tax imposed by any replacement or successor provision of United States tax law, then upon the request of Executive, the Company shall use reasonable efforts to procure a shareholder vote in satisfaction of the shareholder approval requirements described in Treas. Reg. Section 1.280G-1, Q&#38;A-7.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Executive Covenants</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Confidential Information</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  Executive recognizes and acknowledges the competitive and proprietary aspects of the business of the Company, and that as a result of Executive&#8217;s employment, Executive recognizes and acknowledges that s&#47;he has had and will continue to have access to, and has been and will continue to be involved in the development of, Confidential Information (as defined below) of the Company.  As used herein, &#8220;Confidential Information&#8221; shall mean and include trade secrets, knowledge and other confidential information of the Company, which Executive has acquired, no matter from whom or on what matter such knowledge or information may have been acquired, heretofore or hereafter, concerning the content and details of the business of the Company, and which is not known to the general public, including but not limited to&#58; (a) new products, product betterments and other inventions, formulas, processes, methods, materials, material combinations, manner of preparations, technical production procedures and information, alarm and security codes and procedures, sources of technology, and sources of supply of raw and finished materials and other products&#59; (b) financial and accounting records&#59; (c) the identity of employees, consultants, independent contractors, customers, business development partners, licensees, suppliers, creditors or other parties with which the Company has business dealings, the nature of the relationship with such persons, or any other information relating to such persons or the Company&#8217;s dealings with such persons&#59; and (d) computer software used by the Company or provided to the customers of the Company unless publicly available.</font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:65pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 14 -</font></div><div style="text-align:center;"><font><br></font></div></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">For as long as Executive is employed and at all times thereafter, Executive shall not, directly or indirectly, communicate, disclose or divulge to any person or entity, or use for Executive&#8217;s own benefit or the benefit of any person (other than the Company), any Confidential Information, except as permitted in subparagraph (iii) below.  Upon termination of Executive&#8217;s employment, or at any other time at the request of the Company, Executive agrees to deliver promptly to the Company all Confidential Information, including, but not limited to, customer and supplier lists, files and records, in Executive&#8217;s possession or under Executive&#8217;s control.  Executive further agrees that s&#47;he will not make or retain any copies of any of the foregoing and will so represent to the Company upon termination of Executive&#8217;s employment.</font></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">Executive shall disclose immediately to the Company any trade secrets or other Confidential Information conceived or developed by Executive at any time during Executive&#8217;s employment.  Executive hereby assigns and agrees to assign to the Company Executive&#8217;s entire right, title and interest in and to all Confidential Information.  Such assignment shall include, without limitation, the rights to obtain patent or copyright protection, thereon in the United States and foreign countries.  Executive agrees to provide all reasonable assistance to enable the Company to prepare and prosecute any application before any governmental agency for patent or copyright protection or any similar application with respect to any Confidential Information.  Executive further agrees to execute all documents and assignments and to make all oaths necessary to vest ownership of such intellectual property rights in the Company, as the Company may request.  These obligations shall apply whether or not the subject thereof was conceived or developed at the suggestion of the Company, and whether or not developed during regular hours of work or while on the premises of the Company.</font></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(iii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">Executive shall at all times, both during and after termination of this Agreement by either Executive or the Company, maintain in confidence and shall not, without prior written consent of the Company, use, except in the course of performance of Executive&#8217;s duties for the Company or as required by legal process (provided that Executive will promptly notify the Company of such legal process except with respect to any confidential government investigation), disclose or give to others any Confidential Information.  In the event Executive is questioned by anyone not employed by the Company or by an employee of or a consultant to the Company not authorized to receive such information, in regard to any such information or any other secret or confidential work of the Company, or concerning any fact or circumstance relating thereto, Executive will promptly notify the Company.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Non-Competition and Non-Solicitation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  Executive recognizes that the Company is engaged in a competitive business and that the Company has a legitimate interest in protecting its trade secrets, confidential business information, and customer, business </font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:65pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 15 -</font></div><div style="text-align:center;"><font><br></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">development partner, licensee, supplier, and credit and&#47;or financial relationships.  Accordingly, in exchange for valuable consideration, including without limitation Executive&#8217;s access to confidential business information and continued at-will employment, Executive agrees that, during the Term hereof and for a period of eighteen (18) months thereafter, Executive shall not&#58;</font></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">directly or indirectly, whether for himself or for any other person or entity, and whether as a proprietor, principal, shareholder, partner, agent, employee, consultant, independent contractor, or in any other capacity whatsoever, undertake or have any interest in (other than the passive ownership of publicly registered securities representing an ownership interest of less than 1%), engage in or assume any role involving directly or indirectly the Company&#8217;s Field of Interest (or any portion thereof) or any other business in which the Company is engaged and for which the employee has rendered services while employed by the Company, or enter into any agreement to do any of the foregoing&#59; or</font></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">initiate contact with (including without limitation phone calls, press releases and the sending or delivering of announcements), or in any manner solicit, directly or indirectly, any customers, business development partners, licensors, licensees, or creditors (including institutional lenders, bonding companies and trade creditors) of the Company in an attempt to induce or motivate them either to discontinue or modify their then prevailing or future relationship with the Company or to transfer any of their business with the Company to any person or entity other than the Company&#59; or</font></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(iii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">initiate contact with, or in any manner solicit, directly or indirectly, any supplier of goods, services or materials to the Company in an attempt to induce or motivate them either to discontinue or modify their then prevailing or future relationship with the Company or to supply the same or similar inventory, goods, services or materials (except generally available inventory, goods, services or materials) to any person or entity other than the Company&#59; or</font></div><div style="text-indent:72pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(iv)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">directly or indirectly recruit, solicit or otherwise induce or influence any employee or independent contractor of the Company to discontinue or modify his or her employment or engagement with the Company, or employ or contract with any such employee or contractor for the provision of services.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Definition of &#8220;Field of Interest&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  The term Company&#8217;s &#8220;Field of Interest&#8221; shall mean the research, development and commercialization of products and strategies relating to&#58; (i) therapies for genetic disorders or diseases that include cystic fibrosis, Duchenne muscular dystrophy, other diseases caused in whole or part by nonsense (or stop) codons, and other genetic diseases as to which the Company engages in the research, development or commercialization of drugs&#59; anti-angiogenic therapies that target VEGF protein production for cancer&#59; and antiviral therapies for the Hepatitis C virus (HCV)&#59; and (ii) other therapeutic targets, mechanisms of </font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:65pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 16 -</font></div><div style="text-align:center;"><font><br></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">action and&#47;or therapies in which the Company has a research, development or commercialization program.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Definition of &#8220;Customer&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  The term &#8220;customer&#8221; or &#8220;customers&#8221; shall include any person or entity (a) that is a current customer of the Company, (b) that was a customer of the Company at any time during the preceding twenty-four (24) months or (c) to which the Company made a written presentation for the solicitation of business at any time during the preceding twenty-four (24) months.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Reasonableness of Restrictions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  Executive further recognizes and acknowledges that (i) the types of employment which are prohibited by this Section 5 are narrow and reasonable in relation to the skills which represent Executive&#8217;s principal salable asset both to the Company and to Executive&#8217;s other prospective employers, and (ii) the broad geographical scope of the provisions of this Section 5 is reasonable, legitimate and fair to Executive in light of the global nature of the Company&#8217;s business, particularly pharmaceutical research and development, and in light of the limited restrictions on the type of employment prohibited herein compared to the types of employment for which Executive is qualified to earn Executive&#8217;s livelihood.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(f)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Remedies</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  Executive acknowledges that a breach of this Section 5 will cause great and irreparable injury and damage, which cannot be reasonably or adequately compensated by money damages.  Accordingly, Executive acknowledges that the remedies of injunction and specific performance shall be available in the event of such a breach, in addition to money damages, costs and attorneys&#8217; fees, and other legal or equitable remedies, and that the Company shall be entitled as a matter of course to an injunction pending trial, without the posting of bond or other security.  Any period of restriction set forth in this Section 5 shall be extended for a period of time equal to the duration of any breach or violation hereof.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(g)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Notification</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  Any person employing Executive or evidencing any intention to employ Executive may be notified as to the existence and provisions of this Agreement.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(h)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Modification of Covenants&#59; Enforceability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  In the event that any provision of this Section 5 is held to be in any respect an unreasonable restriction, then the court so holding may modify the terms thereof, including the period of time during which it operates or the geographic area to which it applies, or effect any other change to the extent necessary to render this section enforceable, it being acknowledged by the parties that the representations and covenants set forth herein are of the essence of this Agreement.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Subsidiaries</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  For purposes of Sections 5 and 6 of this Agreement, &#8220;Company&#8221; shall include all direct and indirect subsidiaries of the Company.  An entity shall be deemed to be a subsidiary of the Company if the Company directly or indirectly owns or controls 50% or more of the equity interest in such entity.</font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:65pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 17 -</font></div><div style="text-align:center;"><font><br></font></div></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Ownership of Ideas, Copyrights and Patents</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Property of the Company</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  Executive agrees that all ideas, discoveries, creations, manuscripts and properties, innovations, improvements, know&#30;how, inventions, designs, developments, apparatus, techniques, methods, biological processes, cell lines, laboratory notebooks and formulae, whether patentable, copyrightable or not, which Executive may conceive, reduce to practice or develop, alone or in conjunction with another, or others, whether during or out of regular business hours, and whether at the request or upon the suggestion of the Company, or otherwise, in the course of performing services for the Company in any capacity, whether heretofore or hereafter, (collectively, &#8220;the Inventions&#8221;) are and shall be the sole and exclusive property of the Company, and that Executive shall not publish any of the Inventions without the prior written consent of the Company.  Executive hereby assigns to the Company all of Executive&#8217;s right, title and interest in and to all of the foregoing.  Executive further represents and agrees that to the best of Executive&#8217;s knowledge and belief none of the Inventions will violate or infringe upon any right, patent, copyright, trademark or right of privacy, or constitute libel or slander against or violate any other rights of any person, firm or corporation and that Executive will use his&#47;her best efforts to prevent any such violation.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Cooperation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  At any time during or after the Term, Executive agrees that s&#47;he will fully cooperate with the Company, its attorneys and agents in the preparation and filing of all papers and other documents as may be required to perfect the Company&#8217;s rights in and to any of such Inventions, including, but not limited to, executing any lawful document (including, but not limited to, applications, assignments, oaths, declarations and affidavits) and joining in any proceeding to obtain letters patent, copyrights, trademarks or other legal rights of the United States and of any and all other countries on such Inventions, provided that any patent or other legal right so issued to Executive, personally, shall be assigned by Executive to the Company without charge by Executive.  Executive further designates the Company as his&#47;her agent for, and grants to the Company a power of attorney with full power of substitution, which power of attorney shall be deemed coupled with an interest, for the purpose of effecting the foregoing assignments from Executive to the Company.  Company will bear the reasonable expenses which it causes to be incurred in Executive&#8217;s assisting and cooperating hereunder.  Executive waives all claims to moral rights in any Inventions.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">7.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Disclosure to Future Employers</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  The Company may provide in its discretion, a copy of the covenants contained in Sections 5 and 6 of this Agreement to any business or enterprise which Executive may directly, or indirectly, own, manage, operate, finance, join, control or in which Executive participates in the ownership, management, operation, financing, or control, or with which Executive may be connected as an officer, director, employee, partner, principal, agent, representative, consultant or otherwise.</font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:65pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 18 -</font></div><div style="text-align:center;"><font><br></font></div></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">8.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Records</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  Upon termination of Executive&#8217;s relationship with the Company, Executive shall deliver to the Company any property of the Company which may be in Executive&#8217;s possession including products, materials, memoranda, notes, records, reports, or other documents or photocopies of the same.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">9.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Insurance</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  The Company, in its sole discretion, may apply for and procure in its own name (whether or not for its own benefit) policies of insurance insuring Executive&#8217;s life.  Executive agrees to submit to reasonable medical or other examinations and to execute and deliver any applications or other instruments in writing that are reasonably necessary to effectuate such insurance.  No adverse employment actions may be based upon the results of any such exam or the failure by the Company to obtain such insurance.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">10.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">No Conflicting Agreements</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  Executive hereby represents and warrants that Executive has no commitments or obligations inconsistent with this Agreement.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">11.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">&#8220;Market Stand-Off&#8221; Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  Executive agrees, if requested by the Company and an underwriter of common stock (or other securities) of the Company, not to sell or otherwise transfer or dispose of any common stock (or other securities) of the Company held by Executive during a period not to exceed one hundred and eighty (180) days following the effective date of the first underwritten public offering of common stock of the Company, offered on a firm commitment basis pursuant to a registration statement filed with the Securities and Exchange Commission (or any successor agency of the Federal government administrating the Securities Act of 1933, as amend, and the Securities Exchange Act of 1934, as amended) under the Securities Act of 1933, as amended, on Form S-1 or its then equivalent, and to enter into an agreement to such effect.  The Company may impose stop-transfer instructions with respect to the shares (or securities) subject to the foregoing restriction until the end of said period.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">12.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">General</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Notices</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  All notices, requests, consents and other communications hereunder shall be in writing, shall be addressed to the receiving party&#8217;s address as follows&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If to the Company&#58;&#160;PTC Therapeutics Inc.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">  </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;100 Corporate Court</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;South Plainfield, NJ 07080</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;USA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Attention&#58; Legal Department</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Telephone&#58; (908) 222-7000</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;With an email copy to&#58; legal&#64;ptcbio.com</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If to Executive&#58; &#160;Eric Pauwels</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;623 Spring Valley Road</font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:65pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 19 -</font></div><div style="text-align:center;"><font><br></font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Morristown, NJ 07960</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">or to such other address as a party may designate by notice hereunder, and shall be either (i)&#160;delivered by hand, (ii)&#160;sent by overnight courier, or (iii)&#160;sent by registered or certified mail, return receipt requested, postage prepaid.  All notices, requests, consents and other communications hereunder shall be deemed to have been given either (i)&#160;if by hand, at the time of the delivery thereof to the receiving party at the address of such party set forth above, (ii)&#160;if sent by overnight courier, on the next business day following the day such notice is delivered to the courier service, or (iii) if sent by registered or certified mail, on the fifth (5th) business day following the day such mailing is made.</font></div><div><font><br></font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Entire Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  This Agreement embodies the entire agreement and understanding between the parties hereto with respect to the subject matter hereof and supersedes all prior oral or written agreements and understandings relating to the subject matter hereof, except with respect to the equity and fringe benefit arrangements referred to in Subsections 3(c) and (e) above.  No statement, representation, warranty, covenant or agreement of any kind not expressly set forth in this Agreement shall affect, or be used to interpret, change or restrict, the express terms and provisions of this Agreement.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Modifications and Amendments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  The terms and provisions of this Agreement may be modified or amended only by written agreement executed by the parties hereto.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Waivers and Consents</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  The terms and provisions of this Agreement may be waived, or consent for the departure therefrom granted, only by written document executed by the party entitled to the benefits of such terms or provisions.  No such waiver or consent shall be deemed to be or shall constitute a waiver or consent with respect to any other terms or provisions of this Agreement, whether or not similar.  Each such waiver or consent shall be effective only in the specific instance and for the purpose for which it was given, and shall not constitute a continuing waiver or consent.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Assignment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  The Company shall assign its rights and obligations hereunder to any person or entity that succeeds to all or substantially all of the Company&#8217;s business or that aspect of the Company&#8217;s business in which Executive is principally involved.  Executive may not assign Executive&#8217;s rights and obligations under this Agreement without the prior written consent of the Company.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(f)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Benefit</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  All statements, representations, warranties, covenants and agreements in this Agreement shall be binding on the parties hereto and shall inure to the benefit of the respective successors and permitted assigns of each party hereto.  Nothing in this Agreement shall be construed to create any rights or obligations except among the parties hereto, and no person or entity shall be regarded as a third&#30;party beneficiary of this Agreement.</font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:65pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 20 -</font></div><div style="text-align:center;"><font><br></font></div></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(g)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Governing Law</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  This Agreement and the rights and obligations of the parties hereunder shall be construed in accordance with and governed by the law of The State of New Jersey, without giving effect to the conflict of law principles thereof.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(h)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Jurisdiction and Service of Process</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  Any legal action or proceeding with respect to this Agreement shall be brought in the courts of The State of New Jersey or of the United States of America for the</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">District of New Jersey.  By execution and delivery of this Agreement, each of the parties hereto accepts for itself and in respect of its property, generally and unconditionally, the jurisdiction of the aforesaid courts.  Each of the parties hereto irrevocably consents to the service of process of any of the aforementioned courts in any such action or proceeding by the mailing of copies thereof by certified mail, postage prepaid, to the party at its address set forth in Section 12(a) hereof.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Severability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  The parties intend this Agreement to be enforced as written.  However, (i) if any portion or provision of this Agreement shall to any extent be declared illegal or unenforceable by a duly authorized court having jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law&#59; and (ii) if any provision, or part thereof, is held to be unenforceable because of the duration of such provision or the geographic area covered thereby or otherwise, the Company and Executive agrees that the court making such determination shall have the power to reduce the duration and&#47;or geographic area of such provision, and&#47;or to delete specific words and phrases (&#8220;blue-penciling&#8221;), and in its reduced or blue-penciled form such provision shall then be enforceable and shall be enforced.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(j)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Headings and Captions&#59; Interpretation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  The headings and captions of the various subdivisions of this Agreement are for convenience of reference only and shall in no way modify, or affect the meaning or construction of any of the terms or provisions hereof.  The provisions of the following Sections of this Agreement are in addition to, and do not limit, each other&#58; Sections 6 and 5(a)&#59; Sections 7 and 5(g)&#59; Sections 12(k) and 12(f)&#59; and Sections 12(l) and 12(d).</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(k)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Injunctive Relief</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  Executive hereby expressly acknowledges that any breach or threatened breach of any of the terms and&#47;or conditions set forth in Section 5 or 6 of this Agreement will result in substantial, continuing and irreparable injury to the Company.  Therefore, Executive hereby agrees that, in addition to any other remedy that may be available to the Company, the Company shall be entitled to injunctive or other equitable relief by a court of appropriate jurisdiction.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(l)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">No Waiver of Rights, Powers and Remedies</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  No failure or delay by a party hereto in exercising any right, power or remedy under this Agreement, and no course of dealing </font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:65pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 21 -</font></div><div style="text-align:center;"><font><br></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">between the parties hereto, shall operate as a waiver of any such right, power or remedy of the party.  No single or partial exercise of any right, power or remedy under this Agreement by a party hereto, nor any abandonment or discontinuance of steps to enforce any such right, power or remedy, shall preclude such party from any other or further exercise thereof or the exercise of any other right, power or remedy hereunder.  The election of any remedy by a party hereto shall not constitute a waiver of the right of such party to pursue other available remedies.  No notice to or demand on a party not expressly required under this Agreement shall entitle the party receiving such notice or demand to any other or further notice or demand in similar or other circumstances or constitute a waiver of the rights of the party giving such notice or demand to any other or further action in any circumstances without such notice or demand.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(m)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Counterparts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  This Agreement may be executed in one or more counterparts, and by different parties hereto on separate counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(n)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Survival</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  The provisions of Sections 4, 5, 6, 7, 8, 11 and 12 shall survive the termination of this Agreement and Executive&#8217;s employment hereunder in accordance with their terms.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(o)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">WAIVER OF TRIAL BY JURY</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  THE PARTIES IRREVOCABLY WAIVE THEIR RESPECTIVE RIGHT TO A TRIAL BY JURY REGARDING ANY DISPUTE, CLAIM OR CAUSE OF ACTION ARISING OUT OF, CONCERNING, OR RELATED TO EXECUTIVE&#8217;S EMPLOYMENT WITH THE COMPANY OR THIS AGREEMENT.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">(p)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">Knowing and Voluntary Nature of Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.  Executive acknowledges and agrees that Executive is executing this Agreement knowingly and voluntarily and without any duress or undue influence by PTC or anyone else.  Executive further acknowledges and agrees that Executive has carefully read this Agreement and fully understands it, including that Executive is waiving the right to a jury trial.  Executive further agrees that Executive has been provided an opportunity to seek the advice of an attorney of Executive&#8217;s choice before signing this Agreement.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">IN WITNESS THEREOF, the parties hereto have executed this Agreement as of the day and year first above written.</font></div><div style="margin-bottom:24pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">PTC Therapeutics, Inc.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">&#47;s&#47; Mark E. Boulding&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">Name&#58;  Mark E. Boulding</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">Title&#58; &#160;EVP, Chief Legal Officer</font></div><div><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:65pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 22 -</font></div><div style="text-align:center;"><font><br></font></div></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">Agreed and Accepted</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">&#47;s&#47; Eric Pauwels&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">Name&#58; Eric Pauwels</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><div id="i84187e9be43c4fcba8b93646692621d7_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;">EXHIBIT A</font></div><div style="text-align:center;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;">Sample Separation and Release Agreement</font></div><div style="text-align:center;"><font><br></font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;">&#91;Insert Date&#93;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;">&#91;Insert Employee Name&#93;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;">&#91;Insert Employee Address&#93;</font></div><div><font><br></font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">Dear </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;">&#91;Insert Employee Name&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">&#58;</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">In connection with the termination of your employment with PTC Therapeutics, Inc. (the &#8220;Company&#8221;) on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;">&#91;Termination Date&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">, you are eligible to receive the Severance Compensation as described in Section 4 of the Employment Agreement executed between you and the Company on &#91;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;">Insert Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">&#93; (the &#8220;Employment Agreement&#8221;) if you sign and return this letter agreement to me by </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;">&#91;Return Date &#8211; e.g., 21 days from date of receipt of this letter agreement&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">and it becomes binding between you and the Company.  By signing and returning this letter agreement and not revoking your acceptance, you will be agreeing to the terms and conditions set forth in the numbered paragraphs below, including the release of claims set forth in paragraph 3.  Therefore, you are advised to consult with an attorney before signing this letter agreement and you may take up to twenty-one (21) days to do so.  If you sign this letter agreement, you may change your mind and revoke your agreement during the seven (7) day period after you have signed it by notifying me  in writing.  If you do not so revoke, this letter agreement will become a binding agreement between you and the Company upon the expiration of the seven (7) day period.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">If you choose not to sign and return this letter agreement by </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;">&#91;Return Date-Same as Above&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">, or if you timely revoke your acceptance in writing, you shall not receive any Severance Compensation from the Company.  You will, however, receive payment for your final wages and any unused vacation time accrued through the Termination Date, as defined below, on the Company&#8217;s regular payroll date immediately following the Termination Date.  Also, regardless of signing this letter agreement, you may elect to continue receiving group medical insurance pursuant to the federal &#8220;COBRA&#8221; law, 29 U.S.C. &#167;&#160;1161 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">et</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">seq.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">  If you so elect, you shall pay all premium costs on a monthly basis for as long as, and to the extent that, you remain eligible for COBRA  continuation.  You should consult the COBRA materials to be provided by the Company for details regarding these benefits.  All other benefits will cease upon your Termination Date in accordance with the plan documents.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">The following numbered paragraphs set forth the terms and conditions that will apply if you timely sign and return this letter agreement and do not revoke it in writing within the seven (7) day period.</font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 2 -</font></div><div style="text-align:center;"><font><br></font></div></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration: underline;padding-left:9pt;">Termination Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> &#8211; Your effective date of termination from the Company is&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;">&#91;Insert Date&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> (the &#8220;Termination Date&#8221;).</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration: underline;padding-left:9pt;">Release</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> &#8211; In consideration of the payment of the Severance Compensation, which you acknowledge you would not otherwise be entitled to receive, you hereby fully, forever, irrevocably and unconditionally release, remise and discharge the Company, its affiliates, subsidiaries, parent companies, predecessors, and successors, and all of their respective past and present officers, directors, stockholders, partners, members, employees, agents, representatives, plan administrators, attorneys, insurers and fiduciaries (each in their individual and corporate capacities) (collectively, the &#8220;Released Parties&#8221;) from any and all claims, charges, complaints, demands, actions, causes of action, suits, rights, debts, sums of money, costs, accounts, reckonings, covenants, contracts, agreements, promises, doings, omissions, damages, executions, obligations, liabilities, and expenses (including attorneys&#8217; fees and costs), of every kind and nature that you ever had or now have against any or all of the Released Parties, including, but not limited to, any and all claims arising out of or relating to your employment with and&#47;or separation from the Company, including, but not limited to, all claims under Title VII of the Civil Rights Act of 1964, 42 U.S.C. &#167; 2000e </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">et seq.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">, the Americans With Disabilities Act of 1990, 42 U.S.C. &#167; 12101 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">et</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">seq.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">, the Age Discrimination in Employment Act, 29 U.S.C. &#167; 621 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">et seq.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">, the Genetic Information Nondiscrimination Act of 2008, 42 U.S.C. &#167; 2000ff </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">et</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">seq.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">, the Family and Medical Leave Act, 29 U.S.C. &#167; 2601 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">et</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">seq.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">, the Worker Adjustment and Retraining Notification Act (&#8220;WARN&#8221;), 29 U.S.C. &#167; 2101 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">et seq.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">, the Rehabilitation Act of 1973, 29 U.S.C. &#167; 701 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">et</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">seq.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">, Executive Order 11246, Executive Order 11141, the Fair Credit Reporting Act, 15 U.S.C. &#167; 1681 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">et</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">seq.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">, and the Employee Retirement Income Security Act of 1974 (&#8220;ERISA&#8221;), 29 U.S.C. &#167; 1001 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">et</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">seq.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">, all as amended&#59; all claims arising out of the New Jersey Law Against Discrimination, N.J. Stat. Ann.&#160;&#167;&#160;10&#58;5-1 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">et seq.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">, the New Jersey Family Leave Act, N.J. Stat. Ann. &#167; 34&#58;11B-1 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">et seq.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">, the New Jersey Conscientious Employee Protection Act, N.J. Stat. Ann. &#160;&#167;&#160;34&#58;19-1 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">et seq.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">, and the N.J. Stat. Ann.&#160;&#167;&#160;34&#58;11-56.1 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration: underline;">et seq.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> (New Jersey equal pay law), all as amended&#59; all common law claims including, but not limited to, actions in defamation, intentional infliction of emotional distress, misrepresentation, fraud, wrongful discharge, and breach of contract, including without limitation, all claims arising from the Employment Agreement&#59; all state and federal whistleblower claims to the maximum extent permitted by law&#59; all claims to any non-vested ownership interest in the Company, contractual or otherwise&#59; and any claim or damage arising out of your employment with and&#47;or separation from the Company (including a claim for retaliation) under any common law theory or any federal, state or local statute or ordinance not expressly referenced above&#59; provided, however, that nothing in this letter agreement shall (i) prevent you from filing a charge with, cooperating with, or participating in any proceeding before the Equal Employment Opportunity Commission or a state fair </font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 3 -</font></div><div style="text-align:center;"><font><br></font></div></div><div style="padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">employment practices agency (except that you acknowledge that you may not recover any monetary benefits in connection with any such claim, charge or proceeding) or (ii) deprive you of any rights you may have to be indemnified by the Company as provided in any agreement between the Company and you or pursuant to the Company&#8217;s Certificate of Incorporation or by-laws.</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration: underline;padding-left:9pt;">Non-Disclosure, Non-Competition and Non-Solicitation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">&#8211; You acknowledge and reaffirm your obligation to keep confidential and not disclose all non-public information concerning the Company and its clients that you acquired during the course of your employment with the Company, as stated more fully in Section 5 of the Employment Agreement,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">which remains in full force and effect.</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration: underline;padding-left:9pt;">Return of Company Property</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> &#8211; You confirm that you have returned to the Company all keys, files, records (and copies thereof), equipment (including, but not limited to, computer hardware, software and printers, wireless handheld devices, cellular phones, smartphones, tablets, etc.), Company identification, and any other Company-owned property in your possession or control and have left intact all electronic Company documents, including but not limited to those which you developed or helped to develop during your employment.  You further confirm that you have cancelled all accounts for your benefit, if any, in the Company's name, including but not limited to, credit cards, telephone charge cards, cellular phone and&#47;or wireless data accounts and computer accounts.</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration: underline;padding-left:9pt;">Business Expenses and Final Compensation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> &#8211; You acknowledge that you have been reimbursed by the Company for all business expenses incurred in conjunction with the performance of your employment and that no other reimbursements are owed to you.  You further acknowledge that you have received payment in full for all services rendered in conjunction with your employment by the Company, including payment for all wages, bonuses and accrued, unused vacation time, and that no other compensation is owed to you except as provided herein.</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration: underline;padding-left:9pt;">Non-Disparagement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> &#8211; To the extent permitted by law, you understand and agree that as a condition for payment to you of the Severance Compensation herein described, for a period of five years following the date hereof you shall not make any false, disparaging or derogatory statements to any person or entity, including any media outlet, regarding the Company or any of its directors, officers, employees, agents or representatives or about the Company&#8217;s business affairs and financial condition. Further, for a period of five years following the date hereof, neither the Company, nor any of its executive officers or members of its Board will directly or indirectly make, or cause to be made, any false statement, observation or opinion, disparaging your reputation.</font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 4 -</font></div><div style="text-align:center;"><font><br></font></div></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">7.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration: underline;padding-left:9pt;">Continued Assistance</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> - You agree that after the Termination Date you will provide all reasonable cooperation to the Company, including but not limited to, assisting the Company transition your job duties, assisting the Company in defending against and&#47;or prosecuting any litigation or threatened litigation, and performing any other tasks as reasonably requested by the Company.</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;">8.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration: underline;padding-left:9pt;">Cooperation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">&#8211; To the extent permitted by law, you agree to cooperate fully with the Company in the defense or prosecution of any claims or actions which already have been brought, are currently pending, or which may be brought in the future against or on behalf of the Company</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;">,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> whether before a state or federal court, any state or federal government agency, or a mediator or arbitrator.  Your full cooperation in connection with such claims or actions shall include, but not be limited to, being available to meet with counsel to prepare its claims or defenses, to prepare for trial or discovery or an administrative hearing or a mediation or arbitration and to act as a witness when requested by the Company at reasonable times designated by the Company.  You agree that you will notify the Company promptly in the event that you are served with a subpoena or in the event that you are asked to provide a third party with information concerning any actual or potential complaint or claim against the Company.</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;">9.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration: underline;padding-left:9pt;">Amendment and Waiver</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">&#8211; This letter agreement shall be binding upon the parties and may not be modified in any manner, except by an instrument in writing of concurrent or subsequent date signed by duly authorized representatives of the parties hereto.  This letter agreement is binding upon and shall inure to the benefit of the parties and their respective agents, assigns, heirs, executors, successors and administrators.  No delay or omission by the Company in exercising any right under this letter agreement shall operate as a waiver of that or any other right.  A waiver or consent given by the Company on any one occasion shall be effective only in that instance and shall not be construed as a bar to or waiver of any right on any other occasion.</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">10.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration: underline;padding-left:3pt;">Validity</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> &#8211; Should any provision of this letter agreement be declared or be determined by any court of competent jurisdiction to be illegal or invalid, the validity of the remaining parts, terms or provisions shall not be affected thereby and said illegal or invalid part, term or provision shall be deemed not to be a part of this letter agreement.</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">11.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration: underline;padding-left:3pt;">Confidentiality</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> &#8211; To the extent permitted by law, you understand and agree that as a condition for payment to you of the Severance Compensation herein described, the terms and contents of this letter agreement, and the contents of the negotiations and discussions resulting in this letter agreement, shall be maintained as confidential by you and your agents and representatives and shall not be disclosed except to the extent required by federal or state law or as otherwise agreed to in writing by the Company.</font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 5 -</font></div><div style="text-align:center;"><font><br></font></div></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">12.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration: underline;padding-left:3pt;">Nature of Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">&#8211; You understand and agree that this letter agreement is a severance agreement and does not constitute an admission of liability or wrongdoing on the part of the Company.</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">13.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration: underline;padding-left:3pt;">Acknowledgments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;"> &#8211; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">You acknowledge that you have been given at least twenty-one (21) days to consider this letter agreement, and that the Company advised you to consult with an attorney of your own choosing prior to signing this letter agreement.  You understand that you may revoke this letter agreement for a period of seven (7) days after you sign this letter agreement by notifying me in writing, and the letter agreement shall not be effective or enforceable until the expiration of this seven (7) day revocation period. You understand and agree that by entering into this agreement, you are waiving any and all rights or claims you might have under the Age Discrimination in Employment Act, as amended by the Older Workers Benefits Protection Act, and that you have received consideration beyond that to which you were previously entitled.</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">14.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration: underline;padding-left:3pt;">Voluntary Assent</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> &#8211; You affirm that no other promises or agreements of any kind have been made to or with you by any person or entity whatsoever to cause you to sign this letter agreement, and that you fully understand the meaning and intent of this letter agreement.  You state and represent that you have had an opportunity to fully discuss and review the terms of this letter agreement with an attorney.  You further state and represent that you have carefully read this letter agreement, understand the contents herein, freely and voluntarily assent to all of the terms and conditions hereof and sign your name of your own free act.</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">15.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration: underline;padding-left:3pt;">Applicable Law</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> &#8211; This letter agreement shall be interpreted and construed by the laws of the State of New Jersey, without regard to conflict of laws provisions.  You hereby irrevocably submit to and acknowledge and recognize the jurisdiction of the courts of the State of New Jersey, or if appropriate, a federal court located in the State of New Jersey (which courts, for purposes of this letter agreement, are the only courts of competent jurisdiction), over any suit, action or other proceeding arising out of, under or in connection with this letter agreement or the subject matter hereof.</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">16.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration: underline;padding-left:3pt;">Entire Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> &#8211; This letter agreement contains and constitutes the entire understanding and agreement between the parties hereto with respect to your Severance Compensation and the settlement of claims against the Company and cancels all previous oral and written negotiations, agreements and commitments in connection therewith.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;">  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">Nothing in this paragraph, however, shall modify, cancel or supersede your obligations set forth in paragraph 3 herein.</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">17.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration: underline;padding-left:3pt;">Tax Acknowledgement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;"> &#8211; In connection with the payments and consideration provided to you pursuant to this letter agreement, the Company shall withhold and remit to the tax </font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 6 -</font></div><div style="text-align:center;"><font><br></font></div></div><div style="padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">authorities the amounts required under applicable law, and you shall be responsible for all applicable taxes with respect to such payments and consideration under applicable law.  You acknowledge that you are not relying upon the advice or representation of the Company with respect to the tax treatment of any of the Severance Compensation set forth in Section 4 of the Employment Agreement.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">If you have any questions about the matters covered in this letter agreement, please call me at </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;">&#91;Insert Phone Number&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.</font></div><div style="padding-left:216pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">Very truly yours,</font></div><div style="padding-left:216pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">By&#58; &#160;__________________________________</font></div><div style="text-indent:-36pt;padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#91;Name&#93;</font></div><div style="text-indent:252pt;margin-bottom:24pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;">&#91;Title&#93;</font></div><div style="margin-bottom:19pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">I hereby agree to the terms and conditions set forth above.  I have been given at least twenty-one (21) days to consider this letter agreement and I have chosen to execute this on the date below.  I intend that this letter agreement will become a binding agreement between me and the Company if I do not revoke my acceptance in seven (7) days.</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:48.163%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:47.837%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">_____________________________</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;Insert Employee Name&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">_________________________</font></div><div style="margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Date</font></div></td></tr></table></div><div style="text-align:center;margin-top:3pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">To be returned to me</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">by </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;">&#91;Return Date &#8211; e.g., 21 days from date of receipt of this letter&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">.</font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><div id="i84187e9be43c4fcba8b93646692621d7_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">April 10, 2020</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Eric Pauwels</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">76 Lemoyne Lane </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Johns Island, SC 29455</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Dear Eric,</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Congratulations on your proposed appointment to Chief Business Officer of PTC Therapeutics, Inc. Your success with PTC has been impressive and we look forward to your continued contributions to PTC&#8217;s business and mission.  The effective date of your appointment is the date that your appointment is approved by the Board of Directors of PTC following receipt of a signed copy of this letter from you indicating your acceptance of your appointment.  In this new role you will report to our CEO and Founder, Stuart Peltz.  </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Outlined below are details of your appointment&#58;  </font></div><div><font><br></font></div><div style="text-indent:-18pt;padding-left:54pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt;">Your annual base salary will be increased to $490,000 annually, subject to deductions for taxes and other withholdings as required by law. Please allow 1 to 2 pay periods for your new base salary to be reflected in your paycheck. </font></div><div style="padding-left:54pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt;">Your bonus target will increase to 45.00% of your annual salaried earnings paid in accordance with the terms of conditions of PTC&#8217;s annual incentive compensation plan. </font></div><div><font><br></font></div><div style="text-indent:-18pt;padding-left:54pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt;">You will receive a one-time grant of 50,000 stock options to purchase shares of common stock of PTC, and 10,000 restricted stock units</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> subject to formal approval by the Compensation Committee of the Board of Directors (or a majority of PTC&#8217;s independent directors) and to the terms of the applicable grant agreements. The options will vest over four years, with 25% vesting on the one-year anniversary of your grant date and 6.25% vesting every three-month period thereafter over the following three years. The restricted stock units will vest over four years, with 25% vesting annually on the anniversary of the grant date.</font></div><div style="padding-left:36pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:54pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt;">This letter supersedes any other recent discussions or communications from PTC with respect to changes in your pay, title, role in the organization, or equity grants. All other terms of your employment with PTC will remain consistent with existing signed employment and equity agreements and applicable policies.</font></div><div><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">On behalf of PTC, let me again congratulate you on your proposed appointment.  Please return a signed copy of this letter to me by close of business on Monday, April 13</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">th</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, 2020. Feel free to contact me if you have any questions concerning this letter.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;">- 2 -</font></div><div style="text-align:center;"><font><br></font></div></div><div style="margin-top:3pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.910%;"><tr><td style="width:1.0%;"></td><td style="width:43.221%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:52.779%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sincerely,</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accepted by&#58;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Martin Rexroad</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Eric Pauwels</font></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Martin Rexroad</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Eric Pauwels</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SVP, Human Resources </font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">April 12, 2020</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cc&#58; Stuart Peltz</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></font></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;margin-bottom:6pt;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>ptct06302020ex-311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ib4bafe6e20644255bc31e1708b6cb8f8_1"></div><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit&#160;31.1</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATIONS</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, Stuart W. Peltz, certify that&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> I have reviewed this Quarterly Report on Form&#160;10-Q of PTC Therapeutics,&#160;Inc.&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:47.048%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:4.442%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:42.510%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; August 5, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; STUART W. PELTZ</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stuart W. Peltz</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Executive Officer)</font></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>ptct06302020ex-312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i1fc122886e4f49cda9f9ad9b90a7af7d_1"></div><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit&#160;31.2</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATIONS</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, Emily Hill, certify that&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> I have reviewed this Quarterly Report on Form&#160;10-Q of PTC Therapeutics,&#160;Inc.&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:47.048%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:4.442%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:42.510%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; August 5, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; EMILY HILL</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Emily Hill</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Financial Officer)</font></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>ptct06302020ex-321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="idfcc20834ba74218b6f4ae15cee985ec_1"></div><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit&#160;32.1</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION&#160;1350,</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the Quarterly Report on Form&#160;10-Q of PTC Therapeutics,&#160;Inc. (the &#8220;Company&#8221;) for the period ended June&#160;30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Stuart W. Peltz, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, that to his knowledge&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> the Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934&#59; and</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:47.048%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:4.442%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:42.510%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; August 5, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; STUART W. PELTZ</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stuart W. Peltz</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Executive Officer)</font></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>ptct06302020ex-322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i0de99a2ac67942c9b7a590cab99aa7c1_1"></div><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit&#160;32.2</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION&#160;1350,</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the Quarterly Report on Form&#160;10-Q of PTC Therapeutics,&#160;Inc. (the &#8220;Company&#8221;) for the period ended June&#160;30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Emily Hill, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, that to his knowledge&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:38.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> the Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934&#59; and</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:38.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:47.048%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:4.588%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:42.364%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; August 5, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; EMILY HILL</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Emily Hill</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:1pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Financial Officer)</font></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>ptct-20200630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:a91ddaa9-e688-473f-b70e-08f6db5630cb,g:e05438c1-8a2e-4af1-b39d-a16533f5ad44-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ptct="http://www.ptcbio.com/20200630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.ptcbio.com/20200630">
  <xs:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ptct-20200630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ptct-20200630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ptct-20200630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ptct-20200630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.ptcbio.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsunaudited" roleURI="http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited">
        <link:definition>1001002 - Statement - Consolidated Balance Sheets (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsunauditedParenthetical" roleURI="http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunauditedParenthetical">
        <link:definition>1002003 - Statement - Consolidated Balance Sheets (unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsunaudited" roleURI="http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited">
        <link:definition>1003004 - Statement - Consolidated Statements of Operations (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLossunaudited" roleURI="http://www.ptcbio.com/role/ConsolidatedStatementsofComprehensiveLossunaudited">
        <link:definition>1004005 - Statement - Consolidated Statements of Comprehensive Loss (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.ptcbio.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>1005006 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlowsunaudited" roleURI="http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited">
        <link:definition>1006007 - Statement - Consolidated Statements of Cash Flows (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheCompany" roleURI="http://www.ptcbio.com/role/TheCompany">
        <link:definition>2101101 - Disclosure - The Company</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheCompanyNarrativeDetails" roleURI="http://www.ptcbio.com/role/TheCompanyNarrativeDetails">
        <link:definition>2402401 - Disclosure - The Company - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Summaryofsignificantaccountingpolicies" roleURI="http://www.ptcbio.com/role/Summaryofsignificantaccountingpolicies">
        <link:definition>2103102 - Disclosure - Summary of significant accounting policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesPolicies" roleURI="http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of significant accounting policies - (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesTables" roleURI="http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesTables">
        <link:definition>2305301 - Disclosure - Summary of significant accounting policies - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesInventoryDetails" roleURI="http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesInventoryDetails">
        <link:definition>2406402 - Disclosure - Summary of significant accounting policies - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesNarrativeDetails" roleURI="http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails">
        <link:definition>2407403 - Disclosure - Summary of significant accounting policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesReconciliationofcashDetails" roleURI="http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesReconciliationofcashDetails">
        <link:definition>2408404 - Disclosure - Summary of significant accounting policies - Reconciliation of cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.ptcbio.com/role/Leases">
        <link:definition>2109103 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.ptcbio.com/role/LeasesTables">
        <link:definition>2310302 - Disclosure - Leases - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.ptcbio.com/role/LeasesNarrativeDetails">
        <link:definition>2411405 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeasecostsDetails" roleURI="http://www.ptcbio.com/role/LeasesLeasecostsDetails">
        <link:definition>2412406 - Disclosure - Leases - Lease costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesBalancesheetDetails" roleURI="http://www.ptcbio.com/role/LeasesBalancesheetDetails">
        <link:definition>2413407 - Disclosure - Leases - Balance sheet (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalleasetermsDetails" roleURI="http://www.ptcbio.com/role/LeasesSupplementalleasetermsDetails">
        <link:definition>2414408 - Disclosure - Leases - Supplemental lease terms (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeasepaymentsDetails" roleURI="http://www.ptcbio.com/role/LeasesLeasepaymentsDetails">
        <link:definition>2415409 - Disclosure - Leases - Lease payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeasepaymentsDetails_1" roleURI="http://www.ptcbio.com/role/LeasesLeasepaymentsDetails_1">
        <link:definition>2415409 - Disclosure - Leases - Lease payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesCashflowDetails" roleURI="http://www.ptcbio.com/role/LeasesCashflowDetails">
        <link:definition>2416410 - Disclosure - Leases - Cash flow (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitions" roleURI="http://www.ptcbio.com/role/Acquisitions">
        <link:definition>2117104 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsNarrativeDetails" roleURI="http://www.ptcbio.com/role/AcquisitionsNarrativeDetails">
        <link:definition>2418411 - Disclosure - Acquisitions - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsPreliminaryAllocationofpurchasepriceDetails" roleURI="http://www.ptcbio.com/role/AcquisitionsPreliminaryAllocationofpurchasepriceDetails">
        <link:definition>2419412 - Disclosure - Acquisitions - Preliminary Allocation of purchase price (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Fairvalueoffinancialinstrumentsandmarketablesecurities" roleURI="http://www.ptcbio.com/role/Fairvalueoffinancialinstrumentsandmarketablesecurities">
        <link:definition>2120105 - Disclosure - Fair value of financial instruments and marketable securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvalueoffinancialinstrumentsandmarketablesecuritiesTables" roleURI="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesTables">
        <link:definition>2321303 - Disclosure - Fair value of financial instruments and marketable securities - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails" roleURI="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails">
        <link:definition>2422413 - Disclosure - Fair value of financial instruments and marketable securities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvalueoffinancialinstrumentsandmarketablesecuritiesHierarchyDetails" roleURI="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesHierarchyDetails">
        <link:definition>2423414 - Disclosure - Fair value of financial instruments and marketable securities - Hierarchy (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvalueoffinancialinstrumentsandmarketablesecuritiesAvailableforsaleDetails" roleURI="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesAvailableforsaleDetails">
        <link:definition>2424415 - Disclosure - Fair value of financial instruments and marketable securities - Available for sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvalueoffinancialinstrumentsandmarketablesecuritiesFairValueMeasurementInputsandValuationTechniquesDetails" roleURI="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesFairValueMeasurementInputsandValuationTechniquesDetails">
        <link:definition>2425416 - Disclosure - Fair value of financial instruments and marketable securities - Fair Value Measurement Inputs and Valuation Techniques (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvalueoffinancialinstrumentsandmarketablesecuritiesUnrealizedLossPositionsDetails" roleURI="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesUnrealizedLossPositionsDetails">
        <link:definition>2426417 - Disclosure - Fair value of financial instruments and marketable securities - Unrealized Loss Positions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvalueoffinancialinstrumentsandmarketablesecuritiesMarketablesecuritiesDetails" roleURI="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesMarketablesecuritiesDetails">
        <link:definition>2427418 - Disclosure - Fair value of financial instruments and marketable securities - Marketable securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails" roleURI="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails">
        <link:definition>2428419 - Disclosure - Fair value of financial instruments and marketable securities - Warrants and SARs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Othercomprehensiveincomelossandaccumulatedothercomprehensiveitems" roleURI="http://www.ptcbio.com/role/Othercomprehensiveincomelossandaccumulatedothercomprehensiveitems">
        <link:definition>2129106 - Disclosure - Other comprehensive income (loss) and accumulated other comprehensive items</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OthercomprehensiveincomelossandaccumulatedothercomprehensiveitemsTables" roleURI="http://www.ptcbio.com/role/OthercomprehensiveincomelossandaccumulatedothercomprehensiveitemsTables">
        <link:definition>2330304 - Disclosure - Other comprehensive income (loss) and accumulated other comprehensive items - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OthercomprehensiveincomelossandaccumulatedothercomprehensiveitemsNarrativeDetails" roleURI="http://www.ptcbio.com/role/OthercomprehensiveincomelossandaccumulatedothercomprehensiveitemsNarrativeDetails">
        <link:definition>2431420 - Disclosure - Other comprehensive income (loss) and accumulated other comprehensive items - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Accountspayableandaccruedexpenses" roleURI="http://www.ptcbio.com/role/Accountspayableandaccruedexpenses">
        <link:definition>2132107 - Disclosure - Accounts payable and accrued expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountspayableandaccruedexpensesTables" roleURI="http://www.ptcbio.com/role/AccountspayableandaccruedexpensesTables">
        <link:definition>2333305 - Disclosure - Accounts payable and accrued expenses - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountspayableandaccruedexpensesNarrativeDetails" roleURI="http://www.ptcbio.com/role/AccountspayableandaccruedexpensesNarrativeDetails">
        <link:definition>2434421 - Disclosure - Accounts payable and accrued expenses - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Capitalization" roleURI="http://www.ptcbio.com/role/Capitalization">
        <link:definition>2135108 - Disclosure - Capitalization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalizationNarrativeDetails" roleURI="http://www.ptcbio.com/role/CapitalizationNarrativeDetails">
        <link:definition>2436422 - Disclosure - Capitalization - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Netlosspershare" roleURI="http://www.ptcbio.com/role/Netlosspershare">
        <link:definition>2137109 - Disclosure - Net loss per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetlosspershareTables" roleURI="http://www.ptcbio.com/role/NetlosspershareTables">
        <link:definition>2338306 - Disclosure - Net loss per share - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetlosspershareNumeratorandDenominatorDetails" roleURI="http://www.ptcbio.com/role/NetlosspershareNumeratorandDenominatorDetails">
        <link:definition>2439423 - Disclosure - Net loss per share - Numerator and Denominator (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetlosspershareAntidilutiveDetails" roleURI="http://www.ptcbio.com/role/NetlosspershareAntidilutiveDetails">
        <link:definition>2440424 - Disclosure - Net loss per share - Antidilutive (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Stockawardplan" roleURI="http://www.ptcbio.com/role/Stockawardplan">
        <link:definition>2141110 - Disclosure - Stock award plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockawardplanTables" roleURI="http://www.ptcbio.com/role/StockawardplanTables">
        <link:definition>2342307 - Disclosure - Stock award plan - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockawardplanNarrativeDetails" roleURI="http://www.ptcbio.com/role/StockawardplanNarrativeDetails">
        <link:definition>2443425 - Disclosure - Stock award plan - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockawardplanShareBaseCompensationDetails" roleURI="http://www.ptcbio.com/role/StockawardplanShareBaseCompensationDetails">
        <link:definition>2444426 - Disclosure - Stock award plan - Share Base Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockawardplanRestrictedStockDetails" roleURI="http://www.ptcbio.com/role/StockawardplanRestrictedStockDetails">
        <link:definition>2445427 - Disclosure - Stock award plan - Restricted Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockawardplanSharebasedcompensationexpenseDetails" roleURI="http://www.ptcbio.com/role/StockawardplanSharebasedcompensationexpenseDetails">
        <link:definition>2446428 - Disclosure - Stock award plan - Share-based compensation expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.ptcbio.com/role/Debt">
        <link:definition>2147111 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.ptcbio.com/role/DebtTables">
        <link:definition>2348308 - Disclosure - Debt - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://www.ptcbio.com/role/DebtNarrativeDetails">
        <link:definition>2449429 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtConvertibleNotesDetails" roleURI="http://www.ptcbio.com/role/DebtConvertibleNotesDetails">
        <link:definition>2450430 - Disclosure - Debt - Convertible Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtInterestExpenseDetails" roleURI="http://www.ptcbio.com/role/DebtInterestExpenseDetails">
        <link:definition>2451431 - Disclosure - Debt - Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Commitmentsandcontingencies" roleURI="http://www.ptcbio.com/role/Commitmentsandcontingencies">
        <link:definition>2152112 - Disclosure - Commitments and contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandcontingenciesNarrativeDetails" roleURI="http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails">
        <link:definition>2453432 - Disclosure - Commitments and contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenuerecognition" roleURI="http://www.ptcbio.com/role/Revenuerecognition">
        <link:definition>2154113 - Disclosure - Revenue recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuerecognitionNarrativeDetails" roleURI="http://www.ptcbio.com/role/RevenuerecognitionNarrativeDetails">
        <link:definition>2455433 - Disclosure - Revenue recognition - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuerecognitionPerformanceObligationsDetails" roleURI="http://www.ptcbio.com/role/RevenuerecognitionPerformanceObligationsDetails">
        <link:definition>2456434 - Disclosure - Revenue recognition - Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuerecognitionPerformanceObligationsDetails_1" roleURI="http://www.ptcbio.com/role/RevenuerecognitionPerformanceObligationsDetails_1">
        <link:definition>2456434 - Disclosure - Revenue recognition - Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Intangibleassetsandgoodwill" roleURI="http://www.ptcbio.com/role/Intangibleassetsandgoodwill">
        <link:definition>2157114 - Disclosure - Intangible assets and goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsandgoodwillTables" roleURI="http://www.ptcbio.com/role/IntangibleassetsandgoodwillTables">
        <link:definition>2358309 - Disclosure - Intangible assets and goodwill - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsandgoodwillNarrativeDetails" roleURI="http://www.ptcbio.com/role/IntangibleassetsandgoodwillNarrativeDetails">
        <link:definition>2459435 - Disclosure - Intangible assets and goodwill - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsandgoodwillFutureAmortizationDetails" roleURI="http://www.ptcbio.com/role/IntangibleassetsandgoodwillFutureAmortizationDetails">
        <link:definition>2460436 - Disclosure - Intangible assets and goodwill - Future Amortization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Subsequentevents" roleURI="http://www.ptcbio.com/role/Subsequentevents">
        <link:definition>2161115 - Disclosure - Subsequent events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequenteventsNarrativeDetails" roleURI="http://www.ptcbio.com/role/SubsequenteventsNarrativeDetails">
        <link:definition>2462437 - Disclosure - Subsequent events Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ptct_BioElectronMember" abstract="true" name="BioElectronMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ptct_SharesIssuedAssetAcquisition" abstract="false" name="SharesIssuedAssetAcquisition" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_PaymentsToAcquireConvertibleDebtInvestment" abstract="false" name="PaymentsToAcquireConvertibleDebtInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member" abstract="true" name="ConvertibleSeniorNotes1.5DueSeptember152026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ptct_StockIssuedDuringPeriodSharesExchangeRights" abstract="false" name="StockIssuedDuringPeriodSharesExchangeRights" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ptct_LineOfCreditFacilityAdditionalCapacityAvailable" abstract="false" name="LineOfCreditFacilityAdditionalCapacityAvailable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_LongTermIncentivePlan2013Member" abstract="true" name="LongTermIncentivePlan2013Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ptct_CashconsiderationpaymentunderRightsExchangeAgreement" abstract="false" name="CashconsiderationpaymentunderRightsExchangeAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod" abstract="false" name="BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ptct_EmployeeDirectorAndConsultantStockOptionPlanMember" abstract="false" name="EmployeeDirectorAndConsultantStockOptionPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ptct_DevelopmentandPotentialRegulatoryApprovalPaymentObligation" abstract="false" name="DevelopmentandPotentialRegulatoryApprovalPaymentObligation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_A2020inducementstockincentiveplanMember" abstract="true" name="A2020inducementstockincentiveplanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture" abstract="false" name="ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_ProceedsAssignedRoyaltyPaymentAgreement" abstract="false" name="ProceedsAssignedRoyaltyPaymentAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_MilestonePaymentObligations" abstract="false" name="MilestonePaymentObligations" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ptct_PaymentsforAssetAcquisitions" abstract="false" name="PaymentsforAssetAcquisitions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_DiscoveryAgreementsMember" abstract="true" name="DiscoveryAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ptct_SettlementOfDeferredAndContingentConsideration" abstract="false" name="SettlementOfDeferredAndContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_NumberOfOperatingLeases" abstract="false" name="NumberOfOperatingLeases" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ptct_ProbabilityofSuccessMember" abstract="true" name="ProbabilityofSuccessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ptct_RoyaltyPurchaseAgreementPaymentMaximum" abstract="false" name="RoyaltyPurchaseAgreementPaymentMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_GainOfSettlementDevelopmentMilestones" abstract="false" name="GainOfSettlementDevelopmentMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_ContingentLiabilityCancellationAndForfeitureMilestonePotentialAchievementsPriorityReviewVoucherAmount" abstract="false" name="ContingentLiabilityCancellationAndForfeitureMilestonePotentialAchievementsPriorityReviewVoucherAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_NumberOfOperatingLeaseLeaseNotyetCommenced" abstract="false" name="NumberOfOperatingLeaseLeaseNotyetCommenced" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ptct_HopewellCampusMember" abstract="true" name="HopewellCampusMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ptct_SaleOfStockWeightedAveragePricePerShare" abstract="false" name="SaleOfStockWeightedAveragePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="ptct_CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology" abstract="false" name="CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ptct_AssetAcquisitionNetSalesMilestone" abstract="false" name="AssetAcquisitionNetSalesMilestone" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_AssetAcquisitionInProcessResearchAndDevelopment" abstract="false" name="AssetAcquisitionInProcessResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_ConvertibleSeniorNotes3.0PercentDue2022Member" abstract="true" name="ConvertibleSeniorNotes3.0PercentDue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ptct_RoyaltyPurchaseAgreementTerminationPeriod" abstract="false" name="RoyaltyPurchaseAgreementTerminationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ptct_AssetAcquisitionSellingGeneralAndAdministrativeExpense" abstract="false" name="AssetAcquisitionSellingGeneralAndAdministrativeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_PaymentOfFinanceLeasePrincipal" abstract="false" name="PaymentOfFinanceLeasePrincipal" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_ContingentLiabilityCancellationAndForfeiture" abstract="false" name="ContingentLiabilityCancellationAndForfeiture" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ptct_AssetAcquisitionOtherAssets" abstract="false" name="AssetAcquisitionOtherAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod" abstract="false" name="DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ptct_DebtInstrumentConvertiblePeriod" abstract="false" name="DebtInstrumentConvertiblePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ptct_FinanceLeaseMember" abstract="true" name="FinanceLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent" abstract="false" name="BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_PaymentsForAssetAcquisitionsNetAssets" abstract="false" name="PaymentsForAssetAcquisitionsNetAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_LicensingAndCollaborationAgreementMember" abstract="true" name="LicensingAndCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ptct_NetProductSales" abstract="false" name="NetProductSales" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_Percentageofnetproductsales" abstract="false" name="Percentageofnetproductsales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ptct_BridgewaterMember" abstract="true" name="BridgewaterMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ptct_DevelopmentMilestonePaymentObligationsCancellationAndForfeiture" abstract="false" name="DevelopmentMilestonePaymentObligationsCancellationAndForfeiture" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount" abstract="false" name="ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing" abstract="false" name="DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_AssignedRoyaltyPaymentPercentage" abstract="false" name="AssignedRoyaltyPaymentPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ptct_DepositsAndOtherAssetsNoncurrent" abstract="false" name="DepositsAndOtherAssetsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_RightsExchangeAgreementMember" abstract="true" name="RightsExchangeAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ptct_LossOfSettlementRegulatoryMilestones" abstract="false" name="LossOfSettlementRegulatoryMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_InventoriesAndCostOfProductSalesPolicyTextBlock" abstract="false" name="InventoriesAndCostOfProductSalesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="ptct_Termforletterofcredit" abstract="false" name="Termforletterofcredit" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ptct_AssetAcquisitionConsiderationTransferred" abstract="false" name="AssetAcquisitionConsiderationTransferred" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_AssetAcquisitionCash" abstract="false" name="AssetAcquisitionCash" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_UpfrontLicensingFee" abstract="false" name="UpfrontLicensingFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture" abstract="false" name="DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_SalesRebatesAndRoyaltiesCurrent" abstract="false" name="SalesRebatesAndRoyaltiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity" abstract="false" name="BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_EarlyStageCollaborationsMember" abstract="true" name="EarlyStageCollaborationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ptct_UnrealizedGainLossonConvertibleSecurities" abstract="false" name="UnrealizedGainLossonConvertibleSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_MilestoneAxis" abstract="true" name="MilestoneAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="ptct_MilestonePotentialAchievementsRegulatoryApproval" abstract="false" name="MilestonePotentialAchievementsRegulatoryApproval" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_HopewellNewBuildingMember" abstract="true" name="HopewellNewBuildingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ptct_DebtInstrumentAdditionalAmountAvailableForRepurchase" abstract="false" name="DebtInstrumentAdditionalAmountAvailableForRepurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_SharestoissueunderRightsExchangeAgreement" abstract="false" name="SharestoissueunderRightsExchangeAgreement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ptct_RestrictedStockAndRestrictedStockUnitsMember" abstract="true" name="RestrictedStockAndRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ptct_MarathonPharmaceuticalsLLCMember" abstract="true" name="MarathonPharmaceuticalsLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ptct_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsRightsExchangeSettlement" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsRightsExchangeSettlement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue" abstract="false" name="AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_AccruedConsultingAndContractedResearchCurrent" abstract="false" name="AccruedConsultingAndContractedResearchCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member" abstract="true" name="DebtInstrumentConversionPeriodOnOrAfterAugust202018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ptct_DebtInstrumentInterestPaymentPeriod" abstract="false" name="DebtInstrumentInterestPaymentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ptct_LeaseArea" abstract="false" name="LeaseArea" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:areaItemType"/>
  <xs:element id="ptct_MassBioMember" abstract="true" name="MassBioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ptct_InvestmentInMRI" abstract="false" name="InvestmentInMRI" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_AlternativeInvestmentMilestone" abstract="false" name="AlternativeInvestmentMilestone" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_StockIncentivePlan2013Member" abstract="true" name="StockIncentivePlan2013Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ptct_RevenueRecognitionMilestonePotentialAchievements" abstract="false" name="RevenueRecognitionMilestonePotentialAchievements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_OperatingLeaseCostNonCash" abstract="false" name="OperatingLeaseCostNonCash" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_EquityAndLongTermIncentivePlan2009Member" abstract="true" name="EquityAndLongTermIncentivePlan2009Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ptct_ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock" abstract="false" name="ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="ptct_MidCapFinancialTrustMember" abstract="true" name="MidCapFinancialTrustMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ptct_DebtInstrumentFloorInterestRate" abstract="false" name="DebtInstrumentFloorInterestRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ptct_StockAppreciationRightsLiabilityOutstanding" abstract="false" name="StockAppreciationRightsLiabilityOutstanding" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter" abstract="false" name="FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_ConsiderationForAssetAcquisitions" abstract="false" name="ConsiderationForAssetAcquisitions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_AssignedRoyaltyPaymentRetainedPercentage" abstract="false" name="AssignedRoyaltyPaymentRetainedPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ptct_ResearchAndDevelopmentEventMilestonesMember" abstract="true" name="ResearchAndDevelopmentEventMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ptct_FifthAnniversaryMember" abstract="true" name="FifthAnniversaryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ptct_PotentialNetSalesMilestonesDomain" abstract="true" name="PotentialNetSalesMilestonesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ptct_DebtInstrumentConvertibleThresholdBusinessDays" abstract="false" name="DebtInstrumentConvertibleThresholdBusinessDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ptct_CensaMember" abstract="true" name="CensaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ptct_CesnaMember" abstract="true" name="CesnaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ptct_AssetAcquisitionMilestoneAmount" abstract="false" name="AssetAcquisitionMilestoneAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_SalesAllowanceAndOtherRelatedCosts" abstract="false" name="SalesAllowanceAndOtherRelatedCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_LineOfCreditFacilityTerminationAndExitFees" abstract="false" name="LineOfCreditFacilityTerminationAndExitFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member" abstract="true" name="Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ptct_MountainviewMember" abstract="true" name="MountainviewMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone" abstract="false" name="ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_SharesissuedunderRightsExchangeAgreement" abstract="false" name="SharesissuedunderRightsExchangeAgreement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ptct_AgilisMember" abstract="true" name="AgilisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ptct_ContingentConsiderationTransactionFees" abstract="false" name="ContingentConsiderationTransactionFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault" abstract="false" name="ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ptct_EmflazaassetacquisitionMember" abstract="true" name="EmflazaassetacquisitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ptct_LiabilityNetSalesMilestonesandRoyaltiesMember" abstract="true" name="LiabilityNetSalesMilestonesandRoyaltiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ptct_CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets" abstract="false" name="CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_PercentageofSalesforRoyaltiesMember" abstract="true" name="PercentageofSalesforRoyaltiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ptct_DevelopmentandRegulatoryMilestoneMember" abstract="true" name="DevelopmentandRegulatoryMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ptct_Numberofdistributors" abstract="false" name="Numberofdistributors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ptct_PercentOfMarketRate" abstract="false" name="PercentOfMarketRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ptct_DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum" abstract="false" name="DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ptct_TheCampusMember" abstract="true" name="TheCampusMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ptct_EmployeeStockPurchasePlanVotingPercentageLimitPercent" abstract="false" name="EmployeeStockPurchasePlanVotingPercentageLimitPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ptct_MilestoneDomain" abstract="true" name="MilestoneDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ptct_AssetAcquisitionResearchAndDevelopmentExpense" abstract="false" name="AssetAcquisitionResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_PaymentsForAssetAcquisitionsUpfrontPayment" abstract="false" name="PaymentsForAssetAcquisitionsUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders" abstract="false" name="MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ptct_AssetAcquisitionDevelopmentAndRegulatoryMilestones" abstract="false" name="AssetAcquisitionDevelopmentAndRegulatoryMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_PaymentsOnDeferredConsiderationObligation" abstract="false" name="PaymentsOnDeferredConsiderationObligation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_GrantAndCollaborationMember" abstract="true" name="GrantAndCollaborationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable" abstract="false" name="BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_FinanceLeasePresentValueOfExceedsTheFairValue" abstract="false" name="FinanceLeasePresentValueOfExceedsTheFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_Numberofterms" abstract="false" name="Numberofterms" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ptct_LiabilityDevelopmentandRegulatoryMilestoneMember" abstract="true" name="LiabilityDevelopmentandRegulatoryMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ptct_SalesMilestonesMember" abstract="true" name="SalesMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ptct_SharesremainingtoissueunderRightsExchangeAgreement" abstract="false" name="SharesremainingtoissueunderRightsExchangeAgreement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ptct_AssetAcquisitionInitialMilestone" abstract="false" name="AssetAcquisitionInitialMilestone" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_AssetAcquisitionTransactionCosts" abstract="false" name="AssetAcquisitionTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_LoanAdvance" abstract="false" name="LoanAdvance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_NetDeferredTaxLiabilitiesConvertibleDebtInstruments" abstract="false" name="NetDeferredTaxLiabilitiesConvertibleDebtInstruments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_StockIssuedDuringPeriodValueExchangeRights" abstract="false" name="StockIssuedDuringPeriodValueExchangeRights" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_FinanceLeaseCostNonCash" abstract="false" name="FinanceLeaseCostNonCash" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage" abstract="false" name="ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ptct_WellcomeTrustLimitedMember" abstract="true" name="WellcomeTrustLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ptct_CollaborationAndDiscoveryAgreementsMember" abstract="true" name="CollaborationAndDiscoveryAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ptct_AkceaMember" abstract="true" name="AkceaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>ptct-20200630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:a91ddaa9-e688-473f-b70e-08f6db5630cb,g:e05438c1-8a2e-4af1-b39d-a16533f5ad44-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ptcbio.com/role/Cover" xlink:type="simple" xlink:href="ptct-20200630.xsd#Cover"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/Cover" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited" xlink:type="simple" xlink:href="ptct-20200630.xsd#ConsolidatedBalanceSheetsunaudited"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_05893656-980e-4f9c-bf8e-a5fd9804b292" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7e0a3ee3-38c4-4705-a223-857fd852364c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_05893656-980e-4f9c-bf8e-a5fd9804b292" xlink:to="loc_us-gaap_LiabilitiesCurrent_7e0a3ee3-38c4-4705-a223-857fd852364c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_63099c3e-e71f-42a3-9c03-daca005a05e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_05893656-980e-4f9c-bf8e-a5fd9804b292" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_63099c3e-e71f-42a3-9c03-daca005a05e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_c087529f-0a6a-4db2-be94-18e907e104c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_05893656-980e-4f9c-bf8e-a5fd9804b292" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_c087529f-0a6a-4db2-be94-18e907e104c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_6c4529ca-a23f-4c49-a5e8-c47d039bc9d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_05893656-980e-4f9c-bf8e-a5fd9804b292" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_6c4529ca-a23f-4c49-a5e8-c47d039bc9d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_e18aa2b0-d14e-41ce-a498-a091a415a147" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_05893656-980e-4f9c-bf8e-a5fd9804b292" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_e18aa2b0-d14e-41ce-a498-a091a415a147" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_55cd7646-e929-412c-8ba3-021fb1cbc2ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_05893656-980e-4f9c-bf8e-a5fd9804b292" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_55cd7646-e929-412c-8ba3-021fb1cbc2ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_0d39ed0f-8693-4a5e-bb55-31f8a63ae28d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_05893656-980e-4f9c-bf8e-a5fd9804b292" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_0d39ed0f-8693-4a5e-bb55-31f8a63ae28d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_10a4d9e3-4219-4204-afe8-b6cdbfea32ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2c569f58-2f74-4d31-8a72-240fc45167da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_10a4d9e3-4219-4204-afe8-b6cdbfea32ee" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2c569f58-2f74-4d31-8a72-240fc45167da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_9048b396-dfb9-4ace-9385-58d347b3b1fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_10a4d9e3-4219-4204-afe8-b6cdbfea32ee" xlink:to="loc_us-gaap_LongTermDebtCurrent_9048b396-dfb9-4ace-9385-58d347b3b1fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_37bc2868-154b-4dae-bba4-3128363beef8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_10a4d9e3-4219-4204-afe8-b6cdbfea32ee" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_37bc2868-154b-4dae-bba4-3128363beef8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_b6e5e273-b899-401b-ac5b-424b502bdccf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_10a4d9e3-4219-4204-afe8-b6cdbfea32ee" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_b6e5e273-b899-401b-ac5b-424b502bdccf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent_1b9c81f2-ce22-40df-8ee4-a8bb87bacd45" xlink:href="ptct-20200630.xsd#ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_10a4d9e3-4219-4204-afe8-b6cdbfea32ee" xlink:to="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent_1b9c81f2-ce22-40df-8ee4-a8bb87bacd45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_3fe6ce8e-c169-433d-87ec-0873fd5cad86" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_10a4d9e3-4219-4204-afe8-b6cdbfea32ee" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_3fe6ce8e-c169-433d-87ec-0873fd5cad86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_a24bd99a-40a0-47aa-be3a-eafaf80699d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_81385b9a-971b-465a-b383-33ae75daa4b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a24bd99a-40a0-47aa-be3a-eafaf80699d5" xlink:to="loc_us-gaap_AssetsCurrent_81385b9a-971b-465a-b383-33ae75daa4b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_10d1688c-edd2-44b4-b36c-5135b2d89e5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a24bd99a-40a0-47aa-be3a-eafaf80699d5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_10d1688c-edd2-44b4-b36c-5135b2d89e5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DepositsAndOtherAssetsNoncurrent_a11c5524-59e4-4a82-862f-6a387180f1e9" xlink:href="ptct-20200630.xsd#ptct_DepositsAndOtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a24bd99a-40a0-47aa-be3a-eafaf80699d5" xlink:to="loc_ptct_DepositsAndOtherAssetsNoncurrent_a11c5524-59e4-4a82-862f-6a387180f1e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_988dad65-12fe-400f-ab71-f6f96cd4bb4b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a24bd99a-40a0-47aa-be3a-eafaf80699d5" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_988dad65-12fe-400f-ab71-f6f96cd4bb4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_673a30b4-36f9-4b3a-a57b-4982beb7b264" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a24bd99a-40a0-47aa-be3a-eafaf80699d5" xlink:to="loc_us-gaap_Goodwill_673a30b4-36f9-4b3a-a57b-4982beb7b264" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8fac89b1-52e2-4e4e-921f-f9cb745208d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f4b2def8-a608-4f05-bb14-07e973323be8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8fac89b1-52e2-4e4e-921f-f9cb745208d2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f4b2def8-a608-4f05-bb14-07e973323be8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_02ffe220-f319-481a-8a5f-aba337282357" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8fac89b1-52e2-4e4e-921f-f9cb745208d2" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_02ffe220-f319-481a-8a5f-aba337282357" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_643098b6-8916-4fe4-ba1b-5b04d0774a43" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8fac89b1-52e2-4e4e-921f-f9cb745208d2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_643098b6-8916-4fe4-ba1b-5b04d0774a43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_b5f12ece-cb2f-42c3-bd9a-735382ff5f14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8fac89b1-52e2-4e4e-921f-f9cb745208d2" xlink:to="loc_us-gaap_ReceivablesNetCurrent_b5f12ece-cb2f-42c3-bd9a-735382ff5f14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_7890bc79-c779-4b1e-a34c-173362cf3ca5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8fac89b1-52e2-4e4e-921f-f9cb745208d2" xlink:to="loc_us-gaap_InventoryNet_7890bc79-c779-4b1e-a34c-173362cf3ca5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6d4187f9-f939-4112-a36c-68d292988fc6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_864ff759-af8c-416d-a040-5ec9548e19c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6d4187f9-f939-4112-a36c-68d292988fc6" xlink:to="loc_us-gaap_CommonStockValue_864ff759-af8c-416d-a040-5ec9548e19c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_549dd2de-483a-4423-af86-2971c99f230b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6d4187f9-f939-4112-a36c-68d292988fc6" xlink:to="loc_us-gaap_AdditionalPaidInCapital_549dd2de-483a-4423-af86-2971c99f230b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7bba9c33-e68f-430c-adbe-a6b6276b3a32" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6d4187f9-f939-4112-a36c-68d292988fc6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7bba9c33-e68f-430c-adbe-a6b6276b3a32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_fc9d771b-808b-4b3f-996f-e52588672125" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6d4187f9-f939-4112-a36c-68d292988fc6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_fc9d771b-808b-4b3f-996f-e52588672125" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ed7bba9a-4ba4-461e-8959-76f3a93aae65" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6f531849-56a2-4fa4-8978-63d321434e38" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ed7bba9a-4ba4-461e-8959-76f3a93aae65" xlink:to="loc_us-gaap_Liabilities_6f531849-56a2-4fa4-8978-63d321434e38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7ba57249-5be9-45bf-a104-b27b14427159" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ed7bba9a-4ba4-461e-8959-76f3a93aae65" xlink:to="loc_us-gaap_StockholdersEquity_7ba57249-5be9-45bf-a104-b27b14427159" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunauditedParenthetical" xlink:type="simple" xlink:href="ptct-20200630.xsd#ConsolidatedBalanceSheetsunauditedParenthetical"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunauditedParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited" xlink:type="simple" xlink:href="ptct-20200630.xsd#ConsolidatedStatementsofOperationsunaudited"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_09156ba0-9b6d-4207-b029-3e9f71a92d1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_47e66404-171f-4985-bb65-058a12dc0e93" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_09156ba0-9b6d-4207-b029-3e9f71a92d1d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_47e66404-171f-4985-bb65-058a12dc0e93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_dd7d8518-dd05-408e-aa7d-b0d235701a90" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_09156ba0-9b6d-4207-b029-3e9f71a92d1d" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_dd7d8518-dd05-408e-aa7d-b0d235701a90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c856cced-f2ad-44d6-9d7d-b0b6cd7e76be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_09156ba0-9b6d-4207-b029-3e9f71a92d1d" xlink:to="loc_us-gaap_OperatingIncomeLoss_c856cced-f2ad-44d6-9d7d-b0b6cd7e76be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_76da0c84-964c-4817-8915-502180a2912c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6a9eba0e-66f9-48d7-85f3-378a719d3574" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_76da0c84-964c-4817-8915-502180a2912c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6a9eba0e-66f9-48d7-85f3-378a719d3574" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2c42dc3f-811e-40fb-8dde-2271581df635" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_76da0c84-964c-4817-8915-502180a2912c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2c42dc3f-811e-40fb-8dde-2271581df635" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0362f680-c9ec-48e3-ba08-bd6c5d7c5a92" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_e791bf8b-7f64-4ab0-bba9-0c8482fd46cf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0362f680-c9ec-48e3-ba08-bd6c5d7c5a92" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_e791bf8b-7f64-4ab0-bba9-0c8482fd46cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_c61ea7c6-066b-432e-a346-5d0a81b00029" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0362f680-c9ec-48e3-ba08-bd6c5d7c5a92" xlink:to="loc_us-gaap_OperatingExpenses_c61ea7c6-066b-432e-a346-5d0a81b00029" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_fafb6889-b114-4304-bd3d-52854b48b3ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_df2cd763-94c1-424a-a87f-f04e81fac327" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_fafb6889-b114-4304-bd3d-52854b48b3ab" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_df2cd763-94c1-424a-a87f-f04e81fac327" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ef23cc9f-0b80-4b9b-acba-bac02fe36681" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_fafb6889-b114-4304-bd3d-52854b48b3ab" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ef23cc9f-0b80-4b9b-acba-bac02fe36681" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_db645814-18c8-46d4-b1ea-13a98bd59ed1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_fafb6889-b114-4304-bd3d-52854b48b3ab" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_db645814-18c8-46d4-b1ea-13a98bd59ed1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_a7cbedeb-a960-495e-a757-85ee1eedb73d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_fafb6889-b114-4304-bd3d-52854b48b3ab" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_a7cbedeb-a960-495e-a757-85ee1eedb73d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets_0625b400-7080-49fd-b7b8-1fdfff161e30" xlink:href="ptct-20200630.xsd#ptct_CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_fafb6889-b114-4304-bd3d-52854b48b3ab" xlink:to="loc_ptct_CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets_0625b400-7080-49fd-b7b8-1fdfff161e30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_SettlementOfDeferredAndContingentConsideration_9eb5fff1-6e99-4b12-9e6a-b30d0a036834" xlink:href="ptct-20200630.xsd#ptct_SettlementOfDeferredAndContingentConsideration"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_fafb6889-b114-4304-bd3d-52854b48b3ab" xlink:to="loc_ptct_SettlementOfDeferredAndContingentConsideration_9eb5fff1-6e99-4b12-9e6a-b30d0a036834" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" xlink:type="simple" xlink:href="ptct-20200630.xsd#ConsolidatedStatementsofComprehensiveLossunaudited"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_91e7601b-5e44-4ab5-a7ca-168071718c5e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_797627d9-4789-4b4b-a879-05178cdb6754" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_91e7601b-5e44-4ab5-a7ca-168071718c5e" xlink:to="loc_us-gaap_NetIncomeLoss_797627d9-4789-4b4b-a879-05178cdb6754" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_1e616205-40fe-4df2-8144-e63e04343841" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_91e7601b-5e44-4ab5-a7ca-168071718c5e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_1e616205-40fe-4df2-8144-e63e04343841" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_c91f1ae9-49b4-443a-975b-250eb4d25597" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_91e7601b-5e44-4ab5-a7ca-168071718c5e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_c91f1ae9-49b4-443a-975b-250eb4d25597" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="ptct-20200630.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited" xlink:type="simple" xlink:href="ptct-20200630.xsd#ConsolidatedStatementsofCashFlowsunaudited"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_28bb3dde-68e3-4e25-8191-28b646574d23" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ee0a8bcb-10f9-4312-85b0-d132636f0ce8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_28bb3dde-68e3-4e25-8191-28b646574d23" xlink:to="loc_us-gaap_NetIncomeLoss_ee0a8bcb-10f9-4312-85b0-d132636f0ce8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_0815f4b5-4262-408b-9d05-51fa4c6fac76" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_28bb3dde-68e3-4e25-8191-28b646574d23" xlink:to="loc_us-gaap_Depreciation_0815f4b5-4262-408b-9d05-51fa4c6fac76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_OperatingLeaseCostNonCash_be5439cb-910e-4688-93ed-9835fb990e6c" xlink:href="ptct-20200630.xsd#ptct_OperatingLeaseCostNonCash"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_28bb3dde-68e3-4e25-8191-28b646574d23" xlink:to="loc_ptct_OperatingLeaseCostNonCash_be5439cb-910e-4688-93ed-9835fb990e6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_b98d7533-8920-49a1-a2e3-08a9438d78d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_28bb3dde-68e3-4e25-8191-28b646574d23" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_b98d7533-8920-49a1-a2e3-08a9438d78d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_86b04441-8b4f-43a4-9818-e4c118f3a7e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_28bb3dde-68e3-4e25-8191-28b646574d23" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_86b04441-8b4f-43a4-9818-e4c118f3a7e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_UnrealizedGainLossonConvertibleSecurities_d061629f-70f2-40ab-9413-e3d20c5acb05" xlink:href="ptct-20200630.xsd#ptct_UnrealizedGainLossonConvertibleSecurities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_28bb3dde-68e3-4e25-8191-28b646574d23" xlink:to="loc_ptct_UnrealizedGainLossonConvertibleSecurities_d061629f-70f2-40ab-9413-e3d20c5acb05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_a4a4b2cc-2940-4cbd-8856-05d51ae5e0d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_28bb3dde-68e3-4e25-8191-28b646574d23" xlink:to="loc_us-gaap_PaidInKindInterest_a4a4b2cc-2940-4cbd-8856-05d51ae5e0d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_1c77cbf7-7b1c-4201-adc8-bc2a0be99d18" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_28bb3dde-68e3-4e25-8191-28b646574d23" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_1c77cbf7-7b1c-4201-adc8-bc2a0be99d18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_dbb9d69f-8285-4855-8a9e-02ab46a5be40" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_28bb3dde-68e3-4e25-8191-28b646574d23" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_dbb9d69f-8285-4855-8a9e-02ab46a5be40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_cd0db5ec-368a-45c8-92bf-c2e6d849762b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_28bb3dde-68e3-4e25-8191-28b646574d23" xlink:to="loc_us-gaap_ShareBasedCompensation_cd0db5ec-368a-45c8-92bf-c2e6d849762b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_297e05ed-2946-46f2-930e-c9d86b6e10ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_28bb3dde-68e3-4e25-8191-28b646574d23" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_297e05ed-2946-46f2-930e-c9d86b6e10ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_49529428-9e6e-40c5-8fde-9f5ca4b0a871" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_28bb3dde-68e3-4e25-8191-28b646574d23" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_49529428-9e6e-40c5-8fde-9f5ca4b0a871" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3efee68b-8b94-44b5-8446-69d5d0ca7d50" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_28bb3dde-68e3-4e25-8191-28b646574d23" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3efee68b-8b94-44b5-8446-69d5d0ca7d50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_0c231e2f-0163-43d9-bba0-265219f3e656" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_28bb3dde-68e3-4e25-8191-28b646574d23" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_0c231e2f-0163-43d9-bba0-265219f3e656" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDepositOtherAssets_97eed198-1133-4d1e-8da5-d8be4feab9cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_28bb3dde-68e3-4e25-8191-28b646574d23" xlink:to="loc_us-gaap_IncreaseDecreaseInDepositOtherAssets_97eed198-1133-4d1e-8da5-d8be4feab9cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_c272dd29-08e3-4c2d-a2c2-c44aa09966f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_28bb3dde-68e3-4e25-8191-28b646574d23" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_c272dd29-08e3-4c2d-a2c2-c44aa09966f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_2b10ec5b-8bb5-4f69-b4a9-b7f4edff8e32" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_28bb3dde-68e3-4e25-8191-28b646574d23" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_2b10ec5b-8bb5-4f69-b4a9-b7f4edff8e32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_44743928-f18c-440b-abb6-149a4976915a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_28bb3dde-68e3-4e25-8191-28b646574d23" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_44743928-f18c-440b-abb6-149a4976915a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_SettlementOfDeferredAndContingentConsideration_b5a843a8-695a-4497-ad15-d7dfe1fba082" xlink:href="ptct-20200630.xsd#ptct_SettlementOfDeferredAndContingentConsideration"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_28bb3dde-68e3-4e25-8191-28b646574d23" xlink:to="loc_ptct_SettlementOfDeferredAndContingentConsideration_b5a843a8-695a-4497-ad15-d7dfe1fba082" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_SharesIssuedAssetAcquisition_1150315b-9f93-407b-ac84-f49020112561" xlink:href="ptct-20200630.xsd#ptct_SharesIssuedAssetAcquisition"/>
    <link:calculationArc order="20" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_28bb3dde-68e3-4e25-8191-28b646574d23" xlink:to="loc_ptct_SharesIssuedAssetAcquisition_1150315b-9f93-407b-ac84-f49020112561" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_2c70cc90-9dfa-47cd-87b2-3fe237d4f08b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="21" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_28bb3dde-68e3-4e25-8191-28b646574d23" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_2c70cc90-9dfa-47cd-87b2-3fe237d4f08b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_FinanceLeaseCostNonCash_6e2e1c5a-deeb-4b14-8b45-b11a2ce80e57" xlink:href="ptct-20200630.xsd#ptct_FinanceLeaseCostNonCash"/>
    <link:calculationArc order="22" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_28bb3dde-68e3-4e25-8191-28b646574d23" xlink:to="loc_ptct_FinanceLeaseCostNonCash_6e2e1c5a-deeb-4b14-8b45-b11a2ce80e57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_064e4dfd-4cb2-4bc6-a586-a31ed1bcff3d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4a222fd0-fd77-4cfd-9e3e-6cdaa5f84b44" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_064e4dfd-4cb2-4bc6-a586-a31ed1bcff3d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4a222fd0-fd77-4cfd-9e3e-6cdaa5f84b44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2e9f2bc6-c804-428b-b549-f948c28aa9d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_064e4dfd-4cb2-4bc6-a586-a31ed1bcff3d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2e9f2bc6-c804-428b-b549-f948c28aa9d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9ccf73a1-5881-40c3-8920-97f1cdaed688" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_064e4dfd-4cb2-4bc6-a586-a31ed1bcff3d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9ccf73a1-5881-40c3-8920-97f1cdaed688" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c203aa5d-43c3-4501-8ec2-1b9489c08c24" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_064e4dfd-4cb2-4bc6-a586-a31ed1bcff3d" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c203aa5d-43c3-4501-8ec2-1b9489c08c24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_899ad0f1-0196-4b58-b8e6-8af6a3e373e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_40976941-0666-4353-ba2a-11f9d700a00b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_899ad0f1-0196-4b58-b8e6-8af6a3e373e5" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_40976941-0666-4353-ba2a-11f9d700a00b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_PaymentsToAcquireConvertibleDebtInvestment_223c5624-2ac7-4945-bceb-697635b7a1d2" xlink:href="ptct-20200630.xsd#ptct_PaymentsToAcquireConvertibleDebtInvestment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_899ad0f1-0196-4b58-b8e6-8af6a3e373e5" xlink:to="loc_ptct_PaymentsToAcquireConvertibleDebtInvestment_223c5624-2ac7-4945-bceb-697635b7a1d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_ad3105d0-dd52-4fc1-928b-780c76321f47" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_899ad0f1-0196-4b58-b8e6-8af6a3e373e5" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_ad3105d0-dd52-4fc1-928b-780c76321f47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_d647cedc-1d2b-401e-ab36-3d58274dc02f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_899ad0f1-0196-4b58-b8e6-8af6a3e373e5" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_d647cedc-1d2b-401e-ab36-3d58274dc02f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_981c1060-101c-4244-9d32-c0693ce105dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_899ad0f1-0196-4b58-b8e6-8af6a3e373e5" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_981c1060-101c-4244-9d32-c0693ce105dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_c340fe0c-a130-464f-bee4-594a9ad02e1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_899ad0f1-0196-4b58-b8e6-8af6a3e373e5" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_c340fe0c-a130-464f-bee4-594a9ad02e1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a2147190-7b0f-4db9-b65d-1f94f1aa3a50" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_367287a0-e5c5-487e-9d51-1231823c4b8b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a2147190-7b0f-4db9-b65d-1f94f1aa3a50" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_367287a0-e5c5-487e-9d51-1231823c4b8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_995d37c6-8af1-42c9-9ade-7ac5aa429bf8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a2147190-7b0f-4db9-b65d-1f94f1aa3a50" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_995d37c6-8af1-42c9-9ade-7ac5aa429bf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt_36428186-24bf-4fb3-b504-5e6f50c0145b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a2147190-7b0f-4db9-b65d-1f94f1aa3a50" xlink:to="loc_us-gaap_RepaymentsOfSecuredDebt_36428186-24bf-4fb3-b504-5e6f50c0145b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_PaymentsOnDeferredConsiderationObligation_408d08ee-0783-4b7e-a72b-e4c85a81677c" xlink:href="ptct-20200630.xsd#ptct_PaymentsOnDeferredConsiderationObligation"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a2147190-7b0f-4db9-b65d-1f94f1aa3a50" xlink:to="loc_ptct_PaymentsOnDeferredConsiderationObligation_408d08ee-0783-4b7e-a72b-e4c85a81677c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_73142340-1298-46f6-9919-5d3cf6b558fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a2147190-7b0f-4db9-b65d-1f94f1aa3a50" xlink:to="loc_us-gaap_ProceedsFromStockPlans_73142340-1298-46f6-9919-5d3cf6b558fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_PaymentOfFinanceLeasePrincipal_e4a9bc83-b517-4a8e-85f4-647e587fa43b" xlink:href="ptct-20200630.xsd#ptct_PaymentOfFinanceLeasePrincipal"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a2147190-7b0f-4db9-b65d-1f94f1aa3a50" xlink:to="loc_ptct_PaymentOfFinanceLeasePrincipal_e4a9bc83-b517-4a8e-85f4-647e587fa43b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/TheCompany" xlink:type="simple" xlink:href="ptct-20200630.xsd#TheCompany"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/TheCompany" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/TheCompanyNarrativeDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#TheCompanyNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/TheCompanyNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/Summaryofsignificantaccountingpolicies" xlink:type="simple" xlink:href="ptct-20200630.xsd#Summaryofsignificantaccountingpolicies"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/Summaryofsignificantaccountingpolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesPolicies" xlink:type="simple" xlink:href="ptct-20200630.xsd#SummaryofsignificantaccountingpoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesTables" xlink:type="simple" xlink:href="ptct-20200630.xsd#SummaryofsignificantaccountingpoliciesTables"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesInventoryDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#SummaryofsignificantaccountingpoliciesInventoryDetails"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_f011e0fb-614f-4780-85b5-354c6415c161" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_a74f46b1-0e1c-4989-9b93-3ee5fec659e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_f011e0fb-614f-4780-85b5-354c6415c161" xlink:to="loc_us-gaap_InventoryWorkInProcess_a74f46b1-0e1c-4989-9b93-3ee5fec659e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_023ecd12-579e-41f0-adcb-b305ca705975" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_f011e0fb-614f-4780-85b5-354c6415c161" xlink:to="loc_us-gaap_InventoryFinishedGoods_023ecd12-579e-41f0-adcb-b305ca705975" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_79919309-1046-43f4-a081-f08a3d0f3b82" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_f011e0fb-614f-4780-85b5-354c6415c161" xlink:to="loc_us-gaap_InventoryRawMaterials_79919309-1046-43f4-a081-f08a3d0f3b82" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#SummaryofsignificantaccountingpoliciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesReconciliationofcashDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#SummaryofsignificantaccountingpoliciesReconciliationofcashDetails"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesReconciliationofcashDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/Leases" xlink:type="simple" xlink:href="ptct-20200630.xsd#Leases"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/LeasesTables" xlink:type="simple" xlink:href="ptct-20200630.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#LeasesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/LeasesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/LeasesLeasecostsDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#LeasesLeasecostsDetails"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/LeasesLeasecostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_c5905dc4-51f4-4866-a12c-6c968a6e8b4d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_026ba2e3-6db4-4e0a-8359-aedbffa54141" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_c5905dc4-51f4-4866-a12c-6c968a6e8b4d" xlink:to="loc_us-gaap_ShortTermLeaseCost_026ba2e3-6db4-4e0a-8359-aedbffa54141" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_270c0c37-14c3-49ed-bed7-814b801f9a09" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_c5905dc4-51f4-4866-a12c-6c968a6e8b4d" xlink:to="loc_us-gaap_VariableLeaseCost_270c0c37-14c3-49ed-bed7-814b801f9a09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_ee95fc85-9959-437a-a449-a352bdee11e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_c5905dc4-51f4-4866-a12c-6c968a6e8b4d" xlink:to="loc_us-gaap_OperatingLeaseCost_ee95fc85-9959-437a-a449-a352bdee11e5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/LeasesBalancesheetDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#LeasesBalancesheetDetails"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/LeasesBalancesheetDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/LeasesSupplementalleasetermsDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#LeasesSupplementalleasetermsDetails"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/LeasesSupplementalleasetermsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/LeasesLeasepaymentsDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#LeasesLeasepaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/LeasesLeasepaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e4939bcd-1e69-49a1-9671-ecf6a65b12a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_17490424-1c73-4f23-beef-fc582d70823e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e4939bcd-1e69-49a1-9671-ecf6a65b12a3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_17490424-1c73-4f23-beef-fc582d70823e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_210a8af6-4a19-45bb-b9c5-5558e528b906" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e4939bcd-1e69-49a1-9671-ecf6a65b12a3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_210a8af6-4a19-45bb-b9c5-5558e528b906" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_da85854b-9c33-4cae-a134-3a3b0a0ed0d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e4939bcd-1e69-49a1-9671-ecf6a65b12a3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_da85854b-9c33-4cae-a134-3a3b0a0ed0d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_613c2f58-7477-4547-b43b-8fb4920c4048" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e4939bcd-1e69-49a1-9671-ecf6a65b12a3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_613c2f58-7477-4547-b43b-8fb4920c4048" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter_75975078-96a7-488e-aa94-91582e25989e" xlink:href="ptct-20200630.xsd#ptct_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e4939bcd-1e69-49a1-9671-ecf6a65b12a3" xlink:to="loc_ptct_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter_75975078-96a7-488e-aa94-91582e25989e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_5744ad63-f929-4d39-a3e4-34d80d869f7e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_282013b2-61b4-437c-97c1-5a2e4ccddb64" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_5744ad63-f929-4d39-a3e4-34d80d869f7e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_282013b2-61b4-437c-97c1-5a2e4ccddb64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_5e0518f4-7e23-4caa-8624-459bb7a023f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_5744ad63-f929-4d39-a3e4-34d80d869f7e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_5e0518f4-7e23-4caa-8624-459bb7a023f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_dad66c70-d559-42bb-9db5-6a55623b880d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_5744ad63-f929-4d39-a3e4-34d80d869f7e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_dad66c70-d559-42bb-9db5-6a55623b880d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_4d4f319b-507c-401b-9349-c61492ec7e62" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_5744ad63-f929-4d39-a3e4-34d80d869f7e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_4d4f319b-507c-401b-9349-c61492ec7e62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_f1d80b54-4233-4e29-9966-a7ac49ef717c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_5744ad63-f929-4d39-a3e4-34d80d869f7e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_f1d80b54-4233-4e29-9966-a7ac49ef717c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/LeasesLeasepaymentsDetails_1" xlink:type="simple" xlink:href="ptct-20200630.xsd#LeasesLeasepaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/LeasesLeasepaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a69c56f4-35b4-41dd-86fe-7b405bb20a1f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e2a00558-d72b-4cf9-983c-9c08a8bc9c28" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a69c56f4-35b4-41dd-86fe-7b405bb20a1f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e2a00558-d72b-4cf9-983c-9c08a8bc9c28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_80c71bc5-b3c2-476d-8e96-9ae47054f96d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a69c56f4-35b4-41dd-86fe-7b405bb20a1f" xlink:to="loc_us-gaap_OperatingLeaseLiability_80c71bc5-b3c2-476d-8e96-9ae47054f96d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/LeasesCashflowDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#LeasesCashflowDetails"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/LeasesCashflowDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/Acquisitions" xlink:type="simple" xlink:href="ptct-20200630.xsd#Acquisitions"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/Acquisitions" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#AcquisitionsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/AcquisitionsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/AcquisitionsPreliminaryAllocationofpurchasepriceDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#AcquisitionsPreliminaryAllocationofpurchasepriceDetails"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/AcquisitionsPreliminaryAllocationofpurchasepriceDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/Fairvalueoffinancialinstrumentsandmarketablesecurities" xlink:type="simple" xlink:href="ptct-20200630.xsd#Fairvalueoffinancialinstrumentsandmarketablesecurities"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/Fairvalueoffinancialinstrumentsandmarketablesecurities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesTables" xlink:type="simple" xlink:href="ptct-20200630.xsd#FairvalueoffinancialinstrumentsandmarketablesecuritiesTables"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesHierarchyDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#FairvalueoffinancialinstrumentsandmarketablesecuritiesHierarchyDetails"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesHierarchyDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesAvailableforsaleDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#FairvalueoffinancialinstrumentsandmarketablesecuritiesAvailableforsaleDetails"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesAvailableforsaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_952a64c7-1b87-444c-a9b5-5610a4d93dc8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_afa93be1-a84d-47d8-b20e-4390acf419b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_952a64c7-1b87-444c-a9b5-5610a4d93dc8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_afa93be1-a84d-47d8-b20e-4390acf419b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_99633b7f-7865-4872-8066-994590130bc7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_952a64c7-1b87-444c-a9b5-5610a4d93dc8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_99633b7f-7865-4872-8066-994590130bc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3649d863-4992-46e2-9d30-5f51a0eacf0b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_952a64c7-1b87-444c-a9b5-5610a4d93dc8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3649d863-4992-46e2-9d30-5f51a0eacf0b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesFairValueMeasurementInputsandValuationTechniquesDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#FairvalueoffinancialinstrumentsandmarketablesecuritiesFairValueMeasurementInputsandValuationTechniquesDetails"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesFairValueMeasurementInputsandValuationTechniquesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesUnrealizedLossPositionsDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#FairvalueoffinancialinstrumentsandmarketablesecuritiesUnrealizedLossPositionsDetails"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesUnrealizedLossPositionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue_dbc144cc-8b27-4a17-8176-3520ff4264fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_30b01451-49a6-4b6e-8d07-1ae2752afd51" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue_dbc144cc-8b27-4a17-8176-3520ff4264fa" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_30b01451-49a6-4b6e-8d07-1ae2752afd51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_4f32d8f0-29b7-4a33-b432-7f8090709fc8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue_dbc144cc-8b27-4a17-8176-3520ff4264fa" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_4f32d8f0-29b7-4a33-b432-7f8090709fc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_0bd192b5-cc33-44e7-a600-91a52fcd6cfe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_715e1296-7f03-447c-b5d9-132767ec7c6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_0bd192b5-cc33-44e7-a600-91a52fcd6cfe" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_715e1296-7f03-447c-b5d9-132767ec7c6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_da3cfa32-60af-42c3-a367-949cd10ef899" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_0bd192b5-cc33-44e7-a600-91a52fcd6cfe" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_da3cfa32-60af-42c3-a367-949cd10ef899" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesMarketablesecuritiesDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#FairvalueoffinancialinstrumentsandmarketablesecuritiesMarketablesecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesMarketablesecuritiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/Othercomprehensiveincomelossandaccumulatedothercomprehensiveitems" xlink:type="simple" xlink:href="ptct-20200630.xsd#Othercomprehensiveincomelossandaccumulatedothercomprehensiveitems"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/Othercomprehensiveincomelossandaccumulatedothercomprehensiveitems" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/OthercomprehensiveincomelossandaccumulatedothercomprehensiveitemsTables" xlink:type="simple" xlink:href="ptct-20200630.xsd#OthercomprehensiveincomelossandaccumulatedothercomprehensiveitemsTables"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/OthercomprehensiveincomelossandaccumulatedothercomprehensiveitemsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/OthercomprehensiveincomelossandaccumulatedothercomprehensiveitemsNarrativeDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#OthercomprehensiveincomelossandaccumulatedothercomprehensiveitemsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/OthercomprehensiveincomelossandaccumulatedothercomprehensiveitemsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_36074cc3-3965-4068-b949-75c96bf1c0c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_b62ba6c0-3268-4e81-8b60-1ac1b0d0b570" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_36074cc3-3965-4068-b949-75c96bf1c0c1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_b62ba6c0-3268-4e81-8b60-1ac1b0d0b570" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_afa0ff3a-772e-42f1-acca-8c19aa26db22" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_36074cc3-3965-4068-b949-75c96bf1c0c1" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_afa0ff3a-772e-42f1-acca-8c19aa26db22" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/Accountspayableandaccruedexpenses" xlink:type="simple" xlink:href="ptct-20200630.xsd#Accountspayableandaccruedexpenses"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/Accountspayableandaccruedexpenses" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/AccountspayableandaccruedexpensesTables" xlink:type="simple" xlink:href="ptct-20200630.xsd#AccountspayableandaccruedexpensesTables"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/AccountspayableandaccruedexpensesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/AccountspayableandaccruedexpensesNarrativeDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#AccountspayableandaccruedexpensesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/AccountspayableandaccruedexpensesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_30fe1ae5-879f-427f-836c-0ac8492f2285" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a520638c-f7fb-4b25-9fdb-4e7fd4200b1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_30fe1ae5-879f-427f-836c-0ac8492f2285" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a520638c-f7fb-4b25-9fdb-4e7fd4200b1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AccruedConsultingAndContractedResearchCurrent_3178a980-d0a1-4bb5-86bc-85e9efe132c0" xlink:href="ptct-20200630.xsd#ptct_AccruedConsultingAndContractedResearchCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_30fe1ae5-879f-427f-836c-0ac8492f2285" xlink:to="loc_ptct_AccruedConsultingAndContractedResearchCurrent_3178a980-d0a1-4bb5-86bc-85e9efe132c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_fc93393d-d8a9-4077-89f5-9d51131a2dd6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_30fe1ae5-879f-427f-836c-0ac8492f2285" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_fc93393d-d8a9-4077-89f5-9d51131a2dd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_SalesAllowanceAndOtherRelatedCosts_e115509f-7106-4ae2-a913-c3c4584293cf" xlink:href="ptct-20200630.xsd#ptct_SalesAllowanceAndOtherRelatedCosts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_30fe1ae5-879f-427f-836c-0ac8492f2285" xlink:to="loc_ptct_SalesAllowanceAndOtherRelatedCosts_e115509f-7106-4ae2-a913-c3c4584293cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_0353a7b4-f41b-40da-acf5-6791d01d6e3a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_30fe1ae5-879f-427f-836c-0ac8492f2285" xlink:to="loc_us-gaap_AccountsPayableCurrent_0353a7b4-f41b-40da-acf5-6791d01d6e3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_52cf8032-9832-4503-8294-cb571b4538af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_30fe1ae5-879f-427f-836c-0ac8492f2285" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_52cf8032-9832-4503-8294-cb571b4538af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_SalesRebatesAndRoyaltiesCurrent_bec46a7a-bdc5-4045-bb13-8d0580c80026" xlink:href="ptct-20200630.xsd#ptct_SalesRebatesAndRoyaltiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_30fe1ae5-879f-427f-836c-0ac8492f2285" xlink:to="loc_ptct_SalesRebatesAndRoyaltiesCurrent_bec46a7a-bdc5-4045-bb13-8d0580c80026" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/Capitalization" xlink:type="simple" xlink:href="ptct-20200630.xsd#Capitalization"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/Capitalization" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/CapitalizationNarrativeDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#CapitalizationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/CapitalizationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/Netlosspershare" xlink:type="simple" xlink:href="ptct-20200630.xsd#Netlosspershare"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/Netlosspershare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/NetlosspershareTables" xlink:type="simple" xlink:href="ptct-20200630.xsd#NetlosspershareTables"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/NetlosspershareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/NetlosspershareNumeratorandDenominatorDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#NetlosspershareNumeratorandDenominatorDetails"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/NetlosspershareNumeratorandDenominatorDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/NetlosspershareAntidilutiveDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#NetlosspershareAntidilutiveDetails"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/NetlosspershareAntidilutiveDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/Stockawardplan" xlink:type="simple" xlink:href="ptct-20200630.xsd#Stockawardplan"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/Stockawardplan" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/StockawardplanTables" xlink:type="simple" xlink:href="ptct-20200630.xsd#StockawardplanTables"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/StockawardplanTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/StockawardplanNarrativeDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#StockawardplanNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/StockawardplanNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/StockawardplanShareBaseCompensationDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#StockawardplanShareBaseCompensationDetails"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/StockawardplanShareBaseCompensationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/StockawardplanRestrictedStockDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#StockawardplanRestrictedStockDetails"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/StockawardplanRestrictedStockDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/StockawardplanSharebasedcompensationexpenseDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#StockawardplanSharebasedcompensationexpenseDetails"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/StockawardplanSharebasedcompensationexpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/Debt" xlink:type="simple" xlink:href="ptct-20200630.xsd#Debt"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/Debt" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/DebtTables" xlink:type="simple" xlink:href="ptct-20200630.xsd#DebtTables"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/DebtTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#DebtNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/DebtNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/DebtConvertibleNotesDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#DebtConvertibleNotesDetails"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/DebtConvertibleNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_3dce77fc-7d69-45bf-9a17-38c6c0e0089a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_5a7dc917-f70f-4b14-a91a-838a213ebf6e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_3dce77fc-7d69-45bf-9a17-38c6c0e0089a" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_5a7dc917-f70f-4b14-a91a-838a213ebf6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_7db061b2-c898-4b37-a410-df395dfcbea9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_3dce77fc-7d69-45bf-9a17-38c6c0e0089a" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_7db061b2-c898-4b37-a410-df395dfcbea9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_9ead404f-120a-461b-8633-4279f99077ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_3dce77fc-7d69-45bf-9a17-38c6c0e0089a" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_9ead404f-120a-461b-8633-4279f99077ba" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/DebtInterestExpenseDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#DebtInterestExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/DebtInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_c5433a61-3ed9-4fc0-985a-bb7d57da9a39" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_e83ba5d1-0327-4622-8fa5-9af72bc034bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_c5433a61-3ed9-4fc0-985a-bb7d57da9a39" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_e83ba5d1-0327-4622-8fa5-9af72bc034bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_c7d39a44-3380-413e-8591-07a2c105f7b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_c5433a61-3ed9-4fc0-985a-bb7d57da9a39" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_c7d39a44-3380-413e-8591-07a2c105f7b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_53df43df-1814-4cb9-a8c8-6d7b8ac20397" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_c5433a61-3ed9-4fc0-985a-bb7d57da9a39" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_53df43df-1814-4cb9-a8c8-6d7b8ac20397" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/Commitmentsandcontingencies" xlink:type="simple" xlink:href="ptct-20200630.xsd#Commitmentsandcontingencies"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/Commitmentsandcontingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#CommitmentsandcontingenciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/Revenuerecognition" xlink:type="simple" xlink:href="ptct-20200630.xsd#Revenuerecognition"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/Revenuerecognition" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/RevenuerecognitionNarrativeDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#RevenuerecognitionNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/RevenuerecognitionNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/RevenuerecognitionPerformanceObligationsDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#RevenuerecognitionPerformanceObligationsDetails"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/RevenuerecognitionPerformanceObligationsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/RevenuerecognitionPerformanceObligationsDetails_1" xlink:type="simple" xlink:href="ptct-20200630.xsd#RevenuerecognitionPerformanceObligationsDetails_1"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/RevenuerecognitionPerformanceObligationsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/Intangibleassetsandgoodwill" xlink:type="simple" xlink:href="ptct-20200630.xsd#Intangibleassetsandgoodwill"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/Intangibleassetsandgoodwill" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/IntangibleassetsandgoodwillTables" xlink:type="simple" xlink:href="ptct-20200630.xsd#IntangibleassetsandgoodwillTables"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/IntangibleassetsandgoodwillTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/IntangibleassetsandgoodwillNarrativeDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#IntangibleassetsandgoodwillNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/IntangibleassetsandgoodwillNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/IntangibleassetsandgoodwillFutureAmortizationDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#IntangibleassetsandgoodwillFutureAmortizationDetails"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/IntangibleassetsandgoodwillFutureAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_da0fa3da-9680-4dd2-ae48-506aae77eccf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_7028625f-68e2-4339-b9e8-3bd08d7b83d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_da0fa3da-9680-4dd2-ae48-506aae77eccf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_7028625f-68e2-4339-b9e8-3bd08d7b83d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_3aaef6f5-fbaa-4eb3-88ad-551f4b313de5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_da0fa3da-9680-4dd2-ae48-506aae77eccf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_3aaef6f5-fbaa-4eb3-88ad-551f4b313de5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_c3d1c9dc-47d4-4a32-b64c-0ca010836f67" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_da0fa3da-9680-4dd2-ae48-506aae77eccf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_c3d1c9dc-47d4-4a32-b64c-0ca010836f67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ebd5cd02-a723-4ef2-9eba-73dca6498fbf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_da0fa3da-9680-4dd2-ae48-506aae77eccf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ebd5cd02-a723-4ef2-9eba-73dca6498fbf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter_15ece53b-2b86-46c8-adc2-4b925e5e2b0d" xlink:href="ptct-20200630.xsd#ptct_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_da0fa3da-9680-4dd2-ae48-506aae77eccf" xlink:to="loc_ptct_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter_15ece53b-2b86-46c8-adc2-4b925e5e2b0d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/Subsequentevents" xlink:type="simple" xlink:href="ptct-20200630.xsd#Subsequentevents"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/Subsequentevents" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/SubsequenteventsNarrativeDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#SubsequenteventsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/SubsequenteventsNarrativeDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>ptct-20200630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:a91ddaa9-e688-473f-b70e-08f6db5630cb,g:e05438c1-8a2e-4af1-b39d-a16533f5ad44-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/Cover" xlink:type="simple" xlink:href="ptct-20200630.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/Cover" xlink:type="extended" id="i12c9794c7f8e4ce4a6c8ecbd07f03c42_Cover"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited" xlink:type="simple" xlink:href="ptct-20200630.xsd#ConsolidatedBalanceSheetsunaudited"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited" xlink:type="extended" id="i524a4975d7d84b9d9b6408fd72327032_ConsolidatedBalanceSheetsunaudited"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunauditedParenthetical" xlink:type="simple" xlink:href="ptct-20200630.xsd#ConsolidatedBalanceSheetsunauditedParenthetical"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunauditedParenthetical" xlink:type="extended" id="i4e02968ed64c44cc97f179f63cabfd50_ConsolidatedBalanceSheetsunauditedParenthetical"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited" xlink:type="simple" xlink:href="ptct-20200630.xsd#ConsolidatedStatementsofOperationsunaudited"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited" xlink:type="extended" id="i34f45eb8f7294c11879b00426d6f1347_ConsolidatedStatementsofOperationsunaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f3d85031-1c3c-41a9-8f5f-8f5dc8c11554" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_df791ccd-416a-48d6-af3d-c4958b3a427e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f3d85031-1c3c-41a9-8f5f-8f5dc8c11554" xlink:to="loc_us-gaap_RevenuesAbstract_df791ccd-416a-48d6-af3d-c4958b3a427e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_b2831bed-8d0f-4a7a-b7c1-5f1421fa0e19" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_df791ccd-416a-48d6-af3d-c4958b3a427e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_b2831bed-8d0f-4a7a-b7c1-5f1421fa0e19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets_6f0d0bbb-247a-4a2b-a12b-dab6fdb30eed" xlink:href="ptct-20200630.xsd#ptct_CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f3d85031-1c3c-41a9-8f5f-8f5dc8c11554" xlink:to="loc_ptct_CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets_6f0d0bbb-247a-4a2b-a12b-dab6fdb30eed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_2f014078-19e8-4677-bba9-269be3087d68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f3d85031-1c3c-41a9-8f5f-8f5dc8c11554" xlink:to="loc_us-gaap_OperatingExpensesAbstract_2f014078-19e8-4677-bba9-269be3087d68" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_51117bba-89d5-4569-b0af-9768234638fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2f014078-19e8-4677-bba9-269be3087d68" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_51117bba-89d5-4569-b0af-9768234638fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_03d677fe-7543-49fb-9000-c58d41397e9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2f014078-19e8-4677-bba9-269be3087d68" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_03d677fe-7543-49fb-9000-c58d41397e9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_785dfed1-7e38-4550-abd3-785a8526c26e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2f014078-19e8-4677-bba9-269be3087d68" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_785dfed1-7e38-4550-abd3-785a8526c26e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_7a53ae96-e0a5-47da-bdcf-8c1a139680ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2f014078-19e8-4677-bba9-269be3087d68" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_7a53ae96-e0a5-47da-bdcf-8c1a139680ee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_SettlementOfDeferredAndContingentConsideration_c4df97c3-3d62-4324-b1ca-3c789c358df5" xlink:href="ptct-20200630.xsd#ptct_SettlementOfDeferredAndContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2f014078-19e8-4677-bba9-269be3087d68" xlink:to="loc_ptct_SettlementOfDeferredAndContingentConsideration_c4df97c3-3d62-4324-b1ca-3c789c358df5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_2b6fe765-d481-4145-97c4-4a65976cd65f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2f014078-19e8-4677-bba9-269be3087d68" xlink:to="loc_us-gaap_OperatingExpenses_2b6fe765-d481-4145-97c4-4a65976cd65f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e15e895b-28a1-4447-a8af-679485146058" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f3d85031-1c3c-41a9-8f5f-8f5dc8c11554" xlink:to="loc_us-gaap_OperatingIncomeLoss_e15e895b-28a1-4447-a8af-679485146058" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_82d0218d-1f10-4cc7-8d50-aaf5468d93d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f3d85031-1c3c-41a9-8f5f-8f5dc8c11554" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_82d0218d-1f10-4cc7-8d50-aaf5468d93d6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_fff1e502-616f-40e5-9369-b7efa9156fb8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f3d85031-1c3c-41a9-8f5f-8f5dc8c11554" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_fff1e502-616f-40e5-9369-b7efa9156fb8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6a97a525-47de-41d8-95ea-5d841c2be41a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f3d85031-1c3c-41a9-8f5f-8f5dc8c11554" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6a97a525-47de-41d8-95ea-5d841c2be41a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d637157a-3267-49d1-9b28-48a24c14606a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f3d85031-1c3c-41a9-8f5f-8f5dc8c11554" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_d637157a-3267-49d1-9b28-48a24c14606a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_97342dd7-6e8a-41df-b9d6-041e872c9fbc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f3d85031-1c3c-41a9-8f5f-8f5dc8c11554" xlink:to="loc_us-gaap_NetIncomeLoss_97342dd7-6e8a-41df-b9d6-041e872c9fbc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_33b51440-20f8-4ec6-b8d1-1045fc901a97" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f3d85031-1c3c-41a9-8f5f-8f5dc8c11554" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_33b51440-20f8-4ec6-b8d1-1045fc901a97" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_f2818247-6adf-48f7-9aea-7abf0f59afe6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_33b51440-20f8-4ec6-b8d1-1045fc901a97" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_f2818247-6adf-48f7-9aea-7abf0f59afe6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_add9afcb-659a-451b-830e-54f2c7780b1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f3d85031-1c3c-41a9-8f5f-8f5dc8c11554" xlink:to="loc_us-gaap_EarningsPerShareAbstract_add9afcb-659a-451b-830e-54f2c7780b1e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_eb1f796e-f561-423a-9558-5ab400a21559" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_add9afcb-659a-451b-830e-54f2c7780b1e" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_eb1f796e-f561-423a-9558-5ab400a21559" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2bd177e4-fdc9-4ac1-a814-bd6b2a14f3db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f3d85031-1c3c-41a9-8f5f-8f5dc8c11554" xlink:to="loc_us-gaap_StatementTable_2bd177e4-fdc9-4ac1-a814-bd6b2a14f3db" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_839b11a1-58b4-413c-94c2-72332d734323" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2bd177e4-fdc9-4ac1-a814-bd6b2a14f3db" xlink:to="loc_srt_ProductOrServiceAxis_839b11a1-58b4-413c-94c2-72332d734323" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_839b11a1-58b4-413c-94c2-72332d734323_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_839b11a1-58b4-413c-94c2-72332d734323" xlink:to="loc_srt_ProductsAndServicesDomain_839b11a1-58b4-413c-94c2-72332d734323_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2cce3798-64c5-4725-b0da-18bd65e55695" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_839b11a1-58b4-413c-94c2-72332d734323" xlink:to="loc_srt_ProductsAndServicesDomain_2cce3798-64c5-4725-b0da-18bd65e55695" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_371d87f9-5b02-4dee-84af-1816b10a012d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2cce3798-64c5-4725-b0da-18bd65e55695" xlink:to="loc_us-gaap_ProductMember_371d87f9-5b02-4dee-84af-1816b10a012d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_GrantAndCollaborationMember_54c76349-f0a7-459c-9cb5-95abb2b80e07" xlink:href="ptct-20200630.xsd#ptct_GrantAndCollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2cce3798-64c5-4725-b0da-18bd65e55695" xlink:to="loc_ptct_GrantAndCollaborationMember_54c76349-f0a7-459c-9cb5-95abb2b80e07" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" xlink:type="simple" xlink:href="ptct-20200630.xsd#ConsolidatedStatementsofComprehensiveLossunaudited"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" xlink:type="extended" id="ie2de8d68fdc44cdc91b806bf271ec095_ConsolidatedStatementsofComprehensiveLossunaudited"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="ptct-20200630.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i3c1fa26fa4404ebbaebe952388687219_ConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b61415cd-a8a4-403a-a3d3-6d7b653dae56" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6df88fc6-1e9c-4ec7-8b35-8bd3b0f18d1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b61415cd-a8a4-403a-a3d3-6d7b653dae56" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6df88fc6-1e9c-4ec7-8b35-8bd3b0f18d1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_05776ddd-3073-41b7-927c-31cbd5ef4210" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6df88fc6-1e9c-4ec7-8b35-8bd3b0f18d1d" xlink:to="loc_us-gaap_SharesIssued_05776ddd-3073-41b7-927c-31cbd5ef4210" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_372dc859-a347-4038-818f-507ada4ccfb0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6df88fc6-1e9c-4ec7-8b35-8bd3b0f18d1d" xlink:to="loc_us-gaap_StockholdersEquity_372dc859-a347-4038-818f-507ada4ccfb0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3be244d0-9c70-4431-9f08-d313bdf54f05" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6df88fc6-1e9c-4ec7-8b35-8bd3b0f18d1d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3be244d0-9c70-4431-9f08-d313bdf54f05" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2999816f-0a85-48e0-a8da-70dabebc2f2a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6df88fc6-1e9c-4ec7-8b35-8bd3b0f18d1d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2999816f-0a85-48e0-a8da-70dabebc2f2a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_b327e54a-6f83-40ce-ba98-17ef2a57b966" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6df88fc6-1e9c-4ec7-8b35-8bd3b0f18d1d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_b327e54a-6f83-40ce-ba98-17ef2a57b966" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_6c97ee9e-34f1-4978-ad88-37a230a51372" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6df88fc6-1e9c-4ec7-8b35-8bd3b0f18d1d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_6c97ee9e-34f1-4978-ad88-37a230a51372" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_f5295901-98a0-417f-bfaa-78f822fd967c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6df88fc6-1e9c-4ec7-8b35-8bd3b0f18d1d" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_f5295901-98a0-417f-bfaa-78f822fd967c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_StockIssuedDuringPeriodSharesExchangeRights_4c2bd693-88a8-4f5b-abb9-61bb2da4d952" xlink:href="ptct-20200630.xsd#ptct_StockIssuedDuringPeriodSharesExchangeRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6df88fc6-1e9c-4ec7-8b35-8bd3b0f18d1d" xlink:to="loc_ptct_StockIssuedDuringPeriodSharesExchangeRights_4c2bd693-88a8-4f5b-abb9-61bb2da4d952" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_StockIssuedDuringPeriodValueExchangeRights_36ed1eff-72f0-47f9-b99e-eb10de7d635d" xlink:href="ptct-20200630.xsd#ptct_StockIssuedDuringPeriodValueExchangeRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6df88fc6-1e9c-4ec7-8b35-8bd3b0f18d1d" xlink:to="loc_ptct_StockIssuedDuringPeriodValueExchangeRights_36ed1eff-72f0-47f9-b99e-eb10de7d635d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_72f1ffc2-bc20-4c90-8d56-3dde7608ccd1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6df88fc6-1e9c-4ec7-8b35-8bd3b0f18d1d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_72f1ffc2-bc20-4c90-8d56-3dde7608ccd1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_81349c77-ea7f-47fa-addf-88945cb4a3fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6df88fc6-1e9c-4ec7-8b35-8bd3b0f18d1d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_81349c77-ea7f-47fa-addf-88945cb4a3fc" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_5b50808c-a074-4007-a9c3-0ab3f502f981" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6df88fc6-1e9c-4ec7-8b35-8bd3b0f18d1d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_5b50808c-a074-4007-a9c3-0ab3f502f981" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_a323b4c3-aacd-4613-be3f-1fbe4b9189dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6df88fc6-1e9c-4ec7-8b35-8bd3b0f18d1d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_a323b4c3-aacd-4613-be3f-1fbe4b9189dc" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1eb2b786-15e9-4edd-9f9d-3ffb0874b8ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6df88fc6-1e9c-4ec7-8b35-8bd3b0f18d1d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1eb2b786-15e9-4edd-9f9d-3ffb0874b8ab" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_91a418a6-ae86-44e3-ad1f-047a6981b470" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6df88fc6-1e9c-4ec7-8b35-8bd3b0f18d1d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_91a418a6-ae86-44e3-ad1f-047a6981b470" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_fc55e6cb-7a6f-4d15-beae-e88c287b189b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6df88fc6-1e9c-4ec7-8b35-8bd3b0f18d1d" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_fc55e6cb-7a6f-4d15-beae-e88c287b189b" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor_1d3c9520-a101-4b8c-9e89-020541aab766" xlink:href="ptct-20200630.xsd#ptct_AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6df88fc6-1e9c-4ec7-8b35-8bd3b0f18d1d" xlink:to="loc_ptct_AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor_1d3c9520-a101-4b8c-9e89-020541aab766" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPeriodIncreaseDecrease_a969e38c-1952-4c1c-b7ad-3ddef2ee5a31" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6df88fc6-1e9c-4ec7-8b35-8bd3b0f18d1d" xlink:to="loc_us-gaap_StockholdersEquityPeriodIncreaseDecrease_a969e38c-1952-4c1c-b7ad-3ddef2ee5a31" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c4584793-8d2f-4800-9034-a7052b16409f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6df88fc6-1e9c-4ec7-8b35-8bd3b0f18d1d" xlink:to="loc_us-gaap_NetIncomeLoss_c4584793-8d2f-4800-9034-a7052b16409f" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0dfdddc2-0c8a-4043-843d-056bfb1d7b98" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6df88fc6-1e9c-4ec7-8b35-8bd3b0f18d1d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0dfdddc2-0c8a-4043-843d-056bfb1d7b98" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_49de5333-7a62-49f9-8089-9eb15b7d0a6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6b983044-a12d-4930-b2c8-432725293d1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_492538fb-3131-49da-b337-85d1acc745dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_b61415cd-a8a4-403a-a3d3-6d7b653dae56" xlink:to="loc_us-gaap_StatementTable_492538fb-3131-49da-b337-85d1acc745dd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8aad0cb6-386b-4849-8ef3-0cd911225bd7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_492538fb-3131-49da-b337-85d1acc745dd" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8aad0cb6-386b-4849-8ef3-0cd911225bd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8aad0cb6-386b-4849-8ef3-0cd911225bd7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8aad0cb6-386b-4849-8ef3-0cd911225bd7" xlink:to="loc_us-gaap_EquityComponentDomain_8aad0cb6-386b-4849-8ef3-0cd911225bd7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_36184668-7401-43a6-9c91-36dc5deb12ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8aad0cb6-386b-4849-8ef3-0cd911225bd7" xlink:to="loc_us-gaap_EquityComponentDomain_36184668-7401-43a6-9c91-36dc5deb12ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a35e48d7-7cdd-4958-92ce-91f52f0024fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_36184668-7401-43a6-9c91-36dc5deb12ed" xlink:to="loc_us-gaap_CommonStockMember_a35e48d7-7cdd-4958-92ce-91f52f0024fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f1589cd3-c24f-4972-acbf-49c493423563" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_36184668-7401-43a6-9c91-36dc5deb12ed" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f1589cd3-c24f-4972-acbf-49c493423563" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5a1abb0a-d2c3-4be7-9539-ecb5abb74a0e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_36184668-7401-43a6-9c91-36dc5deb12ed" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5a1abb0a-d2c3-4be7-9539-ecb5abb74a0e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_2e6856d7-74c8-4892-8d16-e6c6af04841c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_36184668-7401-43a6-9c91-36dc5deb12ed" xlink:to="loc_us-gaap_RetainedEarningsMember_2e6856d7-74c8-4892-8d16-e6c6af04841c" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited" xlink:type="simple" xlink:href="ptct-20200630.xsd#ConsolidatedStatementsofCashFlowsunaudited"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited" xlink:type="extended" id="i8a311902dbe1484da2792ac7dce2b002_ConsolidatedStatementsofCashFlowsunaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_371604fb-ae60-479e-bd83-4e57f25d1f29" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_93f6e9b3-a5bd-495f-8c13-4a0e6727cd8a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_371604fb-ae60-479e-bd83-4e57f25d1f29" xlink:to="loc_us-gaap_StatementTable_93f6e9b3-a5bd-495f-8c13-4a0e6727cd8a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_e13a98ea-5ae0-4811-a5cb-5e92ad98ca7f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_93f6e9b3-a5bd-495f-8c13-4a0e6727cd8a" xlink:to="loc_srt_RestatementAxis_e13a98ea-5ae0-4811-a5cb-5e92ad98ca7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_e13a98ea-5ae0-4811-a5cb-5e92ad98ca7f_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_e13a98ea-5ae0-4811-a5cb-5e92ad98ca7f" xlink:to="loc_srt_RestatementDomain_e13a98ea-5ae0-4811-a5cb-5e92ad98ca7f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_b521027e-183b-4790-baea-46515a10525d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_e13a98ea-5ae0-4811-a5cb-5e92ad98ca7f" xlink:to="loc_srt_RestatementDomain_b521027e-183b-4790-baea-46515a10525d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/TheCompany" xlink:type="simple" xlink:href="ptct-20200630.xsd#TheCompany"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/TheCompany" xlink:type="extended" id="i80b3500041bc4f8aa9dd46a17d465ace_TheCompany"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/TheCompanyNarrativeDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#TheCompanyNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/TheCompanyNarrativeDetails" xlink:type="extended" id="i53f54b74561e4d8b86e2b697ae7787c6_TheCompanyNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4e596faa-c840-4f4f-ac65-9dc449c78f76" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_ea4464f9-d0f8-46bb-b263-425cab6b43f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e596faa-c840-4f4f-ac65-9dc449c78f76" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_ea4464f9-d0f8-46bb-b263-425cab6b43f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_a091921c-35f3-47e7-a02c-1da411c01e08" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e596faa-c840-4f4f-ac65-9dc449c78f76" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_a091921c-35f3-47e7-a02c-1da411c01e08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity_67a1004a-5fa9-46a3-9644-19682a9f977c" xlink:href="ptct-20200630.xsd#ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e596faa-c840-4f4f-ac65-9dc449c78f76" xlink:to="loc_ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity_67a1004a-5fa9-46a3-9644-19682a9f977c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod_78e54f70-eaa0-4059-b931-6776634592a9" xlink:href="ptct-20200630.xsd#ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e596faa-c840-4f4f-ac65-9dc449c78f76" xlink:to="loc_ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod_78e54f70-eaa0-4059-b931-6776634592a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing_d2d6c4a4-1c3d-4441-9ce5-f82706d0fb56" xlink:href="ptct-20200630.xsd#ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e596faa-c840-4f4f-ac65-9dc449c78f76" xlink:to="loc_ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing_d2d6c4a4-1c3d-4441-9ce5-f82706d0fb56" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f4828cd7-46f9-4ec9-b950-40c67de62815" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e596faa-c840-4f4f-ac65-9dc449c78f76" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f4828cd7-46f9-4ec9-b950-40c67de62815" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_85b995a1-2677-43f3-b27a-82e9465098e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e596faa-c840-4f4f-ac65-9dc449c78f76" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_85b995a1-2677-43f3-b27a-82e9465098e5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_PaymentsforAssetAcquisitions_cf5c7f03-73be-4cb6-9acd-fe2371e7a583" xlink:href="ptct-20200630.xsd#ptct_PaymentsforAssetAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e596faa-c840-4f4f-ac65-9dc449c78f76" xlink:to="loc_ptct_PaymentsforAssetAcquisitions_cf5c7f03-73be-4cb6-9acd-fe2371e7a583" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_LoanAdvance_fbafac76-1be5-4189-891d-c18824c4f519" xlink:href="ptct-20200630.xsd#ptct_LoanAdvance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e596faa-c840-4f4f-ac65-9dc449c78f76" xlink:to="loc_ptct_LoanAdvance_fbafac76-1be5-4189-891d-c18824c4f519" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1_06d199fe-35b2-4b63-b85a-ffa3342255d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e596faa-c840-4f4f-ac65-9dc449c78f76" xlink:to="loc_us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1_06d199fe-35b2-4b63-b85a-ffa3342255d4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_SharesissuedunderRightsExchangeAgreement_090e46a7-c917-40ad-a1f7-fe8e8a42e49d" xlink:href="ptct-20200630.xsd#ptct_SharesissuedunderRightsExchangeAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e596faa-c840-4f4f-ac65-9dc449c78f76" xlink:to="loc_ptct_SharesissuedunderRightsExchangeAgreement_090e46a7-c917-40ad-a1f7-fe8e8a42e49d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_SharesremainingtoissueunderRightsExchangeAgreement_12bc2c00-b362-4ff2-9a06-15ccb8f6217b" xlink:href="ptct-20200630.xsd#ptct_SharesremainingtoissueunderRightsExchangeAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e596faa-c840-4f4f-ac65-9dc449c78f76" xlink:to="loc_ptct_SharesremainingtoissueunderRightsExchangeAgreement_12bc2c00-b362-4ff2-9a06-15ccb8f6217b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount_39ddf1ad-16f9-4ec9-98fd-f8c9baf73650" xlink:href="ptct-20200630.xsd#ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e596faa-c840-4f4f-ac65-9dc449c78f76" xlink:to="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount_39ddf1ad-16f9-4ec9-98fd-f8c9baf73650" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DevelopmentandPotentialRegulatoryApprovalPaymentObligation_3385b729-03f1-45c4-abb0-e88b2d27af67" xlink:href="ptct-20200630.xsd#ptct_DevelopmentandPotentialRegulatoryApprovalPaymentObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e596faa-c840-4f4f-ac65-9dc449c78f76" xlink:to="loc_ptct_DevelopmentandPotentialRegulatoryApprovalPaymentObligation_3385b729-03f1-45c4-abb0-e88b2d27af67" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture_0e6ffc12-49ee-490e-ab4d-9643fe3d2f45" xlink:href="ptct-20200630.xsd#ptct_DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e596faa-c840-4f4f-ac65-9dc449c78f76" xlink:to="loc_ptct_DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture_0e6ffc12-49ee-490e-ab4d-9643fe3d2f45" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture_33c5afef-b046-424c-b2a4-4849537a97e7" xlink:href="ptct-20200630.xsd#ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e596faa-c840-4f4f-ac65-9dc449c78f76" xlink:to="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture_33c5afef-b046-424c-b2a4-4849537a97e7" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone_7acf15de-bc3d-41a2-94a9-958343613ab4" xlink:href="ptct-20200630.xsd#ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e596faa-c840-4f4f-ac65-9dc449c78f76" xlink:to="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone_7acf15de-bc3d-41a2-94a9-958343613ab4" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage_bc05f7b1-1477-4b30-b256-e93f8b592b04" xlink:href="ptct-20200630.xsd#ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e596faa-c840-4f4f-ac65-9dc449c78f76" xlink:to="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage_bc05f7b1-1477-4b30-b256-e93f8b592b04" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_SharestoissueunderRightsExchangeAgreement_8810b9d4-5686-4ca0-adf7-8f96fff4f256" xlink:href="ptct-20200630.xsd#ptct_SharestoissueunderRightsExchangeAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e596faa-c840-4f4f-ac65-9dc449c78f76" xlink:to="loc_ptct_SharestoissueunderRightsExchangeAgreement_8810b9d4-5686-4ca0-adf7-8f96fff4f256" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_CashconsiderationpaymentunderRightsExchangeAgreement_46488ba3-6a70-4f15-882a-a946990784ec" xlink:href="ptct-20200630.xsd#ptct_CashconsiderationpaymentunderRightsExchangeAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e596faa-c840-4f4f-ac65-9dc449c78f76" xlink:to="loc_ptct_CashconsiderationpaymentunderRightsExchangeAgreement_46488ba3-6a70-4f15-882a-a946990784ec" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_290872b7-f809-4dc0-9672-1ad5cb1a75f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e596faa-c840-4f4f-ac65-9dc449c78f76" xlink:to="loc_us-gaap_DebtInstrumentTable_290872b7-f809-4dc0-9672-1ad5cb1a75f7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_59c810ad-8fa6-4563-9472-a2a81749e396" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_290872b7-f809-4dc0-9672-1ad5cb1a75f7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_59c810ad-8fa6-4563-9472-a2a81749e396" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_59c810ad-8fa6-4563-9472-a2a81749e396_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_59c810ad-8fa6-4563-9472-a2a81749e396" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_59c810ad-8fa6-4563-9472-a2a81749e396_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c422ae84-8027-4393-9e34-dbd6fa4b7fdd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_59c810ad-8fa6-4563-9472-a2a81749e396" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c422ae84-8027-4393-9e34-dbd6fa4b7fdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_BioElectronMember_87926918-5808-48f9-8e9b-ae19823a856e" xlink:href="ptct-20200630.xsd#ptct_BioElectronMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c422ae84-8027-4393-9e34-dbd6fa4b7fdd" xlink:to="loc_ptct_BioElectronMember_87926918-5808-48f9-8e9b-ae19823a856e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_23822251-cb8e-4525-8ab6-21c2848834ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_290872b7-f809-4dc0-9672-1ad5cb1a75f7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_23822251-cb8e-4525-8ab6-21c2848834ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_23822251-cb8e-4525-8ab6-21c2848834ad_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_23822251-cb8e-4525-8ab6-21c2848834ad" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_23822251-cb8e-4525-8ab6-21c2848834ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f62a08f1-c5f7-4b01-a622-79da0e94811d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_23822251-cb8e-4525-8ab6-21c2848834ad" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f62a08f1-c5f7-4b01-a622-79da0e94811d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AgilisMember_535009d0-e2ef-4bda-8103-2717a199383b" xlink:href="ptct-20200630.xsd#ptct_AgilisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f62a08f1-c5f7-4b01-a622-79da0e94811d" xlink:to="loc_ptct_AgilisMember_535009d0-e2ef-4bda-8103-2717a199383b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ba27e9d4-2e5f-4464-a0a3-b5f17ca10f7b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_290872b7-f809-4dc0-9672-1ad5cb1a75f7" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ba27e9d4-2e5f-4464-a0a3-b5f17ca10f7b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ba27e9d4-2e5f-4464-a0a3-b5f17ca10f7b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ba27e9d4-2e5f-4464-a0a3-b5f17ca10f7b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ba27e9d4-2e5f-4464-a0a3-b5f17ca10f7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9dc3a72d-c2f7-4b3c-977d-1aae91a47e4f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ba27e9d4-2e5f-4464-a0a3-b5f17ca10f7b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9dc3a72d-c2f7-4b3c-977d-1aae91a47e4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncollaborativeArrangementTransactionsMember_c69c1f2b-0bdb-4e30-84ca-b371a389cb27" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncollaborativeArrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9dc3a72d-c2f7-4b3c-977d-1aae91a47e4f" xlink:to="loc_us-gaap_NoncollaborativeArrangementTransactionsMember_c69c1f2b-0bdb-4e30-84ca-b371a389cb27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_35ec2dbe-cd82-4297-a244-4787694ec130" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_290872b7-f809-4dc0-9672-1ad5cb1a75f7" xlink:to="loc_srt_CounterpartyNameAxis_35ec2dbe-cd82-4297-a244-4787694ec130" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_35ec2dbe-cd82-4297-a244-4787694ec130_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_35ec2dbe-cd82-4297-a244-4787694ec130" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_35ec2dbe-cd82-4297-a244-4787694ec130_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_915d2ea7-0ff4-4fdd-9354-3c9bde0d8027" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_35ec2dbe-cd82-4297-a244-4787694ec130" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_915d2ea7-0ff4-4fdd-9354-3c9bde0d8027" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_MarathonPharmaceuticalsLLCMember_edeab969-92ce-4121-b028-e7b79b3735e0" xlink:href="ptct-20200630.xsd#ptct_MarathonPharmaceuticalsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_915d2ea7-0ff4-4fdd-9354-3c9bde0d8027" xlink:to="loc_ptct_MarathonPharmaceuticalsLLCMember_edeab969-92ce-4121-b028-e7b79b3735e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_cfe5d39c-1554-4a82-9949-65a34ad5c550" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_290872b7-f809-4dc0-9672-1ad5cb1a75f7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_cfe5d39c-1554-4a82-9949-65a34ad5c550" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_cfe5d39c-1554-4a82-9949-65a34ad5c550_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cfe5d39c-1554-4a82-9949-65a34ad5c550" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_cfe5d39c-1554-4a82-9949-65a34ad5c550_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4bc1df1c-dcea-4d2e-bde4-f5d03b6a63eb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cfe5d39c-1554-4a82-9949-65a34ad5c550" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4bc1df1c-dcea-4d2e-bde4-f5d03b6a63eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_2594b7e9-acb7-4921-9330-cb360356b1a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4bc1df1c-dcea-4d2e-bde4-f5d03b6a63eb" xlink:to="loc_us-gaap_ConvertibleDebtMember_2594b7e9-acb7-4921-9330-cb360356b1a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_01e4120b-79e0-446b-8ae4-fa731e89fd12" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_290872b7-f809-4dc0-9672-1ad5cb1a75f7" xlink:to="loc_us-gaap_DebtInstrumentAxis_01e4120b-79e0-446b-8ae4-fa731e89fd12" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_01e4120b-79e0-446b-8ae4-fa731e89fd12_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_01e4120b-79e0-446b-8ae4-fa731e89fd12" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_01e4120b-79e0-446b-8ae4-fa731e89fd12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e04e7c54-4ef4-409e-aab4-b1b00508f450" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_01e4120b-79e0-446b-8ae4-fa731e89fd12" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e04e7c54-4ef4-409e-aab4-b1b00508f450" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member_65387325-f92a-4ebf-b8c8-f0d2e197c1a9" xlink:href="ptct-20200630.xsd#ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e04e7c54-4ef4-409e-aab4-b1b00508f450" xlink:to="loc_ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member_65387325-f92a-4ebf-b8c8-f0d2e197c1a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_e8803872-66e7-49ec-9f61-0f7b1b1a5210" xlink:href="ptct-20200630.xsd#ptct_ConvertibleSeniorNotes3.0PercentDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e04e7c54-4ef4-409e-aab4-b1b00508f450" xlink:to="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_e8803872-66e7-49ec-9f61-0f7b1b1a5210" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b22555a7-b0e6-49ab-a8cb-36d106eb6187" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_290872b7-f809-4dc0-9672-1ad5cb1a75f7" xlink:to="loc_us-gaap_PlanNameAxis_b22555a7-b0e6-49ab-a8cb-36d106eb6187" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b22555a7-b0e6-49ab-a8cb-36d106eb6187_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_b22555a7-b0e6-49ab-a8cb-36d106eb6187" xlink:to="loc_us-gaap_PlanNameDomain_b22555a7-b0e6-49ab-a8cb-36d106eb6187_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_12e6f154-84ce-4882-8ba2-5f7e3c2f05b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_b22555a7-b0e6-49ab-a8cb-36d106eb6187" xlink:to="loc_us-gaap_PlanNameDomain_12e6f154-84ce-4882-8ba2-5f7e3c2f05b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_RightsExchangeAgreementMember_c9a50d04-ac9f-44c0-97d0-3ac15d49e284" xlink:href="ptct-20200630.xsd#ptct_RightsExchangeAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_12e6f154-84ce-4882-8ba2-5f7e3c2f05b2" xlink:to="loc_ptct_RightsExchangeAgreementMember_c9a50d04-ac9f-44c0-97d0-3ac15d49e284" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a4a445de-25e7-4f27-bc9b-4bb62049afad" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_290872b7-f809-4dc0-9672-1ad5cb1a75f7" xlink:to="loc_srt_RangeAxis_a4a445de-25e7-4f27-bc9b-4bb62049afad" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a4a445de-25e7-4f27-bc9b-4bb62049afad_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a4a445de-25e7-4f27-bc9b-4bb62049afad" xlink:to="loc_srt_RangeMember_a4a445de-25e7-4f27-bc9b-4bb62049afad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7b9f7dd2-812d-4847-9a9b-8ffbe59a2bf7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a4a445de-25e7-4f27-bc9b-4bb62049afad" xlink:to="loc_srt_RangeMember_7b9f7dd2-812d-4847-9a9b-8ffbe59a2bf7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1e78fda4-7805-48d9-92fa-76b896ec6807" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7b9f7dd2-812d-4847-9a9b-8ffbe59a2bf7" xlink:to="loc_srt_MinimumMember_1e78fda4-7805-48d9-92fa-76b896ec6807" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0b4a2323-560f-4f37-8237-be71437dac5e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7b9f7dd2-812d-4847-9a9b-8ffbe59a2bf7" xlink:to="loc_srt_MaximumMember_0b4a2323-560f-4f37-8237-be71437dac5e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/Summaryofsignificantaccountingpolicies" xlink:type="simple" xlink:href="ptct-20200630.xsd#Summaryofsignificantaccountingpolicies"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/Summaryofsignificantaccountingpolicies" xlink:type="extended" id="i7e04828a1bec4d14ac468cdb4bf06f4c_Summaryofsignificantaccountingpolicies"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesPolicies" xlink:type="simple" xlink:href="ptct-20200630.xsd#SummaryofsignificantaccountingpoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesPolicies" xlink:type="extended" id="i20fbec21ec6546f18655f00813dd70e4_SummaryofsignificantaccountingpoliciesPolicies"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesTables" xlink:type="simple" xlink:href="ptct-20200630.xsd#SummaryofsignificantaccountingpoliciesTables"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesTables" xlink:type="extended" id="i47602bc73e954daea28bca1ebbf0e6b6_SummaryofsignificantaccountingpoliciesTables"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesInventoryDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#SummaryofsignificantaccountingpoliciesInventoryDetails"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesInventoryDetails" xlink:type="extended" id="id1c69b5de5ff4c3082f759393ac29c6e_SummaryofsignificantaccountingpoliciesInventoryDetails"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#SummaryofsignificantaccountingpoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" xlink:type="extended" id="if0d3ff5a490f470380235d40ea21b2db_SummaryofsignificantaccountingpoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_7e43155a-fd96-46f2-8617-c3e569005294" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_f95d4d10-94d0-4527-87da-d50cb2647519" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_7e43155a-fd96-46f2-8617-c3e569005294" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_f95d4d10-94d0-4527-87da-d50cb2647519" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_0bcd95ef-2059-4130-b918-a2897daae668" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_7e43155a-fd96-46f2-8617-c3e569005294" xlink:to="loc_us-gaap_InventoryWriteDown_0bcd95ef-2059-4130-b918-a2897daae668" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_NetProductSales_d439c8a7-10c5-4527-acc5-639422d2529c" xlink:href="ptct-20200630.xsd#ptct_NetProductSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_7e43155a-fd96-46f2-8617-c3e569005294" xlink:to="loc_ptct_NetProductSales_d439c8a7-10c5-4527-acc5-639422d2529c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_b62c48bf-c6d5-44ac-9af9-96f14d00fbdb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_7e43155a-fd96-46f2-8617-c3e569005294" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_b62c48bf-c6d5-44ac-9af9-96f14d00fbdb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_Termforletterofcredit_2c05763b-f3bf-4239-b253-87ab6d823cb2" xlink:href="ptct-20200630.xsd#ptct_Termforletterofcredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_7e43155a-fd96-46f2-8617-c3e569005294" xlink:to="loc_ptct_Termforletterofcredit_2c05763b-f3bf-4239-b253-87ab6d823cb2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c2d48277-cb2c-4a4e-9b56-37c00a7bb718" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_7e43155a-fd96-46f2-8617-c3e569005294" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c2d48277-cb2c-4a4e-9b56-37c00a7bb718" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_041aefa0-7135-4f6c-b97f-c77fcbeb9221" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_7e43155a-fd96-46f2-8617-c3e569005294" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_041aefa0-7135-4f6c-b97f-c77fcbeb9221" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_dc783458-d974-4737-bb47-5466ac49a422" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_7e43155a-fd96-46f2-8617-c3e569005294" xlink:to="loc_us-gaap_DeferredTaxLiabilities_dc783458-d974-4737-bb47-5466ac49a422" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_713a577b-27bf-41da-a6d5-80182345baa4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_7e43155a-fd96-46f2-8617-c3e569005294" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_713a577b-27bf-41da-a6d5-80182345baa4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_b12623c6-a985-43f5-8f24-5a7fc1b97e38" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_7e43155a-fd96-46f2-8617-c3e569005294" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_b12623c6-a985-43f5-8f24-5a7fc1b97e38" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4ebedbfb-3c0e-4a12-9204-aeb3c4e934f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_b12623c6-a985-43f5-8f24-5a7fc1b97e38" xlink:to="loc_us-gaap_DebtInstrumentAxis_4ebedbfb-3c0e-4a12-9204-aeb3c4e934f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4ebedbfb-3c0e-4a12-9204-aeb3c4e934f9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_4ebedbfb-3c0e-4a12-9204-aeb3c4e934f9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4ebedbfb-3c0e-4a12-9204-aeb3c4e934f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_31557e6c-d0e3-4374-ae0f-d087d850620d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_4ebedbfb-3c0e-4a12-9204-aeb3c4e934f9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_31557e6c-d0e3-4374-ae0f-d087d850620d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_FifthAnniversaryMember_c48d604f-f1a5-4a14-832e-6cd82822f8e9" xlink:href="ptct-20200630.xsd#ptct_FifthAnniversaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31557e6c-d0e3-4374-ae0f-d087d850620d" xlink:to="loc_ptct_FifthAnniversaryMember_c48d604f-f1a5-4a14-832e-6cd82822f8e9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesReconciliationofcashDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#SummaryofsignificantaccountingpoliciesReconciliationofcashDetails"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesReconciliationofcashDetails" xlink:type="extended" id="iad1de429f567461aabd5012270b65c56_SummaryofsignificantaccountingpoliciesReconciliationofcashDetails"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/Leases" xlink:type="simple" xlink:href="ptct-20200630.xsd#Leases"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/Leases" xlink:type="extended" id="ie21e79347ac5444493f83afdae5b1d4d_Leases"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/LeasesTables" xlink:type="simple" xlink:href="ptct-20200630.xsd#LeasesTables"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/LeasesTables" xlink:type="extended" id="i72fbe0a135084243afcaf17210f55f60_LeasesTables"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i29af8602986c4871899a8eaa2615e58a_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_ba1982cd-fd62-4991-a29c-bcfc52bcff4d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_NumberOfOperatingLeases_8bd77c1f-295e-479c-8025-369e23aade93" xlink:href="ptct-20200630.xsd#ptct_NumberOfOperatingLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ba1982cd-fd62-4991-a29c-bcfc52bcff4d" xlink:to="loc_ptct_NumberOfOperatingLeases_8bd77c1f-295e-479c-8025-369e23aade93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_027716f6-e8e6-42a4-9d85-a850006cf8c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ba1982cd-fd62-4991-a29c-bcfc52bcff4d" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_027716f6-e8e6-42a4-9d85-a850006cf8c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_49486be7-8da6-4b5b-9a63-9fcce80f7d33" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ba1982cd-fd62-4991-a29c-bcfc52bcff4d" xlink:to="loc_us-gaap_OperatingLeaseExpense_49486be7-8da6-4b5b-9a63-9fcce80f7d33" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_c71bf4bc-f8ea-4e18-b3c6-9e1807e7bab3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ba1982cd-fd62-4991-a29c-bcfc52bcff4d" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_c71bf4bc-f8ea-4e18-b3c6-9e1807e7bab3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_97922780-7f57-4517-9ed9-574082531fa0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ba1982cd-fd62-4991-a29c-bcfc52bcff4d" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_97922780-7f57-4517-9ed9-574082531fa0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_Numberofterms_be944df5-ee4e-46ce-ae6a-de54fd3aa6b2" xlink:href="ptct-20200630.xsd#ptct_Numberofterms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ba1982cd-fd62-4991-a29c-bcfc52bcff4d" xlink:to="loc_ptct_Numberofterms_be944df5-ee4e-46ce-ae6a-de54fd3aa6b2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_da4d20f0-62c0-47b9-9e42-07e923f37909" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ba1982cd-fd62-4991-a29c-bcfc52bcff4d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_da4d20f0-62c0-47b9-9e42-07e923f37909" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_PercentOfMarketRate_6c09899f-49d1-44c2-b8c6-63397155a60e" xlink:href="ptct-20200630.xsd#ptct_PercentOfMarketRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ba1982cd-fd62-4991-a29c-bcfc52bcff4d" xlink:to="loc_ptct_PercentOfMarketRate_6c09899f-49d1-44c2-b8c6-63397155a60e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_6e52592b-dcdf-4c40-b4e1-c5b7af8693fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ba1982cd-fd62-4991-a29c-bcfc52bcff4d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_6e52592b-dcdf-4c40-b4e1-c5b7af8693fa" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c31545c8-1b64-4791-82bb-84b0289e3b0b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ba1982cd-fd62-4991-a29c-bcfc52bcff4d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c31545c8-1b64-4791-82bb-84b0289e3b0b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_dac91cc7-a0a0-42f0-9c74-561a12de7e37" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ba1982cd-fd62-4991-a29c-bcfc52bcff4d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_dac91cc7-a0a0-42f0-9c74-561a12de7e37" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_NumberOfOperatingLeaseLeaseNotyetCommenced_5219a9dd-1eb7-4551-adfe-b952874d8f79" xlink:href="ptct-20200630.xsd#ptct_NumberOfOperatingLeaseLeaseNotyetCommenced"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ba1982cd-fd62-4991-a29c-bcfc52bcff4d" xlink:to="loc_ptct_NumberOfOperatingLeaseLeaseNotyetCommenced_5219a9dd-1eb7-4551-adfe-b952874d8f79" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_86fc306e-146c-49c4-90b5-21ebf7c9a2dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ba1982cd-fd62-4991-a29c-bcfc52bcff4d" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_86fc306e-146c-49c4-90b5-21ebf7c9a2dc" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_b00e7227-d5a4-46c5-9b96-2bcd884c58a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ba1982cd-fd62-4991-a29c-bcfc52bcff4d" xlink:to="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_b00e7227-d5a4-46c5-9b96-2bcd884c58a3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_01598699-ef9f-423d-91ed-2bfa78450f82" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ba1982cd-fd62-4991-a29c-bcfc52bcff4d" xlink:to="loc_us-gaap_LeaseAndRentalExpense_01598699-ef9f-423d-91ed-2bfa78450f82" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_FinanceLeasePresentValueOfExceedsTheFairValue_b021cecb-4cbb-44b0-9fc5-b5543eeed2bb" xlink:href="ptct-20200630.xsd#ptct_FinanceLeasePresentValueOfExceedsTheFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ba1982cd-fd62-4991-a29c-bcfc52bcff4d" xlink:to="loc_ptct_FinanceLeasePresentValueOfExceedsTheFairValue_b021cecb-4cbb-44b0-9fc5-b5543eeed2bb" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_22f19754-4c7e-4fd3-8328-6a7ad7eef6bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ba1982cd-fd62-4991-a29c-bcfc52bcff4d" xlink:to="loc_us-gaap_OperatingLeaseCost_22f19754-4c7e-4fd3-8328-6a7ad7eef6bc" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ca1a35e2-20f9-4a61-9fa5-81766d995cff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ba1982cd-fd62-4991-a29c-bcfc52bcff4d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ca1a35e2-20f9-4a61-9fa5-81766d995cff" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_LeaseArea_48a091fd-c6ba-4292-9b18-ca0bc26e2e99" xlink:href="ptct-20200630.xsd#ptct_LeaseArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ba1982cd-fd62-4991-a29c-bcfc52bcff4d" xlink:to="loc_ptct_LeaseArea_48a091fd-c6ba-4292-9b18-ca0bc26e2e99" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_f7839595-26d2-45c2-b6d0-56fdd343aa5a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ba1982cd-fd62-4991-a29c-bcfc52bcff4d" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_f7839595-26d2-45c2-b6d0-56fdd343aa5a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_39611e10-7ea9-42d2-bb79-29376c129131" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f7839595-26d2-45c2-b6d0-56fdd343aa5a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_39611e10-7ea9-42d2-bb79-29376c129131" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_39611e10-7ea9-42d2-bb79-29376c129131_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_39611e10-7ea9-42d2-bb79-29376c129131" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_39611e10-7ea9-42d2-bb79-29376c129131_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3ff556ed-41d6-4111-ad12-5cea46d72def" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_39611e10-7ea9-42d2-bb79-29376c129131" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3ff556ed-41d6-4111-ad12-5cea46d72def" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_BioElectronMember_6586a7c8-66ca-4635-8330-0cdbb07a2d49" xlink:href="ptct-20200630.xsd#ptct_BioElectronMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3ff556ed-41d6-4111-ad12-5cea46d72def" xlink:to="loc_ptct_BioElectronMember_6586a7c8-66ca-4635-8330-0cdbb07a2d49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_7a373945-86fe-49b6-b8a4-ed990ca08904" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f7839595-26d2-45c2-b6d0-56fdd343aa5a" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_7a373945-86fe-49b6-b8a4-ed990ca08904" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_7a373945-86fe-49b6-b8a4-ed990ca08904_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_7a373945-86fe-49b6-b8a4-ed990ca08904" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_7a373945-86fe-49b6-b8a4-ed990ca08904_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_ccc2277c-0020-4c95-a271-53c820fd1264" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_7a373945-86fe-49b6-b8a4-ed990ca08904" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_ccc2277c-0020-4c95-a271-53c820fd1264" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_54aa064a-312f-4668-ac25-409bde2e78db" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NJ"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_ccc2277c-0020-4c95-a271-53c820fd1264" xlink:to="loc_stpr_NJ_54aa064a-312f-4668-ac25-409bde2e78db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_HopewellNewBuildingMember_2f009dd4-3185-42e2-a323-484604eb014d" xlink:href="ptct-20200630.xsd#ptct_HopewellNewBuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_ccc2277c-0020-4c95-a271-53c820fd1264" xlink:to="loc_ptct_HopewellNewBuildingMember_2f009dd4-3185-42e2-a323-484604eb014d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_TheCampusMember_b068fd98-44ab-4030-93e6-493554e5cb76" xlink:href="ptct-20200630.xsd#ptct_TheCampusMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_ccc2277c-0020-4c95-a271-53c820fd1264" xlink:to="loc_ptct_TheCampusMember_b068fd98-44ab-4030-93e6-493554e5cb76" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_HopewellCampusMember_a115782b-a2f0-4b62-b209-7d3c5cf050a1" xlink:href="ptct-20200630.xsd#ptct_HopewellCampusMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_ccc2277c-0020-4c95-a271-53c820fd1264" xlink:to="loc_ptct_HopewellCampusMember_a115782b-a2f0-4b62-b209-7d3c5cf050a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_MountainviewMember_4de97b27-cd65-43af-838a-ac350a953182" xlink:href="ptct-20200630.xsd#ptct_MountainviewMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_ccc2277c-0020-4c95-a271-53c820fd1264" xlink:to="loc_ptct_MountainviewMember_4de97b27-cd65-43af-838a-ac350a953182" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_BridgewaterMember_1b9a56c0-58d6-4ce7-b31f-74ec9d6ed404" xlink:href="ptct-20200630.xsd#ptct_BridgewaterMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_ccc2277c-0020-4c95-a271-53c820fd1264" xlink:to="loc_ptct_BridgewaterMember_1b9a56c0-58d6-4ce7-b31f-74ec9d6ed404" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5d62d1b9-f62d-4938-a0da-a19c441ba107" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f7839595-26d2-45c2-b6d0-56fdd343aa5a" xlink:to="loc_srt_RangeAxis_5d62d1b9-f62d-4938-a0da-a19c441ba107" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5d62d1b9-f62d-4938-a0da-a19c441ba107_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5d62d1b9-f62d-4938-a0da-a19c441ba107" xlink:to="loc_srt_RangeMember_5d62d1b9-f62d-4938-a0da-a19c441ba107_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bb1da254-9529-4b01-9db7-f32d3a684fcb" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5d62d1b9-f62d-4938-a0da-a19c441ba107" xlink:to="loc_srt_RangeMember_bb1da254-9529-4b01-9db7-f32d3a684fcb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fe0473ad-b53c-4a7c-8579-2843164d998d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bb1da254-9529-4b01-9db7-f32d3a684fcb" xlink:to="loc_srt_MinimumMember_fe0473ad-b53c-4a7c-8579-2843164d998d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9504c55d-b3d0-4d59-aab0-f5e09ac2aa51" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bb1da254-9529-4b01-9db7-f32d3a684fcb" xlink:to="loc_srt_MaximumMember_9504c55d-b3d0-4d59-aab0-f5e09ac2aa51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7a12f682-164f-4490-bbc5-363af6fb39e1" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f7839595-26d2-45c2-b6d0-56fdd343aa5a" xlink:to="loc_srt_CounterpartyNameAxis_7a12f682-164f-4490-bbc5-363af6fb39e1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7a12f682-164f-4490-bbc5-363af6fb39e1_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_7a12f682-164f-4490-bbc5-363af6fb39e1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7a12f682-164f-4490-bbc5-363af6fb39e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7aadef83-b4f7-49b1-89f5-cc96eddb9503" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_7a12f682-164f-4490-bbc5-363af6fb39e1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7aadef83-b4f7-49b1-89f5-cc96eddb9503" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_HopewellCampusMember_0bb6d684-52dc-415e-a59b-0cc1c133b1fd" xlink:href="ptct-20200630.xsd#ptct_HopewellCampusMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7aadef83-b4f7-49b1-89f5-cc96eddb9503" xlink:to="loc_ptct_HopewellCampusMember_0bb6d684-52dc-415e-a59b-0cc1c133b1fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_MassBioMember_a804abd4-117e-49f1-a09f-a0a3818ba73c" xlink:href="ptct-20200630.xsd#ptct_MassBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7aadef83-b4f7-49b1-89f5-cc96eddb9503" xlink:to="loc_ptct_MassBioMember_a804abd4-117e-49f1-a09f-a0a3818ba73c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_MountainviewMember_3cf6b390-044e-478d-b020-e07c9a7c5403" xlink:href="ptct-20200630.xsd#ptct_MountainviewMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7aadef83-b4f7-49b1-89f5-cc96eddb9503" xlink:to="loc_ptct_MountainviewMember_3cf6b390-044e-478d-b020-e07c9a7c5403" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_61412805-1e95-4ee1-be8c-879318cb9b2a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f7839595-26d2-45c2-b6d0-56fdd343aa5a" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_61412805-1e95-4ee1-be8c-879318cb9b2a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_61412805-1e95-4ee1-be8c-879318cb9b2a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_61412805-1e95-4ee1-be8c-879318cb9b2a" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_61412805-1e95-4ee1-be8c-879318cb9b2a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_e15c393d-9bdc-4f09-96e6-4af89eb1f33d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_61412805-1e95-4ee1-be8c-879318cb9b2a" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_e15c393d-9bdc-4f09-96e6-4af89eb1f33d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_FinanceLeaseMember_2e070d8c-7702-4521-ac80-e6bb1cb6e3cf" xlink:href="ptct-20200630.xsd#ptct_FinanceLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_e15c393d-9bdc-4f09-96e6-4af89eb1f33d" xlink:to="loc_ptct_FinanceLeaseMember_2e070d8c-7702-4521-ac80-e6bb1cb6e3cf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/LeasesLeasecostsDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#LeasesLeasecostsDetails"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/LeasesLeasecostsDetails" xlink:type="extended" id="ia0b0b136d0c440bb9f410502d8b00588_LeasesLeasecostsDetails"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/LeasesBalancesheetDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#LeasesBalancesheetDetails"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/LeasesBalancesheetDetails" xlink:type="extended" id="i5c36afdb22ce49df994280210fed8868_LeasesBalancesheetDetails"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/LeasesSupplementalleasetermsDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#LeasesSupplementalleasetermsDetails"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/LeasesSupplementalleasetermsDetails" xlink:type="extended" id="iba4bd3e9e2f7468c8c0e74a43d3e7bba_LeasesSupplementalleasetermsDetails"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/LeasesLeasepaymentsDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#LeasesLeasepaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/LeasesLeasepaymentsDetails" xlink:type="extended" id="i03cf27e5f81741ada7b9661b95744a20_LeasesLeasepaymentsDetails"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/LeasesCashflowDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#LeasesCashflowDetails"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/LeasesCashflowDetails" xlink:type="extended" id="id0abbcef19e7457997368516e017aa61_LeasesCashflowDetails"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/Acquisitions" xlink:type="simple" xlink:href="ptct-20200630.xsd#Acquisitions"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/Acquisitions" xlink:type="extended" id="iaf98c003a6844f50bcf0561efa9ac7f6_Acquisitions"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#AcquisitionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/AcquisitionsNarrativeDetails" xlink:type="extended" id="i7c6a92ea6111430eb943018deb8992f1_AcquisitionsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a9cf1fac-fa8d-47d7-b3aa-5b0d435e0938" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_PaymentsforAssetAcquisitions_e9001436-2868-4643-b01a-31b976a0db60" xlink:href="ptct-20200630.xsd#ptct_PaymentsforAssetAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a9cf1fac-fa8d-47d7-b3aa-5b0d435e0938" xlink:to="loc_ptct_PaymentsforAssetAcquisitions_e9001436-2868-4643-b01a-31b976a0db60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_PaymentsForAssetAcquisitionsUpfrontPayment_c2880059-3451-4681-8997-6e176d93b03b" xlink:href="ptct-20200630.xsd#ptct_PaymentsForAssetAcquisitionsUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a9cf1fac-fa8d-47d7-b3aa-5b0d435e0938" xlink:to="loc_ptct_PaymentsForAssetAcquisitionsUpfrontPayment_c2880059-3451-4681-8997-6e176d93b03b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_PaymentsForAssetAcquisitionsNetAssets_21d597b0-9901-401d-acb2-c1d30c4506e2" xlink:href="ptct-20200630.xsd#ptct_PaymentsForAssetAcquisitionsNetAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a9cf1fac-fa8d-47d7-b3aa-5b0d435e0938" xlink:to="loc_ptct_PaymentsForAssetAcquisitionsNetAssets_21d597b0-9901-401d-acb2-c1d30c4506e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_77f1e68f-8289-49a6-9ad8-0d716104b86d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a9cf1fac-fa8d-47d7-b3aa-5b0d435e0938" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_77f1e68f-8289-49a6-9ad8-0d716104b86d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_710c2f15-65cd-4ae3-94ef-b75a4ae0e86b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a9cf1fac-fa8d-47d7-b3aa-5b0d435e0938" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_710c2f15-65cd-4ae3-94ef-b75a4ae0e86b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ConsiderationForAssetAcquisitions_d9c48a9f-f737-4008-b77e-636f735fc898" xlink:href="ptct-20200630.xsd#ptct_ConsiderationForAssetAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a9cf1fac-fa8d-47d7-b3aa-5b0d435e0938" xlink:to="loc_ptct_ConsiderationForAssetAcquisitions_d9c48a9f-f737-4008-b77e-636f735fc898" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_5baeb2c9-fb04-4e01-8e44-585a5c7edefa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a9cf1fac-fa8d-47d7-b3aa-5b0d435e0938" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_5baeb2c9-fb04-4e01-8e44-585a5c7edefa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AssetAcquisitionTransactionCosts_9edd1f36-fd23-433d-ad2a-a970ffda84bf" xlink:href="ptct-20200630.xsd#ptct_AssetAcquisitionTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a9cf1fac-fa8d-47d7-b3aa-5b0d435e0938" xlink:to="loc_ptct_AssetAcquisitionTransactionCosts_9edd1f36-fd23-433d-ad2a-a970ffda84bf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AssetAcquisitionConsiderationTransferred_7bf05185-484f-47e3-a9d9-859898d34540" xlink:href="ptct-20200630.xsd#ptct_AssetAcquisitionConsiderationTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a9cf1fac-fa8d-47d7-b3aa-5b0d435e0938" xlink:to="loc_ptct_AssetAcquisitionConsiderationTransferred_7bf05185-484f-47e3-a9d9-859898d34540" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AssetAcquisitionCash_5f552f90-f6d1-4406-934f-b196be3d9a62" xlink:href="ptct-20200630.xsd#ptct_AssetAcquisitionCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a9cf1fac-fa8d-47d7-b3aa-5b0d435e0938" xlink:to="loc_ptct_AssetAcquisitionCash_5f552f90-f6d1-4406-934f-b196be3d9a62" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AssetAcquisitionOtherAssets_838d7e50-4d59-4320-8e90-1f376e32fb0c" xlink:href="ptct-20200630.xsd#ptct_AssetAcquisitionOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a9cf1fac-fa8d-47d7-b3aa-5b0d435e0938" xlink:to="loc_ptct_AssetAcquisitionOtherAssets_838d7e50-4d59-4320-8e90-1f376e32fb0c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AssetAcquisitionInProcessResearchAndDevelopment_1565eb9c-3d1a-4609-85e6-4fd124df168d" xlink:href="ptct-20200630.xsd#ptct_AssetAcquisitionInProcessResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a9cf1fac-fa8d-47d7-b3aa-5b0d435e0938" xlink:to="loc_ptct_AssetAcquisitionInProcessResearchAndDevelopment_1565eb9c-3d1a-4609-85e6-4fd124df168d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AssetAcquisitionResearchAndDevelopmentExpense_75b98270-790d-40f0-81cb-9bb528f885fb" xlink:href="ptct-20200630.xsd#ptct_AssetAcquisitionResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a9cf1fac-fa8d-47d7-b3aa-5b0d435e0938" xlink:to="loc_ptct_AssetAcquisitionResearchAndDevelopmentExpense_75b98270-790d-40f0-81cb-9bb528f885fb" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AssetAcquisitionSellingGeneralAndAdministrativeExpense_9a5c6ab2-081e-429a-887a-3582e4923ee4" xlink:href="ptct-20200630.xsd#ptct_AssetAcquisitionSellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a9cf1fac-fa8d-47d7-b3aa-5b0d435e0938" xlink:to="loc_ptct_AssetAcquisitionSellingGeneralAndAdministrativeExpense_9a5c6ab2-081e-429a-887a-3582e4923ee4" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AssetAcquisitionMilestoneAmount_f3cf9fa9-74b7-4c80-9cb4-5040e9feb073" xlink:href="ptct-20200630.xsd#ptct_AssetAcquisitionMilestoneAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a9cf1fac-fa8d-47d7-b3aa-5b0d435e0938" xlink:to="loc_ptct_AssetAcquisitionMilestoneAmount_f3cf9fa9-74b7-4c80-9cb4-5040e9feb073" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AssetAcquisitionDevelopmentAndRegulatoryMilestones_d01c00fe-3ff1-457f-ab49-1919358f5c88" xlink:href="ptct-20200630.xsd#ptct_AssetAcquisitionDevelopmentAndRegulatoryMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a9cf1fac-fa8d-47d7-b3aa-5b0d435e0938" xlink:to="loc_ptct_AssetAcquisitionDevelopmentAndRegulatoryMilestones_d01c00fe-3ff1-457f-ab49-1919358f5c88" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AssetAcquisitionNetSalesMilestone_558a93be-ffa5-492c-88f3-9ca70517a376" xlink:href="ptct-20200630.xsd#ptct_AssetAcquisitionNetSalesMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a9cf1fac-fa8d-47d7-b3aa-5b0d435e0938" xlink:to="loc_ptct_AssetAcquisitionNetSalesMilestone_558a93be-ffa5-492c-88f3-9ca70517a376" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AssetAcquisitionInitialMilestone_337d8606-afa3-4c3a-8a1a-8318beee96d9" xlink:href="ptct-20200630.xsd#ptct_AssetAcquisitionInitialMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a9cf1fac-fa8d-47d7-b3aa-5b0d435e0938" xlink:to="loc_ptct_AssetAcquisitionInitialMilestone_337d8606-afa3-4c3a-8a1a-8318beee96d9" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense_61d367ef-5bdc-4cf0-a35e-4548f49ba031" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a9cf1fac-fa8d-47d7-b3aa-5b0d435e0938" xlink:to="loc_us-gaap_OtherResearchAndDevelopmentExpense_61d367ef-5bdc-4cf0-a35e-4548f49ba031" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_63585aea-6cad-46fe-812e-ea27e6771c7b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a9cf1fac-fa8d-47d7-b3aa-5b0d435e0938" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_63585aea-6cad-46fe-812e-ea27e6771c7b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0401fd87-a746-4085-b506-25cc5d9c46e7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_63585aea-6cad-46fe-812e-ea27e6771c7b" xlink:to="loc_srt_CounterpartyNameAxis_0401fd87-a746-4085-b506-25cc5d9c46e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0401fd87-a746-4085-b506-25cc5d9c46e7_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_0401fd87-a746-4085-b506-25cc5d9c46e7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0401fd87-a746-4085-b506-25cc5d9c46e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_936ed0c6-52be-4e60-826a-9af6d7056315" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_0401fd87-a746-4085-b506-25cc5d9c46e7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_936ed0c6-52be-4e60-826a-9af6d7056315" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_CesnaMember_c0337b23-b8bb-4d87-b872-479e0b8e9ff7" xlink:href="ptct-20200630.xsd#ptct_CesnaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_936ed0c6-52be-4e60-826a-9af6d7056315" xlink:to="loc_ptct_CesnaMember_c0337b23-b8bb-4d87-b872-479e0b8e9ff7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_CensaMember_fd7c86aa-30e2-4da3-af56-811458d9ef15" xlink:href="ptct-20200630.xsd#ptct_CensaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_936ed0c6-52be-4e60-826a-9af6d7056315" xlink:to="loc_ptct_CensaMember_fd7c86aa-30e2-4da3-af56-811458d9ef15" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/AcquisitionsPreliminaryAllocationofpurchasepriceDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#AcquisitionsPreliminaryAllocationofpurchasepriceDetails"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/AcquisitionsPreliminaryAllocationofpurchasepriceDetails" xlink:type="extended" id="i8ac234ef351540939825fd54dbe11443_AcquisitionsPreliminaryAllocationofpurchasepriceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a4beb240-33b0-4629-813e-2c2b2e262b15" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_dc3a0574-3c1e-44d0-8af9-734909f23e86" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a4beb240-33b0-4629-813e-2c2b2e262b15" xlink:to="loc_us-gaap_Goodwill_dc3a0574-3c1e-44d0-8af9-734909f23e86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c6041647-c125-41a6-b260-a892ea3cc27e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a4beb240-33b0-4629-813e-2c2b2e262b15" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c6041647-c125-41a6-b260-a892ea3cc27e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a5ea5a47-3076-464f-9718-18836ac21099" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c6041647-c125-41a6-b260-a892ea3cc27e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a5ea5a47-3076-464f-9718-18836ac21099" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a5ea5a47-3076-464f-9718-18836ac21099_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a5ea5a47-3076-464f-9718-18836ac21099" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a5ea5a47-3076-464f-9718-18836ac21099_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6bd5e098-b777-49f4-901d-5b3084a9d7b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a5ea5a47-3076-464f-9718-18836ac21099" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6bd5e098-b777-49f4-901d-5b3084a9d7b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AgilisMember_3a6939e2-69d1-472b-9d38-28538082c441" xlink:href="ptct-20200630.xsd#ptct_AgilisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6bd5e098-b777-49f4-901d-5b3084a9d7b3" xlink:to="loc_ptct_AgilisMember_3a6939e2-69d1-472b-9d38-28538082c441" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/Fairvalueoffinancialinstrumentsandmarketablesecurities" xlink:type="simple" xlink:href="ptct-20200630.xsd#Fairvalueoffinancialinstrumentsandmarketablesecurities"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/Fairvalueoffinancialinstrumentsandmarketablesecurities" xlink:type="extended" id="idb8d8bd7234941a2bdf08fb02d584f7b_Fairvalueoffinancialinstrumentsandmarketablesecurities"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesTables" xlink:type="simple" xlink:href="ptct-20200630.xsd#FairvalueoffinancialinstrumentsandmarketablesecuritiesTables"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesTables" xlink:type="extended" id="ie54611ed97124ba695626da14d394f9c_FairvalueoffinancialinstrumentsandmarketablesecuritiesTables"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails" xlink:type="extended" id="i01b7727e4ad14a33959756fa43295411_FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff_2835fe9e-85e2-4d47-b16e-559dfd42c4c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff_2835fe9e-85e2-4d47-b16e-559dfd42c4c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_267bdb3d-93f9-4539-a6d7-45eac284a731" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_267bdb3d-93f9-4539-a6d7-45eac284a731" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalancePrincipalAmount_75b56385-dce8-45a4-adbb-ac9472b1073d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentOwnedBalancePrincipalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_us-gaap_InvestmentOwnedBalancePrincipalAmount_75b56385-dce8-45a4-adbb-ac9472b1073d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_450c90a0-d553-47aa-a71a-5590cd482b89" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_450c90a0-d553-47aa-a71a-5590cd482b89" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ab04ee67-36f3-476b-a0dc-adf93a439bf4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ab04ee67-36f3-476b-a0dc-adf93a439bf4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_0d227233-60da-4c0c-819d-7874d17f7fcc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_us-gaap_DebtInstrumentFairValue_0d227233-60da-4c0c-819d-7874d17f7fcc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_cd270e3a-34b7-4149-907a-46d9e95d62d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_us-gaap_SharePrice_cd270e3a-34b7-4149-907a-46d9e95d62d0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage_99d15f14-7722-43e5-8b63-782eb6349519" xlink:href="ptct-20200630.xsd#ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage_99d15f14-7722-43e5-8b63-782eb6349519" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing_acf946a4-1f51-4bf5-a5cc-24cdc4d2cdff" xlink:href="ptct-20200630.xsd#ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing_acf946a4-1f51-4bf5-a5cc-24cdc4d2cdff" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount_9b5cddd0-2a0e-41fc-8570-b6971684b308" xlink:href="ptct-20200630.xsd#ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount_9b5cddd0-2a0e-41fc-8570-b6971684b308" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone_75a87c41-72cd-457e-aa7c-8ca65206d4ab" xlink:href="ptct-20200630.xsd#ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone_75a87c41-72cd-457e-aa7c-8ca65206d4ab" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable_4e25c145-ccd9-42a2-aaaa-0f8fbaf5bec8" xlink:href="ptct-20200630.xsd#ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable_4e25c145-ccd9-42a2-aaaa-0f8fbaf5bec8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent_324fcaf4-8468-47a6-bce2-268fa557455e" xlink:href="ptct-20200630.xsd#ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent_324fcaf4-8468-47a6-bce2-268fa557455e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_6ca343fc-45db-43d5-9ea6-ce4e1d47f530" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_6ca343fc-45db-43d5-9ea6-ce4e1d47f530" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_InvestmentInMRI_9fdbf6d1-200d-41f1-adb0-e94c2b009429" xlink:href="ptct-20200630.xsd#ptct_InvestmentInMRI"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_ptct_InvestmentInMRI_9fdbf6d1-200d-41f1-adb0-e94c2b009429" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_PaymentsToAcquireConvertibleDebtInvestment_1deba99c-1688-42b7-bc77-0476e6b084bf" xlink:href="ptct-20200630.xsd#ptct_PaymentsToAcquireConvertibleDebtInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_ptct_PaymentsToAcquireConvertibleDebtInvestment_1deba99c-1688-42b7-bc77-0476e6b084bf" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_834de55c-03b2-48b9-b084-032cdea8fcf4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_834de55c-03b2-48b9-b084-032cdea8fcf4" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DebtInstrumentConvertiblePeriod_54082454-95f9-47d8-a20d-e528cfe9663f" xlink:href="ptct-20200630.xsd#ptct_DebtInstrumentConvertiblePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_ptct_DebtInstrumentConvertiblePeriod_54082454-95f9-47d8-a20d-e528cfe9663f" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_72eae560-721e-475e-b3f0-fe47d29e884a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_72eae560-721e-475e-b3f0-fe47d29e884a" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_5d752316-82c3-4670-b003-efe2f4f4c3e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_5d752316-82c3-4670-b003-efe2f4f4c3e6" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_56c58382-e2ea-426f-a9e7-7a28c803f5c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_56c58382-e2ea-426f-a9e7-7a28c803f5c1" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput_a7ef846d-afe4-4401-a6f5-9cf2db72fdcb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_us-gaap_AlternativeInvestmentMeasurementInput_a7ef846d-afe4-4401-a6f5-9cf2db72fdcb" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease_eec4ded1-9055-4ceb-a08c-2762500453f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease_eec4ded1-9055-4ceb-a08c-2762500453f7" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_StockIssuedDuringPeriodSharesExchangeRights_58c9f811-1958-49d9-b9ba-c189dc18a624" xlink:href="ptct-20200630.xsd#ptct_StockIssuedDuringPeriodSharesExchangeRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_ptct_StockIssuedDuringPeriodSharesExchangeRights_58c9f811-1958-49d9-b9ba-c189dc18a624" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_SharesIssuedAssetAcquisition_8d1e97db-67eb-4b72-9a5b-b7a8c70f9c80" xlink:href="ptct-20200630.xsd#ptct_SharesIssuedAssetAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_ptct_SharesIssuedAssetAcquisition_8d1e97db-67eb-4b72-9a5b-b7a8c70f9c80" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_MilestonePaymentObligations_a959fc13-5b5e-4bbd-8551-efc9acd8d476" xlink:href="ptct-20200630.xsd#ptct_MilestonePaymentObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_ptct_MilestonePaymentObligations_a959fc13-5b5e-4bbd-8551-efc9acd8d476" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_25aebca9-9a13-4392-95cb-6f40dcb7c3fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_us-gaap_OperatingExpenses_25aebca9-9a13-4392-95cb-6f40dcb7c3fb" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_GainOfSettlementDevelopmentMilestones_341417bb-9b81-4c0c-b809-206f1e284326" xlink:href="ptct-20200630.xsd#ptct_GainOfSettlementDevelopmentMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_ptct_GainOfSettlementDevelopmentMilestones_341417bb-9b81-4c0c-b809-206f1e284326" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_LossOfSettlementRegulatoryMilestones_58d3ce7f-2393-4a36-a0ae-27264e410d4d" xlink:href="ptct-20200630.xsd#ptct_LossOfSettlementRegulatoryMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_ptct_LossOfSettlementRegulatoryMilestones_58d3ce7f-2393-4a36-a0ae-27264e410d4d" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_507c15a4-8d54-49fe-8997-7ff44e2afc1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_507c15a4-8d54-49fe-8997-7ff44e2afc1c" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ContingentConsiderationTransactionFees_4500991e-48e5-4f3b-b5e7-f774b94f4cc4" xlink:href="ptct-20200630.xsd#ptct_ContingentConsiderationTransactionFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_ptct_ContingentConsiderationTransactionFees_4500991e-48e5-4f3b-b5e7-f774b94f4cc4" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_d5dd7b5c-9208-4eb6-8ae2-477c1816a6df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_d5dd7b5c-9208-4eb6-8ae2-477c1816a6df" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db5fba73-3952-4d19-b0a8-517bb2341ea5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db5fba73-3952-4d19-b0a8-517bb2341ea5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_4c55798c-fb81-4486-92a2-48acda6eb9df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db5fba73-3952-4d19-b0a8-517bb2341ea5" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_4c55798c-fb81-4486-92a2-48acda6eb9df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_4c55798c-fb81-4486-92a2-48acda6eb9df_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_4c55798c-fb81-4486-92a2-48acda6eb9df" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_4c55798c-fb81-4486-92a2-48acda6eb9df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_c91d8d0d-3345-4422-b5e8-75b8b53dab9e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_4c55798c-fb81-4486-92a2-48acda6eb9df" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_c91d8d0d-3345-4422-b5e8-75b8b53dab9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_3746b03e-9afb-438e-bf75-365f733445fa" xlink:href="ptct-20200630.xsd#ptct_LiabilityDevelopmentandRegulatoryMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_c91d8d0d-3345-4422-b5e8-75b8b53dab9e" xlink:to="loc_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_3746b03e-9afb-438e-bf75-365f733445fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_7b4d0789-aa6e-4b2e-bc75-e074498a8d2a" xlink:href="ptct-20200630.xsd#ptct_LiabilityNetSalesMilestonesandRoyaltiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_c91d8d0d-3345-4422-b5e8-75b8b53dab9e" xlink:to="loc_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_7b4d0789-aa6e-4b2e-bc75-e074498a8d2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1b626627-fd6c-4d3f-8f73-5dce57416693" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db5fba73-3952-4d19-b0a8-517bb2341ea5" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1b626627-fd6c-4d3f-8f73-5dce57416693" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1b626627-fd6c-4d3f-8f73-5dce57416693_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1b626627-fd6c-4d3f-8f73-5dce57416693" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1b626627-fd6c-4d3f-8f73-5dce57416693_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1ab84823-e88d-46d8-8a16-5f1ec0c60b6a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1b626627-fd6c-4d3f-8f73-5dce57416693" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1ab84823-e88d-46d8-8a16-5f1ec0c60b6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_053a679e-3171-4fbf-8244-77b2cd56bb9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1ab84823-e88d-46d8-8a16-5f1ec0c60b6a" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_053a679e-3171-4fbf-8244-77b2cd56bb9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_9cf94a5a-19f9-445c-99e3-9173aa29b745" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db5fba73-3952-4d19-b0a8-517bb2341ea5" xlink:to="loc_us-gaap_InvestmentTypeAxis_9cf94a5a-19f9-445c-99e3-9173aa29b745" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_9cf94a5a-19f9-445c-99e3-9173aa29b745_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_9cf94a5a-19f9-445c-99e3-9173aa29b745" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_9cf94a5a-19f9-445c-99e3-9173aa29b745_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_b69bd341-e609-4169-ac8e-4698a502592d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_9cf94a5a-19f9-445c-99e3-9173aa29b745" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_b69bd341-e609-4169-ac8e-4698a502592d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a067ae13-fdc3-4b1a-9798-9ae5f6512f5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b69bd341-e609-4169-ac8e-4698a502592d" xlink:to="loc_us-gaap_CommonStockMember_a067ae13-fdc3-4b1a-9798-9ae5f6512f5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_db09b155-d7f3-4ffb-8bef-2953618d5d5b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db5fba73-3952-4d19-b0a8-517bb2341ea5" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_db09b155-d7f3-4ffb-8bef-2953618d5d5b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_db09b155-d7f3-4ffb-8bef-2953618d5d5b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_db09b155-d7f3-4ffb-8bef-2953618d5d5b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_db09b155-d7f3-4ffb-8bef-2953618d5d5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3e392bd0-cb21-4412-9c07-5b17a41e93c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_db09b155-d7f3-4ffb-8bef-2953618d5d5b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3e392bd0-cb21-4412-9c07-5b17a41e93c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_36318851-89ea-4b51-b99a-674582f3348d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_3e392bd0-cb21-4412-9c07-5b17a41e93c9" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_36318851-89ea-4b51-b99a-674582f3348d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5b6ba8e5-630c-4387-b936-7639bc5de371" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db5fba73-3952-4d19-b0a8-517bb2341ea5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5b6ba8e5-630c-4387-b936-7639bc5de371" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5b6ba8e5-630c-4387-b936-7639bc5de371_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5b6ba8e5-630c-4387-b936-7639bc5de371" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5b6ba8e5-630c-4387-b936-7639bc5de371_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f186164c-0077-460b-a7c5-a1448885e253" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5b6ba8e5-630c-4387-b936-7639bc5de371" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f186164c-0077-460b-a7c5-a1448885e253" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncollaborativeArrangementTransactionsMember_149fdf5d-3c15-4f11-a3c0-28afea90aeb2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncollaborativeArrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f186164c-0077-460b-a7c5-a1448885e253" xlink:to="loc_us-gaap_NoncollaborativeArrangementTransactionsMember_149fdf5d-3c15-4f11-a3c0-28afea90aeb2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4c98d17c-3241-41c9-a0dc-9f6dbf1f48f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db5fba73-3952-4d19-b0a8-517bb2341ea5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4c98d17c-3241-41c9-a0dc-9f6dbf1f48f5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4c98d17c-3241-41c9-a0dc-9f6dbf1f48f5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4c98d17c-3241-41c9-a0dc-9f6dbf1f48f5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4c98d17c-3241-41c9-a0dc-9f6dbf1f48f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ec290769-b572-4775-8b53-310b5b6b8775" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4c98d17c-3241-41c9-a0dc-9f6dbf1f48f5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ec290769-b572-4775-8b53-310b5b6b8775" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AgilisMember_c5cc49e2-e198-47ee-96b5-360b3b4fb34e" xlink:href="ptct-20200630.xsd#ptct_AgilisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ec290769-b572-4775-8b53-310b5b6b8775" xlink:to="loc_ptct_AgilisMember_c5cc49e2-e198-47ee-96b5-360b3b4fb34e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_26a0b69b-f44e-45d3-80d7-412841febc8c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db5fba73-3952-4d19-b0a8-517bb2341ea5" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_26a0b69b-f44e-45d3-80d7-412841febc8c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_26a0b69b-f44e-45d3-80d7-412841febc8c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_26a0b69b-f44e-45d3-80d7-412841febc8c" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_26a0b69b-f44e-45d3-80d7-412841febc8c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_7e87b914-c432-49a2-bba3-b9453f1c5d20" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_26a0b69b-f44e-45d3-80d7-412841febc8c" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_7e87b914-c432-49a2-bba3-b9453f1c5d20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_fce9e988-f294-49da-ae6e-2d7d8df633db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7e87b914-c432-49a2-bba3-b9453f1c5d20" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_fce9e988-f294-49da-ae6e-2d7d8df633db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ProbabilityofSuccessMember_7a51d0b8-d81a-4512-a662-d04e2c993744" xlink:href="ptct-20200630.xsd#ptct_ProbabilityofSuccessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7e87b914-c432-49a2-bba3-b9453f1c5d20" xlink:to="loc_ptct_ProbabilityofSuccessMember_7a51d0b8-d81a-4512-a662-d04e2c993744" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_9f906228-87da-4790-8dc1-c4506413ae16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7e87b914-c432-49a2-bba3-b9453f1c5d20" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_9f906228-87da-4790-8dc1-c4506413ae16" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_7c56d7ce-db7b-4ada-8e4d-68595b1465cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7e87b914-c432-49a2-bba3-b9453f1c5d20" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_7c56d7ce-db7b-4ada-8e4d-68595b1465cd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1829fab0-3390-4e6e-b8d5-2cb260e0c8ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db5fba73-3952-4d19-b0a8-517bb2341ea5" xlink:to="loc_us-gaap_DebtInstrumentAxis_1829fab0-3390-4e6e-b8d5-2cb260e0c8ee" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1829fab0-3390-4e6e-b8d5-2cb260e0c8ee_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1829fab0-3390-4e6e-b8d5-2cb260e0c8ee" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1829fab0-3390-4e6e-b8d5-2cb260e0c8ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_47f29884-9e86-4ac0-bf2d-2d50a0f5d807" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1829fab0-3390-4e6e-b8d5-2cb260e0c8ee" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_47f29884-9e86-4ac0-bf2d-2d50a0f5d807" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_9e76ddce-67f6-4987-a6e6-ad6c9352ae8d" xlink:href="ptct-20200630.xsd#ptct_ConvertibleSeniorNotes3.0PercentDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_47f29884-9e86-4ac0-bf2d-2d50a0f5d807" xlink:to="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_9e76ddce-67f6-4987-a6e6-ad6c9352ae8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member_948551e8-db0e-446d-81c7-21256cc48085" xlink:href="ptct-20200630.xsd#ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_47f29884-9e86-4ac0-bf2d-2d50a0f5d807" xlink:to="loc_ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member_948551e8-db0e-446d-81c7-21256cc48085" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c4d161bf-8fa5-4cf4-999b-51182864c881" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db5fba73-3952-4d19-b0a8-517bb2341ea5" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c4d161bf-8fa5-4cf4-999b-51182864c881" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c4d161bf-8fa5-4cf4-999b-51182864c881_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c4d161bf-8fa5-4cf4-999b-51182864c881" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c4d161bf-8fa5-4cf4-999b-51182864c881_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c9f839eb-9c75-4e39-9da0-bb07f5c53900" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c4d161bf-8fa5-4cf4-999b-51182864c881" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c9f839eb-9c75-4e39-9da0-bb07f5c53900" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_d0fd28d2-c2af-4158-8acf-bb9647d0f5e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c9f839eb-9c75-4e39-9da0-bb07f5c53900" xlink:to="loc_us-gaap_ConvertibleDebtMember_d0fd28d2-c2af-4158-8acf-bb9647d0f5e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_3b3faa7c-e203-4ee2-96cc-1b9fc64878f0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db5fba73-3952-4d19-b0a8-517bb2341ea5" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_3b3faa7c-e203-4ee2-96cc-1b9fc64878f0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_3b3faa7c-e203-4ee2-96cc-1b9fc64878f0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_3b3faa7c-e203-4ee2-96cc-1b9fc64878f0" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_3b3faa7c-e203-4ee2-96cc-1b9fc64878f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_bd30ca5d-9548-4eb1-86b4-12ed05dc913b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_3b3faa7c-e203-4ee2-96cc-1b9fc64878f0" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_bd30ca5d-9548-4eb1-86b4-12ed05dc913b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_cad2bd2c-2e8a-4235-afe7-a712f2939985" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_bd30ca5d-9548-4eb1-86b4-12ed05dc913b" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_cad2bd2c-2e8a-4235-afe7-a712f2939985" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_8a45712d-d529-41b3-a7e8-99c2cbe5b712" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_cad2bd2c-2e8a-4235-afe7-a712f2939985" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_8a45712d-d529-41b3-a7e8-99c2cbe5b712" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e3f10348-8d7e-4415-b924-ade09b43d939" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db5fba73-3952-4d19-b0a8-517bb2341ea5" xlink:to="loc_us-gaap_AwardTypeAxis_e3f10348-8d7e-4415-b924-ade09b43d939" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e3f10348-8d7e-4415-b924-ade09b43d939_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e3f10348-8d7e-4415-b924-ade09b43d939" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e3f10348-8d7e-4415-b924-ade09b43d939_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ec81723f-0fc0-411b-90f8-62205eadda0f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e3f10348-8d7e-4415-b924-ade09b43d939" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ec81723f-0fc0-411b-90f8-62205eadda0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_f8ac0899-6368-458e-b7af-2c609f58e6c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ec81723f-0fc0-411b-90f8-62205eadda0f" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_f8ac0899-6368-458e-b7af-2c609f58e6c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4d66fc25-afd8-4cf3-90e1-fd4ba21f5738" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db5fba73-3952-4d19-b0a8-517bb2341ea5" xlink:to="loc_srt_RangeAxis_4d66fc25-afd8-4cf3-90e1-fd4ba21f5738" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4d66fc25-afd8-4cf3-90e1-fd4ba21f5738_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4d66fc25-afd8-4cf3-90e1-fd4ba21f5738" xlink:to="loc_srt_RangeMember_4d66fc25-afd8-4cf3-90e1-fd4ba21f5738_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d8aa51e7-c556-463d-b8cf-b8ee8e38c06b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4d66fc25-afd8-4cf3-90e1-fd4ba21f5738" xlink:to="loc_srt_RangeMember_d8aa51e7-c556-463d-b8cf-b8ee8e38c06b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2fcf4fb2-1fd1-47ff-9711-dafb860fb6e2" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d8aa51e7-c556-463d-b8cf-b8ee8e38c06b" xlink:to="loc_srt_MinimumMember_2fcf4fb2-1fd1-47ff-9711-dafb860fb6e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_54843027-8e5b-4dc1-a2fa-f3acc5cdc5eb" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d8aa51e7-c556-463d-b8cf-b8ee8e38c06b" xlink:to="loc_srt_MaximumMember_54843027-8e5b-4dc1-a2fa-f3acc5cdc5eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_023bea8e-63be-4471-bbaa-99a72d2a1d7c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d8aa51e7-c556-463d-b8cf-b8ee8e38c06b" xlink:to="loc_srt_WeightedAverageMember_023bea8e-63be-4471-bbaa-99a72d2a1d7c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_801523f6-69d2-4f8b-b1b9-fc5b90687709" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db5fba73-3952-4d19-b0a8-517bb2341ea5" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_801523f6-69d2-4f8b-b1b9-fc5b90687709" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_801523f6-69d2-4f8b-b1b9-fc5b90687709_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_801523f6-69d2-4f8b-b1b9-fc5b90687709" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_801523f6-69d2-4f8b-b1b9-fc5b90687709_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6a412751-122d-4862-a25c-cc0a7e291af4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_801523f6-69d2-4f8b-b1b9-fc5b90687709" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6a412751-122d-4862-a25c-cc0a7e291af4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsMember_0decd93f-93b5-4174-bb76-07f945fd067c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6a412751-122d-4862-a25c-cc0a7e291af4" xlink:to="loc_us-gaap_CommitmentsMember_0decd93f-93b5-4174-bb76-07f945fd067c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_973a6b44-55c5-4abc-8060-0cce99ce01e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db5fba73-3952-4d19-b0a8-517bb2341ea5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_973a6b44-55c5-4abc-8060-0cce99ce01e4" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_973a6b44-55c5-4abc-8060-0cce99ce01e4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_973a6b44-55c5-4abc-8060-0cce99ce01e4" xlink:to="loc_us-gaap_EquityComponentDomain_973a6b44-55c5-4abc-8060-0cce99ce01e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_39bd7aac-570a-43cc-b61b-0798188f5b9d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_973a6b44-55c5-4abc-8060-0cce99ce01e4" xlink:to="loc_us-gaap_EquityComponentDomain_39bd7aac-570a-43cc-b61b-0798188f5b9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2e399af1-8bc1-4e0c-beb7-c4c4c269c6d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_39bd7aac-570a-43cc-b61b-0798188f5b9d" xlink:to="loc_us-gaap_CommonStockMember_2e399af1-8bc1-4e0c-beb7-c4c4c269c6d2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesHierarchyDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#FairvalueoffinancialinstrumentsandmarketablesecuritiesHierarchyDetails"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesHierarchyDetails" xlink:type="extended" id="i98202091b31b4b5591e132f942c7e692_FairvalueoffinancialinstrumentsandmarketablesecuritiesHierarchyDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_221cd572-1bbc-4fc8-8ddc-346bb29fd76f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3e5d86a4-1ace-4cb0-b29e-262942fd2c0f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_221cd572-1bbc-4fc8-8ddc-346bb29fd76f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3e5d86a4-1ace-4cb0-b29e-262942fd2c0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_a7f7debf-105a-48d1-9b49-b6f56b5694f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_221cd572-1bbc-4fc8-8ddc-346bb29fd76f" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_a7f7debf-105a-48d1-9b49-b6f56b5694f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_StockAppreciationRightsLiabilityOutstanding_52bbe26b-212e-4a9c-8420-df01f3a6491b" xlink:href="ptct-20200630.xsd#ptct_StockAppreciationRightsLiabilityOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_221cd572-1bbc-4fc8-8ddc-346bb29fd76f" xlink:to="loc_ptct_StockAppreciationRightsLiabilityOutstanding_52bbe26b-212e-4a9c-8420-df01f3a6491b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable_2ce2158e-a84f-488c-bb5f-436df57eb156" xlink:href="ptct-20200630.xsd#ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_221cd572-1bbc-4fc8-8ddc-346bb29fd76f" xlink:to="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable_2ce2158e-a84f-488c-bb5f-436df57eb156" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_99bc2c80-2b38-4844-a33b-6fb7270e080b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_221cd572-1bbc-4fc8-8ddc-346bb29fd76f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_99bc2c80-2b38-4844-a33b-6fb7270e080b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_8644bb18-f2cc-48b3-8002-25bd6c2c2b34" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_221cd572-1bbc-4fc8-8ddc-346bb29fd76f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_8644bb18-f2cc-48b3-8002-25bd6c2c2b34" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b465ffac-2021-44cf-8b55-fa3ddc5a29dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_221cd572-1bbc-4fc8-8ddc-346bb29fd76f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b465ffac-2021-44cf-8b55-fa3ddc5a29dd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ca1c1d32-291a-4961-bdb4-991b1663f736" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b465ffac-2021-44cf-8b55-fa3ddc5a29dd" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ca1c1d32-291a-4961-bdb4-991b1663f736" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ca1c1d32-291a-4961-bdb4-991b1663f736_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ca1c1d32-291a-4961-bdb4-991b1663f736" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ca1c1d32-291a-4961-bdb4-991b1663f736_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_60e478d4-6625-4f19-b171-d6defb54913e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ca1c1d32-291a-4961-bdb4-991b1663f736" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_60e478d4-6625-4f19-b171-d6defb54913e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_22e69b8e-b41b-4279-88d3-a8d26bd8dad0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_60e478d4-6625-4f19-b171-d6defb54913e" xlink:to="loc_us-gaap_DebtSecuritiesMember_22e69b8e-b41b-4279-88d3-a8d26bd8dad0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_725ba4e0-d301-4f75-b2f4-c2889f4097ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_60e478d4-6625-4f19-b171-d6defb54913e" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_725ba4e0-d301-4f75-b2f4-c2889f4097ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4f865014-e3dd-4ae6-abee-c702fc575ebd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b465ffac-2021-44cf-8b55-fa3ddc5a29dd" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4f865014-e3dd-4ae6-abee-c702fc575ebd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_4f865014-e3dd-4ae6-abee-c702fc575ebd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4f865014-e3dd-4ae6-abee-c702fc575ebd" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_4f865014-e3dd-4ae6-abee-c702fc575ebd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_78778e78-04ce-42bf-b3f4-466105d8d043" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4f865014-e3dd-4ae6-abee-c702fc575ebd" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_78778e78-04ce-42bf-b3f4-466105d8d043" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_d8887520-9359-4a39-918f-75c5d5801132" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_78778e78-04ce-42bf-b3f4-466105d8d043" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_d8887520-9359-4a39-918f-75c5d5801132" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ec26b886-a489-4280-9ce3-56b9eb03221d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b465ffac-2021-44cf-8b55-fa3ddc5a29dd" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ec26b886-a489-4280-9ce3-56b9eb03221d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ec26b886-a489-4280-9ce3-56b9eb03221d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ec26b886-a489-4280-9ce3-56b9eb03221d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ec26b886-a489-4280-9ce3-56b9eb03221d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0508b54d-35cc-46b1-b723-1b2e032bc406" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ec26b886-a489-4280-9ce3-56b9eb03221d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0508b54d-35cc-46b1-b723-1b2e032bc406" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_2e1c0ac0-9730-4f23-8393-8eacdc98eb73" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0508b54d-35cc-46b1-b723-1b2e032bc406" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_2e1c0ac0-9730-4f23-8393-8eacdc98eb73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_4214b5f3-54d3-46bc-a5ea-4cb56a2fab71" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0508b54d-35cc-46b1-b723-1b2e032bc406" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_4214b5f3-54d3-46bc-a5ea-4cb56a2fab71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_b361b5ba-9ce3-4fdb-b1a3-865e4b99956a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0508b54d-35cc-46b1-b723-1b2e032bc406" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_b361b5ba-9ce3-4fdb-b1a3-865e4b99956a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_3a44b304-03fe-45e5-a35a-b202d2896bf3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b465ffac-2021-44cf-8b55-fa3ddc5a29dd" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_3a44b304-03fe-45e5-a35a-b202d2896bf3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_3a44b304-03fe-45e5-a35a-b202d2896bf3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_3a44b304-03fe-45e5-a35a-b202d2896bf3" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_3a44b304-03fe-45e5-a35a-b202d2896bf3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_c3c7d465-0391-424b-b253-6e7965c3710e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_3a44b304-03fe-45e5-a35a-b202d2896bf3" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_c3c7d465-0391-424b-b253-6e7965c3710e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_bf10717a-a161-44f2-b675-f3af7e32f157" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_c3c7d465-0391-424b-b253-6e7965c3710e" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_bf10717a-a161-44f2-b675-f3af7e32f157" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_d3d38954-a8ac-4f95-8d75-5415eaba94fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_bf10717a-a161-44f2-b675-f3af7e32f157" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_d3d38954-a8ac-4f95-8d75-5415eaba94fe" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesAvailableforsaleDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#FairvalueoffinancialinstrumentsandmarketablesecuritiesAvailableforsaleDetails"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesAvailableforsaleDetails" xlink:type="extended" id="iecbadab815744ecebfcdd96b3bbb5a16_FairvalueoffinancialinstrumentsandmarketablesecuritiesAvailableforsaleDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a44e32aa-b204-4895-a2b8-b171a7ad702d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold_65d6048d-3e33-4d54-8ab0-63623aaa754c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a44e32aa-b204-4895-a2b8-b171a7ad702d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold_65d6048d-3e33-4d54-8ab0-63623aaa754c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff_e8dafb70-c004-4771-8fa5-4fea79e9bb21" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a44e32aa-b204-4895-a2b8-b171a7ad702d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff_e8dafb70-c004-4771-8fa5-4fea79e9bb21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_2f156b3d-055d-4e8b-901b-5d168056e185" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a44e32aa-b204-4895-a2b8-b171a7ad702d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_2f156b3d-055d-4e8b-901b-5d168056e185" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8321b69c-4ebe-4848-8a0e-4b6a025fb7c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a44e32aa-b204-4895-a2b8-b171a7ad702d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8321b69c-4ebe-4848-8a0e-4b6a025fb7c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3f3104e8-2ed2-4cd6-ae14-61e9c923641a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a44e32aa-b204-4895-a2b8-b171a7ad702d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3f3104e8-2ed2-4cd6-ae14-61e9c923641a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ff747833-9edd-4809-9a38-f2e4da2230cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a44e32aa-b204-4895-a2b8-b171a7ad702d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ff747833-9edd-4809-9a38-f2e4da2230cc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9dcc2ba7-681a-470c-be9f-ffb7a5ede217" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a44e32aa-b204-4895-a2b8-b171a7ad702d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9dcc2ba7-681a-470c-be9f-ffb7a5ede217" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_ac29493f-8060-401e-bf91-7520d2800b0c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a44e32aa-b204-4895-a2b8-b171a7ad702d" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_ac29493f-8060-401e-bf91-7520d2800b0c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_c3786668-54ac-429c-83bf-61bac40d7ce0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a44e32aa-b204-4895-a2b8-b171a7ad702d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_c3786668-54ac-429c-83bf-61bac40d7ce0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_65dd8abe-70fd-44cc-9329-0abb349e6db2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a44e32aa-b204-4895-a2b8-b171a7ad702d" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_65dd8abe-70fd-44cc-9329-0abb349e6db2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_53e02a71-7747-4352-b079-b4750dff4894" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a44e32aa-b204-4895-a2b8-b171a7ad702d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_53e02a71-7747-4352-b079-b4750dff4894" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue_da3fc451-9a9d-41c3-a664-ded2853d0821" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a44e32aa-b204-4895-a2b8-b171a7ad702d" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue_da3fc451-9a9d-41c3-a664-ded2853d0821" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_83cb10ee-1fec-4407-a6d1-bcc4d511b248" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a44e32aa-b204-4895-a2b8-b171a7ad702d" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_83cb10ee-1fec-4407-a6d1-bcc4d511b248" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_9cc69fb8-04b0-4115-88c2-c96b103d3e7b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_83cb10ee-1fec-4407-a6d1-bcc4d511b248" xlink:to="loc_us-gaap_FinancialInstrumentAxis_9cc69fb8-04b0-4115-88c2-c96b103d3e7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9cc69fb8-04b0-4115-88c2-c96b103d3e7b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9cc69fb8-04b0-4115-88c2-c96b103d3e7b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9cc69fb8-04b0-4115-88c2-c96b103d3e7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fb4ab287-fef3-491e-8a21-a3cbdfd4deb5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9cc69fb8-04b0-4115-88c2-c96b103d3e7b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fb4ab287-fef3-491e-8a21-a3cbdfd4deb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_dc6fe06b-c2b6-40d8-8916-0dee843075f0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fb4ab287-fef3-491e-8a21-a3cbdfd4deb5" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_dc6fe06b-c2b6-40d8-8916-0dee843075f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_d8139a2e-bb7b-4ef5-ac07-1d7744a5473d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fb4ab287-fef3-491e-8a21-a3cbdfd4deb5" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_d8139a2e-bb7b-4ef5-ac07-1d7744a5473d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_e96a833a-f5f2-4380-9fe3-ac2e28e4dd3e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fb4ab287-fef3-491e-8a21-a3cbdfd4deb5" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_e96a833a-f5f2-4380-9fe3-ac2e28e4dd3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_c8afd439-9ec5-4c60-bb18-2101a1b47f08" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fb4ab287-fef3-491e-8a21-a3cbdfd4deb5" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_c8afd439-9ec5-4c60-bb18-2101a1b47f08" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesFairValueMeasurementInputsandValuationTechniquesDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#FairvalueoffinancialinstrumentsandmarketablesecuritiesFairValueMeasurementInputsandValuationTechniquesDetails"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesFairValueMeasurementInputsandValuationTechniquesDetails" xlink:type="extended" id="i32cc587c565c49e6948cbe9884df56b7_FairvalueoffinancialinstrumentsandmarketablesecuritiesFairValueMeasurementInputsandValuationTechniquesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4daa5b09-00e5-4f96-b283-3a96486c0e28" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServicingAssetAtFairValueAmountRollForward_3921fbbe-4565-4ec9-bbe3-8ba7540fb9d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ServicingAssetAtFairValueAmountRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4daa5b09-00e5-4f96-b283-3a96486c0e28" xlink:to="loc_us-gaap_ServicingAssetAtFairValueAmountRollForward_3921fbbe-4565-4ec9-bbe3-8ba7540fb9d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_70407530-2c43-453d-a388-6d2c299e2dbd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ServicingAssetAtFairValueAmountRollForward_3921fbbe-4565-4ec9-bbe3-8ba7540fb9d3" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_70407530-2c43-453d-a388-6d2c299e2dbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_50c2bbbb-4784-4eb5-8165-b688d0a7abbd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ServicingAssetAtFairValueAmountRollForward_3921fbbe-4565-4ec9-bbe3-8ba7540fb9d3" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_50c2bbbb-4784-4eb5-8165-b688d0a7abbd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_6457bf08-cef9-4b4c-a817-1e9f72678c5b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ServicingAssetAtFairValueAmountRollForward_3921fbbe-4565-4ec9-bbe3-8ba7540fb9d3" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_6457bf08-cef9-4b4c-a817-1e9f72678c5b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1f540beb-723e-421d-88cf-2380ab0c759b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ServicingAssetAtFairValueAmountRollForward_3921fbbe-4565-4ec9-bbe3-8ba7540fb9d3" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1f540beb-723e-421d-88cf-2380ab0c759b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput_e95e21df-ea3c-406e-9f2f-81606c83f7eb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4daa5b09-00e5-4f96-b283-3a96486c0e28" xlink:to="loc_us-gaap_AlternativeInvestmentMeasurementInput_e95e21df-ea3c-406e-9f2f-81606c83f7eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c8dfb310-b985-4551-b101-d5ba7e387a09" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4daa5b09-00e5-4f96-b283-3a96486c0e28" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c8dfb310-b985-4551-b101-d5ba7e387a09" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_a4284508-8966-49e7-9470-fb03a595678c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c8dfb310-b985-4551-b101-d5ba7e387a09" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_a4284508-8966-49e7-9470-fb03a595678c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_a4284508-8966-49e7-9470-fb03a595678c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_a4284508-8966-49e7-9470-fb03a595678c" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_a4284508-8966-49e7-9470-fb03a595678c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_26cb6aad-5ddf-4779-90b7-cd4099af93e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_a4284508-8966-49e7-9470-fb03a595678c" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_26cb6aad-5ddf-4779-90b7-cd4099af93e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ProbabilityofSuccessMember_69395e2f-025e-465e-9377-45f3a842aac8" xlink:href="ptct-20200630.xsd#ptct_ProbabilityofSuccessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_26cb6aad-5ddf-4779-90b7-cd4099af93e8" xlink:to="loc_ptct_ProbabilityofSuccessMember_69395e2f-025e-465e-9377-45f3a842aac8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e5859095-5a0e-4ddb-829d-adba8cab9b8d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c8dfb310-b985-4551-b101-d5ba7e387a09" xlink:to="loc_srt_RangeAxis_e5859095-5a0e-4ddb-829d-adba8cab9b8d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e5859095-5a0e-4ddb-829d-adba8cab9b8d_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e5859095-5a0e-4ddb-829d-adba8cab9b8d" xlink:to="loc_srt_RangeMember_e5859095-5a0e-4ddb-829d-adba8cab9b8d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_22a6f582-b883-488e-829d-be67b4266852" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e5859095-5a0e-4ddb-829d-adba8cab9b8d" xlink:to="loc_srt_RangeMember_22a6f582-b883-488e-829d-be67b4266852" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_1db158bc-33ca-49ba-886e-337a4638cca2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c8dfb310-b985-4551-b101-d5ba7e387a09" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_1db158bc-33ca-49ba-886e-337a4638cca2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_1db158bc-33ca-49ba-886e-337a4638cca2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_1db158bc-33ca-49ba-886e-337a4638cca2" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_1db158bc-33ca-49ba-886e-337a4638cca2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_0d2b7f88-4e23-4a2b-a4c0-700fa8ed6d66" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_1db158bc-33ca-49ba-886e-337a4638cca2" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_0d2b7f88-4e23-4a2b-a4c0-700fa8ed6d66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_0f9a7f39-f1ad-456e-a80c-dd7d98fbb04d" xlink:href="ptct-20200630.xsd#ptct_LiabilityNetSalesMilestonesandRoyaltiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_0d2b7f88-4e23-4a2b-a4c0-700fa8ed6d66" xlink:to="loc_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_0f9a7f39-f1ad-456e-a80c-dd7d98fbb04d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_440fb7bb-1a31-4bd2-85be-da514a874b54" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c8dfb310-b985-4551-b101-d5ba7e387a09" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_440fb7bb-1a31-4bd2-85be-da514a874b54" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_440fb7bb-1a31-4bd2-85be-da514a874b54_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_440fb7bb-1a31-4bd2-85be-da514a874b54" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_440fb7bb-1a31-4bd2-85be-da514a874b54_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d463c1b4-525f-4efe-948d-72f695fecfcd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_440fb7bb-1a31-4bd2-85be-da514a874b54" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d463c1b4-525f-4efe-948d-72f695fecfcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AgilisMember_7b9ec34c-f378-4046-a5a6-4c438f50dd96" xlink:href="ptct-20200630.xsd#ptct_AgilisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d463c1b4-525f-4efe-948d-72f695fecfcd" xlink:to="loc_ptct_AgilisMember_7b9ec34c-f378-4046-a5a6-4c438f50dd96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_2c69ac39-e237-42ef-a648-3524b2a48476" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c8dfb310-b985-4551-b101-d5ba7e387a09" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_2c69ac39-e237-42ef-a648-3524b2a48476" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2c69ac39-e237-42ef-a648-3524b2a48476_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_2c69ac39-e237-42ef-a648-3524b2a48476" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2c69ac39-e237-42ef-a648-3524b2a48476_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_06011d31-ecfe-4707-bc14-b220d732af8f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_2c69ac39-e237-42ef-a648-3524b2a48476" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_06011d31-ecfe-4707-bc14-b220d732af8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsMember_30eef7c1-b100-4255-be11-d943e9c8c6f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_06011d31-ecfe-4707-bc14-b220d732af8f" xlink:to="loc_us-gaap_CommitmentsMember_30eef7c1-b100-4255-be11-d943e9c8c6f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8a223f6b-ad9b-4742-ae25-3240e37ed5a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c8dfb310-b985-4551-b101-d5ba7e387a09" xlink:to="loc_us-gaap_AwardTypeAxis_8a223f6b-ad9b-4742-ae25-3240e37ed5a3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a223f6b-ad9b-4742-ae25-3240e37ed5a3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8a223f6b-ad9b-4742-ae25-3240e37ed5a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a223f6b-ad9b-4742-ae25-3240e37ed5a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2b2555f0-61b7-4108-82ab-011443f305db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8a223f6b-ad9b-4742-ae25-3240e37ed5a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2b2555f0-61b7-4108-82ab-011443f305db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_134827a4-ad92-448d-8034-862485621e41" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2b2555f0-61b7-4108-82ab-011443f305db" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_134827a4-ad92-448d-8034-862485621e41" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_72b7a37a-c34d-4804-9c98-f6b112c7bc25" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c8dfb310-b985-4551-b101-d5ba7e387a09" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_72b7a37a-c34d-4804-9c98-f6b112c7bc25" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_72b7a37a-c34d-4804-9c98-f6b112c7bc25_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_72b7a37a-c34d-4804-9c98-f6b112c7bc25" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_72b7a37a-c34d-4804-9c98-f6b112c7bc25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_be50987d-f128-4fa4-81b7-4384ac11e80e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_72b7a37a-c34d-4804-9c98-f6b112c7bc25" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_be50987d-f128-4fa4-81b7-4384ac11e80e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ae0893a0-faf4-424f-93d0-27a54aa1a792" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c8dfb310-b985-4551-b101-d5ba7e387a09" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ae0893a0-faf4-424f-93d0-27a54aa1a792" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ae0893a0-faf4-424f-93d0-27a54aa1a792_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ae0893a0-faf4-424f-93d0-27a54aa1a792" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ae0893a0-faf4-424f-93d0-27a54aa1a792_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_505a358a-6abe-42e1-9b08-22899cf9ad3d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ae0893a0-faf4-424f-93d0-27a54aa1a792" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_505a358a-6abe-42e1-9b08-22899cf9ad3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a3a3492f-3970-453d-9241-0de4869e1320" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_505a358a-6abe-42e1-9b08-22899cf9ad3d" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a3a3492f-3970-453d-9241-0de4869e1320" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesUnrealizedLossPositionsDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#FairvalueoffinancialinstrumentsandmarketablesecuritiesUnrealizedLossPositionsDetails"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesUnrealizedLossPositionsDetails" xlink:type="extended" id="i32c217d809304abcac56ee127cb8e9b3_FairvalueoffinancialinstrumentsandmarketablesecuritiesUnrealizedLossPositionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_35512001-a105-4698-8049-f513f9c10157" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold_aa8536af-041c-43cd-a582-ee1c73fcdbd1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_35512001-a105-4698-8049-f513f9c10157" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold_aa8536af-041c-43cd-a582-ee1c73fcdbd1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_804fb85e-f5e9-4667-9238-49e21b8c4d9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_35512001-a105-4698-8049-f513f9c10157" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_804fb85e-f5e9-4667-9238-49e21b8c4d9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_45afed99-166e-4bc7-8b46-21857d51ce77" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_804fb85e-f5e9-4667-9238-49e21b8c4d9c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_45afed99-166e-4bc7-8b46-21857d51ce77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_5061cd94-0cfa-4cfc-94de-b2c1aafd0c4a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_804fb85e-f5e9-4667-9238-49e21b8c4d9c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_5061cd94-0cfa-4cfc-94de-b2c1aafd0c4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_33900156-26af-44bc-88bc-39734cde9916" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_804fb85e-f5e9-4667-9238-49e21b8c4d9c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_33900156-26af-44bc-88bc-39734cde9916" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract_81e25e67-7b8d-4bb9-8b37-4b23cf465094" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_35512001-a105-4698-8049-f513f9c10157" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract_81e25e67-7b8d-4bb9-8b37-4b23cf465094" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_c35158cb-f90b-4454-8b34-178e4affb77a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract_81e25e67-7b8d-4bb9-8b37-4b23cf465094" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_c35158cb-f90b-4454-8b34-178e4affb77a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_3434431d-1774-4451-aa4d-d0f2ea63e28b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract_81e25e67-7b8d-4bb9-8b37-4b23cf465094" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_3434431d-1774-4451-aa4d-d0f2ea63e28b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue_aedfb6df-3f2e-4c9c-b055-b3f35803bcdf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract_81e25e67-7b8d-4bb9-8b37-4b23cf465094" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue_aedfb6df-3f2e-4c9c-b055-b3f35803bcdf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff_62184ebf-07b3-41b5-a8d4-c90610a60964" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_35512001-a105-4698-8049-f513f9c10157" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff_62184ebf-07b3-41b5-a8d4-c90610a60964" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_28a25a8e-c451-4bb4-83dc-bd673d367aee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_35512001-a105-4698-8049-f513f9c10157" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_28a25a8e-c451-4bb4-83dc-bd673d367aee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_0093fa31-5316-48c4-9055-be222e3268b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_28a25a8e-c451-4bb4-83dc-bd673d367aee" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_0093fa31-5316-48c4-9055-be222e3268b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0093fa31-5316-48c4-9055-be222e3268b5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_0093fa31-5316-48c4-9055-be222e3268b5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0093fa31-5316-48c4-9055-be222e3268b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_dff7459a-76a6-4a2a-9fb5-63fa59f71117" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_0093fa31-5316-48c4-9055-be222e3268b5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_dff7459a-76a6-4a2a-9fb5-63fa59f71117" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_2156e2e1-5695-46d6-8aeb-5bf2ea98a779" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_dff7459a-76a6-4a2a-9fb5-63fa59f71117" xlink:to="loc_us-gaap_DebtSecuritiesMember_2156e2e1-5695-46d6-8aeb-5bf2ea98a779" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4a710b16-1098-4044-b1b9-8a8113d94890" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_28a25a8e-c451-4bb4-83dc-bd673d367aee" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4a710b16-1098-4044-b1b9-8a8113d94890" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4a710b16-1098-4044-b1b9-8a8113d94890_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4a710b16-1098-4044-b1b9-8a8113d94890" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4a710b16-1098-4044-b1b9-8a8113d94890_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7c8f7591-ba33-4338-902c-7f6547ad1dbe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4a710b16-1098-4044-b1b9-8a8113d94890" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7c8f7591-ba33-4338-902c-7f6547ad1dbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_7ede1cc0-211e-4b39-8784-26995cd82f3a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7c8f7591-ba33-4338-902c-7f6547ad1dbe" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_7ede1cc0-211e-4b39-8784-26995cd82f3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_38cd9226-0acb-4ebe-b626-168b72ec2cf6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7c8f7591-ba33-4338-902c-7f6547ad1dbe" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_38cd9226-0acb-4ebe-b626-168b72ec2cf6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_43d2fd39-3ce4-45cd-9f97-fa91c0a36800" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7c8f7591-ba33-4338-902c-7f6547ad1dbe" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_43d2fd39-3ce4-45cd-9f97-fa91c0a36800" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_00d0402e-292b-4a28-a6f3-9f78a3ed50ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7c8f7591-ba33-4338-902c-7f6547ad1dbe" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_00d0402e-292b-4a28-a6f3-9f78a3ed50ae" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesMarketablesecuritiesDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#FairvalueoffinancialinstrumentsandmarketablesecuritiesMarketablesecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesMarketablesecuritiesDetails" xlink:type="extended" id="iad8df26345ef4a1796c1ac49ec6d588b_FairvalueoffinancialinstrumentsandmarketablesecuritiesMarketablesecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentHoldingsLineItems_15ac8559-042c-4cdc-aa40-884938df1476" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentHoldingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_7b19dd08-7d92-416e-bf7b-5aee4cdf111c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentHoldingsLineItems_15ac8559-042c-4cdc-aa40-884938df1476" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_7b19dd08-7d92-416e-bf7b-5aee4cdf111c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue_97ce429d-1f1e-48a1-84e1-17d37c3ef15d" xlink:href="ptct-20200630.xsd#ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentHoldingsLineItems_15ac8559-042c-4cdc-aa40-884938df1476" xlink:to="loc_ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue_97ce429d-1f1e-48a1-84e1-17d37c3ef15d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentHoldingsTable_77e255e4-0087-446c-aa9e-6901b0eec54b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentHoldingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InvestmentHoldingsLineItems_15ac8559-042c-4cdc-aa40-884938df1476" xlink:to="loc_us-gaap_InvestmentHoldingsTable_77e255e4-0087-446c-aa9e-6901b0eec54b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_36164895-e637-4eee-a859-bf18ffbee68b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InvestmentHoldingsTable_77e255e4-0087-446c-aa9e-6901b0eec54b" xlink:to="loc_us-gaap_InvestmentTypeAxis_36164895-e637-4eee-a859-bf18ffbee68b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_36164895-e637-4eee-a859-bf18ffbee68b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_36164895-e637-4eee-a859-bf18ffbee68b" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_36164895-e637-4eee-a859-bf18ffbee68b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_d78da637-fbfc-4263-aba5-be101aec972e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_36164895-e637-4eee-a859-bf18ffbee68b" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_d78da637-fbfc-4263-aba5-be101aec972e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_11277602-ae08-41a1-975e-442f1a4828dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_d78da637-fbfc-4263-aba5-be101aec972e" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_11277602-ae08-41a1-975e-442f1a4828dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_076012c1-cc86-403e-a5e0-76371c09257a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_d78da637-fbfc-4263-aba5-be101aec972e" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_076012c1-cc86-403e-a5e0-76371c09257a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_bfb2e0eb-1b05-464e-9b42-6232b24577a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_d78da637-fbfc-4263-aba5-be101aec972e" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_bfb2e0eb-1b05-464e-9b42-6232b24577a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_d0aeacfd-7262-4a74-9a3e-781f206c7b66" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_d78da637-fbfc-4263-aba5-be101aec972e" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_d0aeacfd-7262-4a74-9a3e-781f206c7b66" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails" xlink:type="extended" id="i40355b70d10a4a0e9f176d93ba7debe1_FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_591c4401-f370-480a-9e63-889e7bf8d2d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput_ce8b8d46-21c8-4ccb-bf35-c70645e8824f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_591c4401-f370-480a-9e63-889e7bf8d2d3" xlink:to="loc_us-gaap_AlternativeInvestmentMeasurementInput_ce8b8d46-21c8-4ccb-bf35-c70645e8824f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1232ca5e-079f-407e-9b93-635eea5c3e4e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_591c4401-f370-480a-9e63-889e7bf8d2d3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1232ca5e-079f-407e-9b93-635eea5c3e4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AlternativeInvestmentMilestone_8a6c80f7-342d-47b8-87da-3852a2f002a0" xlink:href="ptct-20200630.xsd#ptct_AlternativeInvestmentMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_591c4401-f370-480a-9e63-889e7bf8d2d3" xlink:to="loc_ptct_AlternativeInvestmentMilestone_8a6c80f7-342d-47b8-87da-3852a2f002a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5f1e3358-86ac-4ff3-9882-d36d72d72325" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_591c4401-f370-480a-9e63-889e7bf8d2d3" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5f1e3358-86ac-4ff3-9882-d36d72d72325" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2ca17570-b666-4edc-9c23-acb41a263a18" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5f1e3358-86ac-4ff3-9882-d36d72d72325" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2ca17570-b666-4edc-9c23-acb41a263a18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_6aca1d5b-a471-4662-9899-e2093ad3177e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5f1e3358-86ac-4ff3-9882-d36d72d72325" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_6aca1d5b-a471-4662-9899-e2093ad3177e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_a363398f-7a05-490b-980f-a2ffe3d34d49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5f1e3358-86ac-4ff3-9882-d36d72d72325" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_a363398f-7a05-490b-980f-a2ffe3d34d49" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_396277ab-23b2-4fb0-9141-5bed11c6257a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5f1e3358-86ac-4ff3-9882-d36d72d72325" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_396277ab-23b2-4fb0-9141-5bed11c6257a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsRightsExchangeSettlement_0cfbf5ab-9ddd-4335-a1a2-efcfde227826" xlink:href="ptct-20200630.xsd#ptct_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsRightsExchangeSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5f1e3358-86ac-4ff3-9882-d36d72d72325" xlink:to="loc_ptct_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsRightsExchangeSettlement_0cfbf5ab-9ddd-4335-a1a2-efcfde227826" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2d718de6-c511-469c-9bfc-86b714b758d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_804c2636-fdad-412b-80a2-61fbe7534885" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_591c4401-f370-480a-9e63-889e7bf8d2d3" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_804c2636-fdad-412b-80a2-61fbe7534885" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_c608ee76-caea-4143-a004-a74b570c773a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_591c4401-f370-480a-9e63-889e7bf8d2d3" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_c608ee76-caea-4143-a004-a74b570c773a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d7fe6d48-7f54-4f77-89a5-051d631f1e7b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_c608ee76-caea-4143-a004-a74b570c773a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d7fe6d48-7f54-4f77-89a5-051d631f1e7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d7fe6d48-7f54-4f77-89a5-051d631f1e7b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d7fe6d48-7f54-4f77-89a5-051d631f1e7b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d7fe6d48-7f54-4f77-89a5-051d631f1e7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_04ea40a4-a620-4915-a420-d937af6a72cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d7fe6d48-7f54-4f77-89a5-051d631f1e7b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_04ea40a4-a620-4915-a420-d937af6a72cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2778b26a-9d02-4990-8055-bd50821de1fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_04ea40a4-a620-4915-a420-d937af6a72cb" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2778b26a-9d02-4990-8055-bd50821de1fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_959c0fa5-464d-4a6c-bf8c-ffeeba81c690" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_c608ee76-caea-4143-a004-a74b570c773a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_959c0fa5-464d-4a6c-bf8c-ffeeba81c690" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_959c0fa5-464d-4a6c-bf8c-ffeeba81c690_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_959c0fa5-464d-4a6c-bf8c-ffeeba81c690" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_959c0fa5-464d-4a6c-bf8c-ffeeba81c690_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_925a2146-a3b2-47f6-b2f1-1aa764d0456c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_959c0fa5-464d-4a6c-bf8c-ffeeba81c690" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_925a2146-a3b2-47f6-b2f1-1aa764d0456c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AgilisMember_714bf83c-0fb9-449d-b74b-999077e137c2" xlink:href="ptct-20200630.xsd#ptct_AgilisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_925a2146-a3b2-47f6-b2f1-1aa764d0456c" xlink:to="loc_ptct_AgilisMember_714bf83c-0fb9-449d-b74b-999077e137c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_f7a7e258-0aad-46ef-8ee1-d5eb41f29b84" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_c608ee76-caea-4143-a004-a74b570c773a" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_f7a7e258-0aad-46ef-8ee1-d5eb41f29b84" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_f7a7e258-0aad-46ef-8ee1-d5eb41f29b84_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_f7a7e258-0aad-46ef-8ee1-d5eb41f29b84" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_f7a7e258-0aad-46ef-8ee1-d5eb41f29b84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_2aa50289-28c0-4a23-a02a-d8919df71595" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_f7a7e258-0aad-46ef-8ee1-d5eb41f29b84" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_2aa50289-28c0-4a23-a02a-d8919df71595" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_1c8df498-49b9-466c-8ff3-b4e1e7f77803" xlink:href="ptct-20200630.xsd#ptct_LiabilityNetSalesMilestonesandRoyaltiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_2aa50289-28c0-4a23-a02a-d8919df71595" xlink:to="loc_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_1c8df498-49b9-466c-8ff3-b4e1e7f77803" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_d381a6be-b31b-4e75-8759-2500aeb287fe" xlink:href="ptct-20200630.xsd#ptct_LiabilityDevelopmentandRegulatoryMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_2aa50289-28c0-4a23-a02a-d8919df71595" xlink:to="loc_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_d381a6be-b31b-4e75-8759-2500aeb287fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_908c1f65-d87d-48ed-95ad-60ead1dccda0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_c608ee76-caea-4143-a004-a74b570c773a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_908c1f65-d87d-48ed-95ad-60ead1dccda0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_908c1f65-d87d-48ed-95ad-60ead1dccda0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_908c1f65-d87d-48ed-95ad-60ead1dccda0" xlink:to="loc_us-gaap_ClassOfStockDomain_908c1f65-d87d-48ed-95ad-60ead1dccda0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_99611041-44d2-4a16-96f6-5b9c94d46e2a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_908c1f65-d87d-48ed-95ad-60ead1dccda0" xlink:to="loc_us-gaap_ClassOfStockDomain_99611041-44d2-4a16-96f6-5b9c94d46e2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9a5032fc-f2d9-4e77-9bd6-504d6edbb8ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_99611041-44d2-4a16-96f6-5b9c94d46e2a" xlink:to="loc_us-gaap_CommonStockMember_9a5032fc-f2d9-4e77-9bd6-504d6edbb8ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1c923127-ab89-44da-8158-284331c3f1d3" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_c608ee76-caea-4143-a004-a74b570c773a" xlink:to="loc_srt_RangeAxis_1c923127-ab89-44da-8158-284331c3f1d3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1c923127-ab89-44da-8158-284331c3f1d3_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1c923127-ab89-44da-8158-284331c3f1d3" xlink:to="loc_srt_RangeMember_1c923127-ab89-44da-8158-284331c3f1d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_513d4ac8-b1a6-4052-bbba-5ca4b7ab1113" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1c923127-ab89-44da-8158-284331c3f1d3" xlink:to="loc_srt_RangeMember_513d4ac8-b1a6-4052-bbba-5ca4b7ab1113" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_48a2fedc-fc63-44b1-9f3b-f90207c7d70b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_513d4ac8-b1a6-4052-bbba-5ca4b7ab1113" xlink:to="loc_srt_MinimumMember_48a2fedc-fc63-44b1-9f3b-f90207c7d70b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_14058806-304e-4031-972e-bf9df47f8d81" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_513d4ac8-b1a6-4052-bbba-5ca4b7ab1113" xlink:to="loc_srt_MaximumMember_14058806-304e-4031-972e-bf9df47f8d81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_7b413260-159c-4d65-a929-5f58983338f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_c608ee76-caea-4143-a004-a74b570c773a" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_7b413260-159c-4d65-a929-5f58983338f4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_7b413260-159c-4d65-a929-5f58983338f4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_7b413260-159c-4d65-a929-5f58983338f4" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_7b413260-159c-4d65-a929-5f58983338f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_b5798131-8d86-449b-957e-3bd3b7889611" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_7b413260-159c-4d65-a929-5f58983338f4" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_b5798131-8d86-449b-957e-3bd3b7889611" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember_8c1c2eaf-64ae-410a-bd5a-46ddd11dc3e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputOptionVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b5798131-8d86-449b-957e-3bd3b7889611" xlink:to="loc_us-gaap_MeasurementInputOptionVolatilityMember_8c1c2eaf-64ae-410a-bd5a-46ddd11dc3e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_2540822f-c5b4-46e6-8d93-6278f8f60ce9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b5798131-8d86-449b-957e-3bd3b7889611" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_2540822f-c5b4-46e6-8d93-6278f8f60ce9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_bea9d69a-3fc5-4b0e-80a5-e2e8dea70089" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b5798131-8d86-449b-957e-3bd3b7889611" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_bea9d69a-3fc5-4b0e-80a5-e2e8dea70089" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember_5032c5cd-8af2-4434-a1b2-1f56ae24fc9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b5798131-8d86-449b-957e-3bd3b7889611" xlink:to="loc_us-gaap_MeasurementInputSharePriceMember_5032c5cd-8af2-4434-a1b2-1f56ae24fc9c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_SalesMilestonesMember_5168668b-f273-4e1d-a2b9-2f72c3cc6550" xlink:href="ptct-20200630.xsd#ptct_SalesMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b5798131-8d86-449b-957e-3bd3b7889611" xlink:to="loc_ptct_SalesMilestonesMember_5168668b-f273-4e1d-a2b9-2f72c3cc6550" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ProbabilityofSuccessMember_9135777a-f9de-4fad-9a28-48b743dcb7ae" xlink:href="ptct-20200630.xsd#ptct_ProbabilityofSuccessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b5798131-8d86-449b-957e-3bd3b7889611" xlink:to="loc_ptct_ProbabilityofSuccessMember_9135777a-f9de-4fad-9a28-48b743dcb7ae" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_PercentageofSalesforRoyaltiesMember_29805105-1b3f-4398-889a-dbd71a9b1530" xlink:href="ptct-20200630.xsd#ptct_PercentageofSalesforRoyaltiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b5798131-8d86-449b-957e-3bd3b7889611" xlink:to="loc_ptct_PercentageofSalesforRoyaltiesMember_29805105-1b3f-4398-889a-dbd71a9b1530" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DevelopmentandRegulatoryMilestoneMember_ee8cd1fc-187b-47a5-8851-dd0592b38bfc" xlink:href="ptct-20200630.xsd#ptct_DevelopmentandRegulatoryMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b5798131-8d86-449b-957e-3bd3b7889611" xlink:to="loc_ptct_DevelopmentandRegulatoryMilestoneMember_ee8cd1fc-187b-47a5-8851-dd0592b38bfc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_43ba311d-8383-47a5-adbf-7ff3efb9bb80" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b5798131-8d86-449b-957e-3bd3b7889611" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_43ba311d-8383-47a5-adbf-7ff3efb9bb80" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_9b529c9f-ca0c-4dfd-ac83-3cb84324571f" xlink:href="ptct-20200630.xsd#ptct_LiabilityNetSalesMilestonesandRoyaltiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b5798131-8d86-449b-957e-3bd3b7889611" xlink:to="loc_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_9b529c9f-ca0c-4dfd-ac83-3cb84324571f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_PotentialNetSalesMilestonesDomain_85537192-2b6f-4bb3-9b5b-3ae6e0ffe790" xlink:href="ptct-20200630.xsd#ptct_PotentialNetSalesMilestonesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b5798131-8d86-449b-957e-3bd3b7889611" xlink:to="loc_ptct_PotentialNetSalesMilestonesDomain_85537192-2b6f-4bb3-9b5b-3ae6e0ffe790" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_b11aa539-23a0-461c-8657-4050ab17c7ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_c608ee76-caea-4143-a004-a74b570c773a" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_b11aa539-23a0-461c-8657-4050ab17c7ad" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_b11aa539-23a0-461c-8657-4050ab17c7ad_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_b11aa539-23a0-461c-8657-4050ab17c7ad" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_b11aa539-23a0-461c-8657-4050ab17c7ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5ba9193e-ba84-4406-ae2e-a80170f994b8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_b11aa539-23a0-461c-8657-4050ab17c7ad" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5ba9193e-ba84-4406-ae2e-a80170f994b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsMember_e60f3e1f-4c0a-430d-af12-5be1fa2a4221" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5ba9193e-ba84-4406-ae2e-a80170f994b8" xlink:to="loc_us-gaap_CommitmentsMember_e60f3e1f-4c0a-430d-af12-5be1fa2a4221" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_97f85876-2c1f-4af5-b704-ca4a1fc3f4b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5ba9193e-ba84-4406-ae2e-a80170f994b8" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_97f85876-2c1f-4af5-b704-ca4a1fc3f4b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9a46688e-9b8a-4769-bcc6-0baa5a034446" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_c608ee76-caea-4143-a004-a74b570c773a" xlink:to="loc_us-gaap_AwardTypeAxis_9a46688e-9b8a-4769-bcc6-0baa5a034446" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9a46688e-9b8a-4769-bcc6-0baa5a034446_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9a46688e-9b8a-4769-bcc6-0baa5a034446" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9a46688e-9b8a-4769-bcc6-0baa5a034446_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6fe5d22e-3ff6-4565-ab04-f986405e8cf7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9a46688e-9b8a-4769-bcc6-0baa5a034446" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6fe5d22e-3ff6-4565-ab04-f986405e8cf7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_273a1676-8506-4935-9355-e7746063d4b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6fe5d22e-3ff6-4565-ab04-f986405e8cf7" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_273a1676-8506-4935-9355-e7746063d4b4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/Othercomprehensiveincomelossandaccumulatedothercomprehensiveitems" xlink:type="simple" xlink:href="ptct-20200630.xsd#Othercomprehensiveincomelossandaccumulatedothercomprehensiveitems"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/Othercomprehensiveincomelossandaccumulatedothercomprehensiveitems" xlink:type="extended" id="i4c5e3417852e4af5954edd3795bd33f5_Othercomprehensiveincomelossandaccumulatedothercomprehensiveitems"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/OthercomprehensiveincomelossandaccumulatedothercomprehensiveitemsTables" xlink:type="simple" xlink:href="ptct-20200630.xsd#OthercomprehensiveincomelossandaccumulatedothercomprehensiveitemsTables"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/OthercomprehensiveincomelossandaccumulatedothercomprehensiveitemsTables" xlink:type="extended" id="i61fed7f3297e401aa7062e1c8aacf5df_OthercomprehensiveincomelossandaccumulatedothercomprehensiveitemsTables"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/OthercomprehensiveincomelossandaccumulatedothercomprehensiveitemsNarrativeDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#OthercomprehensiveincomelossandaccumulatedothercomprehensiveitemsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/OthercomprehensiveincomelossandaccumulatedothercomprehensiveitemsNarrativeDetails" xlink:type="extended" id="id1a549ac286940ccb9f1f5ba370dea80_OthercomprehensiveincomelossandaccumulatedothercomprehensiveitemsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_538dc3ff-a80d-4161-9c42-67da0cdd0246" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7e94ff2a-ff07-421b-885d-f7f699944b01" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_538dc3ff-a80d-4161-9c42-67da0cdd0246" xlink:to="loc_us-gaap_StockholdersEquity_7e94ff2a-ff07-421b-885d-f7f699944b01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_152a6504-bccb-40bb-a46b-bc7c042ef4d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_538dc3ff-a80d-4161-9c42-67da0cdd0246" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_152a6504-bccb-40bb-a46b-bc7c042ef4d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_65161232-2c5d-4c99-a608-697cc187a7c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_152a6504-bccb-40bb-a46b-bc7c042ef4d1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_65161232-2c5d-4c99-a608-697cc187a7c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_be40e03b-ffcd-40b1-bbf9-ec5c78cdb88c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_152a6504-bccb-40bb-a46b-bc7c042ef4d1" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_be40e03b-ffcd-40b1-bbf9-ec5c78cdb88c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_71ba8b79-5ead-45c8-83bf-b8192e2a230f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_152a6504-bccb-40bb-a46b-bc7c042ef4d1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_71ba8b79-5ead-45c8-83bf-b8192e2a230f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fdbb5a67-89f1-42fb-881a-b7d08de3ccfe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_1451aa01-e9a2-4972-b09f-b7c2a1b84e46" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_538dc3ff-a80d-4161-9c42-67da0cdd0246" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_1451aa01-e9a2-4972-b09f-b7c2a1b84e46" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0c205c18-ef51-47dc-bec4-fa3b2648aeed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_1451aa01-e9a2-4972-b09f-b7c2a1b84e46" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0c205c18-ef51-47dc-bec4-fa3b2648aeed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0c205c18-ef51-47dc-bec4-fa3b2648aeed_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0c205c18-ef51-47dc-bec4-fa3b2648aeed" xlink:to="loc_us-gaap_EquityComponentDomain_0c205c18-ef51-47dc-bec4-fa3b2648aeed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_771d731d-3875-4ebe-948c-82d2b2724f7b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0c205c18-ef51-47dc-bec4-fa3b2648aeed" xlink:to="loc_us-gaap_EquityComponentDomain_771d731d-3875-4ebe-948c-82d2b2724f7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_9147c8a2-3640-470f-9cb2-701d4347502b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_771d731d-3875-4ebe-948c-82d2b2724f7b" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_9147c8a2-3640-470f-9cb2-701d4347502b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_d40fe6b9-e849-401d-b448-13dce5d14a1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_771d731d-3875-4ebe-948c-82d2b2724f7b" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_d40fe6b9-e849-401d-b448-13dce5d14a1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fa76fef7-cc7a-4df3-b7be-c678b94e7ef0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_771d731d-3875-4ebe-948c-82d2b2724f7b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fa76fef7-cc7a-4df3-b7be-c678b94e7ef0" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/Accountspayableandaccruedexpenses" xlink:type="simple" xlink:href="ptct-20200630.xsd#Accountspayableandaccruedexpenses"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/Accountspayableandaccruedexpenses" xlink:type="extended" id="i29416ff66ad8475eaa72a59af8fbf7b6_Accountspayableandaccruedexpenses"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/AccountspayableandaccruedexpensesTables" xlink:type="simple" xlink:href="ptct-20200630.xsd#AccountspayableandaccruedexpensesTables"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/AccountspayableandaccruedexpensesTables" xlink:type="extended" id="i341382204cd84c0fb778c42513d01332_AccountspayableandaccruedexpensesTables"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/AccountspayableandaccruedexpensesNarrativeDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#AccountspayableandaccruedexpensesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/AccountspayableandaccruedexpensesNarrativeDetails" xlink:type="extended" id="i2d63ea8ad11146c09ecd98fc9bc2ef89_AccountspayableandaccruedexpensesNarrativeDetails"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/Capitalization" xlink:type="simple" xlink:href="ptct-20200630.xsd#Capitalization"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/Capitalization" xlink:type="extended" id="idbcf0f278e5f4301a612b3616aeca076_Capitalization"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/CapitalizationNarrativeDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#CapitalizationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/CapitalizationNarrativeDetails" xlink:type="extended" id="i39bcd6025c3041d786b1e965a4b54d17_CapitalizationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_6ae1ebc3-79be-4a70-afca-f001a64e1e5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_b75f0c6b-fcba-4d7f-a1a8-5efc214bf021" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6ae1ebc3-79be-4a70-afca-f001a64e1e5d" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_b75f0c6b-fcba-4d7f-a1a8-5efc214bf021" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3aed0a1c-37a2-4728-8b1c-a085052f0f1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6ae1ebc3-79be-4a70-afca-f001a64e1e5d" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3aed0a1c-37a2-4728-8b1c-a085052f0f1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_d7c9464a-2dd5-46c3-abcb-de9163c8889e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6ae1ebc3-79be-4a70-afca-f001a64e1e5d" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_d7c9464a-2dd5-46c3-abcb-de9163c8889e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_SaleOfStockWeightedAveragePricePerShare_d7e06e40-732d-4e9e-9316-728834a28597" xlink:href="ptct-20200630.xsd#ptct_SaleOfStockWeightedAveragePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6ae1ebc3-79be-4a70-afca-f001a64e1e5d" xlink:to="loc_ptct_SaleOfStockWeightedAveragePricePerShare_d7e06e40-732d-4e9e-9316-728834a28597" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_9a05a235-f866-4eba-97e5-205fd203885c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6ae1ebc3-79be-4a70-afca-f001a64e1e5d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_9a05a235-f866-4eba-97e5-205fd203885c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_SharestoissueunderRightsExchangeAgreement_208cd7c1-060c-4d30-8c51-ca6f4ef021f3" xlink:href="ptct-20200630.xsd#ptct_SharestoissueunderRightsExchangeAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6ae1ebc3-79be-4a70-afca-f001a64e1e5d" xlink:to="loc_ptct_SharestoissueunderRightsExchangeAgreement_208cd7c1-060c-4d30-8c51-ca6f4ef021f3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_bd90a477-19f7-4354-9c4b-4ad3c6e86448" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6ae1ebc3-79be-4a70-afca-f001a64e1e5d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_bd90a477-19f7-4354-9c4b-4ad3c6e86448" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_d695c541-e8b1-4736-b2d0-d3a39ec57015" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6ae1ebc3-79be-4a70-afca-f001a64e1e5d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_d695c541-e8b1-4736-b2d0-d3a39ec57015" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a44dbf5a-199c-4c5c-af10-e7f5d514b906" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_d695c541-e8b1-4736-b2d0-d3a39ec57015" xlink:to="loc_srt_RangeAxis_a44dbf5a-199c-4c5c-af10-e7f5d514b906" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a44dbf5a-199c-4c5c-af10-e7f5d514b906_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a44dbf5a-199c-4c5c-af10-e7f5d514b906" xlink:to="loc_srt_RangeMember_a44dbf5a-199c-4c5c-af10-e7f5d514b906_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a27401f4-135f-4645-ad4b-d9ec74f271ef" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a44dbf5a-199c-4c5c-af10-e7f5d514b906" xlink:to="loc_srt_RangeMember_a27401f4-135f-4645-ad4b-d9ec74f271ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1b911ead-a653-427d-8f76-2849be5d8a30" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a27401f4-135f-4645-ad4b-d9ec74f271ef" xlink:to="loc_srt_MaximumMember_1b911ead-a653-427d-8f76-2849be5d8a30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_46b90fe6-e19a-4603-b36e-5cfd80b5010f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a27401f4-135f-4645-ad4b-d9ec74f271ef" xlink:to="loc_srt_WeightedAverageMember_46b90fe6-e19a-4603-b36e-5cfd80b5010f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e03a5571-1e4b-433a-879e-cc7654b1a325" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_d695c541-e8b1-4736-b2d0-d3a39ec57015" xlink:to="loc_srt_CounterpartyNameAxis_e03a5571-1e4b-433a-879e-cc7654b1a325" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e03a5571-1e4b-433a-879e-cc7654b1a325_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_e03a5571-1e4b-433a-879e-cc7654b1a325" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e03a5571-1e4b-433a-879e-cc7654b1a325_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f5b4dd22-e014-41f1-9f8d-0831294840e8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_e03a5571-1e4b-433a-879e-cc7654b1a325" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f5b4dd22-e014-41f1-9f8d-0831294840e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_CensaMember_606d9954-4e2e-4ca2-99de-5c4404278977" xlink:href="ptct-20200630.xsd#ptct_CensaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f5b4dd22-e014-41f1-9f8d-0831294840e8" xlink:to="loc_ptct_CensaMember_606d9954-4e2e-4ca2-99de-5c4404278977" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_8214ba28-e612-4951-8d2b-a59d1efb2a9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_d695c541-e8b1-4736-b2d0-d3a39ec57015" xlink:to="loc_us-gaap_PlanNameAxis_8214ba28-e612-4951-8d2b-a59d1efb2a9c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8214ba28-e612-4951-8d2b-a59d1efb2a9c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_8214ba28-e612-4951-8d2b-a59d1efb2a9c" xlink:to="loc_us-gaap_PlanNameDomain_8214ba28-e612-4951-8d2b-a59d1efb2a9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a30da467-6232-47c2-8358-8670ed06f7be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_8214ba28-e612-4951-8d2b-a59d1efb2a9c" xlink:to="loc_us-gaap_PlanNameDomain_a30da467-6232-47c2-8358-8670ed06f7be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_RightsExchangeAgreementMember_b6f085e0-bb69-4bb5-ac80-d687ac0e73f2" xlink:href="ptct-20200630.xsd#ptct_RightsExchangeAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_a30da467-6232-47c2-8358-8670ed06f7be" xlink:to="loc_ptct_RightsExchangeAgreementMember_b6f085e0-bb69-4bb5-ac80-d687ac0e73f2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/Netlosspershare" xlink:type="simple" xlink:href="ptct-20200630.xsd#Netlosspershare"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/Netlosspershare" xlink:type="extended" id="id663e439846b402395f6d1bb88d6f0b6_Netlosspershare"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/NetlosspershareTables" xlink:type="simple" xlink:href="ptct-20200630.xsd#NetlosspershareTables"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/NetlosspershareTables" xlink:type="extended" id="ib8bf7220a89b4e0ca8f8efdbd81f9440_NetlosspershareTables"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/NetlosspershareNumeratorandDenominatorDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#NetlosspershareNumeratorandDenominatorDetails"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/NetlosspershareNumeratorandDenominatorDetails" xlink:type="extended" id="i615ee162082c4c568ff8f762bcc00764_NetlosspershareNumeratorandDenominatorDetails"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/NetlosspershareAntidilutiveDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#NetlosspershareAntidilutiveDetails"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/NetlosspershareAntidilutiveDetails" xlink:type="extended" id="i02136cde46e94d9bacad8d75bc7d55da_NetlosspershareAntidilutiveDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e0b66ea6-a646-453e-b46b-0a72412d35dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_927637ae-06c0-4dd0-800c-d52464375777" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e0b66ea6-a646-453e-b46b-0a72412d35dd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_927637ae-06c0-4dd0-800c-d52464375777" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e3a62c1f-cae7-4078-8c00-3f582aee6d00" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e0b66ea6-a646-453e-b46b-0a72412d35dd" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e3a62c1f-cae7-4078-8c00-3f582aee6d00" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_515bd1f1-714a-47aa-b1ca-c9d6313489ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e3a62c1f-cae7-4078-8c00-3f582aee6d00" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_515bd1f1-714a-47aa-b1ca-c9d6313489ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_515bd1f1-714a-47aa-b1ca-c9d6313489ab_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_515bd1f1-714a-47aa-b1ca-c9d6313489ab" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_515bd1f1-714a-47aa-b1ca-c9d6313489ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_273d02bc-17dd-4e6d-9eb6-04dd955a68a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_515bd1f1-714a-47aa-b1ca-c9d6313489ab" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_273d02bc-17dd-4e6d-9eb6-04dd955a68a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_aadc427b-d22c-4b50-81a8-c5b5602597f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_273d02bc-17dd-4e6d-9eb6-04dd955a68a9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_aadc427b-d22c-4b50-81a8-c5b5602597f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_RestrictedStockAndRestrictedStockUnitsMember_d8dd5eab-e40c-4455-b35c-f5234eda0b50" xlink:href="ptct-20200630.xsd#ptct_RestrictedStockAndRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_273d02bc-17dd-4e6d-9eb6-04dd955a68a9" xlink:to="loc_ptct_RestrictedStockAndRestrictedStockUnitsMember_d8dd5eab-e40c-4455-b35c-f5234eda0b50" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/Stockawardplan" xlink:type="simple" xlink:href="ptct-20200630.xsd#Stockawardplan"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/Stockawardplan" xlink:type="extended" id="i44f704f1a37549a0b999a32ffc755adb_Stockawardplan"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/StockawardplanTables" xlink:type="simple" xlink:href="ptct-20200630.xsd#StockawardplanTables"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/StockawardplanTables" xlink:type="extended" id="id2741ba6fb554a0caf731665a858f7e6_StockawardplanTables"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/StockawardplanNarrativeDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#StockawardplanNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/StockawardplanNarrativeDetails" xlink:type="extended" id="ib6fa9bb35ecd46fcbec6834724774163_StockawardplanNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_f60d3758-2d70-4791-99ae-ad6dafe91b9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_f60d3758-2d70-4791-99ae-ad6dafe91b9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_652ec831-d1b3-42ab-b8f7-089ab3e24fcd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_652ec831-d1b3-42ab-b8f7-089ab3e24fcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f2fc676b-6488-4813-ab5b-c60bf1f3b899" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f2fc676b-6488-4813-ab5b-c60bf1f3b899" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_67a7577a-def1-42c0-b287-def5266eef40" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_67a7577a-def1-42c0-b287-def5266eef40" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_482bb1f7-d0fc-4422-9628-6d9f49596361" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_482bb1f7-d0fc-4422-9628-6d9f49596361" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards_daf24700-00ee-4164-93ef-6587f13ea2b0" xlink:href="ptct-20200630.xsd#ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:to="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards_daf24700-00ee-4164-93ef-6587f13ea2b0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber_591e9725-7307-4581-afd9-4e80f2acc277" xlink:href="ptct-20200630.xsd#ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:to="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber_591e9725-7307-4581-afd9-4e80f2acc277" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding_c101ba5b-9180-49c8-b61e-bd83ebd22a8b" xlink:href="ptct-20200630.xsd#ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:to="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding_c101ba5b-9180-49c8-b61e-bd83ebd22a8b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions_092701bc-14f2-424e-aa22-2342ec4c9401" xlink:href="ptct-20200630.xsd#ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:to="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions_092701bc-14f2-424e-aa22-2342ec4c9401" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_706b90af-e057-4373-84ce-5bf665ab213e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_706b90af-e057-4373-84ce-5bf665ab213e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_63f27fb4-62a6-44f0-9800-3d5673772442" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_63f27fb4-62a6-44f0-9800-3d5673772442" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_a229df6a-e928-4373-951f-213f197fd80d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_a229df6a-e928-4373-951f-213f197fd80d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1d47a176-cfbf-4d3d-a4cd-466355d92197" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1d47a176-cfbf-4d3d-a4cd-466355d92197" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_StockAppreciationRightsLiabilityOutstanding_2b99cb6b-8b56-46ec-b948-8a5c27ff99b2" xlink:href="ptct-20200630.xsd#ptct_StockAppreciationRightsLiabilityOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:to="loc_ptct_StockAppreciationRightsLiabilityOutstanding_2b99cb6b-8b56-46ec-b948-8a5c27ff99b2" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_7b082d50-3d0c-49d8-8afe-2f62ea4f408a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_7b082d50-3d0c-49d8-8afe-2f62ea4f408a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_0a40bde1-c0a3-4713-86b4-8f3dccb08bea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_0a40bde1-c0a3-4713-86b4-8f3dccb08bea" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_e616a820-67a4-4f65-8604-372ce1ad5774" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_e616a820-67a4-4f65-8604-372ce1ad5774" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_EmployeeStockPurchasePlanVotingPercentageLimitPercent_ddf523fb-0fcf-41a2-b253-2ac0e76507ad" xlink:href="ptct-20200630.xsd#ptct_EmployeeStockPurchasePlanVotingPercentageLimitPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:to="loc_ptct_EmployeeStockPurchasePlanVotingPercentageLimitPercent_ddf523fb-0fcf-41a2-b253-2ac0e76507ad" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c9ce9045-bee0-4574-8d87-448efd7a102c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c9ce9045-bee0-4574-8d87-448efd7a102c" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d642ad5e-4abd-4984-bf08-1fbe831ecbc4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d642ad5e-4abd-4984-bf08-1fbe831ecbc4" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_00ccd605-cb0d-457d-b22a-98004cd3954d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_00ccd605-cb0d-457d-b22a-98004cd3954d" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_949afd53-e275-4751-8e46-d08a32e382c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_949afd53-e275-4751-8e46-d08a32e382c7" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a494ea1a-ba4a-4910-807e-a62de49e801d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a494ea1a-ba4a-4910-807e-a62de49e801d" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fb4c7b8-9ea2-4387-81a5-53c8f725eac1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fb4c7b8-9ea2-4387-81a5-53c8f725eac1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_f4a3f74f-5e18-435d-ad9e-cb183a4414da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fb4c7b8-9ea2-4387-81a5-53c8f725eac1" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_f4a3f74f-5e18-435d-ad9e-cb183a4414da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_f4a3f74f-5e18-435d-ad9e-cb183a4414da_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_f4a3f74f-5e18-435d-ad9e-cb183a4414da" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_f4a3f74f-5e18-435d-ad9e-cb183a4414da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_c089e4cd-e39c-45bf-85e6-8fd48f5eabaf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_f4a3f74f-5e18-435d-ad9e-cb183a4414da" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_c089e4cd-e39c-45bf-85e6-8fd48f5eabaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_14173e98-03b4-4f6f-9fd6-0fae89ea3889" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_c089e4cd-e39c-45bf-85e6-8fd48f5eabaf" xlink:to="loc_us-gaap_EmployeeStockMember_14173e98-03b4-4f6f-9fd6-0fae89ea3889" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_a16a8252-d6e8-46b9-bc4f-fd9a28448c50" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fb4c7b8-9ea2-4387-81a5-53c8f725eac1" xlink:to="loc_us-gaap_PlanNameAxis_a16a8252-d6e8-46b9-bc4f-fd9a28448c50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a16a8252-d6e8-46b9-bc4f-fd9a28448c50_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_a16a8252-d6e8-46b9-bc4f-fd9a28448c50" xlink:to="loc_us-gaap_PlanNameDomain_a16a8252-d6e8-46b9-bc4f-fd9a28448c50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_dddd67be-8940-48ce-81c8-7a1259a21d7d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_a16a8252-d6e8-46b9-bc4f-fd9a28448c50" xlink:to="loc_us-gaap_PlanNameDomain_dddd67be-8940-48ce-81c8-7a1259a21d7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_StockIncentivePlan2013Member_e2698015-cace-4e69-bac1-9a8d6d11c96d" xlink:href="ptct-20200630.xsd#ptct_StockIncentivePlan2013Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_dddd67be-8940-48ce-81c8-7a1259a21d7d" xlink:to="loc_ptct_StockIncentivePlan2013Member_e2698015-cace-4e69-bac1-9a8d6d11c96d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_EquityAndLongTermIncentivePlan2009Member_0c865123-a9fb-4ddc-94c1-fcf0a281a122" xlink:href="ptct-20200630.xsd#ptct_EquityAndLongTermIncentivePlan2009Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_dddd67be-8940-48ce-81c8-7a1259a21d7d" xlink:to="loc_ptct_EquityAndLongTermIncentivePlan2009Member_0c865123-a9fb-4ddc-94c1-fcf0a281a122" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member_0bd79cd1-9174-472f-8a76-f91745905e02" xlink:href="ptct-20200630.xsd#ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_dddd67be-8940-48ce-81c8-7a1259a21d7d" xlink:to="loc_ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member_0bd79cd1-9174-472f-8a76-f91745905e02" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_LongTermIncentivePlan2013Member_fb58c121-3960-450e-907e-b8b2e26fa4d1" xlink:href="ptct-20200630.xsd#ptct_LongTermIncentivePlan2013Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_dddd67be-8940-48ce-81c8-7a1259a21d7d" xlink:to="loc_ptct_LongTermIncentivePlan2013Member_fb58c121-3960-450e-907e-b8b2e26fa4d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_A2020inducementstockincentiveplanMember_31e02caf-ed9d-4b1d-9a1e-33db7e38d32e" xlink:href="ptct-20200630.xsd#ptct_A2020inducementstockincentiveplanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_dddd67be-8940-48ce-81c8-7a1259a21d7d" xlink:to="loc_ptct_A2020inducementstockincentiveplanMember_31e02caf-ed9d-4b1d-9a1e-33db7e38d32e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bf759f65-cfd7-49d1-a318-f94273ae90ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fb4c7b8-9ea2-4387-81a5-53c8f725eac1" xlink:to="loc_us-gaap_AwardTypeAxis_bf759f65-cfd7-49d1-a318-f94273ae90ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf759f65-cfd7-49d1-a318-f94273ae90ff_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_bf759f65-cfd7-49d1-a318-f94273ae90ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf759f65-cfd7-49d1-a318-f94273ae90ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92aae67e-6c2c-4c20-a000-66e8e2723a54" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_bf759f65-cfd7-49d1-a318-f94273ae90ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92aae67e-6c2c-4c20-a000-66e8e2723a54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_23041f05-922a-4e7f-a63f-2d84a58833af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92aae67e-6c2c-4c20-a000-66e8e2723a54" xlink:to="loc_us-gaap_RestrictedStockMember_23041f05-922a-4e7f-a63f-2d84a58833af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_31cf333b-3bdd-426d-a000-d1c9e2fb17ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92aae67e-6c2c-4c20-a000-66e8e2723a54" xlink:to="loc_us-gaap_StockOptionMember_31cf333b-3bdd-426d-a000-d1c9e2fb17ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_EmployeeDirectorAndConsultantStockOptionPlanMember_7e25720d-ae45-435d-9114-3f1766c54df5" xlink:href="ptct-20200630.xsd#ptct_EmployeeDirectorAndConsultantStockOptionPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92aae67e-6c2c-4c20-a000-66e8e2723a54" xlink:to="loc_ptct_EmployeeDirectorAndConsultantStockOptionPlanMember_7e25720d-ae45-435d-9114-3f1766c54df5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_0a818d80-a2c5-4c7f-9d14-9e221d9361b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92aae67e-6c2c-4c20-a000-66e8e2723a54" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_0a818d80-a2c5-4c7f-9d14-9e221d9361b1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_76d0e187-b178-412c-8f0e-8dd5f8300d5e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fb4c7b8-9ea2-4387-81a5-53c8f725eac1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_76d0e187-b178-412c-8f0e-8dd5f8300d5e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_76d0e187-b178-412c-8f0e-8dd5f8300d5e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_76d0e187-b178-412c-8f0e-8dd5f8300d5e" xlink:to="loc_us-gaap_ClassOfStockDomain_76d0e187-b178-412c-8f0e-8dd5f8300d5e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b0775d64-2817-4336-baf2-3a1640f55be6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_76d0e187-b178-412c-8f0e-8dd5f8300d5e" xlink:to="loc_us-gaap_ClassOfStockDomain_b0775d64-2817-4336-baf2-3a1640f55be6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7a74c49e-c14d-4e3b-98c3-e2a2eeb2811f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b0775d64-2817-4336-baf2-3a1640f55be6" xlink:to="loc_us-gaap_CommonStockMember_7a74c49e-c14d-4e3b-98c3-e2a2eeb2811f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fdeff581-9d31-4d3e-a603-55568320334e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fb4c7b8-9ea2-4387-81a5-53c8f725eac1" xlink:to="loc_srt_RangeAxis_fdeff581-9d31-4d3e-a603-55568320334e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fdeff581-9d31-4d3e-a603-55568320334e_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_fdeff581-9d31-4d3e-a603-55568320334e" xlink:to="loc_srt_RangeMember_fdeff581-9d31-4d3e-a603-55568320334e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4eaf7bdf-6dd2-4a2c-84cc-307579c90ce0" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_fdeff581-9d31-4d3e-a603-55568320334e" xlink:to="loc_srt_RangeMember_4eaf7bdf-6dd2-4a2c-84cc-307579c90ce0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_918a07ff-2669-4399-bd76-f752ba455bd8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4eaf7bdf-6dd2-4a2c-84cc-307579c90ce0" xlink:to="loc_srt_MaximumMember_918a07ff-2669-4399-bd76-f752ba455bd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_33105ab2-9b9b-4b3a-8878-0fb4092d5229" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4eaf7bdf-6dd2-4a2c-84cc-307579c90ce0" xlink:to="loc_srt_MinimumMember_33105ab2-9b9b-4b3a-8878-0fb4092d5229" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/StockawardplanShareBaseCompensationDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#StockawardplanShareBaseCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/StockawardplanShareBaseCompensationDetails" xlink:type="extended" id="i67da9e33c33944d8a2af0887cfed161d_StockawardplanShareBaseCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9a0d98-8e36-4d27-af88-af45b6e6a20a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8c5fe70b-cc6c-45af-b4ef-a0f066d0580c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9a0d98-8e36-4d27-af88-af45b6e6a20a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8c5fe70b-cc6c-45af-b4ef-a0f066d0580c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f0c1d4d1-08b0-4929-859a-20b6b6f871bb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8c5fe70b-cc6c-45af-b4ef-a0f066d0580c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f0c1d4d1-08b0-4929-859a-20b6b6f871bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_145cf9c3-389c-4e6d-9614-3e559c782f86" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8c5fe70b-cc6c-45af-b4ef-a0f066d0580c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_145cf9c3-389c-4e6d-9614-3e559c782f86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b88e8b9a-7298-4470-a53d-ea6c9aedb4aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8c5fe70b-cc6c-45af-b4ef-a0f066d0580c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b88e8b9a-7298-4470-a53d-ea6c9aedb4aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0051e824-6fd5-4dc1-a37b-3e8d114dc081" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8c5fe70b-cc6c-45af-b4ef-a0f066d0580c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0051e824-6fd5-4dc1-a37b-3e8d114dc081" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c884f51b-073b-4275-9ead-a7e6cd776626" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_eb74e9e0-687a-48ff-94d1-c73838438648" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9a0d98-8e36-4d27-af88-af45b6e6a20a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_eb74e9e0-687a-48ff-94d1-c73838438648" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_67e59b40-1494-4729-9650-48d764fff9ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9a0d98-8e36-4d27-af88-af45b6e6a20a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_67e59b40-1494-4729-9650-48d764fff9ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_67a49c6f-b087-43c5-bdee-83e7caf002f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9a0d98-8e36-4d27-af88-af45b6e6a20a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_67a49c6f-b087-43c5-bdee-83e7caf002f6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c1531a45-48ba-4464-a9af-e0305f10ee27" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_67a49c6f-b087-43c5-bdee-83e7caf002f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c1531a45-48ba-4464-a9af-e0305f10ee27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_578d48a4-dab1-4ba5-b412-6e7a87744592" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_67a49c6f-b087-43c5-bdee-83e7caf002f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_578d48a4-dab1-4ba5-b412-6e7a87744592" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d6c21715-5b93-4f8a-a1f5-329c7e99d32f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_67a49c6f-b087-43c5-bdee-83e7caf002f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d6c21715-5b93-4f8a-a1f5-329c7e99d32f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_baa8f5c7-c172-4e0c-a6f2-b354accb10ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_67a49c6f-b087-43c5-bdee-83e7caf002f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_baa8f5c7-c172-4e0c-a6f2-b354accb10ec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_96535bd2-f7f1-4499-983d-009032514ef4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_f259b8bb-9f33-4918-abcc-55b562196d4c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9a0d98-8e36-4d27-af88-af45b6e6a20a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_f259b8bb-9f33-4918-abcc-55b562196d4c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_28776337-9128-4672-9b1d-cefec11800ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9a0d98-8e36-4d27-af88-af45b6e6a20a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_28776337-9128-4672-9b1d-cefec11800ab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5c1ce6cd-291d-4d8b-8be3-fbb54c52c54b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9a0d98-8e36-4d27-af88-af45b6e6a20a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5c1ce6cd-291d-4d8b-8be3-fbb54c52c54b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_899abdc4-e287-40ca-96fb-18aa198b21e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5c1ce6cd-291d-4d8b-8be3-fbb54c52c54b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_899abdc4-e287-40ca-96fb-18aa198b21e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_4be57eed-cd69-4142-80c0-8e7e57975f1b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5c1ce6cd-291d-4d8b-8be3-fbb54c52c54b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_4be57eed-cd69-4142-80c0-8e7e57975f1b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8798e25d-b9c9-4373-bd40-bf6d23f840f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5c1ce6cd-291d-4d8b-8be3-fbb54c52c54b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8798e25d-b9c9-4373-bd40-bf6d23f840f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward_1c52b76c-1a1b-4c0a-a057-ee5f4c436926" xlink:href="ptct-20200630.xsd#ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9a0d98-8e36-4d27-af88-af45b6e6a20a" xlink:to="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward_1c52b76c-1a1b-4c0a-a057-ee5f4c436926" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1571d494-f757-4eb6-a84a-c6d0368f865e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward_1c52b76c-1a1b-4c0a-a057-ee5f4c436926" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1571d494-f757-4eb6-a84a-c6d0368f865e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_4ad7f2d2-c7c8-4a78-8e9d-54e7639800bb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward_1c52b76c-1a1b-4c0a-a057-ee5f4c436926" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_4ad7f2d2-c7c8-4a78-8e9d-54e7639800bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3eabbdd0-8ffd-46f7-a39b-f26f8be7d534" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward_1c52b76c-1a1b-4c0a-a057-ee5f4c436926" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3eabbdd0-8ffd-46f7-a39b-f26f8be7d534" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ef09d825-bcf4-44b0-bf43-38465a045721" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9a0d98-8e36-4d27-af88-af45b6e6a20a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ef09d825-bcf4-44b0-bf43-38465a045721" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_58eef5b5-4d3e-4538-b10e-b3f8da71512a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ef09d825-bcf4-44b0-bf43-38465a045721" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_58eef5b5-4d3e-4538-b10e-b3f8da71512a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ba9b0259-39fb-469f-8a84-2a824af3c322" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ef09d825-bcf4-44b0-bf43-38465a045721" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ba9b0259-39fb-469f-8a84-2a824af3c322" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_29930832-ca2e-4510-8bfa-4306d2c7586f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ef09d825-bcf4-44b0-bf43-38465a045721" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_29930832-ca2e-4510-8bfa-4306d2c7586f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8aba020b-0eae-4c0f-91c4-71cd651ec518" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9a0d98-8e36-4d27-af88-af45b6e6a20a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8aba020b-0eae-4c0f-91c4-71cd651ec518" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_72256b96-cd80-4d72-bed5-274fa979484d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8aba020b-0eae-4c0f-91c4-71cd651ec518" xlink:to="loc_us-gaap_PlanNameAxis_72256b96-cd80-4d72-bed5-274fa979484d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_72256b96-cd80-4d72-bed5-274fa979484d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_72256b96-cd80-4d72-bed5-274fa979484d" xlink:to="loc_us-gaap_PlanNameDomain_72256b96-cd80-4d72-bed5-274fa979484d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8334aad6-a643-47b5-b148-b89d03742e77" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_72256b96-cd80-4d72-bed5-274fa979484d" xlink:to="loc_us-gaap_PlanNameDomain_8334aad6-a643-47b5-b148-b89d03742e77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_A2020inducementstockincentiveplanMember_cbf8f3ec-c8fb-46d7-8df5-05f39349d083" xlink:href="ptct-20200630.xsd#ptct_A2020inducementstockincentiveplanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_8334aad6-a643-47b5-b148-b89d03742e77" xlink:to="loc_ptct_A2020inducementstockincentiveplanMember_cbf8f3ec-c8fb-46d7-8df5-05f39349d083" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_10f2e821-4cf3-425d-9f1b-2225ab528208" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8aba020b-0eae-4c0f-91c4-71cd651ec518" xlink:to="loc_us-gaap_AwardTypeAxis_10f2e821-4cf3-425d-9f1b-2225ab528208" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10f2e821-4cf3-425d-9f1b-2225ab528208_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_10f2e821-4cf3-425d-9f1b-2225ab528208" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10f2e821-4cf3-425d-9f1b-2225ab528208_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_60e7595e-2770-42f0-8f83-718d4f7602cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_10f2e821-4cf3-425d-9f1b-2225ab528208" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_60e7595e-2770-42f0-8f83-718d4f7602cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_956ce41d-ede3-402d-a5fc-dc093a0d42bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_60e7595e-2770-42f0-8f83-718d4f7602cb" xlink:to="loc_us-gaap_StockOptionMember_956ce41d-ede3-402d-a5fc-dc093a0d42bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_98eff86a-4bb2-4bf1-9637-5f9cb3d2dcfd" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8aba020b-0eae-4c0f-91c4-71cd651ec518" xlink:to="loc_srt_RangeAxis_98eff86a-4bb2-4bf1-9637-5f9cb3d2dcfd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_98eff86a-4bb2-4bf1-9637-5f9cb3d2dcfd_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_98eff86a-4bb2-4bf1-9637-5f9cb3d2dcfd" xlink:to="loc_srt_RangeMember_98eff86a-4bb2-4bf1-9637-5f9cb3d2dcfd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b2187bb7-f6fa-4347-bbe1-86d274c466b4" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_98eff86a-4bb2-4bf1-9637-5f9cb3d2dcfd" xlink:to="loc_srt_RangeMember_b2187bb7-f6fa-4347-bbe1-86d274c466b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_dcf2d7cb-fac9-44ba-bd5e-d34db9ea27d7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b2187bb7-f6fa-4347-bbe1-86d274c466b4" xlink:to="loc_srt_MinimumMember_dcf2d7cb-fac9-44ba-bd5e-d34db9ea27d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5bc64016-20d1-42f0-af97-b14aa44beb88" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b2187bb7-f6fa-4347-bbe1-86d274c466b4" xlink:to="loc_srt_MaximumMember_5bc64016-20d1-42f0-af97-b14aa44beb88" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/StockawardplanRestrictedStockDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#StockawardplanRestrictedStockDetails"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/StockawardplanRestrictedStockDetails" xlink:type="extended" id="i3a7b14b9080d4e13bc0862d4061351fb_StockawardplanRestrictedStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7b68311f-c032-4aea-8556-f8f352604f2c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1c3e3d3d-2bbf-456d-a084-4106e599a152" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7b68311f-c032-4aea-8556-f8f352604f2c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1c3e3d3d-2bbf-456d-a084-4106e599a152" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c301341b-20cb-44bb-9577-a43b83191b23" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1c3e3d3d-2bbf-456d-a084-4106e599a152" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c301341b-20cb-44bb-9577-a43b83191b23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_28f6ee99-2320-4882-968d-3094e9cfecff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1c3e3d3d-2bbf-456d-a084-4106e599a152" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_28f6ee99-2320-4882-968d-3094e9cfecff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_031f2b03-f62b-4065-9484-3dbae8f81218" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1c3e3d3d-2bbf-456d-a084-4106e599a152" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_031f2b03-f62b-4065-9484-3dbae8f81218" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_50c76006-47f1-4719-a66d-c9eef8aff500" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1c3e3d3d-2bbf-456d-a084-4106e599a152" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_50c76006-47f1-4719-a66d-c9eef8aff500" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_06e3fc74-dfbf-469e-b34c-97e6ba309471" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3a499f69-62db-4b3a-b9cb-cbde0692d69d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7b68311f-c032-4aea-8556-f8f352604f2c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3a499f69-62db-4b3a-b9cb-cbde0692d69d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ceaed5c9-7dd1-46d3-87f8-74281bb164f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3a499f69-62db-4b3a-b9cb-cbde0692d69d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ceaed5c9-7dd1-46d3-87f8-74281bb164f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8809c242-9a09-40aa-89ae-a2d0d0835e38" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3a499f69-62db-4b3a-b9cb-cbde0692d69d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8809c242-9a09-40aa-89ae-a2d0d0835e38" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_987473f6-de3c-48aa-b5e9-99fd296edbcd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3a499f69-62db-4b3a-b9cb-cbde0692d69d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_987473f6-de3c-48aa-b5e9-99fd296edbcd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c1bfa3ee-1acc-45a4-9c44-8e565f8ece9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3a499f69-62db-4b3a-b9cb-cbde0692d69d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c1bfa3ee-1acc-45a4-9c44-8e565f8ece9b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_143cac3e-4eec-4d43-9e58-498929005c71" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a2b7d5e9-d39e-4030-af50-7a21938f528f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7b68311f-c032-4aea-8556-f8f352604f2c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a2b7d5e9-d39e-4030-af50-7a21938f528f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c1edf007-c91d-47d6-ba3f-d86b487d10bb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a2b7d5e9-d39e-4030-af50-7a21938f528f" xlink:to="loc_us-gaap_AwardTypeAxis_c1edf007-c91d-47d6-ba3f-d86b487d10bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c1edf007-c91d-47d6-ba3f-d86b487d10bb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c1edf007-c91d-47d6-ba3f-d86b487d10bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c1edf007-c91d-47d6-ba3f-d86b487d10bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0d5169f-451a-411e-a2d2-c667398051dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c1edf007-c91d-47d6-ba3f-d86b487d10bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0d5169f-451a-411e-a2d2-c667398051dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_94edc220-d91c-45ab-8959-996ebc7dd966" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0d5169f-451a-411e-a2d2-c667398051dd" xlink:to="loc_us-gaap_RestrictedStockMember_94edc220-d91c-45ab-8959-996ebc7dd966" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/StockawardplanSharebasedcompensationexpenseDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#StockawardplanSharebasedcompensationexpenseDetails"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/StockawardplanSharebasedcompensationexpenseDetails" xlink:type="extended" id="i5cd92492c10d4fa0bbe9a1b32069ad2e_StockawardplanSharebasedcompensationexpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6154f92c-133a-412c-8a9a-88450b9e8729" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber_1ba59890-1679-4466-856e-d1b072e9574a" xlink:href="ptct-20200630.xsd#ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6154f92c-133a-412c-8a9a-88450b9e8729" xlink:to="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber_1ba59890-1679-4466-856e-d1b072e9574a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3b6f5d51-6724-4033-9d6a-dff57a20122f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6154f92c-133a-412c-8a9a-88450b9e8729" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3b6f5d51-6724-4033-9d6a-dff57a20122f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f6c775dc-36fb-4c7a-9f25-a1938def86dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6154f92c-133a-412c-8a9a-88450b9e8729" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f6c775dc-36fb-4c7a-9f25-a1938def86dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0132f841-5053-4b16-9419-a63cfb011617" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6154f92c-133a-412c-8a9a-88450b9e8729" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0132f841-5053-4b16-9419-a63cfb011617" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ee2fd25a-d779-407e-869a-07491548745d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0132f841-5053-4b16-9419-a63cfb011617" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ee2fd25a-d779-407e-869a-07491548745d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ee2fd25a-d779-407e-869a-07491548745d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ee2fd25a-d779-407e-869a-07491548745d" xlink:to="loc_us-gaap_ClassOfStockDomain_ee2fd25a-d779-407e-869a-07491548745d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c6d7bfbd-2539-4ba7-b5c6-a5e1b0bfa37b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ee2fd25a-d779-407e-869a-07491548745d" xlink:to="loc_us-gaap_ClassOfStockDomain_c6d7bfbd-2539-4ba7-b5c6-a5e1b0bfa37b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c67f451f-dcba-4a66-9ded-3372e99b23a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_c6d7bfbd-2539-4ba7-b5c6-a5e1b0bfa37b" xlink:to="loc_us-gaap_CommonStockMember_c67f451f-dcba-4a66-9ded-3372e99b23a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_83498df9-725b-4476-a115-dbddc16d055d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0132f841-5053-4b16-9419-a63cfb011617" xlink:to="loc_us-gaap_PlanNameAxis_83498df9-725b-4476-a115-dbddc16d055d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_83498df9-725b-4476-a115-dbddc16d055d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_83498df9-725b-4476-a115-dbddc16d055d" xlink:to="loc_us-gaap_PlanNameDomain_83498df9-725b-4476-a115-dbddc16d055d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e43ad4b3-9455-457d-8761-918e2504e29e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_83498df9-725b-4476-a115-dbddc16d055d" xlink:to="loc_us-gaap_PlanNameDomain_e43ad4b3-9455-457d-8761-918e2504e29e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_A2020inducementstockincentiveplanMember_487746ce-14e7-4266-bbaf-523acee108c4" xlink:href="ptct-20200630.xsd#ptct_A2020inducementstockincentiveplanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e43ad4b3-9455-457d-8761-918e2504e29e" xlink:to="loc_ptct_A2020inducementstockincentiveplanMember_487746ce-14e7-4266-bbaf-523acee108c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_be6bcd7d-66a6-4863-aee3-066fa94a143f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0132f841-5053-4b16-9419-a63cfb011617" xlink:to="loc_srt_RangeAxis_be6bcd7d-66a6-4863-aee3-066fa94a143f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_be6bcd7d-66a6-4863-aee3-066fa94a143f_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_be6bcd7d-66a6-4863-aee3-066fa94a143f" xlink:to="loc_srt_RangeMember_be6bcd7d-66a6-4863-aee3-066fa94a143f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_095acfb8-e383-4097-84b6-93c3f8aecb3c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_be6bcd7d-66a6-4863-aee3-066fa94a143f" xlink:to="loc_srt_RangeMember_095acfb8-e383-4097-84b6-93c3f8aecb3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a692ab11-1ed1-4f01-a844-9af5971f62c6" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_095acfb8-e383-4097-84b6-93c3f8aecb3c" xlink:to="loc_srt_MinimumMember_a692ab11-1ed1-4f01-a844-9af5971f62c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_63bd236a-5f83-4f6c-a4e9-65e7344e646f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0132f841-5053-4b16-9419-a63cfb011617" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_63bd236a-5f83-4f6c-a4e9-65e7344e646f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_63bd236a-5f83-4f6c-a4e9-65e7344e646f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_63bd236a-5f83-4f6c-a4e9-65e7344e646f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_63bd236a-5f83-4f6c-a4e9-65e7344e646f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_db88f5c0-c32c-40b4-b211-115903e1fb2a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_63bd236a-5f83-4f6c-a4e9-65e7344e646f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_db88f5c0-c32c-40b4-b211-115903e1fb2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c53a5eb6-f8c0-407b-a1c7-57446270e8ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_db88f5c0-c32c-40b4-b211-115903e1fb2a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c53a5eb6-f8c0-407b-a1c7-57446270e8ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_fe86456a-2b98-43f7-9cce-bd22be50670f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_db88f5c0-c32c-40b4-b211-115903e1fb2a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_fe86456a-2b98-43f7-9cce-bd22be50670f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/Debt" xlink:type="simple" xlink:href="ptct-20200630.xsd#Debt"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/Debt" xlink:type="extended" id="i7f52cb2b26bf4af0b33ea8cdd3a29fa8_Debt"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/DebtTables" xlink:type="simple" xlink:href="ptct-20200630.xsd#DebtTables"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/DebtTables" xlink:type="extended" id="i3324236ff58f4272814d3f794f218361_DebtTables">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionLineItems_0061e936-e152-4130-823d-a62760590993" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_a4c11590-39b2-4652-979c-1e05dc06bb9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionLineItems_0061e936-e152-4130-823d-a62760590993" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_a4c11590-39b2-4652-979c-1e05dc06bb9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock_b2c92615-91e7-4415-bf72-dac47b78b963" xlink:href="ptct-20200630.xsd#ptct_ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionLineItems_0061e936-e152-4130-823d-a62760590993" xlink:to="loc_ptct_ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock_b2c92615-91e7-4415-bf72-dac47b78b963" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionTable_adf80bd8-fee0-43fb-b308-633546f7d094" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentRedemptionLineItems_0061e936-e152-4130-823d-a62760590993" xlink:to="loc_us-gaap_DebtInstrumentRedemptionTable_adf80bd8-fee0-43fb-b308-633546f7d094" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5963938b-f4f3-42cb-91b9-47467baf13d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentRedemptionTable_adf80bd8-fee0-43fb-b308-633546f7d094" xlink:to="loc_us-gaap_DebtInstrumentAxis_5963938b-f4f3-42cb-91b9-47467baf13d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5963938b-f4f3-42cb-91b9-47467baf13d3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_5963938b-f4f3-42cb-91b9-47467baf13d3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5963938b-f4f3-42cb-91b9-47467baf13d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6abbf18f-ec01-4505-81e3-caedd35017c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_5963938b-f4f3-42cb-91b9-47467baf13d3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6abbf18f-ec01-4505-81e3-caedd35017c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member_63454bdd-3d53-4a49-82ed-1ec2c781662b" xlink:href="ptct-20200630.xsd#ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6abbf18f-ec01-4505-81e3-caedd35017c7" xlink:to="loc_ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member_63454bdd-3d53-4a49-82ed-1ec2c781662b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_b146009f-9727-45df-a9ad-3d0ab9cae6ee" xlink:href="ptct-20200630.xsd#ptct_ConvertibleSeniorNotes3.0PercentDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6abbf18f-ec01-4505-81e3-caedd35017c7" xlink:to="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_b146009f-9727-45df-a9ad-3d0ab9cae6ee" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#DebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/DebtNarrativeDetails" xlink:type="extended" id="i7cf0e9711c2b42098acb7611642b44f8_DebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_713595ab-e227-45de-af38-4af1093cc90b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_713595ab-e227-45de-af38-4af1093cc90b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_9af732d3-694b-4129-ad51-a3ea6073e084" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_9af732d3-694b-4129-ad51-a3ea6073e084" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_LineOfCreditFacilityAdditionalCapacityAvailable_b53f6807-2422-48a5-a218-be4d7d2cf007" xlink:href="ptct-20200630.xsd#ptct_LineOfCreditFacilityAdditionalCapacityAvailable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_ptct_LineOfCreditFacilityAdditionalCapacityAvailable_b53f6807-2422-48a5-a218-be4d7d2cf007" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_34bd788c-1c8c-4410-864d-2558ec4f52c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_34bd788c-1c8c-4410-864d-2558ec4f52c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_6a2d9aa5-57a9-45d4-b841-cd66bd03c023" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_us-gaap_RepaymentsOfDebt_6a2d9aa5-57a9-45d4-b841-cd66bd03c023" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_32014237-c5b5-4086-ac57-d6b43de37f41" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_us-gaap_LongTermDebt_32014237-c5b5-4086-ac57-d6b43de37f41" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_d6567a53-a6f9-4158-b61f-7b5af3af23f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_d6567a53-a6f9-4158-b61f-7b5af3af23f9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_651bd02a-e392-4a1e-aad5-946c8396e95b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_us-gaap_LongTermDebtCurrent_651bd02a-e392-4a1e-aad5-946c8396e95b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DebtInstrumentFloorInterestRate_1344ac77-cbee-4b7b-a877-84ed5cbaad76" xlink:href="ptct-20200630.xsd#ptct_DebtInstrumentFloorInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_ptct_DebtInstrumentFloorInterestRate_1344ac77-cbee-4b7b-a877-84ed5cbaad76" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_533372ad-a818-481b-b438-3ef07da33ad6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_533372ad-a818-481b-b438-3ef07da33ad6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DebtInstrumentInterestPaymentPeriod_43a5b75f-a582-453e-82ca-35266439bbfa" xlink:href="ptct-20200630.xsd#ptct_DebtInstrumentInterestPaymentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_ptct_DebtInstrumentInterestPaymentPeriod_43a5b75f-a582-453e-82ca-35266439bbfa" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_4ef8710c-b528-43c5-98b2-dafb3ddd21d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_4ef8710c-b528-43c5-98b2-dafb3ddd21d1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DebtInstrumentAdditionalAmountAvailableForRepurchase_0d66aa22-4024-44ce-a8fc-92e7d2f545b2" xlink:href="ptct-20200630.xsd#ptct_DebtInstrumentAdditionalAmountAvailableForRepurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_ptct_DebtInstrumentAdditionalAmountAvailableForRepurchase_0d66aa22-4024-44ce-a8fc-92e7d2f545b2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d428b1f5-8160-40a8-93e2-9e485f2bc7bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d428b1f5-8160-40a8-93e2-9e485f2bc7bf" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_46780711-38cb-4ff6-a0bf-20b5bedaf2ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_46780711-38cb-4ff6-a0bf-20b5bedaf2ec" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_3f78c3dd-9814-42cb-93c0-933b22b49598" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_3f78c3dd-9814-42cb-93c0-933b22b49598" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_fe7124a3-6717-4f92-ad49-2ade56c31c72" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_fe7124a3-6717-4f92-ad49-2ade56c31c72" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_cbf6e9d8-fde1-4492-8e7c-9bf292d028fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_cbf6e9d8-fde1-4492-8e7c-9bf292d028fa" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DebtInstrumentConvertibleThresholdBusinessDays_581a9d1a-3abb-44b9-a013-54a79a25f2be" xlink:href="ptct-20200630.xsd#ptct_DebtInstrumentConvertibleThresholdBusinessDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_ptct_DebtInstrumentConvertibleThresholdBusinessDays_581a9d1a-3abb-44b9-a013-54a79a25f2be" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod_630e7d17-f928-4de0-bb0f-85cdf43d4e36" xlink:href="ptct-20200630.xsd#ptct_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_ptct_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod_630e7d17-f928-4de0-bb0f-85cdf43d4e36" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum_196e33af-3fe1-428b-9675-b42f72acad07" xlink:href="ptct-20200630.xsd#ptct_DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_ptct_DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum_196e33af-3fe1-428b-9675-b42f72acad07" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_002b66d3-7e21-40b4-9f65-870517c8b24c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_002b66d3-7e21-40b4-9f65-870517c8b24c" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_a685ae57-574b-4fb4-96a6-80127da82c1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_a685ae57-574b-4fb4-96a6-80127da82c1e" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_409e6c7c-ad9a-4aa5-9b7f-69a974e553e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_409e6c7c-ad9a-4aa5-9b7f-69a974e553e7" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCumulativeSinkingFundPayments_2cfb6511-140d-4133-b62e-0baa8fd33300" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCumulativeSinkingFundPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_us-gaap_DebtInstrumentCumulativeSinkingFundPayments_2cfb6511-140d-4133-b62e-0baa8fd33300" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault_90b89281-7cf2-44d6-a7bb-dda9317d4e66" xlink:href="ptct-20200630.xsd#ptct_ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_ptct_ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault_90b89281-7cf2-44d6-a7bb-dda9317d4e66" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders_e516bb81-6f91-42d9-8643-ab74d60a1c1f" xlink:href="ptct-20200630.xsd#ptct_MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_ptct_MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders_e516bb81-6f91-42d9-8643-ab74d60a1c1f" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_78224c2e-a5ca-49c4-afb8-0db66501c740" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_us-gaap_DebtInstrumentTerm_78224c2e-a5ca-49c4-afb8-0db66501c740" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_b5fab13a-2902-46aa-a78c-f38e721d0ba7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_b5fab13a-2902-46aa-a78c-f38e721d0ba7" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_NetDeferredTaxLiabilitiesConvertibleDebtInstruments_d5b88cf9-a3b2-40cf-9c74-848f8eeae078" xlink:href="ptct-20200630.xsd#ptct_NetDeferredTaxLiabilitiesConvertibleDebtInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_ptct_NetDeferredTaxLiabilitiesConvertibleDebtInstruments_d5b88cf9-a3b2-40cf-9c74-848f8eeae078" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_9bc85988-5548-4e18-8b7f-624d95e6da68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_us-gaap_DebtInstrumentFairValue_9bc85988-5548-4e18-8b7f-624d95e6da68" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_e3bff46b-dfda-49d6-ae5c-93c62445d5b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_e3bff46b-dfda-49d6-ae5c-93c62445d5b2" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_d2c69cce-85c7-4f6c-b5f8-6fdc849f0560" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_us-gaap_DebtInstrumentTable_d2c69cce-85c7-4f6c-b5f8-6fdc849f0560" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_256a1d10-fecd-4b23-806e-882876cf3e6a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d2c69cce-85c7-4f6c-b5f8-6fdc849f0560" xlink:to="loc_us-gaap_CreditFacilityAxis_256a1d10-fecd-4b23-806e-882876cf3e6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_256a1d10-fecd-4b23-806e-882876cf3e6a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_256a1d10-fecd-4b23-806e-882876cf3e6a" xlink:to="loc_us-gaap_CreditFacilityDomain_256a1d10-fecd-4b23-806e-882876cf3e6a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_0ce74e2a-f138-438a-b2f2-b0dae1cfdcf1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_256a1d10-fecd-4b23-806e-882876cf3e6a" xlink:to="loc_us-gaap_CreditFacilityDomain_0ce74e2a-f138-438a-b2f2-b0dae1cfdcf1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_MidCapFinancialTrustMember_fc7bdffc-7839-4d68-aa51-99ae1fb08f60" xlink:href="ptct-20200630.xsd#ptct_MidCapFinancialTrustMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_0ce74e2a-f138-438a-b2f2-b0dae1cfdcf1" xlink:to="loc_ptct_MidCapFinancialTrustMember_fc7bdffc-7839-4d68-aa51-99ae1fb08f60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_823a3394-5737-46bb-9388-0b57e4132025" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d2c69cce-85c7-4f6c-b5f8-6fdc849f0560" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_823a3394-5737-46bb-9388-0b57e4132025" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_823a3394-5737-46bb-9388-0b57e4132025_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_823a3394-5737-46bb-9388-0b57e4132025" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_823a3394-5737-46bb-9388-0b57e4132025_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_67fb9e8c-b141-4a40-9ec5-6f135b5ed2b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_823a3394-5737-46bb-9388-0b57e4132025" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_67fb9e8c-b141-4a40-9ec5-6f135b5ed2b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_7ef6784b-ed3e-4bb0-a77f-28c66a9b2664" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_67fb9e8c-b141-4a40-9ec5-6f135b5ed2b5" xlink:to="loc_us-gaap_ConvertibleDebtMember_7ef6784b-ed3e-4bb0-a77f-28c66a9b2664" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_621ec3af-e50a-4ad5-bc57-4e7207ea8ccb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d2c69cce-85c7-4f6c-b5f8-6fdc849f0560" xlink:to="loc_us-gaap_DebtInstrumentAxis_621ec3af-e50a-4ad5-bc57-4e7207ea8ccb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_621ec3af-e50a-4ad5-bc57-4e7207ea8ccb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_621ec3af-e50a-4ad5-bc57-4e7207ea8ccb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_621ec3af-e50a-4ad5-bc57-4e7207ea8ccb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6b03553b-77ae-4e0e-9a48-484af22b6522" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_621ec3af-e50a-4ad5-bc57-4e7207ea8ccb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6b03553b-77ae-4e0e-9a48-484af22b6522" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_ea64a473-6b35-490d-a26a-bbc855378930" xlink:href="ptct-20200630.xsd#ptct_ConvertibleSeniorNotes3.0PercentDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6b03553b-77ae-4e0e-9a48-484af22b6522" xlink:to="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_ea64a473-6b35-490d-a26a-bbc855378930" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member_eda44932-2cec-4698-9900-74b28713aa30" xlink:href="ptct-20200630.xsd#ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6b03553b-77ae-4e0e-9a48-484af22b6522" xlink:to="loc_ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member_eda44932-2cec-4698-9900-74b28713aa30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_6b216f35-3816-4482-8ab8-b0add5528bb4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d2c69cce-85c7-4f6c-b5f8-6fdc849f0560" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_6b216f35-3816-4482-8ab8-b0add5528bb4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_6b216f35-3816-4482-8ab8-b0add5528bb4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_6b216f35-3816-4482-8ab8-b0add5528bb4" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_6b216f35-3816-4482-8ab8-b0add5528bb4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_9b1f0bad-87b1-4b9d-a10e-97479e6eaa5b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_6b216f35-3816-4482-8ab8-b0add5528bb4" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_9b1f0bad-87b1-4b9d-a10e-97479e6eaa5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member_131517a7-f75f-4f58-9ca0-f2ee7d82ca76" xlink:href="ptct-20200630.xsd#ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_9b1f0bad-87b1-4b9d-a10e-97479e6eaa5b" xlink:to="loc_ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member_131517a7-f75f-4f58-9ca0-f2ee7d82ca76" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/DebtConvertibleNotesDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#DebtConvertibleNotesDetails"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/DebtConvertibleNotesDetails" xlink:type="extended" id="ie4ceb918cbb342ec9023fcdf0165943d_DebtConvertibleNotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_531e113b-f397-4787-b24d-0d51b760f070" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_e105515f-9513-4fc8-a413-3ef6ab1f970d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_531e113b-f397-4787-b24d-0d51b760f070" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_e105515f-9513-4fc8-a413-3ef6ab1f970d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_6624fb12-6f3a-449d-a46b-b2f98f2be9e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_531e113b-f397-4787-b24d-0d51b760f070" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_6624fb12-6f3a-449d-a46b-b2f98f2be9e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_18cc0fea-33d5-4ab7-a0f6-7246f0c31371" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_531e113b-f397-4787-b24d-0d51b760f070" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_18cc0fea-33d5-4ab7-a0f6-7246f0c31371" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_c7c13b52-a4db-458c-ac75-389a3d1b22d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_531e113b-f397-4787-b24d-0d51b760f070" xlink:to="loc_us-gaap_LongTermDebt_c7c13b52-a4db-458c-ac75-389a3d1b22d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_283360d1-ffa6-4d20-8525-e34badf5aa03" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_531e113b-f397-4787-b24d-0d51b760f070" xlink:to="loc_us-gaap_DebtInstrumentTable_283360d1-ffa6-4d20-8525-e34badf5aa03" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_369cb38f-20f7-41b5-822d-f39ac7dd7f22" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_283360d1-ffa6-4d20-8525-e34badf5aa03" xlink:to="loc_us-gaap_DebtInstrumentAxis_369cb38f-20f7-41b5-822d-f39ac7dd7f22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_369cb38f-20f7-41b5-822d-f39ac7dd7f22_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_369cb38f-20f7-41b5-822d-f39ac7dd7f22" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_369cb38f-20f7-41b5-822d-f39ac7dd7f22_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5b6c0964-c484-44c8-8516-6362dbfaa5e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_369cb38f-20f7-41b5-822d-f39ac7dd7f22" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5b6c0964-c484-44c8-8516-6362dbfaa5e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_dadf34b8-e504-4843-8be4-3550675ba870" xlink:href="ptct-20200630.xsd#ptct_ConvertibleSeniorNotes3.0PercentDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5b6c0964-c484-44c8-8516-6362dbfaa5e0" xlink:to="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_dadf34b8-e504-4843-8be4-3550675ba870" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member_5a8308ca-95cd-4573-aaa4-6d228ee79ef2" xlink:href="ptct-20200630.xsd#ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5b6c0964-c484-44c8-8516-6362dbfaa5e0" xlink:to="loc_ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member_5a8308ca-95cd-4573-aaa4-6d228ee79ef2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_96d44176-c637-4976-8f13-54865f176bb1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_283360d1-ffa6-4d20-8525-e34badf5aa03" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_96d44176-c637-4976-8f13-54865f176bb1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_96d44176-c637-4976-8f13-54865f176bb1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_96d44176-c637-4976-8f13-54865f176bb1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_96d44176-c637-4976-8f13-54865f176bb1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8bfd26df-665b-46b8-b0e2-18663157006c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_96d44176-c637-4976-8f13-54865f176bb1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8bfd26df-665b-46b8-b0e2-18663157006c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_ef2ddcdd-9a25-421b-8a14-fcd92192eafd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8bfd26df-665b-46b8-b0e2-18663157006c" xlink:to="loc_us-gaap_ConvertibleDebtMember_ef2ddcdd-9a25-421b-8a14-fcd92192eafd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/DebtInterestExpenseDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#DebtInterestExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/DebtInterestExpenseDetails" xlink:type="extended" id="i1a418544b1ba495a8205499ba64a8052_DebtInterestExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c5ce49ba-77ea-4784-9641-f8a5d1f1b913" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_6c162be4-743d-4b98-b2af-8691550c9986" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c5ce49ba-77ea-4784-9641-f8a5d1f1b913" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_6c162be4-743d-4b98-b2af-8691550c9986" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_c515d2a4-9fdc-4fc5-a078-dc62e936a9fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c5ce49ba-77ea-4784-9641-f8a5d1f1b913" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_c515d2a4-9fdc-4fc5-a078-dc62e936a9fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_09510b5b-381a-4e54-ba9a-9bf7437ed2f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c5ce49ba-77ea-4784-9641-f8a5d1f1b913" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_09510b5b-381a-4e54-ba9a-9bf7437ed2f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_1339f693-d563-465e-bb62-d7d04e3cabd9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c5ce49ba-77ea-4784-9641-f8a5d1f1b913" xlink:to="loc_us-gaap_InterestExpenseDebt_1339f693-d563-465e-bb62-d7d04e3cabd9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_5bcf12ce-d7aa-4812-ada3-8627f9cf1f1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c5ce49ba-77ea-4784-9641-f8a5d1f1b913" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_5bcf12ce-d7aa-4812-ada3-8627f9cf1f1a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_0a291f25-f53b-4ba1-bc6d-7bf3c45df3d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c5ce49ba-77ea-4784-9641-f8a5d1f1b913" xlink:to="loc_us-gaap_DebtInstrumentTable_0a291f25-f53b-4ba1-bc6d-7bf3c45df3d6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_bc8adf24-7f44-47bb-bd66-aeda7cf81496" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0a291f25-f53b-4ba1-bc6d-7bf3c45df3d6" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_bc8adf24-7f44-47bb-bd66-aeda7cf81496" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bc8adf24-7f44-47bb-bd66-aeda7cf81496_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bc8adf24-7f44-47bb-bd66-aeda7cf81496" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bc8adf24-7f44-47bb-bd66-aeda7cf81496_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_06772697-d7c0-41e6-b87d-aea63a580b38" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bc8adf24-7f44-47bb-bd66-aeda7cf81496" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_06772697-d7c0-41e6-b87d-aea63a580b38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_9f689b48-ca20-41bc-aa91-a0adde33b922" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_06772697-d7c0-41e6-b87d-aea63a580b38" xlink:to="loc_us-gaap_ConvertibleDebtMember_9f689b48-ca20-41bc-aa91-a0adde33b922" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ba1ba97e-ced2-454a-9a26-a3935102e3dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0a291f25-f53b-4ba1-bc6d-7bf3c45df3d6" xlink:to="loc_us-gaap_DebtInstrumentAxis_ba1ba97e-ced2-454a-9a26-a3935102e3dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ba1ba97e-ced2-454a-9a26-a3935102e3dc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_ba1ba97e-ced2-454a-9a26-a3935102e3dc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ba1ba97e-ced2-454a-9a26-a3935102e3dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c58f6323-e53a-436b-b50e-9624c7d50cf3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_ba1ba97e-ced2-454a-9a26-a3935102e3dc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c58f6323-e53a-436b-b50e-9624c7d50cf3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_024c41fa-e558-4ea1-b8a2-cefc4b71a09b" xlink:href="ptct-20200630.xsd#ptct_ConvertibleSeniorNotes3.0PercentDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c58f6323-e53a-436b-b50e-9624c7d50cf3" xlink:to="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_024c41fa-e558-4ea1-b8a2-cefc4b71a09b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member_b23ccdda-ec25-402c-913f-8fc30ae659df" xlink:href="ptct-20200630.xsd#ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c58f6323-e53a-436b-b50e-9624c7d50cf3" xlink:to="loc_ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member_b23ccdda-ec25-402c-913f-8fc30ae659df" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/Commitmentsandcontingencies" xlink:type="simple" xlink:href="ptct-20200630.xsd#Commitmentsandcontingencies"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/Commitmentsandcontingencies" xlink:type="extended" id="i80552278924d4eeb96e1bf2cf7c2074a_Commitmentsandcontingencies"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#CommitmentsandcontingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails" xlink:type="extended" id="i419b117936204b6495357ce388437ed5_CommitmentsandcontingenciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c35d9634-26a7-492e-9ea2-cb40b16be3c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAbstract_748242d7-de50-40d6-9489-28009a442424" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c35d9634-26a7-492e-9ea2-cb40b16be3c0" xlink:to="loc_us-gaap_OtherCommitmentsAbstract_748242d7-de50-40d6-9489-28009a442424" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_UpfrontLicensingFee_7989e115-8540-49b2-b18c-12d6084dedf2" xlink:href="ptct-20200630.xsd#ptct_UpfrontLicensingFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsAbstract_748242d7-de50-40d6-9489-28009a442424" xlink:to="loc_ptct_UpfrontLicensingFee_7989e115-8540-49b2-b18c-12d6084dedf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing_b6491b80-fe76-417e-90ce-e2c86188358d" xlink:href="ptct-20200630.xsd#ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsAbstract_748242d7-de50-40d6-9489-28009a442424" xlink:to="loc_ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing_b6491b80-fe76-417e-90ce-e2c86188358d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount_b2c37660-f1db-4053-836d-50b79cc0f2ad" xlink:href="ptct-20200630.xsd#ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsAbstract_748242d7-de50-40d6-9489-28009a442424" xlink:to="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount_b2c37660-f1db-4053-836d-50b79cc0f2ad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone_fe28810e-567f-4603-9945-be97ef0a5e12" xlink:href="ptct-20200630.xsd#ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsAbstract_748242d7-de50-40d6-9489-28009a442424" xlink:to="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone_fe28810e-567f-4603-9945-be97ef0a5e12" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage_95c13f7e-f24e-4435-b208-c0f25c6ce448" xlink:href="ptct-20200630.xsd#ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsAbstract_748242d7-de50-40d6-9489-28009a442424" xlink:to="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage_95c13f7e-f24e-4435-b208-c0f25c6ce448" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_MilestonePotentialAchievementsRegulatoryApproval_1ae21fd6-12d2-4ba8-ad4f-bd3b0aa207c1" xlink:href="ptct-20200630.xsd#ptct_MilestonePotentialAchievementsRegulatoryApproval"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsAbstract_748242d7-de50-40d6-9489-28009a442424" xlink:to="loc_ptct_MilestonePotentialAchievementsRegulatoryApproval_1ae21fd6-12d2-4ba8-ad4f-bd3b0aa207c1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AssetAcquisitionMilestoneAmount_f8913b57-d1d9-4452-b2b0-34748a38feba" xlink:href="ptct-20200630.xsd#ptct_AssetAcquisitionMilestoneAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c35d9634-26a7-492e-9ea2-cb40b16be3c0" xlink:to="loc_ptct_AssetAcquisitionMilestoneAmount_f8913b57-d1d9-4452-b2b0-34748a38feba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AssetAcquisitionDevelopmentAndRegulatoryMilestones_1a3a41a3-8f13-409f-8e59-1b0afbc413ed" xlink:href="ptct-20200630.xsd#ptct_AssetAcquisitionDevelopmentAndRegulatoryMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c35d9634-26a7-492e-9ea2-cb40b16be3c0" xlink:to="loc_ptct_AssetAcquisitionDevelopmentAndRegulatoryMilestones_1a3a41a3-8f13-409f-8e59-1b0afbc413ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AssetAcquisitionNetSalesMilestone_8be1e4b9-e390-44d3-b2b4-2bdeb7b00798" xlink:href="ptct-20200630.xsd#ptct_AssetAcquisitionNetSalesMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c35d9634-26a7-492e-9ea2-cb40b16be3c0" xlink:to="loc_ptct_AssetAcquisitionNetSalesMilestone_8be1e4b9-e390-44d3-b2b4-2bdeb7b00798" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AssetAcquisitionInitialMilestone_1313ed58-0d17-4b0a-9026-3ce84fa5ea77" xlink:href="ptct-20200630.xsd#ptct_AssetAcquisitionInitialMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c35d9634-26a7-492e-9ea2-cb40b16be3c0" xlink:to="loc_ptct_AssetAcquisitionInitialMilestone_1313ed58-0d17-4b0a-9026-3ce84fa5ea77" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ContingentLiabilityCancellationAndForfeitureMilestonePotentialAchievementsPriorityReviewVoucherAmount_8ef6fbb1-e4de-44fd-bb4b-8d722e587737" xlink:href="ptct-20200630.xsd#ptct_ContingentLiabilityCancellationAndForfeitureMilestonePotentialAchievementsPriorityReviewVoucherAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c35d9634-26a7-492e-9ea2-cb40b16be3c0" xlink:to="loc_ptct_ContingentLiabilityCancellationAndForfeitureMilestonePotentialAchievementsPriorityReviewVoucherAmount_8ef6fbb1-e4de-44fd-bb4b-8d722e587737" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DevelopmentMilestonePaymentObligationsCancellationAndForfeiture_566c1bb1-cf7c-4936-8a2f-3bd70923b6f6" xlink:href="ptct-20200630.xsd#ptct_DevelopmentMilestonePaymentObligationsCancellationAndForfeiture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c35d9634-26a7-492e-9ea2-cb40b16be3c0" xlink:to="loc_ptct_DevelopmentMilestonePaymentObligationsCancellationAndForfeiture_566c1bb1-cf7c-4936-8a2f-3bd70923b6f6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture_3b1fe2c0-04d3-4250-bbf0-32ac81455880" xlink:href="ptct-20200630.xsd#ptct_DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c35d9634-26a7-492e-9ea2-cb40b16be3c0" xlink:to="loc_ptct_DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture_3b1fe2c0-04d3-4250-bbf0-32ac81455880" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ContingentLiabilityCancellationAndForfeiture_70eead8e-007d-401d-9a8a-e42f1a225a42" xlink:href="ptct-20200630.xsd#ptct_ContingentLiabilityCancellationAndForfeiture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c35d9634-26a7-492e-9ea2-cb40b16be3c0" xlink:to="loc_ptct_ContingentLiabilityCancellationAndForfeiture_70eead8e-007d-401d-9a8a-e42f1a225a42" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture_9231d0fd-9aba-4cb8-96ae-f01d492fa115" xlink:href="ptct-20200630.xsd#ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c35d9634-26a7-492e-9ea2-cb40b16be3c0" xlink:to="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture_9231d0fd-9aba-4cb8-96ae-f01d492fa115" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c97ea63b-241d-44e1-9e89-d826919603f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_c35d9634-26a7-492e-9ea2-cb40b16be3c0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c97ea63b-241d-44e1-9e89-d826919603f3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1b5b0b3e-9f89-4a24-a020-c993e2cb7b67" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c97ea63b-241d-44e1-9e89-d826919603f3" xlink:to="loc_srt_ProductOrServiceAxis_1b5b0b3e-9f89-4a24-a020-c993e2cb7b67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1b5b0b3e-9f89-4a24-a020-c993e2cb7b67_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1b5b0b3e-9f89-4a24-a020-c993e2cb7b67" xlink:to="loc_srt_ProductsAndServicesDomain_1b5b0b3e-9f89-4a24-a020-c993e2cb7b67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ce5ccec6-4b00-4f36-a896-e44659f011c8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1b5b0b3e-9f89-4a24-a020-c993e2cb7b67" xlink:to="loc_srt_ProductsAndServicesDomain_ce5ccec6-4b00-4f36-a896-e44659f011c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_8c916c8c-e353-4a8f-a44c-36cdf457cc94" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ce5ccec6-4b00-4f36-a896-e44659f011c8" xlink:to="loc_us-gaap_ProductMember_8c916c8c-e353-4a8f-a44c-36cdf457cc94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_052ca821-17d0-47dc-83f3-1ca7a6b4a5f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c97ea63b-241d-44e1-9e89-d826919603f3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_052ca821-17d0-47dc-83f3-1ca7a6b4a5f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_052ca821-17d0-47dc-83f3-1ca7a6b4a5f4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_052ca821-17d0-47dc-83f3-1ca7a6b4a5f4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_052ca821-17d0-47dc-83f3-1ca7a6b4a5f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7ebf8e81-ae1d-4d72-9ab2-afbf0b5fd858" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_052ca821-17d0-47dc-83f3-1ca7a6b4a5f4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7ebf8e81-ae1d-4d72-9ab2-afbf0b5fd858" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AgilisMember_1b152cbb-28b1-4109-ae48-f2563bce4a01" xlink:href="ptct-20200630.xsd#ptct_AgilisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7ebf8e81-ae1d-4d72-9ab2-afbf0b5fd858" xlink:to="loc_ptct_AgilisMember_1b152cbb-28b1-4109-ae48-f2563bce4a01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_BioElectronMember_aef3889f-b536-43ae-a8b7-c3b133184f04" xlink:href="ptct-20200630.xsd#ptct_BioElectronMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7ebf8e81-ae1d-4d72-9ab2-afbf0b5fd858" xlink:to="loc_ptct_BioElectronMember_aef3889f-b536-43ae-a8b7-c3b133184f04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ffe92da1-2007-4154-8a7e-acb65ec958f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c97ea63b-241d-44e1-9e89-d826919603f3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ffe92da1-2007-4154-8a7e-acb65ec958f4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ffe92da1-2007-4154-8a7e-acb65ec958f4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ffe92da1-2007-4154-8a7e-acb65ec958f4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ffe92da1-2007-4154-8a7e-acb65ec958f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5cab34d5-9ada-427f-982f-db2810d235d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ffe92da1-2007-4154-8a7e-acb65ec958f4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5cab34d5-9ada-427f-982f-db2810d235d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncollaborativeArrangementTransactionsMember_9cfbfd95-8371-4c46-b1bf-47b944b3e3f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncollaborativeArrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5cab34d5-9ada-427f-982f-db2810d235d1" xlink:to="loc_us-gaap_NoncollaborativeArrangementTransactionsMember_9cfbfd95-8371-4c46-b1bf-47b944b3e3f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e0d18d8a-719d-4569-b816-efa9b90f5da6" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c97ea63b-241d-44e1-9e89-d826919603f3" xlink:to="loc_srt_CounterpartyNameAxis_e0d18d8a-719d-4569-b816-efa9b90f5da6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e0d18d8a-719d-4569-b816-efa9b90f5da6_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_e0d18d8a-719d-4569-b816-efa9b90f5da6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e0d18d8a-719d-4569-b816-efa9b90f5da6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fd8ee02f-88d5-4c63-b9d8-01632137f8e3" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_e0d18d8a-719d-4569-b816-efa9b90f5da6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fd8ee02f-88d5-4c63-b9d8-01632137f8e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_WellcomeTrustLimitedMember_b321d7a7-ecf2-44b6-a3e1-0530f5c3dcbb" xlink:href="ptct-20200630.xsd#ptct_WellcomeTrustLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fd8ee02f-88d5-4c63-b9d8-01632137f8e3" xlink:to="loc_ptct_WellcomeTrustLimitedMember_b321d7a7-ecf2-44b6-a3e1-0530f5c3dcbb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_MarathonPharmaceuticalsLLCMember_c3660490-e999-4242-bef7-449f1572c9f9" xlink:href="ptct-20200630.xsd#ptct_MarathonPharmaceuticalsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fd8ee02f-88d5-4c63-b9d8-01632137f8e3" xlink:to="loc_ptct_MarathonPharmaceuticalsLLCMember_c3660490-e999-4242-bef7-449f1572c9f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AkceaMember_dc1d2538-df9f-43f4-8e3d-e8eb3ef50819" xlink:href="ptct-20200630.xsd#ptct_AkceaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fd8ee02f-88d5-4c63-b9d8-01632137f8e3" xlink:to="loc_ptct_AkceaMember_dc1d2538-df9f-43f4-8e3d-e8eb3ef50819" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_CesnaMember_af97b105-1187-4cbb-b788-6885aaea51a8" xlink:href="ptct-20200630.xsd#ptct_CesnaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fd8ee02f-88d5-4c63-b9d8-01632137f8e3" xlink:to="loc_ptct_CesnaMember_af97b105-1187-4cbb-b788-6885aaea51a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_CensaMember_10e515cf-3641-431b-aacc-2eaf144d536c" xlink:href="ptct-20200630.xsd#ptct_CensaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fd8ee02f-88d5-4c63-b9d8-01632137f8e3" xlink:to="loc_ptct_CensaMember_10e515cf-3641-431b-aacc-2eaf144d536c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d74f057c-6496-44ff-b242-fed933a33bfd" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c97ea63b-241d-44e1-9e89-d826919603f3" xlink:to="loc_srt_RangeAxis_d74f057c-6496-44ff-b242-fed933a33bfd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d74f057c-6496-44ff-b242-fed933a33bfd_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d74f057c-6496-44ff-b242-fed933a33bfd" xlink:to="loc_srt_RangeMember_d74f057c-6496-44ff-b242-fed933a33bfd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b562eb75-37cf-4f8a-b45f-94af33cce9e4" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d74f057c-6496-44ff-b242-fed933a33bfd" xlink:to="loc_srt_RangeMember_b562eb75-37cf-4f8a-b45f-94af33cce9e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5f88071e-4e3b-4d91-9e08-4ad2dfe4638f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b562eb75-37cf-4f8a-b45f-94af33cce9e4" xlink:to="loc_srt_MaximumMember_5f88071e-4e3b-4d91-9e08-4ad2dfe4638f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d9b6c690-108f-48ec-bbcd-9c60258dd1a1" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b562eb75-37cf-4f8a-b45f-94af33cce9e4" xlink:to="loc_srt_MinimumMember_d9b6c690-108f-48ec-bbcd-9c60258dd1a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b4f0af43-2491-4c86-9b77-904d3888e4e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c97ea63b-241d-44e1-9e89-d826919603f3" xlink:to="loc_us-gaap_PlanNameAxis_b4f0af43-2491-4c86-9b77-904d3888e4e8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b4f0af43-2491-4c86-9b77-904d3888e4e8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_b4f0af43-2491-4c86-9b77-904d3888e4e8" xlink:to="loc_us-gaap_PlanNameDomain_b4f0af43-2491-4c86-9b77-904d3888e4e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d82a6090-61f8-40fe-b127-5d4d7258756d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_b4f0af43-2491-4c86-9b77-904d3888e4e8" xlink:to="loc_us-gaap_PlanNameDomain_d82a6090-61f8-40fe-b127-5d4d7258756d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_RightsExchangeAgreementMember_6e005b1d-20e9-4756-b94c-5287d071e153" xlink:href="ptct-20200630.xsd#ptct_RightsExchangeAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d82a6090-61f8-40fe-b127-5d4d7258756d" xlink:to="loc_ptct_RightsExchangeAgreementMember_6e005b1d-20e9-4756-b94c-5287d071e153" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/Revenuerecognition" xlink:type="simple" xlink:href="ptct-20200630.xsd#Revenuerecognition"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/Revenuerecognition" xlink:type="extended" id="i38568d655b9f408787dc71ec6b8a8fa7_Revenuerecognition"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/RevenuerecognitionNarrativeDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#RevenuerecognitionNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/RevenuerecognitionNarrativeDetails" xlink:type="extended" id="i42b482a1832d418a9154753f0ef3a30f_RevenuerecognitionNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_fe7bd9cc-178a-4221-9891-9cb12b8e702e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_8a0cb769-b4da-4776-b578-28b42c2edb4e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_fe7bd9cc-178a-4221-9891-9cb12b8e702e" xlink:to="loc_us-gaap_NumberOfOperatingSegments_8a0cb769-b4da-4776-b578-28b42c2edb4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_NetProductSales_6878cd4c-86ae-46b5-9891-4bde43389eb3" xlink:href="ptct-20200630.xsd#ptct_NetProductSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_fe7bd9cc-178a-4221-9891-9cb12b8e702e" xlink:to="loc_ptct_NetProductSales_6878cd4c-86ae-46b5-9891-4bde43389eb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_Percentageofnetproductsales_f95393ae-a668-49fc-afb2-43c7e7509fd1" xlink:href="ptct-20200630.xsd#ptct_Percentageofnetproductsales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_fe7bd9cc-178a-4221-9891-9cb12b8e702e" xlink:to="loc_ptct_Percentageofnetproductsales_f95393ae-a668-49fc-afb2-43c7e7509fd1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_Numberofdistributors_1cad12cf-f1ce-42b8-b859-a099ef263616" xlink:href="ptct-20200630.xsd#ptct_Numberofdistributors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_fe7bd9cc-178a-4221-9891-9cb12b8e702e" xlink:to="loc_ptct_Numberofdistributors_1cad12cf-f1ce-42b8-b859-a099ef263616" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_RevenueRecognitionMilestonePotentialAchievements_9a6b2664-231c-4832-9e6e-aabff487edf4" xlink:href="ptct-20200630.xsd#ptct_RevenueRecognitionMilestonePotentialAchievements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_fe7bd9cc-178a-4221-9891-9cb12b8e702e" xlink:to="loc_ptct_RevenueRecognitionMilestonePotentialAchievements_9a6b2664-231c-4832-9e6e-aabff487edf4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_063cabbc-50c5-4105-aa16-f5eb8ffa1914" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_fe7bd9cc-178a-4221-9891-9cb12b8e702e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_063cabbc-50c5-4105-aa16-f5eb8ffa1914" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8104ff25-38b1-44c1-b6ba-24bf6a7a6d3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_fe7bd9cc-178a-4221-9891-9cb12b8e702e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8104ff25-38b1-44c1-b6ba-24bf6a7a6d3b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_9b95b06c-47ff-48f9-894b-e55aa81b499a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_fe7bd9cc-178a-4221-9891-9cb12b8e702e" xlink:to="loc_us-gaap_Revenues_9b95b06c-47ff-48f9-894b-e55aa81b499a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology_faa7441b-f799-4ad9-8860-b41c6af31864" xlink:href="ptct-20200630.xsd#ptct_CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_fe7bd9cc-178a-4221-9891-9cb12b8e702e" xlink:to="loc_ptct_CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology_faa7441b-f799-4ad9-8860-b41c6af31864" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c1b17be6-68f2-4609-82e7-6f6094f2742c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_fe7bd9cc-178a-4221-9891-9cb12b8e702e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c1b17be6-68f2-4609-82e7-6f6094f2742c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_e75bcefd-cd5d-4080-b8ca-1fb17435d0d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_fe7bd9cc-178a-4221-9891-9cb12b8e702e" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_e75bcefd-cd5d-4080-b8ca-1fb17435d0d4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_534671af-30c3-4601-bd72-048872de5a2c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_e75bcefd-cd5d-4080-b8ca-1fb17435d0d4" xlink:to="loc_srt_RangeAxis_534671af-30c3-4601-bd72-048872de5a2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_534671af-30c3-4601-bd72-048872de5a2c_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_534671af-30c3-4601-bd72-048872de5a2c" xlink:to="loc_srt_RangeMember_534671af-30c3-4601-bd72-048872de5a2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_290c39d4-22b7-43a2-97fb-d886c43e5653" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_534671af-30c3-4601-bd72-048872de5a2c" xlink:to="loc_srt_RangeMember_290c39d4-22b7-43a2-97fb-d886c43e5653" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c639860d-9395-4fff-be53-a750fe3c70f5" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_290c39d4-22b7-43a2-97fb-d886c43e5653" xlink:to="loc_srt_MinimumMember_c639860d-9395-4fff-be53-a750fe3c70f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e89b947b-c322-4b28-ac85-8fcf7f65ea9b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_290c39d4-22b7-43a2-97fb-d886c43e5653" xlink:to="loc_srt_MaximumMember_e89b947b-c322-4b28-ac85-8fcf7f65ea9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f8ddda83-ae3b-41eb-973f-f9d724870ab9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_e75bcefd-cd5d-4080-b8ca-1fb17435d0d4" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f8ddda83-ae3b-41eb-973f-f9d724870ab9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f8ddda83-ae3b-41eb-973f-f9d724870ab9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f8ddda83-ae3b-41eb-973f-f9d724870ab9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f8ddda83-ae3b-41eb-973f-f9d724870ab9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d74028ff-8d55-4092-9a88-b92b4c16ff61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f8ddda83-ae3b-41eb-973f-f9d724870ab9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d74028ff-8d55-4092-9a88-b92b4c16ff61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_CollaborationAndDiscoveryAgreementsMember_d91c5d1f-0d95-4a92-a35a-50d69f8a4819" xlink:href="ptct-20200630.xsd#ptct_CollaborationAndDiscoveryAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d74028ff-8d55-4092-9a88-b92b4c16ff61" xlink:to="loc_ptct_CollaborationAndDiscoveryAgreementsMember_d91c5d1f-0d95-4a92-a35a-50d69f8a4819" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_079618c8-9f8f-4d8f-b200-d4f2da3973ef" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_e75bcefd-cd5d-4080-b8ca-1fb17435d0d4" xlink:to="loc_srt_CounterpartyNameAxis_079618c8-9f8f-4d8f-b200-d4f2da3973ef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_079618c8-9f8f-4d8f-b200-d4f2da3973ef_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_079618c8-9f8f-4d8f-b200-d4f2da3973ef" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_079618c8-9f8f-4d8f-b200-d4f2da3973ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_29b60492-6585-410a-9d72-d2feb341ccc2" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_079618c8-9f8f-4d8f-b200-d4f2da3973ef" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_29b60492-6585-410a-9d72-d2feb341ccc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_0393d7dd-0d7b-4b34-b882-d6e2812c7667" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_e75bcefd-cd5d-4080-b8ca-1fb17435d0d4" xlink:to="loc_srt_StatementGeographicalAxis_0393d7dd-0d7b-4b34-b882-d6e2812c7667" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_0393d7dd-0d7b-4b34-b882-d6e2812c7667_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_0393d7dd-0d7b-4b34-b882-d6e2812c7667" xlink:to="loc_srt_SegmentGeographicalDomain_0393d7dd-0d7b-4b34-b882-d6e2812c7667_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1dfc4c08-90c7-4e64-a475-0c856b908866" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_0393d7dd-0d7b-4b34-b882-d6e2812c7667" xlink:to="loc_srt_SegmentGeographicalDomain_1dfc4c08-90c7-4e64-a475-0c856b908866" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_da7d8114-aa14-4c0b-8cde-cdcb83901997" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1dfc4c08-90c7-4e64-a475-0c856b908866" xlink:to="loc_country_US_da7d8114-aa14-4c0b-8cde-cdcb83901997" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_e827f953-6b2d-4a21-965c-3d62de716f73" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1dfc4c08-90c7-4e64-a475-0c856b908866" xlink:to="loc_us-gaap_NonUsMember_e827f953-6b2d-4a21-965c-3d62de716f73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_746ed63a-2efd-433e-ae2e-2c134dbcb1b8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_e75bcefd-cd5d-4080-b8ca-1fb17435d0d4" xlink:to="loc_srt_ProductOrServiceAxis_746ed63a-2efd-433e-ae2e-2c134dbcb1b8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_746ed63a-2efd-433e-ae2e-2c134dbcb1b8_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_746ed63a-2efd-433e-ae2e-2c134dbcb1b8" xlink:to="loc_srt_ProductsAndServicesDomain_746ed63a-2efd-433e-ae2e-2c134dbcb1b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d18e2955-fc4d-48b7-b205-cf610823c9f4" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_746ed63a-2efd-433e-ae2e-2c134dbcb1b8" xlink:to="loc_srt_ProductsAndServicesDomain_d18e2955-fc4d-48b7-b205-cf610823c9f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_LicensingAndCollaborationAgreementMember_3fdaffd0-a15e-4e64-b64a-18fdea3dbedc" xlink:href="ptct-20200630.xsd#ptct_LicensingAndCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d18e2955-fc4d-48b7-b205-cf610823c9f4" xlink:to="loc_ptct_LicensingAndCollaborationAgreementMember_3fdaffd0-a15e-4e64-b64a-18fdea3dbedc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DiscoveryAgreementsMember_6b86165b-dfa0-4142-b2df-ab82d99ac578" xlink:href="ptct-20200630.xsd#ptct_DiscoveryAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d18e2955-fc4d-48b7-b205-cf610823c9f4" xlink:to="loc_ptct_DiscoveryAgreementsMember_6b86165b-dfa0-4142-b2df-ab82d99ac578" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_EarlyStageCollaborationsMember_1bdd3b42-f950-4e6b-93d3-16073c80e1d0" xlink:href="ptct-20200630.xsd#ptct_EarlyStageCollaborationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d18e2955-fc4d-48b7-b205-cf610823c9f4" xlink:to="loc_ptct_EarlyStageCollaborationsMember_1bdd3b42-f950-4e6b-93d3-16073c80e1d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_MilestoneAxis_cd269ae0-ae8c-4877-b639-648fcff38440" xlink:href="ptct-20200630.xsd#ptct_MilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_e75bcefd-cd5d-4080-b8ca-1fb17435d0d4" xlink:to="loc_ptct_MilestoneAxis_cd269ae0-ae8c-4877-b639-648fcff38440" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_MilestoneDomain_cd269ae0-ae8c-4877-b639-648fcff38440_default" xlink:href="ptct-20200630.xsd#ptct_MilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ptct_MilestoneAxis_cd269ae0-ae8c-4877-b639-648fcff38440" xlink:to="loc_ptct_MilestoneDomain_cd269ae0-ae8c-4877-b639-648fcff38440_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_MilestoneDomain_803396ee-d81b-428b-a1db-c7054e78eed1" xlink:href="ptct-20200630.xsd#ptct_MilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ptct_MilestoneAxis_cd269ae0-ae8c-4877-b639-648fcff38440" xlink:to="loc_ptct_MilestoneDomain_803396ee-d81b-428b-a1db-c7054e78eed1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ResearchAndDevelopmentEventMilestonesMember_21b3578b-c28e-4603-8209-2db624feeb0e" xlink:href="ptct-20200630.xsd#ptct_ResearchAndDevelopmentEventMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptct_MilestoneDomain_803396ee-d81b-428b-a1db-c7054e78eed1" xlink:to="loc_ptct_ResearchAndDevelopmentEventMilestonesMember_21b3578b-c28e-4603-8209-2db624feeb0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_SalesMilestonesMember_dc47aa55-5057-4014-b626-abf5121c79af" xlink:href="ptct-20200630.xsd#ptct_SalesMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptct_MilestoneDomain_803396ee-d81b-428b-a1db-c7054e78eed1" xlink:to="loc_ptct_SalesMilestonesMember_dc47aa55-5057-4014-b626-abf5121c79af" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/RevenuerecognitionPerformanceObligationsDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#RevenuerecognitionPerformanceObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/RevenuerecognitionPerformanceObligationsDetails" xlink:type="extended" id="i74a67f1e0a1a4f7aa9bda923974f0c04_RevenuerecognitionPerformanceObligationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_64b9d1dc-86ed-4488-8674-eb77fa1419ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_a568af28-4d28-4800-adaf-b049d471914f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_64b9d1dc-86ed-4488-8674-eb77fa1419ba" xlink:to="loc_us-gaap_ContractWithCustomerLiability_a568af28-4d28-4800-adaf-b049d471914f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_c1f973d8-1fec-4089-b4fb-758f85ce4725" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_64b9d1dc-86ed-4488-8674-eb77fa1419ba" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_c1f973d8-1fec-4089-b4fb-758f85ce4725" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_06ae4fda-ec27-4fb6-9eb8-c2a507cb5ddb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_64b9d1dc-86ed-4488-8674-eb77fa1419ba" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_06ae4fda-ec27-4fb6-9eb8-c2a507cb5ddb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_742c935e-4af6-4988-88da-f4695138a1be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_64b9d1dc-86ed-4488-8674-eb77fa1419ba" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_742c935e-4af6-4988-88da-f4695138a1be" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_a7cfe3f8-ea4c-45ad-b3dd-b03cb7375a9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_742c935e-4af6-4988-88da-f4695138a1be" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_a7cfe3f8-ea4c-45ad-b3dd-b03cb7375a9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_cc72e617-c2cf-4e3d-a5aa-c99123dbcbfb" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_742c935e-4af6-4988-88da-f4695138a1be" xlink:to="loc_srt_ProductOrServiceAxis_cc72e617-c2cf-4e3d-a5aa-c99123dbcbfb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cc72e617-c2cf-4e3d-a5aa-c99123dbcbfb_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_cc72e617-c2cf-4e3d-a5aa-c99123dbcbfb" xlink:to="loc_srt_ProductsAndServicesDomain_cc72e617-c2cf-4e3d-a5aa-c99123dbcbfb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0b391ad9-cdea-49d3-84d5-95baa319bf21" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_cc72e617-c2cf-4e3d-a5aa-c99123dbcbfb" xlink:to="loc_srt_ProductsAndServicesDomain_0b391ad9-cdea-49d3-84d5-95baa319bf21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_LicensingAndCollaborationAgreementMember_4228e2ca-df2e-4d2b-bb9b-2df7e73835b5" xlink:href="ptct-20200630.xsd#ptct_LicensingAndCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0b391ad9-cdea-49d3-84d5-95baa319bf21" xlink:to="loc_ptct_LicensingAndCollaborationAgreementMember_4228e2ca-df2e-4d2b-bb9b-2df7e73835b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e64a209b-f07e-4be8-b3a6-233b690bdae1" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_742c935e-4af6-4988-88da-f4695138a1be" xlink:to="loc_srt_RangeAxis_e64a209b-f07e-4be8-b3a6-233b690bdae1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e64a209b-f07e-4be8-b3a6-233b690bdae1_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e64a209b-f07e-4be8-b3a6-233b690bdae1" xlink:to="loc_srt_RangeMember_e64a209b-f07e-4be8-b3a6-233b690bdae1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a391d974-cd95-4b8f-83af-311e820c2abc" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e64a209b-f07e-4be8-b3a6-233b690bdae1" xlink:to="loc_srt_RangeMember_a391d974-cd95-4b8f-83af-311e820c2abc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8ab51363-3e21-45e3-bc5c-eed990951f22" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a391d974-cd95-4b8f-83af-311e820c2abc" xlink:to="loc_srt_MinimumMember_8ab51363-3e21-45e3-bc5c-eed990951f22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a1e1c30a-3560-48a5-80d2-4c5005f23630" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a391d974-cd95-4b8f-83af-311e820c2abc" xlink:to="loc_srt_MaximumMember_a1e1c30a-3560-48a5-80d2-4c5005f23630" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/RevenuerecognitionPerformanceObligationsDetails_1" xlink:type="simple" xlink:href="ptct-20200630.xsd#RevenuerecognitionPerformanceObligationsDetails_1"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/RevenuerecognitionPerformanceObligationsDetails_1" xlink:type="extended" id="i473cba334437430b84b3e68a6bb42e0a_RevenuerecognitionPerformanceObligationsDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_64b9d1dc-86ed-4488-8674-eb77fa1419ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_a568af28-4d28-4800-adaf-b049d471914f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_64b9d1dc-86ed-4488-8674-eb77fa1419ba" xlink:to="loc_us-gaap_ContractWithCustomerLiability_a568af28-4d28-4800-adaf-b049d471914f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_c1f973d8-1fec-4089-b4fb-758f85ce4725" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_64b9d1dc-86ed-4488-8674-eb77fa1419ba" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_c1f973d8-1fec-4089-b4fb-758f85ce4725" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_06ae4fda-ec27-4fb6-9eb8-c2a507cb5ddb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_64b9d1dc-86ed-4488-8674-eb77fa1419ba" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_06ae4fda-ec27-4fb6-9eb8-c2a507cb5ddb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_742c935e-4af6-4988-88da-f4695138a1be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_64b9d1dc-86ed-4488-8674-eb77fa1419ba" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_742c935e-4af6-4988-88da-f4695138a1be" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_cc72e617-c2cf-4e3d-a5aa-c99123dbcbfb" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_742c935e-4af6-4988-88da-f4695138a1be" xlink:to="loc_srt_ProductOrServiceAxis_cc72e617-c2cf-4e3d-a5aa-c99123dbcbfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cc72e617-c2cf-4e3d-a5aa-c99123dbcbfb_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_cc72e617-c2cf-4e3d-a5aa-c99123dbcbfb" xlink:to="loc_srt_ProductsAndServicesDomain_cc72e617-c2cf-4e3d-a5aa-c99123dbcbfb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0b391ad9-cdea-49d3-84d5-95baa319bf21" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_cc72e617-c2cf-4e3d-a5aa-c99123dbcbfb" xlink:to="loc_srt_ProductsAndServicesDomain_0b391ad9-cdea-49d3-84d5-95baa319bf21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_LicensingAndCollaborationAgreementMember_4228e2ca-df2e-4d2b-bb9b-2df7e73835b5" xlink:href="ptct-20200630.xsd#ptct_LicensingAndCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0b391ad9-cdea-49d3-84d5-95baa319bf21" xlink:to="loc_ptct_LicensingAndCollaborationAgreementMember_4228e2ca-df2e-4d2b-bb9b-2df7e73835b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e64a209b-f07e-4be8-b3a6-233b690bdae1" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_742c935e-4af6-4988-88da-f4695138a1be" xlink:to="loc_srt_RangeAxis_e64a209b-f07e-4be8-b3a6-233b690bdae1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e64a209b-f07e-4be8-b3a6-233b690bdae1_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e64a209b-f07e-4be8-b3a6-233b690bdae1" xlink:to="loc_srt_RangeMember_e64a209b-f07e-4be8-b3a6-233b690bdae1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a391d974-cd95-4b8f-83af-311e820c2abc" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e64a209b-f07e-4be8-b3a6-233b690bdae1" xlink:to="loc_srt_RangeMember_a391d974-cd95-4b8f-83af-311e820c2abc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8ab51363-3e21-45e3-bc5c-eed990951f22" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a391d974-cd95-4b8f-83af-311e820c2abc" xlink:to="loc_srt_MinimumMember_8ab51363-3e21-45e3-bc5c-eed990951f22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a1e1c30a-3560-48a5-80d2-4c5005f23630" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a391d974-cd95-4b8f-83af-311e820c2abc" xlink:to="loc_srt_MaximumMember_a1e1c30a-3560-48a5-80d2-4c5005f23630" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/Intangibleassetsandgoodwill" xlink:type="simple" xlink:href="ptct-20200630.xsd#Intangibleassetsandgoodwill"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/Intangibleassetsandgoodwill" xlink:type="extended" id="i7b491e17dd304238b848c995a4491ef8_Intangibleassetsandgoodwill"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/IntangibleassetsandgoodwillTables" xlink:type="simple" xlink:href="ptct-20200630.xsd#IntangibleassetsandgoodwillTables"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/IntangibleassetsandgoodwillTables" xlink:type="extended" id="icf2ca4ecce334a62844921795fd8f3c2_IntangibleassetsandgoodwillTables"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/IntangibleassetsandgoodwillNarrativeDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#IntangibleassetsandgoodwillNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/IntangibleassetsandgoodwillNarrativeDetails" xlink:type="extended" id="ib2c2ff61f7bf48919f9cea5d304069d9_IntangibleassetsandgoodwillNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f76740a1-ea57-4486-917f-510177b5f3a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_8337b040-e9aa-4c6f-b385-d48f1e23edef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f76740a1-ea57-4486-917f-510177b5f3a9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_8337b040-e9aa-4c6f-b385-d48f1e23edef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_MilestonePotentialAchievementsRegulatoryApproval_37e4e50a-9f99-4440-b688-c6ccc6f49345" xlink:href="ptct-20200630.xsd#ptct_MilestonePotentialAchievementsRegulatoryApproval"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f76740a1-ea57-4486-917f-510177b5f3a9" xlink:to="loc_ptct_MilestonePotentialAchievementsRegulatoryApproval_37e4e50a-9f99-4440-b688-c6ccc6f49345" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8dc74c37-6519-4095-8698-8999a15ce1bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f76740a1-ea57-4486-917f-510177b5f3a9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8dc74c37-6519-4095-8698-8999a15ce1bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing_29383203-7833-468d-87c5-ca1b6acba834" xlink:href="ptct-20200630.xsd#ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f76740a1-ea57-4486-917f-510177b5f3a9" xlink:to="loc_ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing_29383203-7833-468d-87c5-ca1b6acba834" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1ee7e2b3-d511-44b2-b58a-2b63db79a1c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f76740a1-ea57-4486-917f-510177b5f3a9" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_1ee7e2b3-d511-44b2-b58a-2b63db79a1c6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_ea0dc444-6b5b-4e8e-947f-2057657cfb63" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f76740a1-ea57-4486-917f-510177b5f3a9" xlink:to="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_ea0dc444-6b5b-4e8e-947f-2057657cfb63" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1ab5467f-841e-4ef4-8e6d-f8931f7339d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f76740a1-ea57-4486-917f-510177b5f3a9" xlink:to="loc_us-gaap_Goodwill_1ab5467f-841e-4ef4-8e6d-f8931f7339d1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_UpfrontLicensingFee_5d6cc1d6-24b0-4517-a5ff-af7422e04775" xlink:href="ptct-20200630.xsd#ptct_UpfrontLicensingFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f76740a1-ea57-4486-917f-510177b5f3a9" xlink:to="loc_ptct_UpfrontLicensingFee_5d6cc1d6-24b0-4517-a5ff-af7422e04775" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_70a226d1-ebfb-436a-9702-0e3a02945b09" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f76740a1-ea57-4486-917f-510177b5f3a9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_70a226d1-ebfb-436a-9702-0e3a02945b09" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_9719e98e-507c-4fdf-bcea-c810809270e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f76740a1-ea57-4486-917f-510177b5f3a9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_9719e98e-507c-4fdf-bcea-c810809270e8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ec7cccd8-bf29-4bf7-bf44-a59cf6649f47" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f76740a1-ea57-4486-917f-510177b5f3a9" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ec7cccd8-bf29-4bf7-bf44-a59cf6649f47" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d2e91c3d-0512-4322-85a4-56513c5ce02f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ec7cccd8-bf29-4bf7-bf44-a59cf6649f47" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d2e91c3d-0512-4322-85a4-56513c5ce02f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d2e91c3d-0512-4322-85a4-56513c5ce02f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d2e91c3d-0512-4322-85a4-56513c5ce02f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d2e91c3d-0512-4322-85a4-56513c5ce02f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ba88956-a53f-4c2b-878c-da2e8a1c3643" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d2e91c3d-0512-4322-85a4-56513c5ce02f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ba88956-a53f-4c2b-878c-da2e8a1c3643" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_EmflazaassetacquisitionMember_014be67f-0fa3-436f-a5d3-f1fb1b6c28ce" xlink:href="ptct-20200630.xsd#ptct_EmflazaassetacquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ba88956-a53f-4c2b-878c-da2e8a1c3643" xlink:to="loc_ptct_EmflazaassetacquisitionMember_014be67f-0fa3-436f-a5d3-f1fb1b6c28ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_bae0275a-0b24-4330-915b-40ecd2c7900d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ec7cccd8-bf29-4bf7-bf44-a59cf6649f47" xlink:to="loc_us-gaap_TypeOfArrangementAxis_bae0275a-0b24-4330-915b-40ecd2c7900d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bae0275a-0b24-4330-915b-40ecd2c7900d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bae0275a-0b24-4330-915b-40ecd2c7900d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bae0275a-0b24-4330-915b-40ecd2c7900d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_32f82428-f321-457f-8747-17d7ac10768d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bae0275a-0b24-4330-915b-40ecd2c7900d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_32f82428-f321-457f-8747-17d7ac10768d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncollaborativeArrangementTransactionsMember_5f148ed8-24cd-4a6a-ac08-8241b3b4a8a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncollaborativeArrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_32f82428-f321-457f-8747-17d7ac10768d" xlink:to="loc_us-gaap_NoncollaborativeArrangementTransactionsMember_5f148ed8-24cd-4a6a-ac08-8241b3b4a8a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ce36065f-f30f-4ca4-9044-3b533e3620ee" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ec7cccd8-bf29-4bf7-bf44-a59cf6649f47" xlink:to="loc_srt_CounterpartyNameAxis_ce36065f-f30f-4ca4-9044-3b533e3620ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ce36065f-f30f-4ca4-9044-3b533e3620ee_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_ce36065f-f30f-4ca4-9044-3b533e3620ee" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ce36065f-f30f-4ca4-9044-3b533e3620ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b126ef1-e7f1-49ee-bd75-2e128ba0dbac" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_ce36065f-f30f-4ca4-9044-3b533e3620ee" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b126ef1-e7f1-49ee-bd75-2e128ba0dbac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AkceaMember_50b2490a-b9ff-40db-bc5c-6611c02940a6" xlink:href="ptct-20200630.xsd#ptct_AkceaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b126ef1-e7f1-49ee-bd75-2e128ba0dbac" xlink:to="loc_ptct_AkceaMember_50b2490a-b9ff-40db-bc5c-6611c02940a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_90bfb1b0-bd4f-49be-9eaa-7742ba017436" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ec7cccd8-bf29-4bf7-bf44-a59cf6649f47" xlink:to="loc_srt_RangeAxis_90bfb1b0-bd4f-49be-9eaa-7742ba017436" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_90bfb1b0-bd4f-49be-9eaa-7742ba017436_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_90bfb1b0-bd4f-49be-9eaa-7742ba017436" xlink:to="loc_srt_RangeMember_90bfb1b0-bd4f-49be-9eaa-7742ba017436_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fb8e517e-03cf-4990-9124-1048dea1fbbc" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_90bfb1b0-bd4f-49be-9eaa-7742ba017436" xlink:to="loc_srt_RangeMember_fb8e517e-03cf-4990-9124-1048dea1fbbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_2cc057f3-9bb5-4e6c-8aa7-8af36aaa1e18" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fb8e517e-03cf-4990-9124-1048dea1fbbc" xlink:to="loc_srt_WeightedAverageMember_2cc057f3-9bb5-4e6c-8aa7-8af36aaa1e18" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/IntangibleassetsandgoodwillFutureAmortizationDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#IntangibleassetsandgoodwillFutureAmortizationDetails"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/IntangibleassetsandgoodwillFutureAmortizationDetails" xlink:type="extended" id="i0b3a95c8014944d4a7042b6c12d29698_IntangibleassetsandgoodwillFutureAmortizationDetails"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/Subsequentevents" xlink:type="simple" xlink:href="ptct-20200630.xsd#Subsequentevents"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/Subsequentevents" xlink:type="extended" id="i3e2550fa5b414ae993a8cf65eade192a_Subsequentevents"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/SubsequenteventsNarrativeDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#SubsequenteventsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/SubsequenteventsNarrativeDetails" xlink:type="extended" id="i24c409e3fc7c46839a7f174d05a6f759_SubsequenteventsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_70007dc0-2ea6-427f-9753-1cac6644fbc1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_fb105862-65f1-4722-8dbf-7cc2c53514ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_70007dc0-2ea6-427f-9753-1cac6644fbc1" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_fb105862-65f1-4722-8dbf-7cc2c53514ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_LineOfCreditFacilityTerminationAndExitFees_637c8c9b-dbd0-4586-b2bb-41baef7ef35c" xlink:href="ptct-20200630.xsd#ptct_LineOfCreditFacilityTerminationAndExitFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_70007dc0-2ea6-427f-9753-1cac6644fbc1" xlink:to="loc_ptct_LineOfCreditFacilityTerminationAndExitFees_637c8c9b-dbd0-4586-b2bb-41baef7ef35c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AssignedRoyaltyPaymentPercentage_b1673d9e-b138-4f06-b38c-d222f17eab10" xlink:href="ptct-20200630.xsd#ptct_AssignedRoyaltyPaymentPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_70007dc0-2ea6-427f-9753-1cac6644fbc1" xlink:to="loc_ptct_AssignedRoyaltyPaymentPercentage_b1673d9e-b138-4f06-b38c-d222f17eab10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ProceedsAssignedRoyaltyPaymentAgreement_9e085458-1b0f-47af-a59c-d105f0d4f7f1" xlink:href="ptct-20200630.xsd#ptct_ProceedsAssignedRoyaltyPaymentAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_70007dc0-2ea6-427f-9753-1cac6644fbc1" xlink:to="loc_ptct_ProceedsAssignedRoyaltyPaymentAgreement_9e085458-1b0f-47af-a59c-d105f0d4f7f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AssignedRoyaltyPaymentRetainedPercentage_b21097ab-7171-48cc-a91a-01fbeaf07a24" xlink:href="ptct-20200630.xsd#ptct_AssignedRoyaltyPaymentRetainedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_70007dc0-2ea6-427f-9753-1cac6644fbc1" xlink:to="loc_ptct_AssignedRoyaltyPaymentRetainedPercentage_b21097ab-7171-48cc-a91a-01fbeaf07a24" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_RevenueRecognitionMilestonePotentialAchievements_24ef9226-4645-40d4-b02a-dd1217f9be51" xlink:href="ptct-20200630.xsd#ptct_RevenueRecognitionMilestonePotentialAchievements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_70007dc0-2ea6-427f-9753-1cac6644fbc1" xlink:to="loc_ptct_RevenueRecognitionMilestonePotentialAchievements_24ef9226-4645-40d4-b02a-dd1217f9be51" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_RoyaltyPurchaseAgreementTerminationPeriod_a0c2a76f-7e40-47e9-8338-c1d8b9dff73e" xlink:href="ptct-20200630.xsd#ptct_RoyaltyPurchaseAgreementTerminationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_70007dc0-2ea6-427f-9753-1cac6644fbc1" xlink:to="loc_ptct_RoyaltyPurchaseAgreementTerminationPeriod_a0c2a76f-7e40-47e9-8338-c1d8b9dff73e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_RoyaltyPurchaseAgreementPaymentMaximum_0bd48b62-07f7-4ebe-8fa8-094d3a205b2a" xlink:href="ptct-20200630.xsd#ptct_RoyaltyPurchaseAgreementPaymentMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_70007dc0-2ea6-427f-9753-1cac6644fbc1" xlink:to="loc_ptct_RoyaltyPurchaseAgreementPaymentMaximum_0bd48b62-07f7-4ebe-8fa8-094d3a205b2a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_f6274d59-1560-4c7a-9bc1-a440c2b8a2d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_70007dc0-2ea6-427f-9753-1cac6644fbc1" xlink:to="loc_us-gaap_SubsequentEventTable_f6274d59-1560-4c7a-9bc1-a440c2b8a2d4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7b7a9f3a-3ed0-4850-ad13-cfbfa1b9a04f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_f6274d59-1560-4c7a-9bc1-a440c2b8a2d4" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_7b7a9f3a-3ed0-4850-ad13-cfbfa1b9a04f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7b7a9f3a-3ed0-4850-ad13-cfbfa1b9a04f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7b7a9f3a-3ed0-4850-ad13-cfbfa1b9a04f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7b7a9f3a-3ed0-4850-ad13-cfbfa1b9a04f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c875cc3d-1796-4ec0-bf1d-26d19aa9bc7e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7b7a9f3a-3ed0-4850-ad13-cfbfa1b9a04f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c875cc3d-1796-4ec0-bf1d-26d19aa9bc7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_f9d7a26e-7782-4378-add9-4dfe571e85ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c875cc3d-1796-4ec0-bf1d-26d19aa9bc7e" xlink:to="loc_us-gaap_SubsequentEventMember_f9d7a26e-7782-4378-add9-4dfe571e85ab" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>ptct-20200630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:a91ddaa9-e688-473f-b70e-08f6db5630cb,g:e05438c1-8a2e-4af1-b39d-a16533f5ad44-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_7c717960-fcca-403f-b578-c141de017349_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_e1cd355d-faa6-4c27-b5b2-0016449071f6_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation (loss) gain, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_ResearchAndDevelopmentEventMilestonesMember_2abef5bd-2426-4b81-a468-c2eb3d65d9d9_terseLabel_en-US" xlink:label="lab_ptct_ResearchAndDevelopmentEventMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Event Milestones</link:label>
    <link:label id="lab_ptct_ResearchAndDevelopmentEventMilestonesMember_label_en-US" xlink:label="lab_ptct_ResearchAndDevelopmentEventMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Event Milestones [Member]</link:label>
    <link:label id="lab_ptct_ResearchAndDevelopmentEventMilestonesMember_documentation_en-US" xlink:label="lab_ptct_ResearchAndDevelopmentEventMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to certain research and development events on the basis of which certain milestones are achieved.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ResearchAndDevelopmentEventMilestonesMember" xlink:href="ptct-20200630.xsd#ptct_ResearchAndDevelopmentEventMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_ResearchAndDevelopmentEventMilestonesMember" xlink:to="lab_ptct_ResearchAndDevelopmentEventMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_d5d67e70-b53d-4550-a42e-1f434f2fc43e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_afc59c90-8697-4d4f-a6be-f2e86141f2a9_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to additional paid in capital, equity component of convertible debt</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_EmployeeDirectorAndConsultantStockOptionPlanMember_383e6e5d-35e1-4dd2-a4a2-88bad19a666e_terseLabel_en-US" xlink:label="lab_ptct_EmployeeDirectorAndConsultantStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1998 Employee, Director and Consultant Stock Option Plan</link:label>
    <link:label id="lab_ptct_EmployeeDirectorAndConsultantStockOptionPlanMember_label_en-US" xlink:label="lab_ptct_EmployeeDirectorAndConsultantStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Director And Consultant Stock Option Plan [Member]</link:label>
    <link:label id="lab_ptct_EmployeeDirectorAndConsultantStockOptionPlanMember_documentation_en-US" xlink:label="lab_ptct_EmployeeDirectorAndConsultantStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the 1998 Employee, Director and Consultant Stock Option Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_EmployeeDirectorAndConsultantStockOptionPlanMember" xlink:href="ptct-20200630.xsd#ptct_EmployeeDirectorAndConsultantStockOptionPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_EmployeeDirectorAndConsultantStockOptionPlanMember" xlink:to="lab_ptct_EmployeeDirectorAndConsultantStockOptionPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_dcdab251-047c-495f-81b4-7ae1db730dfa_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_e80d0189-fd09-4529-ae66-f2ed1c12294c_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of product rights and licenses</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_2a06c4c3-fcf4-47a8-a533-b4181768c3fa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant unobservable inputs (level&#160;3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3e4b73b5-9c61-4266-bbb2-43a0a324adbd_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation of deferred and contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_57d07cee-a4e0-4afa-89fa-a1e787c82fae_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SARs</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_SharesIssuedAssetAcquisition_9b63d894-f6c5-4575-8cea-a8fed7ba7332_terseLabel_en-US" xlink:label="lab_ptct_SharesIssuedAssetAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash stock consideration, acquisition</link:label>
    <link:label id="lab_ptct_SharesIssuedAssetAcquisition_label_en-US" xlink:label="lab_ptct_SharesIssuedAssetAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued Asset Acquisition</link:label>
    <link:label id="lab_ptct_SharesIssuedAssetAcquisition_documentation_en-US" xlink:label="lab_ptct_SharesIssuedAssetAcquisition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued Asset Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_SharesIssuedAssetAcquisition" xlink:href="ptct-20200630.xsd#ptct_SharesIssuedAssetAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_SharesIssuedAssetAcquisition" xlink:to="lab_ptct_SharesIssuedAssetAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_40f17408-a1fa-4c69-9851-32f89ca76fe7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1300ef80-134a-48f2-852e-1365cf27693a_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_576e6740-e1eb-4268-8aaf-93bc2598da87_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance obligations satisfied in current period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_0a1ab4cb-1be7-4971-99b2-c97bbf7bb324_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_889d161b-7fe3-460a-bc81-7682a348f672_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_StockIssuedDuringPeriodSharesExchangeRights_153e53cd-38d7-4108-8839-d9b08a2a6dbc_terseLabel_en-US" xlink:label="lab_ptct_StockIssuedDuringPeriodSharesExchangeRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock related to rights exchange (in shares)</link:label>
    <link:label id="lab_ptct_StockIssuedDuringPeriodSharesExchangeRights_label_en-US" xlink:label="lab_ptct_StockIssuedDuringPeriodSharesExchangeRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Exchange Rights</link:label>
    <link:label id="lab_ptct_StockIssuedDuringPeriodSharesExchangeRights_documentation_en-US" xlink:label="lab_ptct_StockIssuedDuringPeriodSharesExchangeRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Exchange Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_StockIssuedDuringPeriodSharesExchangeRights" xlink:href="ptct-20200630.xsd#ptct_StockIssuedDuringPeriodSharesExchangeRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_StockIssuedDuringPeriodSharesExchangeRights" xlink:to="lab_ptct_StockIssuedDuringPeriodSharesExchangeRights" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_InvestmentInMRI_b8ad016b-e692-453a-bf8d-8efee3908b05_terseLabel_en-US" xlink:label="lab_ptct_InvestmentInMRI" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment In MRI</link:label>
    <link:label id="lab_ptct_InvestmentInMRI_label_en-US" xlink:label="lab_ptct_InvestmentInMRI" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment In MRI</link:label>
    <link:label id="lab_ptct_InvestmentInMRI_documentation_en-US" xlink:label="lab_ptct_InvestmentInMRI" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment In MRI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_InvestmentInMRI" xlink:href="ptct-20200630.xsd#ptct_InvestmentInMRI"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_InvestmentInMRI" xlink:to="lab_ptct_InvestmentInMRI" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentOwnedBalancePrincipalAmount_5d754773-b23d-4900-a14c-90d2ca2126ce_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalancePrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares owned</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedBalancePrincipalAmount_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalancePrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, Balance, Principal Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalancePrincipalAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentOwnedBalancePrincipalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedBalancePrincipalAmount" xlink:to="lab_us-gaap_InvestmentOwnedBalancePrincipalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5b82fa00-9e7f-4970-90c0-38441ec0563f_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_31db893b-8661-4896-964b-8b07af6debed_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_f78974ae-3ea2-4982-b5a7-65022fbc6dbb_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of lines of credit</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_10d24459-acd9-4621-b0e4-64c45d5e7444_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7ed75e91-abdb-4db2-a3e8-265663a40774_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_38c46f2e-52a7-49a9-9d43-81f423d1aaa0_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently issued accounting standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_InventoriesAndCostOfProductSalesPolicyTextBlock_09e84584-c398-4ebf-acb0-9d341e7c2bf9_terseLabel_en-US" xlink:label="lab_ptct_InventoriesAndCostOfProductSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory and cost of product sales</link:label>
    <link:label id="lab_ptct_InventoriesAndCostOfProductSalesPolicyTextBlock_label_en-US" xlink:label="lab_ptct_InventoriesAndCostOfProductSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories And Cost Of Product Sales [Policy Text Block]</link:label>
    <link:label id="lab_ptct_InventoriesAndCostOfProductSalesPolicyTextBlock_documentation_en-US" xlink:label="lab_ptct_InventoriesAndCostOfProductSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of accounting policy for inventories and cost of revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_InventoriesAndCostOfProductSalesPolicyTextBlock" xlink:href="ptct-20200630.xsd#ptct_InventoriesAndCostOfProductSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_InventoriesAndCostOfProductSalesPolicyTextBlock" xlink:to="lab_ptct_InventoriesAndCostOfProductSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_92c75663-584e-495a-a498-c352db701ae2_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_2c762276-e556-44ab-89a0-092f2f33d4ed_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_d3234c01-27bd-4cab-90a2-94986b1ddcd3_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_AgilisMember_0cbad199-c77e-4153-affc-230012b6f389_terseLabel_en-US" xlink:label="lab_ptct_AgilisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agilis</link:label>
    <link:label id="lab_ptct_AgilisMember_label_en-US" xlink:label="lab_ptct_AgilisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agilis [Member]</link:label>
    <link:label id="lab_ptct_AgilisMember_documentation_en-US" xlink:label="lab_ptct_AgilisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agilis [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AgilisMember" xlink:href="ptct-20200630.xsd#ptct_AgilisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_AgilisMember" xlink:to="lab_ptct_AgilisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_61257849-f7ad-4e67-8300-d4cf0a7f905b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from public offerings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_DebtInstrumentInterestPaymentPeriod_7742bff0-b2db-44ae-9f48-52cdb6a2bee3_terseLabel_en-US" xlink:label="lab_ptct_DebtInstrumentInterestPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, interest payment period</link:label>
    <link:label id="lab_ptct_DebtInstrumentInterestPaymentPeriod_label_en-US" xlink:label="lab_ptct_DebtInstrumentInterestPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Payment Period</link:label>
    <link:label id="lab_ptct_DebtInstrumentInterestPaymentPeriod_documentation_en-US" xlink:label="lab_ptct_DebtInstrumentInterestPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Payment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DebtInstrumentInterestPaymentPeriod" xlink:href="ptct-20200630.xsd#ptct_DebtInstrumentInterestPaymentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_DebtInstrumentInterestPaymentPeriod" xlink:to="lab_ptct_DebtInstrumentInterestPaymentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_ed8e16d3-decb-4926-baab-5a3c95bc4544_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_label_en-US" xlink:label="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:to="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_62195a75-c28d-49a6-b146-070cb5d4d7a9_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_1f483aef-ffa5-4d22-a07c-180975093fe8_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_e7a8bc4c-d694-49ae-be2e-d8bab36f2005_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding_3657acc4-0896-4938-8aa7-98239e739c00_terseLabel_en-US" xlink:label="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual increase in the number of shares outstanding on the first day of the fiscal year</link:label>
    <link:label id="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding_label_en-US" xlink:label="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation Arrangement by Share based Payment Award Number of Shares Authorized Annual Increase as Percentage of Stock Outstanding</link:label>
    <link:label id="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding_documentation_en-US" xlink:label="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of shares outstanding to be added annually on the first day of each fiscal year in the number of shares authorized.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding" xlink:href="ptct-20200630.xsd#ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding" xlink:to="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_41b9b540-5399-442d-b877-d7947322b034_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock vesting and issuance, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_fb95b005-c7f1-4867-901a-9bf45796e5bf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consecutive trading days, period</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2abf0e75-051a-4b62-bd99-bebede8a12c8_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_948c4ce0-961d-4cc6-a49f-f09e19b593e3_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_a9d18e58-16a1-44d8-af6e-7a2d96b71109_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_f6c525a7-f1a8-44df-a00f-c94869337fae_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock related to equity offering</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_AssetAcquisitionTransactionCosts_868979ad-64df-4e6f-88c7-d5f5d4e264ba_negatedTerseLabel_en-US" xlink:label="lab_ptct_AssetAcquisitionTransactionCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, transaction costs</link:label>
    <link:label id="lab_ptct_AssetAcquisitionTransactionCosts_label_en-US" xlink:label="lab_ptct_AssetAcquisitionTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Transaction Costs</link:label>
    <link:label id="lab_ptct_AssetAcquisitionTransactionCosts_documentation_en-US" xlink:label="lab_ptct_AssetAcquisitionTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AssetAcquisitionTransactionCosts" xlink:href="ptct-20200630.xsd#ptct_AssetAcquisitionTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_AssetAcquisitionTransactionCosts" xlink:to="lab_ptct_AssetAcquisitionTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_4c588ae1-3253-438b-81f9-3ea68fde83e8_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit facility, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_6be7f917-4002-417f-8621-7c29ef6102c7_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_227905ab-30c8-4749-9096-f4f71fce25c0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of components of accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_PaymentsToAcquireConvertibleDebtInvestment_8ddaa96c-a349-463d-8936-644c80782ed0_negatedTerseLabel_en-US" xlink:label="lab_ptct_PaymentsToAcquireConvertibleDebtInvestment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of convertible debt security</link:label>
    <link:label id="lab_ptct_PaymentsToAcquireConvertibleDebtInvestment_9881f978-4f58-42ba-a3a8-fa92db7d29be_verboseLabel_en-US" xlink:label="lab_ptct_PaymentsToAcquireConvertibleDebtInvestment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of convertible debt investment</link:label>
    <link:label id="lab_ptct_PaymentsToAcquireConvertibleDebtInvestment_label_en-US" xlink:label="lab_ptct_PaymentsToAcquireConvertibleDebtInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Convertible Debt Investment</link:label>
    <link:label id="lab_ptct_PaymentsToAcquireConvertibleDebtInvestment_documentation_en-US" xlink:label="lab_ptct_PaymentsToAcquireConvertibleDebtInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Convertible Debt Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_PaymentsToAcquireConvertibleDebtInvestment" xlink:href="ptct-20200630.xsd#ptct_PaymentsToAcquireConvertibleDebtInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_PaymentsToAcquireConvertibleDebtInvestment" xlink:to="lab_ptct_PaymentsToAcquireConvertibleDebtInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_ContingentConsiderationTransactionFees_4e15f87b-85a0-4ab1-b137-b0bdb1de791f_terseLabel_en-US" xlink:label="lab_ptct_ContingentConsiderationTransactionFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration, Transaction Fees</link:label>
    <link:label id="lab_ptct_ContingentConsiderationTransactionFees_label_en-US" xlink:label="lab_ptct_ContingentConsiderationTransactionFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration, Transaction Fees</link:label>
    <link:label id="lab_ptct_ContingentConsiderationTransactionFees_documentation_en-US" xlink:label="lab_ptct_ContingentConsiderationTransactionFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration, Transaction Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ContingentConsiderationTransactionFees" xlink:href="ptct-20200630.xsd#ptct_ContingentConsiderationTransactionFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_ContingentConsiderationTransactionFees" xlink:to="lab_ptct_ContingentConsiderationTransactionFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_8c6518ba-8363-4839-8da8-3de55d6e6596_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Imputed Interest expense</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_dc7e4b91-dbfb-4e30-a94a-96ad98735145_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_c82f4756-f2a8-4944-b242-c2c13fee5efc_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3a5ff805-9bc3-4915-b9d2-d2fca2130cf1_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e472be27-1a8c-48ff-9a41-fe71b6afb41b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b7b92b86-9e51-48a2-bbb3-f8d47678a99c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_356fda4a-03f1-44e4-ae14-231312052b25_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_CensaMember_cef4e997-e146-4b80-8198-13dbd2e32b47_terseLabel_en-US" xlink:label="lab_ptct_CensaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Censa [Member]</link:label>
    <link:label id="lab_ptct_CensaMember_label_en-US" xlink:label="lab_ptct_CensaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Censa [Member]</link:label>
    <link:label id="lab_ptct_CensaMember_documentation_en-US" xlink:label="lab_ptct_CensaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Censa</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_CensaMember" xlink:href="ptct-20200630.xsd#ptct_CensaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_CensaMember" xlink:to="lab_ptct_CensaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_306ee2cc-405f-421f-ac4a-1c80f8fc74b2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_6e5d193c-b52e-4b91-abb6-47cf521bd453_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_AlternativeInvestmentMilestone_3eb73000-2a00-4191-90bc-99cc0a3bad6c_terseLabel_en-US" xlink:label="lab_ptct_AlternativeInvestmentMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Investment, Milestone</link:label>
    <link:label id="lab_ptct_AlternativeInvestmentMilestone_label_en-US" xlink:label="lab_ptct_AlternativeInvestmentMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Investment, Milestone</link:label>
    <link:label id="lab_ptct_AlternativeInvestmentMilestone_documentation_en-US" xlink:label="lab_ptct_AlternativeInvestmentMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Investment, Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AlternativeInvestmentMilestone" xlink:href="ptct-20200630.xsd#ptct_AlternativeInvestmentMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_AlternativeInvestmentMilestone" xlink:to="lab_ptct_AlternativeInvestmentMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_af096c2c-d4f3-4158-bca3-5e07f9c984a6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_f9283b7b-243f-45e0-a842-ff46df716fbf_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_9c2070c2-03fb-40de-8cee-561363c4a073_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_40d3713e-05d3-4150-b3bf-ca00fef94804_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a3b9a9d9-1e66-4083-a815-3c432219c993_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at the end of the period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_6fea15f1-2f52-4d73-ab63-34c665a3c1c0_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_7c893985-154c-40d5-99e8-6766d1eae85e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award requisite service period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_67c16cf8-5049-4180-ab75-a01402033647_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate of the liability component</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a64ed2ce-5de0-4cc0-98fb-db14f3ff65cd_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross&#160;Unrealized, Loss</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_35d6d35d-fc88-410e-b585-47483e609652_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_44abcf1c-4fe0-41e3-9ab9-e66d64b0ff32_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="lab_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_ff051da1-6b1e-4ff2-b106-c913a3de34cc_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in progress</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7aed9860-2357-4136-9162-e2325ede438b_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_90a3d1fc-9c70-4cac-b3cb-ca2a763fea3b_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCumulativeSinkingFundPayments_74127a73-be53-4345-acb4-554548e61919_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCumulativeSinkingFundPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sinking fund</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCumulativeSinkingFundPayments_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCumulativeSinkingFundPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Cumulative Sinking Fund Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCumulativeSinkingFundPayments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCumulativeSinkingFundPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCumulativeSinkingFundPayments" xlink:to="lab_us-gaap_DebtInstrumentCumulativeSinkingFundPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_1f52a0ac-c724-4f55-8505-c657383af226_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading days, number</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_a242c6e2-60b9-4463-94c0-227c3093adee_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_d57a25e1-df7c-48fc-9d45-f0ce6a6e5ec5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_bd2d0a62-b074-40bb-84a0-6bd31d9e0e21_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for operating lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_4ad797a4-8871-4921-91d0-bdbbedd90a40_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_271206f4-edf0-40dc-8926-2dedddcc4484_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities- current</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_fb867d31-b6b3-4248-b656-55b17a706530_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred consideration payable</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_bb7d06ca-c000-4aee-8b8e-200087781dfb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_965f4bac-bb99-40d1-97be-6fe587b5ba3a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_ee46eefd-b133-49fe-9f51-0b23b03a09d9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities in an unrealized loss position greater than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_b7ba5441-3097-4285-8ae3-96e407734d97_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_1d5745c9-74d4-4ffd-9925-4a6ab40bd30c_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Debt discount, net</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_74856e4b-83e4-494a-8661-52a60d9d99ef_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_88be3f4c-db3e-4b67-9d2d-d690cf5e2ce9_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_5bddf46d-5306-4614-b3d8-fcf149a8413c_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_ab86e28a-4599-4e95-9855-b619bdc34196_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue- long term</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3c0074eb-efba-48aa-b167-7295ba80d6a9_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, and restricted cash beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ed3c8750-b733-4294-bc90-9afa36dc43ef_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Cash, cash equivalents and restricted cash per statement of cash flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_1b301ea4-b017-41c3-ab19-1ab1f0cc3c90_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_2936deaa-de5e-4242-96dc-1beab3097023_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9e05a910-3ee4-4ed1-b86f-104118cb8320_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_d0ed8d48-2b49-4c9c-bd03-8ca05b6dbc39_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator for basic and diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_DebtInstrumentAdditionalAmountAvailableForRepurchase_9ed22653-43df-4737-a75f-c7c3532fe259_terseLabel_en-US" xlink:label="lab_ptct_DebtInstrumentAdditionalAmountAvailableForRepurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument additional amount available for repurchase</link:label>
    <link:label id="lab_ptct_DebtInstrumentAdditionalAmountAvailableForRepurchase_label_en-US" xlink:label="lab_ptct_DebtInstrumentAdditionalAmountAvailableForRepurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Additional Amount Available For Repurchase</link:label>
    <link:label id="lab_ptct_DebtInstrumentAdditionalAmountAvailableForRepurchase_documentation_en-US" xlink:label="lab_ptct_DebtInstrumentAdditionalAmountAvailableForRepurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Additional Amount Available For Repurchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DebtInstrumentAdditionalAmountAvailableForRepurchase" xlink:href="ptct-20200630.xsd#ptct_DebtInstrumentAdditionalAmountAvailableForRepurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_DebtInstrumentAdditionalAmountAvailableForRepurchase" xlink:to="lab_ptct_DebtInstrumentAdditionalAmountAvailableForRepurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionLineItems_75fe55ec-4122-49db-907a-90c2142d02fb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionLineItems" xlink:to="lab_us-gaap_DebtInstrumentRedemptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1b497d82-2f66-4596-8ae0-2b6464a60bbe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in the fair value of warrant liability and SARs liability</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_28a649eb-515a-4dc3-a930-2866d40a1eff_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Marketable securities, Less Than 12 Months</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_269607d3-a722-46cb-845b-12abbe1d3fad_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_e65fc843-27ee-44b5-80ed-cbca6737e574_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_7bf71572-adc6-4394-a13b-0f34f3f07625_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_23759127-3837-4376-99ac-95983868aa05_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for finance lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_GrantAndCollaborationMember_3be579ef-be9b-4351-ad80-a6fe55a356b4_terseLabel_en-US" xlink:label="lab_ptct_GrantAndCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and grant revenue</link:label>
    <link:label id="lab_ptct_GrantAndCollaborationMember_label_en-US" xlink:label="lab_ptct_GrantAndCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant And Collaboration [Member]</link:label>
    <link:label id="lab_ptct_GrantAndCollaborationMember_documentation_en-US" xlink:label="lab_ptct_GrantAndCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant And Collaboration [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_GrantAndCollaborationMember" xlink:href="ptct-20200630.xsd#ptct_GrantAndCollaborationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_GrantAndCollaborationMember" xlink:to="lab_ptct_GrantAndCollaborationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_ba7e3c10-8116-43f3-8bf0-4b5f6dd4c813_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_157f5092-b694-44ee-9982-0bedad3ccb39_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5fe1796b-e6e5-4943-9103-be93b5dcfae6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_e9a78546-8018-47b3-952c-c26385e00a59_terseLabel_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of information on the Company's restricted stock</link:label>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_47cd96d6-5eea-437f-b423-27088e7d9aa2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_b615da44-94ea-4e05-bad2-d93d8109562a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired_51660a54-9734-4f91-9ab4-57270a61b3a4_terseLabel_en-US" xlink:label="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total allocation of IPR&amp;D assets</link:label>
    <link:label id="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired_label_en-US" xlink:label="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:to="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_306c3720-8666-4d4f-9a8d-98a8027d094f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, performance obligation, period</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_0b8313cd-997b-4c0c-bfa7-88a5d424c7d1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Line of Credit Arrangements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross" xlink:to="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_396700f5-db50-4e37-a8cf-a00df7e48eab_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_782ddbd8-9aae-47fd-bd93-fc300794270e_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited/Cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_ebf2b4a9-d1a9-4d91-be6f-a59f4b7503a2_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_ContingentLiabilityCancellationAndForfeiture_f8025674-96dd-4fe2-9941-5852823a0b19_terseLabel_en-US" xlink:label="lab_ptct_ContingentLiabilityCancellationAndForfeiture" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Liability, Cancellation and Forfeiture</link:label>
    <link:label id="lab_ptct_ContingentLiabilityCancellationAndForfeiture_label_en-US" xlink:label="lab_ptct_ContingentLiabilityCancellationAndForfeiture" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Liability, Cancellation and Forfeiture</link:label>
    <link:label id="lab_ptct_ContingentLiabilityCancellationAndForfeiture_documentation_en-US" xlink:label="lab_ptct_ContingentLiabilityCancellationAndForfeiture" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Liability, Cancellation and Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ContingentLiabilityCancellationAndForfeiture" xlink:href="ptct-20200630.xsd#ptct_ContingentLiabilityCancellationAndForfeiture"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_ContingentLiabilityCancellationAndForfeiture" xlink:to="lab_ptct_ContingentLiabilityCancellationAndForfeiture" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6125a368-a14c-4026-b264-ffda06746f0c_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4a86b072-7877-450a-9d23-dd63ffaa7b7f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_0fc15e82-52fb-43b2-b653-04b4cae6b5b1_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_c9b8196b-44f5-47b3-8f90-d446053cba48_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_AssetAcquisitionInitialMilestone_ab53a614-7c01-4cf6-9c03-988eb2e2dbd0_terseLabel_en-US" xlink:label="lab_ptct_AssetAcquisitionInitialMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, initial milestone</link:label>
    <link:label id="lab_ptct_AssetAcquisitionInitialMilestone_label_en-US" xlink:label="lab_ptct_AssetAcquisitionInitialMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Initial Milestone</link:label>
    <link:label id="lab_ptct_AssetAcquisitionInitialMilestone_documentation_en-US" xlink:label="lab_ptct_AssetAcquisitionInitialMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Initial Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AssetAcquisitionInitialMilestone" xlink:href="ptct-20200630.xsd#ptct_AssetAcquisitionInitialMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_AssetAcquisitionInitialMilestone" xlink:to="lab_ptct_AssetAcquisitionInitialMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_45471cfb-e44f-47f7-b0ef-627ce8dedfed_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_e4d00576-a97a-4e1f-8810-6eb74b01f9b0_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_50ad45bb-ed66-4b03-9984-6c47eba090bd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of assumptions used to estimate fair values of grants made on the date of grant</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable_bb307db3-22ea-4fa4-b486-6d46806c229f_terseLabel_en-US" xlink:label="lab_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value of deferred consideration payable</link:label>
    <link:label id="lab_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable_64d46e24-e48a-487a-83a1-66e1d1851c1d_verboseLabel_en-US" xlink:label="lab_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred consideration payable</link:label>
    <link:label id="lab_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable_label_en-US" xlink:label="lab_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration, Liability, Deferred Consideration Payable</link:label>
    <link:label id="lab_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable_documentation_en-US" xlink:label="lab_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration, Liability, Deferred Consideration Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable" xlink:href="ptct-20200630.xsd#ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable" xlink:to="lab_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_6087b63f-4bb0-4235-a9e4-c691de4687e1_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of significant accounting policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0e456ac0-2a6a-4ee9-9219-c12a2ec887eb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3aa12063-4d78-4db0-ba9f-00856242e7ae_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_8c079a83-5971-447a-ba0f-e7adabd102af_terseLabel_en-US" xlink:label="lab_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and Regulatory Milestone</link:label>
    <link:label id="lab_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_label_en-US" xlink:label="lab_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Development and Regulatory Milestone [Member]</link:label>
    <link:label id="lab_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_documentation_en-US" xlink:label="lab_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Development and Regulatory Milestone [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember" xlink:href="ptct-20200630.xsd#ptct_LiabilityDevelopmentandRegulatoryMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember" xlink:to="lab_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_58db04b4-ed74-4bb4-8427-208e2b3e3de6_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_a005fe0e-f942-4708-8ac1-d627a5d72920_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_54538a27-7247-486f-8167-d9d2d052b902_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_RightsExchangeAgreementMember_cb8ea5bf-edcc-483c-b60b-a8212e5059ca_terseLabel_en-US" xlink:label="lab_ptct_RightsExchangeAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rights Exchange Agreement [Member]</link:label>
    <link:label id="lab_ptct_RightsExchangeAgreementMember_label_en-US" xlink:label="lab_ptct_RightsExchangeAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rights Exchange Agreement [Member]</link:label>
    <link:label id="lab_ptct_RightsExchangeAgreementMember_documentation_en-US" xlink:label="lab_ptct_RightsExchangeAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rights Exchange Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_RightsExchangeAgreementMember" xlink:href="ptct-20200630.xsd#ptct_RightsExchangeAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_RightsExchangeAgreementMember" xlink:to="lab_ptct_RightsExchangeAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture_85e36762-2012-4f80-a6c1-b5d526afd159_terseLabel_en-US" xlink:label="lab_ptct_DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestone Payment Obligations, Net of Cancellation and Forfeiture</link:label>
    <link:label id="lab_ptct_DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture_label_en-US" xlink:label="lab_ptct_DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestone Payment Obligations, Net of Cancellation and Forfeiture</link:label>
    <link:label id="lab_ptct_DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture_documentation_en-US" xlink:label="lab_ptct_DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestone Payment Obligations, net of cancellation and forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture" xlink:href="ptct-20200630.xsd#ptct_DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture" xlink:to="lab_ptct_DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_0420a880-5b6e-474d-b346-ef49f0a9af8b_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_6dfd4bcc-9649-44b8-bfc7-fcce5ac2b327_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_e12e485b-5c72-48c0-931d-11f0e2458712_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_30700e5c-6379-45a6-b600-2dd4521189ad_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6f5a9a9e-a32b-4a96-9bfe-2cfe24d0dbf0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_62d063bb-cd21-4459-966f-33295c4c4fa8_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_97d3896d-2f30-49de-ad25-349778a6e7e4_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 (excludes the six months ended June 30, 2020)</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payments, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_ccbb117a-6818-4d97-b56d-72305e0875eb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementDomain_c964ea92-646f-4918-8fe7-1f1a9653c53b_terseLabel_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement [Domain]</link:label>
    <link:label id="lab_srt_RestatementDomain_label_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_14b9e326-390a-4b73-bb86-eeb829723f59_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the beginning of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0b21c186-bd9a-439e-9a82-4ae1138c6e53_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_40dd5395-c1e7-4fa3-985d-a8763f6ca82e_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_0456a84d-c7b6-4c7d-b778-771abd2bd86e_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_43bc79e5-50c8-4426-a6c5-e0bc3b72499f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4be0cf2c-5837-4b81-a238-5009a1541be3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold_1aef74ed-cc4f-4792-9b1a-5be458c9f473_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Allowance for Credit Loss, Securities Sold</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Allowance for Credit Loss, Securities Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_a5c706f7-bf4d-4353-b78d-c103aa863e7f_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_eec470a2-4045-448d-a823-939ec5ddbcf6_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault_2a846785-4d45-4176-b9ed-f32347c10d3f_terseLabel_en-US" xlink:label="lab_ptct_ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible instruments principal and unpaid interest payable upon events of default</link:label>
    <link:label id="lab_ptct_ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault_label_en-US" xlink:label="lab_ptct_ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Instruments Principal And Unpaid Interest Payable Upon Events Of Default</link:label>
    <link:label id="lab_ptct_ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault_documentation_en-US" xlink:label="lab_ptct_ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the debt instrument principal and unpaid interest payable upon events of default.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault" xlink:href="ptct-20200630.xsd#ptct_ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault" xlink:to="lab_ptct_ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7a13f75c-c802-4674-bb8d-9fd09706c610_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_76d793f6-0a63-4ed1-bbf0-f77200fe8392_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_2a219249-c11b-4f7b-8a8f-4ca4ed5dc55b_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_26989bcf-afb9-42bf-bb26-f3838d1acfda_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bd48f2b8-a009-4913-afb0-b8b2914e542a_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4d1aa7db-00a3-4368-83b1-1ddbcc27f9ce_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_c2cd4766-4a3b-42f4-b8b3-cacdd39cedbd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, outstanding shares (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseArrangementTypeAxis_e4f0b584-b4a1-47f8-a8e6-acd291297208_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseArrangementTypeAxis_label_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis" xlink:to="lab_us-gaap_LeaseArrangementTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_fcc6b786-6936-440d-8646-629a8ae52c38_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_86318234-ed65-41ec-b14c-3d58078ffb2b_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_1aa1e087-dd82-41f6-ac6d-9c439a789468_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted&#160;prices in&#160;active markets&#160;for identical&#160;assets (level&#160;1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity_94fc15b4-37b0-4c45-af29-3d5349f37275_terseLabel_en-US" xlink:label="lab_ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator for calculation of number of shares of equity interests issued to acquire entity</link:label>
    <link:label id="lab_ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity_label_en-US" xlink:label="lab_ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Numerator For Calculation Of Number Of Shares Of Equity Interests Issued To Acquire Entity</link:label>
    <link:label id="lab_ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity_documentation_en-US" xlink:label="lab_ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Numerator For Calculation Of Number Of Shares Of Equity Interests Issued To Acquire Entity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity" xlink:href="ptct-20200630.xsd#ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity" xlink:to="lab_ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_8aafda7c-47c4-45bd-a975-80cd8fd9f805_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, allowance for credit loss,</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_a4f9294d-88b9-4df9-86b9-cd55119eabdf_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor_1d2014ec-7a3b-4804-945a-92474601f338_terseLabel_en-US" xlink:label="lab_ptct_AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable from investor</link:label>
    <link:label id="lab_ptct_AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor_label_en-US" xlink:label="lab_ptct_AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid In Capital Receivable from Investor</link:label>
    <link:label id="lab_ptct_AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor_documentation_en-US" xlink:label="lab_ptct_AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid In Capital Receivable from Investor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor" xlink:href="ptct-20200630.xsd#ptct_AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor" xlink:to="lab_ptct_AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_918fadb4-e336-40d3-9e91-1d467655fee9_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalization</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_59962e4e-7fbb-4006-9186-65b4ddf64a6d_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_ca8b798f-8039-4854-b7e2-7e122fa9785f_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_NetProductSales_5918f13c-1970-43f6-9c80-9168808ff30e_terseLabel_en-US" xlink:label="lab_ptct_NetProductSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenue</link:label>
    <link:label id="lab_ptct_NetProductSales_label_en-US" xlink:label="lab_ptct_NetProductSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Product Sales</link:label>
    <link:label id="lab_ptct_NetProductSales_documentation_en-US" xlink:label="lab_ptct_NetProductSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount of revenue earned from product sales during the reporting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_NetProductSales" xlink:href="ptct-20200630.xsd#ptct_NetProductSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_NetProductSales" xlink:to="lab_ptct_NetProductSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_650cc599-4244-444c-9c9f-258b4bf2603b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory write-down</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_3250f3d6-f697-40d2-b09f-78c2281694ce_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of asset</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_4822c8bd-6578-4df9-9e6c-47b801ce0c1b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_6b18fca9-55c1-40da-ac70-f391a5e2c09e_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_d1144d59-b9ab-4dc2-bdd8-dbd69fee0b16_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_33f32cef-119e-4256-b658-7d9485d8f5f4_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Gain</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_AssetAcquisitionMilestoneAmount_4333ffcb-8446-4ae8-aced-68dd2081c188_terseLabel_en-US" xlink:label="lab_ptct_AssetAcquisitionMilestoneAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, milestone, amount</link:label>
    <link:label id="lab_ptct_AssetAcquisitionMilestoneAmount_label_en-US" xlink:label="lab_ptct_AssetAcquisitionMilestoneAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Milestone, Amount</link:label>
    <link:label id="lab_ptct_AssetAcquisitionMilestoneAmount_documentation_en-US" xlink:label="lab_ptct_AssetAcquisitionMilestoneAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Milestone, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AssetAcquisitionMilestoneAmount" xlink:href="ptct-20200630.xsd#ptct_AssetAcquisitionMilestoneAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_AssetAcquisitionMilestoneAmount" xlink:to="lab_ptct_AssetAcquisitionMilestoneAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_f1ec9101-b679-487d-a8c6-bf62acbf6e40_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_AccruedConsultingAndContractedResearchCurrent_acd0e9ad-c41a-4f3e-bf3e-d09614adae08_terseLabel_en-US" xlink:label="lab_ptct_AccruedConsultingAndContractedResearchCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting and contracted research</link:label>
    <link:label id="lab_ptct_AccruedConsultingAndContractedResearchCurrent_label_en-US" xlink:label="lab_ptct_AccruedConsultingAndContractedResearchCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Consulting and Contracted Research Current</link:label>
    <link:label id="lab_ptct_AccruedConsultingAndContractedResearchCurrent_documentation_en-US" xlink:label="lab_ptct_AccruedConsultingAndContractedResearchCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for consulting and contracted research.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AccruedConsultingAndContractedResearchCurrent" xlink:href="ptct-20200630.xsd#ptct_AccruedConsultingAndContractedResearchCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_AccruedConsultingAndContractedResearchCurrent" xlink:to="lab_ptct_AccruedConsultingAndContractedResearchCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputOptionVolatilityMember_deaab2de-28b6-466c-8f85-8852f3deea15_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputOptionVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Option Volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputOptionVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputOptionVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Option Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputOptionVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputOptionVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputOptionVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c183664c-bb7b-423d-bbe8-98caff7fb858_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate rent, Initial term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_aebc7eb0-67f7-48ff-81c2-5ad06d12eb11_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_dcdd9e9e-801e-4b34-8f34-0e59a0142b5e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_fc9dd124-1040-413f-893c-02614d7309c9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_aec4eb20-4c5c-45d8-a373-85580bf6ac03_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_4ca81fb1-4560-4882-bb2c-1a9b2c527715_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_label_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock" xlink:to="lab_us-gaap_LongTermDebtTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_75beeb35-796a-437b-a897-68868c4c218b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited/Cancelled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_171fb925-a39e-48c4-94d7-d84681e1bf3b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of share-based compensation expense recorded in the statement of operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_1dccfc9f-0d36-435e-abac-f1bddd66dd63_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested or Expected to vest at the end of the period (in dollars)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions_3c690163-840c-4c88-ac03-0697798c6216_terseLabel_en-US" xlink:label="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement grants for non-statutory stock options (in shares)</link:label>
    <link:label id="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions_label_en-US" xlink:label="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement Grants For Non-Statutory Stock Options</link:label>
    <link:label id="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions_documentation_en-US" xlink:label="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the inducement grants for non-statutory stock options.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions" xlink:href="ptct-20200630.xsd#ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions" xlink:to="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_DevelopmentandPotentialRegulatoryApprovalPaymentObligation_5d85b265-6f94-457c-8cfd-6890de1aba79_terseLabel_en-US" xlink:label="lab_ptct_DevelopmentandPotentialRegulatoryApprovalPaymentObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone, Potential Achievements, Regulatory Approval</link:label>
    <link:label id="lab_ptct_DevelopmentandPotentialRegulatoryApprovalPaymentObligation_label_en-US" xlink:label="lab_ptct_DevelopmentandPotentialRegulatoryApprovalPaymentObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and Potential Regulatory Approval Payment Obligation</link:label>
    <link:label id="lab_ptct_DevelopmentandPotentialRegulatoryApprovalPaymentObligation_documentation_en-US" xlink:label="lab_ptct_DevelopmentandPotentialRegulatoryApprovalPaymentObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and Potential Regulatory Approval Payment Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DevelopmentandPotentialRegulatoryApprovalPaymentObligation" xlink:href="ptct-20200630.xsd#ptct_DevelopmentandPotentialRegulatoryApprovalPaymentObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_DevelopmentandPotentialRegulatoryApprovalPaymentObligation" xlink:to="lab_ptct_DevelopmentandPotentialRegulatoryApprovalPaymentObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_NetDeferredTaxLiabilitiesConvertibleDebtInstruments_9e445746-46b4-4910-b028-93c4d6ad306f_terseLabel_en-US" xlink:label="lab_ptct_NetDeferredTaxLiabilitiesConvertibleDebtInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax liability in connection with convertible notes</link:label>
    <link:label id="lab_ptct_NetDeferredTaxLiabilitiesConvertibleDebtInstruments_label_en-US" xlink:label="lab_ptct_NetDeferredTaxLiabilitiesConvertibleDebtInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Deferred Tax Liabilities Convertible Debt Instruments</link:label>
    <link:label id="lab_ptct_NetDeferredTaxLiabilitiesConvertibleDebtInstruments_documentation_en-US" xlink:label="lab_ptct_NetDeferredTaxLiabilitiesConvertibleDebtInstruments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of net deferred tax liability attributable to taxable temporary differences from issuance of convertible debt instruments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_NetDeferredTaxLiabilitiesConvertibleDebtInstruments" xlink:href="ptct-20200630.xsd#ptct_NetDeferredTaxLiabilitiesConvertibleDebtInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_NetDeferredTaxLiabilitiesConvertibleDebtInstruments" xlink:to="lab_ptct_NetDeferredTaxLiabilitiesConvertibleDebtInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_a1766caf-a2ef-4555-b6d9-98b1dc54e7dc_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease cost</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ca647a1e-6a3a-4b7f-93ee-54c1e3ba451c_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2bc31d09-db41-45dd-9f08-79e7e9fa6d6c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_fb4d8c4d-67b5-45f8-b3fb-a5e3ddbc33f8_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a80e60fc-8dc3-4b87-a403-50c09f854f3c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0c94c743-a05a-4460-90e4-9c857d771efa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_MilestoneDomain_d6895f9d-b405-433c-9b3c-1239f407ee2b_terseLabel_en-US" xlink:label="lab_ptct_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Domain]</link:label>
    <link:label id="lab_ptct_MilestoneDomain_label_en-US" xlink:label="lab_ptct_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Domain]</link:label>
    <link:label id="lab_ptct_MilestoneDomain_documentation_en-US" xlink:label="lab_ptct_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Different categories of milestones defined by agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_MilestoneDomain" xlink:href="ptct-20200630.xsd#ptct_MilestoneDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_MilestoneDomain" xlink:to="lab_ptct_MilestoneDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_f0e91ba0-447f-4751-b367-01295dd1a340_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_7a9ea3b9-b7ee-4bad-bbd4-2c79bae9dbbc_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_cb30fb72-90a7-42ac-98b7-feca363bd2c9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal Term ( in years )</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_bc940e42-e083-47e2-af94-c5f7c94e7dff_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_cd9357c0-957e-48b1-b0de-261a7e3a6071_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_2c5e4b4f-c4c9-43e4-9a69-3f0d1b723a4b_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_7695d91b-d697-4491-a6f8-d6e67e88bdd7_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived intangibles</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e76ad9ee-411f-445e-97f5-fb3578f4d37b_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_a13a2b50-db40-4c36-ad9b-5d9d380ab722_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_Termforletterofcredit_f24d703f-fb92-4c55-8925-de137692cad2_terseLabel_en-US" xlink:label="lab_ptct_Termforletterofcredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term for letter of credit (in years)</link:label>
    <link:label id="lab_ptct_Termforletterofcredit_label_en-US" xlink:label="lab_ptct_Termforletterofcredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term for letter of credit</link:label>
    <link:label id="lab_ptct_Termforletterofcredit_documentation_en-US" xlink:label="lab_ptct_Termforletterofcredit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term for letter of credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_Termforletterofcredit" xlink:href="ptct-20200630.xsd#ptct_Termforletterofcredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_Termforletterofcredit" xlink:to="lab_ptct_Termforletterofcredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_24a7784d-2d65-49ac-bc72-8dbd917b41bd_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_4a645deb-6875-423b-8262-c9a72774a9da_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AlternativeInvestmentMeasurementInput_a29a0e58-279d-440f-8be7-f6e4c0f87a61_terseLabel_en-US" xlink:label="lab_us-gaap_AlternativeInvestmentMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Investment, Measurement Input</link:label>
    <link:label id="lab_us-gaap_AlternativeInvestmentMeasurementInput_label_en-US" xlink:label="lab_us-gaap_AlternativeInvestmentMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Investment, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AlternativeInvestmentMeasurementInput" xlink:to="lab_us-gaap_AlternativeInvestmentMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_8c6586f6-a5bf-47a9-886b-1f782a524e8e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_LongTermIncentivePlan2013Member_2e7350a6-1305-401d-af3b-b93557d01116_terseLabel_en-US" xlink:label="lab_ptct_LongTermIncentivePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2013 Long Term Incentive Plan</link:label>
    <link:label id="lab_ptct_LongTermIncentivePlan2013Member_label_en-US" xlink:label="lab_ptct_LongTermIncentivePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Incentive Plan2013 [Member]</link:label>
    <link:label id="lab_ptct_LongTermIncentivePlan2013Member_documentation_en-US" xlink:label="lab_ptct_LongTermIncentivePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to the 2013 Long Term Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_LongTermIncentivePlan2013Member" xlink:href="ptct-20200630.xsd#ptct_LongTermIncentivePlan2013Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_LongTermIncentivePlan2013Member" xlink:to="lab_ptct_LongTermIncentivePlan2013Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_3c4a7716-bad2-4bbe-bfcb-dd66e1dc760f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_a088565a-f581-4ac4-a5c7-0d9b1a6befed_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_19b4bc42-9fde-4c8d-b1f4-82e1c0260ef3_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_1cd194ee-3006-42e6-8371-a78c2be40c94_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_760b7257-bee8-46a3-8e54-e47e7c710e7e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_6a641a32-d227-47a5-85f2-272780f62ad4_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_0c334057-4b69-4cc8-8fe9-a6d3f303f89c_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f467664e-0144-4c6e-bd59-d07190881f85_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option plan</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db480b6b-7c34-44ab-b9c2-044cb2eae03d_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Awards and Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_ec83b783-7710-4b7b-8ea9-f97a20ab2742_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred consideration payable</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_fcd0d737-11ed-4fd8-88bb-cb2b3cad812c_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investment in ClearPoint</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_cf25719d-23ad-485a-b1a9-442870ae5411_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_1ec8c18e-932a-4151-b82c-c663393fa546_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities in an unrealized loss position greater than 12 months</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Continuous Unrealized Loss Position, 12 Months or Longer, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_daf927b9-846f-4600-a997-0d6c8ff7f72c_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_fefcb4ca-1473-4546-93c8-7f1d9e479bd9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_a7cd995f-c882-40ca-acaa-d27bf229022a_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c1094e2e-ca58-4f68-ba94-f955376aa716_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward_50cabe6b-0f06-4af6-96fe-997d3f62270c_terseLabel_en-US" xlink:label="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value (in thousands)</link:label>
    <link:label id="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward_label_en-US" xlink:label="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options Intrinsic Value [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward" xlink:href="ptct-20200630.xsd#ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward" xlink:to="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_AssetAcquisitionNetSalesMilestone_236a4bc3-67de-4c9d-854f-c109b4ef99f2_terseLabel_en-US" xlink:label="lab_ptct_AssetAcquisitionNetSalesMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, net sales milestone</link:label>
    <link:label id="lab_ptct_AssetAcquisitionNetSalesMilestone_label_en-US" xlink:label="lab_ptct_AssetAcquisitionNetSalesMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Net Sales Milestone</link:label>
    <link:label id="lab_ptct_AssetAcquisitionNetSalesMilestone_documentation_en-US" xlink:label="lab_ptct_AssetAcquisitionNetSalesMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Net Sales Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AssetAcquisitionNetSalesMilestone" xlink:href="ptct-20200630.xsd#ptct_AssetAcquisitionNetSalesMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_AssetAcquisitionNetSalesMilestone" xlink:to="lab_ptct_AssetAcquisitionNetSalesMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_ec6754ea-346a-4201-bc7b-0ab8f24e251f_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_1bc5b84f-8d49-40b3-8f16-ae1962e50093_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_12cc1a48-11af-4aad-9a46-ab9c3bc54f8a_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber_918f6d10-eeef-4f38-9639-6758bf509891_terseLabel_en-US" xlink:label="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation Arrangement by Share based Payment Award Number of Shares Authorized Annual Increase Number</link:label>
    <link:label id="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber_label_en-US" xlink:label="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation Arrangement by Share based Payment Award Number of Shares Authorized Annual Increase Number</link:label>
    <link:label id="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber_documentation_en-US" xlink:label="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of shares to be added annually on the first day of each fiscal year in the number of shares authorized.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber" xlink:href="ptct-20200630.xsd#ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber" xlink:to="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherResearchAndDevelopmentExpense_43bed0c2-dedc-4b3a-b8d6-04bb27456e94_terseLabel_en-US" xlink:label="lab_us-gaap_OtherResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_OtherResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_OtherResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_OtherResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_8f557f65-78f6-46b2-822c-274e2b33381f_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_a0877d96-874f-4a6a-aa1f-8a1a60fe59e6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionTable_656e8326-ca8b-4187-9c23-7980d90090c9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Redemption [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Redemption [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionTable" xlink:to="lab_us-gaap_DebtInstrumentRedemptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesRealizedGainLoss_721751b3-101f-4c38-a557-285003b9dab1_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Realized Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:to="lab_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_013201eb-4f44-497d-be8a-e36e07de15d3_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_AssetAcquisitionConsiderationTransferred_b2def9ff-30f2-498b-b7c0-fb71f3523de5_terseLabel_en-US" xlink:label="lab_ptct_AssetAcquisitionConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, consideration transferred</link:label>
    <link:label id="lab_ptct_AssetAcquisitionConsiderationTransferred_label_en-US" xlink:label="lab_ptct_AssetAcquisitionConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred</link:label>
    <link:label id="lab_ptct_AssetAcquisitionConsiderationTransferred_documentation_en-US" xlink:label="lab_ptct_AssetAcquisitionConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AssetAcquisitionConsiderationTransferred" xlink:href="ptct-20200630.xsd#ptct_AssetAcquisitionConsiderationTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_AssetAcquisitionConsiderationTransferred" xlink:to="lab_ptct_AssetAcquisitionConsiderationTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_5fe4d0e4-08fd-4cab-944f-5b58f5e50219_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock price trigger</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod_c5dc172e-f397-4abc-b9d0-484ce98aad24_terseLabel_en-US" xlink:label="lab_ptct_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consecutive trading-day period</link:label>
    <link:label id="lab_ptct_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod_label_en-US" xlink:label="lab_ptct_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Convertible Threshold Consecutive Trading Day Period</link:label>
    <link:label id="lab_ptct_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod_documentation_en-US" xlink:label="lab_ptct_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold period of specified consecutive trading days within which the maximum product of the closing sale price of shares of the entity's common stock and the applicable conversion rate for such trading day triggers the conversion feature.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod" xlink:href="ptct-20200630.xsd#ptct_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod" xlink:to="lab_ptct_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_PaymentsForAssetAcquisitionsNetAssets_85aa8dbb-8268-49a1-9e6c-9f5fec744829_terseLabel_en-US" xlink:label="lab_ptct_PaymentsForAssetAcquisitionsNetAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for asset acquisitions, net assets</link:label>
    <link:label id="lab_ptct_PaymentsForAssetAcquisitionsNetAssets_label_en-US" xlink:label="lab_ptct_PaymentsForAssetAcquisitionsNetAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Asset Acquisitions, Net Assets</link:label>
    <link:label id="lab_ptct_PaymentsForAssetAcquisitionsNetAssets_documentation_en-US" xlink:label="lab_ptct_PaymentsForAssetAcquisitionsNetAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Asset Acquisitions, Net Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_PaymentsForAssetAcquisitionsNetAssets" xlink:href="ptct-20200630.xsd#ptct_PaymentsForAssetAcquisitionsNetAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_PaymentsForAssetAcquisitionsNetAssets" xlink:to="lab_ptct_PaymentsForAssetAcquisitionsNetAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_LineOfCreditFacilityAdditionalCapacityAvailable_4ea02a8c-2f25-4eba-962b-f7b30f4c8724_terseLabel_en-US" xlink:label="lab_ptct_LineOfCreditFacilityAdditionalCapacityAvailable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit facility, additional capacity available, net product revenue threshold</link:label>
    <link:label id="lab_ptct_LineOfCreditFacilityAdditionalCapacityAvailable_label_en-US" xlink:label="lab_ptct_LineOfCreditFacilityAdditionalCapacityAvailable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Additional Capacity Available</link:label>
    <link:label id="lab_ptct_LineOfCreditFacilityAdditionalCapacityAvailable_documentation_en-US" xlink:label="lab_ptct_LineOfCreditFacilityAdditionalCapacityAvailable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Additional Capacity Available</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_LineOfCreditFacilityAdditionalCapacityAvailable" xlink:href="ptct-20200630.xsd#ptct_LineOfCreditFacilityAdditionalCapacityAvailable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_LineOfCreditFacilityAdditionalCapacityAvailable" xlink:to="lab_ptct_LineOfCreditFacilityAdditionalCapacityAvailable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_1c20aba8-f235-4011-ae94-f6ad8ec61ed3_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1ed8d898-14dc-4cd4-86fb-c06487a480f7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities- noncurrent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_e0ae6c3b-5dc5-43cb-8a04-296ce1974d6e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_2a34a25a-6af5-4636-abbe-658a7fa64b65_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_68170d79-8ba0-4f0c-bfca-1c301b2e28c7_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_de53eca0-c0d0-4315-8667-b347f367b6cb_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration received on transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_2bbd1fc1-b2f0-4fab-86d9-22eed1caaad4_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_9ecc6423-b1de-49e6-905b-dedfb1ff77dc_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_0130f6cd-3dbc-4988-aa53-51a0b6c7dd01_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a3b046a9-c092-499d-9087-e63b24d52ea2_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9c7d94ef-444c-450a-8972-870d6d23dd2a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_LineOfCreditFacilityTerminationAndExitFees_aa89a6ce-4532-492a-9913-4220e7b34f73_terseLabel_en-US" xlink:label="lab_ptct_LineOfCreditFacilityTerminationAndExitFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination and exit fees</link:label>
    <link:label id="lab_ptct_LineOfCreditFacilityTerminationAndExitFees_label_en-US" xlink:label="lab_ptct_LineOfCreditFacilityTerminationAndExitFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Termination and Exit Fees</link:label>
    <link:label id="lab_ptct_LineOfCreditFacilityTerminationAndExitFees_documentation_en-US" xlink:label="lab_ptct_LineOfCreditFacilityTerminationAndExitFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Termination and Exit Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_LineOfCreditFacilityTerminationAndExitFees" xlink:href="ptct-20200630.xsd#ptct_LineOfCreditFacilityTerminationAndExitFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_LineOfCreditFacilityTerminationAndExitFees" xlink:to="lab_ptct_LineOfCreditFacilityTerminationAndExitFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_4a058099-59fb-4744-90ca-fe2f34560cff_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7019b4f4-e60b-44c9-a31b-5f28765c4958_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_2299948b-fd1f-4098-8a11-06aaa88b289b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_DiscoveryAgreementsMember_d79f3447-a3f4-49c5-b4ed-4132f7bc3d40_terseLabel_en-US" xlink:label="lab_ptct_DiscoveryAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discovery Agreements</link:label>
    <link:label id="lab_ptct_DiscoveryAgreementsMember_label_en-US" xlink:label="lab_ptct_DiscoveryAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discovery Agreements [Member]</link:label>
    <link:label id="lab_ptct_DiscoveryAgreementsMember_documentation_en-US" xlink:label="lab_ptct_DiscoveryAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discovery Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DiscoveryAgreementsMember" xlink:href="ptct-20200630.xsd#ptct_DiscoveryAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_DiscoveryAgreementsMember" xlink:to="lab_ptct_DiscoveryAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_EmployeeStockPurchasePlanVotingPercentageLimitPercent_49f79e20-56bc-4e21-a093-e1046135e6f9_terseLabel_en-US" xlink:label="lab_ptct_EmployeeStockPurchasePlanVotingPercentageLimitPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan, voting percentage limit</link:label>
    <link:label id="lab_ptct_EmployeeStockPurchasePlanVotingPercentageLimitPercent_label_en-US" xlink:label="lab_ptct_EmployeeStockPurchasePlanVotingPercentageLimitPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Voting Percentage Limit, Percent</link:label>
    <link:label id="lab_ptct_EmployeeStockPurchasePlanVotingPercentageLimitPercent_documentation_en-US" xlink:label="lab_ptct_EmployeeStockPurchasePlanVotingPercentageLimitPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Voting Percentage Limit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_EmployeeStockPurchasePlanVotingPercentageLimitPercent" xlink:href="ptct-20200630.xsd#ptct_EmployeeStockPurchasePlanVotingPercentageLimitPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_EmployeeStockPurchasePlanVotingPercentageLimitPercent" xlink:to="lab_ptct_EmployeeStockPurchasePlanVotingPercentageLimitPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_PercentOfMarketRate_1e9ca7dd-166d-4339-81bd-9f3e1e1e325c_terseLabel_en-US" xlink:label="lab_ptct_PercentOfMarketRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of market rate</link:label>
    <link:label id="lab_ptct_PercentOfMarketRate_label_en-US" xlink:label="lab_ptct_PercentOfMarketRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent Of Market Rate</link:label>
    <link:label id="lab_ptct_PercentOfMarketRate_documentation_en-US" xlink:label="lab_ptct_PercentOfMarketRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent Of Market Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_PercentOfMarketRate" xlink:href="ptct-20200630.xsd#ptct_PercentOfMarketRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_PercentOfMarketRate" xlink:to="lab_ptct_PercentOfMarketRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfSecuredDebt_066db694-b9f3-40bf-b8e4-ec86d1437380_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of senior secured term loan</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSecuredDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSecuredDebt" xlink:to="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_13fad2d9-beab-4fc8-89e5-f210a0d11d86_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_AssetAcquisitionCash_48bc133a-211d-49e5-832a-42e989d5e740_terseLabel_en-US" xlink:label="lab_ptct_AssetAcquisitionCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, cash</link:label>
    <link:label id="lab_ptct_AssetAcquisitionCash_label_en-US" xlink:label="lab_ptct_AssetAcquisitionCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Cash</link:label>
    <link:label id="lab_ptct_AssetAcquisitionCash_documentation_en-US" xlink:label="lab_ptct_AssetAcquisitionCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AssetAcquisitionCash" xlink:href="ptct-20200630.xsd#ptct_AssetAcquisitionCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_AssetAcquisitionCash" xlink:to="lab_ptct_AssetAcquisitionCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1f7bda37-b63f-4f67-b026-8fb765fddcfb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of historical dilutive common share equivalents outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_212879f2-f83b-44b8-a353-cc64f9ed8052_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum_fb72d6e3-9d6a-4323-b4a3-cf158dad681f_terseLabel_en-US" xlink:label="lab_ptct_DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum product of the closing sale price of shares of the Company's common stock and the applicable conversion rate for such trading day</link:label>
    <link:label id="lab_ptct_DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum_label_en-US" xlink:label="lab_ptct_DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Convertible Threshold Sale Price Of Common Stock Conversion Rate Product Percentage Maximum</link:label>
    <link:label id="lab_ptct_DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum_documentation_en-US" xlink:label="lab_ptct_DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the maximum product of the closing sale price of shares of the entity's common stock and the applicable conversion rate for such trading day.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum" xlink:href="ptct-20200630.xsd#ptct_DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum" xlink:to="lab_ptct_DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_eb5cfa0a-9dc6-49f8-9ea1-8eb4bc6ed631_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_fa7524cb-23cd-4947-9eb7-5aef7dd8c6d8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from issuance of convertible notes</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_03412a55-1a36-4037-8aa9-87fb1cf1e31d_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_7f996808-28b4-4963-ae32-85c1a5dd712a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_FinanceLeaseMember_0903fce1-25c6-45fb-a417-1cbc7aac97bd_terseLabel_en-US" xlink:label="lab_ptct_FinanceLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease</link:label>
    <link:label id="lab_ptct_FinanceLeaseMember_label_en-US" xlink:label="lab_ptct_FinanceLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease [Member]</link:label>
    <link:label id="lab_ptct_FinanceLeaseMember_documentation_en-US" xlink:label="lab_ptct_FinanceLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_FinanceLeaseMember" xlink:href="ptct-20200630.xsd#ptct_FinanceLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_FinanceLeaseMember" xlink:to="lab_ptct_FinanceLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3266ac4b-5042-499f-b685-3d942df02047_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease_b6f9586f-b1c9-40c1-b152-8c3e894885c5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Allowance for Credit Loss, Period Increase (Decrease)</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Allowance for Credit Loss, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_d11a8d5c-8e1b-43dd-8361-45c7ed3c52fd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent_b71b36ab-807e-4966-8e57-07a43eb8e00e_terseLabel_en-US" xlink:label="lab_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred consideration payable</link:label>
    <link:label id="lab_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent_label_en-US" xlink:label="lab_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration, Liability, Deferred Consideration Payable- Current</link:label>
    <link:label id="lab_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent_documentation_en-US" xlink:label="lab_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration, Liability, Deferred Consideration Payable- Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent" xlink:href="ptct-20200630.xsd#ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent" xlink:to="lab_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_2b3b35a6-d528-40b3-9e47-3cad9e21a956_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_MarathonPharmaceuticalsLLCMember_5137888b-3994-424c-a059-deee7dd5e75e_terseLabel_en-US" xlink:label="lab_ptct_MarathonPharmaceuticalsLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marathon Pharmaceuticals, LLC</link:label>
    <link:label id="lab_ptct_MarathonPharmaceuticalsLLCMember_label_en-US" xlink:label="lab_ptct_MarathonPharmaceuticalsLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marathon Pharmaceuticals, LLC [Member]</link:label>
    <link:label id="lab_ptct_MarathonPharmaceuticalsLLCMember_documentation_en-US" xlink:label="lab_ptct_MarathonPharmaceuticalsLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marathon Pharmaceuticals, LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_MarathonPharmaceuticalsLLCMember" xlink:href="ptct-20200630.xsd#ptct_MarathonPharmaceuticalsLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_MarathonPharmaceuticalsLLCMember" xlink:to="lab_ptct_MarathonPharmaceuticalsLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_b2e3ce62-0527-4fa4-adb5-b38c43d73d10_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_4b7b8f09-4f2f-4d79-a3fd-6cef8aae984a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_DevelopmentMilestonePaymentObligationsCancellationAndForfeiture_f8e0309d-1ad1-446a-8e67-bc1f22501976_terseLabel_en-US" xlink:label="lab_ptct_DevelopmentMilestonePaymentObligationsCancellationAndForfeiture" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestone Payment Obligations, Cancellation and Forfeiture</link:label>
    <link:label id="lab_ptct_DevelopmentMilestonePaymentObligationsCancellationAndForfeiture_label_en-US" xlink:label="lab_ptct_DevelopmentMilestonePaymentObligationsCancellationAndForfeiture" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestone Payment Obligations, Cancellation and Forfeiture</link:label>
    <link:label id="lab_ptct_DevelopmentMilestonePaymentObligationsCancellationAndForfeiture_documentation_en-US" xlink:label="lab_ptct_DevelopmentMilestonePaymentObligationsCancellationAndForfeiture" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestone Payment Obligations, Cancellation and Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DevelopmentMilestonePaymentObligationsCancellationAndForfeiture" xlink:href="ptct-20200630.xsd#ptct_DevelopmentMilestonePaymentObligationsCancellationAndForfeiture"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_DevelopmentMilestonePaymentObligationsCancellationAndForfeiture" xlink:to="lab_ptct_DevelopmentMilestonePaymentObligationsCancellationAndForfeiture" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_CesnaMember_ff589709-13d8-4326-8e9b-2acf7c58de01_terseLabel_en-US" xlink:label="lab_ptct_CesnaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cesna [Member]</link:label>
    <link:label id="lab_ptct_CesnaMember_label_en-US" xlink:label="lab_ptct_CesnaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cesna [Member]</link:label>
    <link:label id="lab_ptct_CesnaMember_documentation_en-US" xlink:label="lab_ptct_CesnaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cesna</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_CesnaMember" xlink:href="ptct-20200630.xsd#ptct_CesnaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_CesnaMember" xlink:to="lab_ptct_CesnaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock_ef45f0aa-326f-4fb5-b2e6-cff28b6bf0ef_terseLabel_en-US" xlink:label="lab_ptct_ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of interest expense recognized related to the Convertible Notes</link:label>
    <link:label id="lab_ptct_ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock_label_en-US" xlink:label="lab_ptct_ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Interest Expense Recognized Related To Convertible Debt [Table Text Block]</link:label>
    <link:label id="lab_ptct_ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock_documentation_en-US" xlink:label="lab_ptct_ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of interest expense recognized related to convertible debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock" xlink:href="ptct-20200630.xsd#ptct_ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock" xlink:to="lab_ptct_ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_070b5490-5a9f-42cc-8677-aac5497bb49e_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_d6e09901-14d3-467f-865a-c6929c304de3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_SharesissuedunderRightsExchangeAgreement_84052c8f-7052-44a3-afe6-01fa834c9df9_terseLabel_en-US" xlink:label="lab_ptct_SharesissuedunderRightsExchangeAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, issued (in shares)</link:label>
    <link:label id="lab_ptct_SharesissuedunderRightsExchangeAgreement_label_en-US" xlink:label="lab_ptct_SharesissuedunderRightsExchangeAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under Rights Exchange Agreement</link:label>
    <link:label id="lab_ptct_SharesissuedunderRightsExchangeAgreement_documentation_en-US" xlink:label="lab_ptct_SharesissuedunderRightsExchangeAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under Rights Exchange Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_SharesissuedunderRightsExchangeAgreement" xlink:href="ptct-20200630.xsd#ptct_SharesissuedunderRightsExchangeAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_SharesissuedunderRightsExchangeAgreement" xlink:to="lab_ptct_SharesissuedunderRightsExchangeAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_b6d144d0-c123-4674-8d69-5a47139d4028_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_7621e2ee-9e92-42e6-bd92-937a2ab6e683_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_c759b3d8-1638-428b-ba89-2f4ebd05506f_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_d72e09bc-7b0d-49c6-ad0a-f91d5409f024_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_afe88442-2ea9-4906-bfc1-593f656e1529_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024 and thereafter</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payments, Due Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_a84ffb60-b2d0-4893-8e2d-e9b8fe880592_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_ed01670e-f064-42a8-8636-71bde88ee202_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_75b135d5-0e26-414e-aaba-c598cdb0fc57_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of convertible notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_6501e02e-ed5f-43ec-8c15-e587eed61214_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_FinanceLeaseCostNonCash_d9c0caee-bd5b-4901-af98-630da5c871de_terseLabel_en-US" xlink:label="lab_ptct_FinanceLeaseCostNonCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash finance lease amortization expense</link:label>
    <link:label id="lab_ptct_FinanceLeaseCostNonCash_label_en-US" xlink:label="lab_ptct_FinanceLeaseCostNonCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Cost Non-Cash</link:label>
    <link:label id="lab_ptct_FinanceLeaseCostNonCash_documentation_en-US" xlink:label="lab_ptct_FinanceLeaseCostNonCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Cost Non-Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_FinanceLeaseCostNonCash" xlink:href="ptct-20200630.xsd#ptct_FinanceLeaseCostNonCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_FinanceLeaseCostNonCash" xlink:to="lab_ptct_FinanceLeaseCostNonCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_d7d48fd9-77e7-48bc-b9fe-695fb53b9361_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of financial assets and liabilities that are required to be measured at fair value on a recurring basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member_cb0eb992-cae4-42e4-a8d7-8569b1119a8b_terseLabel_en-US" xlink:label="lab_ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.50% Convertible senior notes due 2026</link:label>
    <link:label id="lab_ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member_label_en-US" xlink:label="lab_ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes, 1.5%, Due September 15, 2026 [Member]</link:label>
    <link:label id="lab_ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member_documentation_en-US" xlink:label="lab_ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes, 1.5%, Due September 15, 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member" xlink:href="ptct-20200630.xsd#ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member" xlink:to="lab_ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_8488f6df-3eff-4a51-9282-4783c74d9d75_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_138d0e0b-5af7-431a-874a-b5a3a4b96f86_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_f93005b2-d18b-443d-bada-5480555228aa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_NJ_74196285-05ae-4391-9746-a23f9b496d75_terseLabel_en-US" xlink:label="lab_stpr_NJ" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW JERSEY</link:label>
    <link:label id="lab_stpr_NJ_label_en-US" xlink:label="lab_stpr_NJ" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW JERSEY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NJ"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_NJ" xlink:to="lab_stpr_NJ" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_PaymentOfFinanceLeasePrincipal_50ddae1e-d228-427c-9852-3779ce2ee66e_negatedTerseLabel_en-US" xlink:label="lab_ptct_PaymentOfFinanceLeasePrincipal" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of finance lease principal</link:label>
    <link:label id="lab_ptct_PaymentOfFinanceLeasePrincipal_label_en-US" xlink:label="lab_ptct_PaymentOfFinanceLeasePrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of Finance Lease Principal</link:label>
    <link:label id="lab_ptct_PaymentOfFinanceLeasePrincipal_documentation_en-US" xlink:label="lab_ptct_PaymentOfFinanceLeasePrincipal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of Finance Lease Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_PaymentOfFinanceLeasePrincipal" xlink:href="ptct-20200630.xsd#ptct_PaymentOfFinanceLeasePrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_PaymentOfFinanceLeasePrincipal" xlink:to="lab_ptct_PaymentOfFinanceLeasePrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dbf04165-ce20-461b-9ed8-08204e1d181e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_e22459af-f2b6-4d52-a8a5-6ad38994cf78_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e2c5fa22-6d26-4cc7-ab6b-980a3e37e345_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders_19c65c41-6a6c-4ddd-aad5-d42a0952291c_terseLabel_en-US" xlink:label="lab_ptct_MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum percentage of principal held by convertible debt instrument holders required to issue notice for declaration of principal and unpaid interest payable upon events of default</link:label>
    <link:label id="lab_ptct_MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders_label_en-US" xlink:label="lab_ptct_MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Percentage Of Debt Principal Amount By Instrument Holders</link:label>
    <link:label id="lab_ptct_MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders_documentation_en-US" xlink:label="lab_ptct_MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the minimum percentage of debt principal amount by instrument holders.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders" xlink:href="ptct-20200630.xsd#ptct_MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders" xlink:to="lab_ptct_MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_8e2ffca9-0e1b-498d-9d07-d91595f86874_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_EmflazaassetacquisitionMember_15cc90e6-3e2c-4318-a6c4-bb1da682156e_terseLabel_en-US" xlink:label="lab_ptct_EmflazaassetacquisitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emflaza asset acquisition</link:label>
    <link:label id="lab_ptct_EmflazaassetacquisitionMember_label_en-US" xlink:label="lab_ptct_EmflazaassetacquisitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emflaza asset acquisition [Member]</link:label>
    <link:label id="lab_ptct_EmflazaassetacquisitionMember_documentation_en-US" xlink:label="lab_ptct_EmflazaassetacquisitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emflaza asset acquisition [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_EmflazaassetacquisitionMember" xlink:href="ptct-20200630.xsd#ptct_EmflazaassetacquisitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_EmflazaassetacquisitionMember" xlink:to="lab_ptct_EmflazaassetacquisitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_c9abc662-1a35-45d5-976e-dc4cd0ff047b_verboseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of shares (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_f025f6a5-c4c8-41aa-a10d-9f7db79267a1_terseLabel_en-US" xlink:label="lab_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.00% Convertible senior notes due 2022</link:label>
    <link:label id="lab_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_label_en-US" xlink:label="lab_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes3.0 Percent Due2022 [Member]</link:label>
    <link:label id="lab_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_documentation_en-US" xlink:label="lab_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to 3.00% convertible senior notes due 2022.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member" xlink:href="ptct-20200630.xsd#ptct_ConvertibleSeniorNotes3.0PercentDue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member" xlink:to="lab_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c9db3647-e4a7-444d-8e46-029d4480a281_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end of the period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c7e793b5-571d-4661-8070-f00bb05c1ac1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d028719a-c9cb-49c9-b02a-27ef9cf034e5_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_PaymentsforAssetAcquisitions_95b87018-2065-461e-a841-6ef5073e114b_terseLabel_en-US" xlink:label="lab_ptct_PaymentsforAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for asset acquisitions</link:label>
    <link:label id="lab_ptct_PaymentsforAssetAcquisitions_label_en-US" xlink:label="lab_ptct_PaymentsforAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Asset Acquisitions</link:label>
    <link:label id="lab_ptct_PaymentsforAssetAcquisitions_documentation_en-US" xlink:label="lab_ptct_PaymentsforAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Asset Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_PaymentsforAssetAcquisitions" xlink:href="ptct-20200630.xsd#ptct_PaymentsforAssetAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_PaymentsforAssetAcquisitions" xlink:to="lab_ptct_PaymentsforAssetAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_4c326aea-a724-4d5c-82bf-051baa267146_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards_912ab600-aaaf-45be-b474-14424b677d94_terseLabel_en-US" xlink:label="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares subject to outstanding awards (in shares)</link:label>
    <link:label id="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards_label_en-US" xlink:label="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation Arrangement by Share based Payment Award Number of Shares Authorized Shares Subject to Outstanding Awards</link:label>
    <link:label id="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards_documentation_en-US" xlink:label="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of shares subject to outstanding awards used to calculate authorized shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards" xlink:href="ptct-20200630.xsd#ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards" xlink:to="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_09062ac5-d867-42bf-9314-e719967b5480_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_271eb597-556b-4d59-a203-3aec200e1925_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of unrealized losses and fair values of available-for-sale securities in a continuous unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_MilestonePotentialAchievementsRegulatoryApproval_b1e5ea2a-1614-4a3f-b9ad-5bd0a7858347_terseLabel_en-US" xlink:label="lab_ptct_MilestonePotentialAchievementsRegulatoryApproval" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments</link:label>
    <link:label id="lab_ptct_MilestonePotentialAchievementsRegulatoryApproval_label_en-US" xlink:label="lab_ptct_MilestonePotentialAchievementsRegulatoryApproval" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone, Potential Achievements, Regulatory Approval</link:label>
    <link:label id="lab_ptct_MilestonePotentialAchievementsRegulatoryApproval_documentation_en-US" xlink:label="lab_ptct_MilestonePotentialAchievementsRegulatoryApproval" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment which the entity is obliged to pay upon regulatory approval</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_MilestonePotentialAchievementsRegulatoryApproval" xlink:href="ptct-20200630.xsd#ptct_MilestonePotentialAchievementsRegulatoryApproval"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_MilestonePotentialAchievementsRegulatoryApproval" xlink:to="lab_ptct_MilestonePotentialAchievementsRegulatoryApproval" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_bd6912e6-2c09-4524-ae4b-d1b2d30617a7_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_04bd85d9-15ea-42bf-8c22-f8fdb94a5a2a_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings (accumulated deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_75655dba-6739-4fe5-a537-91e3688d5c1c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_84e3c776-0901-48a2-bb38-31872fcffeb5_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDepositOtherAssets_f5c3fca1-0ad6-495c-a095-82a01f1232c9_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposits and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDepositOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deposit Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_AssignedRoyaltyPaymentRetainedPercentage_9dbc1c36-d2ba-4bec-bd51-8a637a75e367_terseLabel_en-US" xlink:label="lab_ptct_AssignedRoyaltyPaymentRetainedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assigned royalty payment, retained percentage</link:label>
    <link:label id="lab_ptct_AssignedRoyaltyPaymentRetainedPercentage_label_en-US" xlink:label="lab_ptct_AssignedRoyaltyPaymentRetainedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assigned Royalty Payment, Retained Percentage</link:label>
    <link:label id="lab_ptct_AssignedRoyaltyPaymentRetainedPercentage_documentation_en-US" xlink:label="lab_ptct_AssignedRoyaltyPaymentRetainedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assigned Royalty Payment, Retained Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AssignedRoyaltyPaymentRetainedPercentage" xlink:href="ptct-20200630.xsd#ptct_AssignedRoyaltyPaymentRetainedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_AssignedRoyaltyPaymentRetainedPercentage" xlink:to="lab_ptct_AssignedRoyaltyPaymentRetainedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_e7816b42-2eb2-4832-aac9-d3ead7282080_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets and goodwill</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_27a0b099-4ee3-4735-9101-0de3acd4663e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_54c73a93-cf39-4fe9-8496-6cacffa034a3_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_SharesremainingtoissueunderRightsExchangeAgreement_e954fd85-efd1-4edd-8eb0-4e3115ca0e5c_terseLabel_en-US" xlink:label="lab_ptct_SharesremainingtoissueunderRightsExchangeAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares remaining to issue under Rights Exchange Agreement (in shares)</link:label>
    <link:label id="lab_ptct_SharesremainingtoissueunderRightsExchangeAgreement_label_en-US" xlink:label="lab_ptct_SharesremainingtoissueunderRightsExchangeAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares remaining to issue under Rights Exchange Agreement</link:label>
    <link:label id="lab_ptct_SharesremainingtoissueunderRightsExchangeAgreement_documentation_en-US" xlink:label="lab_ptct_SharesremainingtoissueunderRightsExchangeAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares remaining to issue under Rights Exchange Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_SharesremainingtoissueunderRightsExchangeAgreement" xlink:href="ptct-20200630.xsd#ptct_SharesremainingtoissueunderRightsExchangeAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_SharesremainingtoissueunderRightsExchangeAgreement" xlink:to="lab_ptct_SharesremainingtoissueunderRightsExchangeAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_a439f457-bd72-4bb7-ae0d-2611877d3dd9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_c03bcb64-a70e-47af-aca2-50e59e7a7901_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_50e9e7c9-b7ff-48cf-87b9-3af7ed0213f0_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_Percentageofnetproductsales_325eae1b-2e64-40e8-b954-cd9e672a3391_terseLabel_en-US" xlink:label="lab_ptct_Percentageofnetproductsales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of net product sales</link:label>
    <link:label id="lab_ptct_Percentageofnetproductsales_label_en-US" xlink:label="lab_ptct_Percentageofnetproductsales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of net product sales</link:label>
    <link:label id="lab_ptct_Percentageofnetproductsales_documentation_en-US" xlink:label="lab_ptct_Percentageofnetproductsales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of new product sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_Percentageofnetproductsales" xlink:href="ptct-20200630.xsd#ptct_Percentageofnetproductsales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_Percentageofnetproductsales" xlink:to="lab_ptct_Percentageofnetproductsales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_6878f207-dbdf-499f-aad9-1d8aa03fa6ec_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount_f5c80c2e-3d7a-4835-8b09-3d827c4200ae_terseLabel_en-US" xlink:label="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Priority review voucher amount</link:label>
    <link:label id="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount_label_en-US" xlink:label="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount</link:label>
    <link:label id="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount_documentation_en-US" xlink:label="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount" xlink:href="ptct-20200630.xsd#ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount" xlink:to="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_b37c31a9-0ccf-404a-84dc-a3eb823e6330_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_CollaborationAndDiscoveryAgreementsMember_55830237-9641-455d-8a98-69d99a8f026d_terseLabel_en-US" xlink:label="lab_ptct_CollaborationAndDiscoveryAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Discovery Agreements</link:label>
    <link:label id="lab_ptct_CollaborationAndDiscoveryAgreementsMember_label_en-US" xlink:label="lab_ptct_CollaborationAndDiscoveryAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Discovery Agreements [Member]</link:label>
    <link:label id="lab_ptct_CollaborationAndDiscoveryAgreementsMember_documentation_en-US" xlink:label="lab_ptct_CollaborationAndDiscoveryAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to early stage collaboration and discovery agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_CollaborationAndDiscoveryAgreementsMember" xlink:href="ptct-20200630.xsd#ptct_CollaborationAndDiscoveryAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_CollaborationAndDiscoveryAgreementsMember" xlink:to="lab_ptct_CollaborationAndDiscoveryAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_e25e21bf-4a26-46b2-9176-5b5a7ab8fbca_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_dcb7cf9b-8ed0-4228-8216-2e2f2d1c7fcf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_d793992a-5157-4e5d-9930-480f7fd1c884_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1_2e399891-a9c0-4293-bb20-0d8a40046255_terseLabel_en-US" xlink:label="lab_us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Escrow</link:label>
    <link:label id="lab_us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1_label_en-US" xlink:label="lab_us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Escrow Deposit Disbursements Related to Property Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1" xlink:to="lab_us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_28981c98-98a7-4308-8856-941b017517bc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of the convertible notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServicingAssetAtFairValueAmountRollForward_b807bc02-753e-4d22-b0c0-5f665c1a7be7_terseLabel_en-US" xlink:label="lab_us-gaap_ServicingAssetAtFairValueAmountRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3 roll forward</link:label>
    <link:label id="lab_us-gaap_ServicingAssetAtFairValueAmountRollForward_label_en-US" xlink:label="lab_us-gaap_ServicingAssetAtFairValueAmountRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Servicing Asset at Fair Value, Amount [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServicingAssetAtFairValueAmountRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ServicingAssetAtFairValueAmountRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServicingAssetAtFairValueAmountRollForward" xlink:to="lab_us-gaap_ServicingAssetAtFairValueAmountRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_6538bf71-1fe4-4c31-86ff-8a0d8615e392_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_StockIssuedDuringPeriodValueExchangeRights_5805dce2-fa0a-4be2-8ce0-84c1207500e9_terseLabel_en-US" xlink:label="lab_ptct_StockIssuedDuringPeriodValueExchangeRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock related to rights exchange</link:label>
    <link:label id="lab_ptct_StockIssuedDuringPeriodValueExchangeRights_label_en-US" xlink:label="lab_ptct_StockIssuedDuringPeriodValueExchangeRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Exchange Rights</link:label>
    <link:label id="lab_ptct_StockIssuedDuringPeriodValueExchangeRights_documentation_en-US" xlink:label="lab_ptct_StockIssuedDuringPeriodValueExchangeRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Exchange Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_StockIssuedDuringPeriodValueExchangeRights" xlink:href="ptct-20200630.xsd#ptct_StockIssuedDuringPeriodValueExchangeRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_StockIssuedDuringPeriodValueExchangeRights" xlink:to="lab_ptct_StockIssuedDuringPeriodValueExchangeRights" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_DevelopmentandRegulatoryMilestoneMember_12eca52b-3ec0-444d-916c-c4544e9efd66_terseLabel_en-US" xlink:label="lab_ptct_DevelopmentandRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and Regulatory Milestone</link:label>
    <link:label id="lab_ptct_DevelopmentandRegulatoryMilestoneMember_label_en-US" xlink:label="lab_ptct_DevelopmentandRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and Regulatory Milestone [Member]</link:label>
    <link:label id="lab_ptct_DevelopmentandRegulatoryMilestoneMember_documentation_en-US" xlink:label="lab_ptct_DevelopmentandRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and Regulatory Milestone [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DevelopmentandRegulatoryMilestoneMember" xlink:href="ptct-20200630.xsd#ptct_DevelopmentandRegulatoryMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_DevelopmentandRegulatoryMilestoneMember" xlink:to="lab_ptct_DevelopmentandRegulatoryMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_094265fc-89e2-454f-a395-26c6983d431a_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_21bded23-8c73-43be-9bd6-86b9273cc982_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities- noncurrent</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_4bb63210-ce5a-4185-ad9c-5516e4a78305_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Term</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8a7f8e74-74a3-482e-9cdc-5c40cfe63c05_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_5d7ad4f7-f593-4349-84f0-5703578d6866_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of stock option activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_850f696b-aecd-4a2a-8c90-6482229e34a3_negatedLabel_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_label_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized Debt Issuance Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_MilestonePaymentObligations_8034e48a-8077-482f-8e7f-ffd560603e94_terseLabel_en-US" xlink:label="lab_ptct_MilestonePaymentObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Obligations</link:label>
    <link:label id="lab_ptct_MilestonePaymentObligations_label_en-US" xlink:label="lab_ptct_MilestonePaymentObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Obligations</link:label>
    <link:label id="lab_ptct_MilestonePaymentObligations_documentation_en-US" xlink:label="lab_ptct_MilestonePaymentObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_MilestonePaymentObligations" xlink:href="ptct-20200630.xsd#ptct_MilestonePaymentObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_MilestonePaymentObligations" xlink:to="lab_ptct_MilestonePaymentObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1f0de44c-370d-4dc8-8e85-902df6eb7424_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_40b2d84d-7c7a-4c27-a658-c17812dd1020_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at the end of the period (in dollars)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_945508d2-d2c4-4d88-9ade-b2a721dfcefb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_8f133adc-7c30-43d2-8abb-105d20ac2a92_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts reclassified from other comprehensive items</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_fba659eb-6d90-4f0e-a827-9bd9058156cc_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0174fb06-4f59-4bd4-99fe-a0ff933f048e_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock award plan</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_BridgewaterMember_128602ac-1229-4907-90db-2b47177f3b47_terseLabel_en-US" xlink:label="lab_ptct_BridgewaterMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridgewater [Member]</link:label>
    <link:label id="lab_ptct_BridgewaterMember_label_en-US" xlink:label="lab_ptct_BridgewaterMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridgewater [Member]</link:label>
    <link:label id="lab_ptct_BridgewaterMember_documentation_en-US" xlink:label="lab_ptct_BridgewaterMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridgewater</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_BridgewaterMember" xlink:href="ptct-20200630.xsd#ptct_BridgewaterMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_BridgewaterMember" xlink:to="lab_ptct_BridgewaterMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_27fb26aa-5dee-4274-9c8e-b5505ca55cd2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for asset acquisitions, share, value</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff_21561cf4-faae-4fc3-bc39-4865d7470877_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Allowance for Credit Loss, Writeoff</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Allowance for Credit Loss, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_1cdf3429-a6c2-491a-afec-3499f04e4cb8_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_bb6bd2e9-d81b-43f2-ac1c-ff1f924d9be3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_a0ae5e7c-02d1-4a38-8b6d-be1bd5a565ed_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_880cd3d2-b12e-4dda-b328-73746f62fa0d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage_4820f9bd-ec5d-4050-b43f-5125316cc9d1_terseLabel_en-US" xlink:label="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales</link:label>
    <link:label id="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage_label_en-US" xlink:label="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Liability, Milestone, Potential Achievements, Product Sales Percentage</link:label>
    <link:label id="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage_documentation_en-US" xlink:label="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Liability, Milestone, Potential Achievements, Product Sales Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage" xlink:href="ptct-20200630.xsd#ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage" xlink:to="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_bcd007ca-2b6f-4355-a10b-0ffbea6b7399_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_OperatingLeaseCostNonCash_a82037f5-466c-4b56-8f54-c8380b196141_terseLabel_en-US" xlink:label="lab_ptct_OperatingLeaseCostNonCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash operating lease expense</link:label>
    <link:label id="lab_ptct_OperatingLeaseCostNonCash_label_en-US" xlink:label="lab_ptct_OperatingLeaseCostNonCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost Non-Cash</link:label>
    <link:label id="lab_ptct_OperatingLeaseCostNonCash_documentation_en-US" xlink:label="lab_ptct_OperatingLeaseCostNonCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost Non-Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_OperatingLeaseCostNonCash" xlink:href="ptct-20200630.xsd#ptct_OperatingLeaseCostNonCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_OperatingLeaseCostNonCash" xlink:to="lab_ptct_OperatingLeaseCostNonCash" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_Numberofterms_24154a69-efa1-4877-b11f-34bdb69ff0f9_terseLabel_en-US" xlink:label="lab_ptct_Numberofterms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of terms</link:label>
    <link:label id="lab_ptct_Numberofterms_label_en-US" xlink:label="lab_ptct_Numberofterms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of terms</link:label>
    <link:label id="lab_ptct_Numberofterms_documentation_en-US" xlink:label="lab_ptct_Numberofterms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_Numberofterms" xlink:href="ptct-20200630.xsd#ptct_Numberofterms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_Numberofterms" xlink:to="lab_ptct_Numberofterms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_740a2a98-dc30-4eec-a4f7-72c8f89fde7a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_6b5a6bce-44a1-4260-85b4-de9a3f4fc59d_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_c5d376d9-ab30-4b6a-80e1-49564ce3a6ab_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_DepositsAndOtherAssetsNoncurrent_9a77f54b-4149-48df-8a47-8a369e66afb4_terseLabel_en-US" xlink:label="lab_ptct_DepositsAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposits and other assets</link:label>
    <link:label id="lab_ptct_DepositsAndOtherAssetsNoncurrent_label_en-US" xlink:label="lab_ptct_DepositsAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposits and Other Assets Noncurrent</link:label>
    <link:label id="lab_ptct_DepositsAndOtherAssetsNoncurrent_documentation_en-US" xlink:label="lab_ptct_DepositsAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the carrying value of amounts transferred to third parties for security purposes and other noncurrent assets that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DepositsAndOtherAssetsNoncurrent" xlink:href="ptct-20200630.xsd#ptct_DepositsAndOtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_DepositsAndOtherAssetsNoncurrent" xlink:to="lab_ptct_DepositsAndOtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c70f200a-e733-4ff0-8505-8c66ccb34b18_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_b7b7d90e-1428-4cfa-bd14-ced36412058c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with an employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_5aba2ccb-8858-484f-ae99-d2f9546cd6e8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_51b0a47e-c53c-4614-84a9-9c19ebef41e6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_03892acc-aa5b-4bde-82a5-1133fa53d920_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_2f3ec1bc-4093-4f36-bd88-746a6169e11c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_c3645851-d9fd-4847-a3e2-4de724c51f38_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_c169825d-6d6c-4226-823f-cf1c5f35375a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share-basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_WellcomeTrustLimitedMember_45d81c1a-68a0-4a96-bc49-387bb50c98d9_terseLabel_en-US" xlink:label="lab_ptct_WellcomeTrustLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wellcome trust</link:label>
    <link:label id="lab_ptct_WellcomeTrustLimitedMember_label_en-US" xlink:label="lab_ptct_WellcomeTrustLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wellcome Trust Limited [Member]</link:label>
    <link:label id="lab_ptct_WellcomeTrustLimitedMember_documentation_en-US" xlink:label="lab_ptct_WellcomeTrustLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to The Wellcome Trust Limited.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_WellcomeTrustLimitedMember" xlink:href="ptct-20200630.xsd#ptct_WellcomeTrustLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_WellcomeTrustLimitedMember" xlink:to="lab_ptct_WellcomeTrustLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_07c84d2d-eac4-450c-8dfd-f498102e792a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_811f9119-4114-45b6-b1de-3bab1f5af632_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture_70c735b0-089f-4c2f-bbad-1feb841fbf8d_terseLabel_en-US" xlink:label="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount, Net of Cancellation and Forfeiture</link:label>
    <link:label id="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture_label_en-US" xlink:label="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount, Net of Cancellation and Forfeiture</link:label>
    <link:label id="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture_documentation_en-US" xlink:label="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount, Net of Cancellation and Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture" xlink:href="ptct-20200630.xsd#ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture" xlink:to="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_6968508f-c989-4463-87de-78cf5b5e4b1f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains/(Losses) On Marketable Securities,&#160;net of&#160;tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_88174234-7b02-46ab-8529-0a46c3282096_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ac6be78c-6041-4714-88c9-c36635992580_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b41f4fa6-69f4-45fc-8300-90e6518f1f0c_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_RoyaltyPurchaseAgreementTerminationPeriod_f6f5d319-073e-479c-bad2-5efc1f019de9_terseLabel_en-US" xlink:label="lab_ptct_RoyaltyPurchaseAgreementTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty purchase agreement, termination period</link:label>
    <link:label id="lab_ptct_RoyaltyPurchaseAgreementTerminationPeriod_label_en-US" xlink:label="lab_ptct_RoyaltyPurchaseAgreementTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Termination Period</link:label>
    <link:label id="lab_ptct_RoyaltyPurchaseAgreementTerminationPeriod_documentation_en-US" xlink:label="lab_ptct_RoyaltyPurchaseAgreementTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Termination Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_RoyaltyPurchaseAgreementTerminationPeriod" xlink:href="ptct-20200630.xsd#ptct_RoyaltyPurchaseAgreementTerminationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_RoyaltyPurchaseAgreementTerminationPeriod" xlink:to="lab_ptct_RoyaltyPurchaseAgreementTerminationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_SalesMilestonesMember_9ba6c271-b7d6-4bd6-bda6-6aefd1d7ceb7_terseLabel_en-US" xlink:label="lab_ptct_SalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestones</link:label>
    <link:label id="lab_ptct_SalesMilestonesMember_label_en-US" xlink:label="lab_ptct_SalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestones [Member]</link:label>
    <link:label id="lab_ptct_SalesMilestonesMember_documentation_en-US" xlink:label="lab_ptct_SalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to certain sales events on the basis of which certain milestones are achieved.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_SalesMilestonesMember" xlink:href="ptct-20200630.xsd#ptct_SalesMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_SalesMilestonesMember" xlink:to="lab_ptct_SalesMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_44a6e64d-4f33-4294-be07-5d51c36d9054_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_label_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense" xlink:to="lab_us-gaap_LeaseAndRentalExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_8e54097f-7c3f-496e-8187-faf14d891a82_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_54b45358-4456-4e54-8d54-0aacad350ce8_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross&#160;Unrealized, Gain</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_9fe30c6a-8233-41cc-9be2-8c6e19046ede_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_b3115335-7295-4ec4-8a71-996036c4c303_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_ProceedsAssignedRoyaltyPaymentAgreement_7e5c2eda-1ac0-4b75-80a6-ee58cd7279c0_terseLabel_en-US" xlink:label="lab_ptct_ProceedsAssignedRoyaltyPaymentAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds assigned royalty payment agreement</link:label>
    <link:label id="lab_ptct_ProceedsAssignedRoyaltyPaymentAgreement_label_en-US" xlink:label="lab_ptct_ProceedsAssignedRoyaltyPaymentAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds Assigned Royalty Payment Agreement</link:label>
    <link:label id="lab_ptct_ProceedsAssignedRoyaltyPaymentAgreement_documentation_en-US" xlink:label="lab_ptct_ProceedsAssignedRoyaltyPaymentAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds Assigned Royalty Payment Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ProceedsAssignedRoyaltyPaymentAgreement" xlink:href="ptct-20200630.xsd#ptct_ProceedsAssignedRoyaltyPaymentAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_ProceedsAssignedRoyaltyPaymentAgreement" xlink:to="lab_ptct_ProceedsAssignedRoyaltyPaymentAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_58b290ff-0f96-4dbb-8f54-33240e44962a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease terms - operating leases (years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_aab02759-a2a2-4cc3-98e2-6cecd05eb51f_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2f5c8638-da80-4e62-a4d4-d78247197908_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_45cd799d-5ad4-424b-a985-ce7223706a13_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of other comprehensive income (loss) and the changes in accumulated other comprehensive items</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_52a0d95d-1bf6-42ee-8a9a-a4188c24d9f9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future amortization expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_6ea164a9-4f4a-48b5-ba0f-d803965245d2_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Company</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_8468aea8-5414-43d5-8e0a-4dbd56891e2d_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_ac34df2f-3468-4c03-8ab2-5ba4a878ec84_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_AssetAcquisitionInProcessResearchAndDevelopment_0ce6128a-e2a6-4a2d-951f-e371948ca04a_terseLabel_en-US" xlink:label="lab_ptct_AssetAcquisitionInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, in-process research and development</link:label>
    <link:label id="lab_ptct_AssetAcquisitionInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_ptct_AssetAcquisitionInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, In-process Research and Development</link:label>
    <link:label id="lab_ptct_AssetAcquisitionInProcessResearchAndDevelopment_documentation_en-US" xlink:label="lab_ptct_AssetAcquisitionInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, In-process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AssetAcquisitionInProcessResearchAndDevelopment" xlink:href="ptct-20200630.xsd#ptct_AssetAcquisitionInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_AssetAcquisitionInProcessResearchAndDevelopment" xlink:to="lab_ptct_AssetAcquisitionInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_Numberofdistributors_87538c55-787f-4794-8469-7277e364189a_terseLabel_en-US" xlink:label="lab_ptct_Numberofdistributors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of distributors</link:label>
    <link:label id="lab_ptct_Numberofdistributors_label_en-US" xlink:label="lab_ptct_Numberofdistributors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of distributors</link:label>
    <link:label id="lab_ptct_Numberofdistributors_documentation_en-US" xlink:label="lab_ptct_Numberofdistributors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Distributors</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_Numberofdistributors" xlink:href="ptct-20200630.xsd#ptct_Numberofdistributors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_Numberofdistributors" xlink:to="lab_ptct_Numberofdistributors" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_AssetAcquisitionOtherAssets_02518a4a-dea7-438e-91e2-6bdd916a5329_terseLabel_en-US" xlink:label="lab_ptct_AssetAcquisitionOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, other assets</link:label>
    <link:label id="lab_ptct_AssetAcquisitionOtherAssets_label_en-US" xlink:label="lab_ptct_AssetAcquisitionOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Other Assets</link:label>
    <link:label id="lab_ptct_AssetAcquisitionOtherAssets_documentation_en-US" xlink:label="lab_ptct_AssetAcquisitionOtherAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AssetAcquisitionOtherAssets" xlink:href="ptct-20200630.xsd#ptct_AssetAcquisitionOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_AssetAcquisitionOtherAssets" xlink:to="lab_ptct_AssetAcquisitionOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_MidCapFinancialTrustMember_ec598af0-0997-45ba-b59e-189bd3a15f29_terseLabel_en-US" xlink:label="lab_ptct_MidCapFinancialTrustMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MidCap Financial Trust</link:label>
    <link:label id="lab_ptct_MidCapFinancialTrustMember_label_en-US" xlink:label="lab_ptct_MidCapFinancialTrustMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MidCap Financial Trust [Member]</link:label>
    <link:label id="lab_ptct_MidCapFinancialTrustMember_documentation_en-US" xlink:label="lab_ptct_MidCapFinancialTrustMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MidCap Financial Trust [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_MidCapFinancialTrustMember" xlink:href="ptct-20200630.xsd#ptct_MidCapFinancialTrustMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_MidCapFinancialTrustMember" xlink:to="lab_ptct_MidCapFinancialTrustMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_FinanceLeasePresentValueOfExceedsTheFairValue_2de6db47-6015-4d22-be46-5962fcc1e264_terseLabel_en-US" xlink:label="lab_ptct_FinanceLeasePresentValueOfExceedsTheFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Present Value Of Exceeds The Fair Value</link:label>
    <link:label id="lab_ptct_FinanceLeasePresentValueOfExceedsTheFairValue_label_en-US" xlink:label="lab_ptct_FinanceLeasePresentValueOfExceedsTheFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Present Value Of Exceeds The Fair Value</link:label>
    <link:label id="lab_ptct_FinanceLeasePresentValueOfExceedsTheFairValue_documentation_en-US" xlink:label="lab_ptct_FinanceLeasePresentValueOfExceedsTheFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Present Value Of Exceeds The Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_FinanceLeasePresentValueOfExceedsTheFairValue" xlink:href="ptct-20200630.xsd#ptct_FinanceLeasePresentValueOfExceedsTheFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_FinanceLeasePresentValueOfExceedsTheFairValue" xlink:to="lab_ptct_FinanceLeasePresentValueOfExceedsTheFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_AssetAcquisitionSellingGeneralAndAdministrativeExpense_1afff529-a6ba-41b3-a409-741f75378da7_terseLabel_en-US" xlink:label="lab_ptct_AssetAcquisitionSellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, selling, general And administrative expense</link:label>
    <link:label id="lab_ptct_AssetAcquisitionSellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_ptct_AssetAcquisitionSellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Selling, General And Administrative Expense</link:label>
    <link:label id="lab_ptct_AssetAcquisitionSellingGeneralAndAdministrativeExpense_documentation_en-US" xlink:label="lab_ptct_AssetAcquisitionSellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Selling, General And Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AssetAcquisitionSellingGeneralAndAdministrativeExpense" xlink:href="ptct-20200630.xsd#ptct_AssetAcquisitionSellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_AssetAcquisitionSellingGeneralAndAdministrativeExpense" xlink:to="lab_ptct_AssetAcquisitionSellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_220bd212-5e43-4d44-a82c-231236ee7a85_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Imputed Interest expense</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_17c31076-0127-4beb-b4f7-b6b1f20ad99d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_31cf57c9-a30a-43d3-9ef6-e41b252c585a_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_994f8191-616e-467d-9688-8dfd14a3c637_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_32122cc7-f8af-48ee-9742-5fda9e5046da_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_e5a095b4-35cb-46a0-bf67-da93b993402b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation assumptions</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_efba37ba-38d6-4777-8ea7-bc5cfcad908f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_4368b0f8-57df-4cb1-b852-45958e0b78ed_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share&#8212;basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_fbabcd6c-2373-4aad-9b36-1bcae81bbf23_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_8b4d0dd5-c59e-4c5f-8eea-f8560d081760_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue_edacb879-73e3-46d7-a617-a2b71289c4b5_terseLabel_en-US" xlink:label="lab_ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Marketable securities, More Than 12 Months</link:label>
    <link:label id="lab_ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue_label_en-US" xlink:label="lab_ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities Debt Maturities Over One Year Fair Value</link:label>
    <link:label id="lab_ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue_documentation_en-US" xlink:label="lab_ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of available-for-sale debt securities at fair value maturing after the next fiscal year following the latest fiscal year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue" xlink:href="ptct-20200630.xsd#ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue" xlink:to="lab_ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_0f1b4604-67b5-4a1a-84d0-88011a09832a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_eb426730-e341-4d94-b9af-cf1a8b503bb6_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_d6304f64-4fc7-4f87-b9ce-0779aa84b55a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_f54f8869-f8f4-4754-91f9-a70483d9d68c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24e50b89-37d3-4a26-9318-80d68c4d8ae3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_5965cbb2-16dc-423e-a9d2-24f18a09e1c2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_7a1478bf-ce36-4da2-9ff6-8d1e72a67445_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_f3b4d476-4dd4-4948-bac7-3536a8fe55ec_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_198a468e-7548-437f-96c1-f438168fa879_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate - operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_993e2844-abbf-44b6-b911-8fb3d289d89b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) and accumulated other comprehensive items</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_8bb3bc50-791c-4124-a5b8-2d2660a9fb16_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_900da0e3-3bea-4845-a78e-40356dd5c397_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) and accumulated other comprehensive items</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1d770e84-f511-405b-93cc-7df5c6f5a39e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_f2b72570-9565-4b8d-8d6a-261c9c8a1fe0_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_af32817a-658a-4866-921b-630108f1fa83_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end of the period (in dollars)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing_c1f9e65e-2ecd-4be5-8037-49ab12e794ee_terseLabel_en-US" xlink:label="lab_ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development milestone payments which the entity is obligated to pay</link:label>
    <link:label id="lab_ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing_label_en-US" xlink:label="lab_ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestone Payment Obligations, Due on Second Anniversary Year of Merger Closing</link:label>
    <link:label id="lab_ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing_documentation_en-US" xlink:label="lab_ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the development milestones payments which the entity is obligated to pay under certain contractual agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing" xlink:href="ptct-20200630.xsd#ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing" xlink:to="lab_ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a88122d3-7df6-49c4-ac38-2b8fc4176ea0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number&#160;of options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_c58f9a77-fafb-4ea0-86e7-75f93c84f4eb_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_782d7e94-f6fe-4675-b265-943eed111218_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_6c5ff066-67b2-4b48-9e75-db2f1d28a40b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_3065e56d-3cf7-4875-abe0-0d7c678caed7_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_c3aa232c-d792-45cd-aeab-5fce5189f267_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_22b79fb1-4ee4-4602-a900-f1f65dde2df7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested or Expected to vest at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_089d3241-af0f-44b9-ab18-bcd8ef16c153_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_348322c1-295d-4b10-addc-60690df5b621_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_DebtInstrumentFloorInterestRate_73c1ffba-fcae-4d2c-a503-50494c97fa29_terseLabel_en-US" xlink:label="lab_ptct_DebtInstrumentFloorInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, floor interest rate</link:label>
    <link:label id="lab_ptct_DebtInstrumentFloorInterestRate_label_en-US" xlink:label="lab_ptct_DebtInstrumentFloorInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Floor Interest Rate</link:label>
    <link:label id="lab_ptct_DebtInstrumentFloorInterestRate_documentation_en-US" xlink:label="lab_ptct_DebtInstrumentFloorInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Floor Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DebtInstrumentFloorInterestRate" xlink:href="ptct-20200630.xsd#ptct_DebtInstrumentFloorInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_DebtInstrumentFloorInterestRate" xlink:to="lab_ptct_DebtInstrumentFloorInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_02e46c66-0451-47bf-a06f-58a3c0fc45a8_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate - finance lease</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_765b0ccb-27d7-445b-a92f-3bcb26ef45f8_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_aae48300-e4b9-4e8d-8c46-be22dfb397c9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, authorized shares (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_c524d30f-6927-4bca-b22e-ffeae4ad53cd_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash included in deposits and other assets</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_6f72a0ea-42d3-4ba7-841f-2c2fc6d1c9ac_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_3aad9068-ef59-42b3-b3d0-bceaec2e6ff4_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c4e6f521-3417-432f-ac6c-be42d81df3df_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_28b100e7-d114-4cd2-a4ac-93b068b7b865_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4d02dd32-c569-4340-b2b5-14bd50fb835e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherDebtSecuritiesMember_9cb69e0c-6f93-48ec-892f-4daee5e051f0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government obligations</link:label>
    <link:label id="lab_us-gaap_OtherDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_OtherDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Debt Obligations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherDebtSecuritiesMember" xlink:to="lab_us-gaap_OtherDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_f2d30703-b8e3-4caa-a98f-01c82450b8bd_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_a8c5ab0a-3cbc-4bd0-92ac-7bc010b4b35a_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_UnrealizedGainLossonConvertibleSecurities_34a8af55-3ef5-4891-869c-1ff623bfa460_terseLabel_en-US" xlink:label="lab_ptct_UnrealizedGainLossonConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on ClearPoint convertible debt security</link:label>
    <link:label id="lab_ptct_UnrealizedGainLossonConvertibleSecurities_label_en-US" xlink:label="lab_ptct_UnrealizedGainLossonConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Convertible Securities</link:label>
    <link:label id="lab_ptct_UnrealizedGainLossonConvertibleSecurities_documentation_en-US" xlink:label="lab_ptct_UnrealizedGainLossonConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_UnrealizedGainLossonConvertibleSecurities" xlink:href="ptct-20200630.xsd#ptct_UnrealizedGainLossonConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_UnrealizedGainLossonConvertibleSecurities" xlink:to="lab_ptct_UnrealizedGainLossonConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_6300ffaf-0cad-496b-8f4c-6a04d57472ca_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities- current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_76318e26-efa8-4a21-9bf9-90cb416c9b1f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of discounts on investments, net</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_0bd7de61-b1ea-4a1a-8758-58d9cb8f590d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from lines of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_01bf8a50-3c54-41ad-bdbd-cc267d252dd8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of computation of basic and diluted net loss available to common stockholders</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_3225f078-9425-49a7-b01a-95503d106a56_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_DebtInstrumentConvertibleThresholdBusinessDays_63fdeaf3-7caf-4dbc-ab26-bd2a750d0f4a_terseLabel_en-US" xlink:label="lab_ptct_DebtInstrumentConvertibleThresholdBusinessDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business days, period</link:label>
    <link:label id="lab_ptct_DebtInstrumentConvertibleThresholdBusinessDays_label_en-US" xlink:label="lab_ptct_DebtInstrumentConvertibleThresholdBusinessDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Convertible Threshold Business Days</link:label>
    <link:label id="lab_ptct_DebtInstrumentConvertibleThresholdBusinessDays_documentation_en-US" xlink:label="lab_ptct_DebtInstrumentConvertibleThresholdBusinessDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold period of specified business days within which the maximum product of the closing sale price of shares of the entity's common stock and the applicable conversion rate for such trading day triggers the conversion feature.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DebtInstrumentConvertibleThresholdBusinessDays" xlink:href="ptct-20200630.xsd#ptct_DebtInstrumentConvertibleThresholdBusinessDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_DebtInstrumentConvertibleThresholdBusinessDays" xlink:to="lab_ptct_DebtInstrumentConvertibleThresholdBusinessDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_ff5f249a-fde2-43cf-99cf-8199807611be_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_3efc3e18-2430-4bc8-8c6a-81a65ba677ef_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9dcdb7e8-0780-4c13-863f-3bb9f3684e2f_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_cd691bc7-9e2b-4a47-b8da-9c4dec2ed6a0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration payable- net sales milestones and royalties</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a891b31a-3d33-45ca-bc52-85edd58d982d_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7afdb7ea-13fc-4a3e-8628-2803da9464cc_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_6a1b1489-f033-4582-a5e4-4a4832798e9c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee compensation, benefits, and related accruals</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_20b2892f-a8e9-4699-88ef-805ff0153970_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Interest Issued, number of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d93c281e-5ad2-44e0-bb9a-aae5bac18c57_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 (excludes the six months ended June 30, 2020)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_aa227e48-788a-451c-bdc4-cdab60a0153f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant other observable inputs (level&#160;2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_2274546a-7082-427a-833e-4af01516a68e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of Contract ( in years )</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_3854987c-fd82-4387-82df-7f2007aaef30_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of product rights and licenses</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_acc1f950-8286-4463-bbd5-b78ecba0ba47_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_acbcda0f-a784-4418-9a30-8144f82a4391_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_9073151f-3e01-49e4-8f80-16ed797103dd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of warrant liability</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_AssetAcquisitionDevelopmentAndRegulatoryMilestones_46fe9ef4-a187-4adf-a95f-b79e33cafa0c_terseLabel_en-US" xlink:label="lab_ptct_AssetAcquisitionDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, development and regulatory milestones</link:label>
    <link:label id="lab_ptct_AssetAcquisitionDevelopmentAndRegulatoryMilestones_label_en-US" xlink:label="lab_ptct_AssetAcquisitionDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Development And Regulatory Milestones</link:label>
    <link:label id="lab_ptct_AssetAcquisitionDevelopmentAndRegulatoryMilestones_documentation_en-US" xlink:label="lab_ptct_AssetAcquisitionDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Development And Regulatory Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AssetAcquisitionDevelopmentAndRegulatoryMilestones" xlink:href="ptct-20200630.xsd#ptct_AssetAcquisitionDevelopmentAndRegulatoryMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_AssetAcquisitionDevelopmentAndRegulatoryMilestones" xlink:to="lab_ptct_AssetAcquisitionDevelopmentAndRegulatoryMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_AssignedRoyaltyPaymentPercentage_29cf8376-9ee5-47d5-b4e5-beb6fed2e6c4_terseLabel_en-US" xlink:label="lab_ptct_AssignedRoyaltyPaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assigned royalty payment, percentage</link:label>
    <link:label id="lab_ptct_AssignedRoyaltyPaymentPercentage_label_en-US" xlink:label="lab_ptct_AssignedRoyaltyPaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assigned Royalty Payment, Percentage</link:label>
    <link:label id="lab_ptct_AssignedRoyaltyPaymentPercentage_documentation_en-US" xlink:label="lab_ptct_AssignedRoyaltyPaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assigned Royalty Payment, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AssignedRoyaltyPaymentPercentage" xlink:href="ptct-20200630.xsd#ptct_AssignedRoyaltyPaymentPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_AssignedRoyaltyPaymentPercentage" xlink:to="lab_ptct_AssignedRoyaltyPaymentPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_StockIncentivePlan2013Member_64fb8edf-780c-4730-a284-04aa41eca3b1_terseLabel_en-US" xlink:label="lab_ptct_StockIncentivePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2013 Stock Incentive Plan</link:label>
    <link:label id="lab_ptct_StockIncentivePlan2013Member_label_en-US" xlink:label="lab_ptct_StockIncentivePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan2013 [Member]</link:label>
    <link:label id="lab_ptct_StockIncentivePlan2013Member_documentation_en-US" xlink:label="lab_ptct_StockIncentivePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to the 2013 Stock Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_StockIncentivePlan2013Member" xlink:href="ptct-20200630.xsd#ptct_StockIncentivePlan2013Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_StockIncentivePlan2013Member" xlink:to="lab_ptct_StockIncentivePlan2013Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsAbstract_be44eeff-5d90-4b4f-933b-3d5d41a493d6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsAbstract_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsAbstract" xlink:to="lab_us-gaap_OtherCommitmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_HopewellNewBuildingMember_1d47d008-b403-480a-92e5-676de5e1a2ad_terseLabel_en-US" xlink:label="lab_ptct_HopewellNewBuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Building</link:label>
    <link:label id="lab_ptct_HopewellNewBuildingMember_label_en-US" xlink:label="lab_ptct_HopewellNewBuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hopewell New Building [Member]</link:label>
    <link:label id="lab_ptct_HopewellNewBuildingMember_documentation_en-US" xlink:label="lab_ptct_HopewellNewBuildingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hopewell New Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_HopewellNewBuildingMember" xlink:href="ptct-20200630.xsd#ptct_HopewellNewBuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_HopewellNewBuildingMember" xlink:to="lab_ptct_HopewellNewBuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_08ab239b-ac3a-457a-a58d-862d64c07ff8_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenue</link:label>
    <link:label id="lab_us-gaap_ProductMember_c4b9d683-56bb-4fb4-b598-519735aab07a_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_b5633a8e-4edd-4880-a9be-5aec4b5593aa_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_HopewellCampusMember_8b1012d7-f29c-4d7d-839e-e02eba3dcf6e_terseLabel_en-US" xlink:label="lab_ptct_HopewellCampusMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hopewell Campus</link:label>
    <link:label id="lab_ptct_HopewellCampusMember_label_en-US" xlink:label="lab_ptct_HopewellCampusMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hopewell Campus [Member]</link:label>
    <link:label id="lab_ptct_HopewellCampusMember_documentation_en-US" xlink:label="lab_ptct_HopewellCampusMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hopewell Campus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_HopewellCampusMember" xlink:href="ptct-20200630.xsd#ptct_HopewellCampusMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_HopewellCampusMember" xlink:to="lab_ptct_HopewellCampusMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0ef24707-3cc3-4f19-afdb-eabfbd4c0f2a_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_16149c5e-6197-42b0-a16e-96ec8d9253f4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain on marketable securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputSharePriceMember_72ee5b53-f82a-4ecf-a164-ab25d628700a_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputSharePriceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Share Price</link:label>
    <link:label id="lab_us-gaap_MeasurementInputSharePriceMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputSharePriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Share Price [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputSharePriceMember" xlink:to="lab_us-gaap_MeasurementInputSharePriceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_NumberOfOperatingLeaseLeaseNotyetCommenced_efd19ed3-3682-47da-8d68-218618918b86_terseLabel_en-US" xlink:label="lab_ptct_NumberOfOperatingLeaseLeaseNotyetCommenced" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Operating Lease, Lease Not yet Commenced</link:label>
    <link:label id="lab_ptct_NumberOfOperatingLeaseLeaseNotyetCommenced_label_en-US" xlink:label="lab_ptct_NumberOfOperatingLeaseLeaseNotyetCommenced" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Operating Lease, Lease Not yet Commenced</link:label>
    <link:label id="lab_ptct_NumberOfOperatingLeaseLeaseNotyetCommenced_documentation_en-US" xlink:label="lab_ptct_NumberOfOperatingLeaseLeaseNotyetCommenced" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Operating Lease, Lease Not yet Commenced</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_NumberOfOperatingLeaseLeaseNotyetCommenced" xlink:href="ptct-20200630.xsd#ptct_NumberOfOperatingLeaseLeaseNotyetCommenced"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_NumberOfOperatingLeaseLeaseNotyetCommenced" xlink:to="lab_ptct_NumberOfOperatingLeaseLeaseNotyetCommenced" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets_70b7e3e7-aa4f-43d4-9121-95cd67fd8ee6_terseLabel_en-US" xlink:label="lab_ptct_CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service, Excluding Amortization Of Intangible Assets</link:label>
    <link:label id="lab_ptct_CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_ptct_CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service, Excluding Amortization Of Intangible Assets</link:label>
    <link:label id="lab_ptct_CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets_documentation_en-US" xlink:label="lab_ptct_CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service, Excluding Amortization Of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets" xlink:href="ptct-20200630.xsd#ptct_CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets" xlink:to="lab_ptct_CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityPeriodIncreaseDecrease_8bb5eb75-3dea-4ffc-bdd5-7030b0a66484_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:to="lab_us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_14f71302-7e0d-487b-9e03-fb2c3d908555_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_e53932e5-9261-4a48-99d8-1a1c0abbbc82_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember" xlink:to="lab_us-gaap_DebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_aa3d8466-f579-4293-a280-02e1c98629cc_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5351b812-16b4-4559-9574-297ada8f9608_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member_53b334e4-3cad-4d67-8574-5f8f4f5306b1_terseLabel_en-US" xlink:label="lab_ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2009 Equity and Long Term Incentive Plan and 2013 Stock Incentive Plan</link:label>
    <link:label id="lab_ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member_label_en-US" xlink:label="lab_ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity2009 And Long Term Incentive Plan And Stock Incentive Plan2013 [Member]</link:label>
    <link:label id="lab_ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member_documentation_en-US" xlink:label="lab_ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to the 2009 Equity and Long Term Incentive Plan and 2013 Stock Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member" xlink:href="ptct-20200630.xsd#ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member" xlink:to="lab_ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_89981b11-4543-449f-a888-8b048ea5bf59_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_ef888149-addb-4887-b61a-bde79dd49f84_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net carrying amount</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_6e10a2bb-0c99-4458-9efb-347d7c19678c_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net carrying amount</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_09f5c817-cf68-4c7d-ba09-e5cdaa5ba6ef_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_44f374d7-1ae6-490b-bc66-aaf2da667c6f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_ProbabilityofSuccessMember_30e7b4d0-b488-40f7-aa3e-90337d1e5796_terseLabel_en-US" xlink:label="lab_ptct_ProbabilityofSuccessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of Success [Member]</link:label>
    <link:label id="lab_ptct_ProbabilityofSuccessMember_label_en-US" xlink:label="lab_ptct_ProbabilityofSuccessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of Success [Member]</link:label>
    <link:label id="lab_ptct_ProbabilityofSuccessMember_documentation_en-US" xlink:label="lab_ptct_ProbabilityofSuccessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of Success [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ProbabilityofSuccessMember" xlink:href="ptct-20200630.xsd#ptct_ProbabilityofSuccessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_ProbabilityofSuccessMember" xlink:to="lab_ptct_ProbabilityofSuccessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_SalesRebatesAndRoyaltiesCurrent_c6a3b102-b148-45b2-9cfa-9c1fb12da97e_terseLabel_en-US" xlink:label="lab_ptct_SalesRebatesAndRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales rebates and royalties</link:label>
    <link:label id="lab_ptct_SalesRebatesAndRoyaltiesCurrent_label_en-US" xlink:label="lab_ptct_SalesRebatesAndRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Rebates And Royalties, Current</link:label>
    <link:label id="lab_ptct_SalesRebatesAndRoyaltiesCurrent_documentation_en-US" xlink:label="lab_ptct_SalesRebatesAndRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Rebates And Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_SalesRebatesAndRoyaltiesCurrent" xlink:href="ptct-20200630.xsd#ptct_SalesRebatesAndRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_SalesRebatesAndRoyaltiesCurrent" xlink:to="lab_ptct_SalesRebatesAndRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a115cced-ba4a-4b0d-9466-19b9d5888e2a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ee353c02-4fc2-45b6-a50c-209d2c700ecf_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of fixed assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_BioElectronMember_5543540a-4e4e-47b8-98e9-e480f6105f16_terseLabel_en-US" xlink:label="lab_ptct_BioElectronMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioElectron</link:label>
    <link:label id="lab_ptct_BioElectronMember_label_en-US" xlink:label="lab_ptct_BioElectronMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioElectron [Member]</link:label>
    <link:label id="lab_ptct_BioElectronMember_documentation_en-US" xlink:label="lab_ptct_BioElectronMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioElectron [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_BioElectronMember" xlink:href="ptct-20200630.xsd#ptct_BioElectronMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_BioElectronMember" xlink:to="lab_ptct_BioElectronMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_dfc9d216-8f47-42e9-93b0-78540d7f352b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in the fair value of deferred and contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_4d580745-9a5a-437f-96f3-6604309938c2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_RoyaltyPurchaseAgreementPaymentMaximum_9aed0851-3ea9-4b65-a176-46a9d69b45b2_terseLabel_en-US" xlink:label="lab_ptct_RoyaltyPurchaseAgreementPaymentMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty purchase agreement, payment maximum</link:label>
    <link:label id="lab_ptct_RoyaltyPurchaseAgreementPaymentMaximum_label_en-US" xlink:label="lab_ptct_RoyaltyPurchaseAgreementPaymentMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Payment Maximum</link:label>
    <link:label id="lab_ptct_RoyaltyPurchaseAgreementPaymentMaximum_documentation_en-US" xlink:label="lab_ptct_RoyaltyPurchaseAgreementPaymentMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Payment Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_RoyaltyPurchaseAgreementPaymentMaximum" xlink:href="ptct-20200630.xsd#ptct_RoyaltyPurchaseAgreementPaymentMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_RoyaltyPurchaseAgreementPaymentMaximum" xlink:to="lab_ptct_RoyaltyPurchaseAgreementPaymentMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseTermOfContract1_d0a5851b-85b7-413b-950f-e2d0f9566a63_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Term of Contract</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseTermOfContract1_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:to="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_PotentialNetSalesMilestonesDomain_ab258026-bbf4-4361-9b74-2140302111df_terseLabel_en-US" xlink:label="lab_ptct_PotentialNetSalesMilestonesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Net Sales Milestones [Domain]</link:label>
    <link:label id="lab_ptct_PotentialNetSalesMilestonesDomain_label_en-US" xlink:label="lab_ptct_PotentialNetSalesMilestonesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Net Sales Milestones [Domain]</link:label>
    <link:label id="lab_ptct_PotentialNetSalesMilestonesDomain_documentation_en-US" xlink:label="lab_ptct_PotentialNetSalesMilestonesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Net Sales Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_PotentialNetSalesMilestonesDomain" xlink:href="ptct-20200630.xsd#ptct_PotentialNetSalesMilestonesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_PotentialNetSalesMilestonesDomain" xlink:to="lab_ptct_PotentialNetSalesMilestonesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_MassBioMember_f69bf69b-d08d-4890-b775-b363094e0d6b_terseLabel_en-US" xlink:label="lab_ptct_MassBioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MassBio</link:label>
    <link:label id="lab_ptct_MassBioMember_label_en-US" xlink:label="lab_ptct_MassBioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MassBio [Member]</link:label>
    <link:label id="lab_ptct_MassBioMember_documentation_en-US" xlink:label="lab_ptct_MassBioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MassBio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_MassBioMember" xlink:href="ptct-20200630.xsd#ptct_MassBioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_MassBioMember" xlink:to="lab_ptct_MassBioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_9070fc74-b494-4f27-9c4b-cd9252427227_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on equity investment</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_1d536d10-069d-4470-aea8-e6cdf7fbb228_verboseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on equity investment</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_ca636628-d89a-4c5b-a21a-56049976b9aa_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_29c5702e-fab9-4d36-8bc6-0cb908c6932f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f55d722f-a30a-4343-8454-a4256624182d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining service period for recognition of unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_PaymentsOnDeferredConsiderationObligation_88871f59-e818-4ee7-83d8-d4e7693ba2f4_negatedTerseLabel_en-US" xlink:label="lab_ptct_PaymentsOnDeferredConsiderationObligation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments on deferred consideration obligation</link:label>
    <link:label id="lab_ptct_PaymentsOnDeferredConsiderationObligation_label_en-US" xlink:label="lab_ptct_PaymentsOnDeferredConsiderationObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments On Deferred Consideration Obligation</link:label>
    <link:label id="lab_ptct_PaymentsOnDeferredConsiderationObligation_documentation_en-US" xlink:label="lab_ptct_PaymentsOnDeferredConsiderationObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments On Deferred Consideration Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_PaymentsOnDeferredConsiderationObligation" xlink:href="ptct-20200630.xsd#ptct_PaymentsOnDeferredConsiderationObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_PaymentsOnDeferredConsiderationObligation" xlink:to="lab_ptct_PaymentsOnDeferredConsiderationObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_c4384160-fef2-4983-9ee2-6d74c8086212_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_c5ca03a8-45cd-4b64-b72f-4ff83619fa43_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_4d450571-7b90-4653-942b-f65aa5d993b3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsMember_23833cea-c210-4bbf-a870-d4b0922079a9_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments</link:label>
    <link:label id="lab_us-gaap_CommitmentsMember_label_en-US" xlink:label="lab_us-gaap_CommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsMember" xlink:to="lab_us-gaap_CommitmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_948b91d8-232f-4dd0-9f11-272950e36ab4_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease terms - finance lease (years)</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_d7d9588b-b817-4ac9-9c7f-f9be66e60eaa_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_b5247a6b-584b-41d5-81dd-b2ec393ad1ce_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for asset acquisitions, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_6c2f4098-4b73-4224-9b22-2163a283b3f2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_6ad6b938-189d-4d4e-8c10-bab966a2567b_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_CashconsiderationpaymentunderRightsExchangeAgreement_e93b9f6f-035d-496d-9a82-2534500557a8_terseLabel_en-US" xlink:label="lab_ptct_CashconsiderationpaymentunderRightsExchangeAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash consideration payment under Rights Exchange Agreement</link:label>
    <link:label id="lab_ptct_CashconsiderationpaymentunderRightsExchangeAgreement_label_en-US" xlink:label="lab_ptct_CashconsiderationpaymentunderRightsExchangeAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash consideration payment under Rights Exchange Agreement</link:label>
    <link:label id="lab_ptct_CashconsiderationpaymentunderRightsExchangeAgreement_documentation_en-US" xlink:label="lab_ptct_CashconsiderationpaymentunderRightsExchangeAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash consideration payment under Rights Exchange Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_CashconsiderationpaymentunderRightsExchangeAgreement" xlink:href="ptct-20200630.xsd#ptct_CashconsiderationpaymentunderRightsExchangeAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_CashconsiderationpaymentunderRightsExchangeAgreement" xlink:to="lab_ptct_CashconsiderationpaymentunderRightsExchangeAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_2b520b47-8714-4900-bf1d-c62f1cd8bb93_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_DebtInstrumentConvertiblePeriod_960b134a-ae3e-4b99-be7b-7206be02ba8f_terseLabel_en-US" xlink:label="lab_ptct_DebtInstrumentConvertiblePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, period</link:label>
    <link:label id="lab_ptct_DebtInstrumentConvertiblePeriod_label_en-US" xlink:label="lab_ptct_DebtInstrumentConvertiblePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Period</link:label>
    <link:label id="lab_ptct_DebtInstrumentConvertiblePeriod_documentation_en-US" xlink:label="lab_ptct_DebtInstrumentConvertiblePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DebtInstrumentConvertiblePeriod" xlink:href="ptct-20200630.xsd#ptct_DebtInstrumentConvertiblePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_DebtInstrumentConvertiblePeriod" xlink:to="lab_ptct_DebtInstrumentConvertiblePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_ecbfaccd-cfc9-4579-8e88-f8a047d9a49a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_EarlyStageCollaborationsMember_17365c4f-8fe0-46c2-bcfc-f26fa0ee9c1c_terseLabel_en-US" xlink:label="lab_ptct_EarlyStageCollaborationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early Stage Collaborations</link:label>
    <link:label id="lab_ptct_EarlyStageCollaborationsMember_label_en-US" xlink:label="lab_ptct_EarlyStageCollaborationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early Stage Collaborations [Member]</link:label>
    <link:label id="lab_ptct_EarlyStageCollaborationsMember_documentation_en-US" xlink:label="lab_ptct_EarlyStageCollaborationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early Stage Collaborations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_EarlyStageCollaborationsMember" xlink:href="ptct-20200630.xsd#ptct_EarlyStageCollaborationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_EarlyStageCollaborationsMember" xlink:to="lab_ptct_EarlyStageCollaborationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_a3af39f9-1a95-4f5a-b396-9c83517e1356_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock vesting and issuance, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_1794d5a6-0bb5-4be1-ba97-b9b2f75e0088_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate ( as a percent )</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_d505985f-35e9-492d-978e-84b6fd1add63_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_LicensingAndCollaborationAgreementMember_697a904c-814c-4c94-8a81-e3da425c6bc1_terseLabel_en-US" xlink:label="lab_ptct_LicensingAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing And Collaboration Agreement</link:label>
    <link:label id="lab_ptct_LicensingAndCollaborationAgreementMember_label_en-US" xlink:label="lab_ptct_LicensingAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing And Collaboration Agreement [Member]</link:label>
    <link:label id="lab_ptct_LicensingAndCollaborationAgreementMember_documentation_en-US" xlink:label="lab_ptct_LicensingAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing And Collaboration Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_LicensingAndCollaborationAgreementMember" xlink:href="ptct-20200630.xsd#ptct_LicensingAndCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_LicensingAndCollaborationAgreementMember" xlink:to="lab_ptct_LicensingAndCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_a481d255-3bdc-4756-bafa-bf8a00aca606_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_5cb4fdc2-0b6c-4a5a-a2d0-cdb3938f97e5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_AkceaMember_6488bab7-d1e5-4504-b86b-d0f8d8c07f75_terseLabel_en-US" xlink:label="lab_ptct_AkceaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Akcea</link:label>
    <link:label id="lab_ptct_AkceaMember_label_en-US" xlink:label="lab_ptct_AkceaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Akcea [Member]</link:label>
    <link:label id="lab_ptct_AkceaMember_documentation_en-US" xlink:label="lab_ptct_AkceaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Akcea [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AkceaMember" xlink:href="ptct-20200630.xsd#ptct_AkceaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_AkceaMember" xlink:to="lab_ptct_AkceaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_f11bbc26-11cc-4449-9598-56fcdcccff5c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_50db3366-bc59-4967-bcdd-484ce6926664_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of common stock, percent</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e08e1911-f405-49af-ba5c-da109b7c45e9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_7c04e7ff-345d-4e9d-833a-c4ea8df41618_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_0aa53af3-dad5-45c3-9a68-1d8a16f133a9_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash consideration</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_d2732c71-fd92-47b7-916d-25dba2a1680f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_313c4f38-63f1-47c6-b581-2e5c82e0939a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_5b840112-b2e6-4b17-9ab4-888518b18e1e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_024fbd7f-f135-4f67-9548-3998a33bfd3d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_bbe815b7-d4e1-475a-8138-d52b680c64ce_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities in an unrealized loss position less than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_c7cc9421-93a2-4da7-8440-6ae8baa7e084_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_EquityAndLongTermIncentivePlan2009Member_2383215e-417d-4b56-a3a2-063807f344d6_terseLabel_en-US" xlink:label="lab_ptct_EquityAndLongTermIncentivePlan2009Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2009 Equity and Long Term Incentive Plan</link:label>
    <link:label id="lab_ptct_EquityAndLongTermIncentivePlan2009Member_label_en-US" xlink:label="lab_ptct_EquityAndLongTermIncentivePlan2009Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity And Long Term Incentive Plan2009 [Member]</link:label>
    <link:label id="lab_ptct_EquityAndLongTermIncentivePlan2009Member_documentation_en-US" xlink:label="lab_ptct_EquityAndLongTermIncentivePlan2009Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to the 2009 Equity and Long-Term Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_EquityAndLongTermIncentivePlan2009Member" xlink:href="ptct-20200630.xsd#ptct_EquityAndLongTermIncentivePlan2009Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_EquityAndLongTermIncentivePlan2009Member" xlink:to="lab_ptct_EquityAndLongTermIncentivePlan2009Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_a1d798fb-61cf-487f-b7ab-360361e88eda_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_563e71b9-8d97-4b18-be31-7e6bc40695d6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_37f02deb-b8ef-4e89-9ef5-320f8c1180b8_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of real estate property</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_58b245b0-fec2-491e-8ec3-1977fa9793ba_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities in an unrealized loss position less than 12 months</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Continuous Unrealized Loss Position, Less than 12 Months, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_MilestoneAxis_8655a461-5c19-49ba-9337-476b43c03d13_terseLabel_en-US" xlink:label="lab_ptct_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:label id="lab_ptct_MilestoneAxis_label_en-US" xlink:label="lab_ptct_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:label id="lab_ptct_MilestoneAxis_documentation_en-US" xlink:label="lab_ptct_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information by categories of milestones achieved.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_MilestoneAxis" xlink:href="ptct-20200630.xsd#ptct_MilestoneAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_MilestoneAxis" xlink:to="lab_ptct_MilestoneAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_235560d2-0f8a-4d15-b72c-fe681845e4c2_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_4db5e1d1-a9c7-4f30-b0fd-fc9b3f25cf39_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_3c15aa55-11b3-4335-b9b4-1e6a84f19c16_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_ffe5eec1-0a9e-472a-b11d-5a3ee3db2212_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_LossOfSettlementRegulatoryMilestones_2de59295-81e5-4638-8e9d-e3d708eb163e_terseLabel_en-US" xlink:label="lab_ptct_LossOfSettlementRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Of Settlement, Regulatory Milestones</link:label>
    <link:label id="lab_ptct_LossOfSettlementRegulatoryMilestones_label_en-US" xlink:label="lab_ptct_LossOfSettlementRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Of Settlement, Regulatory Milestones</link:label>
    <link:label id="lab_ptct_LossOfSettlementRegulatoryMilestones_documentation_en-US" xlink:label="lab_ptct_LossOfSettlementRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Of Settlement, Regulatory Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_LossOfSettlementRegulatoryMilestones" xlink:href="ptct-20200630.xsd#ptct_LossOfSettlementRegulatoryMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_LossOfSettlementRegulatoryMilestones" xlink:to="lab_ptct_LossOfSettlementRegulatoryMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_fb733bde-9304-41aa-b00a-3ca66dfe0e41_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income before reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_d194e30d-ff8e-4a50-be02-ff489f227ed2_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_01ac305a-5c05-4846-9e19-76b17afff1dd_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_ConsiderationForAssetAcquisitions_72ab1720-649d-4b21-a8ea-74ce47ad1305_terseLabel_en-US" xlink:label="lab_ptct_ConsiderationForAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration for asset acquisitions</link:label>
    <link:label id="lab_ptct_ConsiderationForAssetAcquisitions_label_en-US" xlink:label="lab_ptct_ConsiderationForAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration for Asset Acquisitions</link:label>
    <link:label id="lab_ptct_ConsiderationForAssetAcquisitions_documentation_en-US" xlink:label="lab_ptct_ConsiderationForAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration for Asset Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ConsiderationForAssetAcquisitions" xlink:href="ptct-20200630.xsd#ptct_ConsiderationForAssetAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_ConsiderationForAssetAcquisitions" xlink:to="lab_ptct_ConsiderationForAssetAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_fa24a3ad-55b3-4f21-b66d-5f9228dd0b7f_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_90c61094-64c6-4804-bfc0-176dd8a5111d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued shares (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_7c066720-2047-4914-b808-7856f46be490_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_af17c882-617d-48a3-a8be-67069c28c1c1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentHoldingsTable_a5ea6f8a-ce35-4dc9-91b7-94321903ed26_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentHoldingsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Holdings [Table]</link:label>
    <link:label id="lab_us-gaap_InvestmentHoldingsTable_label_en-US" xlink:label="lab_us-gaap_InvestmentHoldingsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Holdings [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentHoldingsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentHoldingsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentHoldingsTable" xlink:to="lab_us-gaap_InvestmentHoldingsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_03706672-2449-48b1-b7bd-4dc2bbf81a14_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_3f9058e3-0047-47d5-a101-b15f87f12316_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of convertible notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c74110bc-907f-4df0-93c7-d59ff125bc37_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the beginning of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c16bc010-ba92-46fa-8d9c-b43a7a3c597c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_b1fd0e01-e7a3-4656-b5b2-a3f6e74b1f53_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_18cebeb2-e212-465a-becf-5ebb1cc8b1f5_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_81e7a920-99ef-4d1d-b376-a9716c9ad36a_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_d9ed2e72-8a04-4566-be61-9492748e5f1b_totalLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_cbd491c3-a84b-4a88-8f65-c6d5ebf26938_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of changes in the fair value of the Company's Level 3 valuation for warrant liability and SARs liability</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_fe7e412c-6eeb-4f08-9d9a-b52c776ee9e3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_c96803f5-64f4-4727-8464-43391b24c786_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_SettlementOfDeferredAndContingentConsideration_7ee42925-76d0-41fa-bc50-2a214e59e169_terseLabel_en-US" xlink:label="lab_ptct_SettlementOfDeferredAndContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement of deferred and contingent consideration</link:label>
    <link:label id="lab_ptct_SettlementOfDeferredAndContingentConsideration_label_en-US" xlink:label="lab_ptct_SettlementOfDeferredAndContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Of Deferred And Contingent Consideration</link:label>
    <link:label id="lab_ptct_SettlementOfDeferredAndContingentConsideration_documentation_en-US" xlink:label="lab_ptct_SettlementOfDeferredAndContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Of Deferred And Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_SettlementOfDeferredAndContingentConsideration" xlink:href="ptct-20200630.xsd#ptct_SettlementOfDeferredAndContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_SettlementOfDeferredAndContingentConsideration" xlink:to="lab_ptct_SettlementOfDeferredAndContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_30371cf6-107a-4344-a77c-89831510df19_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_eaffbac2-70d4-456e-b12a-b8cc9677a8c8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1ad724d5-d976-47b5-a7e3-868be20ee555_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_38a7f7f0-3aa2-429b-8a72-7abac221f69e_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_AssetAcquisitionResearchAndDevelopmentExpense_5eb036be-19ea-45be-aaa1-5bf4756e9010_terseLabel_en-US" xlink:label="lab_ptct_AssetAcquisitionResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, research and development expense</link:label>
    <link:label id="lab_ptct_AssetAcquisitionResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_ptct_AssetAcquisitionResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Research And Development Expense</link:label>
    <link:label id="lab_ptct_AssetAcquisitionResearchAndDevelopmentExpense_documentation_en-US" xlink:label="lab_ptct_AssetAcquisitionResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Research And Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AssetAcquisitionResearchAndDevelopmentExpense" xlink:href="ptct-20200630.xsd#ptct_AssetAcquisitionResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_AssetAcquisitionResearchAndDevelopmentExpense" xlink:to="lab_ptct_AssetAcquisitionResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_1dbad3ea-a30d-4c62-83cb-b49567f989af_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2f7f5040-8b41-4298-a864-be5bdc98348d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_8c2a0bac-33ef-4d83-b342-b7bf611f74da_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with an employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f795d5c9-f879-4923-af14-fa0d305914f8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock related to equity offering (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_0d1d41e2-d4df-4a4d-81d1-d4d2ae5ae0ec_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_dd8b8d0a-24bb-4daf-8e6e-0e69e24cc489_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested or Expected to vest at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member_ed671b1b-7076-476d-91b8-65c739c9d3ce_terseLabel_en-US" xlink:label="lab_ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption on or after August 20, 2018</link:label>
    <link:label id="lab_ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member_label_en-US" xlink:label="lab_ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Conversion Period On Or After August202018 [Member]</link:label>
    <link:label id="lab_ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member_documentation_en-US" xlink:label="lab_ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the debt instrument redemption period on or after August 20, 2018.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member" xlink:href="ptct-20200630.xsd#ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member" xlink:to="lab_ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_PaymentsForAssetAcquisitionsUpfrontPayment_e71a9c96-e3f4-4e90-981a-9eec352e1855_terseLabel_en-US" xlink:label="lab_ptct_PaymentsForAssetAcquisitionsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for asset acquisitions, upfront payment</link:label>
    <link:label id="lab_ptct_PaymentsForAssetAcquisitionsUpfrontPayment_label_en-US" xlink:label="lab_ptct_PaymentsForAssetAcquisitionsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Asset Acquisitions, Upfront Payment</link:label>
    <link:label id="lab_ptct_PaymentsForAssetAcquisitionsUpfrontPayment_documentation_en-US" xlink:label="lab_ptct_PaymentsForAssetAcquisitionsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Asset Acquisitions, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_PaymentsForAssetAcquisitionsUpfrontPayment" xlink:href="ptct-20200630.xsd#ptct_PaymentsForAssetAcquisitionsUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_PaymentsForAssetAcquisitionsUpfrontPayment" xlink:to="lab_ptct_PaymentsForAssetAcquisitionsUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_e6d8f0f1-b322-4988-9673-699446ea43dc_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested or Expected to vest at the end of the period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_NumberOfOperatingLeases_25ea2dce-24bb-4309-8455-c821d674d73b_terseLabel_en-US" xlink:label="lab_ptct_NumberOfOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating leases</link:label>
    <link:label id="lab_ptct_NumberOfOperatingLeases_label_en-US" xlink:label="lab_ptct_NumberOfOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Operating Leases</link:label>
    <link:label id="lab_ptct_NumberOfOperatingLeases_documentation_en-US" xlink:label="lab_ptct_NumberOfOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Operating Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_NumberOfOperatingLeases" xlink:href="ptct-20200630.xsd#ptct_NumberOfOperatingLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_NumberOfOperatingLeases" xlink:to="lab_ptct_NumberOfOperatingLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_88f95d4c-1eca-4fe8-b161-46f9837c6ac5_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone_035449f7-f520-49ee-b0d8-2f84a8df7251_terseLabel_en-US" xlink:label="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net sales amount</link:label>
    <link:label id="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone_label_en-US" xlink:label="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Liability, Milestone, Potential Achievements, Net Sales Milestone</link:label>
    <link:label id="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone_documentation_en-US" xlink:label="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Liability, Milestone, Potential Achievements, Net Sales Milestone And Regulatory Approval</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone" xlink:href="ptct-20200630.xsd#ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone" xlink:to="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_LoanAdvance_e21ef5f2-6442-46b7-8458-c77df60314db_terseLabel_en-US" xlink:label="lab_ptct_LoanAdvance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan advance</link:label>
    <link:label id="lab_ptct_LoanAdvance_label_en-US" xlink:label="lab_ptct_LoanAdvance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Advance</link:label>
    <link:label id="lab_ptct_LoanAdvance_documentation_en-US" xlink:label="lab_ptct_LoanAdvance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Advance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_LoanAdvance" xlink:href="ptct-20200630.xsd#ptct_LoanAdvance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_LoanAdvance" xlink:to="lab_ptct_LoanAdvance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncollaborativeArrangementTransactionsMember_f613bde7-f2b5-4818-8db8-a447c96a48a7_terseLabel_en-US" xlink:label="lab_us-gaap_NoncollaborativeArrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-collaborative Arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_NoncollaborativeArrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_NoncollaborativeArrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangement Other than Collaborative [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncollaborativeArrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncollaborativeArrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncollaborativeArrangementTransactionsMember" xlink:to="lab_us-gaap_NoncollaborativeArrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_416daf49-fbce-4149-80c9-d0f336a7b8a8_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_92d1f342-03aa-4079-b226-c023d4ec4dbe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets and liabilities measured at fair value on recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_c8b16d9a-0a19-42f3-a7aa-02451432dc83_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementAxis_b06e0291-e8e2-4438-8cac-ea26e355a603_terseLabel_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement [Axis]</link:label>
    <link:label id="lab_srt_RestatementAxis_label_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_8c8c1c5e-c4a4-449c-bec8-b43f2a520a37_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_a006d586-b619-434f-a8d1-d6c5653e6382_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value. Authorized 125,000,000 shares; issued and outstanding&#160;67,240,679 shares at June 30, 2020. Authorized 125,000,000 shares; issued and&#160;outstanding 61,935,870 shares at December&#160;31, 2019.</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_13a99eae-8968-4f8c-8d67-701756930237_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_GainOfSettlementDevelopmentMilestones_185bda62-f26c-4f16-bcd7-4632ae340ee0_terseLabel_en-US" xlink:label="lab_ptct_GainOfSettlementDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Of Settlement, Development Milestones</link:label>
    <link:label id="lab_ptct_GainOfSettlementDevelopmentMilestones_label_en-US" xlink:label="lab_ptct_GainOfSettlementDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Of Settlement, Development Milestones</link:label>
    <link:label id="lab_ptct_GainOfSettlementDevelopmentMilestones_documentation_en-US" xlink:label="lab_ptct_GainOfSettlementDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Of Settlement, Development Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_GainOfSettlementDevelopmentMilestones" xlink:href="ptct-20200630.xsd#ptct_GainOfSettlementDevelopmentMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_GainOfSettlementDevelopmentMilestones" xlink:to="lab_ptct_GainOfSettlementDevelopmentMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_9dd18eab-b562-4aa6-baa7-420b3cdcf651_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of marketable securities on the balance sheet</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_UpfrontLicensingFee_8b8ef76a-72bb-40d5-a0e1-b7c8dfd4d50c_terseLabel_en-US" xlink:label="lab_ptct_UpfrontLicensingFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront licensing fee</link:label>
    <link:label id="lab_ptct_UpfrontLicensingFee_label_en-US" xlink:label="lab_ptct_UpfrontLicensingFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Licensing Fee</link:label>
    <link:label id="lab_ptct_UpfrontLicensingFee_documentation_en-US" xlink:label="lab_ptct_UpfrontLicensingFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Licensing Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_UpfrontLicensingFee" xlink:href="ptct-20200630.xsd#ptct_UpfrontLicensingFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_UpfrontLicensingFee" xlink:to="lab_ptct_UpfrontLicensingFee" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_SaleOfStockWeightedAveragePricePerShare_31ebf3f4-c4d1-4299-a324-77e93797ef2d_terseLabel_en-US" xlink:label="lab_ptct_SaleOfStockWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, weighted average price per share (in USD per share)</link:label>
    <link:label id="lab_ptct_SaleOfStockWeightedAveragePricePerShare_label_en-US" xlink:label="lab_ptct_SaleOfStockWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Weighted Average Price per Share</link:label>
    <link:label id="lab_ptct_SaleOfStockWeightedAveragePricePerShare_documentation_en-US" xlink:label="lab_ptct_SaleOfStockWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Weighted Average Price per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_SaleOfStockWeightedAveragePricePerShare" xlink:href="ptct-20200630.xsd#ptct_SaleOfStockWeightedAveragePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_SaleOfStockWeightedAveragePricePerShare" xlink:to="lab_ptct_SaleOfStockWeightedAveragePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_544122d1-7a03-4ee1-abef-9ab5bc0696dd_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology_783dd6e8-3f4e-4ca0-a635-94b21bd26c55_terseLabel_en-US" xlink:label="lab_ptct_CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangements research period for applying discovery technology</link:label>
    <link:label id="lab_ptct_CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology_label_en-US" xlink:label="lab_ptct_CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements Research Period for Applying Discovery Technology</link:label>
    <link:label id="lab_ptct_CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology_documentation_en-US" xlink:label="lab_ptct_CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the research period for applying discovery technology.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology" xlink:href="ptct-20200630.xsd#ptct_CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology" xlink:to="lab_ptct_CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_39dc3238-4f18-4f90-b034-3a6b98db10c1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_612bca59-d50c-42e2-a739-8ae04ac87c82_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_aa6ecee8-5677-41e5-a594-aeb4cb3f3ada_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_SharestoissueunderRightsExchangeAgreement_b07bc415-675e-4ed4-b35b-e37d736112c9_terseLabel_en-US" xlink:label="lab_ptct_SharestoissueunderRightsExchangeAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares to issue under Rights Exchange Agreement</link:label>
    <link:label id="lab_ptct_SharestoissueunderRightsExchangeAgreement_label_en-US" xlink:label="lab_ptct_SharestoissueunderRightsExchangeAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares to issue under Rights Exchange Agreement</link:label>
    <link:label id="lab_ptct_SharestoissueunderRightsExchangeAgreement_documentation_en-US" xlink:label="lab_ptct_SharestoissueunderRightsExchangeAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares to issue under Rights Exchange Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_SharestoissueunderRightsExchangeAgreement" xlink:href="ptct-20200630.xsd#ptct_SharestoissueunderRightsExchangeAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_SharestoissueunderRightsExchangeAgreement" xlink:to="lab_ptct_SharestoissueunderRightsExchangeAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_a4eb76e6-342a-421e-90a2-370e58303d7b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9d8517f9-aeac-4545-ab2d-1a4481763312_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, and restricted cash end of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentHoldingsLineItems_3a8f37c6-e947-4462-bd30-4adb98793bee_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentHoldingsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities on the balance sheet</link:label>
    <link:label id="lab_us-gaap_InvestmentHoldingsLineItems_label_en-US" xlink:label="lab_us-gaap_InvestmentHoldingsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Holdings [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentHoldingsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentHoldingsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentHoldingsLineItems" xlink:to="lab_us-gaap_InvestmentHoldingsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_98df72c1-b5a1-4a5e-b5ee-8ff9c7bfe15a_negatedLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized foreign currency transaction (gains) losses, net</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_RestrictedStockAndRestrictedStockUnitsMember_63956a7e-a93c-418a-be17-3e8a6a55ae1d_terseLabel_en-US" xlink:label="lab_ptct_RestrictedStockAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted stock awards and units</link:label>
    <link:label id="lab_ptct_RestrictedStockAndRestrictedStockUnitsMember_label_en-US" xlink:label="lab_ptct_RestrictedStockAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock And Restricted Stock Units [Member]</link:label>
    <link:label id="lab_ptct_RestrictedStockAndRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_ptct_RestrictedStockAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Restricted Stock and Restricted Stock Units (RSUs).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_RestrictedStockAndRestrictedStockUnitsMember" xlink:href="ptct-20200630.xsd#ptct_RestrictedStockAndRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_RestrictedStockAndRestrictedStockUnitsMember" xlink:to="lab_ptct_RestrictedStockAndRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_02a57b69-dcd8-42e5-922f-353cd2858edc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease ROU asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e81b036e-d949-4d1a-97c0-6a535f2c80d6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_82406b08-b65f-4733-b6e9-cdb8d1d28be3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_73a3228e-6de4-4c4d-980a-c97b8deef490_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date&#160;Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_0c0019af-8c49-439f-b0c6-e7103a00cac4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_80797c42-06a0-4b5a-849d-c4a584f40536_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of equity investment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_395d9c4d-97ab-42d6-8aa5-475151b21363_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_a2deb138-1829-4de2-9f03-050f36161a74_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_d9cc8a87-a7a0-4034-8ab7-38b698a5e30c_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the end of the period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_eb9a3315-870c-4c22-98db-0b0d27e33d36_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fd9babf3-f56c-4d65-bc27-77f315cc9c86_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_516089ac-ae23-46c5-85d9-a3dfb2203d34_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_LeaseArea_94f1ded3-f50b-4e4b-96f2-dbb5a46c681a_terseLabel_en-US" xlink:label="lab_ptct_LeaseArea" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Area</link:label>
    <link:label id="lab_ptct_LeaseArea_label_en-US" xlink:label="lab_ptct_LeaseArea" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Area</link:label>
    <link:label id="lab_ptct_LeaseArea_documentation_en-US" xlink:label="lab_ptct_LeaseArea" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Area</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_LeaseArea" xlink:href="ptct-20200630.xsd#ptct_LeaseArea"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_LeaseArea" xlink:to="lab_ptct_LeaseArea" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_eda9d727-0045-461f-bf41-069d546eff55_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activity</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_30ef7c4e-1582-46ac-89ea-fb974731a73a_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_62d586b1-b17f-4d95-ab22-deaf83ef966a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_d57d9399-7ac8-4ed9-99ac-e144f5d5f259_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of discounts on investments, net</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_b3c5609b-1474-48d4-ab0c-f5a6b2717a9d_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_c3d11959-513e-4bb9-b1c2-2491805e2c88_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_a8bc8685-74d4-4c92-b381-d5ff84e8984e_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_15ff31a2-f511-4820-8276-3a1950f1b1b3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of financial instruments and marketable securities</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_28c8e77f-51e8-402a-bf45-757e93e8de10_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining amortization period</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaidInKindInterest_a4133bcd-569f-4763-90c2-8cace9dd1dcd_terseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_label_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest" xlink:to="lab_us-gaap_PaidInKindInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_5ac36e26-2a1f-4cc4-a4c1-903fa70cad6b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_09e5c8db-87de-4614-b4da-631ae553a0cc_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_ContingentLiabilityCancellationAndForfeitureMilestonePotentialAchievementsPriorityReviewVoucherAmount_4d09c2ca-2ec7-4bd3-859c-49509efc78ea_terseLabel_en-US" xlink:label="lab_ptct_ContingentLiabilityCancellationAndForfeitureMilestonePotentialAchievementsPriorityReviewVoucherAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Liability cancellation and forfeiture, Milestone, Potential Achievements, Priority Review Voucher Amount</link:label>
    <link:label id="lab_ptct_ContingentLiabilityCancellationAndForfeitureMilestonePotentialAchievementsPriorityReviewVoucherAmount_label_en-US" xlink:label="lab_ptct_ContingentLiabilityCancellationAndForfeitureMilestonePotentialAchievementsPriorityReviewVoucherAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Liability cancellation and forfeiture, Milestone, Potential Achievements, Priority Review Voucher Amount</link:label>
    <link:label id="lab_ptct_ContingentLiabilityCancellationAndForfeitureMilestonePotentialAchievementsPriorityReviewVoucherAmount_documentation_en-US" xlink:label="lab_ptct_ContingentLiabilityCancellationAndForfeitureMilestonePotentialAchievementsPriorityReviewVoucherAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Liability cancellation and forfeiture, Milestone, Potential Achievements, Priority Review Voucher Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ContingentLiabilityCancellationAndForfeitureMilestonePotentialAchievementsPriorityReviewVoucherAmount" xlink:href="ptct-20200630.xsd#ptct_ContingentLiabilityCancellationAndForfeitureMilestonePotentialAchievementsPriorityReviewVoucherAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_ContingentLiabilityCancellationAndForfeitureMilestonePotentialAchievementsPriorityReviewVoucherAmount" xlink:to="lab_ptct_ContingentLiabilityCancellationAndForfeitureMilestonePotentialAchievementsPriorityReviewVoucherAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_f21b8e5d-e983-46ab-bced-045a055f411c_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_FifthAnniversaryMember_3bd31136-6a4a-44ee-9a32-1c3058f0eaa6_terseLabel_en-US" xlink:label="lab_ptct_FifthAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fifth Anniversary</link:label>
    <link:label id="lab_ptct_FifthAnniversaryMember_label_en-US" xlink:label="lab_ptct_FifthAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fifth Anniversary [Member]</link:label>
    <link:label id="lab_ptct_FifthAnniversaryMember_documentation_en-US" xlink:label="lab_ptct_FifthAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fifth Anniversary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_FifthAnniversaryMember" xlink:href="ptct-20200630.xsd#ptct_FifthAnniversaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_FifthAnniversaryMember" xlink:to="lab_ptct_FifthAnniversaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_3e67dc96-ad49-4d59-963a-f81ecccb3caf_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_MountainviewMember_623c8d93-7aa2-4370-9f5a-63707725ac86_terseLabel_en-US" xlink:label="lab_ptct_MountainviewMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mountainview</link:label>
    <link:label id="lab_ptct_MountainviewMember_label_en-US" xlink:label="lab_ptct_MountainviewMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mountainview [Member]</link:label>
    <link:label id="lab_ptct_MountainviewMember_documentation_en-US" xlink:label="lab_ptct_MountainviewMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mountainview</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_MountainviewMember" xlink:href="ptct-20200630.xsd#ptct_MountainviewMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_MountainviewMember" xlink:to="lab_ptct_MountainviewMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter_fc2fb78e-ad30-4793-a6f9-289d3b070ec3_terseLabel_en-US" xlink:label="lab_ptct_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024 and thereafter</link:label>
    <link:label id="lab_ptct_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter_label_en-US" xlink:label="lab_ptct_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense Year Five And Thereafter</link:label>
    <link:label id="lab_ptct_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter_documentation_en-US" xlink:label="lab_ptct_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense Year Five And Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter" xlink:href="ptct-20200630.xsd#ptct_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter" xlink:to="lab_ptct_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_d0b8f390-0127-40d1-bcc0-1aac874d84c8_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsRightsExchangeSettlement_223583c3-8ef1-4da6-a505-62bcb06ea81b_negatedTerseLabel_en-US" xlink:label="lab_ptct_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsRightsExchangeSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rights Exchange settlement</link:label>
    <link:label id="lab_ptct_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsRightsExchangeSettlement_label_en-US" xlink:label="lab_ptct_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsRightsExchangeSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements, Rights Exchange Settlement</link:label>
    <link:label id="lab_ptct_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsRightsExchangeSettlement_documentation_en-US" xlink:label="lab_ptct_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsRightsExchangeSettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements, Rights Exchange Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsRightsExchangeSettlement" xlink:href="ptct-20200630.xsd#ptct_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsRightsExchangeSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsRightsExchangeSettlement" xlink:to="lab_ptct_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsRightsExchangeSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_b23c8112-4a51-4555-b2b9-c4dae47fb24c_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_bc2c3e88-818a-413c-9e5b-99865cfed924_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_ed8ebc40-7567-4199-bf71-16597645e5cd_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_801f7298-5f92-4fcc-b721-744c249daaf7_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts receivable</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_face7d88-7dbf-4cc9-8554-0faa04320e1a_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_866206ba-ce42-4e5c-84bb-acb0e709e25d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shares excluded from calculation (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_StockAppreciationRightsLiabilityOutstanding_c9417c08-2780-4f3f-b9cd-ca6efb575ada_terseLabel_en-US" xlink:label="lab_ptct_StockAppreciationRightsLiabilityOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock appreciation rights liability</link:label>
    <link:label id="lab_ptct_StockAppreciationRightsLiabilityOutstanding_label_en-US" xlink:label="lab_ptct_StockAppreciationRightsLiabilityOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights Liability Outstanding</link:label>
    <link:label id="lab_ptct_StockAppreciationRightsLiabilityOutstanding_documentation_en-US" xlink:label="lab_ptct_StockAppreciationRightsLiabilityOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount of outstanding stock appreciation rights liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_StockAppreciationRightsLiabilityOutstanding" xlink:href="ptct-20200630.xsd#ptct_StockAppreciationRightsLiabilityOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_StockAppreciationRightsLiabilityOutstanding" xlink:to="lab_ptct_StockAppreciationRightsLiabilityOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_d86617cd-fc91-45ff-b814-5f97f964e3cc_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseArrangementTypeDomain_2e6c7e77-9c20-459a-8674-92f57530db3f_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseArrangementTypeDomain_label_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain" xlink:to="lab_us-gaap_LeaseArrangementTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_a9a4f41d-951a-4cbd-b95e-918ab2d97204_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_e072639d-a77f-410b-ae63-3c93e13d4771_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_0acbebb2-d8f8-4b59-8d6a-7659086702b6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining contractual life of the convertible notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Remaining Discount Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a1796c14-0d41-4a2d-b1ed-0bea1eca9384_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number&#160;of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_afe3101f-c500-4de1-8b87-0400d96f8ba1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of marketable securities accounted for as available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_TheCampusMember_aa3980ba-4800-4d18-b4be-d6ba101f19bd_terseLabel_en-US" xlink:label="lab_ptct_TheCampusMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Campus</link:label>
    <link:label id="lab_ptct_TheCampusMember_label_en-US" xlink:label="lab_ptct_TheCampusMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Campus [Member]</link:label>
    <link:label id="lab_ptct_TheCampusMember_documentation_en-US" xlink:label="lab_ptct_TheCampusMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Campus [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_TheCampusMember" xlink:href="ptct-20200630.xsd#ptct_TheCampusMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_TheCampusMember" xlink:to="lab_ptct_TheCampusMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_4a2e70e3-12d2-49f3-8e36-a39b5985f4e5_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_dc975577-6dcb-441d-8257-293939ed5803_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_365a884b-ab07-4b42-99cb-311f9827e49c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_713bd2b2-b256-453c-bb7b-361ff2b59107_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_83e3ddbe-1f9f-49b3-958d-4a5346189cc9_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_74e61a10-78aa-462a-990f-4d4a75165640_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_818cb247-aa85-417e-b3e6-7f1ff75884fd_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_e6a4b1c1-7020-4bc5-b47e-830d3125b216_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing cash flows from finance lease</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_PercentageofSalesforRoyaltiesMember_94448099-3ac0-44da-9fb4-0a4cf8f2a638_terseLabel_en-US" xlink:label="lab_ptct_PercentageofSalesforRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Sales for Royalties</link:label>
    <link:label id="lab_ptct_PercentageofSalesforRoyaltiesMember_label_en-US" xlink:label="lab_ptct_PercentageofSalesforRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Sales for Royalties [Member]</link:label>
    <link:label id="lab_ptct_PercentageofSalesforRoyaltiesMember_documentation_en-US" xlink:label="lab_ptct_PercentageofSalesforRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Sales for Royalties [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_PercentageofSalesforRoyaltiesMember" xlink:href="ptct-20200630.xsd#ptct_PercentageofSalesforRoyaltiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_PercentageofSalesforRoyaltiesMember" xlink:to="lab_ptct_PercentageofSalesforRoyaltiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue_76784bff-f5be-4cec-863e-92cfa723fbc8_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Unrealized Loss Position, Fair Value</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue_2d2da590-a937-45d1-af70-3c9975bbe3a3_totalLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Unrealized Loss Position, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter_0d1985fb-4139-4c38-9139-29fc24c0bec0_terseLabel_en-US" xlink:label="lab_ptct_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024 and thereafter</link:label>
    <link:label id="lab_ptct_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter_label_en-US" xlink:label="lab_ptct_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five and Thereafter</link:label>
    <link:label id="lab_ptct_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter_documentation_en-US" xlink:label="lab_ptct_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five and Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter" xlink:href="ptct-20200630.xsd#ptct_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter" xlink:to="lab_ptct_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_24a6e532-b7b3-4972-a3b7-7a7b19772682_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale and redemption of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract_c491658b-ad17-4678-846f-40c47cd909a8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Nonrecurring Value Measurement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract" xlink:to="lab_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_df9ae2f9-c921-4ebc-9d32-30adafcc3f26_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_0e8ae10b-87de-4696-9582-bc6adbaf254c_terseLabel_en-US" xlink:label="lab_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Net Sales Milestones and Royalties [Member]</link:label>
    <link:label id="lab_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_label_en-US" xlink:label="lab_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Net Sales Milestones and Royalties [Member]</link:label>
    <link:label id="lab_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_documentation_en-US" xlink:label="lab_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Net Sales Milestones and Royalties [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember" xlink:href="ptct-20200630.xsd#ptct_LiabilityNetSalesMilestonesandRoyaltiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember" xlink:to="lab_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_A2020inducementstockincentiveplanMember_0681215f-5930-4aca-a34b-ce44877ef298_terseLabel_en-US" xlink:label="lab_ptct_A2020inducementstockincentiveplanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 inducement stock incentive plan [Member]</link:label>
    <link:label id="lab_ptct_A2020inducementstockincentiveplanMember_label_en-US" xlink:label="lab_ptct_A2020inducementstockincentiveplanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 inducement stock incentive plan [Member]</link:label>
    <link:label id="lab_ptct_A2020inducementstockincentiveplanMember_documentation_en-US" xlink:label="lab_ptct_A2020inducementstockincentiveplanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 inducement stock incentive plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_A2020inducementstockincentiveplanMember" xlink:href="ptct-20200630.xsd#ptct_A2020inducementstockincentiveplanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_A2020inducementstockincentiveplanMember" xlink:to="lab_ptct_A2020inducementstockincentiveplanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_SalesAllowanceAndOtherRelatedCosts_b606903f-87e3-4b8d-837e-d29d0e80c30c_terseLabel_en-US" xlink:label="lab_ptct_SalesAllowanceAndOtherRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales allowance and other costs</link:label>
    <link:label id="lab_ptct_SalesAllowanceAndOtherRelatedCosts_label_en-US" xlink:label="lab_ptct_SalesAllowanceAndOtherRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Allowance And Other Related Costs</link:label>
    <link:label id="lab_ptct_SalesAllowanceAndOtherRelatedCosts_documentation_en-US" xlink:label="lab_ptct_SalesAllowanceAndOtherRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Allowance And Other Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_SalesAllowanceAndOtherRelatedCosts" xlink:href="ptct-20200630.xsd#ptct_SalesAllowanceAndOtherRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_SalesAllowanceAndOtherRelatedCosts" xlink:to="lab_ptct_SalesAllowanceAndOtherRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_fb0a8b1f-5d5c-4c6c-b302-afee64e77111_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_RevenueRecognitionMilestonePotentialAchievements_50b3ae84-6432-4e3a-b711-04aa6ae90aa2_terseLabel_en-US" xlink:label="lab_ptct_RevenueRecognitionMilestonePotentialAchievements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognition, milestone, potential achievements</link:label>
    <link:label id="lab_ptct_RevenueRecognitionMilestonePotentialAchievements_label_en-US" xlink:label="lab_ptct_RevenueRecognitionMilestonePotentialAchievements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone, Potential Achievements</link:label>
    <link:label id="lab_ptct_RevenueRecognitionMilestonePotentialAchievements_documentation_en-US" xlink:label="lab_ptct_RevenueRecognitionMilestonePotentialAchievements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone, Potential Achievements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_RevenueRecognitionMilestonePotentialAchievements" xlink:href="ptct-20200630.xsd#ptct_RevenueRecognitionMilestonePotentialAchievements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_RevenueRecognitionMilestonePotentialAchievements" xlink:to="lab_ptct_RevenueRecognitionMilestonePotentialAchievements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_c3ede874-8512-48e7-b991-ffb67417cef5_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod_8e4058fb-463c-4e17-ae86-7ffe60759f19_terseLabel_en-US" xlink:label="lab_ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading day period</link:label>
    <link:label id="lab_ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod_label_en-US" xlink:label="lab_ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Interest Issued Or Issuable, Trading Day Period</link:label>
    <link:label id="lab_ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod_documentation_en-US" xlink:label="lab_ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Interest Issued Or Issuable, Trading Day Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod" xlink:href="ptct-20200630.xsd#ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod" xlink:to="lab_ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_6c8cb026-a68d-4a38-b72a-05e18fa6faa3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Ownership Plan (ESOP) Name [Axis]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Ownership Plan (ESOP) Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_eeaf9a1f-4ba7-46b7-b7ab-16098cd39e45_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>ptct-20200630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:a91ddaa9-e688-473f-b70e-08f6db5630cb,g:e05438c1-8a2e-4af1-b39d-a16533f5ad44-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ptcbio.com/role/Cover" xlink:type="simple" xlink:href="ptct-20200630.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_ff4baa13-d179-43aa-b9dd-79350e963045" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_6d4cfe10-b35b-414c-911b-9c6f5364a2d7" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff4baa13-d179-43aa-b9dd-79350e963045" xlink:to="loc_dei_DocumentType_6d4cfe10-b35b-414c-911b-9c6f5364a2d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_bc425f70-2b74-436c-bfe1-636e56877285" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff4baa13-d179-43aa-b9dd-79350e963045" xlink:to="loc_dei_DocumentQuarterlyReport_bc425f70-2b74-436c-bfe1-636e56877285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_3a662775-b8ad-4fe3-9ee6-fea591d643f0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff4baa13-d179-43aa-b9dd-79350e963045" xlink:to="loc_dei_DocumentPeriodEndDate_3a662775-b8ad-4fe3-9ee6-fea591d643f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_40912cb6-96a0-45d0-a7d6-795fff1914e4" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff4baa13-d179-43aa-b9dd-79350e963045" xlink:to="loc_dei_DocumentTransitionReport_40912cb6-96a0-45d0-a7d6-795fff1914e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_79a13a95-9a02-4a1f-a586-f9e05daec03f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff4baa13-d179-43aa-b9dd-79350e963045" xlink:to="loc_dei_EntityFileNumber_79a13a95-9a02-4a1f-a586-f9e05daec03f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_6a6177a9-073f-430e-be5f-dbc904bea633" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff4baa13-d179-43aa-b9dd-79350e963045" xlink:to="loc_dei_EntityRegistrantName_6a6177a9-073f-430e-be5f-dbc904bea633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_2a8496ff-880d-4131-890d-da931554fb02" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff4baa13-d179-43aa-b9dd-79350e963045" xlink:to="loc_dei_EntityIncorporationStateCountryCode_2a8496ff-880d-4131-890d-da931554fb02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_40c765e2-ccd1-4b46-9f17-d23f4e638e62" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff4baa13-d179-43aa-b9dd-79350e963045" xlink:to="loc_dei_EntityTaxIdentificationNumber_40c765e2-ccd1-4b46-9f17-d23f4e638e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_50481d35-8147-468b-9858-4e13f8de4cc5" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff4baa13-d179-43aa-b9dd-79350e963045" xlink:to="loc_dei_EntityAddressAddressLine1_50481d35-8147-468b-9858-4e13f8de4cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_26e947c8-4d3a-47f6-8b84-8942f3e295e6" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff4baa13-d179-43aa-b9dd-79350e963045" xlink:to="loc_dei_EntityAddressCityOrTown_26e947c8-4d3a-47f6-8b84-8942f3e295e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_95b52876-45a2-4bf5-8253-5b6133e8131c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff4baa13-d179-43aa-b9dd-79350e963045" xlink:to="loc_dei_EntityAddressStateOrProvince_95b52876-45a2-4bf5-8253-5b6133e8131c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_32f7a998-03f0-48a6-9927-2c420e8746f8" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff4baa13-d179-43aa-b9dd-79350e963045" xlink:to="loc_dei_EntityAddressPostalZipCode_32f7a998-03f0-48a6-9927-2c420e8746f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_ea4ee9da-42dc-4a32-b66b-334377b1ba9d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff4baa13-d179-43aa-b9dd-79350e963045" xlink:to="loc_dei_CityAreaCode_ea4ee9da-42dc-4a32-b66b-334377b1ba9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_68b5aa23-5148-441c-bb0a-600f9d506bce" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff4baa13-d179-43aa-b9dd-79350e963045" xlink:to="loc_dei_LocalPhoneNumber_68b5aa23-5148-441c-bb0a-600f9d506bce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_08f4f115-1a0e-463a-9786-88f34ffaf048" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff4baa13-d179-43aa-b9dd-79350e963045" xlink:to="loc_dei_EntityCurrentReportingStatus_08f4f115-1a0e-463a-9786-88f34ffaf048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_45e4bffd-53aa-4cba-a9b5-0b9b727e8779" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff4baa13-d179-43aa-b9dd-79350e963045" xlink:to="loc_dei_EntityInteractiveDataCurrent_45e4bffd-53aa-4cba-a9b5-0b9b727e8779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_4c5f1517-c3ae-491b-95a2-3e91befc4fa1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff4baa13-d179-43aa-b9dd-79350e963045" xlink:to="loc_dei_EntityFilerCategory_4c5f1517-c3ae-491b-95a2-3e91befc4fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_9cb5005d-7a8a-49b4-82df-6a66304b5b44" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff4baa13-d179-43aa-b9dd-79350e963045" xlink:to="loc_dei_EntitySmallBusiness_9cb5005d-7a8a-49b4-82df-6a66304b5b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_2fa2d7ed-3fd7-4be2-b695-7ec6ab058e0a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff4baa13-d179-43aa-b9dd-79350e963045" xlink:to="loc_dei_EntityEmergingGrowthCompany_2fa2d7ed-3fd7-4be2-b695-7ec6ab058e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_85cdd09c-bc17-4c7f-bda0-acfe3f2e8ade" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff4baa13-d179-43aa-b9dd-79350e963045" xlink:to="loc_dei_EntityShellCompany_85cdd09c-bc17-4c7f-bda0-acfe3f2e8ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_56a5e50c-46a9-46ca-96f4-1ff63aa304f3" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff4baa13-d179-43aa-b9dd-79350e963045" xlink:to="loc_dei_Security12bTitle_56a5e50c-46a9-46ca-96f4-1ff63aa304f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_ebf22a39-2a49-40f4-b7cc-f05b70d0eb03" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff4baa13-d179-43aa-b9dd-79350e963045" xlink:to="loc_dei_TradingSymbol_ebf22a39-2a49-40f4-b7cc-f05b70d0eb03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_00e570c5-9021-4d11-a05b-5facf0b96fab" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff4baa13-d179-43aa-b9dd-79350e963045" xlink:to="loc_dei_SecurityExchangeName_00e570c5-9021-4d11-a05b-5facf0b96fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_2b49dd73-d690-40d8-bfba-fd6a02f08993" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff4baa13-d179-43aa-b9dd-79350e963045" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_2b49dd73-d690-40d8-bfba-fd6a02f08993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_295d5ef3-bd58-4af4-940e-1012c4d471c2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff4baa13-d179-43aa-b9dd-79350e963045" xlink:to="loc_dei_EntityCentralIndexKey_295d5ef3-bd58-4af4-940e-1012c4d471c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_7ed2ac2c-a856-45e9-a431-92bbabdb78d9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff4baa13-d179-43aa-b9dd-79350e963045" xlink:to="loc_dei_AmendmentFlag_7ed2ac2c-a856-45e9-a431-92bbabdb78d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_1dfa1a08-0956-47ba-8251-9f4859948600" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff4baa13-d179-43aa-b9dd-79350e963045" xlink:to="loc_dei_CurrentFiscalYearEndDate_1dfa1a08-0956-47ba-8251-9f4859948600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_21d78394-1f46-4f7e-b6f7-0ca6359a89d0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff4baa13-d179-43aa-b9dd-79350e963045" xlink:to="loc_dei_DocumentFiscalYearFocus_21d78394-1f46-4f7e-b6f7-0ca6359a89d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_a324f036-d72b-40ca-b7e0-b698f6866d9b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff4baa13-d179-43aa-b9dd-79350e963045" xlink:to="loc_dei_DocumentFiscalPeriodFocus_a324f036-d72b-40ca-b7e0-b698f6866d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited" xlink:type="simple" xlink:href="ptct-20200630.xsd#ConsolidatedBalanceSheetsunaudited"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_f61abf0f-98f3-4c71-b455-7cfa40cfec3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_5d9add88-64a2-4697-889b-651a61679233" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f61abf0f-98f3-4c71-b455-7cfa40cfec3b" xlink:to="loc_us-gaap_AssetsAbstract_5d9add88-64a2-4697-889b-651a61679233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_b72196ef-9673-4feb-8c93-1c40ffc931f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5d9add88-64a2-4697-889b-651a61679233" xlink:to="loc_us-gaap_AssetsCurrentAbstract_b72196ef-9673-4feb-8c93-1c40ffc931f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bede36a9-0db2-447d-90df-5ac111cf338c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b72196ef-9673-4feb-8c93-1c40ffc931f5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bede36a9-0db2-447d-90df-5ac111cf338c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_3720bb28-b361-4c2f-8ee9-c81d6412d984" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b72196ef-9673-4feb-8c93-1c40ffc931f5" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_3720bb28-b361-4c2f-8ee9-c81d6412d984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_92651620-1e75-4281-af59-871f2b168693" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b72196ef-9673-4feb-8c93-1c40ffc931f5" xlink:to="loc_us-gaap_ReceivablesNetCurrent_92651620-1e75-4281-af59-871f2b168693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_deda8f1e-435b-4240-8c59-67968e613cd4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b72196ef-9673-4feb-8c93-1c40ffc931f5" xlink:to="loc_us-gaap_InventoryNet_deda8f1e-435b-4240-8c59-67968e613cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d9c4cf69-db2d-4151-b1c4-59843bc1bc5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b72196ef-9673-4feb-8c93-1c40ffc931f5" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d9c4cf69-db2d-4151-b1c4-59843bc1bc5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d1ad88fd-5cd9-49ab-8a8e-401c62cbd1a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b72196ef-9673-4feb-8c93-1c40ffc931f5" xlink:to="loc_us-gaap_AssetsCurrent_d1ad88fd-5cd9-49ab-8a8e-401c62cbd1a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9f65f468-ebca-48ed-89c9-e987f484a070" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5d9add88-64a2-4697-889b-651a61679233" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9f65f468-ebca-48ed-89c9-e987f484a070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c9a1d9a3-4a27-4f29-893e-0f23bcf9018c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5d9add88-64a2-4697-889b-651a61679233" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c9a1d9a3-4a27-4f29-893e-0f23bcf9018c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b1fd0e5b-927f-49a8-b871-9f4103307bf1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5d9add88-64a2-4697-889b-651a61679233" xlink:to="loc_us-gaap_Goodwill_b1fd0e5b-927f-49a8-b871-9f4103307bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DepositsAndOtherAssetsNoncurrent_bec4861e-b138-49ca-8499-fedacb450a2c" xlink:href="ptct-20200630.xsd#ptct_DepositsAndOtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5d9add88-64a2-4697-889b-651a61679233" xlink:to="loc_ptct_DepositsAndOtherAssetsNoncurrent_bec4861e-b138-49ca-8499-fedacb450a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_036c1dd3-1c74-49d7-be52-379a9e1e9b72" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5d9add88-64a2-4697-889b-651a61679233" xlink:to="loc_us-gaap_Assets_036c1dd3-1c74-49d7-be52-379a9e1e9b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_76bf26e9-29cf-45dd-9f07-037436bbc6fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f61abf0f-98f3-4c71-b455-7cfa40cfec3b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_76bf26e9-29cf-45dd-9f07-037436bbc6fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_231b1b00-4b4c-419f-8eac-c414d09a7c59" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_76bf26e9-29cf-45dd-9f07-037436bbc6fe" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_231b1b00-4b4c-419f-8eac-c414d09a7c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_f466e325-c43b-4e0d-b137-da969f09edf2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_231b1b00-4b4c-419f-8eac-c414d09a7c59" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_f466e325-c43b-4e0d-b137-da969f09edf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_30ab3422-e43e-4f4c-b06b-cf14494e40b9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_231b1b00-4b4c-419f-8eac-c414d09a7c59" xlink:to="loc_us-gaap_LongTermDebtCurrent_30ab3422-e43e-4f4c-b06b-cf14494e40b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f2abf6a5-dfa4-41db-8ad6-49ba9b4cba26" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_231b1b00-4b4c-419f-8eac-c414d09a7c59" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f2abf6a5-dfa4-41db-8ad6-49ba9b4cba26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_85f4fb93-50a4-4fc7-ae20-c130834e9f44" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_231b1b00-4b4c-419f-8eac-c414d09a7c59" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_85f4fb93-50a4-4fc7-ae20-c130834e9f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_3a0be985-3405-4285-9813-77a47c44d791" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_231b1b00-4b4c-419f-8eac-c414d09a7c59" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_3a0be985-3405-4285-9813-77a47c44d791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent_f1d9f0f9-82da-4f1a-835f-c1320c271ff6" xlink:href="ptct-20200630.xsd#ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_231b1b00-4b4c-419f-8eac-c414d09a7c59" xlink:to="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent_f1d9f0f9-82da-4f1a-835f-c1320c271ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7d6ff5b3-009f-4bf9-9e2b-b4a4523df025" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_231b1b00-4b4c-419f-8eac-c414d09a7c59" xlink:to="loc_us-gaap_LiabilitiesCurrent_7d6ff5b3-009f-4bf9-9e2b-b4a4523df025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_b28065c2-b031-4c48-8c1a-7e32781362c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_76bf26e9-29cf-45dd-9f07-037436bbc6fe" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_b28065c2-b031-4c48-8c1a-7e32781362c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_194aa980-8aea-4b92-8a36-73a9a69c278a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_76bf26e9-29cf-45dd-9f07-037436bbc6fe" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_194aa980-8aea-4b92-8a36-73a9a69c278a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_b79b0151-5a31-4900-9812-c7412781762b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_76bf26e9-29cf-45dd-9f07-037436bbc6fe" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_b79b0151-5a31-4900-9812-c7412781762b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_5e2f922e-5007-471d-9b57-9a5f40c53286" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_76bf26e9-29cf-45dd-9f07-037436bbc6fe" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_5e2f922e-5007-471d-9b57-9a5f40c53286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_b8f43e64-bff1-4570-8004-cc258f829774" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_76bf26e9-29cf-45dd-9f07-037436bbc6fe" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_b8f43e64-bff1-4570-8004-cc258f829774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_69d440e3-e876-4201-97ea-ea0944815125" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_76bf26e9-29cf-45dd-9f07-037436bbc6fe" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_69d440e3-e876-4201-97ea-ea0944815125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_1c1e2ba9-9416-47c9-8490-8385328f1458" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_76bf26e9-29cf-45dd-9f07-037436bbc6fe" xlink:to="loc_us-gaap_Liabilities_1c1e2ba9-9416-47c9-8490-8385328f1458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_47f27b27-4f09-40c2-8150-bef73446203a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_76bf26e9-29cf-45dd-9f07-037436bbc6fe" xlink:to="loc_us-gaap_StockholdersEquityAbstract_47f27b27-4f09-40c2-8150-bef73446203a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_181b3fca-3bf8-4f04-8c74-911373013a0e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_47f27b27-4f09-40c2-8150-bef73446203a" xlink:to="loc_us-gaap_CommonStockValue_181b3fca-3bf8-4f04-8c74-911373013a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_8dcf38c5-10b1-4535-a51d-21870033bc3e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_47f27b27-4f09-40c2-8150-bef73446203a" xlink:to="loc_us-gaap_AdditionalPaidInCapital_8dcf38c5-10b1-4535-a51d-21870033bc3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0f73d038-1e19-4a3a-8ce2-db0401efd13c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_47f27b27-4f09-40c2-8150-bef73446203a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0f73d038-1e19-4a3a-8ce2-db0401efd13c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_de99b8b9-d6bc-4d46-81e6-e30d840ed7c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_47f27b27-4f09-40c2-8150-bef73446203a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_de99b8b9-d6bc-4d46-81e6-e30d840ed7c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_459d72ca-ddf8-4ab7-bc92-e3126d8579af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_47f27b27-4f09-40c2-8150-bef73446203a" xlink:to="loc_us-gaap_StockholdersEquity_459d72ca-ddf8-4ab7-bc92-e3126d8579af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_8f37b670-73a7-427f-80f8-f2fc55696ba2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_76bf26e9-29cf-45dd-9f07-037436bbc6fe" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_8f37b670-73a7-427f-80f8-f2fc55696ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunauditedParenthetical" xlink:type="simple" xlink:href="ptct-20200630.xsd#ConsolidatedBalanceSheetsunauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c7c3c717-f5c9-4726-b9a3-3f134ea23a01" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_639e5e31-ec1f-48a5-92d6-65323f71f6c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c7c3c717-f5c9-4726-b9a3-3f134ea23a01" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_639e5e31-ec1f-48a5-92d6-65323f71f6c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_44abbbe5-2f10-4c90-9ea1-b164a2ff5c58" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c7c3c717-f5c9-4726-b9a3-3f134ea23a01" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_44abbbe5-2f10-4c90-9ea1-b164a2ff5c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_98d2149e-55f5-408e-9a16-99b257bb3317" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c7c3c717-f5c9-4726-b9a3-3f134ea23a01" xlink:to="loc_us-gaap_CommonStockSharesIssued_98d2149e-55f5-408e-9a16-99b257bb3317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_dd4ee735-b164-481c-b5eb-c3e281063733" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c7c3c717-f5c9-4726-b9a3-3f134ea23a01" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_dd4ee735-b164-481c-b5eb-c3e281063733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited" xlink:type="simple" xlink:href="ptct-20200630.xsd#ConsolidatedStatementsofOperationsunaudited"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_1aa206dd-9ef5-41b4-9a2b-54f9097ae928" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2bd177e4-fdc9-4ac1-a814-bd6b2a14f3db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1aa206dd-9ef5-41b4-9a2b-54f9097ae928" xlink:to="loc_us-gaap_StatementTable_2bd177e4-fdc9-4ac1-a814-bd6b2a14f3db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_839b11a1-58b4-413c-94c2-72332d734323" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2bd177e4-fdc9-4ac1-a814-bd6b2a14f3db" xlink:to="loc_srt_ProductOrServiceAxis_839b11a1-58b4-413c-94c2-72332d734323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2cce3798-64c5-4725-b0da-18bd65e55695" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_839b11a1-58b4-413c-94c2-72332d734323" xlink:to="loc_srt_ProductsAndServicesDomain_2cce3798-64c5-4725-b0da-18bd65e55695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_371d87f9-5b02-4dee-84af-1816b10a012d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2cce3798-64c5-4725-b0da-18bd65e55695" xlink:to="loc_us-gaap_ProductMember_371d87f9-5b02-4dee-84af-1816b10a012d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_GrantAndCollaborationMember_54c76349-f0a7-459c-9cb5-95abb2b80e07" xlink:href="ptct-20200630.xsd#ptct_GrantAndCollaborationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2cce3798-64c5-4725-b0da-18bd65e55695" xlink:to="loc_ptct_GrantAndCollaborationMember_54c76349-f0a7-459c-9cb5-95abb2b80e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f3d85031-1c3c-41a9-8f5f-8f5dc8c11554" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2bd177e4-fdc9-4ac1-a814-bd6b2a14f3db" xlink:to="loc_us-gaap_StatementLineItems_f3d85031-1c3c-41a9-8f5f-8f5dc8c11554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_df791ccd-416a-48d6-af3d-c4958b3a427e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f3d85031-1c3c-41a9-8f5f-8f5dc8c11554" xlink:to="loc_us-gaap_RevenuesAbstract_df791ccd-416a-48d6-af3d-c4958b3a427e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_b2831bed-8d0f-4a7a-b7c1-5f1421fa0e19" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_df791ccd-416a-48d6-af3d-c4958b3a427e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_b2831bed-8d0f-4a7a-b7c1-5f1421fa0e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets_6f0d0bbb-247a-4a2b-a12b-dab6fdb30eed" xlink:href="ptct-20200630.xsd#ptct_CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f3d85031-1c3c-41a9-8f5f-8f5dc8c11554" xlink:to="loc_ptct_CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets_6f0d0bbb-247a-4a2b-a12b-dab6fdb30eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_2f014078-19e8-4677-bba9-269be3087d68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f3d85031-1c3c-41a9-8f5f-8f5dc8c11554" xlink:to="loc_us-gaap_OperatingExpensesAbstract_2f014078-19e8-4677-bba9-269be3087d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_51117bba-89d5-4569-b0af-9768234638fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2f014078-19e8-4677-bba9-269be3087d68" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_51117bba-89d5-4569-b0af-9768234638fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_03d677fe-7543-49fb-9000-c58d41397e9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2f014078-19e8-4677-bba9-269be3087d68" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_03d677fe-7543-49fb-9000-c58d41397e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_785dfed1-7e38-4550-abd3-785a8526c26e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2f014078-19e8-4677-bba9-269be3087d68" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_785dfed1-7e38-4550-abd3-785a8526c26e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_7a53ae96-e0a5-47da-bdcf-8c1a139680ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2f014078-19e8-4677-bba9-269be3087d68" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_7a53ae96-e0a5-47da-bdcf-8c1a139680ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_SettlementOfDeferredAndContingentConsideration_c4df97c3-3d62-4324-b1ca-3c789c358df5" xlink:href="ptct-20200630.xsd#ptct_SettlementOfDeferredAndContingentConsideration"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2f014078-19e8-4677-bba9-269be3087d68" xlink:to="loc_ptct_SettlementOfDeferredAndContingentConsideration_c4df97c3-3d62-4324-b1ca-3c789c358df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_2b6fe765-d481-4145-97c4-4a65976cd65f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2f014078-19e8-4677-bba9-269be3087d68" xlink:to="loc_us-gaap_OperatingExpenses_2b6fe765-d481-4145-97c4-4a65976cd65f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e15e895b-28a1-4447-a8af-679485146058" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f3d85031-1c3c-41a9-8f5f-8f5dc8c11554" xlink:to="loc_us-gaap_OperatingIncomeLoss_e15e895b-28a1-4447-a8af-679485146058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_82d0218d-1f10-4cc7-8d50-aaf5468d93d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f3d85031-1c3c-41a9-8f5f-8f5dc8c11554" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_82d0218d-1f10-4cc7-8d50-aaf5468d93d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_fff1e502-616f-40e5-9369-b7efa9156fb8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f3d85031-1c3c-41a9-8f5f-8f5dc8c11554" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_fff1e502-616f-40e5-9369-b7efa9156fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6a97a525-47de-41d8-95ea-5d841c2be41a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f3d85031-1c3c-41a9-8f5f-8f5dc8c11554" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6a97a525-47de-41d8-95ea-5d841c2be41a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d637157a-3267-49d1-9b28-48a24c14606a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f3d85031-1c3c-41a9-8f5f-8f5dc8c11554" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_d637157a-3267-49d1-9b28-48a24c14606a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_97342dd7-6e8a-41df-b9d6-041e872c9fbc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f3d85031-1c3c-41a9-8f5f-8f5dc8c11554" xlink:to="loc_us-gaap_NetIncomeLoss_97342dd7-6e8a-41df-b9d6-041e872c9fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_33b51440-20f8-4ec6-b8d1-1045fc901a97" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f3d85031-1c3c-41a9-8f5f-8f5dc8c11554" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_33b51440-20f8-4ec6-b8d1-1045fc901a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_f2818247-6adf-48f7-9aea-7abf0f59afe6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_33b51440-20f8-4ec6-b8d1-1045fc901a97" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_f2818247-6adf-48f7-9aea-7abf0f59afe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_add9afcb-659a-451b-830e-54f2c7780b1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f3d85031-1c3c-41a9-8f5f-8f5dc8c11554" xlink:to="loc_us-gaap_EarningsPerShareAbstract_add9afcb-659a-451b-830e-54f2c7780b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_eb1f796e-f561-423a-9558-5ab400a21559" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_add9afcb-659a-451b-830e-54f2c7780b1e" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_eb1f796e-f561-423a-9558-5ab400a21559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" xlink:type="simple" xlink:href="ptct-20200630.xsd#ConsolidatedStatementsofComprehensiveLossunaudited"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_5918ae87-8758-41ee-8e1a-19c14a973eba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_321daaab-e58a-4999-829e-f11107dd3c5b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_5918ae87-8758-41ee-8e1a-19c14a973eba" xlink:to="loc_us-gaap_NetIncomeLoss_321daaab-e58a-4999-829e-f11107dd3c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_7ea46a8f-d5f0-4738-b513-8cd92692d6dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_5918ae87-8758-41ee-8e1a-19c14a973eba" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_7ea46a8f-d5f0-4738-b513-8cd92692d6dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_4e903c40-8220-4573-8100-a72fc361907f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_7ea46a8f-d5f0-4738-b513-8cd92692d6dd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_4e903c40-8220-4573-8100-a72fc361907f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_edf92f81-2da3-4b99-a9f7-75f7511a0811" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_7ea46a8f-d5f0-4738-b513-8cd92692d6dd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_edf92f81-2da3-4b99-a9f7-75f7511a0811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2ee63b18-5201-4318-a5f3-8c9b66003dd6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_5918ae87-8758-41ee-8e1a-19c14a973eba" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_2ee63b18-5201-4318-a5f3-8c9b66003dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="ptct-20200630.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_8355cc79-7890-4b33-9600-7d63e03b1c59" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_492538fb-3131-49da-b337-85d1acc745dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_8355cc79-7890-4b33-9600-7d63e03b1c59" xlink:to="loc_us-gaap_StatementTable_492538fb-3131-49da-b337-85d1acc745dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8aad0cb6-386b-4849-8ef3-0cd911225bd7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_492538fb-3131-49da-b337-85d1acc745dd" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8aad0cb6-386b-4849-8ef3-0cd911225bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_36184668-7401-43a6-9c91-36dc5deb12ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8aad0cb6-386b-4849-8ef3-0cd911225bd7" xlink:to="loc_us-gaap_EquityComponentDomain_36184668-7401-43a6-9c91-36dc5deb12ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a35e48d7-7cdd-4958-92ce-91f52f0024fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_36184668-7401-43a6-9c91-36dc5deb12ed" xlink:to="loc_us-gaap_CommonStockMember_a35e48d7-7cdd-4958-92ce-91f52f0024fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f1589cd3-c24f-4972-acbf-49c493423563" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_36184668-7401-43a6-9c91-36dc5deb12ed" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f1589cd3-c24f-4972-acbf-49c493423563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5a1abb0a-d2c3-4be7-9539-ecb5abb74a0e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_36184668-7401-43a6-9c91-36dc5deb12ed" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5a1abb0a-d2c3-4be7-9539-ecb5abb74a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_2e6856d7-74c8-4892-8d16-e6c6af04841c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_36184668-7401-43a6-9c91-36dc5deb12ed" xlink:to="loc_us-gaap_RetainedEarningsMember_2e6856d7-74c8-4892-8d16-e6c6af04841c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b61415cd-a8a4-403a-a3d3-6d7b653dae56" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_492538fb-3131-49da-b337-85d1acc745dd" xlink:to="loc_us-gaap_StatementLineItems_b61415cd-a8a4-403a-a3d3-6d7b653dae56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6df88fc6-1e9c-4ec7-8b35-8bd3b0f18d1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b61415cd-a8a4-403a-a3d3-6d7b653dae56" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6df88fc6-1e9c-4ec7-8b35-8bd3b0f18d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_05776ddd-3073-41b7-927c-31cbd5ef4210" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6df88fc6-1e9c-4ec7-8b35-8bd3b0f18d1d" xlink:to="loc_us-gaap_SharesIssued_05776ddd-3073-41b7-927c-31cbd5ef4210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_372dc859-a347-4038-818f-507ada4ccfb0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6df88fc6-1e9c-4ec7-8b35-8bd3b0f18d1d" xlink:to="loc_us-gaap_StockholdersEquity_372dc859-a347-4038-818f-507ada4ccfb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3be244d0-9c70-4431-9f08-d313bdf54f05" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6df88fc6-1e9c-4ec7-8b35-8bd3b0f18d1d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3be244d0-9c70-4431-9f08-d313bdf54f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2999816f-0a85-48e0-a8da-70dabebc2f2a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6df88fc6-1e9c-4ec7-8b35-8bd3b0f18d1d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2999816f-0a85-48e0-a8da-70dabebc2f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_b327e54a-6f83-40ce-ba98-17ef2a57b966" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6df88fc6-1e9c-4ec7-8b35-8bd3b0f18d1d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_b327e54a-6f83-40ce-ba98-17ef2a57b966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_6c97ee9e-34f1-4978-ad88-37a230a51372" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6df88fc6-1e9c-4ec7-8b35-8bd3b0f18d1d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_6c97ee9e-34f1-4978-ad88-37a230a51372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_f5295901-98a0-417f-bfaa-78f822fd967c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6df88fc6-1e9c-4ec7-8b35-8bd3b0f18d1d" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_f5295901-98a0-417f-bfaa-78f822fd967c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_StockIssuedDuringPeriodSharesExchangeRights_4c2bd693-88a8-4f5b-abb9-61bb2da4d952" xlink:href="ptct-20200630.xsd#ptct_StockIssuedDuringPeriodSharesExchangeRights"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6df88fc6-1e9c-4ec7-8b35-8bd3b0f18d1d" xlink:to="loc_ptct_StockIssuedDuringPeriodSharesExchangeRights_4c2bd693-88a8-4f5b-abb9-61bb2da4d952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_StockIssuedDuringPeriodValueExchangeRights_36ed1eff-72f0-47f9-b99e-eb10de7d635d" xlink:href="ptct-20200630.xsd#ptct_StockIssuedDuringPeriodValueExchangeRights"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6df88fc6-1e9c-4ec7-8b35-8bd3b0f18d1d" xlink:to="loc_ptct_StockIssuedDuringPeriodValueExchangeRights_36ed1eff-72f0-47f9-b99e-eb10de7d635d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_72f1ffc2-bc20-4c90-8d56-3dde7608ccd1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6df88fc6-1e9c-4ec7-8b35-8bd3b0f18d1d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_72f1ffc2-bc20-4c90-8d56-3dde7608ccd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_81349c77-ea7f-47fa-addf-88945cb4a3fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6df88fc6-1e9c-4ec7-8b35-8bd3b0f18d1d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_81349c77-ea7f-47fa-addf-88945cb4a3fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_5b50808c-a074-4007-a9c3-0ab3f502f981" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6df88fc6-1e9c-4ec7-8b35-8bd3b0f18d1d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_5b50808c-a074-4007-a9c3-0ab3f502f981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_a323b4c3-aacd-4613-be3f-1fbe4b9189dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6df88fc6-1e9c-4ec7-8b35-8bd3b0f18d1d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_a323b4c3-aacd-4613-be3f-1fbe4b9189dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1eb2b786-15e9-4edd-9f9d-3ffb0874b8ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6df88fc6-1e9c-4ec7-8b35-8bd3b0f18d1d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1eb2b786-15e9-4edd-9f9d-3ffb0874b8ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_91a418a6-ae86-44e3-ad1f-047a6981b470" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6df88fc6-1e9c-4ec7-8b35-8bd3b0f18d1d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_91a418a6-ae86-44e3-ad1f-047a6981b470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_fc55e6cb-7a6f-4d15-beae-e88c287b189b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6df88fc6-1e9c-4ec7-8b35-8bd3b0f18d1d" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_fc55e6cb-7a6f-4d15-beae-e88c287b189b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor_1d3c9520-a101-4b8c-9e89-020541aab766" xlink:href="ptct-20200630.xsd#ptct_AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6df88fc6-1e9c-4ec7-8b35-8bd3b0f18d1d" xlink:to="loc_ptct_AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor_1d3c9520-a101-4b8c-9e89-020541aab766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPeriodIncreaseDecrease_a969e38c-1952-4c1c-b7ad-3ddef2ee5a31" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityPeriodIncreaseDecrease"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6df88fc6-1e9c-4ec7-8b35-8bd3b0f18d1d" xlink:to="loc_us-gaap_StockholdersEquityPeriodIncreaseDecrease_a969e38c-1952-4c1c-b7ad-3ddef2ee5a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c4584793-8d2f-4800-9034-a7052b16409f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6df88fc6-1e9c-4ec7-8b35-8bd3b0f18d1d" xlink:to="loc_us-gaap_NetIncomeLoss_c4584793-8d2f-4800-9034-a7052b16409f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0dfdddc2-0c8a-4043-843d-056bfb1d7b98" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6df88fc6-1e9c-4ec7-8b35-8bd3b0f18d1d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0dfdddc2-0c8a-4043-843d-056bfb1d7b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_49de5333-7a62-49f9-8089-9eb15b7d0a6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6df88fc6-1e9c-4ec7-8b35-8bd3b0f18d1d" xlink:to="loc_us-gaap_SharesIssued_49de5333-7a62-49f9-8089-9eb15b7d0a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6b983044-a12d-4930-b2c8-432725293d1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6df88fc6-1e9c-4ec7-8b35-8bd3b0f18d1d" xlink:to="loc_us-gaap_StockholdersEquity_6b983044-a12d-4930-b2c8-432725293d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited" xlink:type="simple" xlink:href="ptct-20200630.xsd#ConsolidatedStatementsofCashFlowsunaudited"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_c561c5c4-5660-4940-830b-7716a708ce41" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_93f6e9b3-a5bd-495f-8c13-4a0e6727cd8a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c561c5c4-5660-4940-830b-7716a708ce41" xlink:to="loc_us-gaap_StatementTable_93f6e9b3-a5bd-495f-8c13-4a0e6727cd8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_e13a98ea-5ae0-4811-a5cb-5e92ad98ca7f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_93f6e9b3-a5bd-495f-8c13-4a0e6727cd8a" xlink:to="loc_srt_RestatementAxis_e13a98ea-5ae0-4811-a5cb-5e92ad98ca7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_b521027e-183b-4790-baea-46515a10525d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_e13a98ea-5ae0-4811-a5cb-5e92ad98ca7f" xlink:to="loc_srt_RestatementDomain_b521027e-183b-4790-baea-46515a10525d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_371604fb-ae60-479e-bd83-4e57f25d1f29" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_93f6e9b3-a5bd-495f-8c13-4a0e6727cd8a" xlink:to="loc_us-gaap_StatementLineItems_371604fb-ae60-479e-bd83-4e57f25d1f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_267176c6-0297-4539-bf2d-64cc4d83eb68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c561c5c4-5660-4940-830b-7716a708ce41" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_267176c6-0297-4539-bf2d-64cc4d83eb68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3a2d0e27-6cfc-41ee-bdb4-7d955e403400" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_267176c6-0297-4539-bf2d-64cc4d83eb68" xlink:to="loc_us-gaap_NetIncomeLoss_3a2d0e27-6cfc-41ee-bdb4-7d955e403400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0115fd3e-6db5-4deb-bad3-0b073cd54740" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_267176c6-0297-4539-bf2d-64cc4d83eb68" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0115fd3e-6db5-4deb-bad3-0b073cd54740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_3bc8543f-e736-49c6-b168-da809f18a14f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0115fd3e-6db5-4deb-bad3-0b073cd54740" xlink:to="loc_us-gaap_Depreciation_3bc8543f-e736-49c6-b168-da809f18a14f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_OperatingLeaseCostNonCash_182c7d61-fa53-42b5-9ddb-b5bc3014eb22" xlink:href="ptct-20200630.xsd#ptct_OperatingLeaseCostNonCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0115fd3e-6db5-4deb-bad3-0b073cd54740" xlink:to="loc_ptct_OperatingLeaseCostNonCash_182c7d61-fa53-42b5-9ddb-b5bc3014eb22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_FinanceLeaseCostNonCash_12958670-5b36-4130-831c-22ec819949a7" xlink:href="ptct-20200630.xsd#ptct_FinanceLeaseCostNonCash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0115fd3e-6db5-4deb-bad3-0b073cd54740" xlink:to="loc_ptct_FinanceLeaseCostNonCash_12958670-5b36-4130-831c-22ec819949a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_0b78f404-e1fd-401a-9c22-070a85daefd8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0115fd3e-6db5-4deb-bad3-0b073cd54740" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_0b78f404-e1fd-401a-9c22-070a85daefd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_SettlementOfDeferredAndContingentConsideration_7f266bfc-dddf-4942-b748-4bd349b7ae5d" xlink:href="ptct-20200630.xsd#ptct_SettlementOfDeferredAndContingentConsideration"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0115fd3e-6db5-4deb-bad3-0b073cd54740" xlink:to="loc_ptct_SettlementOfDeferredAndContingentConsideration_7f266bfc-dddf-4942-b748-4bd349b7ae5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_SharesIssuedAssetAcquisition_0d3d23dd-a4d4-4e44-bbdd-26fe99455a7b" xlink:href="ptct-20200630.xsd#ptct_SharesIssuedAssetAcquisition"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0115fd3e-6db5-4deb-bad3-0b073cd54740" xlink:to="loc_ptct_SharesIssuedAssetAcquisition_0d3d23dd-a4d4-4e44-bbdd-26fe99455a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_52a22ff0-f53c-42e3-866c-4080dea78550" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0115fd3e-6db5-4deb-bad3-0b073cd54740" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_52a22ff0-f53c-42e3-866c-4080dea78550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_UnrealizedGainLossonConvertibleSecurities_f44430f6-0468-466d-8dc3-d62a5cc3fb98" xlink:href="ptct-20200630.xsd#ptct_UnrealizedGainLossonConvertibleSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0115fd3e-6db5-4deb-bad3-0b073cd54740" xlink:to="loc_ptct_UnrealizedGainLossonConvertibleSecurities_f44430f6-0468-466d-8dc3-d62a5cc3fb98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_9ada0662-ee95-4e1a-aff4-60b29ee1aca0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0115fd3e-6db5-4deb-bad3-0b073cd54740" xlink:to="loc_us-gaap_PaidInKindInterest_9ada0662-ee95-4e1a-aff4-60b29ee1aca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_f346a4cf-2988-4a5c-a1e6-1148ab587ee4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0115fd3e-6db5-4deb-bad3-0b073cd54740" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_f346a4cf-2988-4a5c-a1e6-1148ab587ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_b79f85fe-f068-414e-836b-3ae00f051e8a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0115fd3e-6db5-4deb-bad3-0b073cd54740" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_b79f85fe-f068-414e-836b-3ae00f051e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_a12de459-9a99-43a8-9d3a-cd9186bfb958" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0115fd3e-6db5-4deb-bad3-0b073cd54740" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_a12de459-9a99-43a8-9d3a-cd9186bfb958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_ccb5c011-0358-4632-b269-48b84b5cd61d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0115fd3e-6db5-4deb-bad3-0b073cd54740" xlink:to="loc_us-gaap_ShareBasedCompensation_ccb5c011-0358-4632-b269-48b84b5cd61d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_0b6eac0d-8a3e-4a6e-9492-a3ebf25edc3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0115fd3e-6db5-4deb-bad3-0b073cd54740" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_0b6eac0d-8a3e-4a6e-9492-a3ebf25edc3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5ad9ae9a-dfca-41dc-989b-de9bea62f63b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0115fd3e-6db5-4deb-bad3-0b073cd54740" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5ad9ae9a-dfca-41dc-989b-de9bea62f63b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_ee9beb9f-5fcc-4ac1-b262-f03414c4c28a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5ad9ae9a-dfca-41dc-989b-de9bea62f63b" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_ee9beb9f-5fcc-4ac1-b262-f03414c4c28a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_15c99c77-de40-4009-aa80-e347606891d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5ad9ae9a-dfca-41dc-989b-de9bea62f63b" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_15c99c77-de40-4009-aa80-e347606891d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_013a6d96-2108-4e90-91e2-f32a57e59597" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5ad9ae9a-dfca-41dc-989b-de9bea62f63b" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_013a6d96-2108-4e90-91e2-f32a57e59597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDepositOtherAssets_905d2ffc-f5f5-4df8-bc63-6cf6e2f45360" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5ad9ae9a-dfca-41dc-989b-de9bea62f63b" xlink:to="loc_us-gaap_IncreaseDecreaseInDepositOtherAssets_905d2ffc-f5f5-4df8-bc63-6cf6e2f45360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_ac0274d3-1bc6-4a38-89fc-5ad39bb75815" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5ad9ae9a-dfca-41dc-989b-de9bea62f63b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_ac0274d3-1bc6-4a38-89fc-5ad39bb75815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_95df3c23-0653-4a2c-8c8f-b5a053ff21d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5ad9ae9a-dfca-41dc-989b-de9bea62f63b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_95df3c23-0653-4a2c-8c8f-b5a053ff21d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_5150f2b5-be65-4043-bea8-d4c130b51c7c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5ad9ae9a-dfca-41dc-989b-de9bea62f63b" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_5150f2b5-be65-4043-bea8-d4c130b51c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_424b6bcb-2971-420c-80cc-3f7b2ae8ba90" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_267176c6-0297-4539-bf2d-64cc4d83eb68" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_424b6bcb-2971-420c-80cc-3f7b2ae8ba90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_334f1bfe-bcf3-45af-b092-22c913166c99" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c561c5c4-5660-4940-830b-7716a708ce41" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_334f1bfe-bcf3-45af-b092-22c913166c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_80aa0de7-bab6-4e36-8264-dbb0aef51217" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_334f1bfe-bcf3-45af-b092-22c913166c99" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_80aa0de7-bab6-4e36-8264-dbb0aef51217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_PaymentsToAcquireConvertibleDebtInvestment_c9c0b6e2-0394-4617-b7f8-db610ced544b" xlink:href="ptct-20200630.xsd#ptct_PaymentsToAcquireConvertibleDebtInvestment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_334f1bfe-bcf3-45af-b092-22c913166c99" xlink:to="loc_ptct_PaymentsToAcquireConvertibleDebtInvestment_c9c0b6e2-0394-4617-b7f8-db610ced544b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_da96af19-81ae-44b2-ab29-f175f0f34b21" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_334f1bfe-bcf3-45af-b092-22c913166c99" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_da96af19-81ae-44b2-ab29-f175f0f34b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_e39dbf0f-92bc-4f7b-b940-aa5a1dd38af1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_334f1bfe-bcf3-45af-b092-22c913166c99" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_e39dbf0f-92bc-4f7b-b940-aa5a1dd38af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_096a957d-3c50-4f80-bea4-ff3598cfe905" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_334f1bfe-bcf3-45af-b092-22c913166c99" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_096a957d-3c50-4f80-bea4-ff3598cfe905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_0ab9bb73-846a-42d1-a1a8-ed2bd8d93a3e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_334f1bfe-bcf3-45af-b092-22c913166c99" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_0ab9bb73-846a-42d1-a1a8-ed2bd8d93a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_48fb3181-5084-40e0-b8a7-0423646848ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_334f1bfe-bcf3-45af-b092-22c913166c99" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_48fb3181-5084-40e0-b8a7-0423646848ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_068a7626-1eeb-4e9d-ba70-aaf5abd476a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c561c5c4-5660-4940-830b-7716a708ce41" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_068a7626-1eeb-4e9d-ba70-aaf5abd476a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_58165dfa-961e-48fb-9012-f568ea301e56" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_068a7626-1eeb-4e9d-ba70-aaf5abd476a9" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_58165dfa-961e-48fb-9012-f568ea301e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e8105944-f8da-4a84-b8f1-91467535b898" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_068a7626-1eeb-4e9d-ba70-aaf5abd476a9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e8105944-f8da-4a84-b8f1-91467535b898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt_c41afb4e-16f1-44fe-ba4e-3fe1b2cd2a0b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_068a7626-1eeb-4e9d-ba70-aaf5abd476a9" xlink:to="loc_us-gaap_RepaymentsOfSecuredDebt_c41afb4e-16f1-44fe-ba4e-3fe1b2cd2a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_PaymentsOnDeferredConsiderationObligation_3cd586e3-1a8c-4645-a451-2660c27fb525" xlink:href="ptct-20200630.xsd#ptct_PaymentsOnDeferredConsiderationObligation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_068a7626-1eeb-4e9d-ba70-aaf5abd476a9" xlink:to="loc_ptct_PaymentsOnDeferredConsiderationObligation_3cd586e3-1a8c-4645-a451-2660c27fb525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_66467c4e-8ed9-43bd-9bd6-d04abcfae580" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_068a7626-1eeb-4e9d-ba70-aaf5abd476a9" xlink:to="loc_us-gaap_ProceedsFromStockPlans_66467c4e-8ed9-43bd-9bd6-d04abcfae580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_PaymentOfFinanceLeasePrincipal_88e5f41c-7d45-441c-8d9f-3b853fbccf9a" xlink:href="ptct-20200630.xsd#ptct_PaymentOfFinanceLeasePrincipal"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_068a7626-1eeb-4e9d-ba70-aaf5abd476a9" xlink:to="loc_ptct_PaymentOfFinanceLeasePrincipal_88e5f41c-7d45-441c-8d9f-3b853fbccf9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ee289864-8bb9-42a9-afb7-1f082e1d434c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_068a7626-1eeb-4e9d-ba70-aaf5abd476a9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ee289864-8bb9-42a9-afb7-1f082e1d434c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_be5566a5-ba99-49f7-80cb-2b4ab0e62378" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c561c5c4-5660-4940-830b-7716a708ce41" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_be5566a5-ba99-49f7-80cb-2b4ab0e62378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_00ee7b8d-9f02-427b-8d70-8ae3d164c94f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c561c5c4-5660-4940-830b-7716a708ce41" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_00ee7b8d-9f02-427b-8d70-8ae3d164c94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_14fd479b-4520-412f-bd1e-7862a4f7c605" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c561c5c4-5660-4940-830b-7716a708ce41" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_14fd479b-4520-412f-bd1e-7862a4f7c605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9c772045-369f-40f2-ad70-9eb0a2df97ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c561c5c4-5660-4940-830b-7716a708ce41" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9c772045-369f-40f2-ad70-9eb0a2df97ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_5e3a718f-1806-4b02-bad8-6a0ccc81d4e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c561c5c4-5660-4940-830b-7716a708ce41" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_5e3a718f-1806-4b02-bad8-6a0ccc81d4e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_741d8323-e78d-4f79-a38e-02b10ff9cb44" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_5e3a718f-1806-4b02-bad8-6a0ccc81d4e5" xlink:to="loc_us-gaap_InterestPaidNet_741d8323-e78d-4f79-a38e-02b10ff9cb44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_9cc48d96-30dc-42b2-8f30-0cdc2a086de7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_5e3a718f-1806-4b02-bad8-6a0ccc81d4e5" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_9cc48d96-30dc-42b2-8f30-0cdc2a086de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_dbcfa1fa-b348-4c19-954e-6e96b3b9ba8a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c561c5c4-5660-4940-830b-7716a708ce41" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_dbcfa1fa-b348-4c19-954e-6e96b3b9ba8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_aa508e5f-3a83-4cf2-b817-4bfc6e0fd00c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_dbcfa1fa-b348-4c19-954e-6e96b3b9ba8a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_aa508e5f-3a83-4cf2-b817-4bfc6e0fd00c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2d4d147f-037f-4499-8d94-e9af6f30d143" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_dbcfa1fa-b348-4c19-954e-6e96b3b9ba8a" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2d4d147f-037f-4499-8d94-e9af6f30d143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_972d1e62-f7c3-4c99-a282-e7cef0a2d6b8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_dbcfa1fa-b348-4c19-954e-6e96b3b9ba8a" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_972d1e62-f7c3-4c99-a282-e7cef0a2d6b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_f7b5fdb5-8aa3-457f-806b-8788722be817" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_dbcfa1fa-b348-4c19-954e-6e96b3b9ba8a" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_f7b5fdb5-8aa3-457f-806b-8788722be817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_StockIssuedDuringPeriodValueExchangeRights_db4faa47-c351-4b90-a552-8f698e274a08" xlink:href="ptct-20200630.xsd#ptct_StockIssuedDuringPeriodValueExchangeRights"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_dbcfa1fa-b348-4c19-954e-6e96b3b9ba8a" xlink:to="loc_ptct_StockIssuedDuringPeriodValueExchangeRights_db4faa47-c351-4b90-a552-8f698e274a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/TheCompany" xlink:type="simple" xlink:href="ptct-20200630.xsd#TheCompany"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/TheCompany" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_23e9f2c7-2955-4048-8cd8-30b76809522f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_5128736e-6467-4704-9036-9f10245d2b61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_23e9f2c7-2955-4048-8cd8-30b76809522f" xlink:to="loc_us-gaap_NatureOfOperations_5128736e-6467-4704-9036-9f10245d2b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/TheCompanyNarrativeDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#TheCompanyNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/TheCompanyNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_507dcffc-8dd1-478c-850a-ef50e55ba8f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_290872b7-f809-4dc0-9672-1ad5cb1a75f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_507dcffc-8dd1-478c-850a-ef50e55ba8f9" xlink:to="loc_us-gaap_DebtInstrumentTable_290872b7-f809-4dc0-9672-1ad5cb1a75f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_59c810ad-8fa6-4563-9472-a2a81749e396" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_290872b7-f809-4dc0-9672-1ad5cb1a75f7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_59c810ad-8fa6-4563-9472-a2a81749e396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c422ae84-8027-4393-9e34-dbd6fa4b7fdd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_59c810ad-8fa6-4563-9472-a2a81749e396" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c422ae84-8027-4393-9e34-dbd6fa4b7fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_BioElectronMember_87926918-5808-48f9-8e9b-ae19823a856e" xlink:href="ptct-20200630.xsd#ptct_BioElectronMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c422ae84-8027-4393-9e34-dbd6fa4b7fdd" xlink:to="loc_ptct_BioElectronMember_87926918-5808-48f9-8e9b-ae19823a856e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_23822251-cb8e-4525-8ab6-21c2848834ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_290872b7-f809-4dc0-9672-1ad5cb1a75f7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_23822251-cb8e-4525-8ab6-21c2848834ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f62a08f1-c5f7-4b01-a622-79da0e94811d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_23822251-cb8e-4525-8ab6-21c2848834ad" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f62a08f1-c5f7-4b01-a622-79da0e94811d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AgilisMember_535009d0-e2ef-4bda-8103-2717a199383b" xlink:href="ptct-20200630.xsd#ptct_AgilisMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f62a08f1-c5f7-4b01-a622-79da0e94811d" xlink:to="loc_ptct_AgilisMember_535009d0-e2ef-4bda-8103-2717a199383b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ba27e9d4-2e5f-4464-a0a3-b5f17ca10f7b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_290872b7-f809-4dc0-9672-1ad5cb1a75f7" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ba27e9d4-2e5f-4464-a0a3-b5f17ca10f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9dc3a72d-c2f7-4b3c-977d-1aae91a47e4f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ba27e9d4-2e5f-4464-a0a3-b5f17ca10f7b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9dc3a72d-c2f7-4b3c-977d-1aae91a47e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncollaborativeArrangementTransactionsMember_c69c1f2b-0bdb-4e30-84ca-b371a389cb27" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncollaborativeArrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9dc3a72d-c2f7-4b3c-977d-1aae91a47e4f" xlink:to="loc_us-gaap_NoncollaborativeArrangementTransactionsMember_c69c1f2b-0bdb-4e30-84ca-b371a389cb27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_35ec2dbe-cd82-4297-a244-4787694ec130" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_290872b7-f809-4dc0-9672-1ad5cb1a75f7" xlink:to="loc_srt_CounterpartyNameAxis_35ec2dbe-cd82-4297-a244-4787694ec130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_915d2ea7-0ff4-4fdd-9354-3c9bde0d8027" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_35ec2dbe-cd82-4297-a244-4787694ec130" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_915d2ea7-0ff4-4fdd-9354-3c9bde0d8027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_MarathonPharmaceuticalsLLCMember_edeab969-92ce-4121-b028-e7b79b3735e0" xlink:href="ptct-20200630.xsd#ptct_MarathonPharmaceuticalsLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_915d2ea7-0ff4-4fdd-9354-3c9bde0d8027" xlink:to="loc_ptct_MarathonPharmaceuticalsLLCMember_edeab969-92ce-4121-b028-e7b79b3735e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_cfe5d39c-1554-4a82-9949-65a34ad5c550" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_290872b7-f809-4dc0-9672-1ad5cb1a75f7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_cfe5d39c-1554-4a82-9949-65a34ad5c550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4bc1df1c-dcea-4d2e-bde4-f5d03b6a63eb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cfe5d39c-1554-4a82-9949-65a34ad5c550" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4bc1df1c-dcea-4d2e-bde4-f5d03b6a63eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_2594b7e9-acb7-4921-9330-cb360356b1a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4bc1df1c-dcea-4d2e-bde4-f5d03b6a63eb" xlink:to="loc_us-gaap_ConvertibleDebtMember_2594b7e9-acb7-4921-9330-cb360356b1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_01e4120b-79e0-446b-8ae4-fa731e89fd12" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_290872b7-f809-4dc0-9672-1ad5cb1a75f7" xlink:to="loc_us-gaap_DebtInstrumentAxis_01e4120b-79e0-446b-8ae4-fa731e89fd12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e04e7c54-4ef4-409e-aab4-b1b00508f450" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_01e4120b-79e0-446b-8ae4-fa731e89fd12" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e04e7c54-4ef4-409e-aab4-b1b00508f450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member_65387325-f92a-4ebf-b8c8-f0d2e197c1a9" xlink:href="ptct-20200630.xsd#ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e04e7c54-4ef4-409e-aab4-b1b00508f450" xlink:to="loc_ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member_65387325-f92a-4ebf-b8c8-f0d2e197c1a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_e8803872-66e7-49ec-9f61-0f7b1b1a5210" xlink:href="ptct-20200630.xsd#ptct_ConvertibleSeniorNotes3.0PercentDue2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e04e7c54-4ef4-409e-aab4-b1b00508f450" xlink:to="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_e8803872-66e7-49ec-9f61-0f7b1b1a5210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b22555a7-b0e6-49ab-a8cb-36d106eb6187" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_290872b7-f809-4dc0-9672-1ad5cb1a75f7" xlink:to="loc_us-gaap_PlanNameAxis_b22555a7-b0e6-49ab-a8cb-36d106eb6187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_12e6f154-84ce-4882-8ba2-5f7e3c2f05b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_b22555a7-b0e6-49ab-a8cb-36d106eb6187" xlink:to="loc_us-gaap_PlanNameDomain_12e6f154-84ce-4882-8ba2-5f7e3c2f05b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_RightsExchangeAgreementMember_c9a50d04-ac9f-44c0-97d0-3ac15d49e284" xlink:href="ptct-20200630.xsd#ptct_RightsExchangeAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_12e6f154-84ce-4882-8ba2-5f7e3c2f05b2" xlink:to="loc_ptct_RightsExchangeAgreementMember_c9a50d04-ac9f-44c0-97d0-3ac15d49e284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a4a445de-25e7-4f27-bc9b-4bb62049afad" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_290872b7-f809-4dc0-9672-1ad5cb1a75f7" xlink:to="loc_srt_RangeAxis_a4a445de-25e7-4f27-bc9b-4bb62049afad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7b9f7dd2-812d-4847-9a9b-8ffbe59a2bf7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a4a445de-25e7-4f27-bc9b-4bb62049afad" xlink:to="loc_srt_RangeMember_7b9f7dd2-812d-4847-9a9b-8ffbe59a2bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1e78fda4-7805-48d9-92fa-76b896ec6807" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7b9f7dd2-812d-4847-9a9b-8ffbe59a2bf7" xlink:to="loc_srt_MinimumMember_1e78fda4-7805-48d9-92fa-76b896ec6807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0b4a2323-560f-4f37-8237-be71437dac5e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7b9f7dd2-812d-4847-9a9b-8ffbe59a2bf7" xlink:to="loc_srt_MaximumMember_0b4a2323-560f-4f37-8237-be71437dac5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4e596faa-c840-4f4f-ac65-9dc449c78f76" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_290872b7-f809-4dc0-9672-1ad5cb1a75f7" xlink:to="loc_us-gaap_DebtInstrumentLineItems_4e596faa-c840-4f4f-ac65-9dc449c78f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_ea4464f9-d0f8-46bb-b263-425cab6b43f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e596faa-c840-4f4f-ac65-9dc449c78f76" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_ea4464f9-d0f8-46bb-b263-425cab6b43f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_a091921c-35f3-47e7-a02c-1da411c01e08" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e596faa-c840-4f4f-ac65-9dc449c78f76" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_a091921c-35f3-47e7-a02c-1da411c01e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity_67a1004a-5fa9-46a3-9644-19682a9f977c" xlink:href="ptct-20200630.xsd#ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e596faa-c840-4f4f-ac65-9dc449c78f76" xlink:to="loc_ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity_67a1004a-5fa9-46a3-9644-19682a9f977c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod_78e54f70-eaa0-4059-b931-6776634592a9" xlink:href="ptct-20200630.xsd#ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e596faa-c840-4f4f-ac65-9dc449c78f76" xlink:to="loc_ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod_78e54f70-eaa0-4059-b931-6776634592a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing_d2d6c4a4-1c3d-4441-9ce5-f82706d0fb56" xlink:href="ptct-20200630.xsd#ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e596faa-c840-4f4f-ac65-9dc449c78f76" xlink:to="loc_ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing_d2d6c4a4-1c3d-4441-9ce5-f82706d0fb56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f4828cd7-46f9-4ec9-b950-40c67de62815" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e596faa-c840-4f4f-ac65-9dc449c78f76" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f4828cd7-46f9-4ec9-b950-40c67de62815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_85b995a1-2677-43f3-b27a-82e9465098e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e596faa-c840-4f4f-ac65-9dc449c78f76" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_85b995a1-2677-43f3-b27a-82e9465098e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_PaymentsforAssetAcquisitions_cf5c7f03-73be-4cb6-9acd-fe2371e7a583" xlink:href="ptct-20200630.xsd#ptct_PaymentsforAssetAcquisitions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e596faa-c840-4f4f-ac65-9dc449c78f76" xlink:to="loc_ptct_PaymentsforAssetAcquisitions_cf5c7f03-73be-4cb6-9acd-fe2371e7a583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_LoanAdvance_fbafac76-1be5-4189-891d-c18824c4f519" xlink:href="ptct-20200630.xsd#ptct_LoanAdvance"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e596faa-c840-4f4f-ac65-9dc449c78f76" xlink:to="loc_ptct_LoanAdvance_fbafac76-1be5-4189-891d-c18824c4f519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1_06d199fe-35b2-4b63-b85a-ffa3342255d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e596faa-c840-4f4f-ac65-9dc449c78f76" xlink:to="loc_us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1_06d199fe-35b2-4b63-b85a-ffa3342255d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_SharesissuedunderRightsExchangeAgreement_090e46a7-c917-40ad-a1f7-fe8e8a42e49d" xlink:href="ptct-20200630.xsd#ptct_SharesissuedunderRightsExchangeAgreement"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e596faa-c840-4f4f-ac65-9dc449c78f76" xlink:to="loc_ptct_SharesissuedunderRightsExchangeAgreement_090e46a7-c917-40ad-a1f7-fe8e8a42e49d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_SharesremainingtoissueunderRightsExchangeAgreement_12bc2c00-b362-4ff2-9a06-15ccb8f6217b" xlink:href="ptct-20200630.xsd#ptct_SharesremainingtoissueunderRightsExchangeAgreement"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e596faa-c840-4f4f-ac65-9dc449c78f76" xlink:to="loc_ptct_SharesremainingtoissueunderRightsExchangeAgreement_12bc2c00-b362-4ff2-9a06-15ccb8f6217b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount_39ddf1ad-16f9-4ec9-98fd-f8c9baf73650" xlink:href="ptct-20200630.xsd#ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e596faa-c840-4f4f-ac65-9dc449c78f76" xlink:to="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount_39ddf1ad-16f9-4ec9-98fd-f8c9baf73650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DevelopmentandPotentialRegulatoryApprovalPaymentObligation_3385b729-03f1-45c4-abb0-e88b2d27af67" xlink:href="ptct-20200630.xsd#ptct_DevelopmentandPotentialRegulatoryApprovalPaymentObligation"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e596faa-c840-4f4f-ac65-9dc449c78f76" xlink:to="loc_ptct_DevelopmentandPotentialRegulatoryApprovalPaymentObligation_3385b729-03f1-45c4-abb0-e88b2d27af67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture_0e6ffc12-49ee-490e-ab4d-9643fe3d2f45" xlink:href="ptct-20200630.xsd#ptct_DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e596faa-c840-4f4f-ac65-9dc449c78f76" xlink:to="loc_ptct_DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture_0e6ffc12-49ee-490e-ab4d-9643fe3d2f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture_33c5afef-b046-424c-b2a4-4849537a97e7" xlink:href="ptct-20200630.xsd#ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e596faa-c840-4f4f-ac65-9dc449c78f76" xlink:to="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture_33c5afef-b046-424c-b2a4-4849537a97e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone_7acf15de-bc3d-41a2-94a9-958343613ab4" xlink:href="ptct-20200630.xsd#ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e596faa-c840-4f4f-ac65-9dc449c78f76" xlink:to="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone_7acf15de-bc3d-41a2-94a9-958343613ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage_bc05f7b1-1477-4b30-b256-e93f8b592b04" xlink:href="ptct-20200630.xsd#ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e596faa-c840-4f4f-ac65-9dc449c78f76" xlink:to="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage_bc05f7b1-1477-4b30-b256-e93f8b592b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_SharestoissueunderRightsExchangeAgreement_8810b9d4-5686-4ca0-adf7-8f96fff4f256" xlink:href="ptct-20200630.xsd#ptct_SharestoissueunderRightsExchangeAgreement"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e596faa-c840-4f4f-ac65-9dc449c78f76" xlink:to="loc_ptct_SharestoissueunderRightsExchangeAgreement_8810b9d4-5686-4ca0-adf7-8f96fff4f256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_CashconsiderationpaymentunderRightsExchangeAgreement_46488ba3-6a70-4f15-882a-a946990784ec" xlink:href="ptct-20200630.xsd#ptct_CashconsiderationpaymentunderRightsExchangeAgreement"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e596faa-c840-4f4f-ac65-9dc449c78f76" xlink:to="loc_ptct_CashconsiderationpaymentunderRightsExchangeAgreement_46488ba3-6a70-4f15-882a-a946990784ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/Summaryofsignificantaccountingpolicies" xlink:type="simple" xlink:href="ptct-20200630.xsd#Summaryofsignificantaccountingpolicies"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/Summaryofsignificantaccountingpolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6c41ebda-abe4-4820-84ef-0995ae0c9851" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_e625500b-0b56-472f-9221-6d8194f72e24" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6c41ebda-abe4-4820-84ef-0995ae0c9851" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_e625500b-0b56-472f-9221-6d8194f72e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesPolicies" xlink:type="simple" xlink:href="ptct-20200630.xsd#SummaryofsignificantaccountingpoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b27ee08f-160a-4b8b-8fbb-57ebe3f3aae5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a7e6b63a-0203-4236-906d-9f7bdf744bcc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b27ee08f-160a-4b8b-8fbb-57ebe3f3aae5" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a7e6b63a-0203-4236-906d-9f7bdf744bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_4e163cb0-f6a1-456d-b3bb-5fee8c3326e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b27ee08f-160a-4b8b-8fbb-57ebe3f3aae5" xlink:to="loc_us-gaap_UseOfEstimates_4e163cb0-f6a1-456d-b3bb-5fee8c3326e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_33da96c4-a0e5-4dfc-b3e3-e7dcfe91367c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b27ee08f-160a-4b8b-8fbb-57ebe3f3aae5" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_33da96c4-a0e5-4dfc-b3e3-e7dcfe91367c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_InventoriesAndCostOfProductSalesPolicyTextBlock_a8825b05-c09c-454d-85c3-44cc585f331b" xlink:href="ptct-20200630.xsd#ptct_InventoriesAndCostOfProductSalesPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b27ee08f-160a-4b8b-8fbb-57ebe3f3aae5" xlink:to="loc_ptct_InventoriesAndCostOfProductSalesPolicyTextBlock_a8825b05-c09c-454d-85c3-44cc585f331b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_cd05f88c-d937-4d0c-b526-353ca2e6677d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b27ee08f-160a-4b8b-8fbb-57ebe3f3aae5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_cd05f88c-d937-4d0c-b526-353ca2e6677d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_c1c9e02f-b371-4473-8ee9-7e6e2206bec1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b27ee08f-160a-4b8b-8fbb-57ebe3f3aae5" xlink:to="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_c1c9e02f-b371-4473-8ee9-7e6e2206bec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_9bc0595f-1057-4227-939f-a1b9e1bd706a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b27ee08f-160a-4b8b-8fbb-57ebe3f3aae5" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_9bc0595f-1057-4227-939f-a1b9e1bd706a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_d9dd6d93-2a5f-4123-90cd-5ccca5177756" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b27ee08f-160a-4b8b-8fbb-57ebe3f3aae5" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_d9dd6d93-2a5f-4123-90cd-5ccca5177756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_38d5f5c8-1e42-4322-9018-975b464863b9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b27ee08f-160a-4b8b-8fbb-57ebe3f3aae5" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_38d5f5c8-1e42-4322-9018-975b464863b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_ebacbe0a-db09-4290-b3a2-8f3ae36edb5a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b27ee08f-160a-4b8b-8fbb-57ebe3f3aae5" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_ebacbe0a-db09-4290-b3a2-8f3ae36edb5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_44aa98f0-4c8e-45ab-a85e-265e08883aba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b27ee08f-160a-4b8b-8fbb-57ebe3f3aae5" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_44aa98f0-4c8e-45ab-a85e-265e08883aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesTables" xlink:type="simple" xlink:href="ptct-20200630.xsd#SummaryofsignificantaccountingpoliciesTables"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_56f3227c-e478-4fc2-aa0a-ac8e34c537ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_5f5ea3c0-5bc2-42ef-af98-4b4bd82d1a28" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_56f3227c-e478-4fc2-aa0a-ac8e34c537ef" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_5f5ea3c0-5bc2-42ef-af98-4b4bd82d1a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_ac5e5cb9-bf34-4dc3-9a29-371c86404ab3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_56f3227c-e478-4fc2-aa0a-ac8e34c537ef" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_ac5e5cb9-bf34-4dc3-9a29-371c86404ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesInventoryDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#SummaryofsignificantaccountingpoliciesInventoryDetails"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ab8ac730-2738-4760-a06a-5308425ad3f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_3e130a09-6f97-4b70-b4a9-3a9dd90bd9f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ab8ac730-2738-4760-a06a-5308425ad3f4" xlink:to="loc_us-gaap_InventoryRawMaterials_3e130a09-6f97-4b70-b4a9-3a9dd90bd9f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_0cda9322-589d-45ba-81bd-2504e5c34ed2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ab8ac730-2738-4760-a06a-5308425ad3f4" xlink:to="loc_us-gaap_InventoryWorkInProcess_0cda9322-589d-45ba-81bd-2504e5c34ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_adb3700d-7ec5-4f54-a150-17b3e8645c02" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ab8ac730-2738-4760-a06a-5308425ad3f4" xlink:to="loc_us-gaap_InventoryFinishedGoods_adb3700d-7ec5-4f54-a150-17b3e8645c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_9dc2d3b2-8429-49b1-88f9-5fe87ee63ff0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ab8ac730-2738-4760-a06a-5308425ad3f4" xlink:to="loc_us-gaap_InventoryNet_9dc2d3b2-8429-49b1-88f9-5fe87ee63ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#SummaryofsignificantaccountingpoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4fe2c9b6-d810-44c5-a5ae-63dfbbd7e9a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_b12623c6-a985-43f5-8f24-5a7fc1b97e38" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4fe2c9b6-d810-44c5-a5ae-63dfbbd7e9a8" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_b12623c6-a985-43f5-8f24-5a7fc1b97e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4ebedbfb-3c0e-4a12-9204-aeb3c4e934f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_b12623c6-a985-43f5-8f24-5a7fc1b97e38" xlink:to="loc_us-gaap_DebtInstrumentAxis_4ebedbfb-3c0e-4a12-9204-aeb3c4e934f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_31557e6c-d0e3-4374-ae0f-d087d850620d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_4ebedbfb-3c0e-4a12-9204-aeb3c4e934f9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_31557e6c-d0e3-4374-ae0f-d087d850620d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_FifthAnniversaryMember_c48d604f-f1a5-4a14-832e-6cd82822f8e9" xlink:href="ptct-20200630.xsd#ptct_FifthAnniversaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31557e6c-d0e3-4374-ae0f-d087d850620d" xlink:to="loc_ptct_FifthAnniversaryMember_c48d604f-f1a5-4a14-832e-6cd82822f8e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_7e43155a-fd96-46f2-8617-c3e569005294" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_b12623c6-a985-43f5-8f24-5a7fc1b97e38" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_7e43155a-fd96-46f2-8617-c3e569005294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_f95d4d10-94d0-4527-87da-d50cb2647519" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_7e43155a-fd96-46f2-8617-c3e569005294" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_f95d4d10-94d0-4527-87da-d50cb2647519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_0bcd95ef-2059-4130-b918-a2897daae668" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_7e43155a-fd96-46f2-8617-c3e569005294" xlink:to="loc_us-gaap_InventoryWriteDown_0bcd95ef-2059-4130-b918-a2897daae668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_NetProductSales_d439c8a7-10c5-4527-acc5-639422d2529c" xlink:href="ptct-20200630.xsd#ptct_NetProductSales"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_7e43155a-fd96-46f2-8617-c3e569005294" xlink:to="loc_ptct_NetProductSales_d439c8a7-10c5-4527-acc5-639422d2529c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_b62c48bf-c6d5-44ac-9af9-96f14d00fbdb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_7e43155a-fd96-46f2-8617-c3e569005294" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_b62c48bf-c6d5-44ac-9af9-96f14d00fbdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_Termforletterofcredit_2c05763b-f3bf-4239-b253-87ab6d823cb2" xlink:href="ptct-20200630.xsd#ptct_Termforletterofcredit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_7e43155a-fd96-46f2-8617-c3e569005294" xlink:to="loc_ptct_Termforletterofcredit_2c05763b-f3bf-4239-b253-87ab6d823cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c2d48277-cb2c-4a4e-9b56-37c00a7bb718" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_7e43155a-fd96-46f2-8617-c3e569005294" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c2d48277-cb2c-4a4e-9b56-37c00a7bb718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_041aefa0-7135-4f6c-b97f-c77fcbeb9221" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_7e43155a-fd96-46f2-8617-c3e569005294" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_041aefa0-7135-4f6c-b97f-c77fcbeb9221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_dc783458-d974-4737-bb47-5466ac49a422" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_7e43155a-fd96-46f2-8617-c3e569005294" xlink:to="loc_us-gaap_DeferredTaxLiabilities_dc783458-d974-4737-bb47-5466ac49a422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_713a577b-27bf-41da-a6d5-80182345baa4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_7e43155a-fd96-46f2-8617-c3e569005294" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_713a577b-27bf-41da-a6d5-80182345baa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesReconciliationofcashDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#SummaryofsignificantaccountingpoliciesReconciliationofcashDetails"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesReconciliationofcashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_337c410a-9de6-4b20-87eb-2f7479c74333" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b9e759e8-2abb-4016-8095-645d37ae1e34" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_337c410a-9de6-4b20-87eb-2f7479c74333" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b9e759e8-2abb-4016-8095-645d37ae1e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_15581619-548b-4768-94f8-416848b3206b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_337c410a-9de6-4b20-87eb-2f7479c74333" xlink:to="loc_us-gaap_RestrictedCash_15581619-548b-4768-94f8-416848b3206b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_99afaf4b-120c-4770-8a70-47b8170eaaea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_337c410a-9de6-4b20-87eb-2f7479c74333" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_99afaf4b-120c-4770-8a70-47b8170eaaea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/Leases" xlink:type="simple" xlink:href="ptct-20200630.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_5d8a0637-a229-48b3-9943-4f26f53243c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_40e29328-b100-4bfa-86bd-bf763b05e6e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5d8a0637-a229-48b3-9943-4f26f53243c4" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_40e29328-b100-4bfa-86bd-bf763b05e6e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/LeasesTables" xlink:type="simple" xlink:href="ptct-20200630.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_30b2fed0-3738-4476-8d3c-37839f056a65" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_a3e903f9-b634-4cf7-9332-0a8a44940922" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_30b2fed0-3738-4476-8d3c-37839f056a65" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_a3e903f9-b634-4cf7-9332-0a8a44940922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d5b6262e-e81c-43f5-bac7-45ca7f1f82e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_30b2fed0-3738-4476-8d3c-37839f056a65" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d5b6262e-e81c-43f5-bac7-45ca7f1f82e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_48c62d1a-42d8-447c-9fa0-d037192b0130" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_f7839595-26d2-45c2-b6d0-56fdd343aa5a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_48c62d1a-42d8-447c-9fa0-d037192b0130" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_f7839595-26d2-45c2-b6d0-56fdd343aa5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_39611e10-7ea9-42d2-bb79-29376c129131" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f7839595-26d2-45c2-b6d0-56fdd343aa5a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_39611e10-7ea9-42d2-bb79-29376c129131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3ff556ed-41d6-4111-ad12-5cea46d72def" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_39611e10-7ea9-42d2-bb79-29376c129131" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3ff556ed-41d6-4111-ad12-5cea46d72def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_BioElectronMember_6586a7c8-66ca-4635-8330-0cdbb07a2d49" xlink:href="ptct-20200630.xsd#ptct_BioElectronMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3ff556ed-41d6-4111-ad12-5cea46d72def" xlink:to="loc_ptct_BioElectronMember_6586a7c8-66ca-4635-8330-0cdbb07a2d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_7a373945-86fe-49b6-b8a4-ed990ca08904" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f7839595-26d2-45c2-b6d0-56fdd343aa5a" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_7a373945-86fe-49b6-b8a4-ed990ca08904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_ccc2277c-0020-4c95-a271-53c820fd1264" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_7a373945-86fe-49b6-b8a4-ed990ca08904" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_ccc2277c-0020-4c95-a271-53c820fd1264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_54aa064a-312f-4668-ac25-409bde2e78db" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NJ"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_ccc2277c-0020-4c95-a271-53c820fd1264" xlink:to="loc_stpr_NJ_54aa064a-312f-4668-ac25-409bde2e78db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_HopewellNewBuildingMember_2f009dd4-3185-42e2-a323-484604eb014d" xlink:href="ptct-20200630.xsd#ptct_HopewellNewBuildingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_ccc2277c-0020-4c95-a271-53c820fd1264" xlink:to="loc_ptct_HopewellNewBuildingMember_2f009dd4-3185-42e2-a323-484604eb014d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_TheCampusMember_b068fd98-44ab-4030-93e6-493554e5cb76" xlink:href="ptct-20200630.xsd#ptct_TheCampusMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_ccc2277c-0020-4c95-a271-53c820fd1264" xlink:to="loc_ptct_TheCampusMember_b068fd98-44ab-4030-93e6-493554e5cb76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_HopewellCampusMember_a115782b-a2f0-4b62-b209-7d3c5cf050a1" xlink:href="ptct-20200630.xsd#ptct_HopewellCampusMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_ccc2277c-0020-4c95-a271-53c820fd1264" xlink:to="loc_ptct_HopewellCampusMember_a115782b-a2f0-4b62-b209-7d3c5cf050a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_MountainviewMember_4de97b27-cd65-43af-838a-ac350a953182" xlink:href="ptct-20200630.xsd#ptct_MountainviewMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_ccc2277c-0020-4c95-a271-53c820fd1264" xlink:to="loc_ptct_MountainviewMember_4de97b27-cd65-43af-838a-ac350a953182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_BridgewaterMember_1b9a56c0-58d6-4ce7-b31f-74ec9d6ed404" xlink:href="ptct-20200630.xsd#ptct_BridgewaterMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_ccc2277c-0020-4c95-a271-53c820fd1264" xlink:to="loc_ptct_BridgewaterMember_1b9a56c0-58d6-4ce7-b31f-74ec9d6ed404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5d62d1b9-f62d-4938-a0da-a19c441ba107" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f7839595-26d2-45c2-b6d0-56fdd343aa5a" xlink:to="loc_srt_RangeAxis_5d62d1b9-f62d-4938-a0da-a19c441ba107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bb1da254-9529-4b01-9db7-f32d3a684fcb" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5d62d1b9-f62d-4938-a0da-a19c441ba107" xlink:to="loc_srt_RangeMember_bb1da254-9529-4b01-9db7-f32d3a684fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fe0473ad-b53c-4a7c-8579-2843164d998d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bb1da254-9529-4b01-9db7-f32d3a684fcb" xlink:to="loc_srt_MinimumMember_fe0473ad-b53c-4a7c-8579-2843164d998d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9504c55d-b3d0-4d59-aab0-f5e09ac2aa51" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bb1da254-9529-4b01-9db7-f32d3a684fcb" xlink:to="loc_srt_MaximumMember_9504c55d-b3d0-4d59-aab0-f5e09ac2aa51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7a12f682-164f-4490-bbc5-363af6fb39e1" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f7839595-26d2-45c2-b6d0-56fdd343aa5a" xlink:to="loc_srt_CounterpartyNameAxis_7a12f682-164f-4490-bbc5-363af6fb39e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7aadef83-b4f7-49b1-89f5-cc96eddb9503" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_7a12f682-164f-4490-bbc5-363af6fb39e1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7aadef83-b4f7-49b1-89f5-cc96eddb9503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_HopewellCampusMember_0bb6d684-52dc-415e-a59b-0cc1c133b1fd" xlink:href="ptct-20200630.xsd#ptct_HopewellCampusMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7aadef83-b4f7-49b1-89f5-cc96eddb9503" xlink:to="loc_ptct_HopewellCampusMember_0bb6d684-52dc-415e-a59b-0cc1c133b1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_MassBioMember_a804abd4-117e-49f1-a09f-a0a3818ba73c" xlink:href="ptct-20200630.xsd#ptct_MassBioMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7aadef83-b4f7-49b1-89f5-cc96eddb9503" xlink:to="loc_ptct_MassBioMember_a804abd4-117e-49f1-a09f-a0a3818ba73c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_MountainviewMember_3cf6b390-044e-478d-b020-e07c9a7c5403" xlink:href="ptct-20200630.xsd#ptct_MountainviewMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7aadef83-b4f7-49b1-89f5-cc96eddb9503" xlink:to="loc_ptct_MountainviewMember_3cf6b390-044e-478d-b020-e07c9a7c5403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_61412805-1e95-4ee1-be8c-879318cb9b2a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f7839595-26d2-45c2-b6d0-56fdd343aa5a" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_61412805-1e95-4ee1-be8c-879318cb9b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_e15c393d-9bdc-4f09-96e6-4af89eb1f33d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_61412805-1e95-4ee1-be8c-879318cb9b2a" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_e15c393d-9bdc-4f09-96e6-4af89eb1f33d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_FinanceLeaseMember_2e070d8c-7702-4521-ac80-e6bb1cb6e3cf" xlink:href="ptct-20200630.xsd#ptct_FinanceLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_e15c393d-9bdc-4f09-96e6-4af89eb1f33d" xlink:to="loc_ptct_FinanceLeaseMember_2e070d8c-7702-4521-ac80-e6bb1cb6e3cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_ba1982cd-fd62-4991-a29c-bcfc52bcff4d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f7839595-26d2-45c2-b6d0-56fdd343aa5a" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_ba1982cd-fd62-4991-a29c-bcfc52bcff4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_NumberOfOperatingLeases_8bd77c1f-295e-479c-8025-369e23aade93" xlink:href="ptct-20200630.xsd#ptct_NumberOfOperatingLeases"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ba1982cd-fd62-4991-a29c-bcfc52bcff4d" xlink:to="loc_ptct_NumberOfOperatingLeases_8bd77c1f-295e-479c-8025-369e23aade93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_027716f6-e8e6-42a4-9d85-a850006cf8c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ba1982cd-fd62-4991-a29c-bcfc52bcff4d" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_027716f6-e8e6-42a4-9d85-a850006cf8c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_49486be7-8da6-4b5b-9a63-9fcce80f7d33" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ba1982cd-fd62-4991-a29c-bcfc52bcff4d" xlink:to="loc_us-gaap_OperatingLeaseExpense_49486be7-8da6-4b5b-9a63-9fcce80f7d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_c71bf4bc-f8ea-4e18-b3c6-9e1807e7bab3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ba1982cd-fd62-4991-a29c-bcfc52bcff4d" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_c71bf4bc-f8ea-4e18-b3c6-9e1807e7bab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_97922780-7f57-4517-9ed9-574082531fa0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ba1982cd-fd62-4991-a29c-bcfc52bcff4d" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_97922780-7f57-4517-9ed9-574082531fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_Numberofterms_be944df5-ee4e-46ce-ae6a-de54fd3aa6b2" xlink:href="ptct-20200630.xsd#ptct_Numberofterms"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ba1982cd-fd62-4991-a29c-bcfc52bcff4d" xlink:to="loc_ptct_Numberofterms_be944df5-ee4e-46ce-ae6a-de54fd3aa6b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_da4d20f0-62c0-47b9-9e42-07e923f37909" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ba1982cd-fd62-4991-a29c-bcfc52bcff4d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_da4d20f0-62c0-47b9-9e42-07e923f37909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_PercentOfMarketRate_6c09899f-49d1-44c2-b8c6-63397155a60e" xlink:href="ptct-20200630.xsd#ptct_PercentOfMarketRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ba1982cd-fd62-4991-a29c-bcfc52bcff4d" xlink:to="loc_ptct_PercentOfMarketRate_6c09899f-49d1-44c2-b8c6-63397155a60e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_6e52592b-dcdf-4c40-b4e1-c5b7af8693fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ba1982cd-fd62-4991-a29c-bcfc52bcff4d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_6e52592b-dcdf-4c40-b4e1-c5b7af8693fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c31545c8-1b64-4791-82bb-84b0289e3b0b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ba1982cd-fd62-4991-a29c-bcfc52bcff4d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c31545c8-1b64-4791-82bb-84b0289e3b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_dac91cc7-a0a0-42f0-9c74-561a12de7e37" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ba1982cd-fd62-4991-a29c-bcfc52bcff4d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_dac91cc7-a0a0-42f0-9c74-561a12de7e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_NumberOfOperatingLeaseLeaseNotyetCommenced_5219a9dd-1eb7-4551-adfe-b952874d8f79" xlink:href="ptct-20200630.xsd#ptct_NumberOfOperatingLeaseLeaseNotyetCommenced"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ba1982cd-fd62-4991-a29c-bcfc52bcff4d" xlink:to="loc_ptct_NumberOfOperatingLeaseLeaseNotyetCommenced_5219a9dd-1eb7-4551-adfe-b952874d8f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_86fc306e-146c-49c4-90b5-21ebf7c9a2dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ba1982cd-fd62-4991-a29c-bcfc52bcff4d" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_86fc306e-146c-49c4-90b5-21ebf7c9a2dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_b00e7227-d5a4-46c5-9b96-2bcd884c58a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ba1982cd-fd62-4991-a29c-bcfc52bcff4d" xlink:to="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_b00e7227-d5a4-46c5-9b96-2bcd884c58a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_01598699-ef9f-423d-91ed-2bfa78450f82" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ba1982cd-fd62-4991-a29c-bcfc52bcff4d" xlink:to="loc_us-gaap_LeaseAndRentalExpense_01598699-ef9f-423d-91ed-2bfa78450f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_FinanceLeasePresentValueOfExceedsTheFairValue_b021cecb-4cbb-44b0-9fc5-b5543eeed2bb" xlink:href="ptct-20200630.xsd#ptct_FinanceLeasePresentValueOfExceedsTheFairValue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ba1982cd-fd62-4991-a29c-bcfc52bcff4d" xlink:to="loc_ptct_FinanceLeasePresentValueOfExceedsTheFairValue_b021cecb-4cbb-44b0-9fc5-b5543eeed2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_22f19754-4c7e-4fd3-8328-6a7ad7eef6bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ba1982cd-fd62-4991-a29c-bcfc52bcff4d" xlink:to="loc_us-gaap_OperatingLeaseCost_22f19754-4c7e-4fd3-8328-6a7ad7eef6bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ca1a35e2-20f9-4a61-9fa5-81766d995cff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ba1982cd-fd62-4991-a29c-bcfc52bcff4d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ca1a35e2-20f9-4a61-9fa5-81766d995cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_LeaseArea_48a091fd-c6ba-4292-9b18-ca0bc26e2e99" xlink:href="ptct-20200630.xsd#ptct_LeaseArea"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ba1982cd-fd62-4991-a29c-bcfc52bcff4d" xlink:to="loc_ptct_LeaseArea_48a091fd-c6ba-4292-9b18-ca0bc26e2e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/LeasesLeasecostsDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#LeasesLeasecostsDetails"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/LeasesLeasecostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_aa8f60ac-94c8-46b2-8d41-f3f2b4a0161d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_28719cc0-8804-4824-9a41-0d54da511b17" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_aa8f60ac-94c8-46b2-8d41-f3f2b4a0161d" xlink:to="loc_us-gaap_OperatingLeaseCost_28719cc0-8804-4824-9a41-0d54da511b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_6716767b-092a-44ca-8bfb-cefedb583191" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_aa8f60ac-94c8-46b2-8d41-f3f2b4a0161d" xlink:to="loc_us-gaap_VariableLeaseCost_6716767b-092a-44ca-8bfb-cefedb583191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_8ba7093d-c983-43a2-b88f-22d33f7a54cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_aa8f60ac-94c8-46b2-8d41-f3f2b4a0161d" xlink:to="loc_us-gaap_ShortTermLeaseCost_8ba7093d-c983-43a2-b88f-22d33f7a54cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_ecc569a0-9690-4bf7-9198-b08cff58c1df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_aa8f60ac-94c8-46b2-8d41-f3f2b4a0161d" xlink:to="loc_us-gaap_LeaseCost_ecc569a0-9690-4bf7-9198-b08cff58c1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/LeasesBalancesheetDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#LeasesBalancesheetDetails"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/LeasesBalancesheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2198a949-ac67-4425-85c3-6fd198ff3564" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_02f90bde-174a-47fa-9f8a-2d91c9823157" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2198a949-ac67-4425-85c3-6fd198ff3564" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_02f90bde-174a-47fa-9f8a-2d91c9823157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_81401e51-580d-4951-8440-e392324335ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2198a949-ac67-4425-85c3-6fd198ff3564" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_81401e51-580d-4951-8440-e392324335ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_53debcfa-10a8-4b96-a0c1-9af3c65c7bd2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2198a949-ac67-4425-85c3-6fd198ff3564" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_53debcfa-10a8-4b96-a0c1-9af3c65c7bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_bfcb34dd-420b-4ac5-a07e-a067b1a950c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2198a949-ac67-4425-85c3-6fd198ff3564" xlink:to="loc_us-gaap_OperatingLeaseLiability_bfcb34dd-420b-4ac5-a07e-a067b1a950c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/LeasesSupplementalleasetermsDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#LeasesSupplementalleasetermsDetails"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/LeasesSupplementalleasetermsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_5396db0c-e5ae-4924-8bdd-75ded2409218" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_eea471af-b80d-40d8-b463-8542eff9e24f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5396db0c-e5ae-4924-8bdd-75ded2409218" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_eea471af-b80d-40d8-b463-8542eff9e24f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_039f7f86-628e-43dc-989c-73af1f035368" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5396db0c-e5ae-4924-8bdd-75ded2409218" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_039f7f86-628e-43dc-989c-73af1f035368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_ae75ac78-5db0-4ce7-b0bc-4347247a36f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5396db0c-e5ae-4924-8bdd-75ded2409218" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_ae75ac78-5db0-4ce7-b0bc-4347247a36f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_cedbfc9d-64b6-4878-9c0c-45e80f212191" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5396db0c-e5ae-4924-8bdd-75ded2409218" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_cedbfc9d-64b6-4878-9c0c-45e80f212191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/LeasesLeasepaymentsDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#LeasesLeasepaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/LeasesLeasepaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2adc0a29-d5e3-40fe-adb1-3edaf8353a30" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_bd893bfe-f48d-4ccc-a965-3f0817802484" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2adc0a29-d5e3-40fe-adb1-3edaf8353a30" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_bd893bfe-f48d-4ccc-a965-3f0817802484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_817e6e6b-34f7-436b-b5b0-c4bbe1ae05d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2adc0a29-d5e3-40fe-adb1-3edaf8353a30" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_817e6e6b-34f7-436b-b5b0-c4bbe1ae05d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_bbebc84f-59fc-4f5b-aa99-15589eca56c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2adc0a29-d5e3-40fe-adb1-3edaf8353a30" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_bbebc84f-59fc-4f5b-aa99-15589eca56c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_34a3a5a9-905d-4c83-8ec4-80d2dbc59d51" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2adc0a29-d5e3-40fe-adb1-3edaf8353a30" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_34a3a5a9-905d-4c83-8ec4-80d2dbc59d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter_f8226c2c-11a3-48bf-8c22-e2b138d6b47a" xlink:href="ptct-20200630.xsd#ptct_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2adc0a29-d5e3-40fe-adb1-3edaf8353a30" xlink:to="loc_ptct_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter_f8226c2c-11a3-48bf-8c22-e2b138d6b47a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6e848385-87b2-47ef-b12e-188a8f7d87fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2adc0a29-d5e3-40fe-adb1-3edaf8353a30" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6e848385-87b2-47ef-b12e-188a8f7d87fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_fbb8405c-22a5-460c-b88f-0ee7caa10f49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2adc0a29-d5e3-40fe-adb1-3edaf8353a30" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_fbb8405c-22a5-460c-b88f-0ee7caa10f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_009027f7-59d8-4a7a-831f-23686ff8607d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2adc0a29-d5e3-40fe-adb1-3edaf8353a30" xlink:to="loc_us-gaap_OperatingLeaseLiability_009027f7-59d8-4a7a-831f-23686ff8607d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_a70cce87-b263-439b-b7c1-0020288da854" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2adc0a29-d5e3-40fe-adb1-3edaf8353a30" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_a70cce87-b263-439b-b7c1-0020288da854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_0224f999-0a64-4b47-9b37-7dd742603dcc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2adc0a29-d5e3-40fe-adb1-3edaf8353a30" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_0224f999-0a64-4b47-9b37-7dd742603dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_854244a0-3611-40c7-b8cb-b19050b94de7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2adc0a29-d5e3-40fe-adb1-3edaf8353a30" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_854244a0-3611-40c7-b8cb-b19050b94de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_9039c561-c2fe-4d74-b8c5-630547a1d0dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2adc0a29-d5e3-40fe-adb1-3edaf8353a30" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_9039c561-c2fe-4d74-b8c5-630547a1d0dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_c8ba3230-4dc1-4cd6-a3bc-037f06ca9126" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2adc0a29-d5e3-40fe-adb1-3edaf8353a30" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_c8ba3230-4dc1-4cd6-a3bc-037f06ca9126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_719ed99b-c86f-4a34-9546-3eeab2232b00" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2adc0a29-d5e3-40fe-adb1-3edaf8353a30" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_719ed99b-c86f-4a34-9546-3eeab2232b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_00ed2f19-7831-4d9b-b5ba-01f62639168f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2adc0a29-d5e3-40fe-adb1-3edaf8353a30" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_00ed2f19-7831-4d9b-b5ba-01f62639168f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_5755571e-438e-467a-bc94-c792baa16d30" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2adc0a29-d5e3-40fe-adb1-3edaf8353a30" xlink:to="loc_us-gaap_FinanceLeaseLiability_5755571e-438e-467a-bc94-c792baa16d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/LeasesLeasepaymentsDetails_1" xlink:type="simple" xlink:href="ptct-20200630.xsd#LeasesLeasepaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/LeasesLeasepaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/LeasesCashflowDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#LeasesCashflowDetails"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/LeasesCashflowDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3ce0cf05-1451-4c10-a74f-02402d2b7465" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_1b0d121c-c956-4c10-ab2c-b866eda1c0d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3ce0cf05-1451-4c10-a74f-02402d2b7465" xlink:to="loc_us-gaap_OperatingLeasePayments_1b0d121c-c956-4c10-ab2c-b866eda1c0d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_2c9fb715-2475-40bf-9a01-18afc4d3be5c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3ce0cf05-1451-4c10-a74f-02402d2b7465" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_2c9fb715-2475-40bf-9a01-18afc4d3be5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_6cf5d2aa-4bf3-403a-b58f-0a1f5bd5ad76" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3ce0cf05-1451-4c10-a74f-02402d2b7465" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_6cf5d2aa-4bf3-403a-b58f-0a1f5bd5ad76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_3ebe864c-0aa2-4730-8970-cbcd1412cc4f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3ce0cf05-1451-4c10-a74f-02402d2b7465" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_3ebe864c-0aa2-4730-8970-cbcd1412cc4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/Acquisitions" xlink:type="simple" xlink:href="ptct-20200630.xsd#Acquisitions"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_305dca2d-1485-41a8-af85-c941631d7f8a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_d9eb0da6-caf6-4fc2-93d9-5fe37d228f29" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_305dca2d-1485-41a8-af85-c941631d7f8a" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_d9eb0da6-caf6-4fc2-93d9-5fe37d228f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#AcquisitionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/AcquisitionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_0cf4d39a-da52-4882-8eaf-a103278e96f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_63585aea-6cad-46fe-812e-ea27e6771c7b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_0cf4d39a-da52-4882-8eaf-a103278e96f1" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_63585aea-6cad-46fe-812e-ea27e6771c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0401fd87-a746-4085-b506-25cc5d9c46e7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_63585aea-6cad-46fe-812e-ea27e6771c7b" xlink:to="loc_srt_CounterpartyNameAxis_0401fd87-a746-4085-b506-25cc5d9c46e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_936ed0c6-52be-4e60-826a-9af6d7056315" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_0401fd87-a746-4085-b506-25cc5d9c46e7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_936ed0c6-52be-4e60-826a-9af6d7056315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_CesnaMember_c0337b23-b8bb-4d87-b872-479e0b8e9ff7" xlink:href="ptct-20200630.xsd#ptct_CesnaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_936ed0c6-52be-4e60-826a-9af6d7056315" xlink:to="loc_ptct_CesnaMember_c0337b23-b8bb-4d87-b872-479e0b8e9ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_CensaMember_fd7c86aa-30e2-4da3-af56-811458d9ef15" xlink:href="ptct-20200630.xsd#ptct_CensaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_936ed0c6-52be-4e60-826a-9af6d7056315" xlink:to="loc_ptct_CensaMember_fd7c86aa-30e2-4da3-af56-811458d9ef15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a9cf1fac-fa8d-47d7-b3aa-5b0d435e0938" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_63585aea-6cad-46fe-812e-ea27e6771c7b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a9cf1fac-fa8d-47d7-b3aa-5b0d435e0938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_PaymentsforAssetAcquisitions_e9001436-2868-4643-b01a-31b976a0db60" xlink:href="ptct-20200630.xsd#ptct_PaymentsforAssetAcquisitions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a9cf1fac-fa8d-47d7-b3aa-5b0d435e0938" xlink:to="loc_ptct_PaymentsforAssetAcquisitions_e9001436-2868-4643-b01a-31b976a0db60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_PaymentsForAssetAcquisitionsUpfrontPayment_c2880059-3451-4681-8997-6e176d93b03b" xlink:href="ptct-20200630.xsd#ptct_PaymentsForAssetAcquisitionsUpfrontPayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a9cf1fac-fa8d-47d7-b3aa-5b0d435e0938" xlink:to="loc_ptct_PaymentsForAssetAcquisitionsUpfrontPayment_c2880059-3451-4681-8997-6e176d93b03b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_PaymentsForAssetAcquisitionsNetAssets_21d597b0-9901-401d-acb2-c1d30c4506e2" xlink:href="ptct-20200630.xsd#ptct_PaymentsForAssetAcquisitionsNetAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a9cf1fac-fa8d-47d7-b3aa-5b0d435e0938" xlink:to="loc_ptct_PaymentsForAssetAcquisitionsNetAssets_21d597b0-9901-401d-acb2-c1d30c4506e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_77f1e68f-8289-49a6-9ad8-0d716104b86d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a9cf1fac-fa8d-47d7-b3aa-5b0d435e0938" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_77f1e68f-8289-49a6-9ad8-0d716104b86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_710c2f15-65cd-4ae3-94ef-b75a4ae0e86b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a9cf1fac-fa8d-47d7-b3aa-5b0d435e0938" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_710c2f15-65cd-4ae3-94ef-b75a4ae0e86b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ConsiderationForAssetAcquisitions_d9c48a9f-f737-4008-b77e-636f735fc898" xlink:href="ptct-20200630.xsd#ptct_ConsiderationForAssetAcquisitions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a9cf1fac-fa8d-47d7-b3aa-5b0d435e0938" xlink:to="loc_ptct_ConsiderationForAssetAcquisitions_d9c48a9f-f737-4008-b77e-636f735fc898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_5baeb2c9-fb04-4e01-8e44-585a5c7edefa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a9cf1fac-fa8d-47d7-b3aa-5b0d435e0938" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_5baeb2c9-fb04-4e01-8e44-585a5c7edefa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AssetAcquisitionTransactionCosts_9edd1f36-fd23-433d-ad2a-a970ffda84bf" xlink:href="ptct-20200630.xsd#ptct_AssetAcquisitionTransactionCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a9cf1fac-fa8d-47d7-b3aa-5b0d435e0938" xlink:to="loc_ptct_AssetAcquisitionTransactionCosts_9edd1f36-fd23-433d-ad2a-a970ffda84bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AssetAcquisitionConsiderationTransferred_7bf05185-484f-47e3-a9d9-859898d34540" xlink:href="ptct-20200630.xsd#ptct_AssetAcquisitionConsiderationTransferred"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a9cf1fac-fa8d-47d7-b3aa-5b0d435e0938" xlink:to="loc_ptct_AssetAcquisitionConsiderationTransferred_7bf05185-484f-47e3-a9d9-859898d34540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AssetAcquisitionCash_5f552f90-f6d1-4406-934f-b196be3d9a62" xlink:href="ptct-20200630.xsd#ptct_AssetAcquisitionCash"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a9cf1fac-fa8d-47d7-b3aa-5b0d435e0938" xlink:to="loc_ptct_AssetAcquisitionCash_5f552f90-f6d1-4406-934f-b196be3d9a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AssetAcquisitionOtherAssets_838d7e50-4d59-4320-8e90-1f376e32fb0c" xlink:href="ptct-20200630.xsd#ptct_AssetAcquisitionOtherAssets"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a9cf1fac-fa8d-47d7-b3aa-5b0d435e0938" xlink:to="loc_ptct_AssetAcquisitionOtherAssets_838d7e50-4d59-4320-8e90-1f376e32fb0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AssetAcquisitionInProcessResearchAndDevelopment_1565eb9c-3d1a-4609-85e6-4fd124df168d" xlink:href="ptct-20200630.xsd#ptct_AssetAcquisitionInProcessResearchAndDevelopment"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a9cf1fac-fa8d-47d7-b3aa-5b0d435e0938" xlink:to="loc_ptct_AssetAcquisitionInProcessResearchAndDevelopment_1565eb9c-3d1a-4609-85e6-4fd124df168d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AssetAcquisitionResearchAndDevelopmentExpense_75b98270-790d-40f0-81cb-9bb528f885fb" xlink:href="ptct-20200630.xsd#ptct_AssetAcquisitionResearchAndDevelopmentExpense"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a9cf1fac-fa8d-47d7-b3aa-5b0d435e0938" xlink:to="loc_ptct_AssetAcquisitionResearchAndDevelopmentExpense_75b98270-790d-40f0-81cb-9bb528f885fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AssetAcquisitionSellingGeneralAndAdministrativeExpense_9a5c6ab2-081e-429a-887a-3582e4923ee4" xlink:href="ptct-20200630.xsd#ptct_AssetAcquisitionSellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a9cf1fac-fa8d-47d7-b3aa-5b0d435e0938" xlink:to="loc_ptct_AssetAcquisitionSellingGeneralAndAdministrativeExpense_9a5c6ab2-081e-429a-887a-3582e4923ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AssetAcquisitionMilestoneAmount_f3cf9fa9-74b7-4c80-9cb4-5040e9feb073" xlink:href="ptct-20200630.xsd#ptct_AssetAcquisitionMilestoneAmount"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a9cf1fac-fa8d-47d7-b3aa-5b0d435e0938" xlink:to="loc_ptct_AssetAcquisitionMilestoneAmount_f3cf9fa9-74b7-4c80-9cb4-5040e9feb073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AssetAcquisitionDevelopmentAndRegulatoryMilestones_d01c00fe-3ff1-457f-ab49-1919358f5c88" xlink:href="ptct-20200630.xsd#ptct_AssetAcquisitionDevelopmentAndRegulatoryMilestones"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a9cf1fac-fa8d-47d7-b3aa-5b0d435e0938" xlink:to="loc_ptct_AssetAcquisitionDevelopmentAndRegulatoryMilestones_d01c00fe-3ff1-457f-ab49-1919358f5c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AssetAcquisitionNetSalesMilestone_558a93be-ffa5-492c-88f3-9ca70517a376" xlink:href="ptct-20200630.xsd#ptct_AssetAcquisitionNetSalesMilestone"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a9cf1fac-fa8d-47d7-b3aa-5b0d435e0938" xlink:to="loc_ptct_AssetAcquisitionNetSalesMilestone_558a93be-ffa5-492c-88f3-9ca70517a376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AssetAcquisitionInitialMilestone_337d8606-afa3-4c3a-8a1a-8318beee96d9" xlink:href="ptct-20200630.xsd#ptct_AssetAcquisitionInitialMilestone"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a9cf1fac-fa8d-47d7-b3aa-5b0d435e0938" xlink:to="loc_ptct_AssetAcquisitionInitialMilestone_337d8606-afa3-4c3a-8a1a-8318beee96d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense_61d367ef-5bdc-4cf0-a35e-4548f49ba031" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a9cf1fac-fa8d-47d7-b3aa-5b0d435e0938" xlink:to="loc_us-gaap_OtherResearchAndDevelopmentExpense_61d367ef-5bdc-4cf0-a35e-4548f49ba031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/AcquisitionsPreliminaryAllocationofpurchasepriceDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#AcquisitionsPreliminaryAllocationofpurchasepriceDetails"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/AcquisitionsPreliminaryAllocationofpurchasepriceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_b63460b9-4687-47e5-8731-4e0536f426a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c6041647-c125-41a6-b260-a892ea3cc27e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_b63460b9-4687-47e5-8731-4e0536f426a5" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c6041647-c125-41a6-b260-a892ea3cc27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a5ea5a47-3076-464f-9718-18836ac21099" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c6041647-c125-41a6-b260-a892ea3cc27e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a5ea5a47-3076-464f-9718-18836ac21099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6bd5e098-b777-49f4-901d-5b3084a9d7b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a5ea5a47-3076-464f-9718-18836ac21099" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6bd5e098-b777-49f4-901d-5b3084a9d7b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AgilisMember_3a6939e2-69d1-472b-9d38-28538082c441" xlink:href="ptct-20200630.xsd#ptct_AgilisMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6bd5e098-b777-49f4-901d-5b3084a9d7b3" xlink:to="loc_ptct_AgilisMember_3a6939e2-69d1-472b-9d38-28538082c441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a4beb240-33b0-4629-813e-2c2b2e262b15" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c6041647-c125-41a6-b260-a892ea3cc27e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a4beb240-33b0-4629-813e-2c2b2e262b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_dc3a0574-3c1e-44d0-8af9-734909f23e86" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a4beb240-33b0-4629-813e-2c2b2e262b15" xlink:to="loc_us-gaap_Goodwill_dc3a0574-3c1e-44d0-8af9-734909f23e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/Fairvalueoffinancialinstrumentsandmarketablesecurities" xlink:type="simple" xlink:href="ptct-20200630.xsd#Fairvalueoffinancialinstrumentsandmarketablesecurities"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/Fairvalueoffinancialinstrumentsandmarketablesecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d51932c2-f0b9-478b-91df-3010997933db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_e2973d0e-a5bf-442e-8f99-e7a1b4608244" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d51932c2-f0b9-478b-91df-3010997933db" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_e2973d0e-a5bf-442e-8f99-e7a1b4608244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesTables" xlink:type="simple" xlink:href="ptct-20200630.xsd#FairvalueoffinancialinstrumentsandmarketablesecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_26ae4b2d-0bf6-4baa-90f3-2d27df2afe75" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_fc86ddaf-30a7-42e6-b4ca-e1748525bd86" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_26ae4b2d-0bf6-4baa-90f3-2d27df2afe75" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_fc86ddaf-30a7-42e6-b4ca-e1748525bd86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_6ff4969c-5eed-4346-b40b-c243f47efe3e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_26ae4b2d-0bf6-4baa-90f3-2d27df2afe75" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_6ff4969c-5eed-4346-b40b-c243f47efe3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_aaf9637c-c1a8-487c-8376-29876437c774" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_26ae4b2d-0bf6-4baa-90f3-2d27df2afe75" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_aaf9637c-c1a8-487c-8376-29876437c774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_68801e81-f306-4348-aa30-c44a39b41969" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_26ae4b2d-0bf6-4baa-90f3-2d27df2afe75" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_68801e81-f306-4348-aa30-c44a39b41969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_d94b9483-0a51-44dc-8fa3-63ed35a5c164" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_26ae4b2d-0bf6-4baa-90f3-2d27df2afe75" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_d94b9483-0a51-44dc-8fa3-63ed35a5c164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_b5155f6b-0391-4622-9835-69c6a481e1ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_26ae4b2d-0bf6-4baa-90f3-2d27df2afe75" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_b5155f6b-0391-4622-9835-69c6a481e1ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1f223d78-21ef-47dd-9540-9522a25d529e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db5fba73-3952-4d19-b0a8-517bb2341ea5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1f223d78-21ef-47dd-9540-9522a25d529e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db5fba73-3952-4d19-b0a8-517bb2341ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_4c55798c-fb81-4486-92a2-48acda6eb9df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db5fba73-3952-4d19-b0a8-517bb2341ea5" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_4c55798c-fb81-4486-92a2-48acda6eb9df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_c91d8d0d-3345-4422-b5e8-75b8b53dab9e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_4c55798c-fb81-4486-92a2-48acda6eb9df" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_c91d8d0d-3345-4422-b5e8-75b8b53dab9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_3746b03e-9afb-438e-bf75-365f733445fa" xlink:href="ptct-20200630.xsd#ptct_LiabilityDevelopmentandRegulatoryMilestoneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_c91d8d0d-3345-4422-b5e8-75b8b53dab9e" xlink:to="loc_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_3746b03e-9afb-438e-bf75-365f733445fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_7b4d0789-aa6e-4b2e-bc75-e074498a8d2a" xlink:href="ptct-20200630.xsd#ptct_LiabilityNetSalesMilestonesandRoyaltiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_c91d8d0d-3345-4422-b5e8-75b8b53dab9e" xlink:to="loc_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_7b4d0789-aa6e-4b2e-bc75-e074498a8d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1b626627-fd6c-4d3f-8f73-5dce57416693" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db5fba73-3952-4d19-b0a8-517bb2341ea5" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1b626627-fd6c-4d3f-8f73-5dce57416693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1ab84823-e88d-46d8-8a16-5f1ec0c60b6a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1b626627-fd6c-4d3f-8f73-5dce57416693" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1ab84823-e88d-46d8-8a16-5f1ec0c60b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_053a679e-3171-4fbf-8244-77b2cd56bb9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1ab84823-e88d-46d8-8a16-5f1ec0c60b6a" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_053a679e-3171-4fbf-8244-77b2cd56bb9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_9cf94a5a-19f9-445c-99e3-9173aa29b745" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db5fba73-3952-4d19-b0a8-517bb2341ea5" xlink:to="loc_us-gaap_InvestmentTypeAxis_9cf94a5a-19f9-445c-99e3-9173aa29b745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_b69bd341-e609-4169-ac8e-4698a502592d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_9cf94a5a-19f9-445c-99e3-9173aa29b745" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_b69bd341-e609-4169-ac8e-4698a502592d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a067ae13-fdc3-4b1a-9798-9ae5f6512f5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b69bd341-e609-4169-ac8e-4698a502592d" xlink:to="loc_us-gaap_CommonStockMember_a067ae13-fdc3-4b1a-9798-9ae5f6512f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_db09b155-d7f3-4ffb-8bef-2953618d5d5b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db5fba73-3952-4d19-b0a8-517bb2341ea5" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_db09b155-d7f3-4ffb-8bef-2953618d5d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3e392bd0-cb21-4412-9c07-5b17a41e93c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_db09b155-d7f3-4ffb-8bef-2953618d5d5b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3e392bd0-cb21-4412-9c07-5b17a41e93c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_36318851-89ea-4b51-b99a-674582f3348d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_3e392bd0-cb21-4412-9c07-5b17a41e93c9" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_36318851-89ea-4b51-b99a-674582f3348d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5b6ba8e5-630c-4387-b936-7639bc5de371" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db5fba73-3952-4d19-b0a8-517bb2341ea5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5b6ba8e5-630c-4387-b936-7639bc5de371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f186164c-0077-460b-a7c5-a1448885e253" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5b6ba8e5-630c-4387-b936-7639bc5de371" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f186164c-0077-460b-a7c5-a1448885e253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncollaborativeArrangementTransactionsMember_149fdf5d-3c15-4f11-a3c0-28afea90aeb2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncollaborativeArrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f186164c-0077-460b-a7c5-a1448885e253" xlink:to="loc_us-gaap_NoncollaborativeArrangementTransactionsMember_149fdf5d-3c15-4f11-a3c0-28afea90aeb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4c98d17c-3241-41c9-a0dc-9f6dbf1f48f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db5fba73-3952-4d19-b0a8-517bb2341ea5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4c98d17c-3241-41c9-a0dc-9f6dbf1f48f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ec290769-b572-4775-8b53-310b5b6b8775" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4c98d17c-3241-41c9-a0dc-9f6dbf1f48f5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ec290769-b572-4775-8b53-310b5b6b8775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AgilisMember_c5cc49e2-e198-47ee-96b5-360b3b4fb34e" xlink:href="ptct-20200630.xsd#ptct_AgilisMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ec290769-b572-4775-8b53-310b5b6b8775" xlink:to="loc_ptct_AgilisMember_c5cc49e2-e198-47ee-96b5-360b3b4fb34e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_26a0b69b-f44e-45d3-80d7-412841febc8c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db5fba73-3952-4d19-b0a8-517bb2341ea5" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_26a0b69b-f44e-45d3-80d7-412841febc8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_7e87b914-c432-49a2-bba3-b9453f1c5d20" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_26a0b69b-f44e-45d3-80d7-412841febc8c" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_7e87b914-c432-49a2-bba3-b9453f1c5d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_fce9e988-f294-49da-ae6e-2d7d8df633db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7e87b914-c432-49a2-bba3-b9453f1c5d20" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_fce9e988-f294-49da-ae6e-2d7d8df633db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ProbabilityofSuccessMember_7a51d0b8-d81a-4512-a662-d04e2c993744" xlink:href="ptct-20200630.xsd#ptct_ProbabilityofSuccessMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7e87b914-c432-49a2-bba3-b9453f1c5d20" xlink:to="loc_ptct_ProbabilityofSuccessMember_7a51d0b8-d81a-4512-a662-d04e2c993744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_9f906228-87da-4790-8dc1-c4506413ae16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7e87b914-c432-49a2-bba3-b9453f1c5d20" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_9f906228-87da-4790-8dc1-c4506413ae16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_7c56d7ce-db7b-4ada-8e4d-68595b1465cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7e87b914-c432-49a2-bba3-b9453f1c5d20" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_7c56d7ce-db7b-4ada-8e4d-68595b1465cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1829fab0-3390-4e6e-b8d5-2cb260e0c8ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db5fba73-3952-4d19-b0a8-517bb2341ea5" xlink:to="loc_us-gaap_DebtInstrumentAxis_1829fab0-3390-4e6e-b8d5-2cb260e0c8ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_47f29884-9e86-4ac0-bf2d-2d50a0f5d807" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1829fab0-3390-4e6e-b8d5-2cb260e0c8ee" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_47f29884-9e86-4ac0-bf2d-2d50a0f5d807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_9e76ddce-67f6-4987-a6e6-ad6c9352ae8d" xlink:href="ptct-20200630.xsd#ptct_ConvertibleSeniorNotes3.0PercentDue2022Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_47f29884-9e86-4ac0-bf2d-2d50a0f5d807" xlink:to="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_9e76ddce-67f6-4987-a6e6-ad6c9352ae8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member_948551e8-db0e-446d-81c7-21256cc48085" xlink:href="ptct-20200630.xsd#ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_47f29884-9e86-4ac0-bf2d-2d50a0f5d807" xlink:to="loc_ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member_948551e8-db0e-446d-81c7-21256cc48085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c4d161bf-8fa5-4cf4-999b-51182864c881" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db5fba73-3952-4d19-b0a8-517bb2341ea5" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c4d161bf-8fa5-4cf4-999b-51182864c881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c9f839eb-9c75-4e39-9da0-bb07f5c53900" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c4d161bf-8fa5-4cf4-999b-51182864c881" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c9f839eb-9c75-4e39-9da0-bb07f5c53900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_d0fd28d2-c2af-4158-8acf-bb9647d0f5e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c9f839eb-9c75-4e39-9da0-bb07f5c53900" xlink:to="loc_us-gaap_ConvertibleDebtMember_d0fd28d2-c2af-4158-8acf-bb9647d0f5e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_3b3faa7c-e203-4ee2-96cc-1b9fc64878f0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db5fba73-3952-4d19-b0a8-517bb2341ea5" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_3b3faa7c-e203-4ee2-96cc-1b9fc64878f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_bd30ca5d-9548-4eb1-86b4-12ed05dc913b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_3b3faa7c-e203-4ee2-96cc-1b9fc64878f0" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_bd30ca5d-9548-4eb1-86b4-12ed05dc913b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_cad2bd2c-2e8a-4235-afe7-a712f2939985" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_bd30ca5d-9548-4eb1-86b4-12ed05dc913b" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_cad2bd2c-2e8a-4235-afe7-a712f2939985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_8a45712d-d529-41b3-a7e8-99c2cbe5b712" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_cad2bd2c-2e8a-4235-afe7-a712f2939985" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_8a45712d-d529-41b3-a7e8-99c2cbe5b712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e3f10348-8d7e-4415-b924-ade09b43d939" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db5fba73-3952-4d19-b0a8-517bb2341ea5" xlink:to="loc_us-gaap_AwardTypeAxis_e3f10348-8d7e-4415-b924-ade09b43d939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ec81723f-0fc0-411b-90f8-62205eadda0f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e3f10348-8d7e-4415-b924-ade09b43d939" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ec81723f-0fc0-411b-90f8-62205eadda0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_f8ac0899-6368-458e-b7af-2c609f58e6c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ec81723f-0fc0-411b-90f8-62205eadda0f" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_f8ac0899-6368-458e-b7af-2c609f58e6c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4d66fc25-afd8-4cf3-90e1-fd4ba21f5738" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db5fba73-3952-4d19-b0a8-517bb2341ea5" xlink:to="loc_srt_RangeAxis_4d66fc25-afd8-4cf3-90e1-fd4ba21f5738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d8aa51e7-c556-463d-b8cf-b8ee8e38c06b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4d66fc25-afd8-4cf3-90e1-fd4ba21f5738" xlink:to="loc_srt_RangeMember_d8aa51e7-c556-463d-b8cf-b8ee8e38c06b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2fcf4fb2-1fd1-47ff-9711-dafb860fb6e2" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d8aa51e7-c556-463d-b8cf-b8ee8e38c06b" xlink:to="loc_srt_MinimumMember_2fcf4fb2-1fd1-47ff-9711-dafb860fb6e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_54843027-8e5b-4dc1-a2fa-f3acc5cdc5eb" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d8aa51e7-c556-463d-b8cf-b8ee8e38c06b" xlink:to="loc_srt_MaximumMember_54843027-8e5b-4dc1-a2fa-f3acc5cdc5eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_023bea8e-63be-4471-bbaa-99a72d2a1d7c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d8aa51e7-c556-463d-b8cf-b8ee8e38c06b" xlink:to="loc_srt_WeightedAverageMember_023bea8e-63be-4471-bbaa-99a72d2a1d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_801523f6-69d2-4f8b-b1b9-fc5b90687709" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db5fba73-3952-4d19-b0a8-517bb2341ea5" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_801523f6-69d2-4f8b-b1b9-fc5b90687709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6a412751-122d-4862-a25c-cc0a7e291af4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_801523f6-69d2-4f8b-b1b9-fc5b90687709" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6a412751-122d-4862-a25c-cc0a7e291af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsMember_0decd93f-93b5-4174-bb76-07f945fd067c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6a412751-122d-4862-a25c-cc0a7e291af4" xlink:to="loc_us-gaap_CommitmentsMember_0decd93f-93b5-4174-bb76-07f945fd067c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_973a6b44-55c5-4abc-8060-0cce99ce01e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db5fba73-3952-4d19-b0a8-517bb2341ea5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_973a6b44-55c5-4abc-8060-0cce99ce01e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_39bd7aac-570a-43cc-b61b-0798188f5b9d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_973a6b44-55c5-4abc-8060-0cce99ce01e4" xlink:to="loc_us-gaap_EquityComponentDomain_39bd7aac-570a-43cc-b61b-0798188f5b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2e399af1-8bc1-4e0c-beb7-c4c4c269c6d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_39bd7aac-570a-43cc-b61b-0798188f5b9d" xlink:to="loc_us-gaap_CommonStockMember_2e399af1-8bc1-4e0c-beb7-c4c4c269c6d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db5fba73-3952-4d19-b0a8-517bb2341ea5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff_2835fe9e-85e2-4d47-b16e-559dfd42c4c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff_2835fe9e-85e2-4d47-b16e-559dfd42c4c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_267bdb3d-93f9-4539-a6d7-45eac284a731" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_267bdb3d-93f9-4539-a6d7-45eac284a731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalancePrincipalAmount_75b56385-dce8-45a4-adbb-ac9472b1073d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentOwnedBalancePrincipalAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_us-gaap_InvestmentOwnedBalancePrincipalAmount_75b56385-dce8-45a4-adbb-ac9472b1073d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_450c90a0-d553-47aa-a71a-5590cd482b89" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_450c90a0-d553-47aa-a71a-5590cd482b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ab04ee67-36f3-476b-a0dc-adf93a439bf4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ab04ee67-36f3-476b-a0dc-adf93a439bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_0d227233-60da-4c0c-819d-7874d17f7fcc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_us-gaap_DebtInstrumentFairValue_0d227233-60da-4c0c-819d-7874d17f7fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_cd270e3a-34b7-4149-907a-46d9e95d62d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_us-gaap_SharePrice_cd270e3a-34b7-4149-907a-46d9e95d62d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage_99d15f14-7722-43e5-8b63-782eb6349519" xlink:href="ptct-20200630.xsd#ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage_99d15f14-7722-43e5-8b63-782eb6349519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing_acf946a4-1f51-4bf5-a5cc-24cdc4d2cdff" xlink:href="ptct-20200630.xsd#ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing_acf946a4-1f51-4bf5-a5cc-24cdc4d2cdff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount_9b5cddd0-2a0e-41fc-8570-b6971684b308" xlink:href="ptct-20200630.xsd#ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount_9b5cddd0-2a0e-41fc-8570-b6971684b308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone_75a87c41-72cd-457e-aa7c-8ca65206d4ab" xlink:href="ptct-20200630.xsd#ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone_75a87c41-72cd-457e-aa7c-8ca65206d4ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable_4e25c145-ccd9-42a2-aaaa-0f8fbaf5bec8" xlink:href="ptct-20200630.xsd#ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable_4e25c145-ccd9-42a2-aaaa-0f8fbaf5bec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent_324fcaf4-8468-47a6-bce2-268fa557455e" xlink:href="ptct-20200630.xsd#ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent_324fcaf4-8468-47a6-bce2-268fa557455e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_6ca343fc-45db-43d5-9ea6-ce4e1d47f530" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_6ca343fc-45db-43d5-9ea6-ce4e1d47f530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_InvestmentInMRI_9fdbf6d1-200d-41f1-adb0-e94c2b009429" xlink:href="ptct-20200630.xsd#ptct_InvestmentInMRI"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_ptct_InvestmentInMRI_9fdbf6d1-200d-41f1-adb0-e94c2b009429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_PaymentsToAcquireConvertibleDebtInvestment_1deba99c-1688-42b7-bc77-0476e6b084bf" xlink:href="ptct-20200630.xsd#ptct_PaymentsToAcquireConvertibleDebtInvestment"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_ptct_PaymentsToAcquireConvertibleDebtInvestment_1deba99c-1688-42b7-bc77-0476e6b084bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_834de55c-03b2-48b9-b084-032cdea8fcf4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_834de55c-03b2-48b9-b084-032cdea8fcf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DebtInstrumentConvertiblePeriod_54082454-95f9-47d8-a20d-e528cfe9663f" xlink:href="ptct-20200630.xsd#ptct_DebtInstrumentConvertiblePeriod"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_ptct_DebtInstrumentConvertiblePeriod_54082454-95f9-47d8-a20d-e528cfe9663f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_72eae560-721e-475e-b3f0-fe47d29e884a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_72eae560-721e-475e-b3f0-fe47d29e884a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_5d752316-82c3-4670-b003-efe2f4f4c3e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_5d752316-82c3-4670-b003-efe2f4f4c3e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_56c58382-e2ea-426f-a9e7-7a28c803f5c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_56c58382-e2ea-426f-a9e7-7a28c803f5c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput_a7ef846d-afe4-4401-a6f5-9cf2db72fdcb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_us-gaap_AlternativeInvestmentMeasurementInput_a7ef846d-afe4-4401-a6f5-9cf2db72fdcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease_eec4ded1-9055-4ceb-a08c-2762500453f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease_eec4ded1-9055-4ceb-a08c-2762500453f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_StockIssuedDuringPeriodSharesExchangeRights_58c9f811-1958-49d9-b9ba-c189dc18a624" xlink:href="ptct-20200630.xsd#ptct_StockIssuedDuringPeriodSharesExchangeRights"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_ptct_StockIssuedDuringPeriodSharesExchangeRights_58c9f811-1958-49d9-b9ba-c189dc18a624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_SharesIssuedAssetAcquisition_8d1e97db-67eb-4b72-9a5b-b7a8c70f9c80" xlink:href="ptct-20200630.xsd#ptct_SharesIssuedAssetAcquisition"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_ptct_SharesIssuedAssetAcquisition_8d1e97db-67eb-4b72-9a5b-b7a8c70f9c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_MilestonePaymentObligations_a959fc13-5b5e-4bbd-8551-efc9acd8d476" xlink:href="ptct-20200630.xsd#ptct_MilestonePaymentObligations"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_ptct_MilestonePaymentObligations_a959fc13-5b5e-4bbd-8551-efc9acd8d476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_25aebca9-9a13-4392-95cb-6f40dcb7c3fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_us-gaap_OperatingExpenses_25aebca9-9a13-4392-95cb-6f40dcb7c3fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_GainOfSettlementDevelopmentMilestones_341417bb-9b81-4c0c-b809-206f1e284326" xlink:href="ptct-20200630.xsd#ptct_GainOfSettlementDevelopmentMilestones"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_ptct_GainOfSettlementDevelopmentMilestones_341417bb-9b81-4c0c-b809-206f1e284326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_LossOfSettlementRegulatoryMilestones_58d3ce7f-2393-4a36-a0ae-27264e410d4d" xlink:href="ptct-20200630.xsd#ptct_LossOfSettlementRegulatoryMilestones"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_ptct_LossOfSettlementRegulatoryMilestones_58d3ce7f-2393-4a36-a0ae-27264e410d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_507c15a4-8d54-49fe-8997-7ff44e2afc1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_507c15a4-8d54-49fe-8997-7ff44e2afc1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ContingentConsiderationTransactionFees_4500991e-48e5-4f3b-b5e7-f774b94f4cc4" xlink:href="ptct-20200630.xsd#ptct_ContingentConsiderationTransactionFees"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_ptct_ContingentConsiderationTransactionFees_4500991e-48e5-4f3b-b5e7-f774b94f4cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_d5dd7b5c-9208-4eb6-8ae2-477c1816a6df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1324bed9-1410-4ed3-a18d-cd2eebe77a02" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_d5dd7b5c-9208-4eb6-8ae2-477c1816a6df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesHierarchyDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#FairvalueoffinancialinstrumentsandmarketablesecuritiesHierarchyDetails"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesHierarchyDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_88e36e2e-9fb4-4ad2-87e8-7fc459182b42" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b465ffac-2021-44cf-8b55-fa3ddc5a29dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_88e36e2e-9fb4-4ad2-87e8-7fc459182b42" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b465ffac-2021-44cf-8b55-fa3ddc5a29dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ca1c1d32-291a-4961-bdb4-991b1663f736" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b465ffac-2021-44cf-8b55-fa3ddc5a29dd" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ca1c1d32-291a-4961-bdb4-991b1663f736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_60e478d4-6625-4f19-b171-d6defb54913e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ca1c1d32-291a-4961-bdb4-991b1663f736" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_60e478d4-6625-4f19-b171-d6defb54913e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_22e69b8e-b41b-4279-88d3-a8d26bd8dad0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_60e478d4-6625-4f19-b171-d6defb54913e" xlink:to="loc_us-gaap_DebtSecuritiesMember_22e69b8e-b41b-4279-88d3-a8d26bd8dad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_725ba4e0-d301-4f75-b2f4-c2889f4097ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_60e478d4-6625-4f19-b171-d6defb54913e" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_725ba4e0-d301-4f75-b2f4-c2889f4097ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4f865014-e3dd-4ae6-abee-c702fc575ebd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b465ffac-2021-44cf-8b55-fa3ddc5a29dd" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4f865014-e3dd-4ae6-abee-c702fc575ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_78778e78-04ce-42bf-b3f4-466105d8d043" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4f865014-e3dd-4ae6-abee-c702fc575ebd" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_78778e78-04ce-42bf-b3f4-466105d8d043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_d8887520-9359-4a39-918f-75c5d5801132" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_78778e78-04ce-42bf-b3f4-466105d8d043" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_d8887520-9359-4a39-918f-75c5d5801132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ec26b886-a489-4280-9ce3-56b9eb03221d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b465ffac-2021-44cf-8b55-fa3ddc5a29dd" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ec26b886-a489-4280-9ce3-56b9eb03221d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0508b54d-35cc-46b1-b723-1b2e032bc406" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ec26b886-a489-4280-9ce3-56b9eb03221d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0508b54d-35cc-46b1-b723-1b2e032bc406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_2e1c0ac0-9730-4f23-8393-8eacdc98eb73" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0508b54d-35cc-46b1-b723-1b2e032bc406" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_2e1c0ac0-9730-4f23-8393-8eacdc98eb73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_4214b5f3-54d3-46bc-a5ea-4cb56a2fab71" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0508b54d-35cc-46b1-b723-1b2e032bc406" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_4214b5f3-54d3-46bc-a5ea-4cb56a2fab71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_b361b5ba-9ce3-4fdb-b1a3-865e4b99956a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0508b54d-35cc-46b1-b723-1b2e032bc406" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_b361b5ba-9ce3-4fdb-b1a3-865e4b99956a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_3a44b304-03fe-45e5-a35a-b202d2896bf3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b465ffac-2021-44cf-8b55-fa3ddc5a29dd" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_3a44b304-03fe-45e5-a35a-b202d2896bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_c3c7d465-0391-424b-b253-6e7965c3710e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_3a44b304-03fe-45e5-a35a-b202d2896bf3" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_c3c7d465-0391-424b-b253-6e7965c3710e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_bf10717a-a161-44f2-b675-f3af7e32f157" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_c3c7d465-0391-424b-b253-6e7965c3710e" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_bf10717a-a161-44f2-b675-f3af7e32f157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_d3d38954-a8ac-4f95-8d75-5415eaba94fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_bf10717a-a161-44f2-b675-f3af7e32f157" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_d3d38954-a8ac-4f95-8d75-5415eaba94fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_221cd572-1bbc-4fc8-8ddc-346bb29fd76f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b465ffac-2021-44cf-8b55-fa3ddc5a29dd" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_221cd572-1bbc-4fc8-8ddc-346bb29fd76f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3e5d86a4-1ace-4cb0-b29e-262942fd2c0f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_221cd572-1bbc-4fc8-8ddc-346bb29fd76f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3e5d86a4-1ace-4cb0-b29e-262942fd2c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_a7f7debf-105a-48d1-9b49-b6f56b5694f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_221cd572-1bbc-4fc8-8ddc-346bb29fd76f" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_a7f7debf-105a-48d1-9b49-b6f56b5694f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_StockAppreciationRightsLiabilityOutstanding_52bbe26b-212e-4a9c-8420-df01f3a6491b" xlink:href="ptct-20200630.xsd#ptct_StockAppreciationRightsLiabilityOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_221cd572-1bbc-4fc8-8ddc-346bb29fd76f" xlink:to="loc_ptct_StockAppreciationRightsLiabilityOutstanding_52bbe26b-212e-4a9c-8420-df01f3a6491b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable_2ce2158e-a84f-488c-bb5f-436df57eb156" xlink:href="ptct-20200630.xsd#ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_221cd572-1bbc-4fc8-8ddc-346bb29fd76f" xlink:to="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable_2ce2158e-a84f-488c-bb5f-436df57eb156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_99bc2c80-2b38-4844-a33b-6fb7270e080b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_221cd572-1bbc-4fc8-8ddc-346bb29fd76f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_99bc2c80-2b38-4844-a33b-6fb7270e080b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_8644bb18-f2cc-48b3-8002-25bd6c2c2b34" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_221cd572-1bbc-4fc8-8ddc-346bb29fd76f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_8644bb18-f2cc-48b3-8002-25bd6c2c2b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesAvailableforsaleDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#FairvalueoffinancialinstrumentsandmarketablesecuritiesAvailableforsaleDetails"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesAvailableforsaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1c5aab62-6579-4eb3-9cca-3214a5e25590" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_83cb10ee-1fec-4407-a6d1-bcc4d511b248" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1c5aab62-6579-4eb3-9cca-3214a5e25590" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_83cb10ee-1fec-4407-a6d1-bcc4d511b248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_9cc69fb8-04b0-4115-88c2-c96b103d3e7b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_83cb10ee-1fec-4407-a6d1-bcc4d511b248" xlink:to="loc_us-gaap_FinancialInstrumentAxis_9cc69fb8-04b0-4115-88c2-c96b103d3e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fb4ab287-fef3-491e-8a21-a3cbdfd4deb5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9cc69fb8-04b0-4115-88c2-c96b103d3e7b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fb4ab287-fef3-491e-8a21-a3cbdfd4deb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_dc6fe06b-c2b6-40d8-8916-0dee843075f0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fb4ab287-fef3-491e-8a21-a3cbdfd4deb5" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_dc6fe06b-c2b6-40d8-8916-0dee843075f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_d8139a2e-bb7b-4ef5-ac07-1d7744a5473d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fb4ab287-fef3-491e-8a21-a3cbdfd4deb5" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_d8139a2e-bb7b-4ef5-ac07-1d7744a5473d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_e96a833a-f5f2-4380-9fe3-ac2e28e4dd3e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fb4ab287-fef3-491e-8a21-a3cbdfd4deb5" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_e96a833a-f5f2-4380-9fe3-ac2e28e4dd3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_c8afd439-9ec5-4c60-bb18-2101a1b47f08" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fb4ab287-fef3-491e-8a21-a3cbdfd4deb5" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_c8afd439-9ec5-4c60-bb18-2101a1b47f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a44e32aa-b204-4895-a2b8-b171a7ad702d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_83cb10ee-1fec-4407-a6d1-bcc4d511b248" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a44e32aa-b204-4895-a2b8-b171a7ad702d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold_65d6048d-3e33-4d54-8ab0-63623aaa754c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a44e32aa-b204-4895-a2b8-b171a7ad702d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold_65d6048d-3e33-4d54-8ab0-63623aaa754c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff_e8dafb70-c004-4771-8fa5-4fea79e9bb21" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a44e32aa-b204-4895-a2b8-b171a7ad702d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff_e8dafb70-c004-4771-8fa5-4fea79e9bb21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_2f156b3d-055d-4e8b-901b-5d168056e185" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a44e32aa-b204-4895-a2b8-b171a7ad702d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_2f156b3d-055d-4e8b-901b-5d168056e185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8321b69c-4ebe-4848-8a0e-4b6a025fb7c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a44e32aa-b204-4895-a2b8-b171a7ad702d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8321b69c-4ebe-4848-8a0e-4b6a025fb7c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3f3104e8-2ed2-4cd6-ae14-61e9c923641a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a44e32aa-b204-4895-a2b8-b171a7ad702d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3f3104e8-2ed2-4cd6-ae14-61e9c923641a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ff747833-9edd-4809-9a38-f2e4da2230cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a44e32aa-b204-4895-a2b8-b171a7ad702d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ff747833-9edd-4809-9a38-f2e4da2230cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9dcc2ba7-681a-470c-be9f-ffb7a5ede217" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a44e32aa-b204-4895-a2b8-b171a7ad702d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9dcc2ba7-681a-470c-be9f-ffb7a5ede217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_ac29493f-8060-401e-bf91-7520d2800b0c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a44e32aa-b204-4895-a2b8-b171a7ad702d" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_ac29493f-8060-401e-bf91-7520d2800b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_c3786668-54ac-429c-83bf-61bac40d7ce0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a44e32aa-b204-4895-a2b8-b171a7ad702d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_c3786668-54ac-429c-83bf-61bac40d7ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_65dd8abe-70fd-44cc-9329-0abb349e6db2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a44e32aa-b204-4895-a2b8-b171a7ad702d" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_65dd8abe-70fd-44cc-9329-0abb349e6db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_53e02a71-7747-4352-b079-b4750dff4894" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a44e32aa-b204-4895-a2b8-b171a7ad702d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_53e02a71-7747-4352-b079-b4750dff4894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue_da3fc451-9a9d-41c3-a664-ded2853d0821" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a44e32aa-b204-4895-a2b8-b171a7ad702d" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue_da3fc451-9a9d-41c3-a664-ded2853d0821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesFairValueMeasurementInputsandValuationTechniquesDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#FairvalueoffinancialinstrumentsandmarketablesecuritiesFairValueMeasurementInputsandValuationTechniquesDetails"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesFairValueMeasurementInputsandValuationTechniquesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_45503618-c5e4-402c-9034-474e76de8f51" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c8dfb310-b985-4551-b101-d5ba7e387a09" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_45503618-c5e4-402c-9034-474e76de8f51" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c8dfb310-b985-4551-b101-d5ba7e387a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_a4284508-8966-49e7-9470-fb03a595678c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c8dfb310-b985-4551-b101-d5ba7e387a09" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_a4284508-8966-49e7-9470-fb03a595678c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_26cb6aad-5ddf-4779-90b7-cd4099af93e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_a4284508-8966-49e7-9470-fb03a595678c" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_26cb6aad-5ddf-4779-90b7-cd4099af93e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ProbabilityofSuccessMember_69395e2f-025e-465e-9377-45f3a842aac8" xlink:href="ptct-20200630.xsd#ptct_ProbabilityofSuccessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_26cb6aad-5ddf-4779-90b7-cd4099af93e8" xlink:to="loc_ptct_ProbabilityofSuccessMember_69395e2f-025e-465e-9377-45f3a842aac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e5859095-5a0e-4ddb-829d-adba8cab9b8d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c8dfb310-b985-4551-b101-d5ba7e387a09" xlink:to="loc_srt_RangeAxis_e5859095-5a0e-4ddb-829d-adba8cab9b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_22a6f582-b883-488e-829d-be67b4266852" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e5859095-5a0e-4ddb-829d-adba8cab9b8d" xlink:to="loc_srt_RangeMember_22a6f582-b883-488e-829d-be67b4266852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_1db158bc-33ca-49ba-886e-337a4638cca2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c8dfb310-b985-4551-b101-d5ba7e387a09" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_1db158bc-33ca-49ba-886e-337a4638cca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_0d2b7f88-4e23-4a2b-a4c0-700fa8ed6d66" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_1db158bc-33ca-49ba-886e-337a4638cca2" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_0d2b7f88-4e23-4a2b-a4c0-700fa8ed6d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_0f9a7f39-f1ad-456e-a80c-dd7d98fbb04d" xlink:href="ptct-20200630.xsd#ptct_LiabilityNetSalesMilestonesandRoyaltiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_0d2b7f88-4e23-4a2b-a4c0-700fa8ed6d66" xlink:to="loc_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_0f9a7f39-f1ad-456e-a80c-dd7d98fbb04d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_440fb7bb-1a31-4bd2-85be-da514a874b54" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c8dfb310-b985-4551-b101-d5ba7e387a09" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_440fb7bb-1a31-4bd2-85be-da514a874b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d463c1b4-525f-4efe-948d-72f695fecfcd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_440fb7bb-1a31-4bd2-85be-da514a874b54" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d463c1b4-525f-4efe-948d-72f695fecfcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AgilisMember_7b9ec34c-f378-4046-a5a6-4c438f50dd96" xlink:href="ptct-20200630.xsd#ptct_AgilisMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d463c1b4-525f-4efe-948d-72f695fecfcd" xlink:to="loc_ptct_AgilisMember_7b9ec34c-f378-4046-a5a6-4c438f50dd96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_2c69ac39-e237-42ef-a648-3524b2a48476" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c8dfb310-b985-4551-b101-d5ba7e387a09" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_2c69ac39-e237-42ef-a648-3524b2a48476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_06011d31-ecfe-4707-bc14-b220d732af8f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_2c69ac39-e237-42ef-a648-3524b2a48476" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_06011d31-ecfe-4707-bc14-b220d732af8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsMember_30eef7c1-b100-4255-be11-d943e9c8c6f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_06011d31-ecfe-4707-bc14-b220d732af8f" xlink:to="loc_us-gaap_CommitmentsMember_30eef7c1-b100-4255-be11-d943e9c8c6f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8a223f6b-ad9b-4742-ae25-3240e37ed5a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c8dfb310-b985-4551-b101-d5ba7e387a09" xlink:to="loc_us-gaap_AwardTypeAxis_8a223f6b-ad9b-4742-ae25-3240e37ed5a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2b2555f0-61b7-4108-82ab-011443f305db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8a223f6b-ad9b-4742-ae25-3240e37ed5a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2b2555f0-61b7-4108-82ab-011443f305db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_134827a4-ad92-448d-8034-862485621e41" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2b2555f0-61b7-4108-82ab-011443f305db" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_134827a4-ad92-448d-8034-862485621e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_72b7a37a-c34d-4804-9c98-f6b112c7bc25" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c8dfb310-b985-4551-b101-d5ba7e387a09" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_72b7a37a-c34d-4804-9c98-f6b112c7bc25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_be50987d-f128-4fa4-81b7-4384ac11e80e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_72b7a37a-c34d-4804-9c98-f6b112c7bc25" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_be50987d-f128-4fa4-81b7-4384ac11e80e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ae0893a0-faf4-424f-93d0-27a54aa1a792" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c8dfb310-b985-4551-b101-d5ba7e387a09" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ae0893a0-faf4-424f-93d0-27a54aa1a792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_505a358a-6abe-42e1-9b08-22899cf9ad3d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ae0893a0-faf4-424f-93d0-27a54aa1a792" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_505a358a-6abe-42e1-9b08-22899cf9ad3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a3a3492f-3970-453d-9241-0de4869e1320" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_505a358a-6abe-42e1-9b08-22899cf9ad3d" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a3a3492f-3970-453d-9241-0de4869e1320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4daa5b09-00e5-4f96-b283-3a96486c0e28" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c8dfb310-b985-4551-b101-d5ba7e387a09" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4daa5b09-00e5-4f96-b283-3a96486c0e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServicingAssetAtFairValueAmountRollForward_3921fbbe-4565-4ec9-bbe3-8ba7540fb9d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ServicingAssetAtFairValueAmountRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4daa5b09-00e5-4f96-b283-3a96486c0e28" xlink:to="loc_us-gaap_ServicingAssetAtFairValueAmountRollForward_3921fbbe-4565-4ec9-bbe3-8ba7540fb9d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_70407530-2c43-453d-a388-6d2c299e2dbd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ServicingAssetAtFairValueAmountRollForward_3921fbbe-4565-4ec9-bbe3-8ba7540fb9d3" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_70407530-2c43-453d-a388-6d2c299e2dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_50c2bbbb-4784-4eb5-8165-b688d0a7abbd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ServicingAssetAtFairValueAmountRollForward_3921fbbe-4565-4ec9-bbe3-8ba7540fb9d3" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_50c2bbbb-4784-4eb5-8165-b688d0a7abbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_6457bf08-cef9-4b4c-a817-1e9f72678c5b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ServicingAssetAtFairValueAmountRollForward_3921fbbe-4565-4ec9-bbe3-8ba7540fb9d3" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_6457bf08-cef9-4b4c-a817-1e9f72678c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1f540beb-723e-421d-88cf-2380ab0c759b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ServicingAssetAtFairValueAmountRollForward_3921fbbe-4565-4ec9-bbe3-8ba7540fb9d3" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1f540beb-723e-421d-88cf-2380ab0c759b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput_e95e21df-ea3c-406e-9f2f-81606c83f7eb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4daa5b09-00e5-4f96-b283-3a96486c0e28" xlink:to="loc_us-gaap_AlternativeInvestmentMeasurementInput_e95e21df-ea3c-406e-9f2f-81606c83f7eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesUnrealizedLossPositionsDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#FairvalueoffinancialinstrumentsandmarketablesecuritiesUnrealizedLossPositionsDetails"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesUnrealizedLossPositionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3bc55c27-1fa1-4696-a6ec-55eb9a213d3e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_28a25a8e-c451-4bb4-83dc-bd673d367aee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3bc55c27-1fa1-4696-a6ec-55eb9a213d3e" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_28a25a8e-c451-4bb4-83dc-bd673d367aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_0093fa31-5316-48c4-9055-be222e3268b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_28a25a8e-c451-4bb4-83dc-bd673d367aee" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_0093fa31-5316-48c4-9055-be222e3268b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_dff7459a-76a6-4a2a-9fb5-63fa59f71117" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_0093fa31-5316-48c4-9055-be222e3268b5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_dff7459a-76a6-4a2a-9fb5-63fa59f71117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_2156e2e1-5695-46d6-8aeb-5bf2ea98a779" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_dff7459a-76a6-4a2a-9fb5-63fa59f71117" xlink:to="loc_us-gaap_DebtSecuritiesMember_2156e2e1-5695-46d6-8aeb-5bf2ea98a779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4a710b16-1098-4044-b1b9-8a8113d94890" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_28a25a8e-c451-4bb4-83dc-bd673d367aee" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4a710b16-1098-4044-b1b9-8a8113d94890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7c8f7591-ba33-4338-902c-7f6547ad1dbe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4a710b16-1098-4044-b1b9-8a8113d94890" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7c8f7591-ba33-4338-902c-7f6547ad1dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_7ede1cc0-211e-4b39-8784-26995cd82f3a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7c8f7591-ba33-4338-902c-7f6547ad1dbe" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_7ede1cc0-211e-4b39-8784-26995cd82f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_38cd9226-0acb-4ebe-b626-168b72ec2cf6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7c8f7591-ba33-4338-902c-7f6547ad1dbe" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_38cd9226-0acb-4ebe-b626-168b72ec2cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_43d2fd39-3ce4-45cd-9f97-fa91c0a36800" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7c8f7591-ba33-4338-902c-7f6547ad1dbe" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_43d2fd39-3ce4-45cd-9f97-fa91c0a36800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_00d0402e-292b-4a28-a6f3-9f78a3ed50ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7c8f7591-ba33-4338-902c-7f6547ad1dbe" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_00d0402e-292b-4a28-a6f3-9f78a3ed50ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_35512001-a105-4698-8049-f513f9c10157" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_28a25a8e-c451-4bb4-83dc-bd673d367aee" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_35512001-a105-4698-8049-f513f9c10157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold_aa8536af-041c-43cd-a582-ee1c73fcdbd1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_35512001-a105-4698-8049-f513f9c10157" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold_aa8536af-041c-43cd-a582-ee1c73fcdbd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_804fb85e-f5e9-4667-9238-49e21b8c4d9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_35512001-a105-4698-8049-f513f9c10157" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_804fb85e-f5e9-4667-9238-49e21b8c4d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_45afed99-166e-4bc7-8b46-21857d51ce77" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_804fb85e-f5e9-4667-9238-49e21b8c4d9c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_45afed99-166e-4bc7-8b46-21857d51ce77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_5061cd94-0cfa-4cfc-94de-b2c1aafd0c4a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_804fb85e-f5e9-4667-9238-49e21b8c4d9c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_5061cd94-0cfa-4cfc-94de-b2c1aafd0c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_33900156-26af-44bc-88bc-39734cde9916" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_804fb85e-f5e9-4667-9238-49e21b8c4d9c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_33900156-26af-44bc-88bc-39734cde9916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract_81e25e67-7b8d-4bb9-8b37-4b23cf465094" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_35512001-a105-4698-8049-f513f9c10157" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract_81e25e67-7b8d-4bb9-8b37-4b23cf465094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_c35158cb-f90b-4454-8b34-178e4affb77a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract_81e25e67-7b8d-4bb9-8b37-4b23cf465094" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_c35158cb-f90b-4454-8b34-178e4affb77a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_3434431d-1774-4451-aa4d-d0f2ea63e28b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract_81e25e67-7b8d-4bb9-8b37-4b23cf465094" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_3434431d-1774-4451-aa4d-d0f2ea63e28b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue_aedfb6df-3f2e-4c9c-b055-b3f35803bcdf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract_81e25e67-7b8d-4bb9-8b37-4b23cf465094" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue_aedfb6df-3f2e-4c9c-b055-b3f35803bcdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff_62184ebf-07b3-41b5-a8d4-c90610a60964" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_35512001-a105-4698-8049-f513f9c10157" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff_62184ebf-07b3-41b5-a8d4-c90610a60964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesMarketablesecuritiesDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#FairvalueoffinancialinstrumentsandmarketablesecuritiesMarketablesecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesMarketablesecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1239d72a-e794-464b-b6e8-28099ce27171" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentHoldingsTable_77e255e4-0087-446c-aa9e-6901b0eec54b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentHoldingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1239d72a-e794-464b-b6e8-28099ce27171" xlink:to="loc_us-gaap_InvestmentHoldingsTable_77e255e4-0087-446c-aa9e-6901b0eec54b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_36164895-e637-4eee-a859-bf18ffbee68b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentHoldingsTable_77e255e4-0087-446c-aa9e-6901b0eec54b" xlink:to="loc_us-gaap_InvestmentTypeAxis_36164895-e637-4eee-a859-bf18ffbee68b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_d78da637-fbfc-4263-aba5-be101aec972e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_36164895-e637-4eee-a859-bf18ffbee68b" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_d78da637-fbfc-4263-aba5-be101aec972e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_11277602-ae08-41a1-975e-442f1a4828dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_d78da637-fbfc-4263-aba5-be101aec972e" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_11277602-ae08-41a1-975e-442f1a4828dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_076012c1-cc86-403e-a5e0-76371c09257a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_d78da637-fbfc-4263-aba5-be101aec972e" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_076012c1-cc86-403e-a5e0-76371c09257a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_bfb2e0eb-1b05-464e-9b42-6232b24577a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_d78da637-fbfc-4263-aba5-be101aec972e" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_bfb2e0eb-1b05-464e-9b42-6232b24577a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_d0aeacfd-7262-4a74-9a3e-781f206c7b66" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_d78da637-fbfc-4263-aba5-be101aec972e" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_d0aeacfd-7262-4a74-9a3e-781f206c7b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentHoldingsLineItems_15ac8559-042c-4cdc-aa40-884938df1476" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentHoldingsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentHoldingsTable_77e255e4-0087-446c-aa9e-6901b0eec54b" xlink:to="loc_us-gaap_InvestmentHoldingsLineItems_15ac8559-042c-4cdc-aa40-884938df1476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_7b19dd08-7d92-416e-bf7b-5aee4cdf111c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentHoldingsLineItems_15ac8559-042c-4cdc-aa40-884938df1476" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_7b19dd08-7d92-416e-bf7b-5aee4cdf111c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue_97ce429d-1f1e-48a1-84e1-17d37c3ef15d" xlink:href="ptct-20200630.xsd#ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentHoldingsLineItems_15ac8559-042c-4cdc-aa40-884938df1476" xlink:to="loc_ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue_97ce429d-1f1e-48a1-84e1-17d37c3ef15d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e5002428-913e-4b54-8df2-b272877afc88" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_c608ee76-caea-4143-a004-a74b570c773a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e5002428-913e-4b54-8df2-b272877afc88" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_c608ee76-caea-4143-a004-a74b570c773a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d7fe6d48-7f54-4f77-89a5-051d631f1e7b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_c608ee76-caea-4143-a004-a74b570c773a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d7fe6d48-7f54-4f77-89a5-051d631f1e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_04ea40a4-a620-4915-a420-d937af6a72cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d7fe6d48-7f54-4f77-89a5-051d631f1e7b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_04ea40a4-a620-4915-a420-d937af6a72cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2778b26a-9d02-4990-8055-bd50821de1fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_04ea40a4-a620-4915-a420-d937af6a72cb" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2778b26a-9d02-4990-8055-bd50821de1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_959c0fa5-464d-4a6c-bf8c-ffeeba81c690" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_c608ee76-caea-4143-a004-a74b570c773a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_959c0fa5-464d-4a6c-bf8c-ffeeba81c690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_925a2146-a3b2-47f6-b2f1-1aa764d0456c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_959c0fa5-464d-4a6c-bf8c-ffeeba81c690" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_925a2146-a3b2-47f6-b2f1-1aa764d0456c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AgilisMember_714bf83c-0fb9-449d-b74b-999077e137c2" xlink:href="ptct-20200630.xsd#ptct_AgilisMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_925a2146-a3b2-47f6-b2f1-1aa764d0456c" xlink:to="loc_ptct_AgilisMember_714bf83c-0fb9-449d-b74b-999077e137c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_f7a7e258-0aad-46ef-8ee1-d5eb41f29b84" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_c608ee76-caea-4143-a004-a74b570c773a" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_f7a7e258-0aad-46ef-8ee1-d5eb41f29b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_2aa50289-28c0-4a23-a02a-d8919df71595" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_f7a7e258-0aad-46ef-8ee1-d5eb41f29b84" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_2aa50289-28c0-4a23-a02a-d8919df71595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_1c8df498-49b9-466c-8ff3-b4e1e7f77803" xlink:href="ptct-20200630.xsd#ptct_LiabilityNetSalesMilestonesandRoyaltiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_2aa50289-28c0-4a23-a02a-d8919df71595" xlink:to="loc_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_1c8df498-49b9-466c-8ff3-b4e1e7f77803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_d381a6be-b31b-4e75-8759-2500aeb287fe" xlink:href="ptct-20200630.xsd#ptct_LiabilityDevelopmentandRegulatoryMilestoneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_2aa50289-28c0-4a23-a02a-d8919df71595" xlink:to="loc_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_d381a6be-b31b-4e75-8759-2500aeb287fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_908c1f65-d87d-48ed-95ad-60ead1dccda0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_c608ee76-caea-4143-a004-a74b570c773a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_908c1f65-d87d-48ed-95ad-60ead1dccda0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_99611041-44d2-4a16-96f6-5b9c94d46e2a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_908c1f65-d87d-48ed-95ad-60ead1dccda0" xlink:to="loc_us-gaap_ClassOfStockDomain_99611041-44d2-4a16-96f6-5b9c94d46e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9a5032fc-f2d9-4e77-9bd6-504d6edbb8ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_99611041-44d2-4a16-96f6-5b9c94d46e2a" xlink:to="loc_us-gaap_CommonStockMember_9a5032fc-f2d9-4e77-9bd6-504d6edbb8ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1c923127-ab89-44da-8158-284331c3f1d3" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_c608ee76-caea-4143-a004-a74b570c773a" xlink:to="loc_srt_RangeAxis_1c923127-ab89-44da-8158-284331c3f1d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_513d4ac8-b1a6-4052-bbba-5ca4b7ab1113" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1c923127-ab89-44da-8158-284331c3f1d3" xlink:to="loc_srt_RangeMember_513d4ac8-b1a6-4052-bbba-5ca4b7ab1113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_48a2fedc-fc63-44b1-9f3b-f90207c7d70b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_513d4ac8-b1a6-4052-bbba-5ca4b7ab1113" xlink:to="loc_srt_MinimumMember_48a2fedc-fc63-44b1-9f3b-f90207c7d70b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_14058806-304e-4031-972e-bf9df47f8d81" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_513d4ac8-b1a6-4052-bbba-5ca4b7ab1113" xlink:to="loc_srt_MaximumMember_14058806-304e-4031-972e-bf9df47f8d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_7b413260-159c-4d65-a929-5f58983338f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_c608ee76-caea-4143-a004-a74b570c773a" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_7b413260-159c-4d65-a929-5f58983338f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_b5798131-8d86-449b-957e-3bd3b7889611" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_7b413260-159c-4d65-a929-5f58983338f4" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_b5798131-8d86-449b-957e-3bd3b7889611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember_8c1c2eaf-64ae-410a-bd5a-46ddd11dc3e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputOptionVolatilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b5798131-8d86-449b-957e-3bd3b7889611" xlink:to="loc_us-gaap_MeasurementInputOptionVolatilityMember_8c1c2eaf-64ae-410a-bd5a-46ddd11dc3e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_2540822f-c5b4-46e6-8d93-6278f8f60ce9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b5798131-8d86-449b-957e-3bd3b7889611" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_2540822f-c5b4-46e6-8d93-6278f8f60ce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_bea9d69a-3fc5-4b0e-80a5-e2e8dea70089" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b5798131-8d86-449b-957e-3bd3b7889611" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_bea9d69a-3fc5-4b0e-80a5-e2e8dea70089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember_5032c5cd-8af2-4434-a1b2-1f56ae24fc9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b5798131-8d86-449b-957e-3bd3b7889611" xlink:to="loc_us-gaap_MeasurementInputSharePriceMember_5032c5cd-8af2-4434-a1b2-1f56ae24fc9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_SalesMilestonesMember_5168668b-f273-4e1d-a2b9-2f72c3cc6550" xlink:href="ptct-20200630.xsd#ptct_SalesMilestonesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b5798131-8d86-449b-957e-3bd3b7889611" xlink:to="loc_ptct_SalesMilestonesMember_5168668b-f273-4e1d-a2b9-2f72c3cc6550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ProbabilityofSuccessMember_9135777a-f9de-4fad-9a28-48b743dcb7ae" xlink:href="ptct-20200630.xsd#ptct_ProbabilityofSuccessMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b5798131-8d86-449b-957e-3bd3b7889611" xlink:to="loc_ptct_ProbabilityofSuccessMember_9135777a-f9de-4fad-9a28-48b743dcb7ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_PercentageofSalesforRoyaltiesMember_29805105-1b3f-4398-889a-dbd71a9b1530" xlink:href="ptct-20200630.xsd#ptct_PercentageofSalesforRoyaltiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b5798131-8d86-449b-957e-3bd3b7889611" xlink:to="loc_ptct_PercentageofSalesforRoyaltiesMember_29805105-1b3f-4398-889a-dbd71a9b1530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DevelopmentandRegulatoryMilestoneMember_ee8cd1fc-187b-47a5-8851-dd0592b38bfc" xlink:href="ptct-20200630.xsd#ptct_DevelopmentandRegulatoryMilestoneMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b5798131-8d86-449b-957e-3bd3b7889611" xlink:to="loc_ptct_DevelopmentandRegulatoryMilestoneMember_ee8cd1fc-187b-47a5-8851-dd0592b38bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_43ba311d-8383-47a5-adbf-7ff3efb9bb80" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b5798131-8d86-449b-957e-3bd3b7889611" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_43ba311d-8383-47a5-adbf-7ff3efb9bb80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_9b529c9f-ca0c-4dfd-ac83-3cb84324571f" xlink:href="ptct-20200630.xsd#ptct_LiabilityNetSalesMilestonesandRoyaltiesMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b5798131-8d86-449b-957e-3bd3b7889611" xlink:to="loc_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_9b529c9f-ca0c-4dfd-ac83-3cb84324571f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_PotentialNetSalesMilestonesDomain_85537192-2b6f-4bb3-9b5b-3ae6e0ffe790" xlink:href="ptct-20200630.xsd#ptct_PotentialNetSalesMilestonesDomain"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b5798131-8d86-449b-957e-3bd3b7889611" xlink:to="loc_ptct_PotentialNetSalesMilestonesDomain_85537192-2b6f-4bb3-9b5b-3ae6e0ffe790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_b11aa539-23a0-461c-8657-4050ab17c7ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_c608ee76-caea-4143-a004-a74b570c773a" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_b11aa539-23a0-461c-8657-4050ab17c7ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5ba9193e-ba84-4406-ae2e-a80170f994b8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_b11aa539-23a0-461c-8657-4050ab17c7ad" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5ba9193e-ba84-4406-ae2e-a80170f994b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsMember_e60f3e1f-4c0a-430d-af12-5be1fa2a4221" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5ba9193e-ba84-4406-ae2e-a80170f994b8" xlink:to="loc_us-gaap_CommitmentsMember_e60f3e1f-4c0a-430d-af12-5be1fa2a4221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_97f85876-2c1f-4af5-b704-ca4a1fc3f4b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5ba9193e-ba84-4406-ae2e-a80170f994b8" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_97f85876-2c1f-4af5-b704-ca4a1fc3f4b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9a46688e-9b8a-4769-bcc6-0baa5a034446" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_c608ee76-caea-4143-a004-a74b570c773a" xlink:to="loc_us-gaap_AwardTypeAxis_9a46688e-9b8a-4769-bcc6-0baa5a034446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6fe5d22e-3ff6-4565-ab04-f986405e8cf7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9a46688e-9b8a-4769-bcc6-0baa5a034446" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6fe5d22e-3ff6-4565-ab04-f986405e8cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_273a1676-8506-4935-9355-e7746063d4b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6fe5d22e-3ff6-4565-ab04-f986405e8cf7" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_273a1676-8506-4935-9355-e7746063d4b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_591c4401-f370-480a-9e63-889e7bf8d2d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_c608ee76-caea-4143-a004-a74b570c773a" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_591c4401-f370-480a-9e63-889e7bf8d2d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput_ce8b8d46-21c8-4ccb-bf35-c70645e8824f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_591c4401-f370-480a-9e63-889e7bf8d2d3" xlink:to="loc_us-gaap_AlternativeInvestmentMeasurementInput_ce8b8d46-21c8-4ccb-bf35-c70645e8824f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1232ca5e-079f-407e-9b93-635eea5c3e4e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_591c4401-f370-480a-9e63-889e7bf8d2d3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1232ca5e-079f-407e-9b93-635eea5c3e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AlternativeInvestmentMilestone_8a6c80f7-342d-47b8-87da-3852a2f002a0" xlink:href="ptct-20200630.xsd#ptct_AlternativeInvestmentMilestone"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_591c4401-f370-480a-9e63-889e7bf8d2d3" xlink:to="loc_ptct_AlternativeInvestmentMilestone_8a6c80f7-342d-47b8-87da-3852a2f002a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5f1e3358-86ac-4ff3-9882-d36d72d72325" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_591c4401-f370-480a-9e63-889e7bf8d2d3" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5f1e3358-86ac-4ff3-9882-d36d72d72325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2ca17570-b666-4edc-9c23-acb41a263a18" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5f1e3358-86ac-4ff3-9882-d36d72d72325" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2ca17570-b666-4edc-9c23-acb41a263a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_6aca1d5b-a471-4662-9899-e2093ad3177e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5f1e3358-86ac-4ff3-9882-d36d72d72325" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_6aca1d5b-a471-4662-9899-e2093ad3177e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_a363398f-7a05-490b-980f-a2ffe3d34d49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5f1e3358-86ac-4ff3-9882-d36d72d72325" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_a363398f-7a05-490b-980f-a2ffe3d34d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_396277ab-23b2-4fb0-9141-5bed11c6257a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5f1e3358-86ac-4ff3-9882-d36d72d72325" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_396277ab-23b2-4fb0-9141-5bed11c6257a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsRightsExchangeSettlement_0cfbf5ab-9ddd-4335-a1a2-efcfde227826" xlink:href="ptct-20200630.xsd#ptct_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsRightsExchangeSettlement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5f1e3358-86ac-4ff3-9882-d36d72d72325" xlink:to="loc_ptct_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsRightsExchangeSettlement_0cfbf5ab-9ddd-4335-a1a2-efcfde227826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2d718de6-c511-469c-9bfc-86b714b758d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5f1e3358-86ac-4ff3-9882-d36d72d72325" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2d718de6-c511-469c-9bfc-86b714b758d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_804c2636-fdad-412b-80a2-61fbe7534885" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_591c4401-f370-480a-9e63-889e7bf8d2d3" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_804c2636-fdad-412b-80a2-61fbe7534885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/Othercomprehensiveincomelossandaccumulatedothercomprehensiveitems" xlink:type="simple" xlink:href="ptct-20200630.xsd#Othercomprehensiveincomelossandaccumulatedothercomprehensiveitems"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/Othercomprehensiveincomelossandaccumulatedothercomprehensiveitems" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_6aeeca2d-f5be-457c-93e9-653b60a951d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_748ed883-f553-498e-b848-cdadbbdf9c38" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_6aeeca2d-f5be-457c-93e9-653b60a951d9" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_748ed883-f553-498e-b848-cdadbbdf9c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/OthercomprehensiveincomelossandaccumulatedothercomprehensiveitemsTables" xlink:type="simple" xlink:href="ptct-20200630.xsd#OthercomprehensiveincomelossandaccumulatedothercomprehensiveitemsTables"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/OthercomprehensiveincomelossandaccumulatedothercomprehensiveitemsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_af73dcbb-88a4-4f6d-a522-acdb6d194e2e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_df2ee3c0-b29a-41b3-a68c-6dd2bca5fad2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_af73dcbb-88a4-4f6d-a522-acdb6d194e2e" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_df2ee3c0-b29a-41b3-a68c-6dd2bca5fad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/OthercomprehensiveincomelossandaccumulatedothercomprehensiveitemsNarrativeDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#OthercomprehensiveincomelossandaccumulatedothercomprehensiveitemsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/OthercomprehensiveincomelossandaccumulatedothercomprehensiveitemsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_8aeb899c-46bb-45b4-9d7d-8bd462ba3e05" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_1451aa01-e9a2-4972-b09f-b7c2a1b84e46" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_8aeb899c-46bb-45b4-9d7d-8bd462ba3e05" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_1451aa01-e9a2-4972-b09f-b7c2a1b84e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0c205c18-ef51-47dc-bec4-fa3b2648aeed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_1451aa01-e9a2-4972-b09f-b7c2a1b84e46" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0c205c18-ef51-47dc-bec4-fa3b2648aeed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_771d731d-3875-4ebe-948c-82d2b2724f7b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0c205c18-ef51-47dc-bec4-fa3b2648aeed" xlink:to="loc_us-gaap_EquityComponentDomain_771d731d-3875-4ebe-948c-82d2b2724f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_9147c8a2-3640-470f-9cb2-701d4347502b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_771d731d-3875-4ebe-948c-82d2b2724f7b" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_9147c8a2-3640-470f-9cb2-701d4347502b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_d40fe6b9-e849-401d-b448-13dce5d14a1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_771d731d-3875-4ebe-948c-82d2b2724f7b" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_d40fe6b9-e849-401d-b448-13dce5d14a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fa76fef7-cc7a-4df3-b7be-c678b94e7ef0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_771d731d-3875-4ebe-948c-82d2b2724f7b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fa76fef7-cc7a-4df3-b7be-c678b94e7ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_538dc3ff-a80d-4161-9c42-67da0cdd0246" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_1451aa01-e9a2-4972-b09f-b7c2a1b84e46" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_538dc3ff-a80d-4161-9c42-67da0cdd0246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7e94ff2a-ff07-421b-885d-f7f699944b01" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_538dc3ff-a80d-4161-9c42-67da0cdd0246" xlink:to="loc_us-gaap_StockholdersEquity_7e94ff2a-ff07-421b-885d-f7f699944b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_152a6504-bccb-40bb-a46b-bc7c042ef4d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_538dc3ff-a80d-4161-9c42-67da0cdd0246" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_152a6504-bccb-40bb-a46b-bc7c042ef4d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_65161232-2c5d-4c99-a608-697cc187a7c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_152a6504-bccb-40bb-a46b-bc7c042ef4d1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_65161232-2c5d-4c99-a608-697cc187a7c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_be40e03b-ffcd-40b1-bbf9-ec5c78cdb88c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_152a6504-bccb-40bb-a46b-bc7c042ef4d1" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_be40e03b-ffcd-40b1-bbf9-ec5c78cdb88c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_71ba8b79-5ead-45c8-83bf-b8192e2a230f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_152a6504-bccb-40bb-a46b-bc7c042ef4d1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_71ba8b79-5ead-45c8-83bf-b8192e2a230f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fdbb5a67-89f1-42fb-881a-b7d08de3ccfe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_538dc3ff-a80d-4161-9c42-67da0cdd0246" xlink:to="loc_us-gaap_StockholdersEquity_fdbb5a67-89f1-42fb-881a-b7d08de3ccfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/Accountspayableandaccruedexpenses" xlink:type="simple" xlink:href="ptct-20200630.xsd#Accountspayableandaccruedexpenses"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/Accountspayableandaccruedexpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_c1bd8077-f78d-490c-b49a-7d84df5b66b8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_4911ae3e-6597-47e1-a0f0-71a9d0a1c938" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_c1bd8077-f78d-490c-b49a-7d84df5b66b8" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_4911ae3e-6597-47e1-a0f0-71a9d0a1c938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/AccountspayableandaccruedexpensesTables" xlink:type="simple" xlink:href="ptct-20200630.xsd#AccountspayableandaccruedexpensesTables"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/AccountspayableandaccruedexpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_f09ed484-60ef-446d-b341-ef4b0aebe117" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_cdc7b64f-e3e1-4d7a-b197-0bbc49fb174d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_f09ed484-60ef-446d-b341-ef4b0aebe117" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_cdc7b64f-e3e1-4d7a-b197-0bbc49fb174d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/AccountspayableandaccruedexpensesNarrativeDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#AccountspayableandaccruedexpensesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/AccountspayableandaccruedexpensesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_ed6786ae-5603-47ab-aacf-2397bc7bef6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7cc0e9b5-828f-4eb6-9486-3d87a8865f70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_ed6786ae-5603-47ab-aacf-2397bc7bef6d" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7cc0e9b5-828f-4eb6-9486-3d87a8865f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AccruedConsultingAndContractedResearchCurrent_dd0b412c-3ecb-4438-927d-0ce853510782" xlink:href="ptct-20200630.xsd#ptct_AccruedConsultingAndContractedResearchCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_ed6786ae-5603-47ab-aacf-2397bc7bef6d" xlink:to="loc_ptct_AccruedConsultingAndContractedResearchCurrent_dd0b412c-3ecb-4438-927d-0ce853510782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_fb3b0369-c160-45fd-8466-dfdd1157cfe8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_ed6786ae-5603-47ab-aacf-2397bc7bef6d" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_fb3b0369-c160-45fd-8466-dfdd1157cfe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_SalesAllowanceAndOtherRelatedCosts_b8bc26eb-11f3-4c28-b949-c4d39acbc1c5" xlink:href="ptct-20200630.xsd#ptct_SalesAllowanceAndOtherRelatedCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_ed6786ae-5603-47ab-aacf-2397bc7bef6d" xlink:to="loc_ptct_SalesAllowanceAndOtherRelatedCosts_b8bc26eb-11f3-4c28-b949-c4d39acbc1c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_SalesRebatesAndRoyaltiesCurrent_ab007b86-7a31-438b-9c3a-8a670a6a93d0" xlink:href="ptct-20200630.xsd#ptct_SalesRebatesAndRoyaltiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_ed6786ae-5603-47ab-aacf-2397bc7bef6d" xlink:to="loc_ptct_SalesRebatesAndRoyaltiesCurrent_ab007b86-7a31-438b-9c3a-8a670a6a93d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_22f8efb5-ebf4-45aa-acc3-4d4ebbc38534" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_ed6786ae-5603-47ab-aacf-2397bc7bef6d" xlink:to="loc_us-gaap_AccountsPayableCurrent_22f8efb5-ebf4-45aa-acc3-4d4ebbc38534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_be6cf6cd-c3f0-41f3-bac7-6238ce519992" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_ed6786ae-5603-47ab-aacf-2397bc7bef6d" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_be6cf6cd-c3f0-41f3-bac7-6238ce519992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_aeeb0b7e-e4ae-4109-add5-78d5d38cf158" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_ed6786ae-5603-47ab-aacf-2397bc7bef6d" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_aeeb0b7e-e4ae-4109-add5-78d5d38cf158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/Capitalization" xlink:type="simple" xlink:href="ptct-20200630.xsd#Capitalization"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/Capitalization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_63059b8d-add7-481f-98ea-65053bb08b45" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1de403d6-13a2-424f-9c94-075a11ea8132" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_63059b8d-add7-481f-98ea-65053bb08b45" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1de403d6-13a2-424f-9c94-075a11ea8132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/CapitalizationNarrativeDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#CapitalizationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/CapitalizationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_13dac0e6-7bbb-4b4c-812b-47d77c0b3a60" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_d695c541-e8b1-4736-b2d0-d3a39ec57015" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_13dac0e6-7bbb-4b4c-812b-47d77c0b3a60" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_d695c541-e8b1-4736-b2d0-d3a39ec57015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a44dbf5a-199c-4c5c-af10-e7f5d514b906" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_d695c541-e8b1-4736-b2d0-d3a39ec57015" xlink:to="loc_srt_RangeAxis_a44dbf5a-199c-4c5c-af10-e7f5d514b906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a27401f4-135f-4645-ad4b-d9ec74f271ef" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a44dbf5a-199c-4c5c-af10-e7f5d514b906" xlink:to="loc_srt_RangeMember_a27401f4-135f-4645-ad4b-d9ec74f271ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1b911ead-a653-427d-8f76-2849be5d8a30" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a27401f4-135f-4645-ad4b-d9ec74f271ef" xlink:to="loc_srt_MaximumMember_1b911ead-a653-427d-8f76-2849be5d8a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_46b90fe6-e19a-4603-b36e-5cfd80b5010f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a27401f4-135f-4645-ad4b-d9ec74f271ef" xlink:to="loc_srt_WeightedAverageMember_46b90fe6-e19a-4603-b36e-5cfd80b5010f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e03a5571-1e4b-433a-879e-cc7654b1a325" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_d695c541-e8b1-4736-b2d0-d3a39ec57015" xlink:to="loc_srt_CounterpartyNameAxis_e03a5571-1e4b-433a-879e-cc7654b1a325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f5b4dd22-e014-41f1-9f8d-0831294840e8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_e03a5571-1e4b-433a-879e-cc7654b1a325" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f5b4dd22-e014-41f1-9f8d-0831294840e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_CensaMember_606d9954-4e2e-4ca2-99de-5c4404278977" xlink:href="ptct-20200630.xsd#ptct_CensaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f5b4dd22-e014-41f1-9f8d-0831294840e8" xlink:to="loc_ptct_CensaMember_606d9954-4e2e-4ca2-99de-5c4404278977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_8214ba28-e612-4951-8d2b-a59d1efb2a9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_d695c541-e8b1-4736-b2d0-d3a39ec57015" xlink:to="loc_us-gaap_PlanNameAxis_8214ba28-e612-4951-8d2b-a59d1efb2a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a30da467-6232-47c2-8358-8670ed06f7be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_8214ba28-e612-4951-8d2b-a59d1efb2a9c" xlink:to="loc_us-gaap_PlanNameDomain_a30da467-6232-47c2-8358-8670ed06f7be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_RightsExchangeAgreementMember_b6f085e0-bb69-4bb5-ac80-d687ac0e73f2" xlink:href="ptct-20200630.xsd#ptct_RightsExchangeAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_a30da467-6232-47c2-8358-8670ed06f7be" xlink:to="loc_ptct_RightsExchangeAgreementMember_b6f085e0-bb69-4bb5-ac80-d687ac0e73f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_6ae1ebc3-79be-4a70-afca-f001a64e1e5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_d695c541-e8b1-4736-b2d0-d3a39ec57015" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_6ae1ebc3-79be-4a70-afca-f001a64e1e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_b75f0c6b-fcba-4d7f-a1a8-5efc214bf021" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6ae1ebc3-79be-4a70-afca-f001a64e1e5d" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_b75f0c6b-fcba-4d7f-a1a8-5efc214bf021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3aed0a1c-37a2-4728-8b1c-a085052f0f1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6ae1ebc3-79be-4a70-afca-f001a64e1e5d" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3aed0a1c-37a2-4728-8b1c-a085052f0f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_d7c9464a-2dd5-46c3-abcb-de9163c8889e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6ae1ebc3-79be-4a70-afca-f001a64e1e5d" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_d7c9464a-2dd5-46c3-abcb-de9163c8889e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_SaleOfStockWeightedAveragePricePerShare_d7e06e40-732d-4e9e-9316-728834a28597" xlink:href="ptct-20200630.xsd#ptct_SaleOfStockWeightedAveragePricePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6ae1ebc3-79be-4a70-afca-f001a64e1e5d" xlink:to="loc_ptct_SaleOfStockWeightedAveragePricePerShare_d7e06e40-732d-4e9e-9316-728834a28597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_9a05a235-f866-4eba-97e5-205fd203885c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6ae1ebc3-79be-4a70-afca-f001a64e1e5d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_9a05a235-f866-4eba-97e5-205fd203885c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_SharestoissueunderRightsExchangeAgreement_208cd7c1-060c-4d30-8c51-ca6f4ef021f3" xlink:href="ptct-20200630.xsd#ptct_SharestoissueunderRightsExchangeAgreement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6ae1ebc3-79be-4a70-afca-f001a64e1e5d" xlink:to="loc_ptct_SharestoissueunderRightsExchangeAgreement_208cd7c1-060c-4d30-8c51-ca6f4ef021f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_bd90a477-19f7-4354-9c4b-4ad3c6e86448" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6ae1ebc3-79be-4a70-afca-f001a64e1e5d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_bd90a477-19f7-4354-9c4b-4ad3c6e86448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/Netlosspershare" xlink:type="simple" xlink:href="ptct-20200630.xsd#Netlosspershare"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/Netlosspershare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_583ed745-ffa5-450a-8ac8-7a23c787537c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_a4daff2a-8e2f-45fd-b9d3-7f4c38b1fd1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_583ed745-ffa5-450a-8ac8-7a23c787537c" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_a4daff2a-8e2f-45fd-b9d3-7f4c38b1fd1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/NetlosspershareTables" xlink:type="simple" xlink:href="ptct-20200630.xsd#NetlosspershareTables"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/NetlosspershareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8bf3cb75-c9f2-44e9-b7ba-55757f07c333" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_cd1bedda-b941-413d-90b9-f595a26b1ddb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8bf3cb75-c9f2-44e9-b7ba-55757f07c333" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_cd1bedda-b941-413d-90b9-f595a26b1ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_704b38ca-60aa-4e15-8ce5-67f817cf4739" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8bf3cb75-c9f2-44e9-b7ba-55757f07c333" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_704b38ca-60aa-4e15-8ce5-67f817cf4739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/NetlosspershareNumeratorandDenominatorDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#NetlosspershareNumeratorandDenominatorDetails"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/NetlosspershareNumeratorandDenominatorDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5bcf915e-e9a8-4239-ae8c-071d26c3013e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_acd151b7-175a-4036-9e85-a4b4d61f7210" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5bcf915e-e9a8-4239-ae8c-071d26c3013e" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_acd151b7-175a-4036-9e85-a4b4d61f7210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_f4308855-9606-4fa4-88d1-da8121dee22c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_acd151b7-175a-4036-9e85-a4b4d61f7210" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_f4308855-9606-4fa4-88d1-da8121dee22c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_f9be6df8-a613-451a-ad99-b9bc88bf37af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_f4308855-9606-4fa4-88d1-da8121dee22c" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_f9be6df8-a613-451a-ad99-b9bc88bf37af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_18d93ed2-2cb0-4d27-a55b-ed6bf585ab90" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_acd151b7-175a-4036-9e85-a4b4d61f7210" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_18d93ed2-2cb0-4d27-a55b-ed6bf585ab90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_b10c09ef-d967-4a9c-9cbc-a5823301dbfa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_18d93ed2-2cb0-4d27-a55b-ed6bf585ab90" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_b10c09ef-d967-4a9c-9cbc-a5823301dbfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_b61a7557-f14a-4a22-b971-2dccd9fc9692" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_acd151b7-175a-4036-9e85-a4b4d61f7210" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_b61a7557-f14a-4a22-b971-2dccd9fc9692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_57e2a755-1cf9-43cc-9b83-2f8a2a2ca4b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_b61a7557-f14a-4a22-b971-2dccd9fc9692" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_57e2a755-1cf9-43cc-9b83-2f8a2a2ca4b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/NetlosspershareAntidilutiveDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#NetlosspershareAntidilutiveDetails"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/NetlosspershareAntidilutiveDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ff497aae-b6f0-450e-8785-3945089116e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e3a62c1f-cae7-4078-8c00-3f582aee6d00" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ff497aae-b6f0-450e-8785-3945089116e3" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e3a62c1f-cae7-4078-8c00-3f582aee6d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_515bd1f1-714a-47aa-b1ca-c9d6313489ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e3a62c1f-cae7-4078-8c00-3f582aee6d00" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_515bd1f1-714a-47aa-b1ca-c9d6313489ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_273d02bc-17dd-4e6d-9eb6-04dd955a68a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_515bd1f1-714a-47aa-b1ca-c9d6313489ab" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_273d02bc-17dd-4e6d-9eb6-04dd955a68a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_aadc427b-d22c-4b50-81a8-c5b5602597f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_273d02bc-17dd-4e6d-9eb6-04dd955a68a9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_aadc427b-d22c-4b50-81a8-c5b5602597f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_RestrictedStockAndRestrictedStockUnitsMember_d8dd5eab-e40c-4455-b35c-f5234eda0b50" xlink:href="ptct-20200630.xsd#ptct_RestrictedStockAndRestrictedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_273d02bc-17dd-4e6d-9eb6-04dd955a68a9" xlink:to="loc_ptct_RestrictedStockAndRestrictedStockUnitsMember_d8dd5eab-e40c-4455-b35c-f5234eda0b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e0b66ea6-a646-453e-b46b-0a72412d35dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e3a62c1f-cae7-4078-8c00-3f582aee6d00" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e0b66ea6-a646-453e-b46b-0a72412d35dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_927637ae-06c0-4dd0-800c-d52464375777" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e0b66ea6-a646-453e-b46b-0a72412d35dd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_927637ae-06c0-4dd0-800c-d52464375777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/Stockawardplan" xlink:type="simple" xlink:href="ptct-20200630.xsd#Stockawardplan"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/Stockawardplan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e45e57d5-a3f0-4d26-93d6-06a724c04b92" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_b7c9ce93-1a22-4be3-a8ba-ad900b79da9e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e45e57d5-a3f0-4d26-93d6-06a724c04b92" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_b7c9ce93-1a22-4be3-a8ba-ad900b79da9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/StockawardplanTables" xlink:type="simple" xlink:href="ptct-20200630.xsd#StockawardplanTables"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/StockawardplanTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_67b618ac-6488-4b2d-8166-2dd0680a74ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3d4bea8c-48ed-4c14-b493-69fdfb10d037" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_67b618ac-6488-4b2d-8166-2dd0680a74ec" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3d4bea8c-48ed-4c14-b493-69fdfb10d037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_571c761b-b6ee-4039-a296-46e9c19ecc91" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_67b618ac-6488-4b2d-8166-2dd0680a74ec" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_571c761b-b6ee-4039-a296-46e9c19ecc91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_6a644f48-8e1d-497f-b042-55e9ccbd3831" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_67b618ac-6488-4b2d-8166-2dd0680a74ec" xlink:to="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_6a644f48-8e1d-497f-b042-55e9ccbd3831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2760e930-d38f-4cf6-b02d-4269b7746033" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_67b618ac-6488-4b2d-8166-2dd0680a74ec" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2760e930-d38f-4cf6-b02d-4269b7746033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/StockawardplanNarrativeDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#StockawardplanNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/StockawardplanNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_195826a0-ef51-495e-a103-5ac35417d25e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fb4c7b8-9ea2-4387-81a5-53c8f725eac1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_195826a0-ef51-495e-a103-5ac35417d25e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fb4c7b8-9ea2-4387-81a5-53c8f725eac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_f4a3f74f-5e18-435d-ad9e-cb183a4414da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fb4c7b8-9ea2-4387-81a5-53c8f725eac1" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_f4a3f74f-5e18-435d-ad9e-cb183a4414da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_c089e4cd-e39c-45bf-85e6-8fd48f5eabaf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_f4a3f74f-5e18-435d-ad9e-cb183a4414da" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_c089e4cd-e39c-45bf-85e6-8fd48f5eabaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_14173e98-03b4-4f6f-9fd6-0fae89ea3889" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_c089e4cd-e39c-45bf-85e6-8fd48f5eabaf" xlink:to="loc_us-gaap_EmployeeStockMember_14173e98-03b4-4f6f-9fd6-0fae89ea3889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_a16a8252-d6e8-46b9-bc4f-fd9a28448c50" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fb4c7b8-9ea2-4387-81a5-53c8f725eac1" xlink:to="loc_us-gaap_PlanNameAxis_a16a8252-d6e8-46b9-bc4f-fd9a28448c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_dddd67be-8940-48ce-81c8-7a1259a21d7d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_a16a8252-d6e8-46b9-bc4f-fd9a28448c50" xlink:to="loc_us-gaap_PlanNameDomain_dddd67be-8940-48ce-81c8-7a1259a21d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_StockIncentivePlan2013Member_e2698015-cace-4e69-bac1-9a8d6d11c96d" xlink:href="ptct-20200630.xsd#ptct_StockIncentivePlan2013Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_dddd67be-8940-48ce-81c8-7a1259a21d7d" xlink:to="loc_ptct_StockIncentivePlan2013Member_e2698015-cace-4e69-bac1-9a8d6d11c96d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_EquityAndLongTermIncentivePlan2009Member_0c865123-a9fb-4ddc-94c1-fcf0a281a122" xlink:href="ptct-20200630.xsd#ptct_EquityAndLongTermIncentivePlan2009Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_dddd67be-8940-48ce-81c8-7a1259a21d7d" xlink:to="loc_ptct_EquityAndLongTermIncentivePlan2009Member_0c865123-a9fb-4ddc-94c1-fcf0a281a122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member_0bd79cd1-9174-472f-8a76-f91745905e02" xlink:href="ptct-20200630.xsd#ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_dddd67be-8940-48ce-81c8-7a1259a21d7d" xlink:to="loc_ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member_0bd79cd1-9174-472f-8a76-f91745905e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_LongTermIncentivePlan2013Member_fb58c121-3960-450e-907e-b8b2e26fa4d1" xlink:href="ptct-20200630.xsd#ptct_LongTermIncentivePlan2013Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_dddd67be-8940-48ce-81c8-7a1259a21d7d" xlink:to="loc_ptct_LongTermIncentivePlan2013Member_fb58c121-3960-450e-907e-b8b2e26fa4d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_A2020inducementstockincentiveplanMember_31e02caf-ed9d-4b1d-9a1e-33db7e38d32e" xlink:href="ptct-20200630.xsd#ptct_A2020inducementstockincentiveplanMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_dddd67be-8940-48ce-81c8-7a1259a21d7d" xlink:to="loc_ptct_A2020inducementstockincentiveplanMember_31e02caf-ed9d-4b1d-9a1e-33db7e38d32e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bf759f65-cfd7-49d1-a318-f94273ae90ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fb4c7b8-9ea2-4387-81a5-53c8f725eac1" xlink:to="loc_us-gaap_AwardTypeAxis_bf759f65-cfd7-49d1-a318-f94273ae90ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92aae67e-6c2c-4c20-a000-66e8e2723a54" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_bf759f65-cfd7-49d1-a318-f94273ae90ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92aae67e-6c2c-4c20-a000-66e8e2723a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_23041f05-922a-4e7f-a63f-2d84a58833af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92aae67e-6c2c-4c20-a000-66e8e2723a54" xlink:to="loc_us-gaap_RestrictedStockMember_23041f05-922a-4e7f-a63f-2d84a58833af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_31cf333b-3bdd-426d-a000-d1c9e2fb17ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92aae67e-6c2c-4c20-a000-66e8e2723a54" xlink:to="loc_us-gaap_StockOptionMember_31cf333b-3bdd-426d-a000-d1c9e2fb17ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_EmployeeDirectorAndConsultantStockOptionPlanMember_7e25720d-ae45-435d-9114-3f1766c54df5" xlink:href="ptct-20200630.xsd#ptct_EmployeeDirectorAndConsultantStockOptionPlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92aae67e-6c2c-4c20-a000-66e8e2723a54" xlink:to="loc_ptct_EmployeeDirectorAndConsultantStockOptionPlanMember_7e25720d-ae45-435d-9114-3f1766c54df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_0a818d80-a2c5-4c7f-9d14-9e221d9361b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92aae67e-6c2c-4c20-a000-66e8e2723a54" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_0a818d80-a2c5-4c7f-9d14-9e221d9361b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_76d0e187-b178-412c-8f0e-8dd5f8300d5e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fb4c7b8-9ea2-4387-81a5-53c8f725eac1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_76d0e187-b178-412c-8f0e-8dd5f8300d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b0775d64-2817-4336-baf2-3a1640f55be6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_76d0e187-b178-412c-8f0e-8dd5f8300d5e" xlink:to="loc_us-gaap_ClassOfStockDomain_b0775d64-2817-4336-baf2-3a1640f55be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7a74c49e-c14d-4e3b-98c3-e2a2eeb2811f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b0775d64-2817-4336-baf2-3a1640f55be6" xlink:to="loc_us-gaap_CommonStockMember_7a74c49e-c14d-4e3b-98c3-e2a2eeb2811f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fdeff581-9d31-4d3e-a603-55568320334e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fb4c7b8-9ea2-4387-81a5-53c8f725eac1" xlink:to="loc_srt_RangeAxis_fdeff581-9d31-4d3e-a603-55568320334e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4eaf7bdf-6dd2-4a2c-84cc-307579c90ce0" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_fdeff581-9d31-4d3e-a603-55568320334e" xlink:to="loc_srt_RangeMember_4eaf7bdf-6dd2-4a2c-84cc-307579c90ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_918a07ff-2669-4399-bd76-f752ba455bd8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4eaf7bdf-6dd2-4a2c-84cc-307579c90ce0" xlink:to="loc_srt_MaximumMember_918a07ff-2669-4399-bd76-f752ba455bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_33105ab2-9b9b-4b3a-8878-0fb4092d5229" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4eaf7bdf-6dd2-4a2c-84cc-307579c90ce0" xlink:to="loc_srt_MinimumMember_33105ab2-9b9b-4b3a-8878-0fb4092d5229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fb4c7b8-9ea2-4387-81a5-53c8f725eac1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_f60d3758-2d70-4791-99ae-ad6dafe91b9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_f60d3758-2d70-4791-99ae-ad6dafe91b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_652ec831-d1b3-42ab-b8f7-089ab3e24fcd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_652ec831-d1b3-42ab-b8f7-089ab3e24fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f2fc676b-6488-4813-ab5b-c60bf1f3b899" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f2fc676b-6488-4813-ab5b-c60bf1f3b899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_67a7577a-def1-42c0-b287-def5266eef40" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_67a7577a-def1-42c0-b287-def5266eef40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_482bb1f7-d0fc-4422-9628-6d9f49596361" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_482bb1f7-d0fc-4422-9628-6d9f49596361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards_daf24700-00ee-4164-93ef-6587f13ea2b0" xlink:href="ptct-20200630.xsd#ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:to="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards_daf24700-00ee-4164-93ef-6587f13ea2b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber_591e9725-7307-4581-afd9-4e80f2acc277" xlink:href="ptct-20200630.xsd#ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:to="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber_591e9725-7307-4581-afd9-4e80f2acc277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding_c101ba5b-9180-49c8-b61e-bd83ebd22a8b" xlink:href="ptct-20200630.xsd#ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:to="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding_c101ba5b-9180-49c8-b61e-bd83ebd22a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions_092701bc-14f2-424e-aa22-2342ec4c9401" xlink:href="ptct-20200630.xsd#ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:to="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions_092701bc-14f2-424e-aa22-2342ec4c9401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_706b90af-e057-4373-84ce-5bf665ab213e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_706b90af-e057-4373-84ce-5bf665ab213e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_63f27fb4-62a6-44f0-9800-3d5673772442" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_63f27fb4-62a6-44f0-9800-3d5673772442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_a229df6a-e928-4373-951f-213f197fd80d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_a229df6a-e928-4373-951f-213f197fd80d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1d47a176-cfbf-4d3d-a4cd-466355d92197" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1d47a176-cfbf-4d3d-a4cd-466355d92197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_StockAppreciationRightsLiabilityOutstanding_2b99cb6b-8b56-46ec-b948-8a5c27ff99b2" xlink:href="ptct-20200630.xsd#ptct_StockAppreciationRightsLiabilityOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:to="loc_ptct_StockAppreciationRightsLiabilityOutstanding_2b99cb6b-8b56-46ec-b948-8a5c27ff99b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_7b082d50-3d0c-49d8-8afe-2f62ea4f408a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_7b082d50-3d0c-49d8-8afe-2f62ea4f408a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_0a40bde1-c0a3-4713-86b4-8f3dccb08bea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_0a40bde1-c0a3-4713-86b4-8f3dccb08bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_e616a820-67a4-4f65-8604-372ce1ad5774" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_e616a820-67a4-4f65-8604-372ce1ad5774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_EmployeeStockPurchasePlanVotingPercentageLimitPercent_ddf523fb-0fcf-41a2-b253-2ac0e76507ad" xlink:href="ptct-20200630.xsd#ptct_EmployeeStockPurchasePlanVotingPercentageLimitPercent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:to="loc_ptct_EmployeeStockPurchasePlanVotingPercentageLimitPercent_ddf523fb-0fcf-41a2-b253-2ac0e76507ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c9ce9045-bee0-4574-8d87-448efd7a102c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c9ce9045-bee0-4574-8d87-448efd7a102c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d642ad5e-4abd-4984-bf08-1fbe831ecbc4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d642ad5e-4abd-4984-bf08-1fbe831ecbc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_00ccd605-cb0d-457d-b22a-98004cd3954d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_00ccd605-cb0d-457d-b22a-98004cd3954d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_949afd53-e275-4751-8e46-d08a32e382c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_949afd53-e275-4751-8e46-d08a32e382c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a494ea1a-ba4a-4910-807e-a62de49e801d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31b4ef2f-5290-40a5-877f-9f0791925ddb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a494ea1a-ba4a-4910-807e-a62de49e801d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/StockawardplanShareBaseCompensationDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#StockawardplanShareBaseCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/StockawardplanShareBaseCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_40913ee5-3378-4721-b295-4f768f367a36" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8aba020b-0eae-4c0f-91c4-71cd651ec518" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_40913ee5-3378-4721-b295-4f768f367a36" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8aba020b-0eae-4c0f-91c4-71cd651ec518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_72256b96-cd80-4d72-bed5-274fa979484d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8aba020b-0eae-4c0f-91c4-71cd651ec518" xlink:to="loc_us-gaap_PlanNameAxis_72256b96-cd80-4d72-bed5-274fa979484d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8334aad6-a643-47b5-b148-b89d03742e77" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_72256b96-cd80-4d72-bed5-274fa979484d" xlink:to="loc_us-gaap_PlanNameDomain_8334aad6-a643-47b5-b148-b89d03742e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_A2020inducementstockincentiveplanMember_cbf8f3ec-c8fb-46d7-8df5-05f39349d083" xlink:href="ptct-20200630.xsd#ptct_A2020inducementstockincentiveplanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_8334aad6-a643-47b5-b148-b89d03742e77" xlink:to="loc_ptct_A2020inducementstockincentiveplanMember_cbf8f3ec-c8fb-46d7-8df5-05f39349d083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_10f2e821-4cf3-425d-9f1b-2225ab528208" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8aba020b-0eae-4c0f-91c4-71cd651ec518" xlink:to="loc_us-gaap_AwardTypeAxis_10f2e821-4cf3-425d-9f1b-2225ab528208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_60e7595e-2770-42f0-8f83-718d4f7602cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_10f2e821-4cf3-425d-9f1b-2225ab528208" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_60e7595e-2770-42f0-8f83-718d4f7602cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_956ce41d-ede3-402d-a5fc-dc093a0d42bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_60e7595e-2770-42f0-8f83-718d4f7602cb" xlink:to="loc_us-gaap_StockOptionMember_956ce41d-ede3-402d-a5fc-dc093a0d42bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_98eff86a-4bb2-4bf1-9637-5f9cb3d2dcfd" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8aba020b-0eae-4c0f-91c4-71cd651ec518" xlink:to="loc_srt_RangeAxis_98eff86a-4bb2-4bf1-9637-5f9cb3d2dcfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b2187bb7-f6fa-4347-bbe1-86d274c466b4" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_98eff86a-4bb2-4bf1-9637-5f9cb3d2dcfd" xlink:to="loc_srt_RangeMember_b2187bb7-f6fa-4347-bbe1-86d274c466b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_dcf2d7cb-fac9-44ba-bd5e-d34db9ea27d7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b2187bb7-f6fa-4347-bbe1-86d274c466b4" xlink:to="loc_srt_MinimumMember_dcf2d7cb-fac9-44ba-bd5e-d34db9ea27d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5bc64016-20d1-42f0-af97-b14aa44beb88" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b2187bb7-f6fa-4347-bbe1-86d274c466b4" xlink:to="loc_srt_MaximumMember_5bc64016-20d1-42f0-af97-b14aa44beb88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9a0d98-8e36-4d27-af88-af45b6e6a20a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8aba020b-0eae-4c0f-91c4-71cd651ec518" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9a0d98-8e36-4d27-af88-af45b6e6a20a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8c5fe70b-cc6c-45af-b4ef-a0f066d0580c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9a0d98-8e36-4d27-af88-af45b6e6a20a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8c5fe70b-cc6c-45af-b4ef-a0f066d0580c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f0c1d4d1-08b0-4929-859a-20b6b6f871bb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8c5fe70b-cc6c-45af-b4ef-a0f066d0580c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f0c1d4d1-08b0-4929-859a-20b6b6f871bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_145cf9c3-389c-4e6d-9614-3e559c782f86" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8c5fe70b-cc6c-45af-b4ef-a0f066d0580c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_145cf9c3-389c-4e6d-9614-3e559c782f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b88e8b9a-7298-4470-a53d-ea6c9aedb4aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8c5fe70b-cc6c-45af-b4ef-a0f066d0580c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b88e8b9a-7298-4470-a53d-ea6c9aedb4aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0051e824-6fd5-4dc1-a37b-3e8d114dc081" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8c5fe70b-cc6c-45af-b4ef-a0f066d0580c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0051e824-6fd5-4dc1-a37b-3e8d114dc081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c884f51b-073b-4275-9ead-a7e6cd776626" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8c5fe70b-cc6c-45af-b4ef-a0f066d0580c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c884f51b-073b-4275-9ead-a7e6cd776626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_eb74e9e0-687a-48ff-94d1-c73838438648" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9a0d98-8e36-4d27-af88-af45b6e6a20a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_eb74e9e0-687a-48ff-94d1-c73838438648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_67e59b40-1494-4729-9650-48d764fff9ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9a0d98-8e36-4d27-af88-af45b6e6a20a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_67e59b40-1494-4729-9650-48d764fff9ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_67a49c6f-b087-43c5-bdee-83e7caf002f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9a0d98-8e36-4d27-af88-af45b6e6a20a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_67a49c6f-b087-43c5-bdee-83e7caf002f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c1531a45-48ba-4464-a9af-e0305f10ee27" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_67a49c6f-b087-43c5-bdee-83e7caf002f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c1531a45-48ba-4464-a9af-e0305f10ee27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_578d48a4-dab1-4ba5-b412-6e7a87744592" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_67a49c6f-b087-43c5-bdee-83e7caf002f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_578d48a4-dab1-4ba5-b412-6e7a87744592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d6c21715-5b93-4f8a-a1f5-329c7e99d32f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_67a49c6f-b087-43c5-bdee-83e7caf002f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d6c21715-5b93-4f8a-a1f5-329c7e99d32f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_baa8f5c7-c172-4e0c-a6f2-b354accb10ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_67a49c6f-b087-43c5-bdee-83e7caf002f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_baa8f5c7-c172-4e0c-a6f2-b354accb10ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_96535bd2-f7f1-4499-983d-009032514ef4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_67a49c6f-b087-43c5-bdee-83e7caf002f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_96535bd2-f7f1-4499-983d-009032514ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_f259b8bb-9f33-4918-abcc-55b562196d4c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9a0d98-8e36-4d27-af88-af45b6e6a20a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_f259b8bb-9f33-4918-abcc-55b562196d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_28776337-9128-4672-9b1d-cefec11800ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9a0d98-8e36-4d27-af88-af45b6e6a20a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_28776337-9128-4672-9b1d-cefec11800ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5c1ce6cd-291d-4d8b-8be3-fbb54c52c54b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9a0d98-8e36-4d27-af88-af45b6e6a20a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5c1ce6cd-291d-4d8b-8be3-fbb54c52c54b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_899abdc4-e287-40ca-96fb-18aa198b21e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5c1ce6cd-291d-4d8b-8be3-fbb54c52c54b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_899abdc4-e287-40ca-96fb-18aa198b21e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_4be57eed-cd69-4142-80c0-8e7e57975f1b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5c1ce6cd-291d-4d8b-8be3-fbb54c52c54b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_4be57eed-cd69-4142-80c0-8e7e57975f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8798e25d-b9c9-4373-bd40-bf6d23f840f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5c1ce6cd-291d-4d8b-8be3-fbb54c52c54b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8798e25d-b9c9-4373-bd40-bf6d23f840f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward_1c52b76c-1a1b-4c0a-a057-ee5f4c436926" xlink:href="ptct-20200630.xsd#ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9a0d98-8e36-4d27-af88-af45b6e6a20a" xlink:to="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward_1c52b76c-1a1b-4c0a-a057-ee5f4c436926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1571d494-f757-4eb6-a84a-c6d0368f865e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward_1c52b76c-1a1b-4c0a-a057-ee5f4c436926" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1571d494-f757-4eb6-a84a-c6d0368f865e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_4ad7f2d2-c7c8-4a78-8e9d-54e7639800bb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward_1c52b76c-1a1b-4c0a-a057-ee5f4c436926" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_4ad7f2d2-c7c8-4a78-8e9d-54e7639800bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3eabbdd0-8ffd-46f7-a39b-f26f8be7d534" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward_1c52b76c-1a1b-4c0a-a057-ee5f4c436926" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3eabbdd0-8ffd-46f7-a39b-f26f8be7d534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ef09d825-bcf4-44b0-bf43-38465a045721" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9a0d98-8e36-4d27-af88-af45b6e6a20a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ef09d825-bcf4-44b0-bf43-38465a045721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_58eef5b5-4d3e-4538-b10e-b3f8da71512a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ef09d825-bcf4-44b0-bf43-38465a045721" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_58eef5b5-4d3e-4538-b10e-b3f8da71512a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ba9b0259-39fb-469f-8a84-2a824af3c322" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ef09d825-bcf4-44b0-bf43-38465a045721" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ba9b0259-39fb-469f-8a84-2a824af3c322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_29930832-ca2e-4510-8bfa-4306d2c7586f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ef09d825-bcf4-44b0-bf43-38465a045721" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_29930832-ca2e-4510-8bfa-4306d2c7586f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/StockawardplanRestrictedStockDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#StockawardplanRestrictedStockDetails"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/StockawardplanRestrictedStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_556f52d2-0fe5-462c-acae-921a51a164ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a2b7d5e9-d39e-4030-af50-7a21938f528f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_556f52d2-0fe5-462c-acae-921a51a164ae" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a2b7d5e9-d39e-4030-af50-7a21938f528f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c1edf007-c91d-47d6-ba3f-d86b487d10bb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a2b7d5e9-d39e-4030-af50-7a21938f528f" xlink:to="loc_us-gaap_AwardTypeAxis_c1edf007-c91d-47d6-ba3f-d86b487d10bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0d5169f-451a-411e-a2d2-c667398051dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c1edf007-c91d-47d6-ba3f-d86b487d10bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0d5169f-451a-411e-a2d2-c667398051dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_94edc220-d91c-45ab-8959-996ebc7dd966" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0d5169f-451a-411e-a2d2-c667398051dd" xlink:to="loc_us-gaap_RestrictedStockMember_94edc220-d91c-45ab-8959-996ebc7dd966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7b68311f-c032-4aea-8556-f8f352604f2c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a2b7d5e9-d39e-4030-af50-7a21938f528f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7b68311f-c032-4aea-8556-f8f352604f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1c3e3d3d-2bbf-456d-a084-4106e599a152" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7b68311f-c032-4aea-8556-f8f352604f2c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1c3e3d3d-2bbf-456d-a084-4106e599a152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c301341b-20cb-44bb-9577-a43b83191b23" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1c3e3d3d-2bbf-456d-a084-4106e599a152" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c301341b-20cb-44bb-9577-a43b83191b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_28f6ee99-2320-4882-968d-3094e9cfecff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1c3e3d3d-2bbf-456d-a084-4106e599a152" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_28f6ee99-2320-4882-968d-3094e9cfecff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_031f2b03-f62b-4065-9484-3dbae8f81218" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1c3e3d3d-2bbf-456d-a084-4106e599a152" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_031f2b03-f62b-4065-9484-3dbae8f81218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_50c76006-47f1-4719-a66d-c9eef8aff500" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1c3e3d3d-2bbf-456d-a084-4106e599a152" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_50c76006-47f1-4719-a66d-c9eef8aff500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_06e3fc74-dfbf-469e-b34c-97e6ba309471" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1c3e3d3d-2bbf-456d-a084-4106e599a152" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_06e3fc74-dfbf-469e-b34c-97e6ba309471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3a499f69-62db-4b3a-b9cb-cbde0692d69d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7b68311f-c032-4aea-8556-f8f352604f2c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3a499f69-62db-4b3a-b9cb-cbde0692d69d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ceaed5c9-7dd1-46d3-87f8-74281bb164f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3a499f69-62db-4b3a-b9cb-cbde0692d69d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ceaed5c9-7dd1-46d3-87f8-74281bb164f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8809c242-9a09-40aa-89ae-a2d0d0835e38" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3a499f69-62db-4b3a-b9cb-cbde0692d69d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8809c242-9a09-40aa-89ae-a2d0d0835e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_987473f6-de3c-48aa-b5e9-99fd296edbcd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3a499f69-62db-4b3a-b9cb-cbde0692d69d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_987473f6-de3c-48aa-b5e9-99fd296edbcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c1bfa3ee-1acc-45a4-9c44-8e565f8ece9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3a499f69-62db-4b3a-b9cb-cbde0692d69d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c1bfa3ee-1acc-45a4-9c44-8e565f8ece9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_143cac3e-4eec-4d43-9e58-498929005c71" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3a499f69-62db-4b3a-b9cb-cbde0692d69d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_143cac3e-4eec-4d43-9e58-498929005c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/StockawardplanSharebasedcompensationexpenseDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#StockawardplanSharebasedcompensationexpenseDetails"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/StockawardplanSharebasedcompensationexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_26e44192-11c8-4b57-8549-0d637afdae22" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0132f841-5053-4b16-9419-a63cfb011617" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_26e44192-11c8-4b57-8549-0d637afdae22" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0132f841-5053-4b16-9419-a63cfb011617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ee2fd25a-d779-407e-869a-07491548745d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0132f841-5053-4b16-9419-a63cfb011617" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ee2fd25a-d779-407e-869a-07491548745d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c6d7bfbd-2539-4ba7-b5c6-a5e1b0bfa37b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ee2fd25a-d779-407e-869a-07491548745d" xlink:to="loc_us-gaap_ClassOfStockDomain_c6d7bfbd-2539-4ba7-b5c6-a5e1b0bfa37b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c67f451f-dcba-4a66-9ded-3372e99b23a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_c6d7bfbd-2539-4ba7-b5c6-a5e1b0bfa37b" xlink:to="loc_us-gaap_CommonStockMember_c67f451f-dcba-4a66-9ded-3372e99b23a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_83498df9-725b-4476-a115-dbddc16d055d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0132f841-5053-4b16-9419-a63cfb011617" xlink:to="loc_us-gaap_PlanNameAxis_83498df9-725b-4476-a115-dbddc16d055d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e43ad4b3-9455-457d-8761-918e2504e29e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_83498df9-725b-4476-a115-dbddc16d055d" xlink:to="loc_us-gaap_PlanNameDomain_e43ad4b3-9455-457d-8761-918e2504e29e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_A2020inducementstockincentiveplanMember_487746ce-14e7-4266-bbaf-523acee108c4" xlink:href="ptct-20200630.xsd#ptct_A2020inducementstockincentiveplanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e43ad4b3-9455-457d-8761-918e2504e29e" xlink:to="loc_ptct_A2020inducementstockincentiveplanMember_487746ce-14e7-4266-bbaf-523acee108c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_be6bcd7d-66a6-4863-aee3-066fa94a143f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0132f841-5053-4b16-9419-a63cfb011617" xlink:to="loc_srt_RangeAxis_be6bcd7d-66a6-4863-aee3-066fa94a143f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_095acfb8-e383-4097-84b6-93c3f8aecb3c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_be6bcd7d-66a6-4863-aee3-066fa94a143f" xlink:to="loc_srt_RangeMember_095acfb8-e383-4097-84b6-93c3f8aecb3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a692ab11-1ed1-4f01-a844-9af5971f62c6" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_095acfb8-e383-4097-84b6-93c3f8aecb3c" xlink:to="loc_srt_MinimumMember_a692ab11-1ed1-4f01-a844-9af5971f62c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_63bd236a-5f83-4f6c-a4e9-65e7344e646f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0132f841-5053-4b16-9419-a63cfb011617" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_63bd236a-5f83-4f6c-a4e9-65e7344e646f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_db88f5c0-c32c-40b4-b211-115903e1fb2a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_63bd236a-5f83-4f6c-a4e9-65e7344e646f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_db88f5c0-c32c-40b4-b211-115903e1fb2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c53a5eb6-f8c0-407b-a1c7-57446270e8ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_db88f5c0-c32c-40b4-b211-115903e1fb2a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c53a5eb6-f8c0-407b-a1c7-57446270e8ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_fe86456a-2b98-43f7-9cce-bd22be50670f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_db88f5c0-c32c-40b4-b211-115903e1fb2a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_fe86456a-2b98-43f7-9cce-bd22be50670f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6154f92c-133a-412c-8a9a-88450b9e8729" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0132f841-5053-4b16-9419-a63cfb011617" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6154f92c-133a-412c-8a9a-88450b9e8729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber_1ba59890-1679-4466-856e-d1b072e9574a" xlink:href="ptct-20200630.xsd#ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6154f92c-133a-412c-8a9a-88450b9e8729" xlink:to="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber_1ba59890-1679-4466-856e-d1b072e9574a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3b6f5d51-6724-4033-9d6a-dff57a20122f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6154f92c-133a-412c-8a9a-88450b9e8729" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3b6f5d51-6724-4033-9d6a-dff57a20122f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f6c775dc-36fb-4c7a-9f25-a1938def86dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6154f92c-133a-412c-8a9a-88450b9e8729" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f6c775dc-36fb-4c7a-9f25-a1938def86dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/Debt" xlink:type="simple" xlink:href="ptct-20200630.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0d327a2c-7bbc-40f5-97b4-31edcd2842a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock_f78029b0-3f52-417f-9e99-4d562f9cd83b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0d327a2c-7bbc-40f5-97b4-31edcd2842a3" xlink:to="loc_us-gaap_LongTermDebtTextBlock_f78029b0-3f52-417f-9e99-4d562f9cd83b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/DebtTables" xlink:type="simple" xlink:href="ptct-20200630.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_dce39bc8-17c4-443a-a238-23490a898d8e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionTable_adf80bd8-fee0-43fb-b308-633546f7d094" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_dce39bc8-17c4-443a-a238-23490a898d8e" xlink:to="loc_us-gaap_DebtInstrumentRedemptionTable_adf80bd8-fee0-43fb-b308-633546f7d094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5963938b-f4f3-42cb-91b9-47467baf13d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionTable_adf80bd8-fee0-43fb-b308-633546f7d094" xlink:to="loc_us-gaap_DebtInstrumentAxis_5963938b-f4f3-42cb-91b9-47467baf13d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6abbf18f-ec01-4505-81e3-caedd35017c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_5963938b-f4f3-42cb-91b9-47467baf13d3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6abbf18f-ec01-4505-81e3-caedd35017c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member_63454bdd-3d53-4a49-82ed-1ec2c781662b" xlink:href="ptct-20200630.xsd#ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6abbf18f-ec01-4505-81e3-caedd35017c7" xlink:to="loc_ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member_63454bdd-3d53-4a49-82ed-1ec2c781662b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_b146009f-9727-45df-a9ad-3d0ab9cae6ee" xlink:href="ptct-20200630.xsd#ptct_ConvertibleSeniorNotes3.0PercentDue2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6abbf18f-ec01-4505-81e3-caedd35017c7" xlink:to="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_b146009f-9727-45df-a9ad-3d0ab9cae6ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionLineItems_0061e936-e152-4130-823d-a62760590993" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionTable_adf80bd8-fee0-43fb-b308-633546f7d094" xlink:to="loc_us-gaap_DebtInstrumentRedemptionLineItems_0061e936-e152-4130-823d-a62760590993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_a4c11590-39b2-4652-979c-1e05dc06bb9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionLineItems_0061e936-e152-4130-823d-a62760590993" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_a4c11590-39b2-4652-979c-1e05dc06bb9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock_b2c92615-91e7-4415-bf72-dac47b78b963" xlink:href="ptct-20200630.xsd#ptct_ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionLineItems_0061e936-e152-4130-823d-a62760590993" xlink:to="loc_ptct_ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock_b2c92615-91e7-4415-bf72-dac47b78b963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#DebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f7748a3c-4140-4a85-9e8c-4ff5dcc9d891" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_d2c69cce-85c7-4f6c-b5f8-6fdc849f0560" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f7748a3c-4140-4a85-9e8c-4ff5dcc9d891" xlink:to="loc_us-gaap_DebtInstrumentTable_d2c69cce-85c7-4f6c-b5f8-6fdc849f0560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_256a1d10-fecd-4b23-806e-882876cf3e6a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d2c69cce-85c7-4f6c-b5f8-6fdc849f0560" xlink:to="loc_us-gaap_CreditFacilityAxis_256a1d10-fecd-4b23-806e-882876cf3e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_0ce74e2a-f138-438a-b2f2-b0dae1cfdcf1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_256a1d10-fecd-4b23-806e-882876cf3e6a" xlink:to="loc_us-gaap_CreditFacilityDomain_0ce74e2a-f138-438a-b2f2-b0dae1cfdcf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_MidCapFinancialTrustMember_fc7bdffc-7839-4d68-aa51-99ae1fb08f60" xlink:href="ptct-20200630.xsd#ptct_MidCapFinancialTrustMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_0ce74e2a-f138-438a-b2f2-b0dae1cfdcf1" xlink:to="loc_ptct_MidCapFinancialTrustMember_fc7bdffc-7839-4d68-aa51-99ae1fb08f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_823a3394-5737-46bb-9388-0b57e4132025" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d2c69cce-85c7-4f6c-b5f8-6fdc849f0560" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_823a3394-5737-46bb-9388-0b57e4132025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_67fb9e8c-b141-4a40-9ec5-6f135b5ed2b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_823a3394-5737-46bb-9388-0b57e4132025" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_67fb9e8c-b141-4a40-9ec5-6f135b5ed2b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_7ef6784b-ed3e-4bb0-a77f-28c66a9b2664" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_67fb9e8c-b141-4a40-9ec5-6f135b5ed2b5" xlink:to="loc_us-gaap_ConvertibleDebtMember_7ef6784b-ed3e-4bb0-a77f-28c66a9b2664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_621ec3af-e50a-4ad5-bc57-4e7207ea8ccb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d2c69cce-85c7-4f6c-b5f8-6fdc849f0560" xlink:to="loc_us-gaap_DebtInstrumentAxis_621ec3af-e50a-4ad5-bc57-4e7207ea8ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6b03553b-77ae-4e0e-9a48-484af22b6522" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_621ec3af-e50a-4ad5-bc57-4e7207ea8ccb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6b03553b-77ae-4e0e-9a48-484af22b6522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_ea64a473-6b35-490d-a26a-bbc855378930" xlink:href="ptct-20200630.xsd#ptct_ConvertibleSeniorNotes3.0PercentDue2022Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6b03553b-77ae-4e0e-9a48-484af22b6522" xlink:to="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_ea64a473-6b35-490d-a26a-bbc855378930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member_eda44932-2cec-4698-9900-74b28713aa30" xlink:href="ptct-20200630.xsd#ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6b03553b-77ae-4e0e-9a48-484af22b6522" xlink:to="loc_ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member_eda44932-2cec-4698-9900-74b28713aa30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_6b216f35-3816-4482-8ab8-b0add5528bb4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d2c69cce-85c7-4f6c-b5f8-6fdc849f0560" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_6b216f35-3816-4482-8ab8-b0add5528bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_9b1f0bad-87b1-4b9d-a10e-97479e6eaa5b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_6b216f35-3816-4482-8ab8-b0add5528bb4" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_9b1f0bad-87b1-4b9d-a10e-97479e6eaa5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member_131517a7-f75f-4f58-9ca0-f2ee7d82ca76" xlink:href="ptct-20200630.xsd#ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_9b1f0bad-87b1-4b9d-a10e-97479e6eaa5b" xlink:to="loc_ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member_131517a7-f75f-4f58-9ca0-f2ee7d82ca76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d2c69cce-85c7-4f6c-b5f8-6fdc849f0560" xlink:to="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_713595ab-e227-45de-af38-4af1093cc90b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_713595ab-e227-45de-af38-4af1093cc90b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_9af732d3-694b-4129-ad51-a3ea6073e084" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_9af732d3-694b-4129-ad51-a3ea6073e084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_LineOfCreditFacilityAdditionalCapacityAvailable_b53f6807-2422-48a5-a218-be4d7d2cf007" xlink:href="ptct-20200630.xsd#ptct_LineOfCreditFacilityAdditionalCapacityAvailable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_ptct_LineOfCreditFacilityAdditionalCapacityAvailable_b53f6807-2422-48a5-a218-be4d7d2cf007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_34bd788c-1c8c-4410-864d-2558ec4f52c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_34bd788c-1c8c-4410-864d-2558ec4f52c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_6a2d9aa5-57a9-45d4-b841-cd66bd03c023" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_us-gaap_RepaymentsOfDebt_6a2d9aa5-57a9-45d4-b841-cd66bd03c023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_32014237-c5b5-4086-ac57-d6b43de37f41" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_us-gaap_LongTermDebt_32014237-c5b5-4086-ac57-d6b43de37f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_d6567a53-a6f9-4158-b61f-7b5af3af23f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_d6567a53-a6f9-4158-b61f-7b5af3af23f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_651bd02a-e392-4a1e-aad5-946c8396e95b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_us-gaap_LongTermDebtCurrent_651bd02a-e392-4a1e-aad5-946c8396e95b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DebtInstrumentFloorInterestRate_1344ac77-cbee-4b7b-a877-84ed5cbaad76" xlink:href="ptct-20200630.xsd#ptct_DebtInstrumentFloorInterestRate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_ptct_DebtInstrumentFloorInterestRate_1344ac77-cbee-4b7b-a877-84ed5cbaad76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_533372ad-a818-481b-b438-3ef07da33ad6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_533372ad-a818-481b-b438-3ef07da33ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DebtInstrumentInterestPaymentPeriod_43a5b75f-a582-453e-82ca-35266439bbfa" xlink:href="ptct-20200630.xsd#ptct_DebtInstrumentInterestPaymentPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_ptct_DebtInstrumentInterestPaymentPeriod_43a5b75f-a582-453e-82ca-35266439bbfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_4ef8710c-b528-43c5-98b2-dafb3ddd21d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_4ef8710c-b528-43c5-98b2-dafb3ddd21d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DebtInstrumentAdditionalAmountAvailableForRepurchase_0d66aa22-4024-44ce-a8fc-92e7d2f545b2" xlink:href="ptct-20200630.xsd#ptct_DebtInstrumentAdditionalAmountAvailableForRepurchase"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_ptct_DebtInstrumentAdditionalAmountAvailableForRepurchase_0d66aa22-4024-44ce-a8fc-92e7d2f545b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d428b1f5-8160-40a8-93e2-9e485f2bc7bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d428b1f5-8160-40a8-93e2-9e485f2bc7bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_46780711-38cb-4ff6-a0bf-20b5bedaf2ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_46780711-38cb-4ff6-a0bf-20b5bedaf2ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_3f78c3dd-9814-42cb-93c0-933b22b49598" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_3f78c3dd-9814-42cb-93c0-933b22b49598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_fe7124a3-6717-4f92-ad49-2ade56c31c72" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_fe7124a3-6717-4f92-ad49-2ade56c31c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_cbf6e9d8-fde1-4492-8e7c-9bf292d028fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_cbf6e9d8-fde1-4492-8e7c-9bf292d028fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DebtInstrumentConvertibleThresholdBusinessDays_581a9d1a-3abb-44b9-a013-54a79a25f2be" xlink:href="ptct-20200630.xsd#ptct_DebtInstrumentConvertibleThresholdBusinessDays"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_ptct_DebtInstrumentConvertibleThresholdBusinessDays_581a9d1a-3abb-44b9-a013-54a79a25f2be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod_630e7d17-f928-4de0-bb0f-85cdf43d4e36" xlink:href="ptct-20200630.xsd#ptct_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_ptct_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod_630e7d17-f928-4de0-bb0f-85cdf43d4e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum_196e33af-3fe1-428b-9675-b42f72acad07" xlink:href="ptct-20200630.xsd#ptct_DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_ptct_DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum_196e33af-3fe1-428b-9675-b42f72acad07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_002b66d3-7e21-40b4-9f65-870517c8b24c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_002b66d3-7e21-40b4-9f65-870517c8b24c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_a685ae57-574b-4fb4-96a6-80127da82c1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_a685ae57-574b-4fb4-96a6-80127da82c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_409e6c7c-ad9a-4aa5-9b7f-69a974e553e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_409e6c7c-ad9a-4aa5-9b7f-69a974e553e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCumulativeSinkingFundPayments_2cfb6511-140d-4133-b62e-0baa8fd33300" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCumulativeSinkingFundPayments"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_us-gaap_DebtInstrumentCumulativeSinkingFundPayments_2cfb6511-140d-4133-b62e-0baa8fd33300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault_90b89281-7cf2-44d6-a7bb-dda9317d4e66" xlink:href="ptct-20200630.xsd#ptct_ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_ptct_ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault_90b89281-7cf2-44d6-a7bb-dda9317d4e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders_e516bb81-6f91-42d9-8643-ab74d60a1c1f" xlink:href="ptct-20200630.xsd#ptct_MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_ptct_MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders_e516bb81-6f91-42d9-8643-ab74d60a1c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_78224c2e-a5ca-49c4-afb8-0db66501c740" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_us-gaap_DebtInstrumentTerm_78224c2e-a5ca-49c4-afb8-0db66501c740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_b5fab13a-2902-46aa-a78c-f38e721d0ba7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_b5fab13a-2902-46aa-a78c-f38e721d0ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_NetDeferredTaxLiabilitiesConvertibleDebtInstruments_d5b88cf9-a3b2-40cf-9c74-848f8eeae078" xlink:href="ptct-20200630.xsd#ptct_NetDeferredTaxLiabilitiesConvertibleDebtInstruments"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_ptct_NetDeferredTaxLiabilitiesConvertibleDebtInstruments_d5b88cf9-a3b2-40cf-9c74-848f8eeae078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_9bc85988-5548-4e18-8b7f-624d95e6da68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_us-gaap_DebtInstrumentFairValue_9bc85988-5548-4e18-8b7f-624d95e6da68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_e3bff46b-dfda-49d6-ae5c-93c62445d5b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6c645edf-6c82-4e77-831c-ea75142df6eb" xlink:to="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_e3bff46b-dfda-49d6-ae5c-93c62445d5b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/DebtConvertibleNotesDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#DebtConvertibleNotesDetails"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/DebtConvertibleNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a3b7381d-3efa-4bab-bf28-7aa2198c5e0a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_283360d1-ffa6-4d20-8525-e34badf5aa03" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a3b7381d-3efa-4bab-bf28-7aa2198c5e0a" xlink:to="loc_us-gaap_DebtInstrumentTable_283360d1-ffa6-4d20-8525-e34badf5aa03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_369cb38f-20f7-41b5-822d-f39ac7dd7f22" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_283360d1-ffa6-4d20-8525-e34badf5aa03" xlink:to="loc_us-gaap_DebtInstrumentAxis_369cb38f-20f7-41b5-822d-f39ac7dd7f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5b6c0964-c484-44c8-8516-6362dbfaa5e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_369cb38f-20f7-41b5-822d-f39ac7dd7f22" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5b6c0964-c484-44c8-8516-6362dbfaa5e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_dadf34b8-e504-4843-8be4-3550675ba870" xlink:href="ptct-20200630.xsd#ptct_ConvertibleSeniorNotes3.0PercentDue2022Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5b6c0964-c484-44c8-8516-6362dbfaa5e0" xlink:to="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_dadf34b8-e504-4843-8be4-3550675ba870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member_5a8308ca-95cd-4573-aaa4-6d228ee79ef2" xlink:href="ptct-20200630.xsd#ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5b6c0964-c484-44c8-8516-6362dbfaa5e0" xlink:to="loc_ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member_5a8308ca-95cd-4573-aaa4-6d228ee79ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_96d44176-c637-4976-8f13-54865f176bb1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_283360d1-ffa6-4d20-8525-e34badf5aa03" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_96d44176-c637-4976-8f13-54865f176bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8bfd26df-665b-46b8-b0e2-18663157006c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_96d44176-c637-4976-8f13-54865f176bb1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8bfd26df-665b-46b8-b0e2-18663157006c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_ef2ddcdd-9a25-421b-8a14-fcd92192eafd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8bfd26df-665b-46b8-b0e2-18663157006c" xlink:to="loc_us-gaap_ConvertibleDebtMember_ef2ddcdd-9a25-421b-8a14-fcd92192eafd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_531e113b-f397-4787-b24d-0d51b760f070" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_283360d1-ffa6-4d20-8525-e34badf5aa03" xlink:to="loc_us-gaap_DebtInstrumentLineItems_531e113b-f397-4787-b24d-0d51b760f070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_e105515f-9513-4fc8-a413-3ef6ab1f970d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_531e113b-f397-4787-b24d-0d51b760f070" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_e105515f-9513-4fc8-a413-3ef6ab1f970d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_6624fb12-6f3a-449d-a46b-b2f98f2be9e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_531e113b-f397-4787-b24d-0d51b760f070" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_6624fb12-6f3a-449d-a46b-b2f98f2be9e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_18cc0fea-33d5-4ab7-a0f6-7246f0c31371" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_531e113b-f397-4787-b24d-0d51b760f070" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_18cc0fea-33d5-4ab7-a0f6-7246f0c31371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_c7c13b52-a4db-458c-ac75-389a3d1b22d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_531e113b-f397-4787-b24d-0d51b760f070" xlink:to="loc_us-gaap_LongTermDebt_c7c13b52-a4db-458c-ac75-389a3d1b22d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/DebtInterestExpenseDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#DebtInterestExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/DebtInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_97589870-e66a-4459-8c7f-4c021d3fea11" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_0a291f25-f53b-4ba1-bc6d-7bf3c45df3d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_97589870-e66a-4459-8c7f-4c021d3fea11" xlink:to="loc_us-gaap_DebtInstrumentTable_0a291f25-f53b-4ba1-bc6d-7bf3c45df3d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_bc8adf24-7f44-47bb-bd66-aeda7cf81496" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0a291f25-f53b-4ba1-bc6d-7bf3c45df3d6" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_bc8adf24-7f44-47bb-bd66-aeda7cf81496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_06772697-d7c0-41e6-b87d-aea63a580b38" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bc8adf24-7f44-47bb-bd66-aeda7cf81496" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_06772697-d7c0-41e6-b87d-aea63a580b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_9f689b48-ca20-41bc-aa91-a0adde33b922" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_06772697-d7c0-41e6-b87d-aea63a580b38" xlink:to="loc_us-gaap_ConvertibleDebtMember_9f689b48-ca20-41bc-aa91-a0adde33b922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ba1ba97e-ced2-454a-9a26-a3935102e3dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0a291f25-f53b-4ba1-bc6d-7bf3c45df3d6" xlink:to="loc_us-gaap_DebtInstrumentAxis_ba1ba97e-ced2-454a-9a26-a3935102e3dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c58f6323-e53a-436b-b50e-9624c7d50cf3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_ba1ba97e-ced2-454a-9a26-a3935102e3dc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c58f6323-e53a-436b-b50e-9624c7d50cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_024c41fa-e558-4ea1-b8a2-cefc4b71a09b" xlink:href="ptct-20200630.xsd#ptct_ConvertibleSeniorNotes3.0PercentDue2022Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c58f6323-e53a-436b-b50e-9624c7d50cf3" xlink:to="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_024c41fa-e558-4ea1-b8a2-cefc4b71a09b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member_b23ccdda-ec25-402c-913f-8fc30ae659df" xlink:href="ptct-20200630.xsd#ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c58f6323-e53a-436b-b50e-9624c7d50cf3" xlink:to="loc_ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member_b23ccdda-ec25-402c-913f-8fc30ae659df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c5ce49ba-77ea-4784-9641-f8a5d1f1b913" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0a291f25-f53b-4ba1-bc6d-7bf3c45df3d6" xlink:to="loc_us-gaap_DebtInstrumentLineItems_c5ce49ba-77ea-4784-9641-f8a5d1f1b913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_6c162be4-743d-4b98-b2af-8691550c9986" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c5ce49ba-77ea-4784-9641-f8a5d1f1b913" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_6c162be4-743d-4b98-b2af-8691550c9986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_c515d2a4-9fdc-4fc5-a078-dc62e936a9fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c5ce49ba-77ea-4784-9641-f8a5d1f1b913" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_c515d2a4-9fdc-4fc5-a078-dc62e936a9fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_09510b5b-381a-4e54-ba9a-9bf7437ed2f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c5ce49ba-77ea-4784-9641-f8a5d1f1b913" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_09510b5b-381a-4e54-ba9a-9bf7437ed2f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_1339f693-d563-465e-bb62-d7d04e3cabd9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c5ce49ba-77ea-4784-9641-f8a5d1f1b913" xlink:to="loc_us-gaap_InterestExpenseDebt_1339f693-d563-465e-bb62-d7d04e3cabd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_5bcf12ce-d7aa-4812-ada3-8627f9cf1f1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c5ce49ba-77ea-4784-9641-f8a5d1f1b913" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_5bcf12ce-d7aa-4812-ada3-8627f9cf1f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/Commitmentsandcontingencies" xlink:type="simple" xlink:href="ptct-20200630.xsd#Commitmentsandcontingencies"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/Commitmentsandcontingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4615521c-8ea9-42df-8f8d-953dd2c20abd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6493c410-2af5-4a09-afe9-2eedbb0e684b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4615521c-8ea9-42df-8f8d-953dd2c20abd" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6493c410-2af5-4a09-afe9-2eedbb0e684b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#CommitmentsandcontingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_61f7b415-32ae-43b8-a32d-6005124a49f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c97ea63b-241d-44e1-9e89-d826919603f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_61f7b415-32ae-43b8-a32d-6005124a49f2" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c97ea63b-241d-44e1-9e89-d826919603f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1b5b0b3e-9f89-4a24-a020-c993e2cb7b67" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c97ea63b-241d-44e1-9e89-d826919603f3" xlink:to="loc_srt_ProductOrServiceAxis_1b5b0b3e-9f89-4a24-a020-c993e2cb7b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ce5ccec6-4b00-4f36-a896-e44659f011c8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1b5b0b3e-9f89-4a24-a020-c993e2cb7b67" xlink:to="loc_srt_ProductsAndServicesDomain_ce5ccec6-4b00-4f36-a896-e44659f011c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_8c916c8c-e353-4a8f-a44c-36cdf457cc94" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ce5ccec6-4b00-4f36-a896-e44659f011c8" xlink:to="loc_us-gaap_ProductMember_8c916c8c-e353-4a8f-a44c-36cdf457cc94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_052ca821-17d0-47dc-83f3-1ca7a6b4a5f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c97ea63b-241d-44e1-9e89-d826919603f3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_052ca821-17d0-47dc-83f3-1ca7a6b4a5f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7ebf8e81-ae1d-4d72-9ab2-afbf0b5fd858" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_052ca821-17d0-47dc-83f3-1ca7a6b4a5f4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7ebf8e81-ae1d-4d72-9ab2-afbf0b5fd858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AgilisMember_1b152cbb-28b1-4109-ae48-f2563bce4a01" xlink:href="ptct-20200630.xsd#ptct_AgilisMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7ebf8e81-ae1d-4d72-9ab2-afbf0b5fd858" xlink:to="loc_ptct_AgilisMember_1b152cbb-28b1-4109-ae48-f2563bce4a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_BioElectronMember_aef3889f-b536-43ae-a8b7-c3b133184f04" xlink:href="ptct-20200630.xsd#ptct_BioElectronMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7ebf8e81-ae1d-4d72-9ab2-afbf0b5fd858" xlink:to="loc_ptct_BioElectronMember_aef3889f-b536-43ae-a8b7-c3b133184f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ffe92da1-2007-4154-8a7e-acb65ec958f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c97ea63b-241d-44e1-9e89-d826919603f3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ffe92da1-2007-4154-8a7e-acb65ec958f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5cab34d5-9ada-427f-982f-db2810d235d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ffe92da1-2007-4154-8a7e-acb65ec958f4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5cab34d5-9ada-427f-982f-db2810d235d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncollaborativeArrangementTransactionsMember_9cfbfd95-8371-4c46-b1bf-47b944b3e3f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncollaborativeArrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5cab34d5-9ada-427f-982f-db2810d235d1" xlink:to="loc_us-gaap_NoncollaborativeArrangementTransactionsMember_9cfbfd95-8371-4c46-b1bf-47b944b3e3f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e0d18d8a-719d-4569-b816-efa9b90f5da6" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c97ea63b-241d-44e1-9e89-d826919603f3" xlink:to="loc_srt_CounterpartyNameAxis_e0d18d8a-719d-4569-b816-efa9b90f5da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fd8ee02f-88d5-4c63-b9d8-01632137f8e3" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_e0d18d8a-719d-4569-b816-efa9b90f5da6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fd8ee02f-88d5-4c63-b9d8-01632137f8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_WellcomeTrustLimitedMember_b321d7a7-ecf2-44b6-a3e1-0530f5c3dcbb" xlink:href="ptct-20200630.xsd#ptct_WellcomeTrustLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fd8ee02f-88d5-4c63-b9d8-01632137f8e3" xlink:to="loc_ptct_WellcomeTrustLimitedMember_b321d7a7-ecf2-44b6-a3e1-0530f5c3dcbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_MarathonPharmaceuticalsLLCMember_c3660490-e999-4242-bef7-449f1572c9f9" xlink:href="ptct-20200630.xsd#ptct_MarathonPharmaceuticalsLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fd8ee02f-88d5-4c63-b9d8-01632137f8e3" xlink:to="loc_ptct_MarathonPharmaceuticalsLLCMember_c3660490-e999-4242-bef7-449f1572c9f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AkceaMember_dc1d2538-df9f-43f4-8e3d-e8eb3ef50819" xlink:href="ptct-20200630.xsd#ptct_AkceaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fd8ee02f-88d5-4c63-b9d8-01632137f8e3" xlink:to="loc_ptct_AkceaMember_dc1d2538-df9f-43f4-8e3d-e8eb3ef50819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_CesnaMember_af97b105-1187-4cbb-b788-6885aaea51a8" xlink:href="ptct-20200630.xsd#ptct_CesnaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fd8ee02f-88d5-4c63-b9d8-01632137f8e3" xlink:to="loc_ptct_CesnaMember_af97b105-1187-4cbb-b788-6885aaea51a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_CensaMember_10e515cf-3641-431b-aacc-2eaf144d536c" xlink:href="ptct-20200630.xsd#ptct_CensaMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fd8ee02f-88d5-4c63-b9d8-01632137f8e3" xlink:to="loc_ptct_CensaMember_10e515cf-3641-431b-aacc-2eaf144d536c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d74f057c-6496-44ff-b242-fed933a33bfd" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c97ea63b-241d-44e1-9e89-d826919603f3" xlink:to="loc_srt_RangeAxis_d74f057c-6496-44ff-b242-fed933a33bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b562eb75-37cf-4f8a-b45f-94af33cce9e4" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d74f057c-6496-44ff-b242-fed933a33bfd" xlink:to="loc_srt_RangeMember_b562eb75-37cf-4f8a-b45f-94af33cce9e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5f88071e-4e3b-4d91-9e08-4ad2dfe4638f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b562eb75-37cf-4f8a-b45f-94af33cce9e4" xlink:to="loc_srt_MaximumMember_5f88071e-4e3b-4d91-9e08-4ad2dfe4638f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d9b6c690-108f-48ec-bbcd-9c60258dd1a1" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b562eb75-37cf-4f8a-b45f-94af33cce9e4" xlink:to="loc_srt_MinimumMember_d9b6c690-108f-48ec-bbcd-9c60258dd1a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b4f0af43-2491-4c86-9b77-904d3888e4e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c97ea63b-241d-44e1-9e89-d826919603f3" xlink:to="loc_us-gaap_PlanNameAxis_b4f0af43-2491-4c86-9b77-904d3888e4e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d82a6090-61f8-40fe-b127-5d4d7258756d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_b4f0af43-2491-4c86-9b77-904d3888e4e8" xlink:to="loc_us-gaap_PlanNameDomain_d82a6090-61f8-40fe-b127-5d4d7258756d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_RightsExchangeAgreementMember_6e005b1d-20e9-4756-b94c-5287d071e153" xlink:href="ptct-20200630.xsd#ptct_RightsExchangeAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d82a6090-61f8-40fe-b127-5d4d7258756d" xlink:to="loc_ptct_RightsExchangeAgreementMember_6e005b1d-20e9-4756-b94c-5287d071e153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c35d9634-26a7-492e-9ea2-cb40b16be3c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c97ea63b-241d-44e1-9e89-d826919603f3" xlink:to="loc_us-gaap_StatementLineItems_c35d9634-26a7-492e-9ea2-cb40b16be3c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAbstract_748242d7-de50-40d6-9489-28009a442424" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c35d9634-26a7-492e-9ea2-cb40b16be3c0" xlink:to="loc_us-gaap_OtherCommitmentsAbstract_748242d7-de50-40d6-9489-28009a442424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_UpfrontLicensingFee_7989e115-8540-49b2-b18c-12d6084dedf2" xlink:href="ptct-20200630.xsd#ptct_UpfrontLicensingFee"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAbstract_748242d7-de50-40d6-9489-28009a442424" xlink:to="loc_ptct_UpfrontLicensingFee_7989e115-8540-49b2-b18c-12d6084dedf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing_b6491b80-fe76-417e-90ce-e2c86188358d" xlink:href="ptct-20200630.xsd#ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAbstract_748242d7-de50-40d6-9489-28009a442424" xlink:to="loc_ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing_b6491b80-fe76-417e-90ce-e2c86188358d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount_b2c37660-f1db-4053-836d-50b79cc0f2ad" xlink:href="ptct-20200630.xsd#ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAbstract_748242d7-de50-40d6-9489-28009a442424" xlink:to="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount_b2c37660-f1db-4053-836d-50b79cc0f2ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone_fe28810e-567f-4603-9945-be97ef0a5e12" xlink:href="ptct-20200630.xsd#ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAbstract_748242d7-de50-40d6-9489-28009a442424" xlink:to="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone_fe28810e-567f-4603-9945-be97ef0a5e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage_95c13f7e-f24e-4435-b208-c0f25c6ce448" xlink:href="ptct-20200630.xsd#ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAbstract_748242d7-de50-40d6-9489-28009a442424" xlink:to="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage_95c13f7e-f24e-4435-b208-c0f25c6ce448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_MilestonePotentialAchievementsRegulatoryApproval_1ae21fd6-12d2-4ba8-ad4f-bd3b0aa207c1" xlink:href="ptct-20200630.xsd#ptct_MilestonePotentialAchievementsRegulatoryApproval"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAbstract_748242d7-de50-40d6-9489-28009a442424" xlink:to="loc_ptct_MilestonePotentialAchievementsRegulatoryApproval_1ae21fd6-12d2-4ba8-ad4f-bd3b0aa207c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AssetAcquisitionMilestoneAmount_f8913b57-d1d9-4452-b2b0-34748a38feba" xlink:href="ptct-20200630.xsd#ptct_AssetAcquisitionMilestoneAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c35d9634-26a7-492e-9ea2-cb40b16be3c0" xlink:to="loc_ptct_AssetAcquisitionMilestoneAmount_f8913b57-d1d9-4452-b2b0-34748a38feba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AssetAcquisitionDevelopmentAndRegulatoryMilestones_1a3a41a3-8f13-409f-8e59-1b0afbc413ed" xlink:href="ptct-20200630.xsd#ptct_AssetAcquisitionDevelopmentAndRegulatoryMilestones"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c35d9634-26a7-492e-9ea2-cb40b16be3c0" xlink:to="loc_ptct_AssetAcquisitionDevelopmentAndRegulatoryMilestones_1a3a41a3-8f13-409f-8e59-1b0afbc413ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AssetAcquisitionNetSalesMilestone_8be1e4b9-e390-44d3-b2b4-2bdeb7b00798" xlink:href="ptct-20200630.xsd#ptct_AssetAcquisitionNetSalesMilestone"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c35d9634-26a7-492e-9ea2-cb40b16be3c0" xlink:to="loc_ptct_AssetAcquisitionNetSalesMilestone_8be1e4b9-e390-44d3-b2b4-2bdeb7b00798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AssetAcquisitionInitialMilestone_1313ed58-0d17-4b0a-9026-3ce84fa5ea77" xlink:href="ptct-20200630.xsd#ptct_AssetAcquisitionInitialMilestone"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c35d9634-26a7-492e-9ea2-cb40b16be3c0" xlink:to="loc_ptct_AssetAcquisitionInitialMilestone_1313ed58-0d17-4b0a-9026-3ce84fa5ea77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ContingentLiabilityCancellationAndForfeitureMilestonePotentialAchievementsPriorityReviewVoucherAmount_8ef6fbb1-e4de-44fd-bb4b-8d722e587737" xlink:href="ptct-20200630.xsd#ptct_ContingentLiabilityCancellationAndForfeitureMilestonePotentialAchievementsPriorityReviewVoucherAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c35d9634-26a7-492e-9ea2-cb40b16be3c0" xlink:to="loc_ptct_ContingentLiabilityCancellationAndForfeitureMilestonePotentialAchievementsPriorityReviewVoucherAmount_8ef6fbb1-e4de-44fd-bb4b-8d722e587737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DevelopmentMilestonePaymentObligationsCancellationAndForfeiture_566c1bb1-cf7c-4936-8a2f-3bd70923b6f6" xlink:href="ptct-20200630.xsd#ptct_DevelopmentMilestonePaymentObligationsCancellationAndForfeiture"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c35d9634-26a7-492e-9ea2-cb40b16be3c0" xlink:to="loc_ptct_DevelopmentMilestonePaymentObligationsCancellationAndForfeiture_566c1bb1-cf7c-4936-8a2f-3bd70923b6f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture_3b1fe2c0-04d3-4250-bbf0-32ac81455880" xlink:href="ptct-20200630.xsd#ptct_DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c35d9634-26a7-492e-9ea2-cb40b16be3c0" xlink:to="loc_ptct_DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture_3b1fe2c0-04d3-4250-bbf0-32ac81455880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ContingentLiabilityCancellationAndForfeiture_70eead8e-007d-401d-9a8a-e42f1a225a42" xlink:href="ptct-20200630.xsd#ptct_ContingentLiabilityCancellationAndForfeiture"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c35d9634-26a7-492e-9ea2-cb40b16be3c0" xlink:to="loc_ptct_ContingentLiabilityCancellationAndForfeiture_70eead8e-007d-401d-9a8a-e42f1a225a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture_9231d0fd-9aba-4cb8-96ae-f01d492fa115" xlink:href="ptct-20200630.xsd#ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c35d9634-26a7-492e-9ea2-cb40b16be3c0" xlink:to="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture_9231d0fd-9aba-4cb8-96ae-f01d492fa115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/Revenuerecognition" xlink:type="simple" xlink:href="ptct-20200630.xsd#Revenuerecognition"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/Revenuerecognition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a6ab0911-8fa2-41aa-a565-60f876a54140" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_21d4061a-5cfb-41bd-ae76-aa95368d6fd0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a6ab0911-8fa2-41aa-a565-60f876a54140" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_21d4061a-5cfb-41bd-ae76-aa95368d6fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/RevenuerecognitionNarrativeDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#RevenuerecognitionNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/RevenuerecognitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_28a8429d-9ec4-4887-b752-6d1e971983a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_e75bcefd-cd5d-4080-b8ca-1fb17435d0d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_28a8429d-9ec4-4887-b752-6d1e971983a4" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_e75bcefd-cd5d-4080-b8ca-1fb17435d0d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_534671af-30c3-4601-bd72-048872de5a2c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_e75bcefd-cd5d-4080-b8ca-1fb17435d0d4" xlink:to="loc_srt_RangeAxis_534671af-30c3-4601-bd72-048872de5a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_290c39d4-22b7-43a2-97fb-d886c43e5653" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_534671af-30c3-4601-bd72-048872de5a2c" xlink:to="loc_srt_RangeMember_290c39d4-22b7-43a2-97fb-d886c43e5653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c639860d-9395-4fff-be53-a750fe3c70f5" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_290c39d4-22b7-43a2-97fb-d886c43e5653" xlink:to="loc_srt_MinimumMember_c639860d-9395-4fff-be53-a750fe3c70f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e89b947b-c322-4b28-ac85-8fcf7f65ea9b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_290c39d4-22b7-43a2-97fb-d886c43e5653" xlink:to="loc_srt_MaximumMember_e89b947b-c322-4b28-ac85-8fcf7f65ea9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f8ddda83-ae3b-41eb-973f-f9d724870ab9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_e75bcefd-cd5d-4080-b8ca-1fb17435d0d4" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f8ddda83-ae3b-41eb-973f-f9d724870ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d74028ff-8d55-4092-9a88-b92b4c16ff61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f8ddda83-ae3b-41eb-973f-f9d724870ab9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d74028ff-8d55-4092-9a88-b92b4c16ff61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_CollaborationAndDiscoveryAgreementsMember_d91c5d1f-0d95-4a92-a35a-50d69f8a4819" xlink:href="ptct-20200630.xsd#ptct_CollaborationAndDiscoveryAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d74028ff-8d55-4092-9a88-b92b4c16ff61" xlink:to="loc_ptct_CollaborationAndDiscoveryAgreementsMember_d91c5d1f-0d95-4a92-a35a-50d69f8a4819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_079618c8-9f8f-4d8f-b200-d4f2da3973ef" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_e75bcefd-cd5d-4080-b8ca-1fb17435d0d4" xlink:to="loc_srt_CounterpartyNameAxis_079618c8-9f8f-4d8f-b200-d4f2da3973ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_29b60492-6585-410a-9d72-d2feb341ccc2" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_079618c8-9f8f-4d8f-b200-d4f2da3973ef" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_29b60492-6585-410a-9d72-d2feb341ccc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_0393d7dd-0d7b-4b34-b882-d6e2812c7667" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_e75bcefd-cd5d-4080-b8ca-1fb17435d0d4" xlink:to="loc_srt_StatementGeographicalAxis_0393d7dd-0d7b-4b34-b882-d6e2812c7667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1dfc4c08-90c7-4e64-a475-0c856b908866" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_0393d7dd-0d7b-4b34-b882-d6e2812c7667" xlink:to="loc_srt_SegmentGeographicalDomain_1dfc4c08-90c7-4e64-a475-0c856b908866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_da7d8114-aa14-4c0b-8cde-cdcb83901997" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1dfc4c08-90c7-4e64-a475-0c856b908866" xlink:to="loc_country_US_da7d8114-aa14-4c0b-8cde-cdcb83901997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_e827f953-6b2d-4a21-965c-3d62de716f73" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1dfc4c08-90c7-4e64-a475-0c856b908866" xlink:to="loc_us-gaap_NonUsMember_e827f953-6b2d-4a21-965c-3d62de716f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_746ed63a-2efd-433e-ae2e-2c134dbcb1b8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_e75bcefd-cd5d-4080-b8ca-1fb17435d0d4" xlink:to="loc_srt_ProductOrServiceAxis_746ed63a-2efd-433e-ae2e-2c134dbcb1b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d18e2955-fc4d-48b7-b205-cf610823c9f4" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_746ed63a-2efd-433e-ae2e-2c134dbcb1b8" xlink:to="loc_srt_ProductsAndServicesDomain_d18e2955-fc4d-48b7-b205-cf610823c9f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_LicensingAndCollaborationAgreementMember_3fdaffd0-a15e-4e64-b64a-18fdea3dbedc" xlink:href="ptct-20200630.xsd#ptct_LicensingAndCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d18e2955-fc4d-48b7-b205-cf610823c9f4" xlink:to="loc_ptct_LicensingAndCollaborationAgreementMember_3fdaffd0-a15e-4e64-b64a-18fdea3dbedc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DiscoveryAgreementsMember_6b86165b-dfa0-4142-b2df-ab82d99ac578" xlink:href="ptct-20200630.xsd#ptct_DiscoveryAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d18e2955-fc4d-48b7-b205-cf610823c9f4" xlink:to="loc_ptct_DiscoveryAgreementsMember_6b86165b-dfa0-4142-b2df-ab82d99ac578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_EarlyStageCollaborationsMember_1bdd3b42-f950-4e6b-93d3-16073c80e1d0" xlink:href="ptct-20200630.xsd#ptct_EarlyStageCollaborationsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d18e2955-fc4d-48b7-b205-cf610823c9f4" xlink:to="loc_ptct_EarlyStageCollaborationsMember_1bdd3b42-f950-4e6b-93d3-16073c80e1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_MilestoneAxis_cd269ae0-ae8c-4877-b639-648fcff38440" xlink:href="ptct-20200630.xsd#ptct_MilestoneAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_e75bcefd-cd5d-4080-b8ca-1fb17435d0d4" xlink:to="loc_ptct_MilestoneAxis_cd269ae0-ae8c-4877-b639-648fcff38440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_MilestoneDomain_803396ee-d81b-428b-a1db-c7054e78eed1" xlink:href="ptct-20200630.xsd#ptct_MilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_MilestoneAxis_cd269ae0-ae8c-4877-b639-648fcff38440" xlink:to="loc_ptct_MilestoneDomain_803396ee-d81b-428b-a1db-c7054e78eed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ResearchAndDevelopmentEventMilestonesMember_21b3578b-c28e-4603-8209-2db624feeb0e" xlink:href="ptct-20200630.xsd#ptct_ResearchAndDevelopmentEventMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_MilestoneDomain_803396ee-d81b-428b-a1db-c7054e78eed1" xlink:to="loc_ptct_ResearchAndDevelopmentEventMilestonesMember_21b3578b-c28e-4603-8209-2db624feeb0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_SalesMilestonesMember_dc47aa55-5057-4014-b626-abf5121c79af" xlink:href="ptct-20200630.xsd#ptct_SalesMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_MilestoneDomain_803396ee-d81b-428b-a1db-c7054e78eed1" xlink:to="loc_ptct_SalesMilestonesMember_dc47aa55-5057-4014-b626-abf5121c79af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_fe7bd9cc-178a-4221-9891-9cb12b8e702e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_e75bcefd-cd5d-4080-b8ca-1fb17435d0d4" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_fe7bd9cc-178a-4221-9891-9cb12b8e702e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_8a0cb769-b4da-4776-b578-28b42c2edb4e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_fe7bd9cc-178a-4221-9891-9cb12b8e702e" xlink:to="loc_us-gaap_NumberOfOperatingSegments_8a0cb769-b4da-4776-b578-28b42c2edb4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_NetProductSales_6878cd4c-86ae-46b5-9891-4bde43389eb3" xlink:href="ptct-20200630.xsd#ptct_NetProductSales"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_fe7bd9cc-178a-4221-9891-9cb12b8e702e" xlink:to="loc_ptct_NetProductSales_6878cd4c-86ae-46b5-9891-4bde43389eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_Percentageofnetproductsales_f95393ae-a668-49fc-afb2-43c7e7509fd1" xlink:href="ptct-20200630.xsd#ptct_Percentageofnetproductsales"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_fe7bd9cc-178a-4221-9891-9cb12b8e702e" xlink:to="loc_ptct_Percentageofnetproductsales_f95393ae-a668-49fc-afb2-43c7e7509fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_Numberofdistributors_1cad12cf-f1ce-42b8-b859-a099ef263616" xlink:href="ptct-20200630.xsd#ptct_Numberofdistributors"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_fe7bd9cc-178a-4221-9891-9cb12b8e702e" xlink:to="loc_ptct_Numberofdistributors_1cad12cf-f1ce-42b8-b859-a099ef263616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_RevenueRecognitionMilestonePotentialAchievements_9a6b2664-231c-4832-9e6e-aabff487edf4" xlink:href="ptct-20200630.xsd#ptct_RevenueRecognitionMilestonePotentialAchievements"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_fe7bd9cc-178a-4221-9891-9cb12b8e702e" xlink:to="loc_ptct_RevenueRecognitionMilestonePotentialAchievements_9a6b2664-231c-4832-9e6e-aabff487edf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_063cabbc-50c5-4105-aa16-f5eb8ffa1914" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_fe7bd9cc-178a-4221-9891-9cb12b8e702e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_063cabbc-50c5-4105-aa16-f5eb8ffa1914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8104ff25-38b1-44c1-b6ba-24bf6a7a6d3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_fe7bd9cc-178a-4221-9891-9cb12b8e702e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8104ff25-38b1-44c1-b6ba-24bf6a7a6d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_9b95b06c-47ff-48f9-894b-e55aa81b499a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_fe7bd9cc-178a-4221-9891-9cb12b8e702e" xlink:to="loc_us-gaap_Revenues_9b95b06c-47ff-48f9-894b-e55aa81b499a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology_faa7441b-f799-4ad9-8860-b41c6af31864" xlink:href="ptct-20200630.xsd#ptct_CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_fe7bd9cc-178a-4221-9891-9cb12b8e702e" xlink:to="loc_ptct_CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology_faa7441b-f799-4ad9-8860-b41c6af31864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c1b17be6-68f2-4609-82e7-6f6094f2742c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_fe7bd9cc-178a-4221-9891-9cb12b8e702e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c1b17be6-68f2-4609-82e7-6f6094f2742c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/RevenuerecognitionPerformanceObligationsDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#RevenuerecognitionPerformanceObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/RevenuerecognitionPerformanceObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0bff1634-d5a7-4c06-8798-cf9a3d55274e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_742c935e-4af6-4988-88da-f4695138a1be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0bff1634-d5a7-4c06-8798-cf9a3d55274e" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_742c935e-4af6-4988-88da-f4695138a1be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_a7cfe3f8-ea4c-45ad-b3dd-b03cb7375a9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_742c935e-4af6-4988-88da-f4695138a1be" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_a7cfe3f8-ea4c-45ad-b3dd-b03cb7375a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_cc72e617-c2cf-4e3d-a5aa-c99123dbcbfb" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_742c935e-4af6-4988-88da-f4695138a1be" xlink:to="loc_srt_ProductOrServiceAxis_cc72e617-c2cf-4e3d-a5aa-c99123dbcbfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0b391ad9-cdea-49d3-84d5-95baa319bf21" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_cc72e617-c2cf-4e3d-a5aa-c99123dbcbfb" xlink:to="loc_srt_ProductsAndServicesDomain_0b391ad9-cdea-49d3-84d5-95baa319bf21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_LicensingAndCollaborationAgreementMember_4228e2ca-df2e-4d2b-bb9b-2df7e73835b5" xlink:href="ptct-20200630.xsd#ptct_LicensingAndCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0b391ad9-cdea-49d3-84d5-95baa319bf21" xlink:to="loc_ptct_LicensingAndCollaborationAgreementMember_4228e2ca-df2e-4d2b-bb9b-2df7e73835b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e64a209b-f07e-4be8-b3a6-233b690bdae1" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_742c935e-4af6-4988-88da-f4695138a1be" xlink:to="loc_srt_RangeAxis_e64a209b-f07e-4be8-b3a6-233b690bdae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a391d974-cd95-4b8f-83af-311e820c2abc" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e64a209b-f07e-4be8-b3a6-233b690bdae1" xlink:to="loc_srt_RangeMember_a391d974-cd95-4b8f-83af-311e820c2abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8ab51363-3e21-45e3-bc5c-eed990951f22" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a391d974-cd95-4b8f-83af-311e820c2abc" xlink:to="loc_srt_MinimumMember_8ab51363-3e21-45e3-bc5c-eed990951f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a1e1c30a-3560-48a5-80d2-4c5005f23630" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a391d974-cd95-4b8f-83af-311e820c2abc" xlink:to="loc_srt_MaximumMember_a1e1c30a-3560-48a5-80d2-4c5005f23630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_64b9d1dc-86ed-4488-8674-eb77fa1419ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_742c935e-4af6-4988-88da-f4695138a1be" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_64b9d1dc-86ed-4488-8674-eb77fa1419ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_a568af28-4d28-4800-adaf-b049d471914f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_64b9d1dc-86ed-4488-8674-eb77fa1419ba" xlink:to="loc_us-gaap_ContractWithCustomerLiability_a568af28-4d28-4800-adaf-b049d471914f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_c1f973d8-1fec-4089-b4fb-758f85ce4725" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_64b9d1dc-86ed-4488-8674-eb77fa1419ba" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_c1f973d8-1fec-4089-b4fb-758f85ce4725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_06ae4fda-ec27-4fb6-9eb8-c2a507cb5ddb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_64b9d1dc-86ed-4488-8674-eb77fa1419ba" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_06ae4fda-ec27-4fb6-9eb8-c2a507cb5ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/RevenuerecognitionPerformanceObligationsDetails_1" xlink:type="simple" xlink:href="ptct-20200630.xsd#RevenuerecognitionPerformanceObligationsDetails_1"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/RevenuerecognitionPerformanceObligationsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ptcbio.com/role/Intangibleassetsandgoodwill" xlink:type="simple" xlink:href="ptct-20200630.xsd#Intangibleassetsandgoodwill"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/Intangibleassetsandgoodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ac4c400e-0b16-431c-a51e-fb2215b2f329" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_250ebbb3-a388-45ba-8fb4-87ccc138900e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ac4c400e-0b16-431c-a51e-fb2215b2f329" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_250ebbb3-a388-45ba-8fb4-87ccc138900e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/IntangibleassetsandgoodwillTables" xlink:type="simple" xlink:href="ptct-20200630.xsd#IntangibleassetsandgoodwillTables"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/IntangibleassetsandgoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_171419b8-3a77-4c59-8d34-9051bc818158" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_bc7ba1e1-f042-4dab-bf1c-952070f1efb3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_171419b8-3a77-4c59-8d34-9051bc818158" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_bc7ba1e1-f042-4dab-bf1c-952070f1efb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/IntangibleassetsandgoodwillNarrativeDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#IntangibleassetsandgoodwillNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/IntangibleassetsandgoodwillNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2e009024-ee0c-47b2-9707-bdb6e1ad81d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ec7cccd8-bf29-4bf7-bf44-a59cf6649f47" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2e009024-ee0c-47b2-9707-bdb6e1ad81d9" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ec7cccd8-bf29-4bf7-bf44-a59cf6649f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d2e91c3d-0512-4322-85a4-56513c5ce02f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ec7cccd8-bf29-4bf7-bf44-a59cf6649f47" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d2e91c3d-0512-4322-85a4-56513c5ce02f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ba88956-a53f-4c2b-878c-da2e8a1c3643" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d2e91c3d-0512-4322-85a4-56513c5ce02f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ba88956-a53f-4c2b-878c-da2e8a1c3643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_EmflazaassetacquisitionMember_014be67f-0fa3-436f-a5d3-f1fb1b6c28ce" xlink:href="ptct-20200630.xsd#ptct_EmflazaassetacquisitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ba88956-a53f-4c2b-878c-da2e8a1c3643" xlink:to="loc_ptct_EmflazaassetacquisitionMember_014be67f-0fa3-436f-a5d3-f1fb1b6c28ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_bae0275a-0b24-4330-915b-40ecd2c7900d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ec7cccd8-bf29-4bf7-bf44-a59cf6649f47" xlink:to="loc_us-gaap_TypeOfArrangementAxis_bae0275a-0b24-4330-915b-40ecd2c7900d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_32f82428-f321-457f-8747-17d7ac10768d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bae0275a-0b24-4330-915b-40ecd2c7900d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_32f82428-f321-457f-8747-17d7ac10768d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncollaborativeArrangementTransactionsMember_5f148ed8-24cd-4a6a-ac08-8241b3b4a8a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncollaborativeArrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_32f82428-f321-457f-8747-17d7ac10768d" xlink:to="loc_us-gaap_NoncollaborativeArrangementTransactionsMember_5f148ed8-24cd-4a6a-ac08-8241b3b4a8a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ce36065f-f30f-4ca4-9044-3b533e3620ee" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ec7cccd8-bf29-4bf7-bf44-a59cf6649f47" xlink:to="loc_srt_CounterpartyNameAxis_ce36065f-f30f-4ca4-9044-3b533e3620ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b126ef1-e7f1-49ee-bd75-2e128ba0dbac" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_ce36065f-f30f-4ca4-9044-3b533e3620ee" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b126ef1-e7f1-49ee-bd75-2e128ba0dbac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AkceaMember_50b2490a-b9ff-40db-bc5c-6611c02940a6" xlink:href="ptct-20200630.xsd#ptct_AkceaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b126ef1-e7f1-49ee-bd75-2e128ba0dbac" xlink:to="loc_ptct_AkceaMember_50b2490a-b9ff-40db-bc5c-6611c02940a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_90bfb1b0-bd4f-49be-9eaa-7742ba017436" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ec7cccd8-bf29-4bf7-bf44-a59cf6649f47" xlink:to="loc_srt_RangeAxis_90bfb1b0-bd4f-49be-9eaa-7742ba017436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fb8e517e-03cf-4990-9124-1048dea1fbbc" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_90bfb1b0-bd4f-49be-9eaa-7742ba017436" xlink:to="loc_srt_RangeMember_fb8e517e-03cf-4990-9124-1048dea1fbbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_2cc057f3-9bb5-4e6c-8aa7-8af36aaa1e18" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fb8e517e-03cf-4990-9124-1048dea1fbbc" xlink:to="loc_srt_WeightedAverageMember_2cc057f3-9bb5-4e6c-8aa7-8af36aaa1e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f76740a1-ea57-4486-917f-510177b5f3a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ec7cccd8-bf29-4bf7-bf44-a59cf6649f47" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f76740a1-ea57-4486-917f-510177b5f3a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_8337b040-e9aa-4c6f-b385-d48f1e23edef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f76740a1-ea57-4486-917f-510177b5f3a9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_8337b040-e9aa-4c6f-b385-d48f1e23edef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_MilestonePotentialAchievementsRegulatoryApproval_37e4e50a-9f99-4440-b688-c6ccc6f49345" xlink:href="ptct-20200630.xsd#ptct_MilestonePotentialAchievementsRegulatoryApproval"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f76740a1-ea57-4486-917f-510177b5f3a9" xlink:to="loc_ptct_MilestonePotentialAchievementsRegulatoryApproval_37e4e50a-9f99-4440-b688-c6ccc6f49345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8dc74c37-6519-4095-8698-8999a15ce1bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f76740a1-ea57-4486-917f-510177b5f3a9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8dc74c37-6519-4095-8698-8999a15ce1bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing_29383203-7833-468d-87c5-ca1b6acba834" xlink:href="ptct-20200630.xsd#ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f76740a1-ea57-4486-917f-510177b5f3a9" xlink:to="loc_ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing_29383203-7833-468d-87c5-ca1b6acba834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1ee7e2b3-d511-44b2-b58a-2b63db79a1c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f76740a1-ea57-4486-917f-510177b5f3a9" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_1ee7e2b3-d511-44b2-b58a-2b63db79a1c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_ea0dc444-6b5b-4e8e-947f-2057657cfb63" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f76740a1-ea57-4486-917f-510177b5f3a9" xlink:to="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_ea0dc444-6b5b-4e8e-947f-2057657cfb63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1ab5467f-841e-4ef4-8e6d-f8931f7339d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f76740a1-ea57-4486-917f-510177b5f3a9" xlink:to="loc_us-gaap_Goodwill_1ab5467f-841e-4ef4-8e6d-f8931f7339d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_UpfrontLicensingFee_5d6cc1d6-24b0-4517-a5ff-af7422e04775" xlink:href="ptct-20200630.xsd#ptct_UpfrontLicensingFee"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f76740a1-ea57-4486-917f-510177b5f3a9" xlink:to="loc_ptct_UpfrontLicensingFee_5d6cc1d6-24b0-4517-a5ff-af7422e04775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_70a226d1-ebfb-436a-9702-0e3a02945b09" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f76740a1-ea57-4486-917f-510177b5f3a9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_70a226d1-ebfb-436a-9702-0e3a02945b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_9719e98e-507c-4fdf-bcea-c810809270e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f76740a1-ea57-4486-917f-510177b5f3a9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_9719e98e-507c-4fdf-bcea-c810809270e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/IntangibleassetsandgoodwillFutureAmortizationDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#IntangibleassetsandgoodwillFutureAmortizationDetails"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/IntangibleassetsandgoodwillFutureAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2f544dd7-bc1c-4b2b-8a42-3217b5e29dcb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_c8dc5a7c-2a27-468e-8017-d213a79cebb0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2f544dd7-bc1c-4b2b-8a42-3217b5e29dcb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_c8dc5a7c-2a27-468e-8017-d213a79cebb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_b4cab938-f7c1-406e-b385-09707f7c8533" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2f544dd7-bc1c-4b2b-8a42-3217b5e29dcb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_b4cab938-f7c1-406e-b385-09707f7c8533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_657626f8-5203-4d6f-91ff-5e01aa22ca2f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2f544dd7-bc1c-4b2b-8a42-3217b5e29dcb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_657626f8-5203-4d6f-91ff-5e01aa22ca2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_36620213-cbce-4645-a6a2-01c6b8032ec1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2f544dd7-bc1c-4b2b-8a42-3217b5e29dcb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_36620213-cbce-4645-a6a2-01c6b8032ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter_fc844243-66a4-4423-9736-237a75e9618c" xlink:href="ptct-20200630.xsd#ptct_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2f544dd7-bc1c-4b2b-8a42-3217b5e29dcb" xlink:to="loc_ptct_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter_fc844243-66a4-4423-9736-237a75e9618c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_72fcd5bf-764f-4756-9a46-c120af2315ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2f544dd7-bc1c-4b2b-8a42-3217b5e29dcb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_72fcd5bf-764f-4756-9a46-c120af2315ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/Subsequentevents" xlink:type="simple" xlink:href="ptct-20200630.xsd#Subsequentevents"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/Subsequentevents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_e94f71c4-8794-48f2-ab73-bc15efe74d61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_81b83bce-5b32-4909-9437-7f574bd9082f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_e94f71c4-8794-48f2-ab73-bc15efe74d61" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_81b83bce-5b32-4909-9437-7f574bd9082f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ptcbio.com/role/SubsequenteventsNarrativeDetails" xlink:type="simple" xlink:href="ptct-20200630.xsd#SubsequenteventsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/SubsequenteventsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_766c2d4f-4068-4df2-956a-c77850b86f0c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_f6274d59-1560-4c7a-9bc1-a440c2b8a2d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_766c2d4f-4068-4df2-956a-c77850b86f0c" xlink:to="loc_us-gaap_SubsequentEventTable_f6274d59-1560-4c7a-9bc1-a440c2b8a2d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7b7a9f3a-3ed0-4850-ad13-cfbfa1b9a04f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_f6274d59-1560-4c7a-9bc1-a440c2b8a2d4" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_7b7a9f3a-3ed0-4850-ad13-cfbfa1b9a04f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c875cc3d-1796-4ec0-bf1d-26d19aa9bc7e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7b7a9f3a-3ed0-4850-ad13-cfbfa1b9a04f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c875cc3d-1796-4ec0-bf1d-26d19aa9bc7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_f9d7a26e-7782-4378-add9-4dfe571e85ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c875cc3d-1796-4ec0-bf1d-26d19aa9bc7e" xlink:to="loc_us-gaap_SubsequentEventMember_f9d7a26e-7782-4378-add9-4dfe571e85ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_70007dc0-2ea6-427f-9753-1cac6644fbc1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_f6274d59-1560-4c7a-9bc1-a440c2b8a2d4" xlink:to="loc_us-gaap_SubsequentEventLineItems_70007dc0-2ea6-427f-9753-1cac6644fbc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_fb105862-65f1-4722-8dbf-7cc2c53514ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_70007dc0-2ea6-427f-9753-1cac6644fbc1" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_fb105862-65f1-4722-8dbf-7cc2c53514ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_LineOfCreditFacilityTerminationAndExitFees_637c8c9b-dbd0-4586-b2bb-41baef7ef35c" xlink:href="ptct-20200630.xsd#ptct_LineOfCreditFacilityTerminationAndExitFees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_70007dc0-2ea6-427f-9753-1cac6644fbc1" xlink:to="loc_ptct_LineOfCreditFacilityTerminationAndExitFees_637c8c9b-dbd0-4586-b2bb-41baef7ef35c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AssignedRoyaltyPaymentPercentage_b1673d9e-b138-4f06-b38c-d222f17eab10" xlink:href="ptct-20200630.xsd#ptct_AssignedRoyaltyPaymentPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_70007dc0-2ea6-427f-9753-1cac6644fbc1" xlink:to="loc_ptct_AssignedRoyaltyPaymentPercentage_b1673d9e-b138-4f06-b38c-d222f17eab10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_ProceedsAssignedRoyaltyPaymentAgreement_9e085458-1b0f-47af-a59c-d105f0d4f7f1" xlink:href="ptct-20200630.xsd#ptct_ProceedsAssignedRoyaltyPaymentAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_70007dc0-2ea6-427f-9753-1cac6644fbc1" xlink:to="loc_ptct_ProceedsAssignedRoyaltyPaymentAgreement_9e085458-1b0f-47af-a59c-d105f0d4f7f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_AssignedRoyaltyPaymentRetainedPercentage_b21097ab-7171-48cc-a91a-01fbeaf07a24" xlink:href="ptct-20200630.xsd#ptct_AssignedRoyaltyPaymentRetainedPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_70007dc0-2ea6-427f-9753-1cac6644fbc1" xlink:to="loc_ptct_AssignedRoyaltyPaymentRetainedPercentage_b21097ab-7171-48cc-a91a-01fbeaf07a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_RevenueRecognitionMilestonePotentialAchievements_24ef9226-4645-40d4-b02a-dd1217f9be51" xlink:href="ptct-20200630.xsd#ptct_RevenueRecognitionMilestonePotentialAchievements"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_70007dc0-2ea6-427f-9753-1cac6644fbc1" xlink:to="loc_ptct_RevenueRecognitionMilestonePotentialAchievements_24ef9226-4645-40d4-b02a-dd1217f9be51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_RoyaltyPurchaseAgreementTerminationPeriod_a0c2a76f-7e40-47e9-8338-c1d8b9dff73e" xlink:href="ptct-20200630.xsd#ptct_RoyaltyPurchaseAgreementTerminationPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_70007dc0-2ea6-427f-9753-1cac6644fbc1" xlink:to="loc_ptct_RoyaltyPurchaseAgreementTerminationPeriod_a0c2a76f-7e40-47e9-8338-c1d8b9dff73e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ptct_RoyaltyPurchaseAgreementPaymentMaximum_0bd48b62-07f7-4ebe-8fa8-094d3a205b2a" xlink:href="ptct-20200630.xsd#ptct_RoyaltyPurchaseAgreementPaymentMaximum"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_70007dc0-2ea6-427f-9753-1cac6644fbc1" xlink:to="loc_ptct_RoyaltyPurchaseAgreementPaymentMaximum_0bd48b62-07f7-4ebe-8fa8-094d3a205b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image011.jpg
<TEXT>
begin 644 image011.jpg
MB5!.1PT*&@H    -24A$4@   "0   "4" 8   #[RHOM    "7!(67,  $SE
M  !,Y0%USO"5    EDE$051XG.W.H0$ ( S L/W_-/B92!#-!9GSF7D=V I)
M(2DDA:20%))"4D@*22$I)(6DD!220E)("DDA*22%I) 4DD)22 I)(2DDA:20
M%))"4D@*22$I)(6DD!220E)("DDA*22%I) 4DD)22 I)(2DDA:20%))"4D@*
M22$I)(6DD!220E)("DDA*22%I) 4DD)22 K)!2\!\8^S$T>!     $E%3D2N
#0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image012.jpg
<TEXT>
begin 644 image012.jpg
MB5!.1PT*&@H    -24A$4@  #+(   "=" 8    ::K!,    "7!(67,  $SE
M  !,Y0%USO"5   )34E$051XG.W;,0$ , R L/HWO;I@1Q,%&& >
M        !.9W                 #<860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
M         $@860               $@860               $@860
=         $@LW^E4PHH$!/$     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image111.jpg
<TEXT>
begin 644 image111.jpg
MB5!.1PT*&@H    -24A$4@   "0   $I" 8   #[Z8#R    "7!(67,  $SE
M  !,Y0%USO"5   !$$E$051XG.W.H0$ ( S L/W_-'A,)!/-!9FSS/P.O I)
M(2DDA:20%))"4D@*22$I)(6DD!220E)("DDA*22%I) 4DD)22 I)(2DDA:20
M%))"4D@*22$I)(6DD!220E)("DDA*22%I) 4DD)22 I)(2DDA:20%))"4D@*
M22$I)(6DD!220E)("DDA*22%I) 4DD)22 I)(2DDA:20%))"4D@*22$I)(6D
MD!220E)("DDA*22%I) 4DD)22 I)(2DDA:20%))"4D@*22$I)(6DD!220E)(
M"DDA*22%I) 4DD)22 I)(2DDA:20%))"4D@*22$I)(6DD!220E)("DDA*22%
CI) 4DD)22 I)(2DDZT(7:6=RJ[]?RH\     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>ptct-20200630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2017-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:ptct="http://www.ptcbio.com/20200630"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ptct-20200630.xsd" xlink:type="simple"/>
    <context id="i169de841172649f2b7a67e115481f695_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i53a9a4e5a7004ee289a81b8ed4b249e4_I20200803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
        </entity>
        <period>
            <instant>2020-08-03</instant>
        </period>
    </context>
    <context id="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i45814e0e64094044a82fcf8bbad4c123_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i80823282f4634ae8844d0174883b097c_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i3c2dcea8d5894a6aaba983f5a911388c_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibd94b62990744751ae48321dad1d6eab_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i1856787732484c15a0bc9dd59846d7df_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:GrantAndCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i31e4fee5acef46b09a3f7ab4d447b758_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:GrantAndCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ia37e22b92f244d44941f5498dd31a614_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:GrantAndCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i846b2660ee9a46aa8e191f0a79737479_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:GrantAndCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ieec6c9a44e1a4fa0b02c65d76e099de2_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i2217d6be0da04b3c9aa7801351f5b23f_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ic903ce63d61344bb93ea8a3c7cd2e5fd_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i5f5abb3d22174bc5baaf5959060f4f75_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ieb8114d4f418487782c0740ca1ed1bfc_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ib2522e73523e4feda4f9fd68c9be8c32_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic3ffc2fc75914fddbf65e6f5960bc8d5_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i85184b2a023d436aae89f6d066cfbfec_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i533ee7ba976f46e396724aba128c444e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie459585656ec4c888bad0072cb787216_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if99a5f5b88c44e239963a271d78fd4d0_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ib08418efd9054e53865f0aad58f50b9d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i94b08961287e4bd28403b18fb27d1ef3_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i2e93050dc1a94baf9a24faf44c845fc2_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i9ff2de3d9580494aa4f84424a72b83aa_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i930a0deb5fe14f56b2dfe784709c3a46_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="id107e0ac152043d8b3217fec423c7ff5_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="iaa534d8c4a3b44998ead7885db0ad530_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i42fbe8f0476c44e48fe505660057da1a_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i6ae47019f2ba40a8aefbc1d239cdc94b_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="icfcb85f561bb41318c256dcacaf6a1a2_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i289d8cdd90cd4be0a90a0932fe6572f6_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="id81dc5f706a14ac69c50d7c1adccc558_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i5628af8116db4f9a9c32020225574c39_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ifeea6088e2ed4f849936ae7bdd7cbcfd_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i28563c013fff4be6aba8b90a75baf135_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i6416f0fda976465288b8a99fee841a11_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0c24f8e9d344416dbdacd07f1624ad0c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iebab310c097741efb22ea6ccc61c24b1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if79b05d131bf402dac7e50420745aeff_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9e33cecb164a48a0aa1eba2f1728140b_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3b35f4ed68ad4e4d905a31fd652afbca_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i31d6e1bdb5ca471392964fa03ef36c08_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9bff894d600845e29a8c4faf34680df2_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib5972ed6730144a8ae9bdb30fcd5fffd_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib056d8d4512a4814801eaea43e457f5f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i9d8fb8ff546849248d177b17b67ea09b_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6eadb591f1b34ddaa289055d8b4379c3_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i785bae8d0f37453b828968b15c63b74f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i4042444983714690acf2456c51c245ff_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ice0e67612cf54d9c91dea97e80e5cbec_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i27feb6dc967a41579d7c19c8a1cb7e84_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i24ef21dbfe234c0591a9b24a236878c6_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ib9eece550dff4e4780cef9d288202a33_D20180823-20180823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-23</startDate>
            <endDate>2018-08-23</endDate>
        </period>
    </context>
    <context id="i0e759cb2d2394853b69b11290ac5d21a_I20180823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-23</instant>
        </period>
    </context>
    <context id="if89af7698cdf43d1915f30dc403dc6af_I20200429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:RightsExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-29</instant>
        </period>
    </context>
    <context id="i921570c76d4f4e23870b19798c531218_D20200429-20200429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:RightsExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-29</startDate>
            <endDate>2020-04-29</endDate>
        </period>
    </context>
    <context id="i44fac1cb95fa4331b63d8afeb4d83f20_D20200429-20200429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:RightsExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-29</startDate>
            <endDate>2020-04-29</endDate>
        </period>
    </context>
    <context id="id61e01344c6b402983658d905475cc0f_I20200429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-29</instant>
        </period>
    </context>
    <context id="i56959b5fb9c34914b2d086de6704c201_I20200429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-29</instant>
        </period>
    </context>
    <context id="i56a3188c726c4476a6115fcc0dc1091f_I20200429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-29</instant>
        </period>
    </context>
    <context id="i2869c1675c5a404e9bb85cad2eb71998_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes1.5DueSeptember152026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i28655a9b21d647eb9144da8fa8cdd911_I20150831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-08-31</instant>
        </period>
    </context>
    <context id="ic07a476967de416b843f81c02e185244_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:FifthAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ib5e09658503d4a019b7c66616efd1b4d_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i70f85cc7508547529a1ddd69bf58968d_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i9fcd6ae0b0b244eb992a22b9f010a8a9_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0cac55e0c942455e8be47df4a5540bf5_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i8b2299918005400d83e8169cdceaa098_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if04847b5828f40ffb96ff09abbfbe7f0_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i245f190c344b472682efecbcf65a617f_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i084808ce47024c3e9355cdfb5214b4ee_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i8742fae222d34cac83b189f51096e426_D20200529-20200529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:CensaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-29</startDate>
            <endDate>2020-05-29</endDate>
        </period>
    </context>
    <context id="i28fa54ad024443b18973875cc89f36e3_I20200529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:CensaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-29</instant>
        </period>
    </context>
    <context id="i534a161919c644babf7b581f8815a9ae_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iee26b7ab0eb3427894a7e80a6ab4b557_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i9b91bdabba504b27a63eb72dd4e14072_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:MassBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">ptct:FinanceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iad9435fcf1974f729382cb45345d15cf_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:MassBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">ptct:FinanceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2eddd9a393564222bc0988444831fd19_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:MassBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">ptct:FinanceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i70c896353309469f838542acfc22aa9e_I20200501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ptct:BridgewaterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-01</instant>
        </period>
    </context>
    <context id="iffc234810342492fa6bacab33891f92b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ptct:MountainviewMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i8062aff1c79b49feb68143984343e9ea_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ptct:HopewellCampusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iad498f0eada24a34916bb8f896e4c6a1_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ptct:HopewellCampusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i70364109a58442d999d1529aa97f2b6b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ptct:HopewellNewBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie6a7756ab1084e378dab79f603770a11_I20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="iba78e43751ff4a8f8903200b06897a60_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4b06422408ed4884889f98fec6b585e7_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iab70e96c6dcd4cf38e8acc5f76da5a1c_D20200101-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="i3e35023e351f4322a3c1e517dc55d17f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i40c26ba683a24d9e98f2ec75db288d77_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i99c95301a4884daa9e367f37995284bd_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i0e7e649fe3864de3976f553389445c8b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie9d447580c3b40f3beffae2bafa97465_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i44f6355301964dabbb766e645f3cf148_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i15f90f09637a4cb1bb715dfe4f05297a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i0b16af03a6464f1daa8673b162ab2586_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i761da636d68a44a59452ea0f2aa77729_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i6ca9ba441e8d4540804f886f1cc9c954_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if3c1cca7bff548549723c72b62c5cabd_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ifc5b2ebfb0104a74a263ad842ff6c5b7_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if300ba06104942c0b9bc9c2620d5efae_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i846b553e2ead487080c5135cbfabf245_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i93db7a3e36c54bccb14ea9da633b0ca2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ice1694004db8457f8428afa653a62360_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i093049f7698c438ea17d8d78b2999a3b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i460293d39eb74292bfa8379e3e079d05_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i15b6700152f74cd99d7930f13a61958e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i6422d57bbb764a51b28c5b9584e9df0b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i5f81bf0a978b4c9f9854bd8827a16c63_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia246a01c67a4480ebec435e73307c0dc_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i876ed796b3d14bf1be51f08fb4114515_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i90486133108543398e32deae8f47a34d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2ab2c343b8eb419cbede80402b0f7f2a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id8d66a66f5c44284a1bfe69359df8592_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ib3c822dd8f524ec2a293c01f04eecc3b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i2693d4b1ad594235b8ea223db85dc081_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i18f98e56934a450c999dc68774136109_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i05c1fab5886147afbd189c9f7d96801e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i808602a5926949c8ac25d08dcc142c0a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i26723ef219cf40f79fc4b63185834f6a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i43e763aab42b473cb26af800270f6b3e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes1.5DueSeptember152026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i08c7971cf8d6469fbda565dec2419938_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i5fc57b5184a54d248eb826766cbbb088_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia20c4a3be1bf491aaf06ea4818f97179_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i7e34d9d90204473c8ea049d991956012_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ife1e487e2c3c44508eb4f48b2ea5cd9e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:NoncollaborativeArrangementTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ifa7979ad51144297ab5f7100771cad69_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i163271c9c18a44a7acbdd4d53ae6113f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i15a832ee781448adb2f8888811fbc346_I20200629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-29</instant>
        </period>
    </context>
    <context id="i8aa17e0adf804ca986cfd400e121c2ea_I20200629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-29</instant>
        </period>
    </context>
    <context id="i6094c414acd64e8eb18a8f8306f9c263_I20200629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-29</instant>
        </period>
    </context>
    <context id="if54601c17d0343ec8d9cd0af73df9a5b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i5ca2052e537349099f8500140b79c830_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i82a7d5029292453a9d8665965b2a0597_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i6f89da40eb9542899d61cec5f576ce4d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ibe63e39ea26a457a88e2e66409ca6e52_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:ProbabilityofSuccessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i46d96bc3957b4332a199fc5c2ba22aa2_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i06c3f1148d284ba19fd288779c3f2c67_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:ProbabilityofSuccessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie5a07c3011f2483691088bb12f4ed468_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i307a45a921aa4ac98cbf6914b2e129b6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i442f4b08d467498fa51f7601498e0665_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ief55fa56f05642ae9c7051bbcc123a7e_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1c7c09a50e6e4ba8839d07d7a35718fb_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iaf63c553ba564cb8bd94fab03c3290ab_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4d5a9b90a7664e9ca2c85d0f043d14b8_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i6d889af7642941098bf2c2aadc6af779_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iab08ed7f127f42a4870b894f05e31311_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i34ddd62e28264378a9b8a8810c84e304_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i43a9f70ea53c4278ac5294a289217733_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6901fa0b994f45b1b11bb7852f30e63e_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ic9b011ab666643deb05f06b8b1928ac7_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i69fef5796fd9485e91f00768f2ee4f15_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i492676ae9f954509b5671e6270ebd50f_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i6abf1ab717cb4553b5a379a89528951c_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i0bb52be78ac04fb99f1f51bf469e5f11_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ia63a5a2116d74541955a8c47217140bb_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i7d5cbe2fe3d241869ba45bf5f3259eaf_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:DevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i8e3ab83b0ac24b1f8726a085e96bde2b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:DevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i97b5568d815c48fcaeba6264529028d7_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:ProbabilityofSuccessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i7f2ea92199454f8fbd535326a97a91d7_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:ProbabilityofSuccessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i142a5ba947234d00bdda31557ab02053_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ic24cf29b77fa4211a03dfd961242ace4_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if778d097ba124606b84b432e35ce14f2_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="icde04c74d7d14859bd0c3c1fec8bf23b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:PotentialNetSalesMilestonesDomain</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i841cadf7f1ab42329b55f05f8b682241_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:PotentialNetSalesMilestonesDomain</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="id290d0f494dc48b394820ca85e03d713_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:ProbabilityofSuccessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i7b1d4bc93668470fb8dc3d2484cd7377_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:ProbabilityofSuccessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i032e49103b7940008966b0abb2c816bf_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:PercentageofSalesforRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i7aeb677d725d4e7587c00dcd29b216d8_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:PercentageofSalesforRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia922f94529a94215b26acb871b50ccef_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8a37cc547e3f49848c674109573d923a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i95e964e1da464dd788d6a99f05370274_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0c93370f63d94e1aac4ee54439ff6b56_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iffe61d144e3f45a68d1cf62be52068fc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic6c94b6543dd43d288ab57eb081f624f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iee49fff9a55c42e7a46ef038efca561d_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i37afd9374ab2456f9adc2e123d047a8d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i41984dd1229341a3adf191f855e3437a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:DevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id9f423a27b8747658dbca67347391ba2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:DevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id9cb29f6a24b456e9193911f1294da2e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:ProbabilityofSuccessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i896363143c604488b15264f3f0863d75_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:ProbabilityofSuccessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4e93577925ee429e9cfb5138f9eb301c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia90fac7174b946d2a3f4eb2d0130831f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9de748e71a0a41f892580d81dc59723c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia365849e92bd4987b8c1a8f48af0e949_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:SalesMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie8a23607d13242b087cdf7ef0d75fbf0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:SalesMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2e30234883ae400a8e1754f0ba49366e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:ProbabilityofSuccessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7418d3bad6a54d2d94c44b530ec3c8ef_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:ProbabilityofSuccessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id6558018b150492b8245e18dd9d4171c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:PercentageofSalesforRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i92a0fdc9f2104055b10e7852fda23d64_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:PercentageofSalesforRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i01dac52020be426eb733231d3b86e6ac_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i928aeea3fbed4653a9c7504d776b8545_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ic451340f512342608177bf840c932205_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="id2f410476d4d4014828565f0ff529e4b_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2a5bfe4b544f4ab3b6857b0ebb80918e_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i73427926a3e341daaacaf169fb831162_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i8ea979e0426d48798c5a50c5f7a7aa15_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i8ab1ac66d020429d96c29af31d72ab26_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icdcaac852b5047fa90c10c82a5c82f80_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iddbe94caf0424d3fa43a0628a5730a6f_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="idfb151bb79164c7a924ed3a43feda689_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i31727b5e545f4438bb09f0aee02b36cf_D20190801-20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="i22a6b3907e334ad095459c22452a31a8_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i20afcd7c10c14ac495fc02e16fe69b2d_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if241e524337e420a90c40125ab0af552_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:RightsExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i732b4791ae044c3982d3fc5b40507c4a_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4340507e56e749d38aa6d877e17f6f11_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ie4dfd70561f44b3389920eecf82405aa_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ptct:RestrictedStockAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6512ed24942b4cf78a18c42c69f878df_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ptct:RestrictedStockAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i25d7f62000cb47619cacff7feea40ec4_I20130305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:StockIncentivePlan2013Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-03-05</instant>
        </period>
    </context>
    <context id="iae41b38768a04ebfa621ede89b1e1eba_D20130305-20130305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-03-05</startDate>
            <endDate>2013-03-05</endDate>
        </period>
    </context>
    <context id="i4acdb340b0784c54b281fc72cd460037_D20130305-20130305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-03-05</startDate>
            <endDate>2013-03-05</endDate>
        </period>
    </context>
    <context id="idf26f417473642be92ba8eea00337e07_I20130305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-03-05</instant>
        </period>
    </context>
    <context id="i62a5ccc71de84104a8745951ca1a9aa7_D20130501-20130531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:EquityAndLongTermIncentivePlan2009Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-05-01</startDate>
            <endDate>2013-05-31</endDate>
        </period>
    </context>
    <context id="i65727f1a834a481f8553fbb4bb642903_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:EquityAndLongTermIncentivePlan2009Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i1efd0cb53b6044d78f74b229bd2b52aa_I20130531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-05-31</instant>
        </period>
    </context>
    <context id="ie7090aa93ba846e4b5c5820dcecfd98a_I20130531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ptct:EmployeeDirectorAndConsultantStockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-05-31</instant>
        </period>
    </context>
    <context id="ibf07b2dff77d4ca1a51f7b625a38192b_D20130501-20130531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:LongTermIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-05-01</startDate>
            <endDate>2013-05-31</endDate>
        </period>
    </context>
    <context id="i93ba015b7d0a44aaaf029eb718c780c2_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ifd063a6e802542888865b12d471371c5_D20200101-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:A2020inducementstockincentiveplanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="i12f2cd9f617e471d9081d454d8ab7810_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:A2020inducementstockincentiveplanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i7af21e8197c4484c8a8abf452ef76b07_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibf32b31395a2491ebc2ee0715f74c386_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7a7e99b59db24353a85559f303336e06_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if901bdf36a4e4a1a81a16393f47a9fb6_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i62acf5ed7adb4666851a78792c6fd991_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1d4c0457ced344f0b16ef87b8b77d3ae_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1b0a569c469e4b6596d336467dd05160_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i40fe1e237dd2460982e61df9b93e25de_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i9e1f2793036044c09455f3aed8a471a5_D20160501-20160531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-05-01</startDate>
            <endDate>2016-05-31</endDate>
        </period>
    </context>
    <context id="i8edf5809ef1e4a8c9d7d12ead5870765_I20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-30</instant>
        </period>
    </context>
    <context id="ia49191cff53044aeb0f18b552f15edb0_D20160601-20160630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-06-01</startDate>
            <endDate>2016-06-30</endDate>
        </period>
    </context>
    <context id="ia00d8392741940a5a0455a9ec5a070dc_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4c05af13913c4e2d87e2cca2be0ef9a6_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i23b23527dd664848b751f1f40cd0477f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iacdbc7fbbfab4c83935a46b395d3c1c4_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ib1bd8bc0a2d94ff7b16f1f994b27455f_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i14204fc508b343cb8ca99de636b507e4_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i895a331c1a6f453c87f851e30384f906_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i14ebe4de831348188d0069a40d328e56_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="if5f804d6c3184fdea8f69c3a97350d43_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ide6d6c0db1274c47ab5146ea275d8c88_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ia31f7d7b519f40d5a5aa9977431540c2_I20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ptct:MidCapFinancialTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="i0047c24fb89c4b3aa1349dbfc482fe10_D20170505-20170505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ptct:MidCapFinancialTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-05</startDate>
            <endDate>2017-05-05</endDate>
        </period>
    </context>
    <context id="i624b7b9db16e4728a041aaf0fe8e3bbc_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ptct:MidCapFinancialTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i396045a4f2b246abb303f6334b534fc5_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ptct:MidCapFinancialTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i7a54a031534840f0b962ea11b19c1d3c_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ptct:MidCapFinancialTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="i99e6e03adee54a9ca0a6a21ec4cddd55_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes1.5DueSeptember152026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8dc375e5e9f24bf9b690d042d600041f_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ifbd02289ccd34e7a886bf4e86089dadc_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">ptct:DebtInstrumentConversionPeriodOnOrAfterAugust202018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9710b6f008d64a8e9b038ddfbc4f20cb_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes1.5DueSeptember152026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8781119cc5804767a8721ec1e62367b7_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">ptct:DebtInstrumentConversionPeriodOnOrAfterAugust202018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="idab0eeb8f1e24e3389eda446498f9b4c_D20150801-20150831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-08-01</startDate>
            <endDate>2015-08-31</endDate>
        </period>
    </context>
    <context id="i74ae1a7412804eb39f158945860fdc92_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes1.5DueSeptember152026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i73b5dc373fe54df282ef490ee32d7654_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes1.5DueSeptember152026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0563616514554f76bb3cb942f7310b61_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic9c66ca599c4439faa67414af9011439_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4e58b009dcb346afa5fe00025d1c8d43_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2a6dca67e5ed44bcae174fc956c744bb_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="idb3d2f86e29542fd99ac08fe93500645_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ic1f05bd3af07411fbeaa9695faa9b8f5_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i1f68521ddf23433db2233ba19286dfae_I20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:WellcomeTrustLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-30</instant>
        </period>
    </context>
    <context id="ifdf769cde4f8456998cb633ecc67a74a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:WellcomeTrustLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="id48de54c835343b9b2c5c1d3ce609ab1_I20170420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:MarathonPharmaceuticalsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:NoncollaborativeArrangementTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-04-20</instant>
        </period>
    </context>
    <context id="i2a92bf7bb7524f61a93f2c8959d0be71_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i1b11444730184724a2297b26b10e055d_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:RightsExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i38631b4cb53445c299e2d62fbae00216_D20200629-20200629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:RightsExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-06-29</endDate>
        </period>
    </context>
    <context id="i04fa4a18d65a48a9a4f7a021a18243d8_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:RightsExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4fd11bc6a99940fd88c85b0f84932bf6_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:BioElectronMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="id1c12a4aacaf45c6b83d421f91bcc1a3_I20200529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:CensaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-29</instant>
        </period>
    </context>
    <context id="i652c4548495c438db5c41a0492a229a2_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:AkceaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0753aa5ed002421a95716b8d6332e418_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:AkceaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:NoncollaborativeArrangementTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ia033e797f8104feca5e0e2c9aef70ffb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:AkceaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifed0db43ebe049f185e04d30bd4e1b71_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2020-07-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia96d9cae808a4c3784211e0141d85ae1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2020-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id60b94195bb147c181fa7ec372ed8691_D20111101-20111130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:LicensingAndCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ptct:MilestoneAxis">ptct:ResearchAndDevelopmentEventMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2011-11-01</startDate>
            <endDate>2011-11-30</endDate>
        </period>
    </context>
    <context id="i8b34ee3e697448668a9c788ce80598fb_D20111101-20111130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:LicensingAndCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ptct:MilestoneAxis">ptct:SalesMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2011-11-01</startDate>
            <endDate>2011-11-30</endDate>
        </period>
    </context>
    <context id="ib692f789ea234d29951422720218faa2_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:LicensingAndCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ptct:MilestoneAxis">ptct:ResearchAndDevelopmentEventMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2835b8eed94641e2ab9c3c4491078285_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:LicensingAndCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ptct:MilestoneAxis">ptct:SalesMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic5b76a0a42be443893da3eb686237ab7_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:LicensingAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i298b567a840a479b841a1c7cae6b2b42_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:LicensingAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i21cc52aa842546b39066bbc6d2f4ec24_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:LicensingAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id33464a3934340609397e4ae7f1b281c_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:LicensingAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ib46a34ef31754b4badaaae6fccf85a47_I20170420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:EmflazaassetacquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-04-20</instant>
        </period>
    </context>
    <context id="i667dbebd49c148f3993ce8cc26b0f8f3_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6d48ddbb90814f6daa9feea1cb72ad27_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:EmflazaassetacquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i07ceae4bafba47cea561662c5f6b04a2_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:EmflazaassetacquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i4ef2c3542e8941dea35d5efd0bdc7a5c_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:AkceaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:NoncollaborativeArrangementTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i61a6fc1556ef4b3fa72296db809eb593_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:AkceaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:NoncollaborativeArrangementTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i0b0512f2780f4b8eb0826df908c1fcb3_D20200701-20200701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-01</endDate>
        </period>
    </context>
    <context id="ia95450bc6d4d4073acbfc602735fef93_I20200717">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-17</instant>
        </period>
    </context>
    <context id="i574baa6db99049d2ba9e1203ea243658_D20200717-20200717">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-17</startDate>
            <endDate>2020-07-17</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="operating_lease">
        <measure>ptct:operating_lease</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="term">
        <measure>ptct:Term</measure>
    </unit>
    <unit id="day">
        <measure>ptct:day</measure>
    </unit>
    <unit id="segment">
        <measure>ptct:segment</measure>
    </unit>
    <unit id="number_distributor">
        <measure>ptct:Number_Distributor</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80L2ZyYWc6M2Y3ZGZhMTcwODVjNGQwYWFjMjdlNDhmZTMxMmNmYzkvdGFibGU6MjczOWU3ZjU2MjFiNDQ3MWJkMWUxYjExNDYxNTUyY2QvdGFibGVyYW5nZToyNzM5ZTdmNTYyMWI0NDcxYmQxZTFiMTE0NjE1NTJjZF8yLTEtMS0xLTA_40e3acfb-1f94-4ced-a6bb-3af78fbed39d">0001070081</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80L2ZyYWc6M2Y3ZGZhMTcwODVjNGQwYWFjMjdlNDhmZTMxMmNmYzkvdGFibGU6MjczOWU3ZjU2MjFiNDQ3MWJkMWUxYjExNDYxNTUyY2QvdGFibGVyYW5nZToyNzM5ZTdmNTYyMWI0NDcxYmQxZTFiMTE0NjE1NTJjZF8zLTEtMS0xLTA_ca467985-b091-4a1b-b4ec-845562049d21">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80L2ZyYWc6M2Y3ZGZhMTcwODVjNGQwYWFjMjdlNDhmZTMxMmNmYzkvdGFibGU6MjczOWU3ZjU2MjFiNDQ3MWJkMWUxYjExNDYxNTUyY2QvdGFibGVyYW5nZToyNzM5ZTdmNTYyMWI0NDcxYmQxZTFiMTE0NjE1NTJjZF80LTEtMS0xLTA_8323eb79-531a-4924-a3cc-693d79b8232f">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80L2ZyYWc6M2Y3ZGZhMTcwODVjNGQwYWFjMjdlNDhmZTMxMmNmYzkvdGFibGU6MjczOWU3ZjU2MjFiNDQ3MWJkMWUxYjExNDYxNTUyY2QvdGFibGVyYW5nZToyNzM5ZTdmNTYyMWI0NDcxYmQxZTFiMTE0NjE1NTJjZF81LTEtMS0xLTA_65cce506-fb84-4920-93c9-1a2df67a59aa">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80L2ZyYWc6M2Y3ZGZhMTcwODVjNGQwYWFjMjdlNDhmZTMxMmNmYzkvdGFibGU6MjczOWU3ZjU2MjFiNDQ3MWJkMWUxYjExNDYxNTUyY2QvdGFibGVyYW5nZToyNzM5ZTdmNTYyMWI0NDcxYmQxZTFiMTE0NjE1NTJjZF82LTEtMS0xLTA_a8b1263e-11b9-4768-b54c-1ffb3f4ce29d">Q2</dei:DocumentFiscalPeriodFocus>
    <ptct:DebtInstrumentInterestPaymentPeriod
      contextRef="i7a54a031534840f0b962ea11b19c1d3c_D20170501-20170531"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTM2Mg_e91d3869-d03c-4b8b-84d9-15ddf6e4e1da">P24M</ptct:DebtInstrumentInterestPaymentPeriod>
    <ptct:DebtInstrumentInterestPaymentPeriod
      contextRef="i7a54a031534840f0b962ea11b19c1d3c_D20170501-20170531"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMjc0ODc3OTA4OTc4OA_adc62e20-6b69-4ee6-aa71-28d59137d971">P24M</ptct:DebtInstrumentInterestPaymentPeriod>
    <ptct:DebtInstrumentConvertibleThresholdBusinessDays
      contextRef="i8dc375e5e9f24bf9b690d042d600041f_D20190901-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMzQwMg_7f893db8-e0cf-4d5a-83ac-33f975ce7592">P5D</ptct:DebtInstrumentConvertibleThresholdBusinessDays>
    <ptct:DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod
      contextRef="i8dc375e5e9f24bf9b690d042d600041f_D20190901-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMzQzNQ_36968acf-1345-44be-9245-319a6078d531">P5D</ptct:DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod>
    <us-gaap:DebtInstrumentTerm
      contextRef="idab0eeb8f1e24e3389eda446498f9b4c_D20150801-20150831"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfODk3MQ_ee20cb45-d925-46df-bb1a-8dfa5015d89d">P7Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm
      contextRef="i8dc375e5e9f24bf9b690d042d600041f_D20190901-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfOTYwOA_9ed8f64e-ddb8-4035-b1f3-c92bbadb8041">P7Y</us-gaap:DebtInstrumentTerm>
    <ptct:DebtInstrumentConvertibleThresholdBusinessDays
      contextRef="i8dc375e5e9f24bf9b690d042d600041f_D20190901-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTE4NTA_7f893db8-e0cf-4d5a-83ac-33f975ce7592">P5D</ptct:DebtInstrumentConvertibleThresholdBusinessDays>
    <ptct:DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod
      contextRef="i8dc375e5e9f24bf9b690d042d600041f_D20190901-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTE4ODM_36968acf-1345-44be-9245-319a6078d531">P5D</ptct:DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod>
    <us-gaap:DebtInstrumentTerm
      contextRef="idab0eeb8f1e24e3389eda446498f9b4c_D20150801-20150831"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTc2MzM_ee20cb45-d925-46df-bb1a-8dfa5015d89d">P7Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm
      contextRef="i8dc375e5e9f24bf9b690d042d600041f_D20190901-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTgyNzA_9ed8f64e-ddb8-4035-b1f3-c92bbadb8041">P7Y</us-gaap:DebtInstrumentTerm>
    <dei:DocumentType
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGV4dHJlZ2lvbjpjZWMwYWU2YmIxY2I0ZDJiODYwZjg4MDJhY2JkNDEwYl8yMTg5_7376180a-3994-4715-b277-ffd917f5173c">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGV4dHJlZ2lvbjpjZWMwYWU2YmIxY2I0ZDJiODYwZjg4MDJhY2JkNDEwYl8yMTky_f4b2a679-8e60-492b-97a6-3b4e43afe71b">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGV4dHJlZ2lvbjpjZWMwYWU2YmIxY2I0ZDJiODYwZjg4MDJhY2JkNDEwYl8yMzk_093519b2-02b1-4646-adc7-4702117b29fc">2020-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGV4dHJlZ2lvbjpjZWMwYWU2YmIxY2I0ZDJiODYwZjg4MDJhY2JkNDEwYl8yMTkw_f23d3eec-c99d-4a42-9f02-7ce97cea79a2">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGV4dHJlZ2lvbjpjZWMwYWU2YmIxY2I0ZDJiODYwZjg4MDJhY2JkNDEwYl8yMTkx_90d0cacb-7894-459a-ab83-702926844c52">001-35969</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGV4dHJlZ2lvbjpjZWMwYWU2YmIxY2I0ZDJiODYwZjg4MDJhY2JkNDEwYl8yMTkz_5ada9cc5-0938-418c-b7d9-edfdc199d47a">PTC Therapeutics,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGFibGU6NTgwYTRkOGM5NzNkNDMzMzlmNmFiMmZjZDA2MmU2MDAvdGFibGVyYW5nZTo1ODBhNGQ4Yzk3M2Q0MzMzOWY2YWIyZmNkMDYyZTYwMF8wLTAtMS0xLTA_7769ce35-8b50-4d74-b6dc-768805f141a0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGFibGU6NTgwYTRkOGM5NzNkNDMzMzlmNmFiMmZjZDA2MmU2MDAvdGFibGVyYW5nZTo1ODBhNGQ4Yzk3M2Q0MzMzOWY2YWIyZmNkMDYyZTYwMF8wLTItMS0xLTA_7866f25a-85ed-40a0-b6fc-bd795777815f">04-3416587</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGFibGU6NWNmNGFjZGZlZDc2NDQ2MmE1ZWRjYjM3YmY4YjcwMzMvdGFibGVyYW5nZTo1Y2Y0YWNkZmVkNzY0NDYyYTVlZGNiMzdiZjhiNzAzM18wLTAtMS0xLTA_366a70f5-9bd7-473a-aa3b-e32bf69272a3">100 Corporate Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGFibGU6NWNmNGFjZGZlZDc2NDQ2MmE1ZWRjYjM3YmY4YjcwMzMvdGFibGVyYW5nZTo1Y2Y0YWNkZmVkNzY0NDYyYTVlZGNiMzdiZjhiNzAzM18xLTAtMS0xLTA_421d4f96-75d1-48c5-b4fc-c9ef0eb67c36">South Plainfield,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGFibGU6NWNmNGFjZGZlZDc2NDQ2MmE1ZWRjYjM3YmY4YjcwMzMvdGFibGVyYW5nZTo1Y2Y0YWNkZmVkNzY0NDYyYTVlZGNiMzdiZjhiNzAzM18xLTEtMS0xLTA_44ebea8d-2c67-43f7-bf4d-abe7c4b7bb74">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGFibGU6NWNmNGFjZGZlZDc2NDQ2MmE1ZWRjYjM3YmY4YjcwMzMvdGFibGVyYW5nZTo1Y2Y0YWNkZmVkNzY0NDYyYTVlZGNiMzdiZjhiNzAzM18xLTMtMS0xLTA_1934fed1-0dbd-49b9-8c61-786c472b8c01">07080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGV4dHJlZ2lvbjpjZWMwYWU2YmIxY2I0ZDJiODYwZjg4MDJhY2JkNDEwYl8yMTg1_11d026d8-b6a2-4f48-901c-7f27cc940728">908</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGV4dHJlZ2lvbjpjZWMwYWU2YmIxY2I0ZDJiODYwZjg4MDJhY2JkNDEwYl8yMTg2_e97b9727-f834-4b87-85dd-e4a237ce36ec">222-7000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGFibGU6OTUzMmYxNmIwN2U4NDRlZDgxMGJlMTEwMGYzYmMzNTIvdGFibGVyYW5nZTo5NTMyZjE2YjA3ZTg0NGVkODEwYmUxMTAwZjNiYzM1Ml8xLTAtMS0xLTA_ecaed0bf-61c5-43cb-921f-fb3491fd6247">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGFibGU6OTUzMmYxNmIwN2U4NDRlZDgxMGJlMTEwMGYzYmMzNTIvdGFibGVyYW5nZTo5NTMyZjE2YjA3ZTg0NGVkODEwYmUxMTAwZjNiYzM1Ml8xLTEtMS0xLTA_4d506fb5-02f4-46d6-b80d-c52f92575252">PTCT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGFibGU6OTUzMmYxNmIwN2U4NDRlZDgxMGJlMTEwMGYzYmMzNTIvdGFibGVyYW5nZTo5NTMyZjE2YjA3ZTg0NGVkODEwYmUxMTAwZjNiYzM1Ml8xLTItMS0xLTA_69c01256-f7e3-4f6e-b1d2-28fe1c67cd2f">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGV4dHJlZ2lvbjpjZWMwYWU2YmIxY2I0ZDJiODYwZjg4MDJhY2JkNDEwYl8yMTg3_9f7204b9-b823-485c-b692-07d0e353723c">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGV4dHJlZ2lvbjpjZWMwYWU2YmIxY2I0ZDJiODYwZjg4MDJhY2JkNDEwYl8yMTg4_af9f9ad5-d550-48c8-b1ef-c7353a0e2099">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGFibGU6NjZhMjUwNjY2ZjMyNDE4ZmIzMDlhMTIxMWI1MWE5NmIvdGFibGVyYW5nZTo2NmEyNTA2NjZmMzI0MThmYjMwOWExMjExYjUxYTk2Yl8wLTAtMS0xLTA_8c154f07-81fc-48a7-a4cd-efcebc9c9642">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGFibGU6NjZhMjUwNjY2ZjMyNDE4ZmIzMDlhMTIxMWI1MWE5NmIvdGFibGVyYW5nZTo2NmEyNTA2NjZmMzI0MThmYjMwOWExMjExYjUxYTk2Yl8yLTMtMS0xLTA_040afd5a-4b2f-4d8d-aa90-01da2ca1f5a0">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGFibGU6NjZhMjUwNjY2ZjMyNDE4ZmIzMDlhMTIxMWI1MWE5NmIvdGFibGVyYW5nZTo2NmEyNTA2NjZmMzI0MThmYjMwOWExMjExYjUxYTk2Yl8zLTMtMS0xLTA_bfa6e3f3-a853-4afa-ba34-910b60d0256e">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGV4dHJlZ2lvbjpjZWMwYWU2YmIxY2I0ZDJiODYwZjg4MDJhY2JkNDEwYl8yMTk0_49c8cebb-ec88-4112-9c7c-33be76cfd5a9">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i53a9a4e5a7004ee289a81b8ed4b249e4_I20200803"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xL2ZyYWc6Y2VjMGFlNmJiMWNiNGQyYjg2MGY4ODAyYWNiZDQxMGIvdGV4dHJlZ2lvbjpjZWMwYWU2YmIxY2I0ZDJiODYwZjg4MDJhY2JkNDEwYl8yMTE2_448e30f3-fa47-429d-b8f3-21774d8518cc"
      unitRef="shares">67703214</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMy0yLTEtMS0w_1d1f2d08-5c8d-44b0-8ef7-c8722c7e02db"
      unitRef="usd">158461000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMy00LTEtMS0w_7d3e0215-e687-4311-be7e-3a79f26da6e8"
      unitRef="usd">288028000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfNC0yLTEtMS0w_945419a4-10b1-4db8-9905-d71e4bfae415"
      unitRef="usd">340430000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfNC00LTEtMS0w_cea49b77-2fbf-498f-b629-08f15905ff30"
      unitRef="usd">398535000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfNS0yLTEtMS0w_cff4c314-28b7-473e-b3f1-ad92508c8745"
      unitRef="usd">53644000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfNS00LTEtMS0w_85b8d15a-18bc-4c10-9f04-bb0cb6b3cf38"
      unitRef="usd">55538000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfNi0yLTEtMS0w_1489cc26-158d-44b6-bcfc-0b263565465a"
      unitRef="usd">18373000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfNi00LTEtMS0w_1b4415e0-265f-45f6-9dc7-139d1a594c61"
      unitRef="usd">19285000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfNy0yLTEtMS0w_7fda0302-0f7e-4a83-bd9a-10b3ae89ebfc"
      unitRef="usd">34116000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfNy00LTEtMS0w_fa319f27-8a27-4c64-a984-e425c1f1167f"
      unitRef="usd">17898000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfOC0yLTEtMS0w_335dadaa-1015-47f7-81a7-35b4a0d5cc74"
      unitRef="usd">605024000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfOC00LTEtMS0w_5688a734-346c-46a9-aa5b-681a309eca01"
      unitRef="usd">779284000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfOS0yLTEtMS0w_b7b246a8-9b8f-4c04-9271-10f192aa63ff"
      unitRef="usd">26806000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfOS00LTEtMS0w_4bbb2d87-d742-4ee4-9df7-7036ce94b7e6"
      unitRef="usd">21549000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMTAtMi0xLTEtMA_8dfa9ac0-6522-4f10-b8f7-06509b08cf36"
      unitRef="usd">708814000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMTAtNC0xLTEtMA_97467c54-d1ef-432e-8aa6-b083024b07cb"
      unitRef="usd">710500000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMTEtMi0xLTEtMA_277ee1f9-3921-4621-86e5-5e5add369609"
      unitRef="usd">82341000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMTEtNC0xLTEtMA_0b40967b-361e-4e8e-a63c-940703209a09"
      unitRef="usd">82341000</us-gaap:Goodwill>
    <ptct:DepositsAndOtherAssetsNoncurrent
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMTItMi0xLTEtMA_72a9500e-81d2-492b-8cb2-5509621974ad"
      unitRef="usd">53652000</ptct:DepositsAndOtherAssetsNoncurrent>
    <ptct:DepositsAndOtherAssetsNoncurrent
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMTItNC0xLTEtMA_3ef726bc-151a-4af8-b629-94fd6e6c738b"
      unitRef="usd">30108000</ptct:DepositsAndOtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMTMtMi0xLTEtMA_8febb20e-902e-4d31-995f-1e7b96d8aee8"
      unitRef="usd">1476637000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMTMtNC0xLTEtMA_51041121-b1a2-4077-b2c1-5cfae83e0343"
      unitRef="usd">1623782000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMTYtMi0xLTEtMA_2491c4d0-bb6c-4272-90c0-2401ad527dc4"
      unitRef="usd">164376000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMTYtNC0xLTEtMA_503d834c-d745-4312-bb9d-4c9225daf06c"
      unitRef="usd">159276000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMTctMi0xLTEtMA_c3905214-3d0a-4d12-8acc-95d59b7bf5f0"
      unitRef="usd">18333000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMTctNC0xLTEtMA_e9160177-b046-4986-9ba6-dc143e29ee8f"
      unitRef="usd">20000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMTgtMi0xLTEtMA_aa348a93-a565-41a7-89e6-22266283d984"
      unitRef="usd">7702000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMTgtNC0xLTEtMA_b179cdc4-c110-4ba7-aad9-fff2b5938ab2"
      unitRef="usd">8242000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMTktMi0xLTEtODYxMw_29485bcf-c18c-4ac1-827e-cae2cd73d767"
      unitRef="usd">4180000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMTktNC0xLTEtODYyMg_bbcddd90-4edd-445b-8dbc-6c2d64da6112"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMTktMi0xLTEtMA_1d35d7be-c4c2-4d48-a799-0e279879137c"
      unitRef="usd">4868000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMTktNC0xLTEtMA_b38ccdf9-cc53-43bd-b185-490c07ed2919"
      unitRef="usd">8339000</us-gaap:OtherLiabilitiesCurrent>
    <ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMjAtMi0xLTEtMA_1bce71c1-051c-41ec-8176-19fe0e49c81a"
      unitRef="usd">2384000</ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent>
    <ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMjAtNC0xLTEtMA_65590239-e455-419c-8a8c-291b3ee2ec8a"
      unitRef="usd">40000000</ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMjEtMi0xLTEtMA_265d19d9-1743-4a23-9fdb-c988550b98c1"
      unitRef="usd">201843000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMjEtNC0xLTEtMA_b84ff17b-1278-4bab-84cc-51824e9f79ed"
      unitRef="usd">235857000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMjItMi0xLTEtMA_d05d5225-523b-458a-a34b-8c78453469f5"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMjItNC0xLTEtMA_467ff02d-76f7-4d77-892f-60f646dd27e4"
      unitRef="usd">3415000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMjMtMi0xLTEtMA_3e09e136-8054-42b9-8410-bdade0af5a23"
      unitRef="usd">297029000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMjMtNC0xLTEtMA_50941f33-bd4d-466f-a8d6-edbd58504fe4"
      unitRef="usd">293859000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMjQtMi0xLTEtMA_5b8cc4d9-f2fe-4baa-bb33-4b3f1411b381"
      unitRef="usd">225700000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMjQtNC0xLTEtMA_3057585e-cba1-49f2-896c-84e9077ff287"
      unitRef="usd">356300000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMjYtMi0xLTEtMA_8a58563d-9c62-4877-be43-adeeed28eeff"
      unitRef="usd">130862000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMjYtNC0xLTEtMA_2b6fc2eb-7105-4508-88c2-e30229b62581"
      unitRef="usd">130862000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMjgtMi0xLTEtODYxNw_0b3f5a21-63a2-4883-a74e-fdc452a32488"
      unitRef="usd">22031000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMjgtNC0xLTEtODYyOA_89eb8c33-20ac-44bf-ae37-2c9f4e428fcc"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMjctMi0xLTEtMA_9687328b-3eb2-453a-a046-45daf54d00e2"
      unitRef="usd">26678000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMjctNC0xLTEtMA_0eb62673-180c-4d86-ae3e-13562b650c15"
      unitRef="usd">9159000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMjgtMi0xLTEtMA_464ac03d-384e-4583-97fe-552dafd42b9c"
      unitRef="usd">904143000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMjgtNC0xLTEtMA_1818ad59-4132-4e7a-80c8-66ac2ccfc1a2"
      unitRef="usd">1029452000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjE1M2IzZmQzY2Y1ZDRkMzI4ZmE0ZWU1ZmZhNjBhOWFkXzkzNDU4NDg4MzYzMzM_e4a7a2fe-76ea-4378-a856-7ed013388280"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjE1M2IzZmQzY2Y1ZDRkMzI4ZmE0ZWU1ZmZhNjBhOWFkXzkzNDU4NDg4MzYzMjY_f33fdf9d-d8f5-4b47-baa9-46cba750ccd5"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjE1M2IzZmQzY2Y1ZDRkMzI4ZmE0ZWU1ZmZhNjBhOWFkXzkzNDU4NDg4MzYzNzE_ea607410-5204-43ce-a40c-474b2dcf2009"
      unitRef="shares">67240679</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjE1M2IzZmQzY2Y1ZDRkMzI4ZmE0ZWU1ZmZhNjBhOWFkXzkzNDU4NDg4MzYzNDc_61df78d7-c36e-4b60-9cc0-7199ae8782a4"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjE1M2IzZmQzY2Y1ZDRkMzI4ZmE0ZWU1ZmZhNjBhOWFkXzkzNDU4NDg4MzYzNTk_bfde2791-a766-47da-b161-d11a486fbc76"
      unitRef="shares">61935870</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMzAtMi0xLTEtMA_eb1a72e4-92a0-4556-984c-740f4cb83ca5"
      unitRef="usd">67000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMzAtNC0xLTEtMA_eed0fe19-b40b-4461-91f0-cea5cc03a2ee"
      unitRef="usd">62000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMzEtMi0xLTEtMA_d3a17ddf-b9fe-412a-a491-257e9b42186f"
      unitRef="usd">2067274000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMzEtNC0xLTEtMA_bd57c09f-1e50-42dc-a9ff-50a1c2aac696"
      unitRef="usd">1795351000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMzItMi0xLTEtMA_90dc67ab-23d4-454d-86ba-099c9094b060"
      unitRef="usd">-10016000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMzItNC0xLTEtMA_782281dd-5606-4980-94f6-60ae41698111"
      unitRef="usd">-10584000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMzMtMi0xLTEtMA_7a77db56-f8f2-4ac6-94df-c8d53327cdba"
      unitRef="usd">-1484831000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMzMtNC0xLTEtMA_0c85572c-0d15-47ca-8aad-097b2861824e"
      unitRef="usd">-1190499000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMzQtMi0xLTEtMA_8e8e4ce4-cdae-4ea5-8810-6e99f28a774c"
      unitRef="usd">572494000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMzQtNC0xLTEtMA_40f82721-417d-4682-ba4c-24dd6dd8f4fd"
      unitRef="usd">594330000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMzUtMi0xLTEtMA_7b03c47a-fa2b-40af-a6fa-8e3ea58bae91"
      unitRef="usd">1476637000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xOS9mcmFnOmFkNmVlZjNjZTZjZTQ3MTZiMjNkMzZjMzkxMjI0NjU3L3RhYmxlOmMxYzg4OWY0MTY4ZjRjMzdiYjE5NzQ5OTcxNzRjZTZhL3RhYmxlcmFuZ2U6YzFjODg5ZjQxNjhmNGMzN2JiMTk3NDk5NzE3NGNlNmFfMzUtNC0xLTEtMA_51086afe-a306-4b75-bf0d-161d65cfe2ab"
      unitRef="usd">1623782000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i45814e0e64094044a82fcf8bbad4c123_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMy0yLTEtMS0w_77950a34-3447-4315-9fce-761994118b2f"
      unitRef="usd">75239000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i80823282f4634ae8844d0174883b097c_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMy00LTEtMS0w_e20aa6bf-3ba8-4240-a250-99fef9f159ad"
      unitRef="usd">85476000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i3c2dcea8d5894a6aaba983f5a911388c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMy02LTEtMS0w_71d487ce-8914-4ec1-abb5-ac26755f8daf"
      unitRef="usd">143435000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ibd94b62990744751ae48321dad1d6eab_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMy04LTEtMS0w_eedbac3e-319a-4fce-ae79-51a5e11cafab"
      unitRef="usd">138530000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i1856787732484c15a0bc9dd59846d7df_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfNC0yLTEtMS0w_4b6163cf-d261-4be8-bec1-c24bcec47d4a"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i31e4fee5acef46b09a3f7ab4d447b758_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfNC00LTEtMS0w_86c5aa9c-be64-4bf0-aaad-9beb4e062e8f"
      unitRef="usd">46000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ia37e22b92f244d44941f5498dd31a614_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfNC02LTEtMS0w_ba719783-8a40-4290-a9da-693e1df3cd5a"
      unitRef="usd">63000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i846b2660ee9a46aa8e191f0a79737479_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfNC04LTEtMS0w_42e2a0ce-f744-496d-aca2-3590d2f09712"
      unitRef="usd">575000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfNS0yLTEtMS0w_59a0a5f4-a4e0-4694-9349-2934746ffcde"
      unitRef="usd">75239000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfNS00LTEtMS0w_9f72e5f7-9809-4e3b-9a82-80261c128dcb"
      unitRef="usd">85522000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfNS02LTEtMS0w_8867d62e-ea5b-4c67-979a-661c7526d7de"
      unitRef="usd">143498000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfNS04LTEtMS0w_97325daf-43f8-43a5-91a5-3f702ef8d436"
      unitRef="usd">139105000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <ptct:CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfNy0yLTEtMS0w_416bde12-a1e4-49e9-a2b6-738e9042d2e6"
      unitRef="usd">5304000</ptct:CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets>
    <ptct:CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets
      contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfNy00LTEtMS0w_7fcb60e5-53f5-4fea-abb2-97c468a43c09"
      unitRef="usd">3211000</ptct:CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets>
    <ptct:CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfNy02LTEtMS0w_145b6507-f29f-4ba1-833a-682f3585b4a1"
      unitRef="usd">9389000</ptct:CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets>
    <ptct:CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfNy04LTEtMS0w_3e75a9b2-bd9b-41b3-a616-7320497e6840"
      unitRef="usd">5587000</ptct:CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfOC0yLTEtMS0w_0e20d2ef-d2a6-45e1-aa2b-31bfe79810ae"
      unitRef="usd">8731000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfOC00LTEtMS0w_57ceb3df-b42e-4b63-8bc8-3bd61d22af79"
      unitRef="usd">6575000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfOC02LTEtMS0w_50cc4106-32c4-4945-937d-cd80718ed4ab"
      unitRef="usd">16679000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfOC04LTEtMS0w_19b6dd5a-df96-403b-9b61-2e11f4b47e2e"
      unitRef="usd">12652000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfOS0yLTEtMS0w_d4449995-7252-4ecf-a3c0-f65cbff9d40e"
      unitRef="usd">176525000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfOS00LTEtMS0w_f14155cb-bb7b-48c1-8dd1-defae8eff7a9"
      unitRef="usd">59979000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfOS02LTEtMS0w_a8b118f0-f3d8-4b62-9c28-602a1c074de4"
      unitRef="usd">266632000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfOS04LTEtMS0w_e1caafc7-fa7a-4a5b-b496-95808d714a34"
      unitRef="usd">112544000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTAtMi0xLTEtMA_8d554cd0-677e-48a3-b640-3e93631a2dfb"
      unitRef="usd">53659000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTAtNC0xLTEtMA_bd260256-2fa1-4a72-9598-2e50b99dbb02"
      unitRef="usd">49215000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTAtNi0xLTEtMA_6e8463bb-e2a0-424d-84f7-4b6c517b04a5"
      unitRef="usd">111869000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTAtOC0xLTEtMA_16422856-0b64-4e5e-b9c4-3a77546db3a1"
      unitRef="usd">89760000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTEtMi0xLTEtMA_b73fa5a5-0b9c-42b1-8e19-6b8f1651e993"
      unitRef="usd">-7680000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
      contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTEtNC0xLTEtMA_8d9d2488-cc54-47e1-a626-d23ffd866c20"
      unitRef="usd">-5300000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTEtNi0xLTEtMA_81231436-a7c8-4767-b79c-18857a355c1e"
      unitRef="usd">-8580000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTEtOC0xLTEtMA_1465da65-ff67-4564-b59e-5b636d1a1180"
      unitRef="usd">-26460000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
    <ptct:SettlementOfDeferredAndContingentConsideration
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTItMi0xLTEtMzMwNA_8d043207-259d-4f53-ad14-92a3732af50b"
      unitRef="usd">10613000</ptct:SettlementOfDeferredAndContingentConsideration>
    <ptct:SettlementOfDeferredAndContingentConsideration
      contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTItNC0xLTEtMzMwNA_2bf2cbf9-a229-4cb0-aaf2-fd6f5a0276b8"
      unitRef="usd">0</ptct:SettlementOfDeferredAndContingentConsideration>
    <ptct:SettlementOfDeferredAndContingentConsideration
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTItNi0xLTEtMzMwNA_324b3904-d1fc-467b-875e-34423df0e152"
      unitRef="usd">10613000</ptct:SettlementOfDeferredAndContingentConsideration>
    <ptct:SettlementOfDeferredAndContingentConsideration
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTItOC0xLTEtMzMwNA_c62f6317-c122-4533-b04c-4cbf2d079719"
      unitRef="usd">0</ptct:SettlementOfDeferredAndContingentConsideration>
    <us-gaap:OperatingExpenses
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTItMi0xLTEtMA_94c7f0dc-f848-49cb-9ab4-cedc6151951f"
      unitRef="usd">262512000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTItNC0xLTEtMA_59b8b125-4064-4269-8831-cd30aca7df7b"
      unitRef="usd">124280000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTItNi0xLTEtMA_00952990-e32c-4543-a869-dc7d857505e1"
      unitRef="usd">423762000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTItOC0xLTEtMA_11782fda-1390-4c2d-bd1f-877e3d4da481"
      unitRef="usd">247003000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTMtMi0xLTEtMA_49d3f104-f446-44b0-8e8c-07dea3e6e8c5"
      unitRef="usd">-187273000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTMtNC0xLTEtMA_6663a041-b9c8-4e69-bfa8-644cc9c6319f"
      unitRef="usd">-38758000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTMtNi0xLTEtMA_22ef4b0d-1852-4390-a5c5-a793a72df5d8"
      unitRef="usd">-280264000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTMtOC0xLTEtMA_b24ddabb-d8b3-4340-82ba-662fa33203c7"
      unitRef="usd">-107898000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTQtMi0xLTEtMA_1879a58b-e8b8-484a-8206-ba524c0c68b6"
      unitRef="usd">-5379000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTQtNC0xLTEtMA_b6376e85-eb80-4da0-82bd-9db56edb920a"
      unitRef="usd">-2074000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTQtNi0xLTEtMA_69ecc715-1dc4-48ea-9e51-a36a1b96a41c"
      unitRef="usd">-11021000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTQtOC0xLTEtMA_ba3e37b5-4229-4ab0-97da-853f547e2135"
      unitRef="usd">-4362000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTUtMi0xLTEtMA_d71f264b-b566-4bab-874d-d47e52f6074f"
      unitRef="usd">11309000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTUtNC0xLTEtMA_47cc953d-aef4-4fd8-8ae5-16d675ce3670"
      unitRef="usd">-183000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTUtNi0xLTEtMA_ec4d00dc-eae9-463f-b7e8-172919f9b43b"
      unitRef="usd">-2523000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTUtOC0xLTEtMA_30f19847-1e20-4feb-95ce-c5dd24aef75f"
      unitRef="usd">-292000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTYtMi0xLTEtMA_4068b490-f917-495d-a98a-78add44babc4"
      unitRef="usd">-181343000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTYtNC0xLTEtMA_aa25eefb-58a3-4c82-b06f-b4e6fb9c5577"
      unitRef="usd">-41015000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTYtNi0xLTEtMA_c24f2f3b-9fc8-48a3-866d-62aa2cb3ef22"
      unitRef="usd">-293808000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTYtOC0xLTEtMA_f938a986-007e-49fb-a8d0-42608d65e3cc"
      unitRef="usd">-112552000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTctMi0xLTEtMA_9e6843fd-488a-4f1a-8aea-16a3ac7f6e8d"
      unitRef="usd">84000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTctNC0xLTEtMA_273e9a6f-b19b-4d0a-b367-8aa74eb25286"
      unitRef="usd">774000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTctNi0xLTEtMA_461d866d-6744-4bd7-beb1-254c37f7994f"
      unitRef="usd">306000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTctOC0xLTEtMA_91aefe07-2b2b-4706-828d-82f4ca60d5eb"
      unitRef="usd">1350000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTgtMi0xLTEtMA_582392a0-bef3-4f16-8c26-361e301e72c6"
      unitRef="usd">-181427000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTgtNC0xLTEtMA_8505bb56-ba78-4133-bcea-bfc9c9f1057b"
      unitRef="usd">-41789000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTgtNi0xLTEtMA_faefabd0-25d5-4812-a85c-f40f81016d08"
      unitRef="usd">-294114000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMTgtOC0xLTEtMA_4e639c0d-513d-47ea-b492-04474a9c0333"
      unitRef="usd">-113902000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMjEtMi0xLTEtMA_a8fad56e-88be-429e-bdab-82546ff35a18"
      unitRef="shares">65150780</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMjEtNC0xLTEtMA_8ed598a8-17ac-4a1a-abff-995bf73e9924"
      unitRef="shares">55912748</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMjEtNi0xLTEtMA_4bc33011-aea5-4ea0-94e1-b2dfa8ca5731"
      unitRef="shares">63769958</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMjEtOC0xLTEtMA_eb1fef99-dd70-4ff2-baf0-1dd868bd0ad1"
      unitRef="shares">57113141</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMjItMi0xLTEtMA_903677c7-9807-4c5b-8d8d-7bf814a20c5c"
      unitRef="usdPerShare">-2.78</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMjItNC0xLTEtMA_40f89379-1c18-4824-8f31-e6f3173dd47d"
      unitRef="usdPerShare">-0.75</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMjItNi0xLTEtMA_a0ce7fa1-ad23-477d-9c0c-6fc2957dca24"
      unitRef="usdPerShare">-4.61</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yNS9mcmFnOjQ3NjY3ZGZiMDI5NTRiMjA4YWViZTljNjIxYzEwNmRhL3RhYmxlOmU5MjAxZjQ5MzI3NzQ4NjZiNDg1ODliNDQ4ZmY1YWM3L3RhYmxlcmFuZ2U6ZTkyMDFmNDkzMjc3NDg2NmI0ODU4OWI0NDhmZjVhYzdfMjItOC0xLTEtMA_623c9d87-d5e6-431d-a880-7dc38c30ea84"
      unitRef="usdPerShare">-1.99</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yOC9mcmFnOmM2NGVlMTEyOGExMDRjZTJiNTI4YjBiODk2OWI1MDE1L3RhYmxlOjJmNzA4ODA0N2ZhNTQxMjJhNjhjODc2ZjY0MTVkMGUxL3RhYmxlcmFuZ2U6MmY3MDg4MDQ3ZmE1NDEyMmE2OGM4NzZmNjQxNWQwZTFfMi0yLTEtMS0w_4cc60fe9-2fbb-4ce4-b80b-db3beb2130d2"
      unitRef="usd">-181427000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yOC9mcmFnOmM2NGVlMTEyOGExMDRjZTJiNTI4YjBiODk2OWI1MDE1L3RhYmxlOjJmNzA4ODA0N2ZhNTQxMjJhNjhjODc2ZjY0MTVkMGUxL3RhYmxlcmFuZ2U6MmY3MDg4MDQ3ZmE1NDEyMmE2OGM4NzZmNjQxNWQwZTFfMi00LTEtMS0w_4e2d42b9-3b10-4edc-bfc5-877d6074a79e"
      unitRef="usd">-41789000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yOC9mcmFnOmM2NGVlMTEyOGExMDRjZTJiNTI4YjBiODk2OWI1MDE1L3RhYmxlOjJmNzA4ODA0N2ZhNTQxMjJhNjhjODc2ZjY0MTVkMGUxL3RhYmxlcmFuZ2U6MmY3MDg4MDQ3ZmE1NDEyMmE2OGM4NzZmNjQxNWQwZTFfMi02LTEtMS0w_2cd7001d-d5a9-454d-b826-160b1eb0cda6"
      unitRef="usd">-294114000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yOC9mcmFnOmM2NGVlMTEyOGExMDRjZTJiNTI4YjBiODk2OWI1MDE1L3RhYmxlOjJmNzA4ODA0N2ZhNTQxMjJhNjhjODc2ZjY0MTVkMGUxL3RhYmxlcmFuZ2U6MmY3MDg4MDQ3ZmE1NDEyMmE2OGM4NzZmNjQxNWQwZTFfMi04LTEtMS0w_221da6e6-97b7-4586-88d7-5aee7edd2a99"
      unitRef="usd">-113902000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yOC9mcmFnOmM2NGVlMTEyOGExMDRjZTJiNTI4YjBiODk2OWI1MDE1L3RhYmxlOjJmNzA4ODA0N2ZhNTQxMjJhNjhjODc2ZjY0MTVkMGUxL3RhYmxlcmFuZ2U6MmY3MDg4MDQ3ZmE1NDEyMmE2OGM4NzZmNjQxNWQwZTFfNC0yLTEtMS0w_2cbabe54-0905-4d41-abab-91bb17e3f3b8"
      unitRef="usd">2718000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yOC9mcmFnOmM2NGVlMTEyOGExMDRjZTJiNTI4YjBiODk2OWI1MDE1L3RhYmxlOjJmNzA4ODA0N2ZhNTQxMjJhNjhjODc2ZjY0MTVkMGUxL3RhYmxlcmFuZ2U6MmY3MDg4MDQ3ZmE1NDEyMmE2OGM4NzZmNjQxNWQwZTFfNC00LTEtMS0w_39d52d9e-3efd-4921-9d60-d0adeb800dae"
      unitRef="usd">839000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yOC9mcmFnOmM2NGVlMTEyOGExMDRjZTJiNTI4YjBiODk2OWI1MDE1L3RhYmxlOjJmNzA4ODA0N2ZhNTQxMjJhNjhjODc2ZjY0MTVkMGUxL3RhYmxlcmFuZ2U6MmY3MDg4MDQ3ZmE1NDEyMmE2OGM4NzZmNjQxNWQwZTFfNC02LTEtMS0w_010ecdb7-c45d-4f44-87d8-5c5b9531c3d7"
      unitRef="usd">2655000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yOC9mcmFnOmM2NGVlMTEyOGExMDRjZTJiNTI4YjBiODk2OWI1MDE1L3RhYmxlOjJmNzA4ODA0N2ZhNTQxMjJhNjhjODc2ZjY0MTVkMGUxL3RhYmxlcmFuZ2U6MmY3MDg4MDQ3ZmE1NDEyMmE2OGM4NzZmNjQxNWQwZTFfNC04LTEtMS0w_cd0c15a8-44e6-4174-808c-229b68ed9a75"
      unitRef="usd">898000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yOC9mcmFnOmM2NGVlMTEyOGExMDRjZTJiNTI4YjBiODk2OWI1MDE1L3RhYmxlOjJmNzA4ODA0N2ZhNTQxMjJhNjhjODc2ZjY0MTVkMGUxL3RhYmxlcmFuZ2U6MmY3MDg4MDQ3ZmE1NDEyMmE2OGM4NzZmNjQxNWQwZTFfNS0yLTEtMS0w_90eb952a-8ffd-4cbb-8c33-534ced4ce459"
      unitRef="usd">-10749000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yOC9mcmFnOmM2NGVlMTEyOGExMDRjZTJiNTI4YjBiODk2OWI1MDE1L3RhYmxlOjJmNzA4ODA0N2ZhNTQxMjJhNjhjODc2ZjY0MTVkMGUxL3RhYmxlcmFuZ2U6MmY3MDg4MDQ3ZmE1NDEyMmE2OGM4NzZmNjQxNWQwZTFfNS00LTEtMS0w_440ca2ee-1109-4ee2-b719-ef748fd795f7"
      unitRef="usd">278000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yOC9mcmFnOmM2NGVlMTEyOGExMDRjZTJiNTI4YjBiODk2OWI1MDE1L3RhYmxlOjJmNzA4ODA0N2ZhNTQxMjJhNjhjODc2ZjY0MTVkMGUxL3RhYmxlcmFuZ2U6MmY3MDg4MDQ3ZmE1NDEyMmE2OGM4NzZmNjQxNWQwZTFfNS02LTEtMS0w_173c9639-76d1-4726-a45e-f99b8e73ea97"
      unitRef="usd">-2087000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yOC9mcmFnOmM2NGVlMTEyOGExMDRjZTJiNTI4YjBiODk2OWI1MDE1L3RhYmxlOjJmNzA4ODA0N2ZhNTQxMjJhNjhjODc2ZjY0MTVkMGUxL3RhYmxlcmFuZ2U6MmY3MDg4MDQ3ZmE1NDEyMmE2OGM4NzZmNjQxNWQwZTFfNS04LTEtMS0w_74d1edea-0dd1-41e0-95ad-7d639c25372b"
      unitRef="usd">-438000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yOC9mcmFnOmM2NGVlMTEyOGExMDRjZTJiNTI4YjBiODk2OWI1MDE1L3RhYmxlOjJmNzA4ODA0N2ZhNTQxMjJhNjhjODc2ZjY0MTVkMGUxL3RhYmxlcmFuZ2U6MmY3MDg4MDQ3ZmE1NDEyMmE2OGM4NzZmNjQxNWQwZTFfNi0yLTEtMS0w_2068ff36-45cd-4f6f-b04c-7a4ea8587991"
      unitRef="usd">-189458000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yOC9mcmFnOmM2NGVlMTEyOGExMDRjZTJiNTI4YjBiODk2OWI1MDE1L3RhYmxlOjJmNzA4ODA0N2ZhNTQxMjJhNjhjODc2ZjY0MTVkMGUxL3RhYmxlcmFuZ2U6MmY3MDg4MDQ3ZmE1NDEyMmE2OGM4NzZmNjQxNWQwZTFfNi00LTEtMS0w_f371208a-df8d-41fd-92ce-80a0ae5bfab0"
      unitRef="usd">-40672000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yOC9mcmFnOmM2NGVlMTEyOGExMDRjZTJiNTI4YjBiODk2OWI1MDE1L3RhYmxlOjJmNzA4ODA0N2ZhNTQxMjJhNjhjODc2ZjY0MTVkMGUxL3RhYmxlcmFuZ2U6MmY3MDg4MDQ3ZmE1NDEyMmE2OGM4NzZmNjQxNWQwZTFfNi02LTEtMS0w_1a585871-6556-4d4b-a942-1a43db3110ac"
      unitRef="usd">-293546000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8yOC9mcmFnOmM2NGVlMTEyOGExMDRjZTJiNTI4YjBiODk2OWI1MDE1L3RhYmxlOjJmNzA4ODA0N2ZhNTQxMjJhNjhjODc2ZjY0MTVkMGUxL3RhYmxlcmFuZ2U6MmY3MDg4MDQ3ZmE1NDEyMmE2OGM4NzZmNjQxNWQwZTFfNi04LTEtMS0w_6869036c-5c59-4fb5-8051-bba9f6083fa5"
      unitRef="usd">-113442000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesIssued
      contextRef="ieec6c9a44e1a4fa0b02c65d76e099de2_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfMi0xLTEtMS0w_f2e9ebfd-1ea6-4489-9116-6ff945098026"
      unitRef="shares">62758520</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ieec6c9a44e1a4fa0b02c65d76e099de2_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfMi0zLTEtMS0w_dcb0b5b5-350c-4653-b9b7-fa3e1eef30d6"
      unitRef="usd">62000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2217d6be0da04b3c9aa7801351f5b23f_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfMi01LTEtMS0w_811fe209-6782-4612-94b6-199acb3203f3"
      unitRef="usd">1834061000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic903ce63d61344bb93ea8a3c7cd2e5fd_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfMi03LTEtMS0w_f2901897-2be8-41c4-a072-5fd725eaa42a"
      unitRef="usd">-1985000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5f5abb3d22174bc5baaf5959060f4f75_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfMi05LTEtMS0w_ccf2e1ad-bcb6-4dfb-afa6-32dd5939b15a"
      unitRef="usd">-1303404000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ieb8114d4f418487782c0740ca1ed1bfc_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfMi0xMS0xLTEtMA_07adaf8d-c8d8-468a-93da-fa75d3a8238d"
      unitRef="usd">528734000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ib2522e73523e4feda4f9fd68c9be8c32_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfNC0xLTEtMS0w_7fb2a93b-6232-42a7-8696-422163fcaad2"
      unitRef="shares">106309</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib2522e73523e4feda4f9fd68c9be8c32_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfNC0zLTEtMS0w_1515fb60-bcfb-42db-90ad-af98fb25b5a8"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic3ffc2fc75914fddbf65e6f5960bc8d5_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfNC01LTEtMS0w_38b9b958-8a4b-47a6-81f8-b13937b706c1"
      unitRef="usd">5447000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfNC0xMS0xLTEtMA_c018318d-3873-41fd-b833-f07c88d97c37"
      unitRef="usd">5447000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="ib2522e73523e4feda4f9fd68c9be8c32_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfNi0xLTEtMS0yMDYw_55e45da4-c73f-40e9-a117-eb699e289ec5"
      unitRef="shares">845364</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="ib2522e73523e4feda4f9fd68c9be8c32_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfNi0zLTEtMS0yMDYw_977eb3ff-e8a2-47ef-90f5-ebad31eb9a48"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="ic3ffc2fc75914fddbf65e6f5960bc8d5_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfNi01LTEtMS0yMDYw_77ce7770-a311-4c80-957f-082d0313a8dd"
      unitRef="usd">42868000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfNi0xMS0xLTEtMjA2MA_4dac51fc-3b2b-45dd-8cc9-7de12ff5d0d0"
      unitRef="usd">42869000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <ptct:StockIssuedDuringPeriodSharesExchangeRights
      contextRef="ib2522e73523e4feda4f9fd68c9be8c32_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfNy0xLTEtMS02ODgz_344f5e7f-1710-445e-a886-f0e1d1914054"
      unitRef="shares">2821176</ptct:StockIssuedDuringPeriodSharesExchangeRights>
    <ptct:StockIssuedDuringPeriodValueExchangeRights
      contextRef="ib2522e73523e4feda4f9fd68c9be8c32_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfNy0zLTEtMS0yNTI0_8085dca6-95ef-4302-a143-51f504caae58"
      unitRef="usd">3000</ptct:StockIssuedDuringPeriodValueExchangeRights>
    <ptct:StockIssuedDuringPeriodValueExchangeRights
      contextRef="ic3ffc2fc75914fddbf65e6f5960bc8d5_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfNy01LTEtMS0yNTI0_03495ac0-113f-481d-8c08-001495ae06d8"
      unitRef="usd">150525000</ptct:StockIssuedDuringPeriodValueExchangeRights>
    <ptct:StockIssuedDuringPeriodValueExchangeRights
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfNy0xMS0xLTEtMjUyNA_5f68144d-255b-4772-a021-0b738f24f7f3"
      unitRef="usd">150528000</ptct:StockIssuedDuringPeriodValueExchangeRights>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ib2522e73523e4feda4f9fd68c9be8c32_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfNy0xLTEtMS0w_cac02e9a-1e67-48e5-9bac-f77b4193e115"
      unitRef="shares">654604</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ib2522e73523e4feda4f9fd68c9be8c32_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfNy0zLTEtMS0w_cbd0c577-9134-4568-9762-0256bc611256"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic3ffc2fc75914fddbf65e6f5960bc8d5_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfNy01LTEtMS0w_16fa1798-4eac-42fb-83ae-830084d87b0f"
      unitRef="usd">15057000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfNy0xMS0xLTEtMA_7f921303-193b-4d87-b272-4a2e65e45337"
      unitRef="usd">15058000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ib2522e73523e4feda4f9fd68c9be8c32_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfOC0xLTEtMS0w_87a14ad2-a1ed-4026-85e9-1f2b05c72bd3"
      unitRef="shares">-3985</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfOC0xMS0xLTEtMA_c0c93f51-5575-4938-b4d5-bdbbfd297a83"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ib2522e73523e4feda4f9fd68c9be8c32_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfMTAtMS0xLTEtMjA2MA_135c5d00-f91a-4b44-a629-f23042de973f"
      unitRef="shares">58691</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ib2522e73523e4feda4f9fd68c9be8c32_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfMTAtMy0xLTEtMjA2MA_8fd5b248-654c-42ef-afda-047273c2e065"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ic3ffc2fc75914fddbf65e6f5960bc8d5_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfMTAtNS0xLTEtMjA2MA_8019bfa7-e252-45aa-98cf-e5a29e1a1b7c"
      unitRef="usd">2406000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfMTAtMTEtMS0xLTIwNjA_9ada32c6-2ed7-408a-9417-f6f13e19e7fc"
      unitRef="usd">2406000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic3ffc2fc75914fddbf65e6f5960bc8d5_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfMTEtNS0xLTEtMjA2MA_50b5db7b-4780-4e95-b9db-da41fb1c9888"
      unitRef="usd">16910000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfMTEtMTEtMS0xLTIwNjA_4bad3cb6-c5cc-4308-8890-92666ab7b409"
      unitRef="usd">16910000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfMTMtOS0xLTEtMA_8842f6d1-aae2-4793-8989-829682caf12f"
      unitRef="usd">-181427000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfMTMtMTEtMS0xLTA_fb6dfde5-208e-4718-b255-00b02233922f"
      unitRef="usd">-181427000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i85184b2a023d436aae89f6d066cfbfec_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfMTQtNy0xLTEtMA_0d0e7504-17da-40f3-bfae-64120b59149a"
      unitRef="usd">-8031000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfMTQtMTEtMS0xLTA_886c7099-1b5c-4645-882e-437e2a376268"
      unitRef="usd">-8031000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:SharesIssued
      contextRef="i533ee7ba976f46e396724aba128c444e_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfMTUtMS0xLTEtMA_14f4b538-4a82-460d-909a-b3cb84f1b15a"
      unitRef="shares">67240679</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i533ee7ba976f46e396724aba128c444e_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfMTUtMy0xLTEtMA_9ecdda58-76e5-4293-b300-e8f4498103ad"
      unitRef="usd">67000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie459585656ec4c888bad0072cb787216_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfMTUtNS0xLTEtMA_f0fe2ee2-b693-4a54-ad91-fcfeb066e991"
      unitRef="usd">2067274000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if99a5f5b88c44e239963a271d78fd4d0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfMTUtNy0xLTEtMA_51ef3599-85ef-4f33-a1af-be07b469f24d"
      unitRef="usd">-10016000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib08418efd9054e53865f0aad58f50b9d_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfMTUtOS0xLTEtMA_15d63434-2e5c-4d95-86d4-07d3cde56a00"
      unitRef="usd">-1484831000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjNjOTI1NzYyNDRhYzQ2ZDFhMGQ4NTdlNzhiMjE4Nzc1L3RhYmxlcmFuZ2U6M2M5MjU3NjI0NGFjNDZkMWEwZDg1N2U3OGIyMTg3NzVfMTUtMTEtMS0xLTA_d0bca0ba-83da-4d4b-a935-a9c73291a37d"
      unitRef="usd">572494000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i94b08961287e4bd28403b18fb27d1ef3_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfMi0xLTEtMS0w_36035ac6-be8c-445f-b674-9b3ef74add7c"
      unitRef="shares">58418790</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i94b08961287e4bd28403b18fb27d1ef3_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfMi0zLTEtMS0w_5cb3760d-21ca-4edb-bb5d-8e6fe1144663"
      unitRef="usd">58000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2e93050dc1a94baf9a24faf44c845fc2_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfMi01LTEtMS0w_d984ca3f-d6db-4edd-8cd7-a6d4e4d94be0"
      unitRef="usd">1523115000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9ff2de3d9580494aa4f84424a72b83aa_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfMi03LTEtMS0w_8172c6b3-b339-42f3-8e64-e019c24bc8af"
      unitRef="usd">805000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i930a0deb5fe14f56b2dfe784709c3a46_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfMi05LTEtMS0w_740b9f05-73c9-44aa-9b01-a7bb6c70f86b"
      unitRef="usd">-1011036000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id107e0ac152043d8b3217fec423c7ff5_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfMi0xMS0xLTEtMA_5abf8771-8f65-49ce-a5fa-1e8b88ef778f"
      unitRef="usd">512942000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="iaa534d8c4a3b44998ead7885db0ad530_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfMy0xLTEtMS0xOTY4_e4aa45cd-8936-4f84-96d7-131d655831a8"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iaa534d8c4a3b44998ead7885db0ad530_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfMy0zLTEtMS0xOTc0_df446879-0659-476f-9cf4-9ea96f7bd698"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i42fbe8f0476c44e48fe505660057da1a_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfMy01LTEtMS0xOTk0_d8c646c8-26e7-4bfe-8e68-042e7e98312c"
      unitRef="usd">106000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfMy0xMS0xLTEtMjAxMw_b0fe8603-7097-4f4b-a695-11d37671a2e7"
      unitRef="usd">106000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="iaa534d8c4a3b44998ead7885db0ad530_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfNC0xLTEtMS0w_19b6b8a4-29ec-485d-b072-ca5a472bab25"
      unitRef="shares">230176</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i42fbe8f0476c44e48fe505660057da1a_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfNC01LTEtMS0w_10013fee-0f5c-4d7c-8d82-faa0efe11bf1"
      unitRef="usd">2847000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfNC0xMS0xLTEtMA_d190f108-ba60-4f1b-b99a-bbeadcac900f"
      unitRef="usd">2847000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="iaa534d8c4a3b44998ead7885db0ad530_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfNy0xLTEtMS0w_8e892401-3d0c-4f35-9c46-d19e40baa043"
      unitRef="shares">3500</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfNy0xMS0xLTEtMA_7677c1e2-a5b5-47dd-a59f-755371c665f4"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="iaa534d8c4a3b44998ead7885db0ad530_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfOC0xLTEtMS0w_d258d153-7dee-496a-951b-f861dfc2c470"
      unitRef="shares">54719</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="iaa534d8c4a3b44998ead7885db0ad530_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfOC0zLTEtMS0w_b6868a36-e9f8-4865-a7eb-4a1af0fd8837"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i42fbe8f0476c44e48fe505660057da1a_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfOC01LTEtMS0w_e93e485b-8603-4cb0-b5f9-70f30bce421b"
      unitRef="usd">1564000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfOC0xMS0xLTEtMA_ef8cad18-b2de-499c-ba15-2ec1ef0632bb"
      unitRef="usd">1564000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i42fbe8f0476c44e48fe505660057da1a_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfOS01LTEtMS0w_28fea305-4ed1-44ba-8af7-7df380ea1829"
      unitRef="usd">10920000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfOS0xMS0xLTEtMA_fc4a4dd1-2016-4541-ad21-6e499f6c049c"
      unitRef="usd">10920000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <ptct:AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor
      contextRef="i42fbe8f0476c44e48fe505660057da1a_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfOC01LTEtMS0xOTk0_34eb79fe-152f-40f1-ac36-5d1822758e27"
      unitRef="usd">978000</ptct:AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor>
    <ptct:AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor
      contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfMTAtMTEtMS0xLTA_e2d6c9ed-bba7-4d80-ab99-3b75fa0f1821"
      unitRef="usd">978000</ptct:AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor>
    <us-gaap:NetIncomeLoss
      contextRef="i6ae47019f2ba40a8aefbc1d239cdc94b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfMTEtOS0xLTEtMA_2cad0b29-b5e9-48ed-9c64-9e0ae30c2cfa"
      unitRef="usd">-41789000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfMTEtMTEtMS0xLTA_24aacd74-ddb2-4f26-bf7a-438efad93b8c"
      unitRef="usd">-41789000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="icfcb85f561bb41318c256dcacaf6a1a2_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfMTItNy0xLTEtMA_cf71f8ac-330f-42d4-a4fc-a9cdc550a4ea"
      unitRef="usd">1117000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfMTItMTEtMS0xLTA_65ac12d5-8f28-4cf1-a52b-f23a7d5e99e9"
      unitRef="usd">1117000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:SharesIssued
      contextRef="i289d8cdd90cd4be0a90a0932fe6572f6_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfMTMtMS0xLTEtMA_c82bf398-1146-4663-b2c2-02c511e67a27"
      unitRef="shares">58707185</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i289d8cdd90cd4be0a90a0932fe6572f6_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfMTMtMy0xLTEtMA_cc61b53c-8607-47c6-8497-9c3b6bda0eb6"
      unitRef="usd">58000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id81dc5f706a14ac69c50d7c1adccc558_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfMTMtNS0xLTEtMA_2349c0b1-d349-40b4-9b00-d98cd35d0d7e"
      unitRef="usd">1539530000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5628af8116db4f9a9c32020225574c39_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfMTMtNy0xLTEtMA_5b35455e-13d0-489d-9864-bfc905da5958"
      unitRef="usd">1922000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifeea6088e2ed4f849936ae7bdd7cbcfd_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfMTMtOS0xLTEtMA_17806d18-8b7e-47d4-b241-d035d10e5438"
      unitRef="usd">-1052825000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i28563c013fff4be6aba8b90a75baf135_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOmJhM2RmOTQ0ODZhZjQ2NzQ4YmVjNzM0ZWZiZTA1NzVjL3RhYmxlcmFuZ2U6YmEzZGY5NDQ4NmFmNDY3NDhiZWM3MzRlZmJlMDU3NWNfMTMtMTEtMS0xLTA_397ca147-fd0f-48db-829c-dc2e22b17b4b"
      unitRef="usd">488685000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i6416f0fda976465288b8a99fee841a11_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfMi0xLTEtMS0yMDgw_0a80e41a-0ffe-4f28-a914-731c9ec1528d"
      unitRef="shares">61935870</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i6416f0fda976465288b8a99fee841a11_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfMi0zLTEtMS0yMDgw_3cda82f2-68de-426b-babb-03005003bbf3"
      unitRef="usd">62000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0c24f8e9d344416dbdacd07f1624ad0c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfMi01LTEtMS0yMDgw_cb9a88f7-260d-41e2-9aae-83f58e0468e3"
      unitRef="usd">1795351000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iebab310c097741efb22ea6ccc61c24b1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfMi03LTEtMS0yMDgw_c606efa2-b7b7-440d-978c-7ffda2ccfe8f"
      unitRef="usd">-10584000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if79b05d131bf402dac7e50420745aeff_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfMi05LTEtMS0yMDgw_82c37f3e-c36e-4307-b5be-f793b68df169"
      unitRef="usd">-1190499000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfMi0xMS0xLTEtMjA4MA_6c571f13-fb85-4e5d-93c2-ab9e82fa90be"
      unitRef="usd">594330000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i9e33cecb164a48a0aa1eba2f1728140b_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfNC0xLTEtMS0yMDgw_929f147b-7ed8-4a91-9bf4-90bf802995ce"
      unitRef="shares">368514</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i9e33cecb164a48a0aa1eba2f1728140b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfNC0zLTEtMS0yMDgw_97bc3fe1-ef09-4766-a502-5b64e25275b1"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i3b35f4ed68ad4e4d905a31fd652afbca_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfNC01LTEtMS0yMDgw_f385c5eb-9023-48ca-8501-a403a1ecfee6"
      unitRef="usd">18950000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfNC0xMS0xLTEtMjA4MA_a82ca02f-8a61-403c-936b-da4277522367"
      unitRef="usd">18950000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="i9e33cecb164a48a0aa1eba2f1728140b_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfNi0xLTEtMS0yMDgw_a4b34432-a48b-45bd-bb4f-73454421d049"
      unitRef="shares">845364</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i9e33cecb164a48a0aa1eba2f1728140b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfNi0zLTEtMS0yMDgw_e315c953-f79b-4e24-9f34-5af1e7c4a0bb"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i3b35f4ed68ad4e4d905a31fd652afbca_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfNi01LTEtMS0yMDgw_bd3ed5e2-0d24-4295-b9dc-2cbd4364a425"
      unitRef="usd">42868000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfNi0xMS0xLTEtMjA4MA_0dba8b05-6b8e-4167-b4c2-5558635f1037"
      unitRef="usd">42869000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <ptct:StockIssuedDuringPeriodSharesExchangeRights
      contextRef="i9e33cecb164a48a0aa1eba2f1728140b_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfNy0xLTEtMS0yNTQz_fe43a1f4-28c7-416e-a7c6-928eb19a390c"
      unitRef="shares">2821176</ptct:StockIssuedDuringPeriodSharesExchangeRights>
    <ptct:StockIssuedDuringPeriodValueExchangeRights
      contextRef="i9e33cecb164a48a0aa1eba2f1728140b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfNy0zLTEtMS0yNTQz_82790385-2a3e-4f5c-b135-6e0cefcff4d8"
      unitRef="usd">3000</ptct:StockIssuedDuringPeriodValueExchangeRights>
    <ptct:StockIssuedDuringPeriodValueExchangeRights
      contextRef="i3b35f4ed68ad4e4d905a31fd652afbca_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfNy01LTEtMS0yNTQz_4b213611-12db-4352-b19f-aff321f47c9a"
      unitRef="usd">150525000</ptct:StockIssuedDuringPeriodValueExchangeRights>
    <ptct:StockIssuedDuringPeriodValueExchangeRights
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfNy0xMS0xLTEtMjU0Mw_c8d3a3d9-f7be-48a9-8135-be0d2ae86686"
      unitRef="usd">150528000</ptct:StockIssuedDuringPeriodValueExchangeRights>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i9e33cecb164a48a0aa1eba2f1728140b_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfNy0xLTEtMS0yMDgw_2bc7ec48-6b2e-4a17-b481-ce2fe4c623e4"
      unitRef="shares">1034288</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i9e33cecb164a48a0aa1eba2f1728140b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfNy0zLTEtMS0yMDgw_38b7ed6c-3dd1-4ee4-bec3-fba1901aae4b"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i3b35f4ed68ad4e4d905a31fd652afbca_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfNy01LTEtMS0yMDgw_e07720c3-f04d-41cb-9851-82f34d605444"
      unitRef="usd">25044000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfNy0xMS0xLTEtMjA4MA_34bedc9d-c9fb-4d9e-ac52-ce23339ad75f"
      unitRef="usd">25045000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i9e33cecb164a48a0aa1eba2f1728140b_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfOC0xLTEtMS0yMDgw_3e5f5560-1a10-4c36-8655-87ae1ffdeca8"
      unitRef="shares">176776</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfOC0xMS0xLTEtMjA4MA_0cdd1a98-ac91-4682-9515-47f56b2bb702"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i9e33cecb164a48a0aa1eba2f1728140b_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfOS0xLTEtMS0yMDgw_3de6ec30-3752-4bbe-a80f-d15b78339cb5"
      unitRef="shares">58691</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i9e33cecb164a48a0aa1eba2f1728140b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfOS0zLTEtMS0yMDgw_3f6a6fd5-ef3b-4f5d-88be-2484c28b80c7"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i3b35f4ed68ad4e4d905a31fd652afbca_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfOS01LTEtMS0yMDgw_e17d5dc6-c3f0-4dc6-9193-4cb203234a69"
      unitRef="usd">2406000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfOS0xMS0xLTEtMjA4MA_fd01d958-e11c-42a3-b45f-46db039f3e27"
      unitRef="usd">2406000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3b35f4ed68ad4e4d905a31fd652afbca_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfMTAtNS0xLTEtMjA4MA_7fc0d6e6-baa3-4860-9c9d-2d139cffc613"
      unitRef="usd">32130000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfMTAtMTEtMS0xLTIwODA_89203406-4ae6-418a-b97e-9f6e2c958c2e"
      unitRef="usd">32130000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockholdersEquityPeriodIncreaseDecrease
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfMTItOS0xLTEtMjU0OQ_f28ab753-fe4e-4a4a-988f-767a9d7acabf"
      unitRef="usd">-218000</us-gaap:StockholdersEquityPeriodIncreaseDecrease>
    <us-gaap:StockholdersEquityPeriodIncreaseDecrease
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfMTItMTEtMS0xLTI1NDk_4d46cab0-d0d0-4267-9f2e-4c3e2c7fe6dd"
      unitRef="usd">-218000</us-gaap:StockholdersEquityPeriodIncreaseDecrease>
    <us-gaap:NetIncomeLoss
      contextRef="i31d6e1bdb5ca471392964fa03ef36c08_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfMTMtOS0xLTEtMjA4MA_44fb51ff-d7e6-409f-a1fc-eeda8559df03"
      unitRef="usd">-294114000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfMTMtMTEtMS0xLTIwODA_9fe22c5c-7a4f-4152-8795-3a2a74c43129"
      unitRef="usd">-294114000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i9bff894d600845e29a8c4faf34680df2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfMTQtNy0xLTEtMjA4MA_6e0384da-91b8-427d-a1ca-7144fe019ace"
      unitRef="usd">568000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfMTQtMTEtMS0xLTIwODA_ed7f933e-dbdb-4c29-9e8f-7a831ebab126"
      unitRef="usd">568000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:SharesIssued
      contextRef="i533ee7ba976f46e396724aba128c444e_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfMTUtMS0xLTEtMjA4MA_84f9f4fa-6b51-44f8-b84d-7b6dd46dfb49"
      unitRef="shares">67240679</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i533ee7ba976f46e396724aba128c444e_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfMTUtMy0xLTEtMjA4MA_94294d91-52b0-4f88-b64b-9e765462530b"
      unitRef="usd">67000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie459585656ec4c888bad0072cb787216_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfMTUtNS0xLTEtMjA4MA_2fa51d5f-94b5-4f26-a129-8d18affcf942"
      unitRef="usd">2067274000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if99a5f5b88c44e239963a271d78fd4d0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfMTUtNy0xLTEtMjA4MA_b9d6e181-1fab-4fc2-ace9-023043200962"
      unitRef="usd">-10016000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib08418efd9054e53865f0aad58f50b9d_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfMTUtOS0xLTEtMjA4MA_8e9bd49d-d28a-408a-8176-aaf44d0c2ced"
      unitRef="usd">-1484831000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjgzOGI5ZWQxZDhhMTQ3ZDNhMzRhODQ0ZGViNDdlMTFmL3RhYmxlcmFuZ2U6ODM4YjllZDFkOGExNDdkM2EzNGE4NDRkZWI0N2UxMWZfMTUtMTEtMS0xLTIwODA_9b7dbc17-cd4a-4c59-8e3d-4df9ba66b0bf"
      unitRef="usd">572494000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="ib5972ed6730144a8ae9bdb30fcd5fffd_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfMi0xLTEtMS05NDI_e18ad369-36e0-4e56-b953-e8812bbdecca"
      unitRef="shares">50606147</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ib5972ed6730144a8ae9bdb30fcd5fffd_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfMi0zLTEtMS05ODU_8c82d317-77c4-4eef-b792-8c0582c2a877"
      unitRef="usd">51000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib056d8d4512a4814801eaea43e457f5f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfMi01LTEtMS05ODk_7e68bcaf-5573-4e6d-b475-3fbbc241b634"
      unitRef="usd">1288137000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9d8fb8ff546849248d177b17b67ea09b_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfMi03LTEtMS05OTM_ac75e8bc-1d5a-47a4-90fb-dfb09ff0a392"
      unitRef="usd">1462000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6eadb591f1b34ddaa289055d8b4379c3_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfMi05LTEtMS05OTc_3c1c7425-1e77-4ad5-bef0-45f469f1574c"
      unitRef="usd">-938923000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i785bae8d0f37453b828968b15c63b74f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfMi0xMS0xLTEtMTAwMQ_8f7453dd-e480-49fd-af7a-ef7724956c3e"
      unitRef="usd">350727000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i4042444983714690acf2456c51c245ff_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfNC0xLTEtMS05NTg_8728f80d-c240-4ffc-853d-1de72e39f6a3"
      unitRef="shares">7563725</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4042444983714690acf2456c51c245ff_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfNC0zLTEtMS05ODU_4e4b947a-85a6-441c-aceb-1c86d6bf7e4c"
      unitRef="usd">7000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ice0e67612cf54d9c91dea97e80e5cbec_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfNC01LTEtMS05ODk_2a8b4d60-7c0d-43f7-877b-597f1cf2dfad"
      unitRef="usd">224538000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfNC0xMS0xLTEtMTAwMQ_1ade9f0c-1504-4d6d-88c5-9f1df5c643f9"
      unitRef="usd">224545000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i4042444983714690acf2456c51c245ff_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfNi0xLTEtMS05NTg_075af42e-adc7-410b-b6ea-1f6919c88adc"
      unitRef="shares">311002</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i4042444983714690acf2456c51c245ff_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfNi0zLTEtMS05ODU_ac5b07fc-ea14-439c-aea3-c2217fc67f8b"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ice0e67612cf54d9c91dea97e80e5cbec_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfNi01LTEtMS05ODk_a52e79c0-a660-4f03-8176-2d94d6ecd1b9"
      unitRef="usd">4129000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfNi0xMS0xLTEtMTAwMQ_22da63d3-dc86-4c84-ab5d-89238f350859"
      unitRef="usd">4129000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i4042444983714690acf2456c51c245ff_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfNy0xLTEtMS05NTg_6b302447-42e3-4227-926b-7b2e9935be40"
      unitRef="shares">171592</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfNy0xMS0xLTEtMTAwMQ_97355262-6c92-4aaa-aa6b-32d77869c543"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i4042444983714690acf2456c51c245ff_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfOC0xLTEtMS05NTg_93c51a2f-0dc5-41f0-9907-adbd89054640"
      unitRef="shares">54719</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i4042444983714690acf2456c51c245ff_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfOS0zLTEtMS05ODU_b638f1a0-5a29-4f46-8fad-66059e678007"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ice0e67612cf54d9c91dea97e80e5cbec_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfOS01LTEtMS05ODk_e4bb8063-2c0b-4f0f-86d9-42b33df2d137"
      unitRef="usd">1564000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfOS0xMS0xLTEtMTAwMQ_11c7c0a2-ba1d-4e75-a126-32272f72ea9d"
      unitRef="usd">1564000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ice0e67612cf54d9c91dea97e80e5cbec_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfMTAtNS0xLTEtOTg5_d2c717a4-3f12-4be3-a187-a0c21aca6e4c"
      unitRef="usd">20184000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfMTAtMTEtMS0xLTEwMDE_3b0b40ba-dcf4-4d93-8c1e-d64ebbc64669"
      unitRef="usd">20184000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <ptct:AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor
      contextRef="ice0e67612cf54d9c91dea97e80e5cbec_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfMTEtNS0xLTEtOTg5_bc6f2410-af57-4f6e-9f25-f6db755e7997"
      unitRef="usd">978000</ptct:AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor>
    <ptct:AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfMTEtMTEtMS0xLTEwMDE_dd2200c8-6dcd-4d70-bfd1-4f3d3529029a"
      unitRef="usd">978000</ptct:AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor>
    <us-gaap:NetIncomeLoss
      contextRef="i27feb6dc967a41579d7c19c8a1cb7e84_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfMTItOS0xLTEtOTk3_9fbe362b-5d4c-4cf5-a4f6-9c17479cd22d"
      unitRef="usd">-113902000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfMTItMTEtMS0xLTEwMDE_68ee5d52-c2f9-4f8d-898b-f6a2606da1d8"
      unitRef="usd">-113902000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i24ef21dbfe234c0591a9b24a236878c6_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfMTMtNy0xLTEtOTkz_4dea2be4-1ee7-4895-9ffc-47629e6ee558"
      unitRef="usd">460000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfMTMtMTEtMS0xLTEwMDE_43dcb310-3979-4152-821f-9e672bbe43d3"
      unitRef="usd">460000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:SharesIssued
      contextRef="i289d8cdd90cd4be0a90a0932fe6572f6_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfMTMtMS0xLTEtOTU4_f34608bf-1f8b-40a2-8d68-f0e19da14ac7"
      unitRef="shares">58707185</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i289d8cdd90cd4be0a90a0932fe6572f6_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfMTQtMy0xLTEtOTg1_6bc38f10-596a-435d-93a2-6e666c97f5ea"
      unitRef="usd">58000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id81dc5f706a14ac69c50d7c1adccc558_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfMTQtNS0xLTEtOTg5_4d76cda1-254d-4127-9bc8-29314c6eb8ce"
      unitRef="usd">1539530000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5628af8116db4f9a9c32020225574c39_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfMTQtNy0xLTEtOTkz_09888f02-dd69-4304-9c70-051de38523c7"
      unitRef="usd">1922000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifeea6088e2ed4f849936ae7bdd7cbcfd_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfMTQtOS0xLTEtOTk3_6c79ea74-f073-44a7-b4fe-72ee45e99c22"
      unitRef="usd">-1052825000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i28563c013fff4be6aba8b90a75baf135_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zMS9mcmFnOmE4ZmMzZDU1YjdlODQ3ZjNiMmViOTYxYTViZjQ5MmYyL3RhYmxlOjFhNjUwOWI4MzA0NzRlMTNhYjU1YTA2Zjc0YzlhNDdlL3RhYmxlcmFuZ2U6MWE2NTA5YjgzMDQ3NGUxM2FiNTVhMDZmNzRjOWE0N2VfMTQtMTEtMS0xLTEwMDE_2f415b7e-36c6-4dc7-9247-553cd8beb7dc"
      unitRef="usd">488685000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNC0yLTEtMS0w_0ab8ea0d-1694-41be-9aac-69f602251509"
      unitRef="usd">-294114000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNC00LTEtMS0w_3d77311b-dda9-4cab-82d0-0309deb2c3b2"
      unitRef="usd">-113902000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNi0yLTEtMS0w_20acda61-a07d-44c0-a203-a67484818e5f"
      unitRef="usd">19445000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNi00LTEtMS0w_763d730f-1fee-4c00-a6e9-62c0ef240378"
      unitRef="usd">14760000</us-gaap:Depreciation>
    <ptct:OperatingLeaseCostNonCash
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNy0yLTEtMS0w_2e52a163-ab5a-4634-b8cc-33fda44e3ac9"
      unitRef="usd">2401000</ptct:OperatingLeaseCostNonCash>
    <ptct:OperatingLeaseCostNonCash
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNy00LTEtMS0w_df0385c6-ae66-4575-aed5-5ba0414bba31"
      unitRef="usd">1256000</ptct:OperatingLeaseCostNonCash>
    <ptct:FinanceLeaseCostNonCash
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfOC0yLTEtMS03Njkx_86db4d12-4e11-4541-a9db-e6030b3ce9c3"
      unitRef="usd">41212000</ptct:FinanceLeaseCostNonCash>
    <ptct:FinanceLeaseCostNonCash
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfOC00LTEtMS03Njk1_b6f9f719-3b3a-4d94-b6c3-fcb9b15c3074"
      unitRef="usd">0</ptct:FinanceLeaseCostNonCash>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfOS0yLTEtMS0w_fd3373de-344f-4357-a5f1-32f2d4a3bd60"
      unitRef="usd">8580000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfOS00LTEtMS0w_6be58a22-28ae-4e84-a915-738e2307b23f"
      unitRef="usd">26460000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <ptct:SettlementOfDeferredAndContingentConsideration
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMTAtMi0xLTEtMA_d6385f7c-4a92-4fcb-a2ec-b94223b66968"
      unitRef="usd">10613000</ptct:SettlementOfDeferredAndContingentConsideration>
    <ptct:SettlementOfDeferredAndContingentConsideration
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMTAtNC0xLTEtMA_a3888fc9-0624-4d1e-989a-7d8583571977"
      unitRef="usd">0</ptct:SettlementOfDeferredAndContingentConsideration>
    <ptct:SharesIssuedAssetAcquisition
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMTEtMi0xLTEtMA_c536bd91-53a2-4669-8a82-7ebfe997c0cb"
      unitRef="usd">42869000</ptct:SharesIssuedAssetAcquisition>
    <ptct:SharesIssuedAssetAcquisition
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMTEtNC0xLTEtMA_f9953227-34b6-4bd6-b95f-ba7f341d99ca"
      unitRef="usd">0</ptct:SharesIssuedAssetAcquisition>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMTItMi0xLTEtMA_17da5669-e642-4ff9-aae3-609e99aff8c7"
      unitRef="usd">-1600000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMTItNC0xLTEtMA_4cb264ac-bdd8-4dcc-b749-6040fd2aba70"
      unitRef="usd">129000</us-gaap:UnrealizedGainLossOnInvestments>
    <ptct:UnrealizedGainLossonConvertibleSecurities
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMTMtMi0xLTEtMA_c72c09b0-875a-450d-bd28-8fe2ac5f88cc"
      unitRef="usd">749000</ptct:UnrealizedGainLossonConvertibleSecurities>
    <ptct:UnrealizedGainLossonConvertibleSecurities
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMTMtNC0xLTEtMA_382954fa-6737-4531-b4c2-4063a7bca463"
      unitRef="usd">0</ptct:UnrealizedGainLossonConvertibleSecurities>
    <us-gaap:PaidInKindInterest
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMTQtMi0xLTEtMA_ffa6463e-b783-4ee7-bf36-f902763b78c7"
      unitRef="usd">10993000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMTQtNC0xLTEtMA_0db7809c-589a-4019-87a7-9bf359fed7a3"
      unitRef="usd">4055000</us-gaap:PaidInKindInterest>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMTUtMi0xLTEtMA_8f637b57-7c3d-4602-af34-ea411dd806ff"
      unitRef="usd">-26000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMTUtNC0xLTEtMA_5141bde2-f15e-4c0f-a489-c634ba9002fb"
      unitRef="usd">-50000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMTYtMi0xLTEtMA_0d7b7853-ae4d-4511-998b-71edf9122b29"
      unitRef="usd">635000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMTYtNC0xLTEtMA_561f0280-c5df-497c-a05c-462984dce154"
      unitRef="usd">907000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMTctMi0xLTEtMA_7403c8d3-4b7d-4943-9b7e-eee412fbd80a"
      unitRef="usd">510000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMTctNC0xLTEtMA_224d64eb-1adc-413b-a670-3a3c9b280e03"
      unitRef="usd">280000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:ShareBasedCompensation
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMTgtMi0xLTEtMA_a4be30bb-709a-47e0-8b96-798e48b79faf"
      unitRef="usd">32130000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMTgtNC0xLTEtMA_5d426425-40b3-4bdc-a9b5-a43e1d6076a9"
      unitRef="usd">20184000</us-gaap:ShareBasedCompensation>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMjAtMi0xLTEtMA_71a4fb80-f23f-463d-8e99-ce4815ad97e8"
      unitRef="usd">3248000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMjAtNC0xLTEtMA_051c3df4-f827-4af7-836d-d1f8ee1046b4"
      unitRef="usd">-62000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMjItMi0xLTEtMA_604bd09c-3f26-4e11-85ec-869cad94f5b8"
      unitRef="usd">-943000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMjItNC0xLTEtMA_a1d578c4-9da6-4e71-b8fa-e6e07d87e642"
      unitRef="usd">852000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMjMtMi0xLTEtMA_f892c2f3-8f5f-4fd4-8c59-00011e814a81"
      unitRef="usd">16569000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMjMtNC0xLTEtMA_fa80ba61-43bc-41e1-afa4-c9950d9f2f99"
      unitRef="usd">7250000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMjQtMi0xLTEtMA_64345d57-ceca-4bb1-8aed-bff172910241"
      unitRef="usd">-1860000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMjQtNC0xLTEtMA_183617b9-499e-42d8-8684-3c1504e270c5"
      unitRef="usd">9702000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInDepositOtherAssets
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMjUtMi0xLTEtMzM2Mw_78b76fd8-c177-42af-9d44-0e56d4bf6707"
      unitRef="usd">175000</us-gaap:IncreaseDecreaseInDepositOtherAssets>
    <us-gaap:IncreaseDecreaseInDepositOtherAssets
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMjUtNC0xLTEtMzM2Mw_c12c9f17-0c94-4663-a1d2-fca8184eb507"
      unitRef="usd">9656000</us-gaap:IncreaseDecreaseInDepositOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMjYtMi0xLTEtMzM2Mw_bd8b0c68-9c9c-449c-b4a5-66b9e576c9d5"
      unitRef="usd">-7497000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMjYtNC0xLTEtMzM2Mw_e4455306-ce27-45e9-bdd9-76780c45d782"
      unitRef="usd">-7546000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMjUtMi0xLTEtMA_b581eb94-fa1c-4f5b-91a2-ea94ff5628ac"
      unitRef="usd">-4132000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMjUtNC0xLTEtMA_48a7d2b5-d904-428d-bfd4-8b72dc6f5815"
      unitRef="usd">7395000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMjYtMi0xLTEtMA_9a254b93-4215-4131-a8f2-e3bff3cb8a41"
      unitRef="usd">-3925000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMjYtNC0xLTEtMA_a6800787-c243-4eec-b4d1-a50ffe899295"
      unitRef="usd">2511000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMjctMi0xLTEtMA_68009595-50d8-49b3-84cd-b5ed43651259"
      unitRef="usd">-156364000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMjctNC0xLTEtMA_ef731f5c-1b6c-4e2c-8b8a-b3e475b13d9e"
      unitRef="usd">-72931000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMjktMi0xLTEtMA_b8a449f0-45e8-4211-bd7a-798b156f33e1"
      unitRef="usd">8183000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMjktNC0xLTEtMA_1c978741-b154-4f0c-81ad-e67c33235c7c"
      unitRef="usd">4851000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <ptct:PaymentsToAcquireConvertibleDebtInvestment
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMzAtMi0xLTEtMA_53439327-ffd5-4522-931e-61c3345be39a"
      unitRef="usd">10000000</ptct:PaymentsToAcquireConvertibleDebtInvestment>
    <ptct:PaymentsToAcquireConvertibleDebtInvestment
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMzAtNC0xLTEtMA_dbb7b049-e64c-4452-b0c3-445654ca8b1b"
      unitRef="usd">0</ptct:PaymentsToAcquireConvertibleDebtInvestment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMzEtMi0xLTEtMA_a2c60f64-b4ff-48db-980a-99d6e13d02bb"
      unitRef="usd">367102000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMzEtNC0xLTEtMA_b041975e-81dd-4c27-9c24-e74e811f83c9"
      unitRef="usd">226261000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMzItMi0xLTEtMA_ebaf5ec4-9f79-42a7-a397-41b03e21d0b6"
      unitRef="usd">428490000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMzItNC0xLTEtMA_77fbcaf6-3c52-4520-9628-d49ef6b8ea70"
      unitRef="usd">58424000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMzMtMi0xLTEtMA_23784620-8dc1-4e07-946b-b12cec2e36df"
      unitRef="usd">2422000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMzMtNC0xLTEtMA_0c4ddafd-7899-417a-959e-d81a647e3b08"
      unitRef="usd">11981000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMzQtMi0xLTEtMA_3e45552b-0aae-4250-902f-77b198623285"
      unitRef="usd">0</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMzQtNC0xLTEtMA_c278d908-6a11-4fb1-83f9-550a50f765e6"
      unitRef="usd">4000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMzUtMi0xLTEtMA_2442be8a-3f3b-402c-b28d-347d91e0ea1f"
      unitRef="usd">40783000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMzUtNC0xLTEtMA_eb845a89-3073-428f-aa5f-b3ef12c20efd"
      unitRef="usd">-188669000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMzctMi0xLTEtMA_42e9d20a-81c7-4999-b4be-baa370b5efee"
      unitRef="usd">25045000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMzctNC0xLTEtMA_ba966865-857b-4470-95d8-623fb385fb05"
      unitRef="usd">4129000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMzgtMi0xLTEtMA_f958ff5e-51f3-435e-b244-216d12bbd36c"
      unitRef="usd">18950000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMzgtNC0xLTEtMA_afce5998-2690-4e6a-8d37-eeeb15fff12f"
      unitRef="usd">224545000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:RepaymentsOfSecuredDebt
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMzktMi0xLTEtMA_141c0564-483f-4f32-a82c-98994dc46234"
      unitRef="usd">10000000</us-gaap:RepaymentsOfSecuredDebt>
    <us-gaap:RepaymentsOfSecuredDebt
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfMzktNC0xLTEtMA_57a260ea-738c-4c58-82e5-43529845fdee"
      unitRef="usd">1667000</us-gaap:RepaymentsOfSecuredDebt>
    <ptct:PaymentsOnDeferredConsiderationObligation
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNDItMi0xLTEtMzM5NQ_c2b3c133-f56d-48ec-b2c8-43805a87e319"
      unitRef="usd">35829000</ptct:PaymentsOnDeferredConsiderationObligation>
    <ptct:PaymentsOnDeferredConsiderationObligation
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNDItNC0xLTEtMzM5NQ_3fdaeb8a-cae7-40c2-829b-f8cb27b75588"
      unitRef="usd">0</ptct:PaymentsOnDeferredConsiderationObligation>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNDAtMi0xLTEtMA_9d429e55-0aad-4ac8-8e4a-e5f07d9c41c1"
      unitRef="usd">2406000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNDAtNC0xLTEtMA_7c44a80a-c500-4c2c-91bf-ebfc682114ac"
      unitRef="usd">1564000</us-gaap:ProceedsFromStockPlans>
    <ptct:PaymentOfFinanceLeasePrincipal
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNDEtMi0xLTEtMA_7ba14371-1db9-431f-9d2a-62a4fb9b82e7"
      unitRef="usd">15000000</ptct:PaymentOfFinanceLeasePrincipal>
    <ptct:PaymentOfFinanceLeasePrincipal
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNDEtNC0xLTEtMA_be0c6dc4-9229-4e63-83d4-d60997428276"
      unitRef="usd">0</ptct:PaymentOfFinanceLeasePrincipal>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNDMtMi0xLTEtMA_0d09220b-f6be-4723-ac22-a27323d7c6eb"
      unitRef="usd">-14428000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNDMtNC0xLTEtMA_d088dd0a-0c72-4424-bc54-886b5a54a4a0"
      unitRef="usd">228571000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNDQtMi0xLTEtMA_c16bd481-22d2-4dea-8add-f629e73a5b0c"
      unitRef="usd">442000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNDQtNC0xLTEtMA_e6252d63-c8c0-4e23-ba55-a732f2866903"
      unitRef="usd">-375000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNDUtMi0xLTEtMA_76997401-50f4-436f-b733-d714d66f7646"
      unitRef="usd">-129567000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNDUtNC0xLTEtMA_4198a07f-efff-4e12-9b0e-03a1ceadf6ec"
      unitRef="usd">-33404000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNDYtMi0xLTEtMA_81171aa6-3c8b-437f-912a-dc726ecbc380"
      unitRef="usd">295528000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i785bae8d0f37453b828968b15c63b74f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNDYtNC0xLTEtMA_76c27e72-946e-4271-b601-4e95021ce65c"
      unitRef="usd">169498000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNDctMi0xLTEtMA_51cce6dd-6e3a-4027-b4c2-fd292b0d66bd"
      unitRef="usd">165961000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i28563c013fff4be6aba8b90a75baf135_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNDctNC0xLTEtMA_86512b4d-639f-4a8e-b7ef-9ac82df4097f"
      unitRef="usd">136094000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNDktMi0xLTEtMA_31dd0c64-0241-4fd1-9257-36a4ed2a51f7"
      unitRef="usd">5286000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNDktNC0xLTEtMA_660bf907-694a-4ab0-ab98-e1a2808cc5ff"
      unitRef="usd">3111000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNTAtMi0xLTEtMA_2768a8a2-a888-425c-b850-42d7fdf048a8"
      unitRef="usd">1140000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNTAtNC0xLTEtMA_a517a566-2b98-4bd0-b29b-16cb19edd4ee"
      unitRef="usd">1013000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNTItMi0xLTEtMA_808e8333-3c76-43e3-a358-7b13d8c47702"
      unitRef="usd">2655000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNTItNC0xLTEtMA_cd346860-d6b2-49ab-9a93-8777760b1b9a"
      unitRef="usd">898000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNTMtMi0xLTEtMA_a3af0de8-2d2c-489a-8711-ae29089981f4"
      unitRef="usd">18117000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNTMtNC0xLTEtMA_b3b0516a-4c96-4b31-9dc5-39af42296005"
      unitRef="usd">11643000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNTYtMi0xLTEtNTE5OQ_c14d9087-e89c-4acf-9afe-751a51cf04a7"
      unitRef="usd">41212000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNTYtNC0xLTEtNTIwMw_8add1f2f-0c65-4eef-b8c6-affd0a5b64bd"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNTQtMi0xLTEtMA_ecc4d105-def9-4364-97a0-9de8f78faa64"
      unitRef="usd">12186000</us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNTQtNC0xLTEtMA_1a74b60c-13b2-4041-ae94-c27ec0767f1b"
      unitRef="usd">8269000</us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1>
    <ptct:StockIssuedDuringPeriodValueExchangeRights
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNTktMi0xLTEtNzgzMA_e247d44c-fe47-4006-9e6b-44c72e23f7f1"
      unitRef="usd">150528000</ptct:StockIssuedDuringPeriodValueExchangeRights>
    <ptct:StockIssuedDuringPeriodValueExchangeRights
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8zNC9mcmFnOjk1YjU2ZGE0YzE2ZTQzZjQ4MTJkZTllNDY0OWI4MGI3L3RhYmxlOjcwYjUyNjc4MTgzMzQ5YzliMzdkNzQ5YzQxNDE3MGMxL3RhYmxlcmFuZ2U6NzBiNTI2NzgxODMzNDljOWIzN2Q3NDljNDE0MTcwYzFfNTktNC0xLTEtODEyMw_cfdda05e-a91d-4200-8afc-b5715731f1ca"
      unitRef="usd">0</ptct:StockIssuedDuringPeriodValueExchangeRights>
    <us-gaap:NatureOfOperations
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80MC9mcmFnOmM3MjE3M2MxMmMzZTQwMDdiN2ZhM2JhN2I5MjdiMmMwL3RleHRyZWdpb246YzcyMTczYzEyYzNlNDAwN2I3ZmEzYmE3YjkyN2IyYzBfMTMyNzk_db49635a-ac14-41ff-a96e-bbc353c99e39">The Company&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;PTC Therapeutics,&#160;Inc. (the &#x201c;Company&#x201d; or &#x201c;PTC&#x201d;) is a science-driven global biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. The Company&#x2019;s ability to globally commercialize products is the foundation that drives its continued investment in a robust diversified pipeline of transformative medicines and its mission to provide access to best-in-class treatments for patients who have an unmet medical need. The Company&#x2019;s strategy is to bring best-in-class therapies with differentiated clinical benefit to patients affected by rare disorders and to leverage its global commercial infrastructure to maximize value for its patients and other stakeholders.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;The Company has two products, Translarna&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;"&gt;&#x2122; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;(ataluren) and Emflaza&#x2122; (deflazacort), for the treatment of Duchenne muscular dystrophy, or DMD, a rare, life threatening disorder. Translarna has marketing authorization in the European Economic Area (the &#x201c;EEA&#x201d;) for the treatment of nonsense mutation Duchenne muscular dystrophy, or nmDMD, in ambulatory patients aged 2&#160;years and older and in Brazil for the treatment of nmDMD in ambulatory patients aged 5&#160;years and older, subject to annual renewal and other conditions. In June 2020, the Committee for Medicinal Products for Human Use (the "CHMP") of the European Medicines Agency ("EMA") recommended to remove the statement &#x201c;efficacy has not been demonstrated in non-ambulatory patients&#x201d; from the product label for Translarna. The CHMP's opinion is subject to final approval by the European Commission, which is typically provided within two months of the CHMP's recommendation. Emflaza is approved in the United States for the treatment of DMD in patients two years and older.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has a pipeline of gene therapy product candidates for rare monogenic diseases that affect the central nervous system (&#x201c;CNS&#x201d;) including PTC-AADC for the treatment of Aromatic L-Amino Acid Decarboxylase, or AADC deficiency, a rare CNS disorder arising from reductions in the enzyme AADC that results from mutations in the dopa decarboxylase gene. The Company is preparing a biologics license application ("BLA") for PTC-AADC for the treatment of AADC deficiency in the United States and it anticipates initiating the BLA submission to the United States Food and Drug Administration ("FDA") in the second half of 2020. In January 2020, the Company submitted a marketing authorization application ("MAA") to the EMA for PTC-AADC for the treatment of AADC deficiency in the EEA, and the Company expects an opinion from the CHMP in the first quarter of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;The Company holds the rights for the commercialization of Tegsedi&#x2122; (inotersen) and Waylivra&#x2122; (volanesorsen) for the treatment of rare diseases in countries in Latin America and the Caribbean pursuant to the Company&#x2019;s Collaboration and License Agreement with Akcea Therapeutics, Inc. (&#x201c;Akcea&#x201d;). Tegsedi has received marketing authorization in the United States, the European Union (the &#x201c;EU&#x201d;) and Brazil for the treatment of stage&#160;1 or stage&#160;2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis, or hATTR amyloidosis. Waylivra has received marketing authorization in the EU for the treatment of familial chylomicronemia syndrome, or FCS. The Company filed for marketing authorization for Waylivra for the treatment of FCS with ANVISA, the Brazilian health regulatory authority, in June 2020 and, subject to potential delays in the review process related to the COVID-19 pandemic, expects a regulatory decision on approval from ANVISA in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company also has a spinal muscular atrophy ("SMA") collaboration with F. Hoffman-La Roche&#160;Ltd and Hoffman-La Roche&#160;Inc., referred to collectively as Roche, and the Spinal Muscular Atrophy Foundation ("SMA Foundation"). The lead compound in the SMA program is risdiplam (RG7916, RO7034067). Roche submitted an NDA for risdiplam to the FDA in the fourth quarter of 2019. In April 2020, the FDA extended the Prescription Drug User Fee Act ("PDUFA") date for a decision from May 24, 2020&#160;to August 24, 2020 as a result of additional data that Roche submitted, including comprehensive data from the Sunfish part 2 study. Risdiplam is expected to be indicated in the United States for SMA type 1, 2 and 3 patients, if approved. Roche anticipates submitting an MAA for risdiplam in the EEA imminently.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;On October 25, 2019, the Company completed the acquisition of substantially all of the assets of BioElectron Technology Corporation (&#x201c;BioElectron&#x201d;), a Delaware corporation, including certain compounds that the Company has begun to develop as part of its Bio-e platform, (the &#x201c;Asset Acquisition&#x201d;) pursuant to an asset purchase agreement by and between the Company and BioElectron, dated October 1, 2019 (the &#x201c;Asset Acquisition Agreement&#x201d;). The transaction was accounted for as an asset acquisition. The two most advanced molecules in the Company's Bio-e platform are vatiquinone, formerly known as PTC743, and PTC857. The Company expects to initiate a potential registrational Phase 2 placebo-controlled trial of vatiquinone in approximately 60 children with mitochondrial disease and associated refractory epilepsy in the third quarter of 2020. The Company also expects to initiate a potential registrational Phase 3 trial of vatiquinone in approximately 100 patients with &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;Friedrich ataxia in the fourth quarter of 2020. In the second quarter of 2020, the Company initiated a Phase 1 trial in healthy volunteers to evaluate the safety and pharmacology of PTC857. The Company expects data from the single ascending dose and multiple ascending dose studies from the Phase 1 trial to be available by the end of 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;In addition, the Company has a pipeline of product candidates and discovery programs that are in early clinical, pre-clinical and research and development stages focused on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s marketing authorization for Translarna in the EEA is subject to annual review and renewal by the European Commission following reassessment by the EMA of the benefit-risk balance of the authorization, which the Company refers to as the annual EMA reassessment. This marketing authorization is further subject to the specific obligation to conduct and submit the results of a multi-center, randomized, double-blind, 18-month, placebo-controlled trial, followed by an 18-month open-label extension, according to an agreed protocol, in order to confirm the efficacy and safety of Translarna. The final report on the trial and open-label extension is to be submitted by the Company to the EMA by the end of the third quarter of 2022. The Company refers to the trial and open-label extension together as Study 041.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The marketing authorization in the EEA was last renewed in June 2020 and is effective, unless extended, through August 5, 2021. The renewal was based on the Company&#x2019;s commitment to conduct Study 041 and the totality of the clinical data available from its trials and studies of Translarna for the treatment of nmDMD, including the safety and efficacy results of the Phase 2b and Phase 3 clinical trials. The primary efficacy endpoint was not achieved in either trial within the pre-specified level of statistical significance.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;Translarna is an investigational new drug in the United States. During the first quarter of 2017, the Company filed a New Drug Application, or NDA, over protest with the FDA, for which the FDA granted a standard review. In October 2017, the Office of Drug Evaluation I of the FDA issued a complete response letter for the NDA, stating that it was unable to approve the application in its current form. In response, the Company filed a formal dispute resolution request with the Office of New Drugs of the FDA. In February 2018, the Office of New Drugs of the FDA denied the Company's appeal of the Complete Response Letter. In its response, the Office of New Drugs recommended a possible path forward for the ataluren NDA submission based on the accelerated approval pathway. This would involve a re-submission of an NDA containing the current data on effectiveness of ataluren with new data to be generated on dystrophin production in nmDMD patients&#x2019; muscles. The Company intends to follow the FDA&#x2019;s recommendation and will collect, using newer technologies via procedures and methods that the Company designed, such dystrophin data in a new study, Study 045, which the Company initiated in the fourth quarter of 2018. As a result of intermittent discontinuations of certain elective procedures at the Company's clinical trial site in response to the COVID-19 pandemic, the Company's expected completion of Study 45 has been delayed as certain patients still require final study muscle biopsies. Once the clinical trial site is open for the necessary procedures and patients are able to safely travel to the site, the Company expects to be able to complete the final biopsies and the data from Study 045 would be available thereafter, followed by a potential re-submission of an NDA. Additionally, should a re-submission of an NDA receive accelerated approval, the Office of New Drugs stated that Study 041, which is currently enrolling, could serve as the confirmatory post-approval trial required in connection with the accelerated approval framework.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On August 23, 2018, the Company completed its acquisition of Agilis Biotherapeutics, Inc., or Agilis, pursuant to an Agreement and Plan of Merger, dated as of July 19, 2018 (the &#x201c;Merger Agreement&#x201d;), by and among the Company, Agility Merger Sub, Inc., a Delaware corporation and the Company's wholly owned, indirect subsidiary, Agilis and, solely in its capacity as the representative, agent and attorney-in-fact of the equityholders of Agilis, Shareholder Representative Services LLC, (the "Merger").&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Upon the closing of the Merger, the Company paid to Agilis equityholders total upfront consideration comprised of $49.2 million in cash and 3,500,907 shares of the Company&#x2019;s common stock (the &#x201c;Closing Stock Consideration&#x201d;). The Closing Stock Consideration was determined by dividing $150.0 million by the volume-weighted average price per share of the Company&#x2019;s common stock on the Nasdaq Global Select Market for the 10 consecutive trading-day period ending on the second trading-day immediately preceding the closing of the Merger. Agilis equityholders are entitled to receive contingent payments from the Company based on the achievement of certain development, regulatory and net sales milestones as well as based upon a percentage of net sales of certain products.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;On April 29, 2020, the Company, certain of the former equity holders of Agilis, and, for the limited purposes set forth in the agreement, Shareholder Representative Services LLC, entered into a Rights Exchange Agreement (the &#x201c;Rights Exchange Agreement&#x201d;). Pursuant to the Rights Exchange Agreement, the Company issued 2,821,176 shares of its common stock (the &#x201c;Common Stock Consideration&#x201d;) and paid $36.9&#160;million (the &#x201c;Cash Consideration&#x201d;), in the aggregate, to such former equity holders of Agilis (the &#x201c;Participating Rightholders&#x201d;) in exchange for the cancellation and forfeiture by the Participating Rightholders of their rights to receive certain milestone-based contingent payments under the Merger Agreement, pursuant to which the Company completed the Merger. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;Pursuant to the terms of the Rights Exchange Agreement, the Participating Rightholders have canceled and forfeited their rights under the Merger Agreement to receive (i) $174.0&#160;million, in the aggregate, of potential milestone payments based on the achievement of certain regulatory milestones and (ii) $37.6&#160;million, in the aggregate, of $40.0&#160;million in development milestone payments that would have been due upon the passing of the second anniversary of the closing of the Merger, regardless of whether the milestones are achieved.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;The Rights Exchange Agreement has no effect on the Merger Agreement other than to provide for the cancellation and forfeiture of the Participating Rightholders&#x2019; rights to receive $211.6&#160;million, in the aggregate, of the milestone payments described above. As a result, all other rights and obligations under the Merger Agreement remain in effect pursuant to their terms, including the Company&#x2019;s obligation to pay up to an aggregate maximum amount of $22.4&#160;million upon the achievement of certain development milestones (representing the remaining portion of potential development milestone payments for which rights were not canceled and forfeited pursuant to the Rights Exchange Agreement after deducting the $37.6&#160;million for which rights were canceled and forfeited pursuant to the Rights Exchange Agreement from the $40.0&#160;million in development milestone payments that are due upon the passing of the second anniversary of the closing of the Merger), up to an aggregate maximum amount of $361.0&#160;million upon the achievement of certain regulatory milestones (representing the remaining portion of potential regulatory milestone payments for which rights were not canceled and forfeited pursuant to the Rights Exchange Agreement), up to a maximum aggregate amount of $150.0&#160;million upon the achievement of certain net sales milestones and a percentage of annual net sales for Friedreich ataxia and Angelman syndrome during specified terms, ranging from 2% to 6%, pursuant to the terms of the Merger Agreement. Refer to Note 5 for further details regarding the Rights Exchange Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;On May 29, 2020, the Company completed its acquisition of Censa Pharmaceuticals, Inc., (&#x201c;Censa&#x201d;) pursuant to an Agreement and Plan of Merger, dated as of May 5, 2020, (the "Censa Merger Agreement"), by and among the Company, Hydro Merger Sub, Inc., the Company's wholly owned, indirect subsidiary, and, solely in its capacity as the representative, agent and attorney-in-fact of the securityholders of Censa, Shareholder Representative Services LLC (the "Censa Merger"). The transaction was accounted for as an asset acquisition.  In connection with the Censa Merger, the Company acquired PTC923 (formerly known as CNSA-001), which is being pursued as a possible treatment for orphan metabolic diseases associated with defects in the tetrahydrobiopterin biochemical pathways, including phenylketonuria ("PKU").  Refer to Note 3 for further details.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June&#160;30, 2020, the Company had an accumulated deficit of approximately $1,484.8 million. The Company has financed its operations to date primarily through the private offerings in September 2019 of 1.50% convertible senior notes due 2026 and in August&#160;2015 of 3.00% convertible senior notes due 2022 (see Note 11), public offerings of common stock in February 2014, October 2014, April 2018, January 2019, and September 2019, "at the market offerings" of its common stock, its initial public offering of common stock in June 2013, private placements of its convertible preferred stock, collaborations, bank debt, the Company's credit and security agreement (the "Credit Agreement"), with MidCap Financial Trust, or MidCap Financial, as administrative agent and MidCap Financial and other certain institutions as lenders thereto (see Note 11), grant funding and clinical trial support from governmental and philanthropic organizations and patient advocacy groups in the disease area addressed by the Company&#x2019;s product candidates. Since 2014, the Company has also relied on revenue generated from net sales of Translarna for the treatment of nmDMD in territories outside of the United States, and since May 2017, the Company has generated revenue from net sales of Emflaza for the treatment of DMD in the United States. The Company expects&#160;that cash flows from the sales of its products, together with the Company's cash, cash equivalents and marketable securities, will be sufficient to fund its operations for at least the next twelve months.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="ib9eece550dff4e4780cef9d288202a33_D20180823-20180823"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80MC9mcmFnOmM3MjE3M2MxMmMzZTQwMDdiN2ZhM2JhN2I5MjdiMmMwL3RleHRyZWdpb246YzcyMTczYzEyYzNlNDAwN2I3ZmEzYmE3YjkyN2IyYzBfMTAxNTA_f346ff9d-4282-4a66-8d3d-03f7a6f42656"
      unitRef="usd">49200000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="ib9eece550dff4e4780cef9d288202a33_D20180823-20180823"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80MC9mcmFnOmM3MjE3M2MxMmMzZTQwMDdiN2ZhM2JhN2I5MjdiMmMwL3RleHRyZWdpb246YzcyMTczYzEyYzNlNDAwN2I3ZmEzYmE3YjkyN2IyYzBfMTAxNjU_026d96cf-c21f-412a-9034-74e93df86fe8"
      unitRef="shares">3500907</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <ptct:BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity
      contextRef="i0e759cb2d2394853b69b11290ac5d21a_I20180823"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80MC9mcmFnOmM3MjE3M2MxMmMzZTQwMDdiN2ZhM2JhN2I5MjdiMmMwL3RleHRyZWdpb246YzcyMTczYzEyYzNlNDAwN2I3ZmEzYmE3YjkyN2IyYzBfMTAzMDE_475430ee-2065-4b43-9c13-4a6e51d1872b"
      unitRef="usd">150000000.0</ptct:BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity>
    <ptct:BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod
      contextRef="ib9eece550dff4e4780cef9d288202a33_D20180823-20180823"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80MC9mcmFnOmM3MjE3M2MxMmMzZTQwMDdiN2ZhM2JhN2I5MjdiMmMwL3RleHRyZWdpb246YzcyMTczYzEyYzNlNDAwN2I3ZmEzYmE3YjkyN2IyYzBfMTA0MjQ_6c2423a3-519d-41de-b5e5-0e9dde77c0f4">P10D</ptct:BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod>
    <ptct:SharestoissueunderRightsExchangeAgreement
      contextRef="if89af7698cdf43d1915f30dc403dc6af_I20200429"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80MC9mcmFnOmM3MjE3M2MxMmMzZTQwMDdiN2ZhM2JhN2I5MjdiMmMwL3RleHRyZWdpb246YzcyMTczYzEyYzNlNDAwN2I3ZmEzYmE3YjkyN2IyYzBfNDM5ODA0NjU1OTAwNw_fb75e6f5-7b3f-432c-a757-e7dea335d4c4"
      unitRef="shares">2821176</ptct:SharestoissueunderRightsExchangeAgreement>
    <ptct:CashconsiderationpaymentunderRightsExchangeAgreement
      contextRef="i921570c76d4f4e23870b19798c531218_D20200429-20200429"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80MC9mcmFnOmM3MjE3M2MxMmMzZTQwMDdiN2ZhM2JhN2I5MjdiMmMwL3RleHRyZWdpb246YzcyMTczYzEyYzNlNDAwN2I3ZmEzYmE3YjkyN2IyYzBfNDM5ODA0NjU1OTAxOA_463d6e4b-2074-4a36-be10-25019471ee77"
      unitRef="usd">36900000</ptct:CashconsiderationpaymentunderRightsExchangeAgreement>
    <ptct:ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount
      contextRef="i44fac1cb95fa4331b63d8afeb4d83f20_D20200429-20200429"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80MC9mcmFnOmM3MjE3M2MxMmMzZTQwMDdiN2ZhM2JhN2I5MjdiMmMwL3RleHRyZWdpb246YzcyMTczYzEyYzNlNDAwN2I3ZmEzYmE3YjkyN2IyYzBfNDM5ODA0NjU1OTA2Nw_e6b01f53-07b8-4beb-b2b7-e47f7dc175c9"
      unitRef="usd">174000000.0</ptct:ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount>
    <ptct:DevelopmentMilestonePaymentObligationsCancellationAndForfeiture
      contextRef="i44fac1cb95fa4331b63d8afeb4d83f20_D20200429-20200429"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80MC9mcmFnOmM3MjE3M2MxMmMzZTQwMDdiN2ZhM2JhN2I5MjdiMmMwL3RleHRyZWdpb246YzcyMTczYzEyYzNlNDAwN2I3ZmEzYmE3YjkyN2IyYzBfNDM5ODA0NjU1OTA1Mg_0333cead-06f4-4459-8ed5-840497178955"
      unitRef="usd">37600000</ptct:DevelopmentMilestonePaymentObligationsCancellationAndForfeiture>
    <ptct:DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing
      contextRef="id61e01344c6b402983658d905475cc0f_I20200429"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80MC9mcmFnOmM3MjE3M2MxMmMzZTQwMDdiN2ZhM2JhN2I5MjdiMmMwL3RleHRyZWdpb246YzcyMTczYzEyYzNlNDAwN2I3ZmEzYmE3YjkyN2IyYzBfNDM5ODA0NjU1OTA4Mw_f91f9e6e-f36f-48da-9db5-afa2253a0aa0"
      unitRef="usd">40000000.0</ptct:DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing>
    <ptct:ContingentLiabilityCancellationAndForfeiture
      contextRef="i44fac1cb95fa4331b63d8afeb4d83f20_D20200429-20200429"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80MC9mcmFnOmM3MjE3M2MxMmMzZTQwMDdiN2ZhM2JhN2I5MjdiMmMwL3RleHRyZWdpb246YzcyMTczYzEyYzNlNDAwN2I3ZmEzYmE3YjkyN2IyYzBfNDM5ODA0NjU1OTA5OA_2dfc6811-289b-4b49-9b8f-d199790e6814"
      unitRef="usd">211600000</ptct:ContingentLiabilityCancellationAndForfeiture>
    <ptct:DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture
      contextRef="i44fac1cb95fa4331b63d8afeb4d83f20_D20200429-20200429"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80MC9mcmFnOmM3MjE3M2MxMmMzZTQwMDdiN2ZhM2JhN2I5MjdiMmMwL3RleHRyZWdpb246YzcyMTczYzEyYzNlNDAwN2I3ZmEzYmE3YjkyN2IyYzBfNDM5ODA0NjU1OTE0NA_da5cdf9c-64d8-4490-8d11-05980a4c425a"
      unitRef="usd">22400000</ptct:DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture>
    <ptct:DevelopmentMilestonePaymentObligationsCancellationAndForfeiture
      contextRef="i44fac1cb95fa4331b63d8afeb4d83f20_D20200429-20200429"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80MC9mcmFnOmM3MjE3M2MxMmMzZTQwMDdiN2ZhM2JhN2I5MjdiMmMwL3RleHRyZWdpb246YzcyMTczYzEyYzNlNDAwN2I3ZmEzYmE3YjkyN2IyYzBfNDM5ODA0NjU1OTExNA_166662bc-6888-42ca-98ba-3c2592a782e4"
      unitRef="usd">37600000</ptct:DevelopmentMilestonePaymentObligationsCancellationAndForfeiture>
    <ptct:DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing
      contextRef="id61e01344c6b402983658d905475cc0f_I20200429"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80MC9mcmFnOmM3MjE3M2MxMmMzZTQwMDdiN2ZhM2JhN2I5MjdiMmMwL3RleHRyZWdpb246YzcyMTczYzEyYzNlNDAwN2I3ZmEzYmE3YjkyN2IyYzBfNDM5ODA0NjU1OTEyOQ_32930531-5578-47c4-bd3a-0fe2e030d816"
      unitRef="usd">40000000.0</ptct:DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing>
    <ptct:ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture
      contextRef="i44fac1cb95fa4331b63d8afeb4d83f20_D20200429-20200429"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80MC9mcmFnOmM3MjE3M2MxMmMzZTQwMDdiN2ZhM2JhN2I5MjdiMmMwL3RleHRyZWdpb246YzcyMTczYzEyYzNlNDAwN2I3ZmEzYmE3YjkyN2IyYzBfNDM5ODA0NjU1OTE1OQ_29ea3b68-75d4-4d51-a833-832eb376355d"
      unitRef="usd">361000000.0</ptct:ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture>
    <ptct:ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone
      contextRef="id61e01344c6b402983658d905475cc0f_I20200429"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80MC9mcmFnOmM3MjE3M2MxMmMzZTQwMDdiN2ZhM2JhN2I5MjdiMmMwL3RleHRyZWdpb246YzcyMTczYzEyYzNlNDAwN2I3ZmEzYmE3YjkyN2IyYzBfNDM5ODA0NjU1OTE3NQ_88d1af95-b6b3-46ac-b510-277abe6c74bb"
      unitRef="usd">150000000.0</ptct:ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone>
    <ptct:ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage
      contextRef="i56959b5fb9c34914b2d086de6704c201_I20200429"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80MC9mcmFnOmM3MjE3M2MxMmMzZTQwMDdiN2ZhM2JhN2I5MjdiMmMwL3RleHRyZWdpb246YzcyMTczYzEyYzNlNDAwN2I3ZmEzYmE3YjkyN2IyYzBfNDM5ODA0NjU1OTE5MQ_d6dedafa-cc67-4747-9dc5-dd3e3b2d7fe4"
      unitRef="number">0.02</ptct:ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage>
    <ptct:ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage
      contextRef="i56a3188c726c4476a6115fcc0dc1091f_I20200429"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80MC9mcmFnOmM3MjE3M2MxMmMzZTQwMDdiN2ZhM2JhN2I5MjdiMmMwL3RleHRyZWdpb246YzcyMTczYzEyYzNlNDAwN2I3ZmEzYmE3YjkyN2IyYzBfNDM5ODA0NjU1OTE5NQ_1434504f-58b8-498b-bb9b-009c8fe6fae9"
      unitRef="number">0.06</ptct:ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80MC9mcmFnOmM3MjE3M2MxMmMzZTQwMDdiN2ZhM2JhN2I5MjdiMmMwL3RleHRyZWdpb246YzcyMTczYzEyYzNlNDAwN2I3ZmEzYmE3YjkyN2IyYzBfMTIwNTk_b1bc5f25-dd18-423f-9652-3bb3a1ce453f"
      unitRef="usd">-1484800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2869c1675c5a404e9bb85cad2eb71998_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80MC9mcmFnOmM3MjE3M2MxMmMzZTQwMDdiN2ZhM2JhN2I5MjdiMmMwL3RleHRyZWdpb246YzcyMTczYzEyYzNlNDAwN2I3ZmEzYmE3YjkyN2IyYzBfMTIxNzI_1067a0d9-d5bd-44bf-8e46-16bffcec3a39"
      unitRef="number">0.0150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i28655a9b21d647eb9144da8fa8cdd911_I20150831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80MC9mcmFnOmM3MjE3M2MxMmMzZTQwMDdiN2ZhM2JhN2I5MjdiMmMwL3RleHRyZWdpb246YzcyMTczYzEyYzNlNDAwN2I3ZmEzYmE3YjkyN2IyYzBfMTIyMzE_7c96ac7c-d3ea-44ca-9cb6-11f395c7529f"
      unitRef="number">0.0300</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMjkwNDE_9a1d0591-e5e1-400a-aba1-5adbb597f499">Summary of significant accounting policies&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s complete listing of significant accounting policies is set forth in Note 2 of the notes to the Company&#x2019;s audited financial statements as of December&#160;31, 2019 included in the Company&#x2019;s Annual Report on Form&#160;10-K filed with the Securities and Exchange Commission (the "SEC") on March 2, 2020 (the "2019 Form&#160;10-K"). Additional significant accounting policies adopted during the six month period ended June&#160;30, 2020 are discussed in further detail below.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Basis of presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying financial information as of June&#160;30, 2020 and for the three and six months ended June&#160;30, 2020 and 2019 has been prepared by the Company, without audit, pursuant to the rules&#160;and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States ("GAAP") have been condensed or omitted pursuant to such rules&#160;and regulations. These interim financial statements should be read in conjunction with the Company&#x2019;s audited financial statements as of December&#160;31, 2019 and notes thereto included in the 2019 Form&#160;10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In the opinion of management, the unaudited financial information as of June&#160;30, 2020 and for the three and six months ended June&#160;30, 2020 and 2019 reflects all adjustments, which are normal recurring adjustments, necessary to present a fair statement &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;of financial position, results of operations, stockholders' equity, and cash flows. The results of operations for the three and six month period ended June&#160;30, 2020 are not necessarily indicative of the results to be expected for the year ended December&#160;31, 2020 or for any other interim period or for any other future year.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates in these consolidated financial statements have been made in connection with the calculation of net product sales, certain accruals related to the Company&#x2019;s research and development expenses, valuation procedures for convertible notes, fair value of the contingent consideration, and the provision for or benefit from income taxes. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Restricted cash&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Restricted cash included in deposits and other assets on the consolidated balance sheet relates to an unconditional, irrevocable and transferable letter of credit that was entered into during the twelve-month period ended December 31, 2019 in connection with obligations under a facility lease for our leased biologics manufacturing facility in Hopewell Township, New Jersey. The amount of the letter of credit is $7.5 million, is to be maintained for a term of not less than five years and has the potential to be reduced to $3.8 million if after five years the Company is not in default of its lease. The amount is classified within deposits and other assets on the consolidated balance sheet due to the long-term nature of the letter of credit.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheet that sum to the total of the same amounts shown in the statement of cash flows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.421%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.395%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.582%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.519%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.582%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.522%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Beginning of period- December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;End of period- June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;288,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;158,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted cash included in deposits and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total Cash, cash equivalents and restricted cash per statement of cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;295,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;165,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Marketable securities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company considers securities with original maturities of greater than 90&#160;days to be available for sale securities. Securities under this classification are recorded at fair value and unrealized gains and losses within accumulated other comprehensive income. The estimated fair value of the available for sale securities is determined based on quoted market prices or rates for similar instruments. In addition, the cost of debt securities in this category is adjusted for amortization of premium and accretion of discount to maturity. For available for sale debt securities in an unrealized loss position, the Company assesses whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security's amortized cost basis is written down to fair value. If the criteria are not met, the Company evaluates whether the decline in fair value has resulted from a credit loss or other factors. In making this assessment, management considers, among other factors, the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security are compared to the amortized cost basis of the security. If the present value of the cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss, limited by the amount that the fair value is less than the amortized costs basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income. For the three month and six month periods ended June&#160;30, 2020, no allowance was recorded for credit losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Inventory and cost of product sales&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Inventories are stated at the lower of cost and net realizable value with cost determined on a first-in, first-out basis by product. The Company capitalizes inventory costs associated with products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. Products which may be used in clinical development programs are included in inventory and charged to research and development expense when the product enters the research and development process and no longer can be used for commercial purposes. Inventory used for &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;marketing efforts are charged to selling, general and administrative expense. Amounts related to clinical development programs and marketing efforts are immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the components of the Company&#x2019;s inventory for the periods indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.099%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.672%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.769%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Work in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company periodically reviews its inventories for excess amounts or obsolescence and writes down obsolete or otherwise unmarketable inventory to its estimated net realizable value. For the three months ended June 30, 2020, inventory write downs were immaterial. For the six months ended June 30, 2020, the Company recorded a $0.2 million inventory write-down, primarily related to product approaching expiration.  No write downs were recorded for the three and six month periods ended June&#160;30, 2019. Additionally, though the Company&#x2019;s product is subject to strict quality control and monitoring which it performs throughout the manufacturing processes, certain batches or units of product may not meet quality specifications resulting in a charge to cost of product sales. For the three and six month periods ended June&#160;30, 2020 and 2019, these amounts were immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Cost of product sales&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cost of product sales consists of the cost of inventory sold, manufacturing and supply chain costs, storage costs, amortization of the acquired intangible asset and royalty payments associated with net product sales.  Production costs are expensed as cost of product sales when the related products are sold.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Revenue recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Net product revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company's net product revenue primarily consists of sales of Translarna in territories outside of the U.S. for the treatment of nmDMD and sales of Emflaza in the U.S. for the treatment of DMD.  The Company recognizes revenue when its performance obligations with its customers have been satisfied.  The Company&#x2019;s performance obligations are to provide products based on customer orders from distributors, hospitals, specialty pharmacies or retail pharmacies.  The performance obligations are satisfied at a point in time when the Company&#x2019;s customer obtains control of the product, which is typically upon delivery. The Company invoices its customers after the products have been delivered and invoice payments are generally due within 30 to 90 days of the invoice date.  The Company determines the transaction price based on fixed consideration in its contractual agreements. Contract liabilities arise in certain circumstances when consideration is due for goods the Company has yet to provide. As the Company has identified only one distinct performance obligation, the transaction price is allocated entirely to product sales. In determining the transaction price, a significant financing component does not exist since the timing from when the Company delivers product to when the customers pay for the product is typically less than one year. Customers in certain countries pay in advance of product delivery. In those instances, payment and delivery typically occur in the same month. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company records product sales net of any variable consideration, which includes discounts, allowances, rebates related to Medicaid and other government pricing programs, and distribution fees. The Company uses the expected value or most likely amount method when estimating its variable consideration, unless discount or rebate terms are specified within contracts. The identified variable consideration is recorded as a reduction of revenue at the time revenues from product sales are recognized. These estimates for variable consideration are adjusted to reflect known changes in factors and may impact such estimates in the quarter those changes are known. Revenue recognized does not include amounts of variable consideration that are constrained.  For the three months ended June 30, 2020 and 2019, net product sales outside of the United States were $39.0 million and $57.8 million, respectively, and net product sales in the United States were $36.2 million and $27.6 million, respectively. For the six months ended June 30, 2020 and 2019, net product sales outside of the United States were $79.8 million and $93.0 million, respectively, and net product sales in the United States were $63.6 million and $45.4 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In relation to customer contracts, the Company incurs costs to fulfill a contract but does not incur costs to obtain a contract.  These costs to fulfill a contract do not meet the criteria for capitalization and are expensed as incurred. The Company considers any shipping and handling costs that are incurred after the customer has obtained control of the product as a cost to fulfill a promise. Shipping and handling costs associated with finished goods delivered to customers are recorded as a selling expense.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Collaboration revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The terms of these agreements typically include payments to the Company of one or more of the following: nonrefundable, upfront license fees; milestone payments; research funding and royalties on future product sales. In addition, the Company generates service revenue through agreements that generally provide for fees for research and development services and may include additional payments upon achievement of specified events.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;At the inception of a collaboration arrangement, the Company needs to first evaluate if the arrangement meets the criteria in ASC Topic 808 &#x201c;Collaborative Arrangements&#x201d; to then determine if ASC Topic 606 is applicable by considering whether the collaborator meets the definition of a customer.  If the criteria are met, the Company assesses the promises in the arrangement to identify distinct performance obligations.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For licenses of intellectual property, the Company assesses, at contract inception, whether the intellectual property is distinct from other performance obligations identified in the arrangement.  If the licensing of intellectual property is determined to be distinct, revenue is recognized for nonrefundable, upfront license fees when the license is transferred to the customer and the customer can use and benefit from the license.  If the licensing of intellectual property is determined not to be distinct, then the license will be bundled with other promises in the arrangement into one distinct performance obligation.  The Company needs to determine if the bundled performance obligation is satisfied over time or at a point in time.  If the Company concludes that the nonrefundable, upfront license fees will be recognized over time, the Company will need to assess the appropriate method of measuring proportional performance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For milestone payments, the Company assesses, at contract inception, whether the development or sales-based milestones are considered probable of being achieved.  If it is probable that a significant revenue reversal will occur, the Company will not record revenue until the uncertainty has been resolved.  Milestone payments that are contingent upon regulatory approval are not considered probable of being achieved until the applicable regulatory approvals or other external conditions are obtained as such conditions are not within the Company's control.  If it is probable that a significant revenue reversal will not occur, the Company will estimate the milestone payments using the most likely amount method.  The Company will re-assess the development and sales-based milestones each reporting period to determine the probability of achievement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company recognizes revenue for reimbursements of research and development costs under collaboration agreements as the services are performed. The Company records these reimbursements as revenue and not as a reduction of research and development expenses as the Company has the risks and rewards as the principal in the research and development activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Allowance for doubtful accounts&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company maintains an allowance for estimated losses resulting from the inability of its customers to make required payments. The Company estimates uncollectible amounts based upon current customer receivable balances, the age of customer receivable balances, the customer&#x2019;s financial condition and current economic trends. The allowance for doubtful accounts was $0.2 million as of June&#160;30, 2020 and $0.3 million as of December&#160;31, 2019. Bad debt expense was immaterial for the three and six month periods ended June&#160;30, 2020 and 2019. For the three and six month periods ended June&#160;30, 2020, no allowances were recorded for credit losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Indefinite-lived intangible assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Indefinite-lived intangible assets consist of in process research and development ("IPR&amp;amp;D").  IPR&amp;amp;D acquired directly in a transaction other than a business combination is capitalized if the projects will be further developed or have an alternative future use; otherwise they are expensed. The fair values of IPR&amp;amp;D projects and license agreement assets acquired in business combinations are capitalized. Several methods may be used to determine the estimated fair value of the IPR&amp;amp;D and license agreement asset acquired in a business combination. The Company utilizes the "income method&#x201d; and uses estimated future net cash flows that are derived from projected sales revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, and expected pricing and industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. Intangible assets with indefinite lives, including IPR&amp;amp;D, are tested for impairment if impairment indicators arise and, at a minimum, annually. However, an entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that an indefinite-lived intangible asset&#x2019;s fair value is less than its carrying amount. Otherwise, no further impairment testing is required. The indefinite-lived intangible asset impairment test consists of a one-step analysis that compares the fair value of the intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company considers many factors in evaluating whether the value of its intangible assets with indefinite lives may not be recoverable, including, but not &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;limited to, expected growth rates, the cost of equity and debt capital, general economic conditions, the Company's outlook and market performance of the Company's industry and recent and forecasted financial performance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Goodwill represents the amount of consideration paid in excess of the fair value of net assets acquired as a result of the Company&#x2019;s business acquisitions accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing at a reporting unit level on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. The Company reassess its reporting units as part of its annual segment review. An entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"&gt;O&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;n March 27, 2020, the United States enacted the Coronavirus Aid, Relief, and Economic Security Act, referred to herein as the CARES Act, as a response to the economic uncertainty resulting from a strain of novel coronavirus, COVID-19. The CARES Act includes modifications for net operating loss carryovers and carrybacks, limitations of business interest expense for tax, immediate refund of alternative minimum tax (AMT) credit carryovers as well as a technical correction to the 2017 Tax Cuts and Jobs Act ("the 2017 Tax Act"), referred to herein as the U.S. Tax Act, for qualified improvement property. As of June 30, 2020, the Company expects that these provisions will not have a material impact. Tax provisions of the Act also include the deferral of certain payroll taxes, relief for retaining employees, and other provisions. The Company is evaluating the impact of the Act and currently expects to benefit from the deferral of certain payroll taxes and retention credit through the end of calendar year 2020. The ultimate impact of the CARES Act may differ from this estimate due to changes in interpretations and guidance that may be issued and actions the Company may take in response to the CARES Act. The Company will continue to assess the impact that various provisions will have on its business.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On December 22, 2017, the U.S. government enacted the 2017 Tax Act, which significantly revises U.S. tax law by, among other provisions, lowering the U.S. federal statutory income tax rate to 21%, imposing a mandatory one-time transition tax on previously deferred foreign earnings, and eliminating or reducing certain income tax deductions. The Global Intangible Low-tax Income ("GILTI") provisions of the 2017 Tax Act require the Company to include in its U.S. income tax return foreign subsidiary earnings in excess of an allowable return on the foreign subsidiary&#x2019;s tangible assets. The Company has elected to account for GILTI tax in the period in which it is incurred, and therefore has not provided any deferred tax impacts of GILTI in its consolidated financial statements for the period ended&#160;June&#160;30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss and credit carryforwards. Deferred tax assets and liabilities are measured at rates expected to apply to taxable income in the years in which those temporary differences and carryforwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the statement of operations in the period that includes the enactment date. A valuation allowance is recorded when it is not more likely than not that all or a portion of the net deferred tax assets will be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company recorded a deferred tax liability in conjunction with the Merger of $122.0 million related to the tax basis difference in the IPR&amp;amp;D indefinite-lived intangibles acquired. The Company's policy is to record a deferred tax liability related to acquired IPR&amp;amp;D which may eventually be realized either upon amortization of the asset when the research is completed and a product is successfully launched or the write-off of the asset if it is abandoned or unsuccessful.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. The Company has lease agreements which include lease and non-lease components, which the Company accounts for as a single lease component for all leases. Operating and finance leases are classified as right of use ("ROU") assets, short term lease liabilities, and long term lease liabilities. Operating and finance lease ROU assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. ROU assets are amortized and lease liabilities accrete to yield straight-line expense over the term of the lease. Lease payments included in the measurement of the lease liability are comprised of fixed payments. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Variable lease payments associated with the Company&#x2019;s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented in the Company&#x2019;s consolidated statements of operations in the same line item as expense arising from fixed lease payments for operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet and the Company recognizes lease expense for these leases on a straight-line basis over the lease term.  The Company applies this policy to all underlying asset categories.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A lessee is required to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As most of the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The Company gives consideration to its recent debt issuances as well as publicly available data for instruments with similar characteristics when calculating its incremental borrowing rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The lease term for all of the Company&#x2019;s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. Leasehold improvements are capitalized and depreciated over the lesser of useful life or lease term. See Note 4 Leases for additional information. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Impact of recently adopted accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In December 2019, the FASB issued ASU 2019-12,"Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&#x201d;.  ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principals in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending the existing guidance. For public business entities, the guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. For all other entities, it is effective for annual periods beginning after December 15, 2021 and interim periods in annual periods beginning after December 15, 2022. Early adoption is permitted, including adoption in any interim period. The Company early adopted this guidance January 1, 2020. The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June&#160;2016, the FASB issued ASU No.&#160;2016-13, &#x201c;Financial Instruments &#x2014; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#x201d;. This standard requires financial assets measured at amortized cost basis to be presented at the net amount expected to be collected. This standard is effective for public companies who are SEC filers for fiscal years beginning after December&#160;15, 2019, including interim periods within those years. In November 2019, the FASB issued ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments - Credit Losses, which expands the scope of the practical expedient that allows entities to exclude the accrued interest component of amortized cost from various disclosures required by ASC 326 to also include certain disclosures required by ASC 320. Entities that elect to apply the practical expedient must disclose the total amount of accrued interest that they exclude from their disclosures of amortized cost. The amendments have the same effective dates as ASU 2016-13 (Topic 326) for entities that have not yet adopted that standard. The Company adopted ASU 2016-13 and ASU 2019-11 effective January 1, 2020. The adoption of the guidance did not have a material impact on the consolidated financial statements. The Company has updated its accounting policy for marketable securities within this footnote as well as its fair value footnote (Note 5) with additional disclosures as required by the standard upon adoption. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2018, the FASB issued ASU 2018-13, "Fair Value Measurement (Topic 820), Disclosure Framework&#x2014;Changes to the Disclosure Requirements for Fair Value Measurement". This standard eliminates certain disclosure requirements for fair value measurements for all entities, requires public entities to disclose certain new information and modifies some disclosure requirements. The new guidance is effective for all entities for fiscal years beginning after December 15, 2019 and for interim periods within those fiscal years. An entity is permitted to early adopt either the entire standard or only the provisions that eliminate or modify requirements. Entities can elect to early adopt in interim periods, including periods for which they have not yet issued financial statements or made their financial statements available for issuance. The Company adopted this guidance January 1, 2020.  The adoption of the guidance did not have a material impact on the consolidated financial statements. The Company has updated its fair value footnote (Note 5) with additional and modified disclosures as required by the standard upon adoption. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2018, the FASB issued ASU 2018-15,"Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer&#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract". ASU 2018-15 requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in Accounting Standards Codification 350-40 to determine which implementation costs to defer and recognize as an asset. For public business entities, the guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2019. For all other entities, it is effective for annual periods beginning after &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;December 15, 2020 and interim periods in annual periods beginning after December 15, 2021. Early adoption is permitted, including adoption in any interim period for all entities. The Company adopted this guidance January 1, 2020.  The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In November 2018, the FASB issued ASU 2018-18,"Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&#x201d;.  ASU 2018-18 provides guidance on whether certain transactions between collaborative arrangement participants should be accounted for with revenue under Topic 606. For public business entities, the guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2019. For all other entities, it is effective for annual periods beginning after December 15, 2020 and interim periods in annual periods beginning after December 15, 2021. Early adoption is permitted, including adoption in any interim period for all entities.  The Company adopted this guidance January 1, 2020.  The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMjkwODE_896826cc-6742-410f-834c-142ff750c711">&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Basis of presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying financial information as of June&#160;30, 2020 and for the three and six months ended June&#160;30, 2020 and 2019 has been prepared by the Company, without audit, pursuant to the rules&#160;and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States ("GAAP") have been condensed or omitted pursuant to such rules&#160;and regulations. These interim financial statements should be read in conjunction with the Company&#x2019;s audited financial statements as of December&#160;31, 2019 and notes thereto included in the 2019 Form&#160;10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In the opinion of management, the unaudited financial information as of June&#160;30, 2020 and for the three and six months ended June&#160;30, 2020 and 2019 reflects all adjustments, which are normal recurring adjustments, necessary to present a fair statement &lt;/span&gt;&lt;/div&gt;of financial position, results of operations, stockholders' equity, and cash flows. The results of operations for the three and six month period ended June&#160;30, 2020 are not necessarily indicative of the results to be expected for the year ended December&#160;31, 2020 or for any other interim period or for any other future year.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMjkwNTY_4c5121e6-0534-402f-b079-6a82935d6e7a">&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates in these consolidated financial statements have been made in connection with the calculation of net product sales, certain accruals related to the Company&#x2019;s research and development expenses, valuation procedures for convertible notes, fair value of the contingent consideration, and the provision for or benefit from income taxes. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMjc3Ng_658f14b3-b544-45f9-a5b6-b9c1280a88d9"
      unitRef="usd">7500000</us-gaap:LettersOfCreditOutstandingAmount>
    <ptct:Termforletterofcredit
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMjgyOA_b8d84fb8-6d6d-4142-95da-086659bf18a9">P5Y</ptct:Termforletterofcredit>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="ic07a476967de416b843f81c02e185244_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMjg3MA_41a70b82-c812-4cb4-aec6-a51520771c3f"
      unitRef="usd">3800000</us-gaap:LettersOfCreditOutstandingAmount>
    <ptct:Termforletterofcredit
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMjg4Mg_b8d84fb8-6d6d-4142-95da-086659bf18a9">P5Y</ptct:Termforletterofcredit>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMjkwMzc_0a314bab-c71c-46b3-bab7-248a4a1b3fc6">&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheet that sum to the total of the same amounts shown in the statement of cash flows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.421%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.395%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.582%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.519%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.582%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.522%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Beginning of period- December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;End of period- June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;288,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;158,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted cash included in deposits and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total Cash, cash equivalents and restricted cash per statement of cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;295,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;165,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RhYmxlOjE2MTA0YTc4MzBhNDQyODA5YmY5NTU5NmM5NzAyNGNiL3RhYmxlcmFuZ2U6MTYxMDRhNzgzMGE0NDI4MDliZjk1NTk2Yzk3MDI0Y2JfMS0yLTEtMS0w_7d3e0215-e687-4311-be7e-3a79f26da6e8"
      unitRef="usd">288028000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RhYmxlOjE2MTA0YTc4MzBhNDQyODA5YmY5NTU5NmM5NzAyNGNiL3RhYmxlcmFuZ2U6MTYxMDRhNzgzMGE0NDI4MDliZjk1NTk2Yzk3MDI0Y2JfMS00LTEtMS0w_1d1f2d08-5c8d-44b0-8ef7-c8722c7e02db"
      unitRef="usd">158461000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RhYmxlOjE2MTA0YTc4MzBhNDQyODA5YmY5NTU5NmM5NzAyNGNiL3RhYmxlcmFuZ2U6MTYxMDRhNzgzMGE0NDI4MDliZjk1NTk2Yzk3MDI0Y2JfMi0yLTEtMS0w_6dfa1943-2adf-43f3-aaf4-437ec54a27d0"
      unitRef="usd">7500000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RhYmxlOjE2MTA0YTc4MzBhNDQyODA5YmY5NTU5NmM5NzAyNGNiL3RhYmxlcmFuZ2U6MTYxMDRhNzgzMGE0NDI4MDliZjk1NTk2Yzk3MDI0Y2JfMi00LTEtMS0w_540215d7-ace4-4817-94ce-88377d21340d"
      unitRef="usd">7500000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RhYmxlOjE2MTA0YTc4MzBhNDQyODA5YmY5NTU5NmM5NzAyNGNiL3RhYmxlcmFuZ2U6MTYxMDRhNzgzMGE0NDI4MDliZjk1NTk2Yzk3MDI0Y2JfMy0yLTEtMS0w_1521378e-b2a8-477c-8c9b-bc0c633c3f25"
      unitRef="usd">295528000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RhYmxlOjE2MTA0YTc4MzBhNDQyODA5YmY5NTU5NmM5NzAyNGNiL3RhYmxlcmFuZ2U6MTYxMDRhNzgzMGE0NDI4MDliZjk1NTk2Yzk3MDI0Y2JfMy00LTEtMS0w_1c353283-8f05-41d9-a696-26488fe0d388"
      unitRef="usd">165961000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMjkwNzU_b3e169ed-607b-45dd-aeeb-a4df57dbd117">Marketable securitiesThe Company considers securities with original maturities of greater than 90&#160;days to be available for sale securities. Securities under this classification are recorded at fair value and unrealized gains and losses within accumulated other comprehensive income. The estimated fair value of the available for sale securities is determined based on quoted market prices or rates for similar instruments. In addition, the cost of debt securities in this category is adjusted for amortization of premium and accretion of discount to maturity. For available for sale debt securities in an unrealized loss position, the Company assesses whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security's amortized cost basis is written down to fair value. If the criteria are not met, the Company evaluates whether the decline in fair value has resulted from a credit loss or other factors. In making this assessment, management considers, among other factors, the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security are compared to the amortized cost basis of the security. If the present value of the cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss, limited by the amount that the fair value is less than the amortized costs basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income.</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfNTI2NA_4adeeeed-643b-4e36-82ca-ba7aa0ec431c"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <ptct:InventoriesAndCostOfProductSalesPolicyTextBlock
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMjkwODY_033867fd-d15e-490a-8a56-ef31a91cdcc3">&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Inventory and cost of product sales&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Inventories are stated at the lower of cost and net realizable value with cost determined on a first-in, first-out basis by product. The Company capitalizes inventory costs associated with products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. Products which may be used in clinical development programs are included in inventory and charged to research and development expense when the product enters the research and development process and no longer can be used for commercial purposes. Inventory used for &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;marketing efforts are charged to selling, general and administrative expense. Amounts related to clinical development programs and marketing efforts are immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the components of the Company&#x2019;s inventory for the periods indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.099%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.672%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.769%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Work in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company periodically reviews its inventories for excess amounts or obsolescence and writes down obsolete or otherwise unmarketable inventory to its estimated net realizable value. For the three months ended June 30, 2020, inventory write downs were immaterial. For the six months ended June 30, 2020, the Company recorded a $0.2 million inventory write-down, primarily related to product approaching expiration.  No write downs were recorded for the three and six month periods ended June&#160;30, 2019. Additionally, though the Company&#x2019;s product is subject to strict quality control and monitoring which it performs throughout the manufacturing processes, certain batches or units of product may not meet quality specifications resulting in a charge to cost of product sales. For the three and six month periods ended June&#160;30, 2020 and 2019, these amounts were immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Cost of product sales&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cost of product sales consists of the cost of inventory sold, manufacturing and supply chain costs, storage costs, amortization of the acquired intangible asset and royalty payments associated with net product sales.  Production costs are expensed as cost of product sales when the related products are sold.&lt;/span&gt;&lt;/div&gt;</ptct:InventoriesAndCostOfProductSalesPolicyTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMjkwNzY_9742177a-7fd7-40bf-9301-2fbb248316ad">&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the components of the Company&#x2019;s inventory for the periods indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.099%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.672%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.769%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Work in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RhYmxlOjMwMjY3N2M4NGE1MzRjYTRhNTY2OWEzMmRhODA1ZTM5L3RhYmxlcmFuZ2U6MzAyNjc3Yzg0YTUzNGNhNGE1NjY5YTMyZGE4MDVlMzlfMS0yLTEtMS0w_2484ae53-8d6b-462c-b34c-8956b17cadb7"
      unitRef="usd">877000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RhYmxlOjMwMjY3N2M4NGE1MzRjYTRhNTY2OWEzMmRhODA1ZTM5L3RhYmxlcmFuZ2U6MzAyNjc3Yzg0YTUzNGNhNGE1NjY5YTMyZGE4MDVlMzlfMS00LTEtMS0w_8bd07d88-23f3-44b6-9448-39e0a19fe085"
      unitRef="usd">874000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RhYmxlOjMwMjY3N2M4NGE1MzRjYTRhNTY2OWEzMmRhODA1ZTM5L3RhYmxlcmFuZ2U6MzAyNjc3Yzg0YTUzNGNhNGE1NjY5YTMyZGE4MDVlMzlfMi0yLTEtMS0w_be0ad90d-1d51-4534-a3dc-7240bec9c7f4"
      unitRef="usd">8666000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RhYmxlOjMwMjY3N2M4NGE1MzRjYTRhNTY2OWEzMmRhODA1ZTM5L3RhYmxlcmFuZ2U6MzAyNjc3Yzg0YTUzNGNhNGE1NjY5YTMyZGE4MDVlMzlfMi00LTEtMS0w_dc5256d0-7fa7-4928-a79a-bf29346920b5"
      unitRef="usd">9652000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RhYmxlOjMwMjY3N2M4NGE1MzRjYTRhNTY2OWEzMmRhODA1ZTM5L3RhYmxlcmFuZ2U6MzAyNjc3Yzg0YTUzNGNhNGE1NjY5YTMyZGE4MDVlMzlfMy0yLTEtMS0w_871896be-49f7-4fb5-a6b0-69d16eb0565c"
      unitRef="usd">8830000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RhYmxlOjMwMjY3N2M4NGE1MzRjYTRhNTY2OWEzMmRhODA1ZTM5L3RhYmxlcmFuZ2U6MzAyNjc3Yzg0YTUzNGNhNGE1NjY5YTMyZGE4MDVlMzlfMy00LTEtMS0w_c9303268-0848-4f63-8c4b-bbd22eca7977"
      unitRef="usd">8759000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RhYmxlOjMwMjY3N2M4NGE1MzRjYTRhNTY2OWEzMmRhODA1ZTM5L3RhYmxlcmFuZ2U6MzAyNjc3Yzg0YTUzNGNhNGE1NjY5YTMyZGE4MDVlMzlfNC0yLTEtMS0w_ad52c739-d9f9-4a11-992f-e21a4b4eadc6"
      unitRef="usd">18373000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RhYmxlOjMwMjY3N2M4NGE1MzRjYTRhNTY2OWEzMmRhODA1ZTM5L3RhYmxlcmFuZ2U6MzAyNjc3Yzg0YTUzNGNhNGE1NjY5YTMyZGE4MDVlMzlfNC00LTEtMS0w_fc177104-3f16-438e-9f35-2b1c60786019"
      unitRef="usd">19285000</us-gaap:InventoryNet>
    <us-gaap:InventoryWriteDown
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfNjQ2OQ_58ccd245-2187-41f7-8a5e-ce65228b21c5"
      unitRef="usd">200000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfNjU0OA_7c577c8c-3e29-430e-be41-48343c79c82b"
      unitRef="usd">0</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfNjU0OA_80fc5353-e921-4440-9f1b-3fd216280237"
      unitRef="usd">0</us-gaap:InventoryWriteDown>
    <ptct:NetProductSales
      contextRef="ib5e09658503d4a019b7c66616efd1b4d_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfOTY1Mg_472e88fb-4d6e-4d7b-b5bf-d1b32d6d0959"
      unitRef="usd">39000000.0</ptct:NetProductSales>
    <ptct:NetProductSales
      contextRef="i70f85cc7508547529a1ddd69bf58968d_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfOTY2MA_866acd3e-e209-4752-b956-71dcafbaf816"
      unitRef="usd">57800000</ptct:NetProductSales>
    <ptct:NetProductSales
      contextRef="i9fcd6ae0b0b244eb992a22b9f010a8a9_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfOTcyNQ_af08c740-5c75-4849-b710-027bbf9ae6aa"
      unitRef="usd">36200000</ptct:NetProductSales>
    <ptct:NetProductSales
      contextRef="i0cac55e0c942455e8be47df4a5540bf5_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfOTczMg_95510f06-07a4-4c13-a7c2-0f567fc3ba17"
      unitRef="usd">27600000</ptct:NetProductSales>
    <ptct:NetProductSales
      contextRef="i8b2299918005400d83e8169cdceaa098_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMTA0NDUzNjA0OTMyNjE_bbf8eb57-17c9-4b0a-b53e-0d65aa69baa0"
      unitRef="usd">79800000</ptct:NetProductSales>
    <ptct:NetProductSales
      contextRef="if04847b5828f40ffb96ff09abbfbe7f0_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMTA0NDUzNjA0OTMyODk_1dd9044a-026b-4879-b477-be23aa250530"
      unitRef="usd">93000000.0</ptct:NetProductSales>
    <ptct:NetProductSales
      contextRef="i245f190c344b472682efecbcf65a617f_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMTA0NDUzNjA0OTMzODA_9effde0e-f268-4720-8a85-eb6c2c0b3be9"
      unitRef="usd">63600000</ptct:NetProductSales>
    <ptct:NetProductSales
      contextRef="i084808ce47024c3e9355cdfb5214b4ee_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMTA0NDUzNjA0OTM0MDg_dfd4e89f-6713-4367-8eb4-9874f72feeb5"
      unitRef="usd">45400000</ptct:NetProductSales>
    <us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMjkwNTU_1f5d4488-0d59-44b5-876e-bda73fe80b84">Allowance for doubtful accountsThe Company maintains an allowance for estimated losses resulting from the inability of its customers to make required payments. The Company estimates uncollectible amounts based upon current customer receivable balances, the age of customer receivable balances, the customer&#x2019;s financial condition and current economic trends.</us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMTM2ODg_658bd215-0df9-4581-b56b-5ce4af704251"
      unitRef="usd">200000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMTM3MDQ_4a50c10d-9203-4a86-b9af-de4ccd60cece"
      unitRef="usd">300000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMTM4Mjg_8d4daedc-1e2c-4208-a81a-24349c35c271"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease>
    <us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMTM4Mjg_d9b8c139-e6bc-4734-8fa3-77c65c03de01"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMjkwNjk_f6d92ecd-c7c0-4953-80af-0bb7aaf19941">&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Indefinite-lived intangible assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Indefinite-lived intangible assets consist of in process research and development ("IPR&amp;amp;D").  IPR&amp;amp;D acquired directly in a transaction other than a business combination is capitalized if the projects will be further developed or have an alternative future use; otherwise they are expensed. The fair values of IPR&amp;amp;D projects and license agreement assets acquired in business combinations are capitalized. Several methods may be used to determine the estimated fair value of the IPR&amp;amp;D and license agreement asset acquired in a business combination. The Company utilizes the "income method&#x201d; and uses estimated future net cash flows that are derived from projected sales revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, and expected pricing and industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. Intangible assets with indefinite lives, including IPR&amp;amp;D, are tested for impairment if impairment indicators arise and, at a minimum, annually. However, an entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that an indefinite-lived intangible asset&#x2019;s fair value is less than its carrying amount. Otherwise, no further impairment testing is required. The indefinite-lived intangible asset impairment test consists of a one-step analysis that compares the fair value of the intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company considers many factors in evaluating whether the value of its intangible assets with indefinite lives may not be recoverable, including, but not &lt;/span&gt;&lt;/div&gt;limited to, expected growth rates, the cost of equity and debt capital, general economic conditions, the Company's outlook and market performance of the Company's industry and recent and forecasted financial performance.</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMjkwNDM_500ba435-314d-4208-b28f-eaf233951559">&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Goodwill represents the amount of consideration paid in excess of the fair value of net assets acquired as a result of the Company&#x2019;s business acquisitions accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing at a reporting unit level on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. The Company reassess its reporting units as part of its annual segment review. An entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMjkwODQ_f3186c19-13b2-4ded-946c-7dbd3e7e938a">&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"&gt;O&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;n March 27, 2020, the United States enacted the Coronavirus Aid, Relief, and Economic Security Act, referred to herein as the CARES Act, as a response to the economic uncertainty resulting from a strain of novel coronavirus, COVID-19. The CARES Act includes modifications for net operating loss carryovers and carrybacks, limitations of business interest expense for tax, immediate refund of alternative minimum tax (AMT) credit carryovers as well as a technical correction to the 2017 Tax Cuts and Jobs Act ("the 2017 Tax Act"), referred to herein as the U.S. Tax Act, for qualified improvement property. As of June 30, 2020, the Company expects that these provisions will not have a material impact. Tax provisions of the Act also include the deferral of certain payroll taxes, relief for retaining employees, and other provisions. The Company is evaluating the impact of the Act and currently expects to benefit from the deferral of certain payroll taxes and retention credit through the end of calendar year 2020. The ultimate impact of the CARES Act may differ from this estimate due to changes in interpretations and guidance that may be issued and actions the Company may take in response to the CARES Act. The Company will continue to assess the impact that various provisions will have on its business.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On December 22, 2017, the U.S. government enacted the 2017 Tax Act, which significantly revises U.S. tax law by, among other provisions, lowering the U.S. federal statutory income tax rate to 21%, imposing a mandatory one-time transition tax on previously deferred foreign earnings, and eliminating or reducing certain income tax deductions. The Global Intangible Low-tax Income ("GILTI") provisions of the 2017 Tax Act require the Company to include in its U.S. income tax return foreign subsidiary earnings in excess of an allowable return on the foreign subsidiary&#x2019;s tangible assets. The Company has elected to account for GILTI tax in the period in which it is incurred, and therefore has not provided any deferred tax impacts of GILTI in its consolidated financial statements for the period ended&#160;June&#160;30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss and credit carryforwards. Deferred tax assets and liabilities are measured at rates expected to apply to taxable income in the years in which those temporary differences and carryforwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the statement of operations in the period that includes the enactment date. A valuation allowance is recorded when it is not more likely than not that all or a portion of the net deferred tax assets will be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company recorded a deferred tax liability in conjunction with the Merger of $122.0 million related to the tax basis difference in the IPR&amp;amp;D indefinite-lived intangibles acquired. The Company's policy is to record a deferred tax liability related to acquired IPR&amp;amp;D which may eventually be realized either upon amortization of the asset when the research is completed and a product is successfully launched or the write-off of the asset if it is abandoned or unsuccessful.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:DeferredTaxLiabilities
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMjAxMjc_6b562acd-cf2f-483a-9ac7-0fb0cc01183e"
      unitRef="usd">122000000.0</us-gaap:DeferredTaxLiabilities>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMjkwNDU_3b51ffb8-0517-4160-8c6f-66916517b678">&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. The Company has lease agreements which include lease and non-lease components, which the Company accounts for as a single lease component for all leases. Operating and finance leases are classified as right of use ("ROU") assets, short term lease liabilities, and long term lease liabilities. Operating and finance lease ROU assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. ROU assets are amortized and lease liabilities accrete to yield straight-line expense over the term of the lease. Lease payments included in the measurement of the lease liability are comprised of fixed payments. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Variable lease payments associated with the Company&#x2019;s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented in the Company&#x2019;s consolidated statements of operations in the same line item as expense arising from fixed lease payments for operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet and the Company recognizes lease expense for these leases on a straight-line basis over the lease term.  The Company applies this policy to all underlying asset categories.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A lessee is required to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As most of the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The Company gives consideration to its recent debt issuances as well as publicly available data for instruments with similar characteristics when calculating its incremental borrowing rates.&lt;/span&gt;&lt;/div&gt;The lease term for all of the Company&#x2019;s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. Leasehold improvements are capitalized and depreciated over the lesser of useful life or lease term. See Note 4 Leases for additional information.</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80My9mcmFnOjNmMjMwODI1MzlkMzQ2ZWZhNDMzZWMwMzliOGVjYWU0L3RleHRyZWdpb246M2YyMzA4MjUzOWQzNDZlZmE0MzNlYzAzOWI4ZWNhZTRfMjkwODg_dcf57bc9-1ef9-46fa-9fcf-cfbd1089fee0">&lt;div style="margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Impact of recently adopted accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In December 2019, the FASB issued ASU 2019-12,"Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&#x201d;.  ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principals in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending the existing guidance. For public business entities, the guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. For all other entities, it is effective for annual periods beginning after December 15, 2021 and interim periods in annual periods beginning after December 15, 2022. Early adoption is permitted, including adoption in any interim period. The Company early adopted this guidance January 1, 2020. The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June&#160;2016, the FASB issued ASU No.&#160;2016-13, &#x201c;Financial Instruments &#x2014; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#x201d;. This standard requires financial assets measured at amortized cost basis to be presented at the net amount expected to be collected. This standard is effective for public companies who are SEC filers for fiscal years beginning after December&#160;15, 2019, including interim periods within those years. In November 2019, the FASB issued ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments - Credit Losses, which expands the scope of the practical expedient that allows entities to exclude the accrued interest component of amortized cost from various disclosures required by ASC 326 to also include certain disclosures required by ASC 320. Entities that elect to apply the practical expedient must disclose the total amount of accrued interest that they exclude from their disclosures of amortized cost. The amendments have the same effective dates as ASU 2016-13 (Topic 326) for entities that have not yet adopted that standard. The Company adopted ASU 2016-13 and ASU 2019-11 effective January 1, 2020. The adoption of the guidance did not have a material impact on the consolidated financial statements. The Company has updated its accounting policy for marketable securities within this footnote as well as its fair value footnote (Note 5) with additional disclosures as required by the standard upon adoption. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2018, the FASB issued ASU 2018-13, "Fair Value Measurement (Topic 820), Disclosure Framework&#x2014;Changes to the Disclosure Requirements for Fair Value Measurement". This standard eliminates certain disclosure requirements for fair value measurements for all entities, requires public entities to disclose certain new information and modifies some disclosure requirements. The new guidance is effective for all entities for fiscal years beginning after December 15, 2019 and for interim periods within those fiscal years. An entity is permitted to early adopt either the entire standard or only the provisions that eliminate or modify requirements. Entities can elect to early adopt in interim periods, including periods for which they have not yet issued financial statements or made their financial statements available for issuance. The Company adopted this guidance January 1, 2020.  The adoption of the guidance did not have a material impact on the consolidated financial statements. The Company has updated its fair value footnote (Note 5) with additional and modified disclosures as required by the standard upon adoption. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2018, the FASB issued ASU 2018-15,"Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer&#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract". ASU 2018-15 requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in Accounting Standards Codification 350-40 to determine which implementation costs to defer and recognize as an asset. For public business entities, the guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2019. For all other entities, it is effective for annual periods beginning after &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;December 15, 2020 and interim periods in annual periods beginning after December 15, 2021. Early adoption is permitted, including adoption in any interim period for all entities. The Company adopted this guidance January 1, 2020.  The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In November 2018, the FASB issued ASU 2018-18,"Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&#x201d;.  ASU 2018-18 provides guidance on whether certain transactions between collaborative arrangement participants should be accounted for with revenue under Topic 606. For public business entities, the guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2019. For all other entities, it is effective for annual periods beginning after December 15, 2020 and interim periods in annual periods beginning after December 15, 2021. Early adoption is permitted, including adoption in any interim period for all entities.  The Company adopted this guidance January 1, 2020.  The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xNDI2L2ZyYWc6MGRiNWQ1MGE5ZWFmNDQ1ODliNjRiODdiYTE3MzNmMGUvdGV4dHJlZ2lvbjowZGI1ZDUwYTllYWY0NDU4OWI2NGI4N2JhMTczM2YwZV80Mzk4MDQ2NTUwMjQ0_92f6f939-4207-42b1-9c95-69f641f1a1aa">Acquisition&#x2028;&#x2028;Censa Acquisition&#x2028;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;On May 29, 2020, the Company acquired Censa, pursuant to the Censa Merger Agreement. Upon the closing of the Censa Merger, the Company paid to the Censa securityholders (i) cash consideration of $15.0&#160;million, which consisted of an upfront payment of $10.4&#160;million and an additional $4.6&#160;million for the net assets on Censa's opening balance sheet as of the date of the acquisition, and (ii) 845,364 shares of the Company's common stock, which were valued at $42.9&#160;million based on the closing stock price on the acquisition date. The number of shares issued was determined using a 30-day VWAP pursuant to the Censa Merger Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;The Company determined that substantially all of the fair value is concentrated in PTC923 and accounted for the transaction as an asset acquisition under ASC 805-50.  The purchase price consisted of the cash consideration of $15.0&#160;million and $42.9&#160;million in the Company's common stock, in addition to $0.7&#160;million of acquisition costs. As such, the total consideration transferred was determined to be $58.6&#160;million. The opening balance sheet net assets of $4.6&#160;million, which consisted of cash of $3.8&#160;million and other current assets of $0.8&#160;million, were determined to be non-qualifying assets and recorded at their fair values, respectively. The remaining consideration of $54.0&#160;million was allocated to PTC923. As PTC923 is an IPR&amp;amp;D asset, the Company concluded that it did not have any alternative future use, and accordingly, the fair value amount allocated to the IPR&amp;amp;D was expensed. Of the $54.0&#160;million, $53.3&#160;million is included in research and development expense and $0.7&#160;million is included in selling, general, and administrative expense within the Company's statement of operations for the three and six month periods ended June 30, 2020. In addition, the Company incurred $0.3&#160;million of other expenses related to Censa, which was included in research and development expense for the three and six month periods ended June 30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;Subject to the terms and conditions of the Censa Merger Agreement, Censa securityholders may become entitled to receive contingent payments from the Company based on (i) the achievement of certain development and regulatory milestones up to an aggregate maximum amount of $217.5&#160;million for PTC923's two most advanced programs and receipt of a priority review voucher from the FDA as set forth in the Censa Merger Agreement, (ii) $109&#160;million in development and regulatory milestones for each additional indication of PTC923, (iii) the achievement of certain net sales milestones up to an aggregate maximum amount of $160.0&#160;million, (iv) a percentage of annual net sales during specified terms, ranging from single to low double digits of the applicable net sales threshold amount, and (v) any sublicense fees paid to the Company in consideration of any sublicense of Censa&#x2019;s intellectual property to commercialize PTC923, on a country-by-country basis, which contingent payment shall equal to a mid-double digit percentage of any such sublicense fees. Pursuant to the Censa Merger Agreement, the Company has the option to pay the initial $30.0&#160;million development milestone, for the completion of enrollment of a Phase 3 clinical trial for PTC923 for PKU, if achieved, in cash or shares of the Company&#x2019;s common stock (the &#x201c;Initial Milestone&#x201d;). The Company will record the milestone and royalty payments when they become payable. Milestone payments prior to FDA approval of PTC923 for PKU (or other indications) will be expensed accordingly and milestone payments that will only occur after PTC923 for PKU (or other indications) is FDA approved, will be capitalized and amortized over their expected useful lives.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <ptct:PaymentsforAssetAcquisitions
      contextRef="i8742fae222d34cac83b189f51096e426_D20200529-20200529"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xNDI2L2ZyYWc6MGRiNWQ1MGE5ZWFmNDQ1ODliNjRiODdiYTE3MzNmMGUvdGV4dHJlZ2lvbjowZGI1ZDUwYTllYWY0NDU4OWI2NGI4N2JhMTczM2YwZV80Mzk4MDQ2NTQ5OTcw_ec2eb31e-438d-48f3-a281-25cdc495bf31"
      unitRef="usd">15000000.0</ptct:PaymentsforAssetAcquisitions>
    <ptct:PaymentsForAssetAcquisitionsUpfrontPayment
      contextRef="i8742fae222d34cac83b189f51096e426_D20200529-20200529"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xNDI2L2ZyYWc6MGRiNWQ1MGE5ZWFmNDQ1ODliNjRiODdiYTE3MzNmMGUvdGV4dHJlZ2lvbjowZGI1ZDUwYTllYWY0NDU4OWI2NGI4N2JhMTczM2YwZV80Mzk4MDQ2NTUwMjMw_7c806709-bfa8-43ff-a3a5-a5a801ee982b"
      unitRef="usd">10400000</ptct:PaymentsForAssetAcquisitionsUpfrontPayment>
    <ptct:PaymentsForAssetAcquisitionsNetAssets
      contextRef="i8742fae222d34cac83b189f51096e426_D20200529-20200529"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xNDI2L2ZyYWc6MGRiNWQ1MGE5ZWFmNDQ1ODliNjRiODdiYTE3MzNmMGUvdGV4dHJlZ2lvbjowZGI1ZDUwYTllYWY0NDU4OWI2NGI4N2JhMTczM2YwZV80Mzk4MDQ2NTQ5OTg1_74731d89-eb8a-46ba-aef1-6282a52ce137"
      unitRef="usd">4600000</ptct:PaymentsForAssetAcquisitionsNetAssets>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="i8742fae222d34cac83b189f51096e426_D20200529-20200529"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xNDI2L2ZyYWc6MGRiNWQ1MGE5ZWFmNDQ1ODliNjRiODdiYTE3MzNmMGUvdGV4dHJlZ2lvbjowZGI1ZDUwYTllYWY0NDU4OWI2NGI4N2JhMTczM2YwZV80Mzk4MDQ2NTQ5OTk5_9507216f-a1ca-4b1f-a4d3-483377609a35"
      unitRef="shares">845364</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i8742fae222d34cac83b189f51096e426_D20200529-20200529"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xNDI2L2ZyYWc6MGRiNWQ1MGE5ZWFmNDQ1ODliNjRiODdiYTE3MzNmMGUvdGV4dHJlZ2lvbjowZGI1ZDUwYTllYWY0NDU4OWI2NGI4N2JhMTczM2YwZV80Mzk4MDQ2NTUwMDA4_4e4fb3ea-e784-4396-98bd-189c553c9552"
      unitRef="usd">42900000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <ptct:ConsiderationForAssetAcquisitions
      contextRef="i8742fae222d34cac83b189f51096e426_D20200529-20200529"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xNDI2L2ZyYWc6MGRiNWQ1MGE5ZWFmNDQ1ODliNjRiODdiYTE3MzNmMGUvdGV4dHJlZ2lvbjowZGI1ZDUwYTllYWY0NDU4OWI2NGI4N2JhMTczM2YwZV80Mzk4MDQ2NTUwMDY2_ccc6eeab-0f0a-49aa-b1c8-8d1580a6b202"
      unitRef="usd">15000000.0</ptct:ConsiderationForAssetAcquisitions>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="i8742fae222d34cac83b189f51096e426_D20200529-20200529"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xNDI2L2ZyYWc6MGRiNWQ1MGE5ZWFmNDQ1ODliNjRiODdiYTE3MzNmMGUvdGV4dHJlZ2lvbjowZGI1ZDUwYTllYWY0NDU4OWI2NGI4N2JhMTczM2YwZV80Mzk4MDQ2NTUwMDgx_1f188276-5a63-451b-92e6-13614821c0ca"
      unitRef="shares">42900000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <ptct:AssetAcquisitionTransactionCosts
      contextRef="i8742fae222d34cac83b189f51096e426_D20200529-20200529"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xNDI2L2ZyYWc6MGRiNWQ1MGE5ZWFmNDQ1ODliNjRiODdiYTE3MzNmMGUvdGV4dHJlZ2lvbjowZGI1ZDUwYTllYWY0NDU4OWI2NGI4N2JhMTczM2YwZV80Mzk4MDQ2NTUwMDIz_794c2b66-b343-45b3-a833-d98f71813f15"
      unitRef="usd">-700000</ptct:AssetAcquisitionTransactionCosts>
    <ptct:AssetAcquisitionConsiderationTransferred
      contextRef="i8742fae222d34cac83b189f51096e426_D20200529-20200529"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xNDI2L2ZyYWc6MGRiNWQ1MGE5ZWFmNDQ1ODliNjRiODdiYTE3MzNmMGUvdGV4dHJlZ2lvbjowZGI1ZDUwYTllYWY0NDU4OWI2NGI4N2JhMTczM2YwZV80Mzk4MDQ2NTUwMDM3_ac41794a-bf13-4d49-b56c-261e8ced5b54"
      unitRef="usd">58600000</ptct:AssetAcquisitionConsiderationTransferred>
    <ptct:PaymentsForAssetAcquisitionsNetAssets
      contextRef="i8742fae222d34cac83b189f51096e426_D20200529-20200529"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xNDI2L2ZyYWc6MGRiNWQ1MGE5ZWFmNDQ1ODliNjRiODdiYTE3MzNmMGUvdGV4dHJlZ2lvbjowZGI1ZDUwYTllYWY0NDU4OWI2NGI4N2JhMTczM2YwZV8xOTI0MTQ1MzUyNTI1Mg_fda350ce-3859-4e99-b9b2-23fe1e698597"
      unitRef="usd">4600000</ptct:PaymentsForAssetAcquisitionsNetAssets>
    <ptct:AssetAcquisitionCash
      contextRef="i28fa54ad024443b18973875cc89f36e3_I20200529"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xNDI2L2ZyYWc6MGRiNWQ1MGE5ZWFmNDQ1ODliNjRiODdiYTE3MzNmMGUvdGV4dHJlZ2lvbjowZGI1ZDUwYTllYWY0NDU4OWI2NGI4N2JhMTczM2YwZV80Mzk4MDQ2NTUwMTEx_dc6d342b-f058-4ae7-9ed0-898fe67e061d"
      unitRef="usd">3800000</ptct:AssetAcquisitionCash>
    <ptct:AssetAcquisitionOtherAssets
      contextRef="i28fa54ad024443b18973875cc89f36e3_I20200529"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xNDI2L2ZyYWc6MGRiNWQ1MGE5ZWFmNDQ1ODliNjRiODdiYTE3MzNmMGUvdGV4dHJlZ2lvbjowZGI1ZDUwYTllYWY0NDU4OWI2NGI4N2JhMTczM2YwZV80Mzk4MDQ2NTUwMDUy_955b9deb-f490-416d-86d2-009c7e6c6383"
      unitRef="usd">800000</ptct:AssetAcquisitionOtherAssets>
    <ptct:AssetAcquisitionInProcessResearchAndDevelopment
      contextRef="i28fa54ad024443b18973875cc89f36e3_I20200529"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xNDI2L2ZyYWc6MGRiNWQ1MGE5ZWFmNDQ1ODliNjRiODdiYTE3MzNmMGUvdGV4dHJlZ2lvbjowZGI1ZDUwYTllYWY0NDU4OWI2NGI4N2JhMTczM2YwZV80Mzk4MDQ2NTUwMDk2_c83e0bc5-6e71-4e46-a203-7896afd9a333"
      unitRef="usd">54000000.0</ptct:AssetAcquisitionInProcessResearchAndDevelopment>
    <ptct:AssetAcquisitionInProcessResearchAndDevelopment
      contextRef="i28fa54ad024443b18973875cc89f36e3_I20200529"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xNDI2L2ZyYWc6MGRiNWQ1MGE5ZWFmNDQ1ODliNjRiODdiYTE3MzNmMGUvdGV4dHJlZ2lvbjowZGI1ZDUwYTllYWY0NDU4OWI2NGI4N2JhMTczM2YwZV80Mzk4MDQ2NTUwMTQw_5dae782e-d98a-4a5c-87f2-c58c2b9bc43d"
      unitRef="usd">54000000.0</ptct:AssetAcquisitionInProcessResearchAndDevelopment>
    <ptct:AssetAcquisitionResearchAndDevelopmentExpense
      contextRef="i8742fae222d34cac83b189f51096e426_D20200529-20200529"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xNDI2L2ZyYWc6MGRiNWQ1MGE5ZWFmNDQ1ODliNjRiODdiYTE3MzNmMGUvdGV4dHJlZ2lvbjowZGI1ZDUwYTllYWY0NDU4OWI2NGI4N2JhMTczM2YwZV80Mzk4MDQ2NTUwMTI1_bd6670bf-1cc6-49e4-b292-e595532fa5e5"
      unitRef="usd">53300000</ptct:AssetAcquisitionResearchAndDevelopmentExpense>
    <ptct:AssetAcquisitionSellingGeneralAndAdministrativeExpense
      contextRef="i8742fae222d34cac83b189f51096e426_D20200529-20200529"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xNDI2L2ZyYWc6MGRiNWQ1MGE5ZWFmNDQ1ODliNjRiODdiYTE3MzNmMGUvdGV4dHJlZ2lvbjowZGI1ZDUwYTllYWY0NDU4OWI2NGI4N2JhMTczM2YwZV80Mzk4MDQ2NTUwMTU1_35143be8-ca37-421d-9ea4-caf5ac7e4e2e"
      unitRef="usd">700000</ptct:AssetAcquisitionSellingGeneralAndAdministrativeExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="i8742fae222d34cac83b189f51096e426_D20200529-20200529"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xNDI2L2ZyYWc6MGRiNWQ1MGE5ZWFmNDQ1ODliNjRiODdiYTE3MzNmMGUvdGV4dHJlZ2lvbjowZGI1ZDUwYTllYWY0NDU4OWI2NGI4N2JhMTczM2YwZV8zMjk4NTM0OTIyODc0_e5842f55-35b9-4532-8345-4da17f832dc5"
      unitRef="usd">300000</us-gaap:OtherResearchAndDevelopmentExpense>
    <ptct:AssetAcquisitionMilestoneAmount
      contextRef="i28fa54ad024443b18973875cc89f36e3_I20200529"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xNDI2L2ZyYWc6MGRiNWQ1MGE5ZWFmNDQ1ODliNjRiODdiYTE3MzNmMGUvdGV4dHJlZ2lvbjowZGI1ZDUwYTllYWY0NDU4OWI2NGI4N2JhMTczM2YwZV80Mzk4MDQ2NTUwMTY5_27e3a955-d59c-438f-a958-68fe34703c32"
      unitRef="usd">217500000</ptct:AssetAcquisitionMilestoneAmount>
    <ptct:AssetAcquisitionDevelopmentAndRegulatoryMilestones
      contextRef="i28fa54ad024443b18973875cc89f36e3_I20200529"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xNDI2L2ZyYWc6MGRiNWQ1MGE5ZWFmNDQ1ODliNjRiODdiYTE3MzNmMGUvdGV4dHJlZ2lvbjowZGI1ZDUwYTllYWY0NDU4OWI2NGI4N2JhMTczM2YwZV80Mzk4MDQ2NTUwMTg1_0424ba6a-2fc6-41a0-8d9b-2e1429151054"
      unitRef="usd">109000000</ptct:AssetAcquisitionDevelopmentAndRegulatoryMilestones>
    <ptct:AssetAcquisitionNetSalesMilestone
      contextRef="i28fa54ad024443b18973875cc89f36e3_I20200529"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xNDI2L2ZyYWc6MGRiNWQ1MGE5ZWFmNDQ1ODliNjRiODdiYTE3MzNmMGUvdGV4dHJlZ2lvbjowZGI1ZDUwYTllYWY0NDU4OWI2NGI4N2JhMTczM2YwZV80Mzk4MDQ2NTUwMTk5_0a1a804b-e104-4ea9-a820-fe45026cb622"
      unitRef="usd">160000000.0</ptct:AssetAcquisitionNetSalesMilestone>
    <ptct:AssetAcquisitionInitialMilestone
      contextRef="i28fa54ad024443b18973875cc89f36e3_I20200529"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF8xNDI2L2ZyYWc6MGRiNWQ1MGE5ZWFmNDQ1ODliNjRiODdiYTE3MzNmMGUvdGV4dHJlZ2lvbjowZGI1ZDUwYTllYWY0NDU4OWI2NGI4N2JhMTczM2YwZV80Mzk4MDQ2NTUwMjE1_62022df5-55f6-4bd1-84c0-1d278cff5a19"
      unitRef="usd">30000000.0</ptct:AssetAcquisitionInitialMilestone>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfNDM5ODA0NjUyOTA2OQ_0caea49c-a7ec-4cf9-97bd-4dd7b80d44b7">LeasesThe Company leases office space in South Plainfield, New Jersey for its principal office under three noncancelable operating leases through May 2022 and August 2024, in addition to office space in various countries for international employees primarily through workspace providers. The Company also leases certain vehicles, lab equipment, and office equipment under operating leases. The Company&#x2019;s leases have remaining operating lease terms ranging from 0.3 years to 6.9 years and certain of the leases include renewal options to extend the lease for up to 10 years. Rent expense was approximately $2.6 million, $5.0 million, $1.1 million and $2.1 million for the three and six month periods ended June 30, 2020 and 2019, respectively. &lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;"&gt;&#x2028;&#x2028;On June 19, 2020, the Company entered into a commercial manufacturing service agreement for a term of 12.5 years with MassBiologics of the University of Massachusetts Medical School ("MassBio"). The agreement will expire on December 31, 2032 unless the Company terminates it on 24 months prior written notice to MassBio. Pursuant to the terms of the agreement, MassBio agreed to provide the Company with four dedicated rooms for its gene therapy AADC program. The Company concluded that the agreement contains an embedded lease as the Company controls the use of the four dedicated rooms and the equipment therein. As the present value of the facilities exceeds the assessed fair value, the Company determined that it is a finance lease. Given that the embedded finance lease is designed for the production of PTC&#x2019;s AADC program and would not have an alternate use outside the PTC gene therapy platform without incurring significant costs, the Company determined that the lease should be treated as research and development expense under ASC 730 and accordingly, expensed the present value of all g&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;"&gt;uaranteed future cash payments of $41.2 million during the three and six month periods ending June 30, 2020. Additionally, during the three and six month periods ending June 30, 2020, the Company did not record finance lease costs as these amounts were not material due to timing of entering into the lease. The Company will record finance lease costs in the third quarter of 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The components of operating lease expense were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:33.672%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.643%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.643%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.643%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.501%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating Lease Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fixed lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;304&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;141&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total operating lease cost is a component of operating expenses on the consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:56.187%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.614%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.615%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease ROU asset&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liabilities- current&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liabilities- noncurrent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2028;&#x2028;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:56.064%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.674%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.386%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finance lease liabilities- current&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finance lease liabilities- noncurrent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total finance lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2028;Operating lease ROU asset is a component of deposits and other assets on the consolidated balance sheets. The current portion of operating lease liabilities is a component of other current liabilities on the consolidated balance sheets. The long term portion of operating lease liabilities is a component of other long term liabilities on the consolidated balance sheets.  The Company entered into a lease agreement with COE Bridgewater LLC on March 20, 2020 relating to the lease of office and laboratory space located in Bridgewater, New Jersey. This lease replaced the Company's existing lease on the property beginning on May 1, 2020 and includes additional rental property of approximately 59,000 square feet and is the primary driver of the increase in total operating lease ROU asset and total operating lease liability from December 31, 2029 to June 30, 2020.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Supplemental lease term and discount rate information related to leases was as follows as of June 30, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:56.125%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.644%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.385%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.646%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average remaining lease terms - operating leases (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.38&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average discount rate - operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average remaining lease terms - finance lease (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average discount rate - finance lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2028;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Supplemental cash flow information related to leases was as follows as of June 30, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:56.125%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.644%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.385%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.646%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Month Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Financing cash flows from finance lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finance lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;41,212&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2028;&#x2028;Future minimum lease payments under non-cancelable leases as of June&#160;30, 2020 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:35.134%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:29.140%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:29.142%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finance Lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020 (excludes the six months ended June 30, 2020)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: Imputed Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In conjunction with the Asset Acquisition, the Company acquired BioElectron&#x2019;s lease in Mountainview, California. As substantially all of the fair value of the gross assets acquired was related to vatiquinone, the relative fair value allocated to the right of use asset and corresponding lease liability for the Mountainview lease was determined to be immaterial, and accordingly is not included in the tables above. The future minimum lease payments for the Mountainview lease as of June&#160;30, 2020 are $0.9 million, $1.8 million, and $1.4 million for 2020, 2021 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On August 4, 2019, the Company and Bristol-Myers Squibb Company, (the &#x201c;Landlord&#x201d;), entered into a Lease Agreement&#160;(the &#x201c;Lease&#x201d;), relating to the lease&#160;of approximately 185,000 square feet of office, manufacturing and laboratory space at a facility located in Hopewell Township, New Jersey (the &#x201c;Campus&#x201d;). On March 25, 2020, the Company entered into an amendment increasing the rented space to approximately 220,500 square feet.  As of June 30, 2020, the Lease had not yet commenced, and accordingly, is not reflected in the table above. The rental term of the Lease commenced on July 1, 2020 and has an initial term of fifteen years (the &#x201c;Initial Term&#x201d;), with two consecutive five year renewal periods, each at the Company&#x2019;s option.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The aggregate rent for the Initial Term will be approximately $111.5 million. The rental rate for the renewal periods will be 95% of the Prevailing Market Rate (as defined in the Lease) and determined at the time of the exercise of the renewal. The Company is also responsible for maintaining certain insurance and the payment of proportional taxes, utilities and common area operating expenses. The Lease contains customary events of default, representations, warranties and covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Subject to the terms of the Lease, the Company has a right of first refusal to rent certain other space of the Campus, which would be triggered upon the Landlord&#x2019;s issuance of a second round proposal or letter of intent to another tenant for such space. &lt;/span&gt;&lt;/div&gt;The Company also may seek to build a new separate building on the Campus, which may not contain less than 75,000 square feet (the &#x201c;New Building&#x201d;). Upon receipt of notice of the Company&#x2019;s intention to build the New Building, the Landlord may, in its sole discretion, construct and lease the New Building to the Company or enter into a ground lease with the Company permitting the Company to construct the New Building. Rent terms for the New Building would be determined based on the land value, construction and project costs subject to whether the Landlord or Company constructs the New Building.</us-gaap:LesseeOperatingLeasesTextBlock>
    <ptct:NumberOfOperatingLeases
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfMTEw_390357e0-3ab1-4fb4-93c0-bdc65f0a28e1"
      unitRef="operating_lease">3</ptct:NumberOfOperatingLeases>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i534a161919c644babf7b581f8815a9ae_I20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfNDY3_49dae317-cdae-492a-8eaf-07a5f4382d3a">P0Y3M18D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="iee26b7ab0eb3427894a7e80a6ab4b557_I20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfNDc5_535e75ed-7f0d-4d8d-9e2c-9c201903b78b">P6Y10M24D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfNTY4_d1c62799-21b7-43a1-b21a-108c2c1222e7">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeaseExpense
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfNjAz_e966b4d3-2fba-4bdd-ba10-72991796b543"
      unitRef="usd">2600000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfNjEw_8ce0fdf9-255d-4a45-9bf5-4de50af94db4"
      unitRef="usd">5000000.0</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfMzI5ODUzNDg4ODkxNw_7d58506e-f83a-44b8-9f99-9747e31f8d7f"
      unitRef="usd">1100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfMzI5ODUzNDg4ODkzMg_83ef49ac-45e4-433d-bce4-eaefd4f779cd"
      unitRef="usd">2100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LesseeFinanceLeaseTermOfContract1
      contextRef="i9b91bdabba504b27a63eb72dd4e14072_I20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfMjc0ODc3OTA4MDM1Nw_3e9edc82-814e-4732-b0dc-35005855d277">P12Y6M</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iad9435fcf1974f729382cb45345d15cf_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfMzI5ODUzNDg5ODI3Nw_368d8cea-d495-4cbd-a64a-a61a7b9b59f5"
      unitRef="usd">41200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i2eddd9a393564222bc0988444831fd19_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfMzI5ODUzNDg5ODI3Nw_5e4ce2f2-8cfc-43f1-a210-adfcf0e41fc9"
      unitRef="usd">41200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfNDgwMg_c794adb8-26e4-40ca-b690-867bf928a030">&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The components of operating lease expense were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:33.672%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.643%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.643%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.643%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.501%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating Lease Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fixed lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;304&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;141&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total operating lease cost is a component of operating expenses on the consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:56.187%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.614%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.615%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease ROU asset&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liabilities- current&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liabilities- noncurrent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:56.064%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.674%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.386%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finance lease liabilities- current&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finance lease liabilities- noncurrent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total finance lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;Supplemental lease term and discount rate information related to leases was as follows as of June 30, 2020 and 2019:&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:56.125%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.644%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.385%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.646%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average remaining lease terms - operating leases (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.38&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average discount rate - operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average remaining lease terms - finance lease (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average discount rate - finance lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2028;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Supplemental cash flow information related to leases was as follows as of June 30, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:56.125%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.644%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.385%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.646%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Month Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Financing cash flows from finance lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finance lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;41,212&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjhlNGM5NzRhNWY4ODQyZDg4OGYyMDZlYzkzYmUyZGY0L3RhYmxlcmFuZ2U6OGU0Yzk3NGE1Zjg4NDJkODg4ZjIwNmVjOTNiZTJkZjRfMi0xLTEtMS0w_d5e570b8-7427-4dbd-be79-b07ef76848d5"
      unitRef="usd">1970000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjhlNGM5NzRhNWY4ODQyZDg4OGYyMDZlYzkzYmUyZGY0L3RhYmxlcmFuZ2U6OGU0Yzk3NGE1Zjg4NDJkODg4ZjIwNmVjOTNiZTJkZjRfMi0yLTEtMS0w_3ac1f93f-04e9-410b-81f9-3c24b2c6c77d"
      unitRef="usd">835000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjhlNGM5NzRhNWY4ODQyZDg4OGYyMDZlYzkzYmUyZGY0L3RhYmxlcmFuZ2U6OGU0Yzk3NGE1Zjg4NDJkODg4ZjIwNmVjOTNiZTJkZjRfMi00LTEtMS0w_da5455ed-e67f-4dc1-924a-2f9afc5f249c"
      unitRef="usd">4089000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjhlNGM5NzRhNWY4ODQyZDg4OGYyMDZlYzkzYmUyZGY0L3RhYmxlcmFuZ2U6OGU0Yzk3NGE1Zjg4NDJkODg4ZjIwNmVjOTNiZTJkZjRfMy03LTEtMS0xMzA3_3221c32b-7881-4e84-bb77-42d3fb9f2903"
      unitRef="usd">1647000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjhlNGM5NzRhNWY4ODQyZDg4OGYyMDZlYzkzYmUyZGY0L3RhYmxlcmFuZ2U6OGU0Yzk3NGE1Zjg4NDJkODg4ZjIwNmVjOTNiZTJkZjRfMy0xLTEtMS0w_709cd8e3-c117-4e02-80bc-123b9a0fc56f"
      unitRef="usd">507000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjhlNGM5NzRhNWY4ODQyZDg4OGYyMDZlYzkzYmUyZGY0L3RhYmxlcmFuZ2U6OGU0Yzk3NGE1Zjg4NDJkODg4ZjIwNmVjOTNiZTJkZjRfMy0yLTEtMS0w_40bd3450-4dec-48d2-a5b4-325b984fc522"
      unitRef="usd">161000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjhlNGM5NzRhNWY4ODQyZDg4OGYyMDZlYzkzYmUyZGY0L3RhYmxlcmFuZ2U6OGU0Yzk3NGE1Zjg4NDJkODg4ZjIwNmVjOTNiZTJkZjRfMy00LTEtMS0w_f6f9340e-7e74-4342-a344-9199857a1263"
      unitRef="usd">734000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjhlNGM5NzRhNWY4ODQyZDg4OGYyMDZlYzkzYmUyZGY0L3RhYmxlcmFuZ2U6OGU0Yzk3NGE1Zjg4NDJkODg4ZjIwNmVjOTNiZTJkZjRfNC03LTEtMS0xMzA3_eede8cd4-3fa7-4c8b-9925-4fed2550f376"
      unitRef="usd">304000</us-gaap:VariableLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjhlNGM5NzRhNWY4ODQyZDg4OGYyMDZlYzkzYmUyZGY0L3RhYmxlcmFuZ2U6OGU0Yzk3NGE1Zjg4NDJkODg4ZjIwNmVjOTNiZTJkZjRfNC0xLTEtMS0w_7d13a9f8-85c1-46da-98c9-830ed6078e04"
      unitRef="usd">88000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjhlNGM5NzRhNWY4ODQyZDg4OGYyMDZlYzkzYmUyZGY0L3RhYmxlcmFuZ2U6OGU0Yzk3NGE1Zjg4NDJkODg4ZjIwNmVjOTNiZTJkZjRfNC0yLTEtMS0w_b611711c-b584-4201-aa06-57dc485b57b6"
      unitRef="usd">88000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjhlNGM5NzRhNWY4ODQyZDg4OGYyMDZlYzkzYmUyZGY0L3RhYmxlcmFuZ2U6OGU0Yzk3NGE1Zjg4NDJkODg4ZjIwNmVjOTNiZTJkZjRfNC00LTEtMS0w_4bab1c9a-2867-47fc-b6dd-790d9ca08fd6"
      unitRef="usd">165000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjhlNGM5NzRhNWY4ODQyZDg4OGYyMDZlYzkzYmUyZGY0L3RhYmxlcmFuZ2U6OGU0Yzk3NGE1Zjg4NDJkODg4ZjIwNmVjOTNiZTJkZjRfNS03LTEtMS0xMzA3_f5bbea37-ad80-4674-9dc3-712046494a41"
      unitRef="usd">141000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjhlNGM5NzRhNWY4ODQyZDg4OGYyMDZlYzkzYmUyZGY0L3RhYmxlcmFuZ2U6OGU0Yzk3NGE1Zjg4NDJkODg4ZjIwNmVjOTNiZTJkZjRfNS0xLTEtMS0w_c9532530-d9bf-4cfb-95d7-aa83faac406d"
      unitRef="usd">2565000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjhlNGM5NzRhNWY4ODQyZDg4OGYyMDZlYzkzYmUyZGY0L3RhYmxlcmFuZ2U6OGU0Yzk3NGE1Zjg4NDJkODg4ZjIwNmVjOTNiZTJkZjRfNS0yLTEtMS0w_24fa97f6-e63c-4496-914c-0ff61f0c6a49"
      unitRef="usd">1084000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjhlNGM5NzRhNWY4ODQyZDg4OGYyMDZlYzkzYmUyZGY0L3RhYmxlcmFuZ2U6OGU0Yzk3NGE1Zjg4NDJkODg4ZjIwNmVjOTNiZTJkZjRfNS00LTEtMS0w_e51508b1-cebd-4613-aa19-b395d0502c2a"
      unitRef="usd">4988000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjhlNGM5NzRhNWY4ODQyZDg4OGYyMDZlYzkzYmUyZGY0L3RhYmxlcmFuZ2U6OGU0Yzk3NGE1Zjg4NDJkODg4ZjIwNmVjOTNiZTJkZjRfNi03LTEtMS0xMzA3_ab6bb1a1-fdc0-45a1-a4df-3e44d3f367f6"
      unitRef="usd">2092000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjA1ZjAyOTM5YmVhNzRlY2ZhNzI3MmQ5MDJkNDMzYTcxL3RhYmxlcmFuZ2U6MDVmMDI5MzliZWE3NGVjZmE3MjcyZDkwMmQ0MzNhNzFfMi0xLTEtMS0w_b09120d3-2858-4c8b-998b-548d7621083d"
      unitRef="usd">29475000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjA1ZjAyOTM5YmVhNzRlY2ZhNzI3MmQ5MDJkNDMzYTcxL3RhYmxlcmFuZ2U6MDVmMDI5MzliZWE3NGVjZmE3MjcyZDkwMmQ0MzNhNzFfMi0yLTEtMS0w_8d85015b-72d6-4518-8631-fe249d36c0cc"
      unitRef="usd">13693000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjA1ZjAyOTM5YmVhNzRlY2ZhNzI3MmQ5MDJkNDMzYTcxL3RhYmxlcmFuZ2U6MDVmMDI5MzliZWE3NGVjZmE3MjcyZDkwMmQ0MzNhNzFfNC0xLTEtMS0w_db819f10-15c4-43a1-9524-f66881c26b77"
      unitRef="usd">4868000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjA1ZjAyOTM5YmVhNzRlY2ZhNzI3MmQ5MDJkNDMzYTcxL3RhYmxlcmFuZ2U6MDVmMDI5MzliZWE3NGVjZmE3MjcyZDkwMmQ0MzNhNzFfNC0yLTEtMS0w_003876c3-9642-4a28-ae51-32ac2b7c5460"
      unitRef="usd">5153000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjA1ZjAyOTM5YmVhNzRlY2ZhNzI3MmQ5MDJkNDMzYTcxL3RhYmxlcmFuZ2U6MDVmMDI5MzliZWE3NGVjZmE3MjcyZDkwMmQ0MzNhNzFfNS0xLTEtMS0w_2068e039-355b-4e39-b4ab-761935b813c7"
      unitRef="usd">25510000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjA1ZjAyOTM5YmVhNzRlY2ZhNzI3MmQ5MDJkNDMzYTcxL3RhYmxlcmFuZ2U6MDVmMDI5MzliZWE3NGVjZmE3MjcyZDkwMmQ0MzNhNzFfNS0yLTEtMS0w_3eb63484-fb09-4e93-aaae-463a7695ac37"
      unitRef="usd">9018000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjA1ZjAyOTM5YmVhNzRlY2ZhNzI3MmQ5MDJkNDMzYTcxL3RhYmxlcmFuZ2U6MDVmMDI5MzliZWE3NGVjZmE3MjcyZDkwMmQ0MzNhNzFfNi0xLTEtMS0w_e7e7ce70-8253-453a-af47-d6c2655b68fe"
      unitRef="usd">30378000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjA1ZjAyOTM5YmVhNzRlY2ZhNzI3MmQ5MDJkNDMzYTcxL3RhYmxlcmFuZ2U6MDVmMDI5MzliZWE3NGVjZmE3MjcyZDkwMmQ0MzNhNzFfNi0yLTEtMS0w_05304848-83d1-4862-9773-ab61a44ba8f1"
      unitRef="usd">14171000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjliZjAxZDFmZDc5NTQ3NjhiMGQzNjY1NGU0NmE0MDdhL3RhYmxlcmFuZ2U6OWJmMDFkMWZkNzk1NDc2OGIwZDM2NjU0ZTQ2YTQwN2FfNC0xLTEtMS00NDA3_92f8cbd7-90bb-45e0-b215-eb585d292ee2"
      unitRef="usd">4180000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjliZjAxZDFmZDc5NTQ3NjhiMGQzNjY1NGU0NmE0MDdhL3RhYmxlcmFuZ2U6OWJmMDFkMWZkNzk1NDc2OGIwZDM2NjU0ZTQ2YTQwN2FfNC0yLTEtMS00NDEy_c8349600-1eed-4c2f-87fe-2b5cd6c1169a"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjliZjAxZDFmZDc5NTQ3NjhiMGQzNjY1NGU0NmE0MDdhL3RhYmxlcmFuZ2U6OWJmMDFkMWZkNzk1NDc2OGIwZDM2NjU0ZTQ2YTQwN2FfNS0xLTEtMS00NDA3_09aaa71f-399c-41c9-8bae-98fd51dbf7fa"
      unitRef="usd">22031000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjliZjAxZDFmZDc5NTQ3NjhiMGQzNjY1NGU0NmE0MDdhL3RhYmxlcmFuZ2U6OWJmMDFkMWZkNzk1NDc2OGIwZDM2NjU0ZTQ2YTQwN2FfNS0yLTEtMS00NDEy_b916372e-1032-4be5-980e-13e1f95834c7"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiability
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjliZjAxZDFmZDc5NTQ3NjhiMGQzNjY1NGU0NmE0MDdhL3RhYmxlcmFuZ2U6OWJmMDFkMWZkNzk1NDc2OGIwZDM2NjU0ZTQ2YTQwN2FfNi0xLTEtMS02NDA1_1f96dec5-254c-4914-8706-c980a5e4cf08"
      unitRef="usd">26211000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjliZjAxZDFmZDc5NTQ3NjhiMGQzNjY1NGU0NmE0MDdhL3RhYmxlcmFuZ2U6OWJmMDFkMWZkNzk1NDc2OGIwZDM2NjU0ZTQ2YTQwN2FfNi0zLTEtMS02NDA3_29687407-4d6c-4a90-9cb8-38e0cf9f1401"
      unitRef="usd">0</us-gaap:FinanceLeaseLiability>
    <ptct:LeaseArea
      contextRef="i70c896353309469f838542acfc22aa9e_I20200501"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfNDM5ODA0NjUyOTA1MA_c410803f-2450-4cab-82e1-ae45600bca99"
      unitRef="sqft">59000</ptct:LeaseArea>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjU4MDJmNmJjYTE2ZjQ4ZWQ5OGIzODZhZWRjNjUzYzgyL3RhYmxlcmFuZ2U6NTgwMmY2YmNhMTZmNDhlZDk4YjM4NmFlZGM2NTNjODJfMi0xLTEtMS0w_af614e2b-5e9b-4051-bfca-05fd104c8784">P5Y10M13D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjU4MDJmNmJjYTE2ZjQ4ZWQ5OGIzODZhZWRjNjUzYzgyL3RhYmxlcmFuZ2U6NTgwMmY2YmNhMTZmNDhlZDk4YjM4NmFlZGM2NTNjODJfMi0yLTEtMS0w_04b3ffb3-2927-49fc-8f78-4da2dcacc333">P3Y4M17D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjU4MDJmNmJjYTE2ZjQ4ZWQ5OGIzODZhZWRjNjUzYzgyL3RhYmxlcmFuZ2U6NTgwMmY2YmNhMTZmNDhlZDk4YjM4NmFlZGM2NTNjODJfMy0xLTEtMS0w_6350988c-3b57-4aba-a989-9b2ddca3f2b3"
      unitRef="number">0.0677</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjU4MDJmNmJjYTE2ZjQ4ZWQ5OGIzODZhZWRjNjUzYzgyL3RhYmxlcmFuZ2U6NTgwMmY2YmNhMTZmNDhlZDk4YjM4NmFlZGM2NTNjODJfMy0yLTEtMS0w_713e75bb-c8dc-49c4-a2ae-ecb27ee93b03"
      unitRef="number">0.0733</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjU4MDJmNmJjYTE2ZjQ4ZWQ5OGIzODZhZWRjNjUzYzgyL3RhYmxlcmFuZ2U6NTgwMmY2YmNhMTZmNDhlZDk4YjM4NmFlZGM2NTNjODJfNC0xLTEtMS00NTAw_cb373db2-61c2-4493-942b-690039602ffb">P12Y6M</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjU4MDJmNmJjYTE2ZjQ4ZWQ5OGIzODZhZWRjNjUzYzgyL3RhYmxlcmFuZ2U6NTgwMmY2YmNhMTZmNDhlZDk4YjM4NmFlZGM2NTNjODJfNS0xLTEtMS00NTA2_05c8efa5-bb24-4fa8-aaa1-4d7860fd3e67"
      unitRef="number">0.0780</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjc5MGI1MWIzMzg5ZTRkMjg5MTRkNmY0Zjk1ZDcwNDdlL3RhYmxlcmFuZ2U6NzkwYjUxYjMzODllNGQyODkxNGQ2ZjRmOTVkNzA0N2VfMy0xLTEtMS0zNDc5_8a9afd81-4b36-474c-a65b-5e476337cf03"
      unitRef="usd">3414000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjc5MGI1MWIzMzg5ZTRkMjg5MTRkNmY0Zjk1ZDcwNDdlL3RhYmxlcmFuZ2U6NzkwYjUxYjMzODllNGQyODkxNGQ2ZjRmOTVkNzA0N2VfMy0zLTEtMS02ODI0_8cb36620-fabd-47bf-8af2-58cd738140fa"
      unitRef="usd">1508000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjc5MGI1MWIzMzg5ZTRkMjg5MTRkNmY0Zjk1ZDcwNDdlL3RhYmxlcmFuZ2U6NzkwYjUxYjMzODllNGQyODkxNGQ2ZjRmOTVkNzA0N2VfNC0xLTEtMS00NTQ0_99e74311-6d3f-4325-be4e-9cc1e8c8f579"
      unitRef="usd">15000000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjc5MGI1MWIzMzg5ZTRkMjg5MTRkNmY0Zjk1ZDcwNDdlL3RhYmxlcmFuZ2U6NzkwYjUxYjMzODllNGQyODkxNGQ2ZjRmOTVkNzA0N2VfNC0zLTEtMS00NTQ4_baa7a191-ada0-48e7-b94d-c3bb495c6a13"
      unitRef="usd">0</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjc5MGI1MWIzMzg5ZTRkMjg5MTRkNmY0Zjk1ZDcwNDdlL3RhYmxlcmFuZ2U6NzkwYjUxYjMzODllNGQyODkxNGQ2ZjRmOTVkNzA0N2VfNS0xLTEtMS0zNTE1_0224a9f6-33fb-4aba-b803-633bcfa13eb5"
      unitRef="usd">18117000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjc5MGI1MWIzMzg5ZTRkMjg5MTRkNmY0Zjk1ZDcwNDdlL3RhYmxlcmFuZ2U6NzkwYjUxYjMzODllNGQyODkxNGQ2ZjRmOTVkNzA0N2VfNS0zLTEtMS0zNTE5_65a44c65-ca93-4109-b2a2-15c82800a193"
      unitRef="usd">11643000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjc5MGI1MWIzMzg5ZTRkMjg5MTRkNmY0Zjk1ZDcwNDdlL3RhYmxlcmFuZ2U6NzkwYjUxYjMzODllNGQyODkxNGQ2ZjRmOTVkNzA0N2VfOC0xLTEtMS00NTU0_c3753d39-11fe-459b-9f23-0fa3dd97c60d"
      unitRef="usd">41212000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjc5MGI1MWIzMzg5ZTRkMjg5MTRkNmY0Zjk1ZDcwNDdlL3RhYmxlcmFuZ2U6NzkwYjUxYjMzODllNGQyODkxNGQ2ZjRmOTVkNzA0N2VfOC0zLTEtMS00NTU4_67607836-0beb-44a6-becd-5c4e5fb30ab8"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfNDc5NQ_d0967cb8-db4e-438a-936a-cacf57f8829d">Future minimum lease payments under non-cancelable leases as of June&#160;30, 2020 were as follows:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:35.134%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:29.140%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:29.142%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finance Lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020 (excludes the six months ended June 30, 2020)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: Imputed Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjQwNmJmMmQ1OTNlYzRkMjVhMWU5YzAwNTBmMzVjMTBlL3RhYmxlcmFuZ2U6NDA2YmYyZDU5M2VjNGQyNWExZTljMDA1MGYzNWMxMGVfMS0xLTEtMS0w_a3e7fe89-7bb7-4950-a770-af9391af75d0"
      unitRef="usd">3719000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjQwNmJmMmQ1OTNlYzRkMjVhMWU5YzAwNTBmMzVjMTBlL3RhYmxlcmFuZ2U6NDA2YmYyZDU5M2VjNGQyNWExZTljMDA1MGYzNWMxMGVfMS0yLTEtMS00NTcw_d0e8bb9f-6e03-4c0c-ba6b-4a0e4a8a7852"
      unitRef="usd">3000000</us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjQwNmJmMmQ1OTNlYzRkMjVhMWU5YzAwNTBmMzVjMTBlL3RhYmxlcmFuZ2U6NDA2YmYyZDU5M2VjNGQyNWExZTljMDA1MGYzNWMxMGVfMi0xLTEtMS0w_6438a5ef-90c5-489f-aebd-1a6461f37bc0"
      unitRef="usd">6667000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjQwNmJmMmQ1OTNlYzRkMjVhMWU5YzAwNTBmMzVjMTBlL3RhYmxlcmFuZ2U6NDA2YmYyZDU5M2VjNGQyNWExZTljMDA1MGYzNWMxMGVfMi0yLTEtMS00NTcw_6c5e8cb0-21e8-4e44-864f-a4226abda94c"
      unitRef="usd">3000000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjQwNmJmMmQ1OTNlYzRkMjVhMWU5YzAwNTBmMzVjMTBlL3RhYmxlcmFuZ2U6NDA2YmYyZDU5M2VjNGQyNWExZTljMDA1MGYzNWMxMGVfMy0xLTEtMS0w_826dcba9-5d89-4aad-aac8-52de8262f534"
      unitRef="usd">6314000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjQwNmJmMmQ1OTNlYzRkMjVhMWU5YzAwNTBmMzVjMTBlL3RhYmxlcmFuZ2U6NDA2YmYyZDU5M2VjNGQyNWExZTljMDA1MGYzNWMxMGVfMy0yLTEtMS00NTcw_277978d0-8c2b-4e5e-bc03-f6dcfcf344e9"
      unitRef="usd">3000000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjQwNmJmMmQ1OTNlYzRkMjVhMWU5YzAwNTBmMzVjMTBlL3RhYmxlcmFuZ2U6NDA2YmYyZDU5M2VjNGQyNWExZTljMDA1MGYzNWMxMGVfNC0xLTEtMS0w_29922930-dde2-4de3-b929-e246c93e65cd"
      unitRef="usd">5960000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjQwNmJmMmQ1OTNlYzRkMjVhMWU5YzAwNTBmMzVjMTBlL3RhYmxlcmFuZ2U6NDA2YmYyZDU5M2VjNGQyNWExZTljMDA1MGYzNWMxMGVfNC0yLTEtMS00NTcw_f5d78054-9e6e-493f-9dd1-b4d8294f03d0"
      unitRef="usd">3000000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <ptct:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjQwNmJmMmQ1OTNlYzRkMjVhMWU5YzAwNTBmMzVjMTBlL3RhYmxlcmFuZ2U6NDA2YmYyZDU5M2VjNGQyNWExZTljMDA1MGYzNWMxMGVfNS0xLTEtMS0w_0f017bae-dcf3-4c28-b76c-a53fbf710c40"
      unitRef="usd">14844000</ptct:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjQwNmJmMmQ1OTNlYzRkMjVhMWU5YzAwNTBmMzVjMTBlL3RhYmxlcmFuZ2U6NDA2YmYyZDU5M2VjNGQyNWExZTljMDA1MGYzNWMxMGVfNS0yLTEtMS00NTcw_f1027256-9a22-404b-947b-3cf39970ee03"
      unitRef="usd">27000000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjQwNmJmMmQ1OTNlYzRkMjVhMWU5YzAwNTBmMzVjMTBlL3RhYmxlcmFuZ2U6NDA2YmYyZDU5M2VjNGQyNWExZTljMDA1MGYzNWMxMGVfNi0xLTEtMS0w_fc5d6b65-2515-49fd-a149-9d3bc2fbaa43"
      unitRef="usd">37504000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjQwNmJmMmQ1OTNlYzRkMjVhMWU5YzAwNTBmMzVjMTBlL3RhYmxlcmFuZ2U6NDA2YmYyZDU5M2VjNGQyNWExZTljMDA1MGYzNWMxMGVfNi0yLTEtMS00NTcw_17b388d8-c686-451c-9704-a786783dd609"
      unitRef="usd">39000000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjQwNmJmMmQ1OTNlYzRkMjVhMWU5YzAwNTBmMzVjMTBlL3RhYmxlcmFuZ2U6NDA2YmYyZDU5M2VjNGQyNWExZTljMDA1MGYzNWMxMGVfNy0xLTEtMS0w_747b7fc8-0014-41f7-9d64-6e59966d5bfa"
      unitRef="usd">7126000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjQwNmJmMmQ1OTNlYzRkMjVhMWU5YzAwNTBmMzVjMTBlL3RhYmxlcmFuZ2U6NDA2YmYyZDU5M2VjNGQyNWExZTljMDA1MGYzNWMxMGVfNy0yLTEtMS00NTcw_d4985458-c39c-4b59-ada8-39dfda07cff9"
      unitRef="usd">12789000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjQwNmJmMmQ1OTNlYzRkMjVhMWU5YzAwNTBmMzVjMTBlL3RhYmxlcmFuZ2U6NDA2YmYyZDU5M2VjNGQyNWExZTljMDA1MGYzNWMxMGVfOC0xLTEtMS0w_57061215-8ab3-4973-9d74-8584a316f3d9"
      unitRef="usd">30378000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RhYmxlOjQwNmJmMmQ1OTNlYzRkMjVhMWU5YzAwNTBmMzVjMTBlL3RhYmxlcmFuZ2U6NDA2YmYyZDU5M2VjNGQyNWExZTljMDA1MGYzNWMxMGVfOC0yLTEtMS00NTcw_c9646ab6-5656-4e9a-901a-642013df7ced"
      unitRef="usd">26211000</us-gaap:FinanceLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="iffc234810342492fa6bacab33891f92b_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfMjA3Ng_9dec34ce-6517-4630-be2e-ec8055226881"
      unitRef="usd">900000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="iffc234810342492fa6bacab33891f92b_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfMjA4MA_9bf16824-6dae-43e7-9941-17662efadbc6"
      unitRef="usd">1800000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="iffc234810342492fa6bacab33891f92b_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfMjA4OA_75eda567-c8d9-48b3-a75c-4815d03d6c84"
      unitRef="usd">1400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i8062aff1c79b49feb68143984343e9ea_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfMjg5Nw_6a9de44d-0f52-40f7-8ab5-dc182f787ed6"
      unitRef="sqft">185000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="iad498f0eada24a34916bb8f896e4c6a1_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfMzEzMQ_5bc28d5b-c747-4ec8-ae81-e7023556065d"
      unitRef="sqft">220500</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="iad498f0eada24a34916bb8f896e4c6a1_I20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfMzM3Mg_14394d76-6575-4c31-8773-8cf701e9c13e">P15Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <ptct:Numberofterms
      contextRef="iad498f0eada24a34916bb8f896e4c6a1_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfMzQwMg_fbd5496b-5315-4f49-88a5-409a5b226e45"
      unitRef="term">2</ptct:Numberofterms>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i70364109a58442d999d1529aa97f2b6b_I20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfNDM5ODA0NjUyOTA1Nw_5a47f7f3-6a0f-4530-9520-7739af64af28">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="iad498f0eada24a34916bb8f896e4c6a1_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfMzUzNA_76491cb5-4b4b-42d8-927f-543c43ae017e"
      unitRef="usd">111500000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <ptct:PercentOfMarketRate
      contextRef="iad498f0eada24a34916bb8f896e4c6a1_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfMzU4Ng_c0476244-28df-42f9-b790-2d44872b940f"
      unitRef="number">0.95</ptct:PercentOfMarketRate>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i70364109a58442d999d1529aa97f2b6b_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF80Ni9mcmFnOmUyYmI0NTQ3MDFkZTRlNTFiZjI3NGRiYjRkZGVkMTgzL3RleHRyZWdpb246ZTJiYjQ1NDcwMWRlNGU1MWJmMjc0ZGJiNGRkZWQxODNfNDMwNg_03abb701-0dea-4946-9cd5-2399e9701b95"
      unitRef="sqft">75000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfMTIyMzM_28965538-da05-4de1-a565-a95282828f13">Fair value of financial instruments and marketable securities&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company follows the fair value measurement rules, which provide&#160;guidance on the use of fair value in accounting and disclosure for assets and liabilities when such accounting and disclosure is called for by other accounting literature. These rules&#160;establish a fair value hierarchy for inputs to be used to measure fair value of financial assets and liabilities. This hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels: Level 1 (highest priority), Level 2, and Level 3 (lowest priority).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#xb7;&#160;Level 1&#x2014;Unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the balance sheet date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#xb7;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 2&#x2014;Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves,&#160;etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#xb7;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 3&#x2014;Inputs are unobservable and reflect the Company&#x2019;s assumptions as to what market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cash equivalents and marketable securities are reflected in the accompanying financial statements at fair value. The carrying amount of receivables and accounts payable and accrued expenses approximates fair value due to the short-term nature of those instruments. The carrying amounts for borrowings under the credit and security agreement with MidCap Financial approximate fair value based on market activity for other debt instruments with similar characteristics and comparable risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In May 2019, the Company purchased $4.0 million of shares of ClearPoint Neuro, Inc.'s ("ClearPoint"), formerly known as MRI Interventions, Inc., common stock, at a purchase price of $3.10 per share, in connection with a securities purchase agreement that the Company entered into with ClearPoint, a publicly traded medical device company. The Company determined that the equity investment represents a financial instrument and therefore, recorded it at fair value, which is readily determinable. The equity investment is a component of deposits and other assets on the consolidated balance sheet. During the three and six month periods ended June&#160;30, 2020, the Company recorded unrealized losses of $0.1 million and $1.6 million, respectively, which are components of other expense, net within the consolidated statement of operations. The fair value of the equity investment was $4.6 million as of June&#160;30, 2020. The Company classifies its equity investment in ClearPoint as a Level 1 asset within the fair value hierarchy, as the value is based on a quoted market price in an active market, which is not adjusted.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In January 2020, the Company purchased a $10.0 million convertible note from ClearPoint that the Company can convert into ClearPoint shares at a conversion rate of $6.00 per share at any point throughout the term of the loan, which matures five years from the purchase date.  The Company determined that the convertible note represents an available for sale debt security and the Company has elected to record it at fair value under ASC 825.  The Company classifies its ClearPoint convertible debt security as a Level 2 asset within the fair value hierarchy, as the value is based on inputs other than quoted prices that are observable. The fair value of the ClearPoint convertible debt security is determined at each reporting period by utilizing a Black-Scholes option pricing model, as well as a present value of expected cash flows from the debt security utilizing the risk free rate and the estimated credit spread as of the valuation date as the discount rate. During the three and six month periods ended June&#160;30, 2020, the Company recorded an unrealized gain of $2.1 million and an unrealized loss of $0.7 million, respectively, which are components of other expense and other income, net within the consolidated statement of operations. The fair value of the convertible debt security was $9.3 million as of June&#160;30, 2020. The convertible debt security is considered to be long term and is included as a component of deposits and other assets on the consolidated balance sheet. Other than the equity investment and the convertible debt security, no other items included in deposits and other assets on the consolidated balance sheets are fair valued.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Fair value of certain marketable securities is based upon market prices using quoted prices in active markets for identical assets quoted on the last day of the period. In establishing the estimated fair value of the remaining investments, the Company used the fair value as determined by its investment advisors using observable inputs other than quoted prices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following represents the fair value using the hierarchy described above for the Company&#x2019;s financial assets and liabilities that are required to be measured at fair value on a recurring basis as of June&#160;30, 2020 and December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:51.323%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.538%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.078%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.538%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.373%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.538%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.487%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.538%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.787%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Quoted&#160;prices&lt;br/&gt;in&#160;active&lt;br/&gt;markets&#160;for&lt;br/&gt;identical&#160;assets&lt;br/&gt;(level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant&lt;br/&gt;other&lt;br/&gt;observable&lt;br/&gt;inputs&lt;br/&gt;(level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant&lt;br/&gt;unobservable&lt;br/&gt;inputs&lt;br/&gt;(level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;340,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;340,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Equity investment in ClearPoint&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;ClearPoint convertible debt security&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred consideration payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration payable- development and regulatory milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;136,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;136,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration payable- net sales milestones and royalties &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;89,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;89,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:51.244%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.537%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.209%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.537%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.799%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.537%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.537%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.181%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Quoted&#160;prices&lt;br/&gt;in&#160;active&lt;br/&gt;markets&#160;for&lt;br/&gt;identical&#160;assets&lt;br/&gt;(level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant&lt;br/&gt;other&lt;br/&gt;observable&lt;br/&gt;inputs&lt;br/&gt;(level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant&lt;br/&gt;unobservable&lt;br/&gt;inputs&lt;br/&gt;(level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;398,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;398,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Equity investment in ClearPoint&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Stock appreciation rights liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred consideration payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration payable- development and regulatory milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;290,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;290,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration payable- net sales milestones and royalties &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;65,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;65,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;No transfers of assets between Level 1, Level 2, or Level 3 of the fair value measurement hierarchy occurred during the periods ended June&#160;30, 2020 and December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following is a summary of marketable securities accounted for as available-for-sale securities at June&#160;30, 2020 and December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.120%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.741%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&#160;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;221,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;223,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;337,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;340,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.120%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.741%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&#160;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;157,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;158,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;188,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;189,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;397,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;398,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For available for sale debt securities in an unrealized loss position, the Company assesses whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security's amortized cost basis is written down to fair value. For &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;the three month and six month periods ended June&#160;30, 2020, no write downs occurred. &#160;The Company does not intend to sell the investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be maturity. The Company also reviews its available for sale debt securities in an unrealized loss position and evaluates whether the decline in fair value has resulted from credit losses or other factors. This review is subjective, as it requires management to evaluate whether an event or change in circumstances has occurred in that period that may be related to credit issues. For the three month and six month periods ended June&#160;30, 2020, no allowance was recorded for credit losses. Unrealized gains and losses are reported as a component of accumulated other comprehensive (loss) income in stockholders&#x2019; equity. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For the three month and six month periods ended June&#160;30, 2020, the Company had $0.2&#160;million realized gains from the sale of marketable securities. Realized gains are reported as a component of interest expense, net in the consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of&#160;June&#160;30, 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:19.585%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.334%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.334%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.334%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.334%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.334%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.341%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="33" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Securities in an unrealized loss position less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Securities in an unrealized loss position greater than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of&#160;December&#160;31, 2019 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:19.585%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.334%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.334%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.334%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.334%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.334%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.341%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="33" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Securities in an unrealized loss position less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Securities in an unrealized loss position greater than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;71,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;71,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;95,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;95,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Marketable securities on the balance sheet at June&#160;30, 2020 and December&#160;31, 2019 mature as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.060%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less&#160;Than&lt;br/&gt;12&#160;Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;More&#160;Than&lt;br/&gt;12&#160;Months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;168,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;55,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;255,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;84,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.060%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less&#160;Than&lt;br/&gt;12&#160;Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;More&#160;Than&lt;br/&gt;12&#160;Months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;158,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;139,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;342,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;56,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company classifies all of its marketable securities as current as they are all available for sale and are available for current operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Convertible senior notes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2015, the Company issued $150.0 million of 3.00% convertible senior notes due August&#160;15, 2022 (the &#x201c;2022 Convertible Notes&#x201d;). In September 2019, the Company issued $287.5 million of 1.50% convertible senior notes due September&#160;15, 2026 (the &#x201c;2026 Convertible Notes,&#x201d; together with the &#x201c;2022 Convertible Notes,&#x201d; the &#x201c;Convertible Notes&#x201d;). The Company separately accounted for the liability and equity components of the Convertible Notes by allocating the proceeds between the liability component and equity component, as further discussed in Note&#160;11. The fair value of the Convertible Notes, which differs from their carrying values, is influenced by interest rates, the Company&#x2019;s stock price and stock price volatility and is determined by prices for the Convertible Notes observed in market trading which are Level&#160;2 inputs. The estimated fair value of the 2022 Convertible Notes at June&#160;30, 2020 and December&#160;31, 2019 was $175.2 million and $171.2 million, respectively. The estimated fair value of the 2026 Convertible Notes at June&#160;30, 2020 and December&#160;31, 2019 was $343.8 million and $335.0 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Deferred and contingent consideration payable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Pursuant to the Merger Agreement, Agilis equityholders were previously entitled to receive contingent consideration payments from the Company based on&#160;the achievement of certain development milestones up to an aggregate maximum amount of $60.0 million and&#160;the achievement of certain regulatory approval milestones together with a milestone payment following the receipt of a priority review voucher up to an aggregate maximum amount of $535.0 million. The Company was required to pay $40.0 million of development milestone payments upon the passing of the second anniversary of the closing of the Merger, regardless of whether the applicable milestones have been achieved. The $40.0 million of development milestones were classified as deferred consideration on the Company's consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Pursuant to the terms of the Rights Exchange Agreement, in the three month period ended June 30, 2020, the Company issued 2,821,176 shares of its common stock and paid $36.9&#160;million in the aggregate, to Participating Rightholders, who in exchange have canceled and forfeited their rights under the Merger Agreement to receive (i) $174.0&#160;million, in the aggregate, of potential milestone payments based on the achievement of certain regulatory milestones and (ii) $37.6&#160;million, in the aggregate, of $40.0&#160;million in development milestone payments, or the deferred consideration, that would have been due upon the passing of the second anniversary of the closing of the Merger. As a result of the Rights Exchange Agreement, the remaining deferred consideration payable at June&#160;30, 2020 was $2.4 million, which was also determined to be the fair value. The Company did not apply a discount, as the milestones will be paid within one calendar year.  Accordingly, as of June&#160;30, 2020, the $2.4 million of the deferred consideration payable was classified as current on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;As of result of the Rights Exchange Agreement, the Company recognized a gain of $0.7&#160;million on the settlement of the development milestones and a loss of $11.3&#160;million on the settlement of the regulatory milestones. The $0.7&#160;million gain and $11.3&#160;million loss are included in the settlement of deferred and contingent consideration in the Company&#x2019;s statement of operations for the three and six month periods ended June 30, 2020. Additionally, as of the date of the Rights Exchange Agreement, the Company recognized a gain on the fair value of the contingent consideration of $1.0&#160;million related to the portion of regulatory milestones that were forfeited, which is included in the change in fair value of the deferred and contingent liability within the Company&#x2019;s statement of operations for the three and six month periods ended June 30, 2020. This non-recurring Level 3 fair value measurement was estimated using the same valuation methoolody and unobservable inputs for development and regulatory milestones in the Level 3 valuation section below. In conjunction with the Rights Exchange Agreement, the Company also incurred $2.0 million of transaction fees, which were included in other expense in the Company&#x2019;s statement of operations for the three and six month periods ended June 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Level 3 valuation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The stock appreciation rights ("SARs") liability is classified in other liabilities on the Company&#x2019;s consolidated balance sheets. The SARs liability is marked-to-market each reporting period with the change in fair value recorded as compensation expense on the Company&#x2019;s consolidated statements of operations until the SARs vest. The fair value of the SARs liability is determined at each reporting period by utilizing the Black-Scholes option pricing model. The last payment of the SARs liability was made in the three month period ended March 31, 2020, and accordingly, the balance of the SARS liability as of June 30, 2020 was $0. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The contingent consideration payable is fair valued each reporting period with the change in fair value recorded as a gain or loss within the change in the fair value of deferred and contingent consideration on the consolidated statements of operations.  The fair value of the development and regulatory milestones is estimated utilizing a probability adjusted, discounted cash flow approach. The discount rates are estimated utilizing Corporate B rated bonds maturing in the years of expected payments based on the Company&#x2019;s estimated development timelines for the acquired product candidate. At June&#160;30, 2020, the weighted average discount rate for the development and regulatory milestones was 5.4% and the weighted average probability of success was 43%.  The fair value of the net sales milestones and royalties is determined utilizing an option pricing model with Monte Carlo simulation to simulate a range of possible payment scenarios, and the average of the payments in these scenarios is then discounted to calculate present fair value. At June&#160;30, 2020, the weighted average discount rate for the net sales milestones and royalties was 12.0% and the weighted average probability of success for the net sales milestones was 50%.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The table presented below is a summary of changes in the fair value of the Company&#x2019;s Level 3 valuations for the SARs liability, and the contingent consideration payable for the periods ended June&#160;30, 2020 and June&#160;30, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.549%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:50.533%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.644%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.033%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.644%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.033%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.475%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.038%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3 liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;SARs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration payable- development and regulatory milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration payable- net sales milestones and royalties&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Beginning balance as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;290,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;65,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(15,220)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,186)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Rights Exchange settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(139,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Ending balance as of June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;136,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;89,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.573%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:49.919%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.634%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.858%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.634%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.858%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.467%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.030%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3 liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;SARs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration payable- development and regulatory milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration payable- net sales milestones and royalties&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Beginning balance as of December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;257,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Ending balance as of June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;277,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;58,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following significant unobservable inputs were used in the valuation of the contingent consideration payable for the periods ended June&#160;30, 2020 and December&#160;31, 2019 and of the SARs liability for the period ended December 31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.998%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.415%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.481%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.415%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.823%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.121%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:21.494%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.415%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.038%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="10" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="10" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unobservable Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="10" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration payable- development and regulatory milestones&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="9" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$136,100&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Probability-adjusted discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Potential development and regulatory milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;$0 - $381 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Probabilities of success&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;25% - 94%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Discount rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;4.6% - 6.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Projected years of payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021 - 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent considerable payable- net sales milestones and royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$89,600&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Option-pricing model with Monte Carlo simulation&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Potential net sales milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;$0 - $150 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Probabilities of success&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;25% -94%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Potential percentage of net sales for royalties &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;2% - 6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Projected years of payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022 - 2039&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.998%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.415%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.481%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.415%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.823%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.121%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:21.494%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.415%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.038%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="15" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="15" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unobservable Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="15" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;SARs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="14" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$3,186&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Option-pricing model&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28.93%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.19%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Strike price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;$6.76 - $30.86&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$48.03&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.01 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Contingent consideration payable- development and regulatory milestones&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$290,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Probability-adjusted discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Potential development and regulatory milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;$0- $555 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Probabilities of success&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;25% - 94%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Discount rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;2.2% - 4.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Projected years of payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020 - 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent considerable payable- net sales milestones and royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$65,800&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Option-pricing model with Monte Carlo simulation&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Potential net sales milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;$0 - $150 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Probabilities of success&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;25% - 89%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Potential percentage of net sales for royalties &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;2% - 6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Projected years of payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021 - 2038&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The contingent consideration payables are classified Level 3 liabilities as their valuation requires substantial judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for the various inputs to the valuation approaches, including but not limited to, assumptions involving probability adjusted sales estimates for the gene therapy platform and estimated discount rates, the estimated fair value could be significantly higher or lower than the fair value determined.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfMTIyMzM_b9efc197-7805-45ca-836d-8fae3d3d1ac5">Fair value of financial instruments and marketable securities&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company follows the fair value measurement rules, which provide&#160;guidance on the use of fair value in accounting and disclosure for assets and liabilities when such accounting and disclosure is called for by other accounting literature. These rules&#160;establish a fair value hierarchy for inputs to be used to measure fair value of financial assets and liabilities. This hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels: Level 1 (highest priority), Level 2, and Level 3 (lowest priority).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#xb7;&#160;Level 1&#x2014;Unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the balance sheet date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#xb7;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 2&#x2014;Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves,&#160;etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#xb7;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 3&#x2014;Inputs are unobservable and reflect the Company&#x2019;s assumptions as to what market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cash equivalents and marketable securities are reflected in the accompanying financial statements at fair value. The carrying amount of receivables and accounts payable and accrued expenses approximates fair value due to the short-term nature of those instruments. The carrying amounts for borrowings under the credit and security agreement with MidCap Financial approximate fair value based on market activity for other debt instruments with similar characteristics and comparable risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In May 2019, the Company purchased $4.0 million of shares of ClearPoint Neuro, Inc.'s ("ClearPoint"), formerly known as MRI Interventions, Inc., common stock, at a purchase price of $3.10 per share, in connection with a securities purchase agreement that the Company entered into with ClearPoint, a publicly traded medical device company. The Company determined that the equity investment represents a financial instrument and therefore, recorded it at fair value, which is readily determinable. The equity investment is a component of deposits and other assets on the consolidated balance sheet. During the three and six month periods ended June&#160;30, 2020, the Company recorded unrealized losses of $0.1 million and $1.6 million, respectively, which are components of other expense, net within the consolidated statement of operations. The fair value of the equity investment was $4.6 million as of June&#160;30, 2020. The Company classifies its equity investment in ClearPoint as a Level 1 asset within the fair value hierarchy, as the value is based on a quoted market price in an active market, which is not adjusted.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In January 2020, the Company purchased a $10.0 million convertible note from ClearPoint that the Company can convert into ClearPoint shares at a conversion rate of $6.00 per share at any point throughout the term of the loan, which matures five years from the purchase date.  The Company determined that the convertible note represents an available for sale debt security and the Company has elected to record it at fair value under ASC 825.  The Company classifies its ClearPoint convertible debt security as a Level 2 asset within the fair value hierarchy, as the value is based on inputs other than quoted prices that are observable. The fair value of the ClearPoint convertible debt security is determined at each reporting period by utilizing a Black-Scholes option pricing model, as well as a present value of expected cash flows from the debt security utilizing the risk free rate and the estimated credit spread as of the valuation date as the discount rate. During the three and six month periods ended June&#160;30, 2020, the Company recorded an unrealized gain of $2.1 million and an unrealized loss of $0.7 million, respectively, which are components of other expense and other income, net within the consolidated statement of operations. The fair value of the convertible debt security was $9.3 million as of June&#160;30, 2020. The convertible debt security is considered to be long term and is included as a component of deposits and other assets on the consolidated balance sheet. Other than the equity investment and the convertible debt security, no other items included in deposits and other assets on the consolidated balance sheets are fair valued.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Fair value of certain marketable securities is based upon market prices using quoted prices in active markets for identical assets quoted on the last day of the period. In establishing the estimated fair value of the remaining investments, the Company used the fair value as determined by its investment advisors using observable inputs other than quoted prices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following represents the fair value using the hierarchy described above for the Company&#x2019;s financial assets and liabilities that are required to be measured at fair value on a recurring basis as of June&#160;30, 2020 and December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:51.323%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.538%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.078%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.538%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.373%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.538%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.487%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.538%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.787%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Quoted&#160;prices&lt;br/&gt;in&#160;active&lt;br/&gt;markets&#160;for&lt;br/&gt;identical&#160;assets&lt;br/&gt;(level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant&lt;br/&gt;other&lt;br/&gt;observable&lt;br/&gt;inputs&lt;br/&gt;(level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant&lt;br/&gt;unobservable&lt;br/&gt;inputs&lt;br/&gt;(level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;340,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;340,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Equity investment in ClearPoint&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;ClearPoint convertible debt security&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred consideration payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration payable- development and regulatory milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;136,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;136,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration payable- net sales milestones and royalties &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;89,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;89,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:51.244%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.537%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.209%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.537%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.799%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.537%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.537%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.181%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Quoted&#160;prices&lt;br/&gt;in&#160;active&lt;br/&gt;markets&#160;for&lt;br/&gt;identical&#160;assets&lt;br/&gt;(level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant&lt;br/&gt;other&lt;br/&gt;observable&lt;br/&gt;inputs&lt;br/&gt;(level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant&lt;br/&gt;unobservable&lt;br/&gt;inputs&lt;br/&gt;(level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;398,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;398,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Equity investment in ClearPoint&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Stock appreciation rights liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred consideration payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration payable- development and regulatory milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;290,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;290,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration payable- net sales milestones and royalties &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;65,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;65,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;No transfers of assets between Level 1, Level 2, or Level 3 of the fair value measurement hierarchy occurred during the periods ended June&#160;30, 2020 and December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following is a summary of marketable securities accounted for as available-for-sale securities at June&#160;30, 2020 and December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.120%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.741%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&#160;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;221,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;223,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;337,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;340,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.120%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.741%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&#160;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;157,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;158,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;188,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;189,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;397,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;398,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For available for sale debt securities in an unrealized loss position, the Company assesses whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security's amortized cost basis is written down to fair value. For &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;the three month and six month periods ended June&#160;30, 2020, no write downs occurred. &#160;The Company does not intend to sell the investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be maturity. The Company also reviews its available for sale debt securities in an unrealized loss position and evaluates whether the decline in fair value has resulted from credit losses or other factors. This review is subjective, as it requires management to evaluate whether an event or change in circumstances has occurred in that period that may be related to credit issues. For the three month and six month periods ended June&#160;30, 2020, no allowance was recorded for credit losses. Unrealized gains and losses are reported as a component of accumulated other comprehensive (loss) income in stockholders&#x2019; equity. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For the three month and six month periods ended June&#160;30, 2020, the Company had $0.2&#160;million realized gains from the sale of marketable securities. Realized gains are reported as a component of interest expense, net in the consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of&#160;June&#160;30, 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:19.585%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.334%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.334%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.334%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.334%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.334%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.341%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="33" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Securities in an unrealized loss position less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Securities in an unrealized loss position greater than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of&#160;December&#160;31, 2019 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:19.585%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.334%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.334%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.334%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.334%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.334%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.341%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="33" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Securities in an unrealized loss position less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Securities in an unrealized loss position greater than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;71,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;71,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;95,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;95,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Marketable securities on the balance sheet at June&#160;30, 2020 and December&#160;31, 2019 mature as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.060%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less&#160;Than&lt;br/&gt;12&#160;Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;More&#160;Than&lt;br/&gt;12&#160;Months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;168,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;55,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;255,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;84,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.060%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less&#160;Than&lt;br/&gt;12&#160;Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;More&#160;Than&lt;br/&gt;12&#160;Months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;158,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;139,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;342,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;56,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company classifies all of its marketable securities as current as they are all available for sale and are available for current operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Convertible senior notes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2015, the Company issued $150.0 million of 3.00% convertible senior notes due August&#160;15, 2022 (the &#x201c;2022 Convertible Notes&#x201d;). In September 2019, the Company issued $287.5 million of 1.50% convertible senior notes due September&#160;15, 2026 (the &#x201c;2026 Convertible Notes,&#x201d; together with the &#x201c;2022 Convertible Notes,&#x201d; the &#x201c;Convertible Notes&#x201d;). The Company separately accounted for the liability and equity components of the Convertible Notes by allocating the proceeds between the liability component and equity component, as further discussed in Note&#160;11. The fair value of the Convertible Notes, which differs from their carrying values, is influenced by interest rates, the Company&#x2019;s stock price and stock price volatility and is determined by prices for the Convertible Notes observed in market trading which are Level&#160;2 inputs. The estimated fair value of the 2022 Convertible Notes at June&#160;30, 2020 and December&#160;31, 2019 was $175.2 million and $171.2 million, respectively. The estimated fair value of the 2026 Convertible Notes at June&#160;30, 2020 and December&#160;31, 2019 was $343.8 million and $335.0 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Deferred and contingent consideration payable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Pursuant to the Merger Agreement, Agilis equityholders were previously entitled to receive contingent consideration payments from the Company based on&#160;the achievement of certain development milestones up to an aggregate maximum amount of $60.0 million and&#160;the achievement of certain regulatory approval milestones together with a milestone payment following the receipt of a priority review voucher up to an aggregate maximum amount of $535.0 million. The Company was required to pay $40.0 million of development milestone payments upon the passing of the second anniversary of the closing of the Merger, regardless of whether the applicable milestones have been achieved. The $40.0 million of development milestones were classified as deferred consideration on the Company's consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Pursuant to the terms of the Rights Exchange Agreement, in the three month period ended June 30, 2020, the Company issued 2,821,176 shares of its common stock and paid $36.9&#160;million in the aggregate, to Participating Rightholders, who in exchange have canceled and forfeited their rights under the Merger Agreement to receive (i) $174.0&#160;million, in the aggregate, of potential milestone payments based on the achievement of certain regulatory milestones and (ii) $37.6&#160;million, in the aggregate, of $40.0&#160;million in development milestone payments, or the deferred consideration, that would have been due upon the passing of the second anniversary of the closing of the Merger. As a result of the Rights Exchange Agreement, the remaining deferred consideration payable at June&#160;30, 2020 was $2.4 million, which was also determined to be the fair value. The Company did not apply a discount, as the milestones will be paid within one calendar year.  Accordingly, as of June&#160;30, 2020, the $2.4 million of the deferred consideration payable was classified as current on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;As of result of the Rights Exchange Agreement, the Company recognized a gain of $0.7&#160;million on the settlement of the development milestones and a loss of $11.3&#160;million on the settlement of the regulatory milestones. The $0.7&#160;million gain and $11.3&#160;million loss are included in the settlement of deferred and contingent consideration in the Company&#x2019;s statement of operations for the three and six month periods ended June 30, 2020. Additionally, as of the date of the Rights Exchange Agreement, the Company recognized a gain on the fair value of the contingent consideration of $1.0&#160;million related to the portion of regulatory milestones that were forfeited, which is included in the change in fair value of the deferred and contingent liability within the Company&#x2019;s statement of operations for the three and six month periods ended June 30, 2020. This non-recurring Level 3 fair value measurement was estimated using the same valuation methoolody and unobservable inputs for development and regulatory milestones in the Level 3 valuation section below. In conjunction with the Rights Exchange Agreement, the Company also incurred $2.0 million of transaction fees, which were included in other expense in the Company&#x2019;s statement of operations for the three and six month periods ended June 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Level 3 valuation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The stock appreciation rights ("SARs") liability is classified in other liabilities on the Company&#x2019;s consolidated balance sheets. The SARs liability is marked-to-market each reporting period with the change in fair value recorded as compensation expense on the Company&#x2019;s consolidated statements of operations until the SARs vest. The fair value of the SARs liability is determined at each reporting period by utilizing the Black-Scholes option pricing model. The last payment of the SARs liability was made in the three month period ended March 31, 2020, and accordingly, the balance of the SARS liability as of June 30, 2020 was $0. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The contingent consideration payable is fair valued each reporting period with the change in fair value recorded as a gain or loss within the change in the fair value of deferred and contingent consideration on the consolidated statements of operations.  The fair value of the development and regulatory milestones is estimated utilizing a probability adjusted, discounted cash flow approach. The discount rates are estimated utilizing Corporate B rated bonds maturing in the years of expected payments based on the Company&#x2019;s estimated development timelines for the acquired product candidate. At June&#160;30, 2020, the weighted average discount rate for the development and regulatory milestones was 5.4% and the weighted average probability of success was 43%.  The fair value of the net sales milestones and royalties is determined utilizing an option pricing model with Monte Carlo simulation to simulate a range of possible payment scenarios, and the average of the payments in these scenarios is then discounted to calculate present fair value. At June&#160;30, 2020, the weighted average discount rate for the net sales milestones and royalties was 12.0% and the weighted average probability of success for the net sales milestones was 50%.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The table presented below is a summary of changes in the fair value of the Company&#x2019;s Level 3 valuations for the SARs liability, and the contingent consideration payable for the periods ended June&#160;30, 2020 and June&#160;30, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.549%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:50.533%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.644%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.033%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.644%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.033%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.475%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.038%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3 liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;SARs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration payable- development and regulatory milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration payable- net sales milestones and royalties&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Beginning balance as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;290,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;65,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(15,220)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,186)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Rights Exchange settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(139,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Ending balance as of June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;136,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;89,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.573%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:49.919%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.634%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.858%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.634%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.858%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.467%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.030%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3 liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;SARs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration payable- development and regulatory milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration payable- net sales milestones and royalties&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Beginning balance as of December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;257,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Ending balance as of June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;277,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;58,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following significant unobservable inputs were used in the valuation of the contingent consideration payable for the periods ended June&#160;30, 2020 and December&#160;31, 2019 and of the SARs liability for the period ended December 31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.998%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.415%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.481%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.415%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.823%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.121%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:21.494%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.415%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.038%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="10" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="10" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unobservable Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="10" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration payable- development and regulatory milestones&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="9" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$136,100&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Probability-adjusted discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Potential development and regulatory milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;$0 - $381 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Probabilities of success&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;25% - 94%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Discount rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;4.6% - 6.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Projected years of payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021 - 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent considerable payable- net sales milestones and royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$89,600&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Option-pricing model with Monte Carlo simulation&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Potential net sales milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;$0 - $150 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Probabilities of success&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;25% -94%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Potential percentage of net sales for royalties &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;2% - 6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Projected years of payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022 - 2039&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.998%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.415%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.481%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.415%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.823%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.121%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:21.494%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.415%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.038%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="15" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="15" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unobservable Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="15" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;SARs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="14" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$3,186&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Option-pricing model&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28.93%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.19%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Strike price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;$6.76 - $30.86&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$48.03&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.01 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Contingent consideration payable- development and regulatory milestones&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$290,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Probability-adjusted discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Potential development and regulatory milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;$0- $555 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Probabilities of success&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;25% - 94%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Discount rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;2.2% - 4.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Projected years of payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020 - 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent considerable payable- net sales milestones and royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$65,800&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Option-pricing model with Monte Carlo simulation&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Potential net sales milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;$0 - $150 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Probabilities of success&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;25% - 89%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Potential percentage of net sales for royalties &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;2% - 6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Projected years of payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021 - 2038&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The contingent consideration payables are classified Level 3 liabilities as their valuation requires substantial judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for the various inputs to the valuation approaches, including but not limited to, assumptions involving probability adjusted sales estimates for the gene therapy platform and estimated discount rates, the estimated fair value could be significantly higher or lower than the fair value determined.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount
      contextRef="ie6a7756ab1084e378dab79f603770a11_I20190531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfMjExNw_b20aa176-3db2-47db-9197-a7cb4fe999c8"
      unitRef="usd">4000000.0</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:SharePrice
      contextRef="ie6a7756ab1084e378dab79f603770a11_I20190531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfMjI1NA_aee42b2f-20a7-4be3-a467-c5f505520137"
      unitRef="usdPerShare">3.10</us-gaap:SharePrice>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="iba78e43751ff4a8f8903200b06897a60_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfMjc0Ng_3208edd2-b545-40a9-916a-0ad3b9be3338"
      unitRef="usd">100000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i4b06422408ed4884889f98fec6b585e7_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfNDk0NzgwMjMzNzI3OA_12ed13b2-6e08-4f40-bc06-2c2aa5f9c9ac"
      unitRef="usd">1600000</us-gaap:UnrealizedGainLossOnInvestments>
    <ptct:InvestmentInMRI
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfMjg4Ng_c78e6408-0b61-40b6-b91c-96ac6d2d6070"
      unitRef="usd">4600000</ptct:InvestmentInMRI>
    <ptct:PaymentsToAcquireConvertibleDebtInvestment
      contextRef="iab70e96c6dcd4cf38e8acc5f76da5a1c_D20200101-20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfMzE0Mg_1c7b5500-7ec0-494e-ab7d-72aff0a503d0"
      unitRef="usd">10000000.0</ptct:PaymentsToAcquireConvertibleDebtInvestment>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfMzI1NA_b9cecef0-c7ba-491e-914a-3b8ff941a7bf"
      unitRef="usdPerShare">6.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <ptct:DebtInstrumentConvertiblePeriod
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfMzMyNw_d2a78efa-5746-497a-916f-4a1ce4f85683">P5Y</ptct:DebtInstrumentConvertiblePeriod>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfNDEyOQ_13ab549e-fd34-4090-b219-99016518c13e"
      unitRef="usd">2100000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfNDk0NzgwMjMzNzMzNQ_bcdd07c9-fa5f-4cc7-80c0-d97ba00bfba9"
      unitRef="usd">700000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3e35023e351f4322a3c1e517dc55d17f_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfNDI3Nw_f9087dfe-43c8-475a-889e-080b1a0d3892"
      unitRef="usd">9300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfMTIyMzg_548bd6df-7824-4c0b-8f9d-42f5a072036a">&lt;div style="margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following represents the fair value using the hierarchy described above for the Company&#x2019;s financial assets and liabilities that are required to be measured at fair value on a recurring basis as of June&#160;30, 2020 and December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:51.323%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.538%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.078%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.538%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.373%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.538%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.487%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.538%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.787%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Quoted&#160;prices&lt;br/&gt;in&#160;active&lt;br/&gt;markets&#160;for&lt;br/&gt;identical&#160;assets&lt;br/&gt;(level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant&lt;br/&gt;other&lt;br/&gt;observable&lt;br/&gt;inputs&lt;br/&gt;(level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant&lt;br/&gt;unobservable&lt;br/&gt;inputs&lt;br/&gt;(level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;340,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;340,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Equity investment in ClearPoint&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;ClearPoint convertible debt security&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred consideration payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration payable- development and regulatory milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;136,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;136,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration payable- net sales milestones and royalties &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;89,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;89,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:51.244%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.537%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.209%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.537%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.799%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.537%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.537%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.181%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Quoted&#160;prices&lt;br/&gt;in&#160;active&lt;br/&gt;markets&#160;for&lt;br/&gt;identical&#160;assets&lt;br/&gt;(level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant&lt;br/&gt;other&lt;br/&gt;observable&lt;br/&gt;inputs&lt;br/&gt;(level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant&lt;br/&gt;unobservable&lt;br/&gt;inputs&lt;br/&gt;(level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;398,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;398,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Equity investment in ClearPoint&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Stock appreciation rights liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred consideration payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration payable- development and regulatory milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;290,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;290,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration payable- net sales milestones and royalties &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;65,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;65,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i40c26ba683a24d9e98f2ec75db288d77_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfMi0yLTEtMS0w_cc84f992-a6c5-48be-b333-71cf5691d7ee"
      unitRef="usd">340430000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i99c95301a4884daa9e367f37995284bd_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfMi00LTEtMS0w_9912525c-86b1-4b2e-a327-b182e735bd78"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0e7e649fe3864de3976f553389445c8b_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfMi02LTEtMS0w_aa6fa7d7-5ea3-44fa-a198-9d3487069c8f"
      unitRef="usd">340430000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie9d447580c3b40f3beffae2bafa97465_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfMi04LTEtMS0w_894c8be9-2d70-487b-bb7b-37445381d20b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i44f6355301964dabbb766e645f3cf148_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfMy0yLTEtMS0w_91d2cb34-e2ca-4551-813f-bf882af57f3b"
      unitRef="usd">4594000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i15f90f09637a4cb1bb715dfe4f05297a_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfMy00LTEtMS0w_c8e3fd71-4b16-445f-9c58-dfd843f1a683"
      unitRef="usd">4594000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i0b16af03a6464f1daa8673b162ab2586_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfMy02LTEtMS0w_594f03e1-7474-4865-8d70-812092047c91"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i761da636d68a44a59452ea0f2aa77729_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfMy04LTEtMS0w_279131df-5ec2-4d18-a1a1-4c7895c7bf66"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3e35023e351f4322a3c1e517dc55d17f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfNC0yLTEtMS0w_ce388884-297d-4b67-ba93-aab2762cb9f4"
      unitRef="usd">9251000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6ca9ba441e8d4540804f886f1cc9c954_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfNC00LTEtMS0w_ae0ab5b8-f283-4f81-a52d-f53fb2a58e94"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if3c1cca7bff548549723c72b62c5cabd_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfNC02LTEtMS0w_d4d9e136-7b1e-4c00-ba0b-a9817c033ba6"
      unitRef="usd">9251000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifc5b2ebfb0104a74a263ad842ff6c5b7_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfNC04LTEtMS0w_85a32e7a-9995-4721-b3bd-d3361aac2ce6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable
      contextRef="i44f6355301964dabbb766e645f3cf148_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfNS0yLTEtMS0w_0113eee4-8550-48f1-9ad4-c9332c756085"
      unitRef="usd">2384000</ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable>
    <ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable
      contextRef="i15f90f09637a4cb1bb715dfe4f05297a_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfNS00LTEtMS0w_8e26b56a-582f-4553-b68d-4af09d2dbf89"
      unitRef="usd">0</ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable>
    <ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable
      contextRef="i0b16af03a6464f1daa8673b162ab2586_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfNS02LTEtMS0w_548486ba-c330-4315-8985-a2ef3edfc836"
      unitRef="usd">2384000</ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable>
    <ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable
      contextRef="i761da636d68a44a59452ea0f2aa77729_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfNS04LTEtMS0w_44b0349f-6903-49b3-801f-c3e302a2c283"
      unitRef="usd">0</ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i44f6355301964dabbb766e645f3cf148_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfNi0yLTEtMS0w_98e9569d-4c3e-47bd-9676-d932f08b8537"
      unitRef="usd">136100000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i15f90f09637a4cb1bb715dfe4f05297a_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfNi00LTEtMS0w_163bc132-cadc-4812-9ec2-8a683ed9e000"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i0b16af03a6464f1daa8673b162ab2586_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfNi02LTEtMS0w_c5ed9d7c-2bb4-4ac5-8a89-b4a904dbea89"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i761da636d68a44a59452ea0f2aa77729_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfNi04LTEtMS0w_1eab5a50-af1c-4254-90a4-f13992ef49d8"
      unitRef="usd">136100000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i44f6355301964dabbb766e645f3cf148_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfNy0yLTEtMS0w_a26ca153-72f4-4bd9-bb61-fd2e7a57d230"
      unitRef="usd">89600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i15f90f09637a4cb1bb715dfe4f05297a_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfNy00LTEtMS0w_5090d8cb-70fe-4e3c-8b88-9926ae5b00c5"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i0b16af03a6464f1daa8673b162ab2586_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfNy02LTEtMS0w_d0ccef17-7f7e-4f40-a059-59f776a4935a"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="if300ba06104942c0b9bc9c2620d5efae_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE5YmVjYWQ5NDI5OTQ0NzQ5ZDA1Mzk5MmYxNzA0OWY1L3RhYmxlcmFuZ2U6YTliZWNhZDk0Mjk5NDQ3NDlkMDUzOTkyZjE3MDQ5ZjVfNy04LTEtMS0w_a6bef3b6-9558-44b1-836a-be00ec7b600c"
      unitRef="usd">89600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i846b553e2ead487080c5135cbfabf245_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfMi0yLTEtMS0w_ff8a82ca-9079-4784-9181-8a833c196be3"
      unitRef="usd">398535000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i93db7a3e36c54bccb14ea9da633b0ca2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfMi00LTEtMS0w_0194d6dd-64b2-4d49-bd58-0ed00d9bec4a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ice1694004db8457f8428afa653a62360_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfMi02LTEtMS0w_9adf4bed-c13c-4211-8fc9-ea6725aec5f5"
      unitRef="usd">398535000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i093049f7698c438ea17d8d78b2999a3b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfMi04LTEtMS0w_9d625c0f-8141-444c-b88b-a4b67d67f51e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i846b553e2ead487080c5135cbfabf245_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfMy0yLTEtMS0w_af9c523a-f0b8-42c6-a452-6ebe95233a26"
      unitRef="usd">6194000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i93db7a3e36c54bccb14ea9da633b0ca2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfMy00LTEtMS0w_023f6f4c-3ef4-4323-b720-98902a721be9"
      unitRef="usd">6194000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ice1694004db8457f8428afa653a62360_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfMy02LTEtMS0w_559ea80b-1845-438d-b580-fc81f369cb0a"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i093049f7698c438ea17d8d78b2999a3b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfMy04LTEtMS0w_5851bded-49bd-4a42-995b-c656defce29d"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <ptct:StockAppreciationRightsLiabilityOutstanding
      contextRef="i846b553e2ead487080c5135cbfabf245_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfNC0yLTEtMS0w_394b8273-2c84-48c1-ab18-1d727e6213ea"
      unitRef="usd">3186000</ptct:StockAppreciationRightsLiabilityOutstanding>
    <ptct:StockAppreciationRightsLiabilityOutstanding
      contextRef="i93db7a3e36c54bccb14ea9da633b0ca2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfNC00LTEtMS0w_0c5793bc-6d2c-4b91-a6f7-0ce6c11b343c"
      unitRef="usd">0</ptct:StockAppreciationRightsLiabilityOutstanding>
    <ptct:StockAppreciationRightsLiabilityOutstanding
      contextRef="ice1694004db8457f8428afa653a62360_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfNC02LTEtMS0w_a4ebcd62-b631-4b48-b1cc-65d9ead45700"
      unitRef="usd">0</ptct:StockAppreciationRightsLiabilityOutstanding>
    <ptct:StockAppreciationRightsLiabilityOutstanding
      contextRef="i093049f7698c438ea17d8d78b2999a3b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfNC04LTEtMS0w_5042d08d-3e96-44e6-9d52-0d515750fc11"
      unitRef="usd">3186000</ptct:StockAppreciationRightsLiabilityOutstanding>
    <ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable
      contextRef="i846b553e2ead487080c5135cbfabf245_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfNS0yLTEtMS0w_93f64b0a-a57d-4199-991d-99ca73bc9763"
      unitRef="usd">40000000</ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable>
    <ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable
      contextRef="i93db7a3e36c54bccb14ea9da633b0ca2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfNS00LTEtMS0w_708d3790-e782-4b17-ac99-779169e6e39a"
      unitRef="usd">0</ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable>
    <ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable
      contextRef="ice1694004db8457f8428afa653a62360_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfNS02LTEtMS0w_b0bf3bb4-f53e-45c1-9c84-9c80bb6495e9"
      unitRef="usd">40000000</ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable>
    <ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable
      contextRef="i093049f7698c438ea17d8d78b2999a3b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfNS04LTEtMS0w_32920139-386c-4a4a-ae92-8529fd04560f"
      unitRef="usd">0</ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i846b553e2ead487080c5135cbfabf245_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfNi0yLTEtMS0w_dfe67169-5cf5-4e91-87c3-7e1fb63f1e8a"
      unitRef="usd">290500000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i93db7a3e36c54bccb14ea9da633b0ca2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfNi00LTEtMS0w_f4a139bd-54be-4238-b058-c109a13f4646"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="ice1694004db8457f8428afa653a62360_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfNi02LTEtMS0w_a74e54b2-c501-46c1-b2ba-fcee1ff4acfb"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i093049f7698c438ea17d8d78b2999a3b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfNi04LTEtMS0w_36222f6f-3a1a-47be-8258-7310795a6f97"
      unitRef="usd">290500000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i846b553e2ead487080c5135cbfabf245_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfNy0yLTEtMS0w_9b3c4b08-566a-40cc-9dd2-608e0302fab4"
      unitRef="usd">65800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i93db7a3e36c54bccb14ea9da633b0ca2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfNy00LTEtMS0w_8d679a05-ba01-4978-ba1c-0c044169352e"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ice1694004db8457f8428afa653a62360_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfNy02LTEtMS0w_af157320-5c9f-46ba-83d3-acbf5f211a6b"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i460293d39eb74292bfa8379e3e079d05_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ5OGFiNWFhNzg1NzQ2YzI5NjBiNWZhNGZmYTYxNTlmL3RhYmxlcmFuZ2U6NDk4YWI1YWE3ODU3NDZjMjk2MGI1ZmE0ZmZhNjE1OWZfNy04LTEtMS0w_ad89c3f7-c18b-4678-bd46-db856b578853"
      unitRef="usd">65800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfMTIyNTc_9094496a-0ba1-4841-a02f-d6f89d9ac956">&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following is a summary of marketable securities accounted for as available-for-sale securities at June&#160;30, 2020 and December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.120%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.741%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&#160;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;221,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;223,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;337,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;340,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.120%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.741%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&#160;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;157,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;158,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;188,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;189,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;397,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;398,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i15b6700152f74cd99d7930f13a61958e_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjViZWM2OGIyMzBjZDQ4NjhiNzQzYjliMGYzMTIwMDNkL3RhYmxlcmFuZ2U6NWJlYzY4YjIzMGNkNDg2OGI3NDNiOWIwZjMxMjAwM2RfMy0yLTEtMS0w_b84d683b-1a48-45fe-b50d-64edd8aedb81"
      unitRef="usd">53638000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i15b6700152f74cd99d7930f13a61958e_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjViZWM2OGIyMzBjZDQ4NjhiNzQzYjliMGYzMTIwMDNkL3RhYmxlcmFuZ2U6NWJlYzY4YjIzMGNkNDg2OGI3NDNiOWIwZjMxMjAwM2RfMy00LTEtMS0w_c8bd3206-3445-4723-be66-7017ad494b6e"
      unitRef="usd">178000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i15b6700152f74cd99d7930f13a61958e_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjViZWM2OGIyMzBjZDQ4NjhiNzQzYjliMGYzMTIwMDNkL3RhYmxlcmFuZ2U6NWJlYzY4YjIzMGNkNDg2OGI3NDNiOWIwZjMxMjAwM2RfMy02LTEtMS0w_8cd8c072-f0bd-45f5-a9eb-f7f7a82e18d2"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i15b6700152f74cd99d7930f13a61958e_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjViZWM2OGIyMzBjZDQ4NjhiNzQzYjliMGYzMTIwMDNkL3RhYmxlcmFuZ2U6NWJlYzY4YjIzMGNkNDg2OGI3NDNiOWIwZjMxMjAwM2RfMy04LTEtMS0w_1c874ff1-c655-4c4b-9449-a624e3f42633"
      unitRef="usd">53816000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6422d57bbb764a51b28c5b9584e9df0b_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjViZWM2OGIyMzBjZDQ4NjhiNzQzYjliMGYzMTIwMDNkL3RhYmxlcmFuZ2U6NWJlYzY4YjIzMGNkNDg2OGI3NDNiOWIwZjMxMjAwM2RfNC0yLTEtMS0w_be81a7ae-8d42-41e8-a4f4-e248f64b43c0"
      unitRef="usd">221068000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6422d57bbb764a51b28c5b9584e9df0b_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjViZWM2OGIyMzBjZDQ4NjhiNzQzYjliMGYzMTIwMDNkL3RhYmxlcmFuZ2U6NWJlYzY4YjIzMGNkNDg2OGI3NDNiOWIwZjMxMjAwM2RfNC00LTEtMS0w_9a17a556-18ad-467a-9ffd-efb36003e0c2"
      unitRef="usd">2882000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6422d57bbb764a51b28c5b9584e9df0b_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjViZWM2OGIyMzBjZDQ4NjhiNzQzYjliMGYzMTIwMDNkL3RhYmxlcmFuZ2U6NWJlYzY4YjIzMGNkNDg2OGI3NDNiOWIwZjMxMjAwM2RfNC02LTEtMS0w_622fdfc1-51e1-48d5-9e30-6f84d78ee213"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6422d57bbb764a51b28c5b9584e9df0b_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjViZWM2OGIyMzBjZDQ4NjhiNzQzYjliMGYzMTIwMDNkL3RhYmxlcmFuZ2U6NWJlYzY4YjIzMGNkNDg2OGI3NDNiOWIwZjMxMjAwM2RfNC04LTEtMS0w_bea15efa-c0f8-4b5f-b01b-22e9f2131b24"
      unitRef="usd">223950000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5f81bf0a978b4c9f9854bd8827a16c63_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjViZWM2OGIyMzBjZDQ4NjhiNzQzYjliMGYzMTIwMDNkL3RhYmxlcmFuZ2U6NWJlYzY4YjIzMGNkNDg2OGI3NDNiOWIwZjMxMjAwM2RfNS0yLTEtMS0w_b07df317-34ff-4017-b601-ae6b814453f2"
      unitRef="usd">44492000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5f81bf0a978b4c9f9854bd8827a16c63_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjViZWM2OGIyMzBjZDQ4NjhiNzQzYjliMGYzMTIwMDNkL3RhYmxlcmFuZ2U6NWJlYzY4YjIzMGNkNDg2OGI3NDNiOWIwZjMxMjAwM2RfNS00LTEtMS0w_ee02368e-7cfd-4765-a830-c20e07995d07"
      unitRef="usd">332000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5f81bf0a978b4c9f9854bd8827a16c63_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjViZWM2OGIyMzBjZDQ4NjhiNzQzYjliMGYzMTIwMDNkL3RhYmxlcmFuZ2U6NWJlYzY4YjIzMGNkNDg2OGI3NDNiOWIwZjMxMjAwM2RfNS02LTEtMS0w_6a994bb7-be22-4ae3-9119-769769566b8f"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5f81bf0a978b4c9f9854bd8827a16c63_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjViZWM2OGIyMzBjZDQ4NjhiNzQzYjliMGYzMTIwMDNkL3RhYmxlcmFuZ2U6NWJlYzY4YjIzMGNkNDg2OGI3NDNiOWIwZjMxMjAwM2RfNS04LTEtMS0w_d36fe903-4e11-49b1-a9cd-f0b0cee46701"
      unitRef="usd">44823000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia246a01c67a4480ebec435e73307c0dc_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjViZWM2OGIyMzBjZDQ4NjhiNzQzYjliMGYzMTIwMDNkL3RhYmxlcmFuZ2U6NWJlYzY4YjIzMGNkNDg2OGI3NDNiOWIwZjMxMjAwM2RfNi0yLTEtMS0w_7af971ea-bb46-4fc7-aeae-a606be1823d8"
      unitRef="usd">17823000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia246a01c67a4480ebec435e73307c0dc_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjViZWM2OGIyMzBjZDQ4NjhiNzQzYjliMGYzMTIwMDNkL3RhYmxlcmFuZ2U6NWJlYzY4YjIzMGNkNDg2OGI3NDNiOWIwZjMxMjAwM2RfNi00LTEtMS0w_0a8a5560-6399-49ff-9827-d5611836e0b4"
      unitRef="usd">19000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia246a01c67a4480ebec435e73307c0dc_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjViZWM2OGIyMzBjZDQ4NjhiNzQzYjliMGYzMTIwMDNkL3RhYmxlcmFuZ2U6NWJlYzY4YjIzMGNkNDg2OGI3NDNiOWIwZjMxMjAwM2RfNi02LTEtMS0w_da5d15a1-4d99-4c88-94ab-dcc9be83edfe"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia246a01c67a4480ebec435e73307c0dc_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjViZWM2OGIyMzBjZDQ4NjhiNzQzYjliMGYzMTIwMDNkL3RhYmxlcmFuZ2U6NWJlYzY4YjIzMGNkNDg2OGI3NDNiOWIwZjMxMjAwM2RfNi04LTEtMS0w_29ced024-78f1-4a78-b2a2-034cf3e56376"
      unitRef="usd">17841000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjViZWM2OGIyMzBjZDQ4NjhiNzQzYjliMGYzMTIwMDNkL3RhYmxlcmFuZ2U6NWJlYzY4YjIzMGNkNDg2OGI3NDNiOWIwZjMxMjAwM2RfNy0yLTEtMS0w_32c16888-882f-4fe4-9c09-2435133d57a7"
      unitRef="usd">337021000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjViZWM2OGIyMzBjZDQ4NjhiNzQzYjliMGYzMTIwMDNkL3RhYmxlcmFuZ2U6NWJlYzY4YjIzMGNkNDg2OGI3NDNiOWIwZjMxMjAwM2RfNy00LTEtMS0w_295501be-2653-4756-b30c-2e388cf7b025"
      unitRef="usd">3411000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjViZWM2OGIyMzBjZDQ4NjhiNzQzYjliMGYzMTIwMDNkL3RhYmxlcmFuZ2U6NWJlYzY4YjIzMGNkNDg2OGI3NDNiOWIwZjMxMjAwM2RfNy02LTEtMS0w_124eaa31-99fe-46a5-803f-16fba27cf383"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjViZWM2OGIyMzBjZDQ4NjhiNzQzYjliMGYzMTIwMDNkL3RhYmxlcmFuZ2U6NWJlYzY4YjIzMGNkNDg2OGI3NDNiOWIwZjMxMjAwM2RfNy04LTEtMS0w_130d328e-adcc-45da-bc25-e879b5f89115"
      unitRef="usd">340430000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i876ed796b3d14bf1be51f08fb4114515_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ2MDczNjNmNTU0OTQzNGFiMzZmOTQ1Mjk1ODU2Y2Q5L3RhYmxlcmFuZ2U6NDYwNzM2M2Y1NTQ5NDM0YWIzNmY5NDUyOTU4NTZjZDlfMy0yLTEtMS0w_06b09fa2-89b6-48c4-a326-dc5f433dcfa2"
      unitRef="usd">157936000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i876ed796b3d14bf1be51f08fb4114515_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ2MDczNjNmNTU0OTQzNGFiMzZmOTQ1Mjk1ODU2Y2Q5L3RhYmxlcmFuZ2U6NDYwNzM2M2Y1NTQ5NDM0YWIzNmY5NDUyOTU4NTZjZDlfMy00LTEtMS0w_b90cbc05-fdfd-4874-96e7-28d600691f57"
      unitRef="usd">162000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i876ed796b3d14bf1be51f08fb4114515_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ2MDczNjNmNTU0OTQzNGFiMzZmOTQ1Mjk1ODU2Y2Q5L3RhYmxlcmFuZ2U6NDYwNzM2M2Y1NTQ5NDM0YWIzNmY5NDUyOTU4NTZjZDlfMy02LTEtMS0w_14feb88f-0ebb-49d3-b1be-4c8a3f89451e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i876ed796b3d14bf1be51f08fb4114515_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ2MDczNjNmNTU0OTQzNGFiMzZmOTQ1Mjk1ODU2Y2Q5L3RhYmxlcmFuZ2U6NDYwNzM2M2Y1NTQ5NDM0YWIzNmY5NDUyOTU4NTZjZDlfMy04LTEtMS0w_e14e967d-fca5-4896-8ed3-eb1a2aac3649"
      unitRef="usd">158098000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i90486133108543398e32deae8f47a34d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ2MDczNjNmNTU0OTQzNGFiMzZmOTQ1Mjk1ODU2Y2Q5L3RhYmxlcmFuZ2U6NDYwNzM2M2Y1NTQ5NDM0YWIzNmY5NDUyOTU4NTZjZDlfNC0yLTEtMS0w_6ebad033-1dbb-4fd2-b4dd-6d69cb339aa8"
      unitRef="usd">188778000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i90486133108543398e32deae8f47a34d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ2MDczNjNmNTU0OTQzNGFiMzZmOTQ1Mjk1ODU2Y2Q5L3RhYmxlcmFuZ2U6NDYwNzM2M2Y1NTQ5NDM0YWIzNmY5NDUyOTU4NTZjZDlfNC00LTEtMS0w_a7f1b11f-39ee-444c-8f13-5a2e1911f42d"
      unitRef="usd">576000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i90486133108543398e32deae8f47a34d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ2MDczNjNmNTU0OTQzNGFiMzZmOTQ1Mjk1ODU2Y2Q5L3RhYmxlcmFuZ2U6NDYwNzM2M2Y1NTQ5NDM0YWIzNmY5NDUyOTU4NTZjZDlfNC02LTEtMS0w_0beed1e1-87eb-4eb7-a87d-8a20c7c7be4a"
      unitRef="usd">20000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i90486133108543398e32deae8f47a34d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ2MDczNjNmNTU0OTQzNGFiMzZmOTQ1Mjk1ODU2Y2Q5L3RhYmxlcmFuZ2U6NDYwNzM2M2Y1NTQ5NDM0YWIzNmY5NDUyOTU4NTZjZDlfNC04LTEtMS0w_b7e9765f-3ef1-4ad0-be65-b485eed1444c"
      unitRef="usd">189334000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2ab2c343b8eb419cbede80402b0f7f2a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ2MDczNjNmNTU0OTQzNGFiMzZmOTQ1Mjk1ODU2Y2Q5L3RhYmxlcmFuZ2U6NDYwNzM2M2Y1NTQ5NDM0YWIzNmY5NDUyOTU4NTZjZDlfNS0yLTEtMS0w_8f554fac-8649-4fd4-aefc-d4e40f437a11"
      unitRef="usd">51062000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2ab2c343b8eb419cbede80402b0f7f2a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ2MDczNjNmNTU0OTQzNGFiMzZmOTQ1Mjk1ODU2Y2Q5L3RhYmxlcmFuZ2U6NDYwNzM2M2Y1NTQ5NDM0YWIzNmY5NDUyOTU4NTZjZDlfNS00LTEtMS0w_d01dedba-2dc2-45be-988d-f8a37ca871e1"
      unitRef="usd">49000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2ab2c343b8eb419cbede80402b0f7f2a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ2MDczNjNmNTU0OTQzNGFiMzZmOTQ1Mjk1ODU2Y2Q5L3RhYmxlcmFuZ2U6NDYwNzM2M2Y1NTQ5NDM0YWIzNmY5NDUyOTU4NTZjZDlfNS02LTEtMS0w_114954ef-785c-4694-ab85-9b7a8625690c"
      unitRef="usd">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2ab2c343b8eb419cbede80402b0f7f2a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ2MDczNjNmNTU0OTQzNGFiMzZmOTQ1Mjk1ODU2Y2Q5L3RhYmxlcmFuZ2U6NDYwNzM2M2Y1NTQ5NDM0YWIzNmY5NDUyOTU4NTZjZDlfNS04LTEtMS0w_ea16ca18-f8f5-4f83-919e-1d558e7416af"
      unitRef="usd">51103000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ2MDczNjNmNTU0OTQzNGFiMzZmOTQ1Mjk1ODU2Y2Q5L3RhYmxlcmFuZ2U6NDYwNzM2M2Y1NTQ5NDM0YWIzNmY5NDUyOTU4NTZjZDlfNi0yLTEtMS0w_d9a0b920-bc90-4508-90eb-9b89c5a1dde9"
      unitRef="usd">397776000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ2MDczNjNmNTU0OTQzNGFiMzZmOTQ1Mjk1ODU2Y2Q5L3RhYmxlcmFuZ2U6NDYwNzM2M2Y1NTQ5NDM0YWIzNmY5NDUyOTU4NTZjZDlfNi00LTEtMS0w_9fb94df3-f20c-4b1d-af94-841301385369"
      unitRef="usd">787000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ2MDczNjNmNTU0OTQzNGFiMzZmOTQ1Mjk1ODU2Y2Q5L3RhYmxlcmFuZ2U6NDYwNzM2M2Y1NTQ5NDM0YWIzNmY5NDUyOTU4NTZjZDlfNi02LTEtMS0w_b21b1ccd-190c-485c-b00e-ea3f722b7af5"
      unitRef="usd">28000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjQ2MDczNjNmNTU0OTQzNGFiMzZmOTQ1Mjk1ODU2Y2Q5L3RhYmxlcmFuZ2U6NDYwNzM2M2Y1NTQ5NDM0YWIzNmY5NDUyOTU4NTZjZDlfNi04LTEtMS0w_41d9b3e7-c948-478b-b8c3-e5ba6f974aec"
      unitRef="usd">398535000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfODI0NjMzNzIyNTIwOQ_272f9083-0d5d-4101-87b6-e7b31ebf4493"
      unitRef="usd">200000</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfODI0NjMzNzIyNTIwOQ_e30bfe3b-0846-422d-be17-911abc611604"
      unitRef="usd">200000</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfMTIyNjg_8ddb3720-85e6-4603-b782-312f3737f776">&lt;div style="margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of&#160;June&#160;30, 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:19.585%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.334%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.334%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.334%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.334%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.334%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.341%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="33" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Securities in an unrealized loss position less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Securities in an unrealized loss position greater than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of&#160;December&#160;31, 2019 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:19.585%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.334%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.334%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.334%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.334%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.334%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.341%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="33" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Securities in an unrealized loss position less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Securities in an unrealized loss position greater than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;71,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;71,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;95,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;95,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i5f81bf0a978b4c9f9854bd8827a16c63_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjM1MWRlY2RlYWI1NzQ1MmY5ZDNjMDE3MDRjODA3M2ZhL3RhYmxlcmFuZ2U6MzUxZGVjZGVhYjU3NDUyZjlkM2MwMTcwNGM4MDczZmFfNS0yLTEtMS0w_487e7e9d-1377-4575-8883-dc9de0075307"
      unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
      contextRef="i5f81bf0a978b4c9f9854bd8827a16c63_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjM1MWRlY2RlYWI1NzQ1MmY5ZDNjMDE3MDRjODA3M2ZhL3RhYmxlcmFuZ2U6MzUxZGVjZGVhYjU3NDUyZjlkM2MwMTcwNGM4MDczZmFfNS00LTEtMS0w_538f7937-6bae-443a-8df1-39d80d00b0ee"
      unitRef="usd">594000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i5f81bf0a978b4c9f9854bd8827a16c63_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjM1MWRlY2RlYWI1NzQ1MmY5ZDNjMDE3MDRjODA3M2ZhL3RhYmxlcmFuZ2U6MzUxZGVjZGVhYjU3NDUyZjlkM2MwMTcwNGM4MDczZmFfNS02LTEtMS0w_c5406fd5-7743-472d-9e38-6439e0e6cbe1"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
      contextRef="i5f81bf0a978b4c9f9854bd8827a16c63_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjM1MWRlY2RlYWI1NzQ1MmY5ZDNjMDE3MDRjODA3M2ZhL3RhYmxlcmFuZ2U6MzUxZGVjZGVhYjU3NDUyZjlkM2MwMTcwNGM4MDczZmFfNS04LTEtMS0w_84052e7c-9f01-4ce7-8437-152ce01d66ca"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i5f81bf0a978b4c9f9854bd8827a16c63_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjM1MWRlY2RlYWI1NzQ1MmY5ZDNjMDE3MDRjODA3M2ZhL3RhYmxlcmFuZ2U6MzUxZGVjZGVhYjU3NDUyZjlkM2MwMTcwNGM4MDczZmFfNS0xMC0xLTEtMA_20105428-950e-4991-b0f1-39da54dd4481"
      unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue
      contextRef="i5f81bf0a978b4c9f9854bd8827a16c63_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjM1MWRlY2RlYWI1NzQ1MmY5ZDNjMDE3MDRjODA3M2ZhL3RhYmxlcmFuZ2U6MzUxZGVjZGVhYjU3NDUyZjlkM2MwMTcwNGM4MDczZmFfNS0xMi0xLTEtMA_e3592941-597e-4ad8-95b1-4dd21743e58a"
      unitRef="usd">594000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ia246a01c67a4480ebec435e73307c0dc_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjM1MWRlY2RlYWI1NzQ1MmY5ZDNjMDE3MDRjODA3M2ZhL3RhYmxlcmFuZ2U6MzUxZGVjZGVhYjU3NDUyZjlkM2MwMTcwNGM4MDczZmFfNi0yLTEtMS0w_13c4a842-9787-4136-b52d-5b7d628e5be1"
      unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
      contextRef="ia246a01c67a4480ebec435e73307c0dc_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjM1MWRlY2RlYWI1NzQ1MmY5ZDNjMDE3MDRjODA3M2ZhL3RhYmxlcmFuZ2U6MzUxZGVjZGVhYjU3NDUyZjlkM2MwMTcwNGM4MDczZmFfNi00LTEtMS0w_467ee3d9-8bdf-481e-8ae6-47166c3ee83b"
      unitRef="usd">8602000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ia246a01c67a4480ebec435e73307c0dc_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjM1MWRlY2RlYWI1NzQ1MmY5ZDNjMDE3MDRjODA3M2ZhL3RhYmxlcmFuZ2U6MzUxZGVjZGVhYjU3NDUyZjlkM2MwMTcwNGM4MDczZmFfNi02LTEtMS0w_a3b2bac6-8a69-44b8-b968-5aa67f1f8a76"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
      contextRef="ia246a01c67a4480ebec435e73307c0dc_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjM1MWRlY2RlYWI1NzQ1MmY5ZDNjMDE3MDRjODA3M2ZhL3RhYmxlcmFuZ2U6MzUxZGVjZGVhYjU3NDUyZjlkM2MwMTcwNGM4MDczZmFfNi04LTEtMS0w_df6c9cbb-fe9c-402f-b46f-b09e6a9c37f0"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ia246a01c67a4480ebec435e73307c0dc_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjM1MWRlY2RlYWI1NzQ1MmY5ZDNjMDE3MDRjODA3M2ZhL3RhYmxlcmFuZ2U6MzUxZGVjZGVhYjU3NDUyZjlkM2MwMTcwNGM4MDczZmFfNi0xMC0xLTEtMA_ff05f2ea-45da-4d4d-97ab-26ac2cef9911"
      unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue
      contextRef="ia246a01c67a4480ebec435e73307c0dc_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjM1MWRlY2RlYWI1NzQ1MmY5ZDNjMDE3MDRjODA3M2ZhL3RhYmxlcmFuZ2U6MzUxZGVjZGVhYjU3NDUyZjlkM2MwMTcwNGM4MDczZmFfNi0xMi0xLTEtMA_651a23ac-3d47-481a-bc17-d41df0461430"
      unitRef="usd">8602000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjM1MWRlY2RlYWI1NzQ1MmY5ZDNjMDE3MDRjODA3M2ZhL3RhYmxlcmFuZ2U6MzUxZGVjZGVhYjU3NDUyZjlkM2MwMTcwNGM4MDczZmFfNy0yLTEtMS0w_2fbb1bf1-d6d4-44f7-97ac-f87592cc37c4"
      unitRef="usd">2000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjM1MWRlY2RlYWI1NzQ1MmY5ZDNjMDE3MDRjODA3M2ZhL3RhYmxlcmFuZ2U6MzUxZGVjZGVhYjU3NDUyZjlkM2MwMTcwNGM4MDczZmFfNy00LTEtMS0w_f4ddc2af-2fac-4e0e-80cd-28e94bf54fe9"
      unitRef="usd">9196000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjM1MWRlY2RlYWI1NzQ1MmY5ZDNjMDE3MDRjODA3M2ZhL3RhYmxlcmFuZ2U6MzUxZGVjZGVhYjU3NDUyZjlkM2MwMTcwNGM4MDczZmFfNy02LTEtMS0w_61454cfd-8915-4c3d-9f76-7b83ba9eaed3"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjM1MWRlY2RlYWI1NzQ1MmY5ZDNjMDE3MDRjODA3M2ZhL3RhYmxlcmFuZ2U6MzUxZGVjZGVhYjU3NDUyZjlkM2MwMTcwNGM4MDczZmFfNy04LTEtMS0w_7c874e22-4526-4c50-bf66-b239a4b101a6"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjM1MWRlY2RlYWI1NzQ1MmY5ZDNjMDE3MDRjODA3M2ZhL3RhYmxlcmFuZ2U6MzUxZGVjZGVhYjU3NDUyZjlkM2MwMTcwNGM4MDczZmFfNy0xMC0xLTEtMA_e9f1fa90-5f48-495e-a8a2-43109b8d4155"
      unitRef="usd">2000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjM1MWRlY2RlYWI1NzQ1MmY5ZDNjMDE3MDRjODA3M2ZhL3RhYmxlcmFuZ2U6MzUxZGVjZGVhYjU3NDUyZjlkM2MwMTcwNGM4MDczZmFfNy0xMi0xLTEtMA_f63bd4f5-4d63-4f64-9b75-32eec3517ecb"
      unitRef="usd">9196000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i90486133108543398e32deae8f47a34d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA1Y2MwMzljMjNlODRhOTg5YjA5YzUwYmY4OTcwYTk3L3RhYmxlcmFuZ2U6MDVjYzAzOWMyM2U4NGE5ODliMDljNTBiZjg5NzBhOTdfNS0yLTEtMS0w_d8c4dfb5-05bf-4457-8929-1d597776d15d"
      unitRef="usd">20000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
      contextRef="i90486133108543398e32deae8f47a34d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA1Y2MwMzljMjNlODRhOTg5YjA5YzUwYmY4OTcwYTk3L3RhYmxlcmFuZ2U6MDVjYzAzOWMyM2U4NGE5ODliMDljNTBiZjg5NzBhOTdfNS00LTEtMS0w_fe21f427-0b19-47ba-a08b-ab0f25e614c9"
      unitRef="usd">71779000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i90486133108543398e32deae8f47a34d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA1Y2MwMzljMjNlODRhOTg5YjA5YzUwYmY4OTcwYTk3L3RhYmxlcmFuZ2U6MDVjYzAzOWMyM2U4NGE5ODliMDljNTBiZjg5NzBhOTdfNS02LTEtMS0w_becfb471-88d4-4f21-a672-29aee3f576b6"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
      contextRef="i90486133108543398e32deae8f47a34d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA1Y2MwMzljMjNlODRhOTg5YjA5YzUwYmY4OTcwYTk3L3RhYmxlcmFuZ2U6MDVjYzAzOWMyM2U4NGE5ODliMDljNTBiZjg5NzBhOTdfNS04LTEtMS0w_baa60f21-7d05-41df-b929-b087bd88fc0c"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i90486133108543398e32deae8f47a34d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA1Y2MwMzljMjNlODRhOTg5YjA5YzUwYmY4OTcwYTk3L3RhYmxlcmFuZ2U6MDVjYzAzOWMyM2U4NGE5ODliMDljNTBiZjg5NzBhOTdfNS0xMC0xLTEtMA_6cf890e2-1c17-440f-8855-c5a63bf84756"
      unitRef="usd">20000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue
      contextRef="i90486133108543398e32deae8f47a34d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA1Y2MwMzljMjNlODRhOTg5YjA5YzUwYmY4OTcwYTk3L3RhYmxlcmFuZ2U6MDVjYzAzOWMyM2U4NGE5ODliMDljNTBiZjg5NzBhOTdfNS0xMi0xLTEtMA_b0dbbfea-2fe1-486e-b38a-500f86102222"
      unitRef="usd">71779000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i2ab2c343b8eb419cbede80402b0f7f2a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA1Y2MwMzljMjNlODRhOTg5YjA5YzUwYmY4OTcwYTk3L3RhYmxlcmFuZ2U6MDVjYzAzOWMyM2U4NGE5ODliMDljNTBiZjg5NzBhOTdfNi0yLTEtMS0w_ad13f4c8-b3d9-4e59-9253-d205a3148b3e"
      unitRef="usd">8000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
      contextRef="i2ab2c343b8eb419cbede80402b0f7f2a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA1Y2MwMzljMjNlODRhOTg5YjA5YzUwYmY4OTcwYTk3L3RhYmxlcmFuZ2U6MDVjYzAzOWMyM2U4NGE5ODliMDljNTBiZjg5NzBhOTdfNi00LTEtMS0w_925853b8-8b93-4c70-b073-2009a6c62e89"
      unitRef="usd">24211000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i2ab2c343b8eb419cbede80402b0f7f2a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA1Y2MwMzljMjNlODRhOTg5YjA5YzUwYmY4OTcwYTk3L3RhYmxlcmFuZ2U6MDVjYzAzOWMyM2U4NGE5ODliMDljNTBiZjg5NzBhOTdfNi02LTEtMS0w_8a45f884-a098-4be3-9877-0c202ed07d8b"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
      contextRef="i2ab2c343b8eb419cbede80402b0f7f2a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA1Y2MwMzljMjNlODRhOTg5YjA5YzUwYmY4OTcwYTk3L3RhYmxlcmFuZ2U6MDVjYzAzOWMyM2U4NGE5ODliMDljNTBiZjg5NzBhOTdfNi04LTEtMS0w_1c40938c-3586-4253-a991-c18b0343a3bd"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i2ab2c343b8eb419cbede80402b0f7f2a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA1Y2MwMzljMjNlODRhOTg5YjA5YzUwYmY4OTcwYTk3L3RhYmxlcmFuZ2U6MDVjYzAzOWMyM2U4NGE5ODliMDljNTBiZjg5NzBhOTdfNi0xMC0xLTEtMA_d356f263-a13f-4c87-84d8-d482ab066331"
      unitRef="usd">8000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue
      contextRef="i2ab2c343b8eb419cbede80402b0f7f2a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA1Y2MwMzljMjNlODRhOTg5YjA5YzUwYmY4OTcwYTk3L3RhYmxlcmFuZ2U6MDVjYzAzOWMyM2U4NGE5ODliMDljNTBiZjg5NzBhOTdfNi0xMi0xLTEtMA_141e26f9-0700-4245-9af2-f48855b238af"
      unitRef="usd">24211000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA1Y2MwMzljMjNlODRhOTg5YjA5YzUwYmY4OTcwYTk3L3RhYmxlcmFuZ2U6MDVjYzAzOWMyM2U4NGE5ODliMDljNTBiZjg5NzBhOTdfNy0yLTEtMS0w_7f7a6d6b-f6ae-42ff-8404-e19e0a450276"
      unitRef="usd">28000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA1Y2MwMzljMjNlODRhOTg5YjA5YzUwYmY4OTcwYTk3L3RhYmxlcmFuZ2U6MDVjYzAzOWMyM2U4NGE5ODliMDljNTBiZjg5NzBhOTdfNy00LTEtMS0w_730b04a4-bde8-40f5-a81a-b3459200c56a"
      unitRef="usd">95990000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA1Y2MwMzljMjNlODRhOTg5YjA5YzUwYmY4OTcwYTk3L3RhYmxlcmFuZ2U6MDVjYzAzOWMyM2U4NGE5ODliMDljNTBiZjg5NzBhOTdfNy02LTEtMS0w_e01d4ed0-2ced-4789-b2b8-db8ea375e51d"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA1Y2MwMzljMjNlODRhOTg5YjA5YzUwYmY4OTcwYTk3L3RhYmxlcmFuZ2U6MDVjYzAzOWMyM2U4NGE5ODliMDljNTBiZjg5NzBhOTdfNy04LTEtMS0w_b153aea4-b74f-4781-9958-c2d97f574716"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA1Y2MwMzljMjNlODRhOTg5YjA5YzUwYmY4OTcwYTk3L3RhYmxlcmFuZ2U6MDVjYzAzOWMyM2U4NGE5ODliMDljNTBiZjg5NzBhOTdfNy0xMC0xLTEtMA_0ea1a940-e939-4c01-9a69-b61408ff3476"
      unitRef="usd">28000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA1Y2MwMzljMjNlODRhOTg5YjA5YzUwYmY4OTcwYTk3L3RhYmxlcmFuZ2U6MDVjYzAzOWMyM2U4NGE5ODliMDljNTBiZjg5NzBhOTdfNy0xMi0xLTEtMA_b4b21150-6385-4234-b9a7-e6e0ed9ce5c0"
      unitRef="usd">95990000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfMTIyMzU_a4d31bde-152f-481b-9957-77d9bdb02ae9">&lt;div style="margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Marketable securities on the balance sheet at June&#160;30, 2020 and December&#160;31, 2019 mature as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.060%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less&#160;Than&lt;br/&gt;12&#160;Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;More&#160;Than&lt;br/&gt;12&#160;Months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;168,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;55,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;255,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;84,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.060%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less&#160;Than&lt;br/&gt;12&#160;Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;More&#160;Than&lt;br/&gt;12&#160;Months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;158,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;139,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;342,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;56,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="id8d66a66f5c44284a1bfe69359df8592_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjIxZTQ0OGEyZTE3NDQ5OTViMDc5ODUzYjExYzBmYmU3L3RhYmxlcmFuZ2U6MjFlNDQ4YTJlMTc0NDk5NWIwNzk4NTNiMTFjMGZiZTdfMi0yLTEtMS0w_1f0683c3-7a98-424b-ab7a-5b0ed324dccb"
      unitRef="usd">53816000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue
      contextRef="id8d66a66f5c44284a1bfe69359df8592_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjIxZTQ0OGEyZTE3NDQ5OTViMDc5ODUzYjExYzBmYmU3L3RhYmxlcmFuZ2U6MjFlNDQ4YTJlMTc0NDk5NWIwNzk4NTNiMTFjMGZiZTdfMi00LTEtMS0w_eb0a1202-a2ce-4728-af27-97251175995d"
      unitRef="usd">0</ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ib3c822dd8f524ec2a293c01f04eecc3b_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjIxZTQ0OGEyZTE3NDQ5OTViMDc5ODUzYjExYzBmYmU3L3RhYmxlcmFuZ2U6MjFlNDQ4YTJlMTc0NDk5NWIwNzk4NTNiMTFjMGZiZTdfMy0yLTEtMS0w_8f1d1a03-e00b-4d5a-b76a-b4626f524595"
      unitRef="usd">168250000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue
      contextRef="ib3c822dd8f524ec2a293c01f04eecc3b_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjIxZTQ0OGEyZTE3NDQ5OTViMDc5ODUzYjExYzBmYmU3L3RhYmxlcmFuZ2U6MjFlNDQ4YTJlMTc0NDk5NWIwNzk4NTNiMTFjMGZiZTdfMy00LTEtMS0w_5e783b25-664d-4983-a61b-c96a346df008"
      unitRef="usd">55700000</ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i2693d4b1ad594235b8ea223db85dc081_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjIxZTQ0OGEyZTE3NDQ5OTViMDc5ODUzYjExYzBmYmU3L3RhYmxlcmFuZ2U6MjFlNDQ4YTJlMTc0NDk5NWIwNzk4NTNiMTFjMGZiZTdfNC0yLTEtMS0w_17838488-132d-4aa9-afae-75d618a1d6fc"
      unitRef="usd">26320000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue
      contextRef="i2693d4b1ad594235b8ea223db85dc081_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjIxZTQ0OGEyZTE3NDQ5OTViMDc5ODUzYjExYzBmYmU3L3RhYmxlcmFuZ2U6MjFlNDQ4YTJlMTc0NDk5NWIwNzk4NTNiMTFjMGZiZTdfNC00LTEtMS0w_4b3a0781-7664-4070-b593-44be4e380309"
      unitRef="usd">18503000</ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i18f98e56934a450c999dc68774136109_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjIxZTQ0OGEyZTE3NDQ5OTViMDc5ODUzYjExYzBmYmU3L3RhYmxlcmFuZ2U6MjFlNDQ4YTJlMTc0NDk5NWIwNzk4NTNiMTFjMGZiZTdfNS0yLTEtMS0w_7ff0de10-9450-408d-9cc5-905d5047b6b2"
      unitRef="usd">7201000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue
      contextRef="i18f98e56934a450c999dc68774136109_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjIxZTQ0OGEyZTE3NDQ5OTViMDc5ODUzYjExYzBmYmU3L3RhYmxlcmFuZ2U6MjFlNDQ4YTJlMTc0NDk5NWIwNzk4NTNiMTFjMGZiZTdfNS00LTEtMS0w_f6ef5793-44dc-44c3-8127-6766b3e7c5fe"
      unitRef="usd">10640000</ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjIxZTQ0OGEyZTE3NDQ5OTViMDc5ODUzYjExYzBmYmU3L3RhYmxlcmFuZ2U6MjFlNDQ4YTJlMTc0NDk5NWIwNzk4NTNiMTFjMGZiZTdfNi0yLTEtMS0w_2131f913-57c4-4112-805a-4a3d250f8780"
      unitRef="usd">255587000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjIxZTQ0OGEyZTE3NDQ5OTViMDc5ODUzYjExYzBmYmU3L3RhYmxlcmFuZ2U6MjFlNDQ4YTJlMTc0NDk5NWIwNzk4NTNiMTFjMGZiZTdfNi00LTEtMS0w_c260f1b8-ca1b-4579-a751-0d3baaceab14"
      unitRef="usd">84843000</ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i05c1fab5886147afbd189c9f7d96801e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA2YjdkMTFlOGZjZjRmNTY5M2YwNTk3NmQyYmI0MzgyL3RhYmxlcmFuZ2U6MDZiN2QxMWU4ZmNmNGY1NjkzZjA1OTc2ZDJiYjQzODJfMi0yLTEtMS0w_22d64952-bcde-4e36-a425-d46216100c4d"
      unitRef="usd">158098000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue
      contextRef="i05c1fab5886147afbd189c9f7d96801e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA2YjdkMTFlOGZjZjRmNTY5M2YwNTk3NmQyYmI0MzgyL3RhYmxlcmFuZ2U6MDZiN2QxMWU4ZmNmNGY1NjkzZjA1OTc2ZDJiYjQzODJfMi00LTEtMS0w_d42bc939-674e-43c3-9437-51510267913e"
      unitRef="usd">0</ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i808602a5926949c8ac25d08dcc142c0a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA2YjdkMTFlOGZjZjRmNTY5M2YwNTk3NmQyYmI0MzgyL3RhYmxlcmFuZ2U6MDZiN2QxMWU4ZmNmNGY1NjkzZjA1OTc2ZDJiYjQzODJfMy0yLTEtMS0w_3a1949e7-d776-4a51-b312-30cc53f1ca79"
      unitRef="usd">139596000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue
      contextRef="i808602a5926949c8ac25d08dcc142c0a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA2YjdkMTFlOGZjZjRmNTY5M2YwNTk3NmQyYmI0MzgyL3RhYmxlcmFuZ2U6MDZiN2QxMWU4ZmNmNGY1NjkzZjA1OTc2ZDJiYjQzODJfMy00LTEtMS0w_d139178b-a151-4c4f-9220-517613304d94"
      unitRef="usd">49738000</ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i26723ef219cf40f79fc4b63185834f6a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA2YjdkMTFlOGZjZjRmNTY5M2YwNTk3NmQyYmI0MzgyL3RhYmxlcmFuZ2U6MDZiN2QxMWU4ZmNmNGY1NjkzZjA1OTc2ZDJiYjQzODJfNC0yLTEtMS0w_d88ec30c-4c98-4e07-93df-841120ed8a51"
      unitRef="usd">44724000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue
      contextRef="i26723ef219cf40f79fc4b63185834f6a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA2YjdkMTFlOGZjZjRmNTY5M2YwNTk3NmQyYmI0MzgyL3RhYmxlcmFuZ2U6MDZiN2QxMWU4ZmNmNGY1NjkzZjA1OTc2ZDJiYjQzODJfNC00LTEtMS0w_dffe2be8-0725-4f56-9188-85e270d76ab1"
      unitRef="usd">6379000</ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA2YjdkMTFlOGZjZjRmNTY5M2YwNTk3NmQyYmI0MzgyL3RhYmxlcmFuZ2U6MDZiN2QxMWU4ZmNmNGY1NjkzZjA1OTc2ZDJiYjQzODJfNS0yLTEtMS0w_60c23d5f-2fea-472e-9b45-079e922a721b"
      unitRef="usd">342418000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjA2YjdkMTFlOGZjZjRmNTY5M2YwNTk3NmQyYmI0MzgyL3RhYmxlcmFuZ2U6MDZiN2QxMWU4ZmNmNGY1NjkzZjA1OTc2ZDJiYjQzODJfNS00LTEtMS0w_45c6dd45-7d2d-4578-805e-e4e8d987b54e"
      unitRef="usd">56117000</ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i28655a9b21d647eb9144da8fa8cdd911_I20150831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfNzQ5MQ_20770c23-44d4-4f2c-9144-d6bb43ebd220"
      unitRef="usd">150000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i28655a9b21d647eb9144da8fa8cdd911_I20150831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfNzQ5Nw_b4a1f215-f6d8-463e-9bee-f597b3ec7626"
      unitRef="number">0.0300</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i43e763aab42b473cb26af800270f6b3e_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfNzYxNQ_2f1ab4b2-a38a-4157-bde1-c2ac7e7c80e7"
      unitRef="usd">287500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2869c1675c5a404e9bb85cad2eb71998_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfNzYyMQ_1067a0d9-d5bd-44bf-8e46-16bffcec3a39"
      unitRef="number">0.0150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i08c7971cf8d6469fbda565dec2419938_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfODMzMw_c5611df4-58f3-4167-b1db-32081a51ab12"
      unitRef="usd">175200000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i5fc57b5184a54d248eb826766cbbb088_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfODM0MA_3f10d794-eecf-4900-86b6-df873346cc27"
      unitRef="usd">171200000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i43e763aab42b473cb26af800270f6b3e_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfODQzMA_bf13061a-39da-428e-88f1-e74ef88fadfc"
      unitRef="usd">343800000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i2869c1675c5a404e9bb85cad2eb71998_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfODQzNw_117b0bcb-a879-4244-ab6c-e75f20b39fa6"
      unitRef="usd">335000000.0</us-gaap:DebtInstrumentFairValue>
    <ptct:DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing
      contextRef="ia20c4a3be1bf491aaf06ea4818f97179_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfODcxOQ_04fbdc85-2973-4d67-8476-dbd21b5876c8"
      unitRef="usd">60000000.0</ptct:DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing>
    <ptct:ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount
      contextRef="i7e34d9d90204473c8ea049d991956012_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfODkwNg_40139581-ffee-427d-bc62-6feb409db928"
      unitRef="usd">535000000.0</ptct:ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount>
    <ptct:DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing
      contextRef="ife1e487e2c3c44508eb4f48b2ea5cd9e_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfODk0MQ_6db045fa-0d24-4fca-97da-13db372bd275"
      unitRef="usd">40000000.0</ptct:DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing>
    <ptct:DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing
      contextRef="ife1e487e2c3c44508eb4f48b2ea5cd9e_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfNTQ5NzU1ODE1Mzk0Mg_6db045fa-0d24-4fca-97da-13db372bd275"
      unitRef="usd">40000000.0</ptct:DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing>
    <ptct:StockIssuedDuringPeriodSharesExchangeRights
      contextRef="ifa7979ad51144297ab5f7100771cad69_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfNDM5ODA0NjUyODAwNw_d6668d97-0d38-4796-a180-f836ec03dcc8"
      unitRef="shares">2821176</ptct:StockIssuedDuringPeriodSharesExchangeRights>
    <ptct:SharesIssuedAssetAcquisition
      contextRef="i163271c9c18a44a7acbdd4d53ae6113f_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfNDM5ODA0NjUyODEzNg_8c1e305a-243d-4465-80ed-6979b817982d"
      unitRef="usd">36900000</ptct:SharesIssuedAssetAcquisition>
    <ptct:MilestonePaymentObligations
      contextRef="i15a832ee781448adb2f8888811fbc346_I20200629"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfNDM5ODA0NjUyODAxOA_5cc8416c-c8dd-447e-9fca-58fd3838670e"
      unitRef="usd">174000000.0</ptct:MilestonePaymentObligations>
    <ptct:DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing
      contextRef="i8aa17e0adf804ca986cfd400e121c2ea_I20200629"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfNDM5ODA0NjUyODAzNA_3def36b2-f6b0-4d7f-886c-e3f1857bcbc0"
      unitRef="usd">37600000</ptct:DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing>
    <ptct:DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing
      contextRef="i6094c414acd64e8eb18a8f8306f9c263_I20200629"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfNDM5ODA0NjUyODA0OQ_e436384f-598c-479c-a079-fbf2b63df4e0"
      unitRef="usd">40000000.0</ptct:DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing>
    <ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable
      contextRef="i44f6355301964dabbb766e645f3cf148_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfOTE5OQ_c7c8f0b5-48ca-429a-b0a3-1efa5eccc449"
      unitRef="usd">2400000</ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable>
    <ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent
      contextRef="if54601c17d0343ec8d9cd0af73df9a5b_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfOTMyNg_9efe63af-dfd1-4ba8-9815-7af6205763f5"
      unitRef="usd">2400000</ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent>
    <ptct:GainOfSettlementDevelopmentMilestones
      contextRef="i163271c9c18a44a7acbdd4d53ae6113f_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfNDM5ODA0NjUyODA3OQ_c07471a4-010d-4b2e-8392-cc8e8b009757"
      unitRef="usd">700000</ptct:GainOfSettlementDevelopmentMilestones>
    <ptct:LossOfSettlementRegulatoryMilestones
      contextRef="i163271c9c18a44a7acbdd4d53ae6113f_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfNDM5ODA0NjUyODA2NA_eb20c3af-69f5-4b7d-a9d8-a6cdf239524d"
      unitRef="usd">11300000</ptct:LossOfSettlementRegulatoryMilestones>
    <ptct:GainOfSettlementDevelopmentMilestones
      contextRef="i163271c9c18a44a7acbdd4d53ae6113f_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfNDM5ODA0NjUyODEyMg_b7baa6f2-02fa-4c70-b0ab-8bfee9e9a7fa"
      unitRef="usd">700000</ptct:GainOfSettlementDevelopmentMilestones>
    <ptct:LossOfSettlementRegulatoryMilestones
      contextRef="i163271c9c18a44a7acbdd4d53ae6113f_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfNDM5ODA0NjUyODA5Mw_91750322-72c8-4017-b303-299ab8f30835"
      unitRef="usd">11300000</ptct:LossOfSettlementRegulatoryMilestones>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
      contextRef="i163271c9c18a44a7acbdd4d53ae6113f_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfNDM5ODA0NjUyODEwOA_d0c83173-b263-4ec0-9b59-16f5375365f0"
      unitRef="usd">1000000.0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
    <ptct:ContingentConsiderationTransactionFees
      contextRef="i163271c9c18a44a7acbdd4d53ae6113f_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfNjA0NzMxMzk2OTM4Ng_33136fef-c4a0-472a-8092-a455e6f08d94"
      unitRef="usd">2000000.0</ptct:ContingentConsiderationTransactionFees>
    <ptct:ContingentConsiderationTransactionFees
      contextRef="i5ca2052e537349099f8500140b79c830_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfNjA0NzMxMzk2OTM4Ng_9ba1f5e6-cc92-4e82-bc33-a57430890f94"
      unitRef="usd">2000000.0</ptct:ContingentConsiderationTransactionFees>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i82a7d5029292453a9d8665965b2a0597_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfMTAwNjQ_03354036-172f-43bc-bcb8-87061bcbeb9b"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="i6f89da40eb9542899d61cec5f576ce4d_I20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfMTA3NTU_7e6dde8d-b5dd-4860-9d54-04f2af72a909"
      unitRef="number">0.054</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="ibe63e39ea26a457a88e2e66409ca6e52_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfMTA4MTA_8be8c9e5-513b-4f40-b596-f00ab85306ac"
      unitRef="number">0.43</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="i46d96bc3957b4332a199fc5c2ba22aa2_I20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfMTExOTE_9286b873-a68c-42f6-8d2c-18160b23a9e3"
      unitRef="number">0.120</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="i06c3f1148d284ba19fd288779c3f2c67_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfMTEyNzU_ba55a679-7e39-48d5-ac5d-fabd2e0ff04a"
      unitRef="number">0.50</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfMTIyNDA_4b60bfb0-cace-4dd3-a4f1-cf736f3025c7">&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The table presented below is a summary of changes in the fair value of the Company&#x2019;s Level 3 valuations for the SARs liability, and the contingent consideration payable for the periods ended June&#160;30, 2020 and June&#160;30, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.549%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:50.533%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.644%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.033%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.644%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.033%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.475%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.038%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3 liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;SARs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration payable- development and regulatory milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration payable- net sales milestones and royalties&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Beginning balance as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;290,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;65,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(15,220)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,186)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Rights Exchange settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(139,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Ending balance as of June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;136,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;89,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.573%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:49.919%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.634%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.858%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.634%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.858%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.467%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.030%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3 liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;SARs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration payable- development and regulatory milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration payable- net sales milestones and royalties&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Beginning balance as of December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;257,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Ending balance as of June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;277,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;58,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ie5a07c3011f2483691088bb12f4ed468_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjY3ZTQ4ZjA4YmQ3MTRhNTNhNGIyMzM5ZTllZTZlMjg0L3RhYmxlcmFuZ2U6NjdlNDhmMDhiZDcxNGE1M2E0YjIzMzllOWVlNmUyODRfMi0yLTEtMS0w_2b2e043d-6d53-4ef0-99c4-c883097d99a3"
      unitRef="usd">3186000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i307a45a921aa4ac98cbf6914b2e129b6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjY3ZTQ4ZjA4YmQ3MTRhNTNhNGIyMzM5ZTllZTZlMjg0L3RhYmxlcmFuZ2U6NjdlNDhmMDhiZDcxNGE1M2E0YjIzMzllOWVlNmUyODRfMi00LTEtMS0w_5d21e950-d1b7-44bc-89be-dc505e09ab75"
      unitRef="usd">290500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i442f4b08d467498fa51f7601498e0665_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjY3ZTQ4ZjA4YmQ3MTRhNTNhNGIyMzM5ZTllZTZlMjg0L3RhYmxlcmFuZ2U6NjdlNDhmMDhiZDcxNGE1M2E0YjIzMzllOWVlNmUyODRfMi01LTEtMS0w_4b233b70-29bd-4a14-b044-e226eeed9d10"
      unitRef="usd">65800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjY3ZTQ4ZjA4YmQ3MTRhNTNhNGIyMzM5ZTllZTZlMjg0L3RhYmxlcmFuZ2U6NjdlNDhmMDhiZDcxNGE1M2E0YjIzMzllOWVlNmUyODRfMy0yLTEtMS0w_858ca554-ae81-4eb2-989b-47ca2dba80fb"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="ief55fa56f05642ae9c7051bbcc123a7e_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjY3ZTQ4ZjA4YmQ3MTRhNTNhNGIyMzM5ZTllZTZlMjg0L3RhYmxlcmFuZ2U6NjdlNDhmMDhiZDcxNGE1M2E0YjIzMzllOWVlNmUyODRfMy00LTEtMS0w_81afff1e-6b4b-4e12-bff0-f3bcb235b1a0"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="i1c7c09a50e6e4ba8839d07d7a35718fb_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjY3ZTQ4ZjA4YmQ3MTRhNTNhNGIyMzM5ZTllZTZlMjg0L3RhYmxlcmFuZ2U6NjdlNDhmMDhiZDcxNGE1M2E0YjIzMzllOWVlNmUyODRfMy01LTEtMS0w_bd763250-3308-4906-8e01-6eac1ce5033d"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="iaf63c553ba564cb8bd94fab03c3290ab_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjY3ZTQ4ZjA4YmQ3MTRhNTNhNGIyMzM5ZTllZTZlMjg0L3RhYmxlcmFuZ2U6NjdlNDhmMDhiZDcxNGE1M2E0YjIzMzllOWVlNmUyODRfNC0yLTEtMS0w_480a9ae6-9ba9-494c-a742-bbfd8b83472a"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ief55fa56f05642ae9c7051bbcc123a7e_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjY3ZTQ4ZjA4YmQ3MTRhNTNhNGIyMzM5ZTllZTZlMjg0L3RhYmxlcmFuZ2U6NjdlNDhmMDhiZDcxNGE1M2E0YjIzMzllOWVlNmUyODRfNC00LTEtMS0w_13766409-3d0d-4ace-9688-252c39cfc343"
      unitRef="usd">-15220000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i1c7c09a50e6e4ba8839d07d7a35718fb_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjY3ZTQ4ZjA4YmQ3MTRhNTNhNGIyMzM5ZTllZTZlMjg0L3RhYmxlcmFuZ2U6NjdlNDhmMDhiZDcxNGE1M2E0YjIzMzllOWVlNmUyODRfNC01LTEtMS0w_1f71f2e3-bcbf-4744-9c2c-d3af9e6d6766"
      unitRef="usd">23800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="iaf63c553ba564cb8bd94fab03c3290ab_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjY3ZTQ4ZjA4YmQ3MTRhNTNhNGIyMzM5ZTllZTZlMjg0L3RhYmxlcmFuZ2U6NjdlNDhmMDhiZDcxNGE1M2E0YjIzMzllOWVlNmUyODRfNS0yLTEtMS0w_398cae56-079e-4264-9e5a-408be923673e"
      unitRef="usd">3186000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="ief55fa56f05642ae9c7051bbcc123a7e_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjY3ZTQ4ZjA4YmQ3MTRhNTNhNGIyMzM5ZTllZTZlMjg0L3RhYmxlcmFuZ2U6NjdlNDhmMDhiZDcxNGE1M2E0YjIzMzllOWVlNmUyODRfNS00LTEtMS0w_a1a903c5-b6a7-48bc-b708-cdb6c06ad372"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i1c7c09a50e6e4ba8839d07d7a35718fb_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjY3ZTQ4ZjA4YmQ3MTRhNTNhNGIyMzM5ZTllZTZlMjg0L3RhYmxlcmFuZ2U6NjdlNDhmMDhiZDcxNGE1M2E0YjIzMzllOWVlNmUyODRfNS01LTEtMS0w_9d5e35ca-9a38-4984-babf-d2a4574cb3b6"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <ptct:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsRightsExchangeSettlement
      contextRef="iaf63c553ba564cb8bd94fab03c3290ab_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjY3ZTQ4ZjA4YmQ3MTRhNTNhNGIyMzM5ZTllZTZlMjg0L3RhYmxlcmFuZ2U6NjdlNDhmMDhiZDcxNGE1M2E0YjIzMzllOWVlNmUyODRfNi0yLTEtMS03MTIw_9856f745-fb08-4c6f-b3c9-d316faa7d4ad"
      unitRef="usd">0</ptct:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsRightsExchangeSettlement>
    <ptct:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsRightsExchangeSettlement
      contextRef="ief55fa56f05642ae9c7051bbcc123a7e_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjY3ZTQ4ZjA4YmQ3MTRhNTNhNGIyMzM5ZTllZTZlMjg0L3RhYmxlcmFuZ2U6NjdlNDhmMDhiZDcxNGE1M2E0YjIzMzllOWVlNmUyODRfNi00LTEtMS03MTIw_0488b33e-506e-45b9-a6e1-fc30a287f71a"
      unitRef="usd">139180000</ptct:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsRightsExchangeSettlement>
    <ptct:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsRightsExchangeSettlement
      contextRef="i1c7c09a50e6e4ba8839d07d7a35718fb_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjY3ZTQ4ZjA4YmQ3MTRhNTNhNGIyMzM5ZTllZTZlMjg0L3RhYmxlcmFuZ2U6NjdlNDhmMDhiZDcxNGE1M2E0YjIzMzllOWVlNmUyODRfNi02LTEtMS03MTIw_6a43f3dd-141d-435e-a051-8983951f08c0"
      unitRef="usd">0</ptct:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsRightsExchangeSettlement>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i82a7d5029292453a9d8665965b2a0597_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjY3ZTQ4ZjA4YmQ3MTRhNTNhNGIyMzM5ZTllZTZlMjg0L3RhYmxlcmFuZ2U6NjdlNDhmMDhiZDcxNGE1M2E0YjIzMzllOWVlNmUyODRfNi0yLTEtMS0w_4deafb1f-e9e3-41c9-a885-9849ac20c220"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i4d5a9b90a7664e9ca2c85d0f043d14b8_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjY3ZTQ4ZjA4YmQ3MTRhNTNhNGIyMzM5ZTllZTZlMjg0L3RhYmxlcmFuZ2U6NjdlNDhmMDhiZDcxNGE1M2E0YjIzMzllOWVlNmUyODRfNi00LTEtMS0w_d4a99368-54ec-4508-a69a-c051f782a13f"
      unitRef="usd">136100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i6d889af7642941098bf2c2aadc6af779_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjY3ZTQ4ZjA4YmQ3MTRhNTNhNGIyMzM5ZTllZTZlMjg0L3RhYmxlcmFuZ2U6NjdlNDhmMDhiZDcxNGE1M2E0YjIzMzllOWVlNmUyODRfNi01LTEtMS0w_e7bf967e-6979-436b-85b6-243a908bf51f"
      unitRef="usd">89600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="iab08ed7f127f42a4870b894f05e31311_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjAxMWU0YmUyZjdmMTRhZGY4NzY3YjM3MDdkMzE1OGFhL3RhYmxlcmFuZ2U6MDExZTRiZTJmN2YxNGFkZjg3NjdiMzcwN2QzMTU4YWFfMi0yLTEtMS0w_552a870b-8523-4793-9d98-6578867ab9ce"
      unitRef="usd">3814000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i34ddd62e28264378a9b8a8810c84e304_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjAxMWU0YmUyZjdmMTRhZGY4NzY3YjM3MDdkMzE1OGFhL3RhYmxlcmFuZ2U6MDExZTRiZTJmN2YxNGFkZjg3NjdiMzcwN2QzMTU4YWFfMi00LTEtMS0w_f48ee237-ae59-4dd1-89d2-404cffce951f"
      unitRef="usd">257040000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i43a9f70ea53c4278ac5294a289217733_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjAxMWU0YmUyZjdmMTRhZGY4NzY3YjM3MDdkMzE1OGFhL3RhYmxlcmFuZ2U6MDExZTRiZTJmN2YxNGFkZjg3NjdiMzcwN2QzMTU4YWFfMi01LTEtMS0w_c8f39e57-5f15-40cd-9fe3-6562103502d5"
      unitRef="usd">53200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjAxMWU0YmUyZjdmMTRhZGY4NzY3YjM3MDdkMzE1OGFhL3RhYmxlcmFuZ2U6MDExZTRiZTJmN2YxNGFkZjg3NjdiMzcwN2QzMTU4YWFfMy0yLTEtMS0w_89ca4392-01ed-4e51-a6a7-bfb24f79d77c"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="i6901fa0b994f45b1b11bb7852f30e63e_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjAxMWU0YmUyZjdmMTRhZGY4NzY3YjM3MDdkMzE1OGFhL3RhYmxlcmFuZ2U6MDExZTRiZTJmN2YxNGFkZjg3NjdiMzcwN2QzMTU4YWFfMy00LTEtMS0w_f41cffba-b729-446d-b755-3e00e7d71566"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="ic9b011ab666643deb05f06b8b1928ac7_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjAxMWU0YmUyZjdmMTRhZGY4NzY3YjM3MDdkMzE1OGFhL3RhYmxlcmFuZ2U6MDExZTRiZTJmN2YxNGFkZjg3NjdiMzcwN2QzMTU4YWFfMy01LTEtMS0w_9ac768de-18bf-4c9e-8ef7-27796463055e"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i69fef5796fd9485e91f00768f2ee4f15_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjAxMWU0YmUyZjdmMTRhZGY4NzY3YjM3MDdkMzE1OGFhL3RhYmxlcmFuZ2U6MDExZTRiZTJmN2YxNGFkZjg3NjdiMzcwN2QzMTU4YWFfNC0yLTEtMS0w_e446012a-125d-4460-a526-ec0384f3a43a"
      unitRef="usd">1961000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i6901fa0b994f45b1b11bb7852f30e63e_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjAxMWU0YmUyZjdmMTRhZGY4NzY3YjM3MDdkMzE1OGFhL3RhYmxlcmFuZ2U6MDExZTRiZTJmN2YxNGFkZjg3NjdiMzcwN2QzMTU4YWFfNC00LTEtMS0w_5d2d0526-136f-41b6-8da6-ce732c055d5c"
      unitRef="usd">20360000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ic9b011ab666643deb05f06b8b1928ac7_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjAxMWU0YmUyZjdmMTRhZGY4NzY3YjM3MDdkMzE1OGFhL3RhYmxlcmFuZ2U6MDExZTRiZTJmN2YxNGFkZjg3NjdiMzcwN2QzMTU4YWFfNC01LTEtMS0w_86b3e04f-825c-4810-9089-f084d60ae9ce"
      unitRef="usd">5600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i69fef5796fd9485e91f00768f2ee4f15_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjAxMWU0YmUyZjdmMTRhZGY4NzY3YjM3MDdkMzE1OGFhL3RhYmxlcmFuZ2U6MDExZTRiZTJmN2YxNGFkZjg3NjdiMzcwN2QzMTU4YWFfNS0yLTEtMS0w_9fa8d9ca-eda8-4d04-918c-d0053f098572"
      unitRef="usd">3815000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i6901fa0b994f45b1b11bb7852f30e63e_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjAxMWU0YmUyZjdmMTRhZGY4NzY3YjM3MDdkMzE1OGFhL3RhYmxlcmFuZ2U6MDExZTRiZTJmN2YxNGFkZjg3NjdiMzcwN2QzMTU4YWFfNS00LTEtMS0w_de9c8531-9d46-4a24-af4f-ef31b8fdd85d"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="ic9b011ab666643deb05f06b8b1928ac7_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjAxMWU0YmUyZjdmMTRhZGY4NzY3YjM3MDdkMzE1OGFhL3RhYmxlcmFuZ2U6MDExZTRiZTJmN2YxNGFkZjg3NjdiMzcwN2QzMTU4YWFfNS01LTEtMS0w_47e82508-e7c8-4dc3-833e-6a7c3ce3f2a9"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i492676ae9f954509b5671e6270ebd50f_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjAxMWU0YmUyZjdmMTRhZGY4NzY3YjM3MDdkMzE1OGFhL3RhYmxlcmFuZ2U6MDExZTRiZTJmN2YxNGFkZjg3NjdiMzcwN2QzMTU4YWFfNi0yLTEtMS0w_4ce0d802-2f10-42ad-9613-0c74b0967cd9"
      unitRef="usd">1960000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i6abf1ab717cb4553b5a379a89528951c_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjAxMWU0YmUyZjdmMTRhZGY4NzY3YjM3MDdkMzE1OGFhL3RhYmxlcmFuZ2U6MDExZTRiZTJmN2YxNGFkZjg3NjdiMzcwN2QzMTU4YWFfNi00LTEtMS0w_7306247f-f103-474f-a48b-5a2cf035e309"
      unitRef="usd">277400000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i0bb52be78ac04fb99f1f51bf469e5f11_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOjAxMWU0YmUyZjdmMTRhZGY4NzY3YjM3MDdkMzE1OGFhL3RhYmxlcmFuZ2U6MDExZTRiZTJmN2YxNGFkZjg3NjdiMzcwN2QzMTU4YWFfNi01LTEtMS0w_8ec9235f-a02d-4c4c-bd85-92c1c5be8189"
      unitRef="usd">58800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RleHRyZWdpb246YTJiMWEzYzNhY2RlNGViYTgyMDE5NTEzMDU0MTdiY2VfMTIyNjk_96ee7967-2a84-4ec2-96cf-9917983feadf">&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following significant unobservable inputs were used in the valuation of the contingent consideration payable for the periods ended June&#160;30, 2020 and December&#160;31, 2019 and of the SARs liability for the period ended December 31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.998%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.415%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.481%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.415%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.823%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.121%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:21.494%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.415%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.038%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="10" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="10" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unobservable Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="10" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration payable- development and regulatory milestones&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="9" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$136,100&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Probability-adjusted discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Potential development and regulatory milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;$0 - $381 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Probabilities of success&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;25% - 94%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Discount rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;4.6% - 6.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Projected years of payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021 - 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent considerable payable- net sales milestones and royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$89,600&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Option-pricing model with Monte Carlo simulation&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Potential net sales milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;$0 - $150 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Probabilities of success&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;25% -94%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Potential percentage of net sales for royalties &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;2% - 6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Projected years of payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022 - 2039&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.998%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.415%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.481%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.415%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.823%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.121%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:21.494%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.415%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.038%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="15" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="15" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unobservable Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="15" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;SARs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="14" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$3,186&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Option-pricing model&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28.93%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.19%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Strike price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;$6.76 - $30.86&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$48.03&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.01 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Contingent consideration payable- development and regulatory milestones&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$290,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Probability-adjusted discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Potential development and regulatory milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;$0- $555 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Probabilities of success&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;25% - 94%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Discount rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;2.2% - 4.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Projected years of payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020 - 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent considerable payable- net sales milestones and royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$65,800&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Option-pricing model with Monte Carlo simulation&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Potential net sales milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;$0 - $150 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Probabilities of success&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;25% - 89%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Potential percentage of net sales for royalties &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;2% - 6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Projected years of payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021 - 2038&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ia63a5a2116d74541955a8c47217140bb_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmM1YmE0NjQ0ZmNiMjQyZjdiMzdlMGEyODM5NmU2YTMwL3RhYmxlcmFuZ2U6YzViYTQ2NDRmY2IyNDJmN2IzN2UwYTI4Mzk2ZTZhMzBfMi0yLTEtMS0w_5cc89422-c3b1-48a2-bd8c-674992b90751"
      unitRef="usd">136100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <ptct:AlternativeInvestmentMilestone
      contextRef="i7d5cbe2fe3d241869ba45bf5f3259eaf_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmM1YmE0NjQ0ZmNiMjQyZjdiMzdlMGEyODM5NmU2YTMwL3RhYmxlcmFuZ2U6YzViYTQ2NDRmY2IyNDJmN2IzN2UwYTI4Mzk2ZTZhMzBfMi04LTEtMS0wL3RleHRyZWdpb246ZGIxYjhlMTllZGFiNGM3NTllN2NmMmEyNDA5OGU4OTNfNjA0NzMxMzk1Mjc5MQ_642f3173-8d72-4a63-8bb7-edcdd02da812"
      unitRef="usd">0</ptct:AlternativeInvestmentMilestone>
    <ptct:AlternativeInvestmentMilestone
      contextRef="i8e3ab83b0ac24b1f8726a085e96bde2b_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmM1YmE0NjQ0ZmNiMjQyZjdiMzdlMGEyODM5NmU2YTMwL3RhYmxlcmFuZ2U6YzViYTQ2NDRmY2IyNDJmN2IzN2UwYTI4Mzk2ZTZhMzBfMi04LTEtMS0wL3RleHRyZWdpb246ZGIxYjhlMTllZGFiNGM3NTllN2NmMmEyNDA5OGU4OTNfNjA0NzMxMzk1Mjc5Nw_c5875052-561c-4375-b546-c47afd8b27d4"
      unitRef="usd">381000000</ptct:AlternativeInvestmentMilestone>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="i97b5568d815c48fcaeba6264529028d7_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmM1YmE0NjQ0ZmNiMjQyZjdiMzdlMGEyODM5NmU2YTMwL3RhYmxlcmFuZ2U6YzViYTQ2NDRmY2IyNDJmN2IzN2UwYTI4Mzk2ZTZhMzBfMy04LTEtMS0wL3RleHRyZWdpb246NmMyNjc0Y2NjZTgwNDU0N2JkZWY5MmNkNjZmNjkxYzVfNjA0NzMxMzk1Mjc4NA_9608cc67-54c3-4449-a88d-3a010cbb050d"
      unitRef="number">0.25</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="i7f2ea92199454f8fbd535326a97a91d7_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmM1YmE0NjQ0ZmNiMjQyZjdiMzdlMGEyODM5NmU2YTMwL3RhYmxlcmFuZ2U6YzViYTQ2NDRmY2IyNDJmN2IzN2UwYTI4Mzk2ZTZhMzBfMy04LTEtMS0wL3RleHRyZWdpb246NmMyNjc0Y2NjZTgwNDU0N2JkZWY5MmNkNjZmNjkxYzVfNjA0NzMxMzk1Mjc4OQ_581e6355-0c09-44de-b2a0-6fa895976e97"
      unitRef="number">0.94</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i142a5ba947234d00bdda31557ab02053_I20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmM1YmE0NjQ0ZmNiMjQyZjdiMzdlMGEyODM5NmU2YTMwL3RhYmxlcmFuZ2U6YzViYTQ2NDRmY2IyNDJmN2IzN2UwYTI4Mzk2ZTZhMzBfNC04LTEtMS0wL3RleHRyZWdpb246N2MyNDljMzk2MDA2NGU1ZDkyMGIwNzVhMjY5ZjI0NTdfNjA0NzMxMzk1Mjc4Nw_6cb37775-3fb2-4213-b4a3-1d1f7bf52e3c"
      unitRef="number">0.046</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="ic24cf29b77fa4211a03dfd961242ace4_I20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmM1YmE0NjQ0ZmNiMjQyZjdiMzdlMGEyODM5NmU2YTMwL3RhYmxlcmFuZ2U6YzViYTQ2NDRmY2IyNDJmN2IzN2UwYTI4Mzk2ZTZhMzBfNC04LTEtMS0wL3RleHRyZWdpb246N2MyNDljMzk2MDA2NGU1ZDkyMGIwNzVhMjY5ZjI0NTdfNjA0NzMxMzk1Mjc5Mw_5befb9ef-474f-4b6f-8cfc-bdd3af6a51ea"
      unitRef="number">0.061</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="if778d097ba124606b84b432e35ce14f2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmM1YmE0NjQ0ZmNiMjQyZjdiMzdlMGEyODM5NmU2YTMwL3RhYmxlcmFuZ2U6YzViYTQ2NDRmY2IyNDJmN2IzN2UwYTI4Mzk2ZTZhMzBfNi0yLTEtMS0w_bd21f0c8-b110-44db-84d9-fa10fcd72491"
      unitRef="usd">89600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <ptct:AlternativeInvestmentMilestone
      contextRef="icde04c74d7d14859bd0c3c1fec8bf23b_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmM1YmE0NjQ0ZmNiMjQyZjdiMzdlMGEyODM5NmU2YTMwL3RhYmxlcmFuZ2U6YzViYTQ2NDRmY2IyNDJmN2IzN2UwYTI4Mzk2ZTZhMzBfNi04LTEtMS0wL3RleHRyZWdpb246YzUyNTc5NTExMWM5NDA2Yzg5ZTNmZDRhN2Y3MWNiOWJfNjA0NzMxMzk1Mjc5MQ_c005888c-bab5-4086-a75e-cc224c1d0743"
      unitRef="usd">0</ptct:AlternativeInvestmentMilestone>
    <ptct:AlternativeInvestmentMilestone
      contextRef="i841cadf7f1ab42329b55f05f8b682241_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmM1YmE0NjQ0ZmNiMjQyZjdiMzdlMGEyODM5NmU2YTMwL3RhYmxlcmFuZ2U6YzViYTQ2NDRmY2IyNDJmN2IzN2UwYTI4Mzk2ZTZhMzBfNi04LTEtMS0wL3RleHRyZWdpb246YzUyNTc5NTExMWM5NDA2Yzg5ZTNmZDRhN2Y3MWNiOWJfNjA0NzMxMzk1Mjc5OQ_253e8caf-dbe4-4a93-9ec0-16196d336155"
      unitRef="usd">150000000</ptct:AlternativeInvestmentMilestone>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="id290d0f494dc48b394820ca85e03d713_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmM1YmE0NjQ0ZmNiMjQyZjdiMzdlMGEyODM5NmU2YTMwL3RhYmxlcmFuZ2U6YzViYTQ2NDRmY2IyNDJmN2IzN2UwYTI4Mzk2ZTZhMzBfNy04LTEtMS0wL3RleHRyZWdpb246NGM1Y2MwMTM5NDc1NDBjNDhmYmQwYTkxNjA3YTczZDVfMjc0ODc3OTA2OTQ1Ng_318ca686-1000-4c30-a6ef-5b236c858964"
      unitRef="number">0.25</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="i7b1d4bc93668470fb8dc3d2484cd7377_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmM1YmE0NjQ0ZmNiMjQyZjdiMzdlMGEyODM5NmU2YTMwL3RhYmxlcmFuZ2U6YzViYTQ2NDRmY2IyNDJmN2IzN2UwYTI4Mzk2ZTZhMzBfNy04LTEtMS0wL3RleHRyZWdpb246NGM1Y2MwMTM5NDc1NDBjNDhmYmQwYTkxNjA3YTczZDVfMjc0ODc3OTA2OTQ2Mg_b72d868a-bcd9-4633-9c01-77d72754f423"
      unitRef="number">0.94</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="i032e49103b7940008966b0abb2c816bf_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmM1YmE0NjQ0ZmNiMjQyZjdiMzdlMGEyODM5NmU2YTMwL3RhYmxlcmFuZ2U6YzViYTQ2NDRmY2IyNDJmN2IzN2UwYTI4Mzk2ZTZhMzBfOC04LTEtMS0wL3RleHRyZWdpb246MWIyYTQxOTU1MzE3NDY4MThlYWQ3ZWNlMzk1YzlmMTNfMjc0ODc3OTA2OTQ1Mw_df828af1-925d-4978-bb71-8076718fca22"
      unitRef="number">0.02</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="i7aeb677d725d4e7587c00dcd29b216d8_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmM1YmE0NjQ0ZmNiMjQyZjdiMzdlMGEyODM5NmU2YTMwL3RhYmxlcmFuZ2U6YzViYTQ2NDRmY2IyNDJmN2IzN2UwYTI4Mzk2ZTZhMzBfOC04LTEtMS0wL3RleHRyZWdpb246MWIyYTQxOTU1MzE3NDY4MThlYWQ3ZWNlMzk1YzlmMTNfMjc0ODc3OTA2OTQ1Nw_2b8c4db2-45c2-4bdd-9a4d-44340fa107bf"
      unitRef="number">0.06</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="i46d96bc3957b4332a199fc5c2ba22aa2_I20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmM1YmE0NjQ0ZmNiMjQyZjdiMzdlMGEyODM5NmU2YTMwL3RhYmxlcmFuZ2U6YzViYTQ2NDRmY2IyNDJmN2IzN2UwYTI4Mzk2ZTZhMzBfOS04LTEtMS0w_f16af69f-a6d2-4732-aec8-dd1ec8af39ce"
      unitRef="number">0.120</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ia922f94529a94215b26acb871b50ccef_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE0ZGFhMTA0MWExNTRiMzc5NjE3OWM4OWRkZWZmOTJkL3RhYmxlcmFuZ2U6YTRkYWExMDQxYTE1NGIzNzk2MTc5Yzg5ZGRlZmY5MmRfMi0yLTEtMS0w_9c748396-1948-4713-9c16-0698047cac46"
      unitRef="usd">3186000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="i8a37cc547e3f49848c674109573d923a_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE0ZGFhMTA0MWExNTRiMzc5NjE3OWM4OWRkZWZmOTJkL3RhYmxlcmFuZ2U6YTRkYWExMDQxYTE1NGIzNzk2MTc5Yzg5ZGRlZmY5MmRfMi04LTEtMS0w_84825556-e8a5-4b12-be69-f42b7702148e"
      unitRef="number">28.93</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="i95e964e1da464dd788d6a99f05370274_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE0ZGFhMTA0MWExNTRiMzc5NjE3OWM4OWRkZWZmOTJkL3RhYmxlcmFuZ2U6YTRkYWExMDQxYTE1NGIzNzk2MTc5Yzg5ZGRlZmY5MmRfMy04LTEtMS0w_4ec041bf-7865-4ba4-b8fa-d7c963a837a2"
      unitRef="number">0.19</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="i0c93370f63d94e1aac4ee54439ff6b56_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE0ZGFhMTA0MWExNTRiMzc5NjE3OWM4OWRkZWZmOTJkL3RhYmxlcmFuZ2U6YTRkYWExMDQxYTE1NGIzNzk2MTc5Yzg5ZGRlZmY5MmRfNC04LTEtMS0wL3RleHRyZWdpb246NDdkNDk3NTQwODhjNGVjY2EzOWQwYzNkOTlmMzY1OTlfODI0NjMzNzIwODM0Mw_20894b66-dd38-4b82-964d-cf7fb09c293c"
      unitRef="usdPerShare">6.76</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="iffe61d144e3f45a68d1cf62be52068fc_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE0ZGFhMTA0MWExNTRiMzc5NjE3OWM4OWRkZWZmOTJkL3RhYmxlcmFuZ2U6YTRkYWExMDQxYTE1NGIzNzk2MTc5Yzg5ZGRlZmY5MmRfNC04LTEtMS0wL3RleHRyZWdpb246NDdkNDk3NTQwODhjNGVjY2EzOWQwYzNkOTlmMzY1OTlfODI0NjMzNzIwODM1MQ_222dfdcd-eb29-4b05-9ac6-88885832e529"
      unitRef="usdPerShare">30.86</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="ic6c94b6543dd43d288ab57eb081f624f_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE0ZGFhMTA0MWExNTRiMzc5NjE3OWM4OWRkZWZmOTJkL3RhYmxlcmFuZ2U6YTRkYWExMDQxYTE1NGIzNzk2MTc5Yzg5ZGRlZmY5MmRfNS04LTEtMS0w_d7b99cb5-9f7a-44e7-82a0-38e13028a6bc"
      unitRef="usdPerShare">48.03</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="iee49fff9a55c42e7a46ef038efca561d_D20190101-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE0ZGFhMTA0MWExNTRiMzc5NjE3OWM4OWRkZWZmOTJkL3RhYmxlcmFuZ2U6YTRkYWExMDQxYTE1NGIzNzk2MTc5Yzg5ZGRlZmY5MmRfNi04LTEtMS0w_7e49bbb2-214f-4919-b2da-88043e192e7a">P0Y3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i37afd9374ab2456f9adc2e123d047a8d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE0ZGFhMTA0MWExNTRiMzc5NjE3OWM4OWRkZWZmOTJkL3RhYmxlcmFuZ2U6YTRkYWExMDQxYTE1NGIzNzk2MTc5Yzg5ZGRlZmY5MmRfNy0yLTEtMS0w_5222ca44-157d-45e8-ae93-6fc3880afb10"
      unitRef="usd">290500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <ptct:AlternativeInvestmentMilestone
      contextRef="i41984dd1229341a3adf191f855e3437a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE0ZGFhMTA0MWExNTRiMzc5NjE3OWM4OWRkZWZmOTJkL3RhYmxlcmFuZ2U6YTRkYWExMDQxYTE1NGIzNzk2MTc5Yzg5ZGRlZmY5MmRfNy04LTEtMS0wL3RleHRyZWdpb246MWE0YzFmMjliZGJiNDY2MWIxMWI4YzA4MWI2NTUwMjNfODI0NjMzNzIwODM0NA_2704c2e1-a789-4f84-a319-00f700828811"
      unitRef="usd">0</ptct:AlternativeInvestmentMilestone>
    <ptct:AlternativeInvestmentMilestone
      contextRef="id9f423a27b8747658dbca67347391ba2_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE0ZGFhMTA0MWExNTRiMzc5NjE3OWM4OWRkZWZmOTJkL3RhYmxlcmFuZ2U6YTRkYWExMDQxYTE1NGIzNzk2MTc5Yzg5ZGRlZmY5MmRfNy04LTEtMS0wL3RleHRyZWdpb246MWE0YzFmMjliZGJiNDY2MWIxMWI4YzA4MWI2NTUwMjNfODI0NjMzNzIwODM1Mw_02fda7f6-119f-4e13-8d45-08109729aaa0"
      unitRef="usd">555000000</ptct:AlternativeInvestmentMilestone>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="id9cb29f6a24b456e9193911f1294da2e_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE0ZGFhMTA0MWExNTRiMzc5NjE3OWM4OWRkZWZmOTJkL3RhYmxlcmFuZ2U6YTRkYWExMDQxYTE1NGIzNzk2MTc5Yzg5ZGRlZmY5MmRfOC04LTEtMS0wL3RleHRyZWdpb246NzNlOTc5Yjk3ZTQ1NDJmY2EyY2U4Nzg0NmEwY2RhYzZfODI0NjMzNzIwODMzNg_28c4a25f-6c7f-4cdb-8c2e-f858ea9e5fde"
      unitRef="number">0.25</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="i896363143c604488b15264f3f0863d75_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE0ZGFhMTA0MWExNTRiMzc5NjE3OWM4OWRkZWZmOTJkL3RhYmxlcmFuZ2U6YTRkYWExMDQxYTE1NGIzNzk2MTc5Yzg5ZGRlZmY5MmRfOC04LTEtMS0wL3RleHRyZWdpb246NzNlOTc5Yjk3ZTQ1NDJmY2EyY2U4Nzg0NmEwY2RhYzZfODI0NjMzNzIwODM0MQ_61dbaa03-706b-400d-94c0-1e5e616aadac"
      unitRef="number">0.94</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="i4e93577925ee429e9cfb5138f9eb301c_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE0ZGFhMTA0MWExNTRiMzc5NjE3OWM4OWRkZWZmOTJkL3RhYmxlcmFuZ2U6YTRkYWExMDQxYTE1NGIzNzk2MTc5Yzg5ZGRlZmY5MmRfOS04LTEtMS0wL3RleHRyZWdpb246ZDU0MmQxNWJmYWExNDUyNGJmZmFhOTgwMTc0NTdkNTdfODI0NjMzNzIwODMzOQ_2cfead7a-093d-41da-92d6-8fc18fadd7a3"
      unitRef="number">0.022</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="ia90fac7174b946d2a3f4eb2d0130831f_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE0ZGFhMTA0MWExNTRiMzc5NjE3OWM4OWRkZWZmOTJkL3RhYmxlcmFuZ2U6YTRkYWExMDQxYTE1NGIzNzk2MTc5Yzg5ZGRlZmY5MmRfOS04LTEtMS0wL3RleHRyZWdpb246ZDU0MmQxNWJmYWExNDUyNGJmZmFhOTgwMTc0NTdkNTdfODI0NjMzNzIwODM0NQ_e2805679-2110-478d-bda3-4e3c3438d4da"
      unitRef="number">0.047</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i9de748e71a0a41f892580d81dc59723c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE0ZGFhMTA0MWExNTRiMzc5NjE3OWM4OWRkZWZmOTJkL3RhYmxlcmFuZ2U6YTRkYWExMDQxYTE1NGIzNzk2MTc5Yzg5ZGRlZmY5MmRfMTEtMi0xLTEtMA_395ad3b5-e5b2-4129-8323-c4e828bfb966"
      unitRef="usd">65800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <ptct:AlternativeInvestmentMilestone
      contextRef="ia365849e92bd4987b8c1a8f48af0e949_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE0ZGFhMTA0MWExNTRiMzc5NjE3OWM4OWRkZWZmOTJkL3RhYmxlcmFuZ2U6YTRkYWExMDQxYTE1NGIzNzk2MTc5Yzg5ZGRlZmY5MmRfMTEtOC0xLTEtMC90ZXh0cmVnaW9uOjZjZTJlYWIzZWVkZjRhNjVhMzcxMDVjZWQ5MDRkMmQyXzgyNDYzMzcyMDgzNDM_97987f82-a4b6-48b2-9703-4bdadea5b0d2"
      unitRef="usd">0</ptct:AlternativeInvestmentMilestone>
    <ptct:AlternativeInvestmentMilestone
      contextRef="ie8a23607d13242b087cdf7ef0d75fbf0_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE0ZGFhMTA0MWExNTRiMzc5NjE3OWM4OWRkZWZmOTJkL3RhYmxlcmFuZ2U6YTRkYWExMDQxYTE1NGIzNzk2MTc5Yzg5ZGRlZmY5MmRfMTEtOC0xLTEtMC90ZXh0cmVnaW9uOjZjZTJlYWIzZWVkZjRhNjVhMzcxMDVjZWQ5MDRkMmQyXzgyNDYzMzcyMDgzNTI_2aeef922-a5b9-4bad-bf5a-2d16ff943839"
      unitRef="usd">150000000</ptct:AlternativeInvestmentMilestone>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="i2e30234883ae400a8e1754f0ba49366e_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE0ZGFhMTA0MWExNTRiMzc5NjE3OWM4OWRkZWZmOTJkL3RhYmxlcmFuZ2U6YTRkYWExMDQxYTE1NGIzNzk2MTc5Yzg5ZGRlZmY5MmRfMTItOC0xLTEtMC90ZXh0cmVnaW9uOmJjMDVlZWZmNDhhODQ1NWQ5OGIyNTU2ZGNiMWUzY2IyXzgyNDYzMzcyMDgzMzY_37323882-0da4-4c1f-a817-a1fe87e9dbae"
      unitRef="number">0.25</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="i7418d3bad6a54d2d94c44b530ec3c8ef_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE0ZGFhMTA0MWExNTRiMzc5NjE3OWM4OWRkZWZmOTJkL3RhYmxlcmFuZ2U6YTRkYWExMDQxYTE1NGIzNzk2MTc5Yzg5ZGRlZmY5MmRfMTItOC0xLTEtMC90ZXh0cmVnaW9uOmJjMDVlZWZmNDhhODQ1NWQ5OGIyNTU2ZGNiMWUzY2IyXzgyNDYzMzcyMDgzNDE_873ebec7-ac45-4431-a267-d369d47a2cf9"
      unitRef="number">0.89</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="id6558018b150492b8245e18dd9d4171c_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE0ZGFhMTA0MWExNTRiMzc5NjE3OWM4OWRkZWZmOTJkL3RhYmxlcmFuZ2U6YTRkYWExMDQxYTE1NGIzNzk2MTc5Yzg5ZGRlZmY5MmRfMTMtOC0xLTEtMC90ZXh0cmVnaW9uOjQ3OWNjNDJlMDNjZDQyMjBhMGRlZDE3ZGQ1YWFlZDc5XzgyNDYzMzcyMDgzMzM_b33002cd-8445-4302-b19d-c01ac856597c"
      unitRef="number">0.02</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="i92a0fdc9f2104055b10e7852fda23d64_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE0ZGFhMTA0MWExNTRiMzc5NjE3OWM4OWRkZWZmOTJkL3RhYmxlcmFuZ2U6YTRkYWExMDQxYTE1NGIzNzk2MTc5Yzg5ZGRlZmY5MmRfMTMtOC0xLTEtMC90ZXh0cmVnaW9uOjQ3OWNjNDJlMDNjZDQyMjBhMGRlZDE3ZGQ1YWFlZDc5XzgyNDYzMzcyMDgzMzc_e69b304e-546a-49ec-9e6e-e2f013959b26"
      unitRef="number">0.06</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="i01dac52020be426eb733231d3b86e6ac_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81Mi9mcmFnOmEyYjFhM2MzYWNkZTRlYmE4MjAxOTUxMzA1NDE3YmNlL3RhYmxlOmE0ZGFhMTA0MWExNTRiMzc5NjE3OWM4OWRkZWZmOTJkL3RhYmxlcmFuZ2U6YTRkYWExMDQxYTE1NGIzNzk2MTc5Yzg5ZGRlZmY5MmRfMTQtOC0xLTEtMA_9e8cc096-875d-48ee-bd5b-5fcf6acd1c7b"
      unitRef="number">0.145</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RleHRyZWdpb246MWUxN2ExZWMyNDhkNGNiYmIwYTM4ZjM1NmNhMTliMDVfNDAy_6712ad11-73ce-44a7-91d3-8e4aa5bbf6a9">Other comprehensive income (loss) and accumulated other comprehensive items&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Other comprehensive income (loss) includes changes in equity that are excluded from net income (loss), such as unrealized gains and losses on marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following tables summarize other comprehensive income (loss) and the changes in accumulated other comprehensive items for the three and six months periods ended June&#160;30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:57.590%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.740%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized Gains/(Losses) On Marketable Securities, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total Accumulated Other Comprehensive Items&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,677)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,985)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10,749)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(8,031)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amounts reclassified from other comprehensive items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10,749)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(8,031)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(13,426)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10,016)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:57.590%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.740%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized&lt;br/&gt;Gains/(Losses)&lt;br/&gt;On&lt;br/&gt;Marketable&lt;br/&gt;Securities,&#160;net&lt;br/&gt;of&#160;tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Foreign&lt;br/&gt;Currency&lt;br/&gt;Translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;br/&gt;Accumulated&lt;br/&gt;Other&lt;br/&gt;Comprehensive&lt;br/&gt;Items&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(11,339)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10,584)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,087)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amounts reclassified from other comprehensive items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,087)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(13,426)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10,016)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RleHRyZWdpb246MWUxN2ExZWMyNDhkNGNiYmIwYTM4ZjM1NmNhMTliMDVfNDA2_5df39ff8-00fb-465d-b97a-658dbc21e20c">&lt;div style="margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following tables summarize other comprehensive income (loss) and the changes in accumulated other comprehensive items for the three and six months periods ended June&#160;30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:57.590%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.740%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized Gains/(Losses) On Marketable Securities, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total Accumulated Other Comprehensive Items&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,677)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,985)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10,749)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(8,031)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amounts reclassified from other comprehensive items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10,749)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(8,031)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(13,426)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10,016)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:57.590%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.740%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized&lt;br/&gt;Gains/(Losses)&lt;br/&gt;On&lt;br/&gt;Marketable&lt;br/&gt;Securities,&#160;net&lt;br/&gt;of&#160;tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Foreign&lt;br/&gt;Currency&lt;br/&gt;Translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;br/&gt;Accumulated&lt;br/&gt;Other&lt;br/&gt;Comprehensive&lt;br/&gt;Items&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(11,339)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10,584)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,087)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amounts reclassified from other comprehensive items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,087)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(13,426)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10,016)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquity
      contextRef="i928aeea3fbed4653a9c7504d776b8545_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjRkYzAwNGUyOTYzYTQ1Yjg4MDEyODMxZmUzMmY3MWFjL3RhYmxlcmFuZ2U6NGRjMDA0ZTI5NjNhNDViODgwMTI4MzFmZTMyZjcxYWNfMS0yLTEtMS0yOTc3_0a4b6bb4-d946-4f19-b173-7ee62278bffd"
      unitRef="usd">692000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic451340f512342608177bf840c932205_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjRkYzAwNGUyOTYzYTQ1Yjg4MDEyODMxZmUzMmY3MWFjL3RhYmxlcmFuZ2U6NGRjMDA0ZTI5NjNhNDViODgwMTI4MzFmZTMyZjcxYWNfMS00LTEtMS0yOTgx_1736707e-68e7-441f-b50a-40faa01d5035"
      unitRef="usd">-2677000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic903ce63d61344bb93ea8a3c7cd2e5fd_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjRkYzAwNGUyOTYzYTQ1Yjg4MDEyODMxZmUzMmY3MWFjL3RhYmxlcmFuZ2U6NGRjMDA0ZTI5NjNhNDViODgwMTI4MzFmZTMyZjcxYWNfMS02LTEtMS0yOTg1_25ac70db-d399-4133-88cb-ae37619067bf"
      unitRef="usd">-1985000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="id2f410476d4d4014828565f0ff529e4b_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjRkYzAwNGUyOTYzYTQ1Yjg4MDEyODMxZmUzMmY3MWFjL3RhYmxlcmFuZ2U6NGRjMDA0ZTI5NjNhNDViODgwMTI4MzFmZTMyZjcxYWNfMi0yLTEtMS0yOTc3_a7339f89-c684-4be9-9e73-adf2f251b5ab"
      unitRef="usd">2718000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i2a5bfe4b544f4ab3b6857b0ebb80918e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjRkYzAwNGUyOTYzYTQ1Yjg4MDEyODMxZmUzMmY3MWFjL3RhYmxlcmFuZ2U6NGRjMDA0ZTI5NjNhNDViODgwMTI4MzFmZTMyZjcxYWNfMi00LTEtMS0yOTgx_c35e17e2-3db0-4726-a9b4-508a36c4e98f"
      unitRef="usd">-10749000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjRkYzAwNGUyOTYzYTQ1Yjg4MDEyODMxZmUzMmY3MWFjL3RhYmxlcmFuZ2U6NGRjMDA0ZTI5NjNhNDViODgwMTI4MzFmZTMyZjcxYWNfMi02LTEtMS0yOTg1_4272d426-a8b5-4e6b-91f8-f064197cceee"
      unitRef="usd">-8031000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="id2f410476d4d4014828565f0ff529e4b_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjRkYzAwNGUyOTYzYTQ1Yjg4MDEyODMxZmUzMmY3MWFjL3RhYmxlcmFuZ2U6NGRjMDA0ZTI5NjNhNDViODgwMTI4MzFmZTMyZjcxYWNfMy0yLTEtMS0yOTc3_e52e71f4-0ca7-4155-8fa0-e395f3c40ca2"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i2a5bfe4b544f4ab3b6857b0ebb80918e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjRkYzAwNGUyOTYzYTQ1Yjg4MDEyODMxZmUzMmY3MWFjL3RhYmxlcmFuZ2U6NGRjMDA0ZTI5NjNhNDViODgwMTI4MzFmZTMyZjcxYWNfMy00LTEtMS0yOTgx_778e3199-0f2f-4d0d-985c-13615833cfc9"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjRkYzAwNGUyOTYzYTQ1Yjg4MDEyODMxZmUzMmY3MWFjL3RhYmxlcmFuZ2U6NGRjMDA0ZTI5NjNhNDViODgwMTI4MzFmZTMyZjcxYWNfMy02LTEtMS0yOTg1_3ce054f7-8022-4cd4-a54d-f1365a284e7a"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id2f410476d4d4014828565f0ff529e4b_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjRkYzAwNGUyOTYzYTQ1Yjg4MDEyODMxZmUzMmY3MWFjL3RhYmxlcmFuZ2U6NGRjMDA0ZTI5NjNhNDViODgwMTI4MzFmZTMyZjcxYWNfNC0yLTEtMS0yOTc3_31017551-1f57-4c8d-95e6-4de51cdd82ce"
      unitRef="usd">2718000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i2a5bfe4b544f4ab3b6857b0ebb80918e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjRkYzAwNGUyOTYzYTQ1Yjg4MDEyODMxZmUzMmY3MWFjL3RhYmxlcmFuZ2U6NGRjMDA0ZTI5NjNhNDViODgwMTI4MzFmZTMyZjcxYWNfNC00LTEtMS0yOTgx_500896e5-1372-4334-aeb0-5372b204a8d1"
      unitRef="usd">-10749000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjRkYzAwNGUyOTYzYTQ1Yjg4MDEyODMxZmUzMmY3MWFjL3RhYmxlcmFuZ2U6NGRjMDA0ZTI5NjNhNDViODgwMTI4MzFmZTMyZjcxYWNfNC02LTEtMS0yOTg1_7e79794d-92f5-4b74-b77b-7de20af0e594"
      unitRef="usd">-8031000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i73427926a3e341daaacaf169fb831162_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjRkYzAwNGUyOTYzYTQ1Yjg4MDEyODMxZmUzMmY3MWFjL3RhYmxlcmFuZ2U6NGRjMDA0ZTI5NjNhNDViODgwMTI4MzFmZTMyZjcxYWNfNS0yLTEtMS0yOTc3_cd5682c7-60e4-4c61-bf3b-9e1539ec2c9d"
      unitRef="usd">3410000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8ea979e0426d48798c5a50c5f7a7aa15_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjRkYzAwNGUyOTYzYTQ1Yjg4MDEyODMxZmUzMmY3MWFjL3RhYmxlcmFuZ2U6NGRjMDA0ZTI5NjNhNDViODgwMTI4MzFmZTMyZjcxYWNfNS00LTEtMS0yOTgx_5785b8fa-c6d4-4e1e-80c3-fb4c1fbf0163"
      unitRef="usd">-13426000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if99a5f5b88c44e239963a271d78fd4d0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjRkYzAwNGUyOTYzYTQ1Yjg4MDEyODMxZmUzMmY3MWFjL3RhYmxlcmFuZ2U6NGRjMDA0ZTI5NjNhNDViODgwMTI4MzFmZTMyZjcxYWNfNS02LTEtMS0yOTg1_e438f041-33e9-49fc-8ca3-dbb2eecfe0df"
      unitRef="usd">-10016000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8ab1ac66d020429d96c29af31d72ab26_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjlhYjY4ODI3NDUxODQ1ZDliZGZjM2M3NWEzZWMyMTYyL3RhYmxlcmFuZ2U6OWFiNjg4Mjc0NTE4NDVkOWJkZmMzYzc1YTNlYzIxNjJfMS0yLTEtMS0w_231b37b3-5aee-4ee6-9dea-74832ff619aa"
      unitRef="usd">755000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icdcaac852b5047fa90c10c82a5c82f80_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjlhYjY4ODI3NDUxODQ1ZDliZGZjM2M3NWEzZWMyMTYyL3RhYmxlcmFuZ2U6OWFiNjg4Mjc0NTE4NDVkOWJkZmMzYzc1YTNlYzIxNjJfMS00LTEtMS0w_93a980be-83e8-4ffa-ac43-2ba8b61b4dcf"
      unitRef="usd">-11339000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iebab310c097741efb22ea6ccc61c24b1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjlhYjY4ODI3NDUxODQ1ZDliZGZjM2M3NWEzZWMyMTYyL3RhYmxlcmFuZ2U6OWFiNjg4Mjc0NTE4NDVkOWJkZmMzYzc1YTNlYzIxNjJfMS02LTEtMS0w_ac69a212-bac3-40c4-9f82-28aae3bbcab7"
      unitRef="usd">-10584000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="iddbe94caf0424d3fa43a0628a5730a6f_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjlhYjY4ODI3NDUxODQ1ZDliZGZjM2M3NWEzZWMyMTYyL3RhYmxlcmFuZ2U6OWFiNjg4Mjc0NTE4NDVkOWJkZmMzYzc1YTNlYzIxNjJfMi0yLTEtMS0w_69b897c9-85b3-4135-8603-9009a8113a16"
      unitRef="usd">2655000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="idfb151bb79164c7a924ed3a43feda689_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjlhYjY4ODI3NDUxODQ1ZDliZGZjM2M3NWEzZWMyMTYyL3RhYmxlcmFuZ2U6OWFiNjg4Mjc0NTE4NDVkOWJkZmMzYzc1YTNlYzIxNjJfMi00LTEtMS0w_ab8a9ea6-bf80-4717-b457-06fed989c5e8"
      unitRef="usd">-2087000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjlhYjY4ODI3NDUxODQ1ZDliZGZjM2M3NWEzZWMyMTYyL3RhYmxlcmFuZ2U6OWFiNjg4Mjc0NTE4NDVkOWJkZmMzYzc1YTNlYzIxNjJfMi02LTEtMS0w_8200be1c-cd6b-4bb1-b663-a799f6cf41a7"
      unitRef="usd">568000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="iddbe94caf0424d3fa43a0628a5730a6f_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjlhYjY4ODI3NDUxODQ1ZDliZGZjM2M3NWEzZWMyMTYyL3RhYmxlcmFuZ2U6OWFiNjg4Mjc0NTE4NDVkOWJkZmMzYzc1YTNlYzIxNjJfMy0yLTEtMS0w_f689f47e-b397-4725-8a94-b3aa19ce52f5"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="idfb151bb79164c7a924ed3a43feda689_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjlhYjY4ODI3NDUxODQ1ZDliZGZjM2M3NWEzZWMyMTYyL3RhYmxlcmFuZ2U6OWFiNjg4Mjc0NTE4NDVkOWJkZmMzYzc1YTNlYzIxNjJfMy00LTEtMS0w_07648297-b904-4361-9d19-eeef1425c0cc"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjlhYjY4ODI3NDUxODQ1ZDliZGZjM2M3NWEzZWMyMTYyL3RhYmxlcmFuZ2U6OWFiNjg4Mjc0NTE4NDVkOWJkZmMzYzc1YTNlYzIxNjJfMy02LTEtMS0w_8323dc1a-77db-4ea9-8753-3694ed3a4ad8"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iddbe94caf0424d3fa43a0628a5730a6f_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjlhYjY4ODI3NDUxODQ1ZDliZGZjM2M3NWEzZWMyMTYyL3RhYmxlcmFuZ2U6OWFiNjg4Mjc0NTE4NDVkOWJkZmMzYzc1YTNlYzIxNjJfNC0yLTEtMS0w_d11299b4-44de-4f4c-9683-519c46f268ab"
      unitRef="usd">2655000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="idfb151bb79164c7a924ed3a43feda689_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjlhYjY4ODI3NDUxODQ1ZDliZGZjM2M3NWEzZWMyMTYyL3RhYmxlcmFuZ2U6OWFiNjg4Mjc0NTE4NDVkOWJkZmMzYzc1YTNlYzIxNjJfNC00LTEtMS0w_df2e72e9-ccc3-4dac-b077-4436f8f4f864"
      unitRef="usd">-2087000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjlhYjY4ODI3NDUxODQ1ZDliZGZjM2M3NWEzZWMyMTYyL3RhYmxlcmFuZ2U6OWFiNjg4Mjc0NTE4NDVkOWJkZmMzYzc1YTNlYzIxNjJfNC02LTEtMS0w_4de6fe85-4668-498e-a38c-a27bd8678d33"
      unitRef="usd">568000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i73427926a3e341daaacaf169fb831162_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjlhYjY4ODI3NDUxODQ1ZDliZGZjM2M3NWEzZWMyMTYyL3RhYmxlcmFuZ2U6OWFiNjg4Mjc0NTE4NDVkOWJkZmMzYzc1YTNlYzIxNjJfNS0yLTEtMS0w_143d919f-778e-46e5-98c7-01fbf92139e3"
      unitRef="usd">3410000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8ea979e0426d48798c5a50c5f7a7aa15_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjlhYjY4ODI3NDUxODQ1ZDliZGZjM2M3NWEzZWMyMTYyL3RhYmxlcmFuZ2U6OWFiNjg4Mjc0NTE4NDVkOWJkZmMzYzc1YTNlYzIxNjJfNS00LTEtMS0w_f8547c50-bc0e-419b-9288-77b61d146db7"
      unitRef="usd">-13426000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if99a5f5b88c44e239963a271d78fd4d0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF81OC9mcmFnOjFlMTdhMWVjMjQ4ZDRjYmJiMGEzOGYzNTZjYTE5YjA1L3RhYmxlOjlhYjY4ODI3NDUxODQ1ZDliZGZjM2M3NWEzZWMyMTYyL3RhYmxlcmFuZ2U6OWFiNjg4Mjc0NTE4NDVkOWJkZmMzYzc1YTNlYzIxNjJfNS02LTEtMS0w_227a46e9-9b4b-438f-92d8-3f20f9711f70"
      unitRef="usd">-10016000</us-gaap:StockholdersEquity>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82MS9mcmFnOjMxMDI3ZjA1NzM4NTRkYjg4YTZhOTJlN2EzZDA0YmVlL3RleHRyZWdpb246MzEwMjdmMDU3Mzg1NGRiODhhNmE5MmU3YTNkMDRiZWVfMTM0_e044be2a-5b86-4ad4-ac14-ee35025c5196">Accounts payable and accrued expenses&lt;div style="margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Accounts payable and accrued expenses at June&#160;30, 2020 and December&#160;31, 2019 consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.060%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Employee compensation, benefits, and related accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;38,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Consulting and contracted research&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Sales allowance and other costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;41,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Sales rebates and royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;56,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;42,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;164,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;159,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82MS9mcmFnOjMxMDI3ZjA1NzM4NTRkYjg4YTZhOTJlN2EzZDA0YmVlL3RleHRyZWdpb246MzEwMjdmMDU3Mzg1NGRiODhhNmE5MmU3YTNkMDRiZWVfMTQx_ec7c91b8-93ec-4bd6-b518-755f88935713">&lt;div style="margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Accounts payable and accrued expenses at June&#160;30, 2020 and December&#160;31, 2019 consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.060%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Employee compensation, benefits, and related accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;38,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Consulting and contracted research&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Sales allowance and other costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;41,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Sales rebates and royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;56,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;42,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;164,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;159,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82MS9mcmFnOjMxMDI3ZjA1NzM4NTRkYjg4YTZhOTJlN2EzZDA0YmVlL3RhYmxlOjdmYmQ0ZmJlY2UzYzQwNzBhN2U4MjI5MTFjNDQxNjZmL3RhYmxlcmFuZ2U6N2ZiZDRmYmVjZTNjNDA3MGE3ZTgyMjkxMWM0NDE2NmZfMS0yLTEtMS0w_b18b90f8-849b-4522-9ee0-415ee06caa07"
      unitRef="usd">24861000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82MS9mcmFnOjMxMDI3ZjA1NzM4NTRkYjg4YTZhOTJlN2EzZDA0YmVlL3RhYmxlOjdmYmQ0ZmJlY2UzYzQwNzBhN2U4MjI5MTFjNDQxNjZmL3RhYmxlcmFuZ2U6N2ZiZDRmYmVjZTNjNDA3MGE3ZTgyMjkxMWM0NDE2NmZfMS00LTEtMS0w_1287a6bf-694f-467a-9d90-125cc08516f6"
      unitRef="usd">38889000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <ptct:AccruedConsultingAndContractedResearchCurrent
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82MS9mcmFnOjMxMDI3ZjA1NzM4NTRkYjg4YTZhOTJlN2EzZDA0YmVlL3RhYmxlOjdmYmQ0ZmJlY2UzYzQwNzBhN2U4MjI5MTFjNDQxNjZmL3RhYmxlcmFuZ2U6N2ZiZDRmYmVjZTNjNDA3MGE3ZTgyMjkxMWM0NDE2NmZfMi0yLTEtMS0w_e2a044b2-c2ac-4432-b684-b1c8ca2511d0"
      unitRef="usd">13452000</ptct:AccruedConsultingAndContractedResearchCurrent>
    <ptct:AccruedConsultingAndContractedResearchCurrent
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82MS9mcmFnOjMxMDI3ZjA1NzM4NTRkYjg4YTZhOTJlN2EzZDA0YmVlL3RhYmxlOjdmYmQ0ZmJlY2UzYzQwNzBhN2U4MjI5MTFjNDQxNjZmL3RhYmxlcmFuZ2U6N2ZiZDRmYmVjZTNjNDA3MGE3ZTgyMjkxMWM0NDE2NmZfMi00LTEtMS0w_5057f156-f2cc-49be-860b-06192133b2dd"
      unitRef="usd">12969000</ptct:AccruedConsultingAndContractedResearchCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82MS9mcmFnOjMxMDI3ZjA1NzM4NTRkYjg4YTZhOTJlN2EzZDA0YmVlL3RhYmxlOjdmYmQ0ZmJlY2UzYzQwNzBhN2U4MjI5MTFjNDQxNjZmL3RhYmxlcmFuZ2U6N2ZiZDRmYmVjZTNjNDA3MGE3ZTgyMjkxMWM0NDE2NmZfMy0yLTEtMS0w_eb07f316-e03d-416e-8e35-62858037150c"
      unitRef="usd">3295000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82MS9mcmFnOjMxMDI3ZjA1NzM4NTRkYjg4YTZhOTJlN2EzZDA0YmVlL3RhYmxlOjdmYmQ0ZmJlY2UzYzQwNzBhN2U4MjI5MTFjNDQxNjZmL3RhYmxlcmFuZ2U6N2ZiZDRmYmVjZTNjNDA3MGE3ZTgyMjkxMWM0NDE2NmZfMy00LTEtMS0w_2788dd0a-e4d4-439a-b632-1a716919216c"
      unitRef="usd">3562000</us-gaap:AccruedProfessionalFeesCurrent>
    <ptct:SalesAllowanceAndOtherRelatedCosts
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82MS9mcmFnOjMxMDI3ZjA1NzM4NTRkYjg4YTZhOTJlN2EzZDA0YmVlL3RhYmxlOjdmYmQ0ZmJlY2UzYzQwNzBhN2U4MjI5MTFjNDQxNjZmL3RhYmxlcmFuZ2U6N2ZiZDRmYmVjZTNjNDA3MGE3ZTgyMjkxMWM0NDE2NmZfNC0yLTEtMS0w_2ede34f6-3b92-4d0c-a4e0-f377f1f0a1f6"
      unitRef="usd">45848000</ptct:SalesAllowanceAndOtherRelatedCosts>
    <ptct:SalesAllowanceAndOtherRelatedCosts
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82MS9mcmFnOjMxMDI3ZjA1NzM4NTRkYjg4YTZhOTJlN2EzZDA0YmVlL3RhYmxlOjdmYmQ0ZmJlY2UzYzQwNzBhN2U4MjI5MTFjNDQxNjZmL3RhYmxlcmFuZ2U6N2ZiZDRmYmVjZTNjNDA3MGE3ZTgyMjkxMWM0NDE2NmZfNC00LTEtMS0w_c5f026ea-4085-4b00-857c-db259fa80afd"
      unitRef="usd">41155000</ptct:SalesAllowanceAndOtherRelatedCosts>
    <ptct:SalesRebatesAndRoyaltiesCurrent
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82MS9mcmFnOjMxMDI3ZjA1NzM4NTRkYjg4YTZhOTJlN2EzZDA0YmVlL3RhYmxlOjdmYmQ0ZmJlY2UzYzQwNzBhN2U4MjI5MTFjNDQxNjZmL3RhYmxlcmFuZ2U6N2ZiZDRmYmVjZTNjNDA3MGE3ZTgyMjkxMWM0NDE2NmZfNS0yLTEtMS0w_807e072b-91ab-49aa-a744-c6849904971f"
      unitRef="usd">56870000</ptct:SalesRebatesAndRoyaltiesCurrent>
    <ptct:SalesRebatesAndRoyaltiesCurrent
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82MS9mcmFnOjMxMDI3ZjA1NzM4NTRkYjg4YTZhOTJlN2EzZDA0YmVlL3RhYmxlOjdmYmQ0ZmJlY2UzYzQwNzBhN2U4MjI5MTFjNDQxNjZmL3RhYmxlcmFuZ2U6N2ZiZDRmYmVjZTNjNDA3MGE3ZTgyMjkxMWM0NDE2NmZfNS00LTEtMS0w_bff4afa1-d7d8-40d6-a53c-30cd612b34e6"
      unitRef="usd">42997000</ptct:SalesRebatesAndRoyaltiesCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82MS9mcmFnOjMxMDI3ZjA1NzM4NTRkYjg4YTZhOTJlN2EzZDA0YmVlL3RhYmxlOjdmYmQ0ZmJlY2UzYzQwNzBhN2U4MjI5MTFjNDQxNjZmL3RhYmxlcmFuZ2U6N2ZiZDRmYmVjZTNjNDA3MGE3ZTgyMjkxMWM0NDE2NmZfNi0yLTEtMS0w_16014a96-71b5-43c9-a400-154696c42926"
      unitRef="usd">15465000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82MS9mcmFnOjMxMDI3ZjA1NzM4NTRkYjg4YTZhOTJlN2EzZDA0YmVlL3RhYmxlOjdmYmQ0ZmJlY2UzYzQwNzBhN2U4MjI5MTFjNDQxNjZmL3RhYmxlcmFuZ2U6N2ZiZDRmYmVjZTNjNDA3MGE3ZTgyMjkxMWM0NDE2NmZfNi00LTEtMS0w_44406350-2a30-4ae6-8155-a361fcd43224"
      unitRef="usd">10324000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82MS9mcmFnOjMxMDI3ZjA1NzM4NTRkYjg4YTZhOTJlN2EzZDA0YmVlL3RhYmxlOjdmYmQ0ZmJlY2UzYzQwNzBhN2U4MjI5MTFjNDQxNjZmL3RhYmxlcmFuZ2U6N2ZiZDRmYmVjZTNjNDA3MGE3ZTgyMjkxMWM0NDE2NmZfNy0yLTEtMS0w_310579ca-375c-4914-a17b-48675ce65c8e"
      unitRef="usd">4585000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82MS9mcmFnOjMxMDI3ZjA1NzM4NTRkYjg4YTZhOTJlN2EzZDA0YmVlL3RhYmxlOjdmYmQ0ZmJlY2UzYzQwNzBhN2U4MjI5MTFjNDQxNjZmL3RhYmxlcmFuZ2U6N2ZiZDRmYmVjZTNjNDA3MGE3ZTgyMjkxMWM0NDE2NmZfNy00LTEtMS0w_547d9003-782f-4879-aa4b-ca3578e23c42"
      unitRef="usd">9380000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82MS9mcmFnOjMxMDI3ZjA1NzM4NTRkYjg4YTZhOTJlN2EzZDA0YmVlL3RhYmxlOjdmYmQ0ZmJlY2UzYzQwNzBhN2U4MjI5MTFjNDQxNjZmL3RhYmxlcmFuZ2U6N2ZiZDRmYmVjZTNjNDA3MGE3ZTgyMjkxMWM0NDE2NmZfOC0yLTEtMS0w_ac235f03-1497-4912-b745-243739c7f56b"
      unitRef="usd">164376000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="id69eb5bf465a4fbda9cc437bc1be99a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82MS9mcmFnOjMxMDI3ZjA1NzM4NTRkYjg4YTZhOTJlN2EzZDA0YmVlL3RhYmxlOjdmYmQ0ZmJlY2UzYzQwNzBhN2U4MjI5MTFjNDQxNjZmL3RhYmxlcmFuZ2U6N2ZiZDRmYmVjZTNjNDA3MGE3ZTgyMjkxMWM0NDE2NmZfOC00LTEtMS0w_8b3d7399-ae36-405b-9a89-94a2ccd32983"
      unitRef="usd">159276000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82NC9mcmFnOmM5YTA4NjRiYzE0NTRkZmJiNmU2OWQxZjAzMzdhODRlL3RleHRyZWdpb246YzlhMDg2NGJjMTQ1NGRmYmI2ZTY5ZDFmMDMzN2E4NGVfNDM5ODA0NjUxNjE4MA_4a72dbb0-badd-4225-9c72-d8754c957b30">Capitalization&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2019, the Company entered into an At the Market Offering Sales Agreement (the &#x201c;Sales Agreement&#x201d;) with Cantor Fitzgerald and RBC Capital Markets, LLC (together, the &#x201c;Sales Agents&#x201d;), pursuant to which, the Company may offer and sell shares of its common stock, having an aggregate offering price of up to $125.0 million from time to time through the Sales Agents by any method that is deemed to be an &#x201c;at the market offering&#x201d; as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended. During the three and six month periods ending June 30, 2020, the Company issued and sold an aggregate of 106,309 and 368,514 shares of common stock pursuant to the Sales Agreement at a weighted average public offering price of $53.08 and $52.89 per share, respectively. During the three and six month periods ending June 30, 2020, the Company received net proceeds of $5.4&#160;million and $19.0 million, respectively, after deducting underwriting discounts and commissions and other offering expenses payable by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;As a result of the Rights Exchange Agreement, during the three and six month periods ended June 30, 2020, the Company issued 2,821,176 shares of its common stock to Participating Rightholders. The shares had a fair value of $150.5&#160;million upon issuance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;As a result of the Censa Merger, during the three and six month periods ended June 30, 2020, the Company issued 845,364 shares of the Company's common stock to Censa security holders, which were valued at $42.9&#160;million based on the closing stock price on the acquisition date. The number of shares issued was determined using a 30-day VWAP pursuant to the Censa Merger Agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i31727b5e545f4438bb09f0aee02b36cf_D20190801-20190831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82NC9mcmFnOmM5YTA4NjRiYzE0NTRkZmJiNmU2OWQxZjAzMzdhODRlL3RleHRyZWdpb246YzlhMDg2NGJjMTQ1NGRmYmI2ZTY5ZDFmMDMzN2E4NGVfMzM2_b52c0d2c-2e35-4ccc-a036-7f4039194712"
      unitRef="usd">125000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82NC9mcmFnOmM5YTA4NjRiYzE0NTRkZmJiNmU2OWQxZjAzMzdhODRlL3RleHRyZWdpb246YzlhMDg2NGJjMTQ1NGRmYmI2ZTY5ZDFmMDMzN2E4NGVfNDk0NzgwMjMyNzc1OQ_d8db293a-2be8-4b08-8c33-9ce64469c5e3"
      unitRef="shares">106309</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82NC9mcmFnOmM5YTA4NjRiYzE0NTRkZmJiNmU2OWQxZjAzMzdhODRlL3RleHRyZWdpb246YzlhMDg2NGJjMTQ1NGRmYmI2ZTY5ZDFmMDMzN2E4NGVfNjI5_f757dd07-ce6c-479c-b4e9-1b840cfd7dd7"
      unitRef="shares">368514</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <ptct:SaleOfStockWeightedAveragePricePerShare
      contextRef="i22a6b3907e334ad095459c22452a31a8_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82NC9mcmFnOmM5YTA4NjRiYzE0NTRkZmJiNmU2OWQxZjAzMzdhODRlL3RleHRyZWdpb246YzlhMDg2NGJjMTQ1NGRmYmI2ZTY5ZDFmMDMzN2E4NGVfNDk0NzgwMjMyNzc2Nw_e781cca7-4886-4c6d-a929-b7c38b81d011"
      unitRef="usdPerShare">53.08</ptct:SaleOfStockWeightedAveragePricePerShare>
    <ptct:SaleOfStockWeightedAveragePricePerShare
      contextRef="i20afcd7c10c14ac495fc02e16fe69b2d_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82NC9mcmFnOmM5YTA4NjRiYzE0NTRkZmJiNmU2OWQxZjAzMzdhODRlL3RleHRyZWdpb246YzlhMDg2NGJjMTQ1NGRmYmI2ZTY5ZDFmMDMzN2E4NGVfNzM0_87f756b3-f01f-404a-9d22-095134a167de"
      unitRef="usdPerShare">52.89</ptct:SaleOfStockWeightedAveragePricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82NC9mcmFnOmM5YTA4NjRiYzE0NTRkZmJiNmU2OWQxZjAzMzdhODRlL3RleHRyZWdpb246YzlhMDg2NGJjMTQ1NGRmYmI2ZTY5ZDFmMDMzN2E4NGVfNDk0NzgwMjMyNzg2Mg_4308e0df-225f-449f-93dd-e1eb2e88e53c"
      unitRef="usd">5400000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82NC9mcmFnOmM5YTA4NjRiYzE0NTRkZmJiNmU2OWQxZjAzMzdhODRlL3RleHRyZWdpb246YzlhMDg2NGJjMTQ1NGRmYmI2ZTY5ZDFmMDMzN2E4NGVfNzg1_8f949ced-0834-4182-8675-ce1abdedc007"
      unitRef="usd">19000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <ptct:SharestoissueunderRightsExchangeAgreement
      contextRef="if89af7698cdf43d1915f30dc403dc6af_I20200429"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82NC9mcmFnOmM5YTA4NjRiYzE0NTRkZmJiNmU2OWQxZjAzMzdhODRlL3RleHRyZWdpb246YzlhMDg2NGJjMTQ1NGRmYmI2ZTY5ZDFmMDMzN2E4NGVfMTM3NDM4OTUzNDgyNjc_fb75e6f5-7b3f-432c-a757-e7dea335d4c4"
      unitRef="shares">2821176</ptct:SharestoissueunderRightsExchangeAgreement>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="if241e524337e420a90c40125ab0af552_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82NC9mcmFnOmM5YTA4NjRiYzE0NTRkZmJiNmU2OWQxZjAzMzdhODRlL3RleHRyZWdpb246YzlhMDg2NGJjMTQ1NGRmYmI2ZTY5ZDFmMDMzN2E4NGVfNDM5ODA0NjUxNjE2NA_3b9d13e3-0186-4edf-bdd5-84abfc1b927a"
      unitRef="usd">150500000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="i8742fae222d34cac83b189f51096e426_D20200529-20200529"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82NC9mcmFnOmM5YTA4NjRiYzE0NTRkZmJiNmU2OWQxZjAzMzdhODRlL3RleHRyZWdpb246YzlhMDg2NGJjMTQ1NGRmYmI2ZTY5ZDFmMDMzN2E4NGVfMTM3NDM4OTUzNDkzNDg_9507216f-a1ca-4b1f-a4d3-483377609a35"
      unitRef="shares">845364</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i8742fae222d34cac83b189f51096e426_D20200529-20200529"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82NC9mcmFnOmM5YTA4NjRiYzE0NTRkZmJiNmU2OWQxZjAzMzdhODRlL3RleHRyZWdpb246YzlhMDg2NGJjMTQ1NGRmYmI2ZTY5ZDFmMDMzN2E4NGVfMTM3NDM4OTUzNDk0MTA_4e4fb3ea-e784-4396-98bd-189c553c9552"
      unitRef="usd">42900000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82Ny9mcmFnOjgxNDdkOWMwNWNmZTRjNGJiYTc2OTVmZTM5MmM1OTA4L3RleHRyZWdpb246ODE0N2Q5YzA1Y2ZlNGM0YmJhNzY5NWZlMzkyYzU5MDhfNzc2_77cd41c2-d350-4e8a-8edb-7d9d6d9e4ea3">Net loss per share&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Basic earnings per share is computed by dividing net loss by the weighted-average number of common shares outstanding. Diluted earnings per share is computed by dividing net loss by the weighted-average number of common shares plus the effect of any dilutive potential common shares outstanding during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following tables set forth the computation of basic and diluted net loss per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:34.173%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.407%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.475%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.407%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.615%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.474%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.615%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.614%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.620%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Numerator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(181,427)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(41,789)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(294,114)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(113,902)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Denominator for basic and diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;65,150,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;55,912,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;63,769,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;57,113,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2.78)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.75)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4.61)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.99)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:40.935%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:98.000%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;*In the three and six months ended June&#160;30, 2020 and 2019, the Company experienced a net loss and therefore did not report any dilutive share impact.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table shows historical dilutive common share equivalents outstanding, which are not included in the above historical calculation, as the effect of their inclusion is anti-dilutive during each period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.700%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.636%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.931%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,954,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,853,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unvested restricted stock awards and units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;936,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;665,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,891,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,518,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82Ny9mcmFnOjgxNDdkOWMwNWNmZTRjNGJiYTc2OTVmZTM5MmM1OTA4L3RleHRyZWdpb246ODE0N2Q5YzA1Y2ZlNGM0YmJhNzY5NWZlMzkyYzU5MDhfNzgx_b0cb4bdf-2a35-4dc5-93cc-0a111c22a1ca">The following tables set forth the computation of basic and diluted net loss per share:&lt;div style="margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:34.173%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.407%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.475%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.407%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.615%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.474%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.615%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.614%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.620%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Numerator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(181,427)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(41,789)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(294,114)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(113,902)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Denominator for basic and diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;65,150,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;55,912,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;63,769,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;57,113,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2.78)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.75)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4.61)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.99)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:40.935%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:98.000%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;*In the three and six months ended June&#160;30, 2020 and 2019, the Company experienced a net loss and therefore did not report any dilutive share impact.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82Ny9mcmFnOjgxNDdkOWMwNWNmZTRjNGJiYTc2OTVmZTM5MmM1OTA4L3RhYmxlOmZmNmNmMGFjMzcxZTQxYzJhNDI0YTdhN2ExZjc5OTk3L3RhYmxlcmFuZ2U6ZmY2Y2YwYWMzNzFlNDFjMmE0MjRhN2E3YTFmNzk5OTdfMy0xLTEtMS0w_01288f27-71f1-4587-89b9-e14072c9431e"
      unitRef="usd">-181427000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82Ny9mcmFnOjgxNDdkOWMwNWNmZTRjNGJiYTc2OTVmZTM5MmM1OTA4L3RhYmxlOmZmNmNmMGFjMzcxZTQxYzJhNDI0YTdhN2ExZjc5OTk3L3RhYmxlcmFuZ2U6ZmY2Y2YwYWMzNzFlNDFjMmE0MjRhN2E3YTFmNzk5OTdfMy0zLTEtMS0w_739a5176-9c76-43bb-91c5-a401242b102a"
      unitRef="usd">-41789000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82Ny9mcmFnOjgxNDdkOWMwNWNmZTRjNGJiYTc2OTVmZTM5MmM1OTA4L3RhYmxlOmZmNmNmMGFjMzcxZTQxYzJhNDI0YTdhN2ExZjc5OTk3L3RhYmxlcmFuZ2U6ZmY2Y2YwYWMzNzFlNDFjMmE0MjRhN2E3YTFmNzk5OTdfMy01LTEtMS0w_25460ff2-2cbd-43f5-962f-068e37bfe91e"
      unitRef="usd">-294114000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82Ny9mcmFnOjgxNDdkOWMwNWNmZTRjNGJiYTc2OTVmZTM5MmM1OTA4L3RhYmxlOmZmNmNmMGFjMzcxZTQxYzJhNDI0YTdhN2ExZjc5OTk3L3RhYmxlcmFuZ2U6ZmY2Y2YwYWMzNzFlNDFjMmE0MjRhN2E3YTFmNzk5OTdfMy03LTEtMS0w_f9220f16-4b67-48a9-b34f-28823c25a665"
      unitRef="usd">-113902000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82Ny9mcmFnOjgxNDdkOWMwNWNmZTRjNGJiYTc2OTVmZTM5MmM1OTA4L3RhYmxlOmZmNmNmMGFjMzcxZTQxYzJhNDI0YTdhN2ExZjc5OTk3L3RhYmxlcmFuZ2U6ZmY2Y2YwYWMzNzFlNDFjMmE0MjRhN2E3YTFmNzk5OTdfNS0xLTEtMS0w_0bb14804-66d0-498c-9ccb-3f4b8df26d92"
      unitRef="shares">65150780</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82Ny9mcmFnOjgxNDdkOWMwNWNmZTRjNGJiYTc2OTVmZTM5MmM1OTA4L3RhYmxlOmZmNmNmMGFjMzcxZTQxYzJhNDI0YTdhN2ExZjc5OTk3L3RhYmxlcmFuZ2U6ZmY2Y2YwYWMzNzFlNDFjMmE0MjRhN2E3YTFmNzk5OTdfNS0zLTEtMS0w_1ccda0e1-608c-43d1-b8ca-d4608e946af3"
      unitRef="shares">55912748</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82Ny9mcmFnOjgxNDdkOWMwNWNmZTRjNGJiYTc2OTVmZTM5MmM1OTA4L3RhYmxlOmZmNmNmMGFjMzcxZTQxYzJhNDI0YTdhN2ExZjc5OTk3L3RhYmxlcmFuZ2U6ZmY2Y2YwYWMzNzFlNDFjMmE0MjRhN2E3YTFmNzk5OTdfNS01LTEtMS0w_86073b43-f3d7-4f59-855d-6c55f3658241"
      unitRef="shares">63769958</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82Ny9mcmFnOjgxNDdkOWMwNWNmZTRjNGJiYTc2OTVmZTM5MmM1OTA4L3RhYmxlOmZmNmNmMGFjMzcxZTQxYzJhNDI0YTdhN2ExZjc5OTk3L3RhYmxlcmFuZ2U6ZmY2Y2YwYWMzNzFlNDFjMmE0MjRhN2E3YTFmNzk5OTdfNS03LTEtMS0w_0f5e51c2-de60-4a0d-a240-e134e93dea9b"
      unitRef="shares">57113141</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82Ny9mcmFnOjgxNDdkOWMwNWNmZTRjNGJiYTc2OTVmZTM5MmM1OTA4L3RhYmxlOmZmNmNmMGFjMzcxZTQxYzJhNDI0YTdhN2ExZjc5OTk3L3RhYmxlcmFuZ2U6ZmY2Y2YwYWMzNzFlNDFjMmE0MjRhN2E3YTFmNzk5OTdfNy0xLTEtMS0w_302d7bf4-8bb9-41e1-a216-b52e1c21d490"
      unitRef="usdPerShare">-2.78</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82Ny9mcmFnOjgxNDdkOWMwNWNmZTRjNGJiYTc2OTVmZTM5MmM1OTA4L3RhYmxlOmZmNmNmMGFjMzcxZTQxYzJhNDI0YTdhN2ExZjc5OTk3L3RhYmxlcmFuZ2U6ZmY2Y2YwYWMzNzFlNDFjMmE0MjRhN2E3YTFmNzk5OTdfNy0zLTEtMS0w_90e195a6-b644-4d03-a189-265f99b353ec"
      unitRef="usdPerShare">-0.75</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82Ny9mcmFnOjgxNDdkOWMwNWNmZTRjNGJiYTc2OTVmZTM5MmM1OTA4L3RhYmxlOmZmNmNmMGFjMzcxZTQxYzJhNDI0YTdhN2ExZjc5OTk3L3RhYmxlcmFuZ2U6ZmY2Y2YwYWMzNzFlNDFjMmE0MjRhN2E3YTFmNzk5OTdfNy01LTEtMS0w_59d72ae2-64cd-4006-8033-9e8700ec83cd"
      unitRef="usdPerShare">-4.61</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82Ny9mcmFnOjgxNDdkOWMwNWNmZTRjNGJiYTc2OTVmZTM5MmM1OTA4L3RhYmxlOmZmNmNmMGFjMzcxZTQxYzJhNDI0YTdhN2ExZjc5OTk3L3RhYmxlcmFuZ2U6ZmY2Y2YwYWMzNzFlNDFjMmE0MjRhN2E3YTFmNzk5OTdfNy03LTEtMS0w_14d5d1ea-9a29-4e64-96ef-970b809a52cd"
      unitRef="usdPerShare">-1.99</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82Ny9mcmFnOjgxNDdkOWMwNWNmZTRjNGJiYTc2OTVmZTM5MmM1OTA4L3RleHRyZWdpb246ODE0N2Q5YzA1Y2ZlNGM0YmJhNzY5NWZlMzkyYzU5MDhfNzkx_53fdebf5-0a9d-4927-84fb-2ad87ee05e20">&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table shows historical dilutive common share equivalents outstanding, which are not included in the above historical calculation, as the effect of their inclusion is anti-dilutive during each period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.700%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.636%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.931%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,954,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,853,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unvested restricted stock awards and units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;936,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;665,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,891,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,518,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i732b4791ae044c3982d3fc5b40507c4a_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82Ny9mcmFnOjgxNDdkOWMwNWNmZTRjNGJiYTc2OTVmZTM5MmM1OTA4L3RhYmxlOjI4YTkzYWZjYTliMzRjZDZiZGJhOWNkMmNiZGZmNjM4L3RhYmxlcmFuZ2U6MjhhOTNhZmNhOWIzNGNkNmJkYmE5Y2QyY2JkZmY2MzhfMi0xLTEtMS0w_c76b26af-21e2-49b2-8e7d-c96a7ad3b804"
      unitRef="shares">11954684</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4340507e56e749d38aa6d877e17f6f11_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82Ny9mcmFnOjgxNDdkOWMwNWNmZTRjNGJiYTc2OTVmZTM5MmM1OTA4L3RhYmxlOjI4YTkzYWZjYTliMzRjZDZiZGJhOWNkMmNiZGZmNjM4L3RhYmxlcmFuZ2U6MjhhOTNhZmNhOWIzNGNkNmJkYmE5Y2QyY2JkZmY2MzhfMi0zLTEtMS0w_c827a24d-e847-4feb-9f64-951868e7ea52"
      unitRef="shares">10853301</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie4dfd70561f44b3389920eecf82405aa_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82Ny9mcmFnOjgxNDdkOWMwNWNmZTRjNGJiYTc2OTVmZTM5MmM1OTA4L3RhYmxlOjI4YTkzYWZjYTliMzRjZDZiZGJhOWNkMmNiZGZmNjM4L3RhYmxlcmFuZ2U6MjhhOTNhZmNhOWIzNGNkNmJkYmE5Y2QyY2JkZmY2MzhfMy0xLTEtMS0w_3644920d-bd1c-46e3-9438-e8c5d9a49124"
      unitRef="shares">936922</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6512ed24942b4cf78a18c42c69f878df_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82Ny9mcmFnOjgxNDdkOWMwNWNmZTRjNGJiYTc2OTVmZTM5MmM1OTA4L3RhYmxlOjI4YTkzYWZjYTliMzRjZDZiZGJhOWNkMmNiZGZmNjM4L3RhYmxlcmFuZ2U6MjhhOTNhZmNhOWIzNGNkNmJkYmE5Y2QyY2JkZmY2MzhfMy0zLTEtMS0w_64d23f13-d9b0-47ec-9338-abee7dbb5ca5"
      unitRef="shares">665002</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82Ny9mcmFnOjgxNDdkOWMwNWNmZTRjNGJiYTc2OTVmZTM5MmM1OTA4L3RhYmxlOjI4YTkzYWZjYTliMzRjZDZiZGJhOWNkMmNiZGZmNjM4L3RhYmxlcmFuZ2U6MjhhOTNhZmNhOWIzNGNkNmJkYmE5Y2QyY2JkZmY2MzhfNC0xLTEtMS0w_2506441d-5856-497e-8e4c-79fb7d24cc09"
      unitRef="shares">12891606</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF82Ny9mcmFnOjgxNDdkOWMwNWNmZTRjNGJiYTc2OTVmZTM5MmM1OTA4L3RhYmxlOjI4YTkzYWZjYTliMzRjZDZiZGJhOWNkMmNiZGZmNjM4L3RhYmxlcmFuZ2U6MjhhOTNhZmNhOWIzNGNkNmJkYmE5Y2QyY2JkZmY2MzhfNC0zLTEtMS0w_fc9f85d3-01f8-4e54-87af-cdd4e0a07036"
      unitRef="shares">11518303</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfNzY2Mw_a0a8cbe9-9f71-4a66-adb6-ffa848c2e0a6">Stock award plan&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On March&#160;5, 2013, the Company&#x2019;s Board of Directors approved the 2013 Stock Incentive Plan, which provides for the granting of stock option awards, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards in the aggregate of 739,937 shares of common stock. On March&#160;5, 2013, the Company's Board of Directors approved a grant of 735,324 shares of restricted stock and 4,613 stock options. There are no additional shares available for issuance under this plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In 2009, the Company&#x2019;s shareholders approved the 2009 Equity and Long-Term Incentive Plan, which provides for the granting of stock option awards, restricted stock awards, and other stock-based and cash-based awards, subject to certain adjustments and annual increases. In May&#160;2013, the Company&#x2019;s Board of Directors and stockholders increased by 2,500,000 the number of shares authorized under the 2009 Equity and Long Term Incentive Plan, which provides for the granting of stock option awards, restricted stock awards, and other stock-based and cash-based awards. There are no additional shares available for issuance under this plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In May&#160;2013, the Company&#x2019;s Board of Directors and stockholders approved the 2013 Long Term Incentive Plan, which became effective upon the closing of the Company&#x2019;s initial public offering.&#160; The 2013 Long Term Incentive Plan provides for the grant of incentive stock options, nonstatutory stock options, restricted stock awards and other stock-based awards. The number of shares of common stock reserved for issuance under the 2013 Long Term Incentive Plan is the sum of (1)&#160;122,296 shares of common stock available for issuance under the Company&#x2019;s 2009 Equity and Long Term Incentive Plan and 2013 Stock Incentive Plan, (2) the number of shares (up to 3,040,444 shares) equal to the sum of the number of shares of common stock subject to outstanding awards under the Company&#x2019;s 1998 Employee, Director and Consultant Stock Option Plan, 2009 Equity and Long Term Incentive Plan and 2013 Stock Incentive Plan that expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right plus (3)&#160;an annual increase, to be added on the first day of each fiscal year until the expiration of the 2013 Long Term Incentive Plan, equal to the lowest of 2,500,000 shares of common stock, 4% of the number of shares of common stock outstanding on the first day of the fiscal year and an amount determined by the Company&#x2019;s Board of Directors. As of June&#160;30, 2020, awards for 914,406 shares of common stock are available for issuance under the 2013 Long Term Incentive Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In January 2020, the Company's Board of Directors approved the 2020 Inducement Stock Incentive Plan. The 2020 Inducement Stock Incentive Plan provides for the grant of incentive stock options, nonstatutory stock options, restricted stock awards and other stock-based awards for up to an aggregate of 1,000,000 shares of common stock. Any grants made under the 2020 Inducement Stock Incentive Plan must be made pursuant to the Nasdaq Listing Rule 5635(c)(4) inducement grant exception as a material component of the Company's new hires&#x2019; employment compensation. As of June 30, 2020, awards for 442,880 shares of common stock are available for issuance under the 2020 Inducement Stock Incentive Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;From January&#160;1, 2020 through June&#160;30, 2020, the Company issued a total of 2,515,200 stock options to various employees.&#160; Of those, 542,450 were inducement grants for non-statutory stock options, all of which were made pursuant to the 2020 Inducement Stock Incentive Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A summary of stock option activity is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.777%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.909%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.909%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.740%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Number&#160;of&lt;br/&gt;options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;exercise&lt;br/&gt;price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&lt;br/&gt;term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Aggregate&lt;br/&gt;intrinsic&lt;br/&gt;value (in&lt;br/&gt;thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,043,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;31.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,515,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;50.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,034,288)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(570,167)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;42.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,954,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.48 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;183,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested or Expected to vest at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,690,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.86 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;66,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercisable at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,512,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;31.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.85 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;110,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of grants made in the six months ended June&#160;30, 2020 was contemporaneously estimated on the date of grant using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:63.592%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.410%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:30.798%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six months ended&lt;br/&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;0.40% - 1.45%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;87.50% - 89.31%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;5.75 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company assumed no expected dividends for all grants. The weighted average grant date fair value of options granted during the six month period ended June&#160;30, 2020 was $36.95 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The expected term of options was estimated based on the Company's historical exercise data and the expected volatility of options was estimated based on the Company's historical stock volatility.  The risk-free rate of the options was based on U.S. Government Securities Treasury Constant Maturities yields at the date of grant for a term similar to the expected term of the option. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Restricted Stock Awards and Restricted Stock Units&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2014;Restricted stock awards and restricted stock units are granted subject to certain restrictions, including in some cases service or time conditions (restricted stock). The grant-date fair value of restricted stock awards and restricted stock units, which have been determined based upon the market value of the Company&#x2019;s shares on the grant date, are expensed over the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes information on the Company&#x2019;s restricted stock awards and units:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.888%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.909%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted&#160;Stock&#160;Awards&#160;and&#160;Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant&lt;br/&gt;Date&#160;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;642,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;589,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(229,076)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(65,491)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unvested at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;936,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Stock Appreciation Rights&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2014;SARs entitle the holder to receive, upon exercise, an amount of the Company's common stock or cash (or a combination thereof) determined by reference to appreciation, from and after the date of grant, in the fair market value of a share of the Company's common stock over the measurement price based on the exercise date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In May&#160;2016, a total of 897,290 SARs were granted to non-executive employees (the "2016 SARs"). The 2016 SARs vested annually in equal installments over four years and were settled in cash on each vest date, which required the Company to &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;remeasure the SARs at each reporting period until vesting occurs. For the six month period ended June&#160;30, 2020, a total of 132,136 SARs vested. The last payment of the SARs liability was made in the three month period ended March 31, 2020, and accordingly, the balance of the SARS liability as of June 30, 2020 was $0. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2014;In June 2016, the Company established an Employee Stock Purchase Plan (&#x201c;ESPP&#x201d; or the "Plan&#x201d;) for certain eligible employees. The Plan is administered by the Company&#x2019;s Board of Directors or a committee appointed by the Company's Board of Directors. The total number of shares available for purchase under the Plan is one million shares of the Company&#x2019;s common stock. Employees may participate over a six month period through payroll withholdings and may purchase, at the end of the six month period, the Company&#x2019;s common stock at a purchase price of at least 85% of the closing price of a share of the Company&#x2019;s common stock on the first business day of the offering period or the closing price of a share of the Company&#x2019;s common stock on the last business day of the offering period, whichever is lower. No participant will be granted a right to purchase the Company&#x2019;s common stock under the Plan if such participant would own more than 5% of the total combined voting power of the Company or any subsidiary of the Company after such purchase. For the three and six month periods ended June&#160;30, 2020, the Company recorded $0.3 million and $0.7 million in compensation expense related to the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company recorded share-based compensation expense in the statement of operations related to incentive stock options, nonstatutory stock options, restricted stock awards, restricted stock units and the ESPP as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:40.020%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.909%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.909%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:2.289%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.740%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June&#160;30, 2020, there was approximately $187.2 million of total unrecognized compensation cost related to unvested share-based compensation arrangements granted under the 2009 Equity and Long Term Incentive Plan, the 2013 Long Term Incentive Plan and equity awards made pursuant to the Nasdaq Listing Rule 5635(c)(4) inducement grant exception for new hires. This cost is expected to be recognized as share-based compensation expense over the weighted average remaining service period of approximately 3.08 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i25d7f62000cb47619cacff7feea40ec4_I20130305"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfMjg5_7af3a7ca-7083-4e20-beac-4219f8965865"
      unitRef="shares">739937</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="iae41b38768a04ebfa621ede89b1e1eba_D20130305-20130305"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfMzg3_e1083001-9351-4482-a22e-9972777b063c"
      unitRef="shares">735324</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i4acdb340b0784c54b281fc72cd460037_D20130305-20130305"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfNDIx_25e1bf7e-4c9a-4e07-a0eb-0875c550a56a"
      unitRef="shares">4613</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="idf26f417473642be92ba8eea00337e07_I20130305"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfNDQ5_ee63eb44-f30f-48de-afab-df6305dab68a"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i62a5ccc71de84104a8745951ca1a9aa7_D20130501-20130531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfODU2_2b8c52ee-4b62-4331-8bb5-e440e071a6ed"
      unitRef="shares">2500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i65727f1a834a481f8553fbb4bb642903_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfMTA3OQ_12066613-70c6-45cd-b77f-363106a8d4ff"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i1efd0cb53b6044d78f74b229bd2b52aa_I20130531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfMTYxNA_edfdea0a-1f4b-4064-b1e4-184f16bbb587"
      unitRef="shares">122296</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <ptct:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards
      contextRef="ie7090aa93ba846e4b5c5820dcecfd98a_I20130531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfMTc4Nw_008e7ce6-8326-46eb-b8e2-ca949765a19e"
      unitRef="shares">3040444</ptct:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards>
    <ptct:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber
      contextRef="ibf07b2dff77d4ca1a51f7b625a38192b_D20130501-20130531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfMjM3Mw_a26ea8c7-1067-4668-ba2c-01b062e23bf9"
      unitRef="shares">2500000</ptct:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber>
    <ptct:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding
      contextRef="ibf07b2dff77d4ca1a51f7b625a38192b_D20130501-20130531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfMjQwMA_2b2e4295-c03c-4bd2-9162-9554a96f0d70"
      unitRef="number">0.04</ptct:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i93ba015b7d0a44aaaf029eb718c780c2_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfMjU3NA_1098af7d-66a1-471d-b736-bd5309d47f3a"
      unitRef="shares">914406</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <ptct:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber
      contextRef="ifd063a6e802542888865b12d471371c5_D20200101-20200131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfMjk2OA_d9a862fd-2e4b-496b-b2d1-25bf7ea84a17"
      unitRef="shares">1000000</ptct:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i12f2cd9f617e471d9081d454d8ab7810_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfMzI1NQ_f41151a6-4ca6-4657-b93a-a6a8b9aa1712"
      unitRef="shares">442880</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i7af21e8197c4484c8a8abf452ef76b07_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfMzQxNw_13628c51-abcf-4f4f-92ef-23c75f26e497"
      unitRef="shares">2515200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <ptct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions
      contextRef="i7af21e8197c4484c8a8abf452ef76b07_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfMzQ2Nw_1a4d5f09-6d03-4e9a-af4f-ee64fa43c0df"
      unitRef="shares">542450</ptct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfNzY1Nw_299f641e-4c08-439e-b50e-6c04536f4d76">&lt;div style="margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A summary of stock option activity is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.777%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.909%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.909%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.740%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Number&#160;of&lt;br/&gt;options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;exercise&lt;br/&gt;price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&lt;br/&gt;term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Aggregate&lt;br/&gt;intrinsic&lt;br/&gt;value (in&lt;br/&gt;thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,043,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;31.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,515,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;50.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,034,288)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(570,167)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;42.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,954,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.48 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;183,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested or Expected to vest at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,690,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.86 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;66,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercisable at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,512,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;31.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.85 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;110,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ibf32b31395a2491ebc2ee0715f74c386_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmNkNTNkMzQ0OTdiNjQxMzJiNzE2ZjNhMzM5MTQ5MTIzL3RhYmxlcmFuZ2U6Y2Q1M2QzNDQ5N2I2NDEzMmI3MTZmM2EzMzkxNDkxMjNfMi0yLTEtMS0w_76f45562-a8f9-4eaa-9166-d86f919456c6"
      unitRef="shares">11043939</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ibf32b31395a2491ebc2ee0715f74c386_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmNkNTNkMzQ0OTdiNjQxMzJiNzE2ZjNhMzM5MTQ5MTIzL3RhYmxlcmFuZ2U6Y2Q1M2QzNDQ5N2I2NDEzMmI3MTZmM2EzMzkxNDkxMjNfMi00LTEtMS0w_5255a44e-3ad2-4d0a-b952-2f00ee43fbc5"
      unitRef="usdPerShare">31.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i7af21e8197c4484c8a8abf452ef76b07_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmNkNTNkMzQ0OTdiNjQxMzJiNzE2ZjNhMzM5MTQ5MTIzL3RhYmxlcmFuZ2U6Y2Q1M2QzNDQ5N2I2NDEzMmI3MTZmM2EzMzkxNDkxMjNfMy0yLTEtMS0w_0b5ffdf5-b03b-40fa-8942-a867a6e702f4"
      unitRef="shares">2515200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i7af21e8197c4484c8a8abf452ef76b07_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmNkNTNkMzQ0OTdiNjQxMzJiNzE2ZjNhMzM5MTQ5MTIzL3RhYmxlcmFuZ2U6Y2Q1M2QzNDQ5N2I2NDEzMmI3MTZmM2EzMzkxNDkxMjNfMy00LTEtMS0w_f820c8f7-1dd3-4d25-813a-1b83f50049c4"
      unitRef="usdPerShare">50.98</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i7af21e8197c4484c8a8abf452ef76b07_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmNkNTNkMzQ0OTdiNjQxMzJiNzE2ZjNhMzM5MTQ5MTIzL3RhYmxlcmFuZ2U6Y2Q1M2QzNDQ5N2I2NDEzMmI3MTZmM2EzMzkxNDkxMjNfNC0yLTEtMS0w_839fdff3-1ef6-4787-b346-7b7b8b94c96a"
      unitRef="shares">1034288</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i7af21e8197c4484c8a8abf452ef76b07_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmNkNTNkMzQ0OTdiNjQxMzJiNzE2ZjNhMzM5MTQ5MTIzL3RhYmxlcmFuZ2U6Y2Q1M2QzNDQ5N2I2NDEzMmI3MTZmM2EzMzkxNDkxMjNfNC00LTEtMS0w_df60cd0d-b69e-4a05-9cbd-876c770473d1"
      unitRef="usdPerShare">24.21</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i7af21e8197c4484c8a8abf452ef76b07_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmNkNTNkMzQ0OTdiNjQxMzJiNzE2ZjNhMzM5MTQ5MTIzL3RhYmxlcmFuZ2U6Y2Q1M2QzNDQ5N2I2NDEzMmI3MTZmM2EzMzkxNDkxMjNfNS0yLTEtMS0w_a3061f85-9bf8-4bd8-aca5-c0c629f401bf"
      unitRef="shares">570167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i7af21e8197c4484c8a8abf452ef76b07_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmNkNTNkMzQ0OTdiNjQxMzJiNzE2ZjNhMzM5MTQ5MTIzL3RhYmxlcmFuZ2U6Y2Q1M2QzNDQ5N2I2NDEzMmI3MTZmM2EzMzkxNDkxMjNfNS00LTEtMS0w_b5855fd4-9a40-4b8e-a05c-97575d67de24"
      unitRef="usdPerShare">42.27</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i7a7e99b59db24353a85559f303336e06_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmNkNTNkMzQ0OTdiNjQxMzJiNzE2ZjNhMzM5MTQ5MTIzL3RhYmxlcmFuZ2U6Y2Q1M2QzNDQ5N2I2NDEzMmI3MTZmM2EzMzkxNDkxMjNfNi0yLTEtMS0w_a5351ed6-1a6a-4a14-9901-aa502e5a934b"
      unitRef="shares">11954684</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i7a7e99b59db24353a85559f303336e06_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmNkNTNkMzQ0OTdiNjQxMzJiNzE2ZjNhMzM5MTQ5MTIzL3RhYmxlcmFuZ2U6Y2Q1M2QzNDQ5N2I2NDEzMmI3MTZmM2EzMzkxNDkxMjNfNi00LTEtMS0w_6ea2c514-68e0-4d5c-ad26-61bfcd6d8f0e"
      unitRef="usdPerShare">35.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i7af21e8197c4484c8a8abf452ef76b07_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmNkNTNkMzQ0OTdiNjQxMzJiNzE2ZjNhMzM5MTQ5MTIzL3RhYmxlcmFuZ2U6Y2Q1M2QzNDQ5N2I2NDEzMmI3MTZmM2EzMzkxNDkxMjNfNi02LTEtMS0w_653f2e06-d8cc-43ce-92c7-0ebfcc6a9052">P7Y5M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i7a7e99b59db24353a85559f303336e06_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmNkNTNkMzQ0OTdiNjQxMzJiNzE2ZjNhMzM5MTQ5MTIzL3RhYmxlcmFuZ2U6Y2Q1M2QzNDQ5N2I2NDEzMmI3MTZmM2EzMzkxNDkxMjNfNi04LTEtMS0w_946d0597-9706-4820-a186-ed490a46678e"
      unitRef="usd">183488000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="i7a7e99b59db24353a85559f303336e06_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmNkNTNkMzQ0OTdiNjQxMzJiNzE2ZjNhMzM5MTQ5MTIzL3RhYmxlcmFuZ2U6Y2Q1M2QzNDQ5N2I2NDEzMmI3MTZmM2EzMzkxNDkxMjNfNy0yLTEtMS0w_d23da98d-be3b-43b8-ba72-5f8d15ae418c"
      unitRef="shares">5690848</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="i7a7e99b59db24353a85559f303336e06_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmNkNTNkMzQ0OTdiNjQxMzJiNzE2ZjNhMzM5MTQ5MTIzL3RhYmxlcmFuZ2U6Y2Q1M2QzNDQ5N2I2NDEzMmI3MTZmM2EzMzkxNDkxMjNfNy00LTEtMS0w_e535dbfe-a86b-4767-80b2-8d916dcf52bc"
      unitRef="usdPerShare">39.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i7af21e8197c4484c8a8abf452ef76b07_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmNkNTNkMzQ0OTdiNjQxMzJiNzE2ZjNhMzM5MTQ5MTIzL3RhYmxlcmFuZ2U6Y2Q1M2QzNDQ5N2I2NDEzMmI3MTZmM2EzMzkxNDkxMjNfNy02LTEtMS0w_64ef2a5f-a057-4710-b918-5bebed1d4050">P8Y10M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i7a7e99b59db24353a85559f303336e06_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmNkNTNkMzQ0OTdiNjQxMzJiNzE2ZjNhMzM5MTQ5MTIzL3RhYmxlcmFuZ2U6Y2Q1M2QzNDQ5N2I2NDEzMmI3MTZmM2EzMzkxNDkxMjNfNy04LTEtMS0w_963f890f-89d3-467d-8229-e57371b4bb7d"
      unitRef="usd">66986000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i7a7e99b59db24353a85559f303336e06_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmNkNTNkMzQ0OTdiNjQxMzJiNzE2ZjNhMzM5MTQ5MTIzL3RhYmxlcmFuZ2U6Y2Q1M2QzNDQ5N2I2NDEzMmI3MTZmM2EzMzkxNDkxMjNfOC0yLTEtMS0w_2f8bade9-5527-4807-9f40-1213ec8b5da4"
      unitRef="shares">5512252</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i7a7e99b59db24353a85559f303336e06_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmNkNTNkMzQ0OTdiNjQxMzJiNzE2ZjNhMzM5MTQ5MTIzL3RhYmxlcmFuZ2U6Y2Q1M2QzNDQ5N2I2NDEzMmI3MTZmM2EzMzkxNDkxMjNfOC00LTEtMS0w_479aea93-4508-4c13-89dc-9b43bc80e16a"
      unitRef="usdPerShare">31.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i7af21e8197c4484c8a8abf452ef76b07_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmNkNTNkMzQ0OTdiNjQxMzJiNzE2ZjNhMzM5MTQ5MTIzL3RhYmxlcmFuZ2U6Y2Q1M2QzNDQ5N2I2NDEzMmI3MTZmM2EzMzkxNDkxMjNfOC02LTEtMS0w_7386053f-ab32-48ac-9d2e-4139a9afebf6">P5Y10M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i7a7e99b59db24353a85559f303336e06_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmNkNTNkMzQ0OTdiNjQxMzJiNzE2ZjNhMzM5MTQ5MTIzL3RhYmxlcmFuZ2U6Y2Q1M2QzNDQ5N2I2NDEzMmI3MTZmM2EzMzkxNDkxMjNfOC04LTEtMS0w_b1c9dca9-2448-42d2-8125-e858cef1a772"
      unitRef="usd">110222000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfNzY2OA_30fd4560-6e94-4db5-a113-00313fc5b14c">&lt;div style="margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of grants made in the six months ended June&#160;30, 2020 was contemporaneously estimated on the date of grant using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:63.592%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.410%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:30.798%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six months ended&lt;br/&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;0.40% - 1.45%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;87.50% - 89.31%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;5.75 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="if901bdf36a4e4a1a81a16393f47a9fb6_D20200101-20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOjI0YzVhOWMyNDA1MTQwYWY5MzQ1ZjBmMTY4NzAyODlkL3RhYmxlcmFuZ2U6MjRjNWE5YzI0MDUxNDBhZjkzNDVmMGYxNjg3MDI4OWRfMS0yLTEtMS0wL3RleHRyZWdpb246NWUxYjA5ZTJmZTI5NDIxMGE2OGM3ZDZiZDllZjJmOGRfMjc0ODc3OTA2OTQ2MA_cdbbefaf-8304-4714-96e2-27d6d27db04a"
      unitRef="number">0.0040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i62acf5ed7adb4666851a78792c6fd991_D20200101-20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOjI0YzVhOWMyNDA1MTQwYWY5MzQ1ZjBmMTY4NzAyODlkL3RhYmxlcmFuZ2U6MjRjNWE5YzI0MDUxNDBhZjkzNDVmMGYxNjg3MDI4OWRfMS0yLTEtMS0wL3RleHRyZWdpb246NWUxYjA5ZTJmZTI5NDIxMGE2OGM3ZDZiZDllZjJmOGRfMjc0ODc3OTA2OTQ2Nw_d2a5d902-164e-4a64-878f-619497400f37"
      unitRef="number">0.0145</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="if901bdf36a4e4a1a81a16393f47a9fb6_D20200101-20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOjI0YzVhOWMyNDA1MTQwYWY5MzQ1ZjBmMTY4NzAyODlkL3RhYmxlcmFuZ2U6MjRjNWE5YzI0MDUxNDBhZjkzNDVmMGYxNjg3MDI4OWRfMi0yLTEtMS0wL3RleHRyZWdpb246Mzc5YzNiZGVhZTJjNDU1OTgyNGFmN2VhZTM0YWFjODNfMjc0ODc3OTA2OTQ2Mw_09a38c2a-6c00-4e81-ac4f-0d632aa488b2"
      unitRef="number">0.8750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i62acf5ed7adb4666851a78792c6fd991_D20200101-20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOjI0YzVhOWMyNDA1MTQwYWY5MzQ1ZjBmMTY4NzAyODlkL3RhYmxlcmFuZ2U6MjRjNWE5YzI0MDUxNDBhZjkzNDVmMGYxNjg3MDI4OWRfMi0yLTEtMS0wL3RleHRyZWdpb246Mzc5YzNiZGVhZTJjNDU1OTgyNGFmN2VhZTM0YWFjODNfMjc0ODc3OTA2OTQ3MQ_f2a4e874-06c4-4c46-870c-1caf49ab30ee"
      unitRef="number">0.8931</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i7af21e8197c4484c8a8abf452ef76b07_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOjI0YzVhOWMyNDA1MTQwYWY5MzQ1ZjBmMTY4NzAyODlkL3RhYmxlcmFuZ2U6MjRjNWE5YzI0MDUxNDBhZjkzNDVmMGYxNjg3MDI4OWRfMy0yLTEtMS0wL3RleHRyZWdpb246NjlkY2JkNDA0ZDJlNGY1NThhYmJlOTI2MTJlNzAwYWZfMjc0ODc3OTA2OTQ2NA_db39985b-8389-4b2a-a1a2-8502d266179a">P5Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i7af21e8197c4484c8a8abf452ef76b07_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfMzgxOQ_f81a439b-0013-400f-904d-4a42bad69991"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7af21e8197c4484c8a8abf452ef76b07_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfMzk1OQ_e6e3a19d-02aa-4454-8ee6-1dd6f06fba49"
      unitRef="usdPerShare">36.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfNzY3Mw_9fb18155-5dbc-4af2-83bc-edf2668c1184">&lt;div style="margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes information on the Company&#x2019;s restricted stock awards and units:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.888%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.909%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted&#160;Stock&#160;Awards&#160;and&#160;Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant&lt;br/&gt;Date&#160;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;642,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;589,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(229,076)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(65,491)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unvested at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;936,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i1d4c0457ced344f0b16ef87b8b77d3ae_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmMzM2I1YjU3NjhiMDQ5YjE5YzU0N2UyNjRjNWY1MzE2L3RhYmxlcmFuZ2U6YzMzYjViNTc2OGIwNDliMTljNTQ3ZTI2NGM1ZjUzMTZfMi0yLTEtMS0w_61220bd0-a80a-4833-9041-e7bc1dece498"
      unitRef="shares">642419</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i1d4c0457ced344f0b16ef87b8b77d3ae_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmMzM2I1YjU3NjhiMDQ5YjE5YzU0N2UyNjRjNWY1MzE2L3RhYmxlcmFuZ2U6YzMzYjViNTc2OGIwNDliMTljNTQ3ZTI2NGM1ZjUzMTZfMi00LTEtMS0w_471f27d7-70bd-4615-b7b7-dacdb7de5752"
      unitRef="usdPerShare">24.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i1b0a569c469e4b6596d336467dd05160_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmMzM2I1YjU3NjhiMDQ5YjE5YzU0N2UyNjRjNWY1MzE2L3RhYmxlcmFuZ2U6YzMzYjViNTc2OGIwNDliMTljNTQ3ZTI2NGM1ZjUzMTZfMy0yLTEtMS0w_06ffa462-23f9-4103-9da9-7e2acb977a25"
      unitRef="shares">589070</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1b0a569c469e4b6596d336467dd05160_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmMzM2I1YjU3NjhiMDQ5YjE5YzU0N2UyNjRjNWY1MzE2L3RhYmxlcmFuZ2U6YzMzYjViNTc2OGIwNDliMTljNTQ3ZTI2NGM1ZjUzMTZfMy00LTEtMS0w_ffdbcc4e-6090-4775-9468-7de999e69d29"
      unitRef="usdPerShare">49.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i1b0a569c469e4b6596d336467dd05160_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmMzM2I1YjU3NjhiMDQ5YjE5YzU0N2UyNjRjNWY1MzE2L3RhYmxlcmFuZ2U6YzMzYjViNTc2OGIwNDliMTljNTQ3ZTI2NGM1ZjUzMTZfNC0yLTEtMS0w_71202c27-1a73-4aa6-862b-edc3a780d6e6"
      unitRef="shares">229076</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1b0a569c469e4b6596d336467dd05160_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmMzM2I1YjU3NjhiMDQ5YjE5YzU0N2UyNjRjNWY1MzE2L3RhYmxlcmFuZ2U6YzMzYjViNTc2OGIwNDliMTljNTQ3ZTI2NGM1ZjUzMTZfNC00LTEtMS0w_bda296fa-a088-43c4-acde-14195516f813"
      unitRef="usdPerShare">23.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i1b0a569c469e4b6596d336467dd05160_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmMzM2I1YjU3NjhiMDQ5YjE5YzU0N2UyNjRjNWY1MzE2L3RhYmxlcmFuZ2U6YzMzYjViNTc2OGIwNDliMTljNTQ3ZTI2NGM1ZjUzMTZfNS0yLTEtMS0w_fdedc584-f8cc-44cd-93f2-4806512d3726"
      unitRef="shares">65491</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i1b0a569c469e4b6596d336467dd05160_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmMzM2I1YjU3NjhiMDQ5YjE5YzU0N2UyNjRjNWY1MzE2L3RhYmxlcmFuZ2U6YzMzYjViNTc2OGIwNDliMTljNTQ3ZTI2NGM1ZjUzMTZfNS00LTEtMS0w_2e476590-6b73-4a46-9d88-4164030b8afd"
      unitRef="usdPerShare">36.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i40fe1e237dd2460982e61df9b93e25de_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmMzM2I1YjU3NjhiMDQ5YjE5YzU0N2UyNjRjNWY1MzE2L3RhYmxlcmFuZ2U6YzMzYjViNTc2OGIwNDliMTljNTQ3ZTI2NGM1ZjUzMTZfNi0yLTEtMS0w_f09a2962-8d1f-4495-9743-d6d4386cbbeb"
      unitRef="shares">936922</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i40fe1e237dd2460982e61df9b93e25de_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOmMzM2I1YjU3NjhiMDQ5YjE5YzU0N2UyNjRjNWY1MzE2L3RhYmxlcmFuZ2U6YzMzYjViNTc2OGIwNDliMTljNTQ3ZTI2NGM1ZjUzMTZfNi00LTEtMS0w_46140e20-2d68-4d17-95a6-72b7cf22d236"
      unitRef="usdPerShare">39.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i9e1f2793036044c09455f3aed8a471a5_D20160501-20160531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfNTI2MQ_df063fba-fb33-415a-9bcc-70814adbb7f3"
      unitRef="shares">897290</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="iaf63c553ba564cb8bd94fab03c3290ab_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfNTU3OQ_bf7bc58f-c4aa-4dd4-a44c-e235f6e7085c"
      unitRef="shares">132136</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <ptct:StockAppreciationRightsLiabilityOutstanding
      contextRef="i82a7d5029292453a9d8665965b2a0597_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfNTc2Nw_fbfa588a-dbd1-41af-9b25-469cf3db6a86"
      unitRef="usd">0</ptct:StockAppreciationRightsLiabilityOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i8edf5809ef1e4a8c9d7d12ead5870765_I20160930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfNjExNw_3e6980ae-8741-4cbc-a030-cf87cf9d91cf"
      unitRef="shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="ia49191cff53044aeb0f18b552f15edb0_D20160601-20160630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfNDM5ODA0NjUxOTIwMw_9a670cf4-360c-4039-a1f0-7b84b798788a">P6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="ia49191cff53044aeb0f18b552f15edb0_D20160601-20160630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfNDM5ODA0NjUxOTIwNA_c351d053-f185-4ac7-a2b0-6b6c6d351642">P6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="ia49191cff53044aeb0f18b552f15edb0_D20160601-20160630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfNjM0OA_a0dcb216-bf2e-4c7c-b5a6-d721a159ea79"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <ptct:EmployeeStockPurchasePlanVotingPercentageLimitPercent
      contextRef="ia49191cff53044aeb0f18b552f15edb0_D20160601-20160630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfNjcyNg_b8fdcd20-1e17-49d9-9af2-15aea59734ec"
      unitRef="number">0.05</ptct:EmployeeStockPurchasePlanVotingPercentageLimitPercent>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia00d8392741940a5a0455a9ec5a070dc_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfNjg4OA_84c92ccd-d9b1-4953-b0d4-4831eb726d37"
      unitRef="usd">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4c05af13913c4e2d87e2cca2be0ef9a6_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfNDk0NzgwMjMzMjk0NA_194f3128-d712-42cd-ac5a-ee87ee94a486"
      unitRef="usd">700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfNzY4MQ_1bb736e8-d6d7-4d5e-b040-8504d2d184b4">&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company recorded share-based compensation expense in the statement of operations related to incentive stock options, nonstatutory stock options, restricted stock awards, restricted stock units and the ESPP as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:40.020%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.909%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.909%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:2.289%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.740%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i23b23527dd664848b751f1f40cd0477f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOjcyOTkyMDAxNzRmZDRiNGFhMWJmYjY4YWEyMzEwMzI1L3RhYmxlcmFuZ2U6NzI5OTIwMDE3NGZkNGI0YWExYmZiNjhhYTIzMTAzMjVfMi0yLTEtMS0w_0bacdd0c-f26b-4951-adc3-d711a25df287"
      unitRef="usd">8562000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iacdbc7fbbfab4c83935a46b395d3c1c4_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOjcyOTkyMDAxNzRmZDRiNGFhMWJmYjY4YWEyMzEwMzI1L3RhYmxlcmFuZ2U6NzI5OTIwMDE3NGZkNGI0YWExYmZiNjhhYTIzMTAzMjVfMi00LTEtMS0w_c8a13172-383e-460d-9857-e9ff75b02b50"
      unitRef="usd">5516000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib1bd8bc0a2d94ff7b16f1f994b27455f_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOjcyOTkyMDAxNzRmZDRiNGFhMWJmYjY4YWEyMzEwMzI1L3RhYmxlcmFuZ2U6NzI5OTIwMDE3NGZkNGI0YWExYmZiNjhhYTIzMTAzMjVfMi02LTEtMS0w_096f5453-2c5a-410e-adfc-1f3d1caa7c37"
      unitRef="usd">16741000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i14204fc508b343cb8ca99de636b507e4_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOjcyOTkyMDAxNzRmZDRiNGFhMWJmYjY4YWEyMzEwMzI1L3RhYmxlcmFuZ2U6NzI5OTIwMDE3NGZkNGI0YWExYmZiNjhhYTIzMTAzMjVfMi04LTEtMS0w_d7cfd5ca-ed10-4183-8b0a-64a04f1e77e6"
      unitRef="usd">10203000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i895a331c1a6f453c87f851e30384f906_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOjcyOTkyMDAxNzRmZDRiNGFhMWJmYjY4YWEyMzEwMzI1L3RhYmxlcmFuZ2U6NzI5OTIwMDE3NGZkNGI0YWExYmZiNjhhYTIzMTAzMjVfMy0yLTEtMS0w_45c86b3c-aa3c-4944-81d0-1d735a64f6f2"
      unitRef="usd">8348000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i14ebe4de831348188d0069a40d328e56_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOjcyOTkyMDAxNzRmZDRiNGFhMWJmYjY4YWEyMzEwMzI1L3RhYmxlcmFuZ2U6NzI5OTIwMDE3NGZkNGI0YWExYmZiNjhhYTIzMTAzMjVfMy00LTEtMS0w_30b62cca-703f-4d03-be32-0c4087a44035"
      unitRef="usd">5404000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if5f804d6c3184fdea8f69c3a97350d43_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOjcyOTkyMDAxNzRmZDRiNGFhMWJmYjY4YWEyMzEwMzI1L3RhYmxlcmFuZ2U6NzI5OTIwMDE3NGZkNGI0YWExYmZiNjhhYTIzMTAzMjVfMy02LTEtMS0w_be25b7cf-e56e-45c4-9849-732050f1700e"
      unitRef="usd">15389000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ide6d6c0db1274c47ab5146ea275d8c88_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOjcyOTkyMDAxNzRmZDRiNGFhMWJmYjY4YWEyMzEwMzI1L3RhYmxlcmFuZ2U6NzI5OTIwMDE3NGZkNGI0YWExYmZiNjhhYTIzMTAzMjVfMy04LTEtMS0w_dfd7d826-577a-46f6-8fe7-4dcd0e9ccc68"
      unitRef="usd">9981000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOjcyOTkyMDAxNzRmZDRiNGFhMWJmYjY4YWEyMzEwMzI1L3RhYmxlcmFuZ2U6NzI5OTIwMDE3NGZkNGI0YWExYmZiNjhhYTIzMTAzMjVfNC0yLTEtMS0w_15bda321-798b-43da-976a-6561a1dc6f37"
      unitRef="usd">16910000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOjcyOTkyMDAxNzRmZDRiNGFhMWJmYjY4YWEyMzEwMzI1L3RhYmxlcmFuZ2U6NzI5OTIwMDE3NGZkNGI0YWExYmZiNjhhYTIzMTAzMjVfNC00LTEtMS0w_832045ec-8037-4cdc-ab53-590768bb235c"
      unitRef="usd">10920000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOjcyOTkyMDAxNzRmZDRiNGFhMWJmYjY4YWEyMzEwMzI1L3RhYmxlcmFuZ2U6NzI5OTIwMDE3NGZkNGI0YWExYmZiNjhhYTIzMTAzMjVfNC02LTEtMS0w_3af365f3-68a9-4606-b20d-b91cd6797ad4"
      unitRef="usd">32130000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RhYmxlOjcyOTkyMDAxNzRmZDRiNGFhMWJmYjY4YWEyMzEwMzI1L3RhYmxlcmFuZ2U6NzI5OTIwMDE3NGZkNGI0YWExYmZiNjhhYTIzMTAzMjVfNC04LTEtMS0w_754685f9-5c9b-497d-aa9e-ec86c09f7ef9"
      unitRef="usd">20184000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfNzE5NA_aba44c8a-7747-451c-bfdc-45b2d64ce59c"
      unitRef="usd">187200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83MC9mcmFnOjY5OTJkMTAxMTQyNDRjN2M4MWY3ZTgwYjE2NzhlZjQ0L3RleHRyZWdpb246Njk5MmQxMDExNDI0NGM3YzgxZjdlODBiMTY3OGVmNDRfNzY0NA_354f888e-7ef8-4e1f-a10b-5d8568df277e">P3Y29D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:LongTermDebtTextBlock
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfNDM5ODA0NjUzMTUyMw_66a42d1f-0153-4b2e-9b21-e296489dbb10">Debt&lt;div style="margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;2017 Credit Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In May 2017, the Company entered into the Credit Agreement, which provided for a senior secured term loan facility of $60.0 million, of which $40.0 million was drawn by the Company on May 5, 2017 (the "Credit Facility"). The Company's ability to draw on the remaining $20.0 million under the senior secured term loan facility expired on December 31, 2018. The Company capitalized approximately $0.4 million of debt issuance costs, which were netted against the carrying value of the Credit Facility and were amortized over the term of the Credit Facility.  As of June&#160;30, 2020, the Company had made loan repayments of $21.7 million on the Credit Facility. The remaining balance of the Credit Facility as of&#160;June&#160;30, 2020&#160;was $18.3 million,&#160;which was classified as current portion of long term debt on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Borrowings under the Credit Agreement bore interest at a rate per annum equal to the London Interbank Offered Rate, or LIBOR, (with a LIBOR floor rate of 1.00%) plus 6.15%. The Company was obligated to make interest only payments (payable monthly in arrears) through April 30, 2019. Commencing on May 1, 2019 and continuing for the remaining &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTM2Mg_e91d3869-d03c-4b8b-84d9-15ddf6e4e1da"&gt;twenty-four&lt;/span&gt; months of the facility, the Company was required to make monthly interest payments and monthly principal payments. The principal payments were made based on straight-line amortization of the principal over the &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMjc0ODc3OTA4OTc4OA_adc62e20-6b69-4ee6-aa71-28d59137d971"&gt;twenty-four&lt;/span&gt; month period. The maturity date of the Credit Agreement was May 1, 2021, unless terminated earlier.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;The Credit Facility is subject to certain financial covenants. As of&#160;June&#160;30, 2020, the Company was in compliance with all required covenants. On July 1, 2020, the Company terminated the Credit Facility. Refer to Note 15 for further details.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;2026 Convertible Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In&#160;September 2019, the Company issued, at par value,&#160;$287.5 million&#160;aggregate principal amount of&#160;1.50%&#160;convertible senior notes due 2026, which included an option to purchase up to an additional $37.5 million in aggregate principal amount of the 2026 Convertible Notes. The 2026 Convertible Notes bear cash interest at a rate of&#160;1.50%&#160;per year, payable semi-annually on&#160;March&#160;15&#160;and&#160;September&#160;15&#160;of each year, beginning on&#160;March 15, 2020. The 2026 Convertible Notes will mature on&#160;September 15, 2026, unless earlier repurchased or converted. The net proceeds to the Company from the offering were&#160;$279.3 million after deducting the initial purchasers&#x2019; discounts and commissions and the offering expenses payable by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The 2026 Convertible Notes are governed by an indenture (the "2026 Convertible Notes Indenture") with U.S Bank National Association as trustee (the "2026 Convertible Notes Trustee").&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Holders may convert their 2026 Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding&#160;March 15, 2026&#160;only under the following circumstances:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#xb7;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; during any calendar quarter commencing on or after&#160;December 31, 2019&#160;(and only during such calendar quarter), if the last reported sale price of the Company&#x2019;s common stock for at least&#160;20&#160;trading days (whether or not consecutive) during a period of&#160;30&#160;consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to&#160;130%&#160;of the conversion price on each applicable trading day;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#xb7;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; during the&#160;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMzQwMg_7f893db8-e0cf-4d5a-83ac-33f975ce7592"&gt;five&lt;/span&gt;&#160;business day period after any&#160;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMzQzNQ_36968acf-1345-44be-9245-319a6078d531"&gt;five&lt;/span&gt;&#160;consecutive trading day period (the &#x201c;measurement period&#x201d;) in which the trading price (as defined in the 2026 Convertible Notes Indenture) per $1,000 principal amount of 2026 Convertible Notes for each trading day of the measurement period was less than&#160;98%&#160;of the product of the last reported sale price of the Company&#x2019;s common stock and the conversion rate on each such trading day;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#xb7;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; during any period after the Company has issued notice of redemption until the close of business on the scheduled trading day immediately preceding the relevant redemption date; or&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#xb7;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; upon the occurrence of specified corporate events.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On or after March 15, 2026, until the close of business on the business day immediately preceding the maturity date, holders may convert their 2026 Convertible Notes at any time, regardless of the foregoing circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of the Company's common stock or any combination thereof at the Company's election.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The conversion rate for the 2026 Convertible Notes was initially, and remains, 19.0404 shares of the Company&#x2019;s common stock per $1,000 principal amount of the 2026 Convertible Notes, which is equivalent to an initial conversion price of approximately&#160;$52.52 per share of the Company&#x2019;s common stock. The conversion rate may be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company is not permitted to redeem the 2026 Convertible Notes prior to September 20, 2023. The Company may redeem for cash all or any portion of the 2026 Convertible Notes, at its option, if the last reported sale price of its common stock has been at least 130% of the conversion price then in effect on the last trading day of, and for at least 19 other trading days (whether or not consecutive) during, any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100% of the principal amount of the 2026 Convertible Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the 2026 Convertible Notes, which means that the Company is not required to redeem or retire the 2026 Convertible Notes periodically. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;If the Company undergoes a &#x201c;fundamental change&#x201d; (as defined in the 2026 Convertible Notes Indenture), subject to certain conditions, holders of the 2026 Convertible Notes may require the Company to repurchase for cash all or part of their 2026 Convertible Notes at a repurchase price equal to 100% of the principal amount of the 2026 Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The 2026 Convertible Notes represent senior unsecured obligations and will rank senior in right of payment to the Company&#x2019;s future indebtedness that is expressly subordinated in right of payment to the notes, equal in right of payment to the Company&#x2019;s existing and future unsecured indebtedness that is not so subordinated, effectively junior in right of payment to any of the Company&#x2019;s secured indebtedness to the extent of the value of the assets securing such indebtedness, and structurally subordinated to all existing and future indebtedness and other liabilities (including trade payables) incurred by the Company&#x2019;s subsidiaries. The 2026 Convertible Notes Indenture contains customary events of default with respect to the 2026 Convertible Notes, including that upon certain events of default (including the Company&#x2019;s failure to make any payment of principal or interest on the 2026 Convertible Notes when due and payable) occurring and continuing, the 2026 Convertible Notes Trustee by notice to the Company, or the holders of at least 25% in principal amount of the outstanding 2026 Convertible Notes by notice to the Company and the Convertible Notes Trustee, may, and the 2026 Convertible Notes Trustee at the request of such holders (subject to the provisions of the 2026 Convertible Notes Indenture) shall, declare 100% of the principal of and accrued and unpaid interest, if any, on all the 2026 Convertible Notes to be due and payable. In case of certain events of bankruptcy, insolvency or reorganization, involving the Company or a significant subsidiary, 100% of the principal of and accrued and unpaid interest on the 2026 Convertible Notes will automatically become due and payable. Upon such a declaration of acceleration, such principal and accrued and unpaid interest, if any, will be due and payable immediately.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company accounts for the 2026 Convertible Notes as a liability and equity component where the carrying value of the liability component will be valued based on a similar instrument. In accounting for the issuance of the 2026 Convertible Notes, the Company separated the 2026 Convertible Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of a similar liability that does not have an associated convertible feature. The carrying amount of the equity component representing the conversion option was determined by deducting the fair value of the liability component from the par value of the 2026 Convertible Notes as a whole. The excess of the principal amount of the liability component over its carrying amount, referred to as the debt discount, is amortized to interest expense over the &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfODk3MQ_ee20cb45-d925-46df-bb1a-8dfa5015d89d"&gt;seven&lt;/span&gt;-year term of the 2026 Convertible Notes. The equity component is not re-measured as long as it continues to meet the conditions for equity classification. The equity component recorded at issuance related to the 2026 Convertible Notes was $123.0 million&#160;and was recorded in additional paid-in capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In accounting for the transaction costs related to the issuance of the 2026 Convertible Notes, the Company allocated the total costs incurred to the liability and equity components of the 2026 Convertible Notes based on their relative values. Transaction costs attributable to the liability component are amortized to interest expense over the &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfOTYwOA_9ed8f64e-ddb8-4035-b1f3-c92bbadb8041"&gt;seven&lt;/span&gt;-year term of the 2026 Convertible Notes, and transaction costs attributable to the equity component are netted with the equity components in stockholders&#x2019; equity. Additionally, the Company initially recorded a net deferred tax liability of $25.3 million in connection with the 2026 Convertible Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The 2026 Convertible Notes consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:61.436%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.621%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.387%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.622%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Liability&#160;component&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;287,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;287,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: Debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,319)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: Debt discount, net(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(112,877)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(119,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;170,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;163,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;(1)&#160;Included in the consolidated balance sheets within convertible senior notes (due 2026) and amortized to interest expense over the remaining life of the 2026 Convertible Notes using the effective interest rate method.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June&#160;30, 2020, the remaining contractual life of the 2026 Convertible Notes is approximately 6.2 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table sets forth total interest expense recognized related to the 2026 Convertible Notes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:77.631%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.282%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.306%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:21.163%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.553%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.741%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:20.598%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.557%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortization of debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Effective interest rate of the liability component&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;2022 Convertible Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In&#160;August&#160;2015, the Company issued, at par value,&#160;$150.0 million&#160;aggregate principal amount of&#160;3.00%&#160;convertible senior notes due 2022. The 2022 Convertible Notes bear cash interest at a rate of&#160;3.00%&#160;per year, payable semi-annually on&#160;February&#160;15&#160;and&#160;August&#160;15&#160;of each year, beginning on&#160;February&#160;15, 2016. The 2022 Convertible Notes will mature on&#160;August&#160;15, 2022, unless earlier repurchased or converted. The net proceeds to the Company from the offering were&#160;$145.4 million&#160;after deducting the initial purchasers&#x2019; discounts and commissions and the offering expenses payable by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The 2022 Convertible Notes are governed by an indenture (the "2022 Convertible Notes Indenture") with U.S Bank National Association as trustee (the "2022 Convertible Notes Trustee").&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Holders may convert their 2022 Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding&#160;February&#160;15, 2022&#160;only under the following circumstances:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#xb7;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; during any calendar quarter commencing on or after&#160;September&#160;30, 2015&#160;(and only during such calendar quarter), if the last reported sale price of the Company&#x2019;s common stock for at least&#160;20&#160;trading days (whether or not consecutive) during a period of&#160;30&#160;consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to&#160;130%&#160;of the conversion price on each applicable trading day;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#xb7;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; during the&#160;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTE4NTA_7f893db8-e0cf-4d5a-83ac-33f975ce7592"&gt;five&lt;/span&gt;&#160;business day period after any&#160;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTE4ODM_36968acf-1345-44be-9245-319a6078d531"&gt;five&lt;/span&gt;&#160;consecutive trading day period (the &#x201c;measurement period&#x201d;) in which the trading price (as defined in the 2022 Convertible Notes Indenture) per $1,000 principal amount of 2022 Convertible Notes for each trading day of the measurement period was less than&#160;98%&#160;of the product of the last reported sale price of the Company&#x2019;s common stock and the conversion rate on each such trading day;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#xb7;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; during any period after the Company has issued notice of redemption until the close of business on the scheduled trading day immediately preceding the relevant redemption date; or&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#xb7;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; upon the occurrence of specified corporate events.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On or after February&#160;15, 2022, until the close of business on the business day immediately preceding the maturity date, holders may convert their 2022 Convertible Notes at any time, regardless of the foregoing circumstances. Upon conversion, the Company will pay cash up to the aggregate principal amount of the 2022 Convertible Notes to be converted and deliver shares of its common stock in respect of the remainder, if any, of its conversion obligation in excess of the aggregate principal amount of 2022 Convertible Notes being converted.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The conversion rate for the 2022 Convertible Notes was initially, and remains, 17.7487 shares of the Company&#x2019;s common stock per $1,000 principal amount of the 2022 Convertible Notes, which is equivalent to an initial conversion price of approximately&#160;$56.34&#160;per share of the Company&#x2019;s common stock. The conversion rate may be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company was not permitted to redeem the 2022 Convertible Notes prior to August&#160;20, 2018. As of August 20, 2018, the Company may redeem for cash all or any portion of the 2022 Convertible Notes, at its option, if the last reported sale price of its common stock has been at least 130% of the conversion price then in effect on the last trading day of, and for at least 19 other trading days (whether or not consecutive) during, any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100% of the principal amount of the 2022 Convertible Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the 2022 Convertible Notes, which means that the Company is not required to redeem or retire the 2022 Convertible Notes periodically. There have been no redemptions to date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;If the Company undergoes a &#x201c;fundamental change&#x201d; (as defined in the 2022 Convertible Notes Indenture), subject to certain conditions, holders of the 2022 Convertible Notes may require the Company to repurchase for cash all or part of their 2022 Convertible Notes at a repurchase price equal to 100% of the principal amount of the 2022 Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The 2022 Convertible Notes represent senior unsecured obligations and will rank senior in right of payment to the Company&#x2019;s future indebtedness that is expressly subordinated in right of payment to the notes, equal in right of payment to the Company&#x2019;s existing and future unsecured indebtedness that is not so subordinated, effectively junior in right of payment to any of the Company&#x2019;s secured indebtedness to the extent of the value of the assets securing such indebtedness, and structurally subordinated to all existing and future indebtedness and other liabilities (including trade payables) incurred by the Company&#x2019;s subsidiaries. The 2022 Convertible Notes Indenture contains customary events of default with respect to the 2022 Convertible Notes, including that upon certain events of default (including the Company&#x2019;s failure to make any payment of principal or interest on the 2022 Convertible Notes when due and payable) occurring and continuing, the 2022 Convertible Notes Trustee by notice to the Company, or the holders of at least 25% in principal amount of the outstanding 2022 Convertible Notes by notice to the Company and the Convertible Notes Trustee, may, and the 2022 Convertible Notes Trustee at the request of such holders (subject to the provisions of the 2022 Convertible Notes Indenture) shall, declare 100% of the principal of and accrued and unpaid interest, if any, on all the 2022 Convertible Notes to be due and payable. In case of certain events of bankruptcy, insolvency or reorganization, involving the Company or a significant subsidiary, 100% of the principal of and accrued and unpaid interest on the 2022 Convertible Notes will automatically become due and payable. Upon such a declaration of acceleration, such principal and accrued and unpaid interest, if any, will be due and payable immediately.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company accounts for the 2022 Convertible Notes as a liability and equity component where the carrying value of the liability component will be valued based on a similar instrument. In accounting for the issuance of the 2022 Convertible Notes, the Company separated the 2022 Convertible Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of a similar liability that does not have an associated convertible feature. The carrying amount of the equity component representing the conversion option was determined by deducting the fair value of the liability component from the par value of the 2022 Convertible Notes as a whole. The excess of the principal amount of the liability component over its carrying amount, referred to as the debt discount, is amortized to interest expense over the &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTc2MzM_ee20cb45-d925-46df-bb1a-8dfa5015d89d"&gt;seven&lt;/span&gt;-year term of the 2022 Convertible Notes. The equity component is not re-measured as long as it continues to meet the conditions for equity classification. The equity component recorded at issuance related to the 2022 Convertible Notes was&#160;$57.5 million&#160;and was recorded in additional paid-in capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In accounting for the transaction costs related to the issuance of the 2022 Convertible Notes, the Company allocated the total costs incurred to the liability and equity components of the 2022 Convertible Notes based on their relative values. Transaction costs attributable to the liability component are amortized to interest expense over the &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTgyNzA_9ed8f64e-ddb8-4035-b1f3-c92bbadb8041"&gt;seven&lt;/span&gt;-year term of the 2022 Convertible Notes, and transaction costs attributable to the equity component are netted with the equity components in stockholders&#x2019; equity. Additionally, the Company initially recorded a net deferred tax liability of $22.3 million in connection with the 2022 Convertible Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The 2022 Convertible Notes consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:61.343%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.595%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Liability&#160;component&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: Debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,104)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,329)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: Debt discount, net(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(22,166)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(26,686)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;126,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;121,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;(1)&#160;Included in the consolidated balance sheets within convertible senior notes (due 2022) and amortized to interest expense over the remaining life of the 2022 Convertible Notes using the effective interest rate method.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June&#160;30, 2020, the remaining contractual life of the 2022 Convertible Notes is approximately 2.1 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table sets forth total interest expense recognized related to the 2022 Convertible Notes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.222%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:37.548%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.551%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.285%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.551%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.285%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.551%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.285%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.551%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.593%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortization of debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Effective interest rate of the liability component&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ia31f7d7b519f40d5a5aa9977431540c2_I20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMzcw_f3cf5cff-c1bf-4e00-86c3-79a3f9624a89"
      unitRef="usd">60000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="i0047c24fb89c4b3aa1349dbfc482fe10_D20170505-20170505"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMzgz_3d2cbc42-4308-41ee-b7e5-d55e1cd66c12"
      unitRef="usd">40000000.0</us-gaap:ProceedsFromLinesOfCredit>
    <ptct:LineOfCreditFacilityAdditionalCapacityAvailable
      contextRef="ia31f7d7b519f40d5a5aa9977431540c2_I20170531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfNDc0_aa67c96f-e63c-4c07-95eb-e281d0ba179a"
      unitRef="usd">20000000.0</ptct:LineOfCreditFacilityAdditionalCapacityAvailable>
    <us-gaap:DebtIssuanceCostsLineOfCreditArrangementsGross
      contextRef="ia31f7d7b519f40d5a5aa9977431540c2_I20170531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfNTg5_f0113eef-c4bf-455e-a456-f2169cf96a01"
      unitRef="usd">400000</us-gaap:DebtIssuanceCostsLineOfCreditArrangementsGross>
    <us-gaap:RepaymentsOfDebt
      contextRef="i624b7b9db16e4728a041aaf0fe8e3bbc_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfNzk2_f6d599ee-e91a-4a2c-89e4-39a871295462"
      unitRef="usd">21700000</us-gaap:RepaymentsOfDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="i396045a4f2b246abb303f6334b534fc5_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfODgx_b42ca84d-5c49-44c3-811f-677bdfa914d1"
      unitRef="usd">18300000</us-gaap:LongTermDebtCurrent>
    <ptct:DebtInstrumentFloorInterestRate
      contextRef="ia31f7d7b519f40d5a5aa9977431540c2_I20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTE4MA_8c0afb6d-2a27-4a0c-aa7f-5cc7cc721889"
      unitRef="number">0.0100</ptct:DebtInstrumentFloorInterestRate>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i7a54a031534840f0b962ea11b19c1d3c_D20170501-20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTE4OQ_4208e19c-d5b6-4890-8d52-5e052f33c155"
      unitRef="number">0.0615</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i43e763aab42b473cb26af800270f6b3e_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTg4OQ_2f1ab4b2-a38a-4157-bde1-c2ac7e7c80e7"
      unitRef="usd">287500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i43e763aab42b473cb26af800270f6b3e_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTkyMg_f1d8b5c5-1047-42f4-97af-04d527b0cc7f"
      unitRef="number">0.0150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <ptct:DebtInstrumentAdditionalAmountAvailableForRepurchase
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMjAxNw_751eacf4-01ee-4229-90f7-5de891812580"
      unitRef="usd">37500000</ptct:DebtInstrumentAdditionalAmountAvailableForRepurchase>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i43e763aab42b473cb26af800270f6b3e_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMjE0MA_fc32f055-e4d7-4c53-8ba1-19eb5b5643cc"
      unitRef="number">0.0150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="i99e6e03adee54a9ca0a6a21ec4cddd55_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMjQwNQ_8dde4c46-e3fd-425f-afe2-fe40132e68dc"
      unitRef="usd">279300000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i8dc375e5e9f24bf9b690d042d600041f_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMzExNg_986f3df1-03cf-4c5a-86fa-8339f77059c7"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="ifbd02289ccd34e7a886bf4e86089dadc_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMzE4MA_5c4afc5a-83d6-4077-bd12-9bd505ef9e07"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i8dc375e5e9f24bf9b690d042d600041f_D20190901-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMzMxMw_1aa6b209-310e-4a06-82e4-85f2a91ad5fe"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <ptct:DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum
      contextRef="i08c7971cf8d6469fbda565dec2419938_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMzY4Nw_cce6c2b1-5ca7-491d-8240-0d5478d791d2"
      unitRef="number">0.98</ptct:DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i9710b6f008d64a8e9b038ddfbc4f20cb_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfNDU1NA_8ae608a5-02eb-463f-9680-52b62c162127"
      unitRef="number">19.0404</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i43e763aab42b473cb26af800270f6b3e_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfNDcxNw_5bba4383-e0b8-46da-98d3-a76a354c390e"
      unitRef="usdPerShare">52.52</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="ifbd02289ccd34e7a886bf4e86089dadc_D20190901-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfNTE0OQ_6438c313-5547-4569-a720-dca4bdf52934"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="ifbd02289ccd34e7a886bf4e86089dadc_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfNTIzNg_996c8182-c5b0-47b3-891b-18497efc57a8"
      unitRef="day">19</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="ifbd02289ccd34e7a886bf4e86089dadc_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfNTI5OQ_c107688e-f828-4dbb-a06c-8b806ca79700"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="ifbd02289ccd34e7a886bf4e86089dadc_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfNTQ4OQ_abd63032-d306-4818-9497-91d77f0cb6a5"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentCumulativeSinkingFundPayments
      contextRef="i8781119cc5804767a8721ec1e62367b7_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfNTYzNQ_4f7e1aac-36df-4322-8734-3a7611a09641"
      unitRef="usd">0</us-gaap:DebtInstrumentCumulativeSinkingFundPayments>
    <ptct:ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault
      contextRef="i8dc375e5e9f24bf9b690d042d600041f_D20190901-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfNjA5NQ_8eddb489-3342-4d90-8188-e2400bc59520"
      unitRef="number">1</ptct:ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault>
    <ptct:MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders
      contextRef="i8dc375e5e9f24bf9b690d042d600041f_D20190901-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfNzMwNw_be5058a0-37e3-4983-aa97-80492518de93"
      unitRef="number">0.25</ptct:MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="ifbd02289ccd34e7a886bf4e86089dadc_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfNzU5MA_894ee09c-d008-4717-9766-ce06ab3f5e11"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="ifbd02289ccd34e7a886bf4e86089dadc_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfNzgzMw_f24020d2-49ef-4f72-aeb6-f7f1e6701fc0"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="i9710b6f008d64a8e9b038ddfbc4f20cb_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfOTIxMw_38daba00-bc2e-4b77-bbcc-a3098676b290"
      unitRef="usd">123000000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <ptct:NetDeferredTaxLiabilitiesConvertibleDebtInstruments
      contextRef="i43e763aab42b473cb26af800270f6b3e_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfOTg1MQ_a6fa56e1-62a3-4730-9bbf-ba0397fc61f1"
      unitRef="usd">25300000</ptct:NetDeferredTaxLiabilitiesConvertibleDebtInstruments>
    <us-gaap:ConvertibleDebtTableTextBlock
      contextRef="i74ae1a7412804eb39f158945860fdc92_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTkwNDM_0d4e002d-152b-419a-bdcc-a2940b71258d">&lt;div style="margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The 2026 Convertible Notes consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:61.436%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.621%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.387%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.622%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Liability&#160;component&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;287,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;287,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: Debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,319)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: Debt discount, net(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(112,877)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(119,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;170,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;163,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;(1)&#160;Included in the consolidated balance sheets within convertible senior notes (due 2026) and amortized to interest expense over the remaining life of the 2026 Convertible Notes using the effective interest rate method.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i43e763aab42b473cb26af800270f6b3e_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmNjYTJiOTI2MTAyYjQ2ZDg5ZDliZjhkYmFmN2M1OTFhL3RhYmxlcmFuZ2U6Y2NhMmI5MjYxMDJiNDZkODlkOWJmOGRiYWY3YzU5MWFfMS0yLTEtMS0w_a20cfadd-6bb0-4b8f-965d-67ae81aba07b"
      unitRef="usd">287500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i2869c1675c5a404e9bb85cad2eb71998_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmNjYTJiOTI2MTAyYjQ2ZDg5ZDliZjhkYmFmN2M1OTFhL3RhYmxlcmFuZ2U6Y2NhMmI5MjYxMDJiNDZkODlkOWJmOGRiYWY3YzU5MWFfMS0zLTEtMS0w_5a42722b-de69-43fb-9ee5-36cc2b8342ec"
      unitRef="usd">287500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="i43e763aab42b473cb26af800270f6b3e_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmNjYTJiOTI2MTAyYjQ2ZDg5ZDliZjhkYmFmN2M1OTFhL3RhYmxlcmFuZ2U6Y2NhMmI5MjYxMDJiNDZkODlkOWJmOGRiYWY3YzU5MWFfMi0yLTEtMS0w_9d35f64a-54fa-4d61-94f5-eaa6595d4e1a"
      unitRef="usd">4319000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="i2869c1675c5a404e9bb85cad2eb71998_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmNjYTJiOTI2MTAyYjQ2ZDg5ZDliZjhkYmFmN2M1OTFhL3RhYmxlcmFuZ2U6Y2NhMmI5MjYxMDJiNDZkODlkOWJmOGRiYWY3YzU5MWFfMi0zLTEtMS0w_45c8abc0-ef4b-4acc-9c14-d6ca66d84209"
      unitRef="usd">4567000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i43e763aab42b473cb26af800270f6b3e_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmNjYTJiOTI2MTAyYjQ2ZDg5ZDliZjhkYmFmN2M1OTFhL3RhYmxlcmFuZ2U6Y2NhMmI5MjYxMDJiNDZkODlkOWJmOGRiYWY3YzU5MWFfMy0yLTEtMS0w_f28cab4f-831e-40f1-9ef5-7bac65022efb"
      unitRef="usd">112877000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i2869c1675c5a404e9bb85cad2eb71998_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmNjYTJiOTI2MTAyYjQ2ZDg5ZDliZjhkYmFmN2M1OTFhL3RhYmxlcmFuZ2U6Y2NhMmI5MjYxMDJiNDZkODlkOWJmOGRiYWY3YzU5MWFfMy0zLTEtMS0w_2aeb8697-5884-4b14-b30d-2c3cbe7790be"
      unitRef="usd">119350000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebt
      contextRef="i43e763aab42b473cb26af800270f6b3e_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmNjYTJiOTI2MTAyYjQ2ZDg5ZDliZjhkYmFmN2M1OTFhL3RhYmxlcmFuZ2U6Y2NhMmI5MjYxMDJiNDZkODlkOWJmOGRiYWY3YzU5MWFfNC0yLTEtMS0w_0f6730da-e4a1-4dba-9e01-a6bce2d2be02"
      unitRef="usd">170304000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i2869c1675c5a404e9bb85cad2eb71998_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmNjYTJiOTI2MTAyYjQ2ZDg5ZDliZjhkYmFmN2M1OTFhL3RhYmxlcmFuZ2U6Y2NhMmI5MjYxMDJiNDZkODlkOWJmOGRiYWY3YzU5MWFfNC0zLTEtMS0w_3975cb58-01db-4ab9-bd22-fc55f3310f02"
      unitRef="usd">163583000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentTerm
      contextRef="i73b5dc373fe54df282ef490ee32d7654_D20200401-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTAyNjU_1fac162c-712b-4e22-ad8a-a9815f8d7b5d">P6Y2M12D</us-gaap:DebtInstrumentTerm>
    <ptct:ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock
      contextRef="i74ae1a7412804eb39f158945860fdc92_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTkwNTg_1afd1a8b-da6e-4a2e-bed5-4ca166e7f268">&lt;div style="margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table sets forth total interest expense recognized related to the 2026 Convertible Notes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:77.631%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.282%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.306%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:21.163%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.553%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.741%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:20.598%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.557%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortization of debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Effective interest rate of the liability component&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ptct:ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="i73b5dc373fe54df282ef490ee32d7654_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmJhNzc0M2VmNzkwNTQxYjA5MjZlNmU2OGY3NjhkYzQzL3RhYmxlcmFuZ2U6YmE3NzQzZWY3OTA1NDFiMDkyNmU2ZTY4Zjc2OGRjNDNfMi0yLTEtMS0w_84de16b1-aa8c-464c-bf37-3a3ad1fe8993"
      unitRef="usd">1066000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="i99e6e03adee54a9ca0a6a21ec4cddd55_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmJhNzc0M2VmNzkwNTQxYjA5MjZlNmU2OGY3NjhkYzQzL3RhYmxlcmFuZ2U6YmE3NzQzZWY3OTA1NDFiMDkyNmU2ZTY4Zjc2OGRjNDNfMi02LTEtMS0zMTI5_e06433c8-d825-4452-b60e-9def0792840e"
      unitRef="usd">2142000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i73b5dc373fe54df282ef490ee32d7654_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmJhNzc0M2VmNzkwNTQxYjA5MjZlNmU2OGY3NjhkYzQzL3RhYmxlcmFuZ2U6YmE3NzQzZWY3OTA1NDFiMDkyNmU2ZTY4Zjc2OGRjNDNfMy0yLTEtMS0w_38a21e61-942c-4260-9d9c-c9a1efcca228"
      unitRef="usd">124000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i99e6e03adee54a9ca0a6a21ec4cddd55_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmJhNzc0M2VmNzkwNTQxYjA5MjZlNmU2OGY3NjhkYzQzL3RhYmxlcmFuZ2U6YmE3NzQzZWY3OTA1NDFiMDkyNmU2ZTY4Zjc2OGRjNDNfMy02LTEtMS0zMTI5_5c99c80a-209f-4ecc-8662-8f502a206492"
      unitRef="usd">248000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i73b5dc373fe54df282ef490ee32d7654_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmJhNzc0M2VmNzkwNTQxYjA5MjZlNmU2OGY3NjhkYzQzL3RhYmxlcmFuZ2U6YmE3NzQzZWY3OTA1NDFiMDkyNmU2ZTY4Zjc2OGRjNDNfNC0yLTEtMS0w_209cc0d9-5539-4e6d-b01f-e455c74d66db"
      unitRef="usd">3239000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i99e6e03adee54a9ca0a6a21ec4cddd55_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmJhNzc0M2VmNzkwNTQxYjA5MjZlNmU2OGY3NjhkYzQzL3RhYmxlcmFuZ2U6YmE3NzQzZWY3OTA1NDFiMDkyNmU2ZTY4Zjc2OGRjNDNfNC02LTEtMS0zMTI5_d40a0241-09f5-4706-a9f2-845485eee4de"
      unitRef="usd">6473000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestExpenseDebt
      contextRef="i73b5dc373fe54df282ef490ee32d7654_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmJhNzc0M2VmNzkwNTQxYjA5MjZlNmU2OGY3NjhkYzQzL3RhYmxlcmFuZ2U6YmE3NzQzZWY3OTA1NDFiMDkyNmU2ZTY4Zjc2OGRjNDNfNS0yLTEtMS0w_5c68956f-c403-467c-963a-20c6a1bc193e"
      unitRef="usd">4429000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i99e6e03adee54a9ca0a6a21ec4cddd55_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmJhNzc0M2VmNzkwNTQxYjA5MjZlNmU2OGY3NjhkYzQzL3RhYmxlcmFuZ2U6YmE3NzQzZWY3OTA1NDFiMDkyNmU2ZTY4Zjc2OGRjNDNfNS02LTEtMS02OTQ4_d3c65829-2fdd-4661-8258-c62b029d7ba0"
      unitRef="usd">8863000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i43e763aab42b473cb26af800270f6b3e_I20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmJhNzc0M2VmNzkwNTQxYjA5MjZlNmU2OGY3NjhkYzQzL3RhYmxlcmFuZ2U6YmE3NzQzZWY3OTA1NDFiMDkyNmU2ZTY4Zjc2OGRjNDNfNi0yLTEtMS0w_89d80422-85c5-4242-96fd-dc2a8b181739"
      unitRef="number">0.102</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i43e763aab42b473cb26af800270f6b3e_I20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmJhNzc0M2VmNzkwNTQxYjA5MjZlNmU2OGY3NjhkYzQzL3RhYmxlcmFuZ2U6YmE3NzQzZWY3OTA1NDFiMDkyNmU2ZTY4Zjc2OGRjNDNfNi02LTEtMS0w_5d06bd98-1a13-4243-83a6-a1d420e81f7f"
      unitRef="number">0.102</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i28655a9b21d647eb9144da8fa8cdd911_I20150831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTA0NTQ_e9cd6dba-7609-4a66-bf24-a4caa7f5da03"
      unitRef="usd">150000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i28655a9b21d647eb9144da8fa8cdd911_I20150831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTA0ODc_8cdca5b8-140f-410e-a410-a0116e1dce35"
      unitRef="number">0.0300</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i28655a9b21d647eb9144da8fa8cdd911_I20150831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTA1ODQ_3d0f5b56-e449-4de2-843a-6aa4975617af"
      unitRef="number">0.0300</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="idab0eeb8f1e24e3389eda446498f9b4c_D20150801-20150831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTA4NDk_64bfe4e2-a229-4f40-82a3-5fea56070963"
      unitRef="usd">145400000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i8dc375e5e9f24bf9b690d042d600041f_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTE1NjQ_986f3df1-03cf-4c5a-86fa-8339f77059c7"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="ifbd02289ccd34e7a886bf4e86089dadc_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTE2Mjg_5c4afc5a-83d6-4077-bd12-9bd505ef9e07"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i8dc375e5e9f24bf9b690d042d600041f_D20190901-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTE3NjE_1aa6b209-310e-4a06-82e4-85f2a91ad5fe"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <ptct:DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum
      contextRef="i08c7971cf8d6469fbda565dec2419938_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTIxMzU_cce6c2b1-5ca7-491d-8240-0d5478d791d2"
      unitRef="number">0.98</ptct:DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="idab0eeb8f1e24e3389eda446498f9b4c_D20150801-20150831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTMxNTY_ef22898c-afce-44fb-be8c-fe34ed7dee3c"
      unitRef="number">17.7487</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i28655a9b21d647eb9144da8fa8cdd911_I20150831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTMzMTk_355db875-251a-48dd-8df4-a7037306a82d"
      unitRef="usdPerShare">56.34</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="ifbd02289ccd34e7a886bf4e86089dadc_D20190901-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTM3NzI_6438c313-5547-4569-a720-dca4bdf52934"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="ifbd02289ccd34e7a886bf4e86089dadc_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTM4NTk_996c8182-c5b0-47b3-891b-18497efc57a8"
      unitRef="day">19</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="ifbd02289ccd34e7a886bf4e86089dadc_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTM5MjI_c107688e-f828-4dbb-a06c-8b806ca79700"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="ifbd02289ccd34e7a886bf4e86089dadc_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTQxMTI_abd63032-d306-4818-9497-91d77f0cb6a5"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentCumulativeSinkingFundPayments
      contextRef="i8781119cc5804767a8721ec1e62367b7_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTQyNTg_4f7e1aac-36df-4322-8734-3a7611a09641"
      unitRef="usd">0</us-gaap:DebtInstrumentCumulativeSinkingFundPayments>
    <ptct:ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault
      contextRef="i8dc375e5e9f24bf9b690d042d600041f_D20190901-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTQ3NTc_8eddb489-3342-4d90-8188-e2400bc59520"
      unitRef="number">1</ptct:ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault>
    <ptct:MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders
      contextRef="i8dc375e5e9f24bf9b690d042d600041f_D20190901-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTU5Njk_be5058a0-37e3-4983-aa97-80492518de93"
      unitRef="number">0.25</ptct:MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="ifbd02289ccd34e7a886bf4e86089dadc_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTYyNTI_894ee09c-d008-4717-9766-ce06ab3f5e11"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="ifbd02289ccd34e7a886bf4e86089dadc_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTY0OTU_f24020d2-49ef-4f72-aeb6-f7f1e6701fc0"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="idab0eeb8f1e24e3389eda446498f9b4c_D20150801-20150831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTc4NzU_70f42955-f583-44af-bba5-4ed44a60d2e2"
      unitRef="usd">57500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <ptct:NetDeferredTaxLiabilitiesConvertibleDebtInstruments
      contextRef="i28655a9b21d647eb9144da8fa8cdd911_I20150831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTg1MTM_15466ea5-cd48-4f84-b1b3-ed2a3f4b99af"
      unitRef="usd">22300000</ptct:NetDeferredTaxLiabilitiesConvertibleDebtInstruments>
    <us-gaap:ConvertibleDebtTableTextBlock
      contextRef="i0563616514554f76bb3cb942f7310b61_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTkwNDQ_67190607-a9d8-4a7f-a4fe-de386c00b262">&lt;div style="margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The 2022 Convertible Notes consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:61.343%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.595%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Liability&#160;component&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: Debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,104)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,329)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: Debt discount, net(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(22,166)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(26,686)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;126,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;121,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;(1)&#160;Included in the consolidated balance sheets within convertible senior notes (due 2022) and amortized to interest expense over the remaining life of the 2022 Convertible Notes using the effective interest rate method.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i08c7971cf8d6469fbda565dec2419938_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOjg4ZDk3MDhjM2QyMTQ2YzE4ZWVmYzc0MTBiYjQ1MzdiL3RhYmxlcmFuZ2U6ODhkOTcwOGMzZDIxNDZjMThlZWZjNzQxMGJiNDUzN2JfMS0yLTEtMS0w_19ade0d5-d9aa-4555-ae4c-bd5163fb15a3"
      unitRef="usd">150000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i5fc57b5184a54d248eb826766cbbb088_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOjg4ZDk3MDhjM2QyMTQ2YzE4ZWVmYzc0MTBiYjQ1MzdiL3RhYmxlcmFuZ2U6ODhkOTcwOGMzZDIxNDZjMThlZWZjNzQxMGJiNDUzN2JfMS00LTEtMS0w_3304b0f6-81aa-4bad-b216-27450464d76a"
      unitRef="usd">150000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="i08c7971cf8d6469fbda565dec2419938_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOjg4ZDk3MDhjM2QyMTQ2YzE4ZWVmYzc0MTBiYjQ1MzdiL3RhYmxlcmFuZ2U6ODhkOTcwOGMzZDIxNDZjMThlZWZjNzQxMGJiNDUzN2JfMi0yLTEtMS0w_0be855cf-6ac3-46f2-8c33-b18ac5101558"
      unitRef="usd">1104000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="i5fc57b5184a54d248eb826766cbbb088_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOjg4ZDk3MDhjM2QyMTQ2YzE4ZWVmYzc0MTBiYjQ1MzdiL3RhYmxlcmFuZ2U6ODhkOTcwOGMzZDIxNDZjMThlZWZjNzQxMGJiNDUzN2JfMi00LTEtMS0w_cd434f41-7b3c-4aa1-b10b-7c7179e99945"
      unitRef="usd">1329000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i08c7971cf8d6469fbda565dec2419938_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOjg4ZDk3MDhjM2QyMTQ2YzE4ZWVmYzc0MTBiYjQ1MzdiL3RhYmxlcmFuZ2U6ODhkOTcwOGMzZDIxNDZjMThlZWZjNzQxMGJiNDUzN2JfMy0yLTEtMS0w_556c5f69-3984-4fb9-a94d-db3fc19128bc"
      unitRef="usd">22166000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i5fc57b5184a54d248eb826766cbbb088_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOjg4ZDk3MDhjM2QyMTQ2YzE4ZWVmYzc0MTBiYjQ1MzdiL3RhYmxlcmFuZ2U6ODhkOTcwOGMzZDIxNDZjMThlZWZjNzQxMGJiNDUzN2JfMy00LTEtMS0w_972c2ffc-05a4-4947-8613-d254c65ddda7"
      unitRef="usd">26686000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebt
      contextRef="i08c7971cf8d6469fbda565dec2419938_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOjg4ZDk3MDhjM2QyMTQ2YzE4ZWVmYzc0MTBiYjQ1MzdiL3RhYmxlcmFuZ2U6ODhkOTcwOGMzZDIxNDZjMThlZWZjNzQxMGJiNDUzN2JfNC0yLTEtMS0w_4fddbb1a-9519-4729-8ae1-044ba05e34dd"
      unitRef="usd">126730000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i5fc57b5184a54d248eb826766cbbb088_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOjg4ZDk3MDhjM2QyMTQ2YzE4ZWVmYzc0MTBiYjQ1MzdiL3RhYmxlcmFuZ2U6ODhkOTcwOGMzZDIxNDZjMThlZWZjNzQxMGJiNDUzN2JfNC00LTEtMS0w_22e83d7d-4769-44b9-aec4-100de1683423"
      unitRef="usd">121985000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="ic9c66ca599c4439faa67414af9011439_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTg5Mjc_39ca2c1a-97d2-434e-b6ce-708900ae94c5">P2Y1M6D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <ptct:ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock
      contextRef="i0563616514554f76bb3cb942f7310b61_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTkwNTk_f2d59c63-1b01-43ad-8a60-0dc8d49d28ba">&lt;div style="margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table sets forth total interest expense recognized related to the 2022 Convertible Notes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.222%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:37.548%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.551%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.285%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.551%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.285%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.551%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.285%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.551%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.593%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortization of debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Effective interest rate of the liability component&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ptct:ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="i4e58b009dcb346afa5fe00025d1c8d43_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmE5ZTRjYzI0Yzk2YzRiY2NhYzM3N2I1MmUyNDQ1MjMxL3RhYmxlcmFuZ2U6YTllNGNjMjRjOTZjNGJjY2FjMzc3YjUyZTI0NDUyMzFfMi0yLTEtMS0w_6b25d2f2-f66b-44c1-aa5e-fcb10155f37a"
      unitRef="usd">1125000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="i2a6dca67e5ed44bcae174fc956c744bb_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmE5ZTRjYzI0Yzk2YzRiY2NhYzM3N2I1MmUyNDQ1MjMxL3RhYmxlcmFuZ2U6YTllNGNjMjRjOTZjNGJjY2FjMzc3YjUyZTI0NDUyMzFfMi00LTEtMS0w_ec919709-42d1-4e13-bb9e-58346da4e86b"
      unitRef="usd">1131000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="ic9c66ca599c4439faa67414af9011439_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmE5ZTRjYzI0Yzk2YzRiY2NhYzM3N2I1MmUyNDQ1MjMxL3RhYmxlcmFuZ2U6YTllNGNjMjRjOTZjNGJjY2FjMzc3YjUyZTI0NDUyMzFfMi02LTEtMS0xMjE5_153934c6-c5d8-45d4-8f56-8585b69d2548"
      unitRef="usd">2244000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="idb3d2f86e29542fd99ac08fe93500645_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmE5ZTRjYzI0Yzk2YzRiY2NhYzM3N2I1MmUyNDQ1MjMxL3RhYmxlcmFuZ2U6YTllNGNjMjRjOTZjNGJjY2FjMzc3YjUyZTI0NDUyMzFfMi04LTEtMS0xMjIz_708614db-6c01-4558-98f4-bbb7747ac709"
      unitRef="usd">2241000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i4e58b009dcb346afa5fe00025d1c8d43_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmE5ZTRjYzI0Yzk2YzRiY2NhYzM3N2I1MmUyNDQ1MjMxL3RhYmxlcmFuZ2U6YTllNGNjMjRjOTZjNGJjY2FjMzc3YjUyZTI0NDUyMzFfMy0yLTEtMS0w_05487c82-36ab-4910-a6bc-d20f4e741cad"
      unitRef="usd">114000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i2a6dca67e5ed44bcae174fc956c744bb_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmE5ZTRjYzI0Yzk2YzRiY2NhYzM3N2I1MmUyNDQ1MjMxL3RhYmxlcmFuZ2U6YTllNGNjMjRjOTZjNGJjY2FjMzc3YjUyZTI0NDUyMzFfMy00LTEtMS0w_c9925e63-4b5d-4259-9801-81cf965ee0b2"
      unitRef="usd">103000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="ic9c66ca599c4439faa67414af9011439_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmE5ZTRjYzI0Yzk2YzRiY2NhYzM3N2I1MmUyNDQ1MjMxL3RhYmxlcmFuZ2U6YTllNGNjMjRjOTZjNGJjY2FjMzc3YjUyZTI0NDUyMzFfMy02LTEtMS0xMjE5_76e884e6-587c-4c45-a476-43bcf9fa0808"
      unitRef="usd">225000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="idb3d2f86e29542fd99ac08fe93500645_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmE5ZTRjYzI0Yzk2YzRiY2NhYzM3N2I1MmUyNDQ1MjMxL3RhYmxlcmFuZ2U6YTllNGNjMjRjOTZjNGJjY2FjMzc3YjUyZTI0NDUyMzFfMy04LTEtMS0xMjIz_49c4af5f-3d0b-45dd-bced-65748569c5a5"
      unitRef="usd">202000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i4e58b009dcb346afa5fe00025d1c8d43_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmE5ZTRjYzI0Yzk2YzRiY2NhYzM3N2I1MmUyNDQ1MjMxL3RhYmxlcmFuZ2U6YTllNGNjMjRjOTZjNGJjY2FjMzc3YjUyZTI0NDUyMzFfNC0yLTEtMS0w_30f9778b-a9f3-4c34-a6ad-92afb3256bf5"
      unitRef="usd">2295000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i2a6dca67e5ed44bcae174fc956c744bb_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmE5ZTRjYzI0Yzk2YzRiY2NhYzM3N2I1MmUyNDQ1MjMxL3RhYmxlcmFuZ2U6YTllNGNjMjRjOTZjNGJjY2FjMzc3YjUyZTI0NDUyMzFfNC00LTEtMS0w_79db3967-8d31-4ad2-b5ce-fe9d54990d1a"
      unitRef="usd">2074000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="ic9c66ca599c4439faa67414af9011439_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmE5ZTRjYzI0Yzk2YzRiY2NhYzM3N2I1MmUyNDQ1MjMxL3RhYmxlcmFuZ2U6YTllNGNjMjRjOTZjNGJjY2FjMzc3YjUyZTI0NDUyMzFfNC02LTEtMS0xMjE5_df9cef6c-0775-42fa-84e3-0e45c8ce4f18"
      unitRef="usd">4520000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="idb3d2f86e29542fd99ac08fe93500645_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmE5ZTRjYzI0Yzk2YzRiY2NhYzM3N2I1MmUyNDQ1MjMxL3RhYmxlcmFuZ2U6YTllNGNjMjRjOTZjNGJjY2FjMzc3YjUyZTI0NDUyMzFfNC04LTEtMS0xMjIz_b02ff162-24ab-43e9-86a5-f8f5d8ceb1d2"
      unitRef="usd">4055000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestExpenseDebt
      contextRef="i4e58b009dcb346afa5fe00025d1c8d43_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmE5ZTRjYzI0Yzk2YzRiY2NhYzM3N2I1MmUyNDQ1MjMxL3RhYmxlcmFuZ2U6YTllNGNjMjRjOTZjNGJjY2FjMzc3YjUyZTI0NDUyMzFfNS0yLTEtMS0w_4872a75e-b770-4897-a438-b23693463175"
      unitRef="usd">3534000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i2a6dca67e5ed44bcae174fc956c744bb_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmE5ZTRjYzI0Yzk2YzRiY2NhYzM3N2I1MmUyNDQ1MjMxL3RhYmxlcmFuZ2U6YTllNGNjMjRjOTZjNGJjY2FjMzc3YjUyZTI0NDUyMzFfNS00LTEtMS0w_84be7bd1-f8a6-47dd-9356-3e14f2b39b87"
      unitRef="usd">3308000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="ic9c66ca599c4439faa67414af9011439_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmE5ZTRjYzI0Yzk2YzRiY2NhYzM3N2I1MmUyNDQ1MjMxL3RhYmxlcmFuZ2U6YTllNGNjMjRjOTZjNGJjY2FjMzc3YjUyZTI0NDUyMzFfNS02LTEtMS0xMjE5_eaa870a2-257d-44b9-b9d5-de8eb375a543"
      unitRef="usd">6989000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="idb3d2f86e29542fd99ac08fe93500645_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmE5ZTRjYzI0Yzk2YzRiY2NhYzM3N2I1MmUyNDQ1MjMxL3RhYmxlcmFuZ2U6YTllNGNjMjRjOTZjNGJjY2FjMzc3YjUyZTI0NDUyMzFfNS04LTEtMS0xMjIz_be668c14-b4e1-488e-bf46-b3912ed75f58"
      unitRef="usd">6498000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i08c7971cf8d6469fbda565dec2419938_I20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmE5ZTRjYzI0Yzk2YzRiY2NhYzM3N2I1MmUyNDQ1MjMxL3RhYmxlcmFuZ2U6YTllNGNjMjRjOTZjNGJjY2FjMzc3YjUyZTI0NDUyMzFfNi0yLTEtMS0w_3d8814c8-a2cf-4265-a794-96ed1043b1bc"
      unitRef="number">0.110</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ic1f05bd3af07411fbeaa9695faa9b8f5_I20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmE5ZTRjYzI0Yzk2YzRiY2NhYzM3N2I1MmUyNDQ1MjMxL3RhYmxlcmFuZ2U6YTllNGNjMjRjOTZjNGJjY2FjMzc3YjUyZTI0NDUyMzFfNi00LTEtMS0w_6eea50b3-5772-4dcc-9500-e86d8b509830"
      unitRef="number">0.110</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i08c7971cf8d6469fbda565dec2419938_I20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmE5ZTRjYzI0Yzk2YzRiY2NhYzM3N2I1MmUyNDQ1MjMxL3RhYmxlcmFuZ2U6YTllNGNjMjRjOTZjNGJjY2FjMzc3YjUyZTI0NDUyMzFfNi02LTEtMS0xMjE5_712ab88a-51cc-480e-936e-592e6de42d16"
      unitRef="number">0.110</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ic1f05bd3af07411fbeaa9695faa9b8f5_I20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RhYmxlOmE5ZTRjYzI0Yzk2YzRiY2NhYzM3N2I1MmUyNDQ1MjMxL3RhYmxlcmFuZ2U6YTllNGNjMjRjOTZjNGJjY2FjMzc3YjUyZTI0NDUyMzFfNi04LTEtMS0xMjIz_572682ad-d4d0-475b-9b25-624c1a18ad83"
      unitRef="number">0.110</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfNTk1NQ_f310a8f8-4132-454d-8590-847b8e94fb44">&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Commitments&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;and contingencies&lt;/span&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under various agreements, the Company will be required to pay royalties and milestone payments upon the successful development and commercialization of products. The Company has entered into funding agreements with The Wellcome Trust Limited ("Wellcome Trust") for the research and development of small molecule compounds in connection with the Company's oncology and antibacterial programs. As the Company has discontinued development under its antibacterial program, it no longer expects that milestone and royalty payments from the Company to Wellcome Trust will apply under that agreement, resulting in a change to the total amount of development and regulatory milestone payments the Company may become obligated to pay for this program.  Under the oncology program funding agreement, to the extent that the Company develops and commercializes program intellectual property on a for-profit basis itself or in collaboration with a partner (provided the Company retains overall control of worldwide commercialization), the Company may become obligated to pay to Wellcome Trust development and regulatory milestone payments and single-digit royalties on sales of any research program product. The Company&#x2019;s obligation to pay such royalties would continue on a country-by-country basis until the longer of the expiration of the last patent in the program intellectual property in such country covering the research program product and the expiration of market exclusivity of such product in such country. The Company&#x2019;s first such milestone payment of $0.8 million payable to Wellcome Trust occurred in the second quarter of 2016.  Additional milestone payments of up to an aggregate of $22.4 million may become payable by the Company to Wellcome Trust under this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has also entered into a collaboration agreement with the SMA Foundation. The Company may become obligated to pay the SMA Foundation single-digit royalties on worldwide net product sales of any collaboration product that is successfully developed and subsequently commercialized or, if the Company outlicenses rights to a collaboration product, a specified percentage of certain payments the Company receives from its licensee. The Company is not obligated to make such payments unless and until annual sales of a collaboration product exceed a designated threshold. The Company&#x2019;s obligation to make such payments would end upon the Company's payment to the SMA Foundation of a specified amount.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Pursuant to the asset purchase agreement ("Asset Purchase Agreement") between the Company and Marathon Pharmaceuticals, LLC (now known as Complete Pharma Holdings, LLC), or Marathon, Marathon is entitled to receive contingent payments from the Company based on annual net sales of Emflaza up to a specified aggregate maximum amount over the expected commercial life of the asset. In addition, Marathon has the opportunity to receive a single $50.0 million sales-based milestone.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Pursuant to the Merger Agreement with Agilis, Agilis equityholders were previously entitled to receive contingent consideration payments from the Company based on (i)&#160;the achievement of certain development milestones up to an aggregate maximum amount of $60.0&#160;million, (ii)&#160;the achievement of certain regulatory approval milestones together with a milestone payment following the receipt of a priority review voucher up to an aggregate maximum amount of $535.0&#160;million, (iii)&#160;the achievement of certain net sales milestones up to an aggregate maximum amount of $150.0&#160;million, and (iv)&#160;a percentage of annual net sales for&#160;Friedreich ataxia and Angelman syndrome during specified terms, ranging from 2%-6%. The Company was required to pay $40.0 million of the development milestone payments upon the passing of the second anniversary of the closing of the Merger, regardless of whether the applicable milestones have been achieved. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;Pursuant to the terms of the Rights Exchange Agreement, the Participating Rightholders have canceled and forfeited their rights under the Merger Agreement to receive (i) $174.0&#160;million, in the aggregate, of potential milestone payments based on the achievement of certain regulatory milestones and (ii) $37.6&#160;million, in the aggregate, of $40.0&#160;million in development milestone payments that would have been due upon the passing of the second anniversary of the closing of the Merger, regardless of whether the milestones are achieved.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;The Rights Exchange Agreement has no effect on the Merger Agreement other than to provide for the cancellation and forfeiture of the Participating Rightholders&#x2019; rights to receive $211.6&#160;million, in the aggregate, of the milestone payments described above. As a result, all other rights and obligations under the Merger Agreement remain in effect pursuant to their terms, including the Company&#x2019;s obligation to pay up to an aggregate maximum amount of $22.4&#160;million upon the achievement of certain development milestones (representing the remaining portion of potential development milestone payments for which rights were not canceled and forfeited pursuant to the Rights Exchange Agreement after deducting the $37.6&#160;million for which rights were canceled and forfeited pursuant to the Rights Exchange Agreement from the $40.0&#160;million in development milestone payments that are due upon the passing of the second anniversary of the closing of the Acquisition), up to an aggregate maximum amount of $361.0&#160;million upon the achievement of certain regulatory milestones (representing the remaining portion of potential regulatory milestone payments for which rights were not canceled and forfeited pursuant to the Rights Exchange Agreement), up to a maximum aggregate amount of $150.0&#160;million upon the achievement of certain net sales milestones and a percentage of annual net sales for Friedreich ataxia and Angelman syndrome during specified terms, ranging from 2% to 6%, pursuant to the terms of the Merger Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;Subject to the terms and conditions of the Asset Acquisition Agreement, BioElectron may become entitled to receive contingent milestone payments of up to $200.0 million (in cash or in shares of the Company&#x2019;s common stock, as determined by the Company) from the Company based on the achievement of certain regulatory and net sales milestones.  Subject to the terms and conditions of the Asset Acquisition Agreement, BioElectron may also become entitled to receive contingent payments based on a percentage of net sales of certain products.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;"&gt;Subject to the terms and conditions of the Censa Merger Agreement, Censa securityholders may become entitled to receive contingent payments from the Company based on (i) the achievement of certain development and regulatory milestones up to an aggregate maximum amount of $217.5&#160;million for PTC923's two most advanced programs and receipt of a priority review voucher from the FDA as set forth in the Censa Merger Agreement, (ii) $109&#160;million in development and regulatory milestones for each additional indication of PTC923, (iii) the achievement of certain net sales milestones up to an aggregate maximum amount of $160.0&#160;million, (iv) a percentage of annual net sales during specified terms, ranging from single to low double digits of the applicable net sales threshold amount, and (v) any sublicense fees paid to the Company in consideration of any sublicense of Censa&#x2019;s intellectual property to commercialize PTC923, on a country-by-country basis, which contingent payment shall equal to a mid-double digit percentage of any such sublicense fees. Pursuant to the Censa Merger Agreement, the Company has the option to pay the initial $30.0&#160;million development milestone, for the completion of enrollment of a Phase 3 clinical trial for PTC923 for PKU, if achieved, in cash or shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company also has a Collaboration and License Agreement with Akcea for the commercialization of Tegsedi and Waylivra, and products containing those compounds in countries in Latin America and the Caribbean (the "Akcea Collaboration and License Agreement").  Pursuant to the agreement, the Company paid Akcea an upfront licensing fee, which included an initial payment of $12.0 million. In 2019, a $6.0 million milestone was paid upon receipt of regulatory approval of Waylivra from the EMA and a $4.0 million milestone was paid upon regulatory approval of Tegsedi from ANVISA, the Brazilian health regulatory authority, upon receipt of regulatory approval for Waylivra from ANVISA. In addition, Akcea is eligible to receive an additional milestone payment of $4.0 million upon receipt of regulatory approval for Waylivra from ANVISA. Akcea is also entitled to receive royalty payments subject to certain terms set forth in the Akcea Collaboration and License Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has employment agreements with certain employees which require the funding of a specific level of payments, if certain events, such as a change in control or termination without cause, occur. Additionally, the Company has royalty payments associated with Translarna and Emflaza product net sales, payable quarterly or annually in accordance with the terms of the related agreements. &lt;/span&gt;&lt;/div&gt;From time to time in the ordinary course of its business, the Company is subject to claims, legal proceedings and disputes, including as a result of patients seeking to participate in the Company's clinical trials or otherwise gain access to its product candidates. The Company is not currently aware of any material legal proceedings against it.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ptct:DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing
      contextRef="i1f68521ddf23433db2233ba19286dfae_I20160930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMTU5MQ_a863862d-565d-4a1d-8774-0c8ad362f5e1"
      unitRef="usd">800000</ptct:DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing>
    <ptct:DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing
      contextRef="ifdf769cde4f8456998cb633ecc67a74a_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMTcxNg_388ec3df-e882-4b26-8906-a4803b9feb4c"
      unitRef="usd">22400000</ptct:DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing>
    <ptct:DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing
      contextRef="id48de54c835343b9b2c5c1d3ce609ab1_I20170420"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMjgxNg_575e8867-09d4-4abb-9e97-0296338f9a0e"
      unitRef="usd">50000000.0</ptct:DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing>
    <ptct:DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing
      contextRef="ia20c4a3be1bf491aaf06ea4818f97179_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMTA5OTUxMTYzMzc1Ng_e7f14cc3-516b-47aa-9b44-9d6caeb3d35e"
      unitRef="usd">60000000.0</ptct:DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing>
    <ptct:ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount
      contextRef="i7e34d9d90204473c8ea049d991956012_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMTA5OTUxMTYzMzc5Mg_7aeac0a3-97ef-4bbd-9ef6-ebd0e4098592"
      unitRef="usd">535000000.0</ptct:ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount>
    <ptct:ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone
      contextRef="ia20c4a3be1bf491aaf06ea4818f97179_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMTA5OTUxMTYzMzgyOQ_f74f3069-65fb-4661-b2c8-6e84d15d0ad4"
      unitRef="usd">150000000.0</ptct:ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone>
    <ptct:ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage
      contextRef="i2a92bf7bb7524f61a93f2c8959d0be71_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMTA5OTUxMTYzMzg2Mw_5ee326d4-7640-4abb-986a-1fffe9071dfa"
      unitRef="number">0.02</ptct:ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage>
    <ptct:ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage
      contextRef="ia20c4a3be1bf491aaf06ea4818f97179_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMTA5OTUxMTYzMzg2Nw_afda207b-be2b-4d46-9bf1-48088da03c35"
      unitRef="number">0.06</ptct:ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage>
    <ptct:DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing
      contextRef="if54601c17d0343ec8d9cd0af73df9a5b_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMzU0MQ_3010c54d-b2f6-4970-b21e-8092660f1957"
      unitRef="usd">40000000.0</ptct:DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing>
    <ptct:ContingentLiabilityCancellationAndForfeitureMilestonePotentialAchievementsPriorityReviewVoucherAmount
      contextRef="i1b11444730184724a2297b26b10e055d_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMTkyNDE0NTM1MTIxNjg_f64a271d-4118-430f-ae2f-d894d2aec365"
      unitRef="usd">174000000.0</ptct:ContingentLiabilityCancellationAndForfeitureMilestonePotentialAchievementsPriorityReviewVoucherAmount>
    <ptct:DevelopmentMilestonePaymentObligationsCancellationAndForfeiture
      contextRef="i1b11444730184724a2297b26b10e055d_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMTkyNDE0NTM1MTIxODQ_4b942f20-6fd3-483c-820e-3f720fd06761"
      unitRef="usd">37600000</ptct:DevelopmentMilestonePaymentObligationsCancellationAndForfeiture>
    <ptct:DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing
      contextRef="if54601c17d0343ec8d9cd0af73df9a5b_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMTkyNDE0NTM1MTIxOTk_d4ed802c-383b-4815-8add-a6ee614a3afd"
      unitRef="usd">40000000.0</ptct:DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing>
    <ptct:ContingentLiabilityCancellationAndForfeiture
      contextRef="i38631b4cb53445c299e2d62fbae00216_D20200629-20200629"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMTkyNDE0NTM1MTIwODI_298e3f4f-5ad7-47e2-b854-d5eddd9c4bc2"
      unitRef="usd">211600000</ptct:ContingentLiabilityCancellationAndForfeiture>
    <ptct:DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture
      contextRef="i5ca2052e537349099f8500140b79c830_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMTkyNDE0NTM1MTIwOTg_1a3414bb-6313-477a-a005-5ea6b38ad88a"
      unitRef="usd">22400000</ptct:DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture>
    <ptct:DevelopmentMilestonePaymentObligationsCancellationAndForfeiture
      contextRef="i1b11444730184724a2297b26b10e055d_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMTkyNDE0NTM1MTIxMTM_53364a5a-5a58-4580-940f-ffb2f8e2ad44"
      unitRef="usd">37600000</ptct:DevelopmentMilestonePaymentObligationsCancellationAndForfeiture>
    <ptct:DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing
      contextRef="if54601c17d0343ec8d9cd0af73df9a5b_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMTkyNDE0NTM1MTIyNTk_852c6770-a374-4fd0-94b4-ca54d3833eec"
      unitRef="usd">40000000.0</ptct:DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing>
    <ptct:ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture
      contextRef="i04fa4a18d65a48a9a4f7a021a18243d8_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMTkyNDE0NTM1MTIxMjg_0b27f2ec-ed1d-4818-ae7d-97714523d115"
      unitRef="usd">361000000.0</ptct:ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture>
    <ptct:ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone
      contextRef="ia20c4a3be1bf491aaf06ea4818f97179_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMTkyNDE0NTM1MTIxNDQ_d3e62c6b-e856-49f1-b852-41c573b3a10a"
      unitRef="usd">150000000.0</ptct:ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone>
    <ptct:ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage
      contextRef="i2a92bf7bb7524f61a93f2c8959d0be71_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMTkyNDE0NTM1MTIxNjA_e588ed32-38e1-4c55-8325-39a2f4c88882"
      unitRef="number">0.02</ptct:ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage>
    <ptct:ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage
      contextRef="ia20c4a3be1bf491aaf06ea4818f97179_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMTkyNDE0NTM1MTIxNjQ_f0c081c1-2f64-4bf8-b7cd-5d42aa9cff2e"
      unitRef="number">0.06</ptct:ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage>
    <ptct:DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing
      contextRef="i4fd11bc6a99940fd88c85b0f84932bf6_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMzg3OA_5945d385-2473-4573-abff-42b427415039"
      unitRef="usd">200000000.0</ptct:DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing>
    <ptct:AssetAcquisitionMilestoneAmount
      contextRef="id1c12a4aacaf45c6b83d421f91bcc1a3_I20200529"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMTkyNDE0NTM1MTIyMTQ_ab622ee7-bd46-43f9-8be2-e11cee3e2a1d"
      unitRef="usd">217500000</ptct:AssetAcquisitionMilestoneAmount>
    <ptct:AssetAcquisitionDevelopmentAndRegulatoryMilestones
      contextRef="i28fa54ad024443b18973875cc89f36e3_I20200529"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMTkyNDE0NTM1MTIyMzA_69e3f7b1-7bbc-4742-97eb-0007ec334c2c"
      unitRef="usd">109000000</ptct:AssetAcquisitionDevelopmentAndRegulatoryMilestones>
    <ptct:AssetAcquisitionNetSalesMilestone
      contextRef="i28fa54ad024443b18973875cc89f36e3_I20200529"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMTkyNDE0NTM1MTIyNzQ_a83b54e5-b58a-498f-895e-b59882b26564"
      unitRef="usd">160000000.0</ptct:AssetAcquisitionNetSalesMilestone>
    <ptct:AssetAcquisitionInitialMilestone
      contextRef="i28fa54ad024443b18973875cc89f36e3_I20200529"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfMTkyNDE0NTM1MTIyNDQ_f2570a01-f7e1-47ba-83a0-4fb5d46b593b"
      unitRef="usd">30000000.0</ptct:AssetAcquisitionInitialMilestone>
    <ptct:UpfrontLicensingFee
      contextRef="i652c4548495c438db5c41a0492a229a2_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfNDY1NA_03805483-76b4-4e04-8fef-043d79606ca7"
      unitRef="usd">12000000.0</ptct:UpfrontLicensingFee>
    <ptct:MilestonePotentialAchievementsRegulatoryApproval
      contextRef="i0753aa5ed002421a95716b8d6332e418_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfNDY2OQ_c64a1f1e-40b9-4b89-9483-9e8fb4677bf9"
      unitRef="usd">6000000.0</ptct:MilestonePotentialAchievementsRegulatoryApproval>
    <ptct:MilestonePotentialAchievementsRegulatoryApproval
      contextRef="ia033e797f8104feca5e0e2c9aef70ffb_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfNDc1OA_d97e10b4-f4de-4598-acbc-6b53ce5adbbf"
      unitRef="usd">4000000.0</ptct:MilestonePotentialAchievementsRegulatoryApproval>
    <ptct:MilestonePotentialAchievementsRegulatoryApproval
      contextRef="ia033e797f8104feca5e0e2c9aef70ffb_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84Mi9mcmFnOjQ2NmJiYWE1OTc4OTQ2NjA4MjU0NjRiYTE3OWUyNTAwL3RleHRyZWdpb246NDY2YmJhYTU5Nzg5NDY2MDgyNTQ2NGJhMTc5ZTI1MDBfNTAxMQ_d97e10b4-f4de-4598-acbc-6b53ce5adbbf"
      unitRef="usd">4000000.0</ptct:MilestonePotentialAchievementsRegulatoryApproval>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMTkyNDE0NTM0OTQ5NTk_bfd48147-495f-43f7-bada-efcbbf0acf46">Revenue recognition&lt;div style="margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Net product sales&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company views its operations and manages its business in one operating segment.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the three months ended June 30, 2020 and 2019, net product sales in the United States were $36.2 million and $27.6 million, respectively, consisting solely of Emflaza, and net product sales not in the United States were $39.0 million and $57.8 million, respectively, consisting of Translarna and Tegsedi. For the three months ended June 30, 2020 and 2019, the Company had a total of two and two distributors, respectively, that each accounted for over 10% of the Company's net product sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the six months ended June 30, 2020 and 2019, net product sales in the United States were $63.6 million and $45.4 million, respectively, consisting solely of Emflaza, and net product sales not in the United States were $79.8 million and $93.0 million, respectively, consisting of Translarna and Tegsedi. For the six months ended June 30, 2020 and 2019, the Company had a total of two and two distributors, respectively, that each accounted for over 10% of the Company's net product sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s contract liabilities balances as of June&#160;30, 2020 and as of December 31, 2019 were $7.7 million and $11.7 million, respectively. The Company did not have any contract assets as of June&#160;30, 2020 and as of December 31, 2019. During the three and six month periods ended June&#160;30, 2020, the Company recognized $2.0 million and $4.0 million of revenue, respectively, related to the amounts included in the contract liability balance at the beginning of the period. For the three and six month periods ended June&#160;30, 2019, the Company did not recognize any revenues relating to the contract liability balance at the beginning of the period. The Company has not made significant changes to the judgments made in applying ASC Topic 606 for the three and six month periods ending June&#160;30, 2020 and 2019.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Remaining performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Remaining performance obligations&#160;represent the transaction price for goods the Company has yet to provide. As of June&#160;30, 2020 and December 31, 2019, the aggregate amount of the transaction price allocated to&#160;the remaining performance obligations&#160;relating to Translarna net product revenue was $7.7 million and $11.7 million, respectively.  The Company expects to recognize revenue within the next one year, as the specific timing for satisfying the performance obligations is contingent upon a number of factors, including customers&#x2019; needs and schedules.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Collaboration revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In November 2011, the Company and the Spinal Muscular Atrophy Foundation (SMA Foundation) entered into a licensing and collaboration agreement with F. Hoffman-La Roche&#160;Ltd and Hoffman- La Roche&#160;Inc. (collectively, Roche) for a spinal muscular atrophy program. Under the terms of the agreement, Roche acquired an exclusive worldwide license to the Company&#x2019;s spinal muscular atrophy program.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company is eligible to receive additional payments from Roche if specified events are achieved with respect to each licensed product, including up to $135.0 million in research and development event milestones, up to $325.0 million in sales milestones upon achievement of specified sales events, and up to double digit royalties on worldwide annual net sales of a commercial product.  As of June&#160;30, 2020, the remaining potential research and development event milestones that can be received is $72.5 million. The remaining potential sales milestones as of June&#160;30, 2020 is $325.0 million upon achievement of certain sales events. In addition, the Company is eligible to receive up to double digit royalties on worldwide annual net sales of a commercial product.&lt;/span&gt;&lt;/div&gt;For the three months ended June&#160;30, 2020, the Company did not recognize revenue related to the licensing and collaboration agreement with Roche. For the three months ended June 30, 2019, the Company recognized $0.1 million of revenue related to the licensing and collaboration agreement with Roche. For the six months ended June&#160;30, 2020 and 2019, the Company recognized revenue related to the licensing and collaboration agreement with Roche of $0.1 million and $0.1 million, respectively.</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMTA4_a1a81c25-11f1-4449-a978-c7cde9ca9f0d"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <ptct:NetProductSales
      contextRef="i9fcd6ae0b0b244eb992a22b9f010a8a9_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMTk2_af08c740-5c75-4849-b710-027bbf9ae6aa"
      unitRef="usd">36200000</ptct:NetProductSales>
    <ptct:NetProductSales
      contextRef="i0cac55e0c942455e8be47df4a5540bf5_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMjAz_95510f06-07a4-4c13-a7c2-0f567fc3ba17"
      unitRef="usd">27600000</ptct:NetProductSales>
    <ptct:NetProductSales
      contextRef="ib5e09658503d4a019b7c66616efd1b4d_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMzAz_472e88fb-4d6e-4d7b-b5bf-d1b32d6d0959"
      unitRef="usd">39000000.0</ptct:NetProductSales>
    <ptct:NetProductSales
      contextRef="i70f85cc7508547529a1ddd69bf58968d_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMzEx_866acd3e-e209-4752-b956-71dcafbaf816"
      unitRef="usd">57800000</ptct:NetProductSales>
    <ptct:Numberofdistributors
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfNDM5ODA0NjUyMDE3Ng_81741bec-2a94-49ac-b009-d9f778295217"
      unitRef="number_distributor">2</ptct:Numberofdistributors>
    <ptct:Numberofdistributors
      contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfNDM5ODA0NjUyMDE4NA_32f9c631-bd5c-41b1-b19a-ed9ee7450b52"
      unitRef="number_distributor">2</ptct:Numberofdistributors>
    <ptct:Percentageofnetproductsales
      contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMTA0NDUzNjA0NzA4MDA_2f16e88c-9b37-4e24-ac7b-bc76068b8c31"
      unitRef="number">0.10</ptct:Percentageofnetproductsales>
    <ptct:Percentageofnetproductsales
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMTA0NDUzNjA0NzA4MDA_7f9bd06d-85a9-45e3-a653-5cb9aa4fe20d"
      unitRef="number">0.10</ptct:Percentageofnetproductsales>
    <ptct:NetProductSales
      contextRef="i245f190c344b472682efecbcf65a617f_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMTA0NDUzNjA0Njc3MDk_9effde0e-f268-4720-8a85-eb6c2c0b3be9"
      unitRef="usd">63600000</ptct:NetProductSales>
    <ptct:NetProductSales
      contextRef="i084808ce47024c3e9355cdfb5214b4ee_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMTA0NDUzNjA0Njc3MTY_dfd4e89f-6713-4367-8eb4-9874f72feeb5"
      unitRef="usd">45400000</ptct:NetProductSales>
    <ptct:NetProductSales
      contextRef="i8b2299918005400d83e8169cdceaa098_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMTA0NDUzNjA0Njc4MjA_bbf8eb57-17c9-4b0a-b53e-0d65aa69baa0"
      unitRef="usd">79800000</ptct:NetProductSales>
    <ptct:NetProductSales
      contextRef="if04847b5828f40ffb96ff09abbfbe7f0_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMTA0NDUzNjA0Njc4Mjc_1dd9044a-026b-4879-b477-be23aa250530"
      unitRef="usd">93000000.0</ptct:NetProductSales>
    <ptct:Numberofdistributors
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfNDM5ODA0NjUyMDIwMw_d0cf6d5f-ba6b-4707-8bfc-199ce8aacbfd"
      unitRef="number_distributor">2</ptct:Numberofdistributors>
    <ptct:Numberofdistributors
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfNDM5ODA0NjUyMDIwNg_733256ba-bf74-4ab0-bae6-9bdbccd18d7e"
      unitRef="number_distributor">2</ptct:Numberofdistributors>
    <ptct:Percentageofnetproductsales
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMTA0NDUzNjA0NzI5ODk_143253c6-ab44-4668-ba5a-92d86fec6291"
      unitRef="number">0.10</ptct:Percentageofnetproductsales>
    <ptct:Percentageofnetproductsales
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMTA0NDUzNjA0NzI5ODk_ced704e5-f65d-49f5-9072-abbdd9957254"
      unitRef="number">0.10</ptct:Percentageofnetproductsales>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ifed0db43ebe049f185e04d30bd4e1b71_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfNjcw_d5c384a8-ed79-4ca1-b856-241d60fa7eb4"
      unitRef="usd">7700000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ia96d9cae808a4c3784211e0141d85ae1_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfNjc3_4963a7af-0a1e-471c-a0c6-d8043680b0d5"
      unitRef="usd">11700000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfODE3_01890b70-7daf-4e8c-b9b7-0f719b26ecec"
      unitRef="usd">2000000.0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMTA0NDUzNjA0Njg2NzY_457c7eaf-7707-42d8-b1f1-293277425d4c"
      unitRef="usd">4000000.0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ifed0db43ebe049f185e04d30bd4e1b71_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMTA0NDUzNjA0Njg5MTM_afc4a521-b74c-4b56-9fc1-d5348fb119c3"
      unitRef="usd">7700000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ia96d9cae808a4c3784211e0141d85ae1_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMTA0NDUzNjA0Njg5MTY_45fa3fa1-2f77-4bad-817c-b74afbd85710"
      unitRef="usd">11700000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="ifed0db43ebe049f185e04d30bd4e1b71_I20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfNDM5ODA0NjUyMDE2MA_0e5cee40-52fa-43b1-a5a9-6fd3c79a27b8">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="ia96d9cae808a4c3784211e0141d85ae1_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfNDM5ODA0NjUyMDE2MA_e232d02b-ec5f-4e73-a628-fc77b9155464">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <ptct:RevenueRecognitionMilestonePotentialAchievements
      contextRef="id60b94195bb147c181fa7ec372ed8691_D20111101-20111130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMjI5OQ_b5d2797c-22d9-49a6-be97-f5c192d9a979"
      unitRef="usd">135000000.0</ptct:RevenueRecognitionMilestonePotentialAchievements>
    <ptct:RevenueRecognitionMilestonePotentialAchievements
      contextRef="i8b34ee3e697448668a9c788ce80598fb_D20111101-20111130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMjM1NA_b3e7211b-966e-4134-8c0f-1646572d0124"
      unitRef="usd">325000000.0</ptct:RevenueRecognitionMilestonePotentialAchievements>
    <ptct:RevenueRecognitionMilestonePotentialAchievements
      contextRef="ib692f789ea234d29951422720218faa2_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMjYxMA_74f531b0-c3c7-4cc9-8af0-f22f6b4aaf6a"
      unitRef="usd">72500000</ptct:RevenueRecognitionMilestonePotentialAchievements>
    <ptct:RevenueRecognitionMilestonePotentialAchievements
      contextRef="i2835b8eed94641e2ab9c3c4491078285_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMjY2Nw_bef54e58-5f7c-4dbd-b5a3-bd559ec7b459"
      unitRef="usd">325000000.0</ptct:RevenueRecognitionMilestonePotentialAchievements>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic5b76a0a42be443893da3eb686237ab7_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMTkyNDE0NTM0OTQ5NjQ_48a7f7dc-c9b4-4680-930c-fb68f00acb91"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic5b76a0a42be443893da3eb686237ab7_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMTkyNDE0NTM0OTQ5NjQ_5d452f7d-0a1f-4378-8821-620e061d0fe1"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i298b567a840a479b841a1c7cae6b2b42_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMTA0NDUzNjA0NzIwNzc_f2be9aac-0492-41f7-a68f-cf99926df88d"
      unitRef="usd">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i21cc52aa842546b39066bbc6d2f4ec24_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMTA0NDUzNjA0NzIzMDU_3867a72e-65c6-43fc-9f29-7e865a50a95f"
      unitRef="usd">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id33464a3934340609397e4ae7f1b281c_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF84NS9mcmFnOmExYzNhNDdlN2Q1ODQ2ZjI5NTQyMmVhMzI3ZDZkMWFlL3RleHRyZWdpb246YTFjM2E0N2U3ZDU4NDZmMjk1NDIyZWEzMjdkNmQxYWVfMTA0NDUzNjA0NzIzMTI_21bef64b-11a6-444a-88d7-a2845398d043"
      unitRef="usd">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85MS9mcmFnOjI4ODkzNzRmNzNiNTQ5OTc5MGI2YWVlNmI5MDc3YTJjL3RleHRyZWdpb246Mjg4OTM3NGY3M2I1NDk5NzkwYjZhZWU2YjkwNzdhMmNfNDY3MA_ace62aa6-9a74-4438-85da-3e02c8da27cc">Intangible assets and goodwill&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Definite-lived intangibles&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On April 20, 2017, the Company completed its previously announced acquisition of all rights to Emflaza pursuant to the Asset Purchase Agreement, dated March 15, 2017, and amended on April 20, 2017, by and between the Company and Marathon. The assets acquired by the Company in the transaction include intellectual property rights related to Emflaza, inventories of Emflaza, and certain contractual rights related to Emflaza. In accordance with ASU 2017-01, the Company determined that substantially all of the fair value is concentrated in the Emflaza rights intangible asset and as such accounted for the transaction as an asset acquisition under ASC 805-50 and recorded an intangible asset of $148.4 million, which is being amortized to cost of product sales over its expected useful life of approximately seven years on a straight line basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Marathon is entitled to receive contingent payments from the Company based on annual net sales of Emflaza beginning in 2018, up to a specified aggregate maximum amount over the expected commercial life of the asset. In accordance with the guidance for an asset acquisition, the Company records the milestone payment when it becomes payable to Marathon and increases the cost basis for the Emflaza rights intangible asset. As of June&#160;30, 2020 and 2019, milestone payments of $12.2 million and $8.3 million, respectively, were recorded and are included on the balance sheet within accounts payable and accrued expenses. These payments are being amortized over the remaining useful life of the Emflaza rights asset on a straight line basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Pursuant to the Akcea Collaboration and License Agreement, in May 2019 the Company made a $6.0 million milestone payment to Akcea upon regulatory approval of Waylivra from the EMA. The payment was recorded as an intangible asset and is being amortized to cost of product sales over its expected useful life of approximately ten years on a straight line basis. Additionally, in December 2019, the Company made a $4.0 million milestone payment to Akcea upon regulatory approval of Tegsedi from ANVISA. The payment was recorded as an intangible asset and is being amortized to cost of product sales over its expected useful life of approximately ten years on a straight line basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Akcea is also entitled to receive royalty payments subject to certain terms set forth in the Akcea Collaboration and License Agreement related to sales of Waylivra. In accordance with the guidance for an asset acquisition, the Company will record royalty payments when they become payable to Akcea and increase the cost basis for the Waylivra intangible asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For the three months ended June 30, 2020 and 2019, the Company recognized amortization expense of $8.7 million and $6.6 million, respectively, related to the Emflaza rights, Waylivra, and Tegsedi intangible assets. For the six months ended June 30, 2020 and 2019, the Company recognized amortization expense of $16.7 million and $12.7 million, respectively. The estimated future amortization of the Emflaza rights, Waylivra, and Tegsedi intangible assets is expected to be as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:77.675%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.589%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;132,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The weighted average remaining amortization period of the definite-lived intangibles as of June&#160;30, 2020 is 4.0 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Indefinite-lived intangibles&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In connection with the acquisition of the Company&#x2019;s gene therapy platform from Agilis, the Company acquired rights to PTC-AADC, for the treatment of AADC deficiency. AADC deficiency is a rare CNS disorder arising from reductions in the enzyme AADC that result from mutations in the dopa decarboxylase gene. The gene therapy platform also includes an asset targeting Friedreich ataxia, a rare and life-shortening neurodegenerative disease caused by a single defect in the FXN gene which causes reduced production of the frataxin protein. Additionally, the gene therapy platform includes two other programs targeting CNS disorders, including Angelman syndrome, a rare, genetic, neurological disorder characterized by severe developmental delays.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In accordance with the acquisition method of accounting, the Company allocated the acquisition cost for the Merger to the underlying assets acquired and liabilities assumed, based upon the estimated fair values of those assets and liabilities at the date of acquisition.  The Company classified the fair value of the acquired IPR&amp;amp;D as indefinite lived intangible assets until the successful completion or abandonment of the associated research and development efforts.&#160;The value allocated to the indefinite lived intangible assets was $576.5 million. There have been no changes to the balance of the indefinite-lived intangibles since the Merger.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As a result of the Merger on August 23, 2018, the Company recorded $82.3 million of goodwill. There were no changes to the recorded value of goodwill for the three and six month periods ended June&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="ib46a34ef31754b4badaaae6fccf85a47_I20170420"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85MS9mcmFnOjI4ODkzNzRmNzNiNTQ5OTc5MGI2YWVlNmI5MDc3YTJjL3RleHRyZWdpb246Mjg4OTM3NGY3M2I1NDk5NzkwYjZhZWU2YjkwNzdhMmNfNzYy_0614d237-7cfc-4969-9fc3-48a789a7fbad"
      unitRef="usd">148400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i667dbebd49c148f3993ce8cc26b0f8f3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85MS9mcmFnOjI4ODkzNzRmNzNiNTQ5OTc5MGI2YWVlNmI5MDc3YTJjL3RleHRyZWdpb246Mjg4OTM3NGY3M2I1NDk5NzkwYjZhZWU2YjkwNzdhMmNfODYz_cfeef9fd-460b-4bea-82a3-e7161685298e">P7Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <ptct:MilestonePotentialAchievementsRegulatoryApproval
      contextRef="i6d48ddbb90814f6daa9feea1cb72ad27_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85MS9mcmFnOjI4ODkzNzRmNzNiNTQ5OTc5MGI2YWVlNmI5MDc3YTJjL3RleHRyZWdpb246Mjg4OTM3NGY3M2I1NDk5NzkwYjZhZWU2YjkwNzdhMmNfMTM3Nw_d3cb415a-85c7-42ee-a540-2922cba8792a"
      unitRef="usd">12200000</ptct:MilestonePotentialAchievementsRegulatoryApproval>
    <ptct:MilestonePotentialAchievementsRegulatoryApproval
      contextRef="i07ceae4bafba47cea561662c5f6b04a2_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85MS9mcmFnOjI4ODkzNzRmNzNiNTQ5OTc5MGI2YWVlNmI5MDc3YTJjL3RleHRyZWdpb246Mjg4OTM3NGY3M2I1NDk5NzkwYjZhZWU2YjkwNzdhMmNfMTA0NDUzNjA0Njg4MTU_e9e8abbf-7abb-45a6-a5fd-39a14539f2be"
      unitRef="usd">8300000</ptct:MilestonePotentialAchievementsRegulatoryApproval>
    <ptct:MilestonePotentialAchievementsRegulatoryApproval
      contextRef="i0753aa5ed002421a95716b8d6332e418_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85MS9mcmFnOjI4ODkzNzRmNzNiNTQ5OTc5MGI2YWVlNmI5MDc3YTJjL3RleHRyZWdpb246Mjg4OTM3NGY3M2I1NDk5NzkwYjZhZWU2YjkwNzdhMmNfMTczMw_c64a1f1e-40b9-4b89-9483-9e8fb4677bf9"
      unitRef="usd">6000000.0</ptct:MilestonePotentialAchievementsRegulatoryApproval>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i4ef2c3542e8941dea35d5efd0bdc7a5c_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85MS9mcmFnOjI4ODkzNzRmNzNiNTQ5OTc5MGI2YWVlNmI5MDc3YTJjL3RleHRyZWdpb246Mjg4OTM3NGY3M2I1NDk5NzkwYjZhZWU2YjkwNzdhMmNfMTk1Nw_6f66a841-b072-4fa5-83c3-a4cee59f5aad">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <ptct:MilestonePotentialAchievementsRegulatoryApproval
      contextRef="i61a6fc1556ef4b3fa72296db809eb593_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85MS9mcmFnOjI4ODkzNzRmNzNiNTQ5OTc5MGI2YWVlNmI5MDc3YTJjL3RleHRyZWdpb246Mjg4OTM3NGY3M2I1NDk5NzkwYjZhZWU2YjkwNzdhMmNfMjAzNw_a07a1dea-23dd-4261-b327-c843d6fe30de"
      unitRef="usd">4000000.0</ptct:MilestonePotentialAchievementsRegulatoryApproval>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i4ef2c3542e8941dea35d5efd0bdc7a5c_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85MS9mcmFnOjI4ODkzNzRmNzNiNTQ5OTc5MGI2YWVlNmI5MDc3YTJjL3RleHRyZWdpb246Mjg4OTM3NGY3M2I1NDk5NzkwYjZhZWU2YjkwNzdhMmNfMjI1OQ_854b5d69-a5f7-4361-9fa9-328355965214">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85MS9mcmFnOjI4ODkzNzRmNzNiNTQ5OTc5MGI2YWVlNmI5MDc3YTJjL3RleHRyZWdpb246Mjg4OTM3NGY3M2I1NDk5NzkwYjZhZWU2YjkwNzdhMmNfMjc0Mg_f5e994ad-b9ca-4e29-bf74-c5f9a2ab57da"
      unitRef="usd">8700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85MS9mcmFnOjI4ODkzNzRmNzNiNTQ5OTc5MGI2YWVlNmI5MDc3YTJjL3RleHRyZWdpb246Mjg4OTM3NGY3M2I1NDk5NzkwYjZhZWU2YjkwNzdhMmNfMjc1MA_5865cf7a-7a38-44cc-8ac1-0b6585ab3034"
      unitRef="usd">6600000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85MS9mcmFnOjI4ODkzNzRmNzNiNTQ5OTc5MGI2YWVlNmI5MDc3YTJjL3RleHRyZWdpb246Mjg4OTM3NGY3M2I1NDk5NzkwYjZhZWU2YjkwNzdhMmNfMTA0NDUzNjA0NjkxMzI_b916467c-84d9-4e2b-90d6-76f90212a436"
      unitRef="usd">16700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ie928b90e7ab4477aa99479a0b7c4ec52_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85MS9mcmFnOjI4ODkzNzRmNzNiNTQ5OTc5MGI2YWVlNmI5MDc3YTJjL3RleHRyZWdpb246Mjg4OTM3NGY3M2I1NDk5NzkwYjZhZWU2YjkwNzdhMmNfMTA0NDUzNjA0NjkxMzk_ab104a4c-b6f5-4e37-9dea-0d6b60c1f921"
      unitRef="usd">12700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85MS9mcmFnOjI4ODkzNzRmNzNiNTQ5OTc5MGI2YWVlNmI5MDc3YTJjL3RleHRyZWdpb246Mjg4OTM3NGY3M2I1NDk5NzkwYjZhZWU2YjkwNzdhMmNfNDY2Ng_8db7dd6a-4d41-416e-9ab6-08c438000614">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:77.675%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.589%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;132,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85MS9mcmFnOjI4ODkzNzRmNzNiNTQ5OTc5MGI2YWVlNmI5MDc3YTJjL3RhYmxlOjkwZTVmNDg4OTJiZjRjNGE4ZjVkYTM5OTJiYjIyMWNiL3RhYmxlcmFuZ2U6OTBlNWY0ODg5MmJmNGM0YThmNWRhMzk5MmJiMjIxY2JfMS0yLTEtMS0w_3cb3b30f-824a-4ee4-8363-f8c2efd1fbe1"
      unitRef="usd">17460000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85MS9mcmFnOjI4ODkzNzRmNzNiNTQ5OTc5MGI2YWVlNmI5MDc3YTJjL3RhYmxlOjkwZTVmNDg4OTJiZjRjNGE4ZjVkYTM5OTJiYjIyMWNiL3RhYmxlcmFuZ2U6OTBlNWY0ODg5MmJmNGM0YThmNWRhMzk5MmJiMjIxY2JfMi0yLTEtMS0w_73ac0c62-86fe-4298-bd0e-cf26c9cf14d5"
      unitRef="usd">34920000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85MS9mcmFnOjI4ODkzNzRmNzNiNTQ5OTc5MGI2YWVlNmI5MDc3YTJjL3RhYmxlOjkwZTVmNDg4OTJiZjRjNGE4ZjVkYTM5OTJiYjIyMWNiL3RhYmxlcmFuZ2U6OTBlNWY0ODg5MmJmNGM0YThmNWRhMzk5MmJiMjIxY2JfMy0yLTEtMS0w_db91b32c-20b7-46ec-bef9-a452f641811c"
      unitRef="usd">34920000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85MS9mcmFnOjI4ODkzNzRmNzNiNTQ5OTc5MGI2YWVlNmI5MDc3YTJjL3RhYmxlOjkwZTVmNDg4OTJiZjRjNGE4ZjVkYTM5OTJiYjIyMWNiL3RhYmxlcmFuZ2U6OTBlNWY0ODg5MmJmNGM0YThmNWRhMzk5MmJiMjIxY2JfNC0yLTEtMS0w_37fcbd76-9a76-4cad-998f-f6801c24633d"
      unitRef="usd">34920000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <ptct:FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85MS9mcmFnOjI4ODkzNzRmNzNiNTQ5OTc5MGI2YWVlNmI5MDc3YTJjL3RhYmxlOjkwZTVmNDg4OTJiZjRjNGE4ZjVkYTM5OTJiYjIyMWNiL3RhYmxlcmFuZ2U6OTBlNWY0ODg5MmJmNGM0YThmNWRhMzk5MmJiMjIxY2JfNS0yLTEtMS0w_7059a9ec-4d74-4254-ba14-cc6211699623"
      unitRef="usd">10094000</ptct:FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85MS9mcmFnOjI4ODkzNzRmNzNiNTQ5OTc5MGI2YWVlNmI5MDc3YTJjL3RhYmxlOjkwZTVmNDg4OTJiZjRjNGE4ZjVkYTM5OTJiYjIyMWNiL3RhYmxlcmFuZ2U6OTBlNWY0ODg5MmJmNGM0YThmNWRhMzk5MmJiMjIxY2JfNi0yLTEtMS0w_4ad3e4c4-fe90-4714-aa4d-29d8a1d44c9b"
      unitRef="usd">132314000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i20afcd7c10c14ac495fc02e16fe69b2d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85MS9mcmFnOjI4ODkzNzRmNzNiNTQ5OTc5MGI2YWVlNmI5MDc3YTJjL3RleHRyZWdpb246Mjg4OTM3NGY3M2I1NDk5NzkwYjZhZWU2YjkwNzdhMmNfMzA2Ng_b35c81ac-5e25-47eb-9852-6e1134b4d78c">P4Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:IndefinitelivedIntangibleAssetsAcquired
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85MS9mcmFnOjI4ODkzNzRmNzNiNTQ5OTc5MGI2YWVlNmI5MDc3YTJjL3RleHRyZWdpb246Mjg4OTM3NGY3M2I1NDk5NzkwYjZhZWU2YjkwNzdhMmNfNDM4NQ_b0e6936e-1c61-4f89-b281-40ce3f4a6627"
      unitRef="usd">576500000</us-gaap:IndefinitelivedIntangibleAssetsAcquired>
    <us-gaap:Goodwill
      contextRef="i3a86afcbe18b4917ba65f4643aaff8d5_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85MS9mcmFnOjI4ODkzNzRmNzNiNTQ5OTc5MGI2YWVlNmI5MDc3YTJjL3RleHRyZWdpb246Mjg4OTM3NGY3M2I1NDk5NzkwYjZhZWU2YjkwNzdhMmNfNDU2MQ_22d9704f-76b8-4d10-8928-add32fcdc85e"
      unitRef="usd">82300000</us-gaap:Goodwill>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i169de841172649f2b7a67e115481f695_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85Ny9mcmFnOjI5YTI2MzdjOWZmMjQ1MDE5ZjZjZDMzZjkwNDQ3ZTgyL3RleHRyZWdpb246MjlhMjYzN2M5ZmYyNDUwMTlmNmNkMzNmOTA0NDdlODJfMzI0OA_bf0928cd-9d62-4075-8374-baee4ee0fb98">Subsequent events&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;MidCap Credit Facility Termination&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On July 1, 2020, the Company terminated the Credit Facility. In connection with the termination of the Credit Facility, the Company repaid outstanding principal and accrued interest thereunder totaling $18.4&#160;million and paid an additional $0.6&#160;million in termination and exit fees. All liens and security interests securing the term loan made pursuant to the Credit Facility were released upon termination.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="i0b0512f2780f4b8eb0826df908c1fcb3_D20200701-20200701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85Ny9mcmFnOjI5YTI2MzdjOWZmMjQ1MDE5ZjZjZDMzZjkwNDQ3ZTgyL3RleHRyZWdpb246MjlhMjYzN2M5ZmYyNDUwMTlmNmNkMzNmOTA0NDdlODJfMTkyNDE0NTM1MTQ0MzE_0ec35555-1ee0-49c7-b8d0-7bfa555f95dd"
      unitRef="usd">18400000</us-gaap:RepaymentsOfLinesOfCredit>
    <ptct:LineOfCreditFacilityTerminationAndExitFees
      contextRef="i0b0512f2780f4b8eb0826df908c1fcb3_D20200701-20200701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85Ny9mcmFnOjI5YTI2MzdjOWZmMjQ1MDE5ZjZjZDMzZjkwNDQ3ZTgyL3RleHRyZWdpb246MjlhMjYzN2M5ZmYyNDUwMTlmNmNkMzNmOTA0NDdlODJfMTkyNDE0NTM1MTQ0NDY_697edba4-4939-4a3d-8559-cfa35b82f927"
      unitRef="usd">600000</ptct:LineOfCreditFacilityTerminationAndExitFees>
    <ptct:AssignedRoyaltyPaymentPercentage
      contextRef="ia95450bc6d4d4073acbfc602735fef93_I20200717"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85Ny9mcmFnOjI5YTI2MzdjOWZmMjQ1MDE5ZjZjZDMzZjkwNDQ3ZTgyL3RleHRyZWdpb246MjlhMjYzN2M5ZmYyNDUwMTlmNmNkMzNmOTA0NDdlODJfMTkyNDE0NTM1MTQ0NjA_92fd1ca6-c46a-43f7-ad07-bdee7d44205f"
      unitRef="number">0.42933</ptct:AssignedRoyaltyPaymentPercentage>
    <ptct:ProceedsAssignedRoyaltyPaymentAgreement
      contextRef="i574baa6db99049d2ba9e1203ea243658_D20200717-20200717"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85Ny9mcmFnOjI5YTI2MzdjOWZmMjQ1MDE5ZjZjZDMzZjkwNDQ3ZTgyL3RleHRyZWdpb246MjlhMjYzN2M5ZmYyNDUwMTlmNmNkMzNmOTA0NDdlODJfMTkyNDE0NTM1MTQ1MDg_1d0a8f74-6082-4aa8-b1c9-afac32a89926"
      unitRef="usd">650000000.0</ptct:ProceedsAssignedRoyaltyPaymentAgreement>
    <ptct:AssignedRoyaltyPaymentRetainedPercentage
      contextRef="ia95450bc6d4d4073acbfc602735fef93_I20200717"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85Ny9mcmFnOjI5YTI2MzdjOWZmMjQ1MDE5ZjZjZDMzZjkwNDQ3ZTgyL3RleHRyZWdpb246MjlhMjYzN2M5ZmYyNDUwMTlmNmNkMzNmOTA0NDdlODJfMTkyNDE0NTM1MTQ0Njk_d9dc15ac-b3cd-4cc9-a1d4-1b4ef25be964"
      unitRef="number">0.57067</ptct:AssignedRoyaltyPaymentRetainedPercentage>
    <ptct:RevenueRecognitionMilestonePotentialAchievements
      contextRef="i574baa6db99049d2ba9e1203ea243658_D20200717-20200717"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85Ny9mcmFnOjI5YTI2MzdjOWZmMjQ1MDE5ZjZjZDMzZjkwNDQ3ZTgyL3RleHRyZWdpb246MjlhMjYzN2M5ZmYyNDUwMTlmNmNkMzNmOTA0NDdlODJfMTkyNDE0NTM1MTQ0Nzg_bb1a42e5-a002-4498-b3af-5e923906e57d"
      unitRef="usd">397500000</ptct:RevenueRecognitionMilestonePotentialAchievements>
    <ptct:RoyaltyPurchaseAgreementTerminationPeriod
      contextRef="i574baa6db99049d2ba9e1203ea243658_D20200717-20200717"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85Ny9mcmFnOjI5YTI2MzdjOWZmMjQ1MDE5ZjZjZDMzZjkwNDQ3ZTgyL3RleHRyZWdpb246MjlhMjYzN2M5ZmYyNDUwMTlmNmNkMzNmOTA0NDdlODJfMTkyNDE0NTM1MTQ1MzA_ba6a6d23-bfe0-4bd0-ade5-e51ce396f788">P60D</ptct:RoyaltyPurchaseAgreementTerminationPeriod>
    <ptct:RoyaltyPurchaseAgreementPaymentMaximum
      contextRef="ia95450bc6d4d4073acbfc602735fef93_I20200717"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF85Ny9mcmFnOjI5YTI2MzdjOWZmMjQ1MDE5ZjZjZDMzZjkwNDQ3ZTgyL3RleHRyZWdpb246MjlhMjYzN2M5ZmYyNDUwMTlmNmNkMzNmOTA0NDdlODJfMTkyNDE0NTM1MTQ0OTQ_2342d7f8-0a62-4fca-aa90-7d5a5bbc1751"
      unitRef="usd">1300000000</ptct:RoyaltyPurchaseAgreementPaymentMaximum>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633774648584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Aug. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PTC Therapeutics,&#160;Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3416587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 Corporate Court<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South Plainfield,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">222-7000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PTCT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,703,214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001070081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633940437464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 158,461<span></span>
</td>
<td class="nump">$ 288,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">340,430<span></span>
</td>
<td class="nump">398,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade receivables, net</a></td>
<td class="nump">53,644<span></span>
</td>
<td class="nump">55,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">18,373<span></span>
</td>
<td class="nump">19,285<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">34,116<span></span>
</td>
<td class="nump">17,898<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">605,024<span></span>
</td>
<td class="nump">779,284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">26,806<span></span>
</td>
<td class="nump">21,549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">708,814<span></span>
</td>
<td class="nump">710,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">82,341<span></span>
</td>
<td class="nump">82,341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DepositsAndOtherAssetsNoncurrent', window );">Deposits and other assets</a></td>
<td class="nump">53,652<span></span>
</td>
<td class="nump">30,108<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,476,637<span></span>
</td>
<td class="nump">1,623,782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">164,376<span></span>
</td>
<td class="nump">159,276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">18,333<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">7,702<span></span>
</td>
<td class="nump">8,242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities- current</a></td>
<td class="nump">4,180<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">4,868<span></span>
</td>
<td class="nump">8,339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent', window );">Deferred consideration payable</a></td>
<td class="nump">2,384<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">201,843<span></span>
</td>
<td class="nump">235,857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue- long term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">297,029<span></span>
</td>
<td class="nump">293,859<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration payable</a></td>
<td class="nump">225,700<span></span>
</td>
<td class="nump">356,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">130,862<span></span>
</td>
<td class="nump">130,862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities- noncurrent</a></td>
<td class="nump">22,031<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">26,678<span></span>
</td>
<td class="nump">9,159<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">904,143<span></span>
</td>
<td class="nump">1,029,452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value. Authorized 125,000,000 shares; issued and outstanding&#160;67,240,679 shares at June 30, 2020. Authorized 125,000,000 shares; issued and&#160;outstanding 61,935,870 shares at December&#160;31, 2019.</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">2,067,274<span></span>
</td>
<td class="nump">1,795,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="num">(10,016)<span></span>
</td>
<td class="num">(10,584)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,484,831)<span></span>
</td>
<td class="num">(1,190,499)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">572,494<span></span>
</td>
<td class="nump">594,330<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 1,476,637<span></span>
</td>
<td class="nump">$ 1,623,782<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration, Liability, Deferred Consideration Payable- Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_DepositsAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the carrying value of amounts transferred to third parties for security purposes and other noncurrent assets that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_DepositsAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31931-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e604059-122996<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633769141240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares (in shares)</a></td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued shares (in shares)</a></td>
<td class="nump">67,240,679<span></span>
</td>
<td class="nump">61,935,870<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633774658968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 75,239<span></span>
</td>
<td class="nump">$ 85,522<span></span>
</td>
<td class="nump">$ 143,498<span></span>
</td>
<td class="nump">$ 139,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets', window );">Cost of Goods and Service, Excluding Amortization Of Intangible Assets</a></td>
<td class="nump">5,304<span></span>
</td>
<td class="nump">3,211<span></span>
</td>
<td class="nump">9,389<span></span>
</td>
<td class="nump">5,587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">8,731<span></span>
</td>
<td class="nump">6,575<span></span>
</td>
<td class="nump">16,679<span></span>
</td>
<td class="nump">12,652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">176,525<span></span>
</td>
<td class="nump">59,979<span></span>
</td>
<td class="nump">266,632<span></span>
</td>
<td class="nump">112,544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">53,659<span></span>
</td>
<td class="nump">49,215<span></span>
</td>
<td class="nump">111,869<span></span>
</td>
<td class="nump">89,760<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1', window );">Change in the fair value of deferred and contingent consideration</a></td>
<td class="nump">7,680<span></span>
</td>
<td class="nump">5,300<span></span>
</td>
<td class="nump">8,580<span></span>
</td>
<td class="nump">26,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_SettlementOfDeferredAndContingentConsideration', window );">Settlement of deferred and contingent consideration</a></td>
<td class="nump">10,613<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,613<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">262,512<span></span>
</td>
<td class="nump">124,280<span></span>
</td>
<td class="nump">423,762<span></span>
</td>
<td class="nump">247,003<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(187,273)<span></span>
</td>
<td class="num">(38,758)<span></span>
</td>
<td class="num">(280,264)<span></span>
</td>
<td class="num">(107,898)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense, net</a></td>
<td class="num">(5,379)<span></span>
</td>
<td class="num">(2,074)<span></span>
</td>
<td class="num">(11,021)<span></span>
</td>
<td class="num">(4,362)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">11,309<span></span>
</td>
<td class="num">(183)<span></span>
</td>
<td class="num">(2,523)<span></span>
</td>
<td class="num">(292)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax expense</a></td>
<td class="num">(181,343)<span></span>
</td>
<td class="num">(41,015)<span></span>
</td>
<td class="num">(293,808)<span></span>
</td>
<td class="num">(112,552)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(84)<span></span>
</td>
<td class="num">(774)<span></span>
</td>
<td class="num">(306)<span></span>
</td>
<td class="num">(1,350)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (181,427)<span></span>
</td>
<td class="num">$ (41,789)<span></span>
</td>
<td class="num">$ (294,114)<span></span>
</td>
<td class="num">$ (113,902)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted (in shares)</a></td>
<td class="nump">65,150,780<span></span>
</td>
<td class="nump">55,912,748<span></span>
</td>
<td class="nump">63,769,958<span></span>
</td>
<td class="nump">57,113,141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share-basic and diluted (in dollars per share)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share&#8212;basic and diluted (in dollars per share)</a></td>
<td class="num">$ (2.78)<span></span>
</td>
<td class="num">$ (0.75)<span></span>
</td>
<td class="num">$ (4.61)<span></span>
</td>
<td class="num">$ (1.99)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 75,239<span></span>
</td>
<td class="nump">$ 85,476<span></span>
</td>
<td class="nump">$ 143,435<span></span>
</td>
<td class="nump">$ 138,530<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ptct_GrantAndCollaborationMember', window );">Collaboration and grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">$ 575<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of Goods and Service, Excluding Amortization Of Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_SettlementOfDeferredAndContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Settlement Of Deferred And Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_SettlementOfDeferredAndContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of right to a contingent consideration asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ptct_GrantAndCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ptct_GrantAndCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633774147352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (181,427)<span></span>
</td>
<td class="num">$ (41,789)<span></span>
</td>
<td class="num">$ (294,114)<span></span>
</td>
<td class="num">$ (113,902)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive (loss) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain on marketable securities, net of tax</a></td>
<td class="nump">2,718<span></span>
</td>
<td class="nump">839<span></span>
</td>
<td class="nump">2,655<span></span>
</td>
<td class="nump">898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation (loss) gain, net of tax</a></td>
<td class="num">(10,749)<span></span>
</td>
<td class="nump">278<span></span>
</td>
<td class="num">(2,087)<span></span>
</td>
<td class="num">(438)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (189,458)<span></span>
</td>
<td class="num">$ (40,672)<span></span>
</td>
<td class="num">$ (293,546)<span></span>
</td>
<td class="num">$ (113,442)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633840388680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>AOCI Attributable to Parent</div></th>
<th class="th"><div>Accumulated deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,606,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning of the period at Dec. 31, 2018</a></td>
<td class="nump">$ 350,727<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
<td class="nump">$ 1,288,137<span></span>
</td>
<td class="nump">$ 1,462<span></span>
</td>
<td class="num">$ (938,923)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock related to equity offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,563,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock related to equity offering</a></td>
<td class="nump">224,545<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">224,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_StockIssuedDuringPeriodValueExchangeRights', window );">Issuance of common stock related to rights exchange</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">311,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="nump">4,129<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">4,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock vesting and issuance, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock vesting and issuance, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock in connection with an employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock in connection with an employee stock purchase plan</a></td>
<td class="nump">1,564<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">20,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor', window );">Receivable from investor</a></td>
<td class="nump">978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(113,902)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(113,902)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Comprehensive income</a></td>
<td class="nump">460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,707,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end of the period at Jun. 30, 2019</a></td>
<td class="nump">488,685<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
<td class="nump">1,539,530<span></span>
</td>
<td class="nump">1,922<span></span>
</td>
<td class="num">(1,052,825)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,418,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning of the period at Mar. 31, 2019</a></td>
<td class="nump">512,942<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
<td class="nump">1,523,115<span></span>
</td>
<td class="nump">805<span></span>
</td>
<td class="num">(1,011,036)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock related to equity offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock related to equity offering</a></td>
<td class="nump">106<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="nump">2,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock vesting and issuance, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock vesting and issuance, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock in connection with an employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock in connection with an employee stock purchase plan</a></td>
<td class="nump">1,564<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">10,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor', window );">Receivable from investor</a></td>
<td class="nump">978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(41,789)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41,789)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Comprehensive income</a></td>
<td class="nump">1,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,707,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end of the period at Jun. 30, 2019</a></td>
<td class="nump">488,685<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
<td class="nump">1,539,530<span></span>
</td>
<td class="nump">1,922<span></span>
</td>
<td class="num">(1,052,825)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,935,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning of the period at Dec. 31, 2019</a></td>
<td class="nump">594,330<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
<td class="nump">1,795,351<span></span>
</td>
<td class="num">(10,584)<span></span>
</td>
<td class="num">(1,190,499)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock related to equity offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">368,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock related to equity offering</a></td>
<td class="nump">18,950<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">18,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Payments for asset acquisitions, shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">845,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Payments for asset acquisitions, share, value</a></td>
<td class="nump">42,869<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">42,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_StockIssuedDuringPeriodSharesExchangeRights', window );">Issuance of common stock related to rights exchange (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,821,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_StockIssuedDuringPeriodValueExchangeRights', window );">Issuance of common stock related to rights exchange</a></td>
<td class="nump">150,528<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">150,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,034,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="nump">25,045<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">25,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock vesting and issuance, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock vesting and issuance, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock in connection with an employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock in connection with an employee stock purchase plan</a></td>
<td class="nump">2,406<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">32,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityPeriodIncreaseDecrease', window );">Other</a></td>
<td class="num">(218)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(294,114)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(294,114)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Comprehensive income</a></td>
<td class="nump">568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,240,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end of the period at Jun. 30, 2020</a></td>
<td class="nump">572,494<span></span>
</td>
<td class="nump">$ 67<span></span>
</td>
<td class="nump">2,067,274<span></span>
</td>
<td class="num">(10,016)<span></span>
</td>
<td class="num">(1,484,831)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,758,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning of the period at Mar. 31, 2020</a></td>
<td class="nump">528,734<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
<td class="nump">1,834,061<span></span>
</td>
<td class="num">(1,985)<span></span>
</td>
<td class="num">(1,303,404)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock related to equity offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock related to equity offering</a></td>
<td class="nump">5,447<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">5,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Payments for asset acquisitions, shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">845,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Payments for asset acquisitions, share, value</a></td>
<td class="nump">42,869<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">42,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_StockIssuedDuringPeriodSharesExchangeRights', window );">Issuance of common stock related to rights exchange (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,821,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_StockIssuedDuringPeriodValueExchangeRights', window );">Issuance of common stock related to rights exchange</a></td>
<td class="nump">150,528<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">150,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">654,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="nump">15,058<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">15,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock vesting and issuance, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,985)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock vesting and issuance, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock in connection with an employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock in connection with an employee stock purchase plan</a></td>
<td class="nump">2,406<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">16,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(181,427)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Comprehensive income</a></td>
<td class="num">(8,031)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,031)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,240,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end of the period at Jun. 30, 2020</a></td>
<td class="nump">$ 572,494<span></span>
</td>
<td class="nump">$ 67<span></span>
</td>
<td class="nump">$ 2,067,274<span></span>
</td>
<td class="num">$ (10,016)<span></span>
</td>
<td class="num">$ (1,484,831)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid In Capital Receivable from Investor</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_StockIssuedDuringPeriodSharesExchangeRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Exchange Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_StockIssuedDuringPeriodSharesExchangeRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_StockIssuedDuringPeriodValueExchangeRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Exchange Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_StockIssuedDuringPeriodValueExchangeRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in stockholders' equity during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633770094104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (294,114)<span></span>
</td>
<td class="num">$ (113,902)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization</a></td>
<td class="nump">19,445<span></span>
</td>
<td class="nump">14,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_OperatingLeaseCostNonCash', window );">Non-cash operating lease expense</a></td>
<td class="nump">2,401<span></span>
</td>
<td class="nump">1,256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_FinanceLeaseCostNonCash', window );">Non-cash finance lease amortization expense</a></td>
<td class="nump">41,212<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in valuation of deferred and contingent consideration</a></td>
<td class="nump">8,580<span></span>
</td>
<td class="nump">26,460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_SettlementOfDeferredAndContingentConsideration', window );">Settlement of deferred and contingent consideration</a></td>
<td class="nump">10,613<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_SharesIssuedAssetAcquisition', window );">Non-cash stock consideration, acquisition</a></td>
<td class="nump">42,869<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized loss on equity investment</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="num">(129)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_UnrealizedGainLossonConvertibleSecurities', window );">Unrealized loss on ClearPoint convertible debt security</a></td>
<td class="nump">749<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
<td class="nump">10,993<span></span>
</td>
<td class="nump">4,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposal of asset</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of discounts on investments, net</a></td>
<td class="num">(635)<span></span>
</td>
<td class="num">(907)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">510<span></span>
</td>
<td class="nump">280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Amortization of discounts on investments, net</a></td>
<td class="nump">32,130<span></span>
</td>
<td class="nump">20,184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Unrealized foreign currency transaction (gains) losses, net</a></td>
<td class="num">(3,248)<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Increase (Decrease) in Operating Capital [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory, net</a></td>
<td class="nump">943<span></span>
</td>
<td class="num">(852)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(16,569)<span></span>
</td>
<td class="num">(7,250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Trade receivables, net</a></td>
<td class="nump">1,860<span></span>
</td>
<td class="num">(9,702)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDepositOtherAssets', window );">Deposits and other assets</a></td>
<td class="num">(175)<span></span>
</td>
<td class="num">(9,656)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(7,497)<span></span>
</td>
<td class="num">(7,546)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other long-term liabilities</a></td>
<td class="num">(4,132)<span></span>
</td>
<td class="nump">7,395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(3,925)<span></span>
</td>
<td class="nump">2,511<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(156,364)<span></span>
</td>
<td class="num">(72,931)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of fixed assets</a></td>
<td class="num">(8,183)<span></span>
</td>
<td class="num">(4,851)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_PaymentsToAcquireConvertibleDebtInvestment', window );">Purchase of convertible debt security</a></td>
<td class="num">(10,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(367,102)<span></span>
</td>
<td class="num">(226,261)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sale and redemption of marketable securities</a></td>
<td class="nump">428,490<span></span>
</td>
<td class="nump">58,424<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisition of product rights and licenses</a></td>
<td class="num">(2,422)<span></span>
</td>
<td class="num">(11,981)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Purchase of equity investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">40,783<span></span>
</td>
<td class="num">(188,669)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
<td class="nump">25,045<span></span>
</td>
<td class="nump">4,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from public offerings</a></td>
<td class="nump">18,950<span></span>
</td>
<td class="nump">224,545<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSecuredDebt', window );">Repayment of senior secured term loan</a></td>
<td class="num">(10,000)<span></span>
</td>
<td class="num">(1,667)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_PaymentsOnDeferredConsiderationObligation', window );">Payments on deferred consideration obligation</a></td>
<td class="num">(35,829)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from employee stock purchase plan</a></td>
<td class="nump">2,406<span></span>
</td>
<td class="nump">1,564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_PaymentOfFinanceLeasePrincipal', window );">Payment of finance lease principal</a></td>
<td class="num">(15,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="num">(14,428)<span></span>
</td>
<td class="nump">228,571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
<td class="nump">442<span></span>
</td>
<td class="num">(375)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(129,567)<span></span>
</td>
<td class="num">(33,404)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, and restricted cash beginning of period</a></td>
<td class="nump">295,528<span></span>
</td>
<td class="nump">169,498<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, and restricted cash end of period</a></td>
<td class="nump">158,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">5,286<span></span>
</td>
<td class="nump">3,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">1,140<span></span>
</td>
<td class="nump">1,013<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain on marketable securities, net of tax</a></td>
<td class="nump">2,655<span></span>
</td>
<td class="nump">898<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease obligations</a></td>
<td class="nump">18,117<span></span>
</td>
<td class="nump">11,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right-of-use assets obtained in exchange for finance lease obligations</a></td>
<td class="nump">41,212<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1', window );">Acquisition of product rights and licenses</a></td>
<td class="nump">12,186<span></span>
</td>
<td class="nump">8,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_StockIssuedDuringPeriodValueExchangeRights', window );">Issuance of common stock related to rights exchange</a></td>
<td class="nump">$ 150,528<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_FinanceLeaseCostNonCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Cost Non-Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_FinanceLeaseCostNonCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_OperatingLeaseCostNonCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Cost Non-Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_OperatingLeaseCostNonCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_PaymentOfFinanceLeasePrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of Finance Lease Principal</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_PaymentOfFinanceLeasePrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_PaymentsOnDeferredConsiderationObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments On Deferred Consideration Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_PaymentsOnDeferredConsiderationObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_PaymentsToAcquireConvertibleDebtInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Convertible Debt Investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_PaymentsToAcquireConvertibleDebtInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_SettlementOfDeferredAndContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Settlement Of Deferred And Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_SettlementOfDeferredAndContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_SharesIssuedAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued Asset Acquisition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_SharesIssuedAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_StockIssuedDuringPeriodValueExchangeRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Exchange Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_StockIssuedDuringPeriodValueExchangeRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_UnrealizedGainLossonConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrealized Gain (Loss) on Convertible Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_UnrealizedGainLossonConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30700-110894<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDepositOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDepositOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633765907464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">The Company</a></td>
<td class="text">The Company<div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">PTC Therapeutics,&#160;Inc. (the &#8220;Company&#8221; or &#8220;PTC&#8221;) is a science-driven global biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. The Company&#8217;s ability to globally commercialize products is the foundation that drives its continued investment in a robust diversified pipeline of transformative medicines and its mission to provide access to best-in-class treatments for patients who have an unmet medical need. The Company&#8217;s strategy is to bring best-in-class therapies with differentiated clinical benefit to patients affected by rare disorders and to leverage its global commercial infrastructure to maximize value for its patients and other stakeholders.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company has two products, Translarna</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;">&#8482; </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">(ataluren) and Emflaza&#8482; (deflazacort), for the treatment of Duchenne muscular dystrophy, or DMD, a rare, life threatening disorder. Translarna has marketing authorization in the European Economic Area (the &#8220;EEA&#8221;) for the treatment of nonsense mutation Duchenne muscular dystrophy, or nmDMD, in ambulatory patients aged 2&#160;years and older and in Brazil for the treatment of nmDMD in ambulatory patients aged 5&#160;years and older, subject to annual renewal and other conditions. In June 2020, the Committee for Medicinal Products for Human Use (the "CHMP") of the European Medicines Agency ("EMA") recommended to remove the statement &#8220;efficacy has not been demonstrated in non-ambulatory patients&#8221; from the product label for Translarna. The CHMP's opinion is subject to final approval by the European Commission, which is typically provided within two months of the CHMP's recommendation. Emflaza is approved in the United States for the treatment of DMD in patients two years and older.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has a pipeline of gene therapy product candidates for rare monogenic diseases that affect the central nervous system (&#8220;CNS&#8221;) including PTC-AADC for the treatment of Aromatic L-Amino Acid Decarboxylase, or AADC deficiency, a rare CNS disorder arising from reductions in the enzyme AADC that results from mutations in the dopa decarboxylase gene. The Company is preparing a biologics license application ("BLA") for PTC-AADC for the treatment of AADC deficiency in the United States and it anticipates initiating the BLA submission to the United States Food and Drug Administration ("FDA") in the second half of 2020. In January 2020, the Company submitted a marketing authorization application ("MAA") to the EMA for PTC-AADC for the treatment of AADC deficiency in the EEA, and the Company expects an opinion from the CHMP in the first quarter of 2021.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company holds the rights for the commercialization of Tegsedi&#8482; (inotersen) and Waylivra&#8482; (volanesorsen) for the treatment of rare diseases in countries in Latin America and the Caribbean pursuant to the Company&#8217;s Collaboration and License Agreement with Akcea Therapeutics, Inc. (&#8220;Akcea&#8221;). Tegsedi has received marketing authorization in the United States, the European Union (the &#8220;EU&#8221;) and Brazil for the treatment of stage&#160;1 or stage&#160;2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis, or hATTR amyloidosis. Waylivra has received marketing authorization in the EU for the treatment of familial chylomicronemia syndrome, or FCS. The Company filed for marketing authorization for Waylivra for the treatment of FCS with ANVISA, the Brazilian health regulatory authority, in June 2020 and, subject to potential delays in the review process related to the COVID-19 pandemic, expects a regulatory decision on approval from ANVISA in 2021.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company also has a spinal muscular atrophy ("SMA") collaboration with F. Hoffman-La Roche&#160;Ltd and Hoffman-La Roche&#160;Inc., referred to collectively as Roche, and the Spinal Muscular Atrophy Foundation ("SMA Foundation"). The lead compound in the SMA program is risdiplam (RG7916, RO7034067). Roche submitted an NDA for risdiplam to the FDA in the fourth quarter of 2019. In April 2020, the FDA extended the Prescription Drug User Fee Act ("PDUFA") date for a decision from May 24, 2020&#160;to August 24, 2020 as a result of additional data that Roche submitted, including comprehensive data from the Sunfish part 2 study. Risdiplam is expected to be indicated in the United States for SMA type 1, 2 and 3 patients, if approved. Roche anticipates submitting an MAA for risdiplam in the EEA imminently.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">On October 25, 2019, the Company completed the acquisition of substantially all of the assets of BioElectron Technology Corporation (&#8220;BioElectron&#8221;), a Delaware corporation, including certain compounds that the Company has begun to develop as part of its Bio-e platform, (the &#8220;Asset Acquisition&#8221;) pursuant to an asset purchase agreement by and between the Company and BioElectron, dated October 1, 2019 (the &#8220;Asset Acquisition Agreement&#8221;). The transaction was accounted for as an asset acquisition. The two most advanced molecules in the Company's Bio-e platform are vatiquinone, formerly known as PTC743, and PTC857. The Company expects to initiate a potential registrational Phase 2 placebo-controlled trial of vatiquinone in approximately 60 children with mitochondrial disease and associated refractory epilepsy in the third quarter of 2020. The Company also expects to initiate a potential registrational Phase 3 trial of vatiquinone in approximately 100 patients with </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Friedrich ataxia in the fourth quarter of 2020. In the second quarter of 2020, the Company initiated a Phase 1 trial in healthy volunteers to evaluate the safety and pharmacology of PTC857. The Company expects data from the single ascending dose and multiple ascending dose studies from the Phase 1 trial to be available by the end of 2020.</span></div><div style="text-align:justify;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In addition, the Company has a pipeline of product candidates and discovery programs that are in early clinical, pre-clinical and research and development stages focused on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s marketing authorization for Translarna in the EEA is subject to annual review and renewal by the European Commission following reassessment by the EMA of the benefit-risk balance of the authorization, which the Company refers to as the annual EMA reassessment. This marketing authorization is further subject to the specific obligation to conduct and submit the results of a multi-center, randomized, double-blind, 18-month, placebo-controlled trial, followed by an 18-month open-label extension, according to an agreed protocol, in order to confirm the efficacy and safety of Translarna. The final report on the trial and open-label extension is to be submitted by the Company to the EMA by the end of the third quarter of 2022. The Company refers to the trial and open-label extension together as Study 041.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The marketing authorization in the EEA was last renewed in June 2020 and is effective, unless extended, through August 5, 2021. The renewal was based on the Company&#8217;s commitment to conduct Study 041 and the totality of the clinical data available from its trials and studies of Translarna for the treatment of nmDMD, including the safety and efficacy results of the Phase 2b and Phase 3 clinical trials. The primary efficacy endpoint was not achieved in either trial within the pre-specified level of statistical significance.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Translarna is an investigational new drug in the United States. During the first quarter of 2017, the Company filed a New Drug Application, or NDA, over protest with the FDA, for which the FDA granted a standard review. In October 2017, the Office of Drug Evaluation I of the FDA issued a complete response letter for the NDA, stating that it was unable to approve the application in its current form. In response, the Company filed a formal dispute resolution request with the Office of New Drugs of the FDA. In February 2018, the Office of New Drugs of the FDA denied the Company's appeal of the Complete Response Letter. In its response, the Office of New Drugs recommended a possible path forward for the ataluren NDA submission based on the accelerated approval pathway. This would involve a re-submission of an NDA containing the current data on effectiveness of ataluren with new data to be generated on dystrophin production in nmDMD patients&#8217; muscles. The Company intends to follow the FDA&#8217;s recommendation and will collect, using newer technologies via procedures and methods that the Company designed, such dystrophin data in a new study, Study 045, which the Company initiated in the fourth quarter of 2018. As a result of intermittent discontinuations of certain elective procedures at the Company's clinical trial site in response to the COVID-19 pandemic, the Company's expected completion of Study 45 has been delayed as certain patients still require final study muscle biopsies. Once the clinical trial site is open for the necessary procedures and patients are able to safely travel to the site, the Company expects to be able to complete the final biopsies and the data from Study 045 would be available thereafter, followed by a potential re-submission of an NDA. Additionally, should a re-submission of an NDA receive accelerated approval, the Office of New Drugs stated that Study 041, which is currently enrolling, could serve as the confirmatory post-approval trial required in connection with the accelerated approval framework.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On August 23, 2018, the Company completed its acquisition of Agilis Biotherapeutics, Inc., or Agilis, pursuant to an Agreement and Plan of Merger, dated as of July 19, 2018 (the &#8220;Merger Agreement&#8221;), by and among the Company, Agility Merger Sub, Inc., a Delaware corporation and the Company's wholly owned, indirect subsidiary, Agilis and, solely in its capacity as the representative, agent and attorney-in-fact of the equityholders of Agilis, Shareholder Representative Services LLC, (the "Merger").</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Upon the closing of the Merger, the Company paid to Agilis equityholders total upfront consideration comprised of $49.2 million in cash and 3,500,907 shares of the Company&#8217;s common stock (the &#8220;Closing Stock Consideration&#8221;). The Closing Stock Consideration was determined by dividing $150.0 million by the volume-weighted average price per share of the Company&#8217;s common stock on the Nasdaq Global Select Market for the 10 consecutive trading-day period ending on the second trading-day immediately preceding the closing of the Merger. Agilis equityholders are entitled to receive contingent payments from the Company based on the achievement of certain development, regulatory and net sales milestones as well as based upon a percentage of net sales of certain products.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">On April 29, 2020, the Company, certain of the former equity holders of Agilis, and, for the limited purposes set forth in the agreement, Shareholder Representative Services LLC, entered into a Rights Exchange Agreement (the &#8220;Rights Exchange Agreement&#8221;). Pursuant to the Rights Exchange Agreement, the Company issued 2,821,176 shares of its common stock (the &#8220;Common Stock Consideration&#8221;) and paid $36.9&#160;million (the &#8220;Cash Consideration&#8221;), in the aggregate, to such former equity holders of Agilis (the &#8220;Participating Rightholders&#8221;) in exchange for the cancellation and forfeiture by the Participating Rightholders of their rights to receive certain milestone-based contingent payments under the Merger Agreement, pursuant to which the Company completed the Merger. </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Pursuant to the terms of the Rights Exchange Agreement, the Participating Rightholders have canceled and forfeited their rights under the Merger Agreement to receive (i) $174.0&#160;million, in the aggregate, of potential milestone payments based on the achievement of certain regulatory milestones and (ii) $37.6&#160;million, in the aggregate, of $40.0&#160;million in development milestone payments that would have been due upon the passing of the second anniversary of the closing of the Merger, regardless of whether the milestones are achieved.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Rights Exchange Agreement has no effect on the Merger Agreement other than to provide for the cancellation and forfeiture of the Participating Rightholders&#8217; rights to receive $211.6&#160;million, in the aggregate, of the milestone payments described above. As a result, all other rights and obligations under the Merger Agreement remain in effect pursuant to their terms, including the Company&#8217;s obligation to pay up to an aggregate maximum amount of $22.4&#160;million upon the achievement of certain development milestones (representing the remaining portion of potential development milestone payments for which rights were not canceled and forfeited pursuant to the Rights Exchange Agreement after deducting the $37.6&#160;million for which rights were canceled and forfeited pursuant to the Rights Exchange Agreement from the $40.0&#160;million in development milestone payments that are due upon the passing of the second anniversary of the closing of the Merger), up to an aggregate maximum amount of $361.0&#160;million upon the achievement of certain regulatory milestones (representing the remaining portion of potential regulatory milestone payments for which rights were not canceled and forfeited pursuant to the Rights Exchange Agreement), up to a maximum aggregate amount of $150.0&#160;million upon the achievement of certain net sales milestones and a percentage of annual net sales for Friedreich ataxia and Angelman syndrome during specified terms, ranging from 2% to 6%, pursuant to the terms of the Merger Agreement. Refer to Note 5 for further details regarding the Rights Exchange Agreement.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">On May 29, 2020, the Company completed its acquisition of Censa Pharmaceuticals, Inc., (&#8220;Censa&#8221;) pursuant to an Agreement and Plan of Merger, dated as of May 5, 2020, (the "Censa Merger Agreement"), by and among the Company, Hydro Merger Sub, Inc., the Company's wholly owned, indirect subsidiary, and, solely in its capacity as the representative, agent and attorney-in-fact of the securityholders of Censa, Shareholder Representative Services LLC (the "Censa Merger"). The transaction was accounted for as an asset acquisition.  In connection with the Censa Merger, the Company acquired PTC923 (formerly known as CNSA-001), which is being pursued as a possible treatment for orphan metabolic diseases associated with defects in the tetrahydrobiopterin biochemical pathways, including phenylketonuria ("PKU").  Refer to Note 3 for further details.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, the Company had an accumulated deficit of approximately $1,484.8 million. The Company has financed its operations to date primarily through the private offerings in September 2019 of 1.50% convertible senior notes due 2026 and in August&#160;2015 of 3.00% convertible senior notes due 2022 (see Note 11), public offerings of common stock in February 2014, October 2014, April 2018, January 2019, and September 2019, "at the market offerings" of its common stock, its initial public offering of common stock in June 2013, private placements of its convertible preferred stock, collaborations, bank debt, the Company's credit and security agreement (the "Credit Agreement"), with MidCap Financial Trust, or MidCap Financial, as administrative agent and MidCap Financial and other certain institutions as lenders thereto (see Note 11), grant funding and clinical trial support from governmental and philanthropic organizations and patient advocacy groups in the disease area addressed by the Company&#8217;s product candidates. Since 2014, the Company has also relied on revenue generated from net sales of Translarna for the treatment of nmDMD in territories outside of the United States, and since May 2017, the Company has generated revenue from net sales of Emflaza for the treatment of DMD in the United States. The Company expects&#160;that cash flows from the sales of its products, together with the Company's cash, cash equivalents and marketable securities, will be sufficient to fund its operations for at least the next twelve months.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633764695832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text">Summary of significant accounting policies<div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s complete listing of significant accounting policies is set forth in Note 2 of the notes to the Company&#8217;s audited financial statements as of December&#160;31, 2019 included in the Company&#8217;s Annual Report on Form&#160;10-K filed with the Securities and Exchange Commission (the "SEC") on March 2, 2020 (the "2019 Form&#160;10-K"). Additional significant accounting policies adopted during the six month period ended June&#160;30, 2020 are discussed in further detail below.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Basis of presentation</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying financial information as of June&#160;30, 2020 and for the three and six months ended June&#160;30, 2020 and 2019 has been prepared by the Company, without audit, pursuant to the rules&#160;and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States ("GAAP") have been condensed or omitted pursuant to such rules&#160;and regulations. These interim financial statements should be read in conjunction with the Company&#8217;s audited financial statements as of December&#160;31, 2019 and notes thereto included in the 2019 Form&#160;10-K.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the opinion of management, the unaudited financial information as of June&#160;30, 2020 and for the three and six months ended June&#160;30, 2020 and 2019 reflects all adjustments, which are normal recurring adjustments, necessary to present a fair statement </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">of financial position, results of operations, stockholders' equity, and cash flows. The results of operations for the three and six month period ended June&#160;30, 2020 are not necessarily indicative of the results to be expected for the year ended December&#160;31, 2020 or for any other interim period or for any other future year.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Use of estimates</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates in these consolidated financial statements have been made in connection with the calculation of net product sales, certain accruals related to the Company&#8217;s research and development expenses, valuation procedures for convertible notes, fair value of the contingent consideration, and the provision for or benefit from income taxes. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Restricted cash</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Restricted cash included in deposits and other assets on the consolidated balance sheet relates to an unconditional, irrevocable and transferable letter of credit that was entered into during the twelve-month period ended December 31, 2019 in connection with obligations under a facility lease for our leased biologics manufacturing facility in Hopewell Township, New Jersey. The amount of the letter of credit is $7.5 million, is to be maintained for a term of not less than five years and has the potential to be reduced to $3.8 million if after five years the Company is not in default of its lease. The amount is classified within deposits and other assets on the consolidated balance sheet due to the long-term nature of the letter of credit.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheet that sum to the total of the same amounts shown in the statement of cash flows:</span></div><div style="text-align:center;margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.421%;"><tr><td style="width:1.0%;"/><td style="width:71.395%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.582%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.519%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.582%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.522%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Beginning of period- December 31, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">End of period- June 30, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">288,028&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">158,461&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash included in deposits and other assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Cash, cash equivalents and restricted cash per statement of cash flows</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">295,528&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">165,961&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Marketable securities</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company considers securities with original maturities of greater than 90&#160;days to be available for sale securities. Securities under this classification are recorded at fair value and unrealized gains and losses within accumulated other comprehensive income. The estimated fair value of the available for sale securities is determined based on quoted market prices or rates for similar instruments. In addition, the cost of debt securities in this category is adjusted for amortization of premium and accretion of discount to maturity. For available for sale debt securities in an unrealized loss position, the Company assesses whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security's amortized cost basis is written down to fair value. If the criteria are not met, the Company evaluates whether the decline in fair value has resulted from a credit loss or other factors. In making this assessment, management considers, among other factors, the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security are compared to the amortized cost basis of the security. If the present value of the cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss, limited by the amount that the fair value is less than the amortized costs basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income. For the three month and six month periods ended June&#160;30, 2020, no allowance was recorded for credit losses.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Inventory and cost of product sales</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Inventory</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Inventories are stated at the lower of cost and net realizable value with cost determined on a first-in, first-out basis by product. The Company capitalizes inventory costs associated with products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. Products which may be used in clinical development programs are included in inventory and charged to research and development expense when the product enters the research and development process and no longer can be used for commercial purposes. Inventory used for </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">marketing efforts are charged to selling, general and administrative expense. Amounts related to clinical development programs and marketing efforts are immaterial.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the components of the Company&#8217;s inventory for the periods indicated:</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:71.099%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.769%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">877&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">874&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Work in progress</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,666&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,652&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,830&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,759&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventory</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,373&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,285&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company periodically reviews its inventories for excess amounts or obsolescence and writes down obsolete or otherwise unmarketable inventory to its estimated net realizable value. For the three months ended June 30, 2020, inventory write downs were immaterial. For the six months ended June 30, 2020, the Company recorded a $0.2 million inventory write-down, primarily related to product approaching expiration.  No write downs were recorded for the three and six month periods ended June&#160;30, 2019. Additionally, though the Company&#8217;s product is subject to strict quality control and monitoring which it performs throughout the manufacturing processes, certain batches or units of product may not meet quality specifications resulting in a charge to cost of product sales. For the three and six month periods ended June&#160;30, 2020 and 2019, these amounts were immaterial.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cost of product sales</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cost of product sales consists of the cost of inventory sold, manufacturing and supply chain costs, storage costs, amortization of the acquired intangible asset and royalty payments associated with net product sales.  Production costs are expensed as cost of product sales when the related products are sold.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Revenue recognition</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Net product revenue</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company's net product revenue primarily consists of sales of Translarna in territories outside of the U.S. for the treatment of nmDMD and sales of Emflaza in the U.S. for the treatment of DMD.  The Company recognizes revenue when its performance obligations with its customers have been satisfied.  The Company&#8217;s performance obligations are to provide products based on customer orders from distributors, hospitals, specialty pharmacies or retail pharmacies.  The performance obligations are satisfied at a point in time when the Company&#8217;s customer obtains control of the product, which is typically upon delivery. The Company invoices its customers after the products have been delivered and invoice payments are generally due within 30 to 90 days of the invoice date.  The Company determines the transaction price based on fixed consideration in its contractual agreements. Contract liabilities arise in certain circumstances when consideration is due for goods the Company has yet to provide. As the Company has identified only one distinct performance obligation, the transaction price is allocated entirely to product sales. In determining the transaction price, a significant financing component does not exist since the timing from when the Company delivers product to when the customers pay for the product is typically less than one year. Customers in certain countries pay in advance of product delivery. In those instances, payment and delivery typically occur in the same month. </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company records product sales net of any variable consideration, which includes discounts, allowances, rebates related to Medicaid and other government pricing programs, and distribution fees. The Company uses the expected value or most likely amount method when estimating its variable consideration, unless discount or rebate terms are specified within contracts. The identified variable consideration is recorded as a reduction of revenue at the time revenues from product sales are recognized. These estimates for variable consideration are adjusted to reflect known changes in factors and may impact such estimates in the quarter those changes are known. Revenue recognized does not include amounts of variable consideration that are constrained.  For the three months ended June 30, 2020 and 2019, net product sales outside of the United States were $39.0 million and $57.8 million, respectively, and net product sales in the United States were $36.2 million and $27.6 million, respectively. For the six months ended June 30, 2020 and 2019, net product sales outside of the United States were $79.8 million and $93.0 million, respectively, and net product sales in the United States were $63.6 million and $45.4 million, respectively.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In relation to customer contracts, the Company incurs costs to fulfill a contract but does not incur costs to obtain a contract.  These costs to fulfill a contract do not meet the criteria for capitalization and are expensed as incurred. The Company considers any shipping and handling costs that are incurred after the customer has obtained control of the product as a cost to fulfill a promise. Shipping and handling costs associated with finished goods delivered to customers are recorded as a selling expense.  </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaboration revenue</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The terms of these agreements typically include payments to the Company of one or more of the following: nonrefundable, upfront license fees; milestone payments; research funding and royalties on future product sales. In addition, the Company generates service revenue through agreements that generally provide for fees for research and development services and may include additional payments upon achievement of specified events.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At the inception of a collaboration arrangement, the Company needs to first evaluate if the arrangement meets the criteria in ASC Topic 808 &#8220;Collaborative Arrangements&#8221; to then determine if ASC Topic 606 is applicable by considering whether the collaborator meets the definition of a customer.  If the criteria are met, the Company assesses the promises in the arrangement to identify distinct performance obligations.  </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For licenses of intellectual property, the Company assesses, at contract inception, whether the intellectual property is distinct from other performance obligations identified in the arrangement.  If the licensing of intellectual property is determined to be distinct, revenue is recognized for nonrefundable, upfront license fees when the license is transferred to the customer and the customer can use and benefit from the license.  If the licensing of intellectual property is determined not to be distinct, then the license will be bundled with other promises in the arrangement into one distinct performance obligation.  The Company needs to determine if the bundled performance obligation is satisfied over time or at a point in time.  If the Company concludes that the nonrefundable, upfront license fees will be recognized over time, the Company will need to assess the appropriate method of measuring proportional performance.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For milestone payments, the Company assesses, at contract inception, whether the development or sales-based milestones are considered probable of being achieved.  If it is probable that a significant revenue reversal will occur, the Company will not record revenue until the uncertainty has been resolved.  Milestone payments that are contingent upon regulatory approval are not considered probable of being achieved until the applicable regulatory approvals or other external conditions are obtained as such conditions are not within the Company's control.  If it is probable that a significant revenue reversal will not occur, the Company will estimate the milestone payments using the most likely amount method.  The Company will re-assess the development and sales-based milestones each reporting period to determine the probability of achievement.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company recognizes revenue for reimbursements of research and development costs under collaboration agreements as the services are performed. The Company records these reimbursements as revenue and not as a reduction of research and development expenses as the Company has the risks and rewards as the principal in the research and development activities.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Allowance for doubtful accounts</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company maintains an allowance for estimated losses resulting from the inability of its customers to make required payments. The Company estimates uncollectible amounts based upon current customer receivable balances, the age of customer receivable balances, the customer&#8217;s financial condition and current economic trends. The allowance for doubtful accounts was $0.2 million as of June&#160;30, 2020 and $0.3 million as of December&#160;31, 2019. Bad debt expense was immaterial for the three and six month periods ended June&#160;30, 2020 and 2019. For the three and six month periods ended June&#160;30, 2020, no allowances were recorded for credit losses.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Indefinite-lived intangible assets</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indefinite-lived intangible assets consist of in process research and development ("IPR&amp;D").  IPR&amp;D acquired directly in a transaction other than a business combination is capitalized if the projects will be further developed or have an alternative future use; otherwise they are expensed. The fair values of IPR&amp;D projects and license agreement assets acquired in business combinations are capitalized. Several methods may be used to determine the estimated fair value of the IPR&amp;D and license agreement asset acquired in a business combination. The Company utilizes the "income method&#8221; and uses estimated future net cash flows that are derived from projected sales revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, and expected pricing and industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. Intangible assets with indefinite lives, including IPR&amp;D, are tested for impairment if impairment indicators arise and, at a minimum, annually. However, an entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that an indefinite-lived intangible asset&#8217;s fair value is less than its carrying amount. Otherwise, no further impairment testing is required. The indefinite-lived intangible asset impairment test consists of a one-step analysis that compares the fair value of the intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company considers many factors in evaluating whether the value of its intangible assets with indefinite lives may not be recoverable, including, but not </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">limited to, expected growth rates, the cost of equity and debt capital, general economic conditions, the Company's outlook and market performance of the Company's industry and recent and forecasted financial performance.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Goodwill</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Goodwill represents the amount of consideration paid in excess of the fair value of net assets acquired as a result of the Company&#8217;s business acquisitions accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing at a reporting unit level on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. The Company reassess its reporting units as part of its annual segment review. An entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Income Taxes</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">O</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">n March 27, 2020, the United States enacted the Coronavirus Aid, Relief, and Economic Security Act, referred to herein as the CARES Act, as a response to the economic uncertainty resulting from a strain of novel coronavirus, COVID-19. The CARES Act includes modifications for net operating loss carryovers and carrybacks, limitations of business interest expense for tax, immediate refund of alternative minimum tax (AMT) credit carryovers as well as a technical correction to the 2017 Tax Cuts and Jobs Act ("the 2017 Tax Act"), referred to herein as the U.S. Tax Act, for qualified improvement property. As of June 30, 2020, the Company expects that these provisions will not have a material impact. Tax provisions of the Act also include the deferral of certain payroll taxes, relief for retaining employees, and other provisions. The Company is evaluating the impact of the Act and currently expects to benefit from the deferral of certain payroll taxes and retention credit through the end of calendar year 2020. The ultimate impact of the CARES Act may differ from this estimate due to changes in interpretations and guidance that may be issued and actions the Company may take in response to the CARES Act. The Company will continue to assess the impact that various provisions will have on its business.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On December 22, 2017, the U.S. government enacted the 2017 Tax Act, which significantly revises U.S. tax law by, among other provisions, lowering the U.S. federal statutory income tax rate to 21%, imposing a mandatory one-time transition tax on previously deferred foreign earnings, and eliminating or reducing certain income tax deductions. The Global Intangible Low-tax Income ("GILTI") provisions of the 2017 Tax Act require the Company to include in its U.S. income tax return foreign subsidiary earnings in excess of an allowable return on the foreign subsidiary&#8217;s tangible assets. The Company has elected to account for GILTI tax in the period in which it is incurred, and therefore has not provided any deferred tax impacts of GILTI in its consolidated financial statements for the period ended&#160;June&#160;30, 2020. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss and credit carryforwards. Deferred tax assets and liabilities are measured at rates expected to apply to taxable income in the years in which those temporary differences and carryforwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the statement of operations in the period that includes the enactment date. A valuation allowance is recorded when it is not more likely than not that all or a portion of the net deferred tax assets will be realized.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company recorded a deferred tax liability in conjunction with the Merger of $122.0 million related to the tax basis difference in the IPR&amp;D indefinite-lived intangibles acquired. The Company's policy is to record a deferred tax liability related to acquired IPR&amp;D which may eventually be realized either upon amortization of the asset when the research is completed and a product is successfully launched or the write-off of the asset if it is abandoned or unsuccessful.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Leases</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. The Company has lease agreements which include lease and non-lease components, which the Company accounts for as a single lease component for all leases. Operating and finance leases are classified as right of use ("ROU") assets, short term lease liabilities, and long term lease liabilities. Operating and finance lease ROU assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. ROU assets are amortized and lease liabilities accrete to yield straight-line expense over the term of the lease. Lease payments included in the measurement of the lease liability are comprised of fixed payments. </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Variable lease payments associated with the Company&#8217;s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented in the Company&#8217;s consolidated statements of operations in the same line item as expense arising from fixed lease payments for operating leases.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet and the Company recognizes lease expense for these leases on a straight-line basis over the lease term.  The Company applies this policy to all underlying asset categories.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A lessee is required to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As most of the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The Company gives consideration to its recent debt issuances as well as publicly available data for instruments with similar characteristics when calculating its incremental borrowing rates.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The lease term for all of the Company&#8217;s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. Leasehold improvements are capitalized and depreciated over the lesser of useful life or lease term. See Note 4 Leases for additional information. </span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Impact of recently adopted accounting pronouncements</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the FASB issued ASU 2019-12,"Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&#8221;.  ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principals in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending the existing guidance. For public business entities, the guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. For all other entities, it is effective for annual periods beginning after December 15, 2021 and interim periods in annual periods beginning after December 15, 2022. Early adoption is permitted, including adoption in any interim period. The Company early adopted this guidance January 1, 2020. The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June&#160;2016, the FASB issued ASU No.&#160;2016-13, &#8220;Financial Instruments &#8212; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#8221;. This standard requires financial assets measured at amortized cost basis to be presented at the net amount expected to be collected. This standard is effective for public companies who are SEC filers for fiscal years beginning after December&#160;15, 2019, including interim periods within those years. In November 2019, the FASB issued ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments - Credit Losses, which expands the scope of the practical expedient that allows entities to exclude the accrued interest component of amortized cost from various disclosures required by ASC 326 to also include certain disclosures required by ASC 320. Entities that elect to apply the practical expedient must disclose the total amount of accrued interest that they exclude from their disclosures of amortized cost. The amendments have the same effective dates as ASU 2016-13 (Topic 326) for entities that have not yet adopted that standard. The Company adopted ASU 2016-13 and ASU 2019-11 effective January 1, 2020. The adoption of the guidance did not have a material impact on the consolidated financial statements. The Company has updated its accounting policy for marketable securities within this footnote as well as its fair value footnote (Note 5) with additional disclosures as required by the standard upon adoption. </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued ASU 2018-13, "Fair Value Measurement (Topic 820), Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement". This standard eliminates certain disclosure requirements for fair value measurements for all entities, requires public entities to disclose certain new information and modifies some disclosure requirements. The new guidance is effective for all entities for fiscal years beginning after December 15, 2019 and for interim periods within those fiscal years. An entity is permitted to early adopt either the entire standard or only the provisions that eliminate or modify requirements. Entities can elect to early adopt in interim periods, including periods for which they have not yet issued financial statements or made their financial statements available for issuance. The Company adopted this guidance January 1, 2020.  The adoption of the guidance did not have a material impact on the consolidated financial statements. The Company has updated its fair value footnote (Note 5) with additional and modified disclosures as required by the standard upon adoption. </span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued ASU 2018-15,"Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract". ASU 2018-15 requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in Accounting Standards Codification 350-40 to determine which implementation costs to defer and recognize as an asset. For public business entities, the guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2019. For all other entities, it is effective for annual periods beginning after </span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">December 15, 2020 and interim periods in annual periods beginning after December 15, 2021. Early adoption is permitted, including adoption in any interim period for all entities. The Company adopted this guidance January 1, 2020.  The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2018, the FASB issued ASU 2018-18,"Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&#8221;.  ASU 2018-18 provides guidance on whether certain transactions between collaborative arrangement participants should be accounted for with revenue under Topic 606. For public business entities, the guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2019. For all other entities, it is effective for annual periods beginning after December 15, 2020 and interim periods in annual periods beginning after December 15, 2021. Early adoption is permitted, including adoption in any interim period for all entities.  The Company adopted this guidance January 1, 2020.  The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633765833448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">LeasesThe Company leases office space in South Plainfield, New Jersey for its principal office under three noncancelable operating leases through May 2022 and August 2024, in addition to office space in various countries for international employees primarily through workspace providers. The Company also leases certain vehicles, lab equipment, and office equipment under operating leases. The Company&#8217;s leases have remaining operating lease terms ranging from 0.3 years to 6.9 years and certain of the leases include renewal options to extend the lease for up to 10 years. Rent expense was approximately $2.6 million, $5.0 million, $1.1 million and $2.1 million for the three and six month periods ended June 30, 2020 and 2019, respectively. <div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">&#8232;&#8232;On June 19, 2020, the Company entered into a commercial manufacturing service agreement for a term of 12.5 years with MassBiologics of the University of Massachusetts Medical School ("MassBio"). The agreement will expire on December 31, 2032 unless the Company terminates it on 24 months prior written notice to MassBio. Pursuant to the terms of the agreement, MassBio agreed to provide the Company with four dedicated rooms for its gene therapy AADC program. The Company concluded that the agreement contains an embedded lease as the Company controls the use of the four dedicated rooms and the equipment therein. As the present value of the facilities exceeds the assessed fair value, the Company determined that it is a finance lease. Given that the embedded finance lease is designed for the production of PTC&#8217;s AADC program and would not have an alternate use outside the PTC gene therapy platform without incurring significant costs, the Company determined that the lease should be treated as research and development expense under ASC 730 and accordingly, expensed the present value of all g</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">uaranteed future cash payments of $41.2 million during the three and six month periods ending June 30, 2020. Additionally, during the three and six month periods ending June 30, 2020, the Company did not record finance lease costs as these amounts were not material due to timing of entering into the lease. The Company will record finance lease costs in the third quarter of 2020. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The components of operating lease expense were as follows:</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:33.672%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.643%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.643%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.643%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.501%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30, 2019</span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating Lease Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fixed lease cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,970&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">835&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,089&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,647&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Variable lease cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">507&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">161&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">734&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">304</span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term lease cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">88&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">88&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">165&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">141</span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating lease cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,565&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,084&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,988&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,092&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/></tr></table></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total operating lease cost is a component of operating expenses on the consolidated statements of operations. </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Supplemental balance sheet information related to leases was as follows:</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:56.187%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:18.614%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.615%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease ROU asset</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,475&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,693&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities- current</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,868&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,153&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities- noncurrent</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,510&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,018&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating lease liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,378&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,171&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8232;&#8232;</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:56.064%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:18.674%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.386%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.676%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance lease liabilities- current</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,180&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance lease liabilities- noncurrent</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,031&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total finance lease liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,211&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8232;Operating lease ROU asset is a component of deposits and other assets on the consolidated balance sheets. The current portion of operating lease liabilities is a component of other current liabilities on the consolidated balance sheets. The long term portion of operating lease liabilities is a component of other long term liabilities on the consolidated balance sheets.  The Company entered into a lease agreement with COE Bridgewater LLC on March 20, 2020 relating to the lease of office and laboratory space located in Bridgewater, New Jersey. This lease replaced the Company's existing lease on the property beginning on May 1, 2020 and includes additional rental property of approximately 59,000 square feet and is the primary driver of the increase in total operating lease ROU asset and total operating lease liability from December 31, 2029 to June 30, 2020.  </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Supplemental lease term and discount rate information related to leases was as follows as of June 30, 2020 and 2019:</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:56.125%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:18.644%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.385%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.646%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average remaining lease terms - operating leases (years)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.87</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.38</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average discount rate - operating leases</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.77&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.33&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average remaining lease terms - finance lease (years)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.50</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average discount rate - finance lease</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.80&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8232;</span></div><div style="margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Supplemental cash flow information related to leases was as follows as of June 30, 2020 and 2019:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:56.125%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:18.644%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.385%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.646%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Month Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating cash flows from operating leases</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,414&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,508&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financing cash flows from finance lease</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating leases</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,117&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,643&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance lease</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41,212</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8232;&#8232;Future minimum lease payments under non-cancelable leases as of June&#160;30, 2020 were as follows:</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:35.134%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:29.140%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:29.142%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating Leases</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance Lease</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020 (excludes the six months ended June 30, 2020)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,719&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,667&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,314&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,960&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024 and thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,844&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,504&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Imputed Interest expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,126&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,789&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,378&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,211&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-bottom:8pt;"><span><br/></span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In conjunction with the Asset Acquisition, the Company acquired BioElectron&#8217;s lease in Mountainview, California. As substantially all of the fair value of the gross assets acquired was related to vatiquinone, the relative fair value allocated to the right of use asset and corresponding lease liability for the Mountainview lease was determined to be immaterial, and accordingly is not included in the tables above. The future minimum lease payments for the Mountainview lease as of June&#160;30, 2020 are $0.9 million, $1.8 million, and $1.4 million for 2020, 2021 and 2022, respectively.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On August 4, 2019, the Company and Bristol-Myers Squibb Company, (the &#8220;Landlord&#8221;), entered into a Lease Agreement&#160;(the &#8220;Lease&#8221;), relating to the lease&#160;of approximately 185,000 square feet of office, manufacturing and laboratory space at a facility located in Hopewell Township, New Jersey (the &#8220;Campus&#8221;). On March 25, 2020, the Company entered into an amendment increasing the rented space to approximately 220,500 square feet.  As of June 30, 2020, the Lease had not yet commenced, and accordingly, is not reflected in the table above. The rental term of the Lease commenced on July 1, 2020 and has an initial term of fifteen years (the &#8220;Initial Term&#8221;), with two consecutive five year renewal periods, each at the Company&#8217;s option.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The aggregate rent for the Initial Term will be approximately $111.5 million. The rental rate for the renewal periods will be 95% of the Prevailing Market Rate (as defined in the Lease) and determined at the time of the exercise of the renewal. The Company is also responsible for maintaining certain insurance and the payment of proportional taxes, utilities and common area operating expenses. The Lease contains customary events of default, representations, warranties and covenants.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Subject to the terms of the Lease, the Company has a right of first refusal to rent certain other space of the Campus, which would be triggered upon the Landlord&#8217;s issuance of a second round proposal or letter of intent to another tenant for such space. </span></div>The Company also may seek to build a new separate building on the Campus, which may not contain less than 75,000 square feet (the &#8220;New Building&#8221;). Upon receipt of notice of the Company&#8217;s intention to build the New Building, the Landlord may, in its sole discretion, construct and lease the New Building to the Company or enter into a ground lease with the Company permitting the Company to construct the New Building. Rent terms for the New Building would be determined based on the land value, construction and project costs subject to whether the Landlord or Company constructs the New Building.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633763369368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisition</a></td>
<td class="text">Acquisition&#8232;&#8232;Censa Acquisition&#8232;<div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">On May 29, 2020, the Company acquired Censa, pursuant to the Censa Merger Agreement. Upon the closing of the Censa Merger, the Company paid to the Censa securityholders (i) cash consideration of $15.0&#160;million, which consisted of an upfront payment of $10.4&#160;million and an additional $4.6&#160;million for the net assets on Censa's opening balance sheet as of the date of the acquisition, and (ii) 845,364 shares of the Company's common stock, which were valued at $42.9&#160;million based on the closing stock price on the acquisition date. The number of shares issued was determined using a 30-day VWAP pursuant to the Censa Merger Agreement.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company determined that substantially all of the fair value is concentrated in PTC923 and accounted for the transaction as an asset acquisition under ASC 805-50.  The purchase price consisted of the cash consideration of $15.0&#160;million and $42.9&#160;million in the Company's common stock, in addition to $0.7&#160;million of acquisition costs. As such, the total consideration transferred was determined to be $58.6&#160;million. The opening balance sheet net assets of $4.6&#160;million, which consisted of cash of $3.8&#160;million and other current assets of $0.8&#160;million, were determined to be non-qualifying assets and recorded at their fair values, respectively. The remaining consideration of $54.0&#160;million was allocated to PTC923. As PTC923 is an IPR&amp;D asset, the Company concluded that it did not have any alternative future use, and accordingly, the fair value amount allocated to the IPR&amp;D was expensed. Of the $54.0&#160;million, $53.3&#160;million is included in research and development expense and $0.7&#160;million is included in selling, general, and administrative expense within the Company's statement of operations for the three and six month periods ended June 30, 2020. In addition, the Company incurred $0.3&#160;million of other expenses related to Censa, which was included in research and development expense for the three and six month periods ended June 30, 2020. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Subject to the terms and conditions of the Censa Merger Agreement, Censa securityholders may become entitled to receive contingent payments from the Company based on (i) the achievement of certain development and regulatory milestones up to an aggregate maximum amount of $217.5&#160;million for PTC923's two most advanced programs and receipt of a priority review voucher from the FDA as set forth in the Censa Merger Agreement, (ii) $109&#160;million in development and regulatory milestones for each additional indication of PTC923, (iii) the achievement of certain net sales milestones up to an aggregate maximum amount of $160.0&#160;million, (iv) a percentage of annual net sales during specified terms, ranging from single to low double digits of the applicable net sales threshold amount, and (v) any sublicense fees paid to the Company in consideration of any sublicense of Censa&#8217;s intellectual property to commercialize PTC923, on a country-by-country basis, which contingent payment shall equal to a mid-double digit percentage of any such sublicense fees. Pursuant to the Censa Merger Agreement, the Company has the option to pay the initial $30.0&#160;million development milestone, for the completion of enrollment of a Phase 3 clinical trial for PTC923 for PKU, if achieved, in cash or shares of the Company&#8217;s common stock (the &#8220;Initial Milestone&#8221;). The Company will record the milestone and royalty payments when they become payable. Milestone payments prior to FDA approval of PTC923 for PKU (or other indications) will be expensed accordingly and milestone payments that will only occur after PTC923 for PKU (or other indications) is FDA approved, will be capitalized and amortized over their expected useful lives.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633764650104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value of financial instruments and marketable securities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair value of financial instruments and marketable securities</a></td>
<td class="text">Fair value of financial instruments and marketable securities<div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company follows the fair value measurement rules, which provide&#160;guidance on the use of fair value in accounting and disclosure for assets and liabilities when such accounting and disclosure is called for by other accounting literature. These rules&#160;establish a fair value hierarchy for inputs to be used to measure fair value of financial assets and liabilities. This hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels: Level 1 (highest priority), Level 2, and Level 3 (lowest priority).</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;&#160;Level 1&#8212;Unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the balance sheet date.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 2&#8212;Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves,&#160;etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 3&#8212;Inputs are unobservable and reflect the Company&#8217;s assumptions as to what market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash equivalents and marketable securities are reflected in the accompanying financial statements at fair value. The carrying amount of receivables and accounts payable and accrued expenses approximates fair value due to the short-term nature of those instruments. The carrying amounts for borrowings under the credit and security agreement with MidCap Financial approximate fair value based on market activity for other debt instruments with similar characteristics and comparable risk.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2019, the Company purchased $4.0 million of shares of ClearPoint Neuro, Inc.'s ("ClearPoint"), formerly known as MRI Interventions, Inc., common stock, at a purchase price of $3.10 per share, in connection with a securities purchase agreement that the Company entered into with ClearPoint, a publicly traded medical device company. The Company determined that the equity investment represents a financial instrument and therefore, recorded it at fair value, which is readily determinable. The equity investment is a component of deposits and other assets on the consolidated balance sheet. During the three and six month periods ended June&#160;30, 2020, the Company recorded unrealized losses of $0.1 million and $1.6 million, respectively, which are components of other expense, net within the consolidated statement of operations. The fair value of the equity investment was $4.6 million as of June&#160;30, 2020. The Company classifies its equity investment in ClearPoint as a Level 1 asset within the fair value hierarchy, as the value is based on a quoted market price in an active market, which is not adjusted.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2020, the Company purchased a $10.0 million convertible note from ClearPoint that the Company can convert into ClearPoint shares at a conversion rate of $6.00 per share at any point throughout the term of the loan, which matures five years from the purchase date.  The Company determined that the convertible note represents an available for sale debt security and the Company has elected to record it at fair value under ASC 825.  The Company classifies its ClearPoint convertible debt security as a Level 2 asset within the fair value hierarchy, as the value is based on inputs other than quoted prices that are observable. The fair value of the ClearPoint convertible debt security is determined at each reporting period by utilizing a Black-Scholes option pricing model, as well as a present value of expected cash flows from the debt security utilizing the risk free rate and the estimated credit spread as of the valuation date as the discount rate. During the three and six month periods ended June&#160;30, 2020, the Company recorded an unrealized gain of $2.1 million and an unrealized loss of $0.7 million, respectively, which are components of other expense and other income, net within the consolidated statement of operations. The fair value of the convertible debt security was $9.3 million as of June&#160;30, 2020. The convertible debt security is considered to be long term and is included as a component of deposits and other assets on the consolidated balance sheet. Other than the equity investment and the convertible debt security, no other items included in deposits and other assets on the consolidated balance sheets are fair valued.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Fair value of certain marketable securities is based upon market prices using quoted prices in active markets for identical assets quoted on the last day of the period. In establishing the estimated fair value of the remaining investments, the Company used the fair value as determined by its investment advisors using observable inputs other than quoted prices.</span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following represents the fair value using the hierarchy described above for the Company&#8217;s financial assets and liabilities that are required to be measured at fair value on a recurring basis as of June&#160;30, 2020 and December&#160;31, 2019:</span></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%;"><tr><td style="width:1.0%;"/><td style="width:51.323%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.538%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.078%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.538%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.373%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.538%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.487%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.538%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.787%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted&#160;prices<br/>in&#160;active<br/>markets&#160;for<br/>identical&#160;assets<br/>(level&#160;1)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>other<br/>observable<br/>inputs<br/>(level&#160;2)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>unobservable<br/>inputs<br/>(level&#160;3)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">340,430&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">340,430&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity investment in ClearPoint</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,594&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,594&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ClearPoint convertible debt security</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,251&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,251&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred consideration payable</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,384&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,384&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration payable- development and regulatory milestones</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">136,100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">136,100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration payable- net sales milestones and royalties </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">89,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">89,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%;"><tr><td style="width:1.0%;"/><td style="width:51.244%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.537%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.209%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.537%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.799%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.537%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.537%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.181%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted&#160;prices<br/>in&#160;active<br/>markets&#160;for<br/>identical&#160;assets<br/>(level&#160;1)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>other<br/>observable<br/>inputs<br/>(level&#160;2)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>unobservable<br/>inputs<br/>(level&#160;3)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">398,535&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">398,535&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity investment in ClearPoint</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,194&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,194&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock appreciation rights liability</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,186&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,186&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred consideration payable</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration payable- development and regulatory milestones</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">290,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">290,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration payable- net sales milestones and royalties </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">65,800&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">65,800&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">No transfers of assets between Level 1, Level 2, or Level 3 of the fair value measurement hierarchy occurred during the periods ended June&#160;30, 2020 and December&#160;31, 2019.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following is a summary of marketable securities accounted for as available-for-sale securities at June&#160;30, 2020 and December&#160;31, 2019:</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:44.120%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.741%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross&#160;Unrealized</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,638&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">178&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,816&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">221,068&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,882&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">223,950&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,492&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">332&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,823&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government obligations</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,823&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,841&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">337,021&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,411&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">340,430&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:44.120%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.741%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross&#160;Unrealized</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">157,936&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">162&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">158,098&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">188,778&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">576&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(20)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">189,334&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51,062&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51,103&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">397,776&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">787&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(28)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">398,535&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For available for sale debt securities in an unrealized loss position, the Company assesses whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security's amortized cost basis is written down to fair value. For </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">the three month and six month periods ended June&#160;30, 2020, no write downs occurred. &#160;The Company does not intend to sell the investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be maturity. The Company also reviews its available for sale debt securities in an unrealized loss position and evaluates whether the decline in fair value has resulted from credit losses or other factors. This review is subjective, as it requires management to evaluate whether an event or change in circumstances has occurred in that period that may be related to credit issues. For the three month and six month periods ended June&#160;30, 2020, no allowance was recorded for credit losses. Unrealized gains and losses are reported as a component of accumulated other comprehensive (loss) income in stockholders&#8217; equity. </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three month and six month periods ended June&#160;30, 2020, the Company had $0.2&#160;million realized gains from the sale of marketable securities. Realized gains are reported as a component of interest expense, net in the consolidated statement of operations.</span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of&#160;June&#160;30, 2020 are as follows:</span></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:19.585%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.334%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.334%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.334%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.334%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.334%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.341%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="33" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Securities in an unrealized loss position less than 12 months</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Securities in an unrealized loss position greater than 12 months</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">594&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">594&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government obligations</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,602&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,602&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,196&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,196&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of&#160;December&#160;31, 2019 are as follows:</span></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:19.585%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.334%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.334%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.334%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.334%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.334%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.341%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="33" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Securities in an unrealized loss position less than 12 months</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Securities in an unrealized loss position greater than 12 months</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(20)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">71,779&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(20)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">71,779&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,211&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,211&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(28)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">95,990&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(28)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">95,990&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Marketable securities on the balance sheet at June&#160;30, 2020 and December&#160;31, 2019 mature as follows:</span></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.060%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less&#160;Than<br/>12&#160;Months</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">More&#160;Than<br/>12&#160;Months</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,816&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">168,250&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55,700&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,320&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,503&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government obligations</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,201&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,640&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">255,587&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">84,843&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.060%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less&#160;Than<br/>12&#160;Months</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">More&#160;Than<br/>12&#160;Months</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">158,098&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">139,596&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49,738&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,724&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,379&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">342,418&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56,117&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company classifies all of its marketable securities as current as they are all available for sale and are available for current operations.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Convertible senior notes</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2015, the Company issued $150.0 million of 3.00% convertible senior notes due August&#160;15, 2022 (the &#8220;2022 Convertible Notes&#8221;). In September 2019, the Company issued $287.5 million of 1.50% convertible senior notes due September&#160;15, 2026 (the &#8220;2026 Convertible Notes,&#8221; together with the &#8220;2022 Convertible Notes,&#8221; the &#8220;Convertible Notes&#8221;). The Company separately accounted for the liability and equity components of the Convertible Notes by allocating the proceeds between the liability component and equity component, as further discussed in Note&#160;11. The fair value of the Convertible Notes, which differs from their carrying values, is influenced by interest rates, the Company&#8217;s stock price and stock price volatility and is determined by prices for the Convertible Notes observed in market trading which are Level&#160;2 inputs. The estimated fair value of the 2022 Convertible Notes at June&#160;30, 2020 and December&#160;31, 2019 was $175.2 million and $171.2 million, respectively. The estimated fair value of the 2026 Convertible Notes at June&#160;30, 2020 and December&#160;31, 2019 was $343.8 million and $335.0 million, respectively.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Deferred and contingent consideration payable</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the Merger Agreement, Agilis equityholders were previously entitled to receive contingent consideration payments from the Company based on&#160;the achievement of certain development milestones up to an aggregate maximum amount of $60.0 million and&#160;the achievement of certain regulatory approval milestones together with a milestone payment following the receipt of a priority review voucher up to an aggregate maximum amount of $535.0 million. The Company was required to pay $40.0 million of development milestone payments upon the passing of the second anniversary of the closing of the Merger, regardless of whether the applicable milestones have been achieved. The $40.0 million of development milestones were classified as deferred consideration on the Company's consolidated balance sheets. </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the terms of the Rights Exchange Agreement, in the three month period ended June 30, 2020, the Company issued 2,821,176 shares of its common stock and paid $36.9&#160;million in the aggregate, to Participating Rightholders, who in exchange have canceled and forfeited their rights under the Merger Agreement to receive (i) $174.0&#160;million, in the aggregate, of potential milestone payments based on the achievement of certain regulatory milestones and (ii) $37.6&#160;million, in the aggregate, of $40.0&#160;million in development milestone payments, or the deferred consideration, that would have been due upon the passing of the second anniversary of the closing of the Merger. As a result of the Rights Exchange Agreement, the remaining deferred consideration payable at June&#160;30, 2020 was $2.4 million, which was also determined to be the fair value. The Company did not apply a discount, as the milestones will be paid within one calendar year.  Accordingly, as of June&#160;30, 2020, the $2.4 million of the deferred consideration payable was classified as current on the balance sheet.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As of result of the Rights Exchange Agreement, the Company recognized a gain of $0.7&#160;million on the settlement of the development milestones and a loss of $11.3&#160;million on the settlement of the regulatory milestones. The $0.7&#160;million gain and $11.3&#160;million loss are included in the settlement of deferred and contingent consideration in the Company&#8217;s statement of operations for the three and six month periods ended June 30, 2020. Additionally, as of the date of the Rights Exchange Agreement, the Company recognized a gain on the fair value of the contingent consideration of $1.0&#160;million related to the portion of regulatory milestones that were forfeited, which is included in the change in fair value of the deferred and contingent liability within the Company&#8217;s statement of operations for the three and six month periods ended June 30, 2020. This non-recurring Level 3 fair value measurement was estimated using the same valuation methoolody and unobservable inputs for development and regulatory milestones in the Level 3 valuation section below. In conjunction with the Rights Exchange Agreement, the Company also incurred $2.0 million of transaction fees, which were included in other expense in the Company&#8217;s statement of operations for the three and six month periods ended June 30, 2020.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Level 3 valuation</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The stock appreciation rights ("SARs") liability is classified in other liabilities on the Company&#8217;s consolidated balance sheets. The SARs liability is marked-to-market each reporting period with the change in fair value recorded as compensation expense on the Company&#8217;s consolidated statements of operations until the SARs vest. The fair value of the SARs liability is determined at each reporting period by utilizing the Black-Scholes option pricing model. The last payment of the SARs liability was made in the three month period ended March 31, 2020, and accordingly, the balance of the SARS liability as of June 30, 2020 was $0. </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The contingent consideration payable is fair valued each reporting period with the change in fair value recorded as a gain or loss within the change in the fair value of deferred and contingent consideration on the consolidated statements of operations.  The fair value of the development and regulatory milestones is estimated utilizing a probability adjusted, discounted cash flow approach. The discount rates are estimated utilizing Corporate B rated bonds maturing in the years of expected payments based on the Company&#8217;s estimated development timelines for the acquired product candidate. At June&#160;30, 2020, the weighted average discount rate for the development and regulatory milestones was 5.4% and the weighted average probability of success was 43%.  The fair value of the net sales milestones and royalties is determined utilizing an option pricing model with Monte Carlo simulation to simulate a range of possible payment scenarios, and the average of the payments in these scenarios is then discounted to calculate present fair value. At June&#160;30, 2020, the weighted average discount rate for the net sales milestones and royalties was 12.0% and the weighted average probability of success for the net sales milestones was 50%.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The table presented below is a summary of changes in the fair value of the Company&#8217;s Level 3 valuations for the SARs liability, and the contingent consideration payable for the periods ended June&#160;30, 2020 and June&#160;30, 2019. </span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.549%;"><tr><td style="width:1.0%;"/><td style="width:50.533%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.644%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.033%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.644%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.033%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.475%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.038%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3 liabilities</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SARs</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration payable- development and regulatory milestones</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration payable- net sales milestones and royalties</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Beginning balance as of December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,186&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">290,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">65,800&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(15,220)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,800&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,186)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Rights Exchange settlement</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(139,180)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ending balance as of June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">136,100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">89,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.573%;"><tr><td style="width:1.0%;"/><td style="width:49.919%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.634%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.858%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.634%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.858%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.467%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.030%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3 liabilities</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SARs</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration payable- development and regulatory milestones</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration payable- net sales milestones and royalties</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Beginning balance as of December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,814&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">257,040&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,200&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,961&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,360&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,815)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ending balance as of June 30, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,960&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">277,400&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58,800&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following significant unobservable inputs were used in the valuation of the contingent consideration payable for the periods ended June&#160;30, 2020 and December&#160;31, 2019 and of the SARs liability for the period ended December 31, 2019:</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:18.998%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.415%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.481%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.415%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.823%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.121%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:21.494%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.415%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.038%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value </span></td><td colspan="3" rowspan="10" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Valuation Technique</span></td><td colspan="3" rowspan="10" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unobservable Input</span></td><td colspan="3" rowspan="10" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Range</span></td></tr><tr><td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration payable- development and regulatory milestones<br/></span></td><td colspan="3" rowspan="9" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$136,100</span></td><td colspan="3" style="display:none;"/><td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Probability-adjusted discounted cash flow</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Potential development and regulatory milestones</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">$0 - $381 million</span></div></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Probabilities of success</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">25% - 94%</span></div></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discount rates</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">4.6% - 6.1%</span></div></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Projected years of payments</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021 - 2027</span></td></tr><tr><td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent considerable payable- net sales milestones and royalties</span></td><td colspan="3" style="display:none;"/><td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$89,600</span></td><td colspan="3" style="display:none;"/><td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Option-pricing model with Monte Carlo simulation<br/></span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Potential net sales milestones</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">$0 - $150 million</span></div></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Probabilities of success</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">25% -94%</span></div></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Potential percentage of net sales for royalties </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">2% - 6%</span></div></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discount rate</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.0%</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Projected years of payments</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022 - 2039</span></td></tr></table></div><div style="text-align:center;margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:18.998%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.415%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.481%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.415%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.823%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.121%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:21.494%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.415%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.038%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value </span></td><td colspan="3" rowspan="15" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Valuation Technique</span></td><td colspan="3" rowspan="15" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unobservable Input</span></td><td colspan="3" rowspan="15" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Range</span></td></tr><tr><td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SARs</span></td><td colspan="3" rowspan="14" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$3,186</span></td><td colspan="3" style="display:none;"/><td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Option-pricing model</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Volatility</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28.93%</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk free interest rate</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.19%</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Strike price</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">$6.76 - $30.86</span></div></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of common stock</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$48.03</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected life</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.01 years</span></td></tr><tr><td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Contingent consideration payable- development and regulatory milestones</span></div><div style="text-align:center;"><span><br/></span></div></td><td colspan="3" style="display:none;"/><td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$290,500</span></td><td colspan="3" style="display:none;"/><td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Probability-adjusted discounted cash flow</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Potential development and regulatory milestones</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">$0- $555 million</span></div></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Probabilities of success</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">25% - 94%</span></div></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discount rates</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">2.2% - 4.7%</span></div></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Projected years of payments</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020 - 2026</span></td></tr><tr><td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent considerable payable- net sales milestones and royalties</span></td><td colspan="3" style="display:none;"/><td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$65,800</span></td><td colspan="3" style="display:none;"/><td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Option-pricing model with Monte Carlo simulation<br/></span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Potential net sales milestones</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">$0 - $150 million</span></div></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Probabilities of success</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">25% - 89%</span></div></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Potential percentage of net sales for royalties </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">2% - 6%</span></div></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discount rate</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14.5%</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Projected years of payments</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021 - 2038</span></td></tr></table></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The contingent consideration payables are classified Level 3 liabilities as their valuation requires substantial judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for the various inputs to the valuation approaches, including but not limited to, assumptions involving probability adjusted sales estimates for the gene therapy platform and estimated discount rates, the estimated fair value could be significantly higher or lower than the fair value determined.</span></div><span></span>
</td>
<td class="text">Fair value of financial instruments and marketable securities<div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company follows the fair value measurement rules, which provide&#160;guidance on the use of fair value in accounting and disclosure for assets and liabilities when such accounting and disclosure is called for by other accounting literature. These rules&#160;establish a fair value hierarchy for inputs to be used to measure fair value of financial assets and liabilities. This hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels: Level 1 (highest priority), Level 2, and Level 3 (lowest priority).</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;&#160;Level 1&#8212;Unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the balance sheet date.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 2&#8212;Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves,&#160;etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 3&#8212;Inputs are unobservable and reflect the Company&#8217;s assumptions as to what market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash equivalents and marketable securities are reflected in the accompanying financial statements at fair value. The carrying amount of receivables and accounts payable and accrued expenses approximates fair value due to the short-term nature of those instruments. The carrying amounts for borrowings under the credit and security agreement with MidCap Financial approximate fair value based on market activity for other debt instruments with similar characteristics and comparable risk.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2019, the Company purchased $4.0 million of shares of ClearPoint Neuro, Inc.'s ("ClearPoint"), formerly known as MRI Interventions, Inc., common stock, at a purchase price of $3.10 per share, in connection with a securities purchase agreement that the Company entered into with ClearPoint, a publicly traded medical device company. The Company determined that the equity investment represents a financial instrument and therefore, recorded it at fair value, which is readily determinable. The equity investment is a component of deposits and other assets on the consolidated balance sheet. During the three and six month periods ended June&#160;30, 2020, the Company recorded unrealized losses of $0.1 million and $1.6 million, respectively, which are components of other expense, net within the consolidated statement of operations. The fair value of the equity investment was $4.6 million as of June&#160;30, 2020. The Company classifies its equity investment in ClearPoint as a Level 1 asset within the fair value hierarchy, as the value is based on a quoted market price in an active market, which is not adjusted.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2020, the Company purchased a $10.0 million convertible note from ClearPoint that the Company can convert into ClearPoint shares at a conversion rate of $6.00 per share at any point throughout the term of the loan, which matures five years from the purchase date.  The Company determined that the convertible note represents an available for sale debt security and the Company has elected to record it at fair value under ASC 825.  The Company classifies its ClearPoint convertible debt security as a Level 2 asset within the fair value hierarchy, as the value is based on inputs other than quoted prices that are observable. The fair value of the ClearPoint convertible debt security is determined at each reporting period by utilizing a Black-Scholes option pricing model, as well as a present value of expected cash flows from the debt security utilizing the risk free rate and the estimated credit spread as of the valuation date as the discount rate. During the three and six month periods ended June&#160;30, 2020, the Company recorded an unrealized gain of $2.1 million and an unrealized loss of $0.7 million, respectively, which are components of other expense and other income, net within the consolidated statement of operations. The fair value of the convertible debt security was $9.3 million as of June&#160;30, 2020. The convertible debt security is considered to be long term and is included as a component of deposits and other assets on the consolidated balance sheet. Other than the equity investment and the convertible debt security, no other items included in deposits and other assets on the consolidated balance sheets are fair valued.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Fair value of certain marketable securities is based upon market prices using quoted prices in active markets for identical assets quoted on the last day of the period. In establishing the estimated fair value of the remaining investments, the Company used the fair value as determined by its investment advisors using observable inputs other than quoted prices.</span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following represents the fair value using the hierarchy described above for the Company&#8217;s financial assets and liabilities that are required to be measured at fair value on a recurring basis as of June&#160;30, 2020 and December&#160;31, 2019:</span></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%;"><tr><td style="width:1.0%;"/><td style="width:51.323%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.538%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.078%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.538%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.373%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.538%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.487%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.538%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.787%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted&#160;prices<br/>in&#160;active<br/>markets&#160;for<br/>identical&#160;assets<br/>(level&#160;1)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>other<br/>observable<br/>inputs<br/>(level&#160;2)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>unobservable<br/>inputs<br/>(level&#160;3)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">340,430&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">340,430&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity investment in ClearPoint</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,594&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,594&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ClearPoint convertible debt security</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,251&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,251&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred consideration payable</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,384&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,384&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration payable- development and regulatory milestones</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">136,100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">136,100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration payable- net sales milestones and royalties </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">89,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">89,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%;"><tr><td style="width:1.0%;"/><td style="width:51.244%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.537%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.209%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.537%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.799%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.537%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.537%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.181%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted&#160;prices<br/>in&#160;active<br/>markets&#160;for<br/>identical&#160;assets<br/>(level&#160;1)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>other<br/>observable<br/>inputs<br/>(level&#160;2)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>unobservable<br/>inputs<br/>(level&#160;3)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">398,535&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">398,535&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity investment in ClearPoint</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,194&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,194&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock appreciation rights liability</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,186&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,186&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred consideration payable</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration payable- development and regulatory milestones</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">290,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">290,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration payable- net sales milestones and royalties </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">65,800&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">65,800&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">No transfers of assets between Level 1, Level 2, or Level 3 of the fair value measurement hierarchy occurred during the periods ended June&#160;30, 2020 and December&#160;31, 2019.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following is a summary of marketable securities accounted for as available-for-sale securities at June&#160;30, 2020 and December&#160;31, 2019:</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:44.120%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.741%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross&#160;Unrealized</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,638&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">178&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,816&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">221,068&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,882&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">223,950&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,492&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">332&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,823&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government obligations</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,823&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,841&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">337,021&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,411&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">340,430&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:44.120%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.741%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross&#160;Unrealized</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">157,936&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">162&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">158,098&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">188,778&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">576&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(20)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">189,334&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51,062&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51,103&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">397,776&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">787&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(28)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">398,535&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For available for sale debt securities in an unrealized loss position, the Company assesses whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security's amortized cost basis is written down to fair value. For </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">the three month and six month periods ended June&#160;30, 2020, no write downs occurred. &#160;The Company does not intend to sell the investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be maturity. The Company also reviews its available for sale debt securities in an unrealized loss position and evaluates whether the decline in fair value has resulted from credit losses or other factors. This review is subjective, as it requires management to evaluate whether an event or change in circumstances has occurred in that period that may be related to credit issues. For the three month and six month periods ended June&#160;30, 2020, no allowance was recorded for credit losses. Unrealized gains and losses are reported as a component of accumulated other comprehensive (loss) income in stockholders&#8217; equity. </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three month and six month periods ended June&#160;30, 2020, the Company had $0.2&#160;million realized gains from the sale of marketable securities. Realized gains are reported as a component of interest expense, net in the consolidated statement of operations.</span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of&#160;June&#160;30, 2020 are as follows:</span></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:19.585%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.334%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.334%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.334%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.334%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.334%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.341%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="33" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Securities in an unrealized loss position less than 12 months</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Securities in an unrealized loss position greater than 12 months</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">594&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">594&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government obligations</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,602&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,602&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,196&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,196&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of&#160;December&#160;31, 2019 are as follows:</span></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:19.585%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.334%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.334%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.334%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.334%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.334%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.341%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="33" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Securities in an unrealized loss position less than 12 months</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Securities in an unrealized loss position greater than 12 months</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(20)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">71,779&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(20)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">71,779&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,211&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,211&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(28)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">95,990&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(28)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">95,990&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Marketable securities on the balance sheet at June&#160;30, 2020 and December&#160;31, 2019 mature as follows:</span></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.060%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less&#160;Than<br/>12&#160;Months</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">More&#160;Than<br/>12&#160;Months</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,816&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">168,250&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55,700&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,320&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,503&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government obligations</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,201&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,640&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">255,587&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">84,843&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.060%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less&#160;Than<br/>12&#160;Months</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">More&#160;Than<br/>12&#160;Months</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">158,098&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">139,596&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49,738&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,724&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,379&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">342,418&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56,117&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company classifies all of its marketable securities as current as they are all available for sale and are available for current operations.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Convertible senior notes</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2015, the Company issued $150.0 million of 3.00% convertible senior notes due August&#160;15, 2022 (the &#8220;2022 Convertible Notes&#8221;). In September 2019, the Company issued $287.5 million of 1.50% convertible senior notes due September&#160;15, 2026 (the &#8220;2026 Convertible Notes,&#8221; together with the &#8220;2022 Convertible Notes,&#8221; the &#8220;Convertible Notes&#8221;). The Company separately accounted for the liability and equity components of the Convertible Notes by allocating the proceeds between the liability component and equity component, as further discussed in Note&#160;11. The fair value of the Convertible Notes, which differs from their carrying values, is influenced by interest rates, the Company&#8217;s stock price and stock price volatility and is determined by prices for the Convertible Notes observed in market trading which are Level&#160;2 inputs. The estimated fair value of the 2022 Convertible Notes at June&#160;30, 2020 and December&#160;31, 2019 was $175.2 million and $171.2 million, respectively. The estimated fair value of the 2026 Convertible Notes at June&#160;30, 2020 and December&#160;31, 2019 was $343.8 million and $335.0 million, respectively.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Deferred and contingent consideration payable</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the Merger Agreement, Agilis equityholders were previously entitled to receive contingent consideration payments from the Company based on&#160;the achievement of certain development milestones up to an aggregate maximum amount of $60.0 million and&#160;the achievement of certain regulatory approval milestones together with a milestone payment following the receipt of a priority review voucher up to an aggregate maximum amount of $535.0 million. The Company was required to pay $40.0 million of development milestone payments upon the passing of the second anniversary of the closing of the Merger, regardless of whether the applicable milestones have been achieved. The $40.0 million of development milestones were classified as deferred consideration on the Company's consolidated balance sheets. </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the terms of the Rights Exchange Agreement, in the three month period ended June 30, 2020, the Company issued 2,821,176 shares of its common stock and paid $36.9&#160;million in the aggregate, to Participating Rightholders, who in exchange have canceled and forfeited their rights under the Merger Agreement to receive (i) $174.0&#160;million, in the aggregate, of potential milestone payments based on the achievement of certain regulatory milestones and (ii) $37.6&#160;million, in the aggregate, of $40.0&#160;million in development milestone payments, or the deferred consideration, that would have been due upon the passing of the second anniversary of the closing of the Merger. As a result of the Rights Exchange Agreement, the remaining deferred consideration payable at June&#160;30, 2020 was $2.4 million, which was also determined to be the fair value. The Company did not apply a discount, as the milestones will be paid within one calendar year.  Accordingly, as of June&#160;30, 2020, the $2.4 million of the deferred consideration payable was classified as current on the balance sheet.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As of result of the Rights Exchange Agreement, the Company recognized a gain of $0.7&#160;million on the settlement of the development milestones and a loss of $11.3&#160;million on the settlement of the regulatory milestones. The $0.7&#160;million gain and $11.3&#160;million loss are included in the settlement of deferred and contingent consideration in the Company&#8217;s statement of operations for the three and six month periods ended June 30, 2020. Additionally, as of the date of the Rights Exchange Agreement, the Company recognized a gain on the fair value of the contingent consideration of $1.0&#160;million related to the portion of regulatory milestones that were forfeited, which is included in the change in fair value of the deferred and contingent liability within the Company&#8217;s statement of operations for the three and six month periods ended June 30, 2020. This non-recurring Level 3 fair value measurement was estimated using the same valuation methoolody and unobservable inputs for development and regulatory milestones in the Level 3 valuation section below. In conjunction with the Rights Exchange Agreement, the Company also incurred $2.0 million of transaction fees, which were included in other expense in the Company&#8217;s statement of operations for the three and six month periods ended June 30, 2020.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Level 3 valuation</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The stock appreciation rights ("SARs") liability is classified in other liabilities on the Company&#8217;s consolidated balance sheets. The SARs liability is marked-to-market each reporting period with the change in fair value recorded as compensation expense on the Company&#8217;s consolidated statements of operations until the SARs vest. The fair value of the SARs liability is determined at each reporting period by utilizing the Black-Scholes option pricing model. The last payment of the SARs liability was made in the three month period ended March 31, 2020, and accordingly, the balance of the SARS liability as of June 30, 2020 was $0. </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The contingent consideration payable is fair valued each reporting period with the change in fair value recorded as a gain or loss within the change in the fair value of deferred and contingent consideration on the consolidated statements of operations.  The fair value of the development and regulatory milestones is estimated utilizing a probability adjusted, discounted cash flow approach. The discount rates are estimated utilizing Corporate B rated bonds maturing in the years of expected payments based on the Company&#8217;s estimated development timelines for the acquired product candidate. At June&#160;30, 2020, the weighted average discount rate for the development and regulatory milestones was 5.4% and the weighted average probability of success was 43%.  The fair value of the net sales milestones and royalties is determined utilizing an option pricing model with Monte Carlo simulation to simulate a range of possible payment scenarios, and the average of the payments in these scenarios is then discounted to calculate present fair value. At June&#160;30, 2020, the weighted average discount rate for the net sales milestones and royalties was 12.0% and the weighted average probability of success for the net sales milestones was 50%.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The table presented below is a summary of changes in the fair value of the Company&#8217;s Level 3 valuations for the SARs liability, and the contingent consideration payable for the periods ended June&#160;30, 2020 and June&#160;30, 2019. </span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.549%;"><tr><td style="width:1.0%;"/><td style="width:50.533%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.644%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.033%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.644%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.033%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.475%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.038%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3 liabilities</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SARs</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration payable- development and regulatory milestones</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration payable- net sales milestones and royalties</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Beginning balance as of December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,186&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">290,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">65,800&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(15,220)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,800&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,186)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Rights Exchange settlement</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(139,180)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ending balance as of June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">136,100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">89,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.573%;"><tr><td style="width:1.0%;"/><td style="width:49.919%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.634%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.858%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.634%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.858%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.467%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.030%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3 liabilities</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SARs</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration payable- development and regulatory milestones</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration payable- net sales milestones and royalties</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Beginning balance as of December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,814&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">257,040&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,200&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,961&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,360&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,815)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ending balance as of June 30, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,960&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">277,400&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58,800&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following significant unobservable inputs were used in the valuation of the contingent consideration payable for the periods ended June&#160;30, 2020 and December&#160;31, 2019 and of the SARs liability for the period ended December 31, 2019:</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:18.998%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.415%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.481%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.415%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.823%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.121%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:21.494%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.415%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.038%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value </span></td><td colspan="3" rowspan="10" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Valuation Technique</span></td><td colspan="3" rowspan="10" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unobservable Input</span></td><td colspan="3" rowspan="10" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Range</span></td></tr><tr><td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration payable- development and regulatory milestones<br/></span></td><td colspan="3" rowspan="9" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$136,100</span></td><td colspan="3" style="display:none;"/><td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Probability-adjusted discounted cash flow</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Potential development and regulatory milestones</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">$0 - $381 million</span></div></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Probabilities of success</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">25% - 94%</span></div></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discount rates</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">4.6% - 6.1%</span></div></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Projected years of payments</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021 - 2027</span></td></tr><tr><td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent considerable payable- net sales milestones and royalties</span></td><td colspan="3" style="display:none;"/><td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$89,600</span></td><td colspan="3" style="display:none;"/><td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Option-pricing model with Monte Carlo simulation<br/></span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Potential net sales milestones</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">$0 - $150 million</span></div></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Probabilities of success</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">25% -94%</span></div></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Potential percentage of net sales for royalties </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">2% - 6%</span></div></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discount rate</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.0%</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Projected years of payments</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022 - 2039</span></td></tr></table></div><div style="text-align:center;margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:18.998%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.415%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.481%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.415%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.823%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.121%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:21.494%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.415%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.038%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value </span></td><td colspan="3" rowspan="15" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Valuation Technique</span></td><td colspan="3" rowspan="15" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unobservable Input</span></td><td colspan="3" rowspan="15" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Range</span></td></tr><tr><td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SARs</span></td><td colspan="3" rowspan="14" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$3,186</span></td><td colspan="3" style="display:none;"/><td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Option-pricing model</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Volatility</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28.93%</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk free interest rate</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.19%</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Strike price</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">$6.76 - $30.86</span></div></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of common stock</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$48.03</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected life</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.01 years</span></td></tr><tr><td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Contingent consideration payable- development and regulatory milestones</span></div><div style="text-align:center;"><span><br/></span></div></td><td colspan="3" style="display:none;"/><td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$290,500</span></td><td colspan="3" style="display:none;"/><td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Probability-adjusted discounted cash flow</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Potential development and regulatory milestones</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">$0- $555 million</span></div></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Probabilities of success</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">25% - 94%</span></div></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discount rates</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">2.2% - 4.7%</span></div></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Projected years of payments</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020 - 2026</span></td></tr><tr><td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent considerable payable- net sales milestones and royalties</span></td><td colspan="3" style="display:none;"/><td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$65,800</span></td><td colspan="3" style="display:none;"/><td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Option-pricing model with Monte Carlo simulation<br/></span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Potential net sales milestones</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">$0 - $150 million</span></div></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Probabilities of success</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">25% - 89%</span></div></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Potential percentage of net sales for royalties </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">2% - 6%</span></div></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discount rate</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14.5%</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Projected years of payments</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021 - 2038</span></td></tr></table></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The contingent consideration payables are classified Level 3 liabilities as their valuation requires substantial judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for the various inputs to the valuation approaches, including but not limited to, assumptions involving probability adjusted sales estimates for the gene therapy platform and estimated discount rates, the estimated fair value could be significantly higher or lower than the fair value determined.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633766040024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other comprehensive income (loss) and accumulated other comprehensive items<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Other comprehensive income (loss) and accumulated other comprehensive items</a></td>
<td class="text">Other comprehensive income (loss) and accumulated other comprehensive items<div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other comprehensive income (loss) includes changes in equity that are excluded from net income (loss), such as unrealized gains and losses on marketable securities.</span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following tables summarize other comprehensive income (loss) and the changes in accumulated other comprehensive items for the three and six months periods ended June&#160;30, 2020:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:57.590%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.740%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Gains/(Losses) On Marketable Securities, net of tax</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign Currency Translation</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Accumulated Other Comprehensive Items</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at March 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">692&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,677)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,985)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,718&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,749)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8,031)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amounts reclassified from other comprehensive items</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,718&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,749)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8,031)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,410&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(13,426)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,016)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:57.590%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.740%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized<br/>Gains/(Losses)<br/>On<br/>Marketable<br/>Securities,&#160;net<br/>of&#160;tax</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign<br/>Currency<br/>Translation</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total<br/>Accumulated<br/>Other<br/>Comprehensive<br/>Items</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">755&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11,339)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,584)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,655&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,087)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">568&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amounts reclassified from other comprehensive items</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income (loss)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,655&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,087)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">568&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,410&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(13,426)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,016)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI http://asc.fasb.org/topic&amp;trid=2134417<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633766065096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts payable and accrued expenses<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accounts payable and accrued expenses</a></td>
<td class="text">Accounts payable and accrued expenses<div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accounts payable and accrued expenses at June&#160;30, 2020 and December&#160;31, 2019 consist of the following:</span></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.060%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employee compensation, benefits, and related accruals</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,861&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38,889&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Consulting and contracted research</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,452&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,969&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Professional fees</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,295&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,562&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sales allowance and other costs</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45,848&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41,155&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sales rebates and royalties</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56,870&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42,997&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,465&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,324&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,585&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,380&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">164,376&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">159,276&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633764793016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capitalization<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Capitalization</a></td>
<td class="text">Capitalization<div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2019, the Company entered into an At the Market Offering Sales Agreement (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald and RBC Capital Markets, LLC (together, the &#8220;Sales Agents&#8221;), pursuant to which, the Company may offer and sell shares of its common stock, having an aggregate offering price of up to $125.0 million from time to time through the Sales Agents by any method that is deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended. During the three and six month periods ending June 30, 2020, the Company issued and sold an aggregate of 106,309 and 368,514 shares of common stock pursuant to the Sales Agreement at a weighted average public offering price of $53.08 and $52.89 per share, respectively. During the three and six month periods ending June 30, 2020, the Company received net proceeds of $5.4&#160;million and $19.0 million, respectively, after deducting underwriting discounts and commissions and other offering expenses payable by the Company.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As a result of the Rights Exchange Agreement, during the three and six month periods ended June 30, 2020, the Company issued 2,821,176 shares of its common stock to Participating Rightholders. The shares had a fair value of $150.5&#160;million upon issuance.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As a result of the Censa Merger, during the three and six month periods ended June 30, 2020, the Company issued 845,364 shares of the Company's common stock to Censa security holders, which were valued at $42.9&#160;million based on the closing stock price on the acquisition date. The number of shares issued was determined using a 30-day VWAP pursuant to the Censa Merger Agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633766619624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net loss per share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net loss per share</a></td>
<td class="text">Net loss per share<div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Basic earnings per share is computed by dividing net loss by the weighted-average number of common shares outstanding. Diluted earnings per share is computed by dividing net loss by the weighted-average number of common shares plus the effect of any dilutive potential common shares outstanding during the period.</span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following tables set forth the computation of basic and diluted net loss per share:</span></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:34.173%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.407%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.475%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.407%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.615%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.474%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.615%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.614%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.620%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(181,427)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(41,789)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(294,114)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(113,902)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator for basic and diluted net loss per share</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">65,150,780&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55,912,748&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63,769,958&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">57,113,141&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss per share:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.78)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.75)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.61)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.99)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:40.935%;"><tr><td style="width:1.0%;"/><td style="width:98.000%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">*In the three and six months ended June&#160;30, 2020 and 2019, the Company experienced a net loss and therefore did not report any dilutive share impact.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table shows historical dilutive common share equivalents outstanding, which are not included in the above historical calculation, as the effect of their inclusion is anti-dilutive during each period.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:69.700%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.636%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.931%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock Options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,954,684&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,853,301&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested restricted stock awards and units</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">936,922&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">665,002&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,891,606&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,518,303&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633764738952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock award plan<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock award plan</a></td>
<td class="text">Stock award plan<div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On March&#160;5, 2013, the Company&#8217;s Board of Directors approved the 2013 Stock Incentive Plan, which provides for the granting of stock option awards, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards in the aggregate of 739,937 shares of common stock. On March&#160;5, 2013, the Company's Board of Directors approved a grant of 735,324 shares of restricted stock and 4,613 stock options. There are no additional shares available for issuance under this plan.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In 2009, the Company&#8217;s shareholders approved the 2009 Equity and Long-Term Incentive Plan, which provides for the granting of stock option awards, restricted stock awards, and other stock-based and cash-based awards, subject to certain adjustments and annual increases. In May&#160;2013, the Company&#8217;s Board of Directors and stockholders increased by 2,500,000 the number of shares authorized under the 2009 Equity and Long Term Incentive Plan, which provides for the granting of stock option awards, restricted stock awards, and other stock-based and cash-based awards. There are no additional shares available for issuance under this plan.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May&#160;2013, the Company&#8217;s Board of Directors and stockholders approved the 2013 Long Term Incentive Plan, which became effective upon the closing of the Company&#8217;s initial public offering.&#160; The 2013 Long Term Incentive Plan provides for the grant of incentive stock options, nonstatutory stock options, restricted stock awards and other stock-based awards. The number of shares of common stock reserved for issuance under the 2013 Long Term Incentive Plan is the sum of (1)&#160;122,296 shares of common stock available for issuance under the Company&#8217;s 2009 Equity and Long Term Incentive Plan and 2013 Stock Incentive Plan, (2) the number of shares (up to 3,040,444 shares) equal to the sum of the number of shares of common stock subject to outstanding awards under the Company&#8217;s 1998 Employee, Director and Consultant Stock Option Plan, 2009 Equity and Long Term Incentive Plan and 2013 Stock Incentive Plan that expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right plus (3)&#160;an annual increase, to be added on the first day of each fiscal year until the expiration of the 2013 Long Term Incentive Plan, equal to the lowest of 2,500,000 shares of common stock, 4% of the number of shares of common stock outstanding on the first day of the fiscal year and an amount determined by the Company&#8217;s Board of Directors. As of June&#160;30, 2020, awards for 914,406 shares of common stock are available for issuance under the 2013 Long Term Incentive Plan.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2020, the Company's Board of Directors approved the 2020 Inducement Stock Incentive Plan. The 2020 Inducement Stock Incentive Plan provides for the grant of incentive stock options, nonstatutory stock options, restricted stock awards and other stock-based awards for up to an aggregate of 1,000,000 shares of common stock. Any grants made under the 2020 Inducement Stock Incentive Plan must be made pursuant to the Nasdaq Listing Rule 5635(c)(4) inducement grant exception as a material component of the Company's new hires&#8217; employment compensation. As of June 30, 2020, awards for 442,880 shares of common stock are available for issuance under the 2020 Inducement Stock Incentive Plan.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From January&#160;1, 2020 through June&#160;30, 2020, the Company issued a total of 2,515,200 stock options to various employees.&#160; Of those, 542,450 were inducement grants for non-statutory stock options, all of which were made pursuant to the 2020 Inducement Stock Incentive Plan.</span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A summary of stock option activity is as follows:</span></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:41.777%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.909%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.909%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.740%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number&#160;of<br/>options</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-<br/>average<br/>exercise<br/>price</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-<br/>average<br/>remaining<br/>contractual<br/>term</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate<br/>intrinsic<br/>value (in<br/>thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,043,939&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.67&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,515,200&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50.98&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,034,288)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24.21&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited/Cancelled</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(570,167)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42.27&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at June 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,954,684&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35.84&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.48 years</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">183,488&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested or Expected to vest at June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,690,848&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39.16&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.86 years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">66,986&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable at June 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,512,252&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.61&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.85 years</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">110,222&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of grants made in the six months ended June&#160;30, 2020 was contemporaneously estimated on the date of grant using the following assumptions:</span></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:63.592%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.410%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:30.798%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended<br/>June 30, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">0.40% - 1.45%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">87.50% - 89.31%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">5.75 years</span></div></td></tr></table></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company assumed no expected dividends for all grants. The weighted average grant date fair value of options granted during the six month period ended June&#160;30, 2020 was $36.95 per share.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The expected term of options was estimated based on the Company's historical exercise data and the expected volatility of options was estimated based on the Company's historical stock volatility.  The risk-free rate of the options was based on U.S. Government Securities Treasury Constant Maturities yields at the date of grant for a term similar to the expected term of the option. </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Restricted Stock Awards and Restricted Stock Units</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8212;Restricted stock awards and restricted stock units are granted subject to certain restrictions, including in some cases service or time conditions (restricted stock). The grant-date fair value of restricted stock awards and restricted stock units, which have been determined based upon the market value of the Company&#8217;s shares on the grant date, are expensed over the vesting period.</span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes information on the Company&#8217;s restricted stock awards and units:</span></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:69.888%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.909%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted&#160;Stock&#160;Awards&#160;and&#160;Units</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number&#160;of<br/>Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted<br/>Average<br/>Grant<br/>Date&#160;Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">642,419&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24.50&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">589,070&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49.67&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(229,076)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23.53&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(65,491)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36.11&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested at June 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">936,922&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39.97&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Stock Appreciation Rights</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8212;SARs entitle the holder to receive, upon exercise, an amount of the Company's common stock or cash (or a combination thereof) determined by reference to appreciation, from and after the date of grant, in the fair market value of a share of the Company's common stock over the measurement price based on the exercise date.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May&#160;2016, a total of 897,290 SARs were granted to non-executive employees (the "2016 SARs"). The 2016 SARs vested annually in equal installments over four years and were settled in cash on each vest date, which required the Company to </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">remeasure the SARs at each reporting period until vesting occurs. For the six month period ended June&#160;30, 2020, a total of 132,136 SARs vested. The last payment of the SARs liability was made in the three month period ended March 31, 2020, and accordingly, the balance of the SARS liability as of June 30, 2020 was $0. </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Employee Stock Purchase Plan</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8212;In June 2016, the Company established an Employee Stock Purchase Plan (&#8220;ESPP&#8221; or the "Plan&#8221;) for certain eligible employees. The Plan is administered by the Company&#8217;s Board of Directors or a committee appointed by the Company's Board of Directors. The total number of shares available for purchase under the Plan is one million shares of the Company&#8217;s common stock. Employees may participate over a six month period through payroll withholdings and may purchase, at the end of the six month period, the Company&#8217;s common stock at a purchase price of at least 85% of the closing price of a share of the Company&#8217;s common stock on the first business day of the offering period or the closing price of a share of the Company&#8217;s common stock on the last business day of the offering period, whichever is lower. No participant will be granted a right to purchase the Company&#8217;s common stock under the Plan if such participant would own more than 5% of the total combined voting power of the Company or any subsidiary of the Company after such purchase. For the three and six month periods ended June&#160;30, 2020, the Company recorded $0.3 million and $0.7 million in compensation expense related to the ESPP.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company recorded share-based compensation expense in the statement of operations related to incentive stock options, nonstatutory stock options, restricted stock awards, restricted stock units and the ESPP as follows:</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:40.020%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.909%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.909%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:2.289%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.740%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,562&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,516&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,741&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,203&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,348&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,404&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,389&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,981&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,910&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,920&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,130&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,184&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, there was approximately $187.2 million of total unrecognized compensation cost related to unvested share-based compensation arrangements granted under the 2009 Equity and Long Term Incentive Plan, the 2013 Long Term Incentive Plan and equity awards made pursuant to the Nasdaq Listing Rule 5635(c)(4) inducement grant exception for new hires. This cost is expected to be recognized as share-based compensation expense over the weighted average remaining service period of approximately 3.08 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633766218776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">2017 Credit Facility</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2017, the Company entered into the Credit Agreement, which provided for a senior secured term loan facility of $60.0 million, of which $40.0 million was drawn by the Company on May 5, 2017 (the "Credit Facility"). The Company's ability to draw on the remaining $20.0 million under the senior secured term loan facility expired on December 31, 2018. The Company capitalized approximately $0.4 million of debt issuance costs, which were netted against the carrying value of the Credit Facility and were amortized over the term of the Credit Facility.  As of June&#160;30, 2020, the Company had made loan repayments of $21.7 million on the Credit Facility. The remaining balance of the Credit Facility as of&#160;June&#160;30, 2020&#160;was $18.3 million,&#160;which was classified as current portion of long term debt on the consolidated balance sheet.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Borrowings under the Credit Agreement bore interest at a rate per annum equal to the London Interbank Offered Rate, or LIBOR, (with a LIBOR floor rate of 1.00%) plus 6.15%. The Company was obligated to make interest only payments (payable monthly in arrears) through April 30, 2019. Commencing on May 1, 2019 and continuing for the remaining <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTM2Mg_e91d3869-d03c-4b8b-84d9-15ddf6e4e1da">twenty-four</span> months of the facility, the Company was required to make monthly interest payments and monthly principal payments. The principal payments were made based on straight-line amortization of the principal over the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMjc0ODc3OTA4OTc4OA_adc62e20-6b69-4ee6-aa71-28d59137d971">twenty-four</span> month period. The maturity date of the Credit Agreement was May 1, 2021, unless terminated earlier.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Credit Facility is subject to certain financial covenants. As of&#160;June&#160;30, 2020, the Company was in compliance with all required covenants. On July 1, 2020, the Company terminated the Credit Facility. Refer to Note 15 for further details.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">2026 Convertible Notes</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In&#160;September 2019, the Company issued, at par value,&#160;$287.5 million&#160;aggregate principal amount of&#160;1.50%&#160;convertible senior notes due 2026, which included an option to purchase up to an additional $37.5 million in aggregate principal amount of the 2026 Convertible Notes. The 2026 Convertible Notes bear cash interest at a rate of&#160;1.50%&#160;per year, payable semi-annually on&#160;March&#160;15&#160;and&#160;September&#160;15&#160;of each year, beginning on&#160;March 15, 2020. The 2026 Convertible Notes will mature on&#160;September 15, 2026, unless earlier repurchased or converted. The net proceeds to the Company from the offering were&#160;$279.3 million after deducting the initial purchasers&#8217; discounts and commissions and the offering expenses payable by the Company.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The 2026 Convertible Notes are governed by an indenture (the "2026 Convertible Notes Indenture") with U.S Bank National Association as trustee (the "2026 Convertible Notes Trustee").</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Holders may convert their 2026 Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding&#160;March 15, 2026&#160;only under the following circumstances:</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> during any calendar quarter commencing on or after&#160;December 31, 2019&#160;(and only during such calendar quarter), if the last reported sale price of the Company&#8217;s common stock for at least&#160;20&#160;trading days (whether or not consecutive) during a period of&#160;30&#160;consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to&#160;130%&#160;of the conversion price on each applicable trading day;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> during the&#160;<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMzQwMg_7f893db8-e0cf-4d5a-83ac-33f975ce7592">five</span>&#160;business day period after any&#160;<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMzQzNQ_36968acf-1345-44be-9245-319a6078d531">five</span>&#160;consecutive trading day period (the &#8220;measurement period&#8221;) in which the trading price (as defined in the 2026 Convertible Notes Indenture) per $1,000 principal amount of 2026 Convertible Notes for each trading day of the measurement period was less than&#160;98%&#160;of the product of the last reported sale price of the Company&#8217;s common stock and the conversion rate on each such trading day;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> during any period after the Company has issued notice of redemption until the close of business on the scheduled trading day immediately preceding the relevant redemption date; or</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> upon the occurrence of specified corporate events.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On or after March 15, 2026, until the close of business on the business day immediately preceding the maturity date, holders may convert their 2026 Convertible Notes at any time, regardless of the foregoing circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of the Company's common stock or any combination thereof at the Company's election.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The conversion rate for the 2026 Convertible Notes was initially, and remains, 19.0404 shares of the Company&#8217;s common stock per $1,000 principal amount of the 2026 Convertible Notes, which is equivalent to an initial conversion price of approximately&#160;$52.52 per share of the Company&#8217;s common stock. The conversion rate may be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is not permitted to redeem the 2026 Convertible Notes prior to September 20, 2023. The Company may redeem for cash all or any portion of the 2026 Convertible Notes, at its option, if the last reported sale price of its common stock has been at least 130% of the conversion price then in effect on the last trading day of, and for at least 19 other trading days (whether or not consecutive) during, any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100% of the principal amount of the 2026 Convertible Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the 2026 Convertible Notes, which means that the Company is not required to redeem or retire the 2026 Convertible Notes periodically. </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If the Company undergoes a &#8220;fundamental change&#8221; (as defined in the 2026 Convertible Notes Indenture), subject to certain conditions, holders of the 2026 Convertible Notes may require the Company to repurchase for cash all or part of their 2026 Convertible Notes at a repurchase price equal to 100% of the principal amount of the 2026 Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The 2026 Convertible Notes represent senior unsecured obligations and will rank senior in right of payment to the Company&#8217;s future indebtedness that is expressly subordinated in right of payment to the notes, equal in right of payment to the Company&#8217;s existing and future unsecured indebtedness that is not so subordinated, effectively junior in right of payment to any of the Company&#8217;s secured indebtedness to the extent of the value of the assets securing such indebtedness, and structurally subordinated to all existing and future indebtedness and other liabilities (including trade payables) incurred by the Company&#8217;s subsidiaries. The 2026 Convertible Notes Indenture contains customary events of default with respect to the 2026 Convertible Notes, including that upon certain events of default (including the Company&#8217;s failure to make any payment of principal or interest on the 2026 Convertible Notes when due and payable) occurring and continuing, the 2026 Convertible Notes Trustee by notice to the Company, or the holders of at least 25% in principal amount of the outstanding 2026 Convertible Notes by notice to the Company and the Convertible Notes Trustee, may, and the 2026 Convertible Notes Trustee at the request of such holders (subject to the provisions of the 2026 Convertible Notes Indenture) shall, declare 100% of the principal of and accrued and unpaid interest, if any, on all the 2026 Convertible Notes to be due and payable. In case of certain events of bankruptcy, insolvency or reorganization, involving the Company or a significant subsidiary, 100% of the principal of and accrued and unpaid interest on the 2026 Convertible Notes will automatically become due and payable. Upon such a declaration of acceleration, such principal and accrued and unpaid interest, if any, will be due and payable immediately.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for the 2026 Convertible Notes as a liability and equity component where the carrying value of the liability component will be valued based on a similar instrument. In accounting for the issuance of the 2026 Convertible Notes, the Company separated the 2026 Convertible Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of a similar liability that does not have an associated convertible feature. The carrying amount of the equity component representing the conversion option was determined by deducting the fair value of the liability component from the par value of the 2026 Convertible Notes as a whole. The excess of the principal amount of the liability component over its carrying amount, referred to as the debt discount, is amortized to interest expense over the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfODk3MQ_ee20cb45-d925-46df-bb1a-8dfa5015d89d">seven</span>-year term of the 2026 Convertible Notes. The equity component is not re-measured as long as it continues to meet the conditions for equity classification. The equity component recorded at issuance related to the 2026 Convertible Notes was $123.0 million&#160;and was recorded in additional paid-in capital.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In accounting for the transaction costs related to the issuance of the 2026 Convertible Notes, the Company allocated the total costs incurred to the liability and equity components of the 2026 Convertible Notes based on their relative values. Transaction costs attributable to the liability component are amortized to interest expense over the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfOTYwOA_9ed8f64e-ddb8-4035-b1f3-c92bbadb8041">seven</span>-year term of the 2026 Convertible Notes, and transaction costs attributable to the equity component are netted with the equity components in stockholders&#8217; equity. Additionally, the Company initially recorded a net deferred tax liability of $25.3 million in connection with the 2026 Convertible Notes.</span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The 2026 Convertible Notes consist of the following:</span></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:61.436%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.621%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.387%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.622%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liability&#160;component</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Principal</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">287,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">287,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Debt issuance costs</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,319)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,567)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Debt discount, net(1)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(112,877)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(119,350)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net carrying amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">170,304&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">163,583&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1)&#160;Included in the consolidated balance sheets within convertible senior notes (due 2026) and amortized to interest expense over the remaining life of the 2026 Convertible Notes using the effective interest rate method.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, the remaining contractual life of the 2026 Convertible Notes is approximately 6.2 years.</span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth total interest expense recognized related to the 2026 Convertible Notes:</span></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:77.631%;"><tr><td style="width:1.0%;"/><td style="width:48.282%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.306%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:21.163%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.553%;"/><td style="width:0.1%;"/><td colspan="3" style="display:none;"/><td style="width:0.1%;"/><td style="width:0.741%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:20.598%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.557%;"/><td style="width:0.1%;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contractual interest expense</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,066&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,142&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">124&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">248&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of debt discount</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,239&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,473&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,429&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,863&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effective interest rate of the liability component</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">2022 Convertible Notes</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In&#160;August&#160;2015, the Company issued, at par value,&#160;$150.0 million&#160;aggregate principal amount of&#160;3.00%&#160;convertible senior notes due 2022. The 2022 Convertible Notes bear cash interest at a rate of&#160;3.00%&#160;per year, payable semi-annually on&#160;February&#160;15&#160;and&#160;August&#160;15&#160;of each year, beginning on&#160;February&#160;15, 2016. The 2022 Convertible Notes will mature on&#160;August&#160;15, 2022, unless earlier repurchased or converted. The net proceeds to the Company from the offering were&#160;$145.4 million&#160;after deducting the initial purchasers&#8217; discounts and commissions and the offering expenses payable by the Company.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The 2022 Convertible Notes are governed by an indenture (the "2022 Convertible Notes Indenture") with U.S Bank National Association as trustee (the "2022 Convertible Notes Trustee").</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Holders may convert their 2022 Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding&#160;February&#160;15, 2022&#160;only under the following circumstances:</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> during any calendar quarter commencing on or after&#160;September&#160;30, 2015&#160;(and only during such calendar quarter), if the last reported sale price of the Company&#8217;s common stock for at least&#160;20&#160;trading days (whether or not consecutive) during a period of&#160;30&#160;consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to&#160;130%&#160;of the conversion price on each applicable trading day;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> during the&#160;<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTE4NTA_7f893db8-e0cf-4d5a-83ac-33f975ce7592">five</span>&#160;business day period after any&#160;<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTE4ODM_36968acf-1345-44be-9245-319a6078d531">five</span>&#160;consecutive trading day period (the &#8220;measurement period&#8221;) in which the trading price (as defined in the 2022 Convertible Notes Indenture) per $1,000 principal amount of 2022 Convertible Notes for each trading day of the measurement period was less than&#160;98%&#160;of the product of the last reported sale price of the Company&#8217;s common stock and the conversion rate on each such trading day;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> during any period after the Company has issued notice of redemption until the close of business on the scheduled trading day immediately preceding the relevant redemption date; or</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#183;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> upon the occurrence of specified corporate events.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On or after February&#160;15, 2022, until the close of business on the business day immediately preceding the maturity date, holders may convert their 2022 Convertible Notes at any time, regardless of the foregoing circumstances. Upon conversion, the Company will pay cash up to the aggregate principal amount of the 2022 Convertible Notes to be converted and deliver shares of its common stock in respect of the remainder, if any, of its conversion obligation in excess of the aggregate principal amount of 2022 Convertible Notes being converted.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The conversion rate for the 2022 Convertible Notes was initially, and remains, 17.7487 shares of the Company&#8217;s common stock per $1,000 principal amount of the 2022 Convertible Notes, which is equivalent to an initial conversion price of approximately&#160;$56.34&#160;per share of the Company&#8217;s common stock. The conversion rate may be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company was not permitted to redeem the 2022 Convertible Notes prior to August&#160;20, 2018. As of August 20, 2018, the Company may redeem for cash all or any portion of the 2022 Convertible Notes, at its option, if the last reported sale price of its common stock has been at least 130% of the conversion price then in effect on the last trading day of, and for at least 19 other trading days (whether or not consecutive) during, any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100% of the principal amount of the 2022 Convertible Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the 2022 Convertible Notes, which means that the Company is not required to redeem or retire the 2022 Convertible Notes periodically. There have been no redemptions to date.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If the Company undergoes a &#8220;fundamental change&#8221; (as defined in the 2022 Convertible Notes Indenture), subject to certain conditions, holders of the 2022 Convertible Notes may require the Company to repurchase for cash all or part of their 2022 Convertible Notes at a repurchase price equal to 100% of the principal amount of the 2022 Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The 2022 Convertible Notes represent senior unsecured obligations and will rank senior in right of payment to the Company&#8217;s future indebtedness that is expressly subordinated in right of payment to the notes, equal in right of payment to the Company&#8217;s existing and future unsecured indebtedness that is not so subordinated, effectively junior in right of payment to any of the Company&#8217;s secured indebtedness to the extent of the value of the assets securing such indebtedness, and structurally subordinated to all existing and future indebtedness and other liabilities (including trade payables) incurred by the Company&#8217;s subsidiaries. The 2022 Convertible Notes Indenture contains customary events of default with respect to the 2022 Convertible Notes, including that upon certain events of default (including the Company&#8217;s failure to make any payment of principal or interest on the 2022 Convertible Notes when due and payable) occurring and continuing, the 2022 Convertible Notes Trustee by notice to the Company, or the holders of at least 25% in principal amount of the outstanding 2022 Convertible Notes by notice to the Company and the Convertible Notes Trustee, may, and the 2022 Convertible Notes Trustee at the request of such holders (subject to the provisions of the 2022 Convertible Notes Indenture) shall, declare 100% of the principal of and accrued and unpaid interest, if any, on all the 2022 Convertible Notes to be due and payable. In case of certain events of bankruptcy, insolvency or reorganization, involving the Company or a significant subsidiary, 100% of the principal of and accrued and unpaid interest on the 2022 Convertible Notes will automatically become due and payable. Upon such a declaration of acceleration, such principal and accrued and unpaid interest, if any, will be due and payable immediately.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for the 2022 Convertible Notes as a liability and equity component where the carrying value of the liability component will be valued based on a similar instrument. In accounting for the issuance of the 2022 Convertible Notes, the Company separated the 2022 Convertible Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of a similar liability that does not have an associated convertible feature. The carrying amount of the equity component representing the conversion option was determined by deducting the fair value of the liability component from the par value of the 2022 Convertible Notes as a whole. The excess of the principal amount of the liability component over its carrying amount, referred to as the debt discount, is amortized to interest expense over the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTc2MzM_ee20cb45-d925-46df-bb1a-8dfa5015d89d">seven</span>-year term of the 2022 Convertible Notes. The equity component is not re-measured as long as it continues to meet the conditions for equity classification. The equity component recorded at issuance related to the 2022 Convertible Notes was&#160;$57.5 million&#160;and was recorded in additional paid-in capital.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In accounting for the transaction costs related to the issuance of the 2022 Convertible Notes, the Company allocated the total costs incurred to the liability and equity components of the 2022 Convertible Notes based on their relative values. Transaction costs attributable to the liability component are amortized to interest expense over the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk1Y2Y2MWE1YzcwNzQ5MTBhZTNjZjI5YzVlZTA4ODM4L3NlYzo5NWNmNjFhNWM3MDc0OTEwYWUzY2YyOWM1ZWUwODgzOF83Ni9mcmFnOjkxZjM1ZjVhZGVmMDRmMzM5YTZkNDdmZGJhNzAwMjhlL3RleHRyZWdpb246OTFmMzVmNWFkZWYwNGYzMzlhNmQ0N2ZkYmE3MDAyOGVfMTgyNzA_9ed8f64e-ddb8-4035-b1f3-c92bbadb8041">seven</span>-year term of the 2022 Convertible Notes, and transaction costs attributable to the equity component are netted with the equity components in stockholders&#8217; equity. Additionally, the Company initially recorded a net deferred tax liability of $22.3 million in connection with the 2022 Convertible Notes.</span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The 2022 Convertible Notes consist of the following:</span></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:61.343%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.595%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.596%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liability&#160;component</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Principal</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">150,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">150,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Debt issuance costs</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,104)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,329)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Debt discount, net(1)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(22,166)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(26,686)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net carrying amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">126,730&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">121,985&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1)&#160;Included in the consolidated balance sheets within convertible senior notes (due 2022) and amortized to interest expense over the remaining life of the 2022 Convertible Notes using the effective interest rate method.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, the remaining contractual life of the 2022 Convertible Notes is approximately 2.1 years.</span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth total interest expense recognized related to the 2022 Convertible Notes:</span></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.222%;"><tr><td style="width:1.0%;"/><td style="width:37.548%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.551%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.285%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.551%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.285%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.551%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.285%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.551%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.593%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contractual interest expense</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,125&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,131&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,244&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,241&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">114&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">103&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">225&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">202&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of debt discount</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,295&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,074&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,520&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,055&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,534&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,308&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,989&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,498&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effective interest rate of the liability component</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633765996216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and contingencies</a></td>
<td class="text"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Commitments</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">and contingencies</span><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under various agreements, the Company will be required to pay royalties and milestone payments upon the successful development and commercialization of products. The Company has entered into funding agreements with The Wellcome Trust Limited ("Wellcome Trust") for the research and development of small molecule compounds in connection with the Company's oncology and antibacterial programs. As the Company has discontinued development under its antibacterial program, it no longer expects that milestone and royalty payments from the Company to Wellcome Trust will apply under that agreement, resulting in a change to the total amount of development and regulatory milestone payments the Company may become obligated to pay for this program.  Under the oncology program funding agreement, to the extent that the Company develops and commercializes program intellectual property on a for-profit basis itself or in collaboration with a partner (provided the Company retains overall control of worldwide commercialization), the Company may become obligated to pay to Wellcome Trust development and regulatory milestone payments and single-digit royalties on sales of any research program product. The Company&#8217;s obligation to pay such royalties would continue on a country-by-country basis until the longer of the expiration of the last patent in the program intellectual property in such country covering the research program product and the expiration of market exclusivity of such product in such country. The Company&#8217;s first such milestone payment of $0.8 million payable to Wellcome Trust occurred in the second quarter of 2016.  Additional milestone payments of up to an aggregate of $22.4 million may become payable by the Company to Wellcome Trust under this agreement.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has also entered into a collaboration agreement with the SMA Foundation. The Company may become obligated to pay the SMA Foundation single-digit royalties on worldwide net product sales of any collaboration product that is successfully developed and subsequently commercialized or, if the Company outlicenses rights to a collaboration product, a specified percentage of certain payments the Company receives from its licensee. The Company is not obligated to make such payments unless and until annual sales of a collaboration product exceed a designated threshold. The Company&#8217;s obligation to make such payments would end upon the Company's payment to the SMA Foundation of a specified amount.&#160;</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the asset purchase agreement ("Asset Purchase Agreement") between the Company and Marathon Pharmaceuticals, LLC (now known as Complete Pharma Holdings, LLC), or Marathon, Marathon is entitled to receive contingent payments from the Company based on annual net sales of Emflaza up to a specified aggregate maximum amount over the expected commercial life of the asset. In addition, Marathon has the opportunity to receive a single $50.0 million sales-based milestone.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the Merger Agreement with Agilis, Agilis equityholders were previously entitled to receive contingent consideration payments from the Company based on (i)&#160;the achievement of certain development milestones up to an aggregate maximum amount of $60.0&#160;million, (ii)&#160;the achievement of certain regulatory approval milestones together with a milestone payment following the receipt of a priority review voucher up to an aggregate maximum amount of $535.0&#160;million, (iii)&#160;the achievement of certain net sales milestones up to an aggregate maximum amount of $150.0&#160;million, and (iv)&#160;a percentage of annual net sales for&#160;Friedreich ataxia and Angelman syndrome during specified terms, ranging from 2%-6%. The Company was required to pay $40.0 million of the development milestone payments upon the passing of the second anniversary of the closing of the Merger, regardless of whether the applicable milestones have been achieved. </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Pursuant to the terms of the Rights Exchange Agreement, the Participating Rightholders have canceled and forfeited their rights under the Merger Agreement to receive (i) $174.0&#160;million, in the aggregate, of potential milestone payments based on the achievement of certain regulatory milestones and (ii) $37.6&#160;million, in the aggregate, of $40.0&#160;million in development milestone payments that would have been due upon the passing of the second anniversary of the closing of the Merger, regardless of whether the milestones are achieved.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Rights Exchange Agreement has no effect on the Merger Agreement other than to provide for the cancellation and forfeiture of the Participating Rightholders&#8217; rights to receive $211.6&#160;million, in the aggregate, of the milestone payments described above. As a result, all other rights and obligations under the Merger Agreement remain in effect pursuant to their terms, including the Company&#8217;s obligation to pay up to an aggregate maximum amount of $22.4&#160;million upon the achievement of certain development milestones (representing the remaining portion of potential development milestone payments for which rights were not canceled and forfeited pursuant to the Rights Exchange Agreement after deducting the $37.6&#160;million for which rights were canceled and forfeited pursuant to the Rights Exchange Agreement from the $40.0&#160;million in development milestone payments that are due upon the passing of the second anniversary of the closing of the Acquisition), up to an aggregate maximum amount of $361.0&#160;million upon the achievement of certain regulatory milestones (representing the remaining portion of potential regulatory milestone payments for which rights were not canceled and forfeited pursuant to the Rights Exchange Agreement), up to a maximum aggregate amount of $150.0&#160;million upon the achievement of certain net sales milestones and a percentage of annual net sales for Friedreich ataxia and Angelman syndrome during specified terms, ranging from 2% to 6%, pursuant to the terms of the Merger Agreement.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Subject to the terms and conditions of the Asset Acquisition Agreement, BioElectron may become entitled to receive contingent milestone payments of up to $200.0 million (in cash or in shares of the Company&#8217;s common stock, as determined by the Company) from the Company based on the achievement of certain regulatory and net sales milestones.  Subject to the terms and conditions of the Asset Acquisition Agreement, BioElectron may also become entitled to receive contingent payments based on a percentage of net sales of certain products.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">Subject to the terms and conditions of the Censa Merger Agreement, Censa securityholders may become entitled to receive contingent payments from the Company based on (i) the achievement of certain development and regulatory milestones up to an aggregate maximum amount of $217.5&#160;million for PTC923's two most advanced programs and receipt of a priority review voucher from the FDA as set forth in the Censa Merger Agreement, (ii) $109&#160;million in development and regulatory milestones for each additional indication of PTC923, (iii) the achievement of certain net sales milestones up to an aggregate maximum amount of $160.0&#160;million, (iv) a percentage of annual net sales during specified terms, ranging from single to low double digits of the applicable net sales threshold amount, and (v) any sublicense fees paid to the Company in consideration of any sublicense of Censa&#8217;s intellectual property to commercialize PTC923, on a country-by-country basis, which contingent payment shall equal to a mid-double digit percentage of any such sublicense fees. Pursuant to the Censa Merger Agreement, the Company has the option to pay the initial $30.0&#160;million development milestone, for the completion of enrollment of a Phase 3 clinical trial for PTC923 for PKU, if achieved, in cash or shares of the Company&#8217;s common stock.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company also has a Collaboration and License Agreement with Akcea for the commercialization of Tegsedi and Waylivra, and products containing those compounds in countries in Latin America and the Caribbean (the "Akcea Collaboration and License Agreement").  Pursuant to the agreement, the Company paid Akcea an upfront licensing fee, which included an initial payment of $12.0 million. In 2019, a $6.0 million milestone was paid upon receipt of regulatory approval of Waylivra from the EMA and a $4.0 million milestone was paid upon regulatory approval of Tegsedi from ANVISA, the Brazilian health regulatory authority, upon receipt of regulatory approval for Waylivra from ANVISA. In addition, Akcea is eligible to receive an additional milestone payment of $4.0 million upon receipt of regulatory approval for Waylivra from ANVISA. Akcea is also entitled to receive royalty payments subject to certain terms set forth in the Akcea Collaboration and License Agreement.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has employment agreements with certain employees which require the funding of a specific level of payments, if certain events, such as a change in control or termination without cause, occur. Additionally, the Company has royalty payments associated with Translarna and Emflaza product net sales, payable quarterly or annually in accordance with the terms of the related agreements. </span></div>From time to time in the ordinary course of its business, the Company is subject to claims, legal proceedings and disputes, including as a result of patients seeking to participate in the Company's clinical trials or otherwise gain access to its product candidates. The Company is not currently aware of any material legal proceedings against it.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633765822344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue recognition<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue recognition</a></td>
<td class="text">Revenue recognition<div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Net product sales</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company views its operations and manages its business in one operating segment.  </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended June 30, 2020 and 2019, net product sales in the United States were $36.2 million and $27.6 million, respectively, consisting solely of Emflaza, and net product sales not in the United States were $39.0 million and $57.8 million, respectively, consisting of Translarna and Tegsedi. For the three months ended June 30, 2020 and 2019, the Company had a total of two and two distributors, respectively, that each accounted for over 10% of the Company's net product sales.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the six months ended June 30, 2020 and 2019, net product sales in the United States were $63.6 million and $45.4 million, respectively, consisting solely of Emflaza, and net product sales not in the United States were $79.8 million and $93.0 million, respectively, consisting of Translarna and Tegsedi. For the six months ended June 30, 2020 and 2019, the Company had a total of two and two distributors, respectively, that each accounted for over 10% of the Company's net product sales.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s contract liabilities balances as of June&#160;30, 2020 and as of December 31, 2019 were $7.7 million and $11.7 million, respectively. The Company did not have any contract assets as of June&#160;30, 2020 and as of December 31, 2019. During the three and six month periods ended June&#160;30, 2020, the Company recognized $2.0 million and $4.0 million of revenue, respectively, related to the amounts included in the contract liability balance at the beginning of the period. For the three and six month periods ended June&#160;30, 2019, the Company did not recognize any revenues relating to the contract liability balance at the beginning of the period. The Company has not made significant changes to the judgments made in applying ASC Topic 606 for the three and six month periods ending June&#160;30, 2020 and 2019.  </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Remaining performance obligations</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Remaining performance obligations&#160;represent the transaction price for goods the Company has yet to provide. As of June&#160;30, 2020 and December 31, 2019, the aggregate amount of the transaction price allocated to&#160;the remaining performance obligations&#160;relating to Translarna net product revenue was $7.7 million and $11.7 million, respectively.  The Company expects to recognize revenue within the next one year, as the specific timing for satisfying the performance obligations is contingent upon a number of factors, including customers&#8217; needs and schedules.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Collaboration revenue</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2011, the Company and the Spinal Muscular Atrophy Foundation (SMA Foundation) entered into a licensing and collaboration agreement with F. Hoffman-La Roche&#160;Ltd and Hoffman- La Roche&#160;Inc. (collectively, Roche) for a spinal muscular atrophy program. Under the terms of the agreement, Roche acquired an exclusive worldwide license to the Company&#8217;s spinal muscular atrophy program.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is eligible to receive additional payments from Roche if specified events are achieved with respect to each licensed product, including up to $135.0 million in research and development event milestones, up to $325.0 million in sales milestones upon achievement of specified sales events, and up to double digit royalties on worldwide annual net sales of a commercial product.  As of June&#160;30, 2020, the remaining potential research and development event milestones that can be received is $72.5 million. The remaining potential sales milestones as of June&#160;30, 2020 is $325.0 million upon achievement of certain sales events. In addition, the Company is eligible to receive up to double digit royalties on worldwide annual net sales of a commercial product.</span></div>For the three months ended June&#160;30, 2020, the Company did not recognize revenue related to the licensing and collaboration agreement with Roche. For the three months ended June 30, 2019, the Company recognized $0.1 million of revenue related to the licensing and collaboration agreement with Roche. For the six months ended June&#160;30, 2020 and 2019, the Company recognized revenue related to the licensing and collaboration agreement with Roche of $0.1 million and $0.1 million, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633876479240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets and goodwill<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible assets and goodwill</a></td>
<td class="text">Intangible assets and goodwill<div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Definite-lived intangibles</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 20, 2017, the Company completed its previously announced acquisition of all rights to Emflaza pursuant to the Asset Purchase Agreement, dated March 15, 2017, and amended on April 20, 2017, by and between the Company and Marathon. The assets acquired by the Company in the transaction include intellectual property rights related to Emflaza, inventories of Emflaza, and certain contractual rights related to Emflaza. In accordance with ASU 2017-01, the Company determined that substantially all of the fair value is concentrated in the Emflaza rights intangible asset and as such accounted for the transaction as an asset acquisition under ASC 805-50 and recorded an intangible asset of $148.4 million, which is being amortized to cost of product sales over its expected useful life of approximately seven years on a straight line basis.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Marathon is entitled to receive contingent payments from the Company based on annual net sales of Emflaza beginning in 2018, up to a specified aggregate maximum amount over the expected commercial life of the asset. In accordance with the guidance for an asset acquisition, the Company records the milestone payment when it becomes payable to Marathon and increases the cost basis for the Emflaza rights intangible asset. As of June&#160;30, 2020 and 2019, milestone payments of $12.2 million and $8.3 million, respectively, were recorded and are included on the balance sheet within accounts payable and accrued expenses. These payments are being amortized over the remaining useful life of the Emflaza rights asset on a straight line basis.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the Akcea Collaboration and License Agreement, in May 2019 the Company made a $6.0 million milestone payment to Akcea upon regulatory approval of Waylivra from the EMA. The payment was recorded as an intangible asset and is being amortized to cost of product sales over its expected useful life of approximately ten years on a straight line basis. Additionally, in December 2019, the Company made a $4.0 million milestone payment to Akcea upon regulatory approval of Tegsedi from ANVISA. The payment was recorded as an intangible asset and is being amortized to cost of product sales over its expected useful life of approximately ten years on a straight line basis.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Akcea is also entitled to receive royalty payments subject to certain terms set forth in the Akcea Collaboration and License Agreement related to sales of Waylivra. In accordance with the guidance for an asset acquisition, the Company will record royalty payments when they become payable to Akcea and increase the cost basis for the Waylivra intangible asset. </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three months ended June 30, 2020 and 2019, the Company recognized amortization expense of $8.7 million and $6.6 million, respectively, related to the Emflaza rights, Waylivra, and Tegsedi intangible assets. For the six months ended June 30, 2020 and 2019, the Company recognized amortization expense of $16.7 million and $12.7 million, respectively. The estimated future amortization of the Emflaza rights, Waylivra, and Tegsedi intangible assets is expected to be as follows:</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%;"><tr><td style="width:1.0%;"/><td style="width:77.675%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.589%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of June 30, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,460&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,920&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,920&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,920&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,094&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">132,314&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The weighted average remaining amortization period of the definite-lived intangibles as of June&#160;30, 2020 is 4.0 years.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Indefinite-lived intangibles</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the acquisition of the Company&#8217;s gene therapy platform from Agilis, the Company acquired rights to PTC-AADC, for the treatment of AADC deficiency. AADC deficiency is a rare CNS disorder arising from reductions in the enzyme AADC that result from mutations in the dopa decarboxylase gene. The gene therapy platform also includes an asset targeting Friedreich ataxia, a rare and life-shortening neurodegenerative disease caused by a single defect in the FXN gene which causes reduced production of the frataxin protein. Additionally, the gene therapy platform includes two other programs targeting CNS disorders, including Angelman syndrome, a rare, genetic, neurological disorder characterized by severe developmental delays.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In accordance with the acquisition method of accounting, the Company allocated the acquisition cost for the Merger to the underlying assets acquired and liabilities assumed, based upon the estimated fair values of those assets and liabilities at the date of acquisition.  The Company classified the fair value of the acquired IPR&amp;D as indefinite lived intangible assets until the successful completion or abandonment of the associated research and development efforts.&#160;The value allocated to the indefinite lived intangible assets was $576.5 million. There have been no changes to the balance of the indefinite-lived intangibles since the Merger.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Goodwill</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a result of the Merger on August 23, 2018, the Company recorded $82.3 million of goodwill. There were no changes to the recorded value of goodwill for the three and six month periods ended June&#160;30, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633764489720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent events</a></td>
<td class="text">Subsequent events<div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">MidCap Credit Facility Termination</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On July 1, 2020, the Company terminated the Credit Facility. In connection with the termination of the Credit Facility, the Company repaid outstanding principal and accrued interest thereunder totaling $18.4&#160;million and paid an additional $0.6&#160;million in termination and exit fees. All liens and security interests securing the term loan made pursuant to the Credit Facility were released upon termination.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633765917432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Basis of presentation</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying financial information as of June&#160;30, 2020 and for the three and six months ended June&#160;30, 2020 and 2019 has been prepared by the Company, without audit, pursuant to the rules&#160;and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States ("GAAP") have been condensed or omitted pursuant to such rules&#160;and regulations. These interim financial statements should be read in conjunction with the Company&#8217;s audited financial statements as of December&#160;31, 2019 and notes thereto included in the 2019 Form&#160;10-K.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the opinion of management, the unaudited financial information as of June&#160;30, 2020 and for the three and six months ended June&#160;30, 2020 and 2019 reflects all adjustments, which are normal recurring adjustments, necessary to present a fair statement </span></div>of financial position, results of operations, stockholders' equity, and cash flows. The results of operations for the three and six month period ended June&#160;30, 2020 are not necessarily indicative of the results to be expected for the year ended December&#160;31, 2020 or for any other interim period or for any other future year.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Use of estimates</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates in these consolidated financial statements have been made in connection with the calculation of net product sales, certain accruals related to the Company&#8217;s research and development expenses, valuation procedures for convertible notes, fair value of the contingent consideration, and the provision for or benefit from income taxes. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable securities</a></td>
<td class="text">Marketable securitiesThe Company considers securities with original maturities of greater than 90&#160;days to be available for sale securities. Securities under this classification are recorded at fair value and unrealized gains and losses within accumulated other comprehensive income. The estimated fair value of the available for sale securities is determined based on quoted market prices or rates for similar instruments. In addition, the cost of debt securities in this category is adjusted for amortization of premium and accretion of discount to maturity. For available for sale debt securities in an unrealized loss position, the Company assesses whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security's amortized cost basis is written down to fair value. If the criteria are not met, the Company evaluates whether the decline in fair value has resulted from a credit loss or other factors. In making this assessment, management considers, among other factors, the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security are compared to the amortized cost basis of the security. If the present value of the cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss, limited by the amount that the fair value is less than the amortized costs basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_InventoriesAndCostOfProductSalesPolicyTextBlock', window );">Inventory and cost of product sales</a></td>
<td class="text"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Inventory and cost of product sales</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Inventory</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Inventories are stated at the lower of cost and net realizable value with cost determined on a first-in, first-out basis by product. The Company capitalizes inventory costs associated with products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. Products which may be used in clinical development programs are included in inventory and charged to research and development expense when the product enters the research and development process and no longer can be used for commercial purposes. Inventory used for </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">marketing efforts are charged to selling, general and administrative expense. Amounts related to clinical development programs and marketing efforts are immaterial.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the components of the Company&#8217;s inventory for the periods indicated:</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:71.099%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.769%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">877&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">874&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Work in progress</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,666&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,652&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,830&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,759&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventory</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,373&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,285&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company periodically reviews its inventories for excess amounts or obsolescence and writes down obsolete or otherwise unmarketable inventory to its estimated net realizable value. For the three months ended June 30, 2020, inventory write downs were immaterial. For the six months ended June 30, 2020, the Company recorded a $0.2 million inventory write-down, primarily related to product approaching expiration.  No write downs were recorded for the three and six month periods ended June&#160;30, 2019. Additionally, though the Company&#8217;s product is subject to strict quality control and monitoring which it performs throughout the manufacturing processes, certain batches or units of product may not meet quality specifications resulting in a charge to cost of product sales. For the three and six month periods ended June&#160;30, 2020 and 2019, these amounts were immaterial.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cost of product sales</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cost of product sales consists of the cost of inventory sold, manufacturing and supply chain costs, storage costs, amortization of the acquired intangible asset and royalty payments associated with net product sales.  Production costs are expensed as cost of product sales when the related products are sold.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy', window );">Allowance for doubtful accounts</a></td>
<td class="text">Allowance for doubtful accountsThe Company maintains an allowance for estimated losses resulting from the inability of its customers to make required payments. The Company estimates uncollectible amounts based upon current customer receivable balances, the age of customer receivable balances, the customer&#8217;s financial condition and current economic trends.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy', window );">Indefinite-lived intangible assets</a></td>
<td class="text"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Indefinite-lived intangible assets</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indefinite-lived intangible assets consist of in process research and development ("IPR&amp;D").  IPR&amp;D acquired directly in a transaction other than a business combination is capitalized if the projects will be further developed or have an alternative future use; otherwise they are expensed. The fair values of IPR&amp;D projects and license agreement assets acquired in business combinations are capitalized. Several methods may be used to determine the estimated fair value of the IPR&amp;D and license agreement asset acquired in a business combination. The Company utilizes the "income method&#8221; and uses estimated future net cash flows that are derived from projected sales revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, and expected pricing and industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. Intangible assets with indefinite lives, including IPR&amp;D, are tested for impairment if impairment indicators arise and, at a minimum, annually. However, an entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that an indefinite-lived intangible asset&#8217;s fair value is less than its carrying amount. Otherwise, no further impairment testing is required. The indefinite-lived intangible asset impairment test consists of a one-step analysis that compares the fair value of the intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company considers many factors in evaluating whether the value of its intangible assets with indefinite lives may not be recoverable, including, but not </span></div>limited to, expected growth rates, the cost of equity and debt capital, general economic conditions, the Company's outlook and market performance of the Company's industry and recent and forecasted financial performance.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Goodwill</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Goodwill represents the amount of consideration paid in excess of the fair value of net assets acquired as a result of the Company&#8217;s business acquisitions accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing at a reporting unit level on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. The Company reassess its reporting units as part of its annual segment review. An entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Income Taxes</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">O</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">n March 27, 2020, the United States enacted the Coronavirus Aid, Relief, and Economic Security Act, referred to herein as the CARES Act, as a response to the economic uncertainty resulting from a strain of novel coronavirus, COVID-19. The CARES Act includes modifications for net operating loss carryovers and carrybacks, limitations of business interest expense for tax, immediate refund of alternative minimum tax (AMT) credit carryovers as well as a technical correction to the 2017 Tax Cuts and Jobs Act ("the 2017 Tax Act"), referred to herein as the U.S. Tax Act, for qualified improvement property. As of June 30, 2020, the Company expects that these provisions will not have a material impact. Tax provisions of the Act also include the deferral of certain payroll taxes, relief for retaining employees, and other provisions. The Company is evaluating the impact of the Act and currently expects to benefit from the deferral of certain payroll taxes and retention credit through the end of calendar year 2020. The ultimate impact of the CARES Act may differ from this estimate due to changes in interpretations and guidance that may be issued and actions the Company may take in response to the CARES Act. The Company will continue to assess the impact that various provisions will have on its business.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On December 22, 2017, the U.S. government enacted the 2017 Tax Act, which significantly revises U.S. tax law by, among other provisions, lowering the U.S. federal statutory income tax rate to 21%, imposing a mandatory one-time transition tax on previously deferred foreign earnings, and eliminating or reducing certain income tax deductions. The Global Intangible Low-tax Income ("GILTI") provisions of the 2017 Tax Act require the Company to include in its U.S. income tax return foreign subsidiary earnings in excess of an allowable return on the foreign subsidiary&#8217;s tangible assets. The Company has elected to account for GILTI tax in the period in which it is incurred, and therefore has not provided any deferred tax impacts of GILTI in its consolidated financial statements for the period ended&#160;June&#160;30, 2020. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss and credit carryforwards. Deferred tax assets and liabilities are measured at rates expected to apply to taxable income in the years in which those temporary differences and carryforwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the statement of operations in the period that includes the enactment date. A valuation allowance is recorded when it is not more likely than not that all or a portion of the net deferred tax assets will be realized.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company recorded a deferred tax liability in conjunction with the Merger of $122.0 million related to the tax basis difference in the IPR&amp;D indefinite-lived intangibles acquired. The Company's policy is to record a deferred tax liability related to acquired IPR&amp;D which may eventually be realized either upon amortization of the asset when the research is completed and a product is successfully launched or the write-off of the asset if it is abandoned or unsuccessful.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Leases</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. The Company has lease agreements which include lease and non-lease components, which the Company accounts for as a single lease component for all leases. Operating and finance leases are classified as right of use ("ROU") assets, short term lease liabilities, and long term lease liabilities. Operating and finance lease ROU assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. ROU assets are amortized and lease liabilities accrete to yield straight-line expense over the term of the lease. Lease payments included in the measurement of the lease liability are comprised of fixed payments. </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Variable lease payments associated with the Company&#8217;s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented in the Company&#8217;s consolidated statements of operations in the same line item as expense arising from fixed lease payments for operating leases.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet and the Company recognizes lease expense for these leases on a straight-line basis over the lease term.  The Company applies this policy to all underlying asset categories.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A lessee is required to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As most of the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The Company gives consideration to its recent debt issuances as well as publicly available data for instruments with similar characteristics when calculating its incremental borrowing rates.</span></div>The lease term for all of the Company&#8217;s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. Leasehold improvements are capitalized and depreciated over the lesser of useful life or lease term. See Note 4 Leases for additional information.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently issued accounting standards</a></td>
<td class="text"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Impact of recently adopted accounting pronouncements</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the FASB issued ASU 2019-12,"Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&#8221;.  ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principals in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending the existing guidance. For public business entities, the guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. For all other entities, it is effective for annual periods beginning after December 15, 2021 and interim periods in annual periods beginning after December 15, 2022. Early adoption is permitted, including adoption in any interim period. The Company early adopted this guidance January 1, 2020. The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June&#160;2016, the FASB issued ASU No.&#160;2016-13, &#8220;Financial Instruments &#8212; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#8221;. This standard requires financial assets measured at amortized cost basis to be presented at the net amount expected to be collected. This standard is effective for public companies who are SEC filers for fiscal years beginning after December&#160;15, 2019, including interim periods within those years. In November 2019, the FASB issued ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments - Credit Losses, which expands the scope of the practical expedient that allows entities to exclude the accrued interest component of amortized cost from various disclosures required by ASC 326 to also include certain disclosures required by ASC 320. Entities that elect to apply the practical expedient must disclose the total amount of accrued interest that they exclude from their disclosures of amortized cost. The amendments have the same effective dates as ASU 2016-13 (Topic 326) for entities that have not yet adopted that standard. The Company adopted ASU 2016-13 and ASU 2019-11 effective January 1, 2020. The adoption of the guidance did not have a material impact on the consolidated financial statements. The Company has updated its accounting policy for marketable securities within this footnote as well as its fair value footnote (Note 5) with additional disclosures as required by the standard upon adoption. </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued ASU 2018-13, "Fair Value Measurement (Topic 820), Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement". This standard eliminates certain disclosure requirements for fair value measurements for all entities, requires public entities to disclose certain new information and modifies some disclosure requirements. The new guidance is effective for all entities for fiscal years beginning after December 15, 2019 and for interim periods within those fiscal years. An entity is permitted to early adopt either the entire standard or only the provisions that eliminate or modify requirements. Entities can elect to early adopt in interim periods, including periods for which they have not yet issued financial statements or made their financial statements available for issuance. The Company adopted this guidance January 1, 2020.  The adoption of the guidance did not have a material impact on the consolidated financial statements. The Company has updated its fair value footnote (Note 5) with additional and modified disclosures as required by the standard upon adoption. </span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued ASU 2018-15,"Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract". ASU 2018-15 requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in Accounting Standards Codification 350-40 to determine which implementation costs to defer and recognize as an asset. For public business entities, the guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2019. For all other entities, it is effective for annual periods beginning after </span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">December 15, 2020 and interim periods in annual periods beginning after December 15, 2021. Early adoption is permitted, including adoption in any interim period for all entities. The Company adopted this guidance January 1, 2020.  The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2018, the FASB issued ASU 2018-18,"Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&#8221;.  ASU 2018-18 provides guidance on whether certain transactions between collaborative arrangement participants should be accounted for with revenue under Topic 606. For public business entities, the guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2019. For all other entities, it is effective for annual periods beginning after December 15, 2020 and interim periods in annual periods beginning after December 15, 2021. Early adoption is permitted, including adoption in any interim period for all entities.  The Company adopted this guidance January 1, 2020.  The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_InventoriesAndCostOfProductSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inventories and cost of revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_InventoriesAndCostOfProductSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for indefinite-lived intangible assets (that is, those intangible assets not subject to amortization). This accounting policy also may address how the entity assesses whether events and circumstances continue to support an indefinite useful life and how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32247-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32280-109318<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5144-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633763369368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Reconciliation of cash</a></td>
<td class="text"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheet that sum to the total of the same amounts shown in the statement of cash flows:</span></div><div style="text-align:center;margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.421%;"><tr><td style="width:1.0%;"/><td style="width:71.395%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.582%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.519%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.582%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.522%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Beginning of period- December 31, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">End of period- June 30, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">288,028&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">158,461&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash included in deposits and other assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Cash, cash equivalents and restricted cash per statement of cash flows</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">295,528&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">165,961&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the components of the Company&#8217;s inventory for the periods indicated:</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:71.099%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.769%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">877&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">874&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Work in progress</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,666&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,652&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,830&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,759&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventory</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,373&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,285&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633766030008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease costs</a></td>
<td class="text"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The components of operating lease expense were as follows:</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:33.672%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.643%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.643%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.643%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.501%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30, 2019</span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating Lease Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fixed lease cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,970&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">835&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,089&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,647&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Variable lease cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">507&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">161&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">734&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">304</span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term lease cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">88&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">88&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">165&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">141</span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating lease cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,565&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,084&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,988&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,092&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/></tr></table></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total operating lease cost is a component of operating expenses on the consolidated statements of operations. </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Supplemental balance sheet information related to leases was as follows:</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:56.187%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:18.614%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.615%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease ROU asset</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,475&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,693&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities- current</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,868&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,153&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities- noncurrent</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,510&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,018&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating lease liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,378&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,171&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:56.064%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:18.674%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.386%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.676%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance lease liabilities- current</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,180&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance lease liabilities- noncurrent</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,031&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total finance lease liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,211&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table>Supplemental lease term and discount rate information related to leases was as follows as of June 30, 2020 and 2019:<div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:56.125%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:18.644%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.385%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.646%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average remaining lease terms - operating leases (years)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.87</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.38</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average discount rate - operating leases</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.77&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.33&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average remaining lease terms - finance lease (years)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.50</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average discount rate - finance lease</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.80&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8232;</span></div><div style="margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Supplemental cash flow information related to leases was as follows as of June 30, 2020 and 2019:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:56.125%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:18.644%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.385%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.646%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Month Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating cash flows from operating leases</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,414&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,508&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financing cash flows from finance lease</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating leases</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,117&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,643&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance lease</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41,212</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lease payments</a></td>
<td class="text">Future minimum lease payments under non-cancelable leases as of June&#160;30, 2020 were as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:35.134%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:29.140%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:29.142%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating Leases</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance Lease</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020 (excludes the six months ended June 30, 2020)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,719&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,667&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,314&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,960&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024 and thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,844&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,504&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Imputed Interest expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,126&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,789&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,378&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,211&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633770140968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value of financial instruments and marketable securities - (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of financial assets and liabilities that are required to be measured at fair value on a recurring basis</a></td>
<td class="text"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following represents the fair value using the hierarchy described above for the Company&#8217;s financial assets and liabilities that are required to be measured at fair value on a recurring basis as of June&#160;30, 2020 and December&#160;31, 2019:</span></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%;"><tr><td style="width:1.0%;"/><td style="width:51.323%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.538%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.078%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.538%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.373%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.538%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.487%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.538%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.787%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted&#160;prices<br/>in&#160;active<br/>markets&#160;for<br/>identical&#160;assets<br/>(level&#160;1)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>other<br/>observable<br/>inputs<br/>(level&#160;2)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>unobservable<br/>inputs<br/>(level&#160;3)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">340,430&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">340,430&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity investment in ClearPoint</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,594&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,594&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ClearPoint convertible debt security</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,251&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,251&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred consideration payable</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,384&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,384&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration payable- development and regulatory milestones</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">136,100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">136,100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration payable- net sales milestones and royalties </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">89,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">89,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%;"><tr><td style="width:1.0%;"/><td style="width:51.244%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.537%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.209%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.537%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.799%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.537%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.537%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.181%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted&#160;prices<br/>in&#160;active<br/>markets&#160;for<br/>identical&#160;assets<br/>(level&#160;1)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>other<br/>observable<br/>inputs<br/>(level&#160;2)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>unobservable<br/>inputs<br/>(level&#160;3)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">398,535&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">398,535&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity investment in ClearPoint</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,194&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,194&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock appreciation rights liability</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,186&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,186&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred consideration payable</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration payable- development and regulatory milestones</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">290,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">290,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration payable- net sales milestones and royalties </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">65,800&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">65,800&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary of marketable securities accounted for as available-for-sale securities</a></td>
<td class="text"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following is a summary of marketable securities accounted for as available-for-sale securities at June&#160;30, 2020 and December&#160;31, 2019:</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:44.120%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.741%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross&#160;Unrealized</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,638&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">178&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,816&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">221,068&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,882&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">223,950&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,492&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">332&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,823&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government obligations</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,823&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,841&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">337,021&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,411&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">340,430&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:44.120%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.741%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross&#160;Unrealized</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">157,936&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">162&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">158,098&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">188,778&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">576&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(20)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">189,334&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51,062&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51,103&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">397,776&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">787&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(28)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">398,535&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Summary of unrealized losses and fair values of available-for-sale securities in a continuous unrealized loss position</a></td>
<td class="text"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of&#160;June&#160;30, 2020 are as follows:</span></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:19.585%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.334%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.334%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.334%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.334%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.334%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.341%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="33" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Securities in an unrealized loss position less than 12 months</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Securities in an unrealized loss position greater than 12 months</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">594&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">594&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government obligations</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,602&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,602&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,196&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,196&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of&#160;December&#160;31, 2019 are as follows:</span></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:19.585%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.334%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.334%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.334%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.334%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.334%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.341%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="33" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Securities in an unrealized loss position less than 12 months</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Securities in an unrealized loss position greater than 12 months</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(20)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">71,779&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(20)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">71,779&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,211&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,211&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(28)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">95,990&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(28)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">95,990&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of marketable securities on the balance sheet</a></td>
<td class="text"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Marketable securities on the balance sheet at June&#160;30, 2020 and December&#160;31, 2019 mature as follows:</span></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.060%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less&#160;Than<br/>12&#160;Months</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">More&#160;Than<br/>12&#160;Months</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,816&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">168,250&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55,700&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,320&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,503&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government obligations</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,201&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,640&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">255,587&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">84,843&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.060%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less&#160;Than<br/>12&#160;Months</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">More&#160;Than<br/>12&#160;Months</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">158,098&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">139,596&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49,738&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,724&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,379&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">342,418&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56,117&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of changes in the fair value of the Company's Level 3 valuation for warrant liability and SARs liability</a></td>
<td class="text"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following significant unobservable inputs were used in the valuation of the contingent consideration payable for the periods ended June&#160;30, 2020 and December&#160;31, 2019 and of the SARs liability for the period ended December 31, 2019:</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:18.998%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.415%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.481%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.415%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.823%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.121%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:21.494%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.415%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.038%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value </span></td><td colspan="3" rowspan="10" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Valuation Technique</span></td><td colspan="3" rowspan="10" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unobservable Input</span></td><td colspan="3" rowspan="10" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Range</span></td></tr><tr><td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration payable- development and regulatory milestones<br/></span></td><td colspan="3" rowspan="9" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$136,100</span></td><td colspan="3" style="display:none;"/><td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Probability-adjusted discounted cash flow</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Potential development and regulatory milestones</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">$0 - $381 million</span></div></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Probabilities of success</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">25% - 94%</span></div></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discount rates</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">4.6% - 6.1%</span></div></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Projected years of payments</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021 - 2027</span></td></tr><tr><td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent considerable payable- net sales milestones and royalties</span></td><td colspan="3" style="display:none;"/><td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$89,600</span></td><td colspan="3" style="display:none;"/><td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Option-pricing model with Monte Carlo simulation<br/></span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Potential net sales milestones</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">$0 - $150 million</span></div></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Probabilities of success</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">25% -94%</span></div></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Potential percentage of net sales for royalties </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">2% - 6%</span></div></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discount rate</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.0%</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Projected years of payments</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022 - 2039</span></td></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:18.998%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.415%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.481%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.415%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.823%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.121%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:21.494%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.415%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.038%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value </span></td><td colspan="3" rowspan="15" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Valuation Technique</span></td><td colspan="3" rowspan="15" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unobservable Input</span></td><td colspan="3" rowspan="15" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Range</span></td></tr><tr><td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SARs</span></td><td colspan="3" rowspan="14" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$3,186</span></td><td colspan="3" style="display:none;"/><td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Option-pricing model</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Volatility</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28.93%</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk free interest rate</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.19%</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Strike price</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">$6.76 - $30.86</span></div></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of common stock</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$48.03</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected life</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.01 years</span></td></tr><tr><td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Contingent consideration payable- development and regulatory milestones</span></div><div style="text-align:center;"><span><br/></span></div></td><td colspan="3" style="display:none;"/><td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$290,500</span></td><td colspan="3" style="display:none;"/><td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Probability-adjusted discounted cash flow</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Potential development and regulatory milestones</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">$0- $555 million</span></div></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Probabilities of success</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">25% - 94%</span></div></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discount rates</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">2.2% - 4.7%</span></div></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Projected years of payments</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020 - 2026</span></td></tr><tr><td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent considerable payable- net sales milestones and royalties</span></td><td colspan="3" style="display:none;"/><td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$65,800</span></td><td colspan="3" style="display:none;"/><td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Option-pricing model with Monte Carlo simulation<br/></span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Potential net sales milestones</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">$0 - $150 million</span></div></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Probabilities of success</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">25% - 89%</span></div></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Potential percentage of net sales for royalties </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">2% - 6%</span></div></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discount rate</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14.5%</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Projected years of payments</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021 - 2038</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurement Inputs and Valuation Techniques</a></td>
<td class="text"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The table presented below is a summary of changes in the fair value of the Company&#8217;s Level 3 valuations for the SARs liability, and the contingent consideration payable for the periods ended June&#160;30, 2020 and June&#160;30, 2019. </span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.549%;"><tr><td style="width:1.0%;"/><td style="width:50.533%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.644%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.033%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.644%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.033%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.475%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.038%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3 liabilities</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SARs</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration payable- development and regulatory milestones</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration payable- net sales milestones and royalties</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Beginning balance as of December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,186&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">290,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">65,800&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(15,220)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,800&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,186)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Rights Exchange settlement</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(139,180)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ending balance as of June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">136,100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">89,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.573%;"><tr><td style="width:1.0%;"/><td style="width:49.919%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.634%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.858%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.634%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.858%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.467%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.030%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3 liabilities</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SARs</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration payable- development and regulatory milestones</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration payable- net sales milestones and royalties</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Beginning balance as of December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,814&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">257,040&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,200&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,961&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,360&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,815)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ending balance as of June 30, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,960&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">277,400&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58,800&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118942371&amp;loc=SL82922954-210456<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633764789320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other comprehensive income (loss) and accumulated other comprehensive items - (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Summary of other comprehensive income (loss) and the changes in accumulated other comprehensive items</a></td>
<td class="text"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following tables summarize other comprehensive income (loss) and the changes in accumulated other comprehensive items for the three and six months periods ended June&#160;30, 2020:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:57.590%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.740%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Gains/(Losses) On Marketable Securities, net of tax</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign Currency Translation</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Accumulated Other Comprehensive Items</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at March 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">692&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,677)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,985)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,718&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,749)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8,031)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amounts reclassified from other comprehensive items</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,718&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,749)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8,031)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,410&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(13,426)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,016)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:57.590%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.740%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized<br/>Gains/(Losses)<br/>On<br/>Marketable<br/>Securities,&#160;net<br/>of&#160;tax</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign<br/>Currency<br/>Translation</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total<br/>Accumulated<br/>Other<br/>Comprehensive<br/>Items</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">755&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11,339)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,584)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,655&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,087)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">568&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amounts reclassified from other comprehensive items</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income (loss)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,655&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,087)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">568&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,410&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(13,426)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,016)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633852999368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts payable and accrued expenses - (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of components of accounts payable and accrued expenses</a></td>
<td class="text"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accounts payable and accrued expenses at June&#160;30, 2020 and December&#160;31, 2019 consist of the following:</span></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.060%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employee compensation, benefits, and related accruals</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,861&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38,889&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Consulting and contracted research</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,452&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,969&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Professional fees</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,295&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,562&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sales allowance and other costs</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45,848&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41,155&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sales rebates and royalties</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56,870&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42,997&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,465&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,324&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,585&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,380&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">164,376&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">159,276&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633766045512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net loss per share - (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of computation of basic and diluted net loss available to common stockholders</a></td>
<td class="text">The following tables set forth the computation of basic and diluted net loss per share:<div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:34.173%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.407%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.475%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.407%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.615%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.474%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.615%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.614%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.620%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(181,427)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(41,789)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(294,114)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(113,902)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator for basic and diluted net loss per share</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">65,150,780&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55,912,748&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63,769,958&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">57,113,141&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss per share:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.78)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.75)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.61)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.99)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:40.935%;"><tr><td style="width:1.0%;"/><td style="width:98.000%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">*In the three and six months ended June&#160;30, 2020 and 2019, the Company experienced a net loss and therefore did not report any dilutive share impact.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of historical dilutive common share equivalents outstanding</a></td>
<td class="text"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table shows historical dilutive common share equivalents outstanding, which are not included in the above historical calculation, as the effect of their inclusion is anti-dilutive during each period.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:69.700%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.636%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.931%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock Options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,954,684&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,853,301&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested restricted stock awards and units</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">936,922&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">665,002&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,891,606&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,518,303&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633770439608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock award plan - (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of stock option activity</a></td>
<td class="text"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A summary of stock option activity is as follows:</span></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:41.777%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.909%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.909%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.740%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number&#160;of<br/>options</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-<br/>average<br/>exercise<br/>price</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-<br/>average<br/>remaining<br/>contractual<br/>term</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate<br/>intrinsic<br/>value (in<br/>thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,043,939&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.67&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,515,200&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50.98&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,034,288)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24.21&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited/Cancelled</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(570,167)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42.27&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at June 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,954,684&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35.84&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.48 years</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">183,488&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested or Expected to vest at June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,690,848&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39.16&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.86 years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">66,986&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable at June 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,512,252&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.61&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.85 years</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">110,222&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used to estimate fair values of grants made on the date of grant</a></td>
<td class="text"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of grants made in the six months ended June&#160;30, 2020 was contemporaneously estimated on the date of grant using the following assumptions:</span></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:63.592%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.410%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:30.798%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended<br/>June 30, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">0.40% - 1.45%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">87.50% - 89.31%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">5.75 years</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Summary of information on the Company's restricted stock</a></td>
<td class="text"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes information on the Company&#8217;s restricted stock awards and units:</span></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:69.888%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.909%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted&#160;Stock&#160;Awards&#160;and&#160;Units</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number&#160;of<br/>Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted<br/>Average<br/>Grant<br/>Date&#160;Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">642,419&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24.50&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">589,070&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49.67&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(229,076)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23.53&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(65,491)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36.11&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested at June 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">936,922&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39.97&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of share-based compensation expense recorded in the statement of operations</a></td>
<td class="text"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company recorded share-based compensation expense in the statement of operations related to incentive stock options, nonstatutory stock options, restricted stock awards, restricted stock units and the ESPP as follows:</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:40.020%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.909%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.909%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:2.289%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.740%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,562&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,516&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,741&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,203&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,348&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,404&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,389&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,981&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,910&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,920&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,130&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,184&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633770421000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member', window );">1.50% Convertible senior notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionLineItems', window );"><strong>Debt Instrument, Redemption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Summary of convertible notes</a></td>
<td class="text"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The 2026 Convertible Notes consist of the following:</span></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:61.436%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.621%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.387%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.622%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liability&#160;component</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Principal</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">287,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">287,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Debt issuance costs</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,319)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,567)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Debt discount, net(1)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(112,877)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(119,350)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net carrying amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">170,304&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">163,583&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1)&#160;Included in the consolidated balance sheets within convertible senior notes (due 2026) and amortized to interest expense over the remaining life of the 2026 Convertible Notes using the effective interest rate method.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock', window );">Summary of interest expense recognized related to the Convertible Notes</a></td>
<td class="text"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth total interest expense recognized related to the 2026 Convertible Notes:</span></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:77.631%;"><tr><td style="width:1.0%;"/><td style="width:48.282%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.306%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:21.163%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.553%;"/><td style="width:0.1%;"/><td colspan="3" style="display:none;"/><td style="width:0.1%;"/><td style="width:0.741%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:20.598%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.557%;"/><td style="width:0.1%;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contractual interest expense</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,066&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,142&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">124&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">248&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of debt discount</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,239&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,473&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,429&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,863&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effective interest rate of the liability component</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ptct_ConvertibleSeniorNotes3.0PercentDue2022Member', window );">3.00% Convertible senior notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionLineItems', window );"><strong>Debt Instrument, Redemption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Summary of convertible notes</a></td>
<td class="text"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The 2022 Convertible Notes consist of the following:</span></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:61.343%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.595%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.596%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liability&#160;component</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Principal</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">150,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">150,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Debt issuance costs</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,104)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,329)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Debt discount, net(1)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(22,166)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(26,686)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net carrying amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">126,730&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">121,985&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1)&#160;Included in the consolidated balance sheets within convertible senior notes (due 2022) and amortized to interest expense over the remaining life of the 2022 Convertible Notes using the effective interest rate method.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock', window );">Summary of interest expense recognized related to the Convertible Notes</a></td>
<td class="text"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth total interest expense recognized related to the 2022 Convertible Notes:</span></div><div style="margin-top:8pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.222%;"><tr><td style="width:1.0%;"/><td style="width:37.548%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.551%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.285%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.551%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.285%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.551%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.285%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.551%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.593%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contractual interest expense</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,125&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,131&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,244&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,241&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">114&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">103&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">225&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">202&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of debt discount</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,295&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,074&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,520&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,055&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,534&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,308&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,989&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,498&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effective interest rate of the liability component</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest expense recognized related to convertible debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ptct_ConvertibleSeniorNotes3.0PercentDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ptct_ConvertibleSeniorNotes3.0PercentDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633769756776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets and goodwill - (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Future amortization expense</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%;"><tr><td style="width:1.0%;"/><td style="width:77.675%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.589%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of June 30, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,460&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,920&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,920&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,920&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,094&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">132,314&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633840268952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 29, 2020</div></th>
<th class="th"><div>Aug. 23, 2018</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 29, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Apr. 20, 2017</div></th>
<th class="th"><div>Aug. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings (accumulated deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,484,831)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,190,499)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptct_RightsExchangeAgreementMember', window );">Rights Exchange Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_SharestoissueunderRightsExchangeAgreement', window );">Shares to issue under Rights Exchange Agreement</a></td>
<td class="nump">2,821,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_CashconsiderationpaymentunderRightsExchangeAgreement', window );">Cash consideration payment under Rights Exchange Agreement</a></td>
<td class="nump">$ 36,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible debt | 1.50% Convertible senior notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate ( as a percent )</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible debt | 3.00% Convertible senior notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate ( as a percent )</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_NoncollaborativeArrangementTransactionsMember', window );">Non-collaborative Arrangement Transactions | Marathon Pharmaceuticals, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing', window );">Development milestone payments which the entity is obligated to pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Equity Interest Issued, number of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity', window );">Numerator for calculation of number of shares of equity interests issued to acquire entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod', window );">Trading day period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing', window );">Development milestone payments which the entity is obligated to pay</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture', window );">Development Milestone Payment Obligations, Net of Cancellation and Forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone', window );">Net sales amount</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing', window );">Development milestone payments which the entity is obligated to pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage', window );">Product sales</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing', window );">Development milestone payments which the entity is obligated to pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount', window );">Priority review voucher amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">535,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone', window );">Net sales amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage', window );">Product sales</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis | Rights Exchange Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount', window );">Priority review voucher amount</a></td>
<td class="nump">$ 174,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture', window );">Development Milestone Payment Obligations, Net of Cancellation and Forfeiture</a></td>
<td class="nump">22,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture', window );">Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount, Net of Cancellation and Forfeiture</a></td>
<td class="nump">$ 361,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis | Rights Exchange Agreement [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture', window );">Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount, Net of Cancellation and Forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 361,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis | Non-collaborative Arrangement Transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing', window );">Development milestone payments which the entity is obligated to pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Equity Interest Issued Or Issuable, Trading Day Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Numerator For Calculation Of Number Of Shares Of Equity Interests Issued To Acquire Entity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_CashconsiderationpaymentunderRightsExchangeAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash consideration payment under Rights Exchange Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_CashconsiderationpaymentunderRightsExchangeAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Liability, Milestone, Potential Achievements, Net Sales Milestone And Regulatory Approval</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount, Net of Cancellation and Forfeiture</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Liability, Milestone, Potential Achievements, Product Sales Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the development milestones payments which the entity is obligated to pay under certain contractual agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development Milestone Payment Obligations, net of cancellation and forfeiture</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_SharestoissueunderRightsExchangeAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares to issue under Rights Exchange Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_SharestoissueunderRightsExchangeAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptct_RightsExchangeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptct_RightsExchangeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ptct_ConvertibleSeniorNotes3.0PercentDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ptct_ConvertibleSeniorNotes3.0PercentDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_NoncollaborativeArrangementTransactionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_NoncollaborativeArrangementTransactionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ptct_MarathonPharmaceuticalsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ptct_MarathonPharmaceuticalsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633770140968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of significant accounting policies - Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 877<span></span>
</td>
<td class="nump">$ 874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in progress</a></td>
<td class="nump">8,666<span></span>
</td>
<td class="nump">9,652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">8,830<span></span>
</td>
<td class="nump">8,759<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 18,373<span></span>
</td>
<td class="nump">$ 19,285<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633768737448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for credit loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-down</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of Credit</a></td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_Termforletterofcredit', window );">Term for letter of credit (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease ROU asset</a></td>
<td class="nump">29,475,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,475,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,693,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts receivable</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease', window );">Accounts receivable, allowance for credit loss,</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ptct_FifthAnniversaryMember', window );">Fifth Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of Credit</a></td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_Termforletterofcredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term for letter of credit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_Termforletterofcredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=119407570&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=119407570&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118955202&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=119407570&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31931-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ptct_FifthAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ptct_FifthAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633764513288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of significant accounting policies - Reconciliation of cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 158,461<span></span>
</td>
<td class="nump">$ 288,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash included in deposits and other assets</a></td>
<td class="nump">7,500<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total Cash, cash equivalents and restricted cash per statement of cash flows</a></td>
<td class="nump">$ 165,961<span></span>
</td>
<td class="nump">$ 295,528<span></span>
</td>
<td class="nump">$ 136,094<span></span>
</td>
<td class="nump">$ 169,498<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633769816728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>Term </div>
<div>operating_lease</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>Term </div>
<div>operating_lease</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 01, 2020 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_NumberOfOperatingLeases', window );">Number of operating leases | operating_lease</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease, expense</a></td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal Term ( in years )</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Aggregate rent, Initial term</a></td>
<td class="nump">$ 37,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2020 (excludes the six months ended June 30, 2020)</a></td>
<td class="nump">3,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2021</a></td>
<td class="nump">6,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2022</a></td>
<td class="nump">6,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Fixed lease cost</a></td>
<td class="nump">1,970<span></span>
</td>
<td class="nump">835<span></span>
</td>
<td class="nump">4,089<span></span>
</td>
<td class="nump">1,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 176,525<span></span>
</td>
<td class="nump">$ 59,979<span></span>
</td>
<td class="nump">$ 266,632<span></span>
</td>
<td class="nump">$ 112,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptct_MassBioMember', window );">MassBio | Finance Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseTermOfContract1', window );">Lessee, Finance Lease, Term of Contract</a></td>
<td class="text">12 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 41,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of Contract ( in years )</a></td>
<td class="text">3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of Contract ( in years )</a></td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ptct_HopewellNewBuildingMember', window );">New Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of real estate property | ft&#178;</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal Term ( in years )</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ptct_HopewellCampusMember', window );">Hopewell Campus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of Contract ( in years )</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of real estate property | ft&#178;</a></td>
<td class="nump">220,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_Numberofterms', window );">Number of terms | Term</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Aggregate rent, Initial term</a></td>
<td class="nump">$ 111,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_PercentOfMarketRate', window );">Percent of market rate</a></td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ptct_MountainviewMember', window );">Mountainview</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2020 (excludes the six months ended June 30, 2020)</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2021</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2022</a></td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ptct_BridgewaterMember', window );">Bridgewater [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_LeaseArea', window );">Lease, Area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_LeaseArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease, Area</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_LeaseArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_NumberOfOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Operating Leases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_NumberOfOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_Numberofterms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of terms</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_Numberofterms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_PercentOfMarketRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percent Of Market Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_PercentOfMarketRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ptct_MassBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ptct_MassBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=ptct_FinanceLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=ptct_FinanceLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ptct_HopewellNewBuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ptct_HopewellNewBuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ptct_HopewellCampusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ptct_HopewellCampusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ptct_MountainviewMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ptct_MountainviewMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ptct_BridgewaterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ptct_BridgewaterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633765798568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Lease costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Fixed lease cost</a></td>
<td class="nump">$ 1,970<span></span>
</td>
<td class="nump">$ 835<span></span>
</td>
<td class="nump">$ 4,089<span></span>
</td>
<td class="nump">$ 1,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">507<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="nump">734<span></span>
</td>
<td class="nump">304<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">88<span></span>
</td>
<td class="nump">165<span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total operating lease cost</a></td>
<td class="nump">$ 2,565<span></span>
</td>
<td class="nump">$ 1,084<span></span>
</td>
<td class="nump">$ 4,988<span></span>
</td>
<td class="nump">$ 2,092<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633774154904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Balance sheet (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease ROU asset</a></td>
<td class="nump">$ 29,475<span></span>
</td>
<td class="nump">$ 13,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities- current</a></td>
<td class="nump">4,868<span></span>
</td>
<td class="nump">5,153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities- noncurrent</a></td>
<td class="nump">25,510<span></span>
</td>
<td class="nump">9,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liability</a></td>
<td class="nump">$ 30,378<span></span>
</td>
<td class="nump">$ 14,171<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633764715400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Supplemental lease terms (Details)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease terms - operating leases (years)</a></td>
<td class="text">5 years 10 months 13 days<span></span>
</td>
<td class="text">3 years 4 months 17 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate - operating leases</a></td>
<td class="nump">6.77%<span></span>
</td>
<td class="nump">7.33%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease terms - finance lease (years)</a></td>
<td class="text">12 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate - finance lease</a></td>
<td class="nump">7.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633770031208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Lease payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2020 (excludes the six months ended June 30, 2020)</a></td>
<td class="nump">$ 3,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2021</a></td>
<td class="nump">6,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2022</a></td>
<td class="nump">6,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2023</a></td>
<td class="nump">5,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter', window );">2024 and thereafter</a></td>
<td class="nump">14,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">37,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed Interest expense</a></td>
<td class="nump">7,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">30,378<span></span>
</td>
<td class="nump">$ 14,171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2020 (excludes the six months ended June 30, 2020)</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2021</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2022</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2023</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2024 and thereafter</a></td>
<td class="nump">27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">39,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed Interest expense</a></td>
<td class="nump">12,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total</a></td>
<td class="nump">$ 26,211<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Payments, Due Year Five and Thereafter</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in remainder of fiscal year following latest fiscal year ended.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633764534056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Cash flow (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 3,414<span></span>
</td>
<td class="nump">$ 1,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flows from finance lease</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease obligations</a></td>
<td class="nump">18,117<span></span>
</td>
<td class="nump">11,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right-of-use assets obtained in exchange for finance lease obligations</a></td>
<td class="nump">$ 41,212<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633767913640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 29, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Payments for asset acquisitions, share, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,869<span></span>
</td>
<td class="nump">$ 42,869<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptct_CensaMember', window );">Censa [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_PaymentsforAssetAcquisitions', window );">Payments for asset acquisitions</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_PaymentsForAssetAcquisitionsUpfrontPayment', window );">Payments for asset acquisitions, upfront payment</a></td>
<td class="nump">10,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_PaymentsForAssetAcquisitionsNetAssets', window );">Payments for asset acquisitions, net assets</a></td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Payments for asset acquisitions, shares (in shares)</a></td>
<td class="nump">845,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Payments for asset acquisitions, share, value</a></td>
<td class="nump">$ 42,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ConsiderationForAssetAcquisitions', window );">Consideration for asset acquisitions</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Equity Interest Issued, number of shares (in shares)</a></td>
<td class="nump">42,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_AssetAcquisitionTransactionCosts', window );">Asset acquisition, transaction costs</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_AssetAcquisitionConsiderationTransferred', window );">Asset acquisition, consideration transferred</a></td>
<td class="nump">58,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_AssetAcquisitionCash', window );">Asset acquisition, cash</a></td>
<td class="nump">3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_AssetAcquisitionOtherAssets', window );">Asset acquisition, other assets</a></td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_AssetAcquisitionInProcessResearchAndDevelopment', window );">Asset acquisition, in-process research and development</a></td>
<td class="nump">54,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_AssetAcquisitionResearchAndDevelopmentExpense', window );">Asset acquisition, research and development expense</a></td>
<td class="nump">53,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_AssetAcquisitionSellingGeneralAndAdministrativeExpense', window );">Asset acquisition, selling, general And administrative expense</a></td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_AssetAcquisitionMilestoneAmount', window );">Asset acquisition, milestone, amount</a></td>
<td class="nump">217,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_AssetAcquisitionDevelopmentAndRegulatoryMilestones', window );">Asset acquisition, development and regulatory milestones</a></td>
<td class="nump">109,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_AssetAcquisitionNetSalesMilestone', window );">Asset acquisition, net sales milestone</a></td>
<td class="nump">160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_AssetAcquisitionInitialMilestone', window );">Asset acquisition, initial milestone</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Other Research and Development Expense</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_AssetAcquisitionCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_AssetAcquisitionCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Consideration Transferred</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_AssetAcquisitionDevelopmentAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Development And Regulatory Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_AssetAcquisitionDevelopmentAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_AssetAcquisitionInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, In-process Research and Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_AssetAcquisitionInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_AssetAcquisitionInitialMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Initial Milestone</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_AssetAcquisitionInitialMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_AssetAcquisitionMilestoneAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Milestone, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_AssetAcquisitionMilestoneAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_AssetAcquisitionNetSalesMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Net Sales Milestone</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_AssetAcquisitionNetSalesMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_AssetAcquisitionOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Other Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_AssetAcquisitionOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_AssetAcquisitionResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Research And Development Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_AssetAcquisitionResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_AssetAcquisitionSellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Selling, General And Administrative Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_AssetAcquisitionSellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_AssetAcquisitionTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_AssetAcquisitionTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ConsiderationForAssetAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consideration for Asset Acquisitions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_ConsiderationForAssetAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_PaymentsForAssetAcquisitionsNetAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for Asset Acquisitions, Net Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_PaymentsForAssetAcquisitionsNetAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_PaymentsForAssetAcquisitionsUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for Asset Acquisitions, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_PaymentsForAssetAcquisitionsUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_PaymentsforAssetAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for Asset Acquisitions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_PaymentsforAssetAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ptct_CensaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ptct_CensaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633766012104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions - Preliminary Allocation of purchase price (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 82,341<span></span>
</td>
<td class="nump">$ 82,341<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633756501432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value of financial instruments and marketable securities - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 29, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 29, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2015 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesRealizedGainLoss', window );">Marketable Securities, Realized Gain (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent', window );">Deferred consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,384,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,384,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on equity investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,600,000)<span></span>
</td>
<td class="nump">$ 129,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_InvestmentInMRI', window );">Investment In MRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_PaymentsToAcquireConvertibleDebtInvestment', window );">Purchase of convertible debt investment</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DebtInstrumentConvertiblePeriod', window );">Debt instrument, convertible, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Unrealized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 340,430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340,430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">398,535,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_SharesIssuedAssetAcquisition', window );">Non-cash stock consideration, acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,869,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">262,512,000<span></span>
</td>
<td class="nump">$ 124,280,000<span></span>
</td>
<td class="nump">423,762,000<span></span>
</td>
<td class="nump">247,003,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1', window );">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,680,000)<span></span>
</td>
<td class="num">(5,300,000)<span></span>
</td>
<td class="num">$ (8,580,000)<span></span>
</td>
<td class="num">(26,460,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Debt Securities, Available-for-sale, Unrealized Gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_StockIssuedDuringPeriodSharesExchangeRights', window );">Issuance of common stock related to rights exchange (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,821,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,821,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_CommitmentsMember', window );">Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Liability value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136,100,000<span></span>
</td>
<td class="nump">277,400,000<span></span>
</td>
<td class="nump">$ 136,100,000<span></span>
</td>
<td class="nump">277,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 257,040,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember', window );">SARs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Liability value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1,960,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1,960,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,186,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,814,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ptct_ConvertibleSeniorNotes3.0PercentDue2022Member', window );">3.00% Convertible senior notes due 2022 | Convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate ( as a percent )</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56.34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member', window );">1.50% Convertible senior notes due 2026 | Convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 287,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 287,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 287,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate ( as a percent )</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 343,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 343,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 335,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing', window );">Development milestone payments which the entity is obligated to pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone', window );">Net sales amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent', window );">Deferred consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_SharesIssuedAssetAcquisition', window );">Non-cash stock consideration, acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_MilestonePaymentObligations', window );">Milestone Payment Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 174,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_GainOfSettlementDevelopmentMilestones', window );">Gain Of Settlement, Development Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_LossOfSettlementRegulatoryMilestones', window );">Loss Of Settlement, Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1', window );">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ContingentConsiderationTransactionFees', window );">Contingent Consideration, Transaction Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_StockIssuedDuringPeriodSharesExchangeRights', window );">Issuance of common stock related to rights exchange (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,821,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing', window );">Development milestone payments which the entity is obligated to pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing', window );">Development milestone payments which the entity is obligated to pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount', window );">Priority review voucher amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">535,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone', window );">Net sales amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_NoncollaborativeArrangementTransactionsMember', window );">Non-collaborative Arrangement Transactions | Agilis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing', window );">Development milestone payments which the entity is obligated to pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable', window );">Estimated fair value of deferred consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,384,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,384,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Liability value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 398,535,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalancePrincipalAmount', window );">Shares owned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value of shares (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on equity investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Deferred consideration payable | Recurring basis | Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,251,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,251,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityDevelopmentandRegulatoryMilestoneMember', window );">Development and Regulatory Milestone | Probability of Success [Member] | Minimum | Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityDevelopmentandRegulatoryMilestoneMember', window );">Development and Regulatory Milestone | Probability of Success [Member] | Maximum | Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityDevelopmentandRegulatoryMilestoneMember', window );">Development and Regulatory Milestone | Probability of Success [Member] | Weighted Average [Member] | Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityDevelopmentandRegulatoryMilestoneMember', window );">Development and Regulatory Milestone | Agilis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Liability value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 290,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityDevelopmentandRegulatoryMilestoneMember', window );">Development and Regulatory Milestone | Agilis | Measurement Input, Discount Rate | Minimum | Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityDevelopmentandRegulatoryMilestoneMember', window );">Development and Regulatory Milestone | Agilis | Measurement Input, Discount Rate | Maximum | Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityDevelopmentandRegulatoryMilestoneMember', window );">Development and Regulatory Milestone | Agilis | Measurement Input, Discount Rate | Weighted Average [Member] | Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityNetSalesMilestonesandRoyaltiesMember', window );">Liability, Net Sales Milestones and Royalties [Member] | Probability of Success [Member] | Minimum | Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityNetSalesMilestonesandRoyaltiesMember', window );">Liability, Net Sales Milestones and Royalties [Member] | Probability of Success [Member] | Maximum | Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityNetSalesMilestonesandRoyaltiesMember', window );">Liability, Net Sales Milestones and Royalties [Member] | Probability of Success [Member] | Weighted Average [Member] | Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityNetSalesMilestonesandRoyaltiesMember', window );">Liability, Net Sales Milestones and Royalties [Member] | Agilis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Liability value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityNetSalesMilestonesandRoyaltiesMember', window );">Liability, Net Sales Milestones and Royalties [Member] | Agilis | Measurement Input, Discount Rate | Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration, Liability, Deferred Consideration Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration, Liability, Deferred Consideration Payable- Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ContingentConsiderationTransactionFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Consideration, Transaction Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_ContingentConsiderationTransactionFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Liability, Milestone, Potential Achievements, Net Sales Milestone And Regulatory Approval</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Liability, Milestone, Potential Achievements, Product Sales Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_DebtInstrumentConvertiblePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_DebtInstrumentConvertiblePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the development milestones payments which the entity is obligated to pay under certain contractual agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_GainOfSettlementDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain Of Settlement, Development Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_GainOfSettlementDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_InvestmentInMRI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment In MRI</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_InvestmentInMRI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_LossOfSettlementRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Of Settlement, Regulatory Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_LossOfSettlementRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_MilestonePaymentObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Obligations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_MilestonePaymentObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_PaymentsToAcquireConvertibleDebtInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Convertible Debt Investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_PaymentsToAcquireConvertibleDebtInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_SharesIssuedAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued Asset Acquisition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_SharesIssuedAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_StockIssuedDuringPeriodSharesExchangeRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Exchange Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_StockIssuedDuringPeriodSharesExchangeRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AlternativeInvestmentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure alternative investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AlternativeInvestmentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of right to a contingent consideration asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalancePrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For investments which are quantified by principal amount, the principle balance held at close of period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-12C.Column B)<br> -URI http://asc.fasb.org/extlink&amp;oid=50485924&amp;loc=d3e611225-123010<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14.Column B)<br> -URI http://asc.fasb.org/extlink&amp;oid=50485924&amp;loc=d3e611322-123010<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12.Column B)<br> -URI http://asc.fasb.org/extlink&amp;oid=50485924&amp;loc=d3e611133-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalancePrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_CommitmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_CommitmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ptct_ConvertibleSeniorNotes3.0PercentDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ptct_ConvertibleSeniorNotes3.0PercentDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_NoncollaborativeArrangementTransactionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_NoncollaborativeArrangementTransactionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityDevelopmentandRegulatoryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityDevelopmentandRegulatoryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=ptct_ProbabilityofSuccessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=ptct_ProbabilityofSuccessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityNetSalesMilestonesandRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityNetSalesMilestonesandRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633756430728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair value of financial instruments and marketable securities - Hierarchy (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 340,430<span></span>
</td>
<td class="nump">$ 398,535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration payable</a></td>
<td class="nump">225,700<span></span>
</td>
<td class="nump">356,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs (level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent consideration payable- net sales milestones and royalties</a></td>
<td class="nump">89,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">398,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity investment in ClearPoint</a></td>
<td class="nump">4,594<span></span>
</td>
<td class="nump">6,194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_StockAppreciationRightsLiabilityOutstanding', window );">Stock appreciation rights liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable', window );">Deferred consideration payable</a></td>
<td class="nump">2,384<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration payable</a></td>
<td class="nump">136,100<span></span>
</td>
<td class="nump">290,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent consideration payable- net sales milestones and royalties</a></td>
<td class="nump">89,600<span></span>
</td>
<td class="nump">65,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted&#160;prices in&#160;active markets&#160;for identical&#160;assets (level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity investment in ClearPoint</a></td>
<td class="nump">4,594<span></span>
</td>
<td class="nump">6,194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_StockAppreciationRightsLiabilityOutstanding', window );">Stock appreciation rights liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable', window );">Deferred consideration payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent consideration payable- net sales milestones and royalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant other observable inputs (level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">398,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity investment in ClearPoint</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_StockAppreciationRightsLiabilityOutstanding', window );">Stock appreciation rights liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable', window );">Deferred consideration payable</a></td>
<td class="nump">2,384<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent consideration payable- net sales milestones and royalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant unobservable inputs (level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity investment in ClearPoint</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_StockAppreciationRightsLiabilityOutstanding', window );">Stock appreciation rights liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable', window );">Deferred consideration payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration payable</a></td>
<td class="nump">136,100<span></span>
</td>
<td class="nump">$ 290,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember', window );">Marketable securities | Recurring basis | Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">340,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember', window );">Marketable securities | Recurring basis | Quoted&#160;prices in&#160;active markets&#160;for identical&#160;assets (level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember', window );">Marketable securities | Recurring basis | Significant other observable inputs (level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">340,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember', window );">Marketable securities | Recurring basis | Significant unobservable inputs (level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Deferred consideration payable | Recurring basis | Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">9,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Deferred consideration payable | Recurring basis | Quoted&#160;prices in&#160;active markets&#160;for identical&#160;assets (level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Deferred consideration payable | Recurring basis | Significant other observable inputs (level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">9,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Deferred consideration payable | Recurring basis | Significant unobservable inputs (level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration, Liability, Deferred Consideration Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_StockAppreciationRightsLiabilityOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of outstanding stock appreciation rights liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_StockAppreciationRightsLiabilityOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633769835128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair value of financial instruments and marketable securities - Available for sale (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">337,021<span></span>
</td>
<td class="nump">397,776<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized, Gain</a></td>
<td class="nump">3,411<span></span>
</td>
<td class="nump">787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized, Loss</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">340,430<span></span>
</td>
<td class="nump">398,535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue', window );">Securities in an unrealized loss position less than 12 months</a></td>
<td class="nump">9,196<span></span>
</td>
<td class="nump">95,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue', window );">Securities in an unrealized loss position greater than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue', window );">Debt Securities, Held-to-maturity, Unrealized Loss Position, Fair Value</a></td>
<td class="nump">9,196<span></span>
</td>
<td class="nump">95,990<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">53,638<span></span>
</td>
<td class="nump">157,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized, Gain</a></td>
<td class="nump">178<span></span>
</td>
<td class="nump">162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized, Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">53,816<span></span>
</td>
<td class="nump">158,098<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">221,068<span></span>
</td>
<td class="nump">188,778<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized, Gain</a></td>
<td class="nump">2,882<span></span>
</td>
<td class="nump">576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized, Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">223,950<span></span>
</td>
<td class="nump">189,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue', window );">Securities in an unrealized loss position less than 12 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,779<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue', window );">Securities in an unrealized loss position greater than 12 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue', window );">Debt Securities, Held-to-maturity, Unrealized Loss Position, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,779<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">44,492<span></span>
</td>
<td class="nump">51,062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized, Gain</a></td>
<td class="nump">332<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized, Loss</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">44,823<span></span>
</td>
<td class="nump">51,103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue', window );">Securities in an unrealized loss position less than 12 months</a></td>
<td class="nump">594<span></span>
</td>
<td class="nump">24,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue', window );">Securities in an unrealized loss position greater than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue', window );">Debt Securities, Held-to-maturity, Unrealized Loss Position, Fair Value</a></td>
<td class="nump">594<span></span>
</td>
<td class="nump">$ 24,211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember', window );">Government obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">17,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized, Gain</a></td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized, Loss</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">17,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue', window );">Securities in an unrealized loss position less than 12 months</a></td>
<td class="nump">8,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue', window );">Securities in an unrealized loss position greater than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue', window );">Debt Securities, Held-to-maturity, Unrealized Loss Position, Fair Value</a></td>
<td class="nump">$ 8,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity), in unrealized loss position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity), in continuous unrealized loss position for less than 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity), in continuous unrealized loss position for 12 months or longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633769952120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value of financial instruments and marketable securities - Fair Value Measurement Inputs and Valuation Techniques (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ServicingAssetAtFairValueAmountRollForward', window );"><strong>Level 3 roll forward</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Additions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs (level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ServicingAssetAtFairValueAmountRollForward', window );"><strong>Level 3 roll forward</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent consideration payable- net sales milestones and royalties</a></td>
<td class="nump">89,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember', window );">SARs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ServicingAssetAtFairValueAmountRollForward', window );"><strong>Level 3 roll forward</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent consideration payable- net sales milestones and royalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,960<span></span>
</td>
<td class="nump">$ 3,186<span></span>
</td>
<td class="nump">$ 3,814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="num">(3,186)<span></span>
</td>
<td class="num">(3,815)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_CommitmentsMember', window );">Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ServicingAssetAtFairValueAmountRollForward', window );"><strong>Level 3 roll forward</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent consideration payable- net sales milestones and royalties</a></td>
<td class="nump">136,100<span></span>
</td>
<td class="nump">277,400<span></span>
</td>
<td class="nump">290,500<span></span>
</td>
<td class="nump">257,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="num">(15,220)<span></span>
</td>
<td class="nump">20,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis | Significant unobservable inputs (level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ServicingAssetAtFairValueAmountRollForward', window );"><strong>Level 3 roll forward</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent consideration payable- net sales milestones and royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityNetSalesMilestonesandRoyaltiesMember', window );">Liability, Net Sales Milestones and Royalties [Member] | Agilis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ServicingAssetAtFairValueAmountRollForward', window );"><strong>Level 3 roll forward</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent consideration payable- net sales milestones and royalties</a></td>
<td class="nump">89,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityNetSalesMilestonesandRoyaltiesMember', window );">Liability, Net Sales Milestones and Royalties [Member] | Agilis | Significant unobservable inputs (level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ServicingAssetAtFairValueAmountRollForward', window );"><strong>Level 3 roll forward</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent consideration payable- net sales milestones and royalties</a></td>
<td class="nump">89,600<span></span>
</td>
<td class="nump">58,800<span></span>
</td>
<td class="nump">$ 65,800<span></span>
</td>
<td class="nump">$ 53,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">23,800<span></span>
</td>
<td class="nump">5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ServicingAssetAtFairValueAmountRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ServicingAssetAtFairValueAmountRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_CommitmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_CommitmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityNetSalesMilestonesandRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityNetSalesMilestonesandRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633766669672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair value of financial instruments and marketable securities - Unrealized Loss Positions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Unrealized losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Securities in an unrealized loss position less than 12 months</a></td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">$ (28)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Securities in an unrealized loss position greater than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue', window );">Securities in an unrealized loss position less than 12 months</a></td>
<td class="nump">9,196<span></span>
</td>
<td class="nump">95,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue', window );">Securities in an unrealized loss position greater than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue', window );">Total</a></td>
<td class="nump">9,196<span></span>
</td>
<td class="nump">95,990<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Unrealized losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Securities in an unrealized loss position less than 12 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Securities in an unrealized loss position greater than 12 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue', window );">Securities in an unrealized loss position less than 12 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,779<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue', window );">Securities in an unrealized loss position greater than 12 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,779<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Unrealized losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Securities in an unrealized loss position less than 12 months</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Securities in an unrealized loss position greater than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue', window );">Securities in an unrealized loss position less than 12 months</a></td>
<td class="nump">594<span></span>
</td>
<td class="nump">24,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue', window );">Securities in an unrealized loss position greater than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue', window );">Total</a></td>
<td class="nump">594<span></span>
</td>
<td class="nump">$ 24,211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember', window );">Government obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Unrealized losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Securities in an unrealized loss position less than 12 months</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Securities in an unrealized loss position greater than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue', window );">Securities in an unrealized loss position less than 12 months</a></td>
<td class="nump">8,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue', window );">Securities in an unrealized loss position greater than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue', window );">Total</a></td>
<td class="nump">$ 8,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity), in unrealized loss position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity), in continuous unrealized loss position for less than 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity), in continuous unrealized loss position for 12 months or longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633769910376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair value of financial instruments and marketable securities - Marketable securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentHoldingsLineItems', window );"><strong>Marketable securities on the balance sheet</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Total Marketable securities, Less Than 12 Months</a></td>
<td class="nump">$ 255,587<span></span>
</td>
<td class="nump">$ 342,418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue', window );">Total Marketable securities, More Than 12 Months</a></td>
<td class="nump">84,843<span></span>
</td>
<td class="nump">56,117<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentHoldingsLineItems', window );"><strong>Marketable securities on the balance sheet</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Total Marketable securities, Less Than 12 Months</a></td>
<td class="nump">53,816<span></span>
</td>
<td class="nump">158,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue', window );">Total Marketable securities, More Than 12 Months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentHoldingsLineItems', window );"><strong>Marketable securities on the balance sheet</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Total Marketable securities, Less Than 12 Months</a></td>
<td class="nump">168,250<span></span>
</td>
<td class="nump">139,596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue', window );">Total Marketable securities, More Than 12 Months</a></td>
<td class="nump">55,700<span></span>
</td>
<td class="nump">49,738<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentHoldingsLineItems', window );"><strong>Marketable securities on the balance sheet</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Total Marketable securities, Less Than 12 Months</a></td>
<td class="nump">26,320<span></span>
</td>
<td class="nump">44,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue', window );">Total Marketable securities, More Than 12 Months</a></td>
<td class="nump">18,503<span></span>
</td>
<td class="nump">$ 6,379<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_OtherDebtSecuritiesMember', window );">Government obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentHoldingsLineItems', window );"><strong>Marketable securities on the balance sheet</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Total Marketable securities, Less Than 12 Months</a></td>
<td class="nump">7,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue', window );">Total Marketable securities, More Than 12 Months</a></td>
<td class="nump">$ 10,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of available-for-sale debt securities at fair value maturing after the next fiscal year following the latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentHoldingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentHoldingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_OtherDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_OtherDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633768830392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value of financial instruments and marketable securities - Warrants and SARs (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Changes in the fair value of warrant liability and SARs liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate - finance lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember', window );">SARs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Changes in the fair value of warrant liability and SARs liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">$ 3,814<span></span>
</td>
<td class="nump">$ 3,186<span></span>
</td>
<td class="nump">3,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,186)<span></span>
</td>
<td class="num">(3,815)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsRightsExchangeSettlement', window );">Rights Exchange settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_CommitmentsMember', window );">Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Changes in the fair value of warrant liability and SARs liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">$ 257,040<span></span>
</td>
<td class="nump">290,500<span></span>
</td>
<td class="nump">257,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,220)<span></span>
</td>
<td class="nump">20,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsRightsExchangeSettlement', window );">Rights Exchange settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(139,180)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,100<span></span>
</td>
<td class="nump">277,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_StockAppreciationRightsSARSMember', window );">SARs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Changes in the fair value of warrant liability and SARs liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember', window );">Measurement Input, Option Volatility | SARs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.93<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate | SARs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term | SARs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | SARs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.76<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | SARs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.86<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | Measurement Input, Share Price | SARs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.03<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityNetSalesMilestonesandRoyaltiesMember', window );">Liability, Net Sales Milestones and Royalties [Member] | Minimum | Probability of Success [Member] | Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityNetSalesMilestonesandRoyaltiesMember', window );">Liability, Net Sales Milestones and Royalties [Member] | Maximum | Probability of Success [Member] | Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.89<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityDevelopmentandRegulatoryMilestoneMember', window );">Development and Regulatory Milestone | Minimum | Probability of Success [Member] | Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityDevelopmentandRegulatoryMilestoneMember', window );">Development and Regulatory Milestone | Maximum | Probability of Success [Member] | Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.94<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis | Liability, Net Sales Milestones and Royalties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Changes in the fair value of warrant liability and SARs liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis | Liability, Net Sales Milestones and Royalties [Member] | Measurement Input, Discount Rate | Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.145<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis | Liability, Net Sales Milestones and Royalties [Member] | Minimum | Sales Milestones | Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_AlternativeInvestmentMilestone', window );">Alternative Investment, Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis | Liability, Net Sales Milestones and Royalties [Member] | Minimum | Percentage of Sales for Royalties | Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis | Liability, Net Sales Milestones and Royalties [Member] | Minimum | Potential Net Sales Milestones [Domain] | Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_AlternativeInvestmentMilestone', window );">Alternative Investment, Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis | Liability, Net Sales Milestones and Royalties [Member] | Maximum | Sales Milestones | Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_AlternativeInvestmentMilestone', window );">Alternative Investment, Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis | Liability, Net Sales Milestones and Royalties [Member] | Maximum | Percentage of Sales for Royalties | Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.06<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis | Liability, Net Sales Milestones and Royalties [Member] | Maximum | Potential Net Sales Milestones [Domain] | Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_AlternativeInvestmentMilestone', window );">Alternative Investment, Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis | Development and Regulatory Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Changes in the fair value of warrant liability and SARs liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis | Development and Regulatory Milestone | Minimum | Development and Regulatory Milestone | Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_AlternativeInvestmentMilestone', window );">Alternative Investment, Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis | Development and Regulatory Milestone | Minimum | Measurement Input, Discount Rate | Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Changes in the fair value of warrant liability and SARs liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate - finance lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis | Development and Regulatory Milestone | Maximum | Development and Regulatory Milestone | Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_AlternativeInvestmentMilestone', window );">Alternative Investment, Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 381,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 555,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis | Development and Regulatory Milestone | Maximum | Measurement Input, Discount Rate | Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Changes in the fair value of warrant liability and SARs liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate - finance lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs (level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Changes in the fair value of warrant liability and SARs liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs (level&#160;3) | Agilis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Changes in the fair value of warrant liability and SARs liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs (level&#160;3) | Agilis | Liability, Net Sales Milestones and Royalties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Changes in the fair value of warrant liability and SARs liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">$ 53,200<span></span>
</td>
<td class="nump">65,800<span></span>
</td>
<td class="nump">53,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,800<span></span>
</td>
<td class="nump">5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsRightsExchangeSettlement', window );">Rights Exchange settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89,600<span></span>
</td>
<td class="nump">$ 58,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_AlternativeInvestmentMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Alternative Investment, Milestone</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_AlternativeInvestmentMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsRightsExchangeSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements, Rights Exchange Settlement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsRightsExchangeSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AlternativeInvestmentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure alternative investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AlternativeInvestmentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_CommitmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_CommitmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_StockAppreciationRightsSARSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_StockAppreciationRightsSARSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityNetSalesMilestonesandRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityNetSalesMilestonesandRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=ptct_ProbabilityofSuccessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=ptct_ProbabilityofSuccessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityDevelopmentandRegulatoryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityDevelopmentandRegulatoryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=ptct_SalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=ptct_SalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=ptct_PercentageofSalesforRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=ptct_PercentageofSalesforRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=ptct_PotentialNetSalesMilestonesDomain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=ptct_PotentialNetSalesMilestonesDomain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=ptct_DevelopmentandRegulatoryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=ptct_DevelopmentandRegulatoryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633884077448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other comprehensive income (loss) and accumulated other comprehensive items - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Other comprehensive income (loss) and accumulated other comprehensive items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning of the period</a></td>
<td class="nump">$ 528,734<span></span>
</td>
<td class="nump">$ 594,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income before reclassifications</a></td>
<td class="num">(8,031)<span></span>
</td>
<td class="nump">568<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Amounts reclassified from other comprehensive items</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(8,031)<span></span>
</td>
<td class="nump">568<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end of the period</a></td>
<td class="nump">572,494<span></span>
</td>
<td class="nump">572,494<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized Gains/(Losses) On Marketable Securities,&#160;net of&#160;tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Other comprehensive income (loss) and accumulated other comprehensive items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning of the period</a></td>
<td class="nump">692<span></span>
</td>
<td class="nump">755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income before reclassifications</a></td>
<td class="nump">2,718<span></span>
</td>
<td class="nump">2,655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Amounts reclassified from other comprehensive items</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">2,718<span></span>
</td>
<td class="nump">2,655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end of the period</a></td>
<td class="nump">3,410<span></span>
</td>
<td class="nump">3,410<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign Currency Translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Other comprehensive income (loss) and accumulated other comprehensive items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning of the period</a></td>
<td class="num">(2,677)<span></span>
</td>
<td class="num">(11,339)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income before reclassifications</a></td>
<td class="num">(10,749)<span></span>
</td>
<td class="num">(2,087)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Amounts reclassified from other comprehensive items</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(10,749)<span></span>
</td>
<td class="num">(2,087)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end of the period</a></td>
<td class="num">(13,426)<span></span>
</td>
<td class="num">(13,426)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">AOCI Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Other comprehensive income (loss) and accumulated other comprehensive items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning of the period</a></td>
<td class="num">(1,985)<span></span>
</td>
<td class="num">(10,584)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end of the period</a></td>
<td class="num">$ (10,016)<span></span>
</td>
<td class="num">$ (10,016)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633774305256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts payable and accrued expenses - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation, benefits, and related accruals</a></td>
<td class="nump">$ 24,861<span></span>
</td>
<td class="nump">$ 38,889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_AccruedConsultingAndContractedResearchCurrent', window );">Consulting and contracted research</a></td>
<td class="nump">13,452<span></span>
</td>
<td class="nump">12,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">3,295<span></span>
</td>
<td class="nump">3,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_SalesAllowanceAndOtherRelatedCosts', window );">Sales allowance and other costs</a></td>
<td class="nump">45,848<span></span>
</td>
<td class="nump">41,155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_SalesRebatesAndRoyaltiesCurrent', window );">Sales rebates and royalties</a></td>
<td class="nump">56,870<span></span>
</td>
<td class="nump">42,997<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">15,465<span></span>
</td>
<td class="nump">10,324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">4,585<span></span>
</td>
<td class="nump">9,380<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">$ 164,376<span></span>
</td>
<td class="nump">$ 159,276<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_AccruedConsultingAndContractedResearchCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for consulting and contracted research.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_AccruedConsultingAndContractedResearchCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_SalesAllowanceAndOtherRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales Allowance And Other Related Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_SalesAllowanceAndOtherRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_SalesRebatesAndRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales Rebates And Royalties, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_SalesRebatesAndRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633768192872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capitalization - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 29, 2020</div></th>
<th class="th"><div>Aug. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Apr. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,400<span></span>
</td>
<td class="nump">$ 19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,309<span></span>
</td>
<td class="nump">368,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Payments for asset acquisitions, share, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,869<span></span>
</td>
<td class="nump">$ 42,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptct_RightsExchangeAgreementMember', window );">Rights Exchange Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_SharestoissueunderRightsExchangeAgreement', window );">Shares to issue under Rights Exchange Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,821,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Payments for asset acquisitions, share, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptct_CensaMember', window );">Censa [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Payments for asset acquisitions, shares (in shares)</a></td>
<td class="nump">845,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Payments for asset acquisitions, share, value</a></td>
<td class="nump">$ 42,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_SaleOfStockWeightedAveragePricePerShare', window );">Sale of stock, weighted average price per share (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53.08<span></span>
</td>
<td class="nump">$ 52.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_SaleOfStockWeightedAveragePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Weighted Average Price per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_SaleOfStockWeightedAveragePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_SharestoissueunderRightsExchangeAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares to issue under Rights Exchange Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_SharestoissueunderRightsExchangeAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptct_RightsExchangeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptct_RightsExchangeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ptct_CensaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ptct_CensaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633770898248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net loss per share - Numerator and Denominator (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="num">$ (181,427)<span></span>
</td>
<td class="num">$ (41,789)<span></span>
</td>
<td class="num">$ (294,114)<span></span>
</td>
<td class="num">$ (113,902)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Denominator for basic and diluted net loss per share (in shares)</a></td>
<td class="nump">65,150,780<span></span>
</td>
<td class="nump">55,912,748<span></span>
</td>
<td class="nump">63,769,958<span></span>
</td>
<td class="nump">57,113,141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted (in dollars per share)</a></td>
<td class="num">$ (2.78)<span></span>
</td>
<td class="num">$ (0.75)<span></span>
</td>
<td class="num">$ (4.61)<span></span>
</td>
<td class="num">$ (1.99)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633774028168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net loss per share - Antidilutive (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares excluded from calculation (in shares)</a></td>
<td class="nump">12,891,606<span></span>
</td>
<td class="nump">11,518,303<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares excluded from calculation (in shares)</a></td>
<td class="nump">11,954,684<span></span>
</td>
<td class="nump">10,853,301<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ptct_RestrictedStockAndRestrictedStockUnitsMember', window );">Unvested restricted stock awards and units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares excluded from calculation (in shares)</a></td>
<td class="nump">936,922<span></span>
</td>
<td class="nump">665,002<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ptct_RestrictedStockAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ptct_RestrictedStockAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633769029160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock award plan - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 05, 2013</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>May 31, 2016</div></th>
<th class="th"><div>May 31, 2013</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,910,000<span></span>
</td>
<td class="nump">$ 10,920,000<span></span>
</td>
<td class="nump">$ 32,130,000<span></span>
</td>
<td class="nump">$ 20,184,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 187,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 187,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average remaining service period for recognition of unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">914,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">914,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Unvested restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Grants in period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">589,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,515,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions', window );">Inducement grants for non-statutory stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">542,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Stock option | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.31%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Stock option | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember', window );">SARs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">897,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_StockAppreciationRightsLiabilityOutstanding', window );">Stock appreciation rights liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptct_StockIncentivePlan2013Member', window );">2013 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptct_StockIncentivePlan2013Member', window );">2013 Stock Incentive Plan | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="nump">739,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptct_StockIncentivePlan2013Member', window );">2013 Stock Incentive Plan | Unvested restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Grants in period (in shares)</a></td>
<td class="nump">735,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptct_StockIncentivePlan2013Member', window );">2013 Stock Incentive Plan | Stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">4,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptct_EquityAndLongTermIncentivePlan2009Member', window );">2009 Equity and Long Term Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member', window );">2009 Equity and Long Term Incentive Plan and 2013 Stock Incentive Plan | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member', window );">2009 Equity and Long Term Incentive Plan and 2013 Stock Incentive Plan | 1998 Employee, Director and Consultant Stock Option Plan | Common stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards', window );">Number of shares subject to outstanding awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,040,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptct_LongTermIncentivePlan2013Member', window );">2013 Long Term Incentive Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber', window );">Share based Compensation Arrangement by Share based Payment Award Number of Shares Authorized Annual Increase Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding', window );">Annual increase in the number of shares outstanding on the first day of the fiscal year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptct_A2020inducementstockincentiveplanMember', window );">2020 inducement stock incentive plan [Member] | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">442,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">442,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber', window );">Share based Compensation Arrangement by Share based Payment Award Number of Shares Authorized Annual Increase Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=us-gaap_EmployeeStockMember', window );">Employee Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Award requisite service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_EmployeeStockPurchasePlanVotingPercentageLimitPercent', window );">Employee stock purchase plan, voting percentage limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_EmployeeStockPurchasePlanVotingPercentageLimitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Purchase Plan, Voting Percentage Limit, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_EmployeeStockPurchasePlanVotingPercentageLimitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of shares outstanding to be added annually on the first day of each fiscal year in the number of shares authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares to be added annually on the first day of each fiscal year in the number of shares authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares subject to outstanding awards used to calculate authorized shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the inducement grants for non-statutory stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_StockAppreciationRightsLiabilityOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of outstanding stock appreciation rights liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_StockAppreciationRightsLiabilityOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptct_StockIncentivePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptct_StockIncentivePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptct_EquityAndLongTermIncentivePlan2009Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptct_EquityAndLongTermIncentivePlan2009Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ptct_EmployeeDirectorAndConsultantStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ptct_EmployeeDirectorAndConsultantStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptct_LongTermIncentivePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptct_LongTermIncentivePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptct_A2020inducementstockincentiveplanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptct_A2020inducementstockincentiveplanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633766688888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock award plan - Share Base Compensation (Details) - Stock option - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number&#160;of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the beginning of the period (in shares)</a></td>
<td class="nump">11,043,939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">2,515,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(1,034,288)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited/Cancelled (in shares)</a></td>
<td class="num">(570,167)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the end of the period (in shares)</a></td>
<td class="nump">11,954,684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Vested or Expected to vest at the end of the period (in shares)</a></td>
<td class="nump">5,690,848<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at the end of the period (in shares)</a></td>
<td class="nump">5,512,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 31.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">50.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">24.21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited/Cancelled (in dollars per share)</a></td>
<td class="nump">42.27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the end of the period (in dollars per share)</a></td>
<td class="nump">35.84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Vested or Expected to vest at the end of the period (in dollars per share)</a></td>
<td class="nump">39.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at the end of the period (in dollars per share)</a></td>
<td class="nump">$ 31.61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted- average remaining contractual term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at the end of the period</a></td>
<td class="text">7 years 5 months 23 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Vested or Expected to vest at the end of the period</a></td>
<td class="text">8 years 10 months 9 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at the end of the period</a></td>
<td class="text">5 years 10 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward', window );"><strong>Aggregate intrinsic value (in thousands)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at the end of the period (in dollars)</a></td>
<td class="nump">$ 183,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Vested or Expected to vest at the end of the period (in dollars)</a></td>
<td class="nump">66,986<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at the end of the period (in dollars)</a></td>
<td class="nump">$ 110,222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Valuation assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 9 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Valuation assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (as a percent)</a></td>
<td class="nump">87.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Valuation assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
<td class="nump">1.45%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (as a percent)</a></td>
<td class="nump">89.31%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633770603000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock award plan - Restricted Stock (Details) - Unvested restricted stock<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number&#160;of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance at the beginning of the period (in shares) | shares</a></td>
<td class="nump">642,419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">589,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(229,076)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(65,491)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance at the end of the period (in shares) | shares</a></td>
<td class="nump">936,922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date&#160;Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance at the beginning of the period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 24.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">49.67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">23.53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">36.11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance at the end of the period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 39.97<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633775812776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock award plan - Share-based compensation expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,910<span></span>
</td>
<td class="nump">$ 10,920<span></span>
</td>
<td class="nump">$ 32,130<span></span>
</td>
<td class="nump">$ 20,184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,562<span></span>
</td>
<td class="nump">5,516<span></span>
</td>
<td class="nump">16,741<span></span>
</td>
<td class="nump">10,203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,348<span></span>
</td>
<td class="nump">$ 5,404<span></span>
</td>
<td class="nump">$ 15,389<span></span>
</td>
<td class="nump">$ 9,981<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">914,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">914,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | 2020 inducement stock incentive plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber', window );">Share based Compensation Arrangement by Share based Payment Award Number of Shares Authorized Annual Increase Number</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">442,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">442,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares to be added annually on the first day of each fiscal year in the number of shares authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptct_A2020inducementstockincentiveplanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptct_A2020inducementstockincentiveplanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633768924440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 05, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>day</div>
</th>
<th class="th">
<div>May 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2015 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 297,029,000<span></span>
</td>
<td class="nump">$ 297,029,000<span></span>
</td>
<td class="nump">$ 293,859,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,333,000<span></span>
</td>
<td class="nump">18,333,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DebtInstrumentAdditionalAmountAvailableForRepurchase', window );">Debt instrument additional amount available for repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible debt | 3.00% Convertible senior notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 126,730,000<span></span>
</td>
<td class="nump">$ 126,730,000<span></span>
</td>
<td class="nump">121,985,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000.0<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate ( as a percent )</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net proceeds from issuance of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Trading days, number | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DebtInstrumentConvertibleThresholdBusinessDays', window );">Business days, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod', window );">Consecutive trading-day period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum', window );">Maximum product of the closing sale price of shares of the Company's common stock and the applicable conversion rate for such trading day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.7487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault', window );">Convertible instruments principal and unpaid interest payable upon events of default</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders', window );">Minimum percentage of principal held by convertible debt instrument holders required to issue notice for declaration of principal and unpaid interest payable upon events of default</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term of the convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Adjustments to additional paid in capital, equity component of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_NetDeferredTaxLiabilitiesConvertibleDebtInstruments', window );">Net deferred tax liability in connection with convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,200,000<span></span>
</td>
<td class="nump">$ 175,200,000<span></span>
</td>
<td class="nump">171,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1', window );">Remaining contractual life of the convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible debt | 3.00% Convertible senior notes due 2022 | Redemption on or after August 20, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Trading days, number | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Consecutive trading days, period | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCumulativeSinkingFundPayments', window );">Sinking fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible debt | 1.50% Convertible senior notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,304,000<span></span>
</td>
<td class="nump">170,304,000<span></span>
</td>
<td class="nump">163,583,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 287,500,000<span></span>
</td>
<td class="nump">$ 287,500,000<span></span>
</td>
<td class="nump">$ 287,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate ( as a percent )</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net proceeds from issuance of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 279,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.0404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52.52<span></span>
</td>
<td class="nump">$ 52.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term of the convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Adjustments to additional paid in capital, equity component of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 123,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_NetDeferredTaxLiabilitiesConvertibleDebtInstruments', window );">Net deferred tax liability in connection with convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,300,000<span></span>
</td>
<td class="nump">$ 25,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">343,800,000<span></span>
</td>
<td class="nump">343,800,000<span></span>
</td>
<td class="nump">$ 335,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=ptct_MidCapFinancialTrustMember', window );">MidCap Financial Trust</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from lines of credit</a></td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_LineOfCreditFacilityAdditionalCapacityAvailable', window );">Line of credit facility, additional capacity available, net product revenue threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,300,000<span></span>
</td>
<td class="nump">$ 18,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DebtInstrumentFloorInterestRate', window );">Debt instrument, floor interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DebtInstrumentInterestPaymentPeriod', window );">Debt instrument, interest payment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the debt instrument principal and unpaid interest payable upon events of default.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_DebtInstrumentAdditionalAmountAvailableForRepurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Additional Amount Available For Repurchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_DebtInstrumentAdditionalAmountAvailableForRepurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_DebtInstrumentConvertibleThresholdBusinessDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified business days within which the maximum product of the closing sale price of shares of the entity's common stock and the applicable conversion rate for such trading day triggers the conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_DebtInstrumentConvertibleThresholdBusinessDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which the maximum product of the closing sale price of shares of the entity's common stock and the applicable conversion rate for such trading day triggers the conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum product of the closing sale price of shares of the entity's common stock and the applicable conversion rate for such trading day.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_DebtInstrumentFloorInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Floor Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_DebtInstrumentFloorInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_DebtInstrumentInterestPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Interest Payment Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_DebtInstrumentInterestPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_LineOfCreditFacilityAdditionalCapacityAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Additional Capacity Available</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_LineOfCreditFacilityAdditionalCapacityAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the minimum percentage of debt principal amount by instrument holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_NetDeferredTaxLiabilitiesConvertibleDebtInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net deferred tax liability attributable to taxable temporary differences from issuance of convertible debt instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_NetDeferredTaxLiabilitiesConvertibleDebtInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=51819886&amp;loc=SL6014347-161799<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCumulativeSinkingFundPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative amount paid into a fund, which is used to retire the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCumulativeSinkingFundPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section S45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68176171&amp;loc=SL68176184-208336<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ptct_ConvertibleSeniorNotes3.0PercentDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ptct_ConvertibleSeniorNotes3.0PercentDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=ptct_MidCapFinancialTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=ptct_MidCapFinancialTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633840226504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Convertible Notes (Details) - Convertible debt - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Aug. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ptct_ConvertibleSeniorNotes3.0PercentDue2022Member', window );">3.00% Convertible senior notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal</a></td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="nump">$ 150,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Less: Debt issuance costs</a></td>
<td class="num">(1,104,000)<span></span>
</td>
<td class="num">(1,329,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Debt discount, net</a></td>
<td class="num">(22,166,000)<span></span>
</td>
<td class="num">(26,686,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying amount</a></td>
<td class="nump">126,730,000<span></span>
</td>
<td class="nump">121,985,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member', window );">1.50% Convertible senior notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal</a></td>
<td class="nump">287,500,000<span></span>
</td>
<td class="nump">287,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Less: Debt issuance costs</a></td>
<td class="num">(4,319,000)<span></span>
</td>
<td class="num">(4,567,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Debt discount, net</a></td>
<td class="num">(112,877,000)<span></span>
</td>
<td class="num">(119,350,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying amount</a></td>
<td class="nump">$ 170,304,000<span></span>
</td>
<td class="nump">$ 163,583,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ptct_ConvertibleSeniorNotes3.0PercentDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ptct_ConvertibleSeniorNotes3.0PercentDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633766688344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Interest Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 510<span></span>
</td>
<td class="nump">$ 280<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible debt | 3.00% Convertible senior notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="nump">$ 1,125<span></span>
</td>
<td class="nump">$ 1,131<span></span>
</td>
<td class="nump">2,244<span></span>
</td>
<td class="nump">2,241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="nump">225<span></span>
</td>
<td class="nump">202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">2,295<span></span>
</td>
<td class="nump">2,074<span></span>
</td>
<td class="nump">4,520<span></span>
</td>
<td class="nump">4,055<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total</a></td>
<td class="nump">$ 3,534<span></span>
</td>
<td class="nump">$ 3,308<span></span>
</td>
<td class="nump">$ 6,989<span></span>
</td>
<td class="nump">$ 6,498<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate of the liability component</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible debt | 1.50% Convertible senior notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="nump">$ 1,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">3,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total</a></td>
<td class="nump">$ 4,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate of the liability component</a></td>
<td class="nump">10.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ptct_ConvertibleSeniorNotes3.0PercentDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ptct_ConvertibleSeniorNotes3.0PercentDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633762634984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 29, 2020</div></th>
<th class="th"><div>Apr. 29, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>May 29, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Apr. 20, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptct_AkceaMember', window );">Akcea</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAbstract', window );"><strong>Other Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_UpfrontLicensingFee', window );">Upfront licensing fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptct_AkceaMember', window );">Akcea | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAbstract', window );"><strong>Other Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_MilestonePotentialAchievementsRegulatoryApproval', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptct_CensaMember', window );">Censa [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAbstract', window );"><strong>Other Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_AssetAcquisitionMilestoneAmount', window );">Asset acquisition, milestone, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 217.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_AssetAcquisitionDevelopmentAndRegulatoryMilestones', window );">Asset acquisition, development and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_AssetAcquisitionNetSalesMilestone', window );">Asset acquisition, net sales milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_AssetAcquisitionInitialMilestone', window );">Asset acquisition, initial milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptct_CensaMember', window );">Censa [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAbstract', window );"><strong>Other Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_AssetAcquisitionMilestoneAmount', window );">Asset acquisition, milestone, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 217.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_NoncollaborativeArrangementTransactionsMember', window );">Non-collaborative Arrangement Transactions | Marathon Pharmaceuticals, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAbstract', window );"><strong>Other Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing', window );">Development milestone payments which the entity is obligated to pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_NoncollaborativeArrangementTransactionsMember', window );">Non-collaborative Arrangement Transactions | Akcea</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAbstract', window );"><strong>Other Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_MilestonePotentialAchievementsRegulatoryApproval', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAbstract', window );"><strong>Other Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing', window );">Development milestone payments which the entity is obligated to pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.0<span></span>
</td>
<td class="nump">40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone', window );">Net sales amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture', window );">Development Milestone Payment Obligations, Net of Cancellation and Forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis | Rights Exchange Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAbstract', window );"><strong>Other Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount', window );">Priority review voucher amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ContingentLiabilityCancellationAndForfeitureMilestonePotentialAchievementsPriorityReviewVoucherAmount', window );">Contingent Liability cancellation and forfeiture, Milestone, Potential Achievements, Priority Review Voucher Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DevelopmentMilestonePaymentObligationsCancellationAndForfeiture', window );">Development Milestone Payment Obligations, Cancellation and Forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.6<span></span>
</td>
<td class="nump">37.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture', window );">Development Milestone Payment Obligations, Net of Cancellation and Forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ContingentLiabilityCancellationAndForfeiture', window );">Contingent Liability, Cancellation and Forfeiture</a></td>
<td class="nump">$ 211.6<span></span>
</td>
<td class="nump">211.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture', window );">Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount, Net of Cancellation and Forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 361.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAbstract', window );"><strong>Other Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing', window );">Development milestone payments which the entity is obligated to pay</a></td>
<td class="nump">40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount', window );">Priority review voucher amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">535.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone', window );">Net sales amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis | Maximum | Rights Exchange Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAbstract', window );"><strong>Other Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture', window );">Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount, Net of Cancellation and Forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 361.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAbstract', window );"><strong>Other Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing', window );">Development milestone payments which the entity is obligated to pay</a></td>
<td class="nump">$ 37.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis | Non-collaborative Arrangement Transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAbstract', window );"><strong>Other Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing', window );">Development milestone payments which the entity is obligated to pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_BioElectronMember', window );">BioElectron | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAbstract', window );"><strong>Other Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing', window );">Development milestone payments which the entity is obligated to pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product | Wellcome trust</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAbstract', window );"><strong>Other Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing', window );">Development milestone payments which the entity is obligated to pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product | Wellcome trust | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAbstract', window );"><strong>Other Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing', window );">Development milestone payments which the entity is obligated to pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_AssetAcquisitionDevelopmentAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Development And Regulatory Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_AssetAcquisitionDevelopmentAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_AssetAcquisitionInitialMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Initial Milestone</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_AssetAcquisitionInitialMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_AssetAcquisitionMilestoneAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Milestone, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_AssetAcquisitionMilestoneAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_AssetAcquisitionNetSalesMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Net Sales Milestone</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_AssetAcquisitionNetSalesMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ContingentLiabilityCancellationAndForfeiture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Liability, Cancellation and Forfeiture</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_ContingentLiabilityCancellationAndForfeiture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ContingentLiabilityCancellationAndForfeitureMilestonePotentialAchievementsPriorityReviewVoucherAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Liability cancellation and forfeiture, Milestone, Potential Achievements, Priority Review Voucher Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_ContingentLiabilityCancellationAndForfeitureMilestonePotentialAchievementsPriorityReviewVoucherAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Liability, Milestone, Potential Achievements, Net Sales Milestone And Regulatory Approval</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount, Net of Cancellation and Forfeiture</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Liability, Milestone, Potential Achievements, Product Sales Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_DevelopmentMilestonePaymentObligationsCancellationAndForfeiture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development Milestone Payment Obligations, Cancellation and Forfeiture</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_DevelopmentMilestonePaymentObligationsCancellationAndForfeiture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the development milestones payments which the entity is obligated to pay under certain contractual agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development Milestone Payment Obligations, net of cancellation and forfeiture</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_MilestonePotentialAchievementsRegulatoryApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment which the entity is obliged to pay upon regulatory approval</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_MilestonePotentialAchievementsRegulatoryApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_UpfrontLicensingFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront Licensing Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_UpfrontLicensingFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ptct_AkceaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ptct_AkceaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ptct_CensaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ptct_CensaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_NoncollaborativeArrangementTransactionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_NoncollaborativeArrangementTransactionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ptct_MarathonPharmaceuticalsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ptct_MarathonPharmaceuticalsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptct_RightsExchangeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptct_RightsExchangeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ptct_BioElectronMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ptct_BioElectronMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ptct_WellcomeTrustLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ptct_WellcomeTrustLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633766727224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue recognition - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2011 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>Number_Distributor</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($) </div>
<div>Number_Distributor</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>Number_Distributor </div>
<div>segment</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($) </div>
<div>Number_Distributor</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_Percentageofnetproductsales', window );">Percentage of net product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_Numberofdistributors', window );">Number of distributors | Number_Distributor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,239,000<span></span>
</td>
<td class="nump">$ 85,522,000<span></span>
</td>
<td class="nump">$ 143,498,000<span></span>
</td>
<td class="nump">$ 139,105,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Performance obligations satisfied in current period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ptct_LicensingAndCollaborationAgreementMember', window );">Licensing And Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ptct_LicensingAndCollaborationAgreementMember', window );">Licensing And Collaboration Agreement | Research And Development Event Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_RevenueRecognitionMilestonePotentialAchievements', window );">Revenue recognition, milestone, potential achievements</a></td>
<td class="nump">$ 135,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ptct_LicensingAndCollaborationAgreementMember', window );">Licensing And Collaboration Agreement | Sales Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_RevenueRecognitionMilestonePotentialAchievements', window );">Revenue recognition, milestone, potential achievements</a></td>
<td class="nump">$ 325,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_NetProductSales', window );">Net product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,200,000<span></span>
</td>
<td class="nump">27,600,000<span></span>
</td>
<td class="nump">63,600,000<span></span>
</td>
<td class="nump">45,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_NetProductSales', window );">Net product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,000,000.0<span></span>
</td>
<td class="nump">$ 57,800,000<span></span>
</td>
<td class="nump">$ 79,800,000<span></span>
</td>
<td class="nump">$ 93,000,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_NetProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of revenue earned from product sales during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_NetProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_Numberofdistributors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Distributors</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_Numberofdistributors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_Percentageofnetproductsales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of new product sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_Percentageofnetproductsales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_RevenueRecognitionMilestonePotentialAchievements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone, Potential Achievements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_RevenueRecognitionMilestonePotentialAchievements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ptct_LicensingAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ptct_LicensingAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_MilestoneAxis=ptct_ResearchAndDevelopmentEventMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_MilestoneAxis=ptct_ResearchAndDevelopmentEventMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_MilestoneAxis=ptct_SalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_MilestoneAxis=ptct_SalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633853153720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue recognition - Performance Obligations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2020-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with Customer, Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Deferred consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, performance obligation, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2020-07-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-07-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with Customer, Liability</a></td>
<td class="nump">$ 7.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Deferred consideration payable</a></td>
<td class="nump">$ 7.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, performance obligation, period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2020-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2020-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2020-07-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2020-07-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633769842952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets and goodwill - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Apr. 20, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">$ 8,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,575<span></span>
</td>
<td class="nump">$ 16,679<span></span>
</td>
<td class="nump">$ 12,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefinitelivedIntangibleAssetsAcquired', window );">Total allocation of IPR&amp;D assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">576,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">82,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">176,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,979<span></span>
</td>
<td class="nump">$ 266,632<span></span>
</td>
<td class="nump">112,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Remaining amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptct_AkceaMember', window );">Akcea</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_UpfrontLicensingFee', window );">Upfront licensing fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_NoncollaborativeArrangementTransactionsMember', window );">Non-collaborative Arrangement Transactions | Akcea</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_MilestonePotentialAchievementsRegulatoryApproval', window );">Milestone payments</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_EmflazaassetacquisitionMember', window );">Emflaza asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Finite-Lived intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 148,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_MilestonePotentialAchievementsRegulatoryApproval', window );">Milestone payments</a></td>
<td class="nump">$ 12,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,300<span></span>
</td>
<td class="nump">$ 12,200<span></span>
</td>
<td class="nump">$ 8,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_MilestonePotentialAchievementsRegulatoryApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment which the entity is obliged to pay upon regulatory approval</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_MilestonePotentialAchievementsRegulatoryApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_UpfrontLicensingFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront Licensing Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_UpfrontLicensingFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=116868840&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefinitelivedIntangibleAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefinitelivedIntangibleAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ptct_AkceaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ptct_AkceaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_NoncollaborativeArrangementTransactionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_NoncollaborativeArrangementTransactionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ptct_EmflazaassetacquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ptct_EmflazaassetacquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633766715560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible assets and goodwill - Future Amortization (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2020</a></td>
<td class="nump">$ 17,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2021</a></td>
<td class="nump">34,920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2022</a></td>
<td class="nump">34,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2023</a></td>
<td class="nump">34,920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter', window );">2024 and thereafter</a></td>
<td class="nump">10,094<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 132,314<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Assets, Amortization Expense Year Five And Thereafter</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140633840386648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent events Narrative (Details) - Subsequent Event [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jul. 17, 2020</div></th>
<th class="th"><div>Jul. 01, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayments of lines of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_LineOfCreditFacilityTerminationAndExitFees', window );">Termination and exit fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_AssignedRoyaltyPaymentPercentage', window );">Assigned royalty payment, percentage</a></td>
<td class="nump">42.933%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ProceedsAssignedRoyaltyPaymentAgreement', window );">Proceeds assigned royalty payment agreement</a></td>
<td class="nump">$ 650.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_AssignedRoyaltyPaymentRetainedPercentage', window );">Assigned royalty payment, retained percentage</a></td>
<td class="nump">57.067%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_RevenueRecognitionMilestonePotentialAchievements', window );">Revenue recognition, milestone, potential achievements</a></td>
<td class="nump">$ 397.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_RoyaltyPurchaseAgreementTerminationPeriod', window );">Royalty purchase agreement, termination period</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_RoyaltyPurchaseAgreementPaymentMaximum', window );">Royalty purchase agreement, payment maximum</a></td>
<td class="nump">$ 1,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_AssignedRoyaltyPaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assigned Royalty Payment, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_AssignedRoyaltyPaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_AssignedRoyaltyPaymentRetainedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assigned Royalty Payment, Retained Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_AssignedRoyaltyPaymentRetainedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_LineOfCreditFacilityTerminationAndExitFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Termination and Exit Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_LineOfCreditFacilityTerminationAndExitFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ProceedsAssignedRoyaltyPaymentAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds Assigned Royalty Payment Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_ProceedsAssignedRoyaltyPaymentAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_RevenueRecognitionMilestonePotentialAchievements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone, Potential Achievements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_RevenueRecognitionMilestonePotentialAchievements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_RoyaltyPurchaseAgreementPaymentMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Purchase Agreement, Payment Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_RoyaltyPurchaseAgreementPaymentMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_RoyaltyPurchaseAgreementTerminationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Purchase Agreement, Termination Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_RoyaltyPurchaseAgreementTerminationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>88
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MV\\6R.<YLCEU>9D,AD/J,+L_ME[J6%4&P-H9 $BJ F^Z@Q;]E?PNZM=:4Z-
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M4%X"]FBJOV*JSTZAUTR:$C--?Y?NU#'W""4SW;852K/<$]1LT)V%9UYH6KU
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M1W0:_7EW%?WZRX?HER@OHS^6U:;)RD5S-FM5-)W/V7RX\L7VRMAQY3^J-BN
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MZO\/5=7^_-#]S'/W2^/S_P-02P,$%     @ S(4%41?2!!*W"0  Y2D  !@
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MHW>(1"1RZ%F>?3I. W+HWK=47X_Z?*L<N-8.7#=RBV#N-5E75(]#\!9=(=K
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MM1G>*1P^=++6K^4]R*Z36WVX$1FT&LH ?E]+V>T^J!OLW^R\^1]02P,$%
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MJ_WCV,Z4=#+?TYG7IM=23TD"CV;TU&*WIROF&X\6L!@#_&<9.,OKM /1+HT
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MF_N21U(9$E9@&1A@PS@+B 7"EB'_]/J*\P;' F, DO_YOO*ZB)HH),HE-BU
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M6U9-WA157F>VSWM#ZMW3EQ9C?&T*LUZ8+CL]Q@X?OZ IBGH@T<%<4X->-,U
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M5B%0P::_Q*#09UNBCTGZT+2W!''?T;!=Q0.Q>H__CNUJ:=AXB!R)BI!H&EB
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MHY91]*A'?TE7%Q<,N*A)ZYY)N(6:WWI88^MQBAZ9W+^WM]!&?,150PE&-U#
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ML>.\V)+X6"T(;REWY%LG&5#X6'GEO$"R7AX*U@E7IP1KAQNY53]&,8\^$L\
MPQ3)8D30_XFAW,U&#1MYFEMJ1C\:M(WN)AQ?C^W5LK+A]VXBA)\VUH5''C&,
M.WNL(6] </$VYZD\:KY?3)+D>95/; HNAA5$CEA\OM<0G+-]/W@-BGYFBF);
MK7)P?G+T>)9][0G)7G<D1/A1-[7]E^D5N]&3[\)%QV( IV<Z&!M85QQ%)+6C
ME5DW'C7B:)3YL3Z2"2#$NP^UV+'5\<KIIFS,;3;^$2/I><%)<N#-/42)/.'U
M>Z!81-?O\ VN]>]^QQ"/>5\36 1=7  F52'<4!2V!4"V\3;.5Y;5#.J6R8T
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M/S\[D%*Z^X-\//\\\J+MR9/R/Z\-X;<.#]#WP#3N#TS@?R_[R_\%4$L#!!0
M   ( ,R%!5'4:S'2;0P  )PA   9    >&PO=V]R:W-H965T<R]S:&5E=#$P
M+GAM;*U:6W/;-A;^*QAONIO,T+*HNW.;<9QFFTZRR<1I^["S#Q )26A)0@5
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M@?%DD@Y&;7K+0P;Y QF.CO52'-PJ5D*0!GM_ =616G6PI54D_)&GL!EBG%#
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M/0L:;!Z\V?+]^])XV)2_;I1$^T@'\/O*&-\\$('V#S)>_Q=02P,$%     @
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M<ZW]O;<=MBRX%9=:?96)2T\'1P.6B"4OE?NHU[^+RIXYZ8NULOXO6X>ST^F
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M3ZVKFX^O>%8<OPNX^L6.:*O*I":[="Q!]<NU8RF_0T92Y56PEOH+ULO2E7!
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MTF)!>HGK+6O!C<6B;'AZVL"H?;3F&-2 WA0@3XI\Q)2<" <_?QRP'U+VEC]
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M].DT0M)1&U3E.GT\@R&)R6!NX(<;RF#<V\LO,<"O-AB:8YCX?8YQXB\V;J1
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M1+0?M"$"5Q*!"*=N3V8K#$V1ZS([-5AT!*8*EFWRYJF,6?7-6RG'\.J)E&T
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MH^.3/  ]#K-Q8]7@!\A&61I'?MG2_$?M NA]HY1]W#B!Z1]E^0=02P,$%
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M8\5M]: &WM-5;$C&1FS%BHJ'2G./< @+,F/O=",Q3UYSMRR=SO=I(6I2N,]
M -F_%HHT^.>J28)9$@?QR?29GN5JN!+:RE0VP@G@^'7'<PB_$VQG70@J"U@+
MJ>%.E*VO@G@2A9->^K:A'_8NZA0?C7Y)>@FX1)WS\?2= YZ-)\%HNM\!>YM>
M?!NX)V-\0V^A"SKP!R'U@D8?:<;-<31.PGD?*;\[J!QJYR$ME>$XND;S+>*7
M1$KWFY'N"LFH:;VB=5NM7!WMJ'8!;-QY1-59N2.I=:B"@OXIHX/XXZ?%U3=M
MO"_H0RV%CUV@P[U'2<4&_/1B5:C<_?NDG^U?=PO_J'G8[I^&=-_DDGJBQ#69
M1N')9 #:/[?\P*K&/7%6RM*#R7T6]$)%S1MH?:WHPN\&[*!_\Y[_#5!+ P04
M    " #,A051W3L7R00$  !'"0  &0   'AL+W=O<FMS:&5E=',O<VAE970Q
M-BYX;6R]5MN.VS80_96!T(=NH%A7R]+"-K"7%$V I(MLTCX4?: EVB)6(A62
MLC=_WQE*UGH;[Z) @3[8&HHS9^;,A=3RH/2#J3FW\-@VTJR\VMKN,@A,6?.6
MF9GJN,2=K=(ML[C4N\!TFK/*&;5-$(=A%K1,2&^]=._N]'JI>ML(R>\TF+YM
MF?Y^S1MU6'F1=WSQ6>QJ2R^"];)C.W[/[=?N3N,JF% JT7)IA)*@^7;E7467
MURGI.X7?!3^8$QF(R4:I!UJ\KU9>2 'QAI>6$!@^]OR&-PT!81C?1DQO<DF&
MI_(1_1?'';ELF.$WJOE#5+9>>;D'%=^ROK&?U>%7/O*9$UZI&N/^X3#H)J$'
M96^L:D=CC* 5<GBRQS$/)P;Y2P;Q:!"[N ='+LI;9MEZJ=4!-&DC&@F.JK/&
MX(2DHMQ;C;L"[>SZ$]:]4<9 Q[%4-=-\&5C$I=V@'#&N!XSX!8P,/BII:P/O
M9,6KY_8!QC,%%1^#NHY?!?S0RQDDH0]Q&(>OX"43R<3A)2_@O6-:"KDS<(<D
M[XDD_'FU,59C3_SU"GXZX:<./_U/27P5@X;OTG2LY"L/I\MPO>?>&6"X9D:4
MP(^,GC:$@5*U76]Y!9OO4(F]J% %Y!$#7]J:P\$U*J_>LCW7.'<@^W:#*&I+
M]BU.BL,S@"-L+),$,H-;T3CD_\-QU_3&6?#M%H>7%)@D8 P!1Q@Z9;FT@C4O
M!PQ5K^E!*!BI4-4,OJ"\50T>0VZ';1JT,1@D'FVV=JH##^;."_2Z<;E&Q,$W
M\I,_%.02<37GST8 L(&Y:^![\?C"#K4V_D7%B?2I;S$S5FF8"O\3_!SED9_&
MBPN2T\A?Y(43XR+UHRAU<A0E?A'&%W#+I<)3PF&<RDCQ7[&!;.Y'\Q"=A#"?
M^T44^XLTARSQ%UGA%_,<Y@N?O$5I!#]VY^78GJ=.*-39(K^ -R2&L\5\%--9
M%HUB-"L*$M^\EZX.UJ644 PFL!T2R,\DD%0H=;XSN\'R4:?P1ZHYER7JLR>6
MI(QJ>.PK9%H)3("R>+-T6/_G'38V-J*5]FSCH(8Z&*@%'M!:E-B*D^UI3P+_
MUHL]:[!=G[6G#X=:E#60"L4@9-GTQ$X,_-E&(=().O[*OG&-Z0/[YW3@2N@!
MQ%V6@KA:\7:*:9P&SM#G<1RN#)F>Z<=[J\H'^*TC9P:B",N>^EF>0A3Z^3SQ
MDS""KW+/#547Y\YBB"0:9\<.3%=#KGLID':19'X1QY!A:X5A#%^414+86'D1
M^5F8D8=YE"-L N?.XN#D<L/QV+DKG(Z<7MKAGIO>3E\)5\/E^*0^?&)\9'HG
MD%/#MVA*K>B!'J[M86%5YZ[*C;)X\3JQQB\=KDD!][<*CYYQ00ZF;Z?UWU!+
M P04    " #,A051G5W6#<L,  !-)P  &0   'AL+W=O<FMS:&5E=',O<VAE
M970Q-RYX;6S-6EESVT82_BM37&=7JH(H7#S@JTJ^LDG%L4IRDH>M?1@"0W)B
M$* '@"CEU^_7/;AX2MGX(0^V0&"FI\^O#^#E)C=?BJ52I;A?I5GQ:K LR_7S
MR\LB7JJ5+(;Y6F5X,L_-2I;X:1:7Q=HHF?"F57KIN^[X<B5U-GC]DN]=F]<O
M\ZI,=::NC2BJU4J:AS<JS3>O!MZ@N7&C%\N2;ER^?KF6"W6KRE_6UP:_+ELJ
MB5ZIK-!Y)HR:OQI<><_?A+2>%_RJU:;H70N29);G7^C'#\FK@4L,J53%)5&0
M^'.GWJHT)4)@XVM-<] >21O[UPWU#RP[9)G)0KW-T]]T4BY?#:8#D:BYK-+R
M)M_\6]7RC(A>G*<%_R\V=FT8#$1<%66^JC>#@Y7.[%]Y7^NAMV'J'MG@UQM\
MYML>Q%R^DZ5\_=+D&V%H-:C1!8O*N\&<SL@HMZ7!4XU]Y>O;,H^_"+F1)A'K
M5&8O+TM0I6>7<4WAC:7@'Z$P%A_SK%P6XGV6J&1[_R6X:5GR&Y;>^"<)_EAE
M0Q&XCO!=WSU!+VA%#)A><$S$I33J@DR7B&OY (\JQ94Q,ELHOO[/U:PH#=SC
MOR<."]O#0CXL_ OZ_',4Q*=,?)0F7HH1J<0+'%$NE7B;K]8R>_CG/Z:^-WE1
MB#<Y;<CGXITV\/C<%$*NUR:_@]2TGG8*2_N'+(;<" 9Q#?J.V"PUJ--:G:A"
M(-)YQP(J*G6V(*(%;\S7-I*(M\*I;](I*M:2'QD* CPR"BK5<8G#>=7^'5%E
MN@2/&9C&:<;>K<UD3Q Z8T;D8F'40I:*.)D$D1,%$U&050NZ$^>K%8[F_</3
MVOK7:3U)*[,]9N0$?M@[9D\ 8CUTQE!K7SO%4'R&.. :_[)<R"31=%^F#2UY
M)W4J9ZEB3>NBJ"0, GTDBA2O"S;[$&:" &YTV-Q,:YFGV+-G:#<2[[]6NGQ@
M%G_*L\7%9V56W\SN^YJH'QPQ)N[&LEANV1;>4\U^AP%$F8M8F1+Y [KZ'8A'
M06D=0V99!;WI+$:^*53!.ODH'_YD&&0UGXVZ&GJ)F(&4,W)=QW5=)I=5JQG8
M)\EK8U7E,C?Z#RQN#'18Q>)OI^)OZ8A_7>G[8/28UF8JEBLEU'RN.'6+:IU;
M0(C3O*BU=X@=#631$'-=S5(=8]5<&2QG?9P^^HBEZ"#=+MR*=@>JS8I2EA7$
M?MA]=L2,)U'/LKGGB#M 1Z25(7T>M-UC<L*VM BE&!$^\\Z%Y_N.'XV/'?>(
MK^P;X:DQP@]/)*<S__QP9)Y5:\*.P'%#UPG#!JK/A?I*H(%'/0D/4MB5L8=(
M*%]AU"PA+ZMM=EQ4+XJFXOUJG>8/2CEM$+!D;^$'*!#)B:Q\GVR@6^&^C9+
ME"R%NE_C8 0HMNN,LZ7AV&='V^B"E&&,(C%4X@ O0"2E*UATKC0Y*788M:Z0
M/AMX[,DK< A^:J@0:5X3D+1^L(:7X__*T&_6H(1N,RZKR!H=55LB %DJF# X
M%RS<%LP[M'VF"+"()1OR<VV*4B2 (5A-2<##7!<Q=CTH:6";4J>\CK5@:Y':
M[(]@S9:WH$5!Q-+.+BT<=A9'A-\]V;'ZWG1('GNC$\?F/B%7.01#CV%-NF>0
M$_@[%%?,!FIIU=;23N/*%,*1%SJA>SS>*7$\%O,G5<MYXT<)TYJ'^OBG5V*6
MNN^"1E+%MDX_Y/H-IC^^\N\ [7RTA2TR;[^L]<C73O@;#(H(9)8+]'_)MAF>
M(/X*E15%%>_M!RI1^%D6B?PJ?M(%5R4W%6P^&@>CL_C\+#R'@EK:5FGJ/E9U
MP0*)01,>2AD7'"-'*ZO6;6MG:-"7,'11>ZU0#)A,E+:AS^>P?=QSP]!WIM-C
MBGJJYS[%MSZ8?-6ZL&=9P7:35XOE+H-]H*0#N9TH\Q):L7#BC1R?S-MW(]+_
MG30Z!QBJ.H$@=C^1\G)"PA%D#4>NV% AMVL&JPXXZ<51+Y4I'V\+*B9RT/Y/
M4\=5,[K9+UNI0*,DAKI"$ELID+1X+GYND?$W'H^HY*)W==4&P*=^NBW%.P4^
M:&/ 2O<BX2$^P@"-7R2>X>YP/!'?DPJ@Y4ZUS\3('5(JOE<FUA1V9]@6A(X_
MG9[CJ1\.?4]\:++=Y5O.@"FM&TU<QQM/:%7H#_W)+D=;QB9NHA%:OVE(W(R&
M^#L9AE,&[P*WO&G@A-.I^!488;/J^_NU8JP@@U.*V:,Y<L:1ZTQ!!22CH3<6
MT^%TW)(<CYT(/VO1V+4/D!AY*.)&?JTC3X"U4<>5YSJ^[S-BSB72^)U,*P:?
M/JS4/7>A[\7*SG6H8DAVCMK RI3?X;0Y-BLX</H@()@F+&BS=E*CFT6-BHMV
M3G;L(*Q;A,K*>NMS<;M[Z(TNOES,C2*V #&D.$,DW6'H?B<NA#<,1]]URKW+
M4V!(2HXXG0Q'O&0:#0.OMX9R*?0R:?3RN5_@$#-8@VY)->L335DCJ[&'XLEJ
MRV:>3>W,0!QEY*))*BSWMHZ;B%_4;IM4IM%&JVNQ!HSFR5&-/PO&PVA$JRSX
M61[4EFB]HVA+9Q*;B&K#=+B,-@_ H:GV4'7<$/N2$UG9)]_3[E\XQ.)&1\O*
M8%I#F]IEB$#_C);R+\/;H?@>58+)+%:I&*HL-5+!9ZH?*^#36T[<>/@1N%@_
M?- JI?Q<'O!,-JW57Z%72!VF0<8]Y79\#<5-5P-8Q+SJ:H"]9[_PO(NSG__B
MYD3U<&Q29E3K/ =F)\TNB_LH:=**P0N/BAQM=$P#%$$](U7J5 )INIMG=BJ
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M0&#1F-BP*#0LUJ!^0$4&1P#<"8#,P4"M1 G@:H-N^[786.=ID*?ML]%MB#1
M3=MP[=Q! "8XFP[&E0WR)>CGDM102^#5!I@%+J$ ?27U&8?W4$K5R=X-YH1
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MG*.&P.OND_I==!VH,+'.L@"T(LDPP^[V^\@]P+C'@U/BZ!B?DPD>#1 [BC#
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M\'ZA0!G\%SR@^F-2C_\'4$L#!!0    ( ,R%!5&260W,(0P  *$H   9
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ME@?*$^J[4A?5O4G)01JSOLGFBG_E=5R)5=<$&'1,,JNRIB)9A2K!%TTB3N\
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MPM9)K%!+.L&DOJ%VMI.<%/CO<)!.?R_.+LX'9\U.Q1;!HA54&ML&3AO6$=5
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M&%4^"G@^^+<VE2 (2%<1#:7YE7Y<D5R+!I*?;1SI(NK=IA,IK^$-,NBGU6N
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M%<$D_XF=L]C)60I$2KQLL"1C[)4&]V81>O5]ZU@EIC,ABR8F9]7(:?>9!;=
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MFG N>DF?6]E>L@DX6?IY[',ASKR3!!DDRI!A]?LA=0^!7##O#_"R*HZ08#8
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M4ZF%88%W\:]4]MB[N_QH"*/]>?5A5DR5=94+$>2\G>1*_J/;XN0Z:SDF=&O
M_&ASR\9XH4H0[D(DR!? XH,#_8A@9F+*-,1T@G?<V@%^M19IAE/'_R(<_XL'
M<')!0 XEE;.28,:AU ]*P,DYAVMI#R^4?<009PW$  28=A3'/1I=OWWW5[79
MOOQZ])BPF?\0E;R@?_.6:UAD&@EL58T25:U=T@&BF2VZAC;9@(#-@DXI8.:
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M(&BALT7]DH:W!)4I'F+^ U&R69+?%KJ]T_IH"_$^$.-=<Q<-?W>$/&&HL6R
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M&M0C]"8/2\M7-U* ,)K(.<'.4\QPL2"5TP9K;$5<5Z" ,$WFLL*>TF/RL%0
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M43L'.F^4LG>&(YA^*,N_4$L#!!0    ( ,R%!5'H4: 5Z0,   $)   9
M>&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;)U6WV_;-A#^5P["'II"M459DJW
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M$R>2%WX4[LB@F1J3G/5)/I+9=,AL^KVE1#9=)Z8'WH?@6M5+WCS_9(#@:^E
MN$JP+W-'/>TO,?<OXFD=S[NB(_]%"AV&].,/.0NSG[\%UG4<+$M-"6TC+6;F
M=BO2-:7+K<AG$ME3M^ C;UH*3-B3)HV9%X=%5U:28"A'25YX04;%*"ZH3/4U
MX(0QVD]='8K\)-K6(3A)$R\N0CJ*4C\,$<2JT_KFB1<1U@'&NAI19,?><C9D
M//ONMVQVNM84 XLC41=L\41K@=&=*DUDWKPLBPQV#0VU<7[33MSL8\-1%(?9
MT.=WZ_E_,1Z'AH8JWE=BB?6_H5GM13<S'C3X%]5;JS#CK\X.$&S/@:.;8Q7A
M^7!W<_.B.=XOJ!;LSC';9%/QV'_B:.!ZXG:%A,;G/UTX7Z58X0"\=#=_ [F7
MI$07Z@TI-8'4R^*0%M@,@@CNL 'B4_-@+AH,4>5,\!+G/TGSB0M.[D78EI"C
M00S8:J.\@ *[40CWRJ*&,UJ$06>T8+2(F!=&M&#85[$][N/I>&>6K(6>NXF9
M*G';V&ZL'':'H?RRFT6WXMU$_XGKN<3<5F*&J@$6Q!'H;DKN/JQ:NLGT05F<
M<]UR@?]8"$T">#Y3RFX^R,'PK\KD/U!+ P04    " #,A051/VMG.G<$  "V
M#@  &0   'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6S%5]MNXS80_96!L0LD
M@&I3U,5RX!A(LELTB^PB2-+VH>B#+(UM8B72)>EUTJ_OD+(5!VLK:9NT+R9%
MS9RY\/!8'*^5_FH6B!;NZTJ:T]["VN7)8&"*!=:YZ:LE2GHS4[K.+3WJ^< L
M->:E=ZJK 6<L'=2YD+W)V*]=Z\E8K6PE)%YK,*NZSO7#.59J?=H+>]N%&S%?
M6+<PF(R7^1QOT?Z\O-;T-&A12E&C-$))T#@[[9V%)^<A<P[>XA>!:[,S!U?*
M5*FO[N&R/.TQEQ%66%@'D=/P#2^PJAP2Y?''!K37QG2.N_,M^H^^>"IFFAN\
M4-6OHK2+TU[6@Q)G^:JR-VK]$VX*2AQ>H2KC?V'=V YY#XJ5L:K>.%,&M9#-
MF-]O&K'CD+$##GSCP'W>32"?Y8?<YI.Q5FO0SIK0W,27ZKTI.2'=KMQ:36\%
M^=G)!YQ:^ &.[O)IA>9X/+ $ZEX-B@W >0/ #P"D\%E)NS#P4998/O4?4#)M
M1GR;T3GO!/RTDGV(6 "<<=:!%[451AXO/H 7]A/V'BZ4_(;:"JH2#$JA-$AE
MT4"Y0A<I[8@4MY%B'RGJZN6E-%:OB+<V@!LLL5YZ]OUV1<9P:;$VOW>$2MI0
M26=1M\TA C6#8J<R7]*^/>Q&NULT/7C2I2^^/81NA+$ND"6KF:KH' LY/X$K
MD4]%)>P#V=1+):EBH+W#=N_@ Q983U%#%+J5< 376LA"+/,*W@'/AD'"V,[L
M"HTY =]%8<PJEP42MK$&CN(@"D?';DS2X?&N92E,H5:NVQ+M44@V8<B#;#CT
MLU$0)>P8OI"\%;G6#Y0YY+6SI[CAD 41B]TLC8(DB\#Y7\JB6A&504A?LNN
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M^YSKN9 &*IR1*^L/Z2-4-Y>DYL&JI;^83)6E:XZ?+NABB=H9T/N9(C)L'ER
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M"<VX>9;;WZ$,J)O[BR37]C_9%K8]-(XR;61:@I%!RD3Q2]]*(0X Z*<>X)4
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MCRN\)8'*#?!](J79#?(%JGO7^%]02P,$%     @ S(4%46F7%>7  @  :P<
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MB%]^@D'OM\^4Q7*&JX>0+/^)U',Q(!X_.0'L%PE,=9\:YLV+P+RU1YF21^#
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M*0/Y_R)-Q?Y")2A?)0__!U!+ P04    " #,A051%=X.==\"   W"0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6RE5EUOVC 4_2M6U(=66IOO!"J(
M5 C5-JU25=KN8=J#(898=6QFF]+]^]E.R"!)0[6]$/OFG'-]KDVN1SO&7T2.
MD 1O!:%B;.52;JYM6RQS5$!QQ3:(JC<KQ@LHU92O;;'A"&:&5!#;<YS(+B"F
M5C(RL7N>C-A6$DS1/0=B6Q20_YX@PG9CR[7V@0>\SJ4.V,EH ]=HCN33YIZK
MF5VK9+A 5&!& 4>KL77C7L]BC3> 9XQVXF ,M),%8R]Z\B4;6XY>$")H*;4"
M5(]7-$6$:"&UC%^5IE6GU,3#\5[]UGA77A90H"DCWW$F\[$UL$"&5G!+Y /;
M?4:5GU#K+1D1YA?L2FP866"Y%9(5%5FMH,"T?,*WJ@X'!*733? J@M<D!.\0
M_(K@?S1#4!&"CV8(*X*Q;I?>3>%2*&$RXFP'N$8K-3TPU3=L52],]3F92Z[>
M8L63R3>DJBS )3 #L&1""G">(@DQ$1<J_C1/P?G9!3@#F(+'G&T%I)D8V5(E
MUQ+VLDHT*1-Y[R3RP1VC,A=@1C.4=?#3?G[4P[>5Z=JYMW<^\7H%OV[I%?"=
M3\!S/*=C/=,/T]UAEYW_RS[[Y^Q'Q?#K8^ ;/;__&/RX60C)U9_W9X]F4&L&
M1C-X1_,6OZ$,D/I<=9V94B$R"OJ3]IJXPUC5X_5P(]J@@1\>8](V)G &PV/0
MK"-;%,0UZ,AE6+L,>UT^0X[A@J 31DN1\"!UZ,0-GVV,&[D-GVU,[ <-FVV,
M[P3=+J/:9=3K<IXS+B\EXL4)GU$K]V#0L'D:DK8A;M38\5D')G"[7<:UR[C7
MY2.3D #5@SF4F*Y/6(U;I\D+FZN<MD&N,VAL6-H&!<-F368=Z9RAUS!L'W2"
M O&U:<%"6=A267X-ZFC=Y6],<VO$)^[UU.V(I^I64#;QO_+EE>(.\C6F0A5M
MI5(Y5[':&EZVZ7(BV<;TH063JJN98:YN-HAK@'J_8DSN)SI!?5=*_@!02P,$
M%     @ S(4%4;B@_YIM @  =@8  !D   !X;"]W;W)K<VAE971S+W-H965T
M,SDN>&ULG57);MLP%/P50L@A 9IHE^U %I#8*-JB18(L[:'H@9:?+2(4J9)T
MG/Q]'RE%<+RA[<7B,C.<>:*?\K543[H",.2EYD*/O<J8YM+W=5E!3?6%;$#@
MSD*JFAJ<JJ6O&P5T[D@U]Z,@R/R:,N$5N5N[544N5X8S ;>*Z%5=4_5Z#5RN
MQU[HO2W<L65E[()?Y U=PCV8Q^96X<SO5>:L!J&9%$3!8NQ=A9>3S.(=X#N#
MM=X8$YMD)N63G7R>C[W &@(.I;$*%!_/, '.K1#:^-UI>OV1EK@Y?E/_Z+)C
MEAG5,)'\!YN;:NP-/3*'!5UQ<R?7GZ#+DUJ]4G+M?LFZQ:8(+E?:R+HCHX.:
MB?9)7[HZ;!#"Y  AZ@C1WQ+BCA"[H*TS%VM*#2UR)==$632JV8&KC6-C&B;L
M6[PW"G<9\DSQ%; &FIR3:\JI*(&T=^=T"H8RKL]PY_%^2DY/SL@)88(\5'*E
MJ9CKW#=XO!7QR^ZHZ_:HZ,!17U;B@L3!!Q(%4;"'/CE.GT*)]-#2P]%[NH^A
M^^11GSQR>O'QY#^O9MHHO$V_CFC&O6;L-),#FC<-*&J86!)NU<G=S2.A6H/9
M5ZU6*G-2]L_V7$2C9)#F_O-F479189R-XA[USF?2^TS^R2=G=,8X,PST.=XZ
MI4#LM=RJIAMFDF$VW'*\"TK#](#AM#><_K]A(<41S^F.G2A-PV#+]"YJ%(3#
M_::SWG1VU/2#-)03><#ZZSZSV<[;CH-XL%WA7528A(-PRZV_T15L1_Y&U9()
MC386R LN!IA6M5VNG1C9N$8QDP;;CAM6^&$ 90&XOY#2O$UL[^D_-<4?4$L#
M!!0    ( ,R%!5$_0,"':0(  !,'   9    >&PO=V]R:W-H965T<R]S:&5E
M=#0P+GAM;*U586O;,!#]*\)0V&"-'3MQNI($VI2QC0U"P]8/8Q\4^Q*+RI(G
MG9OFW^^D."89CF%L7VSIK/?NWCM9FNZT>;8% ++74BH["PK$ZC8,;59 R>U
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M18,)>6$.1_!A@KKRI]A:(YV)?EC0K07&+:#O&ZWQ.'$'8WL/SG\#4$L#!!0
M   ( ,R%!5&*M!#!-0,  +@+   9    >&PO=V]R:W-H965T<R]S:&5E=#0Q
M+GAM;+V676^;,!2&_XJ%=M%*6\% @%1)I#;5M$Z=5/5CNYAVX823@ J8V:9)
M__ULH) 6 ]DN=I/8X/<\YQSPBV<[RIYX!"#0/DTR/C<B(?)ST^3K"%+"SV@.
MF;RSH2PE0D[9UN0Y Q*6HC0Q;<ORS)3$F;&8E==NV6)&"Y'$&=PRQ(LT)>SE
M$A*ZFQO8>+UP%V\CH2Z8BUE.MG /XC&_97)F-E'".(6,QS1###9SXP*?+W&@
M!.6*[S'L^,$8J5)6E#ZIR74X-RR5$22P%BH$D7_/L(0D49%D'K_KH$;#5,+#
M\6OTSV7QLI@5X;"DR8\X%-'<" P4PH84B;BCNR]0%S11\=8TX>4OVE5K)U,#
MK0LN:%J+909IG%7_9%\WXD" W1Z!70OL8P5.+7#*0JO,RK*NB""+&:,[Q-1J
M&4T-RMZ4:EE-G*G'>"^8O!M+G5C<@.P!1Y]0.4 Y>9'/2'!T<@6"Q D_E;<>
M[Z_0R8=3] '%&7J(:,%)%O*9*21?13'7->NR8MD]K*]%=H8<ZR.R+=O2R)?#
M\BM82SE6<CQ]*S=EU4WI=E.Z7<9SADO_>;'B@LG7Z== 3*>)Z90QW9Z8JC)T
M OMU4H0RMH@ \7B/4IJ)B"/(0@B1; ,T;3C5M;%B>"5#[</GA>.KDI\UF;E-
M9NY89EC'JE23 Y;G>;Z>-6E8DS&6K6--NBP'NWJ6U["\,9:C8WD=UF3J67J6
MW[#\,9:+Y+NOGJOTS(T ID/['31V [>GSJ!A!X/L!RI(@I(WNU0'#SIPQY]8
M/?!I Y\.PF^ \W-TG>:%D"_P=28+!RX0[.77A(,NC6DG#1_;GCX+;+5F98TW
M06L\5K=LR_&#!E@;C-796=C%/N[)Z\!$\7_8]C7D;1%6SSN+6YO#]C_M_%IV
M)*YU0#QJ@=K-7\N.Q+6VAD=]3;O_<=?8!G"ML^%1:SO& G#7ZFR_']^:'1YV
MNV-= '?MSYGV\UL#Q,,.^/=&@#5N:/M!S]<,MW:(C_!#+3#H['';LS%^;P7=
M9>^[8QX<J]29]AMAVSCCLOT;J;'.?%D4JXZ)U430O#QIK:B0Y[9R&,FC-3"U
M0-[?4"I>)^KPUAS6%W\ 4$L#!!0    ( ,R%!5$ICSQ\M0(  &L'   9
M>&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;*U5WV^;,!#^5RS4AU9:R\] 5Q&D
M)EVU3:M6M>OV,.W!@0.L@LULDW3__6Q#6$)HMH>]@'V^^^[[[N <;QA_%B6
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MJ]5E2@E\<O0 >+_B7#W?Z$-K^U^-^5]02P,$%     @ S(4%49!2H28F @
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M#2<TXP3L[],T+=8?^ ,VKQ ]_S]02P,$%     @ S(4%47C[4<@9!@  R"<
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M\_M2&F26%_G+7-7+>[/_ 5!+ P04    " #,A051\NP*%5\&  #.)@  &0
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MVU,0'7;0LET@BG3$3;H';A>(CJB^;044GXB;3WMB6.>"G'UB&94J-M!CL>%
MQE,]ZX>^9]EY4I7XZ:FJ?(^F-]6SOH5G5&5]ZL[ZSX%FJJ=[FTZ5Q>D1SF1/
MXRYUG;FV92M"4/>!ZAFAVH[LNW_G@XV7C>HWO3XFY3PM*AE,,]G,>Q5(=\OU
MRU/K"\&7S?M'8RX$SYN/"Y9,65D;R.]GG(OO%_4K3=TK;*/_ 5!+ P04
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MP'/? ^0BM\6>R=%P.&R!3^WP*8DT'';"[XZ'AQ8RO#)1O$R?UZ'O,]F0&'A
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M>X(WA&L#=7_+F'P^T?N<S;[VXC]02P,$%     @ S(4%4;QY!B1W P  ;@X
M !D   !X;"]W;W)K<VAE971S+W-H965T-3 N>&ULO5?;CILP$/T5"_6AE=H%
MFWN51&JSZDU=:=7MY=DADV M8&J;9/OWM0D+)!"ZJIJ^)-C,Y<S,\0R>[;FX
MERF 0@]Y5LBYE2I5OK9MF:204WG%2RCTFPT7.55Z*;:V+ 70=:V49S9QG,#.
M*2NLQ:S>NQ6+&:]4Q@JX%4A6>4[%K[>0\?W<PM;CQA>V3979L!>SDF[A#M2W
M\E;HE=U:6;,<"LEX@01LYM8;_'I)'*-02WQGL)>]9V1"67%^;Q8?UW/+,8@@
M@T09$U3_[6 )668L:1P_&Z-6Z],H]I\?K;^K@]?!K*B$)<]^L+5*YU9DH35L
M:)6I+WS_ 9J ?&,OX9FL?]&^D74LE%12\;Q1U@AR5AS^Z4.3B)X"]LXHD$:!
M/%7!;13<.M #LCJL:ZKH8B;X'@DCK:V9ASHWM;:.AA6FC'=*Z+=,ZZG%.\H$
MVM&L L0W:,,*6B2,9H@54HE*UTM)1(NU=BGN0=%5!DA"4@FF&$CT"MV,[C^_
MUGLLDR^TQ+>[:_3\V0OT3-M$7U->26U/SFRET1L,=M(@?7M 2LX@_5055\AU
M7B+B$&=$?3FM?@V)5L=&'<?'ZK;.69LXTB:.U/;<,_;& ]?$5"EH8F4ZC_J-
MJ<N$,[=UYM;.O#/.OG*E:S+J\B7Z#%+JQ-("88)N>*'2T>P>/ 2U!W.X=POB
M^WX4SNQ=/XM#,=<C'HY:L:, O#8 [^\#N.$"GA# P8/?0Q9YD>>>X!]*^0'&
MX3A\OX7O3\)?\CP'41^,DI8@)DH:M":#R_,G;)V%%^=/.$RL&^'@)/U#*>Q'
M3GR&/E&+/[HX?:(!,N<$^Y3$$>RXA1W_@3:BY((JT(-EI7J@)TJ*G:YS.Y=G
M$.X-"GQQ#C4NCN@11,0_K<28G!O[<3!>#]PU;4PN3J3&Q=%)\$-G$,-0S(M#
M]\Q)P-THP-.SX(V4H%ZM:'(/ZR=2JNO2V/L/E.JZ*IYNJ_^$4OX@S21PR: :
M0S'/"XEWIAI=%\?!Y0D5#-D>^<[I9&O$^J,Y<,/X3 3=:,#3L^$]WX$HS)<>
MXJN,;:GYO)ZD4]>U<?0?Z-1U6SS=;O\)G>)!+4+]Q3B>9-+U:N)<G":-BW[]
ML1-XIS/*[ET&S$U,.]WJKWF4P4;K.5>ACDT<+C>'A>)E?3]8<:5O&_5CJB^$
M((R ?K_A7#TNS)6CO6(N?@-02P,$%     @ S(4%439%(L#/"0  1$(  !D
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MYR,29O$L26='6H\8PC2.(AB,:YVZ--+)-.[8%DNE(]<1*D%*LY16?[1#HI(
ML0ITC*BI0F3.6?9^A0C@<T."'U"*P<FAQ%F49&%X5(D1NR2)(0R/"N$?M-@&
MBXV=/!*4O&.J;UONU$VW"]O3C\Z79NK9UOU,TX_,*R0VA$E \5I3PK.Y#DKT
M4ZC?*-[:1G[/E1X+=EGKR8V%,=#W:\[5?F,<N&^!XC]02P,$%     @ S(4%
M4> >F9X;"   'RL  !D   !X;"]W;W)K<VAE971S+W-H965T-3<N>&ULS9KM
MCYLX&L#_%2NZD[K2- %C$UC-C#2OW6FW>Z/.=??#Z3YX@B?A"CAK3*8YW1]_
MMB&8"6"8%JG;#QV2^'EXWOQ[;,/I,^-?\@VE GQ-DRP_FVV$V/Z\6.2K#4U)
M/F=;FLE?GAA/B9 ?^7J1;SDED19*DP5T''^1DCB;G9_J[^[Y^2DK1!)G])Z#
MO$A3PO>7-&'/9S-W=OCB4[S>"/7%XOQT2];T@8K/VWLN/RUJ+5&<TBR/608X
M?3J;7;@_?_ #):!'_![3Y[QQ#90KCXQ]41_NHK.9HRRB"5T)I8+(/SMZ19-$
M:9)V_%DIG=7W5(+-ZX/V6^V\=.:1Y/2*)7_$D=B<S8(9B.@3*1+QB3W_0BN'
ML-*W8DFN_P?/U5AG!E9%+EA:"4L+TC@K_Y*O52 : B[J$8"5 !PKX%4"WE@!
M5 F@8P&O1P!7 GBL@%\)^&--6E8"R[$"0240' LL>P3"2B <>P?7.63.&2U2
M)[LLNK)*=(E=$T'.3SE[!ER-E_K4A:Y3+2\K*\[4E'H07/X:2SEQ_B#8Z@L@
MSX1'8)N0#+P%OQ'.B2IT\.::"A(G^4_RV\\/U^#-WWXZ70AY5R6[6%5WN"SO
M 'ON\)'P.7#P"8".ZW6(7]G%WY-L#CQ7B4.G0_QZ0+Q0XHZ^N]\A?C-D_+ZZ
M>:?T[6CI+L_?C3:]T_-?QGL>=HC??=_=WW_?W3_8Q1_HMB]M"UGA=9G#NLRA
MUN=9RYQM-<95G5MT>K5.3^M$?3HWA-.WBN<16+%4-KF<:/WTJ[JF71DO-?I:
MH^IVNW/7#UU'_CM=[)JY[1CHA+ ]\*X]T(.NUQ[XOCU0QC9 S8$OPH#J,"!K
M&#YGG*[8.HO_>QR'%<M%5Q!0V[=@J7T[=F[,R!=&X]IH;#7Z#]UJI<%D1[E<
M.LC5@5I_Q-D:Y)3OXA4%6\IC%@&Y:@&5@]HI]@2*UWI\9S?& WM*> Y@""*R
MSRVEZ=?N^5:-5RQ-I3FYJGJ+NF6M;CG9[ EJG<'HV7/5C.&%[#[9FLIEFP"/
M>] <=T_V^NL+U:Y.P&]%^DBYRH@>E(.+G>Q6Y#&A.FOOI)[.^BL-PXVJ"EV$
M'/^H^ :'O? [K/T.!Z;+CN:J\J3!@L<K=3F4)]<QW=R9+%-N8XW@6FW6D<Q!
MG!TFQ1MYF>N8=RT([BIUS=#A('26/9/6-11WH;UH&N[9/#,(=[WIXF6(Z-J1
MJ.-%A\.$6F&"V,6P#VZNH9MK)\I=%A6K<@JMR]RI"9&Q[&TNB"@$X_NRZ"K7
M\T%3<3NC""+<9ZD!E6LGU8WLE7H.1/$NCF@6@7U,$QDZD@.BRFTEG>@VR:[8
MF3O.WVW9-/!SEZ_K%3JD$M5"<H;$'.Q(4E =P8@EB2*YM+N,9K?EY?V"9L_V
MYR'NB:4AJFM':AU+07FJ[=%]I=L&NRI<M:00R#XB-K:>Y!KRN7;TO9AL_P,?
MR=<X+5+;ZLYP#T['/6BX!^W<^Q3G7]X^<4HE^F1,); !5UD?+LX!Q>X<85MQ
MPL:ZUD[$.N<[ELC^F<1B/\8\N](@G'NNU3X#6#BP2#[*N5QC#>3<4!:BZ7)N
MT GMZ/R.G-L5.W-D!1(TS(0CF?FZG-N5!LLYMMMG@ GMP'RX^&0#!C1 @\%T
M&388@G8,C>O.-Y669LL+PB4,>UJ>9UCE.=;[_UZN_P8Z;J6D>7M7[>QZEI^>
M@9IG9T]UXK/=RDU,7"ZYN6IP.4AB\JBKJ7/GZK;V8JVMJ&W(2VL-WSP[BM31
M"2A-OLM4;:MSJ?N!#7QC!S_=\L\S8/+LR[\?M[6Y]-I+RKX4&")Z=G#UID#R
M?.1&TS-L\_SI,F*(Y-F)9,)9SCA "K%A7&_@[?/PLM+<C.C2"T-OV1-6 S?/
MOL2RA?5;-HF> : 73A9C9+"&[%A[Y2;Q$K4!M_2P!U'/<90!'+(#SA;8D1M(
M9/B$ICM81(9+R+YJ&M>B+BLMS1 B7QTU=P:P<:!GYY?<@(;@YL]"K2N(W)']
MRK(U^*?:4XQ&,#)T07BZ !J,(/MJY@>>+E66=2.X.M:T#7GIL4$<&HLX$D7Z
MJ)(DKZ;=+6K3#F++>2LRN$-#N!M75/K'"5H.,CA$T^$0&QQB.PY_7 7>XHZE
M(X0P[%DZ8D-6/$36B7+HAF$ ;M)MPO:4GH#K6*Y%A71)R5VQ+"\2H8Y82NE_
ME)GI2/^H0P1L6(ZG8SDV+,=VEK?6'GGQ^!_I+A ,L$+DTM-(/7?0SV"'#N)N
M<1OYGH,<A'K:)C;4QT/4E_GJS>B8K3MN/'V9#OK80!^/@#X8.>5 QY3KF'&&
MG!=95DBDRKAP*D6KL9TY:N/="E%L((_MD*]LB \VR%H1&PJRXQ)KUA4KQSS%
M/%>'EGLUK/PB7TE=ZIROTPF[)6C@>!6;QH"'&@-TI"/U@74YL^.Z_/1;"?_Z
M2)6+_Q[/?VSXCZ?COV_X[_]5^?_.;_,?(1@$Q\N0X7$O?3=]PA\X8OAK3,0K
MO_T<2C]K[YN(OFD5_L"Q:]6[JA9U*$];Y9B&X4]W*.$;O/MVO'_[%OB#WSY4
ML(?1] '??K3P+:]05"I?O/'0]>Y Q[BES>C&LW5[FRDKE%.Y#LIC08]>&.AZ
M16E H3_\D,4W+<*W@_F^X*N-FA9;KHR2^5XU@'ER."+N--.N.< #S/<-\_V!
M)U6'Z5/"?EO;+*O]!.R84(VKLE0]<4OB-.XV>> Q5I_%B\8;<^K5T8^$K^,L
M!PE]DHJ<^5(6#R_?QBP_"+;5+]$],B%8JB\WE$24JP'R]R?&Q.&#>B^O?B?V
M_/]02P,$%     @ S(4%440]E-L=!0  HA8  !D   !X;"]W;W)K<VAE971S
M+W-H965T-3@N>&ULK5AM<YLX$/XK&E_O)IEI (D70\_Q3)/VWF9RETFN[6?%
MK&TF@'R2L)-_?Q)@Y(Y!)FF^V$*PN\^N5L^N--LQ_BC6 !(]%7DI+B=K*3<?
M7%<LUE!0X; -E.K-DO&"2O7(5Z[8<*!I+53D+O&\R"UH5D[FLWKNEL]GK))Y
M5L(M1Z(J"LJ?KR!GN\L)GNPG[K+56NH)=S[;T!7<@_RRN>7JR>VTI%D!I<A8
MB3@L+R<?\8<K/]("]1=?,]B)@S'2KCPP]J@?_DPO)YY&!#DLI%9!U=\6KB'/
MM2:%X[]6Z:2SJ04/QWOMO]7.*V<>J(!KEG_+4KF^G,03E,*25KF\8[L_H'4H
MU/H6+!?U+]JUWWH3M*B$9$4KK! 46=G\TZ<V$ <")!P0(*T J7$WAFJ4GZBD
M\QEG.\3UUTJ;'M2NUM(*7%;J5;F77+W-E)R<WTNV>$1T1WF*-CDMT06Z7U,.
MZ$JYBJY9H99?T#J 9Y] TBP7Y_J;6HQMZA<7Z,O])W3V[AR]0RX26ER@K$1?
MRDR*]VI2C?]=LTK0,A4S5RK8VKB[:"%>-1#) ,0(W;!2K@7Z7*:0?B_O*G<[
MG\G>YRMB5?A753K(]]XCXA'/HL_O8NC7^OP!?7]7Q0/P7W["D?<K6[91$1;%
M0:<XJ!4' XK_J:20*FA9N4)4(KD&] "KK"SUA+*D)S; ,Y:B,Q7C)O+G?1%N
M[(2U';U1MW.,O<!/_&3F;GL0AAW"T(KP=TY+"2?-AT?F28A#Q1S]UJ/.>F2U
M_OD)^"(3I^U'1_8OL.<')([[ 4P[ %,K $4,2\A4 -QK6BX4M9R&,CV&$DX]
M'$W[D<0=DOBEJ0)E^K(DB7N2) F#* [ZL24=ML2*[2L(G2.,H\]/&\7&:BP9
MVJK95T--CJ"&4>+%P<!Z8L_0H3<FI>A##J\&UYKX#EV("0G) +H#LL96IOE6
M%QE(+Q#= E=5$T&[!="&9PNP< XFQ@AY2]9)69Y3+O14$Y3^F#0VXX.8^-@9
MRGILJ!?[HPEH)))&87*X.IZ3#&6.X6IL)^OOR6@DEN ("PD<@@>P&%;&=EH>
MXJ61J,(C5 %QR-!:&;;&=KH>S5$C849',/W0&2(K;#@=VTG]M70U$O7T&'7B
MX&@ M>%_;"\ HXEK),RX=[\.9:8I!3AY(8-QT(<'G1,+U>9QU:97-$<2>&%K
M]0RA$SNACTFZO@"<4#M%SZ"C&**B:4Z)CU+Z;.OZB*%Y@M\Z WM=L%N)6Q>P
MM_<A.>F"*2+$7D3&I&,O9KO:\ AS=!*SJ27$WL=_7*TXK*@$=6"1/%,GSP7:
MTKR">M_(_0GFW&;,E ORXM[>NE][=VEK(SILV6(_&&IKB2D@Q%Y ?I #^\$>
MGP*B*(D'F(^8LD)&G0)&,U\_N.@XDM@C9*!E(Z::D*DUJ;ZJ!&K.SU2(JCAY
M-B2&\<DIQM^OC.+*VL%Z;_2[9U>UWU9)NZML^ S5$WO;?Z-8O:AL+.X;%O>]
M-XVB;[C6M[/@728>+Y8<ZDT/7&<XUQ1P1@6B.GL64,K>F)Y0[#F!][,-HN%2
M_Q27M@N]9;D*0I[)YS'P[$KCJ1/:\1U<?]A[\!OZ=&JA#2WZP=LNM*$TWTYI
M/[#0=L78"4)K( V3^:>8[%4+;5<:)XZ/>_&Y!]>&!?!5?3DJ5!M6E;*Y0>QF
MNPO8C\VUH_F\N;V]H5R=$ 7*8:E$/6>J0L:;"]'F0;)-?0GYP*1D13U< TV!
MZP_4^R5C<O^@#737TO/_ 5!+ P04    " #,A051B6EHYBH#  !L"@  &0
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M/TBX:1,"!.H_W>;Y)_-\JWDZR? DEZ*(E9DT#+FRDT:(QFFA[CQ!SJ';B"&
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M&\L+F6;ZH-PVE3*-]<\#K"83B@">[U+ SNI"G;T['3"]^3=02P,$%     @
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M&SU_@C &^OF*Z^JK-V9@:2;:R5]02P,$%     @ S(4%47P#T+D"!   B1
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M$#5)(K;.J*GV9_" .<>ZY.#3E$A,$_'3R)%J.$URHLKT;6D:G3 -P3W+Y$:
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M,O'$&3HD@A7+A;F3VV]0)=2S?*$4NGB2;15+'1+FVLBD J."A*?EFSU71AP
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M6Q?-PQE$L\*O4$%9J-A-Z8T>GA>4@ IF ;T37CC[U*[7:_OV:Q=5V!Q?%)2
M"F8!O6->61CEPN,H_GJ!BX5M5;B"$E#!OH2,F T5AQB3$E#!+* M\Z'X*<68
ME( *9@%MQ[Q5OKL:GL(MR'5DS (B"]F]Z92"$E#!+" :$^=P!26@@GV!V:>I
MYG[OB3$I 16=@(;=R>'LM%(P!%#5-=PBP/Y2FO(6\F[X6*UQRO)V@<*\,>8"
M]MW8[TY6ZY7%ZU719[\ 4$L#!!0    ( ,R%!5&7=W+D+ (  /8H   :
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M&^IM!'H;ZFT$>MMHLYM ;T.]C4!O0[V-0&]#O8U ;T.]C4!O0[V-0&]'O9U
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M_BV?C?\17+P 4$L! A0#%     @ S(4%40=!36*!    L0   !
M     ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #,A0516TG$
M5.\    K @  $0              @ &O    9&]C4')O<',O8V]R92YX;6Q0
M2P$"% ,4    " #,A051F5R<(Q &  "<)P  $P              @ '- 0
M>&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( ,R%!5&3=<+Q0 4  &\5
M   8              " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q0
M2P$"% ,4    " #,A051"_N_UW@&   ?&@  &               @(&$#0
M>&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ S(4%4<!5_R%Q
M @  \P4  !@              ("!,A0  'AL+W=O<FMS:&5E=',O<VAE970S
M+GAM;%!+ 0(4 Q0    ( ,R%!5$Q@4:/?P8  $ :   8              "
M@=D6  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " #,A051
M*,?/@58#   C"@  &               @(&.'0  >&PO=V]R:W-H965T<R]S
M:&5E=#4N>&UL4$L! A0#%     @ S(4%40[N5$+2"0  =3P  !@
M     ("!&B$  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    (
M ,R%!5$7T@02MPD  .4I   8              " @2(K  !X;"]W;W)K<VAE
M971S+W-H965T-RYX;6Q02P$"% ,4    " #,A051)? %3&L7   41   &
M            @($/-0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#
M%     @ S(4%4<;5A(?/)   .WL  !@              ("!L$P  'AL+W=O
M<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( ,R%!5'4:S'2;0P  )PA
M   9              " @;5Q  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL
M4$L! A0#%     @ S(4%4:^VJ/!P!P  _!(  !D              ("!67X
M 'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " #,A051]S[)
MA#@8  !BIP  &0              @($ A@  >&PO=V]R:W-H965T<R]S:&5E
M=#$R+GAM;%!+ 0(4 Q0    ( ,R%!5'S)?M,HP,  +L)   9
M  " @6^>  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @
MS(4%45J</A[B @  708  !D              ("!2:(  'AL+W=O<FMS:&5E
M=',O<VAE970Q-"YX;6Q02P$"% ,4    " #,A051Q'-96K<$  #_"@  &0
M            @(%BI0  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4
M Q0    ( ,R%!5'=.Q?)! 0  $<)   9              " @5"J  !X;"]W
M;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ S(4%49U=U@W+#
M32<  !D              ("!BZX  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX
M;6Q02P$"% ,4    " #,A051^>&M+3,0  !82@  &0              @(&-
MNP  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( ,R%!5&2
M60W,(0P  *$H   9              " @??+  !X;"]W;W)K<VAE971S+W-H
M965T,3DN>&UL4$L! A0#%     @ S(4%45HE%9!;!@  U!(  !D
M     ("!3]@  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,R%!5&*]ES'_00  #(-   9              "
M@2L* 0!X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ S(4%
M45P,(20M"0  4B,  !D              ("!7P\! 'AL+W=O<FMS:&5E=',O
M<VAE970R-BYX;6Q02P$"% ,4    " #,A051@68E;'0#  #O"   &0
M        @('#& $ >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0
M   ( ,R%!5%$BG1$_@(  %P&   9              " @6X< 0!X;"]W;W)K
M<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ S(4%4>A1H!7I P   0D
M !D              ("!HQ\! 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q0
M2P$"% ,4    " #,A051S0) \"X%  "V#   &0              @('#(P$
M>&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( ,R%!5$_:V<Z
M=P0  +8.   9              " @2@I 0!X;"]W;W)K<VAE971S+W-H965T
M,S$N>&UL4$L! A0#%     @ S(4%4;W3Z%A3 @  _P0  !D
M ("!UBT! 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " #,
MA051A8U)ZUH&  #8'0  &0              @(%@, $ >&PO=V]R:W-H965T
M<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( ,R%!5$]5N<L?@(  %4&   9
M          " @?$V 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#
M%     @ S(4%4=68\.G: P  @PT  !D              ("!ICD! 'AL+W=O
M<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " #,A051:9<5Y< "  !K
M!P  &0              @(&W/0$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM
M;%!+ 0(4 Q0    ( ,R%!5%'K*Z#'P8  %8>   9              " @:Y
M 0!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ S(4%417>
M#G7? @  -PD  !D              ("!!$<! 'AL+W=O<FMS:&5E=',O<VAE
M970S."YX;6Q02P$"% ,4    " #,A051N*#_FFT"  !V!@  &0
M    @($:2@$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    (
M ,R%!5$_0,"':0(  !,'   9              " @;Y, 0!X;"]W;W)K<VAE
M971S+W-H965T-# N>&UL4$L! A0#%     @ S(4%48JT$,$U P  N L  !D
M             ("!7D\! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"
M% ,4    " #,A051*8\\?+4"  !K!P  &0              @('*4@$ >&PO
M=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( ,R%!5&)C\ +1P0
M .$0   9              " @;95 0!X;"]W;W)K<VAE971S+W-H965T-#,N
M>&UL4$L! A0#%     @ S(4%49!2H28F @  C 0  !D              ("!
M-%H! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " #,A051
M&9[HI+0,  !.5   &0              @(&17 $ >&PO=V]R:W-H965T<R]S
M:&5E=#0U+GAM;%!+ 0(4 Q0    ( ,R%!5%X^U'(&08  ,@G   9
M      " @7QI 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%
M  @ S(4%4?+L"A5?!@  SB8  !D              ("!S&\! 'AL+W=O<FMS
M:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    " #,A051#3P*>KP$  !Z%0
M&0              @(%B=@$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+
M 0(4 Q0    ( ,R%!5$YQY5O0P0  .,6   9              " @55[ 0!X
M;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ S(4%4;QY!B1W
M P  ;@X  !D              ("!SW\! 'AL+W=O<FMS:&5E=',O<VAE970U
M,"YX;6Q02P$"% ,4    " #,A051-D4BP,\)  !$0@  &0
M@(%]@P$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( ,R%
M!5$?)$'ZQ00  +@6   9              " @8.- 0!X;"]W;W)K<VAE971S
M+W-H965T-3(N>&UL4$L! A0#%     @ S(4%4?P[UK@H P  .PD  !D
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M=#4W+GAM;%!+ 0(4 Q0    ( ,R%!5%$/93;'04  *(6   9
M  " @5BH 0!X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @
MS(4%48EI:.8J P  ; H  !D              ("!K*T! 'AL+W=O<FMS:&5E
M=',O<VAE970U.2YX;6Q02P$"% ,4    " #,A051D\UC/_(#   7#P  &0
M            @($-L0$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4
M Q0    ( ,R%!5'5;"L?JP@  &PJ   9              " @3:U 0!X;"]W
M;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ S(4%47*;9,41 P
MW0H  !D              ("!&+X! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX
M;6Q02P$"% ,4    " #,A051? /0N0($  ")$   &0              @(%@
MP0$ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( ,R%!5$K
M')^BK08  .4D   9              " @9G% 0!X;"]W;W)K<VAE971S+W-H
M965T-C0N>&UL4$L! A0#%     @ S(4%47B5?CJP!   V!0  !D
M     ("!?<P! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,R%!5'_OC'K; (  "(.   -              "
M 0+? 0!X;"]S='EL97,N>&UL4$L! A0#%     @ S(4%49>*NQS     $P(
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9>&UL4$L%!@    !- $T $A4  )/L 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>297</ContextCount>
  <ElementCount>491</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>84</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Consolidated Balance Sheets (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited</Role>
      <ShortName>Consolidated Balance Sheets (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Consolidated Balance Sheets (unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunauditedParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Consolidated Statements of Operations (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited</Role>
      <ShortName>Consolidated Statements of Operations (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Consolidated Statements of Comprehensive Loss (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/ConsolidatedStatementsofComprehensiveLossunaudited</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Consolidated Statements of Cash Flows (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited</Role>
      <ShortName>Consolidated Statements of Cash Flows (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - The Company</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/TheCompany</Role>
      <ShortName>The Company</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of significant accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/Summaryofsignificantaccountingpolicies</Role>
      <ShortName>Summary of significant accounting policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2109103 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2117104 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2120105 - Disclosure - Fair value of financial instruments and marketable securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/Fairvalueoffinancialinstrumentsandmarketablesecurities</Role>
      <ShortName>Fair value of financial instruments and marketable securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2129106 - Disclosure - Other comprehensive income (loss) and accumulated other comprehensive items</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/Othercomprehensiveincomelossandaccumulatedothercomprehensiveitems</Role>
      <ShortName>Other comprehensive income (loss) and accumulated other comprehensive items</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2132107 - Disclosure - Accounts payable and accrued expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/Accountspayableandaccruedexpenses</Role>
      <ShortName>Accounts payable and accrued expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2135108 - Disclosure - Capitalization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/Capitalization</Role>
      <ShortName>Capitalization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2137109 - Disclosure - Net loss per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/Netlosspershare</Role>
      <ShortName>Net loss per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2141110 - Disclosure - Stock award plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/Stockawardplan</Role>
      <ShortName>Stock award plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2147111 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2152112 - Disclosure - Commitments and contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/Commitmentsandcontingencies</Role>
      <ShortName>Commitments and contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2154113 - Disclosure - Revenue recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/Revenuerecognition</Role>
      <ShortName>Revenue recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2157114 - Disclosure - Intangible assets and goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/Intangibleassetsandgoodwill</Role>
      <ShortName>Intangible assets and goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2161115 - Disclosure - Subsequent events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/Subsequentevents</Role>
      <ShortName>Subsequent events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of significant accounting policies - (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesPolicies</Role>
      <ShortName>Summary of significant accounting policies - (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of significant accounting policies - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesTables</Role>
      <ShortName>Summary of significant accounting policies - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ptcbio.com/role/Summaryofsignificantaccountingpolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2310302 - Disclosure - Leases - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/LeasesTables</Role>
      <ShortName>Leases - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2321303 - Disclosure - Fair value of financial instruments and marketable securities - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesTables</Role>
      <ShortName>Fair value of financial instruments and marketable securities - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ptcbio.com/role/Fairvalueoffinancialinstrumentsandmarketablesecurities</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2330304 - Disclosure - Other comprehensive income (loss) and accumulated other comprehensive items - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/OthercomprehensiveincomelossandaccumulatedothercomprehensiveitemsTables</Role>
      <ShortName>Other comprehensive income (loss) and accumulated other comprehensive items - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ptcbio.com/role/Othercomprehensiveincomelossandaccumulatedothercomprehensiveitems</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2333305 - Disclosure - Accounts payable and accrued expenses - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/AccountspayableandaccruedexpensesTables</Role>
      <ShortName>Accounts payable and accrued expenses - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ptcbio.com/role/Accountspayableandaccruedexpenses</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2338306 - Disclosure - Net loss per share - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/NetlosspershareTables</Role>
      <ShortName>Net loss per share - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ptcbio.com/role/Netlosspershare</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2342307 - Disclosure - Stock award plan - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/StockawardplanTables</Role>
      <ShortName>Stock award plan - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ptcbio.com/role/Stockawardplan</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2348308 - Disclosure - Debt - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DebtTables</Role>
      <ShortName>Debt - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2358309 - Disclosure - Intangible assets and goodwill - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/IntangibleassetsandgoodwillTables</Role>
      <ShortName>Intangible assets and goodwill - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ptcbio.com/role/Intangibleassetsandgoodwill</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - The Company - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/TheCompanyNarrativeDetails</Role>
      <ShortName>The Company - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of significant accounting policies - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesInventoryDetails</Role>
      <ShortName>Summary of significant accounting policies - Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of significant accounting policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails</Role>
      <ShortName>Summary of significant accounting policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Summary of significant accounting policies - Reconciliation of cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesReconciliationofcashDetails</Role>
      <ShortName>Summary of significant accounting policies - Reconciliation of cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Leases - Lease costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/LeasesLeasecostsDetails</Role>
      <ShortName>Leases - Lease costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - Leases - Balance sheet (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/LeasesBalancesheetDetails</Role>
      <ShortName>Leases - Balance sheet (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2414408 - Disclosure - Leases - Supplemental lease terms (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/LeasesSupplementalleasetermsDetails</Role>
      <ShortName>Leases - Supplemental lease terms (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2415409 - Disclosure - Leases - Lease payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/LeasesLeasepaymentsDetails</Role>
      <ShortName>Leases - Lease payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2416410 - Disclosure - Leases - Cash flow (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/LeasesCashflowDetails</Role>
      <ShortName>Leases - Cash flow (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2418411 - Disclosure - Acquisitions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/AcquisitionsNarrativeDetails</Role>
      <ShortName>Acquisitions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2419412 - Disclosure - Acquisitions - Preliminary Allocation of purchase price (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/AcquisitionsPreliminaryAllocationofpurchasepriceDetails</Role>
      <ShortName>Acquisitions - Preliminary Allocation of purchase price (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2422413 - Disclosure - Fair value of financial instruments and marketable securities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails</Role>
      <ShortName>Fair value of financial instruments and marketable securities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2423414 - Disclosure - Fair value of financial instruments and marketable securities - Hierarchy (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesHierarchyDetails</Role>
      <ShortName>Fair value of financial instruments and marketable securities - Hierarchy (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2424415 - Disclosure - Fair value of financial instruments and marketable securities - Available for sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesAvailableforsaleDetails</Role>
      <ShortName>Fair value of financial instruments and marketable securities - Available for sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2425416 - Disclosure - Fair value of financial instruments and marketable securities - Fair Value Measurement Inputs and Valuation Techniques (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesFairValueMeasurementInputsandValuationTechniquesDetails</Role>
      <ShortName>Fair value of financial instruments and marketable securities - Fair Value Measurement Inputs and Valuation Techniques (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2426417 - Disclosure - Fair value of financial instruments and marketable securities - Unrealized Loss Positions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesUnrealizedLossPositionsDetails</Role>
      <ShortName>Fair value of financial instruments and marketable securities - Unrealized Loss Positions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2427418 - Disclosure - Fair value of financial instruments and marketable securities - Marketable securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesMarketablesecuritiesDetails</Role>
      <ShortName>Fair value of financial instruments and marketable securities - Marketable securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2428419 - Disclosure - Fair value of financial instruments and marketable securities - Warrants and SARs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails</Role>
      <ShortName>Fair value of financial instruments and marketable securities - Warrants and SARs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2431420 - Disclosure - Other comprehensive income (loss) and accumulated other comprehensive items - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/OthercomprehensiveincomelossandaccumulatedothercomprehensiveitemsNarrativeDetails</Role>
      <ShortName>Other comprehensive income (loss) and accumulated other comprehensive items - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ptcbio.com/role/OthercomprehensiveincomelossandaccumulatedothercomprehensiveitemsTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2434421 - Disclosure - Accounts payable and accrued expenses - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/AccountspayableandaccruedexpensesNarrativeDetails</Role>
      <ShortName>Accounts payable and accrued expenses - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2436422 - Disclosure - Capitalization - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/CapitalizationNarrativeDetails</Role>
      <ShortName>Capitalization - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2439423 - Disclosure - Net loss per share - Numerator and Denominator (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/NetlosspershareNumeratorandDenominatorDetails</Role>
      <ShortName>Net loss per share - Numerator and Denominator (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2440424 - Disclosure - Net loss per share - Antidilutive (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/NetlosspershareAntidilutiveDetails</Role>
      <ShortName>Net loss per share - Antidilutive (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2443425 - Disclosure - Stock award plan - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/StockawardplanNarrativeDetails</Role>
      <ShortName>Stock award plan - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2444426 - Disclosure - Stock award plan - Share Base Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/StockawardplanShareBaseCompensationDetails</Role>
      <ShortName>Stock award plan - Share Base Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2445427 - Disclosure - Stock award plan - Restricted Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/StockawardplanRestrictedStockDetails</Role>
      <ShortName>Stock award plan - Restricted Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2446428 - Disclosure - Stock award plan - Share-based compensation expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/StockawardplanSharebasedcompensationexpenseDetails</Role>
      <ShortName>Stock award plan - Share-based compensation expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2449429 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2450430 - Disclosure - Debt - Convertible Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.ptcbio.com/role/DebtConvertibleNotesDetails</Role>
      <ShortName>Debt - Convertible Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2451431 - Disclosure - Debt - Interest Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DebtInterestExpenseDetails</Role>
      <ShortName>Debt - Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2453432 - Disclosure - Commitments and contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails</Role>
      <ShortName>Commitments and contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2455433 - Disclosure - Revenue recognition - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/RevenuerecognitionNarrativeDetails</Role>
      <ShortName>Revenue recognition - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2456434 - Disclosure - Revenue recognition - Performance Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/RevenuerecognitionPerformanceObligationsDetails</Role>
      <ShortName>Revenue recognition - Performance Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2459435 - Disclosure - Intangible assets and goodwill - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/IntangibleassetsandgoodwillNarrativeDetails</Role>
      <ShortName>Intangible assets and goodwill - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2460436 - Disclosure - Intangible assets and goodwill - Future Amortization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/IntangibleassetsandgoodwillFutureAmortizationDetails</Role>
      <ShortName>Intangible assets and goodwill - Future Amortization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="ptct-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2462437 - Disclosure - Subsequent events Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/SubsequenteventsNarrativeDetails</Role>
      <ShortName>Subsequent events Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="ptct-20200630.htm">ptct-20200630.htm</File>
    <File>ex101shiratorilicensea.htm</File>
    <File>ex102rpiroyaltypurchas.htm</File>
    <File>ex103kleinemploymentag.htm</File>
    <File>ex104pauwelsemployment.htm</File>
    <File>ptct-20200630.xsd</File>
    <File>ptct-20200630_cal.xml</File>
    <File>ptct-20200630_def.xml</File>
    <File>ptct-20200630_lab.xml</File>
    <File>ptct-20200630_pre.xml</File>
    <File>ptct06302020ex-311.htm</File>
    <File>ptct06302020ex-312.htm</File>
    <File>ptct06302020ex-321.htm</File>
    <File>ptct06302020ex-322.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/stpr/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>94
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ptct-20200630.htm": {
   "axisCustom": 1,
   "axisStandard": 29,
   "contextCount": 297,
   "dts": {
    "calculationLink": {
     "local": [
      "ptct-20200630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ptct-20200630_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "ptct-20200630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ptct-20200630_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ptct-20200630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "ptct-20200630.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 677,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 4,
    "http://www.ptcbio.com/20200630": 6,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 15
   },
   "keyCustom": 93,
   "keyStandard": 398,
   "memberCustom": 36,
   "memberStandard": 40,
   "nsprefix": "ptct",
   "nsuri": "http://www.ptcbio.com/20200630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.ptcbio.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109103 - Disclosure - Leases",
     "role": "http://www.ptcbio.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117104 - Disclosure - Acquisitions",
     "role": "http://www.ptcbio.com/role/Acquisitions",
     "shortName": "Acquisitions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120105 - Disclosure - Fair value of financial instruments and marketable securities",
     "role": "http://www.ptcbio.com/role/Fairvalueoffinancialinstrumentsandmarketablesecurities",
     "shortName": "Fair value of financial instruments and marketable securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129106 - Disclosure - Other comprehensive income (loss) and accumulated other comprehensive items",
     "role": "http://www.ptcbio.com/role/Othercomprehensiveincomelossandaccumulatedothercomprehensiveitems",
     "shortName": "Other comprehensive income (loss) and accumulated other comprehensive items",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132107 - Disclosure - Accounts payable and accrued expenses",
     "role": "http://www.ptcbio.com/role/Accountspayableandaccruedexpenses",
     "shortName": "Accounts payable and accrued expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135108 - Disclosure - Capitalization",
     "role": "http://www.ptcbio.com/role/Capitalization",
     "shortName": "Capitalization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137109 - Disclosure - Net loss per share",
     "role": "http://www.ptcbio.com/role/Netlosspershare",
     "shortName": "Net loss per share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2141110 - Disclosure - Stock award plan",
     "role": "http://www.ptcbio.com/role/Stockawardplan",
     "shortName": "Stock award plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147111 - Disclosure - Debt",
     "role": "http://www.ptcbio.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2152112 - Disclosure - Commitments and contingencies",
     "role": "http://www.ptcbio.com/role/Commitmentsandcontingencies",
     "shortName": "Commitments and contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i3a86afcbe18b4917ba65f4643aaff8d5_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Consolidated Balance Sheets (unaudited)",
     "role": "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited",
     "shortName": "Consolidated Balance Sheets (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i3a86afcbe18b4917ba65f4643aaff8d5_I20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2154113 - Disclosure - Revenue recognition",
     "role": "http://www.ptcbio.com/role/Revenuerecognition",
     "shortName": "Revenue recognition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2157114 - Disclosure - Intangible assets and goodwill",
     "role": "http://www.ptcbio.com/role/Intangibleassetsandgoodwill",
     "shortName": "Intangible assets and goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2161115 - Disclosure - Subsequent events",
     "role": "http://www.ptcbio.com/role/Subsequentevents",
     "shortName": "Subsequent events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of significant accounting policies - (Policies)",
     "role": "http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesPolicies",
     "shortName": "Summary of significant accounting policies - (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of significant accounting policies - (Tables)",
     "role": "http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesTables",
     "shortName": "Summary of significant accounting policies - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310302 - Disclosure - Leases - (Tables)",
     "role": "http://www.ptcbio.com/role/LeasesTables",
     "shortName": "Leases - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321303 - Disclosure - Fair value of financial instruments and marketable securities - (Tables)",
     "role": "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesTables",
     "shortName": "Fair value of financial instruments and marketable securities - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330304 - Disclosure - Other comprehensive income (loss) and accumulated other comprehensive items - (Tables)",
     "role": "http://www.ptcbio.com/role/OthercomprehensiveincomelossandaccumulatedothercomprehensiveitemsTables",
     "shortName": "Other comprehensive income (loss) and accumulated other comprehensive items - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333305 - Disclosure - Accounts payable and accrued expenses - (Tables)",
     "role": "http://www.ptcbio.com/role/AccountspayableandaccruedexpensesTables",
     "shortName": "Accounts payable and accrued expenses - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2338306 - Disclosure - Net loss per share - (Tables)",
     "role": "http://www.ptcbio.com/role/NetlosspershareTables",
     "shortName": "Net loss per share - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i3a86afcbe18b4917ba65f4643aaff8d5_I20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Consolidated Balance Sheets (unaudited) (Parenthetical)",
     "role": "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunauditedParenthetical",
     "shortName": "Consolidated Balance Sheets (unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i3a86afcbe18b4917ba65f4643aaff8d5_I20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2342307 - Disclosure - Stock award plan - (Tables)",
     "role": "http://www.ptcbio.com/role/StockawardplanTables",
     "shortName": "Stock award plan - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i74ae1a7412804eb39f158945860fdc92_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2348308 - Disclosure - Debt - (Tables)",
     "role": "http://www.ptcbio.com/role/DebtTables",
     "shortName": "Debt - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i74ae1a7412804eb39f158945860fdc92_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2358309 - Disclosure - Intangible assets and goodwill - (Tables)",
     "role": "http://www.ptcbio.com/role/IntangibleassetsandgoodwillTables",
     "shortName": "Intangible assets and goodwill - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i3a86afcbe18b4917ba65f4643aaff8d5_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - The Company - Narrative (Details)",
     "role": "http://www.ptcbio.com/role/TheCompanyNarrativeDetails",
     "shortName": "The Company - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i921570c76d4f4e23870b19798c531218_D20200429-20200429",
      "decimals": "-5",
      "lang": "en-US",
      "name": "ptct:CashconsiderationpaymentunderRightsExchangeAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i3a86afcbe18b4917ba65f4643aaff8d5_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of significant accounting policies - Inventory (Details)",
     "role": "http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesInventoryDetails",
     "shortName": "Summary of significant accounting policies - Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i3a86afcbe18b4917ba65f4643aaff8d5_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i3a86afcbe18b4917ba65f4643aaff8d5_I20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Summary of significant accounting policies - Narrative (Details)",
     "role": "http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails",
     "shortName": "Summary of significant accounting policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryWriteDown",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i2936f304a9684c72bba6facb72a1b64b_D20190401-20190630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:InventoryWriteDown",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i3a86afcbe18b4917ba65f4643aaff8d5_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Summary of significant accounting policies - Reconciliation of cash (Details)",
     "role": "http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesReconciliationofcashDetails",
     "shortName": "Summary of significant accounting policies - Reconciliation of cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i3a86afcbe18b4917ba65f4643aaff8d5_I20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i3a86afcbe18b4917ba65f4643aaff8d5_I20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ptct:NumberOfOperatingLeases",
      "reportCount": 1,
      "unitRef": "operating_lease",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.ptcbio.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - Leases - Lease costs (Details)",
     "role": "http://www.ptcbio.com/role/LeasesLeasecostsDetails",
     "shortName": "Leases - Lease costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:VariableLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i3a86afcbe18b4917ba65f4643aaff8d5_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413407 - Disclosure - Leases - Balance sheet (Details)",
     "role": "http://www.ptcbio.com/role/LeasesBalancesheetDetails",
     "shortName": "Leases - Balance sheet (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i3a86afcbe18b4917ba65f4643aaff8d5_I20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Consolidated Statements of Operations (unaudited)",
     "role": "http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited",
     "shortName": "Consolidated Statements of Operations (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ptct:CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i3a86afcbe18b4917ba65f4643aaff8d5_I20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414408 - Disclosure - Leases - Supplemental lease terms (Details)",
     "role": "http://www.ptcbio.com/role/LeasesSupplementalleasetermsDetails",
     "shortName": "Leases - Supplemental lease terms (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i3a86afcbe18b4917ba65f4643aaff8d5_I20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i3a86afcbe18b4917ba65f4643aaff8d5_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415409 - Disclosure - Leases - Lease payments (Details)",
     "role": "http://www.ptcbio.com/role/LeasesLeasepaymentsDetails",
     "shortName": "Leases - Lease payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i3a86afcbe18b4917ba65f4643aaff8d5_I20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416410 - Disclosure - Leases - Cash flow (Details)",
     "role": "http://www.ptcbio.com/role/LeasesCashflowDetails",
     "shortName": "Leases - Cash flow (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodValueAcquisitions",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418411 - Disclosure - Acquisitions - Narrative (Details)",
     "role": "http://www.ptcbio.com/role/AcquisitionsNarrativeDetails",
     "shortName": "Acquisitions - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i8742fae222d34cac83b189f51096e426_D20200529-20200529",
      "decimals": "-5",
      "lang": "en-US",
      "name": "ptct:PaymentsforAssetAcquisitions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i3a86afcbe18b4917ba65f4643aaff8d5_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419412 - Disclosure - Acquisitions - Preliminary Allocation of purchase price (Details)",
     "role": "http://www.ptcbio.com/role/AcquisitionsPreliminaryAllocationofpurchasepriceDetails",
     "shortName": "Acquisitions - Preliminary Allocation of purchase price (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesRealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422413 - Disclosure - Fair value of financial instruments and marketable securities - Narrative (Details)",
     "role": "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
     "shortName": "Fair value of financial instruments and marketable securities - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesRealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i3a86afcbe18b4917ba65f4643aaff8d5_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423414 - Disclosure - Fair value of financial instruments and marketable securities - Hierarchy (Details)",
     "role": "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesHierarchyDetails",
     "shortName": "Fair value of financial instruments and marketable securities - Hierarchy (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i44f6355301964dabbb766e645f3cf148_I20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i3a86afcbe18b4917ba65f4643aaff8d5_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424415 - Disclosure - Fair value of financial instruments and marketable securities - Available for sale (Details)",
     "role": "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesAvailableforsaleDetails",
     "shortName": "Fair value of financial instruments and marketable securities - Available for sale (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i3a86afcbe18b4917ba65f4643aaff8d5_I20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425416 - Disclosure - Fair value of financial instruments and marketable securities - Fair Value Measurement Inputs and Valuation Techniques (Details)",
     "role": "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesFairValueMeasurementInputsandValuationTechniquesDetails",
     "shortName": "Fair value of financial instruments and marketable securities - Fair Value Measurement Inputs and Valuation Techniques (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i3a86afcbe18b4917ba65f4643aaff8d5_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426417 - Disclosure - Fair value of financial instruments and marketable securities - Unrealized Loss Positions (Details)",
     "role": "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesUnrealizedLossPositionsDetails",
     "shortName": "Fair value of financial instruments and marketable securities - Unrealized Loss Positions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Consolidated Statements of Comprehensive Loss (unaudited)",
     "role": "http://www.ptcbio.com/role/ConsolidatedStatementsofComprehensiveLossunaudited",
     "shortName": "Consolidated Statements of Comprehensive Loss (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i3a86afcbe18b4917ba65f4643aaff8d5_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427418 - Disclosure - Fair value of financial instruments and marketable securities - Marketable securities (Details)",
     "role": "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesMarketablesecuritiesDetails",
     "shortName": "Fair value of financial instruments and marketable securities - Marketable securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i3a86afcbe18b4917ba65f4643aaff8d5_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428419 - Disclosure - Fair value of financial instruments and marketable securities - Warrants and SARs (Details)",
     "role": "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails",
     "shortName": "Fair value of financial instruments and marketable securities - Warrants and SARs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "iaf63c553ba564cb8bd94fab03c3290ab_D20200101-20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ptct:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsRightsExchangeSettlement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "ieb8114d4f418487782c0740ca1ed1bfc_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431420 - Disclosure - Other comprehensive income (loss) and accumulated other comprehensive items - Narrative (Details)",
     "role": "http://www.ptcbio.com/role/OthercomprehensiveincomelossandaccumulatedothercomprehensiveitemsNarrativeDetails",
     "shortName": "Other comprehensive income (loss) and accumulated other comprehensive items - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i3a86afcbe18b4917ba65f4643aaff8d5_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434421 - Disclosure - Accounts payable and accrued expenses - Narrative (Details)",
     "role": "http://www.ptcbio.com/role/AccountspayableandaccruedexpensesNarrativeDetails",
     "shortName": "Accounts payable and accrued expenses - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i3a86afcbe18b4917ba65f4643aaff8d5_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436422 - Disclosure - Capitalization - Narrative (Details)",
     "role": "http://www.ptcbio.com/role/CapitalizationNarrativeDetails",
     "shortName": "Capitalization - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439423 - Disclosure - Net loss per share - Numerator and Denominator (Details)",
     "role": "http://www.ptcbio.com/role/NetlosspershareNumeratorandDenominatorDetails",
     "shortName": "Net loss per share - Numerator and Denominator (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440424 - Disclosure - Net loss per share - Antidilutive (Details)",
     "role": "http://www.ptcbio.com/role/NetlosspershareAntidilutiveDetails",
     "shortName": "Net loss per share - Antidilutive (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443425 - Disclosure - Stock award plan - Narrative (Details)",
     "role": "http://www.ptcbio.com/role/StockawardplanNarrativeDetails",
     "shortName": "Stock award plan - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "ibf32b31395a2491ebc2ee0715f74c386_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444426 - Disclosure - Stock award plan - Share Base Compensation (Details)",
     "role": "http://www.ptcbio.com/role/StockawardplanShareBaseCompensationDetails",
     "shortName": "Stock award plan - Share Base Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "ibf32b31395a2491ebc2ee0715f74c386_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i1d4c0457ced344f0b16ef87b8b77d3ae_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445427 - Disclosure - Stock award plan - Restricted Stock (Details)",
     "role": "http://www.ptcbio.com/role/StockawardplanRestrictedStockDetails",
     "shortName": "Stock award plan - Restricted Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i1d4c0457ced344f0b16ef87b8b77d3ae_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "ib5972ed6730144a8ae9bdb30fcd5fffd_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Consolidated Statements of Stockholders' Equity",
     "role": "http://www.ptcbio.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "ib5972ed6730144a8ae9bdb30fcd5fffd_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "ia8668b1a6c474b55b96b3a5a3fd3a286_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446428 - Disclosure - Stock award plan - Share-based compensation expense (Details)",
     "role": "http://www.ptcbio.com/role/StockawardplanSharebasedcompensationexpenseDetails",
     "shortName": "Stock award plan - Share-based compensation expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i23b23527dd664848b751f1f40cd0477f_D20200401-20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i3a86afcbe18b4917ba65f4643aaff8d5_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449429 - Disclosure - Debt - Narrative (Details)",
     "role": "http://www.ptcbio.com/role/DebtNarrativeDetails",
     "shortName": "Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "ptct:DebtInstrumentAdditionalAmountAvailableForRepurchase",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i08c7971cf8d6469fbda565dec2419938_I20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450430 - Disclosure - Debt - Convertible Notes (Details)",
     "role": "http://www.ptcbio.com/role/DebtConvertibleNotesDetails",
     "shortName": "Debt - Convertible Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i08c7971cf8d6469fbda565dec2419938_I20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UnamortizedDebtIssuanceExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfFinancingCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451431 - Disclosure - Debt - Interest Expense (Details)",
     "role": "http://www.ptcbio.com/role/DebtInterestExpenseDetails",
     "shortName": "Debt - Interest Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ptct:ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i4e58b009dcb346afa5fe00025d1c8d43_D20200401-20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i652c4548495c438db5c41a0492a229a2_D20200101-20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "ptct:UpfrontLicensingFee",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453432 - Disclosure - Commitments and contingencies - Narrative (Details)",
     "role": "http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails",
     "shortName": "Commitments and contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "ia033e797f8104feca5e0e2c9aef70ffb_I20191231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "ptct:MilestonePotentialAchievementsRegulatoryApproval",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455433 - Disclosure - Revenue recognition - Narrative (Details)",
     "role": "http://www.ptcbio.com/role/RevenuerecognitionNarrativeDetails",
     "shortName": "Revenue recognition - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "ia96d9cae808a4c3784211e0141d85ae1_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456434 - Disclosure - Revenue recognition - Performance Obligations (Details)",
     "role": "http://www.ptcbio.com/role/RevenuerecognitionPerformanceObligationsDetails",
     "shortName": "Revenue recognition - Performance Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "ia96d9cae808a4c3784211e0141d85ae1_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i667dbebd49c148f3993ce8cc26b0f8f3_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459435 - Disclosure - Intangible assets and goodwill - Narrative (Details)",
     "role": "http://www.ptcbio.com/role/IntangibleassetsandgoodwillNarrativeDetails",
     "shortName": "Intangible assets and goodwill - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i667dbebd49c148f3993ce8cc26b0f8f3_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i3a86afcbe18b4917ba65f4643aaff8d5_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460436 - Disclosure - Intangible assets and goodwill - Future Amortization (Details)",
     "role": "http://www.ptcbio.com/role/IntangibleassetsandgoodwillFutureAmortizationDetails",
     "shortName": "Intangible assets and goodwill - Future Amortization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i3a86afcbe18b4917ba65f4643aaff8d5_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i0b0512f2780f4b8eb0826df908c1fcb3_D20200701-20200701",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfLinesOfCredit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2462437 - Disclosure - Subsequent events Narrative (Details)",
     "role": "http://www.ptcbio.com/role/SubsequenteventsNarrativeDetails",
     "shortName": "Subsequent events Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i0b0512f2780f4b8eb0826df908c1fcb3_D20200701-20200701",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfLinesOfCredit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Consolidated Statements of Cash Flows (unaudited)",
     "role": "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited",
     "shortName": "Consolidated Statements of Cash Flows (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - The Company",
     "role": "http://www.ptcbio.com/role/TheCompany",
     "shortName": "The Company",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of significant accounting policies",
     "role": "http://www.ptcbio.com/role/Summaryofsignificantaccountingpolicies",
     "shortName": "Summary of significant accounting policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20200630.htm",
      "contextRef": "i169de841172649f2b7a67e115481f695_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 84,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ptct_A2020inducementstockincentiveplanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2020 inducement stock incentive plan [Member]",
        "label": "2020 inducement stock incentive plan [Member]",
        "terseLabel": "2020 inducement stock incentive plan [Member]"
       }
      }
     },
     "localname": "A2020inducementstockincentiveplanMember",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails",
      "http://www.ptcbio.com/role/StockawardplanShareBaseCompensationDetails",
      "http://www.ptcbio.com/role/StockawardplanSharebasedcompensationexpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_AccruedConsultingAndContractedResearchCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ptcbio.com/role/AccountspayableandaccruedexpensesNarrativeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for consulting and contracted research.",
        "label": "Accrued Consulting and Contracted Research Current",
        "terseLabel": "Consulting and contracted research"
       }
      }
     },
     "localname": "AccruedConsultingAndContractedResearchCurrent",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/AccountspayableandaccruedexpensesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adjustments to Additional Paid In Capital Receivable from Investor",
        "label": "Adjustments to Additional Paid In Capital Receivable from Investor",
        "terseLabel": "Receivable from investor"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_AgilisMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agilis [Member]",
        "label": "Agilis [Member]",
        "terseLabel": "Agilis"
       }
      }
     },
     "localname": "AgilisMember",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/AcquisitionsPreliminaryAllocationofpurchasepriceDetails",
      "http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesFairValueMeasurementInputsandValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails",
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_AkceaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Akcea [Member]",
        "label": "Akcea [Member]",
        "terseLabel": "Akcea"
       }
      }
     },
     "localname": "AkceaMember",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/IntangibleassetsandgoodwillNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_AlternativeInvestmentMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Alternative Investment, Milestone",
        "label": "Alternative Investment, Milestone",
        "terseLabel": "Alternative Investment, Milestone"
       }
      }
     },
     "localname": "AlternativeInvestmentMilestone",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_AssetAcquisitionCash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset Acquisition, Cash",
        "label": "Asset Acquisition, Cash",
        "terseLabel": "Asset acquisition, cash"
       }
      }
     },
     "localname": "AssetAcquisitionCash",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_AssetAcquisitionConsiderationTransferred": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset Acquisition, Consideration Transferred",
        "label": "Asset Acquisition, Consideration Transferred",
        "terseLabel": "Asset acquisition, consideration transferred"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferred",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_AssetAcquisitionDevelopmentAndRegulatoryMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset Acquisition, Development And Regulatory Milestones",
        "label": "Asset Acquisition, Development And Regulatory Milestones",
        "terseLabel": "Asset acquisition, development and regulatory milestones"
       }
      }
     },
     "localname": "AssetAcquisitionDevelopmentAndRegulatoryMilestones",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/AcquisitionsNarrativeDetails",
      "http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_AssetAcquisitionInProcessResearchAndDevelopment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset Acquisition, In-process Research and Development",
        "label": "Asset Acquisition, In-process Research and Development",
        "terseLabel": "Asset acquisition, in-process research and development"
       }
      }
     },
     "localname": "AssetAcquisitionInProcessResearchAndDevelopment",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_AssetAcquisitionInitialMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset Acquisition, Initial Milestone",
        "label": "Asset Acquisition, Initial Milestone",
        "terseLabel": "Asset acquisition, initial milestone"
       }
      }
     },
     "localname": "AssetAcquisitionInitialMilestone",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/AcquisitionsNarrativeDetails",
      "http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_AssetAcquisitionMilestoneAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset Acquisition, Milestone, Amount",
        "label": "Asset Acquisition, Milestone, Amount",
        "terseLabel": "Asset acquisition, milestone, amount"
       }
      }
     },
     "localname": "AssetAcquisitionMilestoneAmount",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/AcquisitionsNarrativeDetails",
      "http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_AssetAcquisitionNetSalesMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset Acquisition, Net Sales Milestone",
        "label": "Asset Acquisition, Net Sales Milestone",
        "terseLabel": "Asset acquisition, net sales milestone"
       }
      }
     },
     "localname": "AssetAcquisitionNetSalesMilestone",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/AcquisitionsNarrativeDetails",
      "http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_AssetAcquisitionOtherAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset Acquisition, Other Assets",
        "label": "Asset Acquisition, Other Assets",
        "terseLabel": "Asset acquisition, other assets"
       }
      }
     },
     "localname": "AssetAcquisitionOtherAssets",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_AssetAcquisitionResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset Acquisition, Research And Development Expense",
        "label": "Asset Acquisition, Research And Development Expense",
        "terseLabel": "Asset acquisition, research and development expense"
       }
      }
     },
     "localname": "AssetAcquisitionResearchAndDevelopmentExpense",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_AssetAcquisitionSellingGeneralAndAdministrativeExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset Acquisition, Selling, General And Administrative Expense",
        "label": "Asset Acquisition, Selling, General And Administrative Expense",
        "terseLabel": "Asset acquisition, selling, general And administrative expense"
       }
      }
     },
     "localname": "AssetAcquisitionSellingGeneralAndAdministrativeExpense",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_AssetAcquisitionTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset Acquisition, Transaction Costs",
        "label": "Asset Acquisition, Transaction Costs",
        "negatedTerseLabel": "Asset acquisition, transaction costs"
       }
      }
     },
     "localname": "AssetAcquisitionTransactionCosts",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_AssignedRoyaltyPaymentPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Assigned Royalty Payment, Percentage",
        "label": "Assigned Royalty Payment, Percentage",
        "terseLabel": "Assigned royalty payment, percentage"
       }
      }
     },
     "localname": "AssignedRoyaltyPaymentPercentage",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/SubsequenteventsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ptct_AssignedRoyaltyPaymentRetainedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Assigned Royalty Payment, Retained Percentage",
        "label": "Assigned Royalty Payment, Retained Percentage",
        "terseLabel": "Assigned royalty payment, retained percentage"
       }
      }
     },
     "localname": "AssignedRoyaltyPaymentRetainedPercentage",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/SubsequenteventsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of available-for-sale debt securities at fair value maturing after the next fiscal year following the latest fiscal year.",
        "label": "Available For Sale Securities Debt Maturities Over One Year Fair Value",
        "terseLabel": "Total Marketable securities, More Than 12 Months"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesMarketablesecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_BioElectronMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BioElectron [Member]",
        "label": "BioElectron [Member]",
        "terseLabel": "BioElectron"
       }
      }
     },
     "localname": "BioElectronMember",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/LeasesNarrativeDetails",
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_BridgewaterMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bridgewater",
        "label": "Bridgewater [Member]",
        "terseLabel": "Bridgewater [Member]"
       }
      }
     },
     "localname": "BridgewaterMember",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Acquisition, Equity Interest Issued Or Issuable, Trading Day Period",
        "label": "Business Acquisition, Equity Interest Issued Or Issuable, Trading Day Period",
        "terseLabel": "Trading day period"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Acquisition, Numerator For Calculation Of Number Of Shares Of Equity Interests Issued To Acquire Entity",
        "label": "Business Acquisition, Numerator For Calculation Of Number Of Shares Of Equity Interests Issued To Acquire Entity",
        "terseLabel": "Numerator for calculation of number of shares of equity interests issued to acquire entity"
       }
      }
     },
     "localname": "BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Consideration, Liability, Deferred Consideration Payable",
        "label": "Business Combination, Consideration, Liability, Deferred Consideration Payable",
        "terseLabel": "Estimated fair value of deferred consideration payable",
        "verboseLabel": "Deferred consideration payable"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesHierarchyDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Consideration, Liability, Deferred Consideration Payable- Current",
        "label": "Business Combination, Consideration, Liability, Deferred Consideration Payable- Current",
        "terseLabel": "Deferred consideration payable"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_CashconsiderationpaymentunderRightsExchangeAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash consideration payment under Rights Exchange Agreement",
        "label": "Cash consideration payment under Rights Exchange Agreement",
        "terseLabel": "Cash consideration payment under Rights Exchange Agreement"
       }
      }
     },
     "localname": "CashconsiderationpaymentunderRightsExchangeAgreement",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_CensaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Censa",
        "label": "Censa [Member]",
        "terseLabel": "Censa [Member]"
       }
      }
     },
     "localname": "CensaMember",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/AcquisitionsNarrativeDetails",
      "http://www.ptcbio.com/role/CapitalizationNarrativeDetails",
      "http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_CesnaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cesna",
        "label": "Cesna [Member]",
        "terseLabel": "Cesna [Member]"
       }
      }
     },
     "localname": "CesnaMember",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/AcquisitionsNarrativeDetails",
      "http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_CollaborationAndDiscoveryAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to early stage collaboration and discovery agreements.",
        "label": "Collaboration And Discovery Agreements [Member]",
        "terseLabel": "Collaboration And Discovery Agreements"
       }
      }
     },
     "localname": "CollaborationAndDiscoveryAgreementsMember",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the research period for applying discovery technology.",
        "label": "Collaborative Arrangements Research Period for Applying Discovery Technology",
        "terseLabel": "Collaborative arrangements research period for applying discovery technology"
       }
      }
     },
     "localname": "CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ptct_ConsiderationForAssetAcquisitions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Consideration for Asset Acquisitions",
        "label": "Consideration for Asset Acquisitions",
        "terseLabel": "Consideration for asset acquisitions"
       }
      }
     },
     "localname": "ConsiderationForAssetAcquisitions",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_ContingentConsiderationTransactionFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contingent Consideration, Transaction Fees",
        "label": "Contingent Consideration, Transaction Fees",
        "terseLabel": "Contingent Consideration, Transaction Fees"
       }
      }
     },
     "localname": "ContingentConsiderationTransactionFees",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_ContingentLiabilityCancellationAndForfeiture": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contingent Liability, Cancellation and Forfeiture",
        "label": "Contingent Liability, Cancellation and Forfeiture",
        "terseLabel": "Contingent Liability, Cancellation and Forfeiture"
       }
      }
     },
     "localname": "ContingentLiabilityCancellationAndForfeiture",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_ContingentLiabilityCancellationAndForfeitureMilestonePotentialAchievementsPriorityReviewVoucherAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contingent Liability cancellation and forfeiture, Milestone, Potential Achievements, Priority Review Voucher Amount",
        "label": "Contingent Liability cancellation and forfeiture, Milestone, Potential Achievements, Priority Review Voucher Amount",
        "terseLabel": "Contingent Liability cancellation and forfeiture, Milestone, Potential Achievements, Priority Review Voucher Amount"
       }
      }
     },
     "localname": "ContingentLiabilityCancellationAndForfeitureMilestonePotentialAchievementsPriorityReviewVoucherAmount",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contingent Liability, Milestone, Potential Achievements, Net Sales Milestone And Regulatory Approval",
        "label": "Contingent Liability, Milestone, Potential Achievements, Net Sales Milestone",
        "terseLabel": "Net sales amount"
       }
      }
     },
     "localname": "ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount",
        "label": "Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount",
        "terseLabel": "Priority review voucher amount"
       }
      }
     },
     "localname": "ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount, Net of Cancellation and Forfeiture",
        "label": "Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount, Net of Cancellation and Forfeiture",
        "terseLabel": "Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount, Net of Cancellation and Forfeiture"
       }
      }
     },
     "localname": "ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contingent Liability, Milestone, Potential Achievements, Product Sales Percentage",
        "label": "Contingent Liability, Milestone, Potential Achievements, Product Sales Percentage",
        "terseLabel": "Product sales"
       }
      }
     },
     "localname": "ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ptct_ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the debt instrument principal and unpaid interest payable upon events of default.",
        "label": "Convertible Instruments Principal And Unpaid Interest Payable Upon Events Of Default",
        "terseLabel": "Convertible instruments principal and unpaid interest payable upon events of default"
       }
      }
     },
     "localname": "ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Convertible Senior Notes, 1.5%, Due September 15, 2026 [Member]",
        "label": "Convertible Senior Notes, 1.5%, Due September 15, 2026 [Member]",
        "terseLabel": "1.50% Convertible senior notes due 2026"
       }
      }
     },
     "localname": "ConvertibleSeniorNotes1.5DueSeptember152026Member",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/DebtConvertibleNotesDetails",
      "http://www.ptcbio.com/role/DebtInterestExpenseDetails",
      "http://www.ptcbio.com/role/DebtNarrativeDetails",
      "http://www.ptcbio.com/role/DebtTables",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_ConvertibleSeniorNotes3.0PercentDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the information pertaining to 3.00% convertible senior notes due 2022.",
        "label": "Convertible Senior Notes3.0 Percent Due2022 [Member]",
        "terseLabel": "3.00% Convertible senior notes due 2022"
       }
      }
     },
     "localname": "ConvertibleSeniorNotes3.0PercentDue2022Member",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/DebtConvertibleNotesDetails",
      "http://www.ptcbio.com/role/DebtInterestExpenseDetails",
      "http://www.ptcbio.com/role/DebtNarrativeDetails",
      "http://www.ptcbio.com/role/DebtTables",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cost of Goods and Service, Excluding Amortization Of Intangible Assets",
        "label": "Cost of Goods and Service, Excluding Amortization Of Intangible Assets",
        "terseLabel": "Cost of Goods and Service, Excluding Amortization Of Intangible Assets"
       }
      }
     },
     "localname": "CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_DebtInstrumentAdditionalAmountAvailableForRepurchase": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument Additional Amount Available For Repurchase",
        "label": "Debt Instrument Additional Amount Available For Repurchase",
        "terseLabel": "Debt instrument additional amount available for repurchase"
       }
      }
     },
     "localname": "DebtInstrumentAdditionalAmountAvailableForRepurchase",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the debt instrument redemption period on or after August 20, 2018.",
        "label": "Debt Instrument Conversion Period On Or After August202018 [Member]",
        "terseLabel": "Redemption on or after August 20, 2018"
       }
      }
     },
     "localname": "DebtInstrumentConversionPeriodOnOrAfterAugust202018Member",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_DebtInstrumentConvertiblePeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Convertible, Period",
        "label": "Debt Instrument, Convertible, Period",
        "terseLabel": "Debt instrument, convertible, period"
       }
      }
     },
     "localname": "DebtInstrumentConvertiblePeriod",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ptct_DebtInstrumentConvertibleThresholdBusinessDays": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Threshold period of specified business days within which the maximum product of the closing sale price of shares of the entity's common stock and the applicable conversion rate for such trading day triggers the conversion feature.",
        "label": "Debt Instrument Convertible Threshold Business Days",
        "terseLabel": "Business days, period"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdBusinessDays",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ptct_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which the maximum product of the closing sale price of shares of the entity's common stock and the applicable conversion rate for such trading day triggers the conversion feature.",
        "label": "Debt Instrument Convertible Threshold Consecutive Trading Day Period",
        "terseLabel": "Consecutive trading-day period"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ptct_DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the maximum product of the closing sale price of shares of the entity's common stock and the applicable conversion rate for such trading day.",
        "label": "Debt Instrument Convertible Threshold Sale Price Of Common Stock Conversion Rate Product Percentage Maximum",
        "terseLabel": "Maximum product of the closing sale price of shares of the Company's common stock and the applicable conversion rate for such trading day"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ptct_DebtInstrumentFloorInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Floor Interest Rate",
        "label": "Debt Instrument, Floor Interest Rate",
        "terseLabel": "Debt instrument, floor interest rate"
       }
      }
     },
     "localname": "DebtInstrumentFloorInterestRate",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ptct_DebtInstrumentInterestPaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Interest Payment Period",
        "label": "Debt Instrument, Interest Payment Period",
        "terseLabel": "Debt instrument, interest payment period"
       }
      }
     },
     "localname": "DebtInstrumentInterestPaymentPeriod",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ptct_DepositsAndOtherAssetsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the carrying value of amounts transferred to third parties for security purposes and other noncurrent assets that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.",
        "label": "Deposits and Other Assets Noncurrent",
        "terseLabel": "Deposits and other assets"
       }
      }
     },
     "localname": "DepositsAndOtherAssetsNoncurrent",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_DevelopmentMilestonePaymentObligationsCancellationAndForfeiture": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Development Milestone Payment Obligations, Cancellation and Forfeiture",
        "label": "Development Milestone Payment Obligations, Cancellation and Forfeiture",
        "terseLabel": "Development Milestone Payment Obligations, Cancellation and Forfeiture"
       }
      }
     },
     "localname": "DevelopmentMilestonePaymentObligationsCancellationAndForfeiture",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the development milestones payments which the entity is obligated to pay under certain contractual agreements.",
        "label": "Development Milestone Payment Obligations, Due on Second Anniversary Year of Merger Closing",
        "terseLabel": "Development milestone payments which the entity is obligated to pay"
       }
      }
     },
     "localname": "DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/IntangibleassetsandgoodwillNarrativeDetails",
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Development Milestone Payment Obligations, net of cancellation and forfeiture",
        "label": "Development Milestone Payment Obligations, Net of Cancellation and Forfeiture",
        "terseLabel": "Development Milestone Payment Obligations, Net of Cancellation and Forfeiture"
       }
      }
     },
     "localname": "DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_DevelopmentandPotentialRegulatoryApprovalPaymentObligation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Development and Potential Regulatory Approval Payment Obligation",
        "label": "Development and Potential Regulatory Approval Payment Obligation",
        "terseLabel": "Milestone, Potential Achievements, Regulatory Approval"
       }
      }
     },
     "localname": "DevelopmentandPotentialRegulatoryApprovalPaymentObligation",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_DevelopmentandRegulatoryMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Development and Regulatory Milestone [Member]",
        "label": "Development and Regulatory Milestone [Member]",
        "terseLabel": "Development and Regulatory Milestone"
       }
      }
     },
     "localname": "DevelopmentandRegulatoryMilestoneMember",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_DiscoveryAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discovery Agreements [Member]",
        "label": "Discovery Agreements [Member]",
        "terseLabel": "Discovery Agreements"
       }
      }
     },
     "localname": "DiscoveryAgreementsMember",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_EarlyStageCollaborationsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Early Stage Collaborations [Member]",
        "label": "Early Stage Collaborations [Member]",
        "terseLabel": "Early Stage Collaborations"
       }
      }
     },
     "localname": "EarlyStageCollaborationsMember",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_EmflazaassetacquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Emflaza asset acquisition [Member]",
        "label": "Emflaza asset acquisition [Member]",
        "terseLabel": "Emflaza asset acquisition"
       }
      }
     },
     "localname": "EmflazaassetacquisitionMember",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/IntangibleassetsandgoodwillNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_EmployeeDirectorAndConsultantStockOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the 1998 Employee, Director and Consultant Stock Option Plan",
        "label": "Employee Director And Consultant Stock Option Plan [Member]",
        "terseLabel": "1998 Employee, Director and Consultant Stock Option Plan"
       }
      }
     },
     "localname": "EmployeeDirectorAndConsultantStockOptionPlanMember",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_EmployeeStockPurchasePlanVotingPercentageLimitPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee Stock Purchase Plan, Voting Percentage Limit, Percent",
        "label": "Employee Stock Purchase Plan, Voting Percentage Limit, Percent",
        "terseLabel": "Employee stock purchase plan, voting percentage limit"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanVotingPercentageLimitPercent",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to the 2009 Equity and Long Term Incentive Plan and 2013 Stock Incentive Plan.",
        "label": "Equity2009 And Long Term Incentive Plan And Stock Incentive Plan2013 [Member]",
        "terseLabel": "2009 Equity and Long Term Incentive Plan and 2013 Stock Incentive Plan"
       }
      }
     },
     "localname": "Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_EquityAndLongTermIncentivePlan2009Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to the 2009 Equity and Long-Term Incentive Plan.",
        "label": "Equity And Long Term Incentive Plan2009 [Member]",
        "terseLabel": "2009 Equity and Long Term Incentive Plan"
       }
      }
     },
     "localname": "EquityAndLongTermIncentivePlan2009Member",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsRightsExchangeSettlement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements, Rights Exchange Settlement",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements, Rights Exchange Settlement",
        "negatedTerseLabel": "Rights Exchange settlement"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsRightsExchangeSettlement",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_FifthAnniversaryMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fifth Anniversary [Member]",
        "label": "Fifth Anniversary [Member]",
        "terseLabel": "Fifth Anniversary"
       }
      }
     },
     "localname": "FifthAnniversaryMember",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_FinanceLeaseCostNonCash": {
     "auth_ref": [],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Finance Lease, Cost Non-Cash",
        "label": "Finance Lease, Cost Non-Cash",
        "terseLabel": "Non-cash finance lease amortization expense"
       }
      }
     },
     "localname": "FinanceLeaseCostNonCash",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_FinanceLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Finance Lease",
        "label": "Finance Lease [Member]",
        "terseLabel": "Finance Lease"
       }
      }
     },
     "localname": "FinanceLeaseMember",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_FinanceLeasePresentValueOfExceedsTheFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Finance Lease, Present Value Of Exceeds The Fair Value",
        "label": "Finance Lease, Present Value Of Exceeds The Fair Value",
        "terseLabel": "Finance Lease, Present Value Of Exceeds The Fair Value"
       }
      }
     },
     "localname": "FinanceLeasePresentValueOfExceedsTheFairValue",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter": {
     "auth_ref": [],
     "calculation": {
      "http://www.ptcbio.com/role/IntangibleassetsandgoodwillFutureAmortizationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Finite-Lived Intangible Assets, Amortization Expense Year Five And Thereafter",
        "label": "Finite-Lived Intangible Assets, Amortization Expense Year Five And Thereafter",
        "terseLabel": "2024 and thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/IntangibleassetsandgoodwillFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_GainOfSettlementDevelopmentMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gain Of Settlement, Development Milestones",
        "label": "Gain Of Settlement, Development Milestones",
        "terseLabel": "Gain Of Settlement, Development Milestones"
       }
      }
     },
     "localname": "GainOfSettlementDevelopmentMilestones",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_GrantAndCollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Grant And Collaboration [Member]",
        "label": "Grant And Collaboration [Member]",
        "terseLabel": "Collaboration and grant revenue"
       }
      }
     },
     "localname": "GrantAndCollaborationMember",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_HopewellCampusMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hopewell Campus",
        "label": "Hopewell Campus [Member]",
        "terseLabel": "Hopewell Campus"
       }
      }
     },
     "localname": "HopewellCampusMember",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_HopewellNewBuildingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hopewell New Building [Member]",
        "label": "Hopewell New Building [Member]",
        "terseLabel": "New Building"
       }
      }
     },
     "localname": "HopewellNewBuildingMember",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_InventoriesAndCostOfProductSalesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for inventories and cost of revenue.",
        "label": "Inventories And Cost Of Product Sales [Policy Text Block]",
        "terseLabel": "Inventory and cost of product sales"
       }
      }
     },
     "localname": "InventoriesAndCostOfProductSalesPolicyTextBlock",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ptct_InvestmentInMRI": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investment In MRI",
        "label": "Investment In MRI",
        "terseLabel": "Investment In MRI"
       }
      }
     },
     "localname": "InvestmentInMRI",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_LeaseArea": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lease, Area",
        "label": "Lease, Area",
        "terseLabel": "Lease, Area"
       }
      }
     },
     "localname": "LeaseArea",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "ptct_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter": {
     "auth_ref": [],
     "calculation": {
      "http://www.ptcbio.com/role/LeasesLeasepaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Payments, Due Year Five and Thereafter",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five and Thereafter",
        "terseLabel": "2024 and thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesLeasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_LiabilityDevelopmentandRegulatoryMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Liability, Development and Regulatory Milestone [Member]",
        "label": "Liability, Development and Regulatory Milestone [Member]",
        "terseLabel": "Development and Regulatory Milestone"
       }
      }
     },
     "localname": "LiabilityDevelopmentandRegulatoryMilestoneMember",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_LiabilityNetSalesMilestonesandRoyaltiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Liability, Net Sales Milestones and Royalties [Member]",
        "label": "Liability, Net Sales Milestones and Royalties [Member]",
        "terseLabel": "Liability, Net Sales Milestones and Royalties [Member]"
       }
      }
     },
     "localname": "LiabilityNetSalesMilestonesandRoyaltiesMember",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesFairValueMeasurementInputsandValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_LicensingAndCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Licensing And Collaboration Agreement [Member]",
        "label": "Licensing And Collaboration Agreement [Member]",
        "terseLabel": "Licensing And Collaboration Agreement"
       }
      }
     },
     "localname": "LicensingAndCollaborationAgreementMember",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/RevenuerecognitionNarrativeDetails",
      "http://www.ptcbio.com/role/RevenuerecognitionPerformanceObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_LineOfCreditFacilityAdditionalCapacityAvailable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line Of Credit Facility, Additional Capacity Available",
        "label": "Line Of Credit Facility, Additional Capacity Available",
        "terseLabel": "Line of credit facility, additional capacity available, net product revenue threshold"
       }
      }
     },
     "localname": "LineOfCreditFacilityAdditionalCapacityAvailable",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_LineOfCreditFacilityTerminationAndExitFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line of Credit Facility, Termination and Exit Fees",
        "label": "Line of Credit Facility, Termination and Exit Fees",
        "terseLabel": "Termination and exit fees"
       }
      }
     },
     "localname": "LineOfCreditFacilityTerminationAndExitFees",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/SubsequenteventsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_LoanAdvance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Loan Advance",
        "label": "Loan Advance",
        "terseLabel": "Loan advance"
       }
      }
     },
     "localname": "LoanAdvance",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_LongTermIncentivePlan2013Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to the 2013 Long Term Incentive Plan.",
        "label": "Long Term Incentive Plan2013 [Member]",
        "terseLabel": "2013 Long Term Incentive Plan"
       }
      }
     },
     "localname": "LongTermIncentivePlan2013Member",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_LossOfSettlementRegulatoryMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Loss Of Settlement, Regulatory Milestones",
        "label": "Loss Of Settlement, Regulatory Milestones",
        "terseLabel": "Loss Of Settlement, Regulatory Milestones"
       }
      }
     },
     "localname": "LossOfSettlementRegulatoryMilestones",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_MarathonPharmaceuticalsLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Marathon Pharmaceuticals, LLC [Member]",
        "label": "Marathon Pharmaceuticals, LLC [Member]",
        "terseLabel": "Marathon Pharmaceuticals, LLC"
       }
      }
     },
     "localname": "MarathonPharmaceuticalsLLCMember",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_MassBioMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "MassBio",
        "label": "MassBio [Member]",
        "terseLabel": "MassBio"
       }
      }
     },
     "localname": "MassBioMember",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_MidCapFinancialTrustMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "MidCap Financial Trust [Member]",
        "label": "MidCap Financial Trust [Member]",
        "terseLabel": "MidCap Financial Trust"
       }
      }
     },
     "localname": "MidCapFinancialTrustMember",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_MilestoneAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by categories of milestones achieved.",
        "label": "Milestone [Axis]",
        "terseLabel": "Milestone [Axis]"
       }
      }
     },
     "localname": "MilestoneAxis",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ptct_MilestoneDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Different categories of milestones defined by agreements.",
        "label": "Milestone [Domain]",
        "terseLabel": "Milestone [Domain]"
       }
      }
     },
     "localname": "MilestoneDomain",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_MilestonePaymentObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone Payment Obligations",
        "label": "Milestone Payment Obligations",
        "terseLabel": "Milestone Payment Obligations"
       }
      }
     },
     "localname": "MilestonePaymentObligations",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_MilestonePotentialAchievementsRegulatoryApproval": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone payment which the entity is obliged to pay upon regulatory approval",
        "label": "Milestone, Potential Achievements, Regulatory Approval",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "localname": "MilestonePotentialAchievementsRegulatoryApproval",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/IntangibleassetsandgoodwillNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the minimum percentage of debt principal amount by instrument holders.",
        "label": "Minimum Percentage Of Debt Principal Amount By Instrument Holders",
        "terseLabel": "Minimum percentage of principal held by convertible debt instrument holders required to issue notice for declaration of principal and unpaid interest payable upon events of default"
       }
      }
     },
     "localname": "MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ptct_MountainviewMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Mountainview",
        "label": "Mountainview [Member]",
        "terseLabel": "Mountainview"
       }
      }
     },
     "localname": "MountainviewMember",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_NetDeferredTaxLiabilitiesConvertibleDebtInstruments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of net deferred tax liability attributable to taxable temporary differences from issuance of convertible debt instruments.",
        "label": "Net Deferred Tax Liabilities Convertible Debt Instruments",
        "terseLabel": "Net deferred tax liability in connection with convertible notes"
       }
      }
     },
     "localname": "NetDeferredTaxLiabilitiesConvertibleDebtInstruments",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_NetProductSales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the amount of revenue earned from product sales during the reporting period.",
        "label": "Net Product Sales",
        "terseLabel": "Net product revenue"
       }
      }
     },
     "localname": "NetProductSales",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/RevenuerecognitionNarrativeDetails",
      "http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_NumberOfOperatingLeaseLeaseNotyetCommenced": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number Of Operating Lease, Lease Not yet Commenced",
        "label": "Number Of Operating Lease, Lease Not yet Commenced",
        "terseLabel": "Number Of Operating Lease, Lease Not yet Commenced"
       }
      }
     },
     "localname": "NumberOfOperatingLeaseLeaseNotyetCommenced",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ptct_NumberOfOperatingLeases": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number Of Operating Leases",
        "label": "Number Of Operating Leases",
        "terseLabel": "Number of operating leases"
       }
      }
     },
     "localname": "NumberOfOperatingLeases",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ptct_Numberofdistributors": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of Distributors",
        "label": "Number of distributors",
        "terseLabel": "Number of distributors"
       }
      }
     },
     "localname": "Numberofdistributors",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ptct_Numberofterms": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of terms",
        "label": "Number of terms",
        "terseLabel": "Number of terms"
       }
      }
     },
     "localname": "Numberofterms",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ptct_OperatingLeaseCostNonCash": {
     "auth_ref": [],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating Lease, Cost Non-Cash",
        "label": "Operating Lease, Cost Non-Cash",
        "terseLabel": "Non-cash operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseCostNonCash",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_PaymentOfFinanceLeasePrincipal": {
     "auth_ref": [],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payment of Finance Lease Principal",
        "label": "Payment of Finance Lease Principal",
        "negatedTerseLabel": "Payment of finance lease principal"
       }
      }
     },
     "localname": "PaymentOfFinanceLeasePrincipal",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_PaymentsForAssetAcquisitionsNetAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments for Asset Acquisitions, Net Assets",
        "label": "Payments for Asset Acquisitions, Net Assets",
        "terseLabel": "Payments for asset acquisitions, net assets"
       }
      }
     },
     "localname": "PaymentsForAssetAcquisitionsNetAssets",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_PaymentsForAssetAcquisitionsUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments for Asset Acquisitions, Upfront Payment",
        "label": "Payments for Asset Acquisitions, Upfront Payment",
        "terseLabel": "Payments for asset acquisitions, upfront payment"
       }
      }
     },
     "localname": "PaymentsForAssetAcquisitionsUpfrontPayment",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_PaymentsOnDeferredConsiderationObligation": {
     "auth_ref": [],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments On Deferred Consideration Obligation",
        "label": "Payments On Deferred Consideration Obligation",
        "negatedTerseLabel": "Payments on deferred consideration obligation"
       }
      }
     },
     "localname": "PaymentsOnDeferredConsiderationObligation",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_PaymentsToAcquireConvertibleDebtInvestment": {
     "auth_ref": [],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments To Acquire Convertible Debt Investment",
        "label": "Payments To Acquire Convertible Debt Investment",
        "negatedTerseLabel": "Purchase of convertible debt security",
        "verboseLabel": "Purchase of convertible debt investment"
       }
      }
     },
     "localname": "PaymentsToAcquireConvertibleDebtInvestment",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_PaymentsforAssetAcquisitions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments for Asset Acquisitions",
        "label": "Payments for Asset Acquisitions",
        "terseLabel": "Payments for asset acquisitions"
       }
      }
     },
     "localname": "PaymentsforAssetAcquisitions",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/AcquisitionsNarrativeDetails",
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_PercentOfMarketRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percent Of Market Rate",
        "label": "Percent Of Market Rate",
        "terseLabel": "Percent of market rate"
       }
      }
     },
     "localname": "PercentOfMarketRate",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ptct_PercentageofSalesforRoyaltiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of Sales for Royalties [Member]",
        "label": "Percentage of Sales for Royalties [Member]",
        "terseLabel": "Percentage of Sales for Royalties"
       }
      }
     },
     "localname": "PercentageofSalesforRoyaltiesMember",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_Percentageofnetproductsales": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of new product sales",
        "label": "Percentage of net product sales",
        "terseLabel": "Percentage of net product sales"
       }
      }
     },
     "localname": "Percentageofnetproductsales",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ptct_PotentialNetSalesMilestonesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Potential Net Sales Milestones",
        "label": "Potential Net Sales Milestones [Domain]",
        "terseLabel": "Potential Net Sales Milestones [Domain]"
       }
      }
     },
     "localname": "PotentialNetSalesMilestonesDomain",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_ProbabilityofSuccessMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Probability of Success [Member]",
        "label": "Probability of Success [Member]",
        "terseLabel": "Probability of Success [Member]"
       }
      }
     },
     "localname": "ProbabilityofSuccessMember",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesFairValueMeasurementInputsandValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_ProceedsAssignedRoyaltyPaymentAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Proceeds Assigned Royalty Payment Agreement",
        "label": "Proceeds Assigned Royalty Payment Agreement",
        "terseLabel": "Proceeds assigned royalty payment agreement"
       }
      }
     },
     "localname": "ProceedsAssignedRoyaltyPaymentAgreement",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/SubsequenteventsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_ResearchAndDevelopmentEventMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to certain research and development events on the basis of which certain milestones are achieved.",
        "label": "Research And Development Event Milestones [Member]",
        "terseLabel": "Research And Development Event Milestones"
       }
      }
     },
     "localname": "ResearchAndDevelopmentEventMilestonesMember",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_RestrictedStockAndRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to Restricted Stock and Restricted Stock Units (RSUs).",
        "label": "Restricted Stock And Restricted Stock Units [Member]",
        "terseLabel": "Unvested restricted stock awards and units"
       }
      }
     },
     "localname": "RestrictedStockAndRestrictedStockUnitsMember",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/NetlosspershareAntidilutiveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_RevenueRecognitionMilestonePotentialAchievements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognition, Milestone, Potential Achievements",
        "label": "Revenue Recognition, Milestone, Potential Achievements",
        "terseLabel": "Revenue recognition, milestone, potential achievements"
       }
      }
     },
     "localname": "RevenueRecognitionMilestonePotentialAchievements",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/RevenuerecognitionNarrativeDetails",
      "http://www.ptcbio.com/role/SubsequenteventsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_RightsExchangeAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights Exchange Agreement [Member]",
        "label": "Rights Exchange Agreement [Member]",
        "terseLabel": "Rights Exchange Agreement [Member]"
       }
      }
     },
     "localname": "RightsExchangeAgreementMember",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/CapitalizationNarrativeDetails",
      "http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_RoyaltyPurchaseAgreementPaymentMaximum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Royalty Purchase Agreement, Payment Maximum",
        "label": "Royalty Purchase Agreement, Payment Maximum",
        "terseLabel": "Royalty purchase agreement, payment maximum"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementPaymentMaximum",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/SubsequenteventsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_RoyaltyPurchaseAgreementTerminationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Royalty Purchase Agreement, Termination Period",
        "label": "Royalty Purchase Agreement, Termination Period",
        "terseLabel": "Royalty purchase agreement, termination period"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementTerminationPeriod",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/SubsequenteventsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ptct_SaleOfStockWeightedAveragePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of Stock, Weighted Average Price per Share",
        "label": "Sale of Stock, Weighted Average Price per Share",
        "terseLabel": "Sale of stock, weighted average price per share (in USD per share)"
       }
      }
     },
     "localname": "SaleOfStockWeightedAveragePricePerShare",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/CapitalizationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ptct_SalesAllowanceAndOtherRelatedCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.ptcbio.com/role/AccountspayableandaccruedexpensesNarrativeDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sales Allowance And Other Related Costs",
        "label": "Sales Allowance And Other Related Costs",
        "terseLabel": "Sales allowance and other costs"
       }
      }
     },
     "localname": "SalesAllowanceAndOtherRelatedCosts",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/AccountspayableandaccruedexpensesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_SalesMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to certain sales events on the basis of which certain milestones are achieved.",
        "label": "Sales Milestones [Member]",
        "terseLabel": "Sales Milestones"
       }
      }
     },
     "localname": "SalesMilestonesMember",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails",
      "http://www.ptcbio.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_SalesRebatesAndRoyaltiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ptcbio.com/role/AccountspayableandaccruedexpensesNarrativeDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sales Rebates And Royalties, Current",
        "label": "Sales Rebates And Royalties, Current",
        "terseLabel": "Sales rebates and royalties"
       }
      }
     },
     "localname": "SalesRebatesAndRoyaltiesCurrent",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/AccountspayableandaccruedexpensesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of interest expense recognized related to convertible debt.",
        "label": "Schedule Of Interest Expense Recognized Related To Convertible Debt [Table Text Block]",
        "terseLabel": "Summary of interest expense recognized related to the Convertible Notes"
       }
      }
     },
     "localname": "ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ptct_SettlementOfDeferredAndContingentConsideration": {
     "auth_ref": [],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Settlement Of Deferred And Contingent Consideration",
        "label": "Settlement Of Deferred And Contingent Consideration",
        "terseLabel": "Settlement of deferred and contingent consideration"
       }
      }
     },
     "localname": "SettlementOfDeferredAndContingentConsideration",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited",
      "http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the percentage of shares outstanding to be added annually on the first day of each fiscal year in the number of shares authorized.",
        "label": "Share based Compensation Arrangement by Share based Payment Award Number of Shares Authorized Annual Increase as Percentage of Stock Outstanding",
        "terseLabel": "Annual increase in the number of shares outstanding on the first day of the fiscal year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the number of shares to be added annually on the first day of each fiscal year in the number of shares authorized.",
        "label": "Share based Compensation Arrangement by Share based Payment Award Number of Shares Authorized Annual Increase Number",
        "terseLabel": "Share based Compensation Arrangement by Share based Payment Award Number of Shares Authorized Annual Increase Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails",
      "http://www.ptcbio.com/role/StockawardplanSharebasedcompensationexpenseDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the number of shares subject to outstanding awards used to calculate authorized shares.",
        "label": "Share based Compensation Arrangement by Share based Payment Award Number of Shares Authorized Shares Subject to Outstanding Awards",
        "terseLabel": "Number of shares subject to outstanding awards (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the inducement grants for non-statutory stock options.",
        "label": "Inducement Grants For Non-Statutory Stock Options",
        "terseLabel": "Inducement grants for non-statutory stock options (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Intrinsic Value [Roll Forward]",
        "terseLabel": "Aggregate intrinsic value (in thousands)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanShareBaseCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ptct_SharesIssuedAssetAcquisition": {
     "auth_ref": [],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares issued Asset Acquisition",
        "label": "Shares issued Asset Acquisition",
        "terseLabel": "Non-cash stock consideration, acquisition"
       }
      }
     },
     "localname": "SharesIssuedAssetAcquisition",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_SharesissuedunderRightsExchangeAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares issued under Rights Exchange Agreement",
        "label": "Shares issued under Rights Exchange Agreement",
        "terseLabel": "Shares, issued (in shares)"
       }
      }
     },
     "localname": "SharesissuedunderRightsExchangeAgreement",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ptct_SharesremainingtoissueunderRightsExchangeAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares remaining to issue under Rights Exchange Agreement",
        "label": "Shares remaining to issue under Rights Exchange Agreement",
        "terseLabel": "Shares remaining to issue under Rights Exchange Agreement (in shares)"
       }
      }
     },
     "localname": "SharesremainingtoissueunderRightsExchangeAgreement",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ptct_SharestoissueunderRightsExchangeAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares to issue under Rights Exchange Agreement",
        "label": "Shares to issue under Rights Exchange Agreement",
        "terseLabel": "Shares to issue under Rights Exchange Agreement"
       }
      }
     },
     "localname": "SharestoissueunderRightsExchangeAgreement",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/CapitalizationNarrativeDetails",
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ptct_StockAppreciationRightsLiabilityOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the amount of outstanding stock appreciation rights liability.",
        "label": "Stock Appreciation Rights Liability Outstanding",
        "terseLabel": "Stock appreciation rights liability"
       }
      }
     },
     "localname": "StockAppreciationRightsLiabilityOutstanding",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesHierarchyDetails",
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_StockIncentivePlan2013Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to the 2013 Stock Incentive Plan.",
        "label": "Stock Incentive Plan2013 [Member]",
        "terseLabel": "2013 Stock Incentive Plan"
       }
      }
     },
     "localname": "StockIncentivePlan2013Member",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_StockIssuedDuringPeriodSharesExchangeRights": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Exchange Rights",
        "label": "Stock Issued During Period, Shares, Exchange Rights",
        "terseLabel": "Issuance of common stock related to rights exchange (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesExchangeRights",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ptct_StockIssuedDuringPeriodValueExchangeRights": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Exchange Rights",
        "label": "Stock Issued During Period, Value, Exchange Rights",
        "terseLabel": "Issuance of common stock related to rights exchange"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueExchangeRights",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited",
      "http://www.ptcbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_Termforletterofcredit": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term for letter of credit",
        "label": "Term for letter of credit",
        "terseLabel": "Term for letter of credit (in years)"
       }
      }
     },
     "localname": "Termforletterofcredit",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ptct_TheCampusMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Campus [Member]",
        "label": "The Campus [Member]",
        "terseLabel": "The Campus"
       }
      }
     },
     "localname": "TheCampusMember",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_UnrealizedGainLossonConvertibleSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unrealized Gain (Loss) on Convertible Securities",
        "label": "Unrealized Gain (Loss) on Convertible Securities",
        "terseLabel": "Unrealized loss on ClearPoint convertible debt security"
       }
      }
     },
     "localname": "UnrealizedGainLossonConvertibleSecurities",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_UpfrontLicensingFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Upfront Licensing Fee",
        "label": "Upfront Licensing Fee",
        "terseLabel": "Upfront licensing fee"
       }
      }
     },
     "localname": "UpfrontLicensingFee",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/IntangibleassetsandgoodwillNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_WellcomeTrustLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to The Wellcome Trust Limited.",
        "label": "Wellcome Trust Limited [Member]",
        "terseLabel": "Wellcome trust"
       }
      }
     },
     "localname": "WellcomeTrustLimitedMember",
     "nsuri": "http://www.ptcbio.com/20200630",
     "presentation": [
      "http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r51",
      "r101"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/AcquisitionsNarrativeDetails",
      "http://www.ptcbio.com/role/CapitalizationNarrativeDetails",
      "http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/IntangibleassetsandgoodwillNarrativeDetails",
      "http://www.ptcbio.com/role/LeasesNarrativeDetails",
      "http://www.ptcbio.com/role/RevenuerecognitionNarrativeDetails",
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CapitalizationNarrativeDetails",
      "http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails",
      "http://www.ptcbio.com/role/LeasesNarrativeDetails",
      "http://www.ptcbio.com/role/RevenuerecognitionNarrativeDetails",
      "http://www.ptcbio.com/role/RevenuerecognitionPerformanceObligationsDetails",
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails",
      "http://www.ptcbio.com/role/StockawardplanShareBaseCompensationDetails",
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails",
      "http://www.ptcbio.com/role/LeasesNarrativeDetails",
      "http://www.ptcbio.com/role/RevenuerecognitionNarrativeDetails",
      "http://www.ptcbio.com/role/RevenuerecognitionPerformanceObligationsDetails",
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails",
      "http://www.ptcbio.com/role/StockawardplanShareBaseCompensationDetails",
      "http://www.ptcbio.com/role/StockawardplanSharebasedcompensationexpenseDetails",
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r125",
      "r217",
      "r220",
      "r374",
      "r375"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited",
      "http://www.ptcbio.com/role/RevenuerecognitionNarrativeDetails",
      "http://www.ptcbio.com/role/RevenuerecognitionPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited",
      "http://www.ptcbio.com/role/RevenuerecognitionNarrativeDetails",
      "http://www.ptcbio.com/role/RevenuerecognitionPerformanceObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CapitalizationNarrativeDetails",
      "http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesFairValueMeasurementInputsandValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails",
      "http://www.ptcbio.com/role/IntangibleassetsandgoodwillNarrativeDetails",
      "http://www.ptcbio.com/role/LeasesNarrativeDetails",
      "http://www.ptcbio.com/role/RevenuerecognitionNarrativeDetails",
      "http://www.ptcbio.com/role/RevenuerecognitionPerformanceObligationsDetails",
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails",
      "http://www.ptcbio.com/role/StockawardplanShareBaseCompensationDetails",
      "http://www.ptcbio.com/role/StockawardplanSharebasedcompensationexpenseDetails",
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CapitalizationNarrativeDetails",
      "http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesFairValueMeasurementInputsandValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails",
      "http://www.ptcbio.com/role/IntangibleassetsandgoodwillNarrativeDetails",
      "http://www.ptcbio.com/role/LeasesNarrativeDetails",
      "http://www.ptcbio.com/role/RevenuerecognitionNarrativeDetails",
      "http://www.ptcbio.com/role/RevenuerecognitionPerformanceObligationsDetails",
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails",
      "http://www.ptcbio.com/role/StockawardplanShareBaseCompensationDetails",
      "http://www.ptcbio.com/role/StockawardplanSharebasedcompensationexpenseDetails",
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Name of Property [Axis]",
        "terseLabel": "Name of Property [Axis]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Name of Property [Domain]",
        "terseLabel": "Name of Property [Domain]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/AcquisitionsNarrativeDetails",
      "http://www.ptcbio.com/role/CapitalizationNarrativeDetails",
      "http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/IntangibleassetsandgoodwillNarrativeDetails",
      "http://www.ptcbio.com/role/LeasesNarrativeDetails",
      "http://www.ptcbio.com/role/RevenuerecognitionNarrativeDetails",
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Restatement [Axis]",
        "terseLabel": "Restatement [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Restatement [Domain]",
        "terseLabel": "Restatement [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r126",
      "r217",
      "r221",
      "r376",
      "r391",
      "r393"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted Average [Member]"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CapitalizationNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/IntangibleassetsandgoodwillNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_NJ": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "NEW JERSEY",
        "terseLabel": "NEW JERSEY"
       }
      }
     },
     "localname": "NJ",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Accountspayableandaccruedexpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/AccountspayableandaccruedexpensesNarrativeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued expenses",
        "totalLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/AccountspayableandaccruedexpensesNarrativeDetails",
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/AccountspayableandaccruedexpensesNarrativeDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/AccountspayableandaccruedexpensesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization of discounts on investments, net"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r39"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/AccountspayableandaccruedexpensesNarrativeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/AccountspayableandaccruedexpensesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r53",
      "r54",
      "r55",
      "r59",
      "r60"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Unrealized Gains/(Losses) On Marketable Securities,\u00a0net of\u00a0tax"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/OthercomprehensiveincomelossandaccumulatedothercomprehensiveitemsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Other comprehensive income (loss) and accumulated other comprehensive items"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/OthercomprehensiveincomelossandaccumulatedothercomprehensiveitemsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r57",
      "r58",
      "r59"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/OthercomprehensiveincomelossandaccumulatedothercomprehensiveitemsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r56",
      "r59",
      "r60",
      "r291"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "AOCI Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.ptcbio.com/role/OthercomprehensiveincomelossandaccumulatedothercomprehensiveitemsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r52",
      "r59",
      "r60",
      "r291"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/OthercomprehensiveincomelossandaccumulatedothercomprehensiveitemsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt": {
     "auth_ref": [
      "r196"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.",
        "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt",
        "terseLabel": "Adjustments to additional paid in capital, equity component of convertible debt"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r226",
      "r228",
      "r262",
      "r263"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r228",
      "r256",
      "r261"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails",
      "http://www.ptcbio.com/role/StockawardplanSharebasedcompensationexpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r127",
      "r150",
      "r152",
      "r153"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "terseLabel": "Allowance for doubtful accounts receivable"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease)",
        "terseLabel": "Accounts receivable, allowance for credit loss,"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AlternativeInvestmentMeasurementInput": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of input used to measure alternative investment.",
        "label": "Alternative Investment, Measurement Input",
        "terseLabel": "Alternative Investment, Measurement Input"
       }
      }
     },
     "localname": "AlternativeInvestmentMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesFairValueMeasurementInputsandValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r74",
      "r89",
      "r316"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/DebtInterestExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r72",
      "r89",
      "r318"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.ptcbio.com/role/DebtInterestExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited",
      "http://www.ptcbio.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r89",
      "r177",
      "r183"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of acquired intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited",
      "http://www.ptcbio.com/role/IntangibleassetsandgoodwillNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Total shares excluded from calculation (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/NetlosspershareAntidilutiveDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/NetlosspershareAntidilutiveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Net loss per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/NetlosspershareAntidilutiveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/NetlosspershareAntidilutiveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Area of real estate property"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/IntangibleassetsandgoodwillNarrativeDetails",
      "http://www.ptcbio.com/role/RevenuerecognitionNarrativeDetails",
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r141",
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "terseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesAvailableforsaleDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesMarketablesecuritiesDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesUnrealizedLossPositionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r123",
      "r350",
      "r365"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r50"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r135"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesAvailableforsaleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross\u00a0Unrealized, Gain"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesAvailableforsaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r136"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesAvailableforsaleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross\u00a0Unrealized, Loss"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesAvailableforsaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r132",
      "r158"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesAvailableforsaleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesAvailableforsaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain": {
     "auth_ref": [
      "r135"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Unrealized Gain",
        "terseLabel": "Debt Securities, Available-for-sale, Unrealized Gain"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss": {
     "auth_ref": [
      "r136"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss",
        "terseLabel": "Unrealized loss"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]",
        "terseLabel": "Unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesUnrealizedLossPositionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r137",
      "r139",
      "r358"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value",
        "terseLabel": "Total Marketable securities, Less Than 12 Months"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesMarketablesecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r130",
      "r133",
      "r158"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesAvailableforsaleDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Marketable securities",
        "verboseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesAvailableforsaleDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesHierarchyDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r229",
      "r258"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesFairValueMeasurementInputsandValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails",
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails",
      "http://www.ptcbio.com/role/StockawardplanRestrictedStockDetails",
      "http://www.ptcbio.com/role/StockawardplanShareBaseCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of significant accounting policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Summaryofsignificantaccountingpolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/AcquisitionsPreliminaryAllocationofpurchasepriceDetails",
      "http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesFairValueMeasurementInputsandValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails",
      "http://www.ptcbio.com/role/IntangibleassetsandgoodwillNarrativeDetails",
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r277",
      "r278"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/AcquisitionsPreliminaryAllocationofpurchasepriceDetails",
      "http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesFairValueMeasurementInputsandValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails",
      "http://www.ptcbio.com/role/IntangibleassetsandgoodwillNarrativeDetails",
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "terseLabel": "Equity Interest Issued, number of shares (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/AcquisitionsNarrativeDetails",
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1": {
     "auth_ref": [
      "r88",
      "r285"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of right to a contingent consideration asset.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset",
        "negatedTerseLabel": "Change in the fair value of deferred and contingent consideration",
        "terseLabel": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r88",
      "r285"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Change in valuation of deferred and contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r281",
      "r282"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent consideration payable"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Acquisition"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Acquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r279",
      "r280"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "verboseLabel": "Finite-Lived intangibles"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/IntangibleassetsandgoodwillNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r0",
      "r32",
      "r91"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents, and restricted cash end of period",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited",
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited",
      "http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesReconciliationofcashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r85",
      "r91",
      "r96"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodStartLabel": "Cash and cash equivalents, and restricted cash beginning of period",
        "terseLabel": "Total Cash, cash equivalents and restricted cash per statement of cash flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited",
      "http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesReconciliationofcashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r85",
      "r315"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails",
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails",
      "http://www.ptcbio.com/role/StockawardplanSharebasedcompensationexpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CapitalizationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r100",
      "r210",
      "r227"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CapitalizationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r223",
      "r305"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.",
        "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesAvailableforsaleDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesMarketablesecuritiesDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesUnrealizedLossPositionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r192",
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Commitmentsandcontingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsMember": {
     "auth_ref": [
      "r16",
      "r191",
      "r353",
      "r364"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements.",
        "label": "Commitments [Member]",
        "terseLabel": "Commitments"
       }
      }
     },
     "localname": "CommitmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesFairValueMeasurementInputsandValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails",
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails",
      "http://www.ptcbio.com/role/StockawardplanSharebasedcompensationexpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized shares (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued shares (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r19",
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, outstanding shares (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.001 par value. Authorized 125,000,000 shares; issued and outstanding\u00a067,240,679 shares at June 30, 2020. Authorized 125,000,000 shares; issued and\u00a0outstanding 61,935,870 shares at December\u00a031, 2019."
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r63",
      "r65",
      "r66"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "terseLabel": "Other comprehensive income (loss) and accumulated other comprehensive items"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Othercomprehensiveincomelossandaccumulatedothercomprehensiveitems"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesFairValueMeasurementInputsandValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesFairValueMeasurementInputsandValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r212",
      "r213",
      "r218"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Contract with Customer, Liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/RevenuerecognitionPerformanceObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r212",
      "r213",
      "r218"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r212",
      "r213",
      "r218"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue- long term"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r219"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Performance obligations satisfied in current period"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible debt"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtConvertibleNotesDetails",
      "http://www.ptcbio.com/role/DebtInterestExpenseDetails",
      "http://www.ptcbio.com/role/DebtNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.",
        "label": "Convertible Debt Securities [Member]",
        "terseLabel": "Deferred consideration payable"
       }
      }
     },
     "localname": "ConvertibleDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesHierarchyDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.",
        "label": "Convertible Debt [Table Text Block]",
        "terseLabel": "Summary of convertible notes"
       }
      }
     },
     "localname": "ConvertibleDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r223",
      "r225",
      "r377"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesAvailableforsaleDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesMarketablesecuritiesDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesUnrealizedLossPositionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r351",
      "r352",
      "r363"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtConvertibleNotesDetails",
      "http://www.ptcbio.com/role/DebtInterestExpenseDetails",
      "http://www.ptcbio.com/role/DebtNarrativeDetails",
      "http://www.ptcbio.com/role/DebtTables",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails",
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Debt instrument, basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Conversion price per share (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r42",
      "r204",
      "r205",
      "r207"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Conversion ratio"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Convertible, Remaining Discount Amortization Period",
        "terseLabel": "Remaining contractual life of the convertible notes"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Consecutive trading days, period"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "terseLabel": "Stock price trigger"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "terseLabel": "Trading days, number"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentCumulativeSinkingFundPayments": {
     "auth_ref": [
      "r204"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cumulative amount paid into a fund, which is used to retire the debt instrument.",
        "label": "Debt Instrument, Cumulative Sinking Fund Payments",
        "terseLabel": "Sinking fund"
       }
      }
     },
     "localname": "DebtInstrumentCumulativeSinkingFundPayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r317",
      "r319"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/DebtConvertibleNotesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Principal",
        "verboseLabel": "Debt principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtConvertibleNotesDetails",
      "http://www.ptcbio.com/role/DebtNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r311"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Fair value of convertible notes"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r41",
      "r200",
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate of the liability component"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate ( as a percent )"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtConvertibleNotesDetails",
      "http://www.ptcbio.com/role/DebtInterestExpenseDetails",
      "http://www.ptcbio.com/role/DebtNarrativeDetails",
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtConvertibleNotesDetails",
      "http://www.ptcbio.com/role/DebtInterestExpenseDetails",
      "http://www.ptcbio.com/role/DebtNarrativeDetails",
      "http://www.ptcbio.com/role/DebtTables",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails",
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument, Redemption [Line Items]",
        "terseLabel": "Debt Instrument, Redemption [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Redemption price"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentRedemptionTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about debt instruments or arrangements with redemption features. Includes, but is not limited to, description of debt redemption features, percentage price at which debt can be redeemed by the issuer, and period start and end for debt maturity or redemption.",
        "label": "Debt Instrument Redemption [Table]",
        "terseLabel": "Debt Instrument Redemption [Table]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r43",
      "r102",
      "r204",
      "r206",
      "r207",
      "r208",
      "r316",
      "r317",
      "r319",
      "r362"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtConvertibleNotesDetails",
      "http://www.ptcbio.com/role/DebtInterestExpenseDetails",
      "http://www.ptcbio.com/role/DebtNarrativeDetails",
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Term of the convertible notes"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r316",
      "r319"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/DebtConvertibleNotesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedLabel": "Less: Debt discount, net"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross": {
     "auth_ref": [
      "r320"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Line of Credit Arrangements, Gross",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "DebtIssuanceCostsLineOfCreditArrangementsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r134",
      "r158",
      "r164",
      "r167"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss",
        "terseLabel": "Allowance for credit loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in allowance for credit loss of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Period Increase (Decrease)",
        "terseLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Period Increase (Decrease)"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold": {
     "auth_ref": [
      "r165"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease in allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) from sale.",
        "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Securities Sold",
        "terseLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Securities Sold"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesAvailableforsaleDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesUnrealizedLossPositionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff": {
     "auth_ref": [
      "r166"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of writeoff of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Writeoff",
        "terseLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Writeoff"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesAvailableforsaleDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesUnrealizedLossPositionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r146",
      "r162"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesUnrealizedLossPositionsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "negatedTerseLabel": "Securities in an unrealized loss position greater than 12 months",
        "terseLabel": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesAvailableforsaleDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesUnrealizedLossPositionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r146",
      "r162"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesUnrealizedLossPositionsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedTerseLabel": "Securities in an unrealized loss position less than 12 months",
        "terseLabel": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesAvailableforsaleDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesUnrealizedLossPositionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r144",
      "r160"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesUnrealizedLossPositionsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTotalLabel": "Total",
        "terseLabel": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesAvailableforsaleDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesUnrealizedLossPositionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "auth_ref": [
      "r142",
      "r161",
      "r169"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Summary of unrealized losses and fair values of available-for-sale securities in a continuous unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesMember": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.",
        "label": "Debt Securities [Member]",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "DebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesHierarchyDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesUnrealizedLossPositionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r270",
      "r273"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r270",
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "terseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r89",
      "r188"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesUnrealizedLossPositionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r292",
      "r293",
      "r294",
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesUnrealizedLossPositionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock award plan"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Stockawardplan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net loss per share-basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Basic and diluted (in dollars per share)",
        "verboseLabel": "Net loss per share\u2014basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited",
      "http://www.ptcbio.com/role/NetlosspershareNumeratorandDenominatorDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Net loss per share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/NetlosspershareNumeratorandDenominatorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]",
        "terseLabel": "Net loss per share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/NetlosspershareNumeratorandDenominatorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net loss per share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Netlosspershare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r315"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/AccountspayableandaccruedexpensesNarrativeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee compensation, benefits, and related accruals"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/AccountspayableandaccruedexpensesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r257"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average remaining service period for recognition of unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock [Member]"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/NetlosspershareAntidilutiveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of employee stock ownership plan.",
        "label": "Employee Stock Ownership Plan (ESOP) Name [Axis]",
        "terseLabel": "Employee Stock Ownership Plan (ESOP) Name [Axis]"
       }
      }
     },
     "localname": "EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Entities identify multiple employee stock ownership plans by unique name.",
        "label": "Employee Stock Ownership Plan (ESOP), Plan [Domain]",
        "terseLabel": "Employee Stock Ownership Plan (ESOP), Plan [Domain]"
       }
      }
     },
     "localname": "EmployeeStockOwnershipPlanESOPPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/OthercomprehensiveincomelossandaccumulatedothercomprehensiveitemsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r309"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Equity investment in ClearPoint"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1": {
     "auth_ref": [
      "r93",
      "r94",
      "r95"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of escrow deposit disbursements related to property acquisition in noncash investing or financing transactions.",
        "label": "Escrow Deposit Disbursements Related to Property Acquisition",
        "terseLabel": "Escrow"
       }
      }
     },
     "localname": "EscrowDepositDisbursementsRelatedToPropertyAcquisition1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesHierarchyDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Financial assets and liabilities measured at fair value on recurring basis"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesFairValueMeasurementInputsandValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesHierarchyDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r296",
      "r297",
      "r298",
      "r306"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesFairValueMeasurementInputsandValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesHierarchyDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r297",
      "r342"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesFairValueMeasurementInputsandValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesHierarchyDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r305",
      "r306"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesFairValueMeasurementInputsandValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r296",
      "r307"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]",
        "verboseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesHierarchyDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r296",
      "r297",
      "r300",
      "r301",
      "r308"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesFairValueMeasurementInputsandValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesHierarchyDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesHierarchyDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair value of financial instruments and marketable securities"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Fairvalueoffinancialinstrumentsandmarketablesecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r297",
      "r343"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted\u00a0prices in\u00a0active markets\u00a0for identical\u00a0assets (level\u00a01)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r297",
      "r344"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant other observable inputs (level\u00a02)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r297",
      "r345"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant unobservable inputs (level\u00a03)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesFairValueMeasurementInputsandValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesHierarchyDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesFairValueMeasurementInputsandValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Changes in the fair value of warrant liability and SARs liability"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair value of warrant liability"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r302",
      "r306"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r302",
      "r306"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Summary of changes in the fair value of the Company's Level 3 valuation for warrant liability and SARs liability"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesFairValueMeasurementInputsandValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesHierarchyDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r303"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Change in fair value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesFairValueMeasurementInputsandValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "auth_ref": [
      "r304"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesFairValueMeasurementInputsandValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r304"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedTerseLabel": "Payments"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesFairValueMeasurementInputsandValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r302"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Contingent consideration payable- net sales milestones and royalties",
        "verboseLabel": "Liability value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesFairValueMeasurementInputsandValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesHierarchyDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesFairValueMeasurementInputsandValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesHierarchyDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Measurements, Nonrecurring Value Measurement [Abstract]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "FairValueMeasurementsNonrecurringValueMeasurementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesUnrealizedLossPositionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r305",
      "r308"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesHierarchyDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r322",
      "r337"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesLeasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r322"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Finance lease liabilities- current"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r322"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Finance lease liabilities- noncurrent"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/LeasesLeasepaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Payment, Due",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesLeasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/LeasesLeasepaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fifth fiscal year following latest fiscal year.",
        "label": "Finance Lease, Liability, Payments, Due Year Five",
        "terseLabel": "2024 and thereafter"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesLeasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/LeasesLeasepaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Finance Lease, Liability, Payments, Due Year Four",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesLeasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/LeasesLeasepaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in third fiscal year following latest fiscal year.",
        "label": "Finance Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesLeasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/LeasesLeasepaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second fiscal year following latest fiscal year.",
        "label": "Finance Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesLeasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/LeasesLeasepaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in remainder of fiscal year following latest fiscal year ended.",
        "label": "Finance Lease, Liability, Payments, Remainder of Fiscal Year",
        "terseLabel": "2020 (excludes the six months ended June 30, 2020)"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesLeasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r337"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: Imputed Interest expense"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesLeasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r324",
      "r332"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "terseLabel": "Financing cash flows from finance lease"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesCashflowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r321"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under finance lease.",
        "label": "Finance Lease, Right-of-Use Asset",
        "terseLabel": "Finance Lease, Right-of-Use Asset"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r335",
      "r338"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate - finance lease"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails",
      "http://www.ptcbio.com/role/LeasesSupplementalleasetermsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r334",
      "r338"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease terms - finance lease (years)"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesSupplementalleasetermsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r151",
      "r154",
      "r155",
      "r156",
      "r157",
      "r161",
      "r163",
      "r168",
      "r169"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesAvailableforsaleDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesHierarchyDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesUnrealizedLossPositionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/IntangibleassetsandgoodwillNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.ptcbio.com/role/IntangibleassetsandgoodwillFutureAmortizationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/IntangibleassetsandgoodwillFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r184"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/IntangibleassetsandgoodwillFutureAmortizationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/IntangibleassetsandgoodwillFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r184"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/IntangibleassetsandgoodwillFutureAmortizationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/IntangibleassetsandgoodwillFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r184"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/IntangibleassetsandgoodwillFutureAmortizationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/IntangibleassetsandgoodwillFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r178",
      "r179",
      "r182",
      "r186",
      "r347"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesNarrativeDetails",
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/AcquisitionsNarrativeDetails",
      "http://www.ptcbio.com/role/AcquisitionsPreliminaryAllocationofpurchasepriceDetails",
      "http://www.ptcbio.com/role/IntangibleassetsandgoodwillNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r178",
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesNarrativeDetails",
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r182"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/IntangibleassetsandgoodwillFutureAmortizationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/IntangibleassetsandgoodwillFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "terseLabel": "Remaining amortization period"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/IntangibleassetsandgoodwillNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "auth_ref": [
      "r90",
      "r312",
      "r313",
      "r314"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "negatedLabel": "Unrealized foreign currency transaction (gains) losses, net"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedTerseLabel": "Loss on disposal of asset"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r173",
      "r174"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/AcquisitionsPreliminaryAllocationofpurchasepriceDetails",
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited",
      "http://www.ptcbio.com/role/IntangibleassetsandgoodwillNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r97",
      "r175"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy": {
     "auth_ref": [
      "r97",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for indefinite-lived intangible assets (that is, those intangible assets not subject to amortization). This accounting policy also may address how the entity assesses whether events and circumstances continue to support an indefinite useful life and how the entity assesses and measures impairment of such assets.",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Indefinite-lived intangible assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue": {
     "auth_ref": [
      "r143"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesUnrealizedLossPositionsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity), in unrealized loss position.",
        "label": "Debt Securities, Held-to-maturity, Unrealized Loss Position, Fair Value",
        "terseLabel": "Debt Securities, Held-to-maturity, Unrealized Loss Position, Fair Value",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesAvailableforsaleDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesUnrealizedLossPositionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue": {
     "auth_ref": [
      "r146"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesUnrealizedLossPositionsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity), in continuous unrealized loss position for less than 12 months.",
        "label": "Debt Securities, Held-to-maturity, Continuous Unrealized Loss Position, Less than 12 Months, Fair Value",
        "terseLabel": "Securities in an unrealized loss position less than 12 months"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesAvailableforsaleDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesUnrealizedLossPositionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue": {
     "auth_ref": [
      "r146"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesUnrealizedLossPositionsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity), in continuous unrealized loss position for 12 months or longer.",
        "label": "Debt Securities, Held-to-maturity, Continuous Unrealized Loss Position, 12 Months or Longer, Fair Value",
        "terseLabel": "Securities in an unrealized loss position greater than 12 months"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesAvailableforsaleDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesUnrealizedLossPositionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r70",
      "r105",
      "r348",
      "r355",
      "r373"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income tax expense"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanSharebasedcompensationexpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanSharebasedcompensationexpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r99",
      "r122",
      "r275"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r67",
      "r97",
      "r268",
      "r269",
      "r271",
      "r272",
      "r274",
      "r276",
      "r392"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r92"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDepositOtherAssets": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.",
        "label": "Increase (Decrease) in Deposit Assets",
        "negatedLabel": "Deposits and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInDepositOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Receivables",
        "negatedLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInReceivables",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefinitelivedIntangibleAssetsAcquired": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition.",
        "label": "Indefinite-lived Intangible Assets Acquired",
        "terseLabel": "Total allocation of IPR&amp;D assets"
       }
      }
     },
     "localname": "IndefinitelivedIntangibleAssetsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/IntangibleassetsandgoodwillNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible assets and goodwill"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Intangibleassetsandgoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r176",
      "r180"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r74",
      "r201"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/DebtInterestExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/DebtInterestExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.",
        "label": "Interest Expense, Debt, Excluding Amortization",
        "terseLabel": "Contractual interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebtExcludingAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest expense, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r84",
      "r86",
      "r92"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesInventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r1",
      "r49",
      "r171"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesInventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory, net",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited",
      "http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesInventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesInventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in progress"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r172"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Inventory write-down"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentHoldingsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Investment Holdings [Line Items]",
        "terseLabel": "Marketable securities on the balance sheet"
       }
      }
     },
     "localname": "InvestmentHoldingsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesMarketablesecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentHoldingsTable": {
     "auth_ref": [
      "r381",
      "r384",
      "r387",
      "r388"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The investment holdings table is used for any listing of investments. The \"Investment [Axis]\" identifies the investment for which the line items apply. The other axes are used for categorizing the investments and creating useful subtotals. These axes cover different categorizations. The appropriate axes are expected to be used. Additional axes can be added for alternative categorizations.",
        "label": "Investment Holdings [Table]",
        "terseLabel": "Investment Holdings [Table]"
       }
      }
     },
     "localname": "InvestmentHoldingsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesMarketablesecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentOwnedBalancePrincipalAmount": {
     "auth_ref": [
      "r378",
      "r382",
      "r385",
      "r389"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For investments which are quantified by principal amount, the principle balance held at close of period.",
        "label": "Investment Owned, Balance, Principal Amount",
        "terseLabel": "Shares owned"
       }
      }
     },
     "localname": "InvestmentOwnedBalancePrincipalAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r380",
      "r383",
      "r386",
      "r390"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesMarketablesecuritiesDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r380",
      "r383",
      "r386",
      "r390"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investment"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesMarketablesecuritiesDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating Leases, Rent Expense",
        "terseLabel": "Operating Leases, Rent Expense"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseArrangementTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.",
        "label": "Lease Arrangement, Type [Axis]",
        "terseLabel": "Lease Arrangement, Type [Axis]"
       }
      }
     },
     "localname": "LeaseArrangementTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseArrangementTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.",
        "label": "Lease Arrangement, Type [Domain]",
        "terseLabel": "Lease Arrangement, Type [Domain]"
       }
      }
     },
     "localname": "LeaseArrangementTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r336",
      "r338"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/LeasesLeasecostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total operating lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesLeasecostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Lease costs"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeaseTermOfContract1": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Finance Lease, Term of Contract",
        "terseLabel": "Lessee, Finance Lease, Term of Contract"
       }
      }
     },
     "localname": "LesseeFinanceLeaseTermOfContract1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/LeasesLeasepaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ptcbio.com/role/LeasesLeasepaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "terseLabel": "Aggregate rent, Initial term",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesLeasepaymentsDetails",
      "http://www.ptcbio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/LeasesLeasepaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesLeasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/LeasesLeasepaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesLeasepaymentsDetails",
      "http://www.ptcbio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/LeasesLeasepaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesLeasepaymentsDetails",
      "http://www.ptcbio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/LeasesLeasepaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year",
        "terseLabel": "2020 (excludes the six months ended June 30, 2020)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesLeasepaymentsDetails",
      "http://www.ptcbio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/LeasesLeasepaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: Imputed Interest expense"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesLeasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal Term ( in years )"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Term of Contract ( in years )"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letters of Credit"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r25",
      "r354",
      "r369"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r35"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of credit facility, maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r15",
      "r197",
      "r352",
      "r366"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/DebtConvertibleNotesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Net carrying amount",
        "totalLabel": "Net carrying amount"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtConvertibleNotesDetails",
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "terseLabel": "Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited",
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "verboseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited",
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Long-term Debt [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtConvertibleNotesDetails",
      "http://www.ptcbio.com/role/DebtInterestExpenseDetails",
      "http://www.ptcbio.com/role/DebtNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r43",
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtConvertibleNotesDetails",
      "http://www.ptcbio.com/role/DebtInterestExpenseDetails",
      "http://www.ptcbio.com/role/DebtNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r2",
      "r38"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesRealizedGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).",
        "label": "Marketable Securities, Realized Gain (Loss)",
        "terseLabel": "Marketable Securities, Realized Gain (Loss)"
       }
      }
     },
     "localname": "MarketableSecuritiesRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Schedule of marketable securities on the balance sheet"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Measurement Input, Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Measurement Input, Expected Term"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputOptionVolatilityMember": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns.",
        "label": "Measurement Input, Option Volatility [Member]",
        "terseLabel": "Measurement Input, Option Volatility"
       }
      }
     },
     "localname": "MeasurementInputOptionVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Measurement Input, Risk Free Interest Rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using share price of saleable stock.",
        "label": "Measurement Input, Share Price [Member]",
        "terseLabel": "Measurement Input, Share Price"
       }
      }
     },
     "localname": "MeasurementInputSharePriceMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesFairValueMeasurementInputsandValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesFairValueMeasurementInputsandValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r111",
      "r119"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "The Company"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/TheCompany"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r85",
      "r87",
      "r90"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r61",
      "r64",
      "r71",
      "r90",
      "r109",
      "r356",
      "r372"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.ptcbio.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss attributable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited",
      "http://www.ptcbio.com/role/ConsolidatedStatementsofComprehensiveLossunaudited",
      "http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited",
      "http://www.ptcbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r105",
      "r106"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/NetlosspershareNumeratorandDenominatorDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/NetlosspershareNumeratorandDenominatorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently issued accounting standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Non-US"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r93",
      "r94",
      "r95"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Intangible Assets Acquired",
        "terseLabel": "Acquisition of product rights and licenses"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncollaborativeArrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangement Other than Collaborative [Member]",
        "terseLabel": "Non-collaborative Arrangement Transactions"
       }
      }
     },
     "localname": "NoncollaborativeArrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/IntangibleassetsandgoodwillNarrativeDetails",
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "terseLabel": "Summary of information on the Company's restricted stock"
       }
      }
     },
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "terseLabel": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r329",
      "r338"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/LeasesLeasecostsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Fixed lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesLeasecostsDetails",
      "http://www.ptcbio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r323"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease, expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r322"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/LeasesLeasepaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total operating lease liability",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesBalancesheetDetails",
      "http://www.ptcbio.com/role/LeasesLeasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r322"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities- current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesBalancesheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r322"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities- noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesBalancesheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r325",
      "r332"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesCashflowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r321"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease ROU asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesBalancesheetDetails",
      "http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r335",
      "r338"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate - operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesSupplementalleasetermsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r334",
      "r338"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease terms - operating leases (years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesSupplementalleasetermsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r39"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/AccountspayableandaccruedexpensesNarrativeDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/AccountspayableandaccruedexpensesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Commitments [Abstract]",
        "terseLabel": "Other Commitments [Abstract]"
       }
      }
     },
     "localname": "OtherCommitmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r288",
      "r289",
      "r290"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Unrealized gain on marketable securities, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited",
      "http://www.ptcbio.com/role/ConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r288",
      "r289",
      "r290"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "verboseLabel": "Foreign currency translation (loss) gain, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r59",
      "r68"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/OthercomprehensiveincomelossandaccumulatedothercomprehensiveitemsNarrativeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "verboseLabel": "Other comprehensive income before reclassifications"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/OthercomprehensiveincomelossandaccumulatedothercomprehensiveitemsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r62",
      "r65",
      "r68",
      "r203"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/OthercomprehensiveincomelossandaccumulatedothercomprehensiveitemsNarrativeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/OthercomprehensiveincomelossandaccumulatedothercomprehensiveitemsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r62",
      "r65",
      "r288",
      "r289",
      "r290"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Comprehensive income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "verboseLabel": "Other comprehensive (loss) income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherDebtSecuritiesMember": {
     "auth_ref": [
      "r142",
      "r159",
      "r223",
      "r305"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investments in debt securities classified as other.",
        "label": "Other Debt Obligations [Member]",
        "terseLabel": "Government obligations"
       }
      }
     },
     "localname": "OtherDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesAvailableforsaleDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesMarketablesecuritiesDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesUnrealizedLossPositionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r39"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "verboseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r267"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of other research and development expense.",
        "label": "Other Research and Development Expense",
        "terseLabel": "Other Research and Development Expense"
       }
      }
     },
     "localname": "OtherResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaidInKindInterest": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Paid-in-Kind Interest",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "PaidInKindInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r79",
      "r283"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Cash consideration"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "negatedTerseLabel": "Purchase of equity investment"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Acquisition of product rights and licenses"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r131"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of fixed assets"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r229",
      "r258"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CapitalizationNarrativeDetails",
      "http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails",
      "http://www.ptcbio.com/role/StockawardplanShareBaseCompensationDetails",
      "http://www.ptcbio.com/role/StockawardplanSharebasedcompensationexpenseDetails",
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CapitalizationNarrativeDetails",
      "http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails",
      "http://www.ptcbio.com/role/StockawardplanShareBaseCompensationDetails",
      "http://www.ptcbio.com/role/StockawardplanSharebasedcompensationexpenseDetails",
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesHierarchyDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r3",
      "r30",
      "r31"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "terseLabel": "Net proceeds from issuance of convertible notes"
       }
      }
     },
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Net proceeds from public offerings"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r82",
      "r103"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Proceeds from lines of credit"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Sale and redemption of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r81",
      "r259"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Net product revenue",
        "verboseLabel": "Product"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r189",
      "r371"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Fixed assets, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r20",
      "r26",
      "r370",
      "r379"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": {
     "auth_ref": [
      "r26",
      "r97",
      "r128"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.",
        "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/OthercomprehensiveincomelossandaccumulatedothercomprehensiveitemsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": {
     "auth_ref": [
      "r59",
      "r68"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/OthercomprehensiveincomelossandaccumulatedothercomprehensiveitemsNarrativeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.",
        "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent",
        "negatedTerseLabel": "Amounts reclassified from other comprehensive items"
       }
      }
     },
     "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/OthercomprehensiveincomelossandaccumulatedothercomprehensiveitemsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r83"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "terseLabel": "Repayments of debt"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r83",
      "r103"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Repayments of Lines of Credit",
        "terseLabel": "Repayments of lines of credit"
       }
      }
     },
     "localname": "RepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SubsequenteventsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfSecuredDebt": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.",
        "label": "Repayments of Secured Debt",
        "negatedTerseLabel": "Repayment of senior secured term loan"
       }
      }
     },
     "localname": "RepaymentsOfSecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r267",
      "r395"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited",
      "http://www.ptcbio.com/role/IntangibleassetsandgoodwillNarrativeDetails",
      "http://www.ptcbio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanSharebasedcompensationexpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r96",
      "r349",
      "r367"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash included in deposits and other assets"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesReconciliationofcashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Unvested restricted stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails",
      "http://www.ptcbio.com/role/StockawardplanRestrictedStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r22",
      "r209",
      "r368"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "verboseLabel": "Retained earnings (accumulated deficit)"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited",
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r216",
      "r217"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r216",
      "r217"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited",
      "http://www.ptcbio.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r98",
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Revenuerecognition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]",
        "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]"
       }
      }
     },
     "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/RevenuerecognitionNarrativeDetails",
      "http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information when using transition method for cumulative effect in initial period of application for revenue from contract with customer.",
        "label": "Revenue, Initial Application Period Cumulative Effect Transition [Table]",
        "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Table]"
       }
      }
     },
     "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/RevenuerecognitionNarrativeDetails",
      "http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r214"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Deferred consideration payable"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/RevenuerecognitionPerformanceObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/RevenuerecognitionPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Revenue, performance obligation, period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/RevenuerecognitionPerformanceObligationsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in CCYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/RevenuerecognitionPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/RevenuerecognitionPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r69",
      "r120",
      "r121",
      "r124"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r333",
      "r338"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for finance lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited",
      "http://www.ptcbio.com/role/LeasesCashflowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r333",
      "r338"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited",
      "http://www.ptcbio.com/role/LeasesCashflowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Consideration received on transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CapitalizationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares issued in transaction (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CapitalizationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Price per share (in USD per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CapitalizationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of components of accounts payable and accrued expenses"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/AccountspayableandaccruedexpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Summary of other comprehensive income (loss) and the changes in accumulated other comprehensive items"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/OthercomprehensiveincomelossandaccumulatedothercomprehensiveitemsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/NetlosspershareAntidilutiveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of historical dilutive common share equivalents outstanding"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/NetlosspershareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesAvailableforsaleDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesUnrealizedLossPositionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Summary of marketable securities accounted for as available-for-sale securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r138",
      "r140",
      "r145",
      "r146",
      "r147",
      "r148",
      "r357",
      "r359"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesAvailableforsaleDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesUnrealizedLossPositionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of computation of basic and diluted net loss available to common stockholders"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/NetlosspershareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r228",
      "r255",
      "r261"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of share-based compensation expense recorded in the statement of operations"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r296",
      "r297"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of financial assets and liabilities that are required to be measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r178",
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/AcquisitionsNarrativeDetails",
      "http://www.ptcbio.com/role/AcquisitionsPreliminaryAllocationofpurchasepriceDetails",
      "http://www.ptcbio.com/role/IntangibleassetsandgoodwillNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r9",
      "r27",
      "r28",
      "r29"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r10",
      "r96",
      "r349",
      "r367"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Reconciliation of cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r229",
      "r258"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails",
      "http://www.ptcbio.com/role/StockawardplanRestrictedStockDetails",
      "http://www.ptcbio.com/role/StockawardplanShareBaseCompensationDetails",
      "http://www.ptcbio.com/role/StockawardplanSharebasedcompensationexpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r234",
      "r244",
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of assumptions used to estimate fair values of grants made on the date of grant"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Future amortization expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/IntangibleassetsandgoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r73",
      "r170"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanSharebasedcompensationexpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServicingAssetAtFairValueAmountRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Servicing Asset at Fair Value, Amount [Roll Forward]",
        "terseLabel": "Level 3 roll forward"
       }
      }
     },
     "localname": "ServicingAssetAtFairValueAmountRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesFairValueMeasurementInputsandValuationTechniquesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Amortization of discounts on investments, net"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period",
        "terseLabel": "Award requisite service period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanRestrictedStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanRestrictedStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Grants in period (in shares)",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails",
      "http://www.ptcbio.com/role/StockawardplanRestrictedStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanRestrictedStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Balance at the end of the period (in shares)",
        "periodStartLabel": "Balance at the beginning of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanRestrictedStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number\u00a0of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanRestrictedStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Balance at the end of the period (in dollars per share)",
        "periodStartLabel": "Balance at the beginning of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanRestrictedStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date\u00a0Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanRestrictedStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanRestrictedStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanRestrictedStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Valuation assumptions"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanShareBaseCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails",
      "http://www.ptcbio.com/role/StockawardplanShareBaseCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails",
      "http://www.ptcbio.com/role/StockawardplanShareBaseCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Stock option plan",
        "verboseLabel": "Restricted Stock Awards and Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails",
      "http://www.ptcbio.com/role/StockawardplanRestrictedStockDetails",
      "http://www.ptcbio.com/role/StockawardplanShareBaseCompensationDetails",
      "http://www.ptcbio.com/role/StockawardplanSharebasedcompensationexpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails",
      "http://www.ptcbio.com/role/StockawardplanSharebasedcompensationexpenseDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted- average remaining contractual term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanShareBaseCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at the end of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanShareBaseCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable at the end of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanShareBaseCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited/Cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanShareBaseCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails",
      "http://www.ptcbio.com/role/StockawardplanShareBaseCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r258"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Outstanding at the end of the period (in dollars)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanShareBaseCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r236",
      "r258"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at the end of the period (in shares)",
        "periodStartLabel": "Outstanding at the beginning of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanShareBaseCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number\u00a0of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanShareBaseCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at the end of the period (in dollars per share)",
        "periodStartLabel": "Outstanding at the beginning of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanShareBaseCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanShareBaseCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r248"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Vested or Expected to vest at the end of the period (in dollars)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanShareBaseCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Vested or Expected to vest at the end of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanShareBaseCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Vested or Expected to vest at the end of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanShareBaseCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r227",
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesFairValueMeasurementInputsandValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails",
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails",
      "http://www.ptcbio.com/role/StockawardplanRestrictedStockDetails",
      "http://www.ptcbio.com/role/StockawardplanShareBaseCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanShareBaseCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited/Cancelled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanShareBaseCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanShareBaseCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "verboseLabel": "Fair value of shares (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r250",
      "r260"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails",
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails",
      "http://www.ptcbio.com/role/StockawardplanShareBaseCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r258"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable at the end of the period (in dollars)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanShareBaseCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable at the end of the period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanShareBaseCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding at the end of the period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanShareBaseCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested or Expected to vest at the end of the period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanShareBaseCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares",
        "terseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price of common stock, percent"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r330",
      "r338"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/LeasesLeasecostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term Lease, Cost",
        "terseLabel": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesLeasecostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails",
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails",
      "http://www.ptcbio.com/role/StockawardplanSharebasedcompensationexpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r45",
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/OthercomprehensiveincomelossandaccumulatedothercomprehensiveitemsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "verboseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited",
      "http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited",
      "http://www.ptcbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited",
      "http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited",
      "http://www.ptcbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period.",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "SARs"
       }
      }
     },
     "localname": "StockAppreciationRightsSARSMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesFairValueMeasurementInputsandValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesWarrantsandSARsDetails",
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r18",
      "r19",
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Payments for asset acquisitions, shares (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/AcquisitionsNarrativeDetails",
      "http://www.ptcbio.com/role/CapitalizationNarrativeDetails",
      "http://www.ptcbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r18",
      "r19",
      "r203",
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock in connection with an employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r18",
      "r19",
      "r203",
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock related to equity offering (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r18",
      "r19",
      "r203",
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Restricted stock vesting and issuance, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r18",
      "r19",
      "r203",
      "r209",
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)",
        "terseLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.ptcbio.com/role/StockawardplanShareBaseCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r45",
      "r203",
      "r209"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Payments for asset acquisitions, share, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/AcquisitionsNarrativeDetails",
      "http://www.ptcbio.com/role/CapitalizationNarrativeDetails",
      "http://www.ptcbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r18",
      "r19",
      "r203",
      "r209"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock in connection with an employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r18",
      "r19",
      "r203",
      "r209"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock related to equity offering"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r203",
      "r209"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "verboseLabel": "Restricted stock vesting and issuance, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r45",
      "r203",
      "r209"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Stock option"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockawardplanNarrativeDetails",
      "http://www.ptcbio.com/role/StockawardplanShareBaseCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r19",
      "r23",
      "r24",
      "r129"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance at the end of the period",
        "periodStartLabel": "Balance at the beginning of the period",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited",
      "http://www.ptcbio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.ptcbio.com/role/OthercomprehensiveincomelossandaccumulatedothercomprehensiveitemsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Capitalization"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Capitalization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityPeriodIncreaseDecrease": {
     "auth_ref": [
      "r203",
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) in stockholders' equity during the period.",
        "label": "Stockholders' Equity, Period Increase (Decrease)",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "StockholdersEquityPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SubsequenteventsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SubsequenteventsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SubsequenteventsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SubsequenteventsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SubsequenteventsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Subsequentevents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activity"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesAvailableforsaleDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesHierarchyDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesUnrealizedLossPositionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CommitmentsandcontingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/IntangibleassetsandgoodwillNarrativeDetails",
      "http://www.ptcbio.com/role/RevenuerecognitionNarrativeDetails",
      "http://www.ptcbio.com/role/TheCompanyNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/DebtConvertibleNotesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.",
        "label": "Unamortized Debt Issuance Expense",
        "negatedLabel": "Less: Debt issuance costs"
       }
      }
     },
     "localname": "UnamortizedDebtIssuanceExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.",
        "label": "Unrealized Gain (Loss) on Investments",
        "negatedTerseLabel": "Unrealized loss on equity investment",
        "verboseLabel": "Unrealized gain (loss) on equity investment"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofCashFlowsunaudited",
      "http://www.ptcbio.com/role/FairvalueoffinancialinstrumentsandmarketablesecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r331",
      "r338"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/LeasesLeasecostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesLeasecostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Denominator for basic and diluted net loss per share (in shares)",
        "verboseLabel": "Basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited",
      "http://www.ptcbio.com/role/NetlosspershareNumeratorandDenominatorDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted-average shares outstanding:",
        "verboseLabel": "Denominator"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsofOperationsunaudited",
      "http://www.ptcbio.com/role/NetlosspershareNumeratorandDenominatorDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1377-109256"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5074-111524"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5144-111524"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27232-111563"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27337-111563"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27340-111563"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922890-210455"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(g)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=77929361&loc=d3e25218-109307"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4852-112606"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=51819886&loc=SL6014347-161799"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "30",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116868840&loc=d3e2207-128464"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=68176171&loc=SL68176184-208336"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62557-112803"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62652-112803"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=d3e19393-158473"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=6488278&loc=d3e604059-122996"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(2)(i))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12.Column B)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12C(1)(a))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12C)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12C.Column B)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611322-123010"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14.Column B)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611322-123010"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28)",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r396": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r397": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r398": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r399": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r401": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6904-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "8",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "http://asc.fasb.org/topic&trid=2134417"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>95
<FILENAME>0001070081-20-000128-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001070081-20-000128-xbrl.zip
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MEF,Y=PX>:?OP\OCMV^.CRP^(XCA_?W9\?OGO$4TN,BY(!/$F5V4U3Y>X=4]
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M$@^M]%,P,5=Z1!M9U%WM?R!]Y!:C]^=@]!Z/":.WOJ/?*XBHN0DF,I*N\%T
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MQ<VMOR!"9V=,2B+'RDM0#0TB'4<HHEE*8_BN#'YIRK1*4O:\%4V-6J4^YC[
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M\DY!H/7O%6%?[+F&2:W3%:>_V&XPY*7(E-1-B;.F2J^QYODUX\RPXI9%EA)
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M;"\?6M-P)BR$AUB7IS0'U8YS.#%Y X/7\>IMHM;73M0Z'%.BU@CU%+.?C$/
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MIBAZ4"AR9K%F:2<N##;+> +2BDDFTIEFW.>H5FTYI)G#*5NQO38GXOA8P:)
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M#&!(;B*/+$AB:9@RI!).*B+/[K *W5T?&MR*5S>5H9(<-"*G\(+\RL&'W+D
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MEQ5Q=-]];$?(LZ3UWI2@P7(68S85'<=AH#ZA#5$Y:KC+ C<%@^,&;^R'*7G
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MR6YX(H-*B2R2[.4UF45DF CLHU.QR?6F]!0[!"TZPL!G;S='3Y=]\.A^NL>
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M" [@,#.<2#Y9K&!I<Q4E:<.][('%E%66/%Z?>(C_&R"6+[V$:[(QXK2G$Y%
M\>&78X-)4[]II#!=Z#$</7A"DD_/UK_@+D^&$\7Z%4OF^=&+5K?S=GE^'$QP
M6CHTXG+H&.6D?C5)T112>0-QL2;'MK;61(R'7KGW,O+(34"&=;I23$)>4LYH
M^"]2XE +)",3O821JL05DHCHDB'CC1AEEKK\Q71/2MB.,I@8=($YDV\@!<1>
MAEAX6@ '_0VF'/CXL@?V@],UG6P'GK.%6AX%Y/8XTT!N)6SL=NGG5O+_Z9Z
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MO6_U'B60UAGWA9])?NV,3:EXQ0D./#5G&WZ!<!EDJX19&!*+BC6@NJFY."^
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MAY2L[$%8^6@L2ZT"80Q#8:5]*ZU)XV']9P]9SM1F8T8S5O-"<X\E,WK.<,Y
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MUN5ZU**SA'R::V&[1*3"9CQ(&M+"/4S)N %JPY-41ZJ!6S.&*X?(SNT)%?]
MK ); G(KEJ(/="V.8%IZMT&Z'S/9$HTC@IYQ$*U^L3 [8R^<I@EQV7B[(MG=
M0GR +8$[M!DXIHSF*P,U 85"#D,(DAS^"-#3\Y3:BQ3-"]>RA*4T7UCA5+C
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MP_1N4/7<)!O>;[(-+X$;J;,:YELV@A&2WC(]"]G5GGZNHLE)&[^%Y9@5@$L
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M>,V083=G&:G4*_"W4> NQ/]-XJG_'_\?4$L#!!0    ( ,V%!5$[\-GVT*$
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M\#-$3O8OH1+XMPS9*OA\P""AWDVY&L.1#^,TC:?ZO4V!^:0>YC.A4BXC0'*
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M_OCF:/_DY&3Y[RMO7OGC\?[IZ<L-[_V!UJW7#IN0@.'XCQ?'+PH\#0(9C?<
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M;CXH=13L5DVZU90&EZD7G^?0>3[]92@BT)/+-8]$ZK96<H:#D$5 !%S0-8I
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MF[R19?^^^7#0%*^NU. )^[;'CKM2@X:=23M$CIN&VGQ0ZL2-G?!+4D;J[T
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M)+'#D_WE?0%INC K=NY7X"F3."0%>L"_+NZDQ\177\P6Z-^L$<XG'_Y*!%A
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MH&F>X6E;\94;LE0ZQASNK\HST7G3T;R4-KIAIC'01"A%E@>(\D>8UU53!Q&
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M79W?87GADMW+Z=+=/I("M((\4Z.0@(9FEU/<GT6X7 ?-(X&YBUR14 !)0+5
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M?T;Q0RB"L:BJ0^D$>QR)2#."PGGOABET*R/=$VR=)UIK$W#="%@!&DG$3'@
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M$%"&QR8A(Q2F/D)KPG'>6>]IGL*F^ 9M#O:WP((,"^? DQ@)_D!_Z@('K4X
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M2CZ"0N^-67P7L'M:P.ZP70&[=FA>EFX,G</_I)FD2M:Y*3-;8!-G?(9A]:G
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MMM1Y@<O'_"_#ZE:X,*C7[RRMA);6O=DR= .V9V!68BIU0UU]MKH.A+XU PY
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MXFP\R7N^ZF<569]%V:09:%OIZ(ZN"!SV1T66B=;LY,@,7!*)+EC3OYKLOCS
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M7<:QB7T?^ ^H4[8J#5-ZK_]P&*"S,^N#KY@8F2+F&3.(Q&4(BXCD=+Y"?5
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M:SW\K='%]$!Z6F&>;CU3I?F/>W?$&$FM@&Q)Q((69!K64D#IS&]N=6"U3#&
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M[.T3P/VO$//4D6/\@)2B<81N$#-.K6\:5^H2$Y/%ZRY1F8A7B'8, D;WCI_
M-0]?F]^*@/@<LO(M=<+MH#E?>$)7Z;@VL(/[=&X6:$/;5+Q!!=< 0!/&A$@F
M690\*K#PCQ(M^2(-<[I2+SS0^$8E1WR9(6IP%6@P%0+YL$CT4F5H-2-DNZE
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M^.GI:4H>3W@GM\BVZ$G7'?_*F7]%Y_M!K<G;/J#A$S":'RN8NG<'QXE80Y0
MAJ'E*U4XH@Y<_["^0EQ>@15]6N@1%[M9T Z%55P>N*W+)DOF\4QA17OR>V")
MFH;F.MR]8%+]$CSE0WIA5GE7MJ;@W<?!VT:97+;SP[[D3G:7W'U=<G]A'O#-
M'\4N.V*WY[\@UT&V-<F%%PP"QQZG5E_CDHO>FK)0GL6B*YUCS4$O//K$N]5"
M($Z>8^$63S>%M);FB@(#&#_T* ]^$*]>UHZ:\>*!FSVEO(4_[;\OI[UH#$T
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M[#X92K3F,0XXKB4TT3>5VZI5D.IP#4HYY;<CZTIQXZH"?77WS4/*]A*/4U7
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M6H8((;'2D C*!3U:88SR%'NI8YWCW"AQ!A#U'7D!\74?J!2-2^*28;G5IIO
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M.M^C)\E0< A#7!IORJ+F0J)OZ$?KTHBA]7 ZP\2@!0LW)L1[C:<3(9D%#3Y
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M=/@T53_V%S*16GHQ.\A]!PU5XN'M!DO&N8*V?M5-\JN>;/VJ'T=1LU72O^2
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MY&/Q'4"V+2Z)Z3BJ',)!85PR,].B2!^WH!]O!?W#"7I,>-2;)]+[LEM%Z &
M?=672,R@1.33$R2PYMU?,D$-B^;?D6F9I(2:J8FK*Y%@_+]F"FY7QA.!.*F&
M'4MYHJ[JK%3K+G*]D*?T )*KVL^>)IX.[ .V*7>V;(0R&P1$TLI\<:2C88 L
MR/FP.2EV;+AR2IH:>PBU6HL8KLKF_8&X*.&W2J1/-"8@@G>F<9I+(8RD]&K;
M^H!:*SR77&.U+?Y):KG0,A'I*F7W4.0N[/Y<P!DUAO9\%A$=1(6C2D70@\_)
MM:1!. /Y(@!O!L*]S;?=63.^M1^$0+@+ R7U')=!9N4]Z.I.F:>2$[(@R^C&
M%'+R,YKK<0OPR5: /US"2(U289,20\Z]:<]Z42OGG43*#>4/VG0MHO"V$DL"
MDOYZH>ZEI"S#0L71]R+NT^8A#NBL+L?Q<6_'Z78[/M1V_ 7#[39!'Y:9HZ'E
M*,PE9BHD6HU,!F?3^O>5]FN_N"HYY\+ ?M\"G&*0TG)5"O$U9[_"V=[D@5D<
M',A"<&TS?6MDC4'@.0H"W.8>IB2$XK6E>_>02-(*VF>TN-"$8A&THCD1K3ON
M.6_GHO6NO$,/DV (DL403"X4%\+7.=7%B1MB<FCQ(3"\FL>GDO'1=A%0W95:
M:@T%"J$#75O6OD _#!V)E41S98D%ZHS8H\K;S\CDZ,J:?3VB;XMW?##1]ZX9
M528UJMP<<Q))V@9J-U7HQH.==3I4L,"1X3I_U$#P@CB%2A86J0."(1>)&Z(!
MVMW<QCF"6A)H4HD<5?[^13>&8=H?E\#0BELFW!0&,.CGP7\P2"P0%%Q@(DRW
M89P7-6W+@;E)J("G#\&!N:'8U]-M58:'.AE>AVEY5ZE&=ND+2W;%2LP;8L':
MC'/C42M,VV(-#[8MWE@>M/99OOZ]ZKKB \Y0TH)XAQ,0'1/I-%.2!PSQ#58(
MFM>.RQV'@2XS>5[<V O-#&U,SKSCN@%__<OQP?-I<1NW*.M33?2'+> 6^J#G
M1#_?./)YY#P*N.Q'!D9K8BGI+=5]HJ$'V&-,P%.C@BJ+$N6/'A7%>\<OB"3Y
M8;TKDE]LTCD>/S)OF2:N7[H [5G+0Q=+S58F%D0 &Z<#2(>0#!]3&#FK"&YR
MGG&!XI,U&COG=^7;):8O_M+4[/YF=CJ'-2&:NDXR>(<;M_0EIU9PX[4+:BTC
M[,+6N(R=+CF7Y925K'#?C:75%W9@R6<<S,;XBBCG^,PKMT)$1^=R@)Z1;*0M
M"(>_=?7H/4'ATHHA P0/G&]>3</T9]^&=M#B'O1GJW@^!WB'!RG0[DOIV4W6
M7H*=$-=#FV>4/!/<GE&W%IEK2+OFQTAG1H\1LJT'!PI:Q.$2FQ*#2UCS&B1'
M$G>+MURPW6+.<,6RKD12;$/[,-PW*G%$8)PQB]%^: BEIV6*G#1JHC"?UH=K
M=.#J$5VEQ7J-Q,SEC!\+1F3I&4B&N.,P^@BVI) JESQ<K5IL[&%SF34N9O2X
M-8XMN]@#EH=BU^<&Q8KZ2$B,PC)KI5#U+*'TZ?"7CYN,@O7B_!W(=J.ZKS;L
M+4*.Y)UQE*VVH(T4D,DL20"5D9TS(Z,-D <\NI4-4CG>2=SO<" *,6T/W>29
M<:V8#@@FKP+=YPY6>>;UM7&T3-W"*+B&!40"PW<'9,.H(7@FX)BI?U'C2C);
MXT?X1,<F53<PE+OT^?>":U_+R4Z*ED!8'=US1D6)JKY KP*)'M!M,_+ "^1Z
MD -:)+6M\FL+30DA-,*Z>H/9IOZD]CIRYMZK,39AJJK1;;!=+&<#IBW' 3Z#
M!J_+_=TYR*V.D$PQ(Z=UZ>"1S(HO5P@-]8&J=<[0(L;#G?47JN?>UR&B>7'+
M* R[!7B'X+;QOZ$#TA).6)6V?V/7?0FC/D>XAVBK3@V)?98H.V$)*D=!%AO)
M"2H)!$345-YKV3#"4/D!I7:H4O197P+U T)V=.7C/(0.JES$BK#EZ7"5!:8'
MMPRZ5J+@9]332-ZVINM6465G'!/8+696,?"F](M8=H=?BX^Z'NK3K>?MP3)+
MF#H8<;2PYGY@%H=+"_I=_\ZYG)*0#-ZR]B/;--8;ACZ"=<BLG71XV$/!1T:)
MG8-J'L)-=T=Y[(GK*_8)Z168$B"EADQYS^31(?8H;G/R>1"H4)2/6 @5X0\\
M(&,;D!$+O_M\1CB;.4EZ448<79E]N-2ZF3N21>%LQ,/=AWQB5SM[J!,CXC')
MH>4"SD,K?PRF>FF)2_ 4\91OC@PN8(L37K@P4GW38H=K.0JV\:1-BB<]V\:3
ME@[/L^VI]G"@=2J"M?Z]H./K?@7+5E(K]1EE;2VR@2)%2[R7(O!%S-]5/LSC
MJ7P1V;#XJT;]-4]53)[Q*O:%R4#PHT?+^X,#0QCA%M.B+GS1,$L3]:@5WK.M
M:'@HT7 %6D:)FM7Z]Z.KV\96H:6(1*C5XI[E^D9,Z<OUCU&5ESNP3&..9&L[
MG>)$>+V]0 HW[L(VQ[1CFV0BX\5_#5<?R\Q8+ZF@536CF:D9Z>BL:\P"23@Y
MA"6 _J"L]'-5I%S)*<K,8VG6*9\5^'S0,5^*%$$-&4E\R46 CIJRE9W3PE^R
M-P$S=6Q!$>DO].<5*/DIO+;287Z>$N- !.5((>6,BW]QE7@7!V!D%/3.0DG'
MRF0X,9WJ*=[9U6G%8Q9[AP=;N?=P:2!4!R@S[#ISENRF*$F]6&<GW'BK2O%;
MMB-KR-V2%\318FJG9(3EX4"3P>(#51U0W'T\_GE3M^#A=@L^U!84[,$OJGRO
M:XQ$0)M?C\<6(>P6W/IW<Q#?$R/&6" A_?)@S$W&XX&'LTWHG,TPT (:_WMB
M9FOE9H(*TN6@CKEL(^@5",-ID60Z0FCFEK/A BZD]I&OX>R45BC&UL2SN2/2
M#F2BQ3*1.8@:Z%PIA/HT6 NL_W&P&Z5J@5"6+"MN;=A"@ACX7((Q",#"E%7M
MQXAX8:A( 7K9'.-XJS<]D U>2 V"IA+ZP(L^U%5 LLV;LFJD&IN2X@<2M:PP
M/,8L!,8%9/#Y[WQ=!.S>I2WB<H$/9XO0EB4 !0;UJZ*T14REB3]HK._2*F2G
M4M#ZY.TR,,&+SA-"9QR>'1]3S4_07_/48FQ:5[KF^%M._"TZW952U_=Y@897
M0&]^*&#HWNT=1J(@4]X1!F=O5.;X(:CX:U#JH%WI@'4_FN@!)[69T0I%*L(]
MMW19BTT\(B@L"4BF,);:J)C$,%B]KH9IT0F*A<G,35Z;C%<?AS\K95)9SH_[
MD#O:'G(/=<C]R)3<Z]^++4Y[N^:_8(I]LC$Y;><,1\46QU9?XY*'WIJR8)C9
MK,F=K\6!%SQ^PWM:0BA+FF(-%<]RQ$5=R5>LRMJ#F.1"/'I9.ZJ&BZ"M]Y#R
M$OZT?Z_&'0<]#0#_]N;Z I4&R\);15=YLA'G6-1G!E[7&3PZ^-P9[/][>'
ML\EP7YS7IOQS+;H[9XT'X2N?M7=% ]KVFTR9?(S\Z7'TZN_1P=.#9P?;R5O[
MR?O'N_/M+*W]+)W7PM+#90)^)JCL2X1,UW^ZVVL[@_?Y]UIGFHKE2:&'LX-G
MN]'1T='>4^C&=O[6?OXVIO.?KUGW__U-P.5ZIDS&,%!;L810^W_]R^G)\WF=
MC$RQ#Y;/DK$: *L]ZG%D"R4(^>-X\4^7I4FB-ZJYU5GU%8U(_]_3H^/HW9S<
M\[^"#:P7T$:5;H&K&P1</?O2P-7U[O&77?^_%&5IJIJ [&0UG9T>/"+Q:<M6
M(E$KI[][OY5BEQ8C_&VV%=>;HAQ]YS.+VXGE4FASQ^SR$ K B>.F4X5Q+N1:
MYQ\I^QN^I\ 9I99AUKR1C'XJVMJ^,"AHCLA^)$\@YDL\^=#G5S=ESEZY>>U#
MMC&1Y6+Y<DID-.D7=A9ZKBJJV3[2.H\FT.N\-QIF[(=!N 8HP5,BB3)8"\ON
MM\3/:&^UTV73(_E'SX6G1@4F(/CQ-EB(</F0,] K!ZD0U&I6BTZ$%[^AU\E*
M,%7D)UD:+,^T? =^.J.@":LG4UHS-F,L<_VDGN[>JU$S*=UJ*BI$T@^%K-JN
MCRE,LDTN?[ PR248_Z7>.)S+=3OS2\]&16HDHU9SEWS8'^4A];E"> _NL)&N
M;[5PEEJZ3F8K&0[P2R1?2,]%P-'9T6#BL$XE4Y0Y0BA)-. *<2VI^DUIE6I<
M_K(XDNK*0\T3\C_*;F?6#4$-1X2_F\B[2SW6I0@Z3*AK1I7-J3O&BDA42T3O
MLNAEI*V#GL0=$M/88OL6L4O8HQQ_-^B"\GD/HHA@.?H#WE]EBP'^=C^1?"XI
MPF>0Y(4CJJELFRF73V.R.2-+D"]$L!2QD+G22X1G]NOFC]X6M/U3^*-YV9TC
M:FF3H+S7CIWYKEUC,?9$ZVQ8 1*0%B@^L+]!/>I)/ILXT"-)9JG[N'?BMBCC
M@^W$WY"U00A=+L0>6O\N?>(.)(J*U#%DV3I5;(WA!B,& =QA1+U!'"*,I&SO
M4D<M,[1)%[[PBV,,(^7"VV[<ZJ(,&BWJ _Y*K2S#1@X3)1?6*@W8OM3 W5T-
MR+-]#;1CB NZDVU5&9A01>0?6/;EKC9[D# -HR3VNSH_"!95MGA%ERC%5Q$S
M7-Z2+.W0"X$-:O4?&0!,WA 3?K=1CUMJ;@M'/IC4/'<L/>O?D1ZYB)@,U 5"
MA0<$Q6%*D7=^B=#H%:IE_C%$RNNT<C2+)?,G80UWI(<*N1>7E3?DO$),<F0I
M==?E ^PA)J@>26+FILA V+=2// 80($A?5]")=D?"8N[;YTI'TUU^:B%S[:8
MX8,)GQ>L3JQ_+QQ0UWE%JJY;I')^$>9/=E1&CGS5)4,/.CXP==FPBZH8]$YY
M30&4@E)W5#*[144[(N()F_@C:B4R6M1,%,2TM$C>IIP#7LPQU-Z@@4P!N*RE
MI*>40J5'5-':,[WV,CK%?Z5FA2WWT^H9*T%YT9?*[GVEGJ@RM04(H55E2M32
MW'(>@L27V;B?IV<;]UVS/;87'1T\!&'1IIY,VRJ-#Y<VQ8%&D%<_J]OU[\M0
M8,3F92[1!&UA\$ 4=^+#7L@CW255Q27S5EA!4\D<]3Z#3-WB8U%#)UY7_(#]
M^SO&21:^#NR$@\)2G<W%7ID- 6_"!XD*G&E7-.YQJYW;FH\/MKG_WI2F2HTO
MU?R.X_VX]-YP98GU[Z&KS,H4Q\R"(QXP2]G<CQ@N43RA5XBI"&I L(]OR58F
M!6^(QQF^/)]!=Q)E'6!K-9!/ER1(K54CE\SV2\/1SO9,P!IXL;"LX;*:'1QG
MP 'JZZWW[8L$M?3*4E#I;"PE*-P*0OJING)\=7$TX>3B;"'!;9#A7*F<R;3Q
M);^'>TU>K# ?GI+=>:59_^MPN[#L^TV1$%64PSG9@+G?N%(2Q@:?PU?-.,U!
MV_=9^F:NM#ZT<>1 LZ@<(GF8&W\4X05=Y$\'K!7;-CKL$]'5"_:I%0BW=5@/
MCW;4[E=1;WQ;Y?/AJGQJD 6;5;_X.A "5$H\':![QG@,U^4EKX!X+.'NGXI;
M[#("" FW1_Y>V&I^EW?*('</1/$12W5@BE5AT034@S,^;+' 4AY4!49QH**T
M04'8@(Y;0H=%V""V$D5(* >#JLDE9C^0VCT@K"6$%!#L><SD4(>PUI0IDV;&
M<:C*QL:F"E^&42@NM>[B4%CCN+B[>W$0H<)\<M+;J>H"47^Q_X8]2=*L5AAS
MZ4##LV[ GA>&GF X+6U* PW"FCL\$]Z!-:+2&%RAFZ!+)IAJ^UH:/UQ&5FC'
MG3+7G2G45%' 85J;LC/BOCO#1:BI=IH?E4YYK2[WTG %%*=]P9GRGBIOX:M3
M';+1\M@19)>.%ZKF0'R.7)$L;#R\B<I*0%NZS>WU*PZOKG%99+H.PINW2!?+
M,SLM%=9>V!$&K5'6Z+VY!G,-3TM;O2NVZ@,%9JAQ!!@)KM9<F:T[P+(-<8_X
M74Z3U,9LR_9_W$?E[]NC\J&.RI^T8EPF04C47(K1H92YL@#$3:K%A.?H-.Q3
M(GVR0NY&E:9H*HQRPJY9BCE!OM8Q8P]N=&YL67H"E?*'7$P &Y] ;_ZM6C!0
MC$LLJ+$KGC33*I?"4.)C<N9!H+H/03I$-Q85H0/UT &XWI6,&.X-&@ IFRJ1
M#4"DA:^G9 TEE-^<8N<>>$H7/P%-G5>&^^&I_##I_@!J_7N&V,)?XUU_;(57
M9.Z*=/=Q"[3W6X'V<.3:7'@45(6W5,-Q_?LS3"[K$>306%N;TE:PQ;HO)>]7
MU,PH&DE>Z=)Z.WI2)=!TG,]BB5'^!)\Z5'*&:E4QO71$/-$.*1*'T"U2@DJN
M1(<JC($Y8:KK=@FL:P+K%:6.^]T/5,2X([O"BI>(J!,HB\ $U8TR6:A2.U[*
M4!\--"H/]S-^[7A:<,PVH,>57!*4[!Y66'&8Y^@:*@WZ"T-[YW'+LVPKSQZ0
M-/LW04*.H[<4UXJC-V@ L7[S%G> V1CF-^B.I9^GVM&96O"."@$9N-_U!UTF
MH.I(64A;3Y?K^+F-/X3M<M@*7]<YU8J<FEM<Q ;A(@[_*%S$Y@G<Y0E\UD]E
M*\826.C6"0SG\E^R?X+PPT) [+!/N"(\O4AE=B<Z)NN/V(K]K8WDV5)#8P3;
MM& 29J;+%@U"B:U5U7I>,;\Q.3WNZHP="E";L"Z0#C.M*2/ JPUPCZU/ZGIG
MPQSBZNKV.JBPW>][6%,3S32=Z99Y)Y?U!=T2&+R?0(=FZ*2.8VU>Y-#6E@_
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M1#3T\]!;-T@Z/[:KDQ?:372]T*4$A0BQCWXBQE^*"!DM]D#ZWK,RQ@9"Q)<
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M\/8]GKKY3)E:S$P9.3I497U]R;Z=P&:D+9-DA)_42<X&4-:(73MFHGY^AFQ
MY^&XTS]\VTTX2E],E4U>YLI)WS]I)@&YYHZ[H,DOHL^%Y/!L+5?HL,+;!"QO
M(FM1VP DH;U!SY*7($S9*+TD0:-&7[:A-/7J^KN97%I4'7+ON(]$WE$Q\,*@
MELD;$2,D#LR(ZG;]^9!]T?:-X;"@4"[]/&P_&R+N8S^DR5F+F$K\&W/:PM'H
MC\Z@)LAC="!5#A0)&,A&.&E%\$!F4$6N0AV"@'LD LL//42*,3J4%')H(!KK
M W/6$B.RI6P#K\-PZ3V6ESL9I#TG;*/_Y/$7+.UT/'Q<#GPW,S.,F+:62DKF
M0+MLI54@,.0@!**;,S/%*C>]/:$'";M;HQ+P;O3CA<44F^EDF$)GLIGX9AJ%
M8>>D?-S)+X>%RH[/+HC)'\-./$P?Z++A[=-UMHA)Y[)QG@3+&1$Z<!3Y:H\!
MO936\>R$KRZO6!1FK:+UV.F_[Z0/-:$$EFF!.?-@G =7EJ]9#M)9D""32UC=
M3*-%@?8O^N5#ZG:?8N_DM"ZUL3""LYDEC"@ 2\:G]MYF6P:6@D:^^KIV=[#]
MG+:=.\B28W3],,8>'?D!#RDU<.90E2UPHG..*+QPY!Q-%E[? VL[EX!V^O#'
M:8>>V3^LKAA<'OS0:(S2Z#FSD*2Q%(T;ES63QK#S<JM,5<_HSNGT=O]]&HTO
M$^DEE#Y7"ZJP@\8FD$;QG &+&662=,<S;9U!S6H4YRP-F.6GB #A15$J,)LB
M4)AJK<OD)%/07EF53(U&-RJ#XMV/.9 E9,GIH&.($+*TR6(H^Q+HB IYN(HB
MKT3QEY_H-W[!AOU,_<4D%1/E;YY!4I0L T^*FQB4BF6"O[)\8"[8TS&8#G:O
MYOU^)1=[-X7386?<23^]7N2\!=@9_H7=T_3'66O*PTHCG@W3?TY3/YQ=;LWY
MR1=.';TJ;1I^FXG\9)/^P%'G2LT&8E.='LG.3CZ_Y/S#9F<4NH-R<4T($K @
MM$=M)84WT24RXR(%HZ(7UD93X=FAM2A]=[.^I?;?I>M5D6#G@E.2<2Q,))8A
M2ZE-EL8Y)2SX&FS&?$%<SC_^B^Z(PW!T]B*]3]VO"/%V_^1T/)J<P5?9,J^D
MW+)DDBX#@=)JB$DZH[-290P70 5;X6&%*HO* E1I8>O=5E-NDXL 1ED6I >6
MI4^YI-YYS.@,:+66VR7)K5S+[3?JN&BI"E-P9&_1>V^T)@NLL@R9@UW+;>69
M;E5$B:OL6&9.2X,0/"=1XBKF!+GDJ1JLE2C=)\I9%0%BGFO,3*(&#9E3U&*U
MD?2C0"^4U;42H K:HEOC?E41(*-):+3498<? %0.E$C(LD TQ@BW%J"*DK"J
M") .Z#R)#D]EOPM@ED&V5F<>0AE/J4'=BFJYL'LTHEX5$2;>3M**QI>=0*P"
M9X0,1G@M@@I8BX&_>R0U:S=^G0@'Y47RV9-T 1I H25&"R)G38?J,/NR%N'[
M322R9,PCTR3 #D1@WGEB$$(+%E7*55[9=Q_1LJ"]4C)1L!#!&J)]07&I@L_H
MRWXWU4U"KH>Z5WT0;)&;!LOH#<HDR5.!#\%S2.A*5"H]"RAJ)4H5B"#JP=\7
M*$ A<>V ,8C>EOT5B?98S*B51"VD9K42H K:HFJRYP4*$'.22,=TWPN0-B$W
MT49C?:F"A=*O!6@5N>L"!0@T$^3&I$O>@'""6)"5QB69F'&1U8 -W46-[_LH
M&5QY36!Q);*!$)V+AHQ-YN2:N%.V#E'-MP/S7B\-RQDOD7JF/1AO]T/W-*;X
MIC,^>HJCHXU^+/^4'<S>8[=8FYI$.65Q0E1F,L4/J+@7-BA/N$%R,;,ZI%9]
M&[WAR6!(L40M<S%4MMQGAHZ<-82R>(1"B&BM,,AUT'(% -H8C1+%@.%=BK6#
M!P5H9#R4S37!LN03\2N5C)3,E TP5@">R6Z+M=0=:W0B;Z2]C!Q\YCXIGIG-
M'C@'Q6M 6FKGFA8Y:L+ :BXE+Z7-I70V21$3)IO!H(2X$NC=N6M:Y'8?Z$60
M(+U-I%$N^!239<"$9]ED4>$R#=5U30N$AP)\K5'KK * L(#$(Y)V4A&QL\K5
MH*3:MU:<5LGP+7);#ADLL?)HLQ*0@D"*O ,CSP4IA2!KP,G_'K@ZTW%!"A3!
M<XS*@9"*;!\*(:.W*@;JQ7IC4V<FSBW%1DD1/H"@6"C%1X*VQ@"7FK,:Y/G]
M'3+U)>%,!9[1*TMDCHA;]I%;1X&LB4Y;QE/U64*=W- "^8-E5C.!Q!2T Q<L
M!J$BLS$$7K(7:D#O*N:&%DF]M1$R94&LNVQ^85P.X+7D5ED)6=<<FSJS;I#)
M:(GH07@P,GBA,5O&A&%9>UF#X?#U+IFW[!!M,,[PD"D^*V5$?42E522B3T&T
MDS587;?>)?/VI$/EH(Q7G.)U!5& 3=Z2M=<Z>.^97;U==E=?.A998E.P "A]
MXCZ#XXB9Z81@2_!CN*E!D+/:6VTO:LU:DA!=='1/*"3")F1 WQUW2C,N:E0U
M;M7P7GXQNIQX FN2"#( *%9&WS-8+Q*J$%T-&&:QQCOY0N'[+_:["X-N%WV)
MSSKO+U7(IT\C#$6*%I:LLP )K8K=R$C,TF%4G .4Y?5>9<,9,T0W,6JWMAO7
M/NM\&[@R2#,^>SKHG0SZ9:3F7A6YY%H*DA,7^&2AM,'@8X2H)";-N<PU*CB[
M')5>?K59KM!*D9*QI/\6HQ?9EC^<9Q\DG!=+J-X.<=4RQC^Z4]SE\5-$;A+#
MF"V#@,[JD",PEKC@022\%V#\$'>[JTWC%@*S9@X"<, 0-20B8V0^;;:2Z5P6
M]\DUS,L.R18"<U9 D5?@)K*R"TFPT87(,!L9LT-5@TGY:IC6Q0R2!11,B:2D
MD>"8<]DJZC-@WKA JG>_>&XMV:85:*)BPM%_0!S31:NU<EIY@4RY&JSGW_B
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MY*OJY&]%8%%+5"@XU]&  NZ40AO 4'A<UM#48"U3=?.*5VB5E8DJ^"1RDE$
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M<NB,2XQ\9P1KG T*%0LJ&S2(7*TB<DOQGXO""SW'H'6DFX)PT>D@'&:*YXQ
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M(R2@:,=RY%HZF<&@RU[7P*S=?KAS/PVF%ABR2M%@]*"UMHJCL<:)H'-TCM=
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M>! U6$%0<5R7D\4O> A*(.$JU&0W"*:U]T%'D2$% 6M[7T\['*4D!X[229#
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MXE^Z/?)Q*\59]L6F*LY&'/GKTNSUOOR.WWWY0 Y'[GS_R\??U/GQ^6?T 7_
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ME:3 4\PL"A'V1(C*MFA*52.?=%:V7TCN_$EOF)KX/5VIWAPWS0**3*PSX:Q
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M(U32F@5MKR]6UL@-O@XJ?%D*/OO %U(D?G/8:17YD-E+]#2:F>]5RIE#RBF
M!"6 :DR "LX JZ1D#!HE+4JY0:@IZ2KR(9>PS>H*H=EU_JBJZ)L#EJO(I,Q@
M^52PG'6I2QI")#6 L) IY-L 2:T%#$E,O0I">1?!DK"F9*OH&K'H/;9&2)D]
M[D_*L01%H9)&*E22/48;[C%:C$Y^6R#DG6E&N27@(VEGKA^J@\PQC!E@F!A
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M'X*)CU>[,R;6#1-G]'(A,9;(.< XY( J"8&B@0,.M:>(*XD0*C"1R>ONB.?
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M1NCW.F/_<*_[.+_PQD70;PX#_53WHC$3+CKHVE[')YG,;/0@-CJ<]1%3Y4A
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MG#FD*>&2LYLS#&<8?DDP_$SQQAF&ZP+#,S[UH(C42G( H? @DK(!6CJ86F%
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M!J\O?3^5.]_^[,J':M[CDAL_'1W_24^$A&!<!L(4ST327!2]*#11B5G.C;+
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MOZT.)JGS@T=P"H-Q]0$Z57/>,9RC33K_MOOJ,::K94/!F"X4 ILC!-#\CU(
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MIS 85Q^@4S6''H.]VJ3];WL\#T9\MFPH&/&)0F!SA  Z E *H!1 *8!2 *5
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M@B=CK'912;'*"+9MEY28V8,OQ<R>)R]C6 UJ>@U@BK6/U>2T4\8,9^?]X6>
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M-M!=SK6CWD5>V_G;LV;E>#F5^!XVOZ"KQ00PS15/ 2P<EC-''D"F.#Q:X5)
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MAXGEC85F#JVK5NHE$%<$\WBX>H*MPF458$I.8=#Q\HDS#*4LG4RM$SXO,Z!
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MJW;"@@5^'^TS]=PP=G@<B0"DN^<GL9.Y:0Q4%OJNYR8:K@FHRMY$7G=70U^
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MH%2"T@.-3$:9X^:A;SMQEMA!)C,[\S+0R((XCP5WXY"GP$'B8(,[IB<I-XE
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M)S,0SQ\6T]40X5>3Q82JI<2\]K^L2N<-@O&)P&6I:ZI[U)6S8JJ#\S F.^^
M(2RFZ_O_O6YP)?.QZNJ-"&@"-YU.W81_&>504D>)"O4D4DUZS[6 \%1=2+P8
MVU"PHFJI: /V24_#WV&A?#X6BO\#8*'<:G"M-KJ,W2B/(U0V\R '9<EAT@7"
ME: 8.6["'X]VL^54-V_CK2K@<V 4+1,Q]#_HME=J/8\#%230*2T_:4 GY=!M
M_::F =6& 6YB/G>R6# [V_"/@B0V=2+'F( 6_^:]JC-$TQG#O'@I6:5?L4E
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M6OB&:1 .1G,8> 0=,+1>2SP\'#J?"]7\ <$@@"=/!=%-C:@2\)XBMQ1*!"P
M ;(_2NIE!:_!TE(J/NN.:IH_:+0AT0S5;24(#^2E)BB0_DM3EJHW"7V+N,\9
MXMS"(>26+&B&!B0'QI#8]Z[MJ$D3G].)JA<;>"-Z-\Y>:LA),X>?-K\.G[VJ
M$*)T:@DLE\/6%0T-TF1Z4S!8;LWX34,.!034V5_JBB*Q!PLA%G4H&ZOR%92.
MZ5S"##P''2#B@BB$-E#.RDH1YH1]5- D1:W/4N%J=N"=&DXRT&TG>Z.H^0(/
MUENE,'LZTRKJ#@)$?[,&!!O'-5J0@;1E!CR]?]A++(E4WV&_&ZZ!]IBX1)@2
MJP%MJ4U?9D[HLRM83&8\?0:]51OX/&D JWK;)S\5]5POU\!T-BRETR:EP=A3
M;!.K$S7F7M,_I>D/5$EB7ZQJ)[B1G%8VHR&@M7DHP*K;Y]([E&VO'6S< ;7K
M4P0\+:^H@I1PJ=KG%/]LV+R!&NP\,0 .,"' 5@UWK,O'&SZPC7S69UJ;^SW$
M2G78RJ)2EQ:'PAN!UXHPOIH)F19Z=UO#^93>!5?M!G&SCG-(O+:%=E1X/YL
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MRM#GC._BY20#X]!$PII\0YQND]Z'.&-MS"I?5#24GAF&KBJ%*T'&-GGG*1=
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M/!98]T"%U!&N9+*8X-%/%YA"MF_]J[S"VX@?$>")RCB8X06<ZR-424LZXJ4
M!C6;T92W&OMG^!2.I1[KS WGC^-/)?);AF@A+S53PZ\([Z%6*"Z-GT]S0SVY
M%M1FT%X!#6/03$S-U>1AP=)5<)&2 760C]@Q95/0#9W>3E:M3Z_E0S!H"Z)"
M_DI654NB;_(W[ELGAOT.X&T-!U_9$KUNLV0-3'';A-8VMHMQQ3"3PP9JF<'B
MV'A9%YH9X:T 4E+<;9VEKKVDA9=:79K)[^I_K@!*UL=!4&M,%,&AVM<2W776
M@5K[2NH.<NVI&5SB,2N^PN8:*'M;_OT$_S0T"J/HM+O5Q+9F^0J*^TY7M '=
MU)DD*,\HYZ2YN0,J6,!'UO/@>_&%75[\Y^?%1S] 7ORM>>XKEHWD>>(Q&8:"
MLR /L'U/&H<R<B*7R0@!<Q^Y]KZEO. V@^_YN)@42F(-6K4&%G8%]Y<RK <]
M0%'DM2!/E*:?S8V&.C#YU6UHIDUGZ:68_$3%X>.R_*@SJDG;ZN6ZY2O/-XJ5
MBM]SDS("OY"@2I%H;P)&_=2Q-3;Q,/P:YJNGZ\ X&)V%CI.QP ]MWPV$\FEF
M7I+;DN6>[Z>A&X;I$W-(&+KX3+>#ZSV@)6[A4V:)F-2E#!R=']JH07T K!F"
MJZ$:HKI[F**4G@:&-M6J7:V3AS!6OL)1&HVTL6GI1[7)O>/&#D-[H<UUZSS4
M26#53\-#^U:SM$*56[86$)F'/0CT#:HLV1IMJALZ[T%-OI1CJU2Z'%D?J+X7
ME%Y(2=?H,RG.SU7A 168J+0^K;:J@A6R;&1?[>RIK^>=F:N9K>=N:4L&U;W^
M)"F7"I3CN=$&]41K>4[K4SU;]JWA4S:5-IL-*Z=]JUUTLU+\;<79$7ET3MDG
M);1.8>S?QB7_^ 2EU\G!'V>Y[R81=U/;]3//#H04=AI$W(Y%)GP9R]1/V!.3
M7HI"+""1^T'R?]&R/-<+O?2SEN7=36*=F+4\B+W?,LFI-2(7O!=W6T+UH53D
ME)%VKV1A54[995$M:FM8B('U1HX+F2OWYJ'1X=]*$"7(%(>J1J@MYP&&*HMI
MDVX[?'/X5CUDY.ZL1*>R=F4V1D$WFW\ED8U9"M^2!'J)8H^W<QQ8+T[^/#JP
M,3OBM/O"%K-U4HI.ZPZJ7$+<UQDI$O 2\I$00RTOI4;YI#_Q*.$%9 CI7V/B
MOU$.L+ZH0JEB<CXHR8-]&F#BAQ3DAU7U,Z0/=.()VF^(#UO/AJ/3GTV0M3L+
MC,4B[@!NVUSRBRD6Z^+2*^5P-EOH.6Z,5\MZL="QA7^764U;\&RO]P!\M/?S
M3:=%T.KZR0$MAT2;*C*;8 &#U.BUJIB*X*-UKM26GF/*<FR+BI3G_1+T)86U
MKBL.5-3%:O)E%,*JFDSG>2T=<6UL7)=-R:VNG(1E,4)S,$#+,[:L2GC%'#D/
MKAQ)66>[S[7'64YFXW(II<;@;>JZ]#M7\,GKKMN+''P*"[8[LS8?<=S9@'*]
M?NW6*6O#%D,-U/U"48FI9%:Z"5$7ID),!:L(=9J.0<T;[Q%5;/2GV=X2U /A
M>L \S+2*-@I#6.((5-%"X1+1SW#WM%(,[S]?%((II&VM66;HRJT76L%E.LS2
MI0M\:H[YI\5TC2DTL]M?KQ4QSIV5(C*]/)H  N:6BWJ-SHC&2J4_F4M\KXS]
MO>T.JV\HQ[Z]B#B9-GEMEN=12EL\:!E"![:Z*RBZ;,7@9'?*BW1/1@SJT2C(
MZ\;LRLJ6U#<&2S17;AIPVO)*V2O-NW,IR'E4 [TMJ)!*QP]QN(ILE]+RW/]&
MGHL^6M2(T5$M5-45^NQ5" KCQ\I$PU\2ICS,#L@$>P(8AHA^(UB!!7<(68/F
M"!(%P%3=>.(<8J%@Y_6-[<Q(F)H4S39^'Y<9S+X3J'I57MGXI%:)GNW]?O3J
M]&COYPU<KKO!QB;IW:%YRP!U=P':L^X.R?FBFC;K C,3#.@"C)]FB7T+NDDR
M5]5K]&-MY*R/T9C+*R[^_JW%0ALY5MY#O+/*+"8>3$NG>>H2&UW$!7\U+;Z*
M%A=H8*J#08"A.84CH^S0L W"4EC^1KCAL,05:&7J76T3!NH5R_H>0B0R7734
MX/RK&5%.I4JG7$^LO!^J_F-E(@?=C3<^%\HBZ/:SZ!4*FTW6 7#\(9X,4+JD
M7#0V5VCXJH"QU')*?9?)^974==H;3G#50"8:H*80]-F6Z2GR*JH.SAC-"JW]
MNL$F7-$<2=QWU#=8%162[5MWW1)5ZZP:L"CLDL;?CC>&VG"A:&2?=/-9NM_Z
MSJ# K]LKHU#G81-F987WO+MGC6)KIMADKYAWM>$WE0P#4YZ/C<='PDBH0DS[
MEVS+PA1Z!2D.-%7-KS=$(ZE*L#DXQ)J9:1]?O<(8E$.EK5.72B#1[U3#EJ&E
MM;.R6R[3[3B@^_\85]P-,6PL3*ZH<+[J-CA#$MBT 6TEO,[+V7&%33TXJ/UP
M;_\,U5"J%S" #V +TH93J!BW?"2K<VPUE#^T\@MSPT%*OVII_^F66WP8?AI]
MX&=1%D8>PPS4W,NQWRRS4\9CV\DSAW/'=1-?[CUW/>^FU@.=7BI4\J#X,*&D
M&)9FV$.;MW9#DD<; N@I*#^!H4!^2X(F*0W>P%8:[4RK"2FT[U=,&(T;<KE3
M4E"7*5BR(*U7X4%M:I^HDD3:UH4Z@[*H3?Z5,:KZ+50YJG#Y@MH0,;A %XJ!
MXQBJZ7.9Y_UW% 8C0&=RJ1\LINU8_ZA7^15B6<A7F.I?[QS+QP?OSOPL=/,\
M2VPG=+$3>.38"8]R.XI2-X*/LBA.5K,?\E@*X'YQZ$L7^X&PT/5RP3,6"=>)
MTZ<61E7D]!E!U >XQ#M(W$['ND(9=UUX(G0LCG%#+-:!B4'FV,%(4LRITS]/
MSC"'%;7 ;M)7=V"@P$NY7 ,15&@+,%/5)UDAK^*'".^D;$]01>&B%^@[4!F9
MYJ\.V)7JK:=86*[T,Z4<(G,KE%X,!JU2/*E^I1LUUHWV%.8K0DLAAL5XV1@%
MBL_B_%O)T_C^^H!)IO%ALRX5C:2T]?ZZ1 =3%\WG.48H:3=)Q\S[GG#M)=3-
MKMHP\^I4U\UL?9@M!$>O>9GYFC TIK;ZJVF=5P\: Z*#*&3JH6FC"9867C\V
M0[5]]^A[6 M]#I;/26,B43H.V6?Z5SI_?0QK4 >**=9$%K 1N&7/]MZ<O-O[
M6:O5 ZN^ "E),);ZM1TK0[D$QNA-VOS C5.QX$4]\V7UUZL&JP[7PKHGJ'XT
M=D<_'-Q/SX95J7$;E)PFZUE]CA/?[TVEER.]96*<HUL8"6M9R+%0(1+811M9
M0A.1:%Y%NZ,IC4;;MU[U9Z6II+'(M%':S>_N3V.ID90F,\R*IONG[F8+)+!+
MU?QFJ9KQ#Y"J>6OJY6JJ)G,%8W[@"S#:4M!T4NEC!7(B,RXRZ6_+9;Q=R>F_
MQW?C/(T2WX^8$P1NG/A9%B=.%(A0R#AD=U6#?AREX$_30W"%%:VBE6]*ANIP
M[0XK;"P4LG,&!@1I.4#)W6U3:_C)BG!2"D3KL>JUZ]5(=D)G+.U;6^=?->RV
MY5QKK8J[WMZ.CW>CIXF:I1(/!:-I@L+)\%(L_FABTHK3K<P&I6#'.:ADX:-6
M-I4^K6B'BA0*5&P::>-ZIDT4(JI20IW&KVM\05IF]LY(8\" Y,=6 @82= -\
MF=K_7OB=(LR:9-'$7A&,.D=NDP3NJ5,$XD<^QJ+Q#Z#%#SK.FLJ(*73GU.;\
M<1_VD(Y0RFYIC5)Y=:U90:5BE)>Y<C-:+;9)FJAT5)I4_#Z3**N!4K:U/QQ!
M8)OB$":*<<>R$0-=9\*5KH)YD&55$2ZY+GX;U@J.<$NRIR86W;W"8("K,AHU
M.1RFG]5 M8HWO[>O$Q93Y5,DO_0E*\;$S;;JD\5Z/^Q;M,J^-7!.134K#6-+
MG:)):?*4HX\Q>E7VW\DVF2TR6#8:)\T\84ZJBP=VH*X6VKC 2U\70&FL0D<_
M.O" LH"XN6E-SL8<\2]-V^'MF[5Z<VY4#1_#7=JLR-RNF)SVF%9C=]U,VKV(
M"=I^' ]]K,ZV8STW8\_&"]5NI0MEK^%E3'0H6QI?)FM-XIFA-,0V!;[]C&"B
MR>(W[@3Y<Y?SF@S83GX-)A3#&S.@0!-AIP%EQ:GL#Y<\O?^KM,=AK*:N/@?M
MI]*&T$4Y[N4XK959Z\H6N(9:8>H($>"*E39?N\6K7>GR%OCF<0E7.["TT*2S
M:_>WPR$VH99]S_H4(/)AD[W^NBJGY4)S)^V)W?EC$6I,\#R,,Y[:KD2HL2AG
M=IKSW.9Y!G9'DN92.JNF!SP.M@^V($O3((\\%N6I%'X2H,WB.3?Z8W]TY^M1
MDX*F9!"*& 'W&.]60VXH@#OT]HA"H4?=+"OJCHK,X^7P[6\F5V[X]AU]8[O>
M8*^;,VT]4PTFXL#Y^1?K+2DF^=)H!NU=)9[2_:'&5P#EMC,V"NT9977J IO^
M[]OT(4RS0'U[ BI1)]\)TX5F.J-/>4A-B5^#F4OF5#-GI9L BYD*S5HI=U,Q
M6U-E3;5["CJ[Z7Y!^&9JL=;OP^%K96$IH8-B A]JWD+--D 7T3M#,3)\I=FF
M)OO#I"LJ.#6E[K19O53L49CJQB:U$;,B*?^!JD](!E$MBQ:+ PWT@!K0I)&5
M#4IW28[7_@\R"=>7U#O5IJPA#C<T>44OC7BG);<S4W&[F^9SZ^CNQ@D7T_N.
MX^U;AZPR5UF#KS0U/%WHA?:!J:5ZU'7?O8(ZV@Y)V88P9G,2_V8PP6IIN8-.
MGFLSN*E;,D^+0MR08+S1_-R8$*;R6+F:'RX'!GVL@,_;&5B;_ :\)-K,P8[+
M_?81V_4'IK_.RV9?CSIF!"FKWJ_6"Y5"]4IAV6J&YWL1,+Q1WQ7=?Q).<./
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M;V%AO<(XHYX3'5'7/&F^ZO95$*:-G04GFZEJ&TV9VNN+#;?;JD#3%<_R'5N
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MZH-P9\YN>3%>(5<=9)K?\MHG&[)@M[WV!<ZRP#>X&+9%WF+_;XDMC4\<;Q"
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M1.H4<[.>9:86SPE1BAF\8!=&0:O%WS3/&:V>3B4L:'4SM)KQFPB&00_42+-
M$->2(J,4:(-.$LNYLSI59;"7B7J,YL %K7ZN.<X7*QBMR<;P$)[EJV3RQ<ZA
M_S__I2FCOXU^G<N$KQA.9BNMSK#.IJ\VM.=1$,*T\B8 3\%.XVB=2R10CH%^
M:U8$U\2PEAF)<-A0[7VRP7 =M1&,::U5"I%[3](#I=4;LZ*PNG56/9:WS7W_
M:8JZ>K"L>OE06?7JBCN7K/J7FW5=LNI?]OK>*:O^PB(^3WYJ&?2"#+H8S\]M
MMS]:G:I.T0*&TU]>E:Q8&VX_9\_?DO (=N_1KGC)89AM.+[V8V?]C\.==2_R
MM1L'^ZWF^X^G&P?;9./]%[QQ^ XWU\/^N3*)7_\\S,]I?MWYMG'ZC6RL>[KY
M_L/QSGJ3;AQ\P3M;'^GVUL?C#3H7@(\WUM?8KJ%)>Q<4,M@YQ$7$R%$B4'1"
MBT -C9'F('RB'R$,YX$VU^)QI,>R;=^ 92^XU;M@S*O&F/NQ5I_&7C?8_GZ!
MEX>#EY,IO+P[V?6:<2,Q1B3&@+BG"6F5(J).^" ](=+8VLI(LGFQ ,RS"F1Z
M55D 5VAF)0?@E:D>+RZJ]9'@X?,9[0,;:ZTB"3%C/.+$&Z2=C<CH% 0)+JD$
M\$#I,F:/X-!\;:&MBVN@+]SRA0C1A5'>EE'.R]'.$,D4C8A@1A%W40"/Q/ G
MBR09 5)V3I=Z-#GZM7'*XL>XZ23620#I0IEY 5, K@Y *L:G^VY5\X)0]:ET
MD *H-P'4:= _!<V#[ )J2IAM@:C@H'D8PI%66"(/L&I%Y#YA#9J'7*;D&852
MWFC3+1X?*R'_!9T6<*,\9W1Z IVO -/-@.ET!IC8+C52*XX5XD$",%F#D?%.
M(Z8C]LDDPC%YCAZ3%X=,\^']9^+@7VA+O5$>P*7M5B[H41CB4;??&L#WG=#H
M#O9CKS[UXE:%<VWZ^BN-K7Q";4!J''5[%;>;:WQXSAMS49O$ZJGCV\R>>]TA
MM+OPJ$'L'=YU$-,;W708U3C>PAUMYZ11!1C#2:W.H L/JI]O]WJQ:G?8.&X-
M]AMO-]\U?N^UPEX\AAOV&G_]]38_J&E[?K]!1P';=??#_ YPHSR&^E9YO"FU
MX/%YU=H6-J\=='LG#2#.K,YW?37&5F?V"<L5F?T9>_UXDJ<-YJ"^6R\>M>&R
M4#U@] K_M]^(/UK]F>D;3<)1+\_KX*3A(NR-3CY>C?JD049#SD-J=7Q[&&#J
M,M_("V+;C5[=Z7%R W@)>P1__0!0&\3V2>-2V.S_)PW.X*;"7AO)!&/8<&F2
M9EIP:GWRE%IKXDBK$W@.-_$UE+JC@1_437[7>M%.P!(_3[!LQ__]=++S-1PY
MRN7.UI]P_&,&O./F5[CN_1?2S&!XX/'.^S];</VWG:\??VRN;Z2-]:;87%_#
M (@GFUMKI+FVZSG!&K.$*!<8<6\=TC029",7$F/GK3%+J\(L Y<[AWR-_G^&
MMA<;*??WK$BD/Z(GF'R@W-!K 61EHLC? OWT*JH#$AY<6*]BRM/RS2X^9V+0
M:J1>][!Q)E2>FKRIYO(C8!N_Z):K%Z>#_32]ZTPZ&*5*<>)8T#APZZBEBL#B
M!XF%DS*0,ZU=Z[6HF&I>JM#J>YB100.6*MZHTVO^"/0QMV+5+;.(_.8BC)]=
MRO.'9Q:WPD#X\DW-;[_':6?7__EM-(><KBA1K_%%5UH'X# <Q-]&Y(!G;[%T
M&2F-<E$6G&YF,H?JN9SYN=^;RJ][$3G8M]^03?!6;VS[V)[TE_XUWY47=LR9
M&3TW4?5LK/[;]?YU=A4OSVH,2B>NM=?.2ZY\T,Q:JZEWCGFAM3Q+QCPJ(%H7
M67"!8V> XFW2-M(4DL,J7+9=?D[^3]*$V)@5+=CM>Q#3Z[;=O7'J(7^P;,DK
MAGRW;$E>LB5?939=R99\V>M;>A"_BA[$KWS8)1SBIGSA:_6H&)"%%P(Q%G21
M0]OJ3%7)K+[T&^BLBMEO_'(2;:__ZS6PXA',N\]NWO\]5W#E]H[[&:L.#,B_
M"<->7I>K*QZ-%WVM7O-/XR6O#F[!@I/G:?,9.4B^\.;ZGX<;AW\>;&^]HSL'
M'_G.UX]B\_V'T\WUG?V=KY\.-@[@N:=[)V<=)!M;>\?-0QC1X<9^<VOG<&-]
MO[VS_HUO'S3YQN$?[9WW3;H![[BY_N=\WUZ;).&1.B2B<8AC09!+WB(L4B"8
M>ZTT7UH5*UJ=*[6S8$[ELG_OO']OXMHL^_<)]^], 3/N6$J.(6JH0MPDCW12
M&O%@:?#6>\;8TBH#S?O*_5M2F>Y9&IFWF9Z70DI:TP,&;72&66.\EZA"?B.&
MMCY:]4^PZ'_'GI^-TD>T\+:?\[:3&=E$,H&-UAXQ)X"W66>1-=H@XV@ WL82
M=<#;Y(I2)3[_3AOI?YZ)W:SPQ@?BC;>+:2N\\;%YXU3N4X1%)9Q#7H<<;>TY
MLM1&%+VC*D;#' ;>J%;8(_3[>T6\L=CI'LQ.-Y_95(QTS\A(-QNT7%3\>V#U
M<T7%MM:.=[UCB@5'D22>(LX-0X93AZ3!F!F):4IN:970%8&?C9WN;M+<_6[A
MA9/?1N'H3QU]ONB,KE3E>7Q3UAQ0%SO6,[5C78'915.[*WQ_GH-ONHN%US%9
M@9RC'/%D=>XW21 /2DN< HM296WM,4J"OB)MK5BR7@!W?"A)Z$7O@^LUSWDN
MS7(NS?!X=ND<<VD6WO;W&ZG=/;[7G(HS4U5"UTOH^B,"FWF*T.;#5@A K<\M
MM/ESZT>C"<_8;[SK!-CQXRU]#1GF@=N(+ (EE2#YZU-2R7UXH<MZLW2'XGXZ
M-X5OLXQU9%LA^S(:]C#;-?KC9/<JWSXG+Q^"H#7LU:G^(%N=JS[PYN&-Z/?5
M6**,[.E3+UZ5O7A:NF2BS_3K[/V?Q3PNR@POUGS>9W&O>[1Q+)Q=Z 8ENX@T
M(6I.B**2FT2=LE)%0@37)$DC=M<KDSG!!-VYLN1\#-3?]B2#2O^%5/#RHOG^
M VE^_7#:/-T3<,VWYL$>C._3MXW#;;P#8]]9AS&OA_8Y\_GIM^/M@R\_M@^:
MIYOK[?;&^X\GF^O??L!ONG/PZ7!SZY]O&Z=K>(/^,QL$>KJQ[L6NML:FH GB
MCDG$%??(2I%S5KB2C"F?<K 36^:$%_OYBZ]I_]BPD:U>!3-^0M^SD_3\ 2,:
MJIW!45G'N5+6&L.5L=@ISZ,7- ,&,2/ @ \%,)X:,"8E'S?7/^!=[0$H),5
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MHX$?W$P,;GV/0 Q;$UHH6' 3+)B-W<8)Y[6,*/B4 ^2H1DY)CZQ@R25%L.>
M X0O:UZ,Q<587)CHHC+1&XG/P#\+R[P9RSPC/A-,%142&4LIXI@[9+ARB $7
M-4;A&'/#1JJ*L?B92-,OW%B\U1W8]IDJ$(MA/+Y9_FB!@@>P+!<HN D4S 89
M)R^"=%(@*HA W*2 +.$&F<"<I\E9RW/?7K4L\"-(SP^Q\Q:5H15[\ZVR&PO_
MO$=1NO#-F_'->1$:EHQI'33R4DO$!?$(!&>.K-)2:1:"Q#G<PBRD";IDXQ7C
M]&1*LYSUIO'A\&@XB*'Q(=?[B?U!(_XXBIT'ZVM;3"R+*5=_Z816W\,[ 2V\
M^^'AU+7#_%<!BYN Q6PXL^+*J>0UPIAPQ$E2(%]+CF04QD@9A,N]SM4RH;*8
M6HJ%NK#/!6>?%XK5A6W>#]L\4_Z"&RVX !F;&8^X$R:WS-6(F9""Q<JGE'N%
MTV6E%[TTTS/DG<5,?2LS]<-J=;<M93@Z.'H:@^.A.\REB%]AK</[-#1>>UX+
MMEX#6U]V,Z['0='-V9AQH; DE BDK6.(&\5 ^5 <::&Y940F%K*5"B\SI9^/
ME>H6&V_Q.-IBN@">'JVN7MF"4[<PZEYO1@M"W5;[*_AT,WR:U_*\D5Q:)Y&0
M0B(>C44&$XLDIYBPD)2/86F5RF5*R//!J!MMNL7C8S]M-W2NT=!/^J;,M!M:
M_;?K_>OR?BLS,W\P[ ]:Z>2W9]>YZ$,G<Z:#8:?F6<>MP7Y5%+_J1M98\_\9
MMOJM?&BY^OIM]Q!>YJ1A\X%>#(W?6]UW[>@'O6ZGZI:E?NN/PI]:G48S6Y9L
MJ_.]%8^7&V]AJH!]=5IV!6[?Z ]=?V!A86R[#3=LMW,[G/R,9%N]QG?;'L;Q
M-S!A_=PP!X;4GS[ZV/8;O=BVV1DTZ,(5@Q8<@3T7Z[%6QUK?YVX(C^GZ\175
M27DR\G.&_5@_H4I_\-U>+_:/NIU,^Z,7:H^Y:&;"U<6S[S<Z*0\JQ$'L'>8V
M;ODI#J;B$'@V+)!M+U=WMQ[NG^\,+][J-SK= <Q6U9$@Y&G+MZZH%U[6=;_'
ME<96GI8K.PU=,:1+&PU9N-U_WP"U4O*4<4TPXY0;FJP$:@9QG6E#DJ'N$M02
MCUM67CY/:+MULZOFP1K;V-LU,*.,^XBD( IQ6 3D(HTH>HV%H%1J3996\<IY
M^R.05+M=[?#G2 P7%*][A13 FVN[QB4B->5(!IO;G46%C.$$$24EC<D&Y^72
M*EDYKS]/*2!SI^=,!7/565XC'6RN[2H1@Q52(:^#05P[AJP2'CX1$3 +TFN>
MZ>!\I.28#BHTR0M7 06IJ")7BUMN9% $M =4;9^LO&C!:+/36!ONP>@;/,\"
M,6<$()B2WWNM_J#;1LV3V.LW/H/PX=SXA.7&+_GT+!-1_-M?<#J,.U1_DM]^
M76Y4W:HJN <1P=:-GAIK>T"^F9YKH)Z[0SYA>GDMVX!H,A)CVO7A?!5@O3TZ
MZG5_M++0 1+&I=NY_Y\T.+.?-9845%#BE0'%-$4G->',:,Z GYAH\WXFAE!&
M9O<SOL%V7NM%NYD^1=M^!^+?(/[=Z\+6GE%-\:O;M7MBXWA76D!PS@/"2>1,
MEZ2R*52@X(FF26D50^;>6EP8I]?H_V>8Q;D48R7-=E-J>9"#81\,$YPS[&5B
MR43;!I$2.&FW=]* [>=!/ 2)%T1D7XNV8_$8Q-#_A84YCB"7;W6/._W]UM%R
MM;G^!&*/)W/D_=8>'@W[8^I<:<#>:=J>WV]0L3SB([-[9Y[V.PV@CT[(9)^E
M8""/?D78E02?W=2C<>9S;TW7-GMH$XXV6,HMXX9(YW321D;NI247XU2AZ[O0
M]>F[T^;'7>$\U4$XY!4'N13$462C)B@J3)D0$DN1C29 (^(G=+W2R&KC2)69
M]&>K2:OFG_LV5,K4"6P"WST$DO(QG%.YEL<Z5R^FK+J>4;IF=:Y,@+;=R.K<
M6!>MGS2Y>P,([\\A4",9*U7PL'U0N8"N05/+VNWD\JOZ M^$0&=H$N#-OPG#
MWC&\7#]VKB,[;<%H-M-;>'B>Y%='E#"FO=V,:3PH"<J2$HA[1I!6BB'MD\(D
M&D]87%I-K32(L0/D9'O]LUUXYQC@A]%*Y[F=@G1E3+F42V6JN!<N]6'CC_,T
M ;SJ#$U4V?\P>A=[W9S+?]A_Q:SIXS%007)!<",=$BQG%25ND-86/F%CA0.5
M.7*QM#HX[IYG2[!L,,O#RKQTU;96F$E.\OTTYS088P(1U%AK5*).NOO;UI]B
M)Q[;]E9%5:]J-3?6FV)S?0UO''PYV=Q:(R!,"<M54HDA:7%"7#",C* 8P1XW
M-DEN$]5Y?\/JY<U];F_WZLELP RWNJ$/XKH%:08DI1DQ9F+N[!YEFKB--I2-
M\5D5>G;*4<9&NP?:RAY(.A5*3@R0LZP0.""(CRZ>$=QN8F"X'4M\$ /#Z[4K
MG'XYW5C;51)FWX-*PAUW"+B91H:JA 1GGC,;,5$ FH20%7&I96%.K.IEXAG3
MS9DM-R&=2VFE4T'9_2'H#$K^'7NYG?1F BWF6QQ\@G%.%A_1U[?Z?&-OUV.N
M).4<@30/+)4F@YPR&-' N5;4&5!9EU;-^:7_G['D_'<O?K>PJ4"YJ^>UD2>V
M\4OE,4F5NV0DAU=;\-=*E)[QI8S8[P XV?B6\0>L5*L_^7M$1#65C=5-D/9A
ME;N-VJ'3;V49/U-==B)D5TD>D =5#3[" /K#7M5Z>U0$:^QAR4\ 'G;4[>67
MRD*]_1$!&$ $ #;1RJZ:RFUT> @T"AJ+;70G;=I'"4K]>EAC!:)Z=K_A 1*
M(X,Z'K]7GAQX$$R'';8'V<QS!*/.NR4_%1YW;'N][#.;/ ^N@;_[KPI]/@_=
M >AM8]M7)<O.J6?SYH9*&YLZ^E*KUZ]TOV$_+V.WAJ\Q 71SX;.1Q6%TR]JZ
M 7._WP(AX+@[;(?,F 9PQ[W*CC$$LJH?/F/FJT2#5K\_K*@I&^4:(-1U8=&J
MF:R)*8\ *+$=!_ 2^22@R#R:RBY2#V50+7!%L/TA/+\:VDIC?KW/.[EG*  >
M4WEPWXP=HK\=M\)@'Z8;9G,TLYRN*%&O_$576M?OMH>#^-N(2/#L+98NHS=?
M&7H6G9IF^OW5<SGS<[\WC=#8B\C!OOZ&JDIH;VS[V)[TE_XU'TD ^^C,C)Z;
MJ,M#"U[#WOWW&4JML91'Y6UPD047.'9&:V63MI&FD!Q6H98X)[;WS,T/[0EL
MJ/BM<K$/6[ G;0.8/WQW9"O!HOHRL]_1YIS?QOGR; ,:\6'8@OT^G 83=Q.S
MXDW4NV)6O"]M[QC$$<RL<PH3A$.TB!LND?%!(,J,B08.. .ZN[J&M7S6CI.I
M_/<1W4S-V5\R?^]%'UM'%8( W;1FX.&,.EBS\$PY$\K,I\W>>GD.+3(M+F?1
MIP7H#WPV-G**5B_643?9TC#H#7T=EU)'=)R]WQ@)QQL$L*)BO6/O4LT QA$J
MXQ"?\=E'6< :#,9&]_'7<.7TV6>?N-+X5.%4!;UC$7YN2!.<G)'@'#P_C/=C
M.[]/%94S\Y)YVFR-CA7$^VY_4(4*C0'_>#_6L#@[@?#\\:@G=^J?'_-%L6#W
M+S5=%C16[5(C?)+$"J^P N4$V\A\HL:+&+'63._F-LF71J@M/M=7%W/]AI@(
MJ$\Q3':]4<Z'$B[R?%[I2=!2:D>L]%QQ)X0STC$K+$N!6:KE[GJ%21QXYQ2<
MSL0.VU;OG[PSUX$1M;N@$L7^%CS@]W;7?WM:O"'-"=Z\.]F&:YJT>;K]=:/"
MF^W#=[QYL/9C<^O+C^;I&N#).[9]N-$^BS?;@#<POM/MTXW];9KQYI_6]M;>
M27/]G=C8>G?:7/^"FUNAM4W_2<VM#R?-T^8NU48*P30*%HO<U( @*Z1 U@BJ
M\[^)L%HZ .X2PUH&=TD)D=Q3GPCG#E3F2 0FH"Y;S#2V=JD1 <6/,K_I#>/5
MRTJD"5%S0A25W(!TH:Q4D1#!-4G2B-&RDK*L-UI69V+RQ"B4J[0C+KQ%FLF
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MGW?Y5:;$_/<X$2!K5SX7T1@;IYUM5_NPOY]5RP *>UF]"U=OD=2!RP>Z:.K
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M*(;72_/7@HK'DS%I'1_"L_R#*B#KJUUPR\9>?,-;=\Q/.K@JK;P__CZI@0Q
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M]@$,@98[/R;?CN"N?4 W@#B8\[\?]^*8:AC.]80I_.SUJ\D?JZD_;/0]8 6
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MS&RW8'38$A@S9*F/B"NJD4U4(:.H($0)8\2R;I]80J(I-73N:"8.COH#.XJ
M-6Y4JNB\G3QLCGE-:0@Z"<JCIY8:YC$HS3Q&[YDKEL]2,=)\BA:=2" 6,Q0Q
M=H@'89%3$GYP264>;F'$RCJ1&F3G.:)J7GT.MH*/!1_O@(]%67]F:)PIZR(J
MS1P52$H>$#>:(2N)0]Y(R[@,"6.]L@X2HW!!QIJJXZ]XU>8Q2UH^H2OML<CF
M;J;J*R8;*@T+W!$;A.&4B9QY@5(6G!;!8TV*,KY,C--Z/[\, 82CN=:(, J,
M8ZU!-MF(E B2:$N"3'YEG<I51NL7X5YWO*SG2D.!Q^6!QZ*+/S,RSG1Q[IC%
M.0N# F4<<9QK5XI<Q9*[R"/3F&&SLD[TJL"L(&,]=?%7[!K_V(>WZ!W&WJC1
M=_ :-LM=\8N_=JXA.AD=!3 .S]FLO3$F>*F5XH1)@DU1Q9>*</Z\D+H\X1 )
M1@8&%@A'!V2\%\A@$03FRDE'5];5*L6E,DGQBA=T?%YT+)KX,P/C3!-/,B:A
M*M4[>/CA&=*$*B1!,W<L*B]2!$T<KTI>O.(UU<1?L5>\*MC46+C/NVZNGWH$
MF9;$.[7(Z;',1,^LEC9Y%XEVW!#EK!2)2\ZL34D'4<R@I6+[^8T1E#"2#&%(
M*,\1)X0BC85%W+) !4Y::;RRGN5&:%4[Q]N;2[I36*VP6ITF36&U8K[6@=!F
MYJNG$B?B-/*6.,3!DD56"8)P8,Y:'ZTC?&5=\U7-Z[>0].;X;$$2N9)&JZ31
M*FFT2OJ>^_GV2QJMVP_L-,]A8YKBL*32*G.QI-*JWT0MJ;2*M)146K6P84HJ
MK9+8I"0V^:EO#0M/DG5":TFXLLD%HHTW204C-2;Q$4HUE!6C7*>!;A^$;\WV
M;]VMCSO0GB^'K?:V:-+MDU;[&VL=?C[=/OR$FV=[IU?K-.QT6O3SC^;?7_G.
M(;3WXS9I'7P[VSG8(%MM3W<V?^]L'WP^V]K\_6(J+4J#Y$90Y'R(B$<FD>54
MH, E)9)@['E862="KV)SM?90K3UL=2>?LB!4**=0SI-23LFE]<)$,UO)"9PZ
MGTO;2<6!:'+V1L.90H((@JE4AK!8<FDM<YCB*]XP5')IO=6H>(VUQ-0*0Z7A
MQFOKJ0A8!^\)IQ[;8OHL%2/-Y])BEL"01H6"4A)Q*PARC%#$L/>")>*MRIM4
MF5D5YCG2"+_ZV/B"CP4?2]A5?:%Q3ED'U"-*.V1!.T?<\X0,I1B4=24)8Y@'
MPU?6N5E5[#F<0J\>&<NRS9UZL.32>IMD0Z6B+"9*C$\<)V62YTXRHH5F/,FB
MC"\5XUS(I16TCAXT;R";7-(C8H4,"PGEHL(4QZ!!/0?&X:N*\MIYA^J.E_5<
M:2CPN#SP6'3Q9T;&.5T\I4A=U @K*A!/0B)#M$9:1*IP4-(Z0$:YRI0IP%A/
M5?P5>\8?>P/_$_I^GGX$RU;')S7LRU;'29TI::(3+G$I+$\N6.,]9\IYXJ(Q
M%A<S:*G(?CZ/F<2>LB 2HBG:7'$J(N.X .XWT5!J%25N99UQNLI)_3QO;V[#
M8V&UPFIUFC2%U8KU6@="F\L$+;P, 1A,A9PC7RB=,])$%'G4P6CE!(\KZT*N
M$O(<"6D*G]UU _]D3%K'A_ L?V%#_UPO'AP/1YUT^LN->_SUU2ZX96,OON&M
M.^8G'5PE#]@??R>TPL[V?FR\[Q]""T\;OFN'PTX"2&C8;K?13XW.:-@X7&3J
M-NRP 9\'.:,T?!SMQ].&'<3J.CO%G8Q3C2' 2,/VPOCPA4/3&_2/XF"<D7KM
M?' NYU)8RJZO'ORN,X)V^RO[Z!8,QOM^KYJ7X[[N=:"/>OW1G&/A7$ SD71Z
MQU6O+?K+7,\=]8>=_,=W@]B%H]_C+],<!/#,R?,Y75-BW&.+KK0.D.!X%'^9
M="Z>O\7*=>,TV;+XXJ-P\P3(JRL7>G?NY_Y@AKU[$;E!M-^03?!6[VSWQ)X.
M5_YU,>$'R-^E'KW24>/>6*_V-2YZ\J6A'+,O88R9(+ ,4G.2DDTN?R9":*PT
M=F/- JZ)82/K!2DQP3T7TE+.B4K6.6<92U9P*H&35JYY#B7>><6UMA1S::QQ
M24;L(N?)F,33Y>=PKCCQAMOD(Z<$.]!B(E%6>J6$E/):V5B>.7RS]'SJ-3:.
M]^!E<@(">/IH#DX[PR'T4^-_[K*@H:40T.N4!,E5=(9P'JQ.5OL0#*F*@Q"!
M]465\%/KMSMX.K+R]ZDW' V.<SV WZR/&X?0H:-SE4\NI\K7C?_Y<KKS=SAR
ME,OM]N\=:-_9]EEK?YM^Z;8^_M79;N^=-C<_B%;[PUES\RMNMD-GF_Z5JO9_
MWJ58J>R,R(F#.>*)>I2['P7I'&?1!4IQWA@& G9%;VN ;'7SV )G7CO<,"HN
M#AYOQ&\:UD\9>N-P],6.XI\C^!'^B(,,R(!CYP.-Z!L<Z=;)KN.6)$H$2C)H
MQ"7+/J<841)&.1:]DA20BZTM*)OXCSQZ"SFZ$8[C! O&>F:& XHI;?PS@T+>
MYT'Q+]4?YFF^E:^M#I)?_G>M 7CR9SP:C?.:9//OP9 "HJLDL]9QZKABWE%I
MD\:8*IQR0NS%:>(*I#Q0T+9_M !2$H%^=Q19IBWB1"CD0B3(4^M55%[C"%1,
MM5H3CPLIQA.IA!>68QZ-<UIX&VATBABC%_L5"J3<=Z1/@3P(ELKB8% 0+N2J
M3PGIR"4BTB70C3RS+(?6KRVH4?T32#F'@PNH(B^CBKR**JL36&F,^GL1SAXT
M3CJC_<9/T6AVW>S,&R!KWH(<QB.;=PUUP1KT/D, H%4V]?*MNAWK.MW.Z+0R
M!^/_'>>/'J[L]T"*AEG0QUAWZ5$-=YKMRKX'1;6W5YUS-.C[& ,<BJ.3&'N7
M[G]^TX5/6LT6:SH>5%T2.D-_/!Q",SN]ZG&3;B;C%TNV,VA\SQZQ:YNWVCC9
M[_A]N%-*<0!W'O0/\YEPH;>#P6EN<W4'.+,SA,<D^-SS\$1XK\YD4C5RKPTO
M@'VU,U#],@35M^^_P2MW_-B0GO_^O9]MNO-.A?N'"'<$0V1\_^JLX?D07.W;
MO@/5]_OX]<>6?F,TL-F-,WFM;+;_-WZ/W7''4#CQZ'@T''</M!S@HQKD*QVU
M6+@:=M3X_;@WZ6:&*VG&5>.G^;PFAR9)O1HG,%IW(3RLO3**^*1!HY(F.U:%
M% !TE /Z,7U-7E3Q +Z[[#1]:W0'[3QKGNQZ(0D)B2.A$ZC10$'(D> 0HU@3
M*X +"0405&*-7D]W61+N,MPB>:&<()J#<1LHU]%IFHM]>+!YL;Z&[<IP/VRX
M<7-CER6"@S(<Q>@3X@9CI*63*"2M&./2>ZKR<),;AGNU >AW%'WV2W5/;P4J
M"YCNZ4'E?EITD;('2=GG,Y REPC#DEC$3  =FNJ(M$X$1<5C@D\VY)K#C+.U
MJ^$!]P:5^ZG09;@?.-Q@FQ.B'';>(:N5@>'F'%DG/0RW2!0[9I+-MCD3-WAA
M+H'*VUY3V(R@E0X 3/,<&'MO][)F#!^'G3!9>&D<V=.\+/.ZNNIFU^T?QX/A
ML86>&/4K:FG&P1X8!!M[@Q@/*S-A8P\TZ^'$?MCO=T-6[T] 7P>U.G[O](^'
M8.? F9U1%_H7;C, L@&9N[&;#RM;9VHDG%M.SF8;I-\;\U0^8OU^!_3N<='6
MU/# >!:4])!U\?Y1]6?H%B!+,&J&C>.CW #H;;L'+["7,S<<VA^=P^/#AJU\
M,?D>=X% 2['GEKE(7.*&6)NPC);K7#5/$75==;S;0& 5G; Y>X_F]#7^&'?/
MUJQ$[>9QW.K]&:%E8:/7@[X=#.W@-(<J;*7Q@+WO]H?0UV\8-_V/K<^[.$>0
M>"T0-0IT[P"ZM^8*E#$7*'%"*^GURKJ\T7D-"/%3\0/9.@:3LS\ @_,(S'#0
MSN;%\**KP<X.344?I -,^9.I(5_-F*/J"38;J_U!-F7S[()9_KU_[/.]'EVV
M560\F&! @'G6YG2TF,-W0XR0F-#=S4JV"2;H84+^_AP(_CMU3LR$'317.&J[
M&[.>'OXQZ8(O50_\->Z -^Y,W=K\=M+:V^68,",T02G%")J!"LAY29%,T7%L
M@C,4)%S<J!E<]%9E(V"0T7TPAF\0T3N)48HD<JTB]<QS+C"8GCQQ[6BTP@?S
M$*.@0.3C"A!N?MZ5P6$NDD4XT+S YRTR"FP*PH)CB@)0*K&RSG^VOK>0@&?,
M?GS4'[LCCW(P#<#<Q'(=5B,$*'8^1-,C?CP\TZ_C,<LZ[)X=!+A_Y1D]V1_C
M:@7-1T>@_%5A-'/0NV]!\W#9&3J![C"6]B+1KT^B6^W/HG7VE6QM?B#-,Y#N
MO2>5[HG6>QX?%K('/4P-BXLJ[D3Z)QC[_X;5X1Q'6'ETG.W:GH?9L!]C=B*_
M98,C^^G/5SV^Y#.'C0\__+X%A6'>#.F,>W2T#W]I'.84Z(TC:$(_@.T1H$^S
MYZLQ=7HM7"^^%@&&^Q9,Y<L@8)51Q@9!".>@3EHGDB(8*T6\#=+\1#NZW=)Q
M!0=_YI6,3U4;-X\',*'_J-[KSZI5TZX8]\SY5,=O;:IO-L76Y@9N'7P]A=\G
MK9/=(*74P:A<%$PCKHQ$EFB,DF8R>LR"S[H^7=64K!)U-9-78SSLTP!/WS\$
MJ9HL*V4OP9'MW,U=1B2C(!S&$VTYM\IZ%P(/@MDH"6%I(C'\P?KT6#+&$E/E
M1-GPH+Z-HQ3?+AE<D) /9Z K:T\BRW50*6=Y.5H*I'$,2,+$=AJL=TW#RCJ3
M:]?MH)XRP@1[S@VOU0Q>?]@<.]XY&J_'5O-SXAW):Z']?%&<XEBEE?B,^=V)
M#PI&.L5.)H/Q(NE@C'P TQ/UYK(C9MZS\L_._]Y-,H75C,:H-&"9ML'1I/-_
MA"3G&9=3A8::^PGD#5I,D<<Q8OW8VM@5@$B<2(^\#ED>540F:RA")X PIJ7"
M,2\5\07:R06!7%T@D0!C1U-;>I%&/G6M-6[GUIC3>K*X_K-S1Y'3UA(5L0U)
M8^ZMT=*G "I!))1X4*0?*G)%AWX2,3UK;>PRT&F9=!0EZ3#B026D=5Y\8(EH
MH9QW'@-LJK7KLF/>+*5WD2*)#?><<.N#Y!'L,*!6#02/93*>2E:DJ)92A+<^
M[T;.)-,\(6&TS^J91Q8K@Y)+U$D6$H_X&DOL"OG>[&P J1I3YF);+-L"=M0X
MZ1]WPYQ[($>5/9*78JVQ 2B9E]N.NZ-;F#)CE^\A(&Z^U346Y&0MZII%_3NO
MW/,DF1 ,$R-YR!LAE)11@JG,?"+\(>% U43Z]1BZ)0Z'8'*Y3J]Z@_?SKW/N
M^)TNQ%TX^L?X7=_L](&V")@R7GF=L!.(:Y\7^8U%#EN&2$Q61.\]YP8LFK6K
MF=!F:[[C<+4L'C""_?DX.- ?7:QD;Q90<M$3',#@Z?5'E6?M% 0Z1P5FG_OJ
M9'/;!5<(/##?K[*23JIT$(T\*?, ]H(=-$X!'M<:C0WO^X,<2-<]K6X#L^.J
M.(^GQ)U<=()+3#Q1 3/.(BA4Q@=LDP)@,5:X6LCS^_'.OC<LULU3,,,,=)%D
M-J&0 D'<68V,)@(IFR3%0DF6Q,UB/<74GT!EEOJ+WKGSO95CF+_@=WME$1'7
M>=V(^$>5.C7WX9T8:HH*8'3V]WKP,.C1QEXV$^ZHQ#V;7^0C-&XK_1E'HV[U
M'HNTNV*03G0TE@D'*ZZ(Y0@3# :IHQ%I9B@".S5JA[%1>9,D7KMNB_[Y].Q-
MU*9IS\\F[$(_>K41N@&JU+"VLO1?:-R\+'TY-XV+*%T6)0I&8W04^PSRTB10
M8)P*R)J@D94^),J,H%5!.;+&[BM+"YT3=U_<*VA40Q'Z<-K<VW7*62L319@F
M4'^]PEG]=4B[%*.)QJID;X-&%4?=-=:U $O]I&)#-$]V#5$",TJ1HEXCZ'^%
M',,,46.LTXEAS<2M@*6BF[R/I]/SW>,PWNQS%6K"K2)%.Q?6=^<V*=G1^9UF
M"3W.=QZ-5R^K[4N='Q=6,8>+EC'7&ALA5,LZMCNSGRIBS>%?#];C>I?,P7,O
MQW6O74.VGD:2+[;8)J]QP3K;& QR/U6^H_=5EWWJC8/+MM)UE^15-E*FY1BL
M3[8V=@/VFA'%D*.2(1X]1L8)@XA,@BG!I$@Y3\!/O7M5.I:Q=Z)RQ/4'4T%;
MO!@Q]N7E.(SS%;2ITZ/:5GAQ:D]F!'R[*N373?39!LJ)6^-9)GI['YH/W80&
M.;M0C@(8[S=LL/FF'T8[/!Z,'YRMW=DFH>/A-)AT"-.B.GT\90_C:+\/9F88
M[XT\[HWW.E8&\W@38]7H>4T]G[>X]R>],6W9["G#. 8#!S<YJ3;P0X\>'/?&
M?SW?<7M+J*I<5S"6Q]7X/#/B+ Q<O8 &;<"/X;@MO\6WS-8'  EG3;C?-[K5
M;O+6WBYCA,D4$_+<XIS(U"*-P:*T7(@H$]95!:&[;&STEF)!(X *XP8;D[3
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M!4O/$B$<&JRY SE)\$$K9>#/U,MKC*D"Q7>6E-/6V===9X6P4AFD@/Z EH-
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M?D'^I[J%J3T23=W1-?F*B<DFR;P0S($%P+W3+AB>K,/,,VJPK2DQY9H0N0#
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MA*P, .^*462CUR@$ K]L8L;'E75"UZ[ZUO]QJ\BQND#KBY]:\&69XT'?U$@
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M$R;,".-HWHJJ3)5E8L8Y,E4N91DOIQTR1[/],$; )%@O<EJ/BYS*Z!0#SYF
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MI7162>5PX#>6>+T&8N<;U&XP0>Y>KI*(X9'^(!=;SGQ;R[8%<.RYK1!/BN\
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MQQCGCHT>TG"/)DXP5S+PP#'AFN;CJ@FG)*B)W(U3B/BE%*)'5CB]+:WHCT(
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M-#I?&=##]\;&E];NMW]28[N!]\#MY"Y2BX#1)>(V<&0]X2A&)C 57A C2PL
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M6F;;W(ZRP*]<P+$%"%;HP9?H8^M'#%O=[3X(4CGH<T-6OC$<:YPUZ)X3U.-
M/:*Y5!;WWB.+P2Q5B6-FB.&*T%R 4:S.[HG40$G;>=E3O]>I#4%7LU"4_W\
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M) K)Q"_^UU_XKZ!4Y_<N%2V>^#C>U0$M@7L"S><@+(SXJ->-W>&5:"T@1!>
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M)SRH#HZ1%)@[Z@@8RBO;KCY(1_75G5@7 #)16%1E_BS=%W5H:#"$W=&$DOJ
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MV=D^)A;F?KI+R:A>JLL[G^A)D\?!N+G>I$\>")3JO/K/*#6U[[G.7_W>4>?
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M6P,&8'*P00S)/,^IU)@3K0,.7GIFC+W+5O3OQJ/<#U'4GZX ?_M,#T/FA%(
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MBMQ@L"!#M![%$NNQ6F,[I33KZ$LOZLZ.&\4,4YHUCG&0D>XH)A" #NQ7&:
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M1.14>8M4&H)E\)='N,HP>9+]U!-&\T>A+A\HK/)]_[M61ZTNF8F.&R4*4F6
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MJ=R!)PQ81P3HFLZ EF6>H(QJAF!1,%+& &?3F*D\V(P$$F,*J^IC5_DKO>K
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M=7&A14/QP=F"?_G!X-=.5!&3*'F*2CX0#PN]WW5>M8^N&/':P=*S^X_7LAO
MTH?>.#DA(50M?:^JW(06G&X"3L64':0<$R'C&@D>-.(N(TCQ()#7.A-*..Z)
MWMCFFVQ)P:?G=XA*=[*WUE5MWM[B:77D8]&1M^/NK8[\:3IR0N"YL%(;BY$/
MW""NK46PE!RYS.HL<Y)3K**.%%G>ZLCUINHWB.(\9'(^.9S0\\-G9$$(?W;H
MYH[ YH:F[&.&EQ] P6<]0]-@4TM;BS W09B+*18>J+2P= %)1CSB.  +]\#"
M<Y"53&!*?3 ;VX3039G?+\;<<DNMJT[\4;&&5OT]>G;=JK\[5G\3@DVU-["
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M8FNX0 Y,#,1C4,08HF-JG1:8" <D86-[$)E-K8]1K(?9B5*V6BYJ89B7XW'
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MAS@5"M@TK(DD-JA,>(\-!3V'6:OG6CW7ZKE[<?>W>NZ^]-RL'S_/O)3<9T@
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MMCJ=#_58_60YZHN+,K39C!:V>QQ8>L/I9]>C'BR(KQ\_,N5)=$%8AJ-J9<[
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M,8.8&:'#3,/-8@\T+6 %3OSL5^=F!_Q@A';<)D8*-"IYJWA1E9.)DD$,(:J
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MH%E>V]?@? V-K;917^=.WI&<[-#QXA ,H0@L.(O;+(Y@_BY"/@:A'=Y))/-
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MA& :^& W][*L_]^<C"%E;Z OIC*HVFI6\Y_5/WY)\WHV8<N?\X*L OK1+Y_
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MIHM+D<MC5$DD.N75<P-N!A4PM5640F:T*[\J14T'0P-F"OR/7@,'5'">BDW
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ML*;N,90Q4>F:C;T6KX9#F8B78>9'NU'EK($D$J W.K'V#@3/HW,2L.D"]8@
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M^M\%;AA%S/ TY:U]L0 VQ8%>3QM_X/$E8I\1XWIQ"CRQ5;_)2\BJCP)KBRU
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M$<0POI%N4"]%#RW93AKC NM73Z=89\K^J[S&E JPSJ0#6#@$L>8(E%"BWO&
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M(P7%P8VI?!&C<^A374P:\@"]#'Z/%9@UG^5LAOE2>'$Q31!N45U2,7A.);U
M)U3=/N?P%P7JL<A<_J()OC$M9%A\68KRSJ04()D*;)-B1%,^!P-U@D%*(FR:
MBD0N+1#3&_.8U$-) XVVY\41#ZI%EF K#10(Z4(*M*9%&>@D3)35#%TA[;FT
M2&XUI7G/52 QY2+A2/HN!L@&40J2*\R"(LBC^15F >C.@]D5+Y:3CQPX ;!T
M1@K&F_]Y?X3_1V9JY$4,VLR(5U5));0:5<FL*B#EM$24?<K3BI<-<D,S-?$:
ME&X8?J0YBN)C46S9IJ'C\^5G6'2\R"<I&&%*ZE'Q,L/BY4/FR"TS1ZQ#YLA]
M[6V'OL4ENN*-4S%&5#%I4X"PQ8QQ1)?!6X\BM\;R#I&3G5>8U%L)M@#W7F2,
M8B*G0MT"]0&F*[(--,6B>7:)X^5?!'R.JL'L:% Q!\4A)UD%'!]>)+5 R8Z6
MHUF]!'6 876)!N^)V#=E B*+<BT59#7A'2N]$'.0%X7 >Y#)QS*'1.8Q2+P"
MTK0VY8PA\T%T4\SBE#D>LFDJ:*KX%R_269E3=8E0710>,=9J"(!9O4*0E-P6
M>W;*\9PNL\5$ %2H'-!X4I:8]L()Q'12MRDAF("!:1*H3E(&A5+W1=J)3+L1
M56EZ6@>)=IG JU+WG-7-4&NF0-MW3+;X'FZ60W?6&[JS8LK%%DU9B>O <]^M
M$6N;.['VD8-F^5V:KX*YHO=<%=TZ_]:<U[H6*&-E^NW4@5/0H?AP?.<M-[^J
MJV:SXH%V:;MTTD3_XHX--/'5F'>S51--^N===LW$0[R?KIE@0/[@>[V8UE"C
M1(76K35(%"WU'FP'/9C&#]1-35]Z)X:\:]\TWWS ';9PAU2;I?D5_'AT!;N+
MDD-MS_NC=T>C%*]F57_C3DP/1QWZIR@*?=XBUK\LRSEHP0-IIP\:3WS3-M""
M4KCW@GO\+.XI/M;NT,GIR>AE!?K/55[S!U43M3FC1C%*3*A7'KFQAIH!(M,-
M[5]$&Y@?&1 6V'K%3Z+'SS2;L"_JD=&/*:>_81\QI#T($'<3MB9L,WHK*ZIO
MG.09I\L-K*"0S:7(/#S283V0+:R#L=-@Y0:G([ \*9-^&BL6WH(%7*J62; [
MXA_82TFFV%#T3-1,2FR&-0"CV[TB [8V^(XCV;]GI7H+H>>0(>+=+1J$P&DI
M!573+T=5K#9%"!V$B!1^48CB;%I*41;&P$QE&6&;6J)4)-!\^*0'M2(;%</\
M*-HD4/80$K$-"0E44RH2_X3PICW\PK9KE.:*GB]GJGQ<9&T)QZ0L!X%ES*_:
MD))X>;,]4B_08'D53)_8.]Q;V1#+U*+/E>@-B\44/SBA%F'K)%C0INC+;U3Z
MQ>Q;7WR?H %NO/D(LHF;*;D5<&X)!;:8[3_#0NNBU?-7>_^TFEL/_9<*T]M:
M0KJ50B>J"+<7@:\E5R-W-)%G6P'SOB"E^-V<FK8,,SAQUYL+CI39O]!KJ5 0
MX#:DZ!_9&TA1+N%6$ H/L.KW!A?'!IC3/D)4*RZZW$JF2"'4!LQ*8"@4_'HC
MX]+T:NR8@W5=4QVJ%0PDR:MDYR,#(0.:H+R*1.CS';=)\Q7/!+"S3 ^1,\11
M];>)O@P]P3$T65H/3S>!PHY1O:>HR5SFBU(BRJ*@+&8"9$W1P0P2NUQ<7HV.
M%Y?8P4KDU%A2C%%;O[7BNFX0*/3-5]EE22_Q%-VSRG8G:/"YM- :F =8HQ4:
M)!G&JL;.T*H6R37:0QQO?T*)$H80< W>[- 9-(8V'(:".;>$$!1RKFIZ4PB&
MD4LDCJ$7J$Y:7*Y)XC4M:@W>MH?238,BSG,/>]9^ $GC]\\ 7C"!H@"GOM2#
MD80G.16N%U*6U%;"_9==5Y"*KA%8+F] KBJ>@W94U2J#^E)&WP4H1(.W+M2.
M1)=.C;=#J4ZZ,8SW3N-$&Q1:85ZC]";]62Y,XUT"00NO'A&?Z$BW;@$%ORQE
MP7_=YA](^&<,"[4 6*.X3)<"7:K=T"[X];C)W9!+GK!%@9<%/0\Z%H< ?F%J
M%"->&FHA,:OS6G*+/R0\ )DH4Y9*T),VW*&/B<Z'<>O0:Q#MA=<%_1I+U0)/
M@8<*6.SC-]H'%'BAS!N<3MY6J2IL:ED_H*L,O6Z :D_Y6.0N<0DQDA<R6UD_
M .JX)^<L9JIM'UE9VO142PB-.R97H,'P0I;3KB$.BDAA $E@+72 X&;E1.1W
MC%O75P\E2 OHU2L$<& Q5)=2<:DS-(@O),Y%9\!,(6DM"@4]20*7K@L2UKK[
M+M.K\5@;'40H'LDRF8C8;Y[)9DNZ0492MD%+4NA]*)[%+QHQ-4I++LQ!50HC
MO6],:R!"MTN2[T8- 98IR@<FU-=U,J'WL0Z :IM[?S.8(:FSC1-_6%4;OI0'
ML@2R[(*?%BMH$TB"A#@Q9.!T[)0!:'N,&5YSV0<:!C\[.=ZNXPHY1%"L(,EA
MXX=6\+P\.28Y^CJ9ES+>'PBE]35Z+TA\4K^7%Q)^!NCHE9+;"&<C"Z 9M=$E
MR*NW"HSB-S['N:LY48<8"N+3$O&:PD18K=U1:?_I(E%)84K17E259.$BR*%P
M+VA?#HE#MTP<LA]2XM">;Z:\G$2B(F]GMB#V2O0C##]JD=%>P?:BJ>9*M7;!
MB,Y?\KA:H%P0==HW_PHTB"*7UB5<),XFC9]NS36E]^ E:^_4NM?H+E MS1'S
M#U43\>;2*P<V,2NMG50O,1S+N81'M/%0RG1&V9A>"#G5:A[57Z/;G$KR0]FU
M7G%1Q3%(O)9%:T87LA"XF1\=![%G?%1HS$HZTD25WSQO<*^5+XC8J^ZWQ9)4
MT=]-=$'!"*CHEB(,7W5*;7B\XS45("]"@Z<,,+#Y%>XN"=WDJB"D+J#;3SGK
M=QN;@FE<IFU#H92+P)ML[:BM@Y9*S:]QX1(%J&D;IAG>*LFI<<QE);H->N(I
M/%KMRW.[_GKWT%[OB7=R&[PM<%Y-/<L$,PNO:/CUMTO%Y8<N['I^0;:^3!IL
MU& MS" OZ03S_M!/1&VI! HCL&%\G7"YP=T&K4A"7@'; =&@F(4X2TD(:SM)
M#?*9#.P\CJVK#AKLS8:5QARH,=FR:=TN>NQ(*/%%+:F<V)>@YB[;D2AB?3.H
MO7B*#:NF+QT737-V6VN_2M\^>G<XYLWQ]]^.SX]/M00%:6H>=JT-A9'36X2\
M&AB+E9@8FL_\$K2<O(G7YT#N""4KP_E_L.4D_U2U\7Q0;A@H)J5X9)":,5#?
M5HSTW6:_H7$U.H:9@(1K!,ES5N5QC/&'O@.TFTB'SZ_F!Q'W//Z8<(;^]4&@
M+_SR2*VVFS9T0Z) Q_X=CUZ\ITELBNX3DIUP5EI4Q=;^;:-K;5EPC+: \KAL
M ?L:L4V+018'8H_\+,@\X-$*YSABT^6DS%,P^H2C\NKX_/RM_NE1<V8[K;*)
M_[PO%)C7B_=K$C:(<@E'^PI>"^I251:@-;$& 8!^_O+Y.](LA;F! VV*N#63
M'GPCC"4/^>P_K]X=][OU2!CM@;X-Y-QO8UVRJ+KUE.J0( H;7<2+**HG&_KH
MD-UK]$750;#K(DURH9T4NBP';4DLXU;)]@^7<>V:AW8B&C\3@L2)5C?Z)I]1
M!<0A&4TDHV'YVKGL%?@&2 _M^@=%&#=+-,*$'LWDP2-'Z'=()#=W M<Q3YM$
M#!)$T[) L&F]B)'41-DB@ 0CIZY.H-E5G[ >M08]D$\%@,39.ST\>$.G4_RF
M;6"JDM9PD"9-#:RRO&Y 4)K:GX;Q4#TM%T/1/*6E2H^O%#6F($60S;2M5&EC
MFD;4LXK/F(@6H/%&T-GU2!6*]QNZ_N.W[1JZ=I<YG BS"@*K4,2EVP->ICM;
M)&<E=^U::%ER /V;%=+/))-@VI X-FX[/K[]$C!RH 74Y1HV-8?%=+O=&KT^
M2M9^:^;U#BF0;M:C9%QMH!H35LB'TB2Y,BW%]1UV84XZFNZZ^@RA1V*=!]'G
M\-="[UU-2I'6KFQ-56ME'J)R0TSQ5$WQ6$Q1J^90L]4^$CDM$VQ4@BXC_%Q=
M":W@ ^WUML+FQ[?_#"++'X_>O@Y,QS7]X*<C64C0N<TJ?-3^<I5/#/KY(F(5
M$CJX@0U:+0[%<526$GWPIB)D/0%G05&E]W#^HY<<>'(BRG?>G+Q_>2S*=40"
M8:OH$6,@N")79.G)5.%2)3ZISP=6J[7ID7Z%=J%*_N &5_R*B^9 K?>--OO]
MV<M7[_Y%H?Z1+7V,U&-F,FL<&#+7 6/-S9:*-<15"2=8$0H9YJ/P<C;!FI]/
M35LT(E*PXRXON0P!YG6;HG2D54K*5IF)5)ECKA(L-Z5-(K',ES,^LF"+B"0=
MK8,;(H3(S$NU=ZULJ=4^BKAX(P2Z:UR1 OA&/;UO.LT+<O(=N/9FKOV/O#3X
MU[#L1[99A-DBRM!U7!;-/XGL=M($N!3\4H;0Y"^0(X,%/3I709/EZ'E9S<I*
MT\S:QW1U5 4;%-]M RH2J?%R09J5S-6AXGTFNE-3EU0ZQID\QA68-)IEV^"T
M*=)5E8@QGU]C]&,AM+W.'$4MHXK86V/)DU%2B+Q\[->:?F+$C:<E_&XQX4U;
ML>[$2)/]!)L!VUH07)  #8<]_5A@*AXL"]2]P'6$)(-_AUZPO@:^4Z.74YF#
MX+L**6!=4BCNFS8/\MT@3_J<8UH-3,<W1\E5/DF;8!WP)&!5H,96LMT35YT;
M-2 5D,X5(><LL1'8A,_J1B$=2N TA7:/FL5MEN=LN1;+-'L^J96F\QL$L-35
M-3V^]_6X&[-3R 26G%VNG#K+T:=R@ITM$0"BWTM#MO&@J)?  !371Z!I]8B@
M*RW1!IO@3013B.Y26LJ3F2(.S&SU.Q4_:(;HSE@&SYJ85S<;EW;DD/UQR^P/
MYP%F?SQ $;<S;@;>%$.I :.3O$XP@VOYH!9]HUQO>_I=#WJB!IQ/R$92M1MM
MHJ[P.U7$;$7JL0KT8XHR-WH-.4%85,ALBPYZCNJ3DY7)0LM/T9\@9,'K5M<5
M^G7#U^9MB 1GPSIH7-W@#:51BIYK=ZH4Y^E_/\LC+\E\BWE)8 9N9)F,.TEF
M1XG'N1F&3GAAF=&SQ^+>W?5NO5R0Z'E$5^F<S%UA?Y:=].1Z#=*&=J-DT%Y2
M.<)*S3CJNQ,X:=16,,@2JZPJ/;->E%IUDNM1?K<5#"J9!10M Y5CU+VPY6XE
M<_AEUG$M_:D(!06;H^5=K4U'WASJ;X.B38]D @]7Z3=B.62PS^;TH58#L+YV
MHX54Q9Q\3KD- Z^BQ2#JPUS:Z-BVO<IC3 34EM!B=W0J#@C3O+-L52"YJ?YQ
M-9EX/[JW? /2+\D@:B6(:/,JDQ^UMK,M?:F".7H@RX3'!?;2.0(]!3.'J%@7
MR:+F10Z[CG'[FG#YA:M)QI]%I9W=X,[@']B=J?GY64EA[?Y[K"/OIO>\ \(4
ME5+R+;[^%G_H+11^[4+0;)J42 8=G.N,\&Z;*<O6R"T^+!*<GI+J4B!82R$7
M'R@/(::LYGIL 6UY>8O:=8J/52Y%^RJ17RZ-5UE9+QV,;<Q;3556S8ME*)3<
MWG*&5B.#V)8S%F%IGFJVR";L)5CB)[28R*QM$%@$_T7',+DJ1/>OC@L:"Y]8
M\1%X;3Q7(,W-4="'LELQ;+\L\J*D!0641P#-.K:70@X73^DP-T@(IWGZG,TD
MHACN28LIUO]*]'M-09>7]BTJ90WV^<I ;3&(<I@ BY_G\X7L]0QB!!W 5=-E
M71P]\#HE'OH)F3+AJR=*Y*MF5V "%GB!9WBDU24K9*9#)T$3_1\E82\09E\;
MTU-> E3-5*].D2^IE_2TPO%H]"['S%%!U)T6NA6V 24=417/].16!P]K^S2U
MMJ8&FY,CR))R;?6R98@4:';D%5?U(33#=BJ=RI[.E.Y(KCQHU?%FM6J8?RH$
M^8$^(;G>:@61?="//M'ZBFPA9JB6>+3A]3'':D,$XFK@M69L2:I,V3)G):=$
M+Y&.Z,*)4$$N@B4@:BB<#"ET S\G#Z._<3ZH\\A5+ I1A-GMBB2X8MWFMD^9
MZ/%4K)&IJLQ=PF/)[<(T=A@:F5N*W*OBRH=*,@(TNK)*J9Y?"4#54PF/0J!Q
MBS1X O#Z@[=)7'@W5IF_+C6Z3KP?+-=K.P2,![L/M2)(3+)M644F[*+A@0TP
M0)O_C85C4U%]H.: WK:B)M#ZI7*$+9[>E>P+N1:>1H3;)"$J,L3C'TU*6%/&
M$E'ZB+?6-_6^$-04#OVOW19.6)^65NRZD)  9='V+;&"E4ID?%1Y#5K@NA_L
M3A^A!I3NYGG"@5.TH]0@>1WA\0]%)7B9K8/2P?)M,1PFJK3P<#_8UE'0S$9.
MMK^E6# AD4JU(1LLNW3P1])D(N1 %%US)ER\&A-$6S1)*J'22<9%BH'<E1*-
M>-PR6%^W^P:-VFO!878!@M3TU$_X9Y@=-GG K0*6 XQ$WJ]&@U*3J.5'\MZV
M1T&[V$?16UDX69>@$/"V'X4VF=MX=_;U_KTJFG"[BLEU(63A>Z&=GY)VCA4A
M@GF]([UC%:USY7/111NV&Q-=\_F72]!D)J+9U]M_/(=OJ.&V'!_TH*9SCK1]
MQIUA18A[I1'J6+D]B+E*H@ :V=2_%X&U11"\%? -;T:W 6EJHK78#Y:M]9V1
M\D0V&!?_E49H?ZXB KB495RR4!:;$I+(DY&08M 2ZIM!J'UC(E8AA./;!4@,
MU_)^9#_]Z/Z$3'.ZF @HR98GO1,W [7/8P'>:$6.(XR"J02<*8<>[50OSZ\Y
MUND)5!<PP7-8B8SW]/E8I/=1IF,H)VE_CT>^,XYLO;MRQX+KW\\>28W0-3P2
M=(TO 44"F\3T[<+F!']P_2/?Q'F+%V[0$XB?:ERHKP0(RVFSL!?FTTU"7M_>
M.O\\N+=DQG:$P$W[ZOCAV+/<;[6QGGT41EMOK!5I-ZB_LT2RUTA_ JCPJS?X
MD&K1&#P#_J6.P6.'&BZN4#TVFCQ2MT>WE_CG3<9/:VP,367 ^"%"K 11K[P-
MZ4V8.>K$:S[-#0'P(1S<IQ0.DI:2[GS;9">I'ZFTLPU3[IH\8EI#/KZ>U:.;
M-Z5F!&V\.&+T'^P@.G+67I^OM4Z^_6TZ!/(W!_+=!QC(W]?-W&A873'9'"19
M4"LPZL""Z>[2&S1V0_<H5#=/8J.G5&4_1YP>J35$[I'5L7!^L"SG*%KI*=@7
M]K6&H-H(>QI :%,2=YORD)^X4&L03+52"5*H%0(!,:X5L#207^@?EF<_4$S>
M!5U3I78\0\#^>M!M.E:9L..!(LT5,"4]:8!<09]A>U4MO@AM9!6KYQ4P<P5W
MEI25@.Z@7PDGKPC6RB#)>#0! :T2(%0AW;B-3BHZA!U?8+LYTC<[ 'XXC:8I
MN6RKVGF:NJ@V38WD1DNKN*V1Z?ZD<7:0<Z 7>$ K?CJ;E$O.94,*=6R4 Z><
M 4H_A0/@ER5-NP.]T#M=C,<5]-SZ5)"&/*AI6S^@OAHIZ/=LUXNHQJ-:UF*,
M9?ZEGORAH^,MVEKZMFVEZA]$/UIYPHXB>J(IG-3Z8ZHG9?BL68*H&&VC^)V:
MT<Y2-,"&'FZFS"QHW3$:T&_G<!I36^R\CBR0E/5<]=U<N6'J/J%70:2SBG8E
M;1%H6^,D@%;T8ZXY_[@M#NWV$9D&5*44G<@;Z J)F+@!13)5VT#1HUVG)WA$
M9XO_&"C/TBJLMBK.HLUNZKG:A/VCD2ISH]GJM6Y87+;?A6R[%T9K]<\X\MX7
M-:.I4?/FAB!5:8A_V-1Z.F.R G.>3U4Z"]W=)D5]0((IWOJTU8:FQ(SV%2_J
MO)3"3Z8?BN+I;M"XR5MLTDLHD+THFJ9U<'R&J \E(5'):@9%["V*>ML88B!=
MJ^Q!0&F<13!8=8HZ&R<"5QU9D"B1NS#!<(D)$Y'7B$U6S#MR4+!HB?8B^V2/
MM;8Y#6]J8PSJDZS)$M C@?TVIZ+#,DA@;4Y-?9V$_1+Z&&UWMB"5)Y%>8(GY
MLWLGF4=+MKV3IN0C+1BS+A]H)9@\;8"NM,@RTUTG CJ8I!N(05;5ZM@4(A>%
M<^#$I-*(GE6MGY+ROP##OGG.@RE/=SGG:QU*;&CBSL#$WZB8LA;M:8-O-+WV
M6N!,R)";+%=FH64##H;B9"Y5I,S0OF/VK> =+SXG5U1EV&T/1[$S;&+06I>R
M7$DH87JK,#G@&P(U1J&,.T##JW[PF&&MWM/@WZ!Z-IFTL3?X(N,Y7559K;%A
M1)'?DE<#+<!45E'#<*09,-1UOHUB]!NJ-T7['<2X5/54[X45[3;TV)B @\W5
MM5?/9"!U!NQ-THRFGP#%D,S _#?Y33(I]0>/+\$(JH5$J*7:K )MCCIU]+!6
MZ41F^5Y?B50_JGIK <2;V=6J4HT730?XGF(N<'VPI!187-X@)8NM)\6#"M#T
MW5E9O+P>6H![1CE1,,A,8!9IT#$Z<E<+2]-J.&.9<*^'<O'9IMRZM>D:30P]
MN-BY]G[TM$;E>BDZ)4Q+;)4D\JYDLB]3$0]J*%LLVS0L$LB5#,!L,D>U#18"
MMR\E92(K*G*R6W KW'6P9[+QQY0(LRCFTH!'$&)*EIEHJ7)"1M]*Y7OH220*
M]J3 ;LRR=7M59KG(!9<*E0"HXX(X&J!L?:^;]'6T4,4%$Y$VV":6MV/*QLV:
MHB9>#$9D71Z-CBEI"6OFEN/V ?%>F:FNV\P:J2@!M=9%161&7*;)@T;01^QP
MB/6,VD@JVU2\G9I5Z2"3I4Q^T5+F*:M*X #.L0 76,L0[#K+ZU9; Y95T-I$
M/ ,'G,\KV699#GC-)?AC3.(ED3GT>(O' M2%E$Z.+3.IKZ)P"JQQXS1Y]=*+
ML]9M]S@O0+"F J;5S-L$><RU1>;XN#9B;7'0FJUY*R_U@S()=JV .A,10S(M
M%1<[>A"-D9MR#[S,Q< R!&>7T6KLJ-N4?2!ZX+VE8X_:1K2W3JV605W1=:Q)
MW":>";>4(,7)":H9T\3K$R##<HJ*=*OPU?! C?!N1R-*4EPW "-KI\$P:3S$
M#4"W&ERTVI&9L4W,H$0#ZJJLB;VC$P$[1XG.LZ)H/!<>"^H+/-$^A&EAN'S3
MM)HEB.C^K 1+CS8.TZ=H5XBA-_,C44F)"H@LH$Y)KFBPK2%IJB!94#=?2JCN
M3R4FJ[1;*@+GVDCZ+LO?2@5/_;ACB K- =^&N0VR?Z)CXJ9'LB$PS%3]5*0E
MXTR4#LPE ;7^&I%.TQQ0EG\6]I!FQ*F&";@5&&A!M4'90K#US^7GHTFN16LJ
ME-2H2BCDB[Q*%E/4.Q)1WM;O*IV+? TD\LL2 Y.H-RQYFX]+@."-+IRB0IZ)
MF@G*NJ!Z#-!0T'DV2 ?C-6M'0VDR*07H#8Y:$0!WJ1\374;1CDUM99.=UA]P
MW.N8TFI#A/Y1D$],M6WAGS$-1A@ FG^5[@5M$F&N$UTT<Z&L0R[N?$M::'HJ
M#J&>[- G67KS*T1'@\W"#!0XN^;G^E$U58@S)G%//ZFN=FUO=47G!!Y1TF'+
MTQTWQIS0G\23VDS(P&J<[FPJ<_LV=#P\I&ML3M?P'E*ZQOZK>3<:?"A8J[3#
M'6I2( C>?CGZ!/Q/E@)K/*X1&V1L8X*:RHP:$PNZEM>GXC%I 9H_X91CK"Y/
M-6-;Z^VFJHS;V*\$-FAC\2)S':9.<.I7O,7]0IP6,H((ZV>2?R3(.9%M)_.&
MB=W($A)\S[KER80SM2PAJV-*E!#5SBB(13O(MOVODBNUR'G3./OP:PB@CO9?
M-')@+3BG<! )38<U 2O>JG/$5[NGQBJ].VL3#)/U,B*ZO68BY*Y)D:Q5_^:,
MRK@%V)%P:A)GS0@U2*50- $U\KRT;Y(,4>'O"*ZJ1L%WT;A'(VE4Z#UE&WDB
M24N>7RW @P8GWV!<)**#-"9V'XU>*AWS"@2\ZLJ\.45(UYNESKI)M:7JAA^<
M3C8NYBMY09OFU$D[$L2\^I;!(+ <7>^P2Z/;@997W4EJ&C5K;G*C[F7%0:2M
MC^84.7K-T%<NV7?TQ'$<OEM0=NM$KH?.K:FSUZ1M.ZLT_(;M2("KA/PYM0@8
M9(M)AAX[UCPV CZJ$C5Z#RL B.9988[@Y=TPGAQKRKG$-@;+$#O^$<.1+B[E
M5:)8<<65?Y78GO(&JUP5NMHB_GF5SV8J2@_L(YT(Y9/FTB+;*&=R8Y(T6X-P
M]&)1,C:R:@$)QHMC=I>'=2"@^1^-WFV81-\=G6&6UA7\)13_U@[2SJMEU"W?
MQQH;+6MXMX[9^T_7N_IA%-BFA(CM8+]VNS,</03GC(B6H7UQ!IH.IK;+S@RF
M9:V6BN&25_M-K%1J*9^RAI^@$AHV;A\1N6ANW6 TRF1VY0#F&KJCIL2TL5@=
M9+=!U!B"Z&W\SZW!2+</+=5F:5KY9-.(K*F'DHG&HBC*;0*60X$YS6_?N!I(
M31+[D6>:QH:*A^I7)6. *\D@5-\@@<O3UF'2!IA429OC=>O<UR=/?NK$28%A
MRR$<NS>$D)):S))\,G*J3=./9CGB<;$H(7+%P&FY(.0,V*SYJ"+ #O(\@35>
M5I/TFO!Y10) !P.!=9%_:.4@"[3*VM%*[G=3=\%DG@!5$]M:9H,>K]:\0:@@
ME-W9M9/I1_17;L;1AG+?;KVQCE*YY0$)*2.['3<+!.K](= 6IFA]]44KQ\C6
MS)7&[%+!T(DKQX9^WD]*!WK33_#8 $*#./W4EZ@<O7WS2J03U*+I7_L[Z=_)
M^TX\U%U^\'4$"UFQ\(D+KVU!E ZZOND'?VNS;:1BJ\8G?0?TB::E]6HJQWHB
M;?,#&B?Z4(Y%D]ZQ<C>4F3[P*XQU3M!Z";H7E+(F5-&:(.SU>RR"P0W_1C!:
M\MR*AGM-FKZLVI)Z%X&8(P>BJ4G>C#;?:%(6E^2Q)D>GT)JPF_I(M!-O:_7U
M';Z1032"L/=B((E.MR+<GEANA# :KV!K42RK[<$V:<!20=X*-Z.2%2I790UQ
M/;8;NGOH<',MP>/:G1LTVQOK*K2"4C)EAM->.K%]U)@H6#'6BQPV_YK:;;>
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MRWO\)5^E;=#!82.!!9X\@N(6:75J"1APH)4KB1Z8WY3H="1^DFC+"K[EG'.
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M9XE/8S/I!%C[+YB\L>ZFN3.Q4^G%D>_\.Q=)!NN!H7$C,#(>YK@_PED")9)
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M0/7+P,S-(S\H4(ZYQ+3NQA6K%:8?L8K!S,73G\(GJ"P7WIW"0R*@85!;H<$
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M_(;9GK>AW A5&EFNPG@MP6BAB[QEX9&WY?WJHFM<#-^+:0I7^U=0H[Z]6[>
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MJ2(3 # 80@]-TZ3X1R-)N )!VY.$:SD1I]1$Y ]L:QH&L/0RE\0HX4I'AII
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M%Z=KT- $5ZB.N8RI"FNM=64[RG 7#N<U7TH=J[-\>GI\:AJ)7.L/[_"$FH^
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M/+*R'+Z?QVH9_,<R^'=PS^%1YJ#F<K^VJL4!BP,6!RP.6!RP.&!QP.+ :>-
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M] -FQ22.82#\,/[[^?FK"]V_DAH)>S&SCL]=!RM?HS-4$5!G+4<NI]+'YY2
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M3J[-Y%D0<LOZ-)\N _BA7'=EL:!S$HE./"Z2IIVF^,<T7X)< %?ZM"P>'G]
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M%LQ+^)@=1(?. $#_9#\!T&YSQO\D-$OD3"8J\D,.L%XPG_$OXX0C,J$$2*;
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M]NP?L^Z/\6=/R-^67WHQ.__6C3^=SI]QRNG=WW9_\8ZEY+TCH*TETHA,@J%
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M (<4R#SY]+6SQ8[+)_2 1YFAJ$&5-M%B>;."(^7R..*-C])!-NQN+?01^80
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M.^+01\,U"[VVU":R_1%@SX8U3315L<[(G-4?8'*>N\EHCK'+<0YQP"-51HM
MLD!8D@M7*LH+W.)\T,ER$5>OP3>L&&L?_VP84$G"%3.MEP)Y<S$O&3[^^!K\
M%.87O6_RWZ>+BHN#R).TW.#@ H]$>@D$/5%-A(F4>A."84U,B0=1/1O6U-=1
M@P2[VV;QR^XRS/+EZ&SAN$[?083AY_GU-)7,0_:4&"9P:<LZHAED<*4S)L<
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MC0L-)5262F3&HL59SN: EGQI$Y5<79Z?['%S>T7N)[XF_8GG.2Z3XGZ4$7_
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M((N87?:.&%EZ&9:@01<#^K944G 9 C7]\B\>>=&I<V$?N59O[+4*[M9R-N]
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M>,>@LN:Z0XF]=I/$:[#W4M9+#>MWW3<_6FS@<Z0FR$2-=<3CQ" R<"@),8H
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M/<TJ6=JL.\OAV/"(ZWHH,FPC[-J'V[>R'-_#>-A-_NAF,!4_T;>XYB+,EY>
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MH*1T=.Z+"+88K2PFGD(3%__\X;JK*.?<T;J/9AOU=Z-SB$C[#>E ^G6ZN!X
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M6M+7-8TM9Q<3+Q&XLP&4)>O".<TA)::]"-*%$CMI_FR3!EMHOX5T[R/ ]FW
MW6Y-='US(@-*<EG!22=7%&(*!6PI,I?@0W!-L@5WD_;HD=)("_=QX@;,1?=!
M"Q\]N:[(:A2ND)$2B689@U.RSJGCI=-^<>:YZ"UVC7:2OH\)?YS-,%T0XV.\
MN$_IE1"<UM)R+T $0V=;"!*(X  2L\FLE&S7B_FW60R[7O4T=-^O1#<$A8Z.
M*MYJ=G(#U&4JW#+Z'CA'U)*\$8D,E.&UH:.V];Z78> V6FS;WF,352^7H;WJ
MK8$%TJ.DUMF[7I$=&!RD358K#D_>6NM85+5K/=@C)%IV2VK&J [HN9<9 CI%
MIQ$S@%ED0,>X9<5[%=JVVGU<F._>[>O107X?)#2J'Q@O![)=6Z_9,')=.!DR
MD=&))AE9KX6+V@2>%Q2HA&B2S7"/DD?=K+@/;6\H1SA<50UNLU<U-5^^S'*\
M:JB^;)?^_M6[]]>>D"U..[*.1*Q48M$0+%E'$17R$F51P;; TD[*7K#54I4-
M]JGEL-&;C"*/RACGZB111\"WQD.(T0 +M-,CDTJI)I/M[U#QXL,<I9<>HV$W
M**Z7K#\\,,5V?C7&]H?U,;;?V9BDWRYP\BM^ONG!U(&GEFY*"Z9.XYD<@95-
MXXK/0=$M^@.TX,V4K).@PT"68D#IFH(9:(D7[PS9P=G%TN8@?C3@W>%BG#EV
M]]%ODYX6N\P'06<(-W3&.$UVB?)2 _V_AFRM,LS(I$*3:HPSM 1/#X"]C;]]
MM+?5T?B_?UT3\2_T<?F#Y?>K"-_E\J?ZWW^\>W,C[M]___TO7Q8QC*=_B=//
M?UU*^NWB$]E+)+U9_E07\-<\GM#'?#&=UPL9C/'R<[W8S6EZ_S?K"(Z[Q,['
MG[]<[$R%.?ZE?_W.[5TI7+WY#LP&X#O_L<B3E-.?_S1.__7GL8HZ2\6MTR)7
M ]]KE5.2UNN0I"QZU*L$!M7WTM ]C=:O7GUZW6^2P1H"#"\YV2*%MUFQVF64
M&9%Y=(BQZ%2.1\!]:0R*@U]Q5CM/?<T_Y@6.+TZ#B'M$G!X;#\ME#26)HU8>
MHW#&*Q9C\(47'5!:EC(Z=CQ*[I%S9/#@^PN7I+V^_<(W2]+JH-A?O@]HDBY%
M.DEK[*1._3(<?%0"C$W(8DI,-(HO[$EH+W;;I^D%'=/SG_YS.5Y\&]GL52D"
MH11F00D>:N)3@F*+\=XK%5B3\.]]4H:WS)KB9*/5=;CL&\1SW^58PXGC,HY+
M,_!G$E 'D;R^G,W(0OTMS\;3]&M>O"T?\(]78;Z885R,N!9H-%FBY" %4"S4
MP>4FT$<;F1*YJ-0$3RV8>>*(/+G^&WBF#TGMAURFL[S.]?R:A9'1)#XA!8A(
MBU!%[P$-<V"\C9$[BS8V\5F/H'EXA)X>--/3:+P!6#?*<AK'FX6U6,S&X7)1
M#>H/T]^P_L8HD-F>6>V?4F*J@N,00O&0HX[6Q12<:U+7=33E+\ =6/L-J@X?
M6GDW2\SR@"Y8#SK7UN Z.G R% B.>Y$%"LG*T)OJR^[93H<]UBX^8#F7%()&
M4\?W%4Z6<ZF6,T<(-C&7LHQQO97V,%Y+,U]U=7/+E>:(1%;V6.?%60&!>5*$
MC0)Y<"J?U$\==%+SH*9R,RUMLBI.,6'YIG_N"M65O^FDWDTL[[]8%$R3002Y
M:%IN-D4(.2HH=4Z140YS;I)3_B!5I\K':(>%;9W(C]9) ]MUC:;K09D=B&J9
M/+&1JA/W)#]>>]-6HA\,%];R9"5/()W5H#*M-*]<!">2",(*5=I,9A\0#UT;
ME \$AWTDWB)_[_LF26;D/R:SC!?C_\WIS>1KGB^36O]&5-9]\J;P7MGH:(^4
M1C&2 "MT.@<!EO&DI+*:B28(V9?0X7V&'O2[W9KI7SD- M6WZ/TPP\G\8I5!
MD?[G<D7M]: 7Q4HV@?Q?ISSY022<H)0#+E/,.G&%O,D(A&[D/3'@]*6(MGO/
M-@/MBM""UI1<+,1HL5;N2C+,2"#16!>\RC:7)C7UG2E\8J#I41U;XUD]IAT1
MY;7\?_X%OU5C?G653<Y8RG_4/*[#$DQV/_3H]( ]Z5Z[[A>>?.-2C,'D:&O/
MB%:@]EA<":1F,]J+@U[E?7A:3]='MY=]A[0<J;AT0C 520.1E6"MBTK4_MV,
M2REV:^"XM)N=C^\CK6;_E[37S5YI,2(9F=%AXIPK$YG/,7E7H@]1Y.+\;BT]
MQ.$^^GJ-7\:+:L(MC^-#E+'VA*,E_1!%Z]E%(196A'59%R491\-%D(8;S!&9
M-:/MM!TNHSX O..)/<MP+VA*PF R3.@HF:*3VYG LS<:5= J<3O:\>Q>II/]
MJSYULG@[6Z87?X_#DF)Y#E&"]72V*[0,L$2$PJKRZ^!.W228^#!91P=0\2)?
MC:*Z,_+R78Z9))O>3I86,\;ZS5&PNK!H I08JJ5C"Y!-[$#G$D4=W\[:%-WN
M1>7)!GKU@9Q[P=1F^FE1:?N=V%\OJ\CH0ZT0F+^9SR^KGWZ;5HDY,>01I*TA
M9BL<N$ ?D3G-M*#-E;>Y"]N#R*<*I7ZUTZ)2YSNMRVZTO^79DM91LM$KHQ!$
M2N31&1(%AA@@9<^-C,XYWQHU=PAZJ@@Y7.H]9FS<]+*](NI?N?*:TZNOM M^
MS.LT9F:R8F"E2.3K>_+U)3= T'52H7#:VUVVT3XO?!*:;R;A5OD4J[WJQ\M:
M.K[**UGM8:_B?R['\Z4":MTCTRBDAN*,J6$?!&^S)EWKD@23SNDFZ66=*7P2
MV&FKE[X;4*_(64S'E=!+<CI6(IC_]$?\M!SV]W&6EQ==(\%<I V/ S/+OHB2
M@8N:0T135*XF5)'=-I*NKWP2<&@HY1X[5N\ [;)AQ1W,AN09*FN!^V)!2:UJ
M^DT@H209379&J28ML+H2^"2PTU0K/7:^?E $J\R99+R.6G'(9"^3X2P-!)$8
M)(G2YZ@MXWJP,,&@F6T-<=&3O$^=M79WLBPJE4+12!BN\\:BCK4M%H-LBTZ:
MO'7/NF1%/HX!V7UI<..HZWTDV:.SNCZHM L93W34]5X:V#(E^1#QM=2FL(KQ
MHH!+7<CG5;5E.ATQB3!I51&6YRX5 .>AQ4ZCKGM1XAY2ZUEY:_-^@^>\YOVC
MT1*4L E<J7WAG*+S1R>'ZQ-''OV@Y+UDOWU0\AZ"ZS&&7 E9BSY<SRXP!+R2
M#63NZPA$)B%(DT''DAP+FO%.I3B=-+F1@L>GT>,%V?/:?%UOE//L"\X6WVH[
MH.5^DYE$K2T'GJOI+B6"LS[7-!JC5> H11=3N9-B-Q'PA&RAH^7;8]1V">+\
MY7)&+O_\N\>_3N)5BE87(GLWFKI2-[Q)=;PBIT-IH6_;JS.Q10>5DA"0&5>@
M>.'@BTO G.3"*Z=8[A*2>0Q0><!N.Q%2]A%^CPA91A=?URYT5X>9829YKXF$
MVCQ8113@Z^P['95B9+4X;[M=]]QZZ, '?1N93WL06(/<@.M&@$N8NIJ,4.<3
M9L-K>9FN\VY$ -0^D4D3!+:9ZWJ;B"=R^A\MWP8W=6M-'[M0T[*Z[AR:"A^N
MGBUZ/D*V#?(UUJ@B%S&A,A9,[5*B;!3@I';@C&4Y,5-L:)*E<08=>%LI>A^1
M]GWN;KG#NQXB;@IS.C,(P?@Z5TS7.7*T:QEG,;)L91&=3N('7S/\/=<Q"I@V
MD=X0/6M_S8O:_Y .M/DRR^7.J[ME&*\_XNB4X@=I6L_+-D;F.@I7F:"8D%X7
MDW@(SB62=#"C!Z@[0DZ'EWAL?E#?,NM0OA%<*%8(ALX'E5E$5UPN*23'BR<;
M<5URQQ5KK#WLU\O/-;-U2C91^C%/II_'D_KIB#SW_5[0M[SWX>=>=UN=,S>"
M.1%5U,:54@.P(L3(F#5J70_=.3M"/Z\FBW$:7UP>67S0X:E]:V(GY6OB9X)+
M$U-6)GN5?,"(R26K0[1)ZX3KXM_T_",+06\]\7V=D[*<G4('R,4ED5E[+]5:
MQ,O%,A'\;?D)9Y/QY./\.D_OEYLK]TS[G<EH (VJW=;KT)W:88FA%8J+)'5J
M4K+0%P-'5]0>1\>KS]4='WEAC;28@9G(@!QQ!HZQ"$D+992TVJY'&LY"BBOJ
M3] +]!3HO5>\.[CF6Y13Q$\Y7=;<W"/96447LD2SG(H5,=>Q@I9L5SI10!;M
M!.9L$FM2-=XO&X/UZ3H'&)\0 :?.E>I)#S]\V_R I7NNN0ZI1E,M5W4^#B($
M'A&B3T9RJ9S'-LU;VO%TJJCF*9':[][?&V):M C92-FM($47^EJ&6G<1>**)
M;N>"B$Y(/5*=IX"=L#(Q<E"!VU0K@TP"GX,!1C:3UQJ-0_]TX+9K!MMC1=L^
M6FS1@N_SEXOIMYR710!OOU3I7*=!88I*V !)B @J:++#:UESU$'7=@'>EB8=
M[K=2="Y>U:'*6V_%UXOD>_2 5G'S/%_,QG&1TVKRVR2M?><?)/3K5F_)I:0S
M!LBJEA,IK2%(':%H(55.6-/;NEU"[/'6)P*#MM+>NE/T>&FQ)!#KV,$O%WA0
M)YFU)QP=A'R(HO5Y=JI8I@I':>N\*A:\]RA%*=&2PE(8;:?M<!D=?E^Q\3D]
MRZO#;4425O& I@2M%;*(Q4INC$:G7;'9C';1>;CL^NC"L^.)/<MSKRX\P13T
M@=9SCDF9$D..QDEEA;(D<B-'.Y[=>*[PMJFCWR,ND@>5BRB@A6?D/*(&9VT!
M7YCUW N=4A.W_GC2FP]EWD;!W88@KRX7GZ:SVEIU5 Q+M"\Y$,G6%JJ> ^U.
M&3"9A"5['MID:O7.R1D.T.T7R7L/<&Z*A1;A\$,96O4&?3,A<^9R.;AXV<_S
MPR><K&S=^=]J)M[\S615;3PR6N3H)(?$0ZV (3LGT)D"K'I7,@M58INQ 0,Q
M^+(4S@$Y+;HF'<KG1F[^-IO.YR,2>336!##*.5".U]8_.D T+!1>9'"^26BG
M 2\ON!\8#PV&=_5UJGTE4[6Z!#]/9TLN1\9BO<_%&DVNHYDB@R"<K1^U,";G
MHMK<CC9BZ 7LIT!&B[97Q_+U*J6EYO'BGD6GG B!TP&56*EQ'"' &^' )%^4
MU]Y(TZ:?9SN>7G!_(GPT:=C5I_^R^OS^,OQ/CHL/T[>7B_D")VD\^;C\L_F(
MG!BA+&/ 6,YUTIH"+W,!HYTM7&84H5L,>7#2GPWH'P$R>FQ6UH;;5Y/))5Z\
MF<19IC]9_=9(>YZ]%1JLK#/=M>. )7E0V;$B,$;1L9QR$')?\'Y:!/384FT(
M#E_5R_5(?X,?KQN=WEKCH\@9#T@^C.>.%..C@V!XAI"<S"$)@2Z< _8?9N-E
M39PG8NZO%7N:M7+EU+^9I,NX_,65>T]^SJ_329WS=TEO_78K!V ^8EY8XC0"
M5T60ZZ,R()(1**02.:KH%>-M5\;^1+^L@W- PWW4NY,YPC_C>+9J(3J?7WY>
M,?/3'U]R36WX<?QUG/(DO<-%'EE6.R1A@<QT[2IJ)3@5,^A0ZLUR$&3JG94[
MW)6S9[,FSA,K]Q>#/Z]0_UJ_L.4/?R0N;Z0Q,K((6X("(]" 4H6!=S4A.VEC
MI;5"*7%62^,P/E\6RAGA:,,-V>DND9?__#//%S==J?F(#C^?BD'(7KC5'N U
M+T!KOW!O:U>]\[HHWL#$"^*'0L &./=SXQMV,Q.V+-_*3E[SB48\*8O<&H@E
ME-J:/P&JF$ 9([5.7O#U22H]PKIG9IXGO$^)B TP/W( T#(?^<N768[CU>RS
M94.57\88QA?CQ;?;CKD(WL=@ KB@Z7@Q.4+PRH%#'>G<*=Z';KUH]GCILX%8
M4VUL@,W15Z>O+I:_<Q7@OR>PGU;S3$<V,">2KD9(S6;WJ5)8,HAB1$95%'-M
M!K!W(N_9P*NAUC: Z^#+R7[LB'=Y-<TDO\^SKZLA6TN#@J%B(64.D:$$93FY
ME8;,95=DBI%8#KD)%IMP\^R@>WI,;$#Z\;.2#C4I?KOJ;[H<(_>VT%]_KK'%
M.EYP%5T?Y3HPV0D&QJ("50P)VS %THJ8.29M;9/*OG8L/4_,GQX=&X!_W)WD
MG:+(&UHO</+/Z94'>'4_],OX\WAQ37)*M0:N!& EDJ7,44 06H)8]O(SFEE,
MG0S0@U[_;, WD(8V@.K@R[M[Q;:K37ZS '^=3KXN';%5 LJ'Z0(O;O_\]72^
M^'6Z^']Y\2['Z<?),ELK^I@]4QI"SB1(;>F(2,Z"4K6/'SEP3#2IU6G&T;.!
M\WEA8P/JC[Z\:\;9RDCZ>3J[^E;]/3Y*1@DZ'^J<N9#(.7 *0F$.> G929YC
MB&T[!@S"YLOZ.!\4;5@TI[ODVW2+^6X\__?/LYS?U D#))_E+29C,2;#-) ;
MD>JVD.@P%+B\DU$Q2:_5>=U@=.7LV2V-\\+*ALJ?TUW=/72G_\_I!3VF!BZ7
M/'KEL22R!K.PFESMVK ]*P.).90B2R=BNZN/MKR]K(@3XV7#FCC=_=]#/'[(
ML\]\A,JKC!PA8&TUY7EM?FHSH!$I*Y\=X^V.AB8L/<\5<'IT; #^\76@-_TF
M=\IXODW(JU:3O@05;7#@,PI0DIPBQTG*6D97K- 98YL:N+XX&*HC[JG!?!*-
MGTL;W+LMVGZ?U.;SXR\UV/73^[>__3B>5V(NR5;[X5O]YK)98%$HBU4D[<QK
M<HI.@*D.@PO<252*J]3D+ND 6D_?MG904#W8?Z]_Y39OUKA.<OWO]>RZ#G2V
M[$C;E=#3=*9MKOF]D':DVDX)L\B<SS4E*<LZNUR' DYG ZXDY4KM58A=AD0_
M,GCMZ$1[MNC:1UNM474]]EQQ*[-WP&18WC56JR098 4S$8O2N29];C;0,KR?
MTD9Q#Z'C *FW'DJ*R\MF+2"93,@WP4.(M!!*\BB<4BZNMY!].D-)S\,..E@=
M#1H-K4__ZT#-LYIANI=Z=HRV/$"V[6>8)OJ?L;1\G%?DJ[I(7_'HP"(7F@CC
MR3:)?YW;#-,>%;V/2/N>8;H\==Y,:@K(^.LR2X3D+Z^.H2R,=XQKB$@TJ6R(
M1]JGP*-+)G$>O>F6M?/06TX^P70O\=_+^>Y#=GVWB%_U9WPU2;],)Q]K8'*-
M2.:OB&31&<V%!*3SJ4[RBN 5$5EB881B3A+H5A?0]8V/5]E-9-KW:EX168G9
M1BA]_T'8LI"LCXEPRBU9GE:0)8O60*F?M6<ZLWT0<00ICQTJ0VFA1R-O2?T6
M?-_05H)VD0LZH+VI*5,L@Z]7',$%09M>096Z-;_8\:+'J_\^)=ACY\0E;:^J
M'L8WW2WF%87C:SIKW_HK&B4GB,5:QY]\ A5XHI.+9Y R!9NE2U+L;.:_SPL?
MK[9;2+3'IH$WY4-+7Y1^>6F]AF*UKXGCL21;JX0XH.2.-A@EK,3L66D2%[Q#
MQ?/VZ@]7R"FZJ6X5Q'<V)FEM277AJ65PH 53)YK4=SA6]LW^&4K1I^CS?@AO
M7B!F0Z>SB7745Q0,D#$&AMS^+*R0J-N58CT*\.Z:^W?>V-U'OPTPNS9-[,I6
M$)(I7I@&7S-)5;8%T,@"(CF%VCDIVUS;;:3F#//#FBMZVK>66@Q^N3>64/)8
MI)0!9*A3[H1)*Q83CSZ+$KC-;1JUG7X0Y-E!YCCM]!X8NKID_'$\RY%^CWA]
M/9W,Z3S&R>(6J;]]]U=L%MH*1D1FI5<WWIYS!;)P:TS4*A6]5\EF]W<_8_@,
MH:T6\T<VMS]Y_^K=^^N0%CKNDB,1B$@$QIK>F(A @C[YUEX:'MKDD^ZB[!F#
MK8WV6KBG"UPL)?/Z N?SJ\[#2WO2FL0R)[^;MD\'BA/OKK ,=1)K<9*QI!L=
M>5LH>MY!C7X4U2#\=9N>JQ73A:*6X8G[))TFN-"3SJ9-!-[ Y=I 66#6ZF04
M",=KUUII(& 1()$;Q8K6(9O'#($=+OI@"-A'SBTT_[V7RK79A%9%5?,XN:IS
MP<DZ]R[6NC44.0<BDS=QM.]1,KP5<JQZUK5]E&Q[=(_GL\7H73WJ5GF[),I2
MAW;X)'EMT5AKL9@$K;5Q4C I51?[@!YZ2[GT:5VQ=][Z/&V PP7?XVR@&R*N
M[UH[D+''(=\=!_TOZ]TG^A$:6-?A$>+K<>->)T=E+#:D B8E@B76XTC%"))9
M;7WT+.8NN<CGH<4MAW+_2MQ':CTK[^_XQ_CSY><K0CQWR&PI((SQM*MX#R'5
MM!:K14!%YTMR?:GOSIN'.UV/DOVT#\'U?)3^G43UG1 I.:M3', ''T %B> <
M68:,S@OF1=)"="D'Z:;!VV]^A!H\6'!;U^#__>L:][_0Q^4/EM^OW+W+Y4_U
MO_]X]^9&$K___OM?OBQB&$__$J>?_[H4PM)0PWK@UQ25&U/@MK7P8U[@^&)^
MEZKY^/.7BYV9/WL\_:_?Z;_+U]4K[NBT3T[R'XL\23G]^4_C]%]_'AN;T&<I
MHY1>J>108&&DHEARXH:GT1[O.5%#EU]N"LI5\,B2=^ RV? J"0M8G*-_E XF
M&Q3LO-KEWI!^Z@$PM_ITOYM>7/P\G=4?CES4)5L6($93"[RP0"W9!V2%&?*1
MM6-->@BV8><,0][]8KKO<2X]H*+%!7!_7%T-NRPL\J02!^9"'> G/#CMD= 9
M3##%61["F</\T4U"[1%B[5!_ #Y.D>"UUU2FO\VF\_F(*QV+CQ*DJZ6[V23P
MIEZ<9JU]M$X4UR3TVX"7%]"? 49:7:Z_F<\O<_KQ<G8S9FG)QOSV*,J?_LBS
M.":^1L&Y[.C !"OHQ%3*,D M$V0TT6-.06$; W!O4E] VU[#IT@8WR%$DEK)
MXT7MLG&]UD:,:9Z=4&!*TF3AQ9H;:@,M,Y<XI\_,M4D1Z9^7%U2? 48:I!'T
M;U)%YU31/ "S,H"J_3)]Q@1HLXG)6F/$6=H?.TSNX46[FM#V:I)N.C).Z[>N
M=LQZJW4E\1RLRCXS,,XB*%<*^&K31BN==$HZH[I$H0>7>%<&']'><Q[>?1/D
MG*'[<Y\A8[/V03'@RB_KC#T9MKJ6/R9K5"G%Y_/J<[Z-DQ?,#XJ%%DY.?^?1
MVKCE:YMY.5"IVC;ERK:IXY-\-&31L#KR0T8-(>4,3F8;L3 FRKD?O1U9?5D>
MYX6F,W3(.G(\BEQ+CK7&P 4Z Y51@+Y6M3/)=.$L9W%>HP#VX^\1K92!H'J:
ME;47SLZJEGAC'/%!5K5U23E4D#!P4 %)'8H+,-FBLU8I[<5)EE1_/+XLJV.7
MU8GP=@I+;Q>KU]QTXS:9*+CE&G3P$E1Q",B+!BE\M-G[)$63%.]AV7Q98*T7
M6#O4G54_E^VQUP?Y#8BNZ&@A<BM 918!31$0I%888Z #^S0),CTS^K+.6J^S
MEL@[[QN!!]GT1DL=DH!B"QW:RGOP3B9@S#,I-%>YG*8/30N_ZQQO#Q[43A':
M!Q<"^")EG?OD $.,H'701G!ODCK+_,#CV'Y$F^%YA)4&1-D9;G5=V13DA!@I
M+7@N:FMM6[/F>8*82XZ<.\;P++,07U9-\[N*WG#38\EA7VR^2FF) [RX-8+F
M59@O9A@7(QUYK!D!(#RQI)(+X$*64$+0*FH1M3K+1?$@5R]+X608N;\ S,FF
MKNXT%=_EJESZ_NOI9,GJ)5[4#LMBY+S'D**"+*JKPB*"-R4 =XC<NR!XIXK0
MPY;%L+P^HL72/UK[&N$Z$-1:W4@<P?+>MN<V27#: ;.V.=/)FFHY*E<"'(N,
M-D1+/_!6%][N+#H+$;RLQ4</S%8W&T=(XA"6G?4N"YT@^%A+PZV$D!2#4$P2
MLKC:M^4<U^++HCOIHFL-M;[G5ARKB3?$RW@R'\?E_/;;&>Z<)!VLB<"1!U"1
M(2#3%G+6144EC5]/P-XVY*H5B8\(]\=Y26>DZ?OXM:>.#]RR6>_R..+:\E2S
M-HLE=E0.!M IA&@2D\859QHUP6S%T7"(/R?(M<NT.@(O9YC'OMM@?/7QXRQ_
MQ$5>8UQALD4D =%&!PIMW9Y\ JVR-=([QLZSOOU@CE\6TJ/!VWG[(W<9XR.9
M,824R+4JA6Q74^AXESY $::0$6N3ENVNHYNP]+)4S@<QYY0?_S..9TL67LWG
MEY^O_+I)^GM>?)JFZ<7TX[<;ARX7YI,3&D(L"I0*U3=2M6V ,AJ9TE:<5P%S
M=]Z>C0]RKGBYOR3<62V)=^/YOW^>Y;KL\XQ.QW=T&HZTR[GHH%>-*Y66#FH^
M%@197$++-1?GU8>L*V>/:#FTPF/+]7(TF,[):]G$X+4E^<_I!3WF8KSXMF0Q
MH ],: ]R.3O:^#KWURD0Z(3"(J-<G\=]ANME,V\O*Z;IBND!4.?D@#S$XBH8
M+;R7S$ERK5#4W8"381D*@I+,)!&M=J9=64<3EEY62&_>2+_P:>&-]-:IWV%
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MN+ )G8B\24/QSA0^&^@<H) -T.DY"/Z]7GI)WJUPJV(^FTBN "9?AV2@)J?
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M#D/\3MK3M#"/5D*#!LX/4WBS:G;3.)SUN9G(<[!$CU?P7O@Y0CN#;SA7M/K
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M!1?ON1/(--;&'3G4585[IB'+7%!;Y4LK^GX8><\;[K:RG[807..3[5](5'=
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M*^F#7$G_-%G0',>TU\-\CHLY3/+9=)K_/;X[XNIS^?S4XW:^9NZ,=3U_/^I
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M::1E*)G)5SU-BZSFDZ5;39/:SEAIK>%?[#3$,C6A'JF^@EE&)EN-)E;ZO:C
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MG-[M4#[6SC['9_Z(4]4$5I7Y4)*N\/(K+Q[=!?9)@A.60)>'H9S98U]Z36X
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MZK)%$@8"$75<@B2)BIFX,(D(AZ'@01R1@& ?FV8:CB;MW*9OK4H\&YUW2_"
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MM=T[$WKZZH''D-J>O']/JX>;55GEC[Q8IS!_DFJTB?28Q"'W8@Q1H';?>1+
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M"X?$ONM3R=E)1""B#H5$X C&,0X8\A"-)$.8%L+4'GYN1-U476[%!U3)/Z
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MJ][I!3+,C6Y;%<PH80CV>IPQ,J)C;P8UTC>Y2IW\X)M4 '0:7(&U#J!30K5
MLL<\%T!HDYJ&B#$I=UV TRZY7?*HR\)"UQE[KU*?[U.RY'7U^O)-6M)EKCS4
M:U+6LBQ"CSFA3PBDS%/G68)$+EM# 7W?2P***!(X'A([TAI];HS7"5_':#?B
M@T9^L%$ _-ZI8.@QF1G'+&)E'?*)PEI6T!X< C-";8PXF9X KQ),,\+F6,3-
M["$#PW)U\TW^02Z_^3HGJ W'EY^Y6H#+AZDFG27%R__DN%@D$?/C)&30$[X#
M4<*DZ\>\ /HHB:(8ASSBR"A*9RS"W-A/;?: GWD](_&RKBM=IM_!HYRV'DK
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MS&:S*$MJ*/J/471TF#VLE10=./S0TCZ/3P5_D.*ES[PYT?^)5[=";5DCA['
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MQR;:7#O%B875:^3S],+7RS')2<;_Q]\+BRC@[-Z/Z;O[Z!X^J]VD5\VD;]:
M"D X5[-.:I66KV"]JB^615EM ">O^GI!V*/Z3<74>Z&[MX-B=?Z)9 >1JYY
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M7$B4R( 0J R2II?7X;M(I)!)&6&:4AD(<_Y'9V+-S:C]NGUZ(N6KKBLI6LU
M2Y4 RIUNZL<F++A9MRR/>Q*7+^8D+HYGV,"6OLF\^8XW=.SQ7R7HM *M6F"O
M%V@5 S_6!_-59[9;L,7[G$&+]>!-9G*BU40)N%V2$O"BTB2)RC>S^![[A$I<
M:>N*]= YX(.+FKO1IEL2G2-TL*"Z?_K(.MJGM7KR?[<= )HRW6+UT'!M!5E
M$Y0',"&Y6F0CQB!.LPP2PM2O,TI1;I248#+8W);.OJSZ>]4?WY[JC W2<=DC
M;18O=X6?YR7L&+J&4=@3DYD))D[K68?&F[9XU4#SDTI5DWN<G+5]+E;BTT8\
M50N>BB#/%9(AXC%$:2:5%4D(9&D>Y2P.$!?Q#4=MNX'F9D%.3HY^TZ*"6M;;
M#MKVV(XZ9QN%V-3';$9@W7K*=H*$QT.V_5AO><9VHO&5([;3Z\=L^VL6<+UX
M*I]GI6[Z7CP\;G0CHD?U#HC[AU+4&9<+C((D8EC"3/T7(MW0@4BUJP]"27",
M6,YE;KZK-QQU=G:CEOL.-)*#GXJVYUME6"IN![G)-ML#D+[-2<,[WT)8"PT:
MJ4$G-MC)[0-6F[VO!W@GVMJZ@=ERYVH)U_#&U/1A$^X[+?4[W%;:WCS.U_LL
MJDJ(P_+4:A_XH2D/$>(!9&%4>WP(8I[F:AN)LC#..0HB*Y;LX>'F9K\_CR@C
MOP*HF9OG#B;/UKD1] X<E9=7X#<O#2[-<''I^ET9<5('T$S[8S?0\*YQYJ/7
MG_W3ZGF[^5Y4__BH+%,7"M,=.=HSQ2R-0A$) 7.11[JI>@HI5S_E<48B0E.1
M8JO-H_G0<S,K/<E!+?H=T,(#+?W^I$#+;V=Z+";#S SY@=BS23)'UT->N#UB
M+HV5Q>B3&BY[5(Z-V(@GV!DT+HK%^];5;CA\/JSX>_74!<N2G.J,F3"-L;);
MF$)*< XCB03E09($J='Y],41YF:>.B$[;BPE)GAO;(PN SEL<YS X]FT6"-C
M;#^N:K\W$U5G)RK!_ORP?OEW=6]C(M0/QY;A\G,G,0!7U>J^\^L7CO-/OHC-
MGK5QQ^"E#^)V[<-T8S'U5?U,JH+MJ-YY%HD@IPQF--#=@5@*"0\(E'G($Q3D
M,HB0C;,R4HZYF88O:H)*_0K;.29C9\',2YD 6\]V11/&'G#([ED,=>9 OR=G
MJ\D=J'7QPMM_(YXN'9JQHDSJW=R(U[&K<^OCQAG*/JWWCC2EXRE[OQ7_)4CY
ML7@1"R(%Q@A%,!(D5Y8Q4-LXR4*8Y+%,DU2$2604V+<=>&ZF,%(K0-?PM!1$
MJC'MC*(QXF96T >.GLW> ?/^ 9M3)_<=4)(#+3K0LKNS<;9HN31JQF-/:L5L
M$3DV6];WC\Q-Z#A=ZMRI!<%(2IH&D$8\@ CG,<0BXE#D%&M#%21Y9)61</#X
MN=F<G71M7JAM[L$A=F9V93PBO@\&C<&PSRTXJ[/3C(+#$:;-(SBKW4GVP/FK
M[*,J'^I6X=_%0Z$=E=7FBYK3A>!!F&:!@#)(-4D2P1"G<0JSD'+UV0JAEE?3
MH,JY >;VY38R@KV00$MI'E$Y"^+U@,JMT'C^A"U1L8JF#*E^0S#E[&,GBZ4,
M*=4/I0Q>-V[A'2X0R!(:Q@E/8""B%*(0"4@()9 E.6:<!I(E5DUY_E5K<V[L
MFGQ+'8USZ#Q__+?4NEBOZ!:%#VX6^!G4/ECI?KS\^ZQ44,^N0Q9_+S:/[[;5
M9OTDRMV689$F02B"2$#!$PE1+!C$+$R@2' F!$_#*+0*O0Z.-C=3T@D+?E?2
M@D[<WM[8VIX,(&UL3]S@Y]^>C(1NC#6Y#HEC:S(PX-36Y+KN9ZR)P4TW=CO5
MI0]?UJMWI'I<\)P%C @!*4^HCE*&D,@<PS0..$D8SD)N3L)Z89"YV0XE%FQ:
MHK1QM;H+"B#]&IZV1'%D!] ^PL/&PQ5NTT8@M9"ZHSK48CK :&2KU)%8O46_
M5%/,QK=//0.&<0_5_KUOTTCUC/07NZF>NW9DD'17DOJ1%.7?R'(K[JM*;*K[
M%>_,;B&J-JF&?UU]UUVNRF+UH(^4JN/B[XPC+'D.LTQD$&'*(,VE@&F>2)K$
M-(]3(]X8+]+-S0COBO[59K"QPP59 E+K5Q\7+?<:@LTCV0!2ZHKQ?VZ+LJD3
MIP(\M:H#]6>I, (O&B2@&:!T<7D#!J :#<L(L-,7PS" _%;3[3O^W)MIK1FH
M5;L#]_NY[JD'.OWT+.XTK$_Q*Z\[7R_P.PV%.Q5PVDBZ#VQ/ O%>!AG#);8/
M"?PJ5L6ZK!EEPC\G[[?J%\^;.OTR3-22G+99QHP&@N9YI-Q2H:/\ZG\(YAG$
M29K3, QS@JDYXYCM\'-;&I2HP?\\H'BI:CV:0"'@RL)KX6THNZQGQ,!K]XKS
MA#'%1OB&]N@.*/G_9Y--L-,!A,E=C?@HMC1KZ&TXU7Q.P53,:YZFPI*S;2R2
MP\QNUD^=D/]MK,:'+'&CGS)RQZ*K'=5ZI1MT/>D014.#69:ZUE&_K3^_[B]I
MLTKN?R<E_[+5HW^53;GD_7;SN"XUY<X"(XQERB6,A900D22$>80CB#(<LPSQ
MG&=6#=&=2SBWY:F14WNS38TZ(#M1[2O7_<VKX:;C+6?+]\9#BP:IEASTM0,]
M]0!]!?WK.F[A6L<[L)_KMNY[KZC#G8>O.7"Z^W NY+0[$%\8G^Q"O UDWVWQ
M%_)'\;1]:OVJ,,8\$ &%"9$91'%((,X0@30A,4$T3R4V[K!X\.2Y&>A6./-.
MBH<X#1O.F[3W;/!:N1SZAA>UO;5%XN%#)VN+>%:7?BO$\Q>,+!7HPA"]HDQ]
ML/?7U9I6HGS1 8>Z2+/2#(@K5BR+VE@<QB5VQW]_(<5*ESI\6K'EE@O^:=4U
M#EK(/ Z"A$:0AYA"A&*NEC-.8()PD"1)%&%BU=IG,LGG9CK>-00NRHO;AY,M
MJQ4FFW0S!V^64^G[M+(79>Y7N=<)#WW%F[KW"ARJ?G<<=SXHN= (=-5G'0KZ
MA>EP<%A[,?74.2W>F$SX::L_IIZ3D_*1R06P]#LWS^7BR_]99"C,TP@G,$B(
M4-YF'L(\0RDD42QSBO+4,*S0/F]N"\67#W\'_^?#]U\__)>AF]G"<L6YM%?6
MLRDUT-/<F3S4;B"Y7%^I30VN?](F!O?]Q_8YTWB-AT+O?,6C7X\X)NHZV\A^
M;L,W]8FRXIDL%TG .1&A@%RY;Q!%&8,Y3B(89UG.-#]0FHK%2CS4A-F&1T/#
M0QJ]=GGSVIT,[.\5[$(RNT2!+F'KN1/<XCCB"N@&QSX.,)SFT^WA=I"*!+ZY
MQ\WBS,8=?A,=T-R H]T9C!DR@P<N5QXQW>F*F2X'1RF&M]R:Z?5NO51_6&N2
MMQ?1B\OI-($O2K,+?_ZA?JH(JSN0-66AG,H A6D"E34.($I#"G/!U4*%HP")
M4&W%0ZM6 >Y%G)O3=*#7011>)P'U__U5DP7HM*\5.+QI7#VO^\DW/%UYTRGU
MGD/@?39O2.)R#;B?3"YG4KY1.I=KE"_G=#D?R0V/9Z\!N(@BE.1$0AG1%"*N
M?'6"20)3PF.<YXC)S(H"^/)0<[/K)TR2MW18'T#8S.BZP<WW4<U(R&XFVO3;
M97U@M#<ETKS>9]W@#G?$X9=X7WZHN1#*D+!$DBB"*=<UXHQED-!4>9<X(+&(
M,Q$CJXP<:PGF9E_4/B>ZG5Q\&'0SV^(52L\FYP(%^34^J5H-O\SD1@CZ)BL?
M%N+-^<N-,#*A-#=[T(AXYB_%2A^=?Q/J?5UMR(-RVG1%_&X'?_^TWNKTET^K
M:E/6@9O_;.CY%F'.TH2A4+E**5.>$^>0$)Y CB(2Y$D4Y2$S3G\?+<;<K%ZK
M"'C>::)#4+N@)W@42Z[3UX[[98)BIQEH"1 /ZJ;J5ADZE[Y@ LAUJ6YB2U+N
M>M?M1]#[N.WJF11\W[OSF;S6)Z?;9UTEJ_LE54VO0$FV2YN^,N-?%X,@[20O
M@6\7L9W_O1*Z06[- ++3 S2*@)]?P5X5T.HRR6181'XGF92)@L+?Q;-Z7/WV
MZ_[13V>_U?IK['U.S5RI3_;T"W75Y/9FC ?#R^.?/EWD^68$#H+2MS]M$C[N
M!1:1E(PH9T>$FL<!<YCS((,\#Y,\D3C%F4\>[KFMG9HH>JDD]TJ_[8=V>T8K
MT&BZ[3?CV/:Q6; 58<Z<VI<V"F,?,V*;\.%)+LE_D[K2GS#EEE:%7JJ[)/6$
ML3P0*8Q%Q'22.H9J3X @I2$G*8[")#7GHQD<:FXFJQ6VH4  /7$MW+AA; W\
M9F>(>;9,%\$:4Z(ZC)J%@^L,O8F<V!M0M/-*C8 9]#R'GS"==VFDR8$':7;'
M#=6@RA=E8L%R0EF:1C D<0*1IAC-LU1 SA#C@90!RNCB191T;57(63_<YM7M
M#^'OS?W8(WO9U6'JXDNNSP'+2F_$FE^/J<-L$#7S[L:AY-D\UD*!6BK'98H'
MFCJO+VR>/GUAX(%69ROZ#J]P1@H2_SEHMY;OMYK*.VH7'1E$B4Q) M77BR$*
M"8$D#-2>3F:<9GF49L2(2LI^Z+FY14I, S(0P^.A$3-AX#1YP]>SE;C$/*$D
M[X*.H)7='?/')9QO9OUP@/?;Q Z+E5R73TWX72U;&U+H^@N]P6[>?7;MW7<5
M.QR%ZPC^CTM/?&ONCRN:&O!^7'O"#5X>O5Y23H]+RK\^UWE/7[>;:D-67+U5
M?Q>Z.;K@]TIX\B"^BZ?F;>MX9[=D^4.43Y%R)SF-4Y1!@4@&$4(<8H%2&$0Y
M1P@'),)V7(;3ZS"WE:RG@N8KU)^^6''MO^H?G^MFCB.<U8E?# NO>+[3/87[
M?1OQ2(N#^F&/Q!WHL  M&&"'!NC! 30>COW^MYE+YQN,B=68?B?S-O-T=LOT
M1J*,6V-W,>^/Z_)7HA=UMBUKODA]W+?_UX)E(LMCFL D"SE$:1I"'&0!E$%
M:9"PD#"KA=%TX+FM9K^0\A]B0QJGM!/2;ODRQIP'$<["G$"6,WVXR7)(@XC
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M<1QE#"F<B%&6BG/)YF:7.E%!6<L*7AIAK7(RW$^?@0/X5I/BV?SMU0([O>Z
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M/,'$FCGP;SQ/TRQH>RK].]#3L_'L^YJ"1E5PJ*LNGV^U!;6Z=_V03$]E=UL
M_]/B<HO@4=I)MQ#^43_>8DPPXJTTG=]%M2D+ILSH^1W/OMZ=,YHQF5.(!0\@
MBB(,<12F,!*1C'C(,LGD.,).8QGFMCDYG#6=E<"4Y&/Y.<VGPLSX>P;8LU7O
M9-89S$"!.Q"B\=@_Y08,_1!YFHOQ1I2>UCA=)O>T?]1(_UOMQ3;B<_$B^#&5
MPOW3NMP4_UU_WQ_^T,GWXK_4ANW'[^L%S_(XSR,"DS#)(!()AWD>*\N( YE)
M91 Q-FI;?),4<[.(:EL86OK(H\ W=']]0^K;LZWEA[4"X(2;Y0[TE0"M%G=
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MBB A%IF$4O(D#=(@%KE1)?VU@>;FE>U/^#M_H">L14;%$+;#]L,E8KYCFA.
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M)$\4Y]KFS*U.5=R'GAJ/ML)O$LU:^9N&5>!.@58%8$ZO+5I973LQ%M0;#.[
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M89+'G'!,8R6=:G&$FHD1$H=>>2:L]P5"X!M^2Z"!]DL'VE9PT)%\&_/O=2?
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MF5-I^8"R3FT1;"2NFW5N96Y7.$"W4K_"NF<Q[8&7.K^3.?W5;?<J[#1NKJ_
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M3$(4%P(BEN60FF\^RE,<%2I%2%BEA#N-.K6OWT@&&N'KTH]&?&#D!UL%@-'
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MIH88JW4!JT-EW$S#:^;.SGX<:3X"+Q'-1.RI =IB;K\83?YRLYF0(VUN@$E
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M;:*@[NM$F#<ONTO:].7;/^E*- U3=@)5=7BWJ01X]]C$;B]KVU2*@UY:OYD
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M.3@PB@!1:P(V>U7 3]^U,NN?RX,=<P;AO-_I-$MV;.0=^4 %FVN<&[G;S4U
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M*84T20J(4B1D0E*BI%7U :O1QK8^[(0%\_*X^O[V6]48Q<W4[4;8SK;UAMO
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M3.#Z>U_GD/_M5_RS)2D:I:BA\KK_L?[#WV[?>C&'!0)EQ>5[_,;F[\M;=J4
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MA0>#YLQRA3QD:95STFK:1['(4^_OAHB&<Y:]"+:1FI%;)M[B=Q8CSI*QPI5
M22(+V0 ).AM"H]=".6]=ZK.0:.OUW:#1< *S#[$VA8QU4=2:"2^XS%1HD@P/
MZ MA3!T,T))HLUE;K9/K(RYYDH!NZ&@X@=F/:'O#Q[_^]D"0[_$;^Y:/3Q>S
MR3B5U@"_^TFI>O_\%6"YN)SZRS3&[]ZGOVMM^8M/[:7P?#?:#ZQ*OUR0,^\O
M1JN+=P4/I_GM>(IO'2,H9NM*LUNL:>9#IID@$$3)9C(2I%+$Q.P1)QFB>&31
M7:^Y[!=AA8+-.]<+#R;+Q?5WME?@+L3M:V:NWW&R6*"0;UA5R?F4K"6E$IM(
M[0RQU@6B%?.::>/X8R5)A[-ZGXQA*MZK8>+:_O0@\P$WIOO4;QRP&R:"X<QI
M0'EHC-1EAD!L=(*P*&G.^!G+CY03] 6<+6J&Q<\AZGT4*8?(N@' O/*+KR?3
M5/YY\_]=CK_Y"3*S.%F^\O/YU7AZ]A]^<@FC  E$.2B@*:"8I$G$T92)\I$Q
M%K,0]I$[Y8<#J!-U+0#J(!3,:JND 9S]X>?_A*4/$]ADH,=P+;21,)R&P"T)
M0C,TUSP3"^!(M*6/ ./)V4<NA!R.KF=H&J:11SU,]27^!I#T"2+@HD!6%A]@
M><V$XVBR-:>$@5%$<LN(S\H1:UCF@6&(\%C2_W ,/4K-,!T_ZJ'G<)$W@)MW
MTV](]6Q^A2Q@M)F\S0PP."V=CKBD* VD'7=\;4$S$5,5DW.7B&':?]1#R=X"
M;@ <'^=PX<?IS8\+F"X =]_3Y5>8WY/1*+DH8]:.X(9;BM 51A4H%Z+0/HH0
M68CJD>*8PS'3@;9ANH?4@U+?ZF@ 85O$,X]11[G0'9,CTGD4CK>X6BB+FL>
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MI7.E1M$Y2+G.)MB=QF:P=Q LMG?-2CIJ '[O9].S+S _?PWAYBQ&4!^$Y)R
MQ/!19I17H#J0F)F43H*DH8Y%>TC+L!MF)3@=*O,&8/-J-EW)X1_CY==7EXOE
M[!SFU]*ZNED*'#T)[15)Z#J@C%))FB9=V@IX%TKC$?Y(;\D>+GIT(&[8U% E
M8/6NE0:0MO94X3UX?. V+U9EF8,3!*-6Y"5'0SQP2B(3U H)+C_6_>-PA#U'
MU+#II$K(ZDT+#2!JE19Y9.<6G@9P5A$AZ>H*@L(8B EBC)<F2IF,JY*'?(*>
M8=-1E7#4A^R'SEA>-\MY-3L/N"R*1LJ=]C$J9',9?K,^7F^(N_?3C0]Y8XU9
M0J\PN])FQ^/:89Y8H7)9.YQ&;DH+A4[9S3ZI&C;=U3/TAM59 _;ND>5FDLY9
M!4$H11'*@+PXX($$Z:7B(F7*J]P8V-/*]5Z>6-O!/TSB#61<G_4D[QXF<$NU
MBAR#%5&N>TI+;,3U8# $-FC -8_'=_%W/-(Y1OA8+Q-60U,M&*T[,?(=+IB3
MWCM+,60!-+W!<?Q,:&*$=UX[-+[VD<9N_:8F=H37,8+(BHG6P_701 +_<0>@
MM,]%=AYW!>XN'N,"+9<"E2^+Q^&V@.XI)]%(5E:/T;Q*7>!!5#<3B-9#Y_&T
MVH!)O'9-RW2K<_CB?]P1<;E=IH!GQSE@&([BDX:A((,RQ'F,SVE4@MLJ>_$+
M=#43Q]:#89^::0!HCR9[[JX;FZ4 +4G(&=>-,K@-4"I)C%S9;+DSYGA9MQWM
MW3&BUGI ZU,S#0!M.QMTAQ/MDI04!('5<!Q$!'$&70WPU$EIT6K7B5"?)JF9
M2+4>O'K21P/(NL/$B$6&D;;'@%NRTB@HNG+A#5>&L,7R9B;5(Y,G>DUV##,E
M<:@;&3M)O(%DQS,2D29S$U;7J6GI;HKQ,V*=D@#9""DUIZ)*O'G@%;+>V_(<
M%4H]Z:.)N/-.O\MUJ3VS+(@</1$AV\*&)+9<PG2,"2,H$YY6N:*X3<C0G5?Z
M4?&#9-@!TFX"+R<IK>YC^LE'/\: XI6_&*.=&]D4L[!1$49#\>R$(EYA',&9
M-4B("%%4@<T3] Q]D;4*>OJ0?0.^STF,E^>7D])?:^70E5;]<_@*T\7X&ZQ#
MU/>S10E,3S/&JB.*DDE46,( (2"]\+A&@),4J*0,<F*B2@77CG0.FVRM!;F*
MNFH BI]@Z<=32&_\?#J>GBWNL/L:\CB.2VV_<\$&1Y(.D<@D-4H/- %!D\6(
M(YE8J=?&2Z0-FS^M!+B>-=( QAX*:B252X;CKI]2V?5],"1$QY$#QG6RRCB?
MC^.U#YO\K(2A R7>0,3W4A@SLEF8H TM!UHHHU)&:2EREGF.2FFG@Z]RT_XE
MP@8:F#Y4)N%PY?0&MB/W;_VXTL=76(XC>MOWF.FKF>O]5QREL^LS7!VSS6O$
M'2P:9DA6$8V?X9J$4C@O,A,2/,>HL,I-SV.T>;T3 J.T3^>K=Z95-/P1YJN9
M&R,M'"@TS00BRV6BN"*.)TVT$EQDP[*.50YP.M V=%JB9_0\DZ#H13L-^%\/
M)KJ<7"Z_SN;C_X8TDN@)A "*\,PHD=%1XL"7WDJE=CFC .NDWI^A:>C,Q?$
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M9<>S980G+\I$3T>\RX88E8UBS%/+JO1$/2J7 ]<)-+S&A@=5$WO7(Y*YF;W
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M%_:3=]IGM&"6>2#(""<^<$<R,RK3+/ ;51J==J*N29]T4,MXL Z;2(FB2"-
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MM9I0 O-E;^ M4QGN\W*"[MY\?H7+\S_\Y!)&I5$%IQA^"(V1AZ29$U]6I(-
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M2(_+RSGIB%:^)$545*I*Q[O'B!GV E[?$>#!XFX0,ILE)4-D*;-(4@2/8N%
M<"E)DE6B(FBO!53)&SQ.SK#.].%J?@$W>\B\ >1L39#;6$RNG P8YQ(?<5%)
MAQ;3"73R8Q":"J5Q256I[GF4FK9PLX^:MQM:'"SS!H!SWPRO5A-E@)MKJ3IU
M0$MN))1.12@3;P0#ZW)BO 9J'I(R;/NIOG>H T7='%CN.'U )9A8;"\4IX\Z
M(-X'20(+E"IJLZSCUCQ%4$MWC'97]+.XV5/J0P=1=XSE9YB.9_,/LR4LV%_4
MZTO\QL5R93R9PIA(;PRI5L(:P17)CJ-IAI!)L-&23-%*,V<BVYYB\T14M?.K
M6T+/ONJ>'4WV;2)+_(5^A'E$"2*3R!F_#B*MI<@;)UI#V9XA$I<U(R7AS]"
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MSIBM?L!/U1%7IK2EZIW#X-R>8AM$^7T>M]?UE[DODZ=>^ZMUF[F1L:!D-I2
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M]II6V?')/4RNW(>'GJ98GMR\YN/F-3>C W64#,JT"/RKXM_STN$:'7]:;GT
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MA(845)5]]1F:!JYYK 2FOI30 )X^P/<[0IK/IOAIW%R?>C3!+:7WSF9*9+1
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M_M[K@_71"$JX$0A8HRGQ5'NB!+62*Y]$KG*-L=[>>R/13_[['QYA//:3Q4@
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MO89O,)E=E'#UVKA&S[Q0P%'9V1'I-2NMU!6QS&B=G%,HG1H@>I:J;GCZJ8X
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M@FL\!?0&K8]X1K_WZ1\X)T_NC/@[R5](M#7QM*9+7['H*7PT(0I@KA;]"Q_
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ML+EANA2KK*/HPF-MKEFG5_H@:X8:JAR$D"PUB2-'H7[:;,7^\;V_JG?'M[_
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MF[FVE>,;MN?Y_5F8_Q:^7 6BIJ#.@G:K+(4"45US]"))LWAGR$%"ETH;J]F
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M+%;KU6ET,0F#$3@O)*DD'$2OB#N5I0\I)I[T(//T_%K3MIYK8I-&%G 7>/F
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M]+#I3F(W )[?5O7P^FD >?OGB-N=#MR\+?=VY6?*6,<L)T2X%&LW! .!Q4)
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M #F/SZ@DAYASJM=; UF1$CR""UQ!2=E35BHPE#P&<,YG+F@O-7>:"]I'Y@T
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MV-):>" :EB=030.0VZ?];7DS7X1%(I:NAW0DS746H39DS*G6$VA*1*V#G(Q
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MM)C7I?>.&2XKI+4#EKFMO90">"8,R(1.%<HK@K4'0>3AFR8N<QP1(4?)=&J
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MZZ)12-4O5WC3W%'%X)S7AJ0B"\4K(D)M% 4Y"'2!6#5JE/CP1<JFA=D@^N^
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MSA%2'O]\??=!_2<2T?_?__5_ %!+ P04    " #-A05131;3EY<(  !83
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MOV3US:#9HS]R51S];VZY7_\Z_0]02P,$%     @ S84%4=R&,1:("   +DP
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M "?$6'*<_X0#S,92F B+8[$8Q!@*,MQGP@12F0SJH4S32GK I%H%G,%A0XZ
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M=RS,A^J!*+)J>_WX1DX^.;<WI\03(ZKUACC'\S(>^MD\2R6TBC>;=<J7\.^
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M;&EC96YS96$N:'1M4$L! A0#%     @ S84%43OPV?;0H0  GKD& !H
M         ( !F)T  &5X,3 R<G!I<F]Y86QT>7!U<F-H87,N:'1M4$L! A0#
M%     @ S84%4?DCO;US=0  T$L# !H              ( !H#\! &5X,3 S
M:VQE:6YE;7!L;WEM96YT86<N:'1M4$L! A0#%     @ S84%4?MR8--K;P
M$C8# !H              ( !2[4! &5X,3 T<&%U=V5L<V5M<&QO>6UE;G0N
M:'1M4$L! A0#%     @ S84%46DB-H]@1@, Y0(I !$              ( !
M[B0" '!T8W0M,C R,# V,S N:'1M4$L! A0#%     @ S84%4=/-L=2I&
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M,#(P,#8S,%]L86(N>&UL4$L! A0#%     @ S84%454F JB[Z0  K,$* !4
M             ( !1+(' '!T8W0M,C R,# V,S!?<')E+GAM;%!+ 0(4 Q0
M   ( ,V%!5%-%M.7EP@  %A,   6              "  3*<" !P=&-T,#8S
M,#(P,C!E>"TS,3$N:'1M4$L! A0#%     @ S84%4=R&,1:("   +DP  !8
M             ( !_:0( '!T8W0P-C,P,C R,&5X+3,Q,BYH=&U02P$"% ,4
M    " #-A051@$G>>S<%  "!)   %@              @ &YK0@ <'1C=# V
M,S R,#(P97@M,S(Q+FAT;5!+ 0(4 Q0    ( ,V%!5'_RJ!2,@4  %<D   6
M              "  22S" !P=&-T,#8S,#(P,C!E>"TS,C(N:'1M4$L%!@
0   .  X N@,  (JX"     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
